<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1188" width="918">
	<fontspec id="0" size="9" family="Times" color="#000000"/>
	<fontspec id="1" size="11" family="Times" color="#000000"/>
	<fontspec id="2" size="14" family="Times" color="#000000"/>
	<fontspec id="3" size="18" family="Times" color="#000000"/>
	<fontspec id="4" size="14" family="Times" color="#000000"/>
<text top="1124" left="54" width="409" height="12" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="1124" left="486" width="3" height="12" font="0"> </text>
<text top="1124" left="540" width="3" height="12" font="0"> </text>
<text top="1124" left="594" width="3" height="12" font="0"> </text>
<text top="1124" left="648" width="3" height="12" font="0"> </text>
<text top="1124" left="702" width="3" height="12" font="0"> </text>
<text top="1123" left="756" width="3" height="14" font="1"> </text>
<text top="1123" left="810" width="7" height="14" font="1">1</text>
<text top="1121" left="817" width="4" height="16" font="2"> </text>
<text top="1158" left="54" width="4" height="16" font="2"> </text>
<text top="68" left="243" width="443" height="19" font="3"><b>2013 Heart Failure Guideline Data Supplements  </b></text>
<text top="94" left="309" width="304" height="12" font="1">(Section numbers correspond to the full-text guideline.) </text>
<text top="149" left="396" width="130" height="15" font="4"><b>Table of Contents </b></text>
<text top="179" left="54" width="809" height="15" font="2">Data Supplement 1. HFpEF (Section 2.2)............................................................................................................................... 3</text>
<text top="178" left="864" width="4" height="16" font="2"> </text>
<text top="210" left="54" width="809" height="15" font="2">Data Supplement 2. NYHA and AHA/ACC Class (Section 3) .............................................................................................. 4</text>
<text top="209" left="864" width="4" height="16" font="2"> </text>
<text top="241" left="54" width="809" height="15" font="2">Data Supplement 3. Prognosis – Mortality (Section 4.1)........................................................................................................ 5</text>
<text top="240" left="864" width="4" height="16" font="2"> </text>
<text top="272" left="54" width="809" height="15" font="2">Data Supplement 4. Health-Related Quality of Life and Functional Capacity (Section 4.4) ................................................. 7</text>
<text top="271" left="864" width="4" height="16" font="2"> </text>
<text top="303" left="54" width="809" height="15" font="2">Data Supplement 5. Stress Testing (Initial and Serial Evaluation) of the HF Patient (Section 6.1.1) .................................. 11</text>
<text top="302" left="864" width="4" height="16" font="2"> </text>
<text top="334" left="54" width="809" height="15" font="2">Data Supplement 6. Clinical Evaluation – History (Orthopnea) (Section 6.1.1) .................................................................. 13</text>
<text top="332" left="864" width="4" height="16" font="2"> </text>
<text top="364" left="54" width="809" height="15" font="2">Data Supplement 7. Clinical Evaluation – Examination (Section 6.1.1) .............................................................................. 13</text>
<text top="363" left="864" width="4" height="16" font="2"> </text>
<text top="395" left="54" width="809" height="15" font="2">Data Supplement 8. Clinical Evaluation – Risk Scoring (Section 6.1.2) .............................................................................. 16</text>
<text top="394" left="864" width="4" height="16" font="2"> </text>
<text top="426" left="54" width="809" height="15" font="2">Data Supplement 9. Imaging Echocardiography (Section 6.4) ............................................................................................. 18</text>
<text top="425" left="864" width="4" height="16" font="2"> </text>
<text top="457" left="54" width="809" height="15" font="2">Data Supplement 10. Biopsy (Section 6.5.3) ........................................................................................................................ 21</text>
<text top="456" left="864" width="4" height="16" font="2"> </text>
<text top="488" left="54" width="809" height="15" font="2">Data Supplement 11. Stage A: Prevention of HF (Section 7.1) ............................................................................................ 22</text>
<text top="487" left="864" width="4" height="16" font="2"> </text>
<text top="518" left="54" width="809" height="15" font="2">Data Supplement 12. Stage B: Preventing the Syndrome of Clinical HF With Low EF (Section 7.2) ................................ 28</text>
<text top="517" left="864" width="4" height="16" font="2"> </text>
<text top="549" left="54" width="809" height="15" font="2">Data Supplement 13. Stage C: Factors Associated With Outcomes, All Patients (Section 7.3) ........................................... 30</text>
<text top="548" left="864" width="4" height="16" font="2"> </text>
<text top="580" left="54" width="809" height="15" font="2">Data Supplement 14. Nonadherence (Section 7.3.1.1) ......................................................................................................... 38</text>
<text top="579" left="864" width="4" height="16" font="2"> </text>
<text top="611" left="54" width="809" height="15" font="2">Data Supplement 15. Treatment of Sleep Disorders (Section 7.3.1.4) ................................................................................. 47</text>
<text top="610" left="864" width="4" height="16" font="2"> </text>
<text top="642" left="54" width="809" height="15" font="2">Data Supplement 16. Cardiac Rehabilitation-Exercise (Section 7.3.1.6) ............................................................................. 49</text>
<text top="641" left="864" width="4" height="16" font="2"> </text>
<text top="672" left="54" width="809" height="15" font="2">Data Supplement 17. Diuretics Versus Ultrafiltration in Acute Decompensated HF (Section 7.3.2.1) ............................... 60</text>
<text top="671" left="864" width="4" height="16" font="2"> </text>
<text top="703" left="54" width="809" height="15" font="2">Data Supplement 18. ACE Inhibitors (Section 7.3.2.2) ........................................................................................................ 76</text>
<text top="702" left="864" width="4" height="16" font="2"> </text>
<text top="734" left="54" width="809" height="15" font="2">Data Supplement 19. ARBs (Section 7.3.2.3) ....................................................................................................................... 82</text>
<text top="733" left="864" width="4" height="16" font="2"> </text>
<text top="765" left="54" width="809" height="15" font="2">Data Supplement 20. Beta Blockers (Section 7.3.2.4) .......................................................................................................... 85</text>
<text top="764" left="864" width="4" height="16" font="2"> </text>
<text top="796" left="54" width="809" height="15" font="2">Data Supplement 21. Anticoagulation (Section 7.3.2.8.1) .................................................................................................... 89</text>
<text top="795" left="864" width="4" height="16" font="2"> </text>
<text top="827" left="54" width="809" height="15" font="2">Data Supplement 22. Statin Therapy (Section 7.3.2.8.2) ...................................................................................................... 94</text>
<text top="826" left="864" width="4" height="16" font="2"> </text>
<text top="857" left="54" width="809" height="15" font="2">Data Supplement 23. Omega 3 Fatty Acids (Section 7.3.2.8.3) ......................................................................................... 101</text>
<text top="856" left="864" width="4" height="16" font="2"> </text>
<text top="888" left="54" width="809" height="15" font="2">Data Supplement 24. Antiarrhythmic Agents to Avoid in HF (7.3.2.9.2) .......................................................................... 104</text>
<text top="887" left="864" width="4" height="16" font="2"> </text>
<text top="919" left="54" width="809" height="15" font="2">Data Supplement 25. Calcium Channel Blockers to Avoid in HF (Section 7.3.2.9.3) ....................................................... 105</text>
<text top="918" left="864" width="4" height="16" font="2"> </text>
<text top="950" left="54" width="809" height="15" font="2">Data Supplement 26. NSAIDs Use in HF (Section 7.3.2.9.4) ............................................................................................ 106</text>
<text top="949" left="864" width="4" height="16" font="2"> </text>
<text top="981" left="54" width="809" height="15" font="2">Data Supplement 27. Thiazolidinediones in HF (Section 7.3.2.9.5) ................................................................................... 107</text>
<text top="980" left="864" width="4" height="16" font="2"> </text>
<text top="1012" left="54" width="809" height="15" font="2">Data Supplement 28. Device-Based Management (Section 7.3.4) ..................................................................................... 108</text>
<text top="1010" left="864" width="4" height="16" font="2"> </text>
<text top="1042" left="54" width="809" height="15" font="2">Data Supplement 29. CRT (Section 7.3.4.2) ....................................................................................................................... 109</text>
<text top="1041" left="864" width="4" height="16" font="2"> </text>
<text top="1073" left="54" width="809" height="15" font="2">Data Supplement 30. Therapies, Important Considerations (Section 7.4.2) ....................................................................... 114</text>
<text top="1072" left="864" width="4" height="16" font="2"> </text>
<text top="1104" left="54" width="809" height="15" font="2">Data Supplement 31. Sildenafil (Section Section 7.4.2) ..................................................................................................... 120</text>
<text top="1103" left="864" width="4" height="16" font="2"> </text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1188" width="918">
<text top="1124" left="54" width="409" height="12" font="0">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="1124" left="486" width="3" height="12" font="0"> </text>
<text top="1124" left="540" width="3" height="12" font="0"> </text>
<text top="1124" left="594" width="3" height="12" font="0"> </text>
<text top="1124" left="648" width="3" height="12" font="0"> </text>
<text top="1124" left="702" width="3" height="12" font="0"> </text>
<text top="1123" left="756" width="3" height="14" font="1"> </text>
<text top="1123" left="810" width="7" height="14" font="1">2</text>
<text top="1121" left="817" width="4" height="16" font="2"> </text>
<text top="1158" left="54" width="4" height="16" font="2"> </text>
<text top="58" left="54" width="809" height="15" font="2">Data Supplement 32. Inotropes (Section 7.4.4) .................................................................................................................. 123</text>
<text top="57" left="864" width="4" height="16" font="2"> </text>
<text top="89" left="54" width="809" height="15" font="2">Data Supplement 33. Inotropic Agents in HF (Section 7.4.4) ............................................................................................ 135</text>
<text top="88" left="864" width="4" height="16" font="2"> </text>
<text top="120" left="54" width="809" height="15" font="2">Data Supplement 34. Mechanical Circulatory Support (Section 7.4.5) .............................................................................. 136</text>
<text top="119" left="864" width="4" height="16" font="2"> </text>
<text top="150" left="54" width="809" height="15" font="2">Data Supplement 35. LVADs (Section 7.4.5) ..................................................................................................................... 138</text>
<text top="149" left="864" width="4" height="16" font="2"> </text>
<text top="181" left="54" width="809" height="15" font="2">Data Supplement 36. Transplantation (Section 7.4.6) ........................................................................................................ 149</text>
<text top="180" left="864" width="4" height="16" font="2"> </text>
<text top="212" left="54" width="809" height="15" font="2">Data Supplement 37. Comorbidities in the Hospitalized Patient (Section 8.1) .................................................................. 159</text>
<text top="211" left="864" width="4" height="16" font="2"> </text>
<text top="243" left="54" width="809" height="15" font="2">Data Supplement 38. Worsening Renal Function, Mortality and Readmission in Acute HF (Section 8.5) ....................... 161</text>
<text top="242" left="864" width="4" height="16" font="2"> </text>
<text top="274" left="54" width="809" height="15" font="2">Data Supplement 39. Nesiritide (Section 8.7) ..................................................................................................................... 165</text>
<text top="273" left="864" width="4" height="16" font="2"> </text>
<text top="305" left="54" width="809" height="15" font="2">Data Supplement 40. Hospitalized Patients – Oral Medications (Section 8.8) ................................................................... 177</text>
<text top="303" left="864" width="4" height="16" font="2"> </text>
<text top="335" left="54" width="809" height="15" font="2">Data Supplement 41. Atrial Fibrillation (Section 9.1) ........................................................................................................ 186</text>
<text top="334" left="864" width="4" height="16" font="2"> </text>
<text top="366" left="54" width="809" height="15" font="2">Data Supplement 42. HF Disease Management (Section 11.2) .......................................................................................... 187</text>
<text top="365" left="864" width="4" height="16" font="2"> </text>
<text top="397" left="54" width="809" height="15" font="2">Data Supplement 43. Telemonitoring (Section 11.2) ......................................................................................................... 189</text>
<text top="396" left="864" width="4" height="16" font="2"> </text>
<text top="428" left="54" width="809" height="15" font="2">Data Supplement 44. Quality Metrics and Performance Measures (Section 12) ................................................................ 191</text>
<text top="427" left="864" width="4" height="16" font="2"> </text>
<text top="459" left="54" width="809" height="15" font="2">References ........................................................................................................................................................................... 192</text>
<text top="458" left="864" width="4" height="16" font="2"> </text>
<text top="491" left="459" width="5" height="19" font="3"><b> </b></text>
</page>
<page number="3" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="5" size="9" family="Times" color="#000000"/>
	<fontspec id="6" size="11" family="Times" color="#000000"/>
	<fontspec id="7" size="14" family="Times" color="#000000"/>
	<fontspec id="8" size="16" family="Times" color="#000000"/>
	<fontspec id="9" size="14" family="Times" color="#000000"/>
	<fontspec id="10" size="14" family="Times" color="#000000"/>
	<fontspec id="11" size="14" family="Times" color="#0000ff"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">3</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="285" height="21" font="8"><b>Data Supplement 1. HFpEF (Section 2.2) </b></text>
<text top="75" left="48" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="94" left="49" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="75" left="176" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="75" left="304" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="75" left="410" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="415" width="31" height="19" font="9"><b>Size </b></text>
<text top="75" left="565" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="75" left="824" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="75" left="948" width="127" height="19" font="9"><b>Statistical Analysis </b></text>
<text top="94" left="980" width="62" height="19" font="9"><b>(Results) </b></text>
<text top="75" left="1119" width="121" height="19" font="9"><b> Study Limitations </b></text>
<text top="75" left="1301" width="137" height="19" font="9"><b>Findings/ Comments </b></text>
<text top="134" left="89" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="218" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="341" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="429" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="495" width="114" height="19" font="10"><i><b>Inclusion Criteria</b></i><b> </b></text>
<text top="134" left="651" width="119" height="19" font="10"><i><b>Exclusion Criteria</b></i><b> </b></text>
<text top="134" left="857" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="1009" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="1178" width="4" height="19" font="9"><b> </b></text>
<text top="134" left="1368" width="4" height="19" font="9"><b> </b></text>
<text top="161" left="42" width="94" height="19" font="7">Masoudi JACC </text>
<text top="179" left="42" width="80" height="19" font="7">2003;41:217-</text>
<text top="198" left="42" width="30" height="19" font="7">223  </text>
<text top="217" left="42" width="64" height="19" font="11">12535812 </text>
<text top="217" left="106" width="20" height="19" font="7">(1) </text>
<text top="161" left="153" width="110" height="19" font="7">To assess factors </text>
<text top="179" left="153" width="96" height="19" font="7">associated with </text>
<text top="198" left="153" width="116" height="19" font="7">preserved LVSF in </text>
<text top="217" left="153" width="72" height="19" font="7">pts with HF </text>
<text top="161" left="298" width="39" height="19" font="7">Cross </text>
<text top="179" left="298" width="57" height="19" font="7">sectional </text>
<text top="198" left="298" width="77" height="19" font="7">cohort study </text>
<text top="161" left="400" width="163" height="19" font="7">19,710 Medicare </text>
<text top="161" left="533" width="102" height="19" font="7">beneficiary; </text>
<text top="179" left="474" width="103" height="19" font="7">hospitalized with </text>
<text top="198" left="474" width="117" height="19" font="7">principal discharge </text>
<text top="217" left="474" width="138" height="19" font="7">diagnosis of HF; acute </text>
<text top="236" left="474" width="123" height="19" font="7">care hospitalization; </text>
<text top="255" left="474" width="130" height="19" font="7">hospitalized between </text>
<text top="274" left="474" width="91" height="19" font="7">4/1998-3/1999 </text>
<text top="161" left="643" width="129" height="19" font="7">No documentation of </text>
<text top="179" left="643" width="38" height="19" font="7">LVEF </text>
<text top="161" left="791" width="103" height="19" font="7">Preserved LVSF </text>
<text top="161" left="940" width="125" height="19" font="7">Multivariable logistic </text>
<text top="179" left="940" width="128" height="19" font="7">regression to assess </text>
<text top="198" left="940" width="141" height="19" font="7">factors associated with </text>
<text top="217" left="940" width="102" height="19" font="7">preserved LVSF </text>
<text top="161" left="1095" width="122" height="19" font="7">Limited to Medicare </text>
<text top="179" left="1095" width="128" height="19" font="7">population; limited to </text>
<text top="198" left="1095" width="150" height="19" font="7">hospitalized pts; missing </text>
<text top="217" left="1095" width="146" height="19" font="7">LVEF in a portion of the </text>
<text top="236" left="1095" width="66" height="19" font="7">population </text>
<text top="161" left="1277" width="145" height="19" font="7">Factors associated with </text>
<text top="179" left="1277" width="144" height="19" font="7">preserved LVSF, which </text>
<text top="198" left="1277" width="166" height="19" font="7">included gender, advanced </text>
<text top="217" left="1277" width="171" height="19" font="7">age, HTN, AF; and absence </text>
<text top="236" left="1277" width="122" height="19" font="7">of coronary disease </text>
<text top="295" left="42" width="80" height="19" font="7">Owan NEJM </text>
<text top="314" left="42" width="87" height="19" font="7">2006;355:251-</text>
<text top="333" left="42" width="30" height="19" font="7">259  </text>
<text top="352" left="42" width="64" height="19" font="11">16855265 </text>
<text top="352" left="106" width="20" height="19" font="7">(2) </text>
<text top="295" left="153" width="99" height="19" font="7">Define temporal </text>
<text top="314" left="153" width="126" height="19" font="7">trends in prevalence </text>
<text top="333" left="153" width="129" height="19" font="7">of HF with preserved </text>
<text top="352" left="153" width="97" height="19" font="7">LVEF over 15 y </text>
<text top="371" left="153" width="41" height="19" font="7">period </text>
<text top="295" left="298" width="86" height="19" font="7">Retrospective </text>
<text top="314" left="298" width="77" height="19" font="7">cohort study </text>
<text top="295" left="400" width="189" height="19" font="7">4,596 Consecutive </text>
<text top="295" left="552" width="59" height="19" font="7">pts </text>
<text top="295" left="574" width="92" height="19" font="7">admitted </text>
<text top="314" left="474" width="150" height="19" font="7">to Mayo Clinic hospitals; </text>
<text top="333" left="474" width="143" height="19" font="7">Discharge code for HF; </text>
<text top="352" left="474" width="68" height="19" font="7">1987-2001 </text>
<text top="295" left="643" width="129" height="19" font="7">No documentation of </text>
<text top="314" left="643" width="38" height="19" font="7">LVEF </text>
<text top="295" left="791" width="131" height="19" font="7">Proportion of pts with </text>
<text top="314" left="791" width="105" height="19" font="7">preserved LVSF; </text>
<text top="333" left="791" width="50" height="19" font="7">survival </text>
<text top="295" left="940" width="135" height="19" font="7">Linear regression and </text>
<text top="314" left="940" width="102" height="19" font="7">survival analysis </text>
<text top="295" left="1095" width="167" height="19" font="7">Limited to Olmsted County, </text>
<text top="314" left="1095" width="162" height="19" font="7">MN; limited to hospitalized </text>
<text top="333" left="1095" width="138" height="19" font="7">pts; missing LVEF in a </text>
<text top="352" left="1095" width="149" height="19" font="7">portion of the population </text>
<text top="295" left="1277" width="163" height="19" font="7">Overall, more than half the </text>
<text top="314" left="1277" width="156" height="19" font="7">population had preserved </text>
<text top="333" left="1277" width="131" height="19" font="7">LVSF; this proportion </text>
<text top="352" left="1277" width="171" height="19" font="7">increased overtime; survival </text>
<text top="371" left="1277" width="167" height="19" font="7">in pts with HFpEF was only </text>
<text top="390" left="1277" width="170" height="19" font="7">slightly better than for those </text>
<text top="409" left="1277" width="134" height="19" font="7">with HFrEF (HR:0.96) </text>
<text top="438" left="42" width="83" height="19" font="7">Bhatia NEJM </text>
<text top="457" left="42" width="87" height="19" font="7">2006;355:260-</text>
<text top="476" left="42" width="30" height="19" font="7">269  </text>
<text top="495" left="42" width="64" height="19" font="11">16855266 </text>
<text top="495" left="106" width="20" height="19" font="7">(3) </text>
<text top="514" left="42" width="4" height="19" font="7"> </text>
<text top="438" left="153" width="79" height="19" font="7">Evaluate the </text>
<text top="457" left="153" width="97" height="19" font="7">epidemiological </text>
<text top="476" left="153" width="79" height="19" font="7">features and </text>
<text top="495" left="153" width="127" height="19" font="7">outcomes of pts with </text>
<text top="514" left="153" width="111" height="19" font="7">HFpEF vs. HFrEF </text>
<text top="438" left="298" width="86" height="19" font="7">Retrospective </text>
<text top="457" left="298" width="77" height="19" font="7">cohort study </text>
<text top="438" left="400" width="38" height="19" font="7">2,802 </text>
<text top="438" left="474" width="120" height="19" font="7">Pts admitted to 103 </text>
<text top="457" left="474" width="109" height="19" font="7">Ontario hospitals; </text>
<text top="476" left="474" width="95" height="19" font="7">4/1999-3/2001; </text>
<text top="495" left="474" width="138" height="19" font="7">discharge diagnosis of </text>
<text top="514" left="474" width="22" height="19" font="7">HF </text>
<text top="438" left="643" width="129" height="19" font="7">No documentation of </text>
<text top="457" left="643" width="38" height="19" font="7">LVEF </text>
<text top="438" left="791" width="104" height="19" font="7">Death within 1 y; </text>
<text top="457" left="791" width="118" height="19" font="7">readmission for HF </text>
<text top="438" left="940" width="129" height="19" font="7">Multivariable survival </text>
<text top="457" left="940" width="53" height="19" font="7">analysis </text>
<text top="438" left="1095" width="157" height="19" font="7">Limited to Ontario; limited </text>
<text top="457" left="1095" width="165" height="19" font="7">to hospitalized pts; missing </text>
<text top="476" left="1095" width="146" height="19" font="7">LVEF in a portion of the </text>
<text top="495" left="1095" width="66" height="19" font="7">population </text>
<text top="438" left="1277" width="154" height="19" font="7">31% had HFpEF; HFpEF </text>
<text top="457" left="1277" width="182" height="19" font="7">more often female, older, with </text>
<text top="476" left="1277" width="159" height="19" font="7">AF, and HTN; Unadjusted </text>
<text top="495" left="1277" width="153" height="19" font="7">mortality similar (22% for </text>
<text top="514" left="1277" width="170" height="19" font="7">HFpEF vs. 26% for HFrEF); </text>
<text top="533" left="1277" width="181" height="19" font="7">adjusted mortality also similar </text>
<text top="552" left="1277" width="184" height="19" font="7">(aHR:1.13); readmission rates </text>
<text top="571" left="1277" width="179" height="19" font="7">also similar between groups.  </text>
<text top="590" left="42" width="94" height="19" font="7">Lee Circulation </text>
<text top="609" left="42" width="95" height="19" font="7">2009;119:3070-</text>
<text top="628" left="42" width="38" height="19" font="7">3077  </text>
<text top="647" left="42" width="64" height="19" font="11">19506115 </text>
<text top="647" left="106" width="20" height="19" font="7">(4) </text>
<text top="666" left="42" width="4" height="19" font="7"> </text>
<text top="590" left="153" width="70" height="19" font="7">Assess the </text>
<text top="609" left="153" width="114" height="19" font="7">contribution of risk </text>
<text top="628" left="153" width="121" height="19" font="7">factors and disease </text>
<text top="647" left="153" width="99" height="19" font="7">pathogenesis to </text>
<text top="666" left="153" width="47" height="19" font="7">HFpEF </text>
<text top="590" left="298" width="86" height="19" font="7">Retrospective </text>
<text top="609" left="298" width="77" height="19" font="7">cohort study </text>
<text top="590" left="400" width="202" height="19" font="7">534 Framingham </text>
<text top="609" left="474" width="149" height="19" font="7">participants; incident HF </text>
<text top="590" left="643" width="319" height="19" font="7">N/A Factors </text>
<text top="590" left="840" width="191" height="19" font="7">associated </text>
<text top="609" left="791" width="133" height="19" font="7">with HFpEF; Mortality </text>
<text top="590" left="940" width="125" height="19" font="7">Multivariable logistic </text>
<text top="609" left="940" width="96" height="19" font="7">regression (risk </text>
<text top="628" left="940" width="132" height="19" font="7">factors); multivariable </text>
<text top="647" left="940" width="102" height="19" font="7">survival analysis </text>
<text top="666" left="940" width="64" height="19" font="7">(mortality) </text>
<text top="590" left="1095" width="142" height="19" font="7">Limited to Framingham </text>
<text top="609" left="1095" width="137" height="19" font="7">cohort; relatively small </text>
<text top="628" left="1095" width="75" height="19" font="7">sample size </text>
<text top="590" left="1277" width="145" height="19" font="7">Factors associated with </text>
<text top="609" left="1277" width="145" height="19" font="7">HFpEF included female </text>
<text top="628" left="1277" width="164" height="19" font="7">gender; elevated SBP; AF; </text>
<text top="647" left="1277" width="167" height="19" font="7">and absence of CAD. Long-</text>
<text top="666" left="1277" width="171" height="19" font="7">term prognosis equally poor </text>
<text top="685" left="1277" width="138" height="19" font="7">(overall cohort median </text>
<text top="704" left="1277" width="179" height="19" font="7">survival of 2.1 y; 5-y mortality </text>
<text top="723" left="1277" width="39" height="19" font="7">74%). </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="12" size="8" family="Times" color="#000000"/>
	<fontspec id="13" size="13" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">4</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="42" width="75" height="19" font="7">Kane JAMA </text>
<text top="73" left="42" width="87" height="19" font="7">2011;306:856-</text>
<text top="92" left="42" width="30" height="19" font="7">863  </text>
<text top="111" left="42" width="64" height="19" font="11">21862747 </text>
<text top="111" left="106" width="20" height="19" font="7">(5) </text>
<text top="54" left="153" width="126" height="19" font="7">Measure changes in </text>
<text top="73" left="153" width="130" height="19" font="7">diastolic function and </text>
<text top="92" left="153" width="68" height="19" font="7">assess the </text>
<text top="111" left="153" width="128" height="19" font="7">relationship between </text>
<text top="130" left="153" width="53" height="19" font="7">diastolic </text>
<text top="149" left="153" width="132" height="19" font="7">abnormalities and HF </text>
<text top="168" left="153" width="25" height="19" font="7">risk </text>
<text top="54" left="298" width="86" height="19" font="7">Retrospective </text>
<text top="73" left="298" width="77" height="19" font="7">cohort study </text>
<text top="54" left="400" width="34" height="19" font="7">2042 </text>
<text top="54" left="474" width="133" height="19" font="7">Random sample from </text>
<text top="73" left="474" width="140" height="19" font="7">Olmsted County MN in </text>
<text top="92" left="474" width="96" height="19" font="7">1997; age ≥45; </text>
<text top="111" left="474" width="145" height="19" font="7">participating in baseline </text>
<text top="130" left="474" width="83" height="19" font="7">and follow up </text>
<text top="149" left="474" width="83" height="19" font="7">assessments </text>
<text top="54" left="643" width="325" height="19" font="7">N/A Diastolic </text>
<text top="54" left="846" width="173" height="19" font="7">function </text>
<text top="73" left="791" width="114" height="19" font="7">grade; incident HF </text>
<text top="54" left="940" width="129" height="19" font="7">Multivariable survival </text>
<text top="73" left="940" width="53" height="19" font="7">analysis </text>
<text top="54" left="1095" width="167" height="19" font="7">Limited to Olmsted County, </text>
<text top="73" left="1095" width="123" height="19" font="7">MN; limited to those </text>
<text top="92" left="1095" width="102" height="19" font="7">following up for 2</text>
<text top="93" left="1197" width="10" height="12" font="12">nd</text>
<text top="92" left="1207" width="4" height="19" font="7"> </text>
<text top="111" left="1095" width="77" height="19" font="7">examination </text>
<text top="54" left="1277" width="172" height="19" font="7">In 4 y between baseline and </text>
<text top="73" left="1277" width="147" height="19" font="7">follow-up, prevalence of </text>
<text top="92" left="1277" width="125" height="19" font="7">diastolic dysfunction </text>
<text top="111" left="1277" width="150" height="19" font="7">increased from 23.8% to </text>
<text top="130" left="1277" width="173" height="19" font="7">39.2%. Diastolic dysfunction </text>
<text top="149" left="1277" width="168" height="19" font="7">associated with incident HF </text>
<text top="168" left="1277" width="62" height="19" font="7">(HR:1.81) </text>
<text top="187" left="32" width="1429" height="17" font="13">AF indicates atrial fibrillation; CAD, coronary artery disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; LVEF, left ventricular ejection fraction; LVSF, left ventricular </text>
<text top="206" left="32" width="286" height="17" font="13">systolic function; MN, Minnesota; N/A, not applicable</text>
<text top="204" left="319" width="4" height="19" font="7">;</text>
<text top="206" left="323" width="264" height="17" font="13"> pts, patients, and SBP, systolic blood pressure. </text>
<text top="227" left="54" width="4" height="16" font="7"> </text>
<text top="262" left="54" width="413" height="21" font="8"><b>Data Supplement 2. NYHA and AHA/ACC Class (Section 3) </b></text>
<text top="302" left="56" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="321" left="56" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="312" left="204" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="312" left="348" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="302" left="451" width="41" height="19" font="9"><b>Study </b></text>
<text top="321" left="456" width="31" height="19" font="9"><b>Size </b></text>
<text top="312" left="552" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="312" left="813" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="302" left="1005" width="127" height="19" font="9"><b>Statistical Analysis </b></text>
<text top="321" left="1037" width="62" height="19" font="9"><b>(Results) </b></text>
<text top="312" left="1189" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="302" left="1368" width="64" height="19" font="9"><b>Findings/ </b></text>
<text top="321" left="1363" width="74" height="19" font="9"><b>Comments </b></text>
<text top="360" left="96" width="4" height="19" font="7"> </text>
<text top="360" left="245" width="4" height="19" font="7"> </text>
<text top="360" left="385" width="4" height="19" font="7"> </text>
<text top="360" left="469" width="4" height="19" font="7"> </text>
<text top="360" left="533" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="379" left="539" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="360" left="641" width="68" height="19" font="10"><i><b>Exclusion </b></i></text>
<text top="379" left="649" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="360" left="757" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="379" left="752" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="360" left="871" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="379" left="877" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="360" left="1066" width="4" height="19" font="7"> </text>
<text top="360" left="1246" width="4" height="19" font="7"> </text>
<text top="360" left="1398" width="4" height="19" font="7"> </text>
<text top="403" left="42" width="115" height="19" font="7">Madsen BK, 1994  </text>
<text top="422" left="42" width="56" height="19" font="11">8013501 </text>
<text top="422" left="98" width="20" height="19" font="7">(6) </text>
<text top="403" left="167" width="132" height="19" font="7">Predict CHF mortality </text>
<text top="403" left="340" width="77" height="19" font="7">Longitudinal </text>
<text top="422" left="340" width="48" height="19" font="7">registry </text>
<text top="403" left="446" width="26" height="19" font="7">190 </text>
<text top="403" left="509" width="30" height="19" font="7"> N/A </text>
<text top="403" left="632" width="52" height="19" font="7">Must be </text>
<text top="422" left="632" width="71" height="19" font="7">ambulatory </text>
<text top="403" left="730" width="204" height="19" font="7">Death  </text>
<text top="403" left="854" width="289" height="19" font="7">N/A  Kaplan-Meier </text>
<text top="422" left="978" width="145" height="19" font="7">Mortality increased with </text>
<text top="440" left="978" width="165" height="19" font="7">increased NYHA class and </text>
<text top="459" left="978" width="116" height="19" font="7">with decreased EF </text>
<text top="403" left="1171" width="30" height="19" font="7"> N/A </text>
<text top="403" left="1337" width="124" height="19" font="7">Conducted primarily </text>
<text top="422" left="1337" width="81" height="19" font="7">outside  U.S. </text>
<text top="489" left="42" width="104" height="19" font="7">Holland R, 2010  </text>
<text top="508" left="42" width="64" height="19" font="11">20142027 </text>
<text top="508" left="106" width="20" height="19" font="7">(7) </text>
<text top="489" left="167" width="132" height="19" font="7">Predict CHF mortality </text>
<text top="508" left="167" width="123" height="19" font="7">using self-assessed </text>
<text top="527" left="167" width="76" height="19" font="7">NYHA class </text>
<text top="489" left="340" width="77" height="19" font="7">Longitudinal </text>
<text top="508" left="340" width="48" height="19" font="7">registry </text>
<text top="489" left="446" width="26" height="19" font="7">293 </text>
<text top="489" left="509" width="101" height="19" font="7">Adults with CHF </text>
<text top="508" left="509" width="62" height="19" font="7">after CHF </text>
<text top="527" left="509" width="65" height="19" font="7">admission </text>
<text top="489" left="632" width="30" height="19" font="7"> N/A </text>
<text top="489" left="730" width="82" height="19" font="7">Readmission </text>
<text top="508" left="730" width="64" height="19" font="7">over 6 mo </text>
<text top="489" left="850" width="44" height="19" font="7"> MLHF </text>
<text top="508" left="850" width="111" height="19" font="7">questionnaire and </text>
<text top="527" left="850" width="38" height="19" font="7">death </text>
<text top="489" left="978" width="105" height="19" font="7">Survival analysis </text>
<text top="508" left="978" width="171" height="19" font="7">Readmission rate increased </text>
<text top="527" left="978" width="145" height="19" font="7">with higher NYHA class </text>
<text top="489" left="1171" width="149" height="19" font="7">No clinician assessment </text>
<text top="508" left="1171" width="102" height="19" font="7">to compare to pt </text>
<text top="527" left="1171" width="76" height="19" font="7">assessment </text>
<text top="489" left="1337" width="124" height="19" font="7">Conducted primarily </text>
<text top="508" left="1337" width="78" height="19" font="7">outside U.S. </text>
<text top="554" left="42" width="107" height="19" font="7">Anmar KA, 2007  </text>
<text top="573" left="42" width="64" height="19" font="11">17353436 </text>
<text top="573" left="106" width="20" height="19" font="7">(8) </text>
<text top="554" left="167" width="143" height="19" font="7">Measure association of </text>
<text top="573" left="167" width="148" height="19" font="7">HF stages with mortality </text>
<text top="554" left="340" width="40" height="19" font="7">Cross-</text>
<text top="573" left="340" width="57" height="19" font="7">sectional </text>
<text top="592" left="340" width="41" height="19" font="7">cohort </text>
<text top="554" left="446" width="151" height="19" font="7">2,029 Residents </text>
<text top="554" left="573" width="40" height="19" font="7">of </text>
<text top="573" left="509" width="104" height="19" font="7">Olmsted Co, MN </text>
<text top="554" left="632" width="30" height="19" font="7"> N/A </text>
<text top="554" left="730" width="152" height="19" font="7">5-y survival rates  BNP </text>
<text top="554" left="978" width="108" height="19" font="7">Survival analysis  </text>
<text top="573" left="978" width="162" height="19" font="7">HF stages associated with </text>
<text top="592" left="978" width="171" height="19" font="7">progressively worsening 5-y </text>
<text top="611" left="978" width="84" height="19" font="7">survival rates </text>
<text top="554" left="1171" width="86" height="19" font="7">Retrospective </text>
<text top="573" left="1171" width="133" height="19" font="7">classification of stage </text>
<text top="554" left="1337" width="30" height="19" font="7"> N/A </text>
<text top="635" left="42" width="111" height="19" font="7">Goldman L, 1981  </text>
<text top="654" left="42" width="56" height="19" font="11">7296795 </text>
<text top="654" left="98" width="20" height="19" font="7">(9) </text>
<text top="673" left="42" width="4" height="19" font="7"> </text>
<text top="635" left="167" width="112" height="19" font="7">Reproducibility for </text>
<text top="654" left="167" width="148" height="19" font="7">assessing CV functional </text>
<text top="673" left="167" width="35" height="19" font="7">class </text>
<text top="635" left="340" width="77" height="19" font="7">Longitudinal </text>
<text top="654" left="340" width="48" height="19" font="7">registry </text>
<text top="635" left="446" width="19" height="19" font="7">75 </text>
<text top="635" left="509" width="107" height="19" font="7">All those referred </text>
<text top="654" left="509" width="74" height="19" font="7">for treadmill </text>
<text top="673" left="509" width="44" height="19" font="7">testing </text>
<text top="635" left="632" width="30" height="19" font="7"> N/A </text>
<text top="635" left="730" width="93" height="19" font="7">Reproducibility </text>
<text top="654" left="730" width="44" height="19" font="7">testing </text>
<text top="635" left="850" width="30" height="19" font="7"> N/A </text>
<text top="635" left="978" width="122" height="19" font="7">NYHA classification </text>
<text top="654" left="978" width="8" height="19" font="7">  </text>
<text top="635" left="1171" width="30" height="19" font="7"> N/A </text>
<text top="635" left="1337" width="121" height="19" font="7">Reproducibility only </text>
<text top="654" left="1337" width="31" height="19" font="7">56% </text>
<text top="696" left="54" width="1346" height="17" font="13">BNP indicates B-type natriuretic peptide; CHF, congestive heart failure; CV, cardiovascular; EF, ejection fraction; HF, heart failure; MLHF, Minnesota Living with Heart Failure; N/A, not applicable; NYHA, New York Heart Association; and pt, patient. </text>
<text top="734" left="54" width="4" height="16" font="7"> </text>
<text top="773" left="54" width="4" height="16" font="7"> </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="14" size="13" family="Times" color="#0000ff"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">5</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="384" height="21" font="8"><b>Data Supplement 3. Prognosis - Mortality (Section 4.1) </b></text>
<text top="85" left="50" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="104" left="50" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="85" left="177" width="46" height="19" font="9"><b>Aim of </b></text>
<text top="104" left="179" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="263" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="94" left="381" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="94" left="590" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="94" left="888" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="75" left="1050" width="68" height="19" font="9"><b>Statistical </b></text>
<text top="94" left="1055" width="59" height="19" font="9"><b>Analysis </b></text>
<text top="113" left="1053" width="62" height="19" font="9"><b>(Results) </b></text>
<text top="85" left="1153" width="60" height="19" font="9"><b>P Values </b></text>
<text top="104" left="1150" width="66" height="19" font="9"><b>&amp; 95% CI: </b></text>
<text top="94" left="1233" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="85" left="1382" width="64" height="19" font="9"><b>Findings/ </b></text>
<text top="104" left="1378" width="74" height="19" font="9"><b>Comments </b></text>
<text top="154" left="91" width="4" height="19" font="7"> </text>
<text top="154" left="198" width="4" height="19" font="7"> </text>
<text top="154" left="299" width="4" height="19" font="7"> </text>
<text top="154" left="415" width="4" height="19" font="7"> </text>
<text top="144" left="504" width="114" height="19" font="10"><i><b>Inclusion Criteria </b></i></text>
<text top="144" left="673" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="135" left="841" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="154" left="837" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="135" left="933" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="154" left="938" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="154" left="1082" width="4" height="19" font="7"> </text>
<text top="154" left="1181" width="4" height="19" font="7"> </text>
<text top="154" left="1290" width="4" height="19" font="7"> </text>
<text top="154" left="1412" width="4" height="19" font="7"> </text>
<text top="175" left="42" width="86" height="17" font="13">The Seattle HF </text>
<text top="192" left="42" width="98" height="17" font="13">Model: Prediction </text>
<text top="210" left="42" width="94" height="17" font="13">of Survival in HF </text>
<text top="227" left="42" width="100" height="17" font="13">Levy, Wayne Circ </text>
<text top="244" left="42" width="34" height="17" font="13">2006  </text>
<text top="261" left="42" width="58" height="17" font="14">16534009 </text>
<text top="261" left="100" width="25" height="17" font="13">(10) </text>
<text top="279" left="42" width="3" height="17" font="13"> </text>
<text top="175" left="157" width="72" height="17" font="13">Develop and </text>
<text top="192" left="157" width="79" height="17" font="13">validate a risk </text>
<text top="210" left="157" width="55" height="17" font="13">model for </text>
<text top="227" left="157" width="65" height="17" font="13">1,2,and 3-y </text>
<text top="244" left="157" width="50" height="17" font="13">mortality </text>
<text top="175" left="255" width="44" height="17" font="13">Cohort  </text>
<text top="175" left="360" width="96" height="17" font="13">Derivation: 1,125 </text>
<text top="192" left="360" width="95" height="17" font="13">Validation: 9,942 </text>
<text top="175" left="486" width="122" height="17" font="13">Derivation Cohort: EF </text>
<text top="192" left="486" width="140" height="17" font="13">&lt;30%, NYHA class III-IV  </text>
<text top="210" left="486" width="120" height="17" font="13">Validation Cohort: EF </text>
<text top="227" left="486" width="140" height="17" font="13">&lt;40%, NYHA class II-IV   </text>
<text top="244" left="486" width="109" height="17" font="13">Both derivation and </text>
<text top="261" left="486" width="149" height="17" font="13">validation cohorts primarily </text>
<text top="279" left="486" width="136" height="17" font="13">out-pts (both clinical trial </text>
<text top="296" left="486" width="70" height="17" font="13">populations) </text>
<text top="175" left="649" width="27" height="17" font="13"> N/A </text>
<text top="175" left="828" width="72" height="17" font="13">Prediction of </text>
<text top="192" left="828" width="41" height="17" font="13">1,2,3-y </text>
<text top="210" left="828" width="50" height="17" font="13">mortality </text>
<text top="175" left="920" width="253" height="17" font="13">N/A Predicted </text>
<text top="175" left="1086" width="106" height="17" font="13">vs. </text>
<text top="192" left="1031" width="99" height="17" font="13">actual survival for </text>
<text top="210" left="1031" width="75" height="17" font="13">1, 2, and 3 y: </text>
<text top="227" left="1031" width="96" height="17" font="13">88.2% vs 87.8%, </text>
<text top="244" left="1031" width="96" height="17" font="13">79.2% vs 77.6%, </text>
<text top="261" left="1031" width="96" height="17" font="13">71.8% vs. 68.0% </text>
<text top="175" left="1150" width="34" height="17" font="13">ROC: </text>
<text top="192" left="1150" width="66" height="17" font="13">0.729; 95% </text>
<text top="210" left="1150" width="54" height="17" font="13">CI: 0.714-</text>
<text top="227" left="1150" width="34" height="17" font="13">0.744 </text>
<text top="175" left="1229" width="82" height="17" font="13">Population not </text>
<text top="192" left="1229" width="115" height="17" font="13">representative of HF </text>
<text top="210" left="1229" width="121" height="17" font="13">population in general: </text>
<text top="227" left="1229" width="63" height="17" font="13">clinical trial </text>
<text top="244" left="1229" width="124" height="17" font="13">populations, restricted </text>
<text top="261" left="1229" width="132" height="17" font="13">to HF with LVSD.           </text>
<text top="279" left="1229" width="97" height="17" font="13">Estimation of risk </text>
<text top="296" left="1229" width="119" height="17" font="13">score is complex and </text>
<text top="313" left="1229" width="48" height="17" font="13">requires </text>
<text top="330" left="1229" width="118" height="17" font="13">computer/calculator.  </text>
<text top="175" left="1367" width="70" height="17" font="13">24 variables </text>
<text top="192" left="1367" width="85" height="17" font="13">included in risk </text>
<text top="210" left="1367" width="40" height="17" font="13">score   </text>
<text top="356" left="42" width="58" height="17" font="13">Predicting </text>
<text top="373" left="42" width="92" height="17" font="13">Mortality Among </text>
<text top="391" left="42" width="92" height="17" font="13">Pts Hospitalized </text>
<text top="408" left="42" width="45" height="17" font="13">with HF </text>
<text top="425" left="42" width="87" height="17" font="13">(EFFECT) Lee, </text>
<text top="442" left="42" width="85" height="17" font="13">Douglas JAMA </text>
<text top="460" left="42" width="34" height="17" font="13">2003  </text>
<text top="477" left="42" width="58" height="17" font="14">14625335 </text>
<text top="477" left="100" width="25" height="17" font="13">(11) </text>
<text top="356" left="157" width="72" height="17" font="13">Develop and </text>
<text top="373" left="157" width="79" height="17" font="13">validate a risk </text>
<text top="391" left="157" width="83" height="17" font="13">model for 30-d </text>
<text top="408" left="157" width="44" height="17" font="13">and 1-y </text>
<text top="425" left="157" width="50" height="17" font="13">mortality </text>
<text top="356" left="255" width="44" height="17" font="13">Cohort  </text>
<text top="356" left="360" width="96" height="17" font="13">Derivation: 2,624 </text>
<text top="373" left="360" width="95" height="17" font="13">Validation: 1,407 </text>
<text top="356" left="486" width="111" height="17" font="13">No EF requirement; </text>
<text top="373" left="486" width="123" height="17" font="13">Community-based pts </text>
<text top="391" left="486" width="127" height="17" font="13">hospitalized with HF in </text>
<text top="408" left="486" width="124" height="17" font="13">Canada (met modified </text>
<text top="425" left="486" width="137" height="17" font="13">Framingham HF criteria) </text>
<text top="356" left="649" width="155" height="17" font="13">Pts who developed HF after </text>
<text top="373" left="649" width="128" height="17" font="13">admit, transferred from </text>
<text top="391" left="649" width="153" height="17" font="13">different facility, over 105 y, </text>
<text top="408" left="649" width="74" height="17" font="13">nonresidents </text>
<text top="356" left="828" width="72" height="17" font="13">30-d and 1-y </text>
<text top="373" left="828" width="50" height="17" font="13">mortality </text>
<text top="356" left="920" width="27" height="17" font="13"> N/A </text>
<text top="356" left="1031" width="103" height="17" font="13">Derivation Cohort: </text>
<text top="373" left="1031" width="59" height="17" font="13">in-hospital </text>
<text top="391" left="1031" width="88" height="17" font="13">mortality: 8.9%, </text>
<text top="408" left="1031" width="81" height="17" font="13">30-d mortality: </text>
<text top="425" left="1031" width="62" height="17" font="13">10.7%; 1-y </text>
<text top="442" left="1031" width="92" height="17" font="13">mortality: 32.9% </text>
<text top="460" left="1031" width="99" height="17" font="13">Validation cohort: </text>
<text top="477" left="1031" width="59" height="17" font="13">in-hospital </text>
<text top="494" left="1031" width="88" height="17" font="13">mortality: 8.2%, </text>
<text top="511" left="1031" width="81" height="17" font="13">30-d mortality: </text>
<text top="528" left="1031" width="62" height="17" font="13">10.4%; 1-y </text>
<text top="546" left="1031" width="88" height="17" font="13">mortality:30.5% </text>
<text top="356" left="1150" width="62" height="17" font="13">ROC: 0.79 </text>
<text top="373" left="1150" width="46" height="17" font="13">for 30-d </text>
<text top="391" left="1150" width="60" height="17" font="13">mortality;   </text>
<text top="408" left="1150" width="62" height="17" font="13">ROC; 0.76 </text>
<text top="425" left="1150" width="38" height="17" font="13">for 1-y </text>
<text top="442" left="1150" width="50" height="17" font="13">mortality </text>
<text top="356" left="1229" width="306" height="17" font="13">N/A Variables </text>
<text top="356" left="1422" width="127" height="17" font="13">in </text>
<text top="373" left="1367" width="68" height="17" font="13">Model: age, </text>
<text top="391" left="1367" width="87" height="17" font="13">SBP, resp rate, </text>
<text top="408" left="1367" width="80" height="17" font="13">Na &lt;136, Hbg </text>
<text top="425" left="1367" width="93" height="17" font="13">&lt;10, BUN, CVD, </text>
<text top="442" left="1367" width="42" height="17" font="13">COPD, </text>
<text top="460" left="1367" width="57" height="17" font="13">dementia, </text>
<text top="477" left="1367" width="93" height="17" font="13">cirrhosis, cancer </text>
<text top="563" left="42" width="72" height="17" font="13">Predictors of </text>
<text top="581" left="42" width="79" height="17" font="13">Mortality After </text>
<text top="598" left="42" width="92" height="17" font="13">Discharge in pts </text>
<text top="615" left="42" width="86" height="17" font="13">Hospitalized w/ </text>
<text top="632" left="42" width="86" height="17" font="13">HF (OPTIMIZE-</text>
<text top="650" left="42" width="83" height="17" font="13">HF) O'Connor, </text>
<text top="667" left="42" width="88" height="17" font="13">Christopher       </text>
<text top="684" left="42" width="61" height="17" font="13">AHJ 2008  </text>
<text top="701" left="42" width="58" height="17" font="14">18926148 </text>
<text top="701" left="100" width="25" height="17" font="13">(12) </text>
<text top="563" left="157" width="49" height="17" font="13">Develop </text>
<text top="581" left="157" width="43" height="17" font="13">models </text>
<text top="598" left="157" width="70" height="17" font="13">predictive of </text>
<text top="615" left="157" width="68" height="17" font="13">60 and 90 d </text>
<text top="632" left="157" width="50" height="17" font="13">mortality </text>
<text top="563" left="255" width="40" height="17" font="13">Cohort </text>
<text top="581" left="255" width="77" height="17" font="13">study/registry </text>
<text top="563" left="360" width="34" height="17" font="13">4,402 </text>
<text top="563" left="486" width="136" height="17" font="13">No EF criteria (49% with </text>
<text top="581" left="486" width="131" height="17" font="13">LVSD), pts hospitalized </text>
<text top="598" left="486" width="120" height="17" font="13">with HF at institutions </text>
<text top="615" left="486" width="137" height="17" font="13">participating in OPIMIZE-</text>
<text top="632" left="486" width="93" height="17" font="13">HF performance-</text>
<text top="650" left="486" width="124" height="17" font="13">improvement program </text>
<text top="563" left="649" width="27" height="17" font="13"> N/A </text>
<text top="563" left="828" width="68" height="17" font="13">Death at 60-</text>
<text top="581" left="828" width="27" height="17" font="13">90 d </text>
<text top="563" left="920" width="87" height="17" font="13">Hospitalization; </text>
<text top="581" left="920" width="49" height="17" font="13">death or </text>
<text top="598" left="920" width="92" height="17" font="13">rehospitalization </text>
<text top="563" left="1031" width="98" height="17" font="13">60-90 d mortality: </text>
<text top="581" left="1031" width="83" height="17" font="13">8.6%; death or </text>
<text top="598" left="1031" width="96" height="17" font="13">rehospitalization: </text>
<text top="615" left="1031" width="38" height="17" font="13">36.2% </text>
<text top="563" left="1150" width="46" height="17" font="13">c index: </text>
<text top="581" left="1150" width="38" height="17" font="13">0.735; </text>
<text top="598" left="1150" width="27" height="17" font="13">bias-</text>
<text top="615" left="1150" width="64" height="17" font="13">corrected c </text>
<text top="632" left="1150" width="36" height="17" font="13">index: </text>
<text top="650" left="1150" width="34" height="17" font="13">0.723 </text>
<text top="563" left="1229" width="122" height="17" font="13">Validity - assessed by </text>
<text top="581" left="1229" width="71" height="17" font="13">bootstraping </text>
<text top="563" left="1367" width="72" height="17" font="13">Developed a </text>
<text top="581" left="1367" width="66" height="17" font="13">nomogram. </text>
<text top="598" left="1367" width="55" height="17" font="13">Variables </text>
<text top="615" left="1367" width="62" height="17" font="13">included in </text>
<text top="632" left="1367" width="66" height="17" font="13">score: Age, </text>
<text top="650" left="1367" width="74" height="17" font="13">weight, SBP, </text>
<text top="667" left="1367" width="92" height="17" font="13">sodium, Cr, liver </text>
<text top="684" left="1367" width="49" height="17" font="13">disease, </text>
<text top="701" left="1367" width="67" height="17" font="13">depression, </text>
<text top="718" left="1367" width="33" height="17" font="13">RAD  </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">6</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="42" width="72" height="17" font="13">Predictors of </text>
<text top="71" left="42" width="74" height="17" font="13">Mortality and </text>
<text top="88" left="42" width="87" height="17" font="13">Morbidity in Pts </text>
<text top="106" left="42" width="94" height="17" font="13">with Chronic HF  </text>
<text top="123" left="42" width="97" height="17" font="13">Pocock, Stuart     </text>
<text top="140" left="42" width="61" height="17" font="13">EHJ 2006  </text>
<text top="157" left="42" width="58" height="17" font="14">16219658 </text>
<text top="157" left="100" width="25" height="17" font="13">(13) </text>
<text top="54" left="157" width="49" height="17" font="13">Develop </text>
<text top="71" left="157" width="60" height="17" font="13">prognostic </text>
<text top="88" left="157" width="81" height="17" font="13">models for 2-y </text>
<text top="106" left="157" width="50" height="17" font="13">mortality </text>
<text top="54" left="255" width="80" height="17" font="13">Cohorts: used </text>
<text top="71" left="255" width="53" height="17" font="13">pts in the </text>
<text top="88" left="255" width="49" height="17" font="13">CHARM </text>
<text top="106" left="255" width="49" height="17" font="13">program </text>
<text top="54" left="360" width="34" height="17" font="13">7,599 </text>
<text top="54" left="486" width="126" height="17" font="13">No EF criteria; out-pts; </text>
<text top="71" left="486" width="92" height="17" font="13">symptomatic HF </text>
<text top="54" left="649" width="165" height="17" font="13">K &gt;5.5; Cr &gt;265 umol/L; MI or </text>
<text top="71" left="649" width="110" height="17" font="13">stroke in prior 4 wk; </text>
<text top="88" left="649" width="151" height="17" font="13">noncardiac disease limiting </text>
<text top="106" left="649" width="45" height="17" font="13">survival </text>
<text top="54" left="828" width="50" height="17" font="13">Mortality </text>
<text top="54" left="920" width="69" height="17" font="13">CV death or </text>
<text top="71" left="920" width="81" height="17" font="13">hospitalization </text>
<text top="54" left="1031" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1150" width="62" height="17" font="13">ROC:0.75, </text>
<text top="71" left="1150" width="26" height="17" font="13">bias </text>
<text top="88" left="1150" width="58" height="17" font="13">corrected: </text>
<text top="106" left="1150" width="65" height="17" font="13">0.74; ROC: </text>
<text top="123" left="1150" width="62" height="17" font="13">0.73 in low </text>
<text top="140" left="1150" width="56" height="17" font="13">EF and in </text>
<text top="157" left="1150" width="58" height="17" font="13">preserved </text>
<text top="174" left="1150" width="63" height="17" font="13">EF cohorts </text>
<text top="54" left="1229" width="105" height="17" font="13">Population studied </text>
<text top="71" left="1229" width="116" height="17" font="13">not representative of </text>
<text top="88" left="1229" width="101" height="17" font="13">HF in general (pts </text>
<text top="106" left="1229" width="116" height="17" font="13">enrolled in CHARM); </text>
<text top="123" left="1229" width="120" height="17" font="13">validity - assessed by </text>
<text top="140" left="1229" width="81" height="17" font="13">bootstrapping; </text>
<text top="157" left="1229" width="106" height="17" font="13">laboratory data not </text>
<text top="174" left="1229" width="55" height="17" font="13">available. </text>
<text top="54" left="1367" width="70" height="17" font="13">23 variables </text>
<text top="71" left="1367" width="62" height="17" font="13">included in </text>
<text top="88" left="1367" width="37" height="17" font="13">model </text>
<text top="209" left="42" width="98" height="17" font="13">Risk Stratification </text>
<text top="226" left="42" width="74" height="17" font="13">for Inhospital </text>
<text top="243" left="42" width="63" height="17" font="13">Mortality in </text>
<text top="261" left="42" width="44" height="17" font="13">Acutely </text>
<text top="278" left="42" width="93" height="17" font="13">Decompensated </text>
<text top="295" left="42" width="99" height="17" font="13">HF: Classification </text>
<text top="312" left="42" width="90" height="17" font="13">and Regression </text>
<text top="329" left="42" width="85" height="17" font="13">Tree Analysis   </text>
<text top="347" left="42" width="92" height="17" font="13">Fonarow, Gregg </text>
<text top="364" left="42" width="70" height="17" font="13">JAMA 2005  </text>
<text top="381" left="42" width="58" height="17" font="14">15687312 </text>
<text top="381" left="100" width="25" height="17" font="13">(14) </text>
<text top="209" left="157" width="51" height="17" font="13">Estimate </text>
<text top="226" left="157" width="85" height="17" font="13">mortality risk in </text>
<text top="243" left="157" width="20" height="17" font="13">pts </text>
<text top="261" left="157" width="68" height="17" font="13">hospitalized </text>
<text top="278" left="157" width="45" height="17" font="13">with HF </text>
<text top="209" left="255" width="226" height="17" font="13">Cohort/registry Derivation:33,046 </text>
<text top="226" left="360" width="102" height="17" font="13">Validation: 32,229 </text>
<text top="209" left="486" width="131" height="17" font="13">Pts admitted with HF to </text>
<text top="226" left="486" width="149" height="17" font="13">hospital participating in the </text>
<text top="243" left="486" width="138" height="17" font="13">ADHERE registry; no EF </text>
<text top="261" left="486" width="47" height="17" font="13">criteria;  </text>
<text top="209" left="649" width="384" height="17" font="13">None In-hospital </text>
<text top="226" left="828" width="50" height="17" font="13">mortality </text>
<text top="209" left="920" width="27" height="17" font="13"> N/A </text>
<text top="209" left="1031" width="100" height="17" font="13">Classification and </text>
<text top="226" left="1031" width="85" height="17" font="13">regression tree </text>
<text top="243" left="1031" width="92" height="17" font="13">analysis;             </text>
<text top="261" left="1031" width="60" height="17" font="13">In-hospital </text>
<text top="278" left="1031" width="88" height="17" font="13">mortality: 4.1%; </text>
<text top="295" left="1031" width="76" height="17" font="13">95% CI:2.1%-</text>
<text top="312" left="1031" width="38" height="17" font="13">21.9% </text>
<text top="209" left="1150" width="27" height="17" font="13"> N/A </text>
<text top="209" left="1229" width="24" height="17" font="13">N/A </text>
<text top="209" left="1367" width="76" height="17" font="13">Classifies pts </text>
<text top="226" left="1367" width="56" height="17" font="13">into 5 risk </text>
<text top="243" left="1367" width="64" height="17" font="13">categories. </text>
<text top="261" left="1367" width="81" height="17" font="13">Discriminating </text>
<text top="278" left="1367" width="73" height="17" font="13">nodes: BUN; </text>
<text top="295" left="1367" width="48" height="17" font="13">SBP; Cr </text>
<text top="399" left="42" width="87" height="17" font="13">A validated risk </text>
<text top="416" left="42" width="61" height="17" font="13">score of in-</text>
<text top="433" left="42" width="96" height="17" font="13">hospital mortality </text>
<text top="451" left="42" width="78" height="17" font="13">in pts with HF </text>
<text top="468" left="42" width="77" height="17" font="13">from the AHA </text>
<text top="485" left="42" width="92" height="17" font="13">GWTG Program </text>
<text top="502" left="42" width="101" height="17" font="13">Peterson, Pamela </text>
<text top="519" left="42" width="88" height="17" font="13">CircCQO 2010  </text>
<text top="537" left="42" width="58" height="17" font="14">20123668 </text>
<text top="537" left="100" width="25" height="17" font="13">(15) </text>
<text top="399" left="157" width="81" height="17" font="13">Develop a risk </text>
<text top="416" left="157" width="51" height="17" font="13">score for </text>
<text top="433" left="157" width="55" height="17" font="13">inhospital </text>
<text top="451" left="157" width="53" height="17" font="13">mortality  </text>
<text top="399" left="255" width="229" height="17" font="13">Cohort/registry Derivation:27,850; </text>
<text top="399" left="463" width="24" height="17" font="13"> </text>
<text top="416" left="360" width="98" height="17" font="13">Validation:11,933 </text>
<text top="399" left="486" width="131" height="17" font="13">Pts admitted with HF to </text>
<text top="416" left="486" width="135" height="17" font="13">hospitals participating in </text>
<text top="433" left="486" width="132" height="17" font="13">the GWTG-HF program </text>
<text top="399" left="649" width="234" height="17" font="13">Transfers, missing LVEF data  Inhospital </text>
<text top="416" left="828" width="50" height="17" font="13">mortality </text>
<text top="399" left="920" width="7" height="17" font="13">  </text>
<text top="399" left="1031" width="106" height="17" font="13">Inhospital mortality </text>
<text top="416" left="1031" width="87" height="17" font="13">2.86%; C index </text>
<text top="433" left="1031" width="27" height="17" font="13">0.75 </text>
<text top="399" left="1150" width="27" height="17" font="13"> N/A </text>
<text top="399" left="1229" width="123" height="17" font="13">Validation cohort from </text>
<text top="416" left="1229" width="97" height="17" font="13">same population. </text>
<text top="433" left="1229" width="118" height="17" font="13">GWTG is a voluntary </text>
<text top="451" left="1229" width="44" height="17" font="13">registry </text>
<text top="399" left="1367" width="55" height="17" font="13">Variables </text>
<text top="416" left="1367" width="85" height="17" font="13">included in risk </text>
<text top="433" left="1367" width="72" height="17" font="13">score:  SBP, </text>
<text top="451" left="1367" width="81" height="17" font="13">BUN, Sodium, </text>
<text top="468" left="1367" width="87" height="17" font="13">age, heart rate, </text>
<text top="485" left="1367" width="70" height="17" font="13">race, COPD </text>
<text top="555" left="42" width="72" height="17" font="13">Predictors of </text>
<text top="572" left="42" width="55" height="17" font="13">inhospital </text>
<text top="589" left="42" width="83" height="17" font="13">mortality in pts </text>
<text top="606" left="42" width="86" height="17" font="13">hospitalized for </text>
<text top="623" left="42" width="97" height="17" font="13">HF. Insights from </text>
<text top="641" left="42" width="82" height="17" font="13">OPTIMIZE-HF </text>
<text top="658" left="42" width="103" height="17" font="13">Abraham, William  </text>
<text top="675" left="42" width="70" height="17" font="13">JACC 2008  </text>
<text top="692" left="42" width="58" height="17" font="14">18652942 </text>
<text top="692" left="100" width="25" height="17" font="13">(16) </text>
<text top="555" left="157" width="59" height="17" font="13">Develop a </text>
<text top="572" left="157" width="40" height="17" font="13">clinical </text>
<text top="589" left="157" width="56" height="17" font="13">predictive </text>
<text top="606" left="157" width="64" height="17" font="13">model of in-</text>
<text top="623" left="157" width="46" height="17" font="13">hospital </text>
<text top="641" left="157" width="50" height="17" font="13">mortality </text>
<text top="555" left="255" width="84" height="17" font="13">Cohort/registry </text>
<text top="555" left="360" width="41" height="17" font="13">40,201 </text>
<text top="555" left="486" width="131" height="17" font="13">Pts admitted to hospital </text>
<text top="572" left="486" width="145" height="17" font="13">participating in OPTIMIZE-</text>
<text top="589" left="486" width="140" height="17" font="13">HF (registry/performance </text>
<text top="606" left="486" width="148" height="17" font="13">improvement program); no </text>
<text top="623" left="486" width="140" height="17" font="13">EF criteria (LVSD in 49% </text>
<text top="641" left="486" width="131" height="17" font="13">of those with measured </text>
<text top="658" left="486" width="109" height="17" font="13">EF); included those </text>
<text top="675" left="486" width="124" height="17" font="13">admitted with different </text>
<text top="692" left="486" width="103" height="17" font="13">diagnosis than the </text>
<text top="710" left="486" width="146" height="17" font="13">discharge diagnosis of HF </text>
<text top="555" left="649" width="27" height="17" font="13"> N/A </text>
<text top="555" left="828" width="56" height="17" font="13">Inhospital </text>
<text top="572" left="828" width="50" height="17" font="13">mortality </text>
<text top="555" left="920" width="7" height="17" font="13">  </text>
<text top="555" left="1031" width="56" height="17" font="13">Inhospital </text>
<text top="572" left="1031" width="101" height="17" font="13">mortality: 3.8%; C </text>
<text top="589" left="1031" width="60" height="17" font="13">index 0.77 </text>
<text top="555" left="1150" width="27" height="17" font="13"> N/A </text>
<text top="555" left="1229" width="122" height="17" font="13">Validity - assessed by </text>
<text top="572" left="1229" width="78" height="17" font="13">bootstrapping </text>
<text top="555" left="1367" width="84" height="17" font="13">Risk prediction </text>
<text top="572" left="1367" width="93" height="17" font="13">nomogram: age, </text>
<text top="589" left="1367" width="56" height="17" font="13">HR, SBP, </text>
<text top="606" left="1367" width="66" height="17" font="13">sodium, Cr, </text>
<text top="623" left="1367" width="81" height="17" font="13">primary cause </text>
<text top="641" left="1367" width="94" height="17" font="13">for admit, LVSD  </text>
<text top="735" left="42" width="99" height="17" font="13">Predictors of fatal </text>
<text top="753" left="42" width="75" height="17" font="13">and non-fatal </text>
<text top="770" left="42" width="90" height="17" font="13">outcomes in the </text>
<text top="787" left="42" width="61" height="17" font="13">CORONA: </text>
<text top="735" left="157" width="49" height="17" font="13">Develop </text>
<text top="753" left="157" width="60" height="17" font="13">prognostic </text>
<text top="770" left="157" width="56" height="17" font="13">models in </text>
<text top="787" left="157" width="83" height="17" font="13">elderly pts and </text>
<text top="735" left="255" width="44" height="17" font="13">Cohort  </text>
<text top="735" left="360" width="34" height="17" font="13">3,342 </text>
<text top="735" left="486" width="102" height="17" font="13">Pts enrolled in the </text>
<text top="753" left="486" width="144" height="17" font="13">CORONA study.  Pts ≥60 </text>
<text top="770" left="486" width="131" height="17" font="13">y; NYHA class II-IV HF; </text>
<text top="787" left="486" width="116" height="17" font="13">investigator reported </text>
<text top="735" left="649" width="111" height="17" font="13">Recent CV event or </text>
<text top="753" left="649" width="165" height="17" font="13">procedure/operation, acute or </text>
<text top="770" left="649" width="155" height="17" font="13">chronic liver disease or ALT </text>
<text top="787" left="649" width="153" height="17" font="13">&gt;2x ULN; BUN &gt;2.5 mg/dL; </text>
<text top="735" left="828" width="66" height="17" font="13">Composite: </text>
<text top="753" left="828" width="74" height="17" font="13">CV mortality, </text>
<text top="770" left="828" width="79" height="17" font="13">nonfatal MI or </text>
<text top="787" left="828" width="47" height="17" font="13">nonfatal </text>
<text top="735" left="920" width="54" height="17" font="13">All-cause </text>
<text top="753" left="920" width="74" height="17" font="13">mortality; CV </text>
<text top="770" left="920" width="94" height="17" font="13">mortality; fatal or </text>
<text top="787" left="920" width="68" height="17" font="13">nonfatal MI; </text>
<text top="735" left="1031" width="96" height="17" font="13">Total mortality: C </text>
<text top="753" left="1031" width="84" height="17" font="13">index of 0.719; </text>
<text top="770" left="1031" width="95" height="17" font="13">death due to HF: </text>
<text top="787" left="1031" width="90" height="17" font="13">C index of 0.80; </text>
<text top="735" left="1150" width="27" height="17" font="13"> N/A </text>
<text top="735" left="1229" width="106" height="17" font="13">Used a clinical trial </text>
<text top="753" left="1229" width="116" height="17" font="13">population; limited to </text>
<text top="770" left="1229" width="97" height="17" font="13">ischemic etiology </text>
<text top="735" left="1367" width="78" height="17" font="13">Elderly pts on </text>
<text top="753" left="1367" width="79" height="17" font="13">contemporary </text>
<text top="770" left="1367" width="88" height="17" font="13">HF therapy; NT-</text>
<text top="787" left="1367" width="84" height="17" font="13">proBNP added </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="15" size="13" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">7</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="42" width="100" height="17" font="13">incremental value </text>
<text top="71" left="42" width="94" height="17" font="13">of apolipoprotein </text>
<text top="88" left="42" width="53" height="17" font="13">A-1, high-</text>
<text top="106" left="42" width="70" height="17" font="13">sensitivity C-</text>
<text top="123" left="42" width="90" height="17" font="13">reactive peptide </text>
<text top="140" left="42" width="107" height="17" font="13">and NT proBNP      </text>
<text top="157" left="42" width="77" height="17" font="13">Wedel, Hans  </text>
<text top="174" left="42" width="68" height="17" font="13">EJHF 2009  </text>
<text top="192" left="42" width="58" height="17" font="14">19168876 </text>
<text top="192" left="100" width="25" height="17" font="13">(17) </text>
<text top="54" left="157" width="70" height="17" font="13">evaluate the </text>
<text top="71" left="157" width="43" height="17" font="13">relative </text>
<text top="88" left="157" width="60" height="17" font="13">prognostic </text>
<text top="106" left="157" width="81" height="17" font="13">significance of </text>
<text top="123" left="157" width="26" height="17" font="13">new </text>
<text top="140" left="157" width="64" height="17" font="13">biomarkers </text>
<text top="54" left="486" width="120" height="17" font="13">ischemic etiology; EF </text>
<text top="71" left="486" width="144" height="17" font="13">≤40% (or 35% if NYHA II) </text>
<text top="54" left="649" width="146" height="17" font="13">chronic muscle disease or </text>
<text top="71" left="649" width="158" height="17" font="13">unexplained CK &gt;2.5x ULNl; </text>
<text top="88" left="649" width="159" height="17" font="13">TSH &gt;2x ULN; any condition </text>
<text top="106" left="649" width="141" height="17" font="13">substantially reducing life </text>
<text top="123" left="649" width="66" height="17" font="13">expectancy </text>
<text top="54" left="828" width="68" height="17" font="13">stroke (time </text>
<text top="71" left="828" width="51" height="17" font="13">to event) </text>
<text top="54" left="920" width="85" height="17" font="13">death from any </text>
<text top="71" left="920" width="51" height="17" font="13">cause or </text>
<text top="88" left="920" width="81" height="17" font="13">hospitalization </text>
<text top="106" left="920" width="38" height="17" font="13">for HF </text>
<text top="54" left="1031" width="102" height="17" font="13">all-cause mortality </text>
<text top="71" left="1031" width="34" height="17" font="13">or HF </text>
<text top="88" left="1031" width="97" height="17" font="13">hospitalization: C </text>
<text top="106" left="1031" width="100" height="17" font="13">index of 0.701 (all </text>
<text top="123" left="1031" width="92" height="17" font="13">models included </text>
<text top="140" left="1031" width="71" height="17" font="13">NT-proBNP) </text>
<text top="54" left="1367" width="56" height="17" font="13">predictive </text>
<text top="71" left="1367" width="64" height="17" font="13">information </text>
<text top="210" left="42" width="83" height="17" font="13">Comparison of </text>
<text top="227" left="42" width="72" height="17" font="13">Four Clinical </text>
<text top="244" left="42" width="93" height="17" font="13">Prediction Rules </text>
<text top="261" left="42" width="79" height="17" font="13">for Estimating </text>
<text top="278" left="42" width="108" height="17" font="13">Risk in HF               </text>
<text top="296" left="42" width="108" height="17" font="13">Auble, Thomas E    </text>
<text top="313" left="42" width="55" height="17" font="13">Annals of </text>
<text top="330" left="42" width="66" height="17" font="13">Emergency </text>
<text top="347" left="42" width="87" height="17" font="13">Medicine 2007  </text>
<text top="365" left="42" width="58" height="17" font="14">17449141 </text>
<text top="365" left="100" width="25" height="17" font="13">(18) </text>
<text top="210" left="157" width="72" height="17" font="13">Examine the </text>
<text top="227" left="157" width="73" height="17" font="13">performance </text>
<text top="244" left="157" width="64" height="17" font="13">of 4 clinical </text>
<text top="261" left="157" width="57" height="17" font="13">prediction </text>
<text top="278" left="157" width="30" height="17" font="13">rules </text>
<text top="296" left="157" width="59" height="17" font="13">(ADHERE </text>
<text top="313" left="157" width="76" height="17" font="13">decision tree, </text>
<text top="330" left="157" width="55" height="17" font="13">ADHERE </text>
<text top="347" left="157" width="61" height="17" font="13">regression </text>
<text top="365" left="157" width="40" height="17" font="13">model, </text>
<text top="382" left="157" width="55" height="17" font="13">EFFECT, </text>
<text top="399" left="157" width="73" height="17" font="13">Brigham and </text>
<text top="416" left="157" width="54" height="17" font="13">Women's </text>
<text top="433" left="157" width="79" height="17" font="13">Hospital rule)  </text>
<text top="451" left="157" width="68" height="17" font="13">for inpatient </text>
<text top="468" left="157" width="66" height="17" font="13">death, 30-d </text>
<text top="485" left="157" width="62" height="17" font="13">death, and </text>
<text top="502" left="157" width="55" height="17" font="13">inhospital </text>
<text top="519" left="157" width="49" height="17" font="13">death or </text>
<text top="537" left="157" width="43" height="17" font="13">serious </text>
<text top="554" left="157" width="81" height="17" font="13">complications  </text>
<text top="210" left="255" width="40" height="17" font="13">Cohort </text>
<text top="210" left="360" width="41" height="17" font="13">33,533 </text>
<text top="210" left="486" width="126" height="17" font="13">Pts with primary ICD-9 </text>
<text top="227" left="486" width="146" height="17" font="13">discharge diagnosis of HF </text>
<text top="244" left="486" width="112" height="17" font="13">admitted at one of 2 </text>
<text top="261" left="486" width="128" height="17" font="13">Pennsylvania hospitals </text>
<text top="278" left="486" width="69" height="17" font="13">from the ED </text>
<text top="210" left="649" width="27" height="17" font="13"> N/A </text>
<text top="210" left="828" width="56" height="17" font="13">Inhospital </text>
<text top="227" left="828" width="67" height="17" font="13">mortality; in-</text>
<text top="244" left="828" width="46" height="17" font="13">hospital </text>
<text top="261" left="828" width="64" height="17" font="13">mortality or </text>
<text top="278" left="828" width="43" height="17" font="13">serious </text>
<text top="296" left="828" width="75" height="17" font="13">complication; </text>
<text top="313" left="828" width="78" height="17" font="13">30-d mortality </text>
<text top="210" left="920" width="27" height="17" font="13"> N/A </text>
<text top="210" left="1031" width="56" height="17" font="13">Inhospital </text>
<text top="227" left="1031" width="88" height="17" font="13">mortality: 4.5%; </text>
<text top="244" left="1031" width="106" height="17" font="13">Inhospital mortality </text>
<text top="261" left="1031" width="103" height="17" font="13">or serious medical </text>
<text top="278" left="1031" width="75" height="17" font="13">complication: </text>
<text top="296" left="1031" width="70" height="17" font="13">11.2%; 30-d </text>
<text top="313" left="1031" width="85" height="17" font="13">mortality: 7.9% </text>
<text top="330" left="1031" width="85" height="17" font="13">ADHERE rules </text>
<text top="347" left="1031" width="101" height="17" font="13">could not be used </text>
<text top="365" left="1031" width="94" height="17" font="13">in 4.1% because </text>
<text top="382" left="1031" width="98" height="17" font="13">BUN or SCr were </text>
<text top="399" left="1031" width="31" height="17" font="13">N/A.  </text>
<text top="210" left="1150" width="27" height="17" font="13"> N/A </text>
<text top="210" left="1229" width="27" height="17" font="13"> N/A </text>
<text top="210" left="1367" width="57" height="17" font="13">Variability </text>
<text top="227" left="1367" width="84" height="17" font="13">among rules in </text>
<text top="244" left="1367" width="79" height="17" font="13">the number of </text>
<text top="261" left="1367" width="86" height="17" font="13">pts assigned to </text>
<text top="278" left="1367" width="87" height="17" font="13">risk groups and </text>
<text top="296" left="1367" width="75" height="17" font="13">the observed </text>
<text top="313" left="1367" width="85" height="17" font="13">mortality within </text>
<text top="330" left="1367" width="64" height="17" font="13">risk group.  </text>
<text top="347" left="1367" width="51" height="17" font="13">EFFECT </text>
<text top="365" left="1367" width="86" height="17" font="13">identified pts at </text>
<text top="382" left="1367" width="85" height="17" font="13">the lowest risk, </text>
<text top="399" left="1367" width="79" height="17" font="13">ADHERE tree </text>
<text top="416" left="1367" width="93" height="17" font="13">identified largest </text>
<text top="433" left="1367" width="92" height="17" font="13">proportion of pts </text>
<text top="451" left="1367" width="94" height="17" font="13">in the lowest risk </text>
<text top="468" left="1367" width="35" height="17" font="13">group </text>
<text top="572" left="54" width="1390" height="17" font="13">ADHERE indicates Acute Decompensated Heart Failure National Registry; AHA, American Heart Association; BUN, blod urea nitrogen; CHARM, Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity; COPD, chronic obstructive </text>
<text top="589" left="54" width="1405" height="17" font="13">pulmonary disease; CORONA, Controlled Rosuvastatin Multinational Trial in HF; CV, cardiovascular; CVD, cardiovascular disease; ED, emergency department; EF, ejection fraction; EFFECT, Enhanced Feedback for Effective Cardiac Treatment; GWTG, Get </text>
<text top="606" left="54" width="1388" height="17" font="13">With the Guidelines; HF, heart failure; Hgb, hemoglobin; HR, heart rate; ICD-9, international classification of diseases; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; Na, sodium,  N/A, not applicable; NT-proBNP; n-terminal pro-B-type </text>
<text top="624" left="54" width="1390" height="17" font="13">natriuretic peptide; NYHA, New York Heart Association; OPIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; pts, patients; RAD, reactive airway disease; ROC, receiver operating characteristic curve; </text>
<text top="641" left="54" width="632" height="18" font="13">SBP, systolic blood pressure; SCr, serum creatinine; TSH, thyroid stimulating hormone; ULN, upper limit of normal.  </text>
<text top="676" left="54" width="4" height="16" font="7"> </text>
<text top="711" left="54" width="614" height="21" font="8"><b>Data Supplement 4. Health-Related Quality of Life and Functional Capacity (Section 4.4)</b></text>
<text top="714" left="668" width="3" height="17" font="15"><b> </b></text>
<text top="733" left="57" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="752" left="57" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="742" left="171" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="742" left="281" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="733" left="376" width="41" height="19" font="9"><b>Study </b></text>
<text top="752" left="381" width="31" height="19" font="9"><b>Size </b></text>
<text top="742" left="487" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="742" left="740" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="742" left="910" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="742" left="1155" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="742" left="1315" width="134" height="19" font="9"><b>Findings/Comments </b></text>
<text top="783" left="98" width="4" height="19" font="7"> </text>
<text top="783" left="213" width="4" height="19" font="7"> </text>
<text top="783" left="317" width="4" height="19" font="7"> </text>
<text top="783" left="395" width="4" height="19" font="7"> </text>
<text top="773" left="456" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="773" left="576" width="68" height="19" font="10"><i><b>Exclusion </b></i></text>
<text top="773" left="697" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="773" left="792" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="783" left="1002" width="4" height="19" font="7"> </text>
<text top="783" left="1212" width="4" height="19" font="7"> </text>
<text top="783" left="1380" width="4" height="19" font="7"> </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">8</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="462" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="55" left="584" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="55" left="693" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="55" left="798" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="78" left="49" width="88" height="17" font="13">Improvement in </text>
<text top="95" left="49" width="73" height="17" font="13">HRQoL after </text>
<text top="112" left="49" width="81" height="17" font="13">hospitalization </text>
<text top="130" left="49" width="81" height="17" font="13">predicts event-</text>
<text top="147" left="49" width="83" height="17" font="13">free survival in </text>
<text top="164" left="49" width="102" height="17" font="13">pts with advanced </text>
<text top="181" left="49" width="88" height="17" font="13">HF. Moser et al </text>
<text top="198" left="49" width="31" height="17" font="13">2009 </text>
<text top="216" left="49" width="58" height="17" font="14">19879462 </text>
<text top="216" left="107" width="25" height="17" font="13">(19) </text>
<text top="233" left="49" width="3" height="17" font="13"> </text>
<text top="78" left="163" width="96" height="17" font="13">To determine the </text>
<text top="95" left="163" width="61" height="17" font="13">frequency, </text>
<text top="112" left="163" width="80" height="17" font="13">durability, and </text>
<text top="130" left="163" width="60" height="17" font="13">prognostic </text>
<text top="147" left="163" width="81" height="17" font="13">significance of </text>
<text top="164" left="163" width="54" height="17" font="13">improved </text>
<text top="181" left="163" width="73" height="17" font="13">HRQoL after </text>
<text top="198" left="163" width="99" height="17" font="13">hospitalization for </text>
<text top="216" left="163" width="91" height="17" font="13">decompensated </text>
<text top="233" left="163" width="23" height="17" font="13">HF. </text>
<text top="78" left="278" width="62" height="17" font="13">Secondary </text>
<text top="95" left="278" width="61" height="17" font="13">analysis of </text>
<text top="112" left="278" width="76" height="17" font="13">data from the </text>
<text top="130" left="278" width="77" height="17" font="13">ESCAPE trial </text>
<text top="147" left="278" width="3" height="17" font="13"> </text>
<text top="182" left="278" width="3" height="17" font="13"> </text>
<text top="216" left="278" width="3" height="17" font="13"> </text>
<text top="251" left="278" width="3" height="17" font="13"> </text>
<text top="286" left="278" width="3" height="17" font="13"> </text>
<text top="321" left="278" width="3" height="17" font="13"> </text>
<text top="355" left="278" width="3" height="17" font="13"> </text>
<text top="78" left="373" width="168" height="17" font="13">425 Hospitalized </text>
<text top="78" left="504" width="55" height="17" font="13">for </text>
<text top="95" left="433" width="101" height="17" font="13">NYHA class IV, at </text>
<text top="112" left="433" width="105" height="17" font="13">least 1 sign of fluid </text>
<text top="130" left="433" width="51" height="17" font="13">overload </text>
<text top="147" left="433" width="54" height="17" font="13">EF &lt;30% </text>
<text top="164" left="433" width="101" height="17" font="13">history of prior HF </text>
<text top="181" left="433" width="96" height="17" font="13">hospitalization or </text>
<text top="198" left="433" width="70" height="17" font="13">chronic high </text>
<text top="216" left="433" width="74" height="17" font="13">maintenance </text>
<text top="233" left="433" width="79" height="17" font="13">diuretic doses </text>
<text top="250" left="433" width="63" height="17" font="13">survived to </text>
<text top="267" left="433" width="85" height="17" font="13">discharge from </text>
<text top="285" left="433" width="92" height="17" font="13">index admission </text>
<text top="78" left="555" width="60" height="17" font="13">Significant </text>
<text top="95" left="555" width="107" height="17" font="13">comorbid condition </text>
<text top="112" left="555" width="101" height="17" font="13">that could shorten </text>
<text top="130" left="555" width="98" height="17" font="13">life (e.g. cancer),  </text>
<text top="147" left="555" width="96" height="17" font="13">pulmonary artery </text>
<text top="164" left="555" width="51" height="17" font="13">catheter, </text>
<text top="181" left="555" width="66" height="17" font="13">mechanical </text>
<text top="198" left="555" width="74" height="17" font="13">circulatory or </text>
<text top="216" left="555" width="107" height="17" font="13">ventilatory support, </text>
<text top="233" left="555" width="103" height="17" font="13">IV milrinone within </text>
<text top="250" left="555" width="102" height="17" font="13">48 h, dobutamine/ </text>
<text top="267" left="555" width="92" height="17" font="13">dopamine within </text>
<text top="285" left="555" width="109" height="17" font="13">24 h, listed for CTX </text>
<text top="78" left="676" width="45" height="17" font="13">HRQoL </text>
<text top="95" left="676" width="83" height="17" font="13">measured with </text>
<text top="112" left="676" width="70" height="17" font="13">the MLHFQ  </text>
<text top="78" left="784" width="60" height="17" font="13">Event-free </text>
<text top="95" left="784" width="45" height="17" font="13">survival </text>
<text top="78" left="886" width="234" height="17" font="13">At baseline HRQoL was severely impaired </text>
<text top="95" left="886" width="227" height="17" font="13">but improved on average at 1 mo (74.2 ± </text>
<text top="112" left="886" width="235" height="17" font="13">17.4 vs 56.7 ± 22.7) and improved most at </text>
<text top="130" left="886" width="234" height="17" font="13">6 mo. HRQOL worsened in 51 (16.3%) pts </text>
<text top="147" left="886" width="219" height="17" font="13">and remained the same in 49 (15.7%).   </text>
<text top="164" left="886" width="91" height="17" font="13">OR: 3.3; p&lt;.009 </text>
<text top="181" left="886" width="225" height="17" font="13">The only characteristic that distinguished </text>
<text top="198" left="886" width="223" height="17" font="13">among these groups was whether or not </text>
<text top="216" left="886" width="206" height="17" font="13">the pt was too ill to perform the 6-min </text>
<text top="233" left="886" width="180" height="17" font="13">walk. There was a group by time </text>
<text top="250" left="886" width="214" height="17" font="13">interaction; the degree of improvement </text>
<text top="267" left="886" width="206" height="17" font="13">across time differed between pts who </text>
<text top="285" left="886" width="226" height="17" font="13">survived without an event and those who </text>
<text top="302" left="886" width="222" height="17" font="13">died or were rehospitalized by 6 mo. Pts </text>
<text top="319" left="886" width="220" height="17" font="13">with events between 1 and 6 mo did not </text>
<text top="336" left="886" width="201" height="17" font="13">experience as much improvement in </text>
<text top="353" left="886" width="204" height="17" font="13">HRQoL. A decrease in MLHFQ of &gt;5 </text>
<text top="371" left="886" width="232" height="17" font="13">points predicted better event-free survival. </text>
<text top="388" left="886" width="181" height="17" font="13">(p&lt;.0001 group time interaction)  </text>
<text top="78" left="1135" width="145" height="17" font="13">Potential for survivor bias. </text>
<text top="95" left="1135" width="122" height="17" font="13">Self-reported HRQoL. </text>
<text top="112" left="1135" width="140" height="17" font="13">Relatively short follow-up </text>
<text top="130" left="1135" width="85" height="17" font="13">period of 6 mo. </text>
<text top="78" left="1304" width="127" height="17" font="13">In pts hospitalized with </text>
<text top="95" left="1304" width="60" height="17" font="13">severe HF </text>
<text top="112" left="1304" width="154" height="17" font="13">decompensation, HRQoL is </text>
<text top="130" left="1304" width="123" height="17" font="13">seriously impaired but </text>
<text top="147" left="1304" width="124" height="17" font="13">improves substantially </text>
<text top="164" left="1304" width="133" height="17" font="13">within 1 mo for most pts </text>
<text top="181" left="1304" width="153" height="17" font="13">and remains improved for 6 </text>
<text top="198" left="1304" width="144" height="17" font="13">mo. Pts for whom HRQoL </text>
<text top="216" left="1304" width="145" height="17" font="13">does not improve by 1 mo </text>
<text top="233" left="1304" width="133" height="17" font="13">after hospital admission </text>
<text top="250" left="1304" width="153" height="17" font="13">merit specific attention both </text>
<text top="267" left="1304" width="143" height="17" font="13">to improve HRQoL and to </text>
<text top="285" left="1304" width="142" height="17" font="13">address high risk for poor </text>
<text top="302" left="1304" width="104" height="17" font="13">event-free survival </text>
<text top="412" left="49" width="51" height="17" font="13">QoL and </text>
<text top="429" left="49" width="63" height="17" font="13">depressive </text>
<text top="447" left="49" width="93" height="17" font="13">symptoms in the </text>
<text top="464" left="49" width="53" height="17" font="13">elderly: a </text>
<text top="481" left="49" width="67" height="17" font="13">comparison </text>
<text top="498" left="49" width="95" height="17" font="13">between pts with </text>
<text top="515" left="49" width="92" height="17" font="13">HF and age and </text>
<text top="533" left="49" width="92" height="17" font="13">gender matched </text>
<text top="550" left="49" width="63" height="17" font="13">community </text>
<text top="567" left="49" width="98" height="17" font="13">controls. Lesman-</text>
<text top="584" left="49" width="71" height="17" font="13">Leegte et al, </text>
<text top="601" left="49" width="34" height="17" font="13">2009. </text>
<text top="619" left="49" width="58" height="17" font="14">19181289 </text>
<text top="619" left="107" width="25" height="17" font="13">(20) </text>
<text top="412" left="163" width="68" height="17" font="13">To examine </text>
<text top="429" left="163" width="100" height="17" font="13">whether there are </text>
<text top="447" left="163" width="77" height="17" font="13">differences in </text>
<text top="464" left="163" width="51" height="17" font="13">QoL and </text>
<text top="481" left="163" width="63" height="17" font="13">depressive </text>
<text top="498" left="163" width="60" height="17" font="13">symptoms </text>
<text top="515" left="163" width="90" height="17" font="13">between HF pts </text>
<text top="533" left="163" width="89" height="17" font="13">and an age and </text>
<text top="550" left="163" width="92" height="17" font="13">gender matched </text>
<text top="567" left="163" width="49" height="17" font="13">group of </text>
<text top="584" left="163" width="63" height="17" font="13">community-</text>
<text top="601" left="163" width="87" height="17" font="13">dwelling elderly </text>
<text top="619" left="163" width="82" height="17" font="13">and determine </text>
<text top="636" left="163" width="69" height="17" font="13">how chronic </text>
<text top="653" left="163" width="54" height="17" font="13">comorbid </text>
<text top="670" left="163" width="98" height="17" font="13">conditions qualify </text>
<text top="687" left="163" width="64" height="17" font="13">the answer </text>
<text top="412" left="278" width="62" height="17" font="13">Secondary </text>
<text top="429" left="278" width="61" height="17" font="13">analysis of </text>
<text top="447" left="278" width="71" height="17" font="13">COACH trial </text>
<text top="464" left="278" width="53" height="17" font="13">data plus </text>
<text top="481" left="278" width="75" height="17" font="13">enrollment of </text>
<text top="498" left="278" width="73" height="17" font="13">a community </text>
<text top="515" left="278" width="71" height="17" font="13">sample from </text>
<text top="533" left="278" width="70" height="17" font="13">Netherlands </text>
<text top="412" left="373" width="135" height="17" font="13">781 NYHA </text>
<text top="412" left="471" width="66" height="17" font="13">II-IV, </text>
<text top="412" left="500" width="38" height="17" font="13">≥18 y, </text>
<text top="429" left="433" width="85" height="17" font="13">structural heart </text>
<text top="447" left="433" width="53" height="17" font="13">disease.  </text>
<text top="464" left="433" width="3" height="17" font="13"> </text>
<text top="481" left="433" width="109" height="17" font="13">Community sample </text>
<text top="498" left="433" width="103" height="17" font="13">randomly selected </text>
<text top="515" left="433" width="88" height="17" font="13">from population </text>
<text top="533" left="433" width="79" height="17" font="13">≥55 y and not </text>
<text top="550" left="433" width="79" height="17" font="13">living at same </text>
<text top="567" left="433" width="79" height="17" font="13">address. 45% </text>
<text top="584" left="433" width="82" height="17" font="13">response rate. </text>
<text top="412" left="555" width="85" height="17" font="13">Enrollment in a </text>
<text top="429" left="555" width="84" height="17" font="13">study requiring </text>
<text top="447" left="555" width="107" height="17" font="13">additional research </text>
<text top="464" left="555" width="93" height="17" font="13">visits or invasive </text>
<text top="481" left="555" width="102" height="17" font="13">intervention within </text>
<text top="498" left="555" width="105" height="17" font="13">last 6 mo or next 3 </text>
<text top="515" left="555" width="71" height="17" font="13">mo, terminal </text>
<text top="533" left="555" width="85" height="17" font="13">disease, active </text>
<text top="550" left="555" width="61" height="17" font="13">psychiatric </text>
<text top="567" left="555" width="59" height="17" font="13">diagnosis. </text>
<text top="412" left="676" width="85" height="17" font="13">QoL measured </text>
<text top="429" left="676" width="71" height="17" font="13">with Medical </text>
<text top="447" left="676" width="88" height="17" font="13">Outcome Study </text>
<text top="464" left="676" width="92" height="17" font="13">36-item General </text>
<text top="481" left="676" width="81" height="17" font="13">Health Survey </text>
<text top="498" left="676" width="63" height="17" font="13">and Cantril </text>
<text top="515" left="676" width="82" height="17" font="13">Ladder of Life. </text>
<text top="533" left="676" width="65" height="17" font="13">Depressive </text>
<text top="550" left="676" width="85" height="17" font="13">symptoms with </text>
<text top="567" left="676" width="48" height="17" font="13">CES-D.  </text>
<text top="412" left="784" width="46" height="17" font="13">Chronic </text>
<text top="429" left="784" width="59" height="17" font="13">conditions </text>
<text top="447" left="784" width="61" height="17" font="13">abstracted </text>
<text top="464" left="784" width="73" height="17" font="13">from chart of </text>
<text top="481" left="784" width="46" height="17" font="13">pts, self-</text>
<text top="498" left="784" width="66" height="17" font="13">reported by </text>
<text top="515" left="784" width="63" height="17" font="13">community </text>
<text top="533" left="784" width="47" height="17" font="13">sample. </text>
<text top="412" left="886" width="197" height="17" font="13">QoL significantly impaired in HF pts </text>
<text top="429" left="886" width="210" height="17" font="13">compared to matched elderly. Largest </text>
<text top="447" left="886" width="217" height="17" font="13">differences were in physical functioning </text>
<text top="464" left="886" width="189" height="17" font="13">and vitality. Role limitations due to </text>
<text top="481" left="886" width="215" height="17" font="13">physical functioning very low in HF pts. </text>
<text top="498" left="886" width="216" height="17" font="13">QoL was lower in HF pts with COPD or </text>
<text top="515" left="886" width="53" height="17" font="13">diabetes. </text>
<text top="533" left="886" width="215" height="17" font="13">Depressive symptoms higher in HF pts </text>
<text top="550" left="886" width="147" height="17" font="13">(39% vs 21%) all p&lt;0.001. </text>
<text top="567" left="886" width="3" height="17" font="13"> </text>
<text top="584" left="886" width="3" height="17" font="13"> </text>
<text top="601" left="886" width="3" height="17" font="13"> </text>
<text top="619" left="886" width="3" height="17" font="13"> </text>
<text top="412" left="1135" width="147" height="17" font="13">Manner in which comorbid </text>
<text top="429" left="1135" width="144" height="17" font="13">conditions were assessed </text>
<text top="447" left="1135" width="134" height="17" font="13">differed between HF pts </text>
<text top="464" left="1135" width="152" height="17" font="13">and controls. List used was </text>
<text top="481" left="1135" width="90" height="17" font="13">not all inclusive. </text>
<text top="412" left="1304" width="141" height="17" font="13">HF has a large impact on </text>
<text top="429" left="1304" width="113" height="17" font="13">QoL and depressive </text>
<text top="447" left="1304" width="133" height="17" font="13">symptoms, especially in </text>
<text top="464" left="1304" width="92" height="17" font="13">women with HF. </text>
<text top="481" left="1304" width="152" height="17" font="13">Differences persist, even in </text>
<text top="498" left="1304" width="135" height="17" font="13">the absence of common </text>
<text top="515" left="1304" width="124" height="17" font="13">comorbidities. Results </text>
<text top="533" left="1304" width="141" height="17" font="13">demonstrate the need for </text>
<text top="550" left="1304" width="137" height="17" font="13">studies of representative </text>
<text top="567" left="1304" width="98" height="17" font="13">HF pts with direct </text>
<text top="584" left="1304" width="139" height="17" font="13">comparisons to age- and </text>
<text top="601" left="1304" width="143" height="17" font="13">gender-matched controls. </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="7" height="14" font="6">9</text>
<text top="810" left="817" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="38" height="17" font="13">Ethnic </text>
<text top="72" left="49" width="79" height="17" font="13">Differences in </text>
<text top="89" left="49" width="88" height="17" font="13">QoL in Persons </text>
<text top="106" left="49" width="55" height="17" font="13">With HF.  </text>
<text top="124" left="49" width="96" height="17" font="13">Riegel et al 2008 </text>
<text top="141" left="49" width="58" height="17" font="14">18226772 </text>
<text top="141" left="107" width="25" height="17" font="13">(21) </text>
<text top="55" left="163" width="69" height="17" font="13">To compare </text>
<text top="72" left="163" width="82" height="17" font="13">HRQoL in non-</text>
<text top="89" left="163" width="86" height="17" font="13">Hispanic white, </text>
<text top="106" left="163" width="59" height="17" font="13">black, and </text>
<text top="124" left="163" width="87" height="17" font="13">Hispanic adults </text>
<text top="141" left="163" width="45" height="17" font="13">with HF </text>
<text top="55" left="278" width="70" height="17" font="13">Longitudinal </text>
<text top="72" left="278" width="70" height="17" font="13">comparative </text>
<text top="89" left="278" width="58" height="17" font="13">study with </text>
<text top="106" left="278" width="60" height="17" font="13">propensity </text>
<text top="124" left="278" width="43" height="17" font="13">scoring </text>
<text top="55" left="373" width="154" height="17" font="13">1,212 Established </text>
<text top="72" left="433" width="69" height="17" font="13">diagnosis of </text>
<text top="89" left="433" width="66" height="17" font="13">chronic HF  </text>
<text top="55" left="555" width="95" height="17" font="13">Recent MI, USA, </text>
<text top="72" left="555" width="52" height="17" font="13">cognitive </text>
<text top="89" left="555" width="108" height="17" font="13">impairment, severe </text>
<text top="106" left="555" width="61" height="17" font="13">psychiatric </text>
<text top="124" left="555" width="57" height="17" font="13">problems, </text>
<text top="141" left="555" width="74" height="17" font="13">homeless, or </text>
<text top="158" left="555" width="94" height="17" font="13">discharged to an </text>
<text top="175" left="555" width="96" height="17" font="13">extended care or </text>
<text top="192" left="555" width="81" height="17" font="13">skilled nursing </text>
<text top="210" left="555" width="38" height="17" font="13">facility </text>
<text top="55" left="676" width="45" height="17" font="13">HRQoL </text>
<text top="72" left="676" width="83" height="17" font="13">measured with </text>
<text top="89" left="676" width="67" height="17" font="13">the MLHFQ </text>
<text top="55" left="784" width="27" height="17" font="13"> N/A </text>
<text top="55" left="886" width="234" height="17" font="13">HRQoL improved over time (baseline to 3- </text>
<text top="72" left="886" width="180" height="17" font="13">and 6-mo) in all groups but most </text>
<text top="89" left="886" width="227" height="17" font="13">dramatically among Hispanics. Hispanics </text>
<text top="106" left="886" width="221" height="17" font="13">improved more than whites (p&lt;0.0001).  </text>
<text top="124" left="886" width="208" height="17" font="13">Hispanics improved more than blacks </text>
<text top="141" left="886" width="60" height="17" font="13">(p=0.004). </text>
<text top="158" left="886" width="3" height="17" font="13"> </text>
<text top="175" left="886" width="3" height="17" font="13"> </text>
<text top="55" left="1135" width="124" height="17" font="13">Secondary analysis of </text>
<text top="72" left="1135" width="126" height="17" font="13">existing data. Hispanic </text>
<text top="89" left="1135" width="118" height="17" font="13">sample was primarily </text>
<text top="106" left="1135" width="146" height="17" font="13">Mexican so results cannot </text>
<text top="124" left="1135" width="113" height="17" font="13">be generalized to all </text>
<text top="141" left="1135" width="111" height="17" font="13">Hispanics. Samples </text>
<text top="158" left="1135" width="98" height="17" font="13">received different </text>
<text top="175" left="1135" width="150" height="17" font="13">treatments at various sites; </text>
<text top="192" left="1135" width="150" height="17" font="13">treatment was controlled in </text>
<text top="210" left="1135" width="146" height="17" font="13">the analysis. Other factors </text>
<text top="227" left="1135" width="133" height="17" font="13">that could explain these </text>
<text top="244" left="1135" width="114" height="17" font="13">differences were not </text>
<text top="261" left="1135" width="146" height="17" font="13">measured. Cultural bias in </text>
<text top="278" left="1135" width="147" height="17" font="13">the data obtained from the </text>
<text top="296" left="1135" width="114" height="17" font="13">MLHFQ is possible.  </text>
<text top="55" left="1304" width="143" height="17" font="13">Cultural differences in the </text>
<text top="72" left="1304" width="113" height="17" font="13">interpretation of and </text>
<text top="89" left="1304" width="148" height="17" font="13">response to chronic illness </text>
<text top="106" left="1304" width="94" height="17" font="13">may explain why </text>
<text top="124" left="1304" width="129" height="17" font="13">HRQoL improves more </text>
<text top="141" left="1304" width="137" height="17" font="13">over time in Hispanic pts </text>
<text top="158" left="1304" width="129" height="17" font="13">with HF compared with </text>
<text top="175" left="1304" width="88" height="17" font="13">white and black </text>
<text top="192" left="1304" width="23" height="17" font="13">pts. </text>
<text top="314" left="49" width="78" height="17" font="13">The impact of </text>
<text top="331" left="49" width="80" height="17" font="13">chronic HF on </text>
<text top="348" left="49" width="72" height="17" font="13">HRQoL data </text>
<text top="365" left="49" width="84" height="17" font="13">acquired in the </text>
<text top="382" left="49" width="100" height="17" font="13">baseline phase of </text>
<text top="400" left="49" width="79" height="17" font="13">the CARE-HF </text>
<text top="417" left="49" width="82" height="17" font="13">study. Calvert, </text>
<text top="434" left="49" width="81" height="17" font="13">Melanie. 2005 </text>
<text top="451" left="49" width="58" height="17" font="14">15701474 </text>
<text top="451" left="107" width="25" height="17" font="13">(22) </text>
<text top="314" left="163" width="80" height="17" font="13">To assess the </text>
<text top="331" left="163" width="85" height="17" font="13">QoL of pts with </text>
<text top="348" left="163" width="79" height="17" font="13">HF, due to LV </text>
<text top="365" left="163" width="69" height="17" font="13">dysfunction, </text>
<text top="382" left="163" width="79" height="17" font="13">taking optimal </text>
<text top="400" left="163" width="90" height="17" font="13">medical therapy </text>
<text top="417" left="163" width="82" height="17" font="13">using baseline </text>
<text top="434" left="163" width="102" height="17" font="13">QoL assessments </text>
<text top="451" left="163" width="87" height="17" font="13">from the CARE-</text>
<text top="469" left="163" width="84" height="17" font="13">HF trial, and to </text>
<text top="486" left="163" width="70" height="17" font="13">evaluate the </text>
<text top="503" left="163" width="92" height="17" font="13">appropriateness </text>
<text top="520" left="163" width="89" height="17" font="13">of using the EQ-</text>
<text top="537" left="163" width="100" height="17" font="13">5D in pts with HF. </text>
<text top="314" left="278" width="29" height="17" font="13">RCT </text>
<text top="314" left="373" width="24" height="17" font="13">813 </text>
<text top="314" left="433" width="83" height="17" font="13">NYHA II-IV HF </text>
<text top="314" left="555" width="85" height="17" font="13">None specified </text>
<text top="314" left="676" width="79" height="17" font="13">QoL Euroquol </text>
<text top="331" left="676" width="65" height="17" font="13">EQ-5D and </text>
<text top="348" left="676" width="50" height="17" font="13">MLHFQ  </text>
<text top="314" left="784" width="27" height="17" font="13"> N/A </text>
<text top="314" left="886" width="236" height="17" font="13">There is a relationship between the EQ-5D </text>
<text top="331" left="886" width="214" height="17" font="13">score and gender, on average females </text>
<text top="348" left="886" width="202" height="17" font="13">enrolled had a worse QoL than male </text>
<text top="365" left="886" width="73" height="17" font="13">participants.  </text>
<text top="382" left="886" width="235" height="17" font="13">r=-0.08; 95% CI:  -0.13 to -04; p=0.00004   </text>
<text top="400" left="886" width="223" height="17" font="13">Mean EQ-5D score for NYHA III pts was </text>
<text top="417" left="886" width="194" height="17" font="13">higher than for NYHA IV pts (mean </text>
<text top="434" left="886" width="92" height="17" font="13">difference 0.17)  </text>
<text top="451" left="886" width="164" height="17" font="13">p&lt;0.0001;  95% CI: 0.08-0.25 </text>
<text top="469" left="886" width="230" height="17" font="13">Association between MLWHF and EQ-5D </text>
<text top="486" left="886" width="214" height="17" font="13">scores (increasing MLWFH associated </text>
<text top="503" left="886" width="148" height="17" font="13">with a decrease in EQ-5D) </text>
<text top="520" left="886" width="70" height="17" font="13"> r=-0.00795; </text>
<text top="537" left="886" width="242" height="17" font="13">95% CI:  (-0.00885 to -0.00706); p&lt;0.0001   </text>
<text top="555" left="886" width="226" height="17" font="13">HF is shown to have an important impact </text>
<text top="572" left="886" width="219" height="17" font="13">on all aspects of QoL but particularly on </text>
<text top="589" left="886" width="229" height="17" font="13">pts mobility and usual activities and leads </text>
<text top="606" left="886" width="212" height="17" font="13">to significant reductions in comparison </text>
<text top="624" left="886" width="215" height="17" font="13">with a representative sample of the UK </text>
<text top="641" left="886" width="64" height="17" font="13">population. </text>
<text top="314" left="1135" width="143" height="17" font="13">Pts assessed in the study </text>
<text top="331" left="1135" width="154" height="17" font="13">are not a random sample of </text>
<text top="348" left="1135" width="109" height="17" font="13">pts with severe HF. </text>
<text top="365" left="1135" width="142" height="17" font="13">CARE-HF is an int’l study </text>
<text top="382" left="1135" width="103" height="17" font="13">but used available </text>
<text top="400" left="1135" width="123" height="17" font="13">normative data from a </text>
<text top="417" left="1135" width="138" height="17" font="13">representative sample of </text>
<text top="434" left="1135" width="115" height="17" font="13">the UK population to </text>
<text top="451" left="1135" width="155" height="17" font="13">evaluate burden of disease. </text>
<text top="469" left="1135" width="150" height="17" font="13">A study comparing UK and </text>
<text top="486" left="1135" width="124" height="17" font="13">Spanish time trade-off </text>
<text top="503" left="1135" width="135" height="17" font="13">values for EQ-5D health </text>
<text top="520" left="1135" width="139" height="17" font="13">states demonstrated that </text>
<text top="537" left="1135" width="116" height="17" font="13">although the general </text>
<text top="555" left="1135" width="154" height="17" font="13">pattern of value assignation </text>
<text top="572" left="1135" width="129" height="17" font="13">was similar, there were </text>
<text top="589" left="1135" width="115" height="17" font="13">differences in values </text>
<text top="606" left="1135" width="135" height="17" font="13">assigned to a number of </text>
<text top="624" left="1135" width="73" height="17" font="13">health states </text>
<text top="314" left="1304" width="134" height="17" font="13">The impact of HF varies </text>
<text top="331" left="1304" width="151" height="17" font="13">amongst pts but the overall </text>
<text top="348" left="1304" width="149" height="17" font="13">burden of disease appears </text>
<text top="365" left="1304" width="144" height="17" font="13">to be comparable to other </text>
<text top="382" left="1304" width="148" height="17" font="13">chronic conditions such as </text>
<text top="400" left="1304" width="98" height="17" font="13">motor neurone or </text>
<text top="417" left="1304" width="141" height="17" font="13">Parkinson’s disease. The </text>
<text top="434" left="1304" width="137" height="17" font="13">EQ-5D appears to be an </text>
<text top="451" left="1304" width="143" height="17" font="13">acceptable valid measure </text>
<text top="469" left="1304" width="119" height="17" font="13">for use in pts with HF </text>
<text top="486" left="1304" width="156" height="17" font="13">although further evidence of </text>
<text top="503" left="1304" width="146" height="17" font="13">the responsiveness of this </text>
<text top="520" left="1304" width="126" height="17" font="13">measure in such pts is </text>
<text top="537" left="1304" width="52" height="17" font="13">required. </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">10</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="93" height="17" font="13">Characterization </text>
<text top="72" left="49" width="91" height="17" font="13">of HRQoL in HF </text>
<text top="89" left="49" width="20" height="17" font="13">pts </text>
<text top="106" left="49" width="99" height="17" font="13">with preserved vs </text>
<text top="124" left="49" width="54" height="17" font="13">low EF in </text>
<text top="141" left="49" width="100" height="17" font="13">CHARM, Lewis et </text>
<text top="158" left="49" width="47" height="17" font="13">al, 2007 </text>
<text top="175" left="49" width="58" height="17" font="14">17188020 </text>
<text top="175" left="107" width="25" height="17" font="13">(23) </text>
<text top="192" left="49" width="3" height="17" font="13"> </text>
<text top="55" left="163" width="88" height="17" font="13">To characterize </text>
<text top="72" left="163" width="98" height="17" font="13">HRQoL in a large </text>
<text top="89" left="163" width="94" height="17" font="13">population of HF </text>
<text top="106" left="163" width="45" height="17" font="13">pts with </text>
<text top="124" left="163" width="82" height="17" font="13">preserved and </text>
<text top="141" left="163" width="94" height="17" font="13">low LVEF and to </text>
<text top="158" left="163" width="79" height="17" font="13">determine the </text>
<text top="175" left="163" width="40" height="17" font="13">factors </text>
<text top="192" left="163" width="87" height="17" font="13">associated with </text>
<text top="210" left="163" width="84" height="17" font="13">worse HRQoL. </text>
<text top="55" left="278" width="62" height="17" font="13">Secondary </text>
<text top="72" left="278" width="61" height="17" font="13">analysis of </text>
<text top="89" left="278" width="76" height="17" font="13">data from the </text>
<text top="106" left="278" width="72" height="17" font="13">CHARM trial </text>
<text top="55" left="373" width="114" height="17" font="13">2,709 “CHARM-</text>
<text top="72" left="433" width="89" height="17" font="13">Alternative” pts: </text>
<text top="89" left="433" width="94" height="17" font="13">LVEF ≤40% and </text>
<text top="106" left="433" width="90" height="17" font="13">not receiving an </text>
<text top="124" left="433" width="93" height="17" font="13">ACE-I; “CHARM-</text>
<text top="141" left="433" width="101" height="17" font="13">Added” pts: LVEF </text>
<text top="158" left="433" width="96" height="17" font="13">≤40% and taking </text>
<text top="175" left="433" width="80" height="17" font="13">ACE-Is. Pts in </text>
<text top="192" left="433" width="79" height="17" font="13">NYHA class II </text>
<text top="210" left="433" width="107" height="17" font="13">required admission </text>
<text top="227" left="433" width="95" height="17" font="13">to hospital with a </text>
<text top="244" left="433" width="81" height="17" font="13">CV problem in </text>
<text top="261" left="433" width="98" height="17" font="13">prior 6 mo (which </text>
<text top="278" left="433" width="57" height="17" font="13">increased </text>
<text top="296" left="433" width="73" height="17" font="13">proportion of </text>
<text top="313" left="433" width="98" height="17" font="13">NYHA class III/IV </text>
<text top="330" left="433" width="105" height="17" font="13">in CHARM-Added. </text>
<text top="347" left="433" width="53" height="17" font="13">“CHARM-</text>
<text top="365" left="433" width="107" height="17" font="13">Preserved” pts had </text>
<text top="382" left="433" width="95" height="17" font="13">LVEF &gt;40% with </text>
<text top="399" left="433" width="89" height="17" font="13">or without ACEI </text>
<text top="55" left="555" width="27" height="17" font="13"> N/A </text>
<text top="55" left="676" width="27" height="17" font="13">QoL </text>
<text top="55" left="784" width="27" height="17" font="13"> N/A </text>
<text top="55" left="886" width="210" height="17" font="13">9 independent clinical determinants of </text>
<text top="72" left="886" width="226" height="17" font="13">worse HRQoL: younger age, higher BMI, </text>
<text top="89" left="886" width="204" height="17" font="13">lower SBP, female sex, worse NYHA </text>
<text top="106" left="886" width="228" height="17" font="13">class, angina, PND, rest dyspnea, lack of </text>
<text top="124" left="886" width="212" height="17" font="13">ACE-I. Characteristics did not differ by </text>
<text top="141" left="886" width="125" height="17" font="13">group. LVEF was NS.  </text>
<text top="158" left="886" width="3" height="17" font="15"><b> </b></text>
<text top="55" left="1135" width="130" height="17" font="13">Population was healthy </text>
<text top="72" left="1135" width="135" height="17" font="13">enough to enroll so may </text>
<text top="89" left="1135" width="143" height="17" font="13">have fewer comorbidities. </text>
<text top="106" left="1135" width="131" height="17" font="13">Asymptomatic pts were </text>
<text top="124" left="1135" width="145" height="17" font="13">excluded. Only enrolled in </text>
<text top="141" left="1135" width="138" height="17" font="13">Canada and US. Groups </text>
<text top="158" left="1135" width="150" height="17" font="13">without ACE-I therapy may </text>
<text top="175" left="1135" width="144" height="17" font="13">have affected HRQoL. No </text>
<text top="192" left="1135" width="96" height="17" font="13">gold standard for </text>
<text top="210" left="1135" width="109" height="17" font="13">measuring HRQoL. </text>
<text top="55" left="1304" width="112" height="17" font="13">Independent factors </text>
<text top="72" left="1304" width="124" height="17" font="13">associated with worse </text>
<text top="89" left="1304" width="151" height="17" font="13">HRQoL in both populations </text>
<text top="106" left="1304" width="115" height="17" font="13">included female sex, </text>
<text top="124" left="1304" width="142" height="17" font="13">younger age, higher BMI, </text>
<text top="141" left="1304" width="107" height="17" font="13">lower SBP, greater </text>
<text top="158" left="1304" width="122" height="17" font="13">symptom burden, and </text>
<text top="175" left="1304" width="132" height="17" font="13">worse functional status. </text>
<text top="417" left="49" width="82" height="17" font="13">The enigma of </text>
<text top="434" left="49" width="85" height="17" font="13">QoL in pts with </text>
<text top="451" left="49" width="76" height="17" font="13">HF. Dobre D, </text>
<text top="469" left="49" width="31" height="17" font="13">2008 </text>
<text top="486" left="49" width="58" height="17" font="14">17400313 </text>
<text top="486" left="107" width="25" height="17" font="13">(24) </text>
<text top="503" left="49" width="3" height="17" font="13"> </text>
<text top="417" left="163" width="92" height="17" font="13">To review RCTs </text>
<text top="434" left="163" width="100" height="17" font="13">that assessed the </text>
<text top="451" left="163" width="53" height="17" font="13">impact of </text>
<text top="469" left="163" width="83" height="17" font="13">pharmacologic </text>
<text top="486" left="163" width="79" height="17" font="13">treatments on </text>
<text top="503" left="163" width="27" height="17" font="13">QoL </text>
<text top="417" left="278" width="29" height="17" font="13">Brief </text>
<text top="434" left="278" width="76" height="17" font="13">communicatio</text>
<text top="451" left="278" width="10" height="17" font="13">n </text>
<text top="417" left="373" width="27" height="17" font="13"> N/A </text>
<text top="417" left="433" width="72" height="17" font="13">Clinical trials </text>
<text top="417" left="555" width="24" height="17" font="13">N/A </text>
<text top="417" left="676" width="27" height="17" font="13">QoL </text>
<text top="417" left="784" width="47" height="17" font="13">Survival </text>
<text top="417" left="886" width="24" height="17" font="13">N/A<b> </b></text>
<text top="417" left="1135" width="24" height="17" font="13">N/A </text>
<text top="417" left="1304" width="142" height="17" font="13">Life prolonging therapies, </text>
<text top="434" left="1304" width="147" height="17" font="13">such as ACE-Is and ARBs </text>
<text top="451" left="1304" width="140" height="17" font="13">improve modestly or only </text>
<text top="469" left="1304" width="120" height="17" font="13">delay the progressive </text>
<text top="486" left="1304" width="136" height="17" font="13">worsening of QoL in HF. </text>
<text top="503" left="1304" width="149" height="17" font="13">Beta blockers do not affect </text>
<text top="520" left="1304" width="150" height="17" font="13">QoL in any way. Therapies </text>
<text top="537" left="1304" width="129" height="17" font="13">that improve QoL (e.g., </text>
<text top="555" left="1304" width="132" height="17" font="13">inotropic agents) do not </text>
<text top="572" left="1304" width="146" height="17" font="13">seem beneficial in relation </text>
<text top="589" left="1304" width="62" height="17" font="13">to survival. </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="16" size="11" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">11</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="101" height="17" font="13">QoL in individuals </text>
<text top="72" left="49" width="102" height="17" font="13">with HF. Harrison, </text>
<text top="89" left="49" width="87" height="17" font="13">Margaret. 2002 </text>
<text top="106" left="49" width="58" height="17" font="14">12021683 </text>
<text top="106" left="107" width="25" height="17" font="13">(25) </text>
<text top="124" left="49" width="3" height="17" font="13"> </text>
<text top="55" left="163" width="68" height="17" font="13">To evaluate </text>
<text top="72" left="163" width="91" height="17" font="13">whether the use </text>
<text top="89" left="163" width="100" height="17" font="13">of usual providers </text>
<text top="106" left="163" width="34" height="17" font="13">and a </text>
<text top="124" left="163" width="95" height="17" font="13">reorganization of </text>
<text top="141" left="163" width="57" height="17" font="13">discharge </text>
<text top="158" left="163" width="74" height="17" font="13">planning and </text>
<text top="175" left="163" width="81" height="17" font="13">transition care </text>
<text top="192" left="163" width="79" height="17" font="13">with improved </text>
<text top="210" left="163" width="61" height="17" font="13">intersector </text>
<text top="227" left="163" width="49" height="17" font="13">linkages </text>
<text top="244" left="163" width="94" height="17" font="13">between nurses, </text>
<text top="261" left="163" width="80" height="17" font="13">could improve </text>
<text top="278" left="163" width="88" height="17" font="13">QoL and health </text>
<text top="296" left="163" width="48" height="17" font="13">services </text>
<text top="313" left="163" width="72" height="17" font="13">utilization for </text>
<text top="330" left="163" width="61" height="17" font="13">individuals </text>
<text top="347" left="163" width="51" height="17" font="13">admitted </text>
<text top="365" left="163" width="85" height="17" font="13">to hospital with </text>
<text top="382" left="163" width="23" height="17" font="13">HF. </text>
<text top="55" left="278" width="68" height="17" font="13">Prospective </text>
<text top="72" left="278" width="68" height="17" font="13">randomized </text>
<text top="89" left="278" width="23" height="17" font="13">trial </text>
<text top="55" left="373" width="150" height="17" font="13">192 Admitted </text>
<text top="55" left="485" width="50" height="17" font="13">to </text>
<text top="72" left="433" width="81" height="17" font="13">hospital with a </text>
<text top="89" left="433" width="98" height="17" font="13">diagnosis of CHF </text>
<text top="106" left="433" width="85" height="17" font="13">Residing in the </text>
<text top="124" left="433" width="81" height="17" font="13">regional home </text>
<text top="141" left="433" width="68" height="17" font="13">care radius. </text>
<text top="158" left="433" width="85" height="17" font="13">Expected to be </text>
<text top="175" left="433" width="89" height="17" font="13">discharged with </text>
<text top="192" left="433" width="105" height="17" font="13">home nursing care </text>
<text top="210" left="433" width="100" height="17" font="13">English or French </text>
<text top="227" left="433" width="53" height="17" font="13">speaking </text>
<text top="244" left="433" width="101" height="17" font="13">Admitted for more </text>
<text top="261" left="433" width="89" height="17" font="13">than 24 h to the </text>
<text top="278" left="433" width="73" height="17" font="13">nursing units </text>
<text top="55" left="555" width="63" height="17" font="13">Cognitively </text>
<text top="72" left="555" width="106" height="17" font="13">impaired (score &gt;8 </text>
<text top="89" left="555" width="99" height="17" font="13">on Short Portable </text>
<text top="106" left="555" width="79" height="17" font="13">Mental Status </text>
<text top="124" left="555" width="39" height="17" font="13">Exam) </text>
<text top="55" left="676" width="45" height="17" font="13">HRQoL </text>
<text top="72" left="676" width="60" height="17" font="13">(MLWHF), </text>
<text top="89" left="676" width="53" height="17" font="13">symptom </text>
<text top="106" left="676" width="70" height="17" font="13">distress and </text>
<text top="124" left="676" width="75" height="17" font="13">function at 6- </text>
<text top="141" left="676" width="60" height="17" font="13">and 12-wk </text>
<text top="158" left="676" width="80" height="17" font="13">postdischarge </text>
<text top="55" left="784" width="75" height="17" font="13">The no. of all-</text>
<text top="72" left="784" width="57" height="17" font="13">cause ED </text>
<text top="89" left="784" width="80" height="17" font="13">visits, hospital </text>
<text top="106" left="784" width="79" height="17" font="13">readmissions, </text>
<text top="124" left="784" width="51" height="17" font="13">and QoL </text>
<text top="141" left="784" width="83" height="17" font="13">measured with </text>
<text top="158" left="784" width="54" height="17" font="13">a generic </text>
<text top="175" left="784" width="55" height="17" font="13">measure, </text>
<text top="192" left="784" width="46" height="17" font="13">Medical </text>
<text top="210" left="784" width="88" height="17" font="13">Outcome Study </text>
<text top="227" left="784" width="68" height="17" font="13">Short Form  </text>
<text top="55" left="886" width="204" height="17" font="13">The overall MLHFQ score was better </text>
<text top="72" left="886" width="226" height="17" font="13">among the Transitional Care pts than the </text>
<text top="89" left="886" width="83" height="17" font="13">usual care pts: </text>
<text top="106" left="886" width="231" height="17" font="13">At 6 wk after hospital discharge (p=0.002) </text>
<text top="124" left="886" width="181" height="17" font="13">At 12 wk after hospital discharge </text>
<text top="141" left="886" width="56" height="17" font="13">(p&lt;0.001) </text>
<text top="158" left="886" width="191" height="17" font="13">The MLHFQ’s Physical Dimension </text>
<text top="175" left="886" width="207" height="17" font="13">subscale score was better among the </text>
<text top="192" left="886" width="225" height="17" font="13">Transitional Care pts than the usual care </text>
<text top="210" left="886" width="23" height="17" font="13">pts: </text>
<text top="227" left="886" width="224" height="17" font="13">At 6 wk after hospital discharge (p=0.01) </text>
<text top="244" left="886" width="181" height="17" font="13">At 12 wk after hospital discharge </text>
<text top="261" left="886" width="56" height="17" font="13">(p&lt;0.001) </text>
<text top="278" left="886" width="200" height="17" font="13">The MLHFQ’s Emotional Dimension </text>
<text top="296" left="886" width="207" height="17" font="13">subscale score was better among the </text>
<text top="313" left="886" width="225" height="17" font="13">Transitional Care pts than the usual care </text>
<text top="330" left="886" width="193" height="17" font="13">pts at 6 wk after hospital discharge </text>
<text top="347" left="886" width="56" height="17" font="13">(p=0.006) </text>
<text top="365" left="886" width="221" height="17" font="13">46% of the Usual Care group visited the </text>
<text top="382" left="886" width="232" height="17" font="13">ED compared with 29% in the Transitional </text>
<text top="399" left="886" width="115" height="17" font="13">Care group (p=0.03) </text>
<text top="416" left="886" width="231" height="17" font="13">At 12 wk postdischarge, 31% of the Usual </text>
<text top="433" left="886" width="224" height="17" font="13">Care pts had been readmitted compared </text>
<text top="451" left="886" width="204" height="17" font="13">with 23% of the Transitional Care pts </text>
<text top="468" left="886" width="56" height="17" font="13">(p=0.26).  </text>
<text top="55" left="1135" width="130" height="17" font="13">Conducted the trial in a </text>
<text top="72" left="1135" width="141" height="17" font="13">naturalistic manner in the </text>
<text top="89" left="1135" width="139" height="17" font="13">usual setting of care with </text>
<text top="106" left="1135" width="90" height="17" font="13">usual providers. </text>
<text top="124" left="1135" width="152" height="17" font="13">Possibility of contamination </text>
<text top="141" left="1135" width="132" height="17" font="13">with the hospital nurses </text>
<text top="158" left="1135" width="117" height="17" font="13">providing usual care. </text>
<text top="175" left="1135" width="151" height="17" font="13">Pts may have inadvertently </text>
<text top="192" left="1135" width="113" height="17" font="13">alerted the research </text>
<text top="210" left="1135" width="112" height="17" font="13">coordinators of their </text>
<text top="227" left="1135" width="155" height="17" font="13">assignment to usual care or </text>
<text top="244" left="1135" width="94" height="17" font="13">transitional care. </text>
<text top="261" left="1135" width="147" height="17" font="13">With multiple interventions </text>
<text top="278" left="1135" width="123" height="17" font="13">it's not easy to assess </text>
<text top="296" left="1135" width="105" height="17" font="13">neither the relative </text>
<text top="313" left="1135" width="111" height="17" font="13">contribution of each </text>
<text top="330" left="1135" width="106" height="17" font="13">component nor the </text>
<text top="347" left="1135" width="156" height="17" font="13">synergistic effect of the sum </text>
<text top="365" left="1135" width="68" height="17" font="13">of the parts. </text>
<text top="55" left="1304" width="137" height="17" font="13">Transitional Care has an </text>
<text top="72" left="1304" width="131" height="17" font="13">important role to play in </text>
<text top="89" left="1304" width="138" height="17" font="13">altering the course of pts </text>
<text top="106" left="1304" width="141" height="17" font="13">hospitalized with HF. Our </text>
<text top="124" left="1304" width="135" height="17" font="13">results suggest that with </text>
<text top="141" left="1304" width="127" height="17" font="13">modest adjustments to </text>
<text top="158" left="1304" width="113" height="17" font="13">usual discharge and </text>
<text top="175" left="1304" width="142" height="17" font="13">transition from hospital-to-</text>
<text top="192" left="1304" width="135" height="17" font="13">home, pts with CHF can </text>
<text top="210" left="1304" width="148" height="17" font="13">experience improved QoL, </text>
<text top="227" left="1304" width="146" height="17" font="13">and decreased use of ED, </text>
<text top="244" left="1304" width="77" height="17" font="13">for 3 mo after </text>
<text top="261" left="1304" width="111" height="17" font="13">hospitalization. This </text>
<text top="278" left="1304" width="139" height="17" font="13">approach will provide the </text>
<text top="296" left="1304" width="143" height="17" font="13">needed adjunct to current </text>
<text top="313" left="1304" width="112" height="17" font="13">management of HF. </text>
<text top="493" left="54" width="1395" height="17" font="13">ACEI; angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker;  BMI, body mass index; CARE-HF Cardiac Resynchronisation in Heart Failure; CES-D, Center for Epidemiological Studies-Depression scale; CHARM, Candesartan in Heart </text>
<text top="511" left="54" width="1339" height="17" font="13">failure: Assessment of Reduction in Mortality and morbidity; CHF, congestive heart failure; COACH, Comparative study on guideline adherence and patient compliance in heart failure patients; CTX, chest x-ray; CV, cardiovascular; ED, emergency </text>
<text top="528" left="54" width="1391" height="17" font="13">department; EF, ejection fraction; ESCAPE, Evaluation Study of Congestive Heart Failure and PulmonaryArtery Catheterization Effectiveness; HF, heart failure; HRQoL, health-related quality of life; MI, myocardial infarction; MLHFQ score, Minnesota Living </text>
<text top="545" left="54" width="1157" height="17" font="13">With Heart Failure; N/A, not applicable; NYHA, New York Heart Association; pts, patients; PND, Paroxysmal nocturnal dyspnea; QoL, quality of life; RCT, randomized control trial; and SBP, systolic blood pressure. </text>
<text top="562" left="54" width="3" height="15" font="6"> </text>
<text top="587" left="54" width="678" height="21" font="8"><b>Data Supplement 5. Stress Testing (Initial and Serial Evaluation) of the HF Patient (Section 6.1.1) </b></text>
<text top="650" left="70" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="668" left="70" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="668" left="171" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="650" left="277" width="38" height="17" font="15"><b>Study </b></text>
<text top="668" left="280" width="32" height="17" font="15"><b>Type </b></text>
<text top="650" left="340" width="75" height="17" font="15"><b>Background </b></text>
<text top="668" left="352" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="668" left="439" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="668" left="535" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="668" left="620" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="668" left="786" width="51" height="17" font="15"><b>Severity </b></text>
<text top="668" left="926" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="668" left="1086" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="650" left="1202" width="29" height="17" font="15"><b>Trial </b></text>
<text top="668" left="1190" width="57" height="17" font="15"><b>Duration  </b></text>
<text top="616" left="1270" width="62" height="17" font="15"><b>Statistical </b></text>
<text top="633" left="1274" width="54" height="17" font="15"><b>Analysis </b></text>
<text top="650" left="1273" width="56" height="17" font="15"><b>(Results) </b></text>
<text top="668" left="1299" width="3" height="17" font="15"><b> </b></text>
<text top="650" left="1377" width="38" height="17" font="15"><b>Study </b></text>
<text top="668" left="1361" width="69" height="17" font="15"><b>Limitations </b></text>
<text top="701" left="355" width="45" height="15" font="16"><i><b>Pre-trial </b></i></text>
<text top="716" left="353" width="50" height="15" font="16"><i><b>standard </b></i></text>
<text top="732" left="349" width="57" height="15" font="16"><i><b>treatment. </b></i></text>
<text top="685" left="448" width="48" height="15" font="16"><i><b>N (Total) </b></i></text>
<text top="701" left="467" width="10" height="15" font="16"><i><b>n </b></i></text>
<text top="716" left="432" width="80" height="15" font="16"><i><b>(Experimental) </b></i></text>
<text top="732" left="442" width="60" height="15" font="16"><i><b>n (Control) </b></i></text>
<text top="701" left="534" width="54" height="15" font="16"><i><b>Ischemic/ </b></i></text>
<text top="716" left="547" width="25" height="15" font="16"><i><b>Non-</b></i></text>
<text top="732" left="536" width="51" height="15" font="16"><i><b>Ischemic </b></i></text>
<text top="716" left="616" width="52" height="15" font="16"><i><b>Inclusion </b></i></text>
<text top="732" left="621" width="42" height="15" font="16"><i><b>Criteria </b></i></text>
<text top="716" left="693" width="45" height="15" font="16"><i><b>Exclusio</b></i></text>
<text top="732" left="691" width="52" height="15" font="16"><i><b>n Criteria </b></i></text>
<text top="685" left="759" width="46" height="15" font="16"><i><b>Severity </b></i></text>
<text top="701" left="767" width="31" height="15" font="16"><i><b>of HF </b></i></text>
<text top="716" left="761" width="41" height="15" font="16"><i><b>Sympto</b></i></text>
<text top="732" left="773" width="19" height="15" font="16"><i><b>ms </b></i></text>
<text top="685" left="826" width="34" height="15" font="16"><i><b>Study </b></i></text>
<text top="701" left="827" width="31" height="15" font="16"><i><b>Entry </b></i></text>
<text top="716" left="823" width="40" height="15" font="16"><i><b>Sverity </b></i></text>
<text top="732" left="822" width="42" height="15" font="16"><i><b>Criteria </b></i></text>
<text top="716" left="889" width="44" height="15" font="16"><i><b>Primary </b></i></text>
<text top="732" left="886" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="716" left="967" width="63" height="15" font="16"><i><b>Secondary  </b></i></text>
<text top="732" left="971" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="716" left="1052" width="52" height="15" font="16"><i><b>Annualize</b></i></text>
<text top="732" left="1051" width="59" height="15" font="16"><i><b>d Mortality </b></i></text>
<text top="716" left="1127" width="46" height="15" font="16"><i><b>1st Year </b></i></text>
<text top="732" left="1125" width="49" height="15" font="16"><i><b>Mortality </b></i></text>
</page>
<page number="12" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="17" size="13" family="Times" color="#181818"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">12</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="69" height="17" font="13">Defining the </text>
<text top="72" left="61" width="46" height="17" font="13">Optimal </text>
<text top="89" left="61" width="61" height="17" font="13">Prognostic </text>
<text top="106" left="61" width="94" height="17" font="13">Window for CPX </text>
<text top="124" left="61" width="83" height="17" font="13">in Pts with HF. </text>
<text top="141" left="61" width="92" height="17" font="13">Arena et al. Circ </text>
<text top="158" left="61" width="91" height="17" font="13">Heart Fail 2010; </text>
<text top="175" left="61" width="66" height="17" font="13">3: 405-411  </text>
<text top="192" left="61" width="58" height="17" font="14">20200329 </text>
<text top="192" left="119" width="25" height="17" font="13">(26) </text>
<text top="55" left="170" width="64" height="17" font="13">Assess the </text>
<text top="72" left="170" width="57" height="17" font="13">change in </text>
<text top="89" left="170" width="60" height="17" font="13">prognostic </text>
<text top="106" left="170" width="72" height="17" font="13">characteristic</text>
<text top="124" left="170" width="66" height="17" font="13">s of CPX at </text>
<text top="141" left="170" width="75" height="17" font="13">different time </text>
<text top="158" left="170" width="49" height="17" font="13">intervals </text>
<text top="55" left="265" width="120" height="17" font="13">Cohort 1 </text>
<text top="55" left="350" width="62" height="17" font="13">year </text>
<text top="55" left="429" width="59" height="17" font="13">791 </text>
<text top="72" left="429" width="7" height="17" font="13">  </text>
<text top="89" left="429" width="7" height="17" font="13">  </text>
<text top="55" left="528" width="28" height="17" font="13">51% </text>
<text top="72" left="528" width="51" height="17" font="13">ischemic </text>
<text top="55" left="608" width="62" height="17" font="13">HF and LV </text>
<text top="72" left="608" width="66" height="17" font="13">dysfunction </text>
<text top="55" left="690" width="7" height="17" font="13">  </text>
<text top="55" left="757" width="38" height="17" font="13">NYHA </text>
<text top="72" left="757" width="39" height="17" font="13">2.4 +/- </text>
<text top="89" left="757" width="27" height="17" font="13">0.67 </text>
<text top="55" left="821" width="27" height="17" font="13"> N/A </text>
<text top="55" left="879" width="34" height="17" font="13">Major </text>
<text top="72" left="879" width="43" height="17" font="13">cardiac </text>
<text top="89" left="879" width="47" height="17" font="13">events - </text>
<text top="106" left="879" width="53" height="17" font="13">mortality, </text>
<text top="124" left="879" width="57" height="17" font="13">LV device </text>
<text top="141" left="879" width="59" height="17" font="13">implantatio</text>
<text top="158" left="879" width="52" height="17" font="13">n, urgent </text>
<text top="175" left="879" width="31" height="17" font="13">heart </text>
<text top="192" left="879" width="57" height="17" font="13">transplant </text>
<text top="55" left="957" width="46" height="17" font="13">Cardiac </text>
<text top="72" left="957" width="50" height="17" font="13">mortality </text>
<text top="55" left="1050" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1123" width="17" height="17" font="13">75 </text>
<text top="72" left="1123" width="40" height="17" font="13">deaths </text>
<text top="89" left="1123" width="46" height="17" font="13">(of 791) </text>
<text top="55" left="1189" width="38" height="17" font="13">36 mo </text>
<text top="72" left="1189" width="20" height="17" font="13">FU </text>
<text top="55" left="1257" width="86" height="17" font="13">For 24 mo post </text>
<text top="72" left="1257" width="79" height="17" font="13">CPX (high vs. </text>
<text top="89" left="1257" width="85" height="17" font="13">low Ve/VCO2): </text>
<text top="106" left="1257" width="83" height="17" font="13">cardiac events </text>
<text top="124" left="1257" width="80" height="17" font="13">p&lt;0.001 (95% </text>
<text top="141" left="1257" width="75" height="17" font="13">CI: 2.1 - 5.5); </text>
<text top="158" left="1257" width="43" height="17" font="13">cardiac </text>
<text top="175" left="1257" width="50" height="17" font="13">mortality </text>
<text top="192" left="1257" width="80" height="17" font="13">p&lt;0.001 (95% </text>
<text top="210" left="1257" width="72" height="17" font="13">CI: 2.2 - 5.8) </text>
<text top="227" left="1257" width="85" height="17" font="13">HR:dichotomou</text>
<text top="244" left="1257" width="51" height="17" font="13">s3.4; 3.5 </text>
<text top="55" left="1358" width="66" height="17" font="13">Observation</text>
<text top="72" left="1358" width="13" height="17" font="13">al </text>
<text top="262" left="61" width="79" height="17" font="13">Value of peak </text>
<text top="279" left="61" width="92" height="17" font="13">exercise oxygen </text>
<text top="296" left="61" width="91" height="17" font="13">consumption for </text>
<text top="314" left="61" width="93" height="17" font="13">optimal timing of </text>
<text top="331" left="61" width="43" height="17" font="13">cardiac </text>
<text top="348" left="61" width="84" height="17" font="13">transplantation </text>
<text top="365" left="61" width="77" height="17" font="13">in ambulatory </text>
<text top="382" left="61" width="68" height="17" font="13">pts with HF. </text>
<text top="400" left="61" width="76" height="17" font="13">Mancini et al. </text>
<text top="417" left="61" width="61" height="17" font="13">Circulation </text>
<text top="434" left="61" width="72" height="17" font="13">1991;83;778-</text>
<text top="451" left="61" width="27" height="17" font="13">786  </text>
<text top="469" left="61" width="51" height="17" font="14">1999029 </text>
<text top="469" left="112" width="25" height="17" font="13">(27) </text>
<text top="262" left="170" width="76" height="17" font="13">To determine </text>
<text top="279" left="170" width="59" height="17" font="13">if maximal </text>
<text top="296" left="170" width="49" height="17" font="13">exercise </text>
<text top="314" left="170" width="64" height="17" font="13">testing and </text>
<text top="331" left="170" width="79" height="17" font="13">measurement </text>
<text top="348" left="170" width="58" height="17" font="13">of PKVO2 </text>
<text top="365" left="170" width="72" height="17" font="13">identifies pts </text>
<text top="382" left="170" width="81" height="17" font="13">in whom heart </text>
<text top="400" left="170" width="81" height="17" font="13">transplant can </text>
<text top="417" left="170" width="53" height="17" font="13">be safely </text>
<text top="434" left="170" width="49" height="17" font="13">deferred </text>
<text top="262" left="265" width="53" height="17" font="13">Observati</text>
<text top="279" left="265" width="27" height="17" font="13">onal </text>
<text top="296" left="265" width="56" height="17" font="13">prospectiv</text>
<text top="314" left="265" width="48" height="17" font="13">e cohort </text>
<text top="262" left="339" width="54" height="17" font="13">Focus on </text>
<text top="279" left="339" width="70" height="17" font="13">hemodynami</text>
<text top="296" left="339" width="71" height="17" font="13">c and NYHA </text>
<text top="314" left="339" width="31" height="17" font="13">class </text>
<text top="262" left="429" width="24" height="17" font="13">122 </text>
<text top="279" left="429" width="17" height="17" font="13">52 </text>
<text top="296" left="429" width="74" height="17" font="13">(PKVO2&gt;14) </text>
<text top="314" left="429" width="17" height="17" font="13">35 </text>
<text top="331" left="429" width="81" height="17" font="13">(PKVO2=&lt;14) </text>
<text top="262" left="528" width="28" height="17" font="13">46% </text>
<text top="279" left="528" width="51" height="17" font="13">ischemic </text>
<text top="262" left="608" width="66" height="17" font="13">Ambulatory </text>
<text top="279" left="608" width="66" height="17" font="13">pts referred </text>
<text top="296" left="608" width="49" height="17" font="13">for heart </text>
<text top="314" left="608" width="57" height="17" font="13">transplant </text>
<text top="262" left="690" width="42" height="17" font="13">Unable </text>
<text top="279" left="690" width="14" height="17" font="13">to </text>
<text top="296" left="690" width="46" height="17" font="13">perform </text>
<text top="314" left="690" width="49" height="17" font="13">exercise </text>
<text top="331" left="690" width="40" height="17" font="13">testing </text>
<text top="348" left="690" width="38" height="17" font="13">due to </text>
<text top="365" left="690" width="40" height="17" font="13">angina </text>
<text top="262" left="757" width="28" height="17" font="13">70% </text>
<text top="279" left="757" width="38" height="17" font="13">NYHA </text>
<text top="296" left="757" width="14" height="17" font="13">III </text>
<text top="262" left="821" width="27" height="17" font="13"> N/A </text>
<text top="262" left="879" width="47" height="17" font="13">Survival </text>
<text top="262" left="957" width="27" height="17" font="13"> N/A </text>
<text top="262" left="1050" width="27" height="17" font="13"> N/A </text>
<text top="262" left="1123" width="28" height="17" font="13">94% </text>
<text top="279" left="1123" width="45" height="17" font="13">survival </text>
<text top="296" left="1123" width="46" height="17" font="13">in those </text>
<text top="314" left="1123" width="52" height="17" font="13">with high </text>
<text top="331" left="1123" width="44" height="17" font="13">PKVO2 </text>
<text top="348" left="1123" width="47" height="17" font="13">vs. 70% </text>
<text top="365" left="1123" width="51" height="17" font="13">for those </text>
<text top="382" left="1123" width="47" height="17" font="13">with low </text>
<text top="400" left="1123" width="44" height="17" font="13">PKVO2 </text>
<text top="262" left="1189" width="40" height="17" font="13">2 y FU </text>
<text top="262" left="1257" width="48" height="17" font="13">p&lt;0.005 </text>
<text top="262" left="1358" width="31" height="17" font="13">Wide </text>
<text top="279" left="1358" width="49" height="17" font="13">complex </text>
<text top="296" left="1358" width="66" height="17" font="13">tachycardia </text>
<text top="314" left="1358" width="37" height="17" font="13">in 1 pt </text>
<text top="487" left="61" width="77" height="17" font="13">Peak Oxygen </text>
<text top="504" left="61" width="92" height="17" font="13">Consumption as </text>
<text top="521" left="61" width="77" height="17" font="13">a Predictor of </text>
<text top="538" left="61" width="70" height="17" font="13">Death in Pts </text>
<text top="555" left="61" width="48" height="17" font="13">With HF </text>
<text top="573" left="61" width="86" height="17" font="13">Receiving Beta </text>
<text top="590" left="61" width="93" height="17" font="13">Blockers. O'Neill </text>
<text top="607" left="61" width="49" height="17" font="13">JO et al. </text>
<text top="624" left="61" width="61" height="17" font="13">Circulation </text>
<text top="641" left="61" width="86" height="17" font="13">2005;111;2313-</text>
<text top="659" left="61" width="34" height="17" font="13">2318  </text>
<text top="676" left="61" width="58" height="17" font="14">15867168 </text>
<text top="676" left="119" width="25" height="17" font="13">(28) </text>
<text top="487" left="170" width="76" height="17" font="13">To determine </text>
<text top="504" left="170" width="47" height="17" font="13">whether </text>
<text top="521" left="170" width="67" height="17" font="13">PKVO2 is a </text>
<text top="538" left="170" width="43" height="17" font="13">reliable </text>
<text top="555" left="170" width="64" height="17" font="13">indicator of </text>
<text top="573" left="170" width="70" height="17" font="13">prognosis in </text>
<text top="590" left="170" width="48" height="17" font="13">the beta </text>
<text top="607" left="170" width="64" height="17" font="13">blocker era </text>
<text top="487" left="265" width="53" height="17" font="13">Observati</text>
<text top="504" left="265" width="27" height="17" font="13">onal </text>
<text top="521" left="265" width="56" height="17" font="13">prospectiv</text>
<text top="538" left="265" width="48" height="17" font="13">e cohort </text>
<text top="487" left="339" width="67" height="17" font="13">Cutoff of 14 </text>
<text top="504" left="339" width="44" height="17" font="13">mL/kg1 </text>
<text top="487" left="429" width="38" height="17" font="13">2,105; </text>
<text top="504" left="429" width="82" height="17" font="13">n=909 on beta </text>
<text top="521" left="429" width="47" height="17" font="13">blocker; </text>
<text top="538" left="429" width="65" height="17" font="13">n=1,196 no </text>
<text top="555" left="429" width="70" height="17" font="13">beta blocker </text>
<text top="487" left="528" width="28" height="17" font="13">52% </text>
<text top="504" left="528" width="51" height="17" font="13">ischemic </text>
<text top="487" left="608" width="65" height="17" font="13">Referral for </text>
<text top="504" left="608" width="45" height="17" font="13">HF with </text>
<text top="521" left="608" width="66" height="17" font="13">LVEF&lt;35% </text>
<text top="487" left="690" width="53" height="17" font="13">Age &lt;20, </text>
<text top="504" left="690" width="41" height="17" font="13">ESRD, </text>
<text top="521" left="690" width="28" height="17" font="13">prior </text>
<text top="538" left="690" width="29" height="17" font="13">OHT </text>
<text top="487" left="757" width="27" height="17" font="13"> N/A </text>
<text top="487" left="821" width="27" height="17" font="13"> N/A </text>
<text top="487" left="879" width="36" height="17" font="13">Death </text>
<text top="487" left="957" width="51" height="17" font="13">Death or </text>
<text top="504" left="957" width="74" height="17" font="13">transplantatio</text>
<text top="521" left="957" width="10" height="17" font="13">n </text>
<text top="487" left="1050" width="27" height="17" font="13"> N/A </text>
<text top="487" left="1123" width="27" height="17" font="13"> N/A </text>
<text top="487" left="1189" width="27" height="17" font="13"> N/A </text>
<text top="487" left="1257" width="66" height="17" font="13">Pts on beta </text>
<text top="504" left="1257" width="53" height="17" font="13">blockers: </text>
<text top="521" left="1257" width="95" height="17" font="13">Death p&lt;0.001,   </text>
<text top="538" left="1257" width="82" height="17" font="13">(95% CI: 1.18–</text>
<text top="555" left="1257" width="69" height="17" font="13">1.36); death </text>
<text top="573" left="1257" width="81" height="17" font="13">and transplant </text>
<text top="590" left="1257" width="59" height="17" font="13">p&lt;0.001,   </text>
<text top="607" left="1257" width="82" height="17" font="13">(95% CI: 1.18–</text>
<text top="624" left="1257" width="32" height="17" font="13">1.32) </text>
<text top="641" left="1257" width="28" height="17" font="17">aHR:</text>
<text top="640" left="1285" width="5" height="22" font="17"> </text>
<text top="641" left="1290" width="31" height="17" font="13">1.26; </text>
<text top="659" left="1257" width="63" height="17" font="13">1.25  per 1-</text>
<text top="676" left="1257" width="60" height="17" font="13">mL/min/kg </text>
<text top="487" left="1358" width="27" height="17" font="13"> N/A </text>
<text top="694" left="54" width="1363" height="17" font="13">CPX indicates cardiopulmonary exercise testing; EF, ejection fraction; ESRD, end-stage renal disease; FU, follow up; HF, heart failure; pts, patients; LVEF, left ventricular ejection fraction; N/A, not applicable; NYHA, New York Heart Association; OHT, </text>
<text top="711" left="54" width="568" height="17" font="13">orthotopic heart transplantation; PKVO2; peak oxygen consumption; and RCT, randomized control trial.  </text>
<text top="729" left="54" width="4" height="17" font="13"> </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">13</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="532" height="21" font="8"><b>Data Supplement 6. Clinical Evaluation – History (Orthopnea) (Section 6.1.1)</b></text>
<text top="60" left="586" width="4" height="14" font="15"><b> </b></text>
<text top="86" left="63" width="171" height="19" font="9"><b>Study Name, Author, Year </b></text>
<text top="86" left="320" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="86" left="495" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="86" left="601" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="86" left="921" width="226" height="19" font="9"><b>Utility in Detecting Elevated PCWP </b></text>
<text top="117" left="61" width="146" height="19" font="7">Stevenson, LW; Perloff  </text>
<text top="136" left="61" width="153" height="19" font="7">JAMA 1989:261:884-888 </text>
<text top="155" left="61" width="53" height="19" font="11">2913385</text>
<text top="155" left="113" width="35" height="19" font="7">  (29) </text>
<text top="117" left="249" width="159" height="19" font="7">Single center, prospective<b> </b></text>
<text top="117" left="481" width="19" height="19" font="7">50 </text>
<text top="117" left="595" width="53" height="19" font="7">Stage D </text>
<text top="117" left="743" width="190" height="19" font="7">Orthopnea within preceding wk </text>
<text top="136" left="743" width="187" height="19" font="7">91% of 43 pts with PCWP ≥22 </text>
<text top="155" left="743" width="143" height="19" font="7">0/7 pts with PCWP &lt;22<b> </b></text>
<text top="175" left="61" width="175" height="19" font="7">Chakko et al; Am J Medicine </text>
<text top="194" left="61" width="91" height="19" font="7">1991:90:353-9 </text>
<text top="213" left="61" width="53" height="19" font="11">1825901</text>
<text top="213" left="113" width="35" height="19" font="7">  (30) </text>
<text top="175" left="249" width="159" height="19" font="7">Single center, prospective<b> </b></text>
<text top="175" left="481" width="19" height="19" font="7">42 </text>
<text top="175" left="595" width="53" height="19" font="7">Stage D </text>
<text top="175" left="743" width="95" height="19" font="7">For PCWP &gt;20 </text>
<text top="194" left="743" width="326" height="19" font="7">Sensitivity 66%, Specificity 47%, PPV 61%, NPV 37%<b> </b></text>
<text top="232" left="61" width="135" height="19" font="7"> Drazner et al Circ HF </text>
<text top="251" left="61" width="102" height="19" font="7"> 2008:1:170-177 </text>
<text top="270" left="61" width="60" height="19" font="11">19675681</text>
<text top="270" left="121" width="32" height="19" font="7"> (31) </text>
<text top="232" left="249" width="202" height="19" font="7">Multicenter substudy of ESCAPE </text>
<text top="232" left="480" width="95" height="19" font="7">194 (with PAC) </text>
<text top="232" left="595" width="53" height="19" font="7">Stage D </text>
<text top="232" left="743" width="145" height="19" font="7">Orthopnea (≥ 2 pillows) </text>
<text top="251" left="743" width="520" height="19" font="7">OR 2.1 (95% CI: 1.0-4.4); PPV 66%, NPV 51%; +LR 1.15, (-) LR 1.8; all for PCWP&gt;22 </text>
<text top="270" left="743" width="259" height="19" font="7">OR 3.6 (95% CI: 1.02 -12.8) for PCWP&gt;30 </text>
<text top="294" left="54" width="1351" height="17" font="13">ESCAPE indicates Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; LR, likelihood ratio; NPV, negative predictive value; OR, odds ratio; PAC, pulmonary artery catheter; PCWP, Pulmonary Capillary  </text>
<text top="311" left="54" width="364" height="17" font="13">Wedge Pressure; PPV, positive predictive value; and pts, patients. </text>
<text top="329" left="54" width="3" height="17" font="13"> </text>
<text top="355" left="54" width="478" height="21" font="8"><b>Data Supplement 7. Clinical Evaluation - Examination (Section 6.1.1)</b></text>
<text top="358" left="531" width="3" height="17" font="15"><b> </b></text>
<text top="378" left="80" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="397" left="80" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="387" left="212" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="387" left="322" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="387" left="419" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="387" left="831" width="226" height="19" font="9"><b>Utility in Detecting Elevated PCWP </b></text>
<text top="420" left="61" width="386" height="19" font="9"><b>Jugular venous pressure for assessing right atrial pressure </b></text>
<text top="442" left="61" width="99" height="19" font="7">Stevenson, LW; </text>
<text top="461" left="61" width="43" height="19" font="7">Perloff </text>
<text top="480" left="61" width="40" height="19" font="7">JAMA </text>
<text top="499" left="61" width="114" height="19" font="7">1989:261:884-888 </text>
<text top="518" left="61" width="53" height="19" font="11">2913385</text>
<text top="518" left="113" width="35" height="19" font="7">  (29) </text>
<text top="442" left="197" width="87" height="19" font="7">Single center, </text>
<text top="461" left="197" width="73" height="19" font="7">prospective </text>
<text top="442" left="317" width="19" height="19" font="7">50 </text>
<text top="442" left="412" width="53" height="19" font="7">Stage D </text>
<text top="442" left="561" width="311" height="19" font="7">21/28 (75%) of pts with RAP ≥10 had elevated JVP </text>
<text top="538" left="61" width="80" height="19" font="7">Butman et al </text>
<text top="557" left="61" width="39" height="19" font="7">JACC </text>
<text top="576" left="61" width="106" height="19" font="7">1993:22:968-974 </text>
<text top="595" left="61" width="53" height="19" font="11">8409071</text>
<text top="595" left="113" width="35" height="19" font="7">  (32) </text>
<text top="538" left="197" width="87" height="19" font="7">Single center, </text>
<text top="557" left="197" width="73" height="19" font="7">prospective </text>
<text top="538" left="317" width="19" height="19" font="7">52 </text>
<text top="538" left="412" width="53" height="19" font="7">Stage D </text>
<text top="538" left="561" width="214" height="19" font="7">RAP associated with JVD and HJR </text>
<text top="557" left="561" width="157" height="19" font="7"> –HJR,-JVD:   RAP 4 (2)   </text>
<text top="576" left="561" width="150" height="19" font="7">+HJR, -JVD:   RAP 8 (5) </text>
<text top="595" left="561" width="157" height="19" font="7">+HJR, +JVD:  RAP 13 (5) </text>
<text top="629" left="61" width="64" height="19" font="7">Stein et al </text>
<text top="648" left="61" width="29" height="19" font="7">AJC </text>
<text top="667" left="61" width="121" height="19" font="7">1997;80:1615-1618 </text>
<text top="686" left="61" width="53" height="19" font="11">9416951</text>
<text top="686" left="113" width="35" height="19" font="7">  (33) </text>
<text top="629" left="197" width="83" height="19" font="7">Single center </text>
<text top="629" left="317" width="19" height="19" font="7">25 </text>
<text top="629" left="412" width="61" height="19" font="7">Class 3-4 </text>
<text top="629" left="561" width="311" height="19" font="7">RAP estimated from JVP vs. measured RA: r=0.92. </text>
<text top="648" left="561" width="746" height="19" font="7">Clinical estimates underestimate elevated JVP. Interaction between utility of estimated RAP and measured RAP (more of an </text>
<text top="667" left="561" width="575" height="19" font="7">underestimate as measured RAP increased). Bias 0.1 (RAP 0-8), 3.6 (RAP 9-14), 5 (RAP ≥15). </text>
<text top="710" left="61" width="81" height="19" font="7">Drazner et al </text>
<text top="729" left="61" width="50" height="19" font="7">Circ HF </text>
<text top="748" left="61" width="99" height="19" font="7">2008:1:170-177 </text>
<text top="767" left="61" width="60" height="19" font="11">19675681</text>
<text top="767" left="121" width="35" height="19" font="7">  (31) </text>
<text top="719" left="197" width="70" height="19" font="7">Multicenter </text>
<text top="738" left="197" width="73" height="19" font="7">substudy of </text>
<text top="757" left="197" width="59" height="19" font="7">ESCAPE </text>
<text top="729" left="317" width="59" height="19" font="7">194 (with </text>
<text top="748" left="317" width="36" height="19" font="7">PAC) </text>
<text top="738" left="412" width="53" height="19" font="7">Stage D </text>
<text top="729" left="561" width="173" height="19" font="7">Estimated RAP for RAP &gt;12 </text>
<text top="748" left="561" width="66" height="19" font="7"> AUC 0.74 </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">14</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="57" left="61" width="358" height="19" font="9"><b>Jugular Venous Pressure for Detecting Elevated PCWP </b></text>
<text top="79" left="61" width="99" height="19" font="7">Stevenson, LW; </text>
<text top="98" left="61" width="43" height="19" font="7">Perloff </text>
<text top="117" left="61" width="40" height="19" font="7">JAMA </text>
<text top="136" left="61" width="114" height="19" font="7">1989:261:884-888 </text>
<text top="155" left="61" width="53" height="19" font="11">2913385</text>
<text top="155" left="113" width="35" height="19" font="7">  (29) </text>
<text top="79" left="197" width="87" height="19" font="7">Single center, </text>
<text top="98" left="197" width="73" height="19" font="7">prospective </text>
<text top="79" left="317" width="19" height="19" font="7">50 </text>
<text top="79" left="412" width="53" height="19" font="7">Stage D </text>
<text top="79" left="561" width="253" height="19" font="7">Elevated JVP associated with PCWP ≥22 </text>
<text top="98" left="561" width="97" height="19" font="7"> 58% sensitivity </text>
<text top="117" left="561" width="280" height="19" font="7">100% specificity (0/7 with PCWP ≤18 mm Hg) </text>
<text top="136" left="561" width="387" height="19" font="7">However 8/18 pts with PCWP ≥35 mm Hg without elevated JVP </text>
<text top="180" left="61" width="79" height="19" font="7">Chakko et al </text>
<text top="199" left="61" width="92" height="19" font="7">Am J Medicine </text>
<text top="218" left="61" width="106" height="19" font="7">1991;90:353-359 </text>
<text top="237" left="61" width="53" height="19" font="11">1825901</text>
<text top="237" left="113" width="35" height="19" font="7">  (30) </text>
<text top="180" left="197" width="87" height="19" font="7">Single center, </text>
<text top="199" left="197" width="73" height="19" font="7">prospective </text>
<text top="180" left="317" width="19" height="19" font="7">52 </text>
<text top="180" left="412" width="53" height="19" font="7">Stage D </text>
<text top="180" left="561" width="207" height="19" font="7">“High JVP” for PCWP &gt;20 mm Hg </text>
<text top="199" left="561" width="330" height="19" font="7"> Sensitivity 70%, Specificity 79%, PPV 85%, NPV 62% </text>
<text top="274" left="61" width="80" height="19" font="7">Butman et al </text>
<text top="293" left="61" width="39" height="19" font="7">JACC </text>
<text top="312" left="61" width="106" height="19" font="7">1993:22:968-974 </text>
<text top="331" left="61" width="53" height="19" font="11">8409071</text>
<text top="331" left="113" width="35" height="19" font="7">  (32) </text>
<text top="274" left="197" width="87" height="19" font="7">Single center, </text>
<text top="293" left="197" width="73" height="19" font="7">prospective </text>
<text top="274" left="317" width="19" height="19" font="7">52 </text>
<text top="274" left="412" width="53" height="19" font="7">Stage D </text>
<text top="274" left="561" width="549" height="19" font="7">JVD at rest or with HJR for PCWP&gt;18 mm Hg: Sens 81%, Spec 80%, PPV 91%, NPV 63% </text>
<text top="356" left="61" width="80" height="19" font="7">Badgett et al </text>
<text top="375" left="61" width="40" height="19" font="7">JAMA </text>
<text top="394" left="61" width="98" height="19" font="7">1997; 277:1712-</text>
<text top="413" left="61" width="34" height="19" font="7">1719 </text>
<text top="432" left="61" width="53" height="19" font="11">9169900</text>
<text top="432" left="113" width="35" height="19" font="7">  (34) </text>
<text top="356" left="197" width="104" height="19" font="7">Literature review </text>
<text top="375" left="197" width="105" height="19" font="7">“Rational Clinical </text>
<text top="394" left="197" width="83" height="19" font="7">Examination” </text>
<text top="413" left="197" width="40" height="19" font="7">series </text>
<text top="432" left="197" width="8" height="19" font="7">  </text>
<text top="356" left="317" width="23" height="19" font="7">NA </text>
<text top="356" left="412" width="129" height="19" font="7">Stage D citing above </text>
<text top="375" left="412" width="58" height="19" font="7">3 studies </text>
<text top="356" left="561" width="132" height="19" font="7">Suggested algorithm: </text>
<text top="375" left="561" width="747" height="19" font="7">If known low LVEF, and population with high prevalence of increased filling pressure, then elevated JVP is “very helpful” and </text>
<text top="394" left="561" width="350" height="19" font="7">associated with &gt;90% chance of elevated filling pressures </text>
<text top="413" left="561" width="8" height="19" font="7">  </text>
<text top="452" left="61" width="81" height="19" font="7">Drazner et al </text>
<text top="470" left="61" width="50" height="19" font="7">Circ HF </text>
<text top="489" left="61" width="99" height="19" font="7">2008:1:170-177 </text>
<text top="508" left="61" width="60" height="19" font="11">19675681</text>
<text top="508" left="121" width="35" height="19" font="7">  (31) </text>
<text top="452" left="197" width="70" height="19" font="7">Multicenter </text>
<text top="470" left="197" width="73" height="19" font="7">substudy of </text>
<text top="489" left="197" width="59" height="19" font="7">ESCAPE </text>
<text top="452" left="317" width="59" height="19" font="7">194 (with </text>
<text top="470" left="317" width="36" height="19" font="7">PAC) </text>
<text top="452" left="412" width="53" height="19" font="7">Stage D </text>
<text top="452" left="561" width="187" height="19" font="7">JVP≥12 mm Hg for PCWP&gt;22 </text>
<text top="470" left="561" width="462" height="19" font="7"> Sensitivity: 65%, Specificity: 64%, PPV 75%, NPV 52%, +LR 1.79, (-)LR 1.8 </text>
<text top="536" left="61" width="162" height="19" font="9"><b>Prognostic Utility of JVP </b></text>
<text top="558" left="61" width="81" height="19" font="7">Drazner et al </text>
<text top="577" left="61" width="41" height="19" font="7">NEJM </text>
<text top="596" left="61" width="106" height="19" font="7">2001;345:574-81 </text>
<text top="615" left="61" width="60" height="19" font="11">11529211</text>
<text top="615" left="121" width="35" height="19" font="7">  (35) </text>
<text top="634" left="61" width="4" height="19" font="7"> </text>
<text top="558" left="197" width="86" height="19" font="7">Retrospective </text>
<text top="577" left="197" width="68" height="19" font="7">analysis of </text>
<text top="596" left="197" width="50" height="19" font="7">SOLVD </text>
<text top="615" left="197" width="96" height="19" font="7">Treatment Trial </text>
<text top="558" left="317" width="34" height="19" font="7">2569 </text>
<text top="558" left="412" width="53" height="19" font="7">Stage C </text>
<text top="558" left="561" width="229" height="19" font="7">Multivariate analysis for elevated JVP </text>
<text top="577" left="561" width="123" height="19" font="7">Mean f/u 32 months </text>
<text top="596" left="561" width="215" height="19" font="7">Death RR 1.15 (95% CI: 0.95-1.38) </text>
<text top="615" left="561" width="263" height="19" font="7">HF hospitalization 1.32 (95% CI: 1.08-1.62) </text>
<text top="634" left="561" width="303" height="19" font="7">Death/HF hospitalization 1.30 (95% CI: 1.11-1.53) </text>
<text top="654" left="61" width="81" height="19" font="7">Drazner et al </text>
<text top="673" left="61" width="65" height="19" font="7">Am J Med </text>
<text top="692" left="61" width="114" height="19" font="7">2003;114:431-437 </text>
<text top="711" left="61" width="60" height="19" font="11">12727575</text>
<text top="711" left="121" width="35" height="19" font="7">  (36) </text>
<text top="730" left="61" width="4" height="19" font="7"> </text>
<text top="654" left="197" width="86" height="19" font="7">Retrospective </text>
<text top="673" left="197" width="68" height="19" font="7">analysis of </text>
<text top="692" left="197" width="50" height="19" font="7">SOLVD </text>
<text top="711" left="197" width="98" height="19" font="7">Prevention Trial </text>
<text top="654" left="317" width="34" height="19" font="7">4102 </text>
<text top="654" left="412" width="52" height="19" font="7">Stage B </text>
<text top="654" left="561" width="229" height="19" font="7">Multivariate analysis for elevated JVD </text>
<text top="673" left="561" width="137" height="19" font="7">Mean follow-up 34 mo </text>
<text top="692" left="561" width="284" height="19" font="7"> Development of HF RR 1.38 (95% CI: 1.1-1.7) </text>
<text top="711" left="561" width="336" height="19" font="7">Death or Development of HF RR 1.34 (95% CI: 1-1,1.6) </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">15</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="81" height="19" font="7">Drazner et al </text>
<text top="74" left="61" width="50" height="19" font="7">Circ HF </text>
<text top="93" left="61" width="99" height="19" font="7">2008:1:170-177 </text>
<text top="111" left="61" width="60" height="19" font="11">19675681</text>
<text top="111" left="121" width="35" height="19" font="7"> (31)  </text>
<text top="130" left="61" width="4" height="19" font="7"> </text>
<text top="55" left="197" width="70" height="19" font="7">Multicenter </text>
<text top="74" left="197" width="73" height="19" font="7">substudy of </text>
<text top="93" left="197" width="59" height="19" font="7">ESCAPE </text>
<text top="55" left="317" width="59" height="19" font="7">194 (with </text>
<text top="74" left="317" width="36" height="19" font="7">PAC) </text>
<text top="55" left="412" width="53" height="19" font="7">Stage D </text>
<text top="55" left="560" width="126" height="19" font="7">Multivariate analysis </text>
<text top="74" left="561" width="4" height="19" font="7"> </text>
<text top="93" left="561" width="574" height="19" font="7">Enrollment estimated RAP associated with survival outside hospital at 6 mo (Referent RAP&lt;13) </text>
<text top="111" left="561" width="230" height="19" font="7">RAP 13-16 HR 1.2 (95% CI: 0.96-1.5) </text>
<text top="130" left="561" width="211" height="19" font="7">RAP &gt;16 HR 1.6 (95% CI: 1.2-2.1) </text>
<text top="156" left="61" width="71" height="19" font="7">Meyer et al </text>
<text top="175" left="61" width="29" height="19" font="7">AJC </text>
<text top="194" left="61" width="114" height="19" font="7">2009 103:839-844 </text>
<text top="213" left="61" width="96" height="19" font="7">19268742  (37) </text>
<text top="156" left="197" width="86" height="19" font="7">Retrospective </text>
<text top="175" left="197" width="96" height="19" font="7">analysis of DIG </text>
<text top="194" left="197" width="26" height="19" font="7">trial </text>
<text top="156" left="317" width="34" height="19" font="7">7788 </text>
<text top="156" left="412" width="53" height="19" font="7">Stage C </text>
<text top="156" left="561" width="137" height="19" font="7">Mean follow-up 34 mo </text>
<text top="175" left="561" width="4" height="19" font="7"> </text>
<text top="194" left="561" width="121" height="19" font="7">Univariate analysis  </text>
<text top="213" left="561" width="181" height="19" font="7">Elevated JVP associated with </text>
<text top="232" left="561" width="211" height="19" font="7">Death: HR 1.7 (95% CI: 1.54-1.88) </text>
<text top="251" left="561" width="272" height="19" font="7">All-cause hosp: HR 1.35 (95% CI: 1.25-1.47) </text>
<text top="270" left="561" width="645" height="19" font="7">After adjusting for propensity score associations no longer significant; aHR: 0.95 (death), aHR:0.97 (hosp),  </text>
<text top="289" left="561" width="42" height="19" font="7">p&gt;0.5  </text>
<text top="309" left="61" width="374" height="19" font="9"><b>Utility of Valsalva Maneuver for Detecting Elevated PCWP </b></text>
<text top="329" left="61" width="82" height="19" font="7">Schmidt et al </text>
<text top="348" left="61" width="120" height="19" font="7">AJC 1993;71:462-5 </text>
<text top="367" left="61" width="53" height="19" font="11">8430644</text>
<text top="367" left="113" width="35" height="19" font="7">  (38) </text>
<text top="329" left="197" width="74" height="19" font="7">Prospective </text>
<text top="348" left="197" width="80" height="19" font="7">single center </text>
<text top="329" left="317" width="232" height="19" font="7">38 Unknown </text>
<text top="348" left="412" width="110" height="19" font="7"> (%HF not stated) </text>
<text top="329" left="561" width="556" height="19" font="7">Utility of square wave for LVEDP ≥15 mm Hg: sens 100%, spec 91%, PPV 82%, NPV 100% </text>
<text top="387" left="61" width="72" height="19" font="7">Rocca et al </text>
<text top="406" left="61" width="39" height="19" font="7">Chest </text>
<text top="425" left="61" width="102" height="19" font="7">1999; 116:861-7 </text>
<text top="444" left="61" width="64" height="19" font="11">10531144 </text>
<text top="444" left="125" width="28" height="19" font="7">(39) </text>
<text top="387" left="197" width="87" height="19" font="7">Single center, </text>
<text top="406" left="197" width="73" height="19" font="7">prospective </text>
<text top="425" left="197" width="36" height="19" font="7">study </text>
<text top="387" left="317" width="19" height="19" font="7">45 </text>
<text top="387" left="412" width="53" height="19" font="7">Stage C </text>
<text top="387" left="561" width="427" height="19" font="7">Pulse amplitude ratio by Valsalva correlated with BNP (r=0.6, p&lt;0.001) </text>
<text top="463" left="61" width="76" height="19" font="7">Givertz et al </text>
<text top="482" left="61" width="29" height="19" font="7">AJC </text>
<text top="501" left="61" width="102" height="19" font="7">2001 1213-1215 </text>
<text top="520" left="61" width="60" height="19" font="11">11356404</text>
<text top="520" left="121" width="35" height="19" font="7">  (40) </text>
<text top="463" left="197" width="87" height="19" font="7">Single center, </text>
<text top="482" left="197" width="73" height="19" font="7">prospective </text>
<text top="501" left="197" width="98" height="19" font="7">study of Vericor </text>
<text top="520" left="197" width="47" height="19" font="7">system </text>
<text top="463" left="317" width="49" height="19" font="7">30 men </text>
<text top="463" left="412" width="60" height="19" font="7">Class 3/4 </text>
<text top="463" left="561" width="403" height="19" font="7">Predicted PCWP by Valsalva vs measured PCWP: r=0.9, p&lt;0.001. </text>
<text top="482" left="561" width="210" height="19" font="7">Mean difference 0.07 ±2.9 mm Hg </text>
<text top="501" left="561" width="476" height="19" font="7">Predicted PCWP had sensitivity: 91%, specificity: 100% for PCWP ≥18 mm Hg </text>
<text top="540" left="61" width="81" height="19" font="7">Sharma et al </text>
<text top="559" left="61" width="100" height="19" font="7">Arch Intern Med </text>
<text top="578" left="61" width="95" height="19" font="7">2002:162:2084-</text>
<text top="597" left="61" width="34" height="19" font="7">2088 </text>
<text top="615" left="61" width="60" height="19" font="11">12374516</text>
<text top="615" left="121" width="35" height="19" font="7">  (41) </text>
<text top="540" left="197" width="74" height="19" font="7">Prospective </text>
<text top="559" left="197" width="51" height="19" font="7">study of </text>
<text top="578" left="197" width="73" height="19" font="7">commercial </text>
<text top="597" left="197" width="102" height="19" font="7">device (VeriCor) </text>
<text top="615" left="197" width="75" height="19" font="7">at 2 centers </text>
<text top="540" left="317" width="56" height="19" font="7">57 pts (2 </text>
<text top="559" left="317" width="52" height="19" font="7">women) </text>
<text top="540" left="412" width="60" height="19" font="7">Unknown </text>
<text top="559" left="412" width="133" height="19" font="7">Majority pts with CAD </text>
<text top="540" left="561" width="321" height="19" font="7">Pulse amplitude ratio correlated with LVEDP (r=0.86) </text>
<text top="559" left="561" width="299" height="19" font="7">84% of measurements within 4 mm Hg of LVEDP </text>
<text top="635" left="61" width="71" height="19" font="7">Felker et al </text>
<text top="654" left="61" width="92" height="19" font="7">Am J Medicine </text>
<text top="673" left="61" width="114" height="19" font="7">2006;119:117-132 </text>
<text top="692" left="61" width="60" height="19" font="11">16443410</text>
<text top="692" left="121" width="35" height="19" font="7">  (42) </text>
<text top="635" left="197" width="86" height="19" font="7">Review paper </text>
<text top="635" left="317" width="26" height="19" font="7">N/A </text>
<text top="635" left="412" width="26" height="19" font="7">N/A </text>
<text top="635" left="561" width="485" height="19" font="7">Significant correlation between CV response to Valsalva and LV filling pressures </text>
<text top="712" left="54" width="1270" height="17" font="13">AUC indicates area under the concentration curve; BNP, B-Type Natriuretic Peptide; CAD, coronary artery disease; CV, cardiovascular; DIG, Digitalis Investigation Group; f/u, follow-up; ESCAPE, Evaluation Study of Congestive Heart </text>
<text top="729" left="54" width="726" height="17" font="13">Failure and Pulmonary Artery Catheterization Effectiveness HJR, hepatojugular reflux; LVEF, left ventricular ejection fraction; LVEDP,</text>
<text top="731" left="780" width="4" height="16" font="7"> </text>
<text top="729" left="784" width="562" height="17" font="13">Left Ventricular End-Diastolic Pressure; JVD, jugular venous distension; JVP, jugular venous pressure; </text>
<text top="746" left="54" width="1281" height="17" font="13">N/A, not applicable; NPV, negative predictive value; PCWP, Pulmonary Capillary Wedge Pressure; PPV, positive predictive value, Pts, patients; r, Pearson’s correlation coefficient; RAP, right arterial pressure; and SOLVD, Studies of left </text>
<text top="763" left="54" width="129" height="17" font="13">ventricular dysfunction. </text>
<text top="780" left="54" width="3" height="17" font="13"> </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="18" size="14" family="Times" color="#323232"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">16</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="483" height="21" font="8"><b>Data Supplement 8. Clinical Evaluation – Risk Scoring (Section 6.1.2)</b></text>
<text top="57" left="537" width="3" height="17" font="15"><b> </b></text>
<text top="77" left="78" width="138" height="19" font="9"><b>Study Name, Author, </b></text>
<text top="96" left="130" width="33" height="19" font="9"><b>Year </b></text>
<text top="86" left="294" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="86" left="445" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="86" left="545" width="122" height="19" font="9"><b>Patient population </b></text>
<text top="86" left="756" width="64" height="19" font="9"><b>Variables </b></text>
<text top="86" left="1095" width="41" height="19" font="9"><b>Utility </b></text>
<text top="120" left="62" width="54" height="19" font="9"><b>Stage C </b></text>
<text top="142" left="62" width="62" height="19" font="7">Levy et al </text>
<text top="160" left="62" width="68" height="19" font="7">Circulation </text>
<text top="179" left="62" width="129" height="19" font="7">2006;113:1424-1433 </text>
<text top="198" left="62" width="105" height="19" font="7">Seattle HF score </text>
<text top="217" left="62" width="60" height="19" font="11">16534009</text>
<text top="217" left="122" width="35" height="19" font="7">  (10) </text>
<text top="142" left="244" width="164" height="19" font="7">Derivation cohort (PRAISE </text>
<text top="160" left="244" width="116" height="19" font="7">1); then tested in 5 </text>
<text top="179" left="244" width="153" height="19" font="7">additional trial databases </text>
<text top="142" left="432" width="34" height="19" font="7">1125 </text>
<text top="160" left="432" width="74" height="19" font="7">(Derivation) </text>
<text top="179" left="432" width="34" height="19" font="7">9942 </text>
<text top="198" left="432" width="72" height="19" font="7">(Validation) </text>
<text top="217" left="432" width="8" height="19" font="7">  </text>
<text top="142" left="541" width="101" height="19" font="7">Largely Stage C </text>
<text top="142" left="683" width="127" height="19" font="7">Available on website </text>
<text top="142" left="913" width="246" height="19" font="7">2 year survival for scores 0, 1,2,3,4 was: </text>
<text top="160" left="913" width="200" height="19" font="7">93%, 89%, 78% 58%, 30%, 11% </text>
<text top="179" left="913" width="154" height="19" font="7">AUC 0.729 (0.71 to 0.74) </text>
<text top="237" left="62" width="77" height="19" font="7">Pocock et al </text>
<text top="256" left="62" width="72" height="19" font="7">Eur Heart J </text>
<text top="275" left="62" width="91" height="19" font="7">2006;27:65-75 </text>
<text top="294" left="62" width="57" height="19" font="7"> CHARM </text>
<text top="313" left="62" width="60" height="19" font="11">16219658</text>
<text top="313" left="122" width="35" height="19" font="7">  (13) </text>
<text top="237" left="244" width="123" height="19" font="7">Analysis of CHARM </text>
<text top="237" left="432" width="38" height="19" font="7">7,599 </text>
<text top="237" left="541" width="74" height="19" font="7">Stage C HF </text>
<text top="237" left="683" width="77" height="19" font="7">21 variables </text>
<text top="237" left="913" width="96" height="19" font="7">2 year mortality </text>
<text top="256" left="913" width="236" height="19" font="7">Lowest to highest deciles 2.5% to 44% </text>
<text top="275" left="913" width="92" height="19" font="7">C statistic 0.75 </text>
<text top="294" left="913" width="8" height="19" font="7">  </text>
<text top="313" left="913" width="8" height="19" font="7">  </text>
<text top="335" left="62" width="54" height="19" font="9"><b>Stage D </b></text>
<text top="357" left="62" width="91" height="19" font="7">Aaronson et al </text>
<text top="376" left="62" width="68" height="19" font="7">Circulation </text>
<text top="395" left="62" width="99" height="19" font="7">1997;95:2660-7 </text>
<text top="414" left="62" width="117" height="19" font="7"> HF Survival Score </text>
<text top="432" left="62" width="53" height="19" font="11">9193435</text>
<text top="432" left="114" width="28" height="19" font="7">  (2) </text>
<text top="357" left="244" width="154" height="19" font="7">Derivation and Validation </text>
<text top="376" left="244" width="123" height="19" font="7">2 transplant centers </text>
<text top="395" left="244" width="8" height="19" font="7">  </text>
<text top="414" left="244" width="8" height="19" font="7">  </text>
<text top="357" left="432" width="26" height="19" font="7">268 </text>
<text top="376" left="432" width="74" height="19" font="7">(Derivation) </text>
<text top="395" left="432" width="26" height="19" font="7">199 </text>
<text top="414" left="432" width="72" height="19" font="7">(Validation) </text>
<text top="432" left="432" width="4" height="19" font="7"> </text>
<text top="357" left="541" width="53" height="19" font="7">Stage D </text>
<text top="357" left="683" width="204" height="19" font="7">Ischemic cardiomyopathy, resting </text>
<text top="376" left="683" width="180" height="19" font="7">heart rate, LVEF, IVCD (QRS </text>
<text top="395" left="683" width="196" height="19" font="7">duration 0.12 sec of any cause), </text>
<text top="414" left="683" width="193" height="19" font="7">mean resting BP, peak O2, and </text>
<text top="432" left="683" width="195" height="19" font="7">serum sodium PCWP (invasive) </text>
<text top="357" left="913" width="49" height="19" font="7">3 strata </text>
<text top="376" left="913" width="398" height="19" font="7">Event-free survival rates at 1 y for the low-, medium-, and high-risk</text>
<text top="377" left="1311" width="2" height="12" font="12"> </text>
<text top="395" left="913" width="287" height="19" font="7">HFSS strata were 93±2%, 72±5%, and 43±7% </text>
<text top="414" left="913" width="115" height="19" font="7">AUC 1 y 0.76-0.79 </text>
<text top="467" left="62" width="69" height="19" font="7">Lucas et al </text>
<text top="486" left="62" width="72" height="19" font="7">Am Heart J </text>
<text top="505" left="62" width="99" height="19" font="7">2000;140:840-7 </text>
<text top="524" left="62" width="124" height="19" font="7"> “Congestion Score” </text>
<text top="543" left="62" width="60" height="19" font="11">11099986</text>
<text top="543" left="122" width="35" height="19" font="7">  (43) </text>
<text top="467" left="244" width="214" height="19" font="7">Retrospective, single center  146 </text>
<text top="467" left="541" width="53" height="19" font="7">Stage D </text>
<text top="467" left="683" width="214" height="19" font="7">Congestion score: orthopnea, JVD, </text>
<text top="486" left="683" width="208" height="19" font="7">edema, weight gain, new increase </text>
<text top="505" left="683" width="54" height="19" font="7">diuretics </text>
<text top="467" left="913" width="263" height="19" font="7">Post discharge (4-6 wk) score vs. 2 y death </text>
<text top="486" left="913" width="46" height="19" font="7">0: 54% </text>
<text top="505" left="913" width="58" height="19" font="7">1-2: 67% </text>
<text top="524" left="913" width="58" height="19" font="7">3-5: 41% </text>
<text top="562" left="62" width="73" height="19" font="7">Nohria et al </text>
<text top="581" left="62" width="39" height="19" font="7">JACC </text>
<text top="600" left="62" width="121" height="19" font="7">2003:41:1797-1804 </text>
<text top="619" left="62" width="128" height="19" font="7"> “Stevenson profiles” </text>
<text top="638" left="62" width="60" height="19" font="11">12767667</text>
<text top="638" left="122" width="35" height="19" font="7">  (44) </text>
<text top="562" left="244" width="159" height="19" font="7">Prospective, single center </text>
<text top="562" left="432" width="48" height="19" font="7">452 pts </text>
<text top="562" left="541" width="53" height="19" font="7">Stage D </text>
<text top="562" left="683" width="148" height="19" font="7">Stevenson classification </text>
<text top="581" left="683" width="99" height="19" font="7">Profiles A,B,C,L </text>
<text top="600" left="683" width="8" height="19" font="7">  </text>
<text top="619" left="683" width="4" height="19" font="7"> </text>
<text top="562" left="913" width="385" height="19" font="7">Profile B associated with death+urgent transplant in multivariate </text>
<text top="581" left="913" width="172" height="19" font="7">analysis (HR: 2.5, p=0.003). </text>
<text top="658" left="62" width="81" height="19" font="7">Drazner et al </text>
<text top="677" left="62" width="50" height="19" font="7">Circ HF </text>
<text top="696" left="62" width="83" height="19" font="7">2008;1:170-7 </text>
<text top="714" left="62" width="128" height="19" font="7"> “Stevenson profiles” </text>
<text top="733" left="62" width="60" height="19" font="11">19675681</text>
<text top="733" left="122" width="35" height="19" font="7">  (31) </text>
<text top="658" left="244" width="134" height="19" font="7">Substudy of ESCAPE </text>
<text top="658" left="432" width="26" height="19" font="7">388 </text>
<text top="658" left="541" width="53" height="19" font="7">Stage D </text>
<text top="658" left="683" width="148" height="19" font="7">Stevenson classification </text>
<text top="658" left="913" width="383" height="19" font="7">Discharge profile “wet or cold” HR 1.5 (1.1, 2.1) for number of d </text>
<text top="677" left="913" width="301" height="19" font="7">alive outside hosp at 6 mo in multivariate analysis </text>
<text top="753" left="62" width="62" height="19" font="7">Levy et al </text>
<text top="772" left="62" width="100" height="19" font="7">J Heart Lung Tx </text>
<text top="753" left="244" width="154" height="19" font="7">Retrospective analysis of </text>
<text top="772" left="244" width="71" height="19" font="7">REMATCH </text>
<text top="753" left="432" width="26" height="19" font="7">129 </text>
<text top="772" left="432" width="71" height="19" font="7">REMATCH </text>
<text top="753" left="541" width="53" height="19" font="7">Stage D </text>
<text top="753" left="683" width="107" height="19" font="7">Seattle HF Score </text>
<text top="753" left="913" width="267" height="19" font="18">The 1-y ROC was 0.71 (95% CI: 0.62-0.80). </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">17</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="62" width="114" height="19" font="7">2009:28: 231-236. </text>
<text top="74" left="62" width="111" height="19" font="7"> Seattle HF Score </text>
<text top="93" left="62" width="60" height="19" font="11">19285613</text>
<text top="93" left="122" width="35" height="19" font="7">  (45) </text>
<text top="112" left="62" width="95" height="19" font="7">Gorodeski et al </text>
<text top="131" left="62" width="90" height="19" font="7">Circ Heart Fail </text>
<text top="150" left="62" width="99" height="19" font="7">2010;3:706-714 </text>
<text top="169" left="62" width="111" height="19" font="7"> Seattle HF Score </text>
<text top="188" left="62" width="60" height="19" font="11">20798278</text>
<text top="188" left="122" width="35" height="19" font="7">  (46) </text>
<text top="112" left="244" width="134" height="19" font="7">Single center study of </text>
<text top="131" left="244" width="171" height="19" font="7">ambulatory pts presented to </text>
<text top="150" left="244" width="129" height="19" font="7">transplant committee </text>
<text top="112" left="432" width="86" height="19" font="7">215 (between </text>
<text top="131" left="432" width="73" height="19" font="7">2004-2007) </text>
<text top="112" left="541" width="53" height="19" font="7">Stage D </text>
<text top="112" left="683" width="105" height="19" font="7">Seattle HF score </text>
<text top="112" left="913" width="139" height="19" font="7">ACM, VAD, Urgent HT </text>
<text top="131" left="913" width="41" height="19" font="7">2 y f/u </text>
<text top="150" left="913" width="184" height="19" font="7">C index 0.68 (1 yr), 0.65 (2 yr) </text>
<text top="169" left="913" width="328" height="19" font="7">Calibration overestimated survival among UNOS 2 pts </text>
<text top="188" left="913" width="8" height="19" font="7">  </text>
<text top="210" left="62" width="140" height="19" font="9"><b>Hospitalized Patients </b></text>
<text top="232" left="62" width="56" height="19" font="7">Lee et al </text>
<text top="251" left="62" width="40" height="19" font="7">JAMA </text>
<text top="270" left="62" width="129" height="19" font="7">2003:290:2581-2587 </text>
<text top="289" left="62" width="60" height="19" font="11">14625335</text>
<text top="289" left="122" width="35" height="19" font="7">  (11) </text>
<text top="308" left="62" width="4" height="19" font="7"> </text>
<text top="232" left="244" width="138" height="19" font="7">Retrospective study of </text>
<text top="251" left="244" width="170" height="19" font="7">multiple hospitals in Ontario </text>
<text top="270" left="244" width="51" height="19" font="7">Canada </text>
<text top="232" left="432" width="34" height="19" font="7">2624 </text>
<text top="251" left="432" width="67" height="19" font="7">(derivation </text>
<text top="270" left="432" width="73" height="19" font="7">1999-2001) </text>
<text top="289" left="432" width="34" height="19" font="7">1407 </text>
<text top="308" left="432" width="65" height="19" font="7">(validation </text>
<text top="327" left="432" width="73" height="19" font="7">1997-1999) </text>
<text top="346" left="432" width="8" height="19" font="7">  </text>
<text top="365" left="432" width="8" height="19" font="7">  </text>
<text top="384" left="432" width="8" height="19" font="7">  </text>
<text top="402" left="432" width="8" height="19" font="7">  </text>
<text top="232" left="541" width="99" height="19" font="7">Hospitalized pts </text>
<text top="232" left="683" width="208" height="19" font="7">Age, SBP, RR, Na&lt;136, Hgb &lt;10, </text>
<text top="251" left="683" width="184" height="19" font="7">BUN, CVA, Dementia, COPD, </text>
<text top="270" left="683" width="105" height="19" font="7">cirrhosis, Cancer </text>
<text top="232" left="913" width="318" height="19" font="7">Predicted and observed mortality rates matched well </text>
<text top="251" left="913" width="8" height="19" font="7">  </text>
<text top="270" left="913" width="85" height="19" font="7">30 d mortality </text>
<text top="289" left="913" width="125" height="19" font="7">AUC derivation 0.82 </text>
<text top="308" left="913" width="93" height="19" font="7">Validation 0.79 </text>
<text top="327" left="913" width="8" height="19" font="7">  </text>
<text top="346" left="913" width="77" height="19" font="7">1 y mortality </text>
<text top="365" left="913" width="32" height="19" font="7">AUC </text>
<text top="384" left="913" width="95" height="19" font="7">Derivation 0.77 </text>
<text top="402" left="913" width="93" height="19" font="7">Validation 0.76 </text>
<text top="426" left="62" width="86" height="19" font="7">Fonarow et al </text>
<text top="445" left="62" width="40" height="19" font="7">JAMA </text>
<text top="464" left="62" width="114" height="19" font="7">2005:293:572-580 </text>
<text top="483" left="62" width="60" height="19" font="7">ADHERE </text>
<text top="502" left="62" width="60" height="19" font="11">15687312</text>
<text top="502" left="122" width="35" height="19" font="7">  (14) </text>
<text top="426" left="244" width="168" height="19" font="7">CART analysis of ADHERE </text>
<text top="445" left="244" width="168" height="19" font="7">national registry 2001-2003 </text>
<text top="426" left="432" width="45" height="19" font="7">33,046 </text>
<text top="445" left="432" width="71" height="19" font="7">(derivation) </text>
<text top="464" left="432" width="45" height="19" font="7">32,229 </text>
<text top="483" left="432" width="72" height="19" font="7">(Validation) </text>
<text top="502" left="432" width="8" height="19" font="7">  </text>
<text top="426" left="541" width="99" height="19" font="7">Hospitalized pts </text>
<text top="426" left="683" width="330" height="19" font="7">BUN ≥43, SBP&lt;115, SCr ≥2.75 In-hospital </text>
<text top="426" left="979" width="89" height="19" font="7">mortality </text>
<text top="445" left="913" width="83" height="19" font="7">AUC 67-69% </text>
<text top="464" left="913" width="321" height="19" font="7">Morality ranges from 1.8(low risk) to ~25% (high risk) </text>
<text top="483" left="913" width="8" height="19" font="7">  </text>
<text top="521" left="62" width="73" height="19" font="7">Rohde et al </text>
<text top="540" left="62" width="106" height="19" font="7">J Cardiac Failure </text>
<text top="559" left="62" width="106" height="19" font="7">2006;12:587-593 </text>
<text top="578" left="62" width="123" height="19" font="7">“HF Revised Score” </text>
<text top="597" left="62" width="60" height="19" font="11">17045176</text>
<text top="597" left="122" width="35" height="19" font="7">  (47) </text>
<text top="521" left="244" width="153" height="19" font="7">Single center study 2000-</text>
<text top="540" left="244" width="34" height="19" font="7">2004 </text>
<text top="521" left="432" width="26" height="19" font="7">779 </text>
<text top="521" left="541" width="99" height="19" font="7">Hospitalized pts </text>
<text top="521" left="683" width="181" height="19" font="7">Cancer, SBP ≤124, Cr &gt;1,4m </text>
<text top="540" left="683" width="169" height="19" font="7">BUN&gt;37, Na &lt;136, Age&gt;70 </text>
<text top="521" left="913" width="121" height="19" font="7">In-hospital mortality </text>
<text top="540" left="913" width="187" height="19" font="7">Bootstrap C=0.77 (0.689-0.85) </text>
<text top="559" left="913" width="291" height="19" font="7">6 increasing groups: 0,5%, 7%, 10%, 29%, 83% </text>
<text top="617" left="62" width="88" height="19" font="7">Abraham et al </text>
<text top="636" left="62" width="39" height="19" font="7">JACC </text>
<text top="654" left="62" width="106" height="19" font="7">2008;52:347-356 </text>
<text top="673" left="62" width="90" height="19" font="7">OPTIMIZE-HF </text>
<text top="692" left="62" width="60" height="19" font="11">18652942</text>
<text top="692" left="122" width="35" height="19" font="7">  (16) </text>
<text top="617" left="244" width="159" height="19" font="7">Analysis of OPTIMIZE-HF </text>
<text top="636" left="244" width="48" height="19" font="7">registry </text>
<text top="654" left="244" width="68" height="19" font="7">2003-2004 </text>
<text top="673" left="244" width="8" height="19" font="7">  </text>
<text top="617" left="432" width="67" height="19" font="7">48,612 pts </text>
<text top="636" left="432" width="74" height="19" font="7">Validated in </text>
<text top="654" left="432" width="60" height="19" font="7">ADHERE </text>
<text top="673" left="432" width="4" height="19" font="7"> </text>
<text top="617" left="541" width="99" height="19" font="7">Hospitalized pts </text>
<text top="617" left="683" width="77" height="19" font="7">19 variables </text>
<text top="617" left="913" width="121" height="19" font="7">In-hospital mortality </text>
<text top="636" left="913" width="92" height="19" font="7">C statistic 0.77 </text>
<text top="654" left="913" width="163" height="19" font="7">Validation C statistic 0.746 </text>
<text top="673" left="913" width="189" height="19" font="7">Excellent reliability for mortality </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">18</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="62" width="87" height="19" font="7">Peterson et al </text>
<text top="74" left="62" width="132" height="19" font="7">Circ Cardiovasc Qual </text>
<text top="93" left="62" width="65" height="19" font="7">Outcomes </text>
<text top="111" left="62" width="83" height="19" font="7">2010:3:25-32 </text>
<text top="130" left="62" width="50" height="19" font="7"> GWTG </text>
<text top="149" left="62" width="60" height="19" font="11">20123668</text>
<text top="149" left="122" width="32" height="19" font="7"> (15) </text>
<text top="55" left="244" width="171" height="19" font="7">Analysis of GWTG admitted </text>
<text top="74" left="244" width="68" height="19" font="7">2005-2007 </text>
<text top="55" left="432" width="45" height="19" font="7">27,850 </text>
<text top="74" left="432" width="74" height="19" font="7">(Derivation) </text>
<text top="93" left="432" width="45" height="19" font="7">11,933 </text>
<text top="111" left="432" width="72" height="19" font="7">(Validation) </text>
<text top="130" left="432" width="4" height="19" font="7"> </text>
<text top="55" left="541" width="99" height="19" font="7">Hospitalized pts </text>
<text top="55" left="683" width="204" height="19" font="7">Age, SBP, BUN, HR,  Na, COPD, </text>
<text top="74" left="683" width="88" height="19" font="7">nonblack race </text>
<text top="55" left="913" width="121" height="19" font="7">In-hospital mortality </text>
<text top="74" left="913" width="80" height="19" font="7">C index 0.75 </text>
<text top="93" left="913" width="411" height="19" font="7">Predicted probability mortality over deciles ranged from 0.4% - 9.7% </text>
<text top="111" left="913" width="223" height="19" font="7">and corresponded with true mortality </text>
<text top="130" left="913" width="8" height="19" font="7">  </text>
<text top="177" left="62" width="40" height="19" font="9"><b>Other </b></text>
<text top="199" left="62" width="112" height="19" font="7">Gheorghiade et al </text>
<text top="218" left="62" width="132" height="19" font="7">Eur J of Heart Failure </text>
<text top="236" left="62" width="106" height="19" font="7">2010:12:423-433 </text>
<text top="255" left="62" width="147" height="19" font="7"> ESC Congestion Score </text>
<text top="274" left="62" width="64" height="19" font="11"> 20354029</text>
<text top="274" left="126" width="32" height="19" font="7"> (48) </text>
<text top="293" left="62" width="4" height="19" font="7"> </text>
<text top="199" left="244" width="154" height="19" font="7">Scientific Statement from </text>
<text top="218" left="244" width="166" height="19" font="7">Acute HF Committee of HF </text>
<text top="236" left="244" width="120" height="19" font="7">Association of ESC </text>
<text top="199" left="432" width="218" height="19" font="7">N/A N/A </text>
<text top="199" left="683" width="155" height="19" font="7">Congestion </text>
<text top="199" left="755" width="120" height="19" font="7">score </text>
<text top="218" left="683" width="205" height="19" font="7">Bedside assessment (Orthopnea, </text>
<text top="236" left="683" width="113" height="19" font="7">JVD, HM, Edema) </text>
<text top="255" left="683" width="156" height="19" font="7">Lab (BNP or NT proBNP) </text>
<text top="274" left="683" width="91" height="19" font="7">Orthostatic BP </text>
<text top="293" left="683" width="93" height="19" font="7">6 min walk test </text>
<text top="312" left="683" width="55" height="19" font="7">Valsalva </text>
<text top="199" left="913" width="117" height="19" font="7">Needs to be tested </text>
<text top="337" left="54" width="1275" height="17" font="13">ACM indicates all cause mortality; ADHERE, Acute Decompensated Heart Failure National Registry; AUC, area under the curve; BNP, B-type natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; CART, Classification and </text>
<text top="354" left="54" width="1301" height="17" font="13">regression trees; CHARM, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity; COPD, chronic obstructive pulmonary disease; CVA, Cerebrovascular Accident; ESC, European Society of Cardiology; ESCAPE, </text>
<text top="371" left="54" width="1243" height="17" font="13">Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; GWTG, Get With the Guidelines; HF, heart failure; HFSS, heart failure survival score; Hgb, hemoglobin; HR, heart rate; HT, heart </text>
<text top="389" left="54" width="1276" height="17" font="13">transplantation; HM, hepatomegaly; IVCD, intraventricular conduction delay; JVD, jugular venous distension; LVEF, left ventricular ejection fraction; N/A, not applicable; Na, sodium; NT proBNP, n-terminal pro-B-type natriuretic peptide; </text>
<text top="406" left="54" width="1285" height="17" font="13">OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Pts with HF; PCWP, Pulmonary Capillary Wedge Pressure; PRAISE, Prospective Randomized Amlodipine Survival Evaluation; pts, patients; REMATCH, </text>
<text top="423" left="54" width="1263" height="17" font="13">Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure; ROC, receiver operating characteristic curve; RR, respiratory rate; SBP, systolic blood pressure; SCr, serum creatinine; UNOS, United </text>
<text top="440" left="54" width="346" height="17" font="13">Network of Organ Sharing; and VAD, ventricular assist device.  </text>
<text top="457" left="54" width="3" height="15" font="6"> </text>
<text top="473" left="54" width="3" height="15" font="6"> </text>
<text top="497" left="54" width="423" height="21" font="8"><b>Data Supplement 9. Imaging Echocardiography (Section 6.4)</b></text>
<text top="500" left="477" width="3" height="17" font="15"><b> </b></text>
<text top="519" left="73" width="41" height="19" font="9"><b>Study </b></text>
<text top="538" left="71" width="44" height="19" font="9"><b>Name, </b></text>
<text top="557" left="67" width="52" height="19" font="9"><b>Author, </b></text>
<text top="576" left="77" width="33" height="19" font="9"><b>Year </b></text>
<text top="519" left="160" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="519" left="286" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="519" left="400" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="519" left="579" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="519" left="829" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="519" left="1021" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="519" left="1321" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="595" left="91" width="4" height="19" font="7"> </text>
<text top="595" left="202" width="4" height="19" font="7"> </text>
<text top="595" left="323" width="4" height="19" font="7"> </text>
<text top="595" left="434" width="4" height="19" font="7"> </text>
<text top="595" left="515" width="114" height="19" font="10"><i><b>Inclusion Criteria </b></i></text>
<text top="595" left="660" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="595" left="862" width="4" height="19" font="10"><i><b> </b></i></text>
<text top="595" left="1114" width="4" height="19" font="7"> </text>
<text top="595" left="1378" width="4" height="19" font="7"> </text>
<text top="620" left="55" width="50" height="17" font="13">IS. Syed </text>
<text top="637" left="55" width="31" height="17" font="13">2010 </text>
<text top="655" left="55" width="58" height="17" font="14">20159642 </text>
<text top="672" left="55" width="25" height="17" font="13">(49) </text>
<text top="620" left="144" width="112" height="17" font="13">Evaluate LGE-CMR </text>
<text top="637" left="144" width="96" height="17" font="13">in identifying CA; </text>
<text top="655" left="144" width="62" height="17" font="13">investigate </text>
<text top="672" left="144" width="71" height="17" font="13">associations </text>
<text top="689" left="144" width="102" height="17" font="13">between LGE and </text>
<text top="706" left="144" width="118" height="17" font="13">clinical, morphologic, </text>
<text top="724" left="144" width="83" height="17" font="13">functional, and </text>
<text top="741" left="144" width="68" height="17" font="13">biochemical </text>
<text top="758" left="144" width="51" height="17" font="13">features. </text>
<text top="620" left="276" width="83" height="17" font="13">Observational  </text>
<text top="620" left="386" width="70" height="17" font="13">120 (35 with </text>
<text top="637" left="386" width="88" height="17" font="13">positive cardiac </text>
<text top="655" left="386" width="72" height="17" font="13">histology, 49 </text>
<text top="672" left="386" width="85" height="17" font="13">without cardiac </text>
<text top="689" left="386" width="98" height="17" font="13">histology but with </text>
<text top="706" left="386" width="96" height="17" font="13">echo evidence of </text>
<text top="724" left="386" width="83" height="17" font="13">CA, 36 without </text>
<text top="741" left="386" width="96" height="17" font="13">histology or echo </text>
<text top="758" left="386" width="91" height="17" font="13">evidence of CA) </text>
<text top="620" left="498" width="116" height="17" font="13">Histologically proven </text>
<text top="637" left="498" width="129" height="17" font="13">amyloidosis and, in the </text>
<text top="655" left="498" width="132" height="17" font="13">case of AL amyloidosis, </text>
<text top="672" left="498" width="137" height="17" font="13">confirmatory evidence of </text>
<text top="689" left="498" width="141" height="17" font="13">monoclonal protein in the </text>
<text top="706" left="498" width="131" height="17" font="13">serum or urine and/or a </text>
<text top="724" left="498" width="140" height="17" font="13">monoclonal population of </text>
<text top="741" left="498" width="135" height="17" font="13">plasma cells in the bone </text>
<text top="758" left="498" width="48" height="17" font="13">marrow. </text>
<text top="620" left="658" width="119" height="17" font="13">Prior MI, myocarditis, </text>
<text top="637" left="658" width="120" height="17" font="13">prior peripheral blood </text>
<text top="655" left="658" width="52" height="17" font="13">stem cell </text>
<text top="672" left="658" width="102" height="17" font="13">transplantation, or </text>
<text top="689" left="658" width="60" height="17" font="13">prior heart </text>
<text top="706" left="658" width="84" height="17" font="13">transplantation </text>
<text top="620" left="794" width="131" height="17" font="13">LGE-CMR presentation </text>
<text top="637" left="794" width="146" height="17" font="13">in pts with amyloidosis;      </text>
<text top="655" left="794" width="121" height="17" font="13">associations between </text>
<text top="672" left="794" width="96" height="17" font="13">LGE and clinical, </text>
<text top="689" left="794" width="133" height="17" font="13">morphologic, functional, </text>
<text top="706" left="794" width="92" height="17" font="13">and biochemical </text>
<text top="724" left="794" width="55" height="17" font="13">features.  </text>
<text top="620" left="946" width="320" height="17" font="13">Of the 35 pts with histology, abnormal LGE was present in </text>
<text top="637" left="946" width="299" height="17" font="13">97% of the 49 with echo evidence, abnormal LGE was </text>
<text top="655" left="946" width="337" height="17" font="13">present in 86% of the 36 without histology or ECHO evidence </text>
<text top="672" left="946" width="344" height="17" font="13">of CA, abnormal LGE was present in 47%.                                 </text>
<text top="689" left="946" width="313" height="17" font="13">In all pts, LGE presence and pattern was associated with </text>
<text top="706" left="946" width="338" height="17" font="13">NYHA functional class, ECG voltage, LV mass index, RV wall </text>
<text top="724" left="946" width="222" height="17" font="13">thickness, troponin-T, and BNP levels.    </text>
<text top="620" left="1297" width="163" height="17" font="13">No control group,                    </text>
<text top="637" left="1297" width="146" height="17" font="13">cardiac histology was only </text>
<text top="655" left="1297" width="172" height="17" font="13">present in a subset of pts          </text>
<text top="672" left="1297" width="161" height="17" font="13">contraindication to the use of </text>
<text top="689" left="1297" width="20" height="17" font="13">Gd </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="19" size="7" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">19</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="55" width="58" height="17" font="13">V Rizzello </text>
<text top="72" left="55" width="31" height="17" font="13">2009 </text>
<text top="89" left="55" width="55" height="17" font="14">19443475</text>
<text top="89" left="110" width="3" height="17" font="13"> </text>
<text top="106" left="55" width="25" height="17" font="13">(50) </text>
<text top="124" left="55" width="3" height="17" font="13"> </text>
<text top="55" left="144" width="72" height="17" font="13">Evaluate the </text>
<text top="72" left="144" width="106" height="17" font="13">prognosis of viable </text>
<text top="89" left="144" width="111" height="17" font="13">pts with and without </text>
<text top="106" left="144" width="88" height="17" font="13">improvement of </text>
<text top="124" left="144" width="114" height="17" font="13">LVEF after coronary </text>
<text top="141" left="144" width="99" height="17" font="13">revascularisation. </text>
<text top="55" left="276" width="83" height="17" font="13">Observational  </text>
<text top="55" left="386" width="69" height="17" font="13">90; group 1: </text>
<text top="72" left="386" width="81" height="17" font="13">viable pts with </text>
<text top="89" left="386" width="34" height="17" font="13">LVEF </text>
<text top="106" left="386" width="75" height="17" font="13">improvement </text>
<text top="123" left="386" width="94" height="17" font="13">(n = 27); group 2, </text>
<text top="141" left="386" width="98" height="17" font="13">viable pts without </text>
<text top="158" left="386" width="34" height="17" font="13">LVEF </text>
<text top="175" left="386" width="75" height="17" font="13">improvement </text>
<text top="192" left="386" width="94" height="17" font="13">(n = 15), group 3, </text>
<text top="210" left="386" width="80" height="17" font="13">non-viable pts </text>
<text top="227" left="386" width="42" height="17" font="13">(n = 48) </text>
<text top="55" left="498" width="95" height="17" font="13">Pts were already </text>
<text top="72" left="498" width="129" height="17" font="13">scheduled for coronary </text>
<text top="89" left="498" width="96" height="17" font="13">revascularization </text>
<text top="106" left="498" width="111" height="17" font="13">according to clinical </text>
<text top="124" left="498" width="136" height="17" font="13">criteria of reduced LVEF </text>
<text top="141" left="498" width="133" height="17" font="13">(40%), symptoms of HF </text>
<text top="158" left="498" width="82" height="17" font="13">and/or angina, </text>
<text top="175" left="498" width="118" height="17" font="13">presence/absence of </text>
<text top="192" left="498" width="144" height="17" font="13">ischemia and presence of </text>
<text top="210" left="498" width="135" height="17" font="13">critical coronary disease </text>
<text top="227" left="498" width="88" height="17" font="13">at angiography. </text>
<text top="244" left="498" width="98" height="17" font="13">Only pts who had </text>
<text top="261" left="498" width="113" height="17" font="13">undergone coronary </text>
<text top="278" left="498" width="129" height="17" font="13">revascularisation alone </text>
<text top="296" left="498" width="146" height="17" font="13">were included in the study </text>
<text top="55" left="658" width="71" height="17" font="13">Pts who had </text>
<text top="72" left="658" width="96" height="17" font="13">undergone mitral </text>
<text top="89" left="658" width="88" height="17" font="13">valvuloplasty or </text>
<text top="106" left="658" width="107" height="17" font="13">aneurismectomy in </text>
<text top="124" left="658" width="90" height="17" font="13">association with </text>
<text top="141" left="658" width="96" height="17" font="13">revascularisation </text>
<text top="158" left="658" width="86" height="17" font="13">were excluded. </text>
<text top="55" left="794" width="116" height="17" font="13">Cardiac events were </text>
<text top="72" left="794" width="125" height="17" font="13">evaluated during a 4-y </text>
<text top="89" left="794" width="137" height="17" font="13">follow-up (cardiac death, </text>
<text top="106" left="794" width="119" height="17" font="13">new MI, admission to </text>
<text top="124" left="794" width="91" height="17" font="13">hospital for HF)  </text>
<text top="141" left="794" width="7" height="17" font="13">  </text>
<text top="55" left="946" width="313" height="17" font="13">Cardiac event rate was low (4%) in group 1, intermediate </text>
<text top="72" left="946" width="345" height="17" font="13">(21%) in group 2 and high (33%) in group 3.                               </text>
<text top="89" left="946" width="328" height="17" font="13">After revascularization, the mean (SD) LVEF improved from </text>
<text top="106" left="946" width="280" height="17" font="13">32 (9)% to 42 (10)% in group 1, but did not change </text>
<text top="124" left="946" width="345" height="17" font="13">significantly in group 2 and in group 3, p,0.001 by ANOVA.        </text>
<text top="141" left="946" width="329" height="17" font="13">HF symptoms improved in both groups 1 (mean (SD) NYHA </text>
<text top="158" left="946" width="312" height="17" font="13">class from 3.1 (0.9) to 1.7 (0.7)) and 2 (from 3.2 (0.7)-1.7 </text>
<text top="175" left="946" width="322" height="17" font="13">(0.9)), but not in group 3 (from 2.8 (1.0)-2.7 (0.5)), p=0.001 </text>
<text top="192" left="946" width="66" height="17" font="13">by ANOVA. </text>
<text top="210" left="946" width="320" height="17" font="13">The difference in event rate was not statistically significant </text>
<text top="227" left="946" width="310" height="17" font="13">between groups 1 and 2 -small number of pts- but it was </text>
<text top="244" left="946" width="333" height="17" font="13">significant between the 3 groups using Kaplan–Meier p=0.01 </text>
<text top="261" left="946" width="3" height="17" font="13"> </text>
<text top="55" left="1297" width="24" height="17" font="13">N/A </text>
<text top="314" left="55" width="46" height="17" font="13">Kevin C </text>
<text top="331" left="55" width="48" height="17" font="13">Allman   </text>
<text top="348" left="55" width="31" height="17" font="13">2002 </text>
<text top="365" left="55" width="55" height="17" font="14">11923039</text>
<text top="365" left="110" width="3" height="17" font="13"> </text>
<text top="382" left="55" width="25" height="17" font="13">(51) </text>
<text top="314" left="144" width="81" height="17" font="13">Examines late </text>
<text top="331" left="144" width="70" height="17" font="13">survival with </text>
<text top="348" left="144" width="111" height="17" font="13">revascularization vs </text>
<text top="365" left="144" width="118" height="17" font="13">medical therapy after </text>
<text top="382" left="144" width="107" height="17" font="13">myocardial viability </text>
<text top="400" left="144" width="98" height="17" font="13">testing in pts with </text>
<text top="417" left="144" width="112" height="17" font="13">severe CAD and LV </text>
<text top="434" left="144" width="66" height="17" font="13">dysfunction </text>
<text top="314" left="276" width="93" height="17" font="13">Meta-analysis of </text>
<text top="331" left="276" width="76" height="17" font="13">observational </text>
<text top="348" left="276" width="42" height="17" font="13">studies </text>
<text top="314" left="386" width="82" height="17" font="13">3,088 (viability </text>
<text top="331" left="386" width="92" height="17" font="13">demonstrated in </text>
<text top="348" left="386" width="32" height="17" font="13">42%) </text>
<text top="314" left="498" width="118" height="17" font="13">Pts with CAD and LV </text>
<text top="331" left="498" width="122" height="17" font="13">dysfunction who were </text>
<text top="348" left="498" width="118" height="17" font="13">tested for myocardial </text>
<text top="365" left="498" width="112" height="17" font="13">viability with cardiac </text>
<text top="382" left="498" width="139" height="17" font="13">imaging procedures from </text>
<text top="400" left="498" width="103" height="17" font="13">24 viability studies </text>
<text top="417" left="498" width="143" height="17" font="13">reporting pt survival using </text>
<text top="434" left="498" width="100" height="17" font="13">thallium perfusion </text>
<text top="451" left="498" width="79" height="17" font="13">imaging, F-18 </text>
<text top="469" left="498" width="109" height="17" font="13">fluorodeoxyglucose </text>
<text top="486" left="498" width="117" height="17" font="13">metabolic imaging or </text>
<text top="503" left="498" width="113" height="17" font="13">dobutamine ECHO.  </text>
<text top="314" left="658" width="110" height="17" font="13">Those not reporting </text>
<text top="331" left="658" width="92" height="17" font="13">deaths or where </text>
<text top="348" left="658" width="111" height="17" font="13">deaths could not be </text>
<text top="365" left="658" width="102" height="17" font="13">apportioned to pts </text>
<text top="382" left="658" width="83" height="17" font="13">with vs without </text>
<text top="400" left="658" width="74" height="17" font="13">viability were </text>
<text top="417" left="658" width="53" height="17" font="13">excluded </text>
<text top="314" left="794" width="126" height="17" font="13">Annual mortality rates, </text>
<text top="331" left="794" width="125" height="17" font="13">pts followed for 25±10 </text>
<text top="348" left="794" width="27" height="17" font="13">mo.  </text>
<text top="365" left="794" width="7" height="17" font="13">  </text>
<text top="314" left="946" width="336" height="17" font="13">For pts with defined myocardial viability, annual mortality rate </text>
<text top="331" left="946" width="274" height="17" font="13">was 16% in medically treated pts but only 3.2% in </text>
<text top="348" left="946" width="113" height="17" font="13">revascularized pts (χ</text>
<text top="349" left="1059" width="4" height="11" font="19">2</text>
<text top="348" left="1064" width="199" height="17" font="13"> =147, p&lt;0.0001). This represents a </text>
<text top="365" left="946" width="319" height="17" font="13">79.6% relative reduction in risk of death for revascularized </text>
<text top="382" left="946" width="291" height="17" font="13">pts. For pts without viability, annual mortality was not </text>
<text top="400" left="946" width="291" height="17" font="13">significantly different by treatment method: 7.7% with </text>
<text top="417" left="946" width="297" height="17" font="13">revascularization vs 6.2% for medical therapy (p=NS). </text>
<text top="314" left="1297" width="143" height="17" font="13">The individual studies are </text>
<text top="331" left="1297" width="80" height="17" font="13">observational, </text>
<text top="348" left="1297" width="92" height="17" font="13">nonrandomized, </text>
<text top="365" left="1297" width="140" height="17" font="13">unblinded and subject to  </text>
<text top="382" left="1297" width="160" height="17" font="13">publication and other biases. </text>
<text top="400" left="1297" width="159" height="17" font="13">In this metaanalysis, viability </text>
<text top="417" left="1297" width="155" height="17" font="13">could only be interpreted as </text>
<text top="434" left="1297" width="152" height="17" font="13">“present” or “absent” based </text>
<text top="451" left="1297" width="117" height="17" font="13">on individual studies’ </text>
<text top="469" left="1297" width="59" height="17" font="13">definitions </text>
<text top="521" left="55" width="61" height="17" font="13">Beanlands </text>
<text top="538" left="55" width="65" height="17" font="13">RS.    2002 </text>
<text top="555" left="55" width="55" height="17" font="14">12446055</text>
<text top="555" left="110" width="3" height="17" font="13"> </text>
<text top="573" left="55" width="25" height="17" font="13">(52) </text>
<text top="521" left="144" width="107" height="17" font="13">Whether the extent </text>
<text top="538" left="144" width="111" height="17" font="13">of viability or scar is </text>
<text top="555" left="144" width="88" height="17" font="13">important in the </text>
<text top="573" left="144" width="109" height="17" font="13">amount of recovery </text>
<text top="590" left="144" width="99" height="17" font="13">of LV function       </text>
<text top="607" left="144" width="94" height="17" font="13">and to develop a </text>
<text top="624" left="144" width="111" height="17" font="13">model for predicting </text>
<text top="641" left="144" width="79" height="17" font="13">recovery after </text>
<text top="659" left="144" width="96" height="17" font="13">revascularization </text>
<text top="676" left="144" width="111" height="17" font="13">that could be tested </text>
<text top="693" left="144" width="118" height="17" font="13">in a randomized trial. </text>
<text top="521" left="276" width="68" height="17" font="13">Prospective </text>
<text top="538" left="276" width="64" height="17" font="13">multicenter </text>
<text top="555" left="276" width="41" height="17" font="13">cohort  </text>
<text top="521" left="386" width="77" height="17" font="13">82; Complete </text>
<text top="538" left="386" width="78" height="17" font="13">follow-up was </text>
<text top="555" left="386" width="86" height="17" font="13">available on 70 </text>
<text top="573" left="386" width="23" height="17" font="13">pts. </text>
<text top="521" left="498" width="133" height="17" font="13">Pts CAD and severe LV </text>
<text top="538" left="498" width="141" height="17" font="13">dysfunction with EF  35% </text>
<text top="555" left="498" width="106" height="17" font="13">by any quantitative </text>
<text top="573" left="498" width="116" height="17" font="13">technique, who were </text>
<text top="590" left="498" width="111" height="17" font="13">being scheduled for </text>
<text top="607" left="498" width="96" height="17" font="13">revascularization </text>
<text top="521" left="658" width="123" height="17" font="13">PTs with MI within the </text>
<text top="538" left="658" width="90" height="17" font="13">preceding 6 wk, </text>
<text top="555" left="658" width="118" height="17" font="13">severe valve disease </text>
<text top="573" left="658" width="83" height="17" font="13">requiring valve </text>
<text top="590" left="658" width="75" height="17" font="13">replacement, </text>
<text top="607" left="658" width="87" height="17" font="13">requirement for </text>
<text top="624" left="658" width="114" height="17" font="13">aneurysm resection, </text>
<text top="641" left="658" width="119" height="17" font="13">and inability to obtain </text>
<text top="659" left="658" width="101" height="17" font="13">informed consent. </text>
<text top="521" left="794" width="127" height="17" font="13">Absolute change in EF </text>
<text top="538" left="794" width="81" height="17" font="13">determined by </text>
<text top="555" left="794" width="137" height="17" font="13">radionuclide angiograms </text>
<text top="573" left="794" width="31" height="17" font="13">3 mo </text>
<text top="590" left="794" width="119" height="17" font="13">postrevascularization </text>
<text top="607" left="794" width="7" height="17" font="13">  </text>
<text top="521" left="946" width="334" height="17" font="13">Amount of scar was a significant independent predictor of LV </text>
<text top="538" left="946" width="224" height="17" font="13">function recovery after revascularization. </text>
<text top="555" left="946" width="291" height="17" font="13">Across tertiles of scar scores (I, small: 0% to 16%; II, </text>
<text top="573" left="946" width="302" height="17" font="13">moderate: 16% to 27.5%; III, large: 27.5% to 47%), the </text>
<text top="590" left="946" width="319" height="17" font="13">changes in EFs were 9.0±1.9%, 3.7±1.6%, and 1.3±1.5% </text>
<text top="607" left="946" width="175" height="17" font="13">(p=0.003: I vs. III), respectively. </text>
<text top="624" left="946" width="7" height="17" font="13">  </text>
<text top="521" left="1297" width="143" height="17" font="13">Pt population in this study </text>
<text top="538" left="1297" width="125" height="17" font="13">included pts who were </text>
<text top="555" left="1297" width="111" height="17" font="13">predominantly men, </text>
<text top="573" left="1297" width="148" height="17" font="13">predominately between 53-</text>
<text top="590" left="1297" width="148" height="17" font="13">71 y of age (1 SD from the </text>
<text top="607" left="1297" width="130" height="17" font="13">mean), had multivessel </text>
<text top="624" left="1297" width="163" height="17" font="13">disease, and had bypassable </text>
<text top="641" left="1297" width="130" height="17" font="13">vessels.                         </text>
<text top="659" left="1297" width="158" height="17" font="13">Although improvement in LV </text>
<text top="676" left="1297" width="159" height="17" font="13">function has been noted at 3 </text>
<text top="693" left="1297" width="133" height="17" font="13">mo of follow-up in many </text>
<text top="710" left="1297" width="161" height="17" font="13">previous studies, recent data </text>
<text top="727" left="1297" width="152" height="17" font="13">suggest that more recovery </text>
<text top="745" left="1297" width="161" height="17" font="13">may be observed with longer </text>
<text top="762" left="1297" width="79" height="17" font="13">follow-up time </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">20</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="55" width="44" height="17" font="13">Paul R. </text>
<text top="72" left="55" width="72" height="17" font="13">Pagley 1997 </text>
<text top="89" left="55" width="48" height="17" font="14">9264484</text>
<text top="89" left="103" width="3" height="17" font="13"> </text>
<text top="106" left="55" width="25" height="17" font="13">(53) </text>
<text top="55" left="144" width="102" height="17" font="13">Hypothesized that </text>
<text top="72" left="144" width="73" height="17" font="13">pts with poor </text>
<text top="89" left="144" width="107" height="17" font="13">ventricular function </text>
<text top="106" left="144" width="105" height="17" font="13">and predominantly </text>
<text top="124" left="144" width="106" height="17" font="13">viable myocardium </text>
<text top="141" left="144" width="75" height="17" font="13">have a better </text>
<text top="158" left="144" width="79" height="17" font="13">outcome after </text>
<text top="175" left="144" width="87" height="17" font="13">bypass surgery </text>
<text top="192" left="144" width="117" height="17" font="13">compared with those </text>
<text top="210" left="144" width="101" height="17" font="13">with less viability.  </text>
<text top="55" left="276" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="276" width="41" height="17" font="13">cohort  </text>
<text top="55" left="386" width="17" height="17" font="13">70 </text>
<text top="55" left="498" width="107" height="17" font="13">Pts with EFs &lt;40% </text>
<text top="72" left="498" width="146" height="17" font="13">without significant valvular </text>
<text top="89" left="498" width="102" height="17" font="13">disease who were </text>
<text top="106" left="498" width="98" height="17" font="13">referred for a first </text>
<text top="124" left="498" width="138" height="17" font="13">coronary bypass surgery </text>
<text top="141" left="498" width="85" height="17" font="13">and underwent </text>
<text top="158" left="498" width="138" height="17" font="13">preoperative quantitative </text>
<text top="175" left="498" width="136" height="17" font="13">planar 201Tl imaging for </text>
<text top="192" left="498" width="125" height="17" font="13">viability determination. </text>
<text top="55" left="658" width="71" height="17" font="13">Prior CABG, </text>
<text top="72" left="658" width="104" height="17" font="13">coexisting valvular </text>
<text top="89" left="658" width="70" height="17" font="13">disease and </text>
<text top="106" left="658" width="122" height="17" font="13">underwent concurrent </text>
<text top="124" left="658" width="70" height="17" font="13">aortic or MV </text>
<text top="141" left="658" width="122" height="17" font="13">replacement, or those </text>
<text top="158" left="658" width="120" height="17" font="13">with SPECT imaging  </text>
<text top="55" left="794" width="112" height="17" font="13">CV death or cardiac </text>
<text top="72" left="794" width="131" height="17" font="13">transplantation; median </text>
<text top="89" left="794" width="118" height="17" font="13">time to follow-up was </text>
<text top="106" left="794" width="121" height="17" font="13">1177 d (range, 590 to </text>
<text top="124" left="794" width="35" height="17" font="13">1826) </text>
<text top="141" left="794" width="7" height="17" font="13">  </text>
<text top="55" left="946" width="314" height="17" font="13">The viability index was significantly related to 3-y survival </text>
<text top="72" left="946" width="332" height="17" font="13">free of cardiac event (cardiac death or heart transplant) after </text>
<text top="89" left="946" width="327" height="17" font="13">bypass surgery (p=0.011) and was independent of age, EF, </text>
<text top="106" left="946" width="320" height="17" font="13">and number of diseased coronary vessels. Survival free of </text>
<text top="124" left="946" width="316" height="17" font="13">cardiac death or transplantation was significantly better in </text>
<text top="141" left="946" width="266" height="17" font="13">group 1 pts on Kaplan-Meier analysis (p=0.018). </text>
<text top="158" left="946" width="7" height="17" font="13">  </text>
<text top="55" left="1297" width="27" height="17" font="13"> N/A </text>
<text top="228" left="55" width="55" height="17" font="13">Senior R, </text>
<text top="245" left="55" width="31" height="17" font="13">1999 </text>
<text top="262" left="55" width="55" height="17" font="14">10362184</text>
<text top="262" left="110" width="3" height="17" font="13"> </text>
<text top="279" left="55" width="25" height="17" font="13">(54) </text>
<text top="296" left="55" width="3" height="17" font="13"> </text>
<text top="228" left="144" width="88" height="17" font="13">To evaluate the </text>
<text top="245" left="144" width="47" height="17" font="13">effect of </text>
<text top="262" left="144" width="113" height="17" font="13">revascularization on </text>
<text top="279" left="144" width="103" height="17" font="13">survival in pts with </text>
<text top="296" left="144" width="118" height="17" font="13">CHF due to ischemic </text>
<text top="314" left="144" width="62" height="17" font="13">LV systolic </text>
<text top="331" left="144" width="103" height="17" font="13">dysfunction based </text>
<text top="348" left="144" width="105" height="17" font="13">on the presence of </text>
<text top="365" left="144" width="110" height="17" font="13">myocardial viability  </text>
<text top="228" left="276" width="79" height="17" font="13">Observational </text>
<text top="245" left="276" width="70" height="17" font="13">prospective  </text>
<text top="228" left="386" width="17" height="17" font="13">87 </text>
<text top="228" left="498" width="132" height="17" font="13">CHF (NYHA class II-IV) </text>
<text top="245" left="498" width="141" height="17" font="13">for at least 3 mo that was </text>
<text top="262" left="498" width="151" height="17" font="13">treated medically;                </text>
<text top="279" left="498" width="132" height="17" font="13">LVEF ≤35%;                  </text>
<text top="296" left="498" width="136" height="17" font="13">clinical evidence of CAD </text>
<text top="228" left="658" width="106" height="17" font="13">Significant valvular </text>
<text top="245" left="658" width="99" height="17" font="13">disease, unstable </text>
<text top="262" left="658" width="96" height="17" font="13">angina, MI within </text>
<text top="279" left="658" width="79" height="17" font="13">three months, </text>
<text top="296" left="658" width="116" height="17" font="13">sustained ventricular </text>
<text top="314" left="658" width="100" height="17" font="13">tachycardia or AF </text>
<text top="228" left="794" width="116" height="17" font="13">Cardiac deaths were </text>
<text top="245" left="794" width="94" height="17" font="13">defined as those </text>
<text top="262" left="794" width="132" height="17" font="13">resulting from acute MI, </text>
<text top="279" left="794" width="98" height="17" font="13">refractory CHF or </text>
<text top="296" left="794" width="130" height="17" font="13">occurring suddenly and </text>
<text top="314" left="794" width="122" height="17" font="13">not being attributed to </text>
<text top="331" left="794" width="113" height="17" font="13">other known causes </text>
<text top="348" left="794" width="139" height="17" font="13">after a mean follow-up of </text>
<text top="365" left="794" width="66" height="17" font="13">40 ± 17 mo </text>
<text top="228" left="946" width="312" height="17" font="13">Pts with at least 5 segments showing myocardial viability </text>
<text top="245" left="946" width="316" height="17" font="13">underwent revascularization, mortality was reduced by an </text>
<text top="262" left="946" width="325" height="17" font="13">average of 93% which was associated with improvement in </text>
<text top="279" left="946" width="337" height="17" font="13">NYHA class as well as LVEF.                                      Pts with </text>
<text top="296" left="946" width="316" height="17" font="13">&lt;5 segments showing myocardial viability who underwent </text>
<text top="314" left="946" width="333" height="17" font="13">revascularization (and thus, showing mostly scar), and those </text>
<text top="331" left="946" width="323" height="17" font="13">with at least 5 segments demonstrating myocardial viability </text>
<text top="348" left="946" width="314" height="17" font="13">who were treated medically, had a much higher mortality. </text>
<text top="365" left="946" width="112" height="17" font="13">(95% CI: 22%-99%) </text>
<text top="228" left="1297" width="146" height="17" font="13">Single-center study where </text>
<text top="245" left="1297" width="170" height="17" font="13">selection bias is unavoidable.   </text>
<text top="262" left="1297" width="137" height="17" font="13">Selection bias may have </text>
<text top="279" left="1297" width="153" height="17" font="13">favored taking one group to </text>
<text top="296" left="1297" width="120" height="17" font="13">surgery over another. </text>
<text top="385" left="55" width="59" height="17" font="13">Kwon DH  </text>
<text top="402" left="55" width="31" height="17" font="13">2009 </text>
<text top="419" left="55" width="55" height="17" font="14">19356530</text>
<text top="419" left="110" width="3" height="17" font="13"> </text>
<text top="436" left="55" width="25" height="17" font="13">(55) </text>
<text top="385" left="144" width="76" height="17" font="13">To determine </text>
<text top="402" left="144" width="118" height="17" font="13">whether the extent of </text>
<text top="419" left="144" width="107" height="17" font="13">LV scar, measured </text>
<text top="436" left="144" width="87" height="17" font="13">with DHE-CMR </text>
<text top="454" left="144" width="105" height="17" font="13">predicts survival in </text>
<text top="471" left="144" width="96" height="17" font="13">pts with ischemic </text>
<text top="488" left="144" width="116" height="17" font="13">cardiomyopathy ICM </text>
<text top="505" left="144" width="73" height="17" font="13">and severely </text>
<text top="523" left="144" width="85" height="17" font="13">reduced LVEF. </text>
<text top="385" left="276" width="83" height="17" font="13">Observational  </text>
<text top="385" left="386" width="24" height="17" font="13">349 </text>
<text top="385" left="498" width="144" height="17" font="13">Pts with documented ICM </text>
<text top="402" left="498" width="119" height="17" font="13">(on the basis of  70% </text>
<text top="419" left="498" width="115" height="17" font="13">stenosis in at least 1 </text>
<text top="436" left="498" width="146" height="17" font="13">epicardial coronary vessel </text>
<text top="454" left="498" width="127" height="17" font="13">on angiography and/or </text>
<text top="471" left="498" width="136" height="17" font="13">history of MI or coronary </text>
<text top="488" left="498" width="129" height="17" font="13">revascularization), who </text>
<text top="505" left="498" width="115" height="17" font="13">were referred for the </text>
<text top="523" left="498" width="146" height="17" font="13">assessment of myocardial </text>
<text top="540" left="498" width="101" height="17" font="13">viability with CMR </text>
<text top="385" left="658" width="98" height="17" font="13">Pts with standard </text>
<text top="402" left="658" width="32" height="17" font="13">CMR </text>
<text top="419" left="658" width="96" height="17" font="13">contraindications </text>
<text top="436" left="658" width="92" height="17" font="13">including severe </text>
<text top="454" left="658" width="110" height="17" font="13">claustrophobia, AF, </text>
<text top="471" left="658" width="112" height="17" font="13">and the presence of </text>
<text top="488" left="658" width="74" height="17" font="13">pacemakers, </text>
<text top="505" left="658" width="87" height="17" font="13">defibrillators, or </text>
<text top="523" left="658" width="86" height="17" font="13">aneurysm clips </text>
<text top="385" left="794" width="129" height="17" font="13">All-cause mortality was </text>
<text top="402" left="794" width="118" height="17" font="13">ascertained by social </text>
<text top="419" left="794" width="113" height="17" font="13">security death index </text>
<text top="436" left="794" width="139" height="17" font="13">after a mean of follow-up </text>
<text top="454" left="794" width="131" height="17" font="13">2.6 ± 1.2 y (median 2.4 </text>
<text top="471" left="794" width="14" height="17" font="13">y) </text>
<text top="488" left="794" width="7" height="17" font="13">  </text>
<text top="385" left="946" width="338" height="17" font="13">Mean scar percentage and transmurality score were higher in </text>
<text top="402" left="946" width="180" height="17" font="13">pts with events vs those without  </text>
<text top="419" left="946" width="344" height="17" font="13">(39±22 vs 30±20, p=0.003, and 9.7±5 vs. 7.8±5, p=0.004).      </text>
<text top="436" left="946" width="312" height="17" font="13">*On Cox proportional hazard survival analysis, quantified </text>
<text top="454" left="946" width="336" height="17" font="13">scar was greater than the median (30% of total myocardium), </text>
<text top="471" left="946" width="203" height="17" font="13">and female gender predicted events  </text>
<text top="488" left="946" width="313" height="17" font="13">(RR: 1.75; 95% CI: 1.02-3.03 and RR:1.83; 95% CI: 1.06-</text>
<text top="505" left="946" width="179" height="17" font="13">3.16, respectively, both p=0.03). </text>
<text top="385" left="1297" width="111" height="17" font="13">Selection bias of an </text>
<text top="402" left="1297" width="109" height="17" font="13">observational study </text>
<text top="419" left="1297" width="156" height="17" font="13">conducted at a large tertiary </text>
<text top="436" left="1297" width="153" height="17" font="13">referral center.       Only the </text>
<text top="454" left="1297" width="158" height="17" font="13">pts with no contraindications </text>
<text top="471" left="1297" width="126" height="17" font="13">to CMR underwent the </text>
<text top="488" left="1297" width="73" height="17" font="13">examination. </text>
<text top="558" left="55" width="55" height="19" font="7">Ordovas </text>
<text top="577" left="55" width="61" height="19" font="7">KG. 2011 </text>
<text top="596" left="55" width="60" height="19" font="11">22012903</text>
<text top="596" left="116" width="4" height="19" font="7"> </text>
<text top="615" left="55" width="28" height="19" font="7">(56) </text>
<text top="558" left="144" width="30" height="19" font="7"> N/A </text>
<text top="558" left="276" width="87" height="19" font="7">Review paper </text>
<text top="558" left="386" width="26" height="19" font="7">N/A </text>
<text top="558" left="498" width="26" height="19" font="7">N/A </text>
<text top="558" left="658" width="26" height="19" font="7">N/A </text>
<text top="558" left="794" width="26" height="19" font="7">N/A </text>
<text top="558" left="946" width="327" height="17" font="13">An international multicenter study (54) reported a sensitivity </text>
<text top="575" left="946" width="336" height="17" font="13">of 99% for detection of acute infarction and 94% for detection </text>
<text top="592" left="946" width="343" height="17" font="13">of chronic infarction.                                                                    </text>
<text top="609" left="946" width="307" height="17" font="13">Delayed enhancement occurs in both acute and chronic </text>
<text top="627" left="946" width="288" height="17" font="13">(scar) infarctions and in an array of other myocardial </text>
<text top="644" left="946" width="309" height="17" font="13">processes that cause myocardial necrosis, infiltration, or </text>
<text top="661" left="946" width="266" height="17" font="13">fibrosis. These include myocarditis, hypertrophic </text>
<text top="678" left="946" width="289" height="17" font="13">cardiomyopathy, amyloidosis, sarcoidosis, and other </text>
<text top="695" left="946" width="344" height="17" font="13">myocardial conditions.                                                                 </text>
<text top="713" left="946" width="308" height="17" font="13">In several of these diseases, the presence and extent of </text>
<text top="730" left="946" width="279" height="17" font="13">delayed enhancement has prognostic implications. </text>
<text top="558" left="1297" width="24" height="17" font="13">N/A </text>
<text top="748" left="54" width="1389" height="15" font="6">AF, atrial fibrillation; AL, Amyloid Light-chain; ANOVA, analysis of variance; CA, cardiac amyloidosis; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; CMR, cardiovascular magnetic resonance; CV, cardiovascular; DHE-CMR, delayed </text>
<text top="763" left="54" width="1368" height="15" font="6">hyperenhancement cardiac magnetic resonance; ECHO, echocardiography; EF, ejection fraction; Gd, gadolinium; ICM, ischemic cardiomyopathy; LGE-CMR, late gadolinium enhancement cardiac magnetic resonance; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, </text>
<text top="779" left="54" width="1070" height="15" font="6">myocardial infarction; N/A, not applicable; NS, not significant; NYHA, New York Heart Association; pts, patients; RV, right ventricular; SD, standard deviation; and SPECT, single-photon emission computed tomography.  </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="20" size="14" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">21</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="4" height="19" font="7"> </text>
<text top="91" left="54" width="303" height="21" font="8"><b>Data Supplement 10. Biopsy (Section 6.5.3)</b></text>
<text top="94" left="357" width="3" height="17" font="15"><b> </b></text>
<text top="121" left="162" width="171" height="19" font="9"><b>Study Name, Author, Year </b></text>
<text top="121" left="470" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="121" left="628" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="121" left="770" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="121" left="892" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="121" left="1228" width="53" height="19" font="9"><b>Results </b></text>
<text top="141" left="61" width="347" height="19" font="7">Cooper LT, Baughman KL, Feldman AM et al. The role of </text>
<text top="160" left="61" width="353" height="19" font="7">endomyocardial biopsy in the management of CV disease: </text>
<text top="179" left="61" width="290" height="19" font="7">Circulation 2007 November 6;116(19):2216-33.  </text>
<text top="198" left="61" width="64" height="19" font="11">17959655 </text>
<text top="198" left="125" width="24" height="19" font="7">(57)</text>
<text top="198" left="149" width="4" height="19" font="11"> </text>
<text top="141" left="446" width="47" height="19" font="7">Role of </text>
<text top="160" left="446" width="95" height="19" font="7">endomyocadial </text>
<text top="179" left="446" width="62" height="19" font="7">biopsy for </text>
<text top="198" left="446" width="120" height="19" font="7">management of CV </text>
<text top="217" left="446" width="50" height="19" font="7">disease </text>
<text top="141" left="593" width="132" height="19" font="7">A scientific statement </text>
<text top="160" left="593" width="138" height="19" font="7">from the AHA, ACC, &amp; </text>
<text top="179" left="593" width="32" height="19" font="7">ESC </text>
<text top="141" left="753" width="30" height="19" font="7"> N/A </text>
<text top="141" left="872" width="26" height="19" font="7">N/A </text>
<text top="141" left="1048" width="26" height="19" font="7">N/A </text>
<text top="246" left="61" width="348" height="19" font="7">Kasper EK, Agema WR, Hutchins GM, Deckers JW, Hare </text>
<text top="265" left="61" width="366" height="19" font="7">JM, Baughman KL. The causes of dilated cardiomyopathy: a </text>
<text top="284" left="61" width="350" height="19" font="7">clinicopathologic review of 673 consecutive pts. <i>J Am Coll </i></text>
<text top="303" left="61" width="222" height="19" font="20"><i>Cardiol</i> 1994 March 1;23(3):586-90.  </text>
<text top="322" left="61" width="56" height="19" font="11">8113538 </text>
<text top="322" left="117" width="28" height="19" font="7">(58) </text>
<text top="246" left="446" width="129" height="19" font="7">To document causes </text>
<text top="265" left="446" width="109" height="19" font="7">of DCM in a large </text>
<text top="284" left="446" width="134" height="19" font="7">group of adult HF pts  </text>
<text top="246" left="593" width="139" height="19" font="7">Retrospective Cohort   </text>
<text top="246" left="753" width="26" height="19" font="7">673 </text>
<text top="246" left="872" width="150" height="19" font="7">DCM pts with symptoms </text>
<text top="265" left="872" width="154" height="19" font="7">within 6 mo, evaluated at </text>
<text top="284" left="872" width="145" height="19" font="7">Johns Hopkins Hospital </text>
<text top="303" left="872" width="68" height="19" font="7">1982-1991 </text>
<text top="246" left="1048" width="405" height="19" font="7">Most common causes of DCM: idiopathic (47%), myocarditis (12%) </text>
<text top="265" left="1048" width="231" height="19" font="7">and CAD (11%), other causes (31%)   </text>
<text top="354" left="61" width="362" height="19" font="7">Fowles RE, Mason JW. Endomyocardial biopsy.  Ann Intern </text>
<text top="373" left="61" width="219" height="19" font="7">Med 1982 December;97(6):885-94.  </text>
<text top="392" left="61" width="56" height="19" font="11">6756241 </text>
<text top="392" left="117" width="28" height="19" font="7">(59) </text>
<text top="354" left="446" width="107" height="19" font="7">Complication risk </text>
<text top="373" left="446" width="104" height="19" font="7">with RV biopsies </text>
<text top="354" left="593" width="48" height="19" font="7">Review </text>
<text top="354" left="753" width="30" height="19" font="7"> N/A </text>
<text top="354" left="872" width="26" height="19" font="7">N/A </text>
<text top="354" left="1048" width="341" height="19" font="7">Complication  rate of 1% in  4000 biopsies (performed in </text>
<text top="373" left="1048" width="179" height="19" font="7">transplantation and CMP pts) </text>
<text top="392" left="1048" width="360" height="19" font="7">4 tamponade (0.14%), 3 pneumothorax, 3 AF, 1 ventricular  </text>
<text top="411" left="1048" width="304" height="19" font="7">arrhythmia, and 3 focal neurological complications </text>
<text top="430" left="61" width="336" height="19" font="7">Deckers JW, Hare JM, Baughman KL. Complications of </text>
<text top="449" left="61" width="363" height="19" font="7">transvenous right ventricular endomyocardial biopsy in adult </text>
<text top="468" left="61" width="320" height="19" font="7">pts with cardiomyopathy: a seven-year survey of 546 </text>
<text top="487" left="61" width="329" height="19" font="7">consecutive diagnostic procedures in a tertiary referral </text>
<text top="506" left="61" width="313" height="19" font="7">center. <i>J Am Coll Cardiol</i> 1992 January;19(1):43-7.  </text>
<text top="525" left="61" width="56" height="19" font="11">1729344 </text>
<text top="525" left="117" width="24" height="19" font="7">(60)</text>
<text top="525" left="141" width="4" height="19" font="11"> </text>
<text top="544" left="61" width="4" height="19" font="7"> </text>
<text top="563" left="61" width="4" height="19" font="7"> </text>
<text top="430" left="446" width="106" height="19" font="7">To determine the </text>
<text top="449" left="446" width="133" height="19" font="7">incidence, nature and </text>
<text top="468" left="446" width="74" height="19" font="7">subsequent </text>
<text top="487" left="446" width="98" height="19" font="7">management of </text>
<text top="506" left="446" width="86" height="19" font="7">complications </text>
<text top="525" left="446" width="123" height="19" font="7">occurring during RV </text>
<text top="544" left="446" width="99" height="19" font="7">endomyocardial </text>
<text top="563" left="446" width="107" height="19" font="7">biopsy in pts with </text>
<text top="582" left="446" width="99" height="19" font="7">cardiomyopathy </text>
<text top="430" left="593" width="119" height="19" font="7">Prospective Cohort </text>
<text top="430" left="752" width="26" height="19" font="7">546 </text>
<text top="430" left="872" width="155" height="19" font="7">546 consecutive biopsies </text>
<text top="449" left="872" width="130" height="19" font="7">for DCM pts at single </text>
<text top="468" left="872" width="45" height="19" font="7">center, </text>
<text top="430" left="1048" width="174" height="19" font="7">33 total complications (6%):  </text>
<text top="449" left="1048" width="390" height="19" font="7">15 (2.7%) during catheter insertion: 12 arterial punctures (2%), 2 </text>
<text top="468" left="1048" width="375" height="19" font="7">vasovagal reactions (0.4%) and 1 prolonged bleeding (0.2%),  </text>
<text top="487" left="1048" width="364" height="19" font="7">18 (3.3%) during biopsy: 6 arrhythmias (1.1%), 5 conduction </text>
<text top="506" left="1048" width="389" height="19" font="7">abnormalities (1%), 4 possible perforations (0.7%) and 3 definite </text>
<text top="525" left="1048" width="122" height="19" font="7">perforations (0.5%). </text>
<text top="544" left="1048" width="263" height="19" font="7">2 (0.4%) of the 3 pts with a perforation died </text>
<text top="605" left="61" width="330" height="19" font="7">Ardehali H, Qasim A, Cappola T et al. Endomyocardial </text>
<text top="624" left="61" width="326" height="19" font="7">biopsy plays a role in diagnosing pts with unexplained </text>
<text top="643" left="61" width="334" height="19" font="7">cardiomyopathy. Am Heart J 2004 May;147(5):919-23.  </text>
<text top="662" left="61" width="64" height="19" font="11">15131552 </text>
<text top="662" left="125" width="28" height="19" font="7">(61) </text>
<text top="605" left="446" width="132" height="19" font="7">To evaluate the utility </text>
<text top="624" left="446" width="95" height="19" font="7">of RV biopsy in </text>
<text top="643" left="446" width="82" height="19" font="7">confirming or </text>
<text top="662" left="446" width="126" height="19" font="7">excluding a clinically </text>
<text top="681" left="446" width="126" height="19" font="7">suspected diagnosis </text>
<text top="605" left="593" width="114" height="19" font="7">Retrospetive chart </text>
<text top="624" left="593" width="43" height="19" font="7">review </text>
<text top="605" left="753" width="236" height="19" font="7">845 Pts </text>
<text top="605" left="895" width="121" height="19" font="7">with </text>
<text top="605" left="923" width="138" height="19" font="7">initially </text>
<text top="624" left="872" width="77" height="19" font="7">unexplained </text>
<text top="643" left="872" width="142" height="19" font="7">cardiomyopathy (1982- </text>
<text top="662" left="872" width="120" height="19" font="7">1997) at The Johns </text>
<text top="681" left="872" width="113" height="19" font="7">Hopkins Hospital.  </text>
<text top="605" left="1048" width="327" height="19" font="7">Clinical assessment of the etiology inaccurate in 31%  </text>
<text top="624" left="1048" width="293" height="19" font="7">EMBx helps establish the final diagnosis in most </text>
<text top="714" left="61" width="347" height="19" font="7">Holzmann M, Nicko A, Ku¨hl U, et al. Complication rate of </text>
<text top="733" left="61" width="331" height="19" font="7">right ventricular endomyocardial biopsy via the femoral </text>
<text top="752" left="61" width="354" height="19" font="7">approach. A retrospective and prospective study analyzing </text>
<text top="771" left="61" width="314" height="19" font="7">3048 diagnostic procedures over an 11-year period. </text>
<text top="790" left="61" width="184" height="19" font="7">Circulation 2008;118:1722–8.  </text>
<text top="714" left="446" width="83" height="19" font="7">To determine </text>
<text top="733" left="446" width="121" height="19" font="7">complication rate of </text>
<text top="752" left="446" width="65" height="19" font="7">RV biopsy </text>
<text top="714" left="593" width="44" height="19" font="7">Cohort </text>
<text top="714" left="753" width="34" height="19" font="7">2415 </text>
<text top="714" left="872" width="156" height="19" font="7">1919 pts underwent 2505 </text>
<text top="733" left="872" width="142" height="19" font="7">endomyocardial biopsy </text>
<text top="752" left="872" width="130" height="19" font="7">retrospectively (1995-</text>
<text top="771" left="872" width="117" height="19" font="7">2003), and 496 pts </text>
<text top="790" left="872" width="93" height="19" font="7">underwent 543 </text>
<text top="714" left="1048" width="411" height="19" font="7">Major complications cardiac tamponade requiring pericardiocentesis </text>
<text top="733" left="1048" width="411" height="19" font="7">or complete AV block requiring permanent pacing rare: 0.12% in the </text>
<text top="752" left="1048" width="320" height="19" font="7">retrospective study and 0% in the prospective study.  </text>
<text top="771" left="1048" width="364" height="19" font="7">Minor complications such as pericardial effusion, conduction </text>
<text top="790" left="1048" width="389" height="19" font="7">abnormalities, or arrhythmias in 0.20% in the retrospective study </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="21" size="13" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">22</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="64" height="19" font="11">18838566 </text>
<text top="55" left="125" width="28" height="19" font="7">(62) </text>
<text top="55" left="872" width="142" height="19" font="7">endomyocardial biopsy </text>
<text top="74" left="872" width="125" height="19" font="7">prospectively (2004- </text>
<text top="93" left="872" width="108" height="19" font="7">2005) to evaluate </text>
<text top="111" left="872" width="97" height="19" font="7">unexplained LV </text>
<text top="130" left="872" width="76" height="19" font="7">dysfunction  </text>
<text top="55" left="1048" width="207" height="19" font="7">and 5.5% in the prospective study </text>
<text top="150" left="61" width="351" height="19" font="7">Elliott P, Arbustini E. The role of endomyocardial biopsy in </text>
<text top="169" left="61" width="334" height="19" font="7">the management of CV disease: a commentary on joint </text>
<text top="188" left="61" width="360" height="19" font="7">AHA/ACC/ESC guidelines. <i>Heart</i> 2009 May;95(9):759-760.  </text>
<text top="207" left="61" width="64" height="19" font="11">19221107 </text>
<text top="207" left="125" width="28" height="19" font="7">(63) </text>
<text top="226" left="61" width="4" height="19" font="7"> </text>
<text top="150" left="446" width="26" height="19" font="7">N/A </text>
<text top="150" left="593" width="81" height="19" font="7">Commentary </text>
<text top="150" left="753" width="26" height="19" font="7">N/A </text>
<text top="150" left="872" width="26" height="19" font="7">N/A </text>
<text top="150" left="1048" width="228" height="19" font="7">Emphasizes genetic causes of CMP   </text>
<text top="246" left="54" width="1399" height="17" font="13">ACC indicates American College of Cardiology; AHA, American Heart Association; AF, atrial fibrillation; AV, atrioventricular; CAD, coronary artery disease; CMP, cardiomyopathy; DCM, dilated cardiomyopathy; EMBx, endomyocardial biopsy; ESC, European </text>
<text top="263" left="54" width="554" height="17" font="13">Society of Cardiology; LV, left ventricular; N/A, not applicable; pts, patients; and RV, right ventricular.  </text>
<text top="283" left="54" width="4" height="16" font="7"> </text>
<text top="318" left="54" width="423" height="21" font="8"><b>Data Supplement 11. Stage A: Prevention of HF (Section 7.1)</b></text>
<text top="321" left="477" width="3" height="17" font="15"><b> </b></text>
<text top="340" left="81" width="89" height="19" font="9"><b>Study Name,  </b></text>
<text top="358" left="81" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="340" left="228" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="340" left="358" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="340" left="475" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="340" left="649" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="340" left="855" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="340" left="961" width="32" height="19" font="9"><b>Trial </b></text>
<text top="358" left="948" width="59" height="19" font="9"><b>Duration </b></text>
<text top="377" left="952" width="50" height="19" font="9"><b>(Years) </b></text>
<text top="340" left="1028" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="340" left="1286" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="398" left="485" width="53" height="17" font="21"><i><b>N (Total) </b></i></text>
<text top="415" left="461" width="100" height="17" font="21"><i><b>n (Experimental) </b></i></text>
<text top="432" left="478" width="66" height="17" font="21"><i><b>n (Control) </b></i></text>
<text top="430" left="586" width="252" height="19" font="10"><i><b>Inclusion Criteria  Exclusion Criteria </b></i></text>
<text top="450" left="55" width="124" height="17" font="13">Lloyd-Jones et al, The </text>
<text top="467" left="55" width="83" height="17" font="13">lifetime risk for </text>
<text top="484" left="55" width="86" height="17" font="13">developing HF; </text>
<text top="502" left="55" width="99" height="17" font="13">Circulation, 2002; </text>
<text top="519" left="55" width="86" height="17" font="13">106:3068-3072 </text>
<text top="536" left="55" width="55" height="17" font="14">12473553</text>
<text top="536" left="110" width="29" height="17" font="13"> (64) </text>
<text top="450" left="204" width="133" height="17" font="13">Examine  lifetime risk of </text>
<text top="467" left="204" width="133" height="17" font="13">developing CHF among </text>
<text top="484" left="204" width="122" height="17" font="13">those without incident </text>
<text top="502" left="204" width="114" height="17" font="13">or prevalent disease </text>
<text top="450" left="352" width="68" height="17" font="13">Prospective </text>
<text top="467" left="352" width="38" height="17" font="13">cohort </text>
<text top="450" left="454" width="31" height="17" font="13">8229 </text>
<text top="467" left="454" width="7" height="17" font="13">  </text>
<text top="484" left="454" width="3" height="17" font="13"> </text>
<text top="450" left="582" width="85" height="17" font="13">Free of CHF at </text>
<text top="467" left="582" width="49" height="17" font="13">baseline </text>
<text top="450" left="717" width="27" height="17" font="13"> N/A </text>
<text top="450" left="852" width="27" height="17" font="13"> N/A </text>
<text top="450" left="940" width="24" height="17" font="13">N/A </text>
<text top="450" left="1027" width="184" height="17" font="13">Lifetime risk is 1 in 5 for men and </text>
<text top="467" left="1027" width="169" height="17" font="13">women; significant association </text>
<text top="484" left="1027" width="175" height="17" font="13">between MI and HTN in lifetime </text>
<text top="502" left="1027" width="72" height="17" font="13">risk of CHF.  </text>
<text top="450" left="1230" width="206" height="17" font="13">Subjects mostly white and results not </text>
<text top="467" left="1230" width="159" height="17" font="13">generalizable to other races. </text>
<text top="554" left="55" width="120" height="17" font="13">Vasan et al, Residual </text>
<text top="571" left="55" width="83" height="17" font="13">lifetime risk for </text>
<text top="588" left="55" width="105" height="17" font="13">developing HTN in </text>
<text top="606" left="55" width="114" height="17" font="13">middle-aged women </text>
<text top="623" left="55" width="94" height="17" font="13">and men; JAMA, </text>
<text top="640" left="55" width="120" height="17" font="13">2002:287:1003-1010. </text>
<text top="657" left="55" width="55" height="17" font="14">11866648</text>
<text top="657" left="110" width="29" height="17" font="13"> (65) </text>
<text top="675" left="55" width="3" height="17" font="13"> </text>
<text top="554" left="204" width="114" height="17" font="13">Quantify risk of HTN </text>
<text top="571" left="204" width="74" height="17" font="13">development </text>
<text top="554" left="352" width="68" height="17" font="13">Prospective </text>
<text top="571" left="352" width="38" height="17" font="13">cohort </text>
<text top="554" left="454" width="34" height="17" font="13"> 1298 </text>
<text top="571" left="454" width="7" height="17" font="13">  </text>
<text top="554" left="582" width="100" height="17" font="13">Ages 55-65 y and </text>
<text top="571" left="582" width="81" height="17" font="13">free of HTN at </text>
<text top="588" left="582" width="53" height="17" font="13">baseline. </text>
<text top="554" left="717" width="24" height="17" font="13">N/A </text>
<text top="554" left="852" width="24" height="17" font="13">N/A </text>
<text top="554" left="940" width="24" height="17" font="13">N/A </text>
<text top="554" left="1027" width="134" height="17" font="13">Residual lifetime risk for </text>
<text top="571" left="1027" width="176" height="17" font="13">developing HTN was 90%. Risk </text>
<text top="588" left="1027" width="152" height="17" font="13">did not differ by sex or age, </text>
<text top="606" left="1027" width="169" height="17" font="13">lifetime risk for women vs men </text>
<text top="623" left="1027" width="164" height="17" font="13">aged 55 y, HR: 0.91 (95% CI, </text>
<text top="640" left="1027" width="175" height="17" font="13">0.80-1.04); for those aged 65 y, </text>
<text top="657" left="1027" width="159" height="17" font="13">HR:0.88 (95% CI, 0.76-1.04) </text>
<text top="675" left="1027" width="7" height="17" font="13">  </text>
<text top="554" left="1230" width="210" height="17" font="13">Measured HTN in middle age, when a </text>
<text top="571" left="1230" width="215" height="17" font="13">large portion of people develop HTN at </text>
<text top="588" left="1230" width="197" height="17" font="13">younger ages so actual risk may be </text>
<text top="606" left="1230" width="226" height="17" font="13">different for younger people. Did not take </text>
<text top="623" left="1230" width="198" height="17" font="13">into account other risks for HTN like </text>
<text top="640" left="1230" width="225" height="17" font="13">obesity, family history of high BP, dietary </text>
<text top="657" left="1230" width="190" height="17" font="13">sodium and potassium intake, and </text>
<text top="675" left="1230" width="119" height="17" font="13">alcohol consumption  </text>
<text top="693" left="55" width="84" height="17" font="13">Levy et al, The </text>
<text top="710" left="55" width="125" height="17" font="13">progression from HTN </text>
<text top="727" left="55" width="86" height="17" font="13">to CHF; JAMA, </text>
<text top="744" left="55" width="103" height="17" font="13">1996;275:1557-62 </text>
<text top="761" left="55" width="48" height="17" font="14">8622246</text>
<text top="761" left="103" width="29" height="17" font="13"> (66) </text>
<text top="693" left="204" width="116" height="17" font="13">Analysis of expected </text>
<text top="710" left="204" width="126" height="17" font="13">rates of HF associated </text>
<text top="727" left="204" width="123" height="17" font="13">with diagnosis of HTN </text>
<text top="693" left="352" width="68" height="17" font="13">Prospective </text>
<text top="710" left="352" width="38" height="17" font="13">cohort </text>
<text top="693" left="454" width="34" height="17" font="13">5,143 </text>
<text top="710" left="454" width="7" height="17" font="13">  </text>
<text top="727" left="454" width="7" height="17" font="13">  </text>
<text top="693" left="582" width="85" height="17" font="13">Free of CHF at </text>
<text top="710" left="582" width="53" height="17" font="13">baseline. </text>
<text top="693" left="717" width="204" height="17" font="13">N/A Developmen</text>
<text top="710" left="852" width="40" height="17" font="13">t of HF </text>
<text top="693" left="940" width="17" height="17" font="13">20 </text>
<text top="693" left="1027" width="176" height="17" font="13">Those with HTN at a higher risk </text>
<text top="710" left="1027" width="50" height="17" font="13">for CHF: </text>
<text top="727" left="1027" width="161" height="17" font="13">Men, HR: 2.04; 95% CI: 1.50-</text>
<text top="744" left="1027" width="31" height="17" font="13">2.78; </text>
<text top="761" left="1027" width="180" height="17" font="13">Women, HR: 3.21; 95% CI: 2.20-</text>
<text top="779" left="1027" width="27" height="17" font="13">4.67 </text>
<text top="693" left="1230" width="206" height="17" font="13">Subjects mostly white and results not </text>
<text top="710" left="1230" width="208" height="17" font="13">generalizable to other races. Possible </text>
<text top="727" left="1230" width="217" height="17" font="13">misclassification bias as some subjects </text>
<text top="744" left="1230" width="176" height="17" font="13">diagnosed w/HTN before use of </text>
<text top="761" left="1230" width="105" height="17" font="13">echocardiography. </text>
</page>
<page number="23" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">23</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1027" width="179" height="17" font="13">PAR for CHF in those with HTN: </text>
<text top="72" left="1027" width="185" height="17" font="13">39% for men and 59% in women. </text>
<text top="90" left="55" width="130" height="17" font="13">Wilhelmsen et al, HF in </text>
<text top="107" left="55" width="125" height="17" font="13">the general population </text>
<text top="124" left="55" width="124" height="17" font="13">of men: morbidity, risk </text>
<text top="142" left="55" width="128" height="17" font="13">factors, and prognosis; </text>
<text top="159" left="55" width="72" height="17" font="13">J Intern Med </text>
<text top="176" left="55" width="103" height="17" font="13">2001;249:253-261 </text>
<text top="193" left="55" width="55" height="17" font="14">11285045</text>
<text top="193" left="110" width="29" height="17" font="13"> (67) </text>
<text top="90" left="204" width="109" height="17" font="13">Identification of risk </text>
<text top="107" left="204" width="116" height="17" font="13">associated with HTN </text>
<text top="90" left="352" width="62" height="17" font="13">Population-</text>
<text top="107" left="352" width="37" height="17" font="13">based </text>
<text top="124" left="352" width="67" height="17" font="13">intervention </text>
<text top="142" left="352" width="23" height="17" font="13">trial </text>
<text top="90" left="454" width="34" height="17" font="13">7,495 </text>
<text top="107" left="454" width="7" height="17" font="13">  </text>
<text top="124" left="454" width="7" height="17" font="13">  </text>
<text top="90" left="582" width="27" height="17" font="13"> N/A </text>
<text top="90" left="717" width="24" height="17" font="13">N/A </text>
<text top="90" left="852" width="69" height="17" font="13">Developmen</text>
<text top="107" left="852" width="40" height="17" font="13">t of HF </text>
<text top="90" left="940" width="17" height="17" font="13">27 </text>
<text top="90" left="1027" width="163" height="17" font="13">CAD and HTN were the most </text>
<text top="107" left="1027" width="185" height="17" font="13">common concomitant diseases in </text>
<text top="124" left="1027" width="93" height="17" font="13">HF pts (79.1%).  </text>
<text top="90" left="1230" width="24" height="17" font="13">N/A </text>
<text top="211" left="55" width="133" height="17" font="13">Kostis, et al, Prevention </text>
<text top="228" left="55" width="50" height="17" font="13">of HF by </text>
<text top="246" left="55" width="121" height="17" font="13">antihypertensive drug </text>
<text top="263" left="55" width="99" height="17" font="13">treatment in older </text>
<text top="280" left="55" width="118" height="17" font="13">persons with isolated </text>
<text top="297" left="55" width="112" height="17" font="13">systolic HTN; JAMA </text>
<text top="314" left="55" width="107" height="17" font="13">1997;278:212-216. </text>
<text top="332" left="55" width="48" height="17" font="14">9218667</text>
<text top="332" left="103" width="29" height="17" font="13"> (68) </text>
<text top="211" left="204" width="127" height="17" font="13">To assess the effect of </text>
<text top="228" left="204" width="120" height="17" font="13">antihypertensive care </text>
<text top="246" left="204" width="127" height="17" font="13">on the incidence of HF </text>
<text top="263" left="204" width="133" height="17" font="13">in older pts with systolic </text>
<text top="280" left="204" width="29" height="17" font="13">HTN </text>
<text top="211" left="352" width="29" height="17" font="13">RCT </text>
<text top="211" left="454" width="109" height="17" font="13">4,736; 2,365; 2,371 </text>
<text top="211" left="582" width="107" height="17" font="13">Age ≥60y, Isolated </text>
<text top="228" left="582" width="104" height="17" font="13">systolic HTN: SBP </text>
<text top="246" left="582" width="117" height="17" font="13">160-219 mm Hg with </text>
<text top="263" left="582" width="99" height="17" font="13">DBP &lt;90 mm Hg. </text>
<text top="211" left="717" width="105" height="17" font="13">Recent MI, CABG, </text>
<text top="228" left="717" width="109" height="17" font="13">DM, alcohol abuse, </text>
<text top="246" left="717" width="120" height="17" font="13">demential stroke, AF, </text>
<text top="263" left="717" width="52" height="17" font="13">AV block,</text>
<text top="264" left="769" width="4" height="16" font="7"> </text>
<text top="263" left="772" width="54" height="17" font="13">multiform </text>
<text top="280" left="717" width="120" height="17" font="13">premature ventricular </text>
<text top="297" left="717" width="73" height="17" font="13">contractions, </text>
<text top="314" left="717" width="92" height="17" font="13">bradycardia &lt;50 </text>
<text top="332" left="717" width="103" height="17" font="13">beats/min; diuretic </text>
<text top="349" left="717" width="48" height="17" font="13">therapy. </text>
<text top="211" left="852" width="55" height="17" font="13">Fatal and </text>
<text top="228" left="852" width="71" height="17" font="13">non-fatal HF </text>
<text top="211" left="940" width="183" height="17" font="13">4.5 49% </text>
<text top="211" left="1055" width="121" height="17" font="13">reduction </text>
<text top="228" left="1027" width="161" height="17" font="13">RR: 0.51; 95% CI: 0.37-0.71; </text>
<text top="246" left="1027" width="41" height="17" font="13">p&lt;.001 </text>
<text top="211" left="1230" width="221" height="17" font="13">Noteworthy that pts with prior MI had an </text>
<text top="228" left="1230" width="108" height="17" font="13">80% risk reduction. </text>
<text top="367" left="55" width="118" height="17" font="13">Staessen, Wang and </text>
<text top="384" left="55" width="114" height="17" font="13">Thijs; CV prevention </text>
<text top="401" left="55" width="112" height="17" font="13">and BP reduction: a </text>
<text top="418" left="55" width="118" height="17" font="13">quantitative overview </text>
<text top="436" left="55" width="122" height="17" font="13">updated until 1 March </text>
<text top="453" left="55" width="103" height="17" font="13">2003; J Hypertens </text>
<text top="470" left="55" width="110" height="17" font="13">2003;21:1055-1076 </text>
<text top="487" left="55" width="55" height="17" font="14">12777939</text>
<text top="487" left="110" width="29" height="17" font="13"> (69) </text>
<text top="505" left="55" width="3" height="17" font="13"> </text>
<text top="367" left="204" width="127" height="17" font="13">Assessment of various </text>
<text top="384" left="204" width="86" height="17" font="13">drugs and their </text>
<text top="401" left="204" width="87" height="17" font="13">reduction of HF </text>
<text top="367" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="367" left="454" width="48" height="17" font="13">120,574 </text>
<text top="384" left="454" width="7" height="17" font="13">  </text>
<text top="401" left="454" width="7" height="17" font="13">  </text>
<text top="367" left="582" width="27" height="17" font="13"> N/A </text>
<text top="367" left="717" width="27" height="17" font="13"> N/A </text>
<text top="367" left="852" width="60" height="17" font="13">CV events </text>
<text top="367" left="940" width="27" height="17" font="13"> N/A </text>
<text top="367" left="1027" width="165" height="17" font="13">CCB, resulted in better stroke </text>
<text top="384" left="1027" width="153" height="17" font="13">protection than older drugs: </text>
<text top="401" left="1027" width="145" height="17" font="13">including (-8%, p=0.07) or </text>
<text top="418" left="1027" width="152" height="17" font="13">excluding verapamil (-10%, </text>
<text top="436" left="1027" width="175" height="17" font="13">p=0.02), as well as ARB (-24%, </text>
<text top="453" left="1027" width="169" height="17" font="13">p=0.0002). The opposite trend </text>
<text top="470" left="1027" width="172" height="17" font="13">was observed for ACEI (+10%, </text>
<text top="487" left="1027" width="160" height="17" font="13">Pp=0.03). The risk of HFwas </text>
<text top="505" left="1027" width="151" height="17" font="13">higher (p&lt; 0.0001) on CCB </text>
<text top="522" left="1027" width="150" height="17" font="13">(+33%) and alpha blockers </text>
<text top="539" left="1027" width="167" height="17" font="13">(+102%) than on conventional </text>
<text top="556" left="1027" width="145" height="17" font="13">therapy involving diuretics </text>
<text top="367" left="1230" width="27" height="17" font="13"> N/A </text>
<text top="574" left="55" width="85" height="17" font="13">Sciaretta, et al; </text>
<text top="591" left="55" width="94" height="17" font="13">Antihypertensive </text>
<text top="608" left="55" width="79" height="17" font="13">treatment and </text>
<text top="626" left="55" width="120" height="17" font="13">development of HF in </text>
<text top="643" left="55" width="87" height="17" font="13">hypertension: a </text>
<text top="660" left="55" width="132" height="17" font="13">Bayesian network meta-</text>
<text top="677" left="55" width="117" height="17" font="13">analysis of studies in </text>
<text top="695" left="55" width="124" height="17" font="13">pts with HTN and high </text>
<text top="712" left="55" width="46" height="17" font="13">CV risk. </text>
<text top="729" left="55" width="125" height="17" font="13">Arch Intern Med. 2011 </text>
<text top="746" left="55" width="126" height="17" font="13">Mar 14;171(5):384-94. </text>
<text top="763" left="55" width="55" height="17" font="14">21059964</text>
<text top="763" left="110" width="29" height="17" font="13"> (70) </text>
<text top="781" left="55" width="7" height="17" font="13">  </text>
<text top="574" left="204" width="131" height="17" font="13">Compare various drugs </text>
<text top="591" left="204" width="84" height="17" font="13">and risk for HF </text>
<text top="574" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="574" left="454" width="48" height="17" font="13">223,313 </text>
<text top="591" left="454" width="7" height="17" font="13">  </text>
<text top="608" left="454" width="7" height="17" font="13">  </text>
<text top="574" left="582" width="99" height="17" font="13">Studies had to be </text>
<text top="591" left="582" width="94" height="17" font="13">RCTs from 1997-</text>
<text top="608" left="582" width="108" height="17" font="13">2009; pts with HTN </text>
<text top="626" left="582" width="85" height="17" font="13">or a population </text>
<text top="643" left="582" width="94" height="17" font="13">characterized as </text>
<text top="660" left="582" width="105" height="17" font="13">having a “high” CV </text>
<text top="677" left="582" width="94" height="17" font="13">risk profile and a </text>
<text top="695" left="582" width="115" height="17" font="13">predominance of pts </text>
<text top="712" left="582" width="121" height="17" font="13">with HTN (&gt;65%); the </text>
<text top="729" left="582" width="101" height="17" font="13">sample size ≥200 </text>
<text top="746" left="582" width="111" height="17" font="13">pts; and information </text>
<text top="763" left="582" width="87" height="17" font="13">on the absolute </text>
<text top="781" left="582" width="113" height="17" font="13">incidence of HF and </text>
<text top="574" left="717" width="27" height="17" font="13"> N/A </text>
<text top="574" left="852" width="20" height="17" font="13">HF </text>
<text top="574" left="940" width="27" height="17" font="13"> N/A </text>
<text top="574" left="1027" width="176" height="17" font="13">Diuretics vs. placebo: OR: 0.59; </text>
<text top="591" left="1027" width="113" height="17" font="13">95% CrI: 0.47-0.73;  </text>
<text top="608" left="1027" width="189" height="17" font="13">ACE-I vs. placebo: OR: 0.71; 95% </text>
<text top="626" left="1027" width="85" height="17" font="13">CrI: 0.59-0.85;  </text>
<text top="643" left="1027" width="168" height="17" font="13">ARB: OR: 0.71; 95% CrI: 0.59-</text>
<text top="660" left="1027" width="31" height="17" font="13">0.85. </text>
<text top="677" left="1027" width="157" height="17" font="13">Beta blockers and CCB less </text>
<text top="695" left="1027" width="49" height="17" font="13">effective </text>
<text top="574" left="1230" width="27" height="17" font="13"> N/A </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">24</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="582" width="86" height="17" font="13">other major CV </text>
<text top="72" left="582" width="43" height="17" font="13">events  </text>
<text top="90" left="55" width="118" height="17" font="13">Lind et al, Glycaemic </text>
<text top="107" left="55" width="133" height="17" font="13">control and incidence of </text>
<text top="124" left="55" width="116" height="17" font="13">HF in 20985 pts with </text>
<text top="142" left="55" width="107" height="17" font="13">type 1 diabetes: an </text>
<text top="159" left="55" width="116" height="17" font="13">observational study.  </text>
<text top="176" left="55" width="118" height="17" font="13">Lancet 2011; Jun 24. </text>
<text top="193" left="55" width="55" height="17" font="14">21705065</text>
<text top="193" left="110" width="29" height="17" font="13"> (71) </text>
<text top="90" left="204" width="135" height="17" font="13">Assessment of glycemic </text>
<text top="107" left="204" width="124" height="17" font="13">control and risk for HF </text>
<text top="90" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="90" left="454" width="41" height="17" font="13">20,985 </text>
<text top="107" left="454" width="52" height="17" font="13">or higher </text>
<text top="124" left="454" width="66" height="17" font="13">A1C &lt;6.5% </text>
<text top="90" left="582" width="64" height="17" font="13">Type 1 DM </text>
<text top="90" left="717" width="27" height="17" font="13"> N/A </text>
<text top="90" left="852" width="20" height="17" font="13">HF </text>
<text top="90" left="940" width="24" height="17" font="13">N/A </text>
<text top="90" left="1027" width="159" height="17" font="13">A1C ≥10.5% vs A1C &lt;6.5%: </text>
<text top="107" left="1027" width="168" height="17" font="13">aHR: 3.98; 95% CI: 2.23-7.14; </text>
<text top="124" left="1027" width="45" height="17" font="13">p&lt;.001; </text>
<text top="90" left="1230" width="207" height="17" font="13">Used hospital admissions and did not </text>
<text top="107" left="1230" width="206" height="17" font="13">include asymptomatic HF pts, so true </text>
<text top="124" left="1230" width="184" height="17" font="13">incidence of HF underestimated.  </text>
<text top="211" left="55" width="124" height="17" font="13">Pfister, et al, A clinical </text>
<text top="228" left="55" width="126" height="17" font="13">risk score for HF in pts </text>
<text top="246" left="55" width="112" height="17" font="13">with type 2 diabetes </text>
<text top="263" left="55" width="107" height="17" font="13">and macrovascular </text>
<text top="280" left="55" width="128" height="17" font="13">disease: an analysis of </text>
<text top="297" left="55" width="122" height="17" font="13">the PROactive study.  </text>
<text top="314" left="55" width="130" height="17" font="13">Int J Cardiol. 2011;May </text>
<text top="332" left="55" width="21" height="17" font="13">31. </text>
<text top="349" left="55" width="55" height="17" font="14">21636144</text>
<text top="349" left="110" width="29" height="17" font="13"> (72) </text>
<text top="211" left="204" width="109" height="17" font="13">Identification of risk </text>
<text top="228" left="204" width="110" height="17" font="13">associated with DM </text>
<text top="211" left="352" width="32" height="17" font="13"> RCT </text>
<text top="211" left="454" width="34" height="17" font="13">4,951 </text>
<text top="228" left="454" width="7" height="17" font="13">  </text>
<text top="246" left="454" width="7" height="17" font="13">  </text>
<text top="211" left="582" width="64" height="17" font="13">Type 2 DM </text>
<text top="211" left="717" width="27" height="17" font="13"> N/A </text>
<text top="211" left="852" width="20" height="17" font="13">HF </text>
<text top="211" left="940" width="10" height="17" font="13">3 </text>
<text top="211" left="1027" width="169" height="17" font="13">Medium risk: HR: 3.5; 95% CI: </text>
<text top="228" left="1027" width="100" height="17" font="13">2.0-6.2; p&lt;0.0001 </text>
<text top="246" left="1027" width="178" height="17" font="13">High risk: HR: 10.5; 95% CI: 6.3-</text>
<text top="263" left="1027" width="86" height="17" font="13">17.6; p&lt;0.0001 </text>
<text top="280" left="1027" width="7" height="17" font="13">  </text>
<text top="297" left="1027" width="7" height="17" font="13">  </text>
<text top="211" left="1230" width="217" height="17" font="13">HF was pre-defined by investigator, but </text>
<text top="228" left="1230" width="217" height="17" font="13">rather reported as SAE in the trial. Trial </text>
<text top="246" left="1230" width="215" height="17" font="13">population may not be generalizable to </text>
<text top="263" left="1230" width="107" height="17" font="13">clinical population.  </text>
<text top="367" left="55" width="92" height="17" font="13">Kenchaiah et al, </text>
<text top="384" left="55" width="126" height="17" font="13">Obesity and the risk of </text>
<text top="401" left="55" width="67" height="17" font="13">HF.  NEJM, </text>
<text top="418" left="55" width="107" height="17" font="13">2002;347:305-313. </text>
<text top="436" left="55" width="55" height="17" font="14">12151467</text>
<text top="436" left="110" width="29" height="17" font="13"> (73) </text>
<text top="367" left="204" width="126" height="17" font="13">Assessment of HF risk </text>
<text top="384" left="204" width="130" height="17" font="13">associated with obesity </text>
<text top="367" left="352" width="68" height="17" font="13">Prospective </text>
<text top="384" left="352" width="38" height="17" font="13">cohort </text>
<text top="367" left="454" width="34" height="17" font="13">5,881 </text>
<text top="384" left="454" width="7" height="17" font="13">  </text>
<text top="401" left="454" width="7" height="17" font="13">  </text>
<text top="367" left="582" width="64" height="17" font="13">≥30 y; BMI </text>
<text top="384" left="582" width="107" height="17" font="13">≥18.5;free of HF at </text>
<text top="401" left="582" width="49" height="17" font="13">baseline </text>
<text top="367" left="717" width="27" height="17" font="13"> N/A </text>
<text top="367" left="852" width="20" height="17" font="13">HF </text>
<text top="367" left="940" width="21" height="17" font="13"> 14 </text>
<text top="367" left="1027" width="180" height="17" font="13">Women, HR: 2.12; 95% CI: 1.51-</text>
<text top="384" left="1027" width="27" height="17" font="13">2.97 </text>
<text top="401" left="1027" width="189" height="17" font="13">Men, HR: 1.90; 95% CI: 1.30-2.79 </text>
<text top="418" left="1027" width="7" height="17" font="13">  </text>
<text top="436" left="1027" width="7" height="17" font="13">  </text>
<text top="367" left="1230" width="200" height="17" font="13">Possible misclassification of HF and </text>
<text top="384" left="1230" width="204" height="17" font="13">subjects mostly white and results not </text>
<text top="401" left="1230" width="159" height="17" font="13">generalizable to other races. </text>
<text top="454" left="55" width="106" height="17" font="13">Kenchaiah, Sesso, </text>
<text top="471" left="55" width="117" height="17" font="13">Gaziano, Body mass </text>
<text top="488" left="55" width="107" height="17" font="13">index and vigorous </text>
<text top="505" left="55" width="133" height="17" font="13">physical activity and the </text>
<text top="522" left="55" width="131" height="17" font="13">risk of HF among men.  </text>
<text top="540" left="55" width="65" height="17" font="13">Circulation, </text>
<text top="557" left="55" width="93" height="17" font="13">2009;119:44-52. </text>
<text top="574" left="55" width="55" height="17" font="14">19103991</text>
<text top="574" left="110" width="29" height="17" font="13"> (74) </text>
<text top="454" left="204" width="107" height="17" font="13">Assessment of risk </text>
<text top="471" left="204" width="130" height="17" font="13">associated with obesity </text>
<text top="488" left="204" width="120" height="17" font="13">and effect of exercise </text>
<text top="454" left="352" width="68" height="17" font="13">Prospective </text>
<text top="471" left="352" width="41" height="17" font="13">cohort, </text>
<text top="488" left="352" width="60" height="17" font="13">secondary </text>
<text top="505" left="352" width="61" height="17" font="13">analysis of </text>
<text top="522" left="352" width="32" height="17" font="13">RCT  </text>
<text top="454" left="454" width="41" height="17" font="13">21,094 </text>
<text top="471" left="454" width="7" height="17" font="13">  </text>
<text top="488" left="454" width="7" height="17" font="13">  </text>
<text top="454" left="582" width="113" height="17" font="13">Free of known heart </text>
<text top="471" left="582" width="112" height="17" font="13">disease at baseline. </text>
<text top="454" left="717" width="27" height="17" font="13"> N/A </text>
<text top="454" left="852" width="70" height="17" font="13">Incidence of </text>
<text top="471" left="852" width="20" height="17" font="13">HF </text>
<text top="454" left="940" width="31" height="17" font="13">20.5  </text>
<text top="454" left="1027" width="182" height="17" font="13">Every 1 kg/m2 increase in BMI is </text>
<text top="471" left="1027" width="178" height="17" font="13">associated with 11% (95% CI: 9-</text>
<text top="488" left="1027" width="147" height="17" font="13">13) increase in risk of HF.  </text>
<text top="505" left="1027" width="171" height="17" font="13">Compared to lean active men:  </text>
<text top="522" left="1027" width="178" height="17" font="13">Lean inactive: HR:1.19; 95% CI: </text>
<text top="540" left="1027" width="163" height="17" font="13">0.94-1.51, Overweight active: </text>
<text top="557" left="1027" width="165" height="17" font="13">HR:1.49; 95% CI: 1.30-1.71),  </text>
<text top="574" left="1027" width="170" height="17" font="13">Overweight inactive: HR: 1.78; </text>
<text top="591" left="1027" width="117" height="17" font="13">95% CI: 1.43- 2.23),  </text>
<text top="608" left="1027" width="181" height="17" font="13">Obese active: HR: 2.68; 95% CI: </text>
<text top="626" left="1027" width="172" height="17" font="13">2.08-3.45, Obese inactive: HR: </text>
<text top="643" left="1027" width="133" height="17" font="13">3.93; 95% CI: 2.60-5.96 </text>
<text top="454" left="1230" width="229" height="17" font="13">Low incidence of HF as cohort comprised </text>
<text top="471" left="1230" width="220" height="17" font="13">of physicians who are healthier than the </text>
<text top="488" left="1230" width="215" height="17" font="13">general population. BMI measures and </text>
<text top="505" left="1230" width="195" height="17" font="13">physical activity were self-reported. </text>
<text top="522" left="1230" width="198" height="17" font="13">These measures were only taken at </text>
<text top="540" left="1230" width="215" height="17" font="13">baseline and tend to change over time. </text>
<text top="557" left="1230" width="211" height="17" font="13">This cohort consisted only of men and </text>
<text top="574" left="1230" width="200" height="17" font="13">results not generalizable to women.  </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="22" size="13" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">25</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="55" width="95" height="17" font="13">Verdecchia et al, </text>
<text top="72" left="55" width="122" height="17" font="13">Effects of telmisartan, </text>
<text top="89" left="55" width="95" height="17" font="13">ramipril and their </text>
<text top="106" left="55" width="127" height="17" font="13">combination on LVH in </text>
<text top="124" left="55" width="101" height="17" font="13">individuals at high </text>
<text top="141" left="55" width="85" height="17" font="13">vascular risk in </text>
<text top="158" left="55" width="96" height="17" font="13">ONTARGET and </text>
<text top="175" left="55" width="87" height="17" font="13">TRANSCEND.  </text>
<text top="192" left="55" width="61" height="17" font="13">Circulation </text>
<text top="210" left="55" width="120" height="17" font="13">2009;120:1380-1389. </text>
<text top="227" left="55" width="55" height="17" font="14">19770395</text>
<text top="227" left="110" width="29" height="17" font="13"> (75) </text>
<text top="55" left="204" width="105" height="17" font="13">Evaluate effects of </text>
<text top="72" left="204" width="123" height="17" font="13">ACE, ARB, or both on </text>
<text top="89" left="204" width="128" height="17" font="13">development of LVH in </text>
<text top="106" left="204" width="128" height="17" font="13">pts with atherosclerotic </text>
<text top="124" left="204" width="49" height="17" font="13">disease. </text>
<text top="55" left="352" width="215" height="17" font="13">RCT 23,165 </text>
<text top="55" left="495" width="90" height="17" font="13">for </text>
<text top="72" left="454" width="78" height="17" font="13">ONTARGET,  </text>
<text top="89" left="454" width="47" height="17" font="13">5,343 in </text>
<text top="106" left="454" width="80" height="17" font="13">TRANSCEND </text>
<text top="124" left="454" width="7" height="17" font="13">  </text>
<text top="141" left="454" width="7" height="17" font="13">  </text>
<text top="55" left="582" width="97" height="17" font="13">Hx of CAD, PAD, </text>
<text top="72" left="582" width="91" height="17" font="13">cerebrovascular </text>
<text top="89" left="582" width="53" height="17" font="13">disease.  </text>
<text top="55" left="717" width="27" height="17" font="13"> N/A </text>
<text top="55" left="852" width="27" height="17" font="13">LVH </text>
<text top="55" left="940" width="10" height="17" font="13">5 </text>
<text top="55" left="1027" width="137" height="17" font="13">Telmisartan vs placebo:  </text>
<text top="72" left="1027" width="162" height="17" font="13">OR: 0.79; 95% CI: 0.68-0.91; </text>
<text top="89" left="1027" width="62" height="17" font="13">p<i>=</i>0.0017.  </text>
<text top="106" left="1027" width="134" height="17" font="13">Telmisartan vs. ramipril: </text>
<text top="124" left="1027" width="162" height="17" font="13">OR: 0.92; 95% CI; 0.83-1.01; </text>
<text top="141" left="1027" width="41" height="17" font="13">p=0.07 </text>
<text top="158" left="1027" width="188" height="17" font="13">Telmisartan + ramipril vs. ramipril: </text>
<text top="175" left="1027" width="166" height="17" font="13">OR:  0.93; 95% CI: 0.84-1.02; </text>
<text top="192" left="1027" width="45" height="17" font="22"><i>p=</i>0.12) </text>
<text top="210" left="1027" width="158" height="17" font="13">Telmisartan vs telmisartan + </text>
<text top="227" left="1027" width="47" height="17" font="13">ramipril: </text>
<text top="244" left="1027" width="159" height="17" font="13">OR: 1.01; 95% CI: 0.91-1.12 </text>
<text top="55" left="1230" width="211" height="17" font="13">Diagnosis of LVH was based on ECG, </text>
<text top="72" left="1230" width="151" height="17" font="13">which is less sensitive than </text>
<text top="89" left="1230" width="187" height="17" font="13">echocardiography and was binary </text>
<text top="106" left="1230" width="178" height="17" font="13">(yes/no) instead of quantitative.  </text>
<text top="262" left="55" width="120" height="17" font="13">Braunwald et al; ACE </text>
<text top="279" left="55" width="101" height="17" font="13">inhibition in stable </text>
<text top="296" left="55" width="139" height="17" font="13">coronary artery disease.  </text>
<text top="314" left="55" width="123" height="17" font="13">NEJM 2004;351:2058-</text>
<text top="331" left="55" width="34" height="17" font="13">2068. </text>
<text top="348" left="55" width="55" height="17" font="14">15531767</text>
<text top="348" left="110" width="29" height="17" font="13"> (76) </text>
<text top="262" left="204" width="119" height="17" font="13">Evaluate the effect of </text>
<text top="279" left="204" width="130" height="17" font="13">trandolapril on vascular </text>
<text top="296" left="204" width="40" height="17" font="13">events </text>
<text top="262" left="352" width="211" height="17" font="13">RCT 8,290; </text>
<text top="279" left="454" width="103" height="17" font="13">4,158 (trandolpril); </text>
<text top="296" left="454" width="89" height="17" font="13">4,132 (placebo) </text>
<text top="262" left="582" width="68" height="17" font="13">Stable CAD </text>
<text top="262" left="717" width="27" height="17" font="13"> N/A </text>
<text top="262" left="852" width="55" height="17" font="13">Major CV </text>
<text top="279" left="852" width="40" height="17" font="13">events </text>
<text top="262" left="940" width="21" height="17" font="13">4.8 </text>
<text top="262" left="1027" width="161" height="17" font="13">HR: 0.95; 95% CI: 0.88-1.06; </text>
<text top="279" left="1027" width="41" height="17" font="13">p=0.43 </text>
<text top="262" left="1230" width="221" height="17" font="13">Results not significant possibly because </text>
<text top="279" left="1230" width="225" height="17" font="13">the pts enrolled were at lower risk for CV </text>
<text top="296" left="1230" width="225" height="17" font="13">events compared to other trials of ACEI.  </text>
<text top="366" left="55" width="104" height="17" font="13">Mills et al, Primary </text>
<text top="383" left="55" width="75" height="17" font="13">prevention of </text>
<text top="400" left="55" width="133" height="17" font="13">cardiovascualr mortality </text>
<text top="418" left="55" width="122" height="17" font="13">and events with statin </text>
<text top="435" left="55" width="121" height="17" font="13">treatments. J Am Coll </text>
<text top="452" left="55" width="125" height="17" font="13">Cardiol; 2008;52:1769-</text>
<text top="469" left="55" width="31" height="17" font="13">1781 </text>
<text top="487" left="55" width="55" height="17" font="14">19022156</text>
<text top="487" left="110" width="29" height="17" font="13"> (77) </text>
<text top="366" left="204" width="119" height="17" font="13">Evaluation of primary </text>
<text top="383" left="204" width="135" height="17" font="13">prevention of CV events </text>
<text top="400" left="204" width="64" height="17" font="13">with statins </text>
<text top="366" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="366" left="454" width="41" height="17" font="13">53,371 </text>
<text top="383" left="454" width="7" height="17" font="13">  </text>
<text top="400" left="454" width="7" height="17" font="13">  </text>
<text top="366" left="582" width="27" height="17" font="13"> N/A </text>
<text top="366" left="717" width="27" height="17" font="13"> N/A </text>
<text top="366" left="852" width="55" height="17" font="13">Major CV </text>
<text top="383" left="852" width="40" height="17" font="13">events </text>
<text top="366" left="940" width="27" height="17" font="13"> N/A </text>
<text top="366" left="1027" width="165" height="17" font="13"> RR: 0.84; 95% CI: 0.77-0.95; </text>
<text top="383" left="1027" width="48" height="17" font="13">p=0.004 </text>
<text top="366" left="1230" width="27" height="17" font="13"> N/A </text>
<text top="505" left="55" width="126" height="17" font="13">Taylor et al, Statins for </text>
<text top="522" left="55" width="126" height="17" font="13">the primary prevention </text>
<text top="539" left="55" width="87" height="17" font="13">of CV disease.  </text>
<text top="556" left="55" width="133" height="17" font="13">Cocrane Database Syst </text>
<text top="573" left="55" width="125" height="17" font="13">Rev, 2011; CD004816 </text>
<text top="591" left="55" width="55" height="17" font="14">21249663</text>
<text top="591" left="110" width="29" height="17" font="13"> (78) </text>
<text top="608" left="55" width="3" height="17" font="13"> </text>
<text top="505" left="204" width="130" height="17" font="13">Assess benefit and risk </text>
<text top="522" left="204" width="131" height="17" font="13">of statins for prevention </text>
<text top="539" left="204" width="43" height="17" font="13">of CVD </text>
<text top="505" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="505" left="454" width="41" height="17" font="13">34,272 </text>
<text top="522" left="454" width="7" height="17" font="13">  </text>
<text top="539" left="454" width="7" height="17" font="13">  </text>
<text top="505" left="582" width="113" height="17" font="13">RCTs of statins with </text>
<text top="522" left="582" width="115" height="17" font="13">minimum duration of </text>
<text top="539" left="582" width="122" height="17" font="13">1 y and f/u of 6 mo, in </text>
<text top="556" left="582" width="79" height="17" font="13">adults with no </text>
<text top="573" left="582" width="107" height="17" font="13">restrictions on their </text>
<text top="591" left="582" width="95" height="17" font="13">total LDL or HDL </text>
<text top="608" left="582" width="101" height="17" font="13">cholesterol levels, </text>
<text top="625" left="582" width="121" height="17" font="13">and where ≤10% had </text>
<text top="642" left="582" width="103" height="17" font="13">a hx of CVD, were </text>
<text top="659" left="582" width="53" height="17" font="13">included. </text>
<text top="505" left="717" width="27" height="17" font="13"> N/A </text>
<text top="505" left="852" width="54" height="17" font="13">All-cause </text>
<text top="522" left="852" width="74" height="17" font="13">mortality and </text>
<text top="539" left="852" width="74" height="17" font="13">fatal/nonfatal </text>
<text top="556" left="852" width="29" height="17" font="13">CVD </text>
<text top="505" left="940" width="27" height="17" font="13"> N/A </text>
<text top="505" left="1027" width="111" height="17" font="13">All-cause mortality:  </text>
<text top="522" left="1027" width="165" height="17" font="13">RR: 0.84; 95% CI: 0.73-0.96)  </text>
<text top="539" left="1027" width="115" height="17" font="13">Fatal/non-fatal CVD: </text>
<text top="556" left="1027" width="158" height="17" font="13">RR: 0.70, 95% CI: 0.61-0.79 </text>
<text top="505" left="1230" width="27" height="17" font="13"> N/A </text>
<text top="677" left="55" width="90" height="17" font="13">Abramson et al; </text>
<text top="695" left="55" width="98" height="17" font="13">Moderate alcohol </text>
<text top="712" left="55" width="133" height="17" font="13">consumption and risk fo </text>
<text top="729" left="55" width="92" height="17" font="13">HF among older </text>
<text top="746" left="55" width="94" height="17" font="13">persons.  JAMA, </text>
<text top="763" left="55" width="120" height="17" font="13">2001;285:1971-1977. </text>
<text top="781" left="55" width="58" height="17" font="14">11308433 </text>
<text top="781" left="113" width="25" height="17" font="13">(79) </text>
<text top="677" left="204" width="107" height="17" font="13">Assessment of risk </text>
<text top="695" left="204" width="130" height="17" font="13">associated with alcohol </text>
<text top="712" left="204" width="110" height="17" font="13">use in older adults.  </text>
<text top="677" left="352" width="68" height="17" font="13">Prospective </text>
<text top="695" left="352" width="38" height="17" font="13">cohort </text>
<text top="677" left="454" width="34" height="17" font="13">2,235 </text>
<text top="695" left="454" width="7" height="17" font="13">  </text>
<text top="712" left="454" width="7" height="17" font="13">  </text>
<text top="677" left="582" width="105" height="17" font="13">Age ≥65 y; lived in </text>
<text top="695" left="582" width="107" height="17" font="13">New Haven, Conn, </text>
<text top="712" left="582" width="96" height="17" font="13">and free of HF at </text>
<text top="729" left="582" width="49" height="17" font="13">baseline </text>
<text top="677" left="717" width="81" height="17" font="13">Heavy alcohol </text>
<text top="695" left="717" width="102" height="17" font="13">consumption (&gt;70 </text>
<text top="712" left="717" width="24" height="17" font="13">oz.) </text>
<text top="677" left="852" width="48" height="17" font="13">New HF </text>
<text top="677" left="940" width="27" height="17" font="13"> N/A </text>
<text top="677" left="1027" width="181" height="17" font="13">No alcohol: aRR: 1.00 (referent), </text>
<text top="695" left="1027" width="185" height="17" font="13">1-20 oz: aRR: 0.79; 95% CI: 0.60-</text>
<text top="712" left="1027" width="38" height="17" font="13">1.02),  </text>
<text top="729" left="1027" width="164" height="17" font="13">21-70 oz: aRR: 0.53; 95% CI: </text>
<text top="746" left="1027" width="62" height="17" font="13">0.32-0.88.  </text>
<text top="763" left="1027" width="99" height="17" font="13">(p for trend=0.02) </text>
<text top="677" left="1230" width="215" height="17" font="13">Observational study, could not account </text>
<text top="695" left="1230" width="199" height="17" font="13">for all possible confounders, alcohol </text>
<text top="712" left="1230" width="178" height="17" font="13">consumption was self-reported.  </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">26</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="55" width="111" height="17" font="13">Walsh et al; Alcohol </text>
<text top="72" left="55" width="120" height="17" font="13">consumption and risk </text>
<text top="89" left="55" width="80" height="17" font="13">for CHF in the </text>
<text top="106" left="55" width="106" height="17" font="13">Framingham Heart </text>
<text top="124" left="55" width="133" height="17" font="13">Study.  Ann Intern Med, </text>
<text top="141" left="55" width="110" height="17" font="13">2002; 136:181-191. </text>
<text top="158" left="55" width="55" height="17" font="14">11827493</text>
<text top="158" left="110" width="29" height="17" font="13"> (80) </text>
<text top="55" left="204" width="107" height="17" font="13">Assessment of risk </text>
<text top="72" left="204" width="130" height="17" font="13">associated with alcohol </text>
<text top="89" left="204" width="23" height="17" font="13">use </text>
<text top="55" left="352" width="66" height="17" font="13">Community </text>
<text top="72" left="352" width="75" height="17" font="13">based cohort </text>
<text top="55" left="454" width="34" height="17" font="13">7,223 </text>
<text top="72" left="454" width="7" height="17" font="13">  </text>
<text top="89" left="454" width="7" height="17" font="13">  </text>
<text top="55" left="582" width="27" height="17" font="13"> N/A </text>
<text top="55" left="717" width="27" height="17" font="13"> N/A </text>
<text top="55" left="852" width="57" height="17" font="13">New CHF </text>
<text top="55" left="940" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1027" width="188" height="17" font="13">Compared to men who consumed </text>
<text top="72" left="1027" width="183" height="17" font="13">&lt;1 drink/wk, men who consumed </text>
<text top="89" left="1027" width="188" height="17" font="13">8-14 drinks/wk: HR for CHF: 0.41; </text>
<text top="106" left="1027" width="106" height="17" font="13">95% CI: 0.21-0.81. </text>
<text top="124" left="1027" width="180" height="17" font="13">In women: those who consumed </text>
<text top="141" left="1027" width="178" height="17" font="13">3-7 drinks/wk HR: 0.49; 95% CI: </text>
<text top="158" left="1027" width="179" height="17" font="13">0.25-0.96,  compared with those </text>
<text top="175" left="1027" width="156" height="17" font="13">who consumed &lt;1 drink/wk. </text>
<text top="55" left="1230" width="197" height="17" font="13"> Self-reported alcohol consumption. </text>
<text top="193" left="55" width="131" height="17" font="13">Choueiri et al, CHF risk </text>
<text top="210" left="55" width="96" height="17" font="13">in pts with breast </text>
<text top="228" left="55" width="114" height="17" font="13">cancer treaated with </text>
<text top="245" left="55" width="117" height="17" font="13">bevacizumab.  J Clin </text>
<text top="262" left="55" width="115" height="17" font="13">Oncol, 2011; 29:632-</text>
<text top="279" left="55" width="27" height="17" font="13">638. </text>
<text top="296" left="55" width="55" height="17" font="14">21205755</text>
<text top="296" left="110" width="29" height="17" font="13"> (81) </text>
<text top="193" left="204" width="115" height="17" font="13">Risk of CHF pts with </text>
<text top="210" left="204" width="131" height="17" font="13">breast cancer receiving </text>
<text top="228" left="204" width="76" height="17" font="13">bevacizumab </text>
<text top="193" left="352" width="79" height="17" font="13">Meta analysis </text>
<text top="193" left="454" width="34" height="17" font="13">3,784 </text>
<text top="210" left="454" width="7" height="17" font="13">  </text>
<text top="228" left="454" width="7" height="17" font="13">  </text>
<text top="193" left="582" width="91" height="17" font="13">RCTs published </text>
<text top="210" left="582" width="97" height="17" font="13">between January </text>
<text top="228" left="582" width="113" height="17" font="13">1966-March 2010 in </text>
<text top="245" left="582" width="47" height="17" font="13">English. </text>
<text top="193" left="717" width="27" height="17" font="13"> N/A </text>
<text top="193" left="852" width="57" height="17" font="13">New CHF </text>
<text top="193" left="940" width="27" height="17" font="13"> N/A </text>
<text top="193" left="1027" width="168" height="17" font="13">RR: 4.74; 95% CI; 1.84-12.19; </text>
<text top="210" left="1027" width="52" height="17" font="13">p=0.001) </text>
<text top="193" left="1230" width="217" height="17" font="13">Data on other risk factors for CHF were </text>
<text top="210" left="1230" width="159" height="17" font="13">not collected or unavailable.  </text>
<text top="314" left="55" width="118" height="17" font="13">Du et al; Cardiac risk </text>
<text top="332" left="55" width="108" height="17" font="13">associated with the </text>
<text top="349" left="55" width="130" height="17" font="13">receipt of anthracycline </text>
<text top="366" left="55" width="118" height="17" font="13">and trastuzumab in a </text>
<text top="383" left="55" width="100" height="17" font="13">alarge nationwide </text>
<text top="400" left="55" width="125" height="17" font="13">cohort of older women </text>
<text top="418" left="55" width="107" height="17" font="13">with breast cancer, </text>
<text top="435" left="55" width="132" height="17" font="13">1998-2005. Med Oncol, </text>
<text top="452" left="55" width="74" height="17" font="13">2010;Oct 22. </text>
<text top="469" left="55" width="55" height="17" font="14">20967512</text>
<text top="469" left="110" width="29" height="17" font="13"> (82) </text>
<text top="314" left="204" width="48" height="17" font="13">New HF </text>
<text top="314" left="352" width="49" height="17" font="13">Registry </text>
<text top="314" left="454" width="41" height="17" font="13">47,806 </text>
<text top="332" left="454" width="7" height="17" font="13">  </text>
<text top="349" left="454" width="7" height="17" font="13">  </text>
<text top="314" left="582" width="109" height="17" font="13">Women with breast </text>
<text top="332" left="582" width="79" height="17" font="13">cancer ≥65 y  </text>
<text top="314" left="717" width="27" height="17" font="13"> N/A </text>
<text top="314" left="852" width="48" height="17" font="13">New HF </text>
<text top="314" left="940" width="27" height="17" font="13"> N/A </text>
<text top="314" left="1027" width="189" height="17" font="13">HR: 1.19 anthracycline alone, HR: </text>
<text top="332" left="1027" width="187" height="17" font="13">1.97 trastuzumab alone, HR: 2.37 </text>
<text top="349" left="1027" width="40" height="17" font="13">combo </text>
<text top="314" left="1230" width="27" height="17" font="13"> N/A </text>
<text top="487" left="55" width="109" height="17" font="13">Sawaya et al; Early </text>
<text top="505" left="55" width="134" height="17" font="13">detection and prediction </text>
<text top="522" left="55" width="101" height="17" font="13">of cardiotoxicity in </text>
<text top="539" left="55" width="123" height="17" font="13">chemotherapy treated </text>
<text top="556" left="55" width="104" height="17" font="13">pts.  Am J Cardiol, </text>
<text top="573" left="55" width="110" height="17" font="13">2011; 107:1375-80. </text>
<text top="591" left="55" width="55" height="17" font="14">21371685</text>
<text top="591" left="110" width="29" height="17" font="13"> (83) </text>
<text top="487" left="204" width="107" height="17" font="13">To assess whether </text>
<text top="505" left="204" width="69" height="17" font="13">early ECHO </text>
<text top="522" left="204" width="98" height="17" font="13">measurements of </text>
<text top="539" left="204" width="131" height="17" font="13">myocardial deformation </text>
<text top="556" left="204" width="126" height="17" font="13">and biomarkers (hsTnI </text>
<text top="573" left="204" width="95" height="17" font="13">and NT-proBNP) </text>
<text top="591" left="204" width="94" height="17" font="13">could predict the </text>
<text top="608" left="204" width="87" height="17" font="13">development of </text>
<text top="625" left="204" width="128" height="17" font="13">chemotherapy-induced </text>
<text top="642" left="204" width="107" height="17" font="13">cardiotoxicity in pts </text>
<text top="659" left="204" width="67" height="17" font="13">treated with </text>
<text top="677" left="204" width="106" height="17" font="13">anthracyclines and </text>
<text top="694" left="204" width="75" height="17" font="13">trastuzumab. </text>
<text top="487" left="352" width="68" height="17" font="13">Prospective </text>
<text top="505" left="352" width="38" height="17" font="13">cohort </text>
<text top="487" left="454" width="21" height="17" font="13"> 43 </text>
<text top="505" left="454" width="7" height="17" font="13">  </text>
<text top="522" left="454" width="7" height="17" font="13">  </text>
<text top="487" left="582" width="75" height="17" font="13"> &gt;18 y of age </text>
<text top="505" left="582" width="116" height="17" font="13">diagnosed with HER-</text>
<text top="522" left="582" width="98" height="17" font="13">2-overexpressing </text>
<text top="539" left="582" width="102" height="17" font="13">breast cancer and </text>
<text top="556" left="582" width="107" height="17" font="13">either scheduled to </text>
<text top="573" left="582" width="98" height="17" font="13">receive treatment </text>
<text top="591" left="582" width="52" height="17" font="13">including </text>
<text top="608" left="582" width="106" height="17" font="13">anthracyclines and </text>
<text top="625" left="582" width="85" height="17" font="13">trastuzumab or </text>
<text top="642" left="582" width="116" height="17" font="13">scheduled to receive </text>
<text top="659" left="582" width="99" height="17" font="13">trastuzumab after </text>
<text top="677" left="582" width="50" height="17" font="13">previous </text>
<text top="694" left="582" width="76" height="17" font="13">anthracycline </text>
<text top="711" left="582" width="59" height="17" font="13">treatment. </text>
<text top="487" left="717" width="94" height="17" font="13"> Pts with LVEFs  </text>
<text top="505" left="717" width="36" height="17" font="13">≤50% </text>
<text top="487" left="852" width="68" height="17" font="13">Cardiotoxicit</text>
<text top="505" left="852" width="10" height="17" font="13">y </text>
<text top="487" left="940" width="27" height="17" font="13"> N/A </text>
<text top="487" left="1027" width="183" height="17" font="13">Elevated hsTnI at 3 mo (p =0.02) </text>
<text top="505" left="1027" width="167" height="17" font="13">and a decrease in longitudinal </text>
<text top="522" left="1027" width="33" height="17" font="13">strain </text>
<text top="539" left="1027" width="168" height="17" font="13">between baseline and 3 mo (p </text>
<text top="556" left="1027" width="164" height="17" font="13">=0.02) remained independent </text>
<text top="573" left="1027" width="176" height="17" font="13">predictors of later cardiotoxicity. </text>
<text top="591" left="1027" width="187" height="17" font="13">Neither the change in NT-proBNP </text>
<text top="608" left="1027" width="175" height="17" font="13">between baseline and 3 mo nor </text>
<text top="625" left="1027" width="178" height="17" font="13">an NT-proBNP level higher than </text>
<text top="642" left="1027" width="171" height="17" font="13">normal limits at 3 mo predicted </text>
<text top="659" left="1027" width="78" height="17" font="13">cardiotoxicity  </text>
<text top="677" left="1027" width="7" height="17" font="13">  </text>
<text top="694" left="1027" width="7" height="17" font="13">  </text>
<text top="487" left="1230" width="106" height="17" font="13"> Small sample size </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">27</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="55" width="92" height="17" font="13">McKie et al; The </text>
<text top="72" left="55" width="131" height="17" font="13">prognostic value of NT- </text>
<text top="89" left="55" width="122" height="17" font="13">proBNP for death and </text>
<text top="106" left="55" width="116" height="17" font="13">CV events in healthy </text>
<text top="124" left="55" width="122" height="17" font="13">normal and stage A/B </text>
<text top="141" left="55" width="131" height="17" font="13">HF subjects.  J Am Coll </text>
<text top="158" left="55" width="125" height="17" font="13">Cardiol, 2010;55:2140-</text>
<text top="175" left="55" width="34" height="17" font="13">2147. </text>
<text top="192" left="55" width="55" height="17" font="14">20447539</text>
<text top="192" left="110" width="29" height="17" font="13"> (84) </text>
<text top="55" left="204" width="94" height="17" font="13">NT-proBNP as a </text>
<text top="72" left="204" width="123" height="17" font="13">predictor of death, CV </text>
<text top="89" left="204" width="40" height="17" font="13">events </text>
<text top="55" left="352" width="196" height="17" font="13">Cohort 1,991 </text>
<text top="72" left="454" width="7" height="17" font="13">  </text>
<text top="89" left="454" width="7" height="17" font="13">  </text>
<text top="55" left="582" width="105" height="17" font="13">Age ≥45 y, lives in </text>
<text top="72" left="582" width="95" height="17" font="13">Olmsted County, </text>
<text top="89" left="582" width="60" height="17" font="13">Minnesota </text>
<text top="55" left="717" width="75" height="17" font="13">Symptomatic </text>
<text top="72" left="717" width="112" height="17" font="13">HF (stages C and D </text>
<text top="89" left="717" width="24" height="17" font="13">HF) </text>
<text top="55" left="852" width="63" height="17" font="13">Death, HF, </text>
<text top="72" left="852" width="49" height="17" font="13">CVA, MI </text>
<text top="55" left="940" width="57" height="17" font="13"> 8.9 years </text>
<text top="55" left="1027" width="178" height="17" font="13">HR:1.26 per log increase in fully </text>
<text top="72" left="1027" width="176" height="17" font="13">adjusted model in stage A/B pts </text>
<text top="89" left="1027" width="172" height="17" font="13">(95% CI: 1.05–1.51; p=0.015).  </text>
<text top="106" left="1027" width="183" height="17" font="13">NT-proBNP was not predictive of </text>
<text top="124" left="1027" width="185" height="17" font="13">death or CV events in the healthy </text>
<text top="141" left="1027" width="99" height="17" font="13">normal subgroup. </text>
<text top="55" left="1230" width="213" height="17" font="13">Underpowered to detect association of </text>
<text top="72" left="1230" width="230" height="17" font="13">NT-proBNP with adverse outcomes in the </text>
<text top="89" left="1230" width="142" height="17" font="13">healthy normal subgroup. </text>
<text top="210" left="55" width="87" height="17" font="13">Velagaleti et al; </text>
<text top="228" left="55" width="122" height="17" font="13">Multimarker approach </text>
<text top="245" left="55" width="129" height="17" font="13">for the prediction of HF </text>
<text top="262" left="55" width="89" height="17" font="13">incidence in the </text>
<text top="279" left="55" width="135" height="17" font="13">community.  Circulation, </text>
<text top="296" left="55" width="120" height="17" font="13">2010;122:1700-1706. </text>
<text top="314" left="55" width="55" height="17" font="14">20937976</text>
<text top="314" left="110" width="29" height="17" font="13"> (85) </text>
<text top="210" left="204" width="122" height="17" font="13">Evaluation of markers </text>
<text top="228" left="204" width="124" height="17" font="13">for HF development in </text>
<text top="245" left="204" width="83" height="17" font="13">the community </text>
<text top="210" left="352" width="196" height="17" font="13">Cohort 2,754 </text>
<text top="228" left="454" width="7" height="17" font="13">  </text>
<text top="245" left="454" width="7" height="17" font="13">  </text>
<text top="210" left="582" width="66" height="17" font="13"> Free of HF </text>
<text top="210" left="717" width="27" height="17" font="13"> N/A </text>
<text top="210" left="852" width="20" height="17" font="13">HF </text>
<text top="210" left="940" width="27" height="17" font="13"> N/A </text>
<text top="210" left="1027" width="172" height="17" font="13">BNP: aHR: 1.52; 95% CI: 1.24–</text>
<text top="228" left="1027" width="89" height="17" font="13">1.87; p&lt;0.0001  </text>
<text top="245" left="1027" width="182" height="17" font="13">UACR: aHR: 1.35; 95% CI: 1.11–</text>
<text top="262" left="1027" width="79" height="17" font="13">1.66; p=0.004 </text>
<text top="210" left="1230" width="206" height="17" font="13">Subjects mostly white and results not </text>
<text top="228" left="1230" width="159" height="17" font="13">generalizable to other races. </text>
<text top="332" left="55" width="103" height="17" font="13">Blecker et al; High </text>
<text top="349" left="55" width="132" height="17" font="13">normal albuminuria and </text>
<text top="366" left="55" width="90" height="17" font="13">risk of HF in the </text>
<text top="383" left="55" width="101" height="17" font="13">community.  Am J </text>
<text top="400" left="55" width="100" height="17" font="13">Kidney Dis, 2011; </text>
<text top="418" left="55" width="55" height="17" font="13">58:47-55. </text>
<text top="435" left="55" width="55" height="17" font="14">21549463</text>
<text top="435" left="110" width="29" height="17" font="13"> (86) </text>
<text top="332" left="204" width="74" height="17" font="13">Evaluation of </text>
<text top="349" left="204" width="124" height="17" font="13">albuminuria as risk for </text>
<text top="366" left="204" width="46" height="17" font="13">new HF </text>
<text top="332" left="352" width="203" height="17" font="13">Cohort 10,975 </text>
<text top="349" left="454" width="7" height="17" font="13">  </text>
<text top="366" left="454" width="7" height="17" font="13">  </text>
<text top="332" left="582" width="66" height="17" font="13"> Free of HF </text>
<text top="332" left="717" width="27" height="17" font="13"> N/A </text>
<text top="332" left="852" width="20" height="17" font="13">HF </text>
<text top="332" left="940" width="27" height="17" font="13"> 8.3  </text>
<text top="332" left="1027" width="169" height="17" font="13">aHR: 1.54 (95% CI,:1.12-2.11) </text>
<text top="349" left="1027" width="165" height="17" font="13">UACR normal to intermediate-</text>
<text top="366" left="1027" width="183" height="17" font="13">normal; aHR: 1.91 (95% CI: 1.38-</text>
<text top="383" left="1027" width="162" height="17" font="13">2.66) high-normal; aHR: 2.49 </text>
<text top="400" left="1027" width="179" height="17" font="13">(95% CI: 1.77-3.50) micro; aHR: </text>
<text top="418" left="1027" width="176" height="17" font="13">3.47 (95% CI: 2.10-5.72) macro </text>
<text top="435" left="1027" width="56" height="17" font="13">(p&lt;0.001) </text>
<text top="332" left="1230" width="27" height="17" font="13"> N/A </text>
<text top="453" left="55" width="79" height="17" font="13">deFilippi et al; </text>
<text top="470" left="55" width="113" height="17" font="13">Association of serial </text>
<text top="487" left="55" width="114" height="17" font="13">measures of cardiac </text>
<text top="505" left="55" width="102" height="17" font="13">troponin T using a </text>
<text top="522" left="55" width="112" height="17" font="13">sensitive assay with </text>
<text top="539" left="55" width="110" height="17" font="13">incident HF and CV </text>
<text top="556" left="55" width="137" height="17" font="13">mortality in older adults.  </text>
<text top="573" left="55" width="129" height="17" font="13">JAMA, 2010; 304:2494-</text>
<text top="591" left="55" width="34" height="17" font="13">2502. </text>
<text top="608" left="55" width="55" height="17" font="14">21078811</text>
<text top="608" left="110" width="29" height="17" font="13"> (87) </text>
<text top="453" left="204" width="101" height="17" font="13">Assessment as to </text>
<text top="470" left="204" width="128" height="17" font="13">whether baseline cTnT </text>
<text top="487" left="204" width="124" height="17" font="13">or changes predict HF </text>
<text top="453" left="352" width="196" height="17" font="13">Cohort 4,221 </text>
<text top="470" left="454" width="7" height="17" font="13">  </text>
<text top="487" left="454" width="7" height="17" font="13">  </text>
<text top="453" left="582" width="27" height="17" font="13"> N/A </text>
<text top="453" left="717" width="27" height="17" font="13"> N/A </text>
<text top="453" left="852" width="20" height="17" font="13">HF </text>
<text top="453" left="940" width="27" height="17" font="13">11.8 </text>
<text top="453" left="1027" width="52" height="17" font="13">Complex </text>
<text top="470" left="1027" width="181" height="17" font="13">&gt;99th percentile at baseline: 6.4; </text>
<text top="487" left="1027" width="163" height="17" font="13">change from neg to pos: 1.61 </text>
<text top="505" left="1027" width="53" height="17" font="13">increase. </text>
<text top="453" left="1230" width="208" height="17" font="13">Samples were available in ~3/4 of the </text>
<text top="470" left="1230" width="188" height="17" font="13">cohort at baseline, and differential </text>
<text top="487" left="1230" width="209" height="17" font="13">absence of cTnT measures may have </text>
<text top="505" left="1230" width="200" height="17" font="13">introduced bias into the estimates of </text>
<text top="522" left="1230" width="198" height="17" font="13">associations with HF and CV death. </text>
<text top="626" left="55" width="132" height="17" font="13">Heidenreich, et al, Cost-</text>
<text top="643" left="55" width="89" height="17" font="13">effectiveness of </text>
<text top="660" left="55" width="124" height="17" font="13">screening with BNP to </text>
<text top="677" left="55" width="135" height="17" font="13">identify pts with reduced </text>
<text top="695" left="55" width="97" height="17" font="13">LVEF.  J Am Coll </text>
<text top="712" left="55" width="125" height="17" font="13">Cardiol, 2004;43:1019-</text>
<text top="729" left="55" width="34" height="17" font="13">1026. </text>
<text top="746" left="55" width="55" height="17" font="14">15028361</text>
<text top="746" left="110" width="29" height="17" font="13"> (88) </text>
<text top="626" left="204" width="118" height="17" font="13">Cost effectiveness of </text>
<text top="643" left="204" width="86" height="17" font="13">BNP screening </text>
<text top="626" left="352" width="69" height="17" font="13">Cost benefit </text>
<text top="643" left="352" width="48" height="17" font="13">analysis </text>
<text top="626" left="454" width="24" height="17" font="13">N/A </text>
<text top="626" left="582" width="104" height="17" font="13">Asymptomatic pts. </text>
<text top="626" left="717" width="27" height="17" font="13"> N/A </text>
<text top="626" left="852" width="27" height="17" font="13"> N/A </text>
<text top="626" left="940" width="27" height="17" font="13"> N/A </text>
<text top="626" left="1027" width="133" height="17" font="13">BNP testing followed by </text>
<text top="643" left="1027" width="150" height="17" font="13">echocardiography is a cost-</text>
<text top="660" left="1027" width="106" height="17" font="13">effective screening </text>
<text top="677" left="1027" width="164" height="17" font="13">strategy for men and possibly </text>
<text top="695" left="1027" width="166" height="17" font="13">women at age 60 y - for every </text>
<text top="712" left="1027" width="158" height="17" font="13">125 men screened,1 y of life </text>
<text top="729" left="1027" width="157" height="17" font="13">would be gained at a cost of </text>
<text top="746" left="1027" width="51" height="17" font="13">$23,500. </text>
<text top="626" left="1230" width="124" height="17" font="13">Did not evaluate other </text>
<text top="643" left="1230" width="179" height="17" font="13">blood tests such as pro-BNP as  </text>
<text top="660" left="1230" width="216" height="17" font="13">prevalence and outcome data were not </text>
<text top="677" left="1230" width="59" height="17" font="13">available.  </text>
<text top="764" left="54" width="1405" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; AV, atrioventricular; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive </text>
<text top="781" left="54" width="1400" height="17" font="13">heart failure; cTnT, cardiac troponin T; CV, cardiovascular; CVA, cerebrovascular accident; CVD, cardiovascular disease; DM, diabetes mellitus; DBP, diastolic blood pressure; ECG, electrocardiography; HDL, high density lipoprotein; HF, heart failure; hsTnI, </text>
</page>
<page number="28" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">28</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="1400" height="17" font="13">high-sensitivity troponin I; HTN, hypertension; LDL, low density lipoprotein; Hx, history; LVH, left ventricular hypertrophy; MI, myocardial infarction; N/A, not applicable; N-terminal pro–B-type natriuretic peptide; ONTARGET, Ongoing Telmisartan Along and in </text>
<text top="71" left="54" width="1361" height="17" font="13">Combination with Ramipril Global Endpoint Trial; PAD, peripheral arterial disease; PAR, population attributable risk; pro-BNP, pro–B-type natriuretic peptide; pts, patients; RCT, randomized clinical trial; SAE, serious adverse event; SBP, systolic blood </text>
<text top="88" left="54" width="883" height="17" font="13">pressure; TRANSCEND, Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with CV Disease; and UACR, urinary albumin-to-creatinine ratio. </text>
<text top="106" left="54" width="3" height="17" font="13"> </text>
<text top="132" left="54" width="679" height="21" font="8"><b>Data Supplement 12. Stage B: Preventing the Syndrome of Clinical HF With Low EF (Section 7.2) </b></text>
<text top="172" left="69" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="191" left="69" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="191" left="181" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="172" left="288" width="41" height="19" font="9"><b>Study </b></text>
<text top="191" left="291" width="35" height="19" font="9"><b>Type </b></text>
<text top="172" left="353" width="41" height="19" font="9"><b>Study </b></text>
<text top="191" left="358" width="31" height="19" font="9"><b>Size </b></text>
<text top="191" left="466" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="191" left="730" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="153" left="907" width="68" height="19" font="9"><b>Statistical </b></text>
<text top="172" left="911" width="59" height="19" font="9"><b>Analysis </b></text>
<text top="191" left="910" width="62" height="19" font="9"><b>(Results) </b></text>
<text top="172" left="1020" width="74" height="19" font="9"><b>P Values &amp; </b></text>
<text top="191" left="1030" width="53" height="19" font="9"><b>95% CI: </b></text>
<text top="172" left="1126" width="56" height="19" font="9"><b>OR: HR: </b></text>
<text top="191" left="1140" width="28" height="19" font="9"><b>RR: </b></text>
<text top="172" left="1237" width="41" height="19" font="9"><b>Study </b></text>
<text top="191" left="1220" width="76" height="19" font="9"><b>Limitations </b></text>
<text top="172" left="1346" width="64" height="19" font="9"><b>Findings/ </b></text>
<text top="191" left="1341" width="74" height="19" font="9"><b>Comments </b></text>
<text top="211" left="435" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="230" left="441" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="211" left="552" width="68" height="19" font="10"><i><b>Exclusion </b></i></text>
<text top="230" left="560" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="211" left="677" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="230" left="673" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="211" left="786" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="230" left="791" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="255" left="61" width="89" height="17" font="15"><b>ACE Inhibitors</b> </text>
<text top="273" left="61" width="49" height="17" font="13">Effect of </text>
<text top="290" left="61" width="70" height="17" font="13">Captopril on </text>
<text top="307" left="61" width="74" height="17" font="13">Mortality and </text>
<text top="324" left="61" width="87" height="17" font="13">Morbidity in Pts </text>
<text top="342" left="61" width="98" height="17" font="13">with LVD after MI </text>
<text top="359" left="61" width="89" height="17" font="13">Pfeffer, Marc A; </text>
<text top="376" left="61" width="68" height="17" font="13">NEJM 1992 </text>
<text top="393" left="61" width="44" height="17" font="13">(SAVE) </text>
<text top="410" left="61" width="48" height="17" font="14">1386652</text>
<text top="410" left="109" width="29" height="17" font="13"> (89) </text>
<text top="273" left="175" width="63" height="17" font="13">Investigate </text>
<text top="290" left="175" width="97" height="17" font="13">whether captopril </text>
<text top="307" left="175" width="74" height="17" font="13">could reduce </text>
<text top="324" left="175" width="77" height="17" font="13">morbidity and </text>
<text top="342" left="175" width="83" height="17" font="13">mortality in pts </text>
<text top="359" left="175" width="89" height="17" font="13">with LVSD after </text>
<text top="376" left="175" width="34" height="17" font="13">an MI </text>
<text top="273" left="286" width="29" height="17" font="13">RCT </text>
<text top="273" left="344" width="34" height="17" font="13">2,331 </text>
<text top="273" left="415" width="90" height="17" font="13">Within 3-60 d of </text>
<text top="290" left="415" width="95" height="17" font="13">MI; EF &lt;40%; no </text>
<text top="307" left="415" width="65" height="17" font="13">overt HF or </text>
<text top="324" left="415" width="51" height="17" font="13">ischemic </text>
<text top="342" left="415" width="87" height="17" font="13">symptoms; age </text>
<text top="359" left="415" width="51" height="17" font="13">21-80 y;  </text>
<text top="273" left="531" width="89" height="17" font="13">Cr &gt; 2.5 mg/dL; </text>
<text top="290" left="531" width="43" height="17" font="13">relative </text>
<text top="307" left="531" width="103" height="17" font="13">contraindication to </text>
<text top="324" left="531" width="84" height="17" font="13">ACEI; need for </text>
<text top="342" left="531" width="74" height="17" font="13">ACEI to treat </text>
<text top="359" left="531" width="107" height="17" font="13">symptomatic HF or </text>
<text top="376" left="531" width="64" height="17" font="13">HTN; other </text>
<text top="393" left="531" width="101" height="17" font="13">conditions limiting </text>
<text top="410" left="531" width="103" height="17" font="13">survival; &#34;unstable </text>
<text top="428" left="531" width="93" height="17" font="13">course&#34; after MI  </text>
<text top="273" left="653" width="54" height="17" font="13">All-cause </text>
<text top="290" left="653" width="74" height="17" font="13">mortality; CV </text>
<text top="307" left="653" width="53" height="17" font="13">mortality; </text>
<text top="324" left="653" width="61" height="17" font="13">mortality &amp; </text>
<text top="342" left="653" width="94" height="17" font="13">derease in EF of </text>
<text top="359" left="653" width="43" height="17" font="13">9 units; </text>
<text top="376" left="653" width="87" height="17" font="13">development of </text>
<text top="393" left="653" width="98" height="17" font="13">overt HF (despite </text>
<text top="410" left="653" width="73" height="17" font="13">diuretics and </text>
<text top="428" left="653" width="94" height="17" font="13">digoxin therapy); </text>
<text top="445" left="653" width="99" height="17" font="13">hospitalization for </text>
<text top="462" left="653" width="64" height="17" font="13">HF; fatal or </text>
<text top="479" left="653" width="102" height="17" font="13">nonfatal MI; mean </text>
<text top="496" left="653" width="78" height="17" font="13">f/u 42 months </text>
<text top="273" left="768" width="27" height="17" font="13"> N/A </text>
<text top="273" left="889" width="24" height="17" font="13">N/A </text>
<text top="273" left="1005" width="93" height="17" font="13">Risk Reduction:  </text>
<text top="290" left="1005" width="164" height="17" font="13">All-cause mortality 19% (95% </text>
<text top="307" left="1005" width="117" height="17" font="13">CI: 3-32% p=0.019);  </text>
<text top="324" left="1005" width="179" height="17" font="13">death from CV cause 21% (95% </text>
<text top="342" left="1005" width="117" height="17" font="13">CI: 5-35%; p&lt;0.001); </text>
<text top="359" left="1005" width="176" height="17" font="13">development of severe HF 37% </text>
<text top="376" left="1005" width="160" height="17" font="13">(95% CI: 20-50%; p&lt;0.001);  </text>
<text top="393" left="1005" width="180" height="17" font="13">HF hospitalization 22% (95% CI: </text>
<text top="410" left="1005" width="171" height="17" font="13">4-37%; p= 0.019); recurrent MI </text>
<text top="428" left="1005" width="177" height="17" font="13">25% (95% CI: 5-40%; p=0.015)  </text>
<text top="445" left="1005" width="7" height="17" font="13">  </text>
<text top="273" left="1199" width="92" height="17" font="13">Low rate of beta </text>
<text top="290" left="1199" width="70" height="17" font="13">blocker use; </text>
<text top="307" left="1199" width="101" height="17" font="13">Recruitment 1987-</text>
<text top="324" left="1199" width="92" height="17" font="13">1990: significant </text>
<text top="342" left="1199" width="63" height="17" font="13">changes in </text>
<text top="359" left="1199" width="96" height="17" font="13">revascularization </text>
<text top="376" left="1199" width="57" height="17" font="13">strategies </text>
<text top="273" left="1328" width="72" height="17" font="13">Reduction in </text>
<text top="290" left="1328" width="84" height="17" font="13">severe HF and </text>
<text top="307" left="1328" width="20" height="17" font="13">HF </text>
<text top="324" left="1328" width="81" height="17" font="13">hospitalization </text>
<text top="342" left="1328" width="86" height="17" font="13">among pts with </text>
<text top="359" left="1328" width="77" height="17" font="13">MI and LVSD </text>
<text top="376" left="1328" width="42" height="17" font="13">without </text>
<text top="393" left="1328" width="93" height="17" font="13">symptoms of HF </text>
<text top="514" left="61" width="100" height="17" font="13">Effect of Enalapril </text>
<text top="532" left="61" width="91" height="17" font="13">on Mortality and </text>
<text top="549" left="61" width="96" height="17" font="13">the Development </text>
<text top="566" left="61" width="47" height="17" font="13">of HF in </text>
<text top="583" left="61" width="81" height="17" font="13">Asymptomatic </text>
<text top="600" left="61" width="99" height="17" font="13">Pts with Reduced </text>
<text top="618" left="61" width="62" height="17" font="13">LVEF. The </text>
<text top="635" left="61" width="45" height="17" font="13">SOLVD </text>
<text top="652" left="61" width="76" height="17" font="13">Investigators. </text>
<text top="669" left="61" width="68" height="17" font="13">NEJM 1992 </text>
<text top="687" left="61" width="49" height="17" font="13">(SOLVD </text>
<text top="704" left="61" width="66" height="17" font="13">Prevention) </text>
<text top="721" left="61" width="51" height="17" font="14">1463530 </text>
<text top="721" left="112" width="25" height="17" font="13">(90) </text>
<text top="514" left="175" width="89" height="17" font="13">Study the effect </text>
<text top="532" left="175" width="66" height="17" font="13">of an ACEI, </text>
<text top="549" left="175" width="70" height="17" font="13">enalapril, on </text>
<text top="566" left="175" width="89" height="17" font="13">outcomes in pts </text>
<text top="583" left="175" width="81" height="17" font="13">with LVSD not </text>
<text top="600" left="175" width="81" height="17" font="13">receiving drug </text>
<text top="618" left="175" width="82" height="17" font="13">therapy for HF </text>
<text top="514" left="286" width="212" height="17" font="13">RCT 4228  EF&lt;35%; </text>
<text top="514" left="469" width="50" height="17" font="13">not </text>
<text top="532" left="415" width="53" height="17" font="13">receiving </text>
<text top="549" left="415" width="95" height="17" font="13">diuretics, digoxin </text>
<text top="566" left="415" width="101" height="17" font="13">or vasodilators for </text>
<text top="583" left="415" width="103" height="17" font="13">HF (asymptomatic </text>
<text top="600" left="415" width="40" height="17" font="13">LVSD) </text>
<text top="514" left="531" width="27" height="17" font="13"> N/A </text>
<text top="514" left="653" width="54" height="17" font="13">All-cause </text>
<text top="532" left="653" width="87" height="17" font="13">mortality; mean </text>
<text top="549" left="653" width="88" height="17" font="13">f/u 37.4 months </text>
<text top="514" left="768" width="90" height="17" font="13">Development of </text>
<text top="532" left="768" width="105" height="17" font="13">HF &amp; mortality; HF </text>
<text top="549" left="768" width="93" height="17" font="13">hospitalization &amp; </text>
<text top="566" left="768" width="50" height="17" font="13">mortality </text>
<text top="514" left="889" width="234" height="17" font="13">N/A Risk </text>
<text top="514" left="1032" width="154" height="17" font="13">Reduction: </text>
<text top="514" left="1094" width="95" height="17" font="13"> </text>
<text top="532" left="1005" width="176" height="17" font="13">All-cause mortality 8% (95% CI: </text>
<text top="549" left="1005" width="160" height="17" font="13">95% CI -8 - 21%; p=0.3); CV </text>
<text top="566" left="1005" width="151" height="17" font="13">mortality 12% (95% CI: -3 - </text>
<text top="583" left="1005" width="84" height="17" font="13">26%; p=0.12);  </text>
<text top="600" left="1005" width="169" height="17" font="13">mortality &amp; development of HF </text>
<text top="618" left="1005" width="128" height="17" font="13">29% (95% CI: 21-36%; </text>
<text top="635" left="1005" width="59" height="17" font="13">p&lt;0.001);  </text>
<text top="652" left="1005" width="163" height="17" font="13">mortality &amp; HF hospitalization </text>
<text top="669" left="1005" width="174" height="17" font="13">20% (95% CI: 9-30%; p&lt;0.001) </text>
<text top="687" left="1005" width="7" height="17" font="13">  </text>
<text top="514" left="1199" width="92" height="17" font="13">Low rate of beta-</text>
<text top="532" left="1199" width="66" height="17" font="13">blocker use </text>
<text top="514" left="1328" width="72" height="17" font="13">Reduction in </text>
<text top="532" left="1328" width="57" height="17" font="13">combined </text>
<text top="549" left="1328" width="70" height="17" font="13">endpoints of </text>
<text top="566" left="1328" width="87" height="17" font="13">development of </text>
<text top="583" left="1328" width="81" height="17" font="13">HF &amp; mortality </text>
<text top="600" left="1328" width="44" height="17" font="13">and HF </text>
<text top="618" left="1328" width="81" height="17" font="13">hospitalization </text>
<text top="635" left="1328" width="74" height="17" font="13">and mortality </text>
<text top="652" left="1328" width="86" height="17" font="13">among pts with </text>
<text top="669" left="1328" width="79" height="17" font="13">asymptomatic </text>
<text top="687" left="1328" width="36" height="17" font="13">LVSD </text>
</page>
<page number="29" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">29</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="98" height="17" font="13">Effect of enalapril </text>
<text top="72" left="61" width="89" height="17" font="13">on 12-y survival </text>
<text top="89" left="61" width="43" height="17" font="13">and life </text>
<text top="106" left="61" width="99" height="17" font="13">expectancy in pts </text>
<text top="124" left="61" width="75" height="17" font="13">with LVSD: a </text>
<text top="141" left="61" width="106" height="17" font="13">follow-up study.      </text>
<text top="158" left="61" width="107" height="17" font="13">Jong, P                   </text>
<text top="175" left="61" width="71" height="17" font="13">Lancet 2003 </text>
<text top="192" left="61" width="58" height="17" font="14">12788569 </text>
<text top="192" left="119" width="25" height="17" font="13">(91) </text>
<text top="55" left="175" width="94" height="17" font="13">12-y follow-up of </text>
<text top="72" left="175" width="59" height="17" font="13">SOLVD to </text>
<text top="89" left="175" width="82" height="17" font="13">establish if the </text>
<text top="106" left="175" width="50" height="17" font="13">mortality </text>
<text top="124" left="175" width="79" height="17" font="13">reduction with </text>
<text top="141" left="175" width="91" height="17" font="13">enalapril among </text>
<text top="158" left="175" width="90" height="17" font="13">pts with HF was </text>
<text top="175" left="175" width="80" height="17" font="13">sustained and </text>
<text top="192" left="175" width="54" height="17" font="13">wheather </text>
<text top="210" left="175" width="60" height="17" font="13">susequent </text>
<text top="227" left="175" width="67" height="17" font="13">reduction in </text>
<text top="244" left="175" width="85" height="17" font="13">mortality would </text>
<text top="261" left="175" width="86" height="17" font="13">emerge among </text>
<text top="278" left="175" width="59" height="17" font="13">those with </text>
<text top="296" left="175" width="79" height="17" font="13">asymptomatic </text>
<text top="313" left="175" width="60" height="17" font="13">ventricular </text>
<text top="330" left="175" width="66" height="17" font="13">dysfunction </text>
<text top="55" left="286" width="110" height="17" font="13">Cohort 5,165 </text>
<text top="55" left="415" width="71" height="17" font="13">SOLVED </text>
<text top="72" left="415" width="85" height="17" font="13">prevention and </text>
<text top="89" left="415" width="79" height="17" font="13">treatment trial </text>
<text top="106" left="415" width="95" height="17" font="13">populations alive </text>
<text top="124" left="415" width="90" height="17" font="13">at completion of </text>
<text top="141" left="415" width="35" height="17" font="13">RCTs </text>
<text top="55" left="531" width="27" height="17" font="13"> N/A </text>
<text top="55" left="653" width="54" height="17" font="13">All-cause </text>
<text top="72" left="653" width="50" height="17" font="13">mortality </text>
<text top="55" left="768" width="27" height="17" font="13"> N/A </text>
<text top="55" left="889" width="100" height="17" font="13">In combined trials </text>
<text top="72" left="889" width="90" height="17" font="13">(Prevention and </text>
<text top="89" left="889" width="67" height="17" font="13">Treatment), </text>
<text top="106" left="889" width="50" height="17" font="13">enalapril </text>
<text top="124" left="889" width="98" height="17" font="13">extended median </text>
<text top="141" left="889" width="86" height="17" font="13">survival 9.4 mo </text>
<text top="158" left="889" width="100" height="17" font="13">(95% CI 2.8-16.5; </text>
<text top="175" left="889" width="52" height="17" font="13">p=0.004) </text>
<text top="55" left="1005" width="173" height="17" font="13">In the Prevention Trial mortality </text>
<text top="72" left="1005" width="155" height="17" font="13">50.9% in enalapril group vs. </text>
<text top="89" left="1005" width="136" height="17" font="13">56.4% in placebo group; </text>
<text top="106" left="1005" width="52" height="17" font="13">p=0.001. </text>
<text top="124" left="1005" width="133" height="17" font="13">In overall cohort, HR for </text>
<text top="141" left="1005" width="137" height="17" font="13">mortality 0.9 (0.84-0.95); </text>
<text top="158" left="1005" width="142" height="17" font="13">p=0.0003 for enalapril vs. </text>
<text top="175" left="1005" width="47" height="17" font="13">placebo </text>
<text top="55" left="1199" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1328" width="90" height="17" font="13">Mortality benefit </text>
<text top="72" left="1328" width="64" height="17" font="13">of enalapril </text>
<text top="89" left="1328" width="86" height="17" font="13">among pts with </text>
<text top="106" left="1328" width="79" height="17" font="13">asymptomatic </text>
<text top="124" left="1328" width="39" height="17" font="13">LVSD  </text>
<text top="348" left="61" width="44" height="17" font="15"><b>Statins </b></text>
<text top="371" left="61" width="88" height="17" font="13">Intensive Statin </text>
<text top="389" left="61" width="93" height="17" font="13">Therapy and the </text>
<text top="406" left="61" width="41" height="17" font="13">Risk of </text>
<text top="423" left="61" width="83" height="17" font="13">Hospitalization </text>
<text top="440" left="61" width="84" height="17" font="13">for HF After an </text>
<text top="457" left="61" width="62" height="17" font="13">ACS in the </text>
<text top="475" left="61" width="90" height="17" font="13">PROVE IT-TIMI </text>
<text top="492" left="61" width="69" height="17" font="13">22 Study      </text>
<text top="509" left="61" width="98" height="17" font="13">Scirica, Benjamin </text>
<text top="526" left="61" width="94" height="17" font="13">M              JACC </text>
<text top="543" left="61" width="31" height="17" font="13">2006 </text>
<text top="561" left="61" width="58" height="17" font="14">16750703 </text>
<text top="561" left="119" width="25" height="17" font="13">(92) </text>
<text top="371" left="175" width="60" height="17" font="13">Determine </text>
<text top="389" left="175" width="47" height="17" font="13">whether </text>
<text top="406" left="175" width="81" height="17" font="13">intensive satin </text>
<text top="423" left="175" width="92" height="17" font="13">therapy reduces </text>
<text top="440" left="175" width="81" height="17" font="13">hospitalization </text>
<text top="457" left="175" width="77" height="17" font="13">for HF in high </text>
<text top="475" left="175" width="98" height="17" font="13">risk pts (intensive </text>
<text top="492" left="175" width="77" height="17" font="13">statin therapy </text>
<text top="509" left="175" width="82" height="17" font="13">simvastatin 80 </text>
<text top="526" left="175" width="75" height="17" font="13">vs. moderate </text>
<text top="543" left="175" width="77" height="17" font="13">statin therapy </text>
<text top="561" left="175" width="64" height="17" font="13">pravastatin </text>
<text top="578" left="175" width="38" height="17" font="13">40mg) </text>
<text top="371" left="286" width="29" height="17" font="13">RCT </text>
<text top="371" left="344" width="34" height="17" font="13">4,162 </text>
<text top="371" left="415" width="100" height="17" font="13">ACS (AMI or high-</text>
<text top="389" left="415" width="99" height="17" font="13">risk UA) within 10 </text>
<text top="406" left="415" width="103" height="17" font="13">d; total cholesterol </text>
<text top="423" left="415" width="72" height="17" font="13">&lt;240 mg/dL; </text>
<text top="440" left="415" width="96" height="17" font="13">stable condition;  </text>
<text top="371" left="531" width="107" height="17" font="13">Life-expectancy &lt;2 </text>
<text top="389" left="531" width="92" height="17" font="13">y; PCI within the </text>
<text top="406" left="531" width="94" height="17" font="13">prior 6 mo (other </text>
<text top="423" left="531" width="101" height="17" font="13">than for qualifying </text>
<text top="440" left="531" width="79" height="17" font="13">event); CABG </text>
<text top="457" left="531" width="69" height="17" font="13">within 2 mo; </text>
<text top="475" left="531" width="86" height="17" font="13">planned CABG </text>
<text top="371" left="653" width="101" height="17" font="13">Hospitalization for </text>
<text top="389" left="653" width="88" height="17" font="13">HF (time to first </text>
<text top="406" left="653" width="101" height="17" font="13">HF hospitalization </text>
<text top="423" left="653" width="103" height="17" font="13">that occurred 30 d </text>
<text top="440" left="653" width="80" height="17" font="13">or longer after </text>
<text top="457" left="653" width="85" height="17" font="13">randomization) </text>
<text top="371" left="768" width="305" height="17" font="13">MI Meta-analysis </text>
<text top="371" left="969" width="118" height="17" font="13">of </text>
<text top="389" left="889" width="90" height="17" font="13">4 large RCTs of </text>
<text top="406" left="889" width="77" height="17" font="13">statin therapy </text>
<text top="423" left="889" width="75" height="17" font="13">(TNT, A to Z, </text>
<text top="440" left="889" width="90" height="17" font="13">IDEAL, PROVE-</text>
<text top="457" left="889" width="96" height="17" font="13">IT)    N=27,546    </text>
<text top="475" left="889" width="92" height="17" font="13">Reduction in HF </text>
<text top="492" left="889" width="85" height="17" font="13">hospitalization: </text>
<text top="509" left="889" width="84" height="17" font="13">OR: 0.73; 95% </text>
<text top="526" left="889" width="78" height="17" font="13">CI: 0.63-0.84; </text>
<text top="543" left="889" width="86" height="17" font="13">p&lt;0.001 [x2 for </text>
<text top="561" left="889" width="89" height="17" font="13">heterogeneity = </text>
<text top="578" left="889" width="83" height="17" font="13">2.25, p=0.523) </text>
<text top="371" left="1005" width="165" height="17" font="13">Atorvastatin 80mg associated </text>
<text top="389" left="1005" width="112" height="17" font="13">with reduction in HF </text>
<text top="406" left="1005" width="170" height="17" font="13">hospitalization: 1.6% vs. 3.1%; </text>
<text top="423" left="1005" width="158" height="17" font="13">HR 0.55; 95% CI: 0.35-0.85; </text>
<text top="440" left="1005" width="182" height="17" font="13">p=0.008                                        </text>
<text top="457" left="1005" width="155" height="17" font="13">when adjusted for history or </text>
<text top="475" left="1005" width="175" height="17" font="13">prior HF HR 0.55; 95% CI: 0.35-</text>
<text top="492" left="1005" width="79" height="17" font="13">0.36; p=0.008 </text>
<text top="509" left="1005" width="7" height="17" font="13">  </text>
<text top="371" left="1199" width="72" height="17" font="13">Sub-study of </text>
<text top="389" left="1199" width="113" height="17" font="13">PROVE IT-TIMI 22.  </text>
<text top="406" left="1199" width="88" height="17" font="13">Did not exclude </text>
<text top="423" left="1199" width="107" height="17" font="13">those with prior HF </text>
<text top="440" left="1199" width="61" height="17" font="13">(low rates) </text>
<text top="371" left="1328" width="91" height="17" font="13">In pts with ACS, </text>
<text top="389" left="1328" width="85" height="17" font="13">intensive statin </text>
<text top="406" left="1328" width="92" height="17" font="13">therapy reduced </text>
<text top="423" left="1328" width="103" height="17" font="13">new onset HF        </text>
<text top="440" left="1328" width="87" height="17" font="13">Also perfomred </text>
<text top="457" left="1328" width="93" height="17" font="13">meta-analysis of </text>
<text top="475" left="1328" width="74" height="17" font="13">4 large statin </text>
<text top="492" left="1328" width="86" height="17" font="13">trials (2 ACS, 1 </text>
<text top="509" left="1328" width="61" height="17" font="13">hx of MI, 1 </text>
<text top="526" left="1328" width="92" height="17" font="13">clinically evident </text>
<text top="543" left="1328" width="34" height="17" font="13">CHD) </text>
<text top="561" left="1328" width="81" height="17" font="13">demonstrating </text>
<text top="578" left="1328" width="54" height="17" font="13">benefit of </text>
<text top="595" left="1328" width="92" height="17" font="13">intensive stating </text>
<text top="612" left="1328" width="57" height="17" font="13">therapy in </text>
<text top="630" left="1328" width="81" height="17" font="13">preventing HF </text>
<text top="647" left="1328" width="81" height="17" font="13">hospitalizaiton </text>
<text top="665" left="61" width="100" height="17" font="13">Early Intensive vs </text>
<text top="682" left="61" width="59" height="17" font="13">a Delayed </text>
<text top="699" left="61" width="75" height="17" font="13">Conservative </text>
<text top="716" left="61" width="67" height="17" font="13">Simvastatin </text>
<text top="734" left="61" width="83" height="17" font="13">Strategy in Pts </text>
<text top="751" left="61" width="96" height="17" font="13">with ACS. Phase </text>
<text top="768" left="61" width="81" height="17" font="13">Z of the A to Z </text>
<text top="785" left="61" width="85" height="17" font="13">Trial.                 </text>
<text top="665" left="175" width="69" height="17" font="13">To compare </text>
<text top="682" left="175" width="92" height="17" font="13">early initiation of </text>
<text top="699" left="175" width="69" height="17" font="13">an intensive </text>
<text top="716" left="175" width="81" height="17" font="13">statin regimen </text>
<text top="734" left="175" width="72" height="17" font="13">with delayed </text>
<text top="751" left="175" width="98" height="17" font="13">initiation of a less </text>
<text top="768" left="175" width="52" height="17" font="13">intensive </text>
<text top="785" left="175" width="81" height="17" font="13">regimen in pts </text>
<text top="665" left="286" width="199" height="17" font="13">RCT 4,479  STEMI </text>
<text top="665" left="456" width="44" height="17" font="13">or </text>
<text top="682" left="415" width="80" height="17" font="13">NSTEMI; total </text>
<text top="699" left="415" width="95" height="17" font="13">cholesterol ≤250 </text>
<text top="716" left="415" width="103" height="17" font="13">mg/dL; age 21-80; </text>
<text top="734" left="415" width="103" height="17" font="13">at least 1 high-risk </text>
<text top="751" left="415" width="76" height="17" font="13">characteristic </text>
<text top="768" left="415" width="88" height="17" font="13">(&gt;70, DM, hx of </text>
<text top="785" left="415" width="76" height="17" font="13">CAD, PVD or </text>
<text top="665" left="531" width="90" height="17" font="13">Receiving statin </text>
<text top="682" left="531" width="95" height="17" font="13">therapy, planned </text>
<text top="699" left="531" width="66" height="17" font="13">CABG, PCI </text>
<text top="716" left="531" width="92" height="17" font="13">planned within 2 </text>
<text top="734" left="531" width="102" height="17" font="13">wks of enrollment, </text>
<text top="751" left="531" width="90" height="17" font="13">ALT level &gt;20% </text>
<text top="768" left="531" width="48" height="17" font="13">ULN, Cr </text>
<text top="785" left="531" width="65" height="17" font="13">&gt;2.0mg/dL, </text>
<text top="665" left="653" width="86" height="17" font="13">Composite: CV </text>
<text top="682" left="653" width="89" height="17" font="13">death, non-fatal </text>
<text top="699" left="653" width="90" height="17" font="13">MI, readmission </text>
<text top="716" left="653" width="87" height="17" font="13">for ACS, stroke </text>
<text top="665" left="768" width="55" height="17" font="13">Individual </text>
<text top="682" left="768" width="84" height="17" font="13">components of </text>
<text top="699" left="768" width="95" height="17" font="13">primary endpoint </text>
<text top="716" left="768" width="24" height="17" font="13">and </text>
<text top="734" left="768" width="89" height="17" font="13">reascularization </text>
<text top="751" left="768" width="38" height="17" font="13">due to </text>
<text top="768" left="768" width="71" height="17" font="13">documented </text>
<text top="785" left="768" width="108" height="17" font="13">ischemia, all-cause </text>
<text top="665" left="889" width="27" height="17" font="13"> N/A </text>
<text top="665" left="1005" width="154" height="17" font="13">New onset HF reduced with </text>
<text top="682" left="1005" width="172" height="17" font="13">intensive therapy: 5% vs 3.7%; </text>
<text top="699" left="1005" width="158" height="17" font="13">HR 0.72; 95% CI: 0.53-0.98; </text>
<text top="716" left="1005" width="154" height="17" font="13">p=0.04                                  </text>
<text top="734" left="1005" width="137" height="17" font="13">Primary endpoint did not </text>
<text top="751" left="1005" width="171" height="17" font="13">achieve significance: 16.7% vs </text>
<text top="768" left="1005" width="169" height="17" font="13">14.4%; HR 0.89; 95% CI: 0.76-</text>
<text top="785" left="1005" width="72" height="17" font="13">1.04; p=0.14 </text>
<text top="665" left="1199" width="109" height="17" font="13">Development of HF </text>
<text top="682" left="1199" width="96" height="17" font="13">was a secondary </text>
<text top="699" left="1199" width="110" height="17" font="13">endpoint            Did </text>
<text top="716" left="1199" width="111" height="17" font="13">not achieve primary </text>
<text top="734" left="1199" width="81" height="17" font="13">endpoint          </text>
<text top="665" left="1328" width="91" height="17" font="13">In pts with ACS, </text>
<text top="682" left="1328" width="85" height="17" font="13">intensive statin </text>
<text top="699" left="1328" width="92" height="17" font="13">therapy reduced </text>
<text top="716" left="1328" width="79" height="17" font="13">new onset HF </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">30</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="100" height="17" font="13">de Lemos, James </text>
<text top="72" left="61" width="92" height="17" font="13">A.             JAMA </text>
<text top="89" left="61" width="31" height="17" font="13">2004 </text>
<text top="106" left="61" width="58" height="17" font="14">15337732 </text>
<text top="106" left="119" width="25" height="17" font="13">(93) </text>
<text top="55" left="175" width="54" height="17" font="13">with ACS </text>
<text top="55" left="415" width="90" height="17" font="13">stroke, elevated </text>
<text top="72" left="415" width="53" height="17" font="13">CKMB or </text>
<text top="89" left="415" width="93" height="17" font="13">trooponin levels, </text>
<text top="106" left="415" width="93" height="17" font="13">recurrent angina </text>
<text top="124" left="415" width="98" height="17" font="13">with ST changes, </text>
<text top="141" left="415" width="96" height="17" font="13">ECG evidence of </text>
<text top="158" left="415" width="91" height="17" font="13">ischemia on pre-</text>
<text top="175" left="415" width="93" height="17" font="13">discharge stress </text>
<text top="192" left="415" width="91" height="17" font="13">test, multivessel </text>
<text top="210" left="415" width="50" height="17" font="13">disease) </text>
<text top="55" left="531" width="70" height="17" font="13">concomitant </text>
<text top="72" left="531" width="70" height="17" font="13">therapy with </text>
<text top="89" left="531" width="93" height="17" font="13">agents known to </text>
<text top="106" left="531" width="107" height="17" font="13">enhance myopathy </text>
<text top="124" left="531" width="84" height="17" font="13">risk; prior hx of </text>
<text top="141" left="531" width="74" height="17" font="13">non-exercise </text>
<text top="158" left="531" width="100" height="17" font="13">related elevations </text>
<text top="175" left="531" width="48" height="17" font="13">in CK or </text>
<text top="192" left="531" width="75" height="17" font="13">nontraumatic </text>
<text top="210" left="531" width="89" height="17" font="13">rhabdomyolysis </text>
<text top="55" left="768" width="80" height="17" font="13">mortality, new-</text>
<text top="72" left="768" width="53" height="17" font="13">onset HF </text>
<text top="89" left="768" width="55" height="17" font="13">(requiring </text>
<text top="106" left="768" width="83" height="17" font="13">medications or </text>
<text top="124" left="768" width="89" height="17" font="13">hospitalization), </text>
<text top="141" left="768" width="102" height="17" font="13">CV hosptialization </text>
<text top="55" left="1005" width="7" height="17" font="13">  </text>
<text top="228" left="54" width="1382" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; ACS acute coronary syndrome; ALT, alanine aminotransferase; AMI, acute myocardial infarction; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CHD, chronic heart disease; </text>
<text top="245" left="54" width="1349" height="17" font="13">CKMB, creatine kinase-MB; Cr, creatinine; CV, cardiovascular; DM, diabetes mellitus; ESG, electrocardiogram; EF, ejection fraction; f/u, follow-up; HF, heart failure; HTN, hypertension; hx, history; LVSD, left ventricular systolic dysfunction; LVD, left </text>
<text top="262" left="54" width="1378" height="17" font="13">ventricular dysfunction; MI, myocardial infarction; NSTEMI, non-ST elevation mysocardial infarction; PCI, Percutaneous coronary intervention; PROVE IT-TIMI 22, Pravastatin or Atorvastatin Evaluation and Infection Therapy -- Thrombolysis in Myocardial </text>
<text top="279" left="54" width="1406" height="17" font="13">Infarction 22; Pts, patients; PVD, Peripheral artery disease; RCT, randomized control trial; SAVE, The Survival and Ventricular Enlargement trial; SOVLD, Studies of Left Ventricular Dysfunction; STEMI, ST elevation myocardial infarction; UA, unstable angina; </text>
<text top="296" left="54" width="174" height="17" font="13">and ULN, upper limit of normal. </text>
<text top="314" left="54" width="3" height="17" font="13"> </text>
<text top="348" left="22" width="213" height="21" font="8"><b>Data Supplement 13. Stage C: </b></text>
<text top="350" left="235" width="309" height="19" font="9"><b>Factors Associated With Outcomes, All Patients</b></text>
<text top="348" left="544" width="92" height="21" font="8"><b> (Section 7.3)</b></text>
<text top="351" left="636" width="3" height="17" font="15"><b> </b></text>
<text top="370" left="43" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="392" left="44" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="392" left="161" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="392" left="271" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="370" left="373" width="41" height="19" font="9"><b>Study </b></text>
<text top="392" left="378" width="31" height="19" font="9"><b>Size </b></text>
<text top="392" left="475" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="392" left="727" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="392" left="903" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="392" left="1144" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="392" left="1312" width="134" height="19" font="9"><b>Findings/Comments </b></text>
<text top="429" left="451" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="451" left="457" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="429" left="557" width="68" height="19" font="10"><i><b>Exclusion </b></i></text>
<text top="451" left="566" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="429" left="674" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="451" left="670" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="429" left="782" width="73" height="19" font="10"><i><b>Secondary </b></i></text>
<text top="451" left="787" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="488" left="28" width="58" height="17" font="13">Education </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">31</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="60" height="17" font="13">Long-term </text>
<text top="72" left="28" width="95" height="17" font="13">prospective RCT </text>
<text top="89" left="28" width="86" height="17" font="13">using repetitive </text>
<text top="106" left="28" width="102" height="17" font="13">education at 6-mo </text>
<text top="124" left="28" width="73" height="17" font="13">intervals and </text>
<text top="141" left="28" width="99" height="17" font="13">monitoring for the </text>
<text top="158" left="28" width="94" height="17" font="13">adherence in HF </text>
<text top="175" left="28" width="60" height="17" font="13">outpt (The </text>
<text top="192" left="28" width="100" height="17" font="13">REMADHE Trial). </text>
<text top="210" left="28" width="86" height="17" font="13">Bocchi, Edimar </text>
<text top="227" left="28" width="77" height="17" font="13">Alcides. 2008<b> </b></text>
<text top="259" left="28" width="58" height="17" font="14">12196335 </text>
<text top="259" left="86" width="25" height="17" font="13">(94)<b> </b></text>
<text top="55" left="157" width="76" height="17" font="13">To determine </text>
<text top="72" left="157" width="57" height="17" font="13">whether a </text>
<text top="89" left="157" width="46" height="17" font="13">disease </text>
<text top="106" left="157" width="75" height="17" font="13">management </text>
<text top="124" left="157" width="74" height="17" font="13">program with </text>
<text top="141" left="157" width="52" height="17" font="13">repeated </text>
<text top="158" left="157" width="90" height="17" font="13">multidisciplinary </text>
<text top="175" left="157" width="81" height="17" font="13">education and </text>
<text top="192" left="157" width="57" height="17" font="13">telephone </text>
<text top="210" left="157" width="64" height="17" font="13">monitoring  </text>
<text top="227" left="157" width="66" height="17" font="13">benefits HF </text>
<text top="244" left="157" width="75" height="17" font="13">outpt already </text>
<text top="261" left="157" width="83" height="17" font="13">under the care </text>
<text top="278" left="157" width="69" height="17" font="13">of a with HF </text>
<text top="296" left="157" width="64" height="17" font="13">experience </text>
<text top="313" left="157" width="69" height="17" font="13">cardiologist.<b> </b></text>
<text top="55" left="265" width="29" height="17" font="13">RCT<b> </b></text>
<text top="55" left="366" width="24" height="17" font="13">350<b> </b></text>
<text top="55" left="433" width="87" height="17" font="13">Diagnosed with </text>
<text top="72" left="433" width="20" height="17" font="13">HF<b> </b></text>
<text top="55" left="544" width="24" height="17" font="13">N/A<b> </b></text>
<text top="55" left="651" width="94" height="17" font="13">Combined death </text>
<text top="72" left="651" width="98" height="17" font="13">or unplanned first </text>
<text top="89" left="651" width="81" height="17" font="13">hospitalization </text>
<text top="106" left="651" width="51" height="17" font="13">and QoL </text>
<text top="123" left="651" width="50" height="17" font="13">changes<b> </b></text>
<text top="55" left="764" width="87" height="17" font="13">Hospitalization,<b> </b></text>
<text top="87" left="764" width="58" height="17" font="13">death and </text>
<text top="104" left="764" width="65" height="17" font="13">adherence.<b> </b></text>
<text top="55" left="886" width="140" height="17" font="13">In the intervention group: </text>
<text top="72" left="886" width="108" height="17" font="13">QoL improved and <b> </b></text>
<text top="104" left="886" width="216" height="17" font="13">Lower:  deaths (p&lt;0.003) or unplanned </text>
<text top="121" left="886" width="194" height="17" font="13">hospitalizations (p=0.008;  95% CI: </text>
<text top="139" left="886" width="217" height="17" font="13">0.43- 0.88) , hospitalizations(p&lt;0.001) , </text>
<text top="156" left="886" width="173" height="17" font="13">total hospital d during follow-up </text>
<text top="173" left="886" width="191" height="17" font="13">(p&lt;0.001), and ED visits (p&lt;0.001) </text>
<text top="190" left="886" width="3" height="17" font="13"> </text>
<text top="207" left="886" width="173" height="17" font="13">No difference in estimated total </text>
<text top="225" left="886" width="209" height="17" font="13">mortality (p=ns; 95% CI: 0.55-1.13) or </text>
<text top="242" left="886" width="194" height="17" font="13">death during hospitalization (p=ns;  </text>
<text top="259" left="886" width="103" height="17" font="13">95%CI: 0.53-1.41)<b> </b></text>
<text top="55" left="1119" width="118" height="17" font="13">Absence of blinding.  </text>
<text top="72" left="1119" width="150" height="17" font="13">Perception of better QoL in </text>
<text top="89" left="1119" width="146" height="17" font="13">the intervention group due </text>
<text top="106" left="1119" width="153" height="17" font="13">healthcare provider support </text>
<text top="124" left="1119" width="147" height="17" font="13">as needed. Confouding by </text>
<text top="141" left="1119" width="97" height="17" font="13">social conditions.<b> </b></text>
<text top="55" left="1295" width="150" height="17" font="13">Despite modest adherence </text>
<text top="72" left="1295" width="158" height="17" font="13">program reduced unplanned </text>
<text top="89" left="1295" width="157" height="17" font="13">hospitalization, total hospital </text>
<text top="106" left="1295" width="147" height="17" font="13">d, the need for emergency </text>
<text top="123" left="1295" width="139" height="17" font="13">care and improved QoL. <b> </b></text>
<text top="350" left="28" width="105" height="17" font="13">Effect of discharge </text>
<text top="368" left="28" width="83" height="17" font="13">instructions on </text>
<text top="385" left="28" width="83" height="17" font="13">readmission of </text>
<text top="402" left="28" width="113" height="17" font="13">hospitalized pts with </text>
<text top="419" left="28" width="90" height="17" font="13">HF: do all of the </text>
<text top="436" left="28" width="111" height="17" font="13">joint commission on </text>
<text top="454" left="28" width="87" height="17" font="13">accreditation of </text>
<text top="471" left="28" width="61" height="17" font="13">healthcare </text>
<text top="488" left="28" width="96" height="17" font="13">organizations HF </text>
<text top="505" left="28" width="85" height="17" font="13">core measures </text>
<text top="523" left="28" width="106" height="17" font="13">reflect better care? </text>
<text top="540" left="28" width="105" height="17" font="13">VanSuch, M. 2006<b> </b></text>
<text top="572" left="28" width="55" height="17" font="14">17142589</text>
<text top="572" left="83" width="29" height="17" font="13"> (95) </text>
<text top="350" left="157" width="76" height="17" font="13">To determine </text>
<text top="368" left="157" width="47" height="17" font="13">whether </text>
<text top="385" left="157" width="84" height="17" font="13">documentation </text>
<text top="402" left="157" width="79" height="17" font="13">of compliance </text>
<text top="419" left="157" width="92" height="17" font="13">with any or all of </text>
<text top="436" left="157" width="79" height="17" font="13">the 6 required </text>
<text top="454" left="157" width="57" height="17" font="13">discharge </text>
<text top="471" left="157" width="78" height="17" font="13">instructions is </text>
<text top="488" left="157" width="83" height="17" font="13">correlated with </text>
<text top="505" left="157" width="89" height="17" font="13">readmissions to </text>
<text top="523" left="157" width="60" height="17" font="13">hospital or </text>
<text top="540" left="157" width="53" height="17" font="13">mortality.<b> </b></text>
<text top="350" left="265" width="79" height="17" font="13">Retrospective </text>
<text top="368" left="265" width="33" height="17" font="13">study<b> </b></text>
<text top="350" left="366" width="24" height="17" font="13">782<b> </b></text>
<text top="350" left="433" width="63" height="17" font="13">Age &gt;18 y, </text>
<text top="368" left="433" width="49" height="17" font="13">principal </text>
<text top="385" left="433" width="92" height="17" font="13">diagnosis of HF, </text>
<text top="402" left="433" width="73" height="17" font="13">hypertensive </text>
<text top="419" left="433" width="77" height="17" font="13">heart disease </text>
<text top="436" left="433" width="63" height="17" font="13">with HF, or </text>
<text top="454" left="433" width="73" height="17" font="13">hypertensive </text>
<text top="471" left="433" width="86" height="17" font="13">heart and renal </text>
<text top="488" left="433" width="98" height="17" font="13">disease with HF,  </text>
<text top="505" left="433" width="77" height="17" font="13">discharged to </text>
<text top="523" left="433" width="72" height="17" font="13">home, home </text>
<text top="540" left="433" width="76" height="17" font="13">care or home </text>
<text top="557" left="433" width="68" height="17" font="13">care with IV </text>
<text top="574" left="433" width="59" height="17" font="13">treatment <b> </b></text>
<text top="350" left="544" width="85" height="17" font="13">Pts discharged </text>
<text top="368" left="544" width="51" height="17" font="13">to skilled </text>
<text top="385" left="544" width="91" height="17" font="13">nursing facilities </text>
<text top="402" left="544" width="80" height="17" font="13">or other acute-</text>
<text top="419" left="544" width="83" height="17" font="13">care hospitals.<b> </b></text>
<text top="350" left="651" width="89" height="17" font="13">Time to:             </text>
<text top="368" left="651" width="58" height="17" font="13">death and </text>
<text top="385" left="651" width="88" height="17" font="13">readmission for </text>
<text top="402" left="651" width="34" height="17" font="13">HF or </text>
<text top="419" left="651" width="88" height="17" font="13">readmission for </text>
<text top="436" left="651" width="59" height="17" font="13">any cause<b> </b></text>
<text top="350" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="350" left="886" width="220" height="17" font="13">68% of pts received all instructions, and </text>
<text top="368" left="886" width="157" height="17" font="13">6% received no instructions. </text>
<text top="385" left="886" width="3" height="17" font="13"> </text>
<text top="402" left="886" width="204" height="17" font="13">Pts with all instructions (compared to </text>
<text top="419" left="886" width="209" height="17" font="13">those who missed at least one type of </text>
<text top="436" left="886" width="217" height="17" font="13">instruction) were significantly less likely </text>
<text top="454" left="886" width="204" height="17" font="13">to be readmitted for any cause or HF </text>
<text top="471" left="886" width="60" height="17" font="13">(p= 0.003) </text>
<text top="488" left="886" width="3" height="17" font="13"> </text>
<text top="505" left="886" width="157" height="17" font="13">Documentation of discharge </text>
<text top="523" left="886" width="174" height="17" font="13">instructions was correlated with </text>
<text top="540" left="886" width="152" height="17" font="13">reduced readmission rates. </text>
<text top="557" left="886" width="3" height="17" font="13"> </text>
<text top="574" left="886" width="218" height="17" font="13">No association between documentation </text>
<text top="591" left="886" width="184" height="17" font="13">of discharge and instructions and </text>
<text top="608" left="886" width="53" height="17" font="13">mortality.<b> </b></text>
<text top="350" left="1119" width="157" height="17" font="13">Discharge instructions given </text>
<text top="368" left="1119" width="116" height="17" font="13">but not documented. </text>
<text top="385" left="1119" width="157" height="17" font="13">Discharge instructions could </text>
<text top="402" left="1119" width="151" height="17" font="13">be a surrogate indicator for </text>
<text top="419" left="1119" width="158" height="17" font="13">another intervention such as </text>
<text top="436" left="1119" width="151" height="17" font="13">higher quality nursing care. </text>
<text top="454" left="1119" width="112" height="17" font="13">Pt factor could have </text>
<text top="471" left="1119" width="130" height="17" font="13">influenced confounding </text>
<text top="488" left="1119" width="43" height="17" font="13">results. </text>
<text top="505" left="1119" width="130" height="17" font="13">Generalizability limited. </text>
<text top="523" left="1119" width="145" height="17" font="13">No active follow-up.           </text>
<text top="540" left="1119" width="118" height="17" font="13">Not all quality of care </text>
<text top="557" left="1119" width="146" height="17" font="13">outcomes were assessed.<b> </b></text>
<text top="350" left="1295" width="157" height="17" font="13">Documentation of discharge </text>
<text top="368" left="1295" width="64" height="17" font="13">information </text>
<text top="385" left="1295" width="156" height="17" font="13">and pt education appears to </text>
<text top="402" left="1295" width="165" height="17" font="13">be associated with reductions </text>
<text top="419" left="1295" width="114" height="17" font="13">in both mortality and </text>
<text top="436" left="1295" width="83" height="17" font="13">readmissions. <b> </b></text>
</page>
<page number="32" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">32</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="59" height="17" font="13">Discharge </text>
<text top="72" left="28" width="110" height="17" font="13">education improves </text>
<text top="89" left="28" width="110" height="17" font="13">clinical outcomes in </text>
<text top="106" left="28" width="111" height="17" font="13">pts with chronic HF. </text>
<text top="123" left="28" width="96" height="17" font="13">Koelling, T. 2005<b> </b></text>
<text top="156" left="28" width="55" height="17" font="14">15642765</text>
<text top="156" left="83" width="29" height="17" font="13"> (96) </text>
<text top="55" left="157" width="59" height="17" font="13">To assess </text>
<text top="72" left="157" width="71" height="17" font="13">whether a pt </text>
<text top="89" left="157" width="57" height="17" font="13">discharge </text>
<text top="106" left="157" width="57" height="17" font="13">education </text>
<text top="124" left="157" width="74" height="17" font="13">program (the </text>
<text top="141" left="157" width="33" height="17" font="13">study </text>
<text top="158" left="157" width="71" height="17" font="13">intervention) </text>
<text top="175" left="157" width="94" height="17" font="13">improves clinical </text>
<text top="192" left="157" width="70" height="17" font="13">outcomes in </text>
<text top="210" left="157" width="86" height="17" font="13">chronic HF pts.<b> </b></text>
<text top="55" left="265" width="29" height="17" font="13">RCT<b> </b></text>
<text top="55" left="366" width="24" height="17" font="13">223<b> </b></text>
<text top="55" left="433" width="66" height="17" font="13">Admitted to </text>
<text top="72" left="433" width="81" height="17" font="13">hospital with a </text>
<text top="89" left="433" width="89" height="17" font="13">diagnosis of HF </text>
<text top="106" left="433" width="95" height="17" font="13">and documented </text>
<text top="124" left="433" width="80" height="17" font="13">left ventricular </text>
<text top="141" left="433" width="44" height="17" font="13">systolic </text>
<text top="158" left="433" width="89" height="17" font="13">dysfunction (EF </text>
<text top="175" left="433" width="39" height="17" font="13">&lt;40%)<b> </b></text>
<text top="55" left="544" width="79" height="17" font="13">Evaluation for </text>
<text top="72" left="544" width="91" height="17" font="13">cardiac surgery, </text>
<text top="89" left="544" width="66" height="17" font="13">Noncardiac </text>
<text top="106" left="544" width="82" height="17" font="13">illness likely to </text>
<text top="124" left="544" width="81" height="17" font="13">increase 6-mo </text>
<text top="141" left="544" width="64" height="17" font="13">mortality or </text>
<text top="158" left="544" width="81" height="17" font="13">hospitalization </text>
<text top="175" left="544" width="76" height="17" font="13">risk, Inpatient </text>
<text top="192" left="544" width="43" height="17" font="13">cardiac </text>
<text top="210" left="544" width="84" height="17" font="13">transplantation </text>
<text top="227" left="544" width="59" height="17" font="13">evaluation<b> </b></text>
<text top="55" left="651" width="100" height="17" font="13">Total number of d </text>
<text top="72" left="651" width="83" height="17" font="13">hospitalized or </text>
<text top="89" left="651" width="99" height="17" font="13">dead in the 180-d </text>
<text top="106" left="651" width="94" height="17" font="13">follow-up period.<b> </b></text>
<text top="55" left="764" width="86" height="17" font="13">Clinical events, </text>
<text top="72" left="764" width="87" height="17" font="13">symptoms, and </text>
<text top="89" left="764" width="107" height="17" font="13">self-care practices.<b> </b></text>
<text top="55" left="886" width="213" height="17" font="13">The intervention group versus controls </text>
<text top="72" left="886" width="215" height="17" font="13">had fewer d hospitalized or dead in the </text>
<text top="89" left="886" width="188" height="17" font="13">180-d follow-up period (p= 0.009), </text>
<text top="106" left="886" width="210" height="17" font="13">lower risk of rehospitalization or death </text>
<text top="124" left="886" width="183" height="17" font="13">(RR: 0.65; 95% CI: 0.45-0.93, p= </text>
<text top="141" left="886" width="209" height="17" font="13">0.018), as well as lower costs of care, </text>
<text top="158" left="886" width="216" height="17" font="13">including cost of the intervention (lower </text>
<text top="175" left="886" width="151" height="17" font="13">by $2823 per pt, p= 0.035).<b> </b></text>
<text top="55" left="1119" width="141" height="17" font="13">May not be generalizable-</text>
<text top="72" left="1119" width="157" height="17" font="13">only 223 (38%) participated. </text>
<text top="89" left="1119" width="128" height="17" font="13">pts being evaluated for </text>
<text top="106" left="1119" width="151" height="17" font="13">transplantation not studied. </text>
<text top="124" left="1119" width="154" height="17" font="13">Pts followed by the UMHFP </text>
<text top="141" left="1119" width="107" height="17" font="13">not enrolled. Nurse </text>
<text top="158" left="1119" width="161" height="17" font="13">coordinator unblined. Lack of </text>
<text top="175" left="1119" width="137" height="17" font="13">reliability of self-reported </text>
<text top="192" left="1119" width="111" height="17" font="13">self-care measures.<b> </b></text>
<text top="55" left="1295" width="162" height="17" font="13">A 1-h teaching session at the </text>
<text top="72" left="1295" width="143" height="17" font="13">time of hospital discharge </text>
<text top="89" left="1295" width="154" height="17" font="13">resulted in improved clinical </text>
<text top="106" left="1295" width="140" height="17" font="13">outcomes, increased self-</text>
<text top="124" left="1295" width="140" height="17" font="13">care and adherence, and </text>
<text top="141" left="1295" width="148" height="17" font="13">reduced cost of care in pts </text>
<text top="158" left="1295" width="92" height="17" font="13">with systolic HF.<b> </b></text>
<text top="264" left="28" width="72" height="17" font="13">Effects of an </text>
<text top="281" left="28" width="81" height="17" font="13">interactive CD-</text>
<text top="298" left="28" width="97" height="17" font="13">program on 6 mo </text>
<text top="316" left="28" width="107" height="17" font="13">readmission rate in </text>
<text top="333" left="28" width="111" height="17" font="13">pts with HF- a RCT. </text>
<text top="350" left="28" width="83" height="17" font="13">Linne, A. 2006<b> </b></text>
<text top="382" left="28" width="55" height="17" font="14">16796760</text>
<text top="382" left="83" width="29" height="17" font="13"> (97) </text>
<text top="264" left="157" width="88" height="17" font="13">To evaluate the </text>
<text top="281" left="157" width="91" height="17" font="13">impact of added </text>
<text top="298" left="157" width="54" height="17" font="13">CD-ROM </text>
<text top="316" left="157" width="74" height="17" font="13">education on </text>
<text top="333" left="157" width="94" height="17" font="13">readmission rate </text>
<text top="350" left="157" width="86" height="17" font="13">or death during </text>
<text top="367" left="157" width="34" height="17" font="13">6 mo.<b> </b></text>
<text top="264" left="265" width="29" height="17" font="13">RCT<b> </b></text>
<text top="264" left="366" width="24" height="17" font="13">230<b> </b></text>
<text top="264" left="433" width="91" height="17" font="13">Diagnosis of HF </text>
<text top="281" left="433" width="83" height="17" font="13">(either LVEF &lt; </text>
<text top="298" left="433" width="98" height="17" font="13">40% by ECHO or </text>
<text top="316" left="433" width="67" height="17" font="13">at least 2 of </text>
<text top="333" left="433" width="77" height="17" font="13">these criteria: </text>
<text top="350" left="433" width="95" height="17" font="13">pulmonary rates, </text>
<text top="367" left="433" width="58" height="17" font="13">peripheral </text>
<text top="384" left="433" width="76" height="17" font="13">edema, a 3rd </text>
<text top="402" left="433" width="92" height="17" font="13">heart sound and </text>
<text top="419" left="433" width="83" height="17" font="13">signs of HF on </text>
<text top="436" left="433" width="71" height="17" font="13">chest x-ray).<b> </b></text>
<text top="264" left="544" width="48" height="17" font="13">Somatic </text>
<text top="281" left="544" width="49" height="17" font="13">disease, </text>
<text top="298" left="544" width="48" height="17" font="13">physical </text>
<text top="316" left="544" width="79" height="17" font="13">handicap with </text>
<text top="333" left="544" width="48" height="17" font="13">difficulty </text>
<text top="350" left="544" width="86" height="17" font="13">communicating </text>
<text top="367" left="544" width="64" height="17" font="13">or handling </text>
<text top="384" left="544" width="52" height="17" font="13">technical </text>
<text top="402" left="544" width="64" height="17" font="13">equipment, </text>
<text top="419" left="544" width="94" height="17" font="13">inability to speak </text>
<text top="436" left="544" width="53" height="17" font="13">Swedish, </text>
<text top="453" left="544" width="75" height="17" font="13">incompliance </text>
<text top="471" left="544" width="38" height="17" font="13">due to </text>
<text top="488" left="544" width="70" height="17" font="13">alcohol/drug </text>
<text top="505" left="544" width="86" height="17" font="13">abuse or major </text>
<text top="522" left="544" width="61" height="17" font="13">psychiatric </text>
<text top="539" left="544" width="41" height="17" font="13">illness, </text>
<text top="557" left="544" width="84" height="17" font="13">Participation in </text>
<text top="574" left="544" width="68" height="17" font="13">another trial<b> </b></text>
<text top="264" left="651" width="97" height="17" font="13">Difference in rate </text>
<text top="281" left="651" width="66" height="17" font="13">of all cause </text>
<text top="298" left="651" width="94" height="17" font="13">readmission and </text>
<text top="316" left="651" width="100" height="17" font="13">death within 6 mo </text>
<text top="333" left="651" width="88" height="17" font="13">after discharge.<b> </b></text>
<text top="264" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="264" left="886" width="190" height="17" font="13">Intervention group achieved better </text>
<text top="281" left="886" width="191" height="17" font="13">knowledge and a marginally better </text>
<text top="298" left="886" width="97" height="17" font="13">outcome (p=NS).<b> </b></text>
<text top="331" left="886" width="7" height="17" font="13"> <b> </b></text>
<text top="264" left="1119" width="117" height="17" font="13">Only 37% completed </text>
<text top="281" left="1119" width="138" height="17" font="13">questionnaire, pts had to </text>
<text top="298" left="1119" width="158" height="17" font="13">come twice to the CD-based </text>
<text top="316" left="1119" width="160" height="17" font="13">education, first as inpts, then </text>
<text top="333" left="1119" width="117" height="17" font="13">2 wk after discharge. </text>
<text top="350" left="1119" width="163" height="17" font="13">Returning to the hospital may </text>
<text top="367" left="1119" width="101" height="17" font="13">have discouraged </text>
<text top="384" left="1119" width="73" height="17" font="13">participation, </text>
<text top="402" left="1119" width="129" height="17" font="13">especially in sicker pts.<b> </b></text>
<text top="264" left="1295" width="148" height="17" font="13">Additional education of HF </text>
<text top="281" left="1295" width="122" height="17" font="13">pts with an interactive </text>
<text top="298" left="1295" width="141" height="17" font="13">program had no effect on </text>
<text top="316" left="1295" width="143" height="17" font="13">readmission rate or death </text>
<text top="333" left="1295" width="157" height="17" font="13">within 6 mo after discharge. <b> </b></text>
</page>
<page number="33" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">33</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="95" height="17" font="13">Computer-based </text>
<text top="72" left="28" width="94" height="17" font="13">education for pts </text>
<text top="89" left="28" width="103" height="17" font="13">with chronic HF. A </text>
<text top="106" left="28" width="71" height="17" font="13">randomized, </text>
<text top="124" left="28" width="60" height="17" font="13">controlled, </text>
<text top="141" left="28" width="100" height="17" font="13">multicenter trial of </text>
<text top="158" left="28" width="77" height="17" font="13">the effects on </text>
<text top="175" left="28" width="66" height="17" font="13">knowledge, </text>
<text top="192" left="28" width="89" height="17" font="13">compliance and </text>
<text top="210" left="28" width="109" height="17" font="13">QoL. Stromberg, A. </text>
<text top="227" left="28" width="31" height="17" font="13">2006<b> </b></text>
<text top="259" left="28" width="58" height="17" font="14">16469469 </text>
<text top="259" left="86" width="29" height="17" font="13"> (98) </text>
<text top="55" left="157" width="88" height="17" font="13">To evaluate the </text>
<text top="72" left="157" width="64" height="17" font="13">effects of a </text>
<text top="89" left="157" width="85" height="17" font="13">single-session, </text>
<text top="106" left="157" width="59" height="17" font="13">interactive </text>
<text top="124" left="157" width="92" height="17" font="13">computer-based </text>
<text top="141" left="157" width="66" height="17" font="13">educational </text>
<text top="158" left="157" width="66" height="17" font="13">program on </text>
<text top="175" left="157" width="66" height="17" font="13">knowledge, </text>
<text top="192" left="157" width="89" height="17" font="13">compliance and </text>
<text top="210" left="157" width="83" height="17" font="13">QoL in HF pts. </text>
<text top="227" left="157" width="59" height="17" font="13">To assess </text>
<text top="244" left="157" width="42" height="17" font="13">gender </text>
<text top="261" left="157" width="67" height="17" font="13">differences.<b> </b></text>
<text top="55" left="265" width="29" height="17" font="13">RCT<b> </b></text>
<text top="55" left="366" width="24" height="17" font="13">154<b> </b></text>
<text top="55" left="433" width="91" height="17" font="13">Diagnosis of HF<b> </b></text>
<text top="55" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="55" left="651" width="78" height="17" font="13">Knowledge of </text>
<text top="72" left="651" width="79" height="17" font="13">HF, treatment </text>
<text top="89" left="651" width="92" height="17" font="13">compliance, self-</text>
<text top="106" left="651" width="81" height="17" font="13">care and QoL.<b> </b></text>
<text top="55" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="55" left="886" width="208" height="17" font="13">Computer-based group (intervention), </text>
<text top="72" left="886" width="204" height="17" font="13">knowledge increased: After 1 mo: p= </text>
<text top="89" left="886" width="34" height="17" font="13">0.07,  </text>
<text top="106" left="886" width="108" height="17" font="13">After 6 mo: p= 0.03 </text>
<text top="124" left="886" width="3" height="17" font="13"> </text>
<text top="141" left="886" width="220" height="17" font="13">Women: significantly lower QoL and did </text>
<text top="158" left="886" width="212" height="17" font="13">not improve after 6 mo as men did (p= </text>
<text top="175" left="886" width="49" height="17" font="13">0.0001). </text>
<text top="192" left="886" width="3" height="17" font="13"> </text>
<text top="210" left="886" width="187" height="17" font="13">No differences between groups in </text>
<text top="227" left="886" width="164" height="17" font="13">compliance, self-care or QoL.<b> </b></text>
<text top="55" left="1119" width="161" height="17" font="13">Data on knowledge collected </text>
<text top="72" left="1119" width="126" height="17" font="13">through questionnaire, </text>
<text top="89" left="1119" width="104" height="17" font="13">small sample size.<b> </b></text>
<text top="55" left="1295" width="152" height="17" font="13">Computer-based education </text>
<text top="72" left="1295" width="153" height="17" font="13">increased knowledge about </text>
<text top="89" left="1295" width="148" height="17" font="13">HF compared to traditional </text>
<text top="106" left="1295" width="87" height="17" font="13">teaching alone.<b> </b></text>
<text top="294" left="28" width="93" height="17" font="13">Long-term result </text>
<text top="312" left="28" width="96" height="17" font="13">after a telephone </text>
<text top="329" left="28" width="80" height="17" font="13">intervention in </text>
<text top="346" left="28" width="66" height="17" font="13">chronic HF. </text>
<text top="363" left="28" width="100" height="17" font="13">Ferrante, D. 2010<b> </b></text>
<text top="395" left="28" width="55" height="17" font="14">20650358</text>
<text top="395" left="83" width="29" height="17" font="13"> (99) </text>
<text top="294" left="157" width="84" height="17" font="13">To assess rate </text>
<text top="312" left="157" width="72" height="17" font="13">of death and </text>
<text top="329" left="157" width="81" height="17" font="13">hospitalization </text>
<text top="346" left="157" width="92" height="17" font="13">for HF 1 and 3 y </text>
<text top="363" left="157" width="38" height="17" font="13">after a </text>
<text top="380" left="157" width="91" height="17" font="13">randomized trial </text>
<text top="398" left="157" width="71" height="17" font="13">of telephone </text>
<text top="415" left="157" width="92" height="17" font="13">intervention with </text>
<text top="432" left="157" width="70" height="17" font="13">education to </text>
<text top="449" left="157" width="47" height="17" font="13">improve </text>
<text top="466" left="157" width="79" height="17" font="13">compliance in </text>
<text top="484" left="157" width="76" height="17" font="13">stable HF pts </text>
<text top="501" left="157" width="49" height="17" font="13">with HF.<b> </b></text>
<text top="294" left="265" width="85" height="17" font="13">Follow-up after </text>
<text top="311" left="265" width="39" height="17" font="13">a RCT<b> </b></text>
<text top="294" left="366" width="34" height="17" font="13">1,518<b> </b></text>
<text top="294" left="433" width="59" height="17" font="13">Outpt with </text>
<text top="312" left="433" width="83" height="17" font="13">stable, chronic </text>
<text top="329" left="433" width="20" height="17" font="13">HF<b> </b></text>
<text top="294" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="294" left="651" width="60" height="17" font="13">Death and </text>
<text top="312" left="651" width="99" height="17" font="13">hospitalization for </text>
<text top="329" left="651" width="77" height="17" font="13">HF, 1 and 3 y </text>
<text top="346" left="651" width="95" height="17" font="13">after intervention </text>
<text top="363" left="651" width="41" height="17" font="13">ended.<b> </b></text>
<text top="294" left="764" width="332" height="17" font="13">Long term benefits<b>  </b>Rate of death or hospitalization for HF </text>
<text top="312" left="886" width="172" height="17" font="13">lower in the intervention group: </text>
<text top="329" left="886" width="209" height="17" font="13">1 y: RR: 0.81; p= 0.013  95% CI: 0.69-</text>
<text top="346" left="886" width="27" height="17" font="13">0.96 </text>
<text top="363" left="886" width="191" height="17" font="13">3 y : RR: 0.72; p= 0.0004  95% CI: </text>
<text top="380" left="886" width="55" height="17" font="13">0.60-0.87 </text>
<text top="398" left="886" width="3" height="17" font="13"> </text>
<text top="415" left="886" width="178" height="17" font="13">Benefit caused by a reduction in </text>
<text top="432" left="886" width="148" height="17" font="13">admission for HF after 3 y <b> </b></text>
<text top="464" left="886" width="157" height="17" font="13">Functional capacity better in </text>
<text top="481" left="886" width="105" height="17" font="13">intervention group <b> </b></text>
<text top="514" left="886" width="205" height="17" font="13">Pts who showed improvement in 1 or </text>
<text top="531" left="886" width="200" height="17" font="13">more of 3 key compliance indicators </text>
<text top="548" left="886" width="204" height="17" font="13">(diet, weight control, and medication) </text>
<text top="565" left="886" width="209" height="17" font="13">had lower risks of events (p&lt; 0.0001).<b> </b></text>
<text top="294" left="1119" width="155" height="17" font="13">Classification bias of events </text>
<text top="311" left="1119" width="138" height="17" font="13">due to open trial design. <b> </b></text>
<text top="294" left="1295" width="154" height="17" font="13">Benefit observed during the </text>
<text top="312" left="1295" width="158" height="17" font="13">intervention period persisted </text>
<text top="329" left="1295" width="159" height="17" font="13">and was sustained 1 and 3 y </text>
<text top="346" left="1295" width="157" height="17" font="13">after the intervention ended. </text>
<text top="363" left="1295" width="125" height="17" font="13">This maybe due to the </text>
<text top="380" left="1295" width="137" height="17" font="13">intervention impact on pt </text>
<text top="398" left="1295" width="114" height="17" font="13">behavior and habits.<b> </b></text>
<text top="598" left="28" width="43" height="17" font="13">HF self-</text>
<text top="615" left="28" width="75" height="17" font="13">management </text>
<text top="633" left="28" width="70" height="17" font="13">education: a </text>
<text top="650" left="28" width="114" height="17" font="13">systematic review of </text>
<text top="667" left="28" width="77" height="17" font="13">the evidence. </text>
<text top="684" left="28" width="86" height="17" font="13">Boren, S. 2009<b> </b></text>
<text top="716" left="28" width="55" height="17" font="14">21631856</text>
<text top="716" left="83" width="36" height="17" font="13"> (100) </text>
<text top="598" left="157" width="60" height="17" font="13">To identify </text>
<text top="615" left="157" width="66" height="17" font="13">educational </text>
<text top="633" left="157" width="68" height="17" font="13">content and </text>
<text top="650" left="157" width="87" height="17" font="13">techniques that </text>
<text top="667" left="157" width="40" height="17" font="13">lead to </text>
<text top="684" left="157" width="84" height="17" font="13">successful self-</text>
<text top="702" left="157" width="75" height="17" font="13">management </text>
<text top="719" left="157" width="71" height="17" font="13">and improve </text>
<text top="736" left="157" width="60" height="17" font="13">outcomes.<b> </b></text>
<text top="598" left="265" width="63" height="17" font="13">Systematic </text>
<text top="615" left="265" width="87" height="17" font="13">review of RCTs<b> </b></text>
<text top="598" left="366" width="54" height="17" font="13">7,413 pts </text>
<text top="615" left="366" width="45" height="17" font="13">from 35 </text>
<text top="633" left="366" width="29" height="17" font="13">trials<b> </b></text>
<text top="598" left="433" width="94" height="17" font="13">RCTs evaluating </text>
<text top="615" left="433" width="33" height="17" font="13">a self-</text>
<text top="633" left="433" width="75" height="17" font="13">management </text>
<text top="650" left="433" width="57" height="17" font="13">education </text>
<text top="667" left="433" width="74" height="17" font="13">program with </text>
<text top="684" left="433" width="85" height="17" font="13">patient-specific </text>
<text top="702" left="433" width="51" height="17" font="13">outcome </text>
<text top="719" left="433" width="61" height="17" font="13">measures.<b> </b></text>
<text top="598" left="544" width="94" height="17" font="13">Not randomized, </text>
<text top="615" left="544" width="59" height="17" font="13">No control </text>
<text top="633" left="544" width="38" height="17" font="13">group, </text>
<text top="650" left="544" width="83" height="17" font="13">Not in English, </text>
<text top="667" left="544" width="55" height="17" font="13">Failure to </text>
<text top="684" left="544" width="63" height="17" font="13">identify the </text>
<text top="702" left="544" width="78" height="17" font="13">content of the </text>
<text top="719" left="544" width="53" height="17" font="13">program, </text>
<text top="736" left="544" width="94" height="17" font="13">Providing similar </text>
<text top="753" left="544" width="66" height="17" font="13">educational </text>
<text top="770" left="544" width="72" height="17" font="13">content in all </text>
<text top="788" left="544" width="67" height="17" font="13">study arms, </text>
<text top="598" left="651" width="70" height="17" font="13">Satisfaction, </text>
<text top="615" left="651" width="74" height="17" font="13">learning, self-</text>
<text top="633" left="651" width="81" height="17" font="13">care behavior, </text>
<text top="650" left="651" width="66" height="17" font="13">medication, </text>
<text top="667" left="651" width="40" height="17" font="13">clinical </text>
<text top="684" left="651" width="78" height="17" font="13">improvement, </text>
<text top="702" left="651" width="35" height="17" font="13">social </text>
<text top="719" left="651" width="66" height="17" font="13">functioning, </text>
<text top="736" left="651" width="46" height="17" font="13">hospital </text>
<text top="753" left="651" width="89" height="17" font="13">admissions and </text>
<text top="770" left="651" width="79" height="17" font="13">readmissions, </text>
<text top="788" left="651" width="77" height="17" font="13">mortality, and </text>
<text top="598" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="598" left="886" width="212" height="17" font="13">Programs incorporated 20 educational </text>
<text top="615" left="886" width="209" height="17" font="13">topics in 4 categories- knowledge and </text>
<text top="633" left="886" width="197" height="17" font="13">self-management, social interaction </text>
<text top="650" left="886" width="200" height="17" font="13">and support, fluid management, and </text>
<text top="667" left="886" width="213" height="17" font="13">diet and activity. 113 unique outcomes </text>
<text top="684" left="886" width="186" height="17" font="13">were measured and 53% showed </text>
<text top="702" left="886" width="213" height="17" font="13">significant improvement in at least one </text>
<text top="719" left="886" width="36" height="17" font="13">study. </text>
<text top="736" left="886" width="178" height="17" font="13">Education on: sodium restriction </text>
<text top="753" left="886" width="198" height="17" font="13">associated with decreased mortality </text>
<text top="770" left="886" width="171" height="17" font="13">(p=0.07), appropriate follow-up </text>
<text top="788" left="886" width="174" height="17" font="13">associated with decreased cost </text>
<text top="598" left="1119" width="142" height="17" font="13">Unable to combine all the </text>
<text top="615" left="1119" width="152" height="17" font="13">results. Difficult to compare </text>
<text top="633" left="1119" width="139" height="17" font="13">interventions due to poor </text>
<text top="650" left="1119" width="135" height="17" font="13">descriptions, and lack of </text>
<text top="667" left="1119" width="95" height="17" font="13">transparency. All </text>
<text top="684" left="1119" width="94" height="17" font="13">interventions not </text>
<text top="701" left="1119" width="75" height="17" font="13">reproducible.<b> </b></text>
<text top="598" left="1295" width="161" height="17" font="13">Review supports the benefits </text>
<text top="615" left="1295" width="153" height="17" font="13">of educational interventions </text>
<text top="633" left="1295" width="152" height="17" font="13">in chronic HF and suggests </text>
<text top="650" left="1295" width="155" height="17" font="13">that some topics are related </text>
<text top="667" left="1295" width="118" height="17" font="13">to certain outcomes. <b> </b></text>
</page>
<page number="34" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">34</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="544" width="85" height="17" font="13">Did not identify </text>
<text top="72" left="544" width="66" height="17" font="13">educational </text>
<text top="89" left="544" width="63" height="17" font="13">techniques </text>
<text top="106" left="544" width="33" height="17" font="13">used, </text>
<text top="124" left="544" width="84" height="17" font="13">Measured only </text>
<text top="141" left="544" width="79" height="17" font="13">knowledge as </text>
<text top="158" left="544" width="71" height="17" font="13">an outcome.<b> </b></text>
<text top="55" left="651" width="29" height="17" font="13">cost.<b> </b></text>
<text top="55" left="886" width="216" height="17" font="13">(p=0.10), management and recognition </text>
<text top="72" left="886" width="207" height="17" font="13">of worsening function associated with </text>
<text top="89" left="886" width="187" height="17" font="13">lower social functioning (p= 0.10). </text>
<text top="106" left="886" width="196" height="17" font="13">Discussion of fluids associated with </text>
<text top="124" left="886" width="188" height="17" font="13">increased hospitalization (p=0.01) </text>
<text top="141" left="886" width="160" height="17" font="13">and increased cost (p=0.10).<b> </b></text>
<text top="191" left="28" width="108" height="17" font="13">Effect of sequential </text>
<text top="208" left="28" width="81" height="17" font="13">education and </text>
<text top="225" left="28" width="110" height="17" font="13">monitoring program </text>
<text top="243" left="28" width="114" height="17" font="13">on QoL components </text>
<text top="260" left="28" width="110" height="17" font="13">in HF. Cruz, Fatima </text>
<text top="277" left="28" width="94" height="17" font="13">das Dores. 2010<b> </b></text>
<text top="309" left="28" width="55" height="17" font="14">20670963</text>
<text top="309" left="83" width="36" height="17" font="13"> (101) </text>
<text top="341" left="28" width="3" height="17" font="13"> </text>
<text top="191" left="157" width="85" height="17" font="13">To determine if </text>
<text top="208" left="157" width="84" height="17" font="13">a DMP applied </text>
<text top="225" left="157" width="75" height="17" font="13">over the long-</text>
<text top="243" left="157" width="61" height="17" font="13">term could </text>
<text top="260" left="157" width="48" height="17" font="13">produce </text>
<text top="277" left="157" width="87" height="17" font="13">different effects </text>
<text top="294" left="157" width="81" height="17" font="13">on each of the </text>
<text top="311" left="157" width="27" height="17" font="13">QoL </text>
<text top="329" left="157" width="74" height="17" font="13">components.<b> </b></text>
<text top="191" left="265" width="79" height="17" font="13">Retrospective </text>
<text top="208" left="265" width="48" height="17" font="13">analysis </text>
<text top="225" left="265" width="75" height="17" font="13">(Extension of </text>
<text top="243" left="265" width="65" height="17" font="13">REMADHE </text>
<text top="260" left="265" width="73" height="17" font="13">trial, a RCT) <b> </b></text>
<text top="191" left="366" width="24" height="17" font="13">412<b> </b></text>
<text top="191" left="433" width="37" height="17" font="13">Under </text>
<text top="208" left="433" width="92" height="17" font="13">ambulatory care </text>
<text top="225" left="433" width="64" height="17" font="13">in a tertiary </text>
<text top="243" left="433" width="80" height="17" font="13">referral center </text>
<text top="260" left="433" width="89" height="17" font="13">and followed by </text>
<text top="277" left="433" width="76" height="17" font="13">a cardiologist </text>
<text top="294" left="433" width="89" height="17" font="13">with experience </text>
<text top="311" left="433" width="36" height="17" font="13">in HF. </text>
<text top="329" left="433" width="50" height="17" font="13">Age &gt;18 </text>
<text top="346" left="433" width="84" height="17" font="13">Irreversible HF </text>
<text top="363" left="433" width="75" height="17" font="13">based on the </text>
<text top="380" left="433" width="50" height="17" font="13">modified </text>
<text top="398" left="433" width="73" height="17" font="13">Framingham </text>
<text top="415" left="433" width="72" height="17" font="13">criteria for at </text>
<text top="432" left="433" width="61" height="17" font="13">least 6-mo<b> </b></text>
<text top="191" left="544" width="94" height="17" font="13">Unable to attend </text>
<text top="208" left="544" width="66" height="17" font="13">educational </text>
<text top="225" left="544" width="92" height="17" font="13">sessions or who </text>
<text top="243" left="544" width="70" height="17" font="13">could not be </text>
<text top="260" left="544" width="82" height="17" font="13">monitored due </text>
<text top="277" left="544" width="53" height="17" font="13">to lack of </text>
<text top="294" left="544" width="82" height="17" font="13">transportation, </text>
<text top="311" left="544" width="67" height="17" font="13">or  social or </text>
<text top="329" left="544" width="86" height="17" font="13">communication </text>
<text top="346" left="544" width="48" height="17" font="13">barriers, </text>
<text top="363" left="544" width="81" height="17" font="13">MI or unstable </text>
<text top="380" left="544" width="75" height="17" font="13">angina within </text>
<text top="398" left="544" width="61" height="17" font="13">past 6 mo, </text>
<text top="415" left="544" width="87" height="17" font="13">cardiac surgery </text>
<text top="432" left="544" width="80" height="17" font="13">or angioplasty </text>
<text top="449" left="544" width="72" height="17" font="13">within past 6 </text>
<text top="466" left="544" width="24" height="17" font="13">mo, </text>
<text top="484" left="544" width="83" height="17" font="13">hospitalized or </text>
<text top="501" left="544" width="46" height="17" font="13">recently </text>
<text top="518" left="544" width="67" height="17" font="13">discharged, </text>
<text top="535" left="544" width="64" height="17" font="13">any severe </text>
<text top="552" left="544" width="51" height="17" font="13">systemic </text>
<text top="570" left="544" width="70" height="17" font="13">disease that </text>
<text top="587" left="544" width="70" height="17" font="13">could impair </text>
<text top="604" left="544" width="53" height="17" font="13">expected </text>
<text top="621" left="544" width="48" height="17" font="13">survival, </text>
<text top="638" left="544" width="89" height="17" font="13">procedures that </text>
<text top="656" left="544" width="85" height="17" font="13">could influence </text>
<text top="673" left="544" width="56" height="17" font="13">follow-up, </text>
<text top="690" left="544" width="75" height="17" font="13">pregnancy or </text>
<text top="707" left="544" width="74" height="17" font="13">child-bearing </text>
<text top="724" left="544" width="50" height="17" font="13">potential<b> </b></text>
<text top="191" left="651" width="86" height="17" font="13">Change in QoL </text>
<text top="208" left="651" width="70" height="17" font="13">components </text>
<text top="225" left="651" width="90" height="17" font="13">during follow-up<b> </b></text>
<text top="191" left="764" width="87" height="17" font="13">Influence of the </text>
<text top="208" left="764" width="74" height="17" font="13">QoL score at </text>
<text top="225" left="764" width="80" height="17" font="13">baseline on pt </text>
<text top="243" left="764" width="49" height="17" font="13">survival.<b> </b></text>
<text top="191" left="886" width="186" height="17" font="13">Improved in the DMP intervention </text>
<text top="208" left="886" width="38" height="17" font="13">group: </text>
<text top="225" left="886" width="150" height="17" font="13">Global QoL scores: p&lt;0.01 </text>
<text top="243" left="886" width="158" height="17" font="13">Physical component: p&lt;0.01 </text>
<text top="260" left="886" width="167" height="17" font="13">Emotional component: p&lt;0.01<b> </b></text>
<text top="292" left="886" width="7" height="17" font="13"> <b> </b></text>
<text top="191" left="1119" width="141" height="17" font="13">QoL can be confounding. </text>
<text top="208" left="1119" width="154" height="17" font="13">Loss of data due to morality </text>
<text top="225" left="1119" width="147" height="17" font="13">during follow-up may have </text>
<text top="243" left="1119" width="129" height="17" font="13">influenced QoL scores. </text>
<text top="260" left="1119" width="140" height="17" font="13">Retrospective analysis of </text>
<text top="277" left="1119" width="146" height="17" font="13">quality of life components.<b> </b></text>
<text top="191" left="1295" width="138" height="17" font="13">Improvement of QoL is a </text>
<text top="208" left="1295" width="144" height="17" font="13">fundamental target for the </text>
<text top="225" left="1295" width="150" height="17" font="13">success of treatment of pts </text>
<text top="243" left="1295" width="165" height="17" font="13">with HF. Specific components </text>
<text top="260" left="1295" width="153" height="17" font="13">of the QoL assessment can </text>
<text top="277" left="1295" width="155" height="17" font="13">behave differently over time </text>
<text top="294" left="1295" width="137" height="17" font="13">and should stimulate the </text>
<text top="311" left="1295" width="96" height="17" font="13">identification and </text>
<text top="329" left="1295" width="114" height="17" font="13">development of new </text>
<text top="346" left="1295" width="157" height="17" font="13">strategies and interventions. </text>
<text top="363" left="1295" width="150" height="17" font="13">Targeting male pts and the </text>
<text top="380" left="1295" width="161" height="17" font="13">emotional components of the </text>
<text top="398" left="1295" width="146" height="17" font="13">QoL assessment in DMPs </text>
<text top="415" left="1295" width="157" height="17" font="13">may be important in order to </text>
<text top="432" left="1295" width="129" height="17" font="13">achieve a greater early </text>
<text top="449" left="1295" width="118" height="17" font="13">improvement in QoL.<b> </b></text>
<text top="757" left="28" width="87" height="17" font="13">Social Support  </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">35</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="107" height="17" font="13">Long-term effect of </text>
<text top="72" left="28" width="107" height="17" font="13">social relationships </text>
<text top="89" left="28" width="100" height="17" font="13">on mortality in pts </text>
<text top="106" left="28" width="110" height="17" font="13">with CHF. Murberg, </text>
<text top="123" left="28" width="66" height="17" font="13">Terje. 2004<b> </b></text>
<text top="156" left="28" width="55" height="17" font="14">15666956</text>
<text top="156" left="83" width="36" height="17" font="13"> (102) </text>
<text top="188" left="28" width="3" height="17" font="13"> </text>
<text top="55" left="157" width="88" height="17" font="13">To evaluate the </text>
<text top="72" left="157" width="88" height="17" font="13">effects of social </text>
<text top="89" left="157" width="89" height="17" font="13">relationships on </text>
<text top="106" left="157" width="82" height="17" font="13">morality risk in </text>
<text top="124" left="157" width="85" height="17" font="13">pts with stable, </text>
<text top="141" left="157" width="72" height="17" font="13">symptomatic </text>
<text top="158" left="157" width="23" height="17" font="13">HF.<b> </b></text>
<text top="55" left="265" width="57" height="17" font="13">Follow-up </text>
<text top="72" left="265" width="33" height="17" font="13">study<b> </b></text>
<text top="55" left="366" width="24" height="17" font="13">119<b> </b></text>
<text top="55" left="433" width="87" height="17" font="13">Diagnosed with </text>
<text top="72" left="433" width="20" height="17" font="13">HF<b> </b></text>
<text top="55" left="544" width="56" height="17" font="13">Unable to </text>
<text top="72" left="544" width="53" height="17" font="13">complete </text>
<text top="89" left="544" width="21" height="17" font="13">the </text>
<text top="106" left="544" width="83" height="17" font="13">questionnaires </text>
<text top="124" left="544" width="78" height="17" font="13">due to mental </text>
<text top="141" left="544" width="66" height="17" font="13">debilitation, </text>
<text top="158" left="544" width="81" height="17" font="13">previous heart </text>
<text top="175" left="544" width="84" height="17" font="13">transplantation<b> </b></text>
<text top="55" left="651" width="93" height="17" font="13">Perceived social </text>
<text top="72" left="651" width="68" height="17" font="13">support and </text>
<text top="89" left="651" width="52" height="17" font="13">isolation.<b> </b></text>
<text top="55" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="55" left="886" width="205" height="17" font="13">Social isolation a significant predictor </text>
<text top="72" left="886" width="215" height="17" font="13">of mortality (controlling for neuroticism, </text>
<text top="89" left="886" width="210" height="17" font="13">HF severity, functional status, gender, </text>
<text top="106" left="886" width="197" height="17" font="13">age): RR= 1.36; 95% CI: 1.04-1.78; </text>
<text top="123" left="886" width="41" height="17" font="13">p&lt;0.03<b> </b></text>
<text top="55" left="1115" width="103" height="17" font="13">Small sample size<b> </b></text>
<text top="55" left="1295" width="93" height="17" font="13">Perceived social </text>
<text top="72" left="1295" width="137" height="17" font="13">isolation an independent </text>
<text top="89" left="1295" width="148" height="17" font="13">predictor of mortality in HF </text>
<text top="106" left="1295" width="141" height="17" font="13">pts during a 6-y follow-up </text>
<text top="124" left="1295" width="154" height="17" font="13">period. Experience of social </text>
<text top="141" left="1295" width="150" height="17" font="13">isolation seems to be more </text>
<text top="158" left="1295" width="139" height="17" font="13">critical than lack of social </text>
<text top="175" left="1295" width="48" height="17" font="13">support.<b> </b></text>
<text top="221" left="28" width="113" height="17" font="13">The importance and </text>
<text top="238" left="28" width="88" height="17" font="13">impact of social </text>
<text top="255" left="28" width="62" height="17" font="13">support on </text>
<text top="273" left="28" width="115" height="17" font="13">outcomes in pts with </text>
<text top="290" left="28" width="107" height="17" font="13">HF: An overview of </text>
<text top="307" left="28" width="111" height="17" font="13">the literature. Luttik, </text>
<text top="324" left="28" width="58" height="17" font="13">M.L. 2005<b> </b></text>
<text top="356" left="28" width="55" height="17" font="14">15870586</text>
<text top="356" left="83" width="36" height="17" font="13"> (103) </text>
<text top="221" left="157" width="77" height="17" font="13">To review the </text>
<text top="238" left="157" width="68" height="17" font="13">literature on </text>
<text top="255" left="157" width="42" height="17" font="13">what is </text>
<text top="273" left="157" width="69" height="17" font="13">scientifically </text>
<text top="290" left="157" width="94" height="17" font="13">known about the </text>
<text top="307" left="157" width="88" height="17" font="13">impact of social </text>
<text top="324" left="157" width="62" height="17" font="13">support on </text>
<text top="341" left="157" width="70" height="17" font="13">outcomes in </text>
<text top="359" left="157" width="68" height="17" font="13">pts with HF.<b> </b></text>
<text top="221" left="265" width="44" height="17" font="13">Review<b> </b></text>
<text top="221" left="366" width="17" height="17" font="13">17 </text>
<text top="238" left="366" width="42" height="17" font="13">studies<b> </b></text>
<text top="221" left="433" width="68" height="17" font="13">Studies that </text>
<text top="238" left="433" width="89" height="17" font="13">investigated the </text>
<text top="255" left="433" width="66" height="17" font="13">relationship </text>
<text top="273" left="433" width="85" height="17" font="13">between social </text>
<text top="290" left="433" width="68" height="17" font="13">support and </text>
<text top="307" left="433" width="48" height="17" font="13">different </text>
<text top="324" left="433" width="93" height="17" font="13">outcomes in HF.<b> </b></text>
<text top="221" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="221" left="651" width="81" height="17" font="13">Social support </text>
<text top="238" left="651" width="72" height="17" font="13">and different </text>
<text top="255" left="651" width="90" height="17" font="13">outcomes in HF </text>
<text top="273" left="651" width="77" height="17" font="13">(readmission, </text>
<text top="290" left="651" width="80" height="17" font="13">mortality, QoL </text>
<text top="307" left="651" width="95" height="17" font="13">and depression).<b> </b></text>
<text top="221" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="221" left="886" width="189" height="17" font="13">4 studies found clear relationships </text>
<text top="238" left="886" width="153" height="17" font="13">between social support and </text>
<text top="255" left="886" width="196" height="17" font="13">rehospitalizations and mortality; the </text>
<text top="273" left="886" width="167" height="17" font="13">relationship between QoL and </text>
<text top="290" left="886" width="148" height="17" font="13">depression was less clear.<b> </b></text>
<text top="322" left="886" width="7" height="17" font="13"> <b> </b></text>
<text top="221" left="1115" width="67" height="17" font="13">None noted<b> </b></text>
<text top="221" left="1295" width="142" height="17" font="13">Social support is a strong </text>
<text top="238" left="1295" width="111" height="17" font="13">predictor of hospital </text>
<text top="255" left="1295" width="163" height="17" font="13">readmissions and mortality in </text>
<text top="273" left="1295" width="159" height="17" font="13">HF pts. Emotional support in </text>
<text top="290" left="1295" width="160" height="17" font="13">particular is important. Some </text>
<text top="307" left="1295" width="155" height="17" font="13">studies show that support is </text>
<text top="324" left="1295" width="165" height="17" font="13">also related to the prevalence </text>
<text top="341" left="1295" width="127" height="17" font="13">of depression and with </text>
<text top="359" left="1295" width="104" height="17" font="13">remission of major </text>
<text top="376" left="1295" width="129" height="17" font="13">depression in HF. Less </text>
<text top="393" left="1295" width="121" height="17" font="13">evidence to support a </text>
<text top="410" left="1295" width="151" height="17" font="13">relationship between social </text>
<text top="427" left="1295" width="98" height="17" font="13">support and QoL.<b> </b></text>
<text top="461" left="28" width="101" height="17" font="13">Social deprivation </text>
<text top="478" left="28" width="99" height="17" font="13">increases cardiac </text>
<text top="495" left="28" width="88" height="17" font="13">hospitalisations </text>
<text top="512" left="28" width="76" height="17" font="13">in chronic HF </text>
<text top="529" left="28" width="85" height="17" font="13">independent of </text>
<text top="547" left="28" width="46" height="17" font="13">disease </text>
<text top="564" left="28" width="113" height="17" font="13">severity and diuretic </text>
<text top="581" left="28" width="90" height="17" font="13">non-adherence. </text>
<text top="598" left="28" width="103" height="17" font="13">Struthers, A. 2000<b> </b></text>
<text top="630" left="28" width="55" height="17" font="14">10618326</text>
<text top="630" left="83" width="36" height="17" font="13"> (104) </text>
<text top="461" left="157" width="68" height="17" font="13">To examine </text>
<text top="478" left="157" width="82" height="17" font="13">whether social </text>
<text top="495" left="157" width="87" height="17" font="13">deprivation has </text>
<text top="512" left="157" width="88" height="17" font="13">an independent </text>
<text top="529" left="157" width="51" height="17" font="13">effect on </text>
<text top="547" left="157" width="64" height="17" font="13">emergency </text>
<text top="564" left="157" width="43" height="17" font="13">cardiac </text>
<text top="581" left="157" width="94" height="17" font="13">hospitalization in </text>
<text top="598" left="157" width="88" height="17" font="13">pts with chronic </text>
<text top="615" left="157" width="23" height="17" font="13">HF.<b> </b></text>
<text top="460" left="265" width="73" height="17" font="13">Cohort study<b> </b></text>
<text top="460" left="366" width="24" height="17" font="13">478<b> </b></text>
<text top="461" left="433" width="94" height="17" font="13">Admitted with an </text>
<text top="478" left="433" width="67" height="17" font="13">MI between </text>
<text top="495" left="433" width="79" height="17" font="13">January 1989-</text>
<text top="512" left="433" width="91" height="17" font="13">December 1992 </text>
<text top="529" left="433" width="24" height="17" font="13">and </text>
<text top="547" left="433" width="76" height="17" font="13">subsequently </text>
<text top="564" left="433" width="68" height="17" font="13">admitted for </text>
<text top="581" left="433" width="63" height="17" font="13">chronic HF </text>
<text top="598" left="433" width="97" height="17" font="13">between January </text>
<text top="615" left="433" width="95" height="17" font="13">1989- December </text>
<text top="633" left="433" width="96" height="17" font="13">1992, ≥3 diuretic </text>
<text top="650" left="433" width="97" height="17" font="13">prescriptions had </text>
<text top="667" left="433" width="75" height="17" font="13">to have been </text>
<text top="684" left="433" width="59" height="17" font="13">dispensed </text>
<text top="701" left="433" width="97" height="17" font="13">between January </text>
<text top="719" left="433" width="82" height="17" font="13">1993- January </text>
<text top="736" left="433" width="34" height="17" font="13">1994.<b> </b></text>
<text top="460" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="461" left="651" width="66" height="17" font="13">Emergency </text>
<text top="478" left="651" width="46" height="17" font="13">hospital </text>
<text top="495" left="651" width="85" height="17" font="13">admissions (all </text>
<text top="512" left="651" width="84" height="17" font="13">causes and for </text>
<text top="529" left="651" width="85" height="17" font="13">cardiac causes </text>
<text top="546" left="651" width="30" height="17" font="13">only)<b> </b></text>
<text top="460" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="461" left="886" width="167" height="17" font="13">Social deprivation significantly </text>
<text top="478" left="886" width="188" height="17" font="13">associated with an increase in the </text>
<text top="495" left="886" width="189" height="17" font="13">number of cardiac hospitalizations </text>
<text top="512" left="886" width="60" height="17" font="13">(p=0.007). </text>
<text top="529" left="886" width="3" height="17" font="13"> </text>
<text top="547" left="886" width="213" height="17" font="13">Effect mainly caused by increasing the </text>
<text top="564" left="886" width="204" height="17" font="13">proportion of pts hospitalized in each </text>
<text top="581" left="886" width="159" height="17" font="13">deprivation category. 26% in </text>
<text top="598" left="886" width="198" height="17" font="13">deprivation category 1–2 vs. 40% in </text>
<text top="615" left="886" width="194" height="17" font="13">deprivation category 5–6 (p= 0.03). </text>
<text top="633" left="886" width="3" height="17" font="13"> </text>
<text top="650" left="886" width="200" height="17" font="13">Effect of deprivation: independent of </text>
<text top="667" left="886" width="189" height="17" font="13">disease severity (as judged by the </text>
<text top="684" left="886" width="189" height="17" font="13">dose of prescribed diuretic), death </text>
<text top="701" left="886" width="189" height="17" font="13">rate, and duration of each hospital </text>
<text top="719" left="886" width="186" height="17" font="13">stay. Non-adherence with diuretic </text>
<text top="736" left="886" width="207" height="17" font="13">treatment could not account for these </text>
<text top="753" left="886" width="83" height="17" font="13">findings either.<b> </b></text>
<text top="461" left="1115" width="135" height="17" font="13">Assessed adherence by </text>
<text top="478" left="1115" width="129" height="17" font="13">whether pt had enough </text>
<text top="495" left="1115" width="73" height="17" font="13">tablets in the </text>
<text top="512" left="1115" width="105" height="17" font="13">house to cover the </text>
<text top="529" left="1115" width="134" height="17" font="13">appropriate time period- </text>
<text top="547" left="1115" width="140" height="17" font="13">measuring pt’s maximum </text>
<text top="564" left="1115" width="156" height="17" font="13">possible level of adherence. </text>
<text top="581" left="1115" width="116" height="17" font="13">Poor adherence was </text>
<text top="598" left="1115" width="151" height="17" font="13">associated with being male </text>
<text top="615" left="1115" width="146" height="17" font="13">versus female but not with </text>
<text top="633" left="1115" width="144" height="17" font="13">age, social deprivation, or </text>
<text top="650" left="1115" width="148" height="17" font="13">diuretic dose. It is possible </text>
<text top="667" left="1115" width="148" height="17" font="13">that diuretics caused more </text>
<text top="684" left="1115" width="71" height="17" font="13">troublesome </text>
<text top="701" left="1115" width="141" height="17" font="13">urinary symptoms in men </text>
<text top="719" left="1115" width="127" height="17" font="13">because of prostatism, </text>
<text top="736" left="1115" width="161" height="17" font="13">leading to poorer adherence.<b> </b></text>
<text top="461" left="1295" width="157" height="17" font="13">Social deprivation increases </text>
<text top="478" left="1295" width="77" height="17" font="13">the chance of </text>
<text top="495" left="1295" width="92" height="17" font="13">rehospitalization </text>
<text top="512" left="1295" width="131" height="17" font="13">independent of disease </text>
<text top="529" left="1295" width="99" height="17" font="13">severity. Possible </text>
<text top="547" left="1295" width="161" height="17" font="13">explanations are that doctors </text>
<text top="564" left="1295" width="124" height="17" font="13">who look after socially </text>
<text top="581" left="1295" width="144" height="17" font="13">deprived pts have a lower </text>
<text top="598" left="1295" width="115" height="17" font="13">threshold for cardiac </text>
<text top="615" left="1295" width="154" height="17" font="13">hospitalization or that social </text>
<text top="633" left="1295" width="153" height="17" font="13">deprivation alters the way a </text>
<text top="650" left="1295" width="161" height="17" font="13">HF pt accesses medical care </text>
<text top="667" left="1295" width="135" height="17" font="13">during decompensation. </text>
<text top="684" left="1295" width="144" height="17" font="13">Understanding how social </text>
<text top="701" left="1295" width="150" height="17" font="13">deprivation influences both </text>
<text top="719" left="1295" width="159" height="17" font="13">doctor and pt behavior in the </text>
<text top="736" left="1295" width="165" height="17" font="13">prehospital phase is crucial to </text>
<text top="753" left="1295" width="154" height="17" font="13">reduce the amplifying effect </text>
<text top="770" left="1295" width="146" height="17" font="13">that social deprivation has </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">36</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="886" width="3" height="17" font="15"><b> </b></text>
<text top="55" left="1295" width="134" height="17" font="13">cardiac hospitalizations.<b> </b></text>
<text top="88" left="28" width="105" height="17" font="13">Social support and </text>
<text top="105" left="28" width="87" height="17" font="13">self-care in HF. </text>
<text top="122" left="28" width="100" height="17" font="13">Gallager, R. 2011<b> </b></text>
<text top="154" left="28" width="55" height="17" font="14">21372734</text>
<text top="154" left="83" width="36" height="17" font="13"> (105) </text>
<text top="88" left="157" width="76" height="17" font="13">To determine </text>
<text top="105" left="157" width="67" height="17" font="13">the types of </text>
<text top="122" left="157" width="79" height="17" font="13">social support </text>
<text top="139" left="157" width="84" height="17" font="13">provided to HF </text>
<text top="157" left="157" width="64" height="17" font="13">pts and the </text>
<text top="174" left="157" width="40" height="17" font="13">impact </text>
<text top="191" left="157" width="61" height="17" font="13">of differing </text>
<text top="208" left="157" width="83" height="17" font="13">levels of social </text>
<text top="225" left="157" width="81" height="17" font="13">support on HF </text>
<text top="243" left="157" width="73" height="17" font="13">pts’ self-care<b> </b></text>
<text top="88" left="265" width="36" height="17" font="13">Cross-</text>
<text top="105" left="265" width="59" height="17" font="13">sectional,  </text>
<text top="122" left="265" width="62" height="17" font="13">descriptive </text>
<text top="139" left="265" width="76" height="17" font="13">(COACH sub-</text>
<text top="156" left="265" width="44" height="17" font="13">study  )<b> </b></text>
<text top="88" left="366" width="24" height="17" font="13">333<b> </b></text>
<text top="88" left="433" width="66" height="17" font="13">Admitted to </text>
<text top="105" left="433" width="97" height="17" font="13">hospital for HF at </text>
<text top="122" left="433" width="59" height="17" font="13">least once </text>
<text top="139" left="433" width="90" height="17" font="13">before the initial </text>
<text top="157" left="433" width="95" height="17" font="13">hospitalization of </text>
<text top="174" left="433" width="96" height="17" font="13">the original study </text>
<text top="191" left="433" width="59" height="17" font="13">Age &gt;18 y </text>
<text top="208" left="433" width="67" height="17" font="13">NYHA II-IV; </text>
<text top="225" left="433" width="66" height="17" font="13">evidence of </text>
<text top="243" left="433" width="60" height="17" font="13">underlying </text>
<text top="260" left="433" width="85" height="17" font="13">structural heart </text>
<text top="277" left="433" width="46" height="17" font="13">disease<b> </b></text>
<text top="88" left="544" width="64" height="17" font="13">Undergone </text>
<text top="105" left="544" width="87" height="17" font="13">cardiac surgery </text>
<text top="122" left="544" width="72" height="17" font="13">or PCI in the </text>
<text top="139" left="544" width="84" height="17" font="13">previous 6 mo, </text>
<text top="157" left="544" width="57" height="17" font="13">or if these </text>
<text top="174" left="544" width="79" height="17" font="13">procedures or </text>
<text top="191" left="544" width="31" height="17" font="13">heart </text>
<text top="208" left="544" width="84" height="17" font="13">transplantation </text>
<text top="225" left="544" width="76" height="17" font="13">was planned, </text>
<text top="243" left="544" width="56" height="17" font="13">Unable to </text>
<text top="260" left="544" width="94" height="17" font="13">participate in the </text>
<text top="277" left="544" width="48" height="17" font="13">COACH </text>
<text top="294" left="544" width="81" height="17" font="13">intervention or </text>
<text top="311" left="544" width="87" height="17" font="13">to complete the </text>
<text top="329" left="544" width="82" height="17" font="13">data collection </text>
<text top="346" left="544" width="34" height="17" font="13">forms<b> </b></text>
<text top="88" left="651" width="77" height="17" font="13">Self-care and </text>
<text top="105" left="651" width="79" height="17" font="13">social support<b> </b></text>
<text top="88" left="764" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="88" left="886" width="213" height="17" font="13">High level of support, compared to low </text>
<text top="105" left="886" width="154" height="17" font="13">or moderate levels reported </text>
<text top="122" left="886" width="206" height="17" font="13">significantly better self-care (p= .002) </text>
<text top="139" left="886" width="3" height="17" font="13"> </text>
<text top="157" left="886" width="212" height="17" font="13">High level of social support, compared </text>
<text top="174" left="886" width="189" height="17" font="13">medium or low levels, significantly </text>
<text top="191" left="886" width="194" height="17" font="13">more likely to: consult with a health </text>
<text top="208" left="886" width="216" height="17" font="13">professional for weight gain (p= 0.011), </text>
<text top="225" left="886" width="198" height="17" font="13">limit fluid intake (p= 0.02), take their </text>
<text top="243" left="886" width="173" height="17" font="13">medication (p= 0.017), get a flu </text>
<text top="260" left="886" width="187" height="17" font="13">shot(p= 0.001), and exercise on a </text>
<text top="277" left="886" width="137" height="17" font="13">regular basis (p&lt; 0.001).<b> </b></text>
<text top="88" left="1115" width="150" height="17" font="13">Secondary analysis. Social </text>
<text top="105" left="1115" width="148" height="17" font="13">support not prespecified in </text>
<text top="122" left="1115" width="78" height="17" font="13">COACH trial.  </text>
<text top="139" left="1115" width="160" height="17" font="13">The measure and categories </text>
<text top="157" left="1115" width="144" height="17" font="13">of social support have not </text>
<text top="174" left="1115" width="154" height="17" font="13">been used previously either </text>
<text top="191" left="1115" width="161" height="17" font="13">separately or as a composite </text>
<text top="208" left="1115" width="55" height="17" font="13">measure. </text>
<text top="225" left="1115" width="163" height="17" font="13">It is likely that other important </text>
<text top="243" left="1115" width="163" height="17" font="13">factors influence HF self-care </text>
<text top="260" left="1115" width="154" height="17" font="13">behavior as the multivariate </text>
<text top="277" left="1115" width="141" height="17" font="13">model was not adequate.<b> </b></text>
<text top="88" left="1295" width="127" height="17" font="13">The presence of social </text>
<text top="105" left="1295" width="146" height="17" font="13">support by a partner is not </text>
<text top="122" left="1295" width="161" height="17" font="13">sufficient to influence HF pts’ </text>
<text top="139" left="1295" width="135" height="17" font="13">self-care. Social support </text>
<text top="157" left="1295" width="152" height="17" font="13">provided by partners needs </text>
<text top="174" left="1295" width="161" height="17" font="13">to be of a quality and content </text>
<text top="191" left="1295" width="116" height="17" font="13">that matches HF pts’ </text>
<text top="208" left="1295" width="119" height="17" font="13">perception of need to </text>
<text top="225" left="1295" width="110" height="17" font="13">influence self-care. <b> </b></text>
<text top="379" left="28" width="85" height="17" font="13">Comorbidities   </text>
<text top="412" left="28" width="102" height="17" font="13">A qualitative meta-</text>
<text top="429" left="28" width="105" height="17" font="13">analysis of HF self-</text>
<text top="446" left="28" width="80" height="17" font="13">care practices </text>
<text top="463" left="28" width="102" height="17" font="13">among individuals </text>
<text top="481" left="28" width="71" height="17" font="13">with multiple </text>
<text top="498" left="28" width="54" height="17" font="13">comorbid </text>
<text top="515" left="28" width="113" height="17" font="13">conditions. Dickson, </text>
<text top="532" left="28" width="46" height="17" font="13">V. 2011<b> </b></text>
<text top="564" left="28" width="55" height="17" font="14">21549299</text>
<text top="564" left="83" width="36" height="17" font="13"> (106) </text>
<text top="412" left="157" width="88" height="17" font="13">To explore how </text>
<text top="429" left="157" width="66" height="17" font="13">comorbidity </text>
<text top="446" left="157" width="79" height="17" font="13">influences HF </text>
<text top="463" left="157" width="51" height="17" font="13">self-care<b> </b></text>
<text top="412" left="265" width="61" height="17" font="13">Qualitative </text>
<text top="429" left="265" width="79" height="17" font="13">meta-analysis<b> </b></text>
<text top="412" left="366" width="37" height="17" font="13">99 pts </text>
<text top="429" left="366" width="38" height="17" font="13">from 3 </text>
<text top="446" left="366" width="29" height="17" font="13">trials<b> </b></text>
<text top="412" left="433" width="81" height="17" font="13">Mixed method </text>
<text top="429" left="433" width="46" height="17" font="13">studies. </text>
<text top="446" left="433" width="95" height="17" font="13">Included pts with </text>
<text top="463" left="433" width="88" height="17" font="13">HF with at least </text>
<text top="481" left="433" width="64" height="17" font="13">1 comorbid </text>
<text top="498" left="433" width="53" height="17" font="13">condition<b> </b></text>
<text top="412" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="412" left="651" width="103" height="17" font="13">Perceptions about </text>
<text top="429" left="651" width="110" height="17" font="13">HF and HF selfcare<b> </b></text>
<text top="412" left="784" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="412" left="886" width="207" height="17" font="13">Narrative accounts revealed the most </text>
<text top="429" left="886" width="215" height="17" font="13">challenging self-care skills:  adherence </text>
<text top="446" left="886" width="182" height="17" font="13">to diet, symptom monitoring, and </text>
<text top="463" left="886" width="196" height="17" font="13">differentiating symptoms of multiple </text>
<text top="481" left="886" width="62" height="17" font="13">conditions. </text>
<text top="498" left="886" width="3" height="17" font="13"> </text>
<text top="515" left="886" width="167" height="17" font="13">Emerging themes included: 1) </text>
<text top="532" left="886" width="200" height="17" font="13">attitudes drive self-care prioritization </text>
<text top="550" left="886" width="214" height="17" font="13">and 2) fragmented self-care instruction </text>
<text top="567" left="886" width="210" height="17" font="13">leads to poor self-care integration and </text>
<text top="584" left="886" width="120" height="17" font="13">self-care skill deficits.<b> </b></text>
<text top="412" left="1115" width="164" height="17" font="13">Generalizability limited due to </text>
<text top="429" left="1115" width="128" height="17" font="13">homogeneous sample. </text>
<text top="446" left="1115" width="135" height="17" font="13">Interpretation of findings </text>
<text top="463" left="1115" width="130" height="17" font="13">relied on interview data </text>
<text top="481" left="1115" width="145" height="17" font="13">available from the primary </text>
<text top="498" left="1115" width="46" height="17" font="13">studies. </text>
<text top="515" left="1115" width="133" height="17" font="13">Findings may be baised </text>
<text top="532" left="1115" width="129" height="17" font="13">because samples were </text>
<text top="550" left="1115" width="150" height="17" font="13">recruited from HF specialty </text>
<text top="567" left="1115" width="132" height="17" font="13">settings, possibly better </text>
<text top="584" left="1115" width="131" height="17" font="13">managed clinically than </text>
<text top="601" left="1115" width="116" height="17" font="13">community samples.<b> </b></text>
<text top="412" left="1295" width="133" height="17" font="13">Individuals with multiple </text>
<text top="429" left="1295" width="123" height="17" font="13">chronic conditions are </text>
<text top="446" left="1295" width="153" height="17" font="13">vulnerable to poor self-care </text>
<text top="463" left="1295" width="121" height="17" font="13">because of difficulties </text>
<text top="481" left="1295" width="144" height="17" font="13">prioritizing and integrating </text>
<text top="498" left="1295" width="165" height="17" font="13">multiple protocols. Adherence </text>
<text top="515" left="1295" width="149" height="17" font="13">to a low-salt diet, symptom </text>
<text top="532" left="1295" width="165" height="17" font="13">monitoring, and differentiating </text>
<text top="550" left="1295" width="153" height="17" font="13">symptoms of HF from other </text>
<text top="567" left="1295" width="123" height="17" font="13">chronic conditions are </text>
<text top="584" left="1295" width="132" height="17" font="13">particularly challenging. </text>
<text top="601" left="1295" width="161" height="17" font="13">Difficulty integrating self-care </text>
<text top="618" left="1295" width="137" height="17" font="13">of different diseases and </text>
<text top="636" left="1295" width="131" height="17" font="13">fragmented instructions </text>
<text top="653" left="1295" width="148" height="17" font="13">regarding those conditions </text>
<text top="670" left="1295" width="126" height="17" font="13">may contribute to poor </text>
<text top="687" left="1295" width="60" height="17" font="13">outcomes.<b> </b></text>
</page>
<page number="37" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">37</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="63" height="17" font="13">Psychiatric </text>
<text top="72" left="28" width="90" height="17" font="13">comorbidity and </text>
<text top="89" left="28" width="42" height="17" font="13">greater </text>
<text top="106" left="28" width="107" height="17" font="13">hospitalization risk, </text>
<text top="124" left="28" width="114" height="17" font="13">longer length of stay </text>
<text top="141" left="28" width="62" height="17" font="13">and higher </text>
<text top="158" left="28" width="114" height="17" font="13">hospitalization costs </text>
<text top="175" left="28" width="105" height="17" font="13">in older adults with </text>
<text top="192" left="28" width="114" height="17" font="13">HF. Sayers, Steven. </text>
<text top="210" left="28" width="31" height="17" font="13">2007<b> </b></text>
<text top="242" left="28" width="55" height="17" font="14">17714458</text>
<text top="242" left="83" width="36" height="17" font="13"> (107) </text>
<text top="55" left="157" width="62" height="17" font="13">To explore </text>
<text top="72" left="157" width="71" height="17" font="13">associations </text>
<text top="89" left="157" width="50" height="17" font="13">between </text>
<text top="106" left="157" width="62" height="17" font="13">psychiatric </text>
<text top="124" left="157" width="90" height="17" font="13">comorbidity and </text>
<text top="141" left="157" width="92" height="17" font="13">rehospitalization </text>
<text top="158" left="157" width="77" height="17" font="13">risk, length of </text>
<text top="175" left="157" width="85" height="17" font="13">hospitalization, </text>
<text top="192" left="157" width="69" height="17" font="13">and costs in </text>
<text top="210" left="157" width="85" height="17" font="13">adults with HF.<b> </b></text>
<text top="55" left="265" width="73" height="17" font="13">Cohort study<b> </b></text>
<text top="55" left="366" width="38" height="17" font="13">21429<b> </b></text>
<text top="55" left="433" width="54" height="17" font="13">Medicare </text>
<text top="72" left="433" width="72" height="17" font="13">beneficiaries </text>
<text top="89" left="433" width="68" height="17" font="13">hospitalized </text>
<text top="106" left="433" width="72" height="17" font="13">during 1999.<b> </b></text>
<text top="55" left="544" width="76" height="17" font="13">HF was not a </text>
<text top="72" left="544" width="94" height="17" font="13">primary cause of </text>
<text top="89" left="544" width="82" height="17" font="13">any admission </text>
<text top="106" left="544" width="72" height="17" font="13">during 1999, </text>
<text top="124" left="544" width="57" height="17" font="13">Comorbid </text>
<text top="141" left="544" width="68" height="17" font="13">dementia or </text>
<text top="158" left="544" width="74" height="17" font="13">organic brain </text>
<text top="175" left="544" width="57" height="17" font="13">syndrome </text>
<text top="192" left="544" width="55" height="17" font="13">diagnosis<b> </b></text>
<text top="55" left="651" width="63" height="17" font="13">Psychiatric </text>
<text top="72" left="651" width="90" height="17" font="13">comorbidity and </text>
<text top="89" left="651" width="118" height="17" font="13">rehospitalization risk, </text>
<text top="106" left="651" width="51" height="17" font="13">length of </text>
<text top="124" left="651" width="109" height="17" font="13">hospitalization, and </text>
<text top="141" left="651" width="36" height="17" font="13">costs.<b> </b></text>
<text top="55" left="784" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="55" left="886" width="204" height="17" font="13">Overall, 15.8% of pts hospitalized for </text>
<text top="72" left="886" width="152" height="17" font="13">HF had a coded psychiatric </text>
<text top="89" left="886" width="70" height="17" font="13">comorbidity. </text>
<text top="106" left="886" width="3" height="17" font="13"> </text>
<text top="124" left="886" width="180" height="17" font="13">Most commonly coded comorbid </text>
<text top="141" left="886" width="198" height="17" font="13">psychiatric disorder was depression </text>
<text top="158" left="886" width="184" height="17" font="13">(8.5% of the sample) (p&lt; 0.001).  </text>
<text top="175" left="886" width="3" height="17" font="13"> </text>
<text top="192" left="886" width="206" height="17" font="13">Most forms of psychiatric comorbidity </text>
<text top="210" left="886" width="210" height="17" font="13">were associated with greater inpatient </text>
<text top="227" left="886" width="202" height="17" font="13">utilization, including risk of additional </text>
<text top="244" left="886" width="168" height="17" font="13">hospitalizations, d of stay, and </text>
<text top="261" left="886" width="195" height="17" font="13">hospitalization charges (p&lt; 0.001).  </text>
<text top="278" left="886" width="3" height="17" font="13"> </text>
<text top="296" left="886" width="171" height="17" font="13">Additional hospitalization costs </text>
<text top="313" left="886" width="215" height="17" font="13">associated with psychiatric comorbidity </text>
<text top="330" left="886" width="197" height="17" font="13">ranged up to $7,763, and additional </text>
<text top="347" left="886" width="202" height="17" font="13">length of stay ranged up to 1.4 d (p&lt; </text>
<text top="364" left="886" width="42" height="17" font="13">0.001).<b> </b></text>
<text top="55" left="1115" width="115" height="17" font="13">Claims usage based </text>
<text top="72" left="1115" width="110" height="17" font="13">administrative data. </text>
<text top="89" left="1115" width="130" height="17" font="13">Information unavailable </text>
<text top="106" left="1115" width="155" height="17" font="13">regarding the severity of HF </text>
<text top="124" left="1115" width="80" height="17" font="13">in the sample. </text>
<text top="141" left="1115" width="162" height="17" font="13">The possibility that outcomes </text>
<text top="158" left="1115" width="143" height="17" font="13">may be worse for pts with </text>
<text top="175" left="1115" width="152" height="17" font="13">coded comorbid psychiatric </text>
<text top="192" left="1115" width="59" height="17" font="13">diagnoses </text>
<text top="210" left="1115" width="155" height="17" font="13">as opposed to the presence </text>
<text top="227" left="1115" width="158" height="17" font="13">of the conditions themselves </text>
<text top="244" left="1115" width="150" height="17" font="13">cannot be excluded. Cross-</text>
<text top="261" left="1115" width="95" height="17" font="13">sectional design.<b> </b></text>
<text top="55" left="1295" width="129" height="17" font="13">Psychiatric comorbidity </text>
<text top="72" left="1295" width="129" height="17" font="13">appears in a significant </text>
<text top="89" left="1295" width="148" height="17" font="13">minority of pts hospitalized </text>
<text top="106" left="1295" width="149" height="17" font="13">for HF and may affect their </text>
<text top="124" left="1295" width="120" height="17" font="13">clinical and economic </text>
<text top="141" left="1295" width="156" height="17" font="13">outcomes. The associations </text>
<text top="158" left="1295" width="111" height="17" font="13">between psychiatric </text>
<text top="175" left="1295" width="127" height="17" font="13">comorbidity and use of </text>
<text top="192" left="1295" width="160" height="17" font="13">inpatient care are likely to be </text>
<text top="210" left="1295" width="138" height="17" font="13">underestimated because </text>
<text top="227" left="1295" width="164" height="17" font="13">psychiatric illness is known to </text>
<text top="244" left="1295" width="146" height="17" font="13">be under detected in older </text>
<text top="261" left="1295" width="141" height="17" font="13">adults and in hospitalized </text>
<text top="278" left="1295" width="69" height="17" font="13">medical pts.<b> </b></text>
<text top="398" left="28" width="95" height="17" font="13">The relevance of </text>
<text top="415" left="28" width="114" height="17" font="13">comorbidities for HF </text>
<text top="432" left="28" width="113" height="17" font="13">treatment in primary </text>
<text top="449" left="28" width="99" height="17" font="13">care: A European </text>
<text top="466" left="28" width="98" height="17" font="13">survey. Sturm, H. </text>
<text top="483" left="28" width="31" height="17" font="13">2006<b> </b></text>
<text top="516" left="28" width="55" height="17" font="14">16084761</text>
<text top="516" left="83" width="36" height="17" font="13"> (108) </text>
<text top="398" left="157" width="76" height="17" font="13">To determine </text>
<text top="415" left="157" width="87" height="17" font="13">the impact of pt </text>
<text top="432" left="157" width="82" height="17" font="13">characteristics </text>
<text top="449" left="157" width="24" height="17" font="13">and </text>
<text top="466" left="157" width="93" height="17" font="13">comorbidities on </text>
<text top="484" left="157" width="63" height="17" font="13">chronic HF </text>
<text top="501" left="157" width="79" height="17" font="13">management, </text>
<text top="518" left="157" width="80" height="17" font="13">and to identify </text>
<text top="535" left="157" width="48" height="17" font="13">areas of </text>
<text top="552" left="157" width="87" height="17" font="13">prescribing that </text>
<text top="570" left="157" width="50" height="17" font="13">could be </text>
<text top="587" left="157" width="57" height="17" font="13">improved.<b> </b></text>
<text top="398" left="265" width="64" height="17" font="13">Descriptive </text>
<text top="415" left="265" width="33" height="17" font="13">study<b> </b></text>
<text top="397" left="366" width="41" height="17" font="13">11,062<b> </b></text>
<text top="398" left="433" width="71" height="17" font="13">Diagnosis of </text>
<text top="415" left="433" width="63" height="17" font="13">chronic HF </text>
<text top="432" left="433" width="88" height="17" font="13">and/or a history </text>
<text top="449" left="433" width="90" height="17" font="13">of MI during a 2-</text>
<text top="466" left="433" width="71" height="17" font="13">mo period in </text>
<text top="483" left="433" width="31" height="17" font="13">1999<b> </b></text>
<text top="397" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="398" left="651" width="81" height="17" font="13">Influence of pt </text>
<text top="415" left="651" width="99" height="17" font="13">characteristics on </text>
<text top="432" left="651" width="82" height="17" font="13">drug regimens<b> </b></text>
<text top="397" left="784" width="7" height="17" font="13"> <b> </b></text>
<text top="398" left="886" width="216" height="17" font="13">Combined drug regimens given to 48% </text>
<text top="415" left="886" width="200" height="17" font="13">of HF pts (2.2 drugs on average). Pt </text>
<text top="432" left="886" width="191" height="17" font="13">characteristics accounted for 35%, </text>
<text top="449" left="886" width="209" height="17" font="13">42% and 10% of the variance in 1-, 2- </text>
<text top="466" left="886" width="196" height="17" font="13">and 3-drug regimens, respectively.  </text>
<text top="484" left="886" width="3" height="17" font="13"> </text>
<text top="501" left="886" width="198" height="17" font="13">MI, AF, DM, HTN, and lung disease </text>
<text top="518" left="886" width="207" height="17" font="13">influenced prescribing most (OR=1.3; </text>
<text top="535" left="886" width="93" height="17" font="13">95% CI: 1.2-1.4) </text>
<text top="552" left="886" width="3" height="17" font="13"> </text>
<text top="570" left="886" width="204" height="17" font="13">AF made all combinations containing </text>
<text top="587" left="886" width="142" height="17" font="13">beta blockers more likely. </text>
<text top="604" left="886" width="3" height="17" font="13"> </text>
<text top="621" left="886" width="210" height="17" font="13">For single drug regimes, MI increased </text>
<text top="638" left="886" width="196" height="17" font="13">the likelihood of non-recommended </text>
<text top="656" left="886" width="195" height="17" font="13">beta blocker monotherapy while for </text>
<text top="673" left="886" width="200" height="17" font="13">combination therapy, recommended </text>
<text top="690" left="886" width="145" height="17" font="13">regimes were most likely.  </text>
<text top="707" left="886" width="3" height="17" font="13"> </text>
<text top="725" left="886" width="211" height="17" font="13">For both HTN and DM, ACEI were the </text>
<text top="742" left="886" width="210" height="17" font="13">most likely single drug, while the most </text>
<text top="759" left="886" width="215" height="17" font="13">likely second drugs were beta blockers </text>
<text top="776" left="886" width="147" height="17" font="13">in HTN and digoxin in DM.<b> </b></text>
<text top="398" left="1115" width="141" height="17" font="13">Drug regimens defined to </text>
<text top="415" left="1115" width="141" height="17" font="13">make comparisons within </text>
<text top="432" left="1115" width="143" height="17" font="13">levels of similar treatment </text>
<text top="449" left="1115" width="101" height="17" font="13">intensity possible. </text>
<text top="466" left="1115" width="155" height="17" font="13">Adherence rates depend on </text>
<text top="483" left="1115" width="110" height="17" font="13">the indicators used.<b> </b></text>
<text top="398" left="1295" width="137" height="17" font="13">Pt characteristics have a </text>
<text top="415" left="1295" width="163" height="17" font="13">clear impact on prescribing in </text>
<text top="432" left="1295" width="165" height="17" font="13">European primary care. Up to </text>
<text top="449" left="1295" width="154" height="17" font="13">56% of drug regimens were </text>
<text top="466" left="1295" width="97" height="17" font="13">rational, taking pt </text>
<text top="484" left="1295" width="155" height="17" font="13">characteristics into account. </text>
<text top="501" left="1295" width="133" height="17" font="13">Situations of insufficient </text>
<text top="518" left="1295" width="159" height="17" font="13">prescribing, such as pts post </text>
<text top="535" left="1295" width="143" height="17" font="13">MI, need to be addressed </text>
<text top="552" left="1295" width="66" height="17" font="13">specifically.<b> </b></text>
</page>
<page number="38" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">38</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="77" height="17" font="13">Frequent non-</text>
<text top="72" left="28" width="43" height="17" font="13">cardiac </text>
<text top="89" left="28" width="109" height="17" font="13">comorbidities in pts </text>
<text top="106" left="28" width="92" height="17" font="13">with chronic HF. </text>
<text top="124" left="28" width="85" height="17" font="13">Dahlstrom, Ulf. </text>
<text top="141" left="28" width="31" height="17" font="13">2005<b> </b></text>
<text top="173" left="28" width="55" height="17" font="14">15718170</text>
<text top="173" left="83" width="36" height="17" font="13"> (109) </text>
<text top="55" left="157" width="75" height="17" font="13">To discuss in </text>
<text top="72" left="157" width="85" height="17" font="13">more detail the </text>
<text top="89" left="157" width="70" height="17" font="13">impact of co-</text>
<text top="106" left="157" width="45" height="17" font="13">existing </text>
<text top="124" left="157" width="58" height="17" font="13">HTN, DM, </text>
<text top="141" left="157" width="72" height="17" font="13">COPD in pts </text>
<text top="158" left="157" width="49" height="17" font="13">with HF.<b> </b></text>
<text top="55" left="265" width="44" height="17" font="13">Review<b> </b></text>
<text top="55" left="366" width="17" height="17" font="13">37 </text>
<text top="72" left="366" width="42" height="17" font="13">studies<b> </b></text>
<text top="55" left="433" width="85" height="17" font="13">None specified<b> </b></text>
<text top="55" left="544" width="85" height="17" font="13">None specified<b> </b></text>
<text top="55" left="651" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="55" left="784" width="27" height="17" font="13"> N/A<b> </b></text>
<text top="55" left="886" width="207" height="17" font="13">About 50% of pts with untreated HTN </text>
<text top="72" left="886" width="193" height="17" font="13">will develop HF. Pressure overload </text>
<text top="89" left="886" width="173" height="17" font="13">leads to the development of LV </text>
<text top="106" left="886" width="209" height="17" font="13">hypertrophy and diastolic dysfunction. </text>
<text top="124" left="886" width="3" height="17" font="13"> </text>
<text top="141" left="886" width="191" height="17" font="13">DM occurs in about 20–30% of pts </text>
<text top="158" left="886" width="49" height="17" font="13">with HF. </text>
<text top="175" left="886" width="3" height="17" font="13"> </text>
<text top="192" left="886" width="192" height="17" font="13">COPD occurs in approximately 20–</text>
<text top="210" left="886" width="85" height="17" font="13">30% of HF pts. </text>
<text top="227" left="886" width="3" height="17" font="13"> </text>
<text top="244" left="886" width="200" height="17" font="13">Anemia occurs in 20–30% of HF pts </text>
<text top="261" left="886" width="180" height="17" font="13">and is associated with functional </text>
<text top="278" left="886" width="195" height="17" font="13">impairment and increased mortality </text>
<text top="296" left="886" width="196" height="17" font="13">and morbidity. Combined treatment </text>
<text top="313" left="886" width="194" height="17" font="13">with erythropoietin and intravenous </text>
<text top="330" left="886" width="198" height="17" font="13">iron has shown beneficial effects on </text>
<text top="347" left="886" width="181" height="17" font="13">clinical symptoms and morbidity.<b> </b></text>
<text top="55" left="1115" width="141" height="17" font="13">No limitations addressed.<b> </b></text>
<text top="55" left="1295" width="151" height="17" font="13">This review of the literature </text>
<text top="72" left="1295" width="141" height="17" font="13">clearly demonstrates that </text>
<text top="89" left="1295" width="161" height="17" font="13">noncardiac comorbidities are </text>
<text top="106" left="1295" width="153" height="17" font="13">common in pts with HF and </text>
<text top="124" left="1295" width="114" height="17" font="13">that it is important to </text>
<text top="141" left="1295" width="149" height="17" font="13">recognize these conditions </text>
<text top="158" left="1295" width="24" height="17" font="13">and </text>
<text top="175" left="1295" width="157" height="17" font="13">take them into consideration </text>
<text top="192" left="1295" width="158" height="17" font="13">when selecting treatment for </text>
<text top="210" left="1295" width="124" height="17" font="13">these pts. Appropriate </text>
<text top="227" left="1295" width="150" height="17" font="13">treatment of the HF as well </text>
<text top="244" left="1295" width="158" height="17" font="13">as the concomitant diseases </text>
<text top="261" left="1295" width="159" height="17" font="13">will improve the prognosis of </text>
<text top="278" left="1295" width="57" height="17" font="13">these pts.<b> </b></text>
<text top="385" left="22" width="1402" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; CHF, congestive heart failure; COACH, Community Outreach and Cardiovascular Health; DM, diabetes mellitus; DMP, disease management program; ECHO, echocardiogram; ED, </text>
<text top="403" left="22" width="1419" height="17" font="13">emergency department;  EF, ejection fraction; HF, heart failure; HTN, hypertension; IV, intravenous; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not applicable; NS, not significant; NYHA, New York Heart Association; PCI; percutaneous </text>
<text top="420" left="22" width="1330" height="17" font="13">coronary intervention; pts, patients; QoL, quality of life; RCT, randomized control trial; REHMADE, Repetitive Education at Six-Month Intervals and Monitoring for Adherence in Heart Failure; UMHFP, University of Michigan Heart Failure Program </text>
<text top="440" left="54" width="4" height="16" font="7"> </text>
<text top="475" left="27" width="373" height="21" font="8"><b>Data Supplement 14. Nonadherence (Section 7.3.1.1) </b></text>
<text top="497" left="50" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="516" left="51" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="516" left="191" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="516" left="315" width="70" height="17" font="15"><b>Study Type </b></text>
<text top="497" left="410" width="38" height="17" font="15"><b>Study </b></text>
<text top="516" left="415" width="28" height="17" font="15"><b>Size </b></text>
<text top="516" left="523" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="516" left="783" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="516" left="953" width="171" height="17" font="15"><b>Statistical Analysis (Results) </b></text>
<text top="516" left="1184" width="106" height="17" font="15"><b>Study Limitations </b></text>
<text top="497" left="1371" width="58" height="17" font="15"><b>Findings/ </b></text>
<text top="516" left="1366" width="67" height="17" font="15"><b>Comments </b></text>
<text top="552" left="491" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="572" left="496" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="552" left="606" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="572" left="613" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="552" left="729" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="572" left="726" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="552" left="840" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="572" left="845" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="607" left="28" width="95" height="17" font="15"><b>Noncompliance </b></text>
</page>
<page number="39" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">39</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="112" height="17" font="13">Use of telehealth by </text>
<text top="72" left="28" width="81" height="17" font="13">older adults to </text>
<text top="89" left="28" width="119" height="17" font="13">manage HF. Dansky, </text>
<text top="106" left="28" width="46" height="17" font="13">K. 2008 </text>
<text top="124" left="28" width="55" height="17" font="14">20078015</text>
<text top="124" left="83" width="36" height="17" font="13"> (110) </text>
<text top="55" left="163" width="101" height="17" font="13">To investigate the </text>
<text top="72" left="163" width="123" height="17" font="13">influence of telehealth </text>
<text top="89" left="163" width="129" height="17" font="13">on self-management of </text>
<text top="106" left="163" width="103" height="17" font="13">HF in older adults. </text>
<text top="55" left="311" width="178" height="17" font="13">RCT 284 </text>
<text top="55" left="468" width="76" height="17" font="13">Admitted to a </text>
<text top="72" left="468" width="71" height="17" font="13">home health </text>
<text top="89" left="468" width="47" height="17" font="13">agency, </text>
<text top="106" left="468" width="60" height="17" font="13">Primary or </text>
<text top="124" left="468" width="60" height="17" font="13">secondary </text>
<text top="141" left="468" width="89" height="17" font="13">diagnosis of HF </text>
<text top="55" left="584" width="85" height="17" font="13">None specified </text>
<text top="55" left="702" width="101" height="17" font="13">Self-management </text>
<text top="72" left="702" width="37" height="17" font="13">of HF. </text>
<text top="55" left="819" width="27" height="17" font="13"> N/A </text>
<text top="55" left="940" width="176" height="17" font="13">Confidence is a predictor of self-</text>
<text top="72" left="940" width="135" height="17" font="13">management behaviors. </text>
<text top="89" left="940" width="3" height="17" font="13"> </text>
<text top="106" left="940" width="191" height="17" font="13">Pts using a video-based telehealth </text>
<text top="124" left="940" width="183" height="17" font="13">system showed the greatest gain </text>
<text top="141" left="940" width="184" height="17" font="13">in confidence levels with time (p= </text>
<text top="158" left="940" width="42" height="17" font="13">0.035). </text>
<text top="55" left="1149" width="106" height="17" font="13">Small sample size. </text>
<text top="72" left="1149" width="175" height="17" font="13">The home health agencies may </text>
<text top="89" left="1149" width="137" height="17" font="13">have limited the external </text>
<text top="106" left="1149" width="111" height="17" font="13">validity of the study. </text>
<text top="124" left="1149" width="159" height="17" font="13">Examination of the effects of </text>
<text top="141" left="1149" width="167" height="17" font="13">the telehealth interventions on </text>
<text top="158" left="1149" width="147" height="17" font="13">specific behaviors was not </text>
<text top="175" left="1149" width="52" height="17" font="13">possible. </text>
<text top="55" left="1338" width="88" height="17" font="13">Confidence is a </text>
<text top="72" left="1338" width="110" height="17" font="13">positive predictor of </text>
<text top="89" left="1338" width="102" height="17" font="13">self-management, </text>
<text top="106" left="1338" width="74" height="17" font="13">which should </text>
<text top="124" left="1338" width="82" height="17" font="13">encourage the </text>
<text top="141" left="1338" width="87" height="17" font="13">development of </text>
<text top="158" left="1338" width="97" height="17" font="13">interventions that </text>
<text top="175" left="1338" width="119" height="17" font="13">focus on building self-</text>
<text top="192" left="1338" width="123" height="17" font="13">care confidence in HF </text>
<text top="210" left="1338" width="100" height="17" font="13">pts. These results </text>
<text top="227" left="1338" width="77" height="17" font="13">contradict the </text>
<text top="244" left="1338" width="116" height="17" font="13">stereotype that older </text>
<text top="261" left="1338" width="112" height="17" font="13">adults are unable or </text>
<text top="278" left="1338" width="87" height="17" font="13">unwilling to use </text>
<text top="296" left="1338" width="66" height="17" font="13">technology. </text>
<text top="329" left="28" width="109" height="17" font="13">Characteristics and </text>
<text top="346" left="28" width="112" height="17" font="13">inhospital outcomes </text>
<text top="363" left="28" width="110" height="17" font="13">for nonadherent pts </text>
<text top="380" left="28" width="94" height="17" font="13">with HF: findings </text>
<text top="398" left="28" width="94" height="17" font="13">from GWTG-HF. </text>
<text top="415" left="28" width="120" height="17" font="13">Ambardekar, A. 2009 </text>
<text top="432" left="28" width="55" height="17" font="14">19781426</text>
<text top="432" left="83" width="36" height="17" font="13"> (111) </text>
<text top="329" left="163" width="96" height="17" font="13">To determine the </text>
<text top="346" left="163" width="85" height="17" font="13">characteristics, </text>
<text top="363" left="163" width="117" height="17" font="13">treatments, quality of </text>
<text top="380" left="163" width="110" height="17" font="13">care, and inhospital </text>
<text top="398" left="163" width="90" height="17" font="13">outcomes of pts </text>
<text top="415" left="163" width="127" height="17" font="13">nonadherent to dietary </text>
<text top="432" left="163" width="126" height="17" font="13">and medication advice </text>
<text top="449" left="163" width="126" height="17" font="13">as precipitating factors </text>
<text top="466" left="163" width="122" height="17" font="13">for HF hospitalization. </text>
<text top="329" left="311" width="73" height="17" font="13">Cohort study </text>
<text top="329" left="402" width="41" height="17" font="13">54,322 </text>
<text top="329" left="468" width="79" height="17" font="13">Ages &gt;18, pts </text>
<text top="346" left="468" width="83" height="17" font="13">reported in the </text>
<text top="363" left="468" width="62" height="17" font="13">GWTG-HF </text>
<text top="380" left="468" width="82" height="17" font="13">database from </text>
<text top="398" left="468" width="92" height="17" font="13">January 1, 2005-</text>
<text top="415" left="468" width="81" height="17" font="13">December 30, </text>
<text top="432" left="468" width="31" height="17" font="13">2007 </text>
<text top="329" left="584" width="72" height="17" font="13">Pts with new </text>
<text top="346" left="584" width="93" height="17" font="13">diagnoses of HF </text>
<text top="329" left="702" width="92" height="17" font="13">2 groups: Those </text>
<text top="346" left="702" width="49" height="17" font="13">in whom </text>
<text top="363" left="702" width="82" height="17" font="13">nonadherence </text>
<text top="380" left="702" width="98" height="17" font="13">contributed to HF </text>
<text top="398" left="702" width="83" height="17" font="13">admission and </text>
<text top="415" left="702" width="76" height="17" font="13">those without </text>
<text top="432" left="702" width="85" height="17" font="13">nonadherence. </text>
<text top="329" left="819" width="105" height="17" font="13">Hospital outcomes </text>
<text top="346" left="819" width="104" height="17" font="13">and quality of care </text>
<text top="363" left="819" width="41" height="17" font="13">among </text>
<text top="380" left="819" width="92" height="17" font="13">nonadherent pts </text>
<text top="398" left="819" width="109" height="17" font="13">vs. those who were </text>
<text top="415" left="819" width="55" height="17" font="13">adherent. </text>
<text top="329" left="940" width="128" height="17" font="13">Multivariate analysis of </text>
<text top="346" left="940" width="181" height="17" font="13">characteristics of nonadherence: </text>
<text top="363" left="940" width="170" height="17" font="13">Younger age (per y decrease)  </text>
<text top="395" left="940" width="182" height="17" font="13">p&lt;0.0001; 95% CI: 1.019-1.026;  </text>
<text top="427" left="940" width="143" height="17" font="13">Male gender (vs. female)  </text>
<text top="460" left="940" width="186" height="17" font="13">p&lt;0.0001; 95% CI: (1.196-1.358); </text>
<text top="477" left="940" width="145" height="17" font="13">Nonwhite race (vs. white)  </text>
<text top="509" left="940" width="175" height="17" font="13">p&lt;0.0001; 95% CI: 1.358-1.632 </text>
<text top="526" left="940" width="136" height="17" font="13">No health insurance (vs. </text>
<text top="543" left="940" width="61" height="17" font="13">insurance) </text>
<text top="576" left="940" width="175" height="17" font="13">p&lt;0.0001; 95% CI: 1.236-1.633 </text>
<text top="608" left="940" width="185" height="17" font="13">Multivariate analysis of outcomes </text>
<text top="625" left="940" width="176" height="17" font="13">with vs. without nonadherence:  </text>
<text top="657" left="940" width="143" height="17" font="13">Mortality 1.55% v. 3.49%; </text>
<text top="690" left="940" width="158" height="17" font="13">p&lt;0.0001 95% CI: 0.51-0.86 </text>
<text top="707" left="940" width="198" height="17" font="13">Mean length of stay 4.99 d vs. 5.63  </text>
<text top="724" left="940" width="164" height="17" font="13">p= 0.0017; 95% CI: 0.92-0.97 </text>
<text top="329" left="1149" width="175" height="17" font="13">Rates of nonadherence may be </text>
<text top="346" left="1149" width="148" height="17" font="13">underestimated due to self </text>
<text top="363" left="1149" width="169" height="17" font="13">reporting and biased based on </text>
<text top="380" left="1149" width="174" height="17" font="13">pt characteristics. GWTG-HF is </text>
<text top="398" left="1149" width="162" height="17" font="13">a voluntary program so could </text>
<text top="415" left="1149" width="173" height="17" font="13">over-represent high-performing </text>
<text top="432" left="1149" width="153" height="17" font="13">hospitals. Data collected by </text>
<text top="449" left="1149" width="165" height="17" font="13">chart reviews, only in-hospital </text>
<text top="466" left="1149" width="174" height="17" font="13">measures were tracked so long </text>
<text top="483" left="1149" width="137" height="17" font="13">term follow-up unknown. </text>
<text top="329" left="1338" width="107" height="17" font="13">Nonadherence is a </text>
<text top="346" left="1338" width="111" height="17" font="13">common precipitant </text>
<text top="363" left="1338" width="103" height="17" font="13">for HF admission.  </text>
<text top="380" left="1338" width="63" height="17" font="13">Medication </text>
<text top="398" left="1338" width="82" height="17" font="13">nonadherence </text>
<text top="415" left="1338" width="103" height="17" font="13">greater in younger </text>
<text top="432" left="1338" width="115" height="17" font="13">pts, ethnic minorities </text>
<text top="449" left="1338" width="81" height="17" font="13">and uninsured </text>
<text top="466" left="1338" width="90" height="17" font="13">whereas dietary </text>
<text top="484" left="1338" width="107" height="17" font="13">nonadherence was </text>
<text top="501" left="1338" width="101" height="17" font="13">observed in older, </text>
<text top="518" left="1338" width="87" height="17" font="13">overweight and </text>
<text top="535" left="1338" width="72" height="17" font="13">diabetic pts.  </text>
<text top="552" left="1338" width="94" height="17" font="13">Nonadherent pts </text>
<text top="570" left="1338" width="122" height="17" font="13">present with evidence </text>
<text top="587" left="1338" width="90" height="17" font="13">of lower EF and </text>
<text top="604" left="1338" width="86" height="17" font="13">greater volume </text>
<text top="621" left="1338" width="118" height="17" font="13">overload yet have an </text>
<text top="638" left="1338" width="96" height="17" font="13">inhospital course </text>
<text top="656" left="1338" width="104" height="17" font="13">characterized by a </text>
<text top="673" left="1338" width="94" height="17" font="13">shorter LOS and </text>
<text top="690" left="1338" width="120" height="17" font="13">lower mortality.  Care </text>
<text top="707" left="1338" width="106" height="17" font="13">of nonadherent pts </text>
<text top="725" left="1338" width="116" height="17" font="13">conformed with Joint </text>
<text top="742" left="1338" width="98" height="17" font="13">Commission core </text>
<text top="759" left="1338" width="92" height="17" font="13">measures but at </text>
<text top="776" left="1338" width="120" height="17" font="13">lower rates with other </text>
</page>
<page number="40" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">40</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1338" width="90" height="17" font="13">guideline-based </text>
<text top="72" left="1338" width="57" height="17" font="13">therapies. </text>
<text top="105" left="28" width="94" height="17" font="13">Utilization of and </text>
<text top="122" left="28" width="103" height="17" font="13">adherence to drug </text>
<text top="139" left="28" width="85" height="17" font="13">therapy among </text>
<text top="157" left="28" width="53" height="17" font="13">Medicaid </text>
<text top="174" left="28" width="98" height="17" font="13">beneficiaries with </text>
<text top="191" left="28" width="92" height="17" font="13">CHF. Bagchi, A. </text>
<text top="208" left="28" width="31" height="17" font="13">2007 </text>
<text top="225" left="28" width="55" height="17" font="14">17919558</text>
<text top="225" left="83" width="36" height="17" font="13"> (112) </text>
<text top="105" left="163" width="96" height="17" font="13">To determine the </text>
<text top="122" left="163" width="111" height="17" font="13">number of Medicaid </text>
<text top="139" left="163" width="121" height="17" font="13">beneficiaries with HF, </text>
<text top="157" left="163" width="121" height="17" font="13">identify the rate of HF </text>
<text top="174" left="163" width="105" height="17" font="13">drug use, estimate </text>
<text top="191" left="163" width="96" height="17" font="13">adherence rates, </text>
<text top="208" left="163" width="90" height="17" font="13">examine factors </text>
<text top="225" left="163" width="107" height="17" font="13">associated with HF </text>
<text top="243" left="163" width="131" height="17" font="13">drug use and treatment </text>
<text top="260" left="163" width="133" height="17" font="13">adherence, and explore </text>
<text top="277" left="163" width="106" height="17" font="13">policy implications. </text>
<text top="105" left="311" width="27" height="17" font="13"> N/A </text>
<text top="105" left="402" width="41" height="17" font="13">45,572 </text>
<text top="105" left="468" width="48" height="17" font="13">Living in </text>
<text top="122" left="468" width="58" height="17" font="13">Arkansas, </text>
<text top="139" left="468" width="103" height="17" font="13">California, Indiana </text>
<text top="157" left="468" width="86" height="17" font="13">or New Jersey, </text>
<text top="174" left="468" width="99" height="17" font="13">enrolled in fee-for </text>
<text top="191" left="468" width="95" height="17" font="13">service Medicaid </text>
<text top="208" left="468" width="83" height="17" font="13">with pharmacy </text>
<text top="225" left="468" width="94" height="17" font="13">benefit coverage </text>
<text top="243" left="468" width="92" height="17" font="13">during 1998 and </text>
<text top="260" left="468" width="71" height="17" font="13">1999 or until </text>
<text top="277" left="468" width="34" height="17" font="13">death </text>
<text top="294" left="468" width="92" height="17" font="13">HF (hospitalized </text>
<text top="311" left="468" width="84" height="17" font="13">and diagnosed </text>
<text top="329" left="468" width="83" height="17" font="13">during 1998 or </text>
<text top="346" left="468" width="99" height="17" font="13">diagnosed on ≥ 2 </text>
<text top="363" left="468" width="95" height="17" font="13">ambulatory visits </text>
<text top="380" left="468" width="72" height="17" font="13">during 1998) </text>
<text top="105" left="584" width="91" height="17" font="13">Stays in nursing </text>
<text top="122" left="584" width="95" height="17" font="13">home facilities at </text>
<text top="139" left="584" width="87" height="17" font="13">any time during </text>
<text top="156" left="584" width="31" height="17" font="13">1999 </text>
<text top="105" left="702" width="100" height="17" font="13">Adherence based </text>
<text top="122" left="702" width="21" height="17" font="13">on: </text>
<text top="139" left="702" width="103" height="17" font="13">MPR (no. of d a pt </text>
<text top="157" left="702" width="87" height="17" font="13">is supplied with </text>
<text top="174" left="702" width="78" height="17" font="13">&gt;1 HF drug in </text>
<text top="191" left="702" width="98" height="17" font="13">relation to the no. </text>
<text top="208" left="702" width="91" height="17" font="13">of dbetween the </text>
<text top="225" left="702" width="92" height="17" font="13">pt's first and last </text>
<text top="243" left="702" width="67" height="17" font="13">prescription </text>
<text top="260" left="702" width="41" height="17" font="13">dates), </text>
<text top="277" left="702" width="81" height="17" font="13">MP (no.of d of </text>
<text top="294" left="702" width="100" height="17" font="13">continuous use of </text>
<text top="311" left="702" width="89" height="17" font="13">HF medications </text>
<text top="329" left="702" width="46" height="17" font="13">per mo) </text>
<text top="105" left="819" width="27" height="17" font="13"> N/A </text>
<text top="105" left="940" width="183" height="17" font="13">Odds of having a HF prescription </text>
<text top="122" left="940" width="169" height="17" font="13">claim were higher with people: </text>
<text top="139" left="940" width="110" height="17" font="13">Age 65-74 vs. &lt;65:  </text>
<text top="172" left="940" width="164" height="17" font="13">p&lt;0.01; 95% CI: 1.193- 1.344 </text>
<text top="189" left="940" width="110" height="17" font="13">Age 75-84 vs. &lt;65:  </text>
<text top="221" left="940" width="168" height="17" font="13">p&lt;0.01;  95% CI: 1.458- 1.676 </text>
<text top="238" left="940" width="100" height="17" font="13">Age &gt;85 vs. &lt;65:  </text>
<text top="270" left="940" width="164" height="17" font="13">p&lt;0.01; 95% CI: 1.162, 1.353 </text>
<text top="303" left="940" width="3" height="17" font="13"> </text>
<text top="320" left="940" width="82" height="17" font="13">Dual Eligible :  </text>
<text top="352" left="940" width="164" height="17" font="13">p&lt;0.01;  95% CI: 1.466-1.580 </text>
<text top="369" left="940" width="58" height="17" font="13">Disabled:  </text>
<text top="401" left="940" width="164" height="17" font="13">p&lt;0.01;  95% CI: 1.388-1.537 </text>
<text top="419" left="940" width="66" height="17" font="13">Had CAD :  </text>
<text top="451" left="940" width="164" height="17" font="13">p&lt;0.01;  95% CI: 3.309-3.676 </text>
<text top="483" left="940" width="55" height="17" font="13">Had DM:  </text>
<text top="500" left="940" width="164" height="17" font="13">p&lt;0.01  95% CI: 2.085- 2.284 </text>
<text top="517" left="940" width="155" height="17" font="13">Hospitalized for HF in 1998: </text>
<text top="535" left="940" width="161" height="17" font="13">p&lt;0.01; 95% CI: 1.579-1.701 </text>
<text top="552" left="940" width="3" height="17" font="13"> </text>
<text top="569" left="940" width="183" height="17" font="13">Odds of having a HF prescription </text>
<text top="586" left="940" width="144" height="17" font="13">claim were lower among - </text>
<text top="604" left="940" width="104" height="17" font="13">Blacks vs. whites:  </text>
<text top="621" left="940" width="164" height="17" font="13">p&lt;0.01;  95% CI: 0.735-0.795 </text>
<text top="638" left="940" width="180" height="17" font="13">Other /unknown ethnic group vs. </text>
<text top="655" left="940" width="45" height="17" font="13">whites:  </text>
<text top="672" left="940" width="164" height="17" font="13">p&lt;0.01  95% CI: 0.840,-0.919 </text>
<text top="690" left="940" width="96" height="17" font="13">Men vs. women:  </text>
<text top="707" left="940" width="161" height="17" font="13">p&lt;0.01  95% CI: 0.722-0.775 </text>
<text top="724" left="940" width="3" height="17" font="13"> </text>
<text top="741" left="940" width="187" height="17" font="13">Adherence better among age &gt;85 </text>
<text top="759" left="940" width="175" height="17" font="13">y than &lt;64 y, men than women, </text>
<text top="776" left="940" width="179" height="17" font="13">racial and ethnic minorities, dual </text>
<text top="105" left="1149" width="118" height="17" font="13">Measures of use and </text>
<text top="122" left="1149" width="163" height="17" font="13">adherence are proxies based </text>
<text top="139" left="1149" width="159" height="17" font="13">on prescriptions filled versus </text>
<text top="157" left="1149" width="149" height="17" font="13">observations; findings may </text>
<text top="174" left="1149" width="169" height="17" font="13">overestimate adherence to HF </text>
<text top="191" left="1149" width="72" height="17" font="13">medications. </text>
<text top="208" left="1149" width="165" height="17" font="13">Diagnoses recorded in claims </text>
<text top="225" left="1149" width="173" height="17" font="13">may be incomplete, resulting in </text>
<text top="243" left="1149" width="167" height="17" font="13">the omission of some pts from </text>
<text top="260" left="1149" width="57" height="17" font="13">the study. </text>
<text top="277" left="1149" width="165" height="17" font="13">Limited number of states may </text>
<text top="294" left="1149" width="129" height="17" font="13">lead to biased results if </text>
<text top="311" left="1149" width="171" height="17" font="13">Medicaid beneficiaries in study </text>
<text top="329" left="1149" width="164" height="17" font="13">states are different than other </text>
<text top="346" left="1149" width="40" height="17" font="13">states. </text>
<text top="105" left="1338" width="112" height="17" font="13">15.2% of diagnosed </text>
<text top="122" left="1338" width="123" height="17" font="13">beneficiaries were not </text>
<text top="139" left="1338" width="76" height="17" font="13">using any HF </text>
<text top="157" left="1338" width="110" height="17" font="13">medications. Adults </text>
<text top="174" left="1338" width="104" height="17" font="13">&lt;65 y, men, ethnic </text>
<text top="191" left="1338" width="81" height="17" font="13">minorities with </text>
<text top="208" left="1338" width="111" height="17" font="13">hospital admissions </text>
<text top="225" left="1338" width="108" height="17" font="13">for conditions other </text>
<text top="243" left="1338" width="75" height="17" font="13">than HF, and </text>
<text top="260" left="1338" width="98" height="17" font="13">beneficiaries with </text>
<text top="277" left="1338" width="104" height="17" font="13">high CDPS scores </text>
<text top="294" left="1338" width="122" height="17" font="13">had lower adherence. </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">41</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="940" width="177" height="17" font="13">eligible and disabled, those with </text>
<text top="72" left="940" width="189" height="17" font="13">CAD or DM, those with HF related </text>
<text top="89" left="940" width="134" height="17" font="13">hospitalization (p&lt;0.01). </text>
<text top="106" left="940" width="3" height="17" font="13"> </text>
<text top="124" left="940" width="196" height="17" font="13">Adherence lower among those with </text>
<text top="141" left="940" width="170" height="17" font="13">larger proportions of claims for </text>
<text top="158" left="940" width="176" height="17" font="13">generic HF drugs, higher CDPS </text>
<text top="175" left="940" width="190" height="17" font="13">risk scores and those with non-HF-</text>
<text top="192" left="940" width="184" height="17" font="13">related Hospitalizations (p&lt;0.01). </text>
<text top="225" left="28" width="118" height="17" font="13">Drug copayment and </text>
<text top="243" left="28" width="118" height="17" font="13">adherence in chronic </text>
<text top="260" left="28" width="100" height="17" font="13">HF: effect on cost </text>
<text top="277" left="28" width="116" height="17" font="13">and outcomes. Cole, </text>
<text top="294" left="28" width="46" height="17" font="13">A. 2006 </text>
<text top="311" left="28" width="55" height="17" font="14">16863491</text>
<text top="311" left="83" width="36" height="17" font="13"> (113) </text>
<text top="225" left="163" width="90" height="17" font="13">To measure the </text>
<text top="243" left="163" width="112" height="17" font="13">associations among </text>
<text top="260" left="163" width="134" height="17" font="13">prescription copayment, </text>
<text top="277" left="163" width="113" height="17" font="13">drug adherence and </text>
<text top="294" left="163" width="104" height="17" font="13">subsequent health </text>
<text top="311" left="163" width="135" height="17" font="13">outcomes in pts with HF </text>
<text top="225" left="311" width="79" height="17" font="13">Retrospective </text>
<text top="243" left="311" width="75" height="17" font="13">Cohort Study </text>
<text top="225" left="402" width="34" height="17" font="13">5,259 </text>
<text top="243" left="402" width="53" height="17" font="13">receiving </text>
<text top="260" left="402" width="29" height="17" font="13">ACE </text>
<text top="277" left="402" width="47" height="17" font="13">inhibitor </text>
<text top="294" left="402" width="3" height="17" font="13"> </text>
<text top="311" left="402" width="34" height="17" font="13">5,144 </text>
<text top="329" left="402" width="53" height="17" font="13">receiving </text>
<text top="346" left="402" width="29" height="17" font="13">Beta </text>
<text top="363" left="402" width="51" height="17" font="13">Blockers </text>
<text top="380" left="402" width="3" height="17" font="13"> </text>
<text top="398" left="402" width="34" height="17" font="13">2,373 </text>
<text top="415" left="402" width="53" height="17" font="13">receiving </text>
<text top="432" left="402" width="27" height="17" font="13">both </text>
<text top="225" left="468" width="57" height="17" font="13">In Ingenix </text>
<text top="243" left="468" width="85" height="17" font="13">Research Data </text>
<text top="260" left="468" width="92" height="17" font="13">Mart, diagnosed </text>
<text top="277" left="468" width="73" height="17" font="13">with HF, and </text>
<text top="294" left="468" width="60" height="17" font="13">enrolled in </text>
<text top="311" left="468" width="66" height="17" font="13">commercial </text>
<text top="329" left="468" width="92" height="17" font="13">and/or Medicare </text>
<text top="346" left="468" width="76" height="17" font="13">supplemental </text>
<text top="363" left="468" width="80" height="17" font="13">plans in 2002; </text>
<text top="380" left="468" width="73" height="17" font="13">≥2 physician </text>
<text top="398" left="468" width="45" height="17" font="13">visits or </text>
<text top="415" left="468" width="87" height="17" font="13">hospitalizations </text>
<text top="432" left="468" width="88" height="17" font="13">related to HF in </text>
<text top="449" left="468" width="34" height="17" font="13">2002; </text>
<text top="466" left="468" width="85" height="17" font="13">$100-10,000 in </text>
<text top="484" left="468" width="94" height="17" font="13">costs associated </text>
<text top="501" left="468" width="45" height="17" font="13">with HF </text>
<text top="518" left="468" width="72" height="17" font="13">diagnoses in </text>
<text top="535" left="468" width="34" height="17" font="13">2002; </text>
<text top="552" left="468" width="72" height="17" font="13">continuously </text>
<text top="570" left="468" width="97" height="17" font="13">enrolled in health </text>
<text top="587" left="468" width="74" height="17" font="13">plan for all of </text>
<text top="604" left="468" width="98" height="17" font="13">2002 and at least </text>
<text top="621" left="468" width="68" height="17" font="13">1 d in 2003. </text>
<text top="638" left="468" width="98" height="17" font="13">ACEI and/or beta </text>
<text top="656" left="468" width="49" height="17" font="13">blockers </text>
<text top="673" left="468" width="103" height="17" font="13">dispensed at least </text>
<text top="690" left="468" width="35" height="17" font="13">twice. </text>
<text top="225" left="584" width="68" height="17" font="13">Receiving 1 </text>
<text top="243" left="584" width="76" height="17" font="13">dispensing of </text>
<text top="260" left="584" width="36" height="17" font="13">ACEI, </text>
<text top="277" left="584" width="63" height="17" font="13">receiving 1 </text>
<text top="294" left="584" width="103" height="17" font="13">dispensing of beta </text>
<text top="311" left="584" width="76" height="17" font="13">blockers, had </text>
<text top="329" left="584" width="87" height="17" font="13">switched ACEI, </text>
<text top="346" left="584" width="103" height="17" font="13">had switched beta </text>
<text top="363" left="584" width="83" height="17" font="13">blockers, MPR </text>
<text top="380" left="584" width="95" height="17" font="13">&lt;20% or &gt;120%, </text>
<text top="398" left="584" width="82" height="17" font="13">had conflicting </text>
<text top="415" left="584" width="68" height="17" font="13">data in their </text>
<text top="432" left="584" width="62" height="17" font="13">dispensing </text>
<text top="449" left="584" width="44" height="17" font="13">records </text>
<text top="225" left="702" width="70" height="17" font="13">Total cost of </text>
<text top="243" left="702" width="88" height="17" font="13">health care and </text>
<text top="260" left="702" width="99" height="17" font="13">hospitalization for </text>
<text top="277" left="702" width="54" height="17" font="13">HF MPR: </text>
<text top="294" left="702" width="93" height="17" font="13">proportion of d a </text>
<text top="311" left="702" width="103" height="17" font="13">pt was exposed to </text>
<text top="329" left="702" width="70" height="17" font="13">a drug while </text>
<text top="346" left="702" width="63" height="17" font="13">receiving a </text>
<text top="363" left="702" width="48" height="17" font="13">regimen </text>
<text top="225" left="819" width="27" height="17" font="13"> N/A </text>
<text top="225" left="940" width="148" height="17" font="13">For pts taking ACEI, a $10 </text>
<text top="243" left="940" width="152" height="17" font="13">increase in copayment was </text>
<text top="260" left="940" width="183" height="17" font="13">associated with a 2.6% decrease </text>
<text top="277" left="940" width="159" height="17" font="13">in MPR (95% CI: 2.0 - 3.1%) </text>
<text top="294" left="940" width="3" height="17" font="13"> </text>
<text top="311" left="940" width="170" height="17" font="13">This change in adherence was </text>
<text top="329" left="940" width="91" height="17" font="13">associated with: </text>
<text top="346" left="940" width="163" height="17" font="13">a predicted 0.8% decrease in </text>
<text top="363" left="940" width="161" height="17" font="13">medical costs (95 %CI: -4.2 - </text>
<text top="380" left="940" width="36" height="17" font="13">2.5%) </text>
<text top="398" left="940" width="179" height="17" font="13">a predicted 6.1% increase in the </text>
<text top="415" left="940" width="178" height="17" font="13">risk of hospitalization for chronic </text>
<text top="432" left="940" width="138" height="17" font="13">HF (95% CI: 0.5 - 12%).  </text>
<text top="449" left="940" width="3" height="17" font="13"> </text>
<text top="466" left="940" width="192" height="17" font="13">For pts taking beta blockers, a $10 </text>
<text top="484" left="940" width="152" height="17" font="13">increase in copayment was </text>
<text top="501" left="940" width="183" height="17" font="13">associated with a 1.8% decrease </text>
<text top="518" left="940" width="159" height="17" font="13">in MPR (95% CI: 1.4 - 2.2%) </text>
<text top="535" left="940" width="3" height="17" font="13"> </text>
<text top="552" left="940" width="170" height="17" font="13">This change in adherence was </text>
<text top="570" left="940" width="91" height="17" font="13">associated with: </text>
<text top="587" left="940" width="163" height="17" font="13">a predicted 2.8% decrease in </text>
<text top="604" left="940" width="161" height="17" font="13">medical costs (95% CI: -5.9 - </text>
<text top="621" left="940" width="42" height="17" font="13">0.1%).  </text>
<text top="638" left="940" width="179" height="17" font="13">a predicted 8.7% increase in the </text>
<text top="656" left="940" width="178" height="17" font="13">risk of hospitalization for chronic </text>
<text top="673" left="940" width="142" height="17" font="13">HF (95% CI: 3.8 - 13.8%) </text>
<text top="225" left="1149" width="164" height="17" font="13">Using prescription dispensing </text>
<text top="243" left="1149" width="172" height="17" font="13">data to assess drug adherence </text>
<text top="260" left="1149" width="167" height="17" font="13">eliminates pts to whom a drug </text>
<text top="277" left="1149" width="171" height="17" font="13">is dispensed only once so may </text>
<text top="294" left="1149" width="135" height="17" font="13">have contributed to high </text>
<text top="311" left="1149" width="119" height="17" font="13">adherence observed. </text>
<text top="329" left="1149" width="142" height="17" font="13">Dispensing data does not </text>
<text top="346" left="1149" width="121" height="17" font="13">capture actual usage. </text>
<text top="363" left="1149" width="150" height="17" font="13">ACEI more expensive than </text>
<text top="380" left="1149" width="139" height="17" font="13">beta blockers resulting in </text>
<text top="398" left="1149" width="105" height="17" font="13">higher copayment. </text>
<text top="415" left="1149" width="172" height="17" font="13">Total medical costs might have </text>
<text top="432" left="1149" width="150" height="17" font="13">been insensitive to specific </text>
<text top="449" left="1149" width="158" height="17" font="13">changes in adherence to HF </text>
<text top="466" left="1149" width="57" height="17" font="13">therapies. </text>
<text top="225" left="1338" width="111" height="17" font="13">Among pts with HF, </text>
<text top="243" left="1338" width="66" height="17" font="13">higher drug </text>
<text top="260" left="1338" width="100" height="17" font="13">copayments were </text>
<text top="277" left="1338" width="87" height="17" font="13">associated with </text>
<text top="294" left="1338" width="104" height="17" font="13">poorer adherence, </text>
<text top="311" left="1338" width="71" height="17" font="13">although the </text>
<text top="329" left="1338" width="118" height="17" font="13">magnitude of change </text>
<text top="346" left="1338" width="122" height="17" font="13">was small and did not </text>
<text top="363" left="1338" width="97" height="17" font="13">affect total health </text>
<text top="380" left="1338" width="99" height="17" font="13">care costs. It was </text>
<text top="398" left="1338" width="116" height="17" font="13">sufficient to increase </text>
<text top="415" left="1338" width="118" height="17" font="13">risk of hospitalization </text>
<text top="432" left="1338" width="82" height="17" font="13">for HF though. </text>
</page>
<page number="42" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">42</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="78" height="17" font="13">The impact of </text>
<text top="72" left="28" width="104" height="17" font="13">perceived adverse </text>
<text top="89" left="28" width="120" height="17" font="13">effects on medication </text>
<text top="106" left="28" width="106" height="17" font="13">changes in HF pts. </text>
<text top="124" left="28" width="108" height="17" font="13">De Smedt, R. 2010 </text>
<text top="141" left="28" width="55" height="17" font="14">20142025</text>
<text top="141" left="83" width="36" height="17" font="13"> (114) </text>
<text top="55" left="163" width="128" height="17" font="13">To evaluate the impact </text>
<text top="72" left="163" width="118" height="17" font="13">of perceived adverse </text>
<text top="89" left="163" width="87" height="17" font="13">HF drug effects </text>
<text top="55" left="311" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="311" width="75" height="17" font="13">Cohort Study </text>
<text top="55" left="402" width="24" height="17" font="13">754 </text>
<text top="55" left="468" width="88" height="17" font="13">Hospitalized for </text>
<text top="72" left="468" width="92" height="17" font="13">symptomatic HF </text>
<text top="89" left="468" width="95" height="17" font="13">NYHA class II-IV </text>
<text top="106" left="468" width="50" height="17" font="13">Age &gt;18 </text>
<text top="124" left="468" width="68" height="17" font="13">Evidence of </text>
<text top="141" left="468" width="54" height="17" font="13">structural </text>
<text top="158" left="468" width="92" height="17" font="13">underlying heart </text>
<text top="175" left="468" width="46" height="17" font="13">disease </text>
<text top="55" left="584" width="48" height="17" font="13">Invasive </text>
<text top="72" left="584" width="98" height="17" font="13">procedures in the </text>
<text top="89" left="584" width="73" height="17" font="13">mo before or </text>
<text top="106" left="584" width="92" height="17" font="13">planned within 3 </text>
<text top="124" left="584" width="98" height="17" font="13">mo after baseline </text>
<text top="141" left="584" width="105" height="17" font="13">Already enrolled in </text>
<text top="158" left="584" width="74" height="17" font="13">other studies </text>
<text top="175" left="584" width="57" height="17" font="13">Follow-up </text>
<text top="192" left="584" width="69" height="17" font="13">treatment at </text>
<text top="210" left="584" width="96" height="17" font="13">another HF clinic </text>
<text top="55" left="702" width="54" height="17" font="13">Impact of </text>
<text top="72" left="702" width="104" height="17" font="13">perceived adverse </text>
<text top="89" left="702" width="57" height="17" font="13">effects on </text>
<text top="106" left="702" width="79" height="17" font="13">likelihood and </text>
<text top="124" left="702" width="104" height="17" font="13">type of changes of </text>
<text top="141" left="702" width="89" height="17" font="13">potential causal </text>
<text top="158" left="702" width="83" height="17" font="13">cardiovascular </text>
<text top="175" left="702" width="74" height="17" font="13">medication &amp; </text>
<text top="192" left="702" width="62" height="17" font="13">initiation of </text>
<text top="210" left="702" width="76" height="17" font="13">medication to </text>
<text top="227" left="702" width="69" height="17" font="13">alleviate the </text>
<text top="244" left="702" width="84" height="17" font="13">adverse effect. </text>
<text top="55" left="819" width="7" height="17" font="13">  </text>
<text top="55" left="940" width="155" height="17" font="13">Risk of a related medication </text>
<text top="72" left="940" width="196" height="17" font="13">change significantly increased after </text>
<text top="89" left="940" width="180" height="17" font="13">dry cough, nausea, dizziness, or </text>
<text top="106" left="940" width="180" height="17" font="13">diarrhea. Dry cough showing the </text>
<text top="124" left="940" width="195" height="17" font="13">highest increase in risk (83%; 95%  </text>
<text top="141" left="940" width="79" height="17" font="13">CI: 1.35-2.49) </text>
<text top="158" left="940" width="3" height="17" font="13"> </text>
<text top="175" left="940" width="180" height="17" font="13">Pts with gout had a 4-fold higher </text>
<text top="192" left="940" width="166" height="17" font="13">likelihood of having alleviating </text>
<text top="210" left="940" width="177" height="17" font="13">medication started or intensified </text>
<text top="227" left="940" width="111" height="17" font="13">(95% CI: 2.23-8.05) </text>
<text top="259" left="940" width="190" height="17" font="13">With dry cough, a 10-fold increase </text>
<text top="276" left="940" width="170" height="17" font="13">in the likelihood of having ACE </text>
<text top="293" left="940" width="189" height="17" font="13">inhibitor switched to an ARB (95% </text>
<text top="311" left="940" width="79" height="17" font="13">CI: 3.2-35.55) </text>
<text top="343" left="940" width="180" height="17" font="13">Pts with gout had a 3-fold higher </text>
<text top="360" left="940" width="157" height="17" font="13">likelihood of having diuretics </text>
<text top="377" left="940" width="161" height="17" font="13">temporarily discontinued and </text>
<text top="395" left="940" width="189" height="17" font="13">reinitiated at a lower dosage (95% </text>
<text top="412" left="940" width="85" height="17" font="13">CI: 1.09-10.04) </text>
<text top="55" left="1149" width="145" height="17" font="13">Cannot be certain that the </text>
<text top="72" left="1149" width="150" height="17" font="13">reported problems resulted </text>
<text top="89" left="1149" width="162" height="17" font="13">from medication. Focused on </text>
<text top="106" left="1149" width="157" height="17" font="13">specific medication changes </text>
<text top="124" left="1149" width="155" height="17" font="13">and did not take all possible </text>
<text top="141" left="1149" width="170" height="17" font="13">adequate actions into account. </text>
<text top="158" left="1149" width="163" height="17" font="13">Recall bias possible- pts may </text>
<text top="175" left="1149" width="172" height="17" font="13">not have reported all perceived </text>
<text top="192" left="1149" width="174" height="17" font="13">problems in the questionnaires. </text>
<text top="55" left="1338" width="85" height="17" font="13">A considerable </text>
<text top="72" left="1338" width="98" height="17" font="13">number of HF pts </text>
<text top="89" left="1338" width="105" height="17" font="13">perceived possible </text>
<text top="106" left="1338" width="122" height="17" font="13">AEs. The likelihood of </text>
<text top="124" left="1338" width="96" height="17" font="13">medication being </text>
<text top="141" left="1338" width="98" height="17" font="13">changed after pts </text>
<text top="158" left="1338" width="108" height="17" font="13">perceived AEs was </text>
<text top="175" left="1338" width="122" height="17" font="13">low. A high number of </text>
<text top="192" left="1338" width="70" height="17" font="13">pts perceive </text>
<text top="210" left="1338" width="86" height="17" font="13">medication AE. </text>
<text top="453" left="28" width="72" height="17" font="13">Associations </text>
<text top="470" left="28" width="101" height="17" font="13">between outpt HF </text>
<text top="487" left="28" width="89" height="17" font="13">process-of-care </text>
<text top="505" left="28" width="81" height="17" font="13">measures and </text>
<text top="522" left="28" width="108" height="17" font="13">mortality. Fonarow, </text>
<text top="539" left="28" width="47" height="17" font="13">G. 2011 </text>
<text top="556" left="28" width="55" height="17" font="14">21464053</text>
<text top="556" left="83" width="36" height="17" font="13"> (115) </text>
<text top="453" left="163" width="88" height="17" font="13">To examine the </text>
<text top="470" left="163" width="72" height="17" font="13">relationships </text>
<text top="487" left="163" width="125" height="17" font="13">between adherence to </text>
<text top="505" left="163" width="109" height="17" font="13">several current and </text>
<text top="522" left="163" width="55" height="17" font="13">emerging </text>
<text top="539" left="163" width="97" height="17" font="13">outpt HF process </text>
<text top="556" left="163" width="122" height="17" font="13">measures and clinical </text>
<text top="573" left="163" width="60" height="17" font="13">outcomes. </text>
<text top="453" left="311" width="73" height="17" font="13">Longitudinal/ </text>
<text top="470" left="311" width="49" height="17" font="13">Registry </text>
<text top="453" left="402" width="41" height="17" font="13">15,177 </text>
<text top="453" left="468" width="98" height="17" font="13">Clinical diagnosis </text>
<text top="470" left="468" width="96" height="17" font="13">of HF or post-MI, </text>
<text top="487" left="468" width="91" height="17" font="13">LVEF &lt;35%, ≥2 </text>
<text top="505" left="468" width="99" height="17" font="13">office visits with a </text>
<text top="522" left="468" width="99" height="17" font="13">cardiologist in the </text>
<text top="539" left="468" width="42" height="17" font="13">last 2 y </text>
<text top="453" left="584" width="105" height="17" font="13">Noncardiovascular </text>
<text top="470" left="584" width="98" height="17" font="13">medical condition </text>
<text top="487" left="584" width="105" height="17" font="13">associated with an </text>
<text top="505" left="584" width="102" height="17" font="13">estimated survival </text>
<text top="522" left="584" width="94" height="17" font="13">of &lt;1 y, received </text>
<text top="539" left="584" width="43" height="17" font="13">cardiac </text>
<text top="556" left="584" width="84" height="17" font="13">transplantation </text>
<text top="453" left="702" width="90" height="17" font="13">Process-of-care </text>
<text top="470" left="702" width="81" height="17" font="13">HF measures: </text>
<text top="487" left="702" width="90" height="17" font="13">ACE inhibitor or </text>
<text top="505" left="702" width="83" height="17" font="13">ARB use, beta </text>
<text top="522" left="702" width="70" height="17" font="13">blocker use, </text>
<text top="539" left="702" width="68" height="17" font="13">aldosterone </text>
<text top="556" left="702" width="87" height="17" font="13">antagonist use, </text>
<text top="573" left="702" width="77" height="17" font="13">anticoagulant </text>
<text top="591" left="702" width="96" height="17" font="13">therapy for AF or </text>
<text top="608" left="702" width="92" height="17" font="13">flutter, CRT with </text>
<text top="625" left="702" width="78" height="17" font="13">defibrillator or </text>
<text top="642" left="702" width="96" height="17" font="13">pacemaker, ICD, </text>
<text top="660" left="702" width="101" height="17" font="13">and HF education </text>
<text top="677" left="702" width="86" height="17" font="13">for eligible pts.  </text>
<text top="453" left="819" width="7" height="17" font="13">  </text>
<text top="453" left="940" width="147" height="17" font="13">Each 10% improvement in </text>
<text top="470" left="940" width="174" height="17" font="13">composite care was associated </text>
<text top="487" left="940" width="179" height="17" font="13">with a 13% lower odds of 24-mo </text>
<text top="505" left="940" width="191" height="17" font="13">mortality (p &lt;0.0001; 95% CI: 0.84-</text>
<text top="522" left="940" width="32" height="17" font="13">0.90) </text>
<text top="539" left="940" width="3" height="17" font="13"> </text>
<text top="556" left="940" width="164" height="17" font="13">All process measures, except </text>
<text top="573" left="940" width="185" height="17" font="13">aldosterone antagonist use, were </text>
<text top="591" left="940" width="172" height="17" font="13">each independently associated </text>
<text top="608" left="940" width="177" height="17" font="13">with improved 24-mo survival (p </text>
<text top="625" left="940" width="175" height="17" font="13">&lt;0.01 for all except aldosterone </text>
<text top="642" left="940" width="91" height="17" font="13">antagonist use). </text>
<text top="675" left="940" width="3" height="17" font="13"> </text>
<text top="692" left="940" width="3" height="17" font="13"> </text>
<text top="709" left="940" width="3" height="17" font="13"> </text>
<text top="726" left="940" width="3" height="17" font="13"> </text>
<text top="743" left="940" width="3" height="17" font="13"> </text>
<text top="760" left="940" width="3" height="17" font="13"> </text>
<text top="453" left="1149" width="152" height="17" font="13">Errors and omissions in the </text>
<text top="470" left="1149" width="162" height="17" font="13">medical chart review process </text>
<text top="487" left="1149" width="118" height="17" font="13">could have occurred. </text>
<text top="505" left="1149" width="176" height="17" font="13">NYHA functional status was not </text>
<text top="522" left="1149" width="137" height="17" font="13">quantified in many of the </text>
<text top="539" left="1149" width="140" height="17" font="13">records, and was instead </text>
<text top="556" left="1149" width="113" height="17" font="13">based on qualitative </text>
<text top="573" left="1149" width="126" height="17" font="13">description. This study </text>
<text top="591" left="1149" width="122" height="17" font="13">analyzed medications </text>
<text top="608" left="1149" width="174" height="17" font="13">prescribed rather than actual pt </text>
<text top="625" left="1149" width="164" height="17" font="13">adherence. Follow-up on vital </text>
<text top="642" left="1149" width="168" height="17" font="13">status was not achieved for all </text>
<text top="659" left="1149" width="107" height="17" font="13">pts. Race/ethnicity, </text>
<text top="677" left="1149" width="149" height="17" font="13">socioeconomic status or pt </text>
<text top="694" left="1149" width="176" height="17" font="13">adherence may be confounding </text>
<text top="711" left="1149" width="153" height="17" font="13">variables. Findings may not </text>
<text top="728" left="1149" width="154" height="17" font="13">apply to practices that differ </text>
<text top="746" left="1149" width="159" height="17" font="13">from the IMPROVE HF outpt </text>
<text top="763" left="1149" width="148" height="17" font="13">cardiology practices in this </text>
<text top="453" left="1338" width="65" height="17" font="13">These data </text>
<text top="470" left="1338" width="96" height="17" font="13">demonstrate that </text>
<text top="487" left="1338" width="95" height="17" font="13">adherence to HF </text>
<text top="505" left="1338" width="122" height="17" font="13">process measures for </text>
<text top="522" left="1338" width="92" height="17" font="13">ACEI/ARB, beta </text>
<text top="539" left="1338" width="46" height="17" font="13">blocker, </text>
<text top="556" left="1338" width="104" height="17" font="13">anticoagulation for </text>
<text top="573" left="1338" width="123" height="17" font="13">AF, and HF education </text>
<text top="591" left="1338" width="79" height="17" font="13">is significantly </text>
<text top="608" left="1338" width="87" height="17" font="13">associated with </text>
<text top="625" left="1338" width="120" height="17" font="13">survival in outpts with </text>
<text top="642" left="1338" width="81" height="17" font="13">HF. These HF </text>
<text top="659" left="1338" width="101" height="17" font="13">measures may be </text>
<text top="677" left="1338" width="112" height="17" font="13">useful for assessing </text>
<text top="694" left="1338" width="101" height="17" font="13">and improving HF </text>
<text top="711" left="1338" width="31" height="17" font="13">care. </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">43</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1149" width="36" height="17" font="13">study. </text>
<text top="88" left="28" width="83" height="17" font="13">A nurse-based </text>
<text top="105" left="28" width="75" height="17" font="13">management </text>
<text top="122" left="28" width="102" height="17" font="13">program in HF pts </text>
<text top="139" left="28" width="110" height="17" font="13">affects females and </text>
<text top="157" left="28" width="72" height="17" font="13">persons with </text>
<text top="174" left="28" width="118" height="17" font="13">cognitive dysfunction </text>
<text top="191" left="28" width="105" height="17" font="13">most. Karlsson, M. </text>
<text top="208" left="28" width="31" height="17" font="13">2005 </text>
<text top="225" left="28" width="55" height="17" font="14">16009290</text>
<text top="225" left="83" width="36" height="17" font="13"> (116) </text>
<text top="88" left="163" width="127" height="17" font="13">To assess the effect of </text>
<text top="105" left="163" width="82" height="17" font="13">a nurse-based </text>
<text top="122" left="163" width="124" height="17" font="13">management program </text>
<text top="139" left="163" width="130" height="17" font="13">aimed at increasing HF </text>
<text top="157" left="163" width="119" height="17" font="13">pts' knowledge about </text>
<text top="174" left="163" width="120" height="17" font="13">disease and self-care </text>
<text top="191" left="163" width="132" height="17" font="13">and to relate the results </text>
<text top="208" left="163" width="131" height="17" font="13">to gender and cognitive </text>
<text top="225" left="163" width="50" height="17" font="13">function. </text>
<text top="88" left="311" width="68" height="17" font="13">Substudy of </text>
<text top="105" left="311" width="78" height="17" font="13">the OPTIMAL </text>
<text top="122" left="311" width="55" height="17" font="13">project- a </text>
<text top="139" left="311" width="29" height="17" font="13">RCT </text>
<text top="88" left="402" width="24" height="17" font="13">208 </text>
<text top="88" left="468" width="50" height="17" font="13">Age &gt;60 </text>
<text top="105" left="468" width="46" height="17" font="13">Systolic </text>
<text top="122" left="468" width="66" height="17" font="13">dysfunction </text>
<text top="139" left="468" width="54" height="17" font="13">EF &lt;45% </text>
<text top="156" left="468" width="64" height="17" font="13">NYHA II-IV </text>
<text top="88" left="584" width="85" height="17" font="13">None specified </text>
<text top="88" left="702" width="91" height="17" font="13">Pt knowledge of </text>
<text top="105" left="702" width="98" height="17" font="13">HF and self-care. </text>
<text top="88" left="819" width="27" height="17" font="13"> N/A </text>
<text top="88" left="940" width="189" height="17" font="13">At baseline men knew more about </text>
<text top="105" left="940" width="188" height="17" font="13">HF compared to women (p&lt;0.01). </text>
<text top="122" left="940" width="3" height="17" font="13"> </text>
<text top="139" left="940" width="186" height="17" font="13">Females in the intervention group </text>
<text top="157" left="940" width="183" height="17" font="13">increased their knowledge of self-</text>
<text top="174" left="940" width="181" height="17" font="13">care between baseline and 6 mo </text>
<text top="191" left="940" width="173" height="17" font="13">compared to the female control </text>
<text top="208" left="940" width="91" height="17" font="13">group (p &lt;0.05). </text>
<text top="225" left="940" width="3" height="17" font="13"> </text>
<text top="243" left="940" width="164" height="17" font="13">Pts with cognitive dysfunction </text>
<text top="260" left="940" width="164" height="17" font="13">(MMSE &lt;24) presented lower </text>
<text top="277" left="940" width="193" height="17" font="13">scores on knowledge as compared </text>
<text top="294" left="940" width="175" height="17" font="13">to those with a MMSE of &gt;24 at </text>
<text top="311" left="940" width="154" height="17" font="13">baseline. These differences </text>
<text top="329" left="940" width="187" height="17" font="13">disappeared after the intervention </text>
<text top="346" left="940" width="53" height="17" font="13">(p&lt;0.01). </text>
<text top="88" left="1149" width="169" height="17" font="13">Some pts were included one d </text>
<text top="105" left="1149" width="133" height="17" font="13">after hospitalization and </text>
<text top="122" left="1149" width="163" height="17" font="13">some the d before discharge; </text>
<text top="139" left="1149" width="154" height="17" font="13">condition improvement may </text>
<text top="157" left="1149" width="143" height="17" font="13">explain low number of pts </text>
<text top="174" left="1149" width="171" height="17" font="13">scoring low on the MMSE; The </text>
<text top="191" left="1149" width="159" height="17" font="13">drop-out rate was high in the </text>
<text top="208" left="1149" width="100" height="17" font="13">MMSE sub-study. </text>
<text top="225" left="1149" width="3" height="17" font="13"> </text>
<text top="88" left="1338" width="105" height="17" font="13">Nurse-based outpt </text>
<text top="105" left="1338" width="107" height="17" font="13">clinic with specially </text>
<text top="122" left="1338" width="81" height="17" font="13">trained nurses </text>
<text top="139" left="1338" width="122" height="17" font="13">effective in increasing </text>
<text top="157" left="1338" width="110" height="17" font="13">pt knowledge about </text>
<text top="174" left="1338" width="105" height="17" font="13">self-care. Females </text>
<text top="191" left="1338" width="83" height="17" font="13">and those with </text>
<text top="208" left="1338" width="116" height="17" font="13">cognitive impairment </text>
<text top="225" left="1338" width="84" height="17" font="13">gain from such </text>
<text top="243" left="1338" width="59" height="17" font="13">programs. </text>
</page>
<page number="44" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">44</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="65" height="17" font="13">Pharmacist </text>
<text top="72" left="28" width="81" height="17" font="13">intervention to </text>
<text top="89" left="28" width="110" height="17" font="13">improve medication </text>
<text top="106" left="28" width="98" height="17" font="13">adherence in HF. </text>
<text top="124" left="28" width="93" height="17" font="13">Murray, M. 2007 </text>
<text top="141" left="28" width="55" height="17" font="14">10030506</text>
<text top="141" left="83" width="7" height="17" font="13">  </text>
<text top="158" left="28" width="32" height="17" font="13">(117) </text>
<text top="55" left="163" width="133" height="17" font="13">To determine whether a </text>
<text top="72" left="163" width="131" height="17" font="13">pharmacist intervention </text>
<text top="89" left="163" width="116" height="17" font="13">improves medication </text>
<text top="106" left="163" width="122" height="17" font="13">adherence and health </text>
<text top="124" left="163" width="115" height="17" font="13">outcomes compared </text>
<text top="141" left="163" width="126" height="17" font="13">with usual care for low-</text>
<text top="158" left="163" width="111" height="17" font="13">income pts with HF. </text>
<text top="55" left="311" width="178" height="17" font="13">RCT 314 </text>
<text top="55" left="468" width="63" height="17" font="13">Age &gt;50 y, </text>
<text top="72" left="468" width="57" height="17" font="13">confirmed </text>
<text top="89" left="468" width="92" height="17" font="13">diagnosis of HF, </text>
<text top="106" left="468" width="94" height="17" font="13">regularly used at </text>
<text top="124" left="468" width="60" height="17" font="13">least 1 CV </text>
<text top="141" left="468" width="81" height="17" font="13">medication for </text>
<text top="158" left="468" width="91" height="17" font="13">HF, not using or </text>
<text top="175" left="468" width="84" height="17" font="13">not planning to </text>
<text top="192" left="468" width="96" height="17" font="13">use a medication </text>
<text top="210" left="468" width="54" height="17" font="13">container </text>
<text top="227" left="468" width="85" height="17" font="13">adherence aid, </text>
<text top="244" left="468" width="66" height="17" font="13">access to a </text>
<text top="261" left="468" width="46" height="17" font="13">working </text>
<text top="278" left="468" width="85" height="17" font="13">telephone, and </text>
<text top="296" left="468" width="99" height="17" font="13">adequate hearing </text>
<text top="55" left="584" width="56" height="17" font="13">Dementia </text>
<text top="55" left="702" width="63" height="17" font="13">Medication </text>
<text top="72" left="702" width="62" height="17" font="13">adherence </text>
<text top="89" left="702" width="97" height="17" font="13">(tracked by using </text>
<text top="106" left="702" width="56" height="17" font="13">electronic </text>
<text top="124" left="702" width="79" height="17" font="13">monitors) and </text>
<text top="141" left="702" width="40" height="17" font="13">clinical </text>
<text top="158" left="702" width="104" height="17" font="13">exacerbations that </text>
<text top="175" left="702" width="93" height="17" font="13">required visits to </text>
<text top="192" left="702" width="55" height="17" font="13">the ED or </text>
<text top="210" left="702" width="85" height="17" font="13">hospitalization. </text>
<text top="55" left="819" width="81" height="17" font="13">Health-related </text>
<text top="72" left="819" width="95" height="17" font="13">QoL, satisfaction </text>
<text top="89" left="819" width="83" height="17" font="13">with pharmacy </text>
<text top="106" left="819" width="103" height="17" font="13">services, and total </text>
<text top="124" left="819" width="98" height="17" font="13">direct health care </text>
<text top="141" left="819" width="36" height="17" font="13">costs. </text>
<text top="55" left="940" width="180" height="17" font="13">Medication adherence greater in </text>
<text top="72" left="940" width="180" height="17" font="13">the intervention group 78.8% vs. </text>
<text top="89" left="940" width="185" height="17" font="13">67.9% usual care group (95% CI: </text>
<text top="106" left="940" width="56" height="17" font="13">5.0-16.7). </text>
<text top="124" left="940" width="3" height="17" font="13"> </text>
<text top="141" left="940" width="172" height="17" font="13">At 3 mo, adherence decreased </text>
<text top="158" left="940" width="183" height="17" font="13">70.6% in intervention and 66.7 in </text>
<text top="175" left="940" width="165" height="17" font="13">usual care (95% CI: -5.9-6.5). </text>
<text top="192" left="940" width="3" height="17" font="13"> </text>
<text top="210" left="940" width="150" height="17" font="13">Medications were taken on </text>
<text top="227" left="940" width="185" height="17" font="13">schedule 47.2% in the usual care </text>
<text top="244" left="940" width="163" height="17" font="13">and 53.1% in the intervention </text>
<text top="261" left="940" width="139" height="17" font="13">group (95%CI: 0.4-11.5). </text>
<text top="278" left="940" width="3" height="17" font="13"> </text>
<text top="296" left="940" width="194" height="17" font="13">At the end of intervention, taking of </text>
<text top="313" left="940" width="193" height="17" font="13">medication on schedule decreased </text>
<text top="330" left="940" width="191" height="17" font="13">48.9% for usual care and 48.6% in </text>
<text top="347" left="940" width="168" height="17" font="13">intervention (95% CI: -5.9-6.5) </text>
<text top="365" left="940" width="3" height="17" font="13"> </text>
<text top="382" left="940" width="186" height="17" font="13">ED visits and hospital admissions </text>
<text top="399" left="940" width="194" height="17" font="13">were 19.4% less in the intervention </text>
<text top="416" left="940" width="149" height="17" font="13">group (95% CI: 0.73-0.93). </text>
<text top="433" left="940" width="3" height="17" font="13"> </text>
<text top="451" left="940" width="172" height="17" font="13">Annual direct health care costs </text>
<text top="468" left="940" width="163" height="17" font="13">were lower in the intervention </text>
<text top="485" left="940" width="170" height="17" font="13">group (95% CI: $-7603-$1338) </text>
<text top="55" left="1149" width="163" height="17" font="13">Pts were not permitted to use </text>
<text top="72" left="1149" width="117" height="17" font="13">medication container </text>
<text top="89" left="1149" width="94" height="17" font="13">adherence aids.  </text>
<text top="106" left="1149" width="126" height="17" font="13">Intervention involved 1 </text>
<text top="124" left="1149" width="166" height="17" font="13">pharmacist and a single study </text>
<text top="141" left="1149" width="131" height="17" font="13">site that served a large, </text>
<text top="158" left="1149" width="163" height="17" font="13">indigent, inner-city population </text>
<text top="175" left="1149" width="40" height="17" font="13">of pts.  </text>
<text top="192" left="1149" width="163" height="17" font="13">Because the intervention had </text>
<text top="210" left="1149" width="156" height="17" font="13">several components, results </text>
<text top="227" left="1149" width="149" height="17" font="13">could not be attributed to a </text>
<text top="244" left="1149" width="103" height="17" font="13">single component. </text>
<text top="55" left="1338" width="75" height="17" font="13">A pharmacist </text>
<text top="72" left="1338" width="122" height="17" font="13">intervention for outpts </text>
<text top="89" left="1338" width="116" height="17" font="13">with HF can improve </text>
<text top="106" left="1338" width="75" height="17" font="13">adherence to </text>
<text top="124" left="1338" width="83" height="17" font="13">cardiovascular </text>
<text top="141" left="1338" width="93" height="17" font="13">medications and </text>
<text top="158" left="1338" width="118" height="17" font="13">decrease health care </text>
<text top="175" left="1338" width="103" height="17" font="13">use and costs, but </text>
<text top="192" left="1338" width="111" height="17" font="13">the benefit probably </text>
<text top="210" left="1338" width="48" height="17" font="13">requires </text>
<text top="227" left="1338" width="117" height="17" font="13">constant intervention </text>
<text top="244" left="1338" width="104" height="17" font="13">because the effect </text>
<text top="261" left="1338" width="111" height="17" font="13">dissipates when the </text>
<text top="278" left="1338" width="113" height="17" font="13">intervention ceases. </text>
<text top="518" left="28" width="112" height="17" font="13">Short and long-term </text>
<text top="535" left="28" width="113" height="17" font="13">results of a program </text>
<text top="552" left="28" width="113" height="17" font="13">for the prevention of </text>
<text top="570" left="28" width="100" height="17" font="13">readmissions and </text>
<text top="587" left="28" width="108" height="17" font="13">mortality in pts with </text>
<text top="604" left="28" width="84" height="17" font="13">HF: are effects </text>
<text top="621" left="28" width="92" height="17" font="13">maintained after </text>
<text top="638" left="28" width="70" height="17" font="13">stopping the </text>
<text top="656" left="28" width="111" height="17" font="13">program? Ojeda, S. </text>
<text top="673" left="28" width="31" height="17" font="13">2005 </text>
<text top="690" left="28" width="55" height="17" font="14">16051519</text>
<text top="690" left="83" width="7" height="17" font="13">  </text>
<text top="707" left="28" width="32" height="17" font="13">(118) </text>
<text top="518" left="163" width="115" height="17" font="13">To evaluate whether </text>
<text top="535" left="163" width="125" height="17" font="13">improvement obtained </text>
<text top="552" left="163" width="122" height="17" font="13">during an intervention </text>
<text top="570" left="163" width="79" height="17" font="13">program were </text>
<text top="587" left="163" width="112" height="17" font="13">maintained after the </text>
<text top="604" left="163" width="125" height="17" font="13">program was stopped. </text>
<text top="518" left="311" width="178" height="17" font="13">RCT 153 </text>
<text top="518" left="468" width="101" height="17" font="13">Discharged with a </text>
<text top="535" left="468" width="100" height="17" font="13">primary diagnosis </text>
<text top="552" left="468" width="82" height="17" font="13">of HF from the </text>
<text top="570" left="468" width="46" height="17" font="13">hospital </text>
<text top="587" left="468" width="93" height="17" font="13">cardiology ward. </text>
<text top="518" left="584" width="101" height="17" font="13">Terminal disease, </text>
<text top="535" left="584" width="98" height="17" font="13">expected survival </text>
<text top="552" left="584" width="98" height="17" font="13">&lt;6 mo, possibility </text>
<text top="570" left="584" width="104" height="17" font="13">of specific etiology </text>
<text top="587" left="584" width="103" height="17" font="13">treatment, wait list </text>
<text top="604" left="584" width="49" height="17" font="13">for heart </text>
<text top="621" left="584" width="57" height="17" font="13">transplant </text>
<text top="518" left="702" width="69" height="17" font="13">Decrease in </text>
<text top="535" left="702" width="100" height="17" font="13">readmissions due </text>
<text top="552" left="702" width="87" height="17" font="13">to HF and in all-</text>
<text top="570" left="702" width="86" height="17" font="13">cause mortality </text>
<text top="587" left="702" width="59" height="17" font="13">event-free </text>
<text top="604" left="702" width="92" height="17" font="13">survival, defined </text>
<text top="621" left="702" width="83" height="17" font="13">on the basis of </text>
<text top="638" left="702" width="89" height="17" font="13">time to death or </text>
<text top="656" left="702" width="93" height="17" font="13">HF readmission. </text>
<text top="518" left="819" width="66" height="17" font="13">Changes in </text>
<text top="535" left="819" width="93" height="17" font="13">pharmacological </text>
<text top="552" left="819" width="79" height="17" font="13">treatment and </text>
<text top="570" left="819" width="102" height="17" font="13">changes in quality </text>
<text top="587" left="819" width="83" height="17" font="13">of life MLHFQ  </text>
<text top="518" left="940" width="171" height="17" font="13">During the 16 +8 mo treatment </text>
<text top="535" left="940" width="170" height="17" font="13">period, intervention group had: </text>
<text top="552" left="940" width="174" height="17" font="13">Lower rate of HF readmissions  </text>
<text top="585" left="940" width="162" height="17" font="13">(p &lt;0.01), and Less all-cause </text>
<text top="602" left="940" width="165" height="17" font="13">mortality Improvement in QoL </text>
<text top="619" left="940" width="50" height="17" font="13">(p=0.03) </text>
<text top="651" left="940" width="3" height="17" font="13"> </text>
<text top="669" left="940" width="170" height="17" font="13">1 y after the intervention, there </text>
<text top="686" left="940" width="181" height="17" font="13">were no differences between the </text>
<text top="703" left="940" width="94" height="17" font="13">groups (p=0.03). </text>
<text top="518" left="1149" width="173" height="17" font="13">Results cannot be extrapolated </text>
<text top="535" left="1149" width="154" height="17" font="13">to all HF pts since the study </text>
<text top="552" left="1149" width="171" height="17" font="13">included pts discharged from a </text>
<text top="570" left="1149" width="152" height="17" font="13">cardiology service, who are </text>
<text top="587" left="1149" width="172" height="17" font="13">usually younger and with fewer </text>
<text top="604" left="1149" width="83" height="17" font="13">co-morbidities. </text>
<text top="518" left="1338" width="117" height="17" font="13">This intervention can </text>
<text top="535" left="1338" width="114" height="17" font="13">reduce HF morbidity </text>
<text top="552" left="1338" width="98" height="17" font="13">and mortality and </text>
<text top="570" left="1338" width="119" height="17" font="13">improve quality of life </text>
<text top="587" left="1338" width="114" height="17" font="13">but favorable effects </text>
<text top="604" left="1338" width="82" height="17" font="13">decrease after </text>
<text top="621" left="1338" width="114" height="17" font="13">program ends. Long-</text>
<text top="638" left="1338" width="105" height="17" font="13">term programs are </text>
<text top="656" left="1338" width="112" height="17" font="13">required to maintain </text>
<text top="673" left="1338" width="98" height="17" font="13">beneficial effects. </text>
</page>
<page number="45" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">45</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="105" height="17" font="13">Excessive daytime </text>
<text top="72" left="28" width="74" height="17" font="13">sleepiness is </text>
<text top="89" left="28" width="116" height="17" font="13">associated with poor </text>
<text top="106" left="28" width="63" height="17" font="13">medication </text>
<text top="124" left="28" width="111" height="17" font="13">adherence in adults </text>
<text top="141" left="28" width="117" height="17" font="13">with HF. Riegel, et al </text>
<text top="158" left="28" width="31" height="17" font="13">2011 </text>
<text top="175" left="28" width="55" height="17" font="14">21440873</text>
<text top="175" left="83" width="36" height="17" font="13"> (119) </text>
<text top="55" left="163" width="85" height="17" font="13">To determine if </text>
<text top="72" left="163" width="124" height="17" font="13">medication adherence </text>
<text top="89" left="163" width="131" height="17" font="13">differs in adults with HF </text>
<text top="106" left="163" width="124" height="17" font="13">and EDS compared to </text>
<text top="124" left="163" width="129" height="17" font="13">those without EDS and </text>
<text top="141" left="163" width="126" height="17" font="13">to test cognition as the </text>
<text top="158" left="163" width="101" height="17" font="13">mechanism of the </text>
<text top="175" left="163" width="37" height="17" font="13">effect. </text>
<text top="55" left="311" width="68" height="17" font="13">Prospective </text>
<text top="72" left="311" width="38" height="17" font="13">cohort </text>
<text top="89" left="311" width="67" height="17" font="13">comparison </text>
<text top="106" left="311" width="33" height="17" font="13">study </text>
<text top="55" left="402" width="24" height="17" font="13">280 </text>
<text top="55" left="468" width="92" height="17" font="13">Chronic stage C </text>
<text top="72" left="468" width="81" height="17" font="13">HF confirmed, </text>
<text top="89" left="468" width="94" height="17" font="13">able to complete </text>
<text top="106" left="468" width="68" height="17" font="13">the protocol </text>
<text top="124" left="468" width="90" height="17" font="13">(vision, hearing, </text>
<text top="141" left="468" width="94" height="17" font="13">English literacy), </text>
<text top="158" left="468" width="102" height="17" font="13">no more than mild </text>
<text top="175" left="468" width="52" height="17" font="13">cognitive </text>
<text top="192" left="468" width="64" height="17" font="13">impairment </text>
<text top="55" left="584" width="85" height="17" font="13">Living in a long </text>
<text top="72" left="584" width="98" height="17" font="13">term care setting, </text>
<text top="89" left="584" width="96" height="17" font="13">working nights or </text>
<text top="106" left="584" width="80" height="17" font="13">rotating shifts, </text>
<text top="124" left="584" width="68" height="17" font="13">renal failure </text>
<text top="141" left="584" width="98" height="17" font="13">requiring dialysis, </text>
<text top="158" left="584" width="62" height="17" font="13">imminently </text>
<text top="175" left="584" width="88" height="17" font="13">terminal illness, </text>
<text top="192" left="584" width="101" height="17" font="13">plans to move out </text>
<text top="210" left="584" width="105" height="17" font="13">of the area, history </text>
<text top="227" left="584" width="99" height="17" font="13">of serious drug or </text>
<text top="244" left="584" width="92" height="17" font="13">alcohol abuse in </text>
<text top="261" left="584" width="75" height="17" font="13">prior y, major </text>
<text top="278" left="584" width="64" height="17" font="13">depression </text>
<text top="55" left="702" width="75" height="17" font="13">Self-reported </text>
<text top="72" left="702" width="63" height="17" font="13">medication </text>
<text top="89" left="702" width="72" height="17" font="13">adherence    </text>
<text top="55" left="819" width="55" height="17" font="13">Cognition </text>
<text top="72" left="819" width="94" height="17" font="13">measured with a </text>
<text top="89" left="819" width="55" height="17" font="13">battery of </text>
<text top="106" left="819" width="109" height="17" font="13">neuropsychological </text>
<text top="123" left="819" width="29" height="17" font="13">tests </text>
<text top="55" left="940" width="156" height="17" font="13">62% were nonadherent with </text>
<text top="72" left="940" width="118" height="17" font="13">medication regimen.  </text>
<text top="104" left="940" width="170" height="17" font="13">Medication nonadherence was </text>
<text top="121" left="940" width="195" height="17" font="13">significantly more common in those </text>
<text top="138" left="940" width="57" height="17" font="13">with EDS  </text>
<text top="171" left="940" width="180" height="17" font="13">Subjects with EDS and cognitive </text>
<text top="188" left="940" width="185" height="17" font="13">decline were &gt;2 times more likely </text>
<text top="205" left="940" width="167" height="17" font="13">to be nonadherent (aOR 2.36, </text>
<text top="222" left="940" width="155" height="17" font="13">95%CI: 1.12-4.99; p=.033).  </text>
<text top="255" left="940" width="158" height="17" font="13">Secondary models using the </text>
<text top="272" left="940" width="149" height="17" font="13">Epworth Sleepiness score: </text>
<text top="304" left="940" width="150" height="17" font="13">The odds of nonadherence </text>
<text top="321" left="940" width="172" height="17" font="13">increased by 11% for each unit </text>
<text top="338" left="940" width="191" height="17" font="13">increase in ED (aOR 1.11, 95%CI: </text>
<text top="356" left="940" width="108" height="17" font="13">1.04-1.19; p=.025). </text>
<text top="388" left="940" width="154" height="17" font="13">Subjects with EDS and mild </text>
<text top="405" left="940" width="178" height="17" font="13">cognitive decline were 1.6 times </text>
<text top="422" left="940" width="193" height="17" font="13">more likely to be nonadherent over </text>
<text top="440" left="940" width="191" height="17" font="13">6 mo follow-up (aOR 1.61; 95%CI: </text>
<text top="457" left="940" width="108" height="17" font="13">1-03-2.50; p=.001). </text>
<text top="474" left="940" width="3" height="17" font="13"> </text>
<text top="506" left="940" width="176" height="17" font="13">The group with EDS but without </text>
<text top="523" left="940" width="167" height="17" font="13">cognitive decline was twice as </text>
<text top="541" left="940" width="187" height="17" font="13">likely to be nonadherent (p=.014). </text>
<text top="573" left="940" width="148" height="17" font="13">9% increase in the odds of </text>
<text top="590" left="940" width="153" height="17" font="13">nonadherence for each unit </text>
<text top="607" left="940" width="145" height="17" font="13">increase in EDS (p=.001). </text>
<text top="639" left="940" width="146" height="17" font="13">Lack of cognitive vigilance </text>
<text top="657" left="940" width="173" height="17" font="13">associated with nonadherence. </text>
<text top="674" left="940" width="50" height="17" font="13">(p=.024) </text>
<text top="55" left="1149" width="150" height="17" font="13">Medication adherence was </text>
<text top="72" left="1149" width="76" height="17" font="13">self-reported. </text>
<text top="55" left="1338" width="87" height="17" font="13">HF pts who are </text>
<text top="72" left="1338" width="117" height="17" font="13">sleepy have difficulty </text>
<text top="89" left="1338" width="114" height="17" font="13">paying attention and </text>
<text top="106" left="1338" width="102" height="17" font="13">thus forget to take </text>
<text top="123" left="1338" width="103" height="17" font="13">their medications.  </text>
</page>
<page number="46" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">46</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="118" height="17" font="13">Compliance with non-</text>
<text top="72" left="28" width="93" height="17" font="13">pharmacological </text>
<text top="89" left="28" width="101" height="17" font="13">recommendations </text>
<text top="106" left="28" width="107" height="17" font="13">and outcome in HF </text>
<text top="124" left="28" width="106" height="17" font="13">pts, van der Wal et </text>
<text top="141" left="28" width="47" height="17" font="13">al, 2010 </text>
<text top="158" left="28" width="55" height="17" font="14">20436049</text>
<text top="158" left="83" width="36" height="17" font="13"> (120) </text>
<text top="55" left="163" width="101" height="17" font="13">To investigate the </text>
<text top="72" left="163" width="115" height="17" font="13">association between </text>
<text top="89" left="163" width="116" height="17" font="13">compliance with non-</text>
<text top="106" left="163" width="93" height="17" font="13">pharmacological </text>
<text top="124" left="163" width="132" height="17" font="13">recommendations (diet, </text>
<text top="141" left="163" width="86" height="17" font="13">fluid restriction, </text>
<text top="158" left="163" width="133" height="17" font="13">weighing, exercise) and </text>
<text top="175" left="163" width="132" height="17" font="13">outcome in pts with HF. </text>
<text top="55" left="311" width="62" height="17" font="13">Secondary </text>
<text top="72" left="311" width="61" height="17" font="13">analysis of </text>
<text top="89" left="311" width="76" height="17" font="13">data from the </text>
<text top="106" left="311" width="71" height="17" font="13">COACH trial </text>
<text top="55" left="402" width="24" height="17" font="13">830 </text>
<text top="55" left="468" width="51" height="17" font="13">Recently </text>
<text top="72" left="468" width="86" height="17" font="13">hospitalized for </text>
<text top="89" left="468" width="96" height="17" font="13">symptomatic HF, </text>
<text top="106" left="468" width="94" height="17" font="13">confirmed by the </text>
<text top="124" left="468" width="94" height="17" font="13">cardiologist, with </text>
<text top="141" left="468" width="70" height="17" font="13">evidence for </text>
<text top="158" left="468" width="92" height="17" font="13">underlying heart </text>
<text top="175" left="468" width="49" height="17" font="13">disease. </text>
<text top="55" left="584" width="48" height="17" font="13">Invasive </text>
<text top="72" left="584" width="102" height="17" font="13">intervention within </text>
<text top="89" left="584" width="88" height="17" font="13">the last 6 mo or </text>
<text top="106" left="584" width="86" height="17" font="13">planned for the </text>
<text top="124" left="584" width="61" height="17" font="13">next 3 mo, </text>
<text top="141" left="584" width="64" height="17" font="13">inclusion in </text>
<text top="158" left="584" width="103" height="17" font="13">another study with </text>
<text top="175" left="584" width="101" height="17" font="13">additional visits to </text>
<text top="192" left="584" width="66" height="17" font="13">provider, or </text>
<text top="210" left="584" width="105" height="17" font="13">evaluation of CTX. </text>
<text top="55" left="702" width="76" height="17" font="13">Composite of </text>
<text top="72" left="702" width="68" height="17" font="13">death or HF </text>
<text top="89" left="702" width="94" height="17" font="13">readmission and </text>
<text top="106" left="702" width="79" height="17" font="13">the number of </text>
<text top="123" left="702" width="81" height="17" font="13">unfavorable d. </text>
<text top="55" left="819" width="74" height="17" font="13">mortality and </text>
<text top="72" left="819" width="107" height="17" font="13">readmission for HF </text>
<text top="55" left="940" width="146" height="17" font="13">Pts non-compliant with ≥1 </text>
<text top="72" left="940" width="195" height="17" font="13">recommendations had a higher risk </text>
<text top="89" left="940" width="167" height="17" font="13">of mortality or HF readmission </text>
<text top="106" left="940" width="56" height="17" font="13">(p=0.01).  </text>
<text top="124" left="940" width="192" height="17" font="13">Non-compliance with exercise was </text>
<text top="141" left="940" width="184" height="17" font="13">associated with an increased risk </text>
<text top="158" left="940" width="172" height="17" font="13">for mortality or HF readmission </text>
<text top="175" left="940" width="53" height="17" font="13">(p&lt;0.01). </text>
<text top="192" left="940" width="146" height="17" font="13">Non-compliance with daily </text>
<text top="210" left="940" width="182" height="17" font="13">weighing was associated with an </text>
<text top="227" left="940" width="196" height="17" font="13">increased risk of mortality (p=0.02). </text>
<text top="244" left="940" width="189" height="17" font="13">Non-compliance (overall) and non-</text>
<text top="261" left="940" width="170" height="17" font="13">compliance with exercise were </text>
<text top="278" left="940" width="196" height="17" font="13">associated with a higher risk for HF </text>
<text top="296" left="940" width="123" height="17" font="13">readmission (p&lt;0.05). </text>
<text top="313" left="940" width="141" height="17" font="13">Pts who were overall non-</text>
<text top="330" left="940" width="172" height="17" font="13">compliant or with weighing and </text>
<text top="347" left="940" width="189" height="17" font="13">exercise had more unfavourable d </text>
<text top="364" left="940" width="160" height="17" font="13">than compliant pts (p= 0.01). </text>
<text top="55" left="1149" width="122" height="17" font="13">Almost half had a first </text>
<text top="72" left="1149" width="147" height="17" font="13">diagnosis of HF during the </text>
<text top="89" left="1149" width="165" height="17" font="13">index hospitalization and then </text>
<text top="106" left="1149" width="158" height="17" font="13">compliance was evaluated 1 </text>
<text top="124" left="1149" width="144" height="17" font="13">mo after discharge, which </text>
<text top="141" left="1149" width="157" height="17" font="13">could have influenced rates. </text>
<text top="158" left="1149" width="140" height="17" font="13">'Unfavorable d' difficult to </text>
<text top="175" left="1149" width="175" height="17" font="13">evaluate. Self-report instrument </text>
<text top="192" left="1149" width="164" height="17" font="13">used to measure compliance. </text>
<text top="210" left="1149" width="159" height="17" font="13">Socially desirable responses </text>
<text top="227" left="1149" width="52" height="17" font="13">possible. </text>
<text top="55" left="1338" width="101" height="17" font="13">HF pts who follow </text>
<text top="72" left="1338" width="61" height="17" font="13">prescribed </text>
<text top="89" left="1338" width="104" height="17" font="13">nonpharmacologic </text>
<text top="106" left="1338" width="109" height="17" font="13">therapy have better </text>
<text top="124" left="1338" width="118" height="17" font="13">outcomes than those </text>
<text top="141" left="1338" width="118" height="17" font="13">who do not. Exercise </text>
<text top="158" left="1338" width="98" height="17" font="13">and monitoring of </text>
<text top="175" left="1338" width="95" height="17" font="13">daily weights are </text>
<text top="192" left="1338" width="124" height="17" font="13">particularly important.  </text>
<text top="398" left="28" width="106" height="17" font="13">Nonpharmacologic </text>
<text top="415" left="28" width="111" height="17" font="13">Measures and Drug </text>
<text top="432" left="28" width="102" height="17" font="13">Compliance in Pts </text>
<text top="449" left="28" width="106" height="17" font="13">with HF: Data from </text>
<text top="466" left="28" width="111" height="17" font="13">the EuroHF Survey, </text>
<text top="484" left="28" width="113" height="17" font="13">Lainscak et al, 2007 </text>
<text top="501" left="28" width="55" height="17" font="14">17378994</text>
<text top="501" left="83" width="36" height="17" font="13"> (121) </text>
<text top="518" left="28" width="3" height="17" font="13"> </text>
<text top="398" left="163" width="135" height="17" font="13">To describe the recall of </text>
<text top="415" left="163" width="99" height="17" font="13">and adherence to </text>
<text top="432" left="163" width="104" height="17" font="13">nonpharmacologic </text>
<text top="449" left="163" width="133" height="17" font="13">advice of pts enrolled in </text>
<text top="466" left="163" width="97" height="17" font="13">the European HF </text>
<text top="483" left="163" width="42" height="17" font="13">Survey </text>
<text top="398" left="311" width="64" height="17" font="13">Descriptive </text>
<text top="415" left="311" width="73" height="17" font="13">survey of pts </text>
<text top="432" left="311" width="52" height="17" font="13">from 115 </text>
<text top="449" left="311" width="52" height="17" font="13">hospitals </text>
<text top="466" left="311" width="45" height="17" font="13">from 24 </text>
<text top="484" left="311" width="57" height="17" font="13">European </text>
<text top="501" left="311" width="53" height="17" font="13">countries </text>
<text top="397" left="402" width="34" height="17" font="13">2,331 </text>
<text top="398" left="468" width="98" height="17" font="13">Clinical diagnosis </text>
<text top="415" left="468" width="34" height="17" font="13">of HF </text>
<text top="397" left="584" width="7" height="17" font="13">  </text>
<text top="398" left="702" width="75" height="17" font="13">Self-reported </text>
<text top="415" left="702" width="75" height="17" font="13">adherence to </text>
<text top="432" left="702" width="104" height="17" font="13">nonpharmacologic </text>
<text top="449" left="702" width="39" height="17" font="13">advice </text>
<text top="397" left="819" width="7" height="17" font="13">  </text>
<text top="398" left="940" width="172" height="17" font="13">After hospitalization for HF, pts </text>
<text top="415" left="940" width="188" height="17" font="13">recalled receiving 4.1 ±  2.7 items </text>
<text top="432" left="940" width="159" height="17" font="13">of advice with some regional </text>
<text top="449" left="940" width="159" height="17" font="13">differences. Recall of dietary </text>
<text top="466" left="940" width="183" height="17" font="13">advice was higher (63%) than for </text>
<text top="484" left="940" width="178" height="17" font="13">influenza vaccination (36%) and </text>
<text top="501" left="940" width="162" height="17" font="13">avoidance of NSAIDS (17%). </text>
<text top="518" left="940" width="169" height="17" font="13">Among those who recalled the </text>
<text top="535" left="940" width="161" height="17" font="13">advice, many did not follow it </text>
<text top="552" left="940" width="170" height="17" font="13">completely (cholesterol and fat </text>
<text top="570" left="940" width="162" height="17" font="13">intake 61%; dietary salt 63%; </text>
<text top="587" left="940" width="149" height="17" font="13">influenza vaccination 75%; </text>
<text top="604" left="940" width="192" height="17" font="13">avoidance of NSAIDS 80%). A few </text>
<text top="621" left="940" width="183" height="17" font="13">indicated they ignored the advice </text>
<text top="638" left="940" width="177" height="17" font="13">completely. Pts who recalled &gt;4 </text>
<text top="656" left="940" width="153" height="17" font="13">items versus &lt;4 items were </text>
<text top="673" left="940" width="184" height="17" font="13">younger and more often received </text>
<text top="690" left="940" width="147" height="17" font="13">ACE-I (71% vs 62%), beta </text>
<text top="707" left="940" width="156" height="17" font="13">blockers (51% vs 38%), and </text>
<text top="724" left="940" width="167" height="17" font="13">spironolactone (25% vs 21%). </text>
<text top="398" left="1149" width="157" height="17" font="13">Younger pts who were more </text>
<text top="415" left="1149" width="165" height="17" font="13">mobile and had greater social </text>
<text top="432" left="1149" width="150" height="17" font="13">support were more likely to </text>
<text top="449" left="1149" width="143" height="17" font="13">attend interview. Possible </text>
<text top="466" left="1149" width="87" height="17" font="13">response bias.  </text>
<text top="398" left="1338" width="98" height="17" font="13">Younger age and </text>
<text top="415" left="1338" width="81" height="17" font="13">prescription of </text>
<text top="432" left="1338" width="66" height="17" font="13">appropriate </text>
<text top="449" left="1338" width="83" height="17" font="13">pharmacologic </text>
<text top="466" left="1338" width="77" height="17" font="13">treatment are </text>
<text top="484" left="1338" width="87" height="17" font="13">associated with </text>
<text top="501" left="1338" width="115" height="17" font="13">higher rates of recall </text>
<text top="518" left="1338" width="114" height="17" font="13">and implementation. </text>
<text top="758" left="54" width="1402" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AE, adverse event; AF, atrial fibrillation; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CDPS, Chronic illness and disability payment system; CHF, congestive heart failure; COACH, </text>
<text top="775" left="54" width="1396" height="17" font="13">Community Outreach and Cardiovascular Health; CTX, chest x-ray; CRT, Cardiac resynchronization therapy; CV, cardiovascular; DM, diabetes mellitus; ED, emergency department; EDS, excessive daytime sleepiness;  EF, ejection fraction; GWTG-HF; Get </text>
<text top="792" left="54" width="1383" height="17" font="13">with the Guidelines-Heart Failure; HF, heart failure; ICD, implantable cardioverter-defibrillator; IMPROVE-HF, The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting; LOS, length of stay; LVEF, left ventricular </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">47</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="1353" height="17" font="13">ejection fraction; MI, myocardial infarction; MLHFQ, Minnesota Living with Heart Failure questionnaire; MMSE, Mini Mental State Examination; MP, Medication Persistence; MPR, medication possession ratio, N/A, not applicable; NSAID, nonsteroidal </text>
<text top="71" left="54" width="1087" height="17" font="13">antiinflammatory drugs; NYHA, New York Heart Association; OPTIMAL, optimising congestive heart failure outpatient clinic project; pts, patients; QoL, quality of life; and RCT, randomized clinical trial.  </text>
<text top="103" left="54" width="3" height="17" font="13"> </text>
<text top="136" left="54" width="476" height="21" font="8"><b>Data Supplement 15. Treatment of Sleep Disorders (Section 7.3.1.4) </b></text>
<text top="157" left="84" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="176" left="84" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="157" left="216" width="86" height="19" font="9"><b>Aim of study </b></text>
<text top="157" left="341" width="41" height="19" font="9"><b>Study </b></text>
<text top="176" left="344" width="35" height="19" font="9"><b>Type </b></text>
<text top="157" left="412" width="41" height="19" font="9"><b>Study </b></text>
<text top="176" left="418" width="31" height="19" font="9"><b>Size </b></text>
<text top="157" left="533" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="157" left="826" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="157" left="1028" width="127" height="19" font="9"><b>Statistical Analysis </b></text>
<text top="176" left="1061" width="62" height="19" font="9"><b>(Results) </b></text>
<text top="157" left="1199" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="157" left="1364" width="64" height="19" font="9"><b>Findings/ </b></text>
<text top="176" left="1360" width="74" height="19" font="9"><b>Comments </b></text>
<text top="215" left="125" width="4" height="19" font="7"> </text>
<text top="215" left="257" width="4" height="19" font="7"> </text>
<text top="215" left="360" width="4" height="19" font="7"> </text>
<text top="215" left="431" width="4" height="19" font="7"> </text>
<text top="215" left="480" width="114" height="19" font="10"><i><b>Inclusion Criteria </b></i></text>
<text top="215" left="637" width="68" height="19" font="10"><i><b>Exclusion </b></i></text>
<text top="234" left="646" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="215" left="744" width="117" height="19" font="10"><i><b>Primary Endpoint </b></i></text>
<text top="215" left="898" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="234" left="904" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="215" left="1090" width="4" height="19" font="7"> </text>
<text top="215" left="1256" width="4" height="19" font="7"> </text>
<text top="215" left="1395" width="4" height="19" font="7"> </text>
<text top="258" left="61" width="111" height="17" font="13">Continuous positive </text>
<text top="275" left="61" width="108" height="17" font="13">airway pressure for </text>
<text top="292" left="61" width="111" height="17" font="13">central sleep apnea </text>
<text top="309" left="61" width="109" height="17" font="13">and HF (CANPAP). </text>
<text top="327" left="61" width="102" height="17" font="13">Bradley, T.D. et al </text>
<text top="344" left="61" width="31" height="17" font="13">2005 </text>
<text top="361" left="61" width="55" height="17" font="14">16282177</text>
<text top="361" left="116" width="36" height="17" font="13"> (122) </text>
<text top="258" left="205" width="62" height="17" font="13">To test the </text>
<text top="275" left="205" width="86" height="17" font="13">hypothesis that </text>
<text top="292" left="205" width="55" height="17" font="13">long-term </text>
<text top="309" left="205" width="98" height="17" font="13">treatment of CSA </text>
<text top="327" left="205" width="95" height="17" font="13">with CPAP in HF </text>
<text top="344" left="205" width="72" height="17" font="13">pts receiving </text>
<text top="361" left="205" width="89" height="17" font="13">optimal medical </text>
<text top="378" left="205" width="92" height="17" font="13">therapy reduces </text>
<text top="395" left="205" width="77" height="17" font="13">the combined </text>
<text top="413" left="205" width="103" height="17" font="13">rates of death and </text>
<text top="430" left="205" width="92" height="17" font="13">heart transplant. </text>
<text top="258" left="325" width="55" height="17" font="13">11 center </text>
<text top="275" left="325" width="29" height="17" font="13">RCT </text>
<text top="258" left="412" width="24" height="17" font="13">258 </text>
<text top="258" left="467" width="135" height="17" font="13">18-79 y, NYHA II-IV, HF </text>
<text top="275" left="467" width="139" height="17" font="13">due to ischemia, HTN, or </text>
<text top="292" left="467" width="126" height="17" font="13">idiopathic DCM, stable </text>
<text top="309" left="467" width="99" height="17" font="13">condition, optimal </text>
<text top="327" left="467" width="126" height="17" font="13">medical therapy for 1+ </text>
<text top="344" left="467" width="125" height="17" font="13">mo, LVEF &lt;40%, CSA </text>
<text top="361" left="467" width="89" height="17" font="13">with ≥15 apnea-</text>
<text top="378" left="467" width="123" height="17" font="13">hypopnea index (AHI) </text>
<text top="395" left="467" width="134" height="17" font="13">and &gt;50% of AHI had to </text>
<text top="413" left="467" width="64" height="17" font="13">be central.  </text>
<text top="258" left="620" width="86" height="17" font="13">Pregnancy, MI, </text>
<text top="275" left="620" width="75" height="17" font="13">USA, cardiac </text>
<text top="292" left="620" width="79" height="17" font="13">surgery within </text>
<text top="309" left="620" width="92" height="17" font="13">prior 3 mo, OSA </text>
<text top="258" left="735" width="92" height="17" font="13">Death and heart </text>
<text top="275" left="735" width="84" height="17" font="13">transplantation </text>
<text top="258" left="883" width="93" height="17" font="13">Hospitalizations, </text>
<text top="275" left="883" width="72" height="17" font="13">EF, exercise </text>
<text top="292" left="883" width="82" height="17" font="13">capacity, QoL, </text>
<text top="309" left="883" width="90" height="17" font="13">neurohormones </text>
<text top="258" left="1000" width="167" height="17" font="13">No difference between control </text>
<text top="275" left="1000" width="153" height="17" font="13">(n=130) and CPAP (n=128) </text>
<text top="292" left="1000" width="113" height="17" font="13">groups in number of </text>
<text top="309" left="1000" width="150" height="17" font="13">hospitalizations, QoL, ANP </text>
<text top="327" left="1000" width="167" height="17" font="13">levels. No difference in overall </text>
<text top="344" left="1000" width="117" height="17" font="13">event rates (p=0.54). </text>
<text top="258" left="1196" width="84" height="17" font="13">Underpowered </text>
<text top="275" left="1196" width="120" height="17" font="13">because trial stopped </text>
<text top="292" left="1196" width="70" height="17" font="13">early for low </text>
<text top="309" left="1196" width="61" height="17" font="13">enrollment </text>
<text top="258" left="1331" width="118" height="17" font="13">CPAP did not extend </text>
<text top="275" left="1331" width="77" height="17" font="13">life, decrease </text>
<text top="292" left="1331" width="124" height="17" font="13">transplant rate in CSA </text>
<text top="309" left="1331" width="117" height="17" font="13">but may be indicated </text>
<text top="327" left="1331" width="51" height="17" font="13">for OSA. </text>
<text top="448" left="61" width="111" height="17" font="13">Suppresion CSA by </text>
<text top="465" left="61" width="119" height="17" font="13">CPAP and transplant-</text>
<text top="482" left="61" width="106" height="17" font="13">free survival in HF. </text>
<text top="499" left="61" width="77" height="17" font="13">Arzt, M. 2007 </text>
<text top="517" left="61" width="55" height="17" font="14">17562959</text>
<text top="517" left="116" width="36" height="17" font="13"> (123) </text>
<text top="448" left="205" width="80" height="17" font="13">To investigate </text>
<text top="465" left="205" width="47" height="17" font="13">whether </text>
<text top="482" left="205" width="83" height="17" font="13">suppression of </text>
<text top="499" left="205" width="68" height="17" font="13">CSA below  </text>
<text top="517" left="205" width="70" height="17" font="13">threshold by </text>
<text top="534" left="205" width="72" height="17" font="13">CPAP would </text>
<text top="551" left="205" width="105" height="17" font="13">improve LVEF and </text>
<text top="568" left="205" width="92" height="17" font="13">heart transplant–</text>
<text top="585" left="205" width="73" height="17" font="13">free survival. </text>
<text top="448" left="325" width="52" height="17" font="13">Post-hoc </text>
<text top="465" left="325" width="72" height="17" font="13">analysis of a </text>
<text top="482" left="325" width="68" height="17" font="13">randomized </text>
<text top="499" left="325" width="27" height="17" font="13">trial. </text>
<text top="448" left="412" width="24" height="17" font="13">210 </text>
<text top="448" left="467" width="86" height="17" font="13">Age 18 to 79 y, </text>
<text top="465" left="467" width="64" height="17" font="13">NYHA II-IV </text>
<text top="482" left="467" width="112" height="17" font="13">HF due to ischemic, </text>
<text top="499" left="467" width="91" height="17" font="13">hypertensive, or </text>
<text top="517" left="467" width="90" height="17" font="13">idiopathic DCM, </text>
<text top="534" left="467" width="123" height="17" font="13">stabilized with optimal </text>
<text top="551" left="467" width="122" height="17" font="13">medical therapy for at </text>
<text top="568" left="467" width="77" height="17" font="13">least 1 month </text>
<text top="585" left="467" width="73" height="17" font="13">LVEF &lt;40%, </text>
<text top="603" left="467" width="113" height="17" font="13">Central sleep apnea </text>
<text top="448" left="620" width="66" height="17" font="13">Pregnancy, </text>
<text top="465" left="620" width="72" height="17" font="13">MI, Unstable </text>
<text top="482" left="620" width="87" height="17" font="13">angina, cardiac </text>
<text top="499" left="620" width="90" height="17" font="13">surgery within 3 </text>
<text top="517" left="620" width="98" height="17" font="13">mo of enrollment, </text>
<text top="534" left="620" width="29" height="17" font="13">OSA </text>
<text top="448" left="735" width="114" height="17" font="13">Combined rate of all-</text>
<text top="465" left="735" width="132" height="17" font="13">cause mortality or heart </text>
<text top="482" left="735" width="84" height="17" font="13">transplantation </text>
<text top="448" left="883" width="97" height="17" font="13">Apnea-hypopnea </text>
<text top="465" left="883" width="99" height="17" font="13">index (AHI) mean </text>
<text top="482" left="883" width="92" height="17" font="13">nocturnal SaO2, </text>
<text top="499" left="883" width="58" height="17" font="13">and LVEF </text>
<text top="448" left="1000" width="172" height="17" font="13">Despite similar CPAP pressure </text>
<text top="465" left="1000" width="183" height="17" font="13">and hours of use in the 2 groups, </text>
<text top="482" left="1000" width="140" height="17" font="13">CPAP-CSA– suppressed </text>
<text top="499" left="1000" width="174" height="17" font="13">subjects, compared to controls, </text>
<text top="517" left="1000" width="74" height="17" font="13">experienced: </text>
<text top="534" left="1000" width="175" height="17" font="13">A greater increase in LVEF at 3 </text>
<text top="551" left="1000" width="77" height="17" font="13">mo (p=0.001) </text>
<text top="568" left="1000" width="3" height="17" font="13"> </text>
<text top="585" left="1000" width="162" height="17" font="13">Significantly better transplant-</text>
<text top="603" left="1000" width="176" height="17" font="13">free survival (HR: 0.37; 95% CI: </text>
<text top="620" left="1000" width="125" height="17" font="13">0.142-0.967; p=0.043) </text>
<text top="637" left="1000" width="3" height="17" font="13"> </text>
<text top="654" left="1000" width="3" height="17" font="13"> </text>
<text top="671" left="1000" width="3" height="17" font="13"> </text>
<text top="689" left="1000" width="3" height="17" font="13"> </text>
<text top="706" left="1000" width="3" height="17" font="13"> </text>
<text top="723" left="1000" width="3" height="17" font="13"> </text>
<text top="740" left="1000" width="3" height="17" font="13"> </text>
<text top="758" left="1000" width="3" height="17" font="13"> </text>
<text top="775" left="1000" width="3" height="17" font="13"> </text>
<text top="448" left="1196" width="85" height="17" font="13">Stratification of </text>
<text top="465" left="1196" width="99" height="17" font="13">CPAP-treated pts </text>
<text top="482" left="1196" width="54" height="17" font="13">based on </text>
<text top="499" left="1196" width="91" height="17" font="13">polysomnogram </text>
<text top="517" left="1196" width="118" height="17" font="13">performed 3 mo after </text>
<text top="534" left="1196" width="84" height="17" font="13">randomization. </text>
<text top="551" left="1196" width="118" height="17" font="13">Because suppressed </text>
<text top="568" left="1196" width="105" height="17" font="13">and unsuppressed </text>
<text top="585" left="1196" width="107" height="17" font="13">status could not be </text>
<text top="603" left="1196" width="93" height="17" font="13">ascertained until </text>
<text top="620" left="1196" width="109" height="17" font="13">completion of PSG, </text>
<text top="637" left="1196" width="115" height="17" font="13">events that occurred </text>
<text top="654" left="1196" width="112" height="17" font="13">during the first 3 mo </text>
<text top="671" left="1196" width="70" height="17" font="13">could not be </text>
<text top="689" left="1196" width="84" height="17" font="13">included; more </text>
<text top="706" left="1196" width="105" height="17" font="13">deaths occurred in </text>
<text top="723" left="1196" width="122" height="17" font="13">the pts randomized to </text>
<text top="740" left="1196" width="119" height="17" font="13">CPAP than control (5 </text>
<text top="758" left="1196" width="37" height="17" font="13">vs. 3). </text>
<text top="775" left="1196" width="94" height="17" font="13">The CPAP-CSA–</text>
<text top="448" left="1331" width="124" height="17" font="13">These results suggest </text>
<text top="465" left="1331" width="117" height="17" font="13">that in HF pts, CPAP </text>
<text top="482" left="1331" width="101" height="17" font="13">may improve both </text>
<text top="499" left="1331" width="90" height="17" font="13">LVEF and heart </text>
<text top="517" left="1331" width="86" height="17" font="13">transplant–free </text>
<text top="534" left="1331" width="96" height="17" font="13">survival if CSA is </text>
<text top="551" left="1331" width="125" height="17" font="13">suppressed soon after </text>
<text top="568" left="1331" width="53" height="17" font="13">it begins. </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">48</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="1000" width="3" height="17" font="13"> </text>
<text top="71" left="1000" width="3" height="17" font="13"> </text>
<text top="54" left="1196" width="102" height="17" font="13">suppressed group </text>
<text top="71" left="1196" width="111" height="17" font="13">was younger, had a </text>
<text top="88" left="1196" width="118" height="17" font="13">lower AHI, and had a </text>
<text top="106" left="1196" width="74" height="17" font="13">slightly lower </text>
<text top="123" left="1196" width="113" height="17" font="13">proportion of central </text>
<text top="140" left="1196" width="87" height="17" font="13">events than the </text>
<text top="157" left="1196" width="69" height="17" font="13">CPAP CSA–</text>
<text top="174" left="1196" width="116" height="17" font="13">unsuppressed group </text>
<text top="192" left="61" width="111" height="17" font="13">Effect of continuous </text>
<text top="210" left="61" width="84" height="17" font="13">positive airway </text>
<text top="227" left="61" width="101" height="17" font="13">pressure on sleep </text>
<text top="244" left="61" width="96" height="17" font="13">structure in heart </text>
<text top="261" left="61" width="122" height="17" font="13">failure pts with central </text>
<text top="278" left="61" width="74" height="17" font="13">sleep apnea. </text>
<text top="296" left="61" width="118" height="17" font="13">Ruttanaumpawan, P. </text>
<text top="313" left="61" width="31" height="17" font="13">2009 </text>
<text top="330" left="61" width="55" height="17" font="14">19189783</text>
<text top="330" left="116" width="36" height="17" font="13"> (124) </text>
<text top="192" left="205" width="76" height="17" font="13">To determine </text>
<text top="210" left="205" width="47" height="17" font="13">whether </text>
<text top="227" left="205" width="107" height="17" font="13">attenuation of CSA </text>
<text top="244" left="205" width="86" height="17" font="13">by CPAP in pts </text>
<text top="261" left="205" width="92" height="17" font="13">with HF reduces </text>
<text top="278" left="205" width="92" height="17" font="13">the frequency of </text>
<text top="296" left="205" width="78" height="17" font="13">arousals from </text>
<text top="313" left="205" width="100" height="17" font="13">sleep or improves </text>
<text top="330" left="205" width="87" height="17" font="13">sleep structure. </text>
<text top="192" left="325" width="29" height="17" font="13">RCT </text>
<text top="192" left="412" width="24" height="17" font="13">205 </text>
<text top="192" left="467" width="86" height="17" font="13">Age 18 to 79 y; </text>
<text top="210" left="467" width="67" height="17" font="13">NYHA II -IV </text>
<text top="227" left="467" width="112" height="17" font="13">HF due to ischemic, </text>
<text top="244" left="467" width="76" height="17" font="13">hypertensive, </text>
<text top="261" left="467" width="101" height="17" font="13">oridiopathic DCM, </text>
<text top="278" left="467" width="115" height="17" font="13">stabilized on optimal </text>
<text top="296" left="467" width="136" height="17" font="13">medical therapy ≥ 1 mo, </text>
<text top="313" left="467" width="86" height="17" font="13">LVEF &lt;40% by </text>
<text top="330" left="467" width="70" height="17" font="13">radionuclide </text>
<text top="347" left="467" width="103" height="17" font="13">angiography, CSA </text>
<text top="365" left="467" width="133" height="17" font="13">defined as an AHI ≥ 15, </text>
<text top="382" left="467" width="118" height="17" font="13">with &gt;50% of apneas </text>
<text top="399" left="467" width="128" height="17" font="13">and hypopneas central </text>
<text top="416" left="467" width="51" height="17" font="13">in nature </text>
<text top="192" left="620" width="66" height="17" font="13">Pregnancy, </text>
<text top="210" left="620" width="21" height="17" font="13">MI, </text>
<text top="227" left="620" width="78" height="17" font="13">UA or cardiac </text>
<text top="244" left="620" width="90" height="17" font="13">surgery within 3 </text>
<text top="261" left="620" width="98" height="17" font="13">mo of enrollment, </text>
<text top="278" left="620" width="96" height="17" font="13">obstructive sleep </text>
<text top="296" left="620" width="38" height="17" font="13">apnea </text>
<text top="192" left="735" width="130" height="17" font="13">Apnea-hypopnea index </text>
<text top="210" left="735" width="95" height="17" font="13">and frequency of </text>
<text top="227" left="735" width="53" height="17" font="13">arousals. </text>
<text top="192" left="883" width="27" height="17" font="13"> N/A </text>
<text top="192" left="1000" width="169" height="17" font="13">In controls, there no change in </text>
<text top="210" left="1000" width="166" height="17" font="13">AHI or frequency of arousals.  </text>
<text top="227" left="1000" width="3" height="17" font="13"> </text>
<text top="244" left="1000" width="174" height="17" font="13">In CPAP group, AHI decreased </text>
<text top="261" left="1000" width="149" height="17" font="13">significantly but neither the </text>
<text top="278" left="1000" width="175" height="17" font="13">frequency of arousals nor sleep </text>
<text top="296" left="1000" width="169" height="17" font="13">structure changed significantly </text>
<text top="313" left="1000" width="60" height="17" font="13">(p&lt;0.001). </text>
<text top="330" left="1000" width="3" height="17" font="13"> </text>
<text top="347" left="1000" width="3" height="17" font="13"> </text>
<text top="383" left="1000" width="7" height="17" font="13">  </text>
<text top="192" left="1196" width="86" height="17" font="13">Did not classify </text>
<text top="210" left="1196" width="100" height="17" font="13">arousals as being </text>
<text top="227" left="1196" width="100" height="17" font="13">respiratory or non-</text>
<text top="244" left="1196" width="106" height="17" font="13">respiratory related, </text>
<text top="261" left="1196" width="114" height="17" font="13">and did not examine </text>
<text top="278" left="1196" width="67" height="17" font="13">their timing. </text>
<text top="192" left="1331" width="124" height="17" font="13">Attenuation of CSA by </text>
<text top="210" left="1331" width="129" height="17" font="13">CPAP does not reduce </text>
<text top="227" left="1331" width="114" height="17" font="13">arousal frequency in </text>
<text top="244" left="1331" width="115" height="17" font="13">HF pts. Arousals not </text>
<text top="261" left="1331" width="126" height="17" font="13">mainly a consequence </text>
<text top="278" left="1331" width="113" height="17" font="13">of CSA and may not </text>
<text top="296" left="1331" width="118" height="17" font="13">have been a defense </text>
<text top="313" left="1331" width="80" height="17" font="13">mechanism to </text>
<text top="330" left="1331" width="111" height="17" font="13">terminate apneas in </text>
<text top="347" left="1331" width="123" height="17" font="13">the same way they do </text>
<text top="365" left="1331" width="46" height="17" font="13">in OSA. </text>
<text top="444" left="61" width="121" height="17" font="13">Relationship between </text>
<text top="461" left="61" width="126" height="17" font="13">beta blocker treatment </text>
<text top="478" left="61" width="104" height="17" font="13">and the severity of </text>
<text top="495" left="61" width="108" height="17" font="13">CSA in chronic HF. </text>
<text top="512" left="61" width="95" height="17" font="13">Tamura, A. 2007 </text>
<text top="530" left="61" width="55" height="17" font="14">17218566</text>
<text top="530" left="116" width="36" height="17" font="13"> (125) </text>
<text top="444" left="205" width="88" height="17" font="13">To examine the </text>
<text top="461" left="205" width="66" height="17" font="13">relationship </text>
<text top="478" left="205" width="90" height="17" font="13">between use of  </text>
<text top="495" left="205" width="101" height="17" font="13">beta blockers and </text>
<text top="512" left="205" width="66" height="17" font="13">the severity </text>
<text top="530" left="205" width="79" height="17" font="13">of CSA in HF. </text>
<text top="444" left="325" width="104" height="17" font="13">Cohort study  45 </text>
<text top="444" left="467" width="131" height="17" font="13">Chronic HF NYHA II-III  </text>
<text top="461" left="467" width="73" height="17" font="13">LVEF &lt;50%. </text>
<text top="444" left="620" width="51" height="17" font="13">Previous </text>
<text top="461" left="620" width="91" height="17" font="13">cerebrovascular </text>
<text top="478" left="620" width="49" height="17" font="13">disease, </text>
<text top="495" left="620" width="89" height="17" font="13">Recent (&lt;6 mo) </text>
<text top="512" left="620" width="85" height="17" font="13">acute coronary </text>
<text top="530" left="620" width="61" height="17" font="13">syndrome, </text>
<text top="547" left="620" width="43" height="17" font="13">chronic </text>
<text top="564" left="620" width="62" height="17" font="13">respiratory </text>
<text top="581" left="620" width="46" height="17" font="13">disease </text>
<text top="444" left="735" width="105" height="17" font="13">Polysomnography, </text>
<text top="461" left="735" width="105" height="17" font="13">echocardiography, </text>
<text top="478" left="735" width="110" height="17" font="13">plasma BNP levels  </text>
<text top="444" left="883" width="27" height="17" font="13"> N/A </text>
<text top="444" left="1000" width="150" height="17" font="13">Pts receiving beta blockers </text>
<text top="461" left="1000" width="165" height="17" font="13">compared to pts not receiving </text>
<text top="478" left="1000" width="104" height="17" font="13">beta blockers had: </text>
<text top="495" left="1000" width="120" height="17" font="13">lower AHI, lower CAI. </text>
<text top="512" left="1000" width="165" height="17" font="13">Negatively correlated with the </text>
<text top="530" left="1000" width="156" height="17" font="13">dose of carvedilol were: AHI </text>
<text top="547" left="1000" width="24" height="17" font="13">CAI </text>
<text top="564" left="1000" width="3" height="17" font="13"> </text>
<text top="581" left="1000" width="154" height="17" font="13">Multiple regression analysis </text>
<text top="598" left="1000" width="180" height="17" font="13">selected no use of beta blockers </text>
<text top="616" left="1000" width="180" height="17" font="13">as an independent factor of CAI. </text>
<text top="633" left="1000" width="3" height="17" font="13"> </text>
<text top="650" left="1000" width="136" height="17" font="13">In 5 pts with CAI &gt;5 who </text>
<text top="667" left="1000" width="172" height="17" font="13">underwent serial sleep studies, </text>
<text top="685" left="1000" width="180" height="17" font="13">CAI decreased significantly after </text>
<text top="702" left="1000" width="125" height="17" font="13">6 mo of treatment with </text>
<text top="719" left="1000" width="62" height="17" font="13">carvedilol.  </text>
<text top="444" left="1196" width="106" height="17" font="13">Small sample size. </text>
<text top="461" left="1196" width="94" height="17" font="13">Did not measure </text>
<text top="478" left="1196" width="40" height="17" font="13">central </text>
<text top="495" left="1196" width="107" height="17" font="13">chemosensitivity to </text>
<text top="512" left="1196" width="32" height="17" font="13">CO2. </text>
<text top="444" left="1331" width="125" height="17" font="13">In pts with chronic HF, </text>
<text top="461" left="1331" width="82" height="17" font="13">CAI was lower </text>
<text top="478" left="1331" width="121" height="17" font="13">according to the dose </text>
<text top="495" left="1331" width="113" height="17" font="13">of beta blockers. No </text>
<text top="512" left="1331" width="117" height="17" font="13">use of  beta blockers </text>
<text top="530" left="1331" width="105" height="17" font="13">was independently </text>
<text top="547" left="1331" width="129" height="17" font="13">associated with CAI.  6 </text>
<text top="564" left="1331" width="115" height="17" font="13">mo of treatment with </text>
<text top="581" left="1331" width="116" height="17" font="13">carvedilol decreased </text>
<text top="598" left="1331" width="105" height="17" font="13">CAI. These results </text>
<text top="616" left="1331" width="101" height="17" font="13">suggest that  beta </text>
<text top="633" left="1331" width="114" height="17" font="13">blocker therapy may </text>
<text top="650" left="1331" width="101" height="17" font="13">dose-dependently </text>
<text top="667" left="1331" width="115" height="17" font="13">suppress CSA in pts </text>
<text top="685" left="1331" width="92" height="17" font="13">with chronic HF. </text>
<text top="737" left="61" width="113" height="17" font="13">Influence of CRT on </text>
<text top="754" left="61" width="127" height="17" font="13">different types of SDB. </text>
<text top="771" left="61" width="111" height="17" font="13">Oldenburg, O. 2007 </text>
<text top="788" left="61" width="55" height="17" font="14">17467333</text>
<text top="788" left="116" width="36" height="17" font="13"> (126) </text>
<text top="737" left="205" width="101" height="17" font="13">To investigate the </text>
<text top="754" left="205" width="95" height="17" font="13">influence of CRT </text>
<text top="771" left="205" width="104" height="17" font="13">on SDB in pts with </text>
<text top="788" left="205" width="64" height="17" font="13">severe HF. </text>
<text top="737" left="325" width="68" height="17" font="13">Prospective </text>
<text top="754" left="325" width="25" height="17" font="13">non-</text>
<text top="771" left="325" width="68" height="17" font="13">randomized </text>
<text top="788" left="325" width="33" height="17" font="13">study </text>
<text top="737" left="412" width="17" height="17" font="13">77 </text>
<text top="737" left="467" width="96" height="17" font="13">Eligible for CRT,  </text>
<text top="754" left="467" width="123" height="17" font="13">present with dyspnea, </text>
<text top="771" left="467" width="67" height="17" font="13">NYHA III-IV </text>
<text top="788" left="467" width="122" height="17" font="13">LBBB with QRS ≥150 </text>
<text top="737" left="620" width="88" height="17" font="13">None specified. </text>
<text top="737" left="735" width="98" height="17" font="13">Cardiorespiratory </text>
<text top="754" left="735" width="105" height="17" font="13">polygraphy. NYHA </text>
<text top="771" left="735" width="106" height="17" font="13">class, frequency of </text>
<text top="788" left="735" width="50" height="17" font="13">nycturia, </text>
<text top="737" left="883" width="27" height="17" font="13"> N/A </text>
<text top="737" left="1000" width="155" height="17" font="13">CSA was documented in 36 </text>
<text top="754" left="1000" width="182" height="17" font="13">(47%) pts, OSA in 26 (34%), and </text>
<text top="771" left="1000" width="116" height="17" font="13">no SDB in 15 (19%). </text>
<text top="788" left="1000" width="3" height="17" font="13"> </text>
<text top="737" left="1196" width="96" height="17" font="13">Categorization of </text>
<text top="754" left="1196" width="80" height="17" font="13">hemodynamic </text>
<text top="771" left="1196" width="118" height="17" font="13">response based on a </text>
<text top="788" left="1196" width="118" height="17" font="13">novel scoring system </text>
<text top="737" left="1331" width="119" height="17" font="13">In pts with severe HF </text>
<text top="754" left="1331" width="120" height="17" font="13">eligible for CRT, CSA </text>
<text top="771" left="1331" width="127" height="17" font="13">is common and can be </text>
<text top="788" left="1331" width="108" height="17" font="13">influenced by CRT. </text>
</page>
<page number="49" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">49</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="467" width="130" height="17" font="13">msec, LVEDD ≥60mm, </text>
<text top="71" left="467" width="88" height="17" font="13">LVEF of ≤35%, </text>
<text top="88" left="467" width="96" height="17" font="13">peak VO2 during </text>
<text top="106" left="467" width="74" height="17" font="13">standardized </text>
<text top="123" left="467" width="94" height="17" font="13">cardiopulmonary </text>
<text top="140" left="467" width="118" height="17" font="13">exercise testing, ≤18 </text>
<text top="157" left="467" width="128" height="17" font="13">ml/kg/min, during initial </text>
<text top="174" left="467" width="116" height="17" font="13">testing of several LV-</text>
<text top="192" left="467" width="79" height="17" font="13">lead positions </text>
<text top="209" left="467" width="122" height="17" font="13">(posterolateral veins), </text>
<text top="226" left="467" width="112" height="17" font="13">RV-stimulation sites </text>
<text top="243" left="467" width="95" height="17" font="13">(apex vs. RVOT) </text>
<text top="261" left="467" width="131" height="17" font="13">and LV vs. biventricular </text>
<text top="278" left="467" width="127" height="17" font="13">pacing, pulse pressure </text>
<text top="295" left="467" width="82" height="17" font="13">as a surrogate </text>
<text top="312" left="467" width="73" height="17" font="13">parameter of </text>
<text top="329" left="467" width="120" height="17" font="13">haemodynamic acute </text>
<text top="347" left="467" width="92" height="17" font="13">response had to </text>
<text top="364" left="467" width="105" height="17" font="13">increase by &gt;10%. </text>
<text top="54" left="735" width="94" height="17" font="13">cardiopulmonary </text>
<text top="71" left="735" width="115" height="17" font="13">exercise, 6-min walk </text>
<text top="88" left="735" width="51" height="17" font="13">test, and </text>
<text top="106" left="735" width="101" height="17" font="13">echocardiography </text>
<text top="123" left="735" width="69" height="17" font="13">parameters. </text>
<text top="54" left="1000" width="162" height="17" font="13">Sleep disordered parameters </text>
<text top="71" left="1000" width="145" height="17" font="13">improved in CSA pts only: </text>
<text top="88" left="1000" width="180" height="17" font="13">AHI, SaO2min, Desaturation (p&lt; </text>
<text top="106" left="1000" width="38" height="17" font="13">0.001) </text>
<text top="123" left="1000" width="3" height="17" font="13"> </text>
<text top="140" left="1000" width="158" height="17" font="13">Daytime capillary pCO2 was </text>
<text top="157" left="1000" width="161" height="17" font="13">significantly lower in CSA pts </text>
<text top="174" left="1000" width="176" height="17" font="13">compared to those without SDB </text>
<text top="192" left="1000" width="163" height="17" font="13">with a trend towards increase </text>
<text top="209" left="1000" width="107" height="17" font="13">with CRT (p=0.02). </text>
<text top="226" left="1000" width="3" height="17" font="13"> </text>
<text top="243" left="1000" width="148" height="17" font="13">After classifying short term </text>
<text top="261" left="1000" width="173" height="17" font="13">clinical and hemodynamic CRT </text>
<text top="278" left="1000" width="126" height="17" font="13">effects, improved SDB </text>
<text top="295" left="1000" width="172" height="17" font="13">parameters in CSA occurred in </text>
<text top="312" left="1000" width="151" height="17" font="13">responders only (p=0.004). </text>
<text top="329" left="1000" width="7" height="17" font="13">  </text>
<text top="54" left="1196" width="96" height="17" font="13">not prospectively </text>
<text top="71" left="1196" width="56" height="17" font="13">validated. </text>
<text top="88" left="1196" width="76" height="17" font="13">Prospectively </text>
<text top="106" left="1196" width="97" height="17" font="13">followed CRT pts </text>
<text top="123" left="1196" width="104" height="17" font="13">without calculating </text>
<text top="140" left="1196" width="91" height="17" font="13">statistical power </text>
<text top="157" left="1196" width="44" height="17" font="13">needed </text>
<text top="174" left="1196" width="103" height="17" font="13">to show results for </text>
<text top="192" left="1196" width="94" height="17" font="13">pts without SDB, </text>
<text top="209" left="1196" width="106" height="17" font="13">those with OSA, or </text>
<text top="226" left="1196" width="95" height="17" font="13">CSA in advance. </text>
<text top="54" left="1331" width="126" height="17" font="13">Improvement depends </text>
<text top="71" left="1331" width="112" height="17" font="13">on good clinical and </text>
<text top="88" left="1331" width="80" height="17" font="13">hemodynamic </text>
<text top="106" left="1331" width="100" height="17" font="13">response to CRT. </text>
<text top="382" left="54" width="1379" height="17" font="13">AHI indicates apnea hypopnoea index; ANP, atrial natriuretic peptide; BNP, B-Type natriuretic peptide; CAI, central apnea index; CPAP, continuous positive airway pressure; CRT, cardiac resynchronisation therapy; CSA, central sleep apnea; DM, dilated </text>
<text top="399" left="54" width="1405" height="17" font="13">cardiomyopathy;  EF, ejection fraction; HF, heart failure; HTN, hypertension; LBBB, left bundle branch block; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not applicable; NYHA, New York </text>
<text top="416" left="54" width="1073" height="17" font="13">Heart Association; OSA, obstructive sleep apnea; pts, patients; QoL, quality of life;  RV, right ventricular; RVOT, right ventricular outflow tract; SDB, sleep disordered breathing; UA, unstable angina. </text>
<text top="433" left="54" width="4" height="19" font="7"> </text>
<text top="470" left="54" width="491" height="21" font="8"><b>Data Supplement 16. Cardiac Rehabilitation-Exercise (Section 7.3.1.6) </b></text>
<text top="492" left="68" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="510" left="69" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="492" left="193" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="492" left="329" width="41" height="19" font="9"><b>Study </b></text>
<text top="510" left="332" width="35" height="19" font="9"><b>Type </b></text>
<text top="492" left="413" width="41" height="19" font="9"><b>Study </b></text>
<text top="510" left="418" width="31" height="19" font="9"><b>Size </b></text>
<text top="492" left="580" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="492" left="894" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="492" left="1073" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="492" left="1295" width="134" height="19" font="9"><b>Findings/Comments </b></text>
<text top="534" left="108" width="8" height="19" font="7">  </text>
<text top="534" left="233" width="8" height="19" font="7">  </text>
<text top="534" left="346" width="8" height="19" font="7">  </text>
<text top="534" left="400" width="8" height="19" font="7">  </text>
<text top="534" left="502" width="114" height="19" font="10"><i><b>Inclusion Criteria </b></i></text>
<text top="534" left="666" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="534" left="819" width="117" height="19" font="10"><i><b>Primary Endpoint </b></i></text>
<text top="534" left="962" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="553" left="967" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="534" left="1163" width="8" height="19" font="7">  </text>
<text top="553" left="1163" width="8" height="19" font="7">  </text>
<text top="534" left="1358" width="8" height="19" font="7">  </text>
</page>
<page number="50" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">50</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="85" height="17" font="13">Antiremodeling </text>
<text top="71" left="61" width="74" height="17" font="13">effect of long-</text>
<text top="88" left="61" width="77" height="17" font="13">term exercise </text>
<text top="106" left="61" width="76" height="17" font="13">training in pts </text>
<text top="123" left="61" width="61" height="17" font="13">with stable </text>
<text top="140" left="61" width="66" height="17" font="13">chronic HF. </text>
<text top="157" left="61" width="61" height="17" font="13">Giannuzzi, </text>
<text top="174" left="61" width="86" height="17" font="13">Pantaleo. 2003 </text>
<text top="192" left="61" width="58" height="17" font="14">12860904 </text>
<text top="192" left="119" width="32" height="17" font="13">(127) </text>
<text top="209" left="61" width="3" height="17" font="13"> </text>
<text top="54" left="174" width="123" height="17" font="13">To determine whether </text>
<text top="71" left="174" width="105" height="17" font="13">long-term exercise </text>
<text top="88" left="174" width="123" height="17" font="13">training may influence </text>
<text top="106" left="174" width="85" height="17" font="13">LV volume and </text>
<text top="123" left="174" width="101" height="17" font="13">function in a large </text>
<text top="140" left="174" width="96" height="17" font="13">cohort of pts with </text>
<text top="157" left="174" width="102" height="17" font="13">stable chronic HF. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="17" height="17" font="13">90 </text>
<text top="54" left="481" width="149" height="17" font="13">HF secondary to idiopathic </text>
<text top="71" left="481" width="120" height="17" font="13">DCM, IHD or valvular </text>
<text top="88" left="481" width="46" height="17" font="13">disease </text>
<text top="106" left="481" width="128" height="17" font="13">LVEF &lt;35% by ECHO. </text>
<text top="123" left="481" width="148" height="17" font="13">Clinical stability for at least </text>
<text top="140" left="481" width="122" height="17" font="13">3 mo under optimized </text>
<text top="157" left="481" width="44" height="17" font="13">therapy </text>
<text top="174" left="481" width="62" height="17" font="13">NYHA II-III </text>
<text top="192" left="481" width="151" height="17" font="13">Peak oxygen uptake (VO2) </text>
<text top="209" left="481" width="98" height="17" font="13">&lt; 20mL/kg/min at </text>
<text top="226" left="481" width="85" height="17" font="13">ergospirometry </text>
<text top="243" left="481" width="148" height="17" font="13">Echocardiographic images </text>
<text top="261" left="481" width="125" height="17" font="13">of adequate quality for </text>
<text top="278" left="481" width="114" height="17" font="13">quantitative analysis </text>
<text top="54" left="649" width="122" height="17" font="13">Any systemic disease </text>
<text top="71" left="649" width="94" height="17" font="13">limiting exercise, </text>
<text top="88" left="649" width="71" height="17" font="13">hypertrophic </text>
<text top="106" left="649" width="94" height="17" font="13">cardiomyopathy, </text>
<text top="123" left="649" width="145" height="17" font="13">Valvular disease requiring </text>
<text top="140" left="649" width="48" height="17" font="13">surgery, </text>
<text top="157" left="649" width="92" height="17" font="13">Angina pectoris, </text>
<text top="174" left="649" width="118" height="17" font="13">Sustained ventricular </text>
<text top="192" left="649" width="71" height="17" font="13">arrhythmias, </text>
<text top="209" left="649" width="120" height="17" font="13">Severe hypertension, </text>
<text top="226" left="649" width="147" height="17" font="13">Excess variability &gt;10% at </text>
<text top="243" left="649" width="144" height="17" font="13">baseline cardiopulmonary </text>
<text top="261" left="649" width="72" height="17" font="13">exercise test </text>
<text top="54" left="815" width="97" height="17" font="13">Cardiopulmonary </text>
<text top="71" left="815" width="92" height="17" font="13">exercise testing, </text>
<text top="88" left="815" width="43" height="17" font="13">6MWT, </text>
<text top="106" left="815" width="105" height="17" font="13">echocardiography, </text>
<text top="123" left="815" width="54" height="17" font="13">and QoL. </text>
<text top="54" left="953" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1056" width="187" height="17" font="13">Differences from baseline to 6 mo </text>
<text top="71" left="1056" width="211" height="17" font="13">improved in the intervention group for: </text>
<text top="88" left="1056" width="79" height="17" font="13">EF (p&lt;0.001); </text>
<text top="106" left="1056" width="140" height="17" font="13">Work capacity (p&lt;0.001); </text>
<text top="123" left="1056" width="119" height="17" font="13">Peak VO2 (p&lt;0.006); </text>
<text top="140" left="1056" width="156" height="17" font="13">Walking distance (p&lt;0.001); </text>
<text top="157" left="1056" width="80" height="17" font="13">QoL (p&lt;0.01); </text>
<text top="174" left="1056" width="198" height="17" font="13">LV volumes (diminished) (p&lt;0.001); </text>
<text top="192" left="1056" width="176" height="17" font="13">Trend to fewer readmissions for </text>
<text top="209" left="1056" width="169" height="17" font="13">worsening dyspnea<b>  </b>(p&lt; 0.05)  </text>
<text top="226" left="1056" width="3" height="17" font="13"> </text>
<text top="243" left="1056" width="213" height="17" font="13">LV volumes increased in control group </text>
<text top="261" left="1056" width="53" height="17" font="13">(p= 0.05)<b> </b></text>
<text top="54" left="1291" width="116" height="17" font="13">In stable chronic HF, </text>
<text top="71" left="1291" width="111" height="17" font="13">long-term moderate </text>
<text top="88" left="1291" width="133" height="17" font="13">exercise training has no </text>
<text top="106" left="1291" width="135" height="17" font="13">detrimental effect on left </text>
<text top="123" left="1291" width="133" height="17" font="13">ventricular volumes and </text>
<text top="140" left="1291" width="98" height="17" font="13">function; rather, it </text>
<text top="157" left="1291" width="116" height="17" font="13">attenuates abnormal </text>
<text top="174" left="1291" width="142" height="17" font="13">remodeling. Furthermore, </text>
<text top="192" left="1291" width="132" height="17" font="13">exercise training is safe </text>
<text top="209" left="1291" width="86" height="17" font="13">and effective in </text>
<text top="226" left="1291" width="106" height="17" font="13">improving exercise </text>
<text top="243" left="1291" width="108" height="17" font="13">tolerance and QoL. </text>
<text top="297" left="61" width="59" height="17" font="13">Combined </text>
<text top="314" left="61" width="62" height="17" font="13">endurance-</text>
<text top="331" left="61" width="59" height="17" font="13">resistance </text>
<text top="349" left="61" width="63" height="17" font="13">training vs. </text>
<text top="366" left="61" width="62" height="17" font="13">endurance </text>
<text top="383" left="61" width="76" height="17" font="13">training in pts </text>
<text top="400" left="61" width="92" height="17" font="13">with chronic HF: </text>
<text top="417" left="61" width="76" height="17" font="13">a prospective </text>
<text top="435" left="61" width="68" height="17" font="13">randomized </text>
<text top="452" left="61" width="87" height="17" font="13">study. Beckers, </text>
<text top="469" left="61" width="62" height="17" font="13">Paul. 2008 </text>
<text top="486" left="61" width="58" height="17" font="14">18515805 </text>
<text top="486" left="119" width="32" height="17" font="13">(128) </text>
<text top="504" left="61" width="3" height="17" font="13"> </text>
<text top="297" left="174" width="90" height="17" font="13">To compare the </text>
<text top="314" left="174" width="110" height="17" font="13">effects of combined </text>
<text top="331" left="174" width="122" height="17" font="13">endurance-resistance </text>
<text top="349" left="174" width="69" height="17" font="13">training with </text>
<text top="366" left="174" width="62" height="17" font="13">endurance </text>
<text top="383" left="174" width="87" height="17" font="13">training only on </text>
<text top="400" left="174" width="93" height="17" font="13">submaximal and </text>
<text top="417" left="174" width="98" height="17" font="13">maximal exercise </text>
<text top="435" left="174" width="112" height="17" font="13">capacity, ventilatory </text>
<text top="452" left="174" width="60" height="17" font="13">prognostic </text>
<text top="469" left="174" width="105" height="17" font="13">parameters, safety </text>
<text top="486" left="174" width="42" height="17" font="13">issues, </text>
<text top="504" left="174" width="109" height="17" font="13">and QoL in pts with </text>
<text top="521" left="174" width="66" height="17" font="13">chronic HF. </text>
<text top="297" left="312" width="68" height="17" font="13">Prospective </text>
<text top="314" left="312" width="68" height="17" font="13">randomized </text>
<text top="331" left="312" width="33" height="17" font="13">study </text>
<text top="297" left="400" width="17" height="17" font="13">58 </text>
<text top="297" left="481" width="154" height="17" font="13">Chronic HF due to ischemic </text>
<text top="314" left="481" width="144" height="17" font="13">or dilated cardiomyopathy </text>
<text top="331" left="481" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="349" left="481" width="66" height="17" font="13">NYHA II-III. </text>
<text top="366" left="481" width="106" height="17" font="13">Optimal and stable </text>
<text top="383" left="481" width="148" height="17" font="13">pharmacological treatment </text>
<text top="297" left="649" width="86" height="17" font="13">Recent ACS or </text>
<text top="314" left="649" width="129" height="17" font="13">revascularization in the </text>
<text top="331" left="649" width="61" height="17" font="13">past 3 mo, </text>
<text top="349" left="649" width="114" height="17" font="13">actively listed on the </text>
<text top="366" left="649" width="79" height="17" font="13">transplant list, </text>
<text top="383" left="649" width="98" height="17" font="13">logistic problems, </text>
<text top="400" left="649" width="145" height="17" font="13">exercise limited by angina </text>
<text top="417" left="649" width="113" height="17" font="13">or peripheral arterial </text>
<text top="435" left="649" width="103" height="17" font="13">occlusive disease, </text>
<text top="452" left="649" width="105" height="17" font="13">cerebrovascular or </text>
<text top="469" left="649" width="137" height="17" font="13">musculoskeletal disease </text>
<text top="486" left="649" width="110" height="17" font="13">preventing exercise </text>
<text top="504" left="649" width="47" height="17" font="13">training, </text>
<text top="521" left="649" width="117" height="17" font="13">respiratory limitation  </text>
<text top="297" left="815" width="156" height="17" font="13">Steady-state workload  VO</text>
<text top="303" left="971" width="4" height="11" font="19">2</text>
<text top="297" left="975" width="37" height="17" font="13"> peak, </text>
<text top="314" left="953" width="59" height="17" font="13">ventilatory </text>
<text top="331" left="953" width="60" height="17" font="13">prognostic </text>
<text top="349" left="953" width="69" height="17" font="13">parameters, </text>
<text top="366" left="953" width="59" height="17" font="13">upper and </text>
<text top="383" left="953" width="59" height="17" font="13">lower limb </text>
<text top="400" left="953" width="75" height="17" font="13">strength, and </text>
<text top="417" left="953" width="27" height="17" font="13">QoL </text>
<text top="297" left="1056" width="213" height="17" font="13">In the combined endurance-resistance </text>
<text top="314" left="1056" width="202" height="17" font="13">training (compared to the endurance </text>
<text top="331" left="1056" width="86" height="17" font="13">training group): </text>
<text top="349" left="1056" width="143" height="17" font="13">SSW increased: p=0.007; </text>
<text top="366" left="1056" width="174" height="17" font="13">Decrease in heart rate at SSW: </text>
<text top="383" left="1056" width="52" height="17" font="13">p=0.002; </text>
<text top="400" left="1056" width="18" height="17" font="13">VO</text>
<text top="406" left="1074" width="4" height="11" font="19">2</text>
<text top="400" left="1078" width="157" height="17" font="13"> peak halftime was reduced: </text>
<text top="417" left="1056" width="48" height="17" font="13">p=0.001 </text>
<text top="435" left="1056" width="177" height="17" font="13">Maximal strength in upper limbs </text>
<text top="452" left="1056" width="108" height="17" font="13">increased: p&lt;0.001 </text>
<text top="469" left="1056" width="219" height="17" font="13">HRQoL improved (reported decrease of </text>
<text top="486" left="1056" width="212" height="17" font="13">cardiac symptoms): p= 0.003; 95% CI: </text>
<text top="504" left="1056" width="66" height="17" font="13">1.11-12.46.<b> </b></text>
<text top="297" left="1291" width="100" height="17" font="13">In chronic HF pts, </text>
<text top="314" left="1291" width="119" height="17" font="13">combined endurance-</text>
<text top="331" left="1291" width="137" height="17" font="13">resistance training had a </text>
<text top="349" left="1291" width="133" height="17" font="13">more pronounced effect </text>
<text top="366" left="1291" width="135" height="17" font="13">on submaximal exercise </text>
<text top="383" left="1291" width="94" height="17" font="13">capacity, muscle </text>
<text top="400" left="1291" width="128" height="17" font="13">strength, and quality of </text>
<text top="417" left="1291" width="111" height="17" font="13">life. The absence of </text>
<text top="435" left="1291" width="124" height="17" font="13">unfavorable effects on </text>
<text top="452" left="1291" width="80" height="17" font="13">left ventricular </text>
<text top="469" left="1291" width="141" height="17" font="13">remodelling and outcome </text>
<text top="486" left="1291" width="139" height="17" font="13">parameters is reassuring </text>
<text top="504" left="1291" width="106" height="17" font="13">and might facilitate </text>
<text top="521" left="1291" width="139" height="17" font="13">further implementation of </text>
<text top="538" left="1291" width="120" height="17" font="13">this particular training </text>
<text top="555" left="1291" width="53" height="17" font="13">modality. </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">51</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="83" height="17" font="13">Comparison of </text>
<text top="71" left="61" width="83" height="17" font="13">hospital-based </text>
<text top="88" left="61" width="74" height="17" font="13">versus home-</text>
<text top="106" left="61" width="86" height="17" font="13">based exercise </text>
<text top="123" left="61" width="76" height="17" font="13">training in pts </text>
<text top="140" left="61" width="88" height="17" font="13">with HF: effects </text>
<text top="157" left="61" width="73" height="17" font="13">on functional </text>
<text top="174" left="61" width="82" height="17" font="13">capacity, QoL, </text>
<text top="192" left="61" width="77" height="17" font="13">psyhcological </text>
<text top="209" left="61" width="87" height="17" font="13">symptoms, and </text>
<text top="226" left="61" width="80" height="17" font="13">hemodynamic </text>
<text top="243" left="61" width="69" height="17" font="13">parameters. </text>
<text top="261" left="61" width="92" height="17" font="13">Karapolat, Hale. </text>
<text top="278" left="61" width="31" height="17" font="13">2009 </text>
<text top="295" left="61" width="58" height="17" font="14">19641843 </text>
<text top="295" left="119" width="32" height="17" font="13">(129) </text>
<text top="312" left="61" width="3" height="17" font="13"> </text>
<text top="54" left="174" width="90" height="17" font="13">To compare the </text>
<text top="71" left="174" width="88" height="17" font="13">effects of home-</text>
<text top="88" left="174" width="61" height="17" font="13">based and </text>
<text top="106" left="174" width="83" height="17" font="13">hospital-based </text>
<text top="123" left="174" width="122" height="17" font="13">exercise programs on </text>
<text top="140" left="174" width="101" height="17" font="13">exercise capacity, </text>
<text top="157" left="174" width="107" height="17" font="13">QoL, psychological </text>
<text top="174" left="174" width="87" height="17" font="13">symptoms, and </text>
<text top="192" left="174" width="80" height="17" font="13">hemodynamic </text>
<text top="209" left="174" width="122" height="17" font="13">parameters in HF pts. </text>
<text top="54" left="312" width="72" height="17" font="13">Randomized </text>
<text top="71" left="312" width="33" height="17" font="13">study </text>
<text top="54" left="400" width="17" height="17" font="13">74 </text>
<text top="54" left="481" width="139" height="17" font="13">Diagnosed with HF for at </text>
<text top="71" left="481" width="64" height="17" font="13">least 3 mo, </text>
<text top="88" left="481" width="145" height="17" font="13">HF as a result of ischemic </text>
<text top="106" left="481" width="64" height="17" font="13">and dilated </text>
<text top="123" left="481" width="94" height="17" font="13">cardiomyopathy, </text>
<text top="140" left="481" width="156" height="17" font="13">clinical stability for at least 3 </text>
<text top="157" left="481" width="93" height="17" font="13">mo, LVEF &lt;40% </text>
<text top="174" left="481" width="133" height="17" font="13">NYHA II-III, optimal and </text>
<text top="192" left="481" width="144" height="17" font="13">standard pharmacological </text>
<text top="209" left="481" width="144" height="17" font="13">treatment, ability to speak </text>
<text top="226" left="481" width="136" height="17" font="13">and understand Turkish, </text>
<text top="243" left="481" width="125" height="17" font="13">absence of psychiatric </text>
<text top="261" left="481" width="139" height="17" font="13">disease, ability to remain </text>
<text top="278" left="481" width="152" height="17" font="13">stable during exercise tests </text>
<text top="54" left="649" width="139" height="17" font="13">Neurological, orthopedic, </text>
<text top="71" left="649" width="125" height="17" font="13">peripheral vascular, or </text>
<text top="88" left="649" width="150" height="17" font="13">severe pulmonary disease, </text>
<text top="106" left="649" width="87" height="17" font="13">NYHA class IV, </text>
<text top="123" left="649" width="70" height="17" font="13">UA pectoris, </text>
<text top="140" left="649" width="108" height="17" font="13">poorly controlled or </text>
<text top="157" left="649" width="139" height="17" font="13">exercise-induced cardiac </text>
<text top="174" left="649" width="71" height="17" font="13">arrhythmias, </text>
<text top="192" left="649" width="81" height="17" font="13">recent ACS or </text>
<text top="209" left="649" width="145" height="17" font="13">revascularization (&lt;3 mo), </text>
<text top="226" left="649" width="135" height="17" font="13">significant valvular heart </text>
<text top="243" left="649" width="142" height="17" font="13">disease, AF, uncontrolled </text>
<text top="261" left="649" width="135" height="17" font="13">arterial HTN, performing </text>
<text top="278" left="649" width="148" height="17" font="13">exercise training at regular </text>
<text top="295" left="649" width="107" height="17" font="13">intervals during the </text>
<text top="312" left="649" width="82" height="17" font="13">previous 6 wk. </text>
<text top="54" left="815" width="103" height="17" font="13">Exercise capacity, </text>
<text top="71" left="815" width="107" height="17" font="13">QoL, psychological </text>
<text top="88" left="815" width="87" height="17" font="13">symptoms, and </text>
<text top="106" left="815" width="80" height="17" font="13">hemodynamic </text>
<text top="123" left="815" width="66" height="17" font="13">parameters </text>
<text top="54" left="953" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1056" width="216" height="17" font="13">After the exercise programs, significant </text>
<text top="71" left="1056" width="194" height="17" font="13">improvement was observed in both </text>
<text top="88" left="1056" width="162" height="17" font="13">groups (all p&lt;0.05) including: </text>
<text top="106" left="1056" width="49" height="17" font="13">Peak VO</text>
<text top="111" left="1105" width="9" height="11" font="19">2; </text>
<text top="106" left="1114" width="117" height="17" font="13">6MWT; Subscales of </text>
<text top="123" left="1056" width="207" height="17" font="13">physical function, general health, and </text>
<text top="140" left="1056" width="127" height="17" font="13">vitality of short form 36 </text>
<text top="157" left="1056" width="150" height="17" font="13">Beck Depression Inventory </text>
<text top="174" left="1056" width="34" height="17" font="13">LVEF </text>
<text top="192" left="1056" width="3" height="17" font="13"> </text>
<text top="209" left="1056" width="213" height="17" font="13">A comparison of the 2 exercise groups </text>
<text top="226" left="1056" width="189" height="17" font="13">revealed no significant differences </text>
<text top="243" left="1056" width="209" height="17" font="13">between them regarding the analyzed </text>
<text top="261" left="1056" width="56" height="17" font="13">variables.<b> </b></text>
<text top="278" left="1056" width="3" height="17" font="15"><b> </b></text>
<text top="54" left="1291" width="133" height="17" font="13">Both the hospital-based </text>
<text top="71" left="1291" width="96" height="17" font="13">and home-based </text>
<text top="88" left="1291" width="90" height="17" font="13">exercise groups </text>
<text top="106" left="1291" width="134" height="17" font="13">improved significantly in </text>
<text top="123" left="1291" width="56" height="17" font="13">functional </text>
<text top="140" left="1291" width="82" height="17" font="13">capacity, QoL, </text>
<text top="157" left="1291" width="126" height="17" font="13">depression symptoms, </text>
<text top="174" left="1291" width="117" height="17" font="13">and LVEF. Based on </text>
<text top="192" left="1291" width="138" height="17" font="13">these results, we believe </text>
<text top="209" left="1291" width="108" height="17" font="13">that physicians can </text>
<text top="226" left="1291" width="140" height="17" font="13">recommend home-based </text>
<text top="243" left="1291" width="113" height="17" font="13">exercise under strict </text>
<text top="261" left="1291" width="139" height="17" font="13">supervision for stable HF </text>
<text top="278" left="1291" width="23" height="17" font="13">pts. </text>
<text top="337" left="61" width="63" height="17" font="13">Endurance </text>
<text top="355" left="61" width="93" height="17" font="13">exercise training </text>
<text top="372" left="61" width="89" height="17" font="13">in older pts with </text>
<text top="389" left="61" width="91" height="17" font="13">HF: results from </text>
<text top="406" left="61" width="81" height="17" font="13">a randomized, </text>
<text top="424" left="61" width="96" height="17" font="13">controlled, single-</text>
<text top="441" left="61" width="56" height="17" font="13">blind trial. </text>
<text top="458" left="61" width="93" height="17" font="13">Brubaker, Peter. </text>
<text top="475" left="61" width="31" height="17" font="13">2009 </text>
<text top="492" left="61" width="58" height="17" font="14">20121952 </text>
<text top="492" left="119" width="32" height="17" font="13">(130) </text>
<text top="337" left="174" width="123" height="17" font="13">To determine whether </text>
<text top="355" left="174" width="93" height="17" font="13">exercise training </text>
<text top="372" left="174" width="103" height="17" font="13">improves exercise </text>
<text top="389" left="174" width="124" height="17" font="13">capacity and   HRQoL </text>
<text top="406" left="174" width="116" height="17" font="13">in older persons with </text>
<text top="424" left="174" width="43" height="17" font="13">HFrEF. </text>
<text top="337" left="312" width="29" height="17" font="13">RCT </text>
<text top="337" left="400" width="17" height="17" font="13">59 </text>
<text top="337" left="481" width="63" height="17" font="13">Age &gt;60 y, </text>
<text top="355" left="481" width="124" height="17" font="13">diagnosed with HfrEF, </text>
<text top="372" left="481" width="69" height="17" font="13">LVEF &lt;45% </text>
<text top="337" left="649" width="131" height="17" font="13">Valvular disease as the </text>
<text top="355" left="649" width="147" height="17" font="13">primary etiology of HFrEF, </text>
<text top="372" left="649" width="109" height="17" font="13">recent stroke or MI, </text>
<text top="389" left="649" width="103" height="17" font="13">uncontrolled HTN, </text>
<text top="406" left="649" width="149" height="17" font="13">any other condition limiting </text>
<text top="424" left="649" width="97" height="17" font="13">exercise duration </text>
<text top="337" left="815" width="50" height="17" font="13">Exercise </text>
<text top="355" left="815" width="94" height="17" font="13">performance, LV </text>
<text top="372" left="815" width="125" height="17" font="13">structure and function, </text>
<text top="389" left="815" width="89" height="17" font="13">neuroendocrine </text>
<text top="406" left="815" width="79" height="17" font="13">activation and </text>
<text top="424" left="815" width="48" height="17" font="13">HRQoL. </text>
<text top="337" left="953" width="27" height="17" font="13"> N/A </text>
<text top="337" left="1056" width="189" height="17" font="13">Better in Exercise Training Group: </text>
<text top="355" left="1056" width="196" height="17" font="13">Mean cycle ergometer distance per </text>
<text top="372" left="1056" width="102" height="17" font="13">session (p=0.001) </text>
<text top="389" left="1056" width="206" height="17" font="13">Combined walking &amp; cycling distance </text>
<text top="406" left="1056" width="56" height="17" font="13">(p=0.001) </text>
<text top="424" left="1056" width="174" height="17" font="13">Peak exercise workload (watts) </text>
<text top="441" left="1056" width="56" height="17" font="13">(p=0.007) </text>
<text top="458" left="1056" width="198" height="17" font="13">Exercise time (seconds) on the bike </text>
<text top="475" left="1056" width="56" height="17" font="13">(p=0.002) </text>
<text top="492" left="1056" width="197" height="17" font="13">All other outcome measures did not </text>
<text top="510" left="1056" width="103" height="17" font="13">show significance. </text>
<text top="337" left="1291" width="98" height="17" font="13">Failed to produce </text>
<text top="355" left="1291" width="128" height="17" font="13">consistent benefits in a </text>
<text top="372" left="1291" width="137" height="17" font="13">cohort or elderly pts with </text>
<text top="389" left="1291" width="123" height="17" font="13">HFrEF that included a </text>
<text top="406" left="1291" width="113" height="17" font="13">significant portion of </text>
<text top="424" left="1291" width="124" height="17" font="13">women. Exercise time </text>
<text top="441" left="1291" width="107" height="17" font="13">and peak workload </text>
<text top="458" left="1291" width="95" height="17" font="13">increased but VO</text>
<text top="464" left="1386" width="4" height="11" font="19">2</text>
<text top="458" left="1390" width="37" height="17" font="13"> peak, </text>
<text top="475" left="1291" width="139" height="17" font="13">the primary outcome, did </text>
<text top="492" left="1291" width="118" height="17" font="13">not. Exercise training </text>
<text top="510" left="1291" width="137" height="17" font="13">failed to provide benefits </text>
<text top="527" left="1291" width="125" height="17" font="13">in any of the 4 primary </text>
<text top="544" left="1291" width="60" height="17" font="13">endpoints. </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">52</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="55" height="17" font="13">Effects of </text>
<text top="71" left="61" width="93" height="17" font="13">exercise training </text>
<text top="88" left="61" width="90" height="17" font="13">on health status </text>
<text top="106" left="61" width="58" height="17" font="13">in pts with </text>
<text top="123" left="61" width="66" height="17" font="13">chronic HF. </text>
<text top="140" left="61" width="86" height="17" font="13">Flynn, Kathryn. </text>
<text top="157" left="61" width="31" height="17" font="13">2009 </text>
<text top="174" left="61" width="58" height="17" font="14">19351942 </text>
<text top="174" left="119" width="32" height="17" font="13">(131) </text>
<text top="54" left="174" width="115" height="17" font="13">To test the effects of </text>
<text top="71" left="174" width="110" height="17" font="13">exercise training on </text>
<text top="88" left="174" width="114" height="17" font="13">health status among </text>
<text top="106" left="174" width="68" height="17" font="13">pts with HF. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="34" height="17" font="13">2,331 </text>
<text top="54" left="481" width="148" height="17" font="13">Medically stable, HF outpt, </text>
<text top="71" left="481" width="73" height="17" font="13">LVEF &lt;35%, </text>
<text top="88" left="481" width="67" height="17" font="13">NYHA II-IV, </text>
<text top="106" left="481" width="135" height="17" font="13">ability and willingness to </text>
<text top="123" left="481" width="141" height="17" font="13">undergo exercise training </text>
<text top="54" left="649" width="109" height="17" font="13">Unable to exercise, </text>
<text top="71" left="649" width="103" height="17" font="13">already exercising </text>
<text top="88" left="649" width="98" height="17" font="13">regularly (&gt;1/wk), </text>
<text top="106" left="649" width="139" height="17" font="13">had experienced a major </text>
<text top="123" left="649" width="148" height="17" font="13">CV event in the previous 6 </text>
<text top="140" left="649" width="18" height="17" font="13">wk </text>
<text top="54" left="815" width="75" height="17" font="13">Health status </text>
<text top="71" left="815" width="96" height="17" font="13">(assessed by the </text>
<text top="88" left="815" width="43" height="17" font="13">KCCQ) </text>
<text top="54" left="953" width="7" height="17" font="13">  </text>
<text top="54" left="1056" width="199" height="17" font="13">At 3 mo the KCCQ overall summary </text>
<text top="71" left="1056" width="211" height="17" font="13">score improved by a greater degree in </text>
<text top="88" left="1056" width="208" height="17" font="13">the exercise training group (p&lt; 0.001; </text>
<text top="106" left="1056" width="107" height="17" font="13">95% CI: 0.84-3.01) </text>
<text top="123" left="1056" width="3" height="17" font="13"> </text>
<text top="140" left="1056" width="221" height="17" font="13">At 3 mo there were no further significant </text>
<text top="157" left="1056" width="187" height="17" font="13">changes in KCCQ score for either </text>
<text top="174" left="1056" width="214" height="17" font="13">group (p= 0.85), resulting in sustained, </text>
<text top="192" left="1056" width="195" height="17" font="13">greater improvement overall for the </text>
<text top="209" left="1056" width="147" height="17" font="13">exercise group (p&lt; 0.001). </text>
<text top="226" left="1056" width="3" height="17" font="13"> </text>
<text top="243" left="1056" width="215" height="17" font="13">Changes from baseline to 12 mo in the </text>
<text top="261" left="1056" width="196" height="17" font="13">KCCQ overall summary score were </text>
<text top="278" left="1056" width="200" height="17" font="13">associated with changes in exercise </text>
<text top="295" left="1056" width="30" height="17" font="13">time: </text>
<text top="312" left="1056" width="219" height="17" font="13">Cardiopulmonary exercise test: (r=0.28; </text>
<text top="329" left="1056" width="59" height="17" font="13">p&lt; 0.001)  </text>
<text top="347" left="1056" width="192" height="17" font="13">Peak O2 consumption: (r=0.21; p&lt; </text>
<text top="364" left="1056" width="42" height="17" font="13">0.001)  </text>
<text top="381" left="1056" width="3" height="17" font="13"> </text>
<text top="398" left="1056" width="213" height="17" font="13">6-min walk distance (r=0.18; p&lt;0.001)  </text>
<text top="415" left="1056" width="3" height="17" font="13"> </text>
<text top="433" left="1056" width="217" height="17" font="13">Based on these relationships, a 49.7-m </text>
<text top="450" left="1056" width="219" height="17" font="13">change in distance walked corresponds </text>
<text top="467" left="1056" width="215" height="17" font="13">to an individual's change of 5 points on </text>
<text top="484" left="1056" width="190" height="17" font="13">the KCCQ overall summary score. </text>
<text top="54" left="1291" width="94" height="17" font="13">Exercise training </text>
<text top="71" left="1291" width="120" height="17" font="13">conferred modest but </text>
<text top="88" left="1291" width="121" height="17" font="13">statistically significant </text>
<text top="106" left="1291" width="117" height="17" font="13">improvements in self-</text>
<text top="123" left="1291" width="122" height="17" font="13">reported health status </text>
<text top="140" left="1291" width="116" height="17" font="13">compared with usual </text>
<text top="157" left="1291" width="117" height="17" font="13">care without training. </text>
<text top="174" left="1291" width="133" height="17" font="13">Improvements occurred </text>
<text top="192" left="1291" width="135" height="17" font="13">early and persisted over </text>
<text top="209" left="1291" width="30" height="17" font="13">time. </text>
<text top="520" left="61" width="64" height="17" font="13">Resistance </text>
<text top="537" left="61" width="100" height="17" font="13">training increases </text>
<text top="555" left="61" width="62" height="17" font="13">6-min walk </text>
<text top="572" left="61" width="62" height="17" font="13">distance in </text>
<text top="589" left="61" width="66" height="17" font="13">people with </text>
<text top="606" left="61" width="77" height="17" font="13">chronic HF: a </text>
<text top="624" left="61" width="61" height="17" font="13">systematic </text>
<text top="641" left="61" width="88" height="17" font="13">review. Hwang, </text>
<text top="658" left="61" width="75" height="17" font="13">Chueh-Lung. </text>
<text top="675" left="61" width="31" height="17" font="13">2010 </text>
<text top="692" left="61" width="58" height="17" font="14">20482475 </text>
<text top="692" left="119" width="32" height="17" font="13">(132) </text>
<text top="520" left="174" width="85" height="17" font="13">To determine if </text>
<text top="537" left="174" width="103" height="17" font="13">resistance training </text>
<text top="555" left="174" width="85" height="17" font="13">improves heart </text>
<text top="572" left="174" width="99" height="17" font="13">function, exercise </text>
<text top="589" left="174" width="112" height="17" font="13">capacity and QoL in </text>
<text top="606" left="174" width="109" height="17" font="13">people with chronic </text>
<text top="624" left="174" width="96" height="17" font="13">HF more than no </text>
<text top="641" left="174" width="114" height="17" font="13">intervention or usual </text>
<text top="658" left="174" width="31" height="17" font="13">care. </text>
<text top="520" left="312" width="63" height="17" font="13">Systematic </text>
<text top="537" left="312" width="64" height="17" font="13">review with </text>
<text top="555" left="312" width="31" height="17" font="13">meta-</text>
<text top="572" left="312" width="61" height="17" font="13">analysis of </text>
<text top="589" left="312" width="68" height="17" font="13">randomized </text>
<text top="606" left="312" width="29" height="17" font="13">trials </text>
<text top="520" left="400" width="44" height="17" font="13">241 pts </text>
<text top="537" left="400" width="68" height="17" font="13">from 8 trials </text>
<text top="520" left="481" width="126" height="17" font="13">Adults with chronic HF </text>
<text top="537" left="481" width="152" height="17" font="13">Diagnosis based on clinical </text>
<text top="555" left="481" width="116" height="17" font="13">signs or LVEF &lt;40% </text>
<text top="520" left="649" width="85" height="17" font="13">None specified </text>
<text top="520" left="815" width="96" height="17" font="13">Cardiac function, </text>
<text top="537" left="815" width="101" height="17" font="13">exercise capacity, </text>
<text top="555" left="815" width="30" height="17" font="13">QoL. </text>
<text top="520" left="953" width="27" height="17" font="13"> N/A </text>
<text top="520" left="1056" width="175" height="17" font="13">Resistance training significantly </text>
<text top="537" left="1056" width="209" height="17" font="13">increased 6-min walk distance: WMD: </text>
<text top="555" left="1056" width="120" height="17" font="13">52m; 95% CI: 19-85  <b> </b></text>
<text top="520" left="1291" width="108" height="17" font="13">Resistance training </text>
<text top="537" left="1291" width="119" height="17" font="13">increased 6-min walk </text>
<text top="555" left="1291" width="138" height="17" font="13">distance compared to no </text>
<text top="572" left="1291" width="140" height="17" font="13">training, but had no other </text>
<text top="589" left="1291" width="107" height="17" font="13">benefits on cardiac </text>
<text top="606" left="1291" width="99" height="17" font="13">function, exercise </text>
<text top="624" left="1291" width="133" height="17" font="13">capacity, or QoL if used </text>
<text top="641" left="1291" width="138" height="17" font="13">along or as an adjunct to </text>
<text top="658" left="1291" width="141" height="17" font="13">aerobic training in people </text>
<text top="675" left="1291" width="92" height="17" font="13">with chronic HF. </text>
</page>
<page number="53" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">53</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="79" height="17" font="13">A randomized </text>
<text top="71" left="61" width="57" height="17" font="13">trial of the </text>
<text top="88" left="61" width="95" height="17" font="13">addition of home-</text>
<text top="106" left="61" width="100" height="17" font="13">based exercise to </text>
<text top="123" left="61" width="74" height="17" font="13">specialist HF </text>
<text top="140" left="61" width="85" height="17" font="13">nurse care: the </text>
<text top="157" left="61" width="69" height="17" font="13">Birmingham </text>
<text top="174" left="61" width="78" height="17" font="13">Rehabilitation </text>
<text top="192" left="61" width="42" height="17" font="13">Uptake </text>
<text top="209" left="61" width="75" height="17" font="13">Maximization </text>
<text top="226" left="61" width="96" height="17" font="13">study for pts with </text>
<text top="243" left="61" width="73" height="17" font="13">CHF (BRUM-</text>
<text top="261" left="61" width="69" height="17" font="13">CHF) study. </text>
<text top="278" left="61" width="95" height="17" font="13">Jolly, Kate. 2009 </text>
<text top="295" left="61" width="58" height="17" font="14">19168520 </text>
<text top="295" left="119" width="32" height="17" font="13">(133) </text>
<text top="54" left="174" width="80" height="17" font="13">To assess the </text>
<text top="71" left="174" width="99" height="17" font="13">effectiveness of a </text>
<text top="88" left="174" width="121" height="17" font="13">home-based exercise </text>
<text top="106" left="174" width="122" height="17" font="13">program in addition to </text>
<text top="123" left="174" width="108" height="17" font="13">specialist HF nurse </text>
<text top="140" left="174" width="31" height="17" font="13">care. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="24" height="17" font="13">169 </text>
<text top="54" left="481" width="129" height="17" font="13">LVEF &lt;40% on ECHO; </text>
<text top="71" left="481" width="137" height="17" font="13">had a severity of at least </text>
<text top="88" left="481" width="148" height="17" font="13">NYHA II in the previous 24 </text>
<text top="106" left="481" width="24" height="17" font="13">mo; </text>
<text top="123" left="481" width="148" height="17" font="13">clinically stable for 4 wk; in </text>
<text top="140" left="481" width="143" height="17" font="13">receipt of optimal medical </text>
<text top="157" left="481" width="154" height="17" font="13">treatment and in the care of </text>
<text top="174" left="481" width="149" height="17" font="13">a specialist HF nurse team </text>
<text top="192" left="481" width="151" height="17" font="13">from 2 acute hospital trusts </text>
<text top="209" left="481" width="146" height="17" font="13">and 1 primary care trust in </text>
<text top="226" left="481" width="146" height="17" font="13">the West-Midlands region, </text>
<text top="243" left="481" width="24" height="17" font="13">UK; </text>
<text top="261" left="481" width="152" height="17" font="13">not considered high-risk for </text>
<text top="278" left="481" width="131" height="17" font="13">a home-based exercise </text>
<text top="295" left="481" width="53" height="17" font="13">program. </text>
<text top="54" left="649" width="53" height="17" font="13">NYHA IV </text>
<text top="71" left="649" width="21" height="17" font="13">MI; </text>
<text top="88" left="649" width="151" height="17" font="13">revascularization within the </text>
<text top="106" left="649" width="61" height="17" font="13">past 4 mo; </text>
<text top="123" left="649" width="73" height="17" font="13">hypotension; </text>
<text top="140" left="649" width="24" height="17" font="13">UA; </text>
<text top="157" left="649" width="147" height="17" font="13">ventricular or symptomatic </text>
<text top="174" left="649" width="71" height="17" font="13">arrhythmias; </text>
<text top="192" left="649" width="142" height="17" font="13">obstructive aortic valvular </text>
<text top="209" left="649" width="49" height="17" font="13">disease; </text>
<text top="226" left="649" width="42" height="17" font="13">COPD; </text>
<text top="243" left="649" width="134" height="17" font="13">hypertrophic obstructive </text>
<text top="261" left="649" width="94" height="17" font="13">cardiomyopathy; </text>
<text top="278" left="649" width="131" height="17" font="13">severe musculoskeletal </text>
<text top="295" left="649" width="115" height="17" font="13">problems preventing </text>
<text top="312" left="649" width="53" height="17" font="13">exercise; </text>
<text top="329" left="649" width="107" height="17" font="13">case-note reported </text>
<text top="347" left="649" width="57" height="17" font="13">dementia; </text>
<text top="364" left="649" width="144" height="17" font="13">current severe psychiatric </text>
<text top="381" left="649" width="48" height="17" font="13">disorder </text>
<text top="54" left="815" width="120" height="17" font="13">Disease-specific QoL </text>
<text top="71" left="815" width="95" height="17" font="13">measured by the </text>
<text top="88" left="815" width="46" height="17" font="13">MLHFQ </text>
<text top="54" left="953" width="62" height="17" font="13">Composite </text>
<text top="71" left="953" width="64" height="17" font="13">outcome of </text>
<text top="88" left="953" width="49" height="17" font="13">death or </text>
<text top="106" left="953" width="84" height="17" font="13">admission with </text>
<text top="123" left="953" width="34" height="17" font="13">HF or </text>
<text top="140" left="953" width="63" height="17" font="13">myocardial </text>
<text top="157" left="953" width="57" height="17" font="13">infarction. </text>
<text top="174" left="953" width="79" height="17" font="13">Psychological </text>
<text top="192" left="953" width="81" height="17" font="13">wellbeing, self-</text>
<text top="209" left="953" width="49" height="17" font="13">reported </text>
<text top="226" left="953" width="48" height="17" font="13">physical </text>
<text top="243" left="953" width="78" height="17" font="13">activity, blood </text>
<text top="261" left="953" width="55" height="17" font="13">pressure, </text>
<text top="278" left="953" width="44" height="17" font="13">generic </text>
<text top="295" left="953" width="72" height="17" font="13">HRQoL, and </text>
<text top="312" left="953" width="64" height="17" font="13">health care </text>
<text top="329" left="953" width="58" height="17" font="13">utilization. </text>
<text top="54" left="1056" width="209" height="17" font="13">At 6 mo, there was no between-group </text>
<text top="71" left="1056" width="209" height="17" font="13">difference in the disease-specific QoL </text>
<text top="88" left="1056" width="161" height="17" font="13">MLHFQ (95% CI: -7.87-2.80) </text>
<text top="106" left="1056" width="3" height="17" font="13"> </text>
<text top="123" left="1056" width="216" height="17" font="13">At 12 mo, there was no between-group </text>
<text top="140" left="1056" width="209" height="17" font="13">difference in the disease-specific QoL </text>
<text top="157" left="1056" width="161" height="17" font="13">MLHFQ (95% CI: -5.87-4.76)<b> </b></text>
<text top="174" left="1056" width="3" height="17" font="13"> </text>
<text top="192" left="1056" width="3" height="17" font="13"> </text>
<text top="209" left="1056" width="167" height="17" font="13">The only secondary outcomes </text>
<text top="226" left="1056" width="163" height="17" font="13">significant for exercise group: </text>
<text top="243" left="1056" width="194" height="17" font="13">Higher generic QoL scores at 6 mo </text>
<text top="261" left="1056" width="111" height="17" font="13">(95% CI: 0.04-0.18) </text>
<text top="278" left="1056" width="213" height="17" font="13">Lower hospital anxiety and depression </text>
<text top="295" left="1056" width="211" height="17" font="13">scale score at 12 mo (95% CI: -2.00 - -</text>
<text top="312" left="1056" width="32" height="17" font="13">0.14) </text>
<text top="329" left="1056" width="3" height="17" font="13"> </text>
<text top="347" left="1056" width="191" height="17" font="13">At 6 mo, the control group showed </text>
<text top="364" left="1056" width="177" height="17" font="13">deterioration in physical activity, </text>
<text top="381" left="1056" width="196" height="17" font="13">exercise capacity and generic QoL. </text>
<text top="54" left="1291" width="106" height="17" font="13">This study failed to </text>
<text top="71" left="1291" width="122" height="17" font="13">demonstrate a benefit </text>
<text top="88" left="1291" width="119" height="17" font="13">from the addition of a </text>
<text top="106" left="1291" width="121" height="17" font="13">home-based exercise </text>
<text top="123" left="1291" width="136" height="17" font="13">program in a community-</text>
<text top="140" left="1291" width="120" height="17" font="13">based HF population. </text>
<text top="157" left="1291" width="108" height="17" font="13">Further evidence is </text>
<text top="174" left="1291" width="120" height="17" font="13">needed to assess the </text>
<text top="192" left="1291" width="54" height="17" font="13">suitability </text>
<text top="209" left="1291" width="135" height="17" font="13">of home-based exercise </text>
<text top="226" left="1291" width="91" height="17" font="13">programs in this </text>
<text top="243" left="1291" width="64" height="17" font="13">population. </text>
<text top="405" left="61" width="94" height="17" font="13">Exercise training </text>
<text top="422" left="61" width="89" height="17" font="13">in older pts with </text>
<text top="439" left="61" width="44" height="17" font="13">HF and </text>
<text top="457" left="61" width="81" height="17" font="13">preserved EF. </text>
<text top="474" left="61" width="97" height="17" font="13">Kitzman, Dalane. </text>
<text top="491" left="61" width="31" height="17" font="13">2010 </text>
<text top="508" left="61" width="58" height="17" font="14">20852060 </text>
<text top="508" left="119" width="32" height="17" font="13">(134) </text>
<text top="405" left="174" width="124" height="17" font="13">To test the hypothesis </text>
<text top="422" left="174" width="87" height="17" font="13">that supervised </text>
<text top="439" left="174" width="106" height="17" font="13">exercise training in </text>
<text top="457" left="174" width="118" height="17" font="13">older pts with HFpEF </text>
<text top="474" left="174" width="103" height="17" font="13">would improve the </text>
<text top="491" left="174" width="44" height="17" font="13">primary </text>
<text top="508" left="174" width="94" height="17" font="13">outcome of peak </text>
<text top="525" left="174" width="67" height="17" font="13">exercise VO</text>
<text top="531" left="241" width="4" height="11" font="19">2</text>
<text top="525" left="246" width="48" height="17" font="13"> and the </text>
<text top="543" left="174" width="124" height="17" font="13">secondary outcome of </text>
<text top="560" left="174" width="121" height="17" font="13">disease-specific QoL. </text>
<text top="405" left="312" width="29" height="17" font="13">RCT </text>
<text top="405" left="400" width="17" height="17" font="13">53 </text>
<text top="405" left="481" width="143" height="17" font="13">Stable with no medication </text>
<text top="422" left="481" width="107" height="17" font="13">changes for &gt;6 wk; </text>
<text top="439" left="481" width="146" height="17" font="13">HFpEF defined as history, </text>
<text top="457" left="481" width="149" height="17" font="13">symptoms and signs of HF </text>
<text top="474" left="481" width="140" height="17" font="13">Preserved LVEF (&gt;50%); </text>
<text top="491" left="481" width="141" height="17" font="13">no evidence of significant </text>
<text top="508" left="481" width="115" height="17" font="13">coronary, valvular or </text>
<text top="525" left="481" width="144" height="17" font="13">pulmonary disease or any </text>
<text top="543" left="481" width="154" height="17" font="13">other medical condition that </text>
<text top="560" left="481" width="151" height="17" font="13">could mimic HF symptoms. </text>
<text top="405" left="649" width="106" height="17" font="13">Contraindication to </text>
<text top="422" left="649" width="150" height="17" font="13">exercise testing or training; </text>
<text top="439" left="649" width="110" height="17" font="13">unable to perform a </text>
<text top="457" left="649" width="127" height="17" font="13">valid baseline exercise </text>
<text top="474" left="649" width="27" height="17" font="13">test; </text>
<text top="491" left="649" width="109" height="17" font="13">currently exercising </text>
<text top="508" left="649" width="54" height="17" font="13">regularly; </text>
<text top="525" left="649" width="107" height="17" font="13">had known cancer; </text>
<text top="543" left="649" width="89" height="17" font="13">significant renal </text>
<text top="560" left="649" width="69" height="17" font="13">dysfunction; </text>
<text top="577" left="649" width="100" height="17" font="13">substance abuse; </text>
<text top="594" left="649" width="124" height="17" font="13">uncontrolled diabetes; </text>
<text top="612" left="649" width="57" height="17" font="13">dementia, </text>
<text top="629" left="649" width="145" height="17" font="13">History of noncompliance; </text>
<text top="646" left="649" width="127" height="17" font="13">any other disorder that </text>
<text top="663" left="649" width="86" height="17" font="13">would preclude </text>
<text top="680" left="649" width="103" height="17" font="13">participation in the </text>
<text top="698" left="649" width="147" height="17" font="13">intervention and follow-up. </text>
<text top="405" left="815" width="124" height="17" font="13">Peak exercise oxygen </text>
<text top="422" left="815" width="40" height="17" font="13">uptake </text>
<text top="405" left="953" width="52" height="17" font="13">QoL; LV  </text>
<text top="422" left="953" width="68" height="17" font="13">morphology </text>
<text top="439" left="953" width="74" height="17" font="13">and function, </text>
<text top="457" left="953" width="24" height="17" font="13">and </text>
<text top="474" left="953" width="89" height="17" font="13">neuroendocrine </text>
<text top="491" left="953" width="47" height="17" font="13">function </text>
<text top="405" left="1056" width="221" height="17" font="13">Peak exercise oxygen uptake increased </text>
<text top="422" left="1056" width="205" height="17" font="13">significantly in the exercise treatment </text>
<text top="439" left="1056" width="202" height="17" font="13">group compared to the control group </text>
<text top="457" left="1056" width="70" height="17" font="13">(p= 0.0002). </text>
<text top="474" left="1056" width="3" height="17" font="13"> </text>
<text top="491" left="1056" width="217" height="17" font="13">There were significant improvements in </text>
<text top="508" left="1056" width="198" height="17" font="13">peak power output, exercise time, 6-</text>
<text top="525" left="1056" width="204" height="17" font="13">minute walk distance, and ventilatory </text>
<text top="543" left="1056" width="57" height="17" font="13">anaerobic </text>
<text top="560" left="1056" width="133" height="17" font="13">threshold (all p&lt; 0.002). </text>
<text top="577" left="1056" width="3" height="17" font="13"> </text>
<text top="594" left="1056" width="217" height="17" font="13">There was improvement in the physical </text>
<text top="612" left="1056" width="211" height="17" font="13">quality of life score (but not in the total </text>
<text top="629" left="1056" width="94" height="17" font="13">score) (p= 0.03).<b> </b></text>
<text top="405" left="1291" width="98" height="17" font="13">This randomized, </text>
<text top="422" left="1291" width="126" height="17" font="13">controlled, single-blind </text>
<text top="439" left="1291" width="103" height="17" font="13">study showed that </text>
<text top="457" left="1291" width="142" height="17" font="13">16 wk of exercise training </text>
<text top="474" left="1291" width="76" height="17" font="13">was safe and </text>
<text top="491" left="1291" width="121" height="17" font="13">significantly improved </text>
<text top="508" left="1291" width="123" height="17" font="13">peak and submaximal </text>
<text top="525" left="1291" width="135" height="17" font="13">exercise performance in </text>
<text top="543" left="1291" width="76" height="17" font="13">older pts with </text>
<text top="560" left="1291" width="123" height="17" font="13">HFpEF. These results </text>
<text top="577" left="1291" width="93" height="17" font="13">suggest that this </text>
<text top="594" left="1291" width="114" height="17" font="13">nonpharmacological </text>
<text top="612" left="1291" width="121" height="17" font="13">intervention may be a </text>
<text top="629" left="1291" width="138" height="17" font="13">worthwhile consideration </text>
<text top="646" left="1291" width="136" height="17" font="13">for pts with this common </text>
<text top="663" left="1291" width="92" height="17" font="13">and increasingly </text>
<text top="680" left="1291" width="105" height="17" font="13">prevalent disorder. </text>
</page>
<page number="54" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">54</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="55" height="17" font="13">Effects of </text>
<text top="71" left="61" width="93" height="17" font="13">exercise training </text>
<text top="88" left="61" width="81" height="17" font="13">in pts with HF: </text>
<text top="106" left="61" width="70" height="17" font="13">the exercise </text>
<text top="123" left="61" width="96" height="17" font="13">rehabilitation trial </text>
<text top="140" left="61" width="56" height="17" font="13">(EXERT). </text>
<text top="157" left="61" width="57" height="17" font="13">McKelvie, </text>
<text top="174" left="61" width="75" height="17" font="13">Robert. 2002 </text>
<text top="192" left="61" width="58" height="17" font="14">12094184 </text>
<text top="192" left="119" width="32" height="17" font="13">(135) </text>
<text top="54" left="174" width="88" height="17" font="13">To examine the </text>
<text top="71" left="174" width="102" height="17" font="13">effects of exercise </text>
<text top="88" left="174" width="117" height="17" font="13">training on functional </text>
<text top="106" left="174" width="107" height="17" font="13">capacity in pts with </text>
<text top="123" left="174" width="23" height="17" font="13">HF. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="24" height="17" font="13">181 </text>
<text top="54" left="481" width="146" height="17" font="13">Documented clinical signs </text>
<text top="71" left="481" width="117" height="17" font="13">and symptoms of HF </text>
<text top="88" left="481" width="73" height="17" font="13">LVEF &lt;40%, </text>
<text top="106" left="481" width="62" height="17" font="13">NYHA I-III, </text>
<text top="123" left="481" width="120" height="17" font="13">6MWT distance &lt;500 </text>
<text top="140" left="481" width="41" height="17" font="13">meters </text>
<text top="54" left="649" width="138" height="17" font="13">Inability to attend regular </text>
<text top="71" left="649" width="148" height="17" font="13">exercise training sessions; </text>
<text top="88" left="649" width="144" height="17" font="13">exercise testing limited by </text>
<text top="106" left="649" width="146" height="17" font="13">angina or leg claudication; </text>
<text top="123" left="649" width="139" height="17" font="13">abnormal blood pressure </text>
<text top="140" left="649" width="117" height="17" font="13">response to exercise </text>
<text top="157" left="649" width="47" height="17" font="13">testing;  </text>
<text top="174" left="649" width="105" height="17" font="13">cerebrovascular or </text>
<text top="192" left="649" width="91" height="17" font="13">musculoskeletal </text>
<text top="209" left="649" width="107" height="17" font="13">disease preventing </text>
<text top="226" left="649" width="150" height="17" font="13">exercise testing or training; </text>
<text top="243" left="649" width="120" height="17" font="13">respiratory limitation;  </text>
<text top="261" left="649" width="94" height="17" font="13">poorly controlled </text>
<text top="278" left="649" width="114" height="17" font="13">cardiac arrhythmias; </text>
<text top="295" left="649" width="139" height="17" font="13">any noncardiac condition </text>
<text top="312" left="649" width="141" height="17" font="13">affecting regular exercise </text>
<text top="329" left="649" width="122" height="17" font="13">training or decreasing </text>
<text top="347" left="649" width="48" height="17" font="13">survival. </text>
<text top="54" left="815" width="269" height="17" font="13">6MWT Peak </text>
<text top="54" left="985" width="142" height="17" font="13">oxygen </text>
<text top="71" left="953" width="44" height="17" font="13">uptake, </text>
<text top="88" left="953" width="49" height="17" font="13">dynamic </text>
<text top="106" left="953" width="42" height="17" font="13">muscle </text>
<text top="123" left="953" width="81" height="17" font="13">strength, QoL, </text>
<text top="140" left="953" width="67" height="17" font="13">and cardiac </text>
<text top="157" left="953" width="47" height="17" font="13">function </text>
<text top="54" left="1056" width="185" height="17" font="13">Significant increase in 6-min walk </text>
<text top="71" left="1056" width="215" height="17" font="13">distance at 3 and 12 mo (p= 0.026) but </text>
<text top="88" left="1056" width="188" height="17" font="13">no between-group differences (p= </text>
<text top="106" left="1056" width="42" height="17" font="13">0.081). </text>
<text top="123" left="1056" width="3" height="17" font="13"> </text>
<text top="140" left="1056" width="181" height="17" font="13">Incremental peak oxygen uptake </text>
<text top="157" left="1056" width="174" height="17" font="13">increased in the exercise group </text>
<text top="174" left="1056" width="162" height="17" font="13">compared with control group: </text>
<text top="192" left="1056" width="109" height="17" font="13">At 3 mo: (p=0.014); </text>
<text top="209" left="1056" width="112" height="17" font="13">At 12 mo: (p=0.014) </text>
<text top="226" left="1056" width="3" height="17" font="13"> </text>
<text top="243" left="1056" width="193" height="17" font="13">At 3 mo, compared with the control </text>
<text top="261" left="1056" width="217" height="17" font="13">group, increases were seen in exercise </text>
<text top="278" left="1056" width="56" height="17" font="13">group for: </text>
<text top="295" left="1056" width="76" height="17" font="13">Arm Curl and </text>
<text top="312" left="1056" width="149" height="17" font="13">Knee Extension: (p=0.014) </text>
<text top="329" left="1056" width="3" height="17" font="13"> </text>
<text top="347" left="1056" width="194" height="17" font="13">No significant changes observed in </text>
<text top="364" left="1056" width="134" height="17" font="13">cardiac function or QoL. </text>
<text top="54" left="1291" width="94" height="17" font="13">Exercise training </text>
<text top="71" left="1291" width="127" height="17" font="13">improves peak oxygen </text>
<text top="88" left="1291" width="112" height="17" font="13">uptake and strength </text>
<text top="106" left="1291" width="101" height="17" font="13">during supervised </text>
<text top="123" left="1291" width="124" height="17" font="13">training. Over the final </text>
<text top="140" left="1291" width="133" height="17" font="13">9 mo of the study, there </text>
<text top="157" left="1291" width="89" height="17" font="13">was little further </text>
<text top="174" left="1291" width="141" height="17" font="13">improvement, suggesting </text>
<text top="192" left="1291" width="135" height="17" font="13">that some supervision is </text>
<text top="209" left="1291" width="123" height="17" font="13">required for these pts. </text>
<text top="226" left="1291" width="130" height="17" font="13">There were no adverse </text>
<text top="243" left="1291" width="100" height="17" font="13">effects on cardiac </text>
<text top="261" left="1291" width="101" height="17" font="13">function or clinical </text>
<text top="278" left="1291" width="43" height="17" font="13">events. </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">55</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="59" height="17" font="13">Combined </text>
<text top="71" left="61" width="85" height="17" font="13">endurance and </text>
<text top="88" left="61" width="90" height="17" font="13">muscle strength </text>
<text top="106" left="61" width="97" height="17" font="13">training in female </text>
<text top="123" left="61" width="99" height="17" font="13">and male pts with </text>
<text top="140" left="61" width="66" height="17" font="13">chronic HF. </text>
<text top="157" left="61" width="81" height="17" font="13">Miche, Eckart. </text>
<text top="174" left="61" width="31" height="17" font="13">2008 </text>
<text top="192" left="61" width="58" height="17" font="14">18432395 </text>
<text top="192" left="119" width="32" height="17" font="13">(136) </text>
<text top="54" left="174" width="122" height="17" font="13">To evaluate the effect </text>
<text top="71" left="174" width="81" height="17" font="13">of a combined </text>
<text top="88" left="174" width="85" height="17" font="13">endurance and </text>
<text top="106" left="174" width="90" height="17" font="13">muscle strength </text>
<text top="123" left="174" width="110" height="17" font="13">training program on </text>
<text top="140" left="174" width="113" height="17" font="13">clinical performance </text>
<text top="157" left="174" width="89" height="17" font="13">data and health-</text>
<text top="174" left="174" width="115" height="17" font="13">related psychosocial </text>
<text top="192" left="174" width="120" height="17" font="13">factors in women and </text>
<text top="209" left="174" width="31" height="17" font="13">men. </text>
<text top="54" left="312" width="27" height="17" font="13">Non-</text>
<text top="71" left="312" width="68" height="17" font="13">randomized </text>
<text top="88" left="312" width="74" height="17" font="13">study of men </text>
<text top="106" left="312" width="66" height="17" font="13">vs. women. </text>
<text top="54" left="400" width="24" height="17" font="13">285 </text>
<text top="54" left="481" width="105" height="17" font="13">Stable chronic HF; </text>
<text top="71" left="481" width="73" height="17" font="13">LVEF &lt;45%; </text>
<text top="88" left="481" width="143" height="17" font="13">Peak VO2 &lt;20 ml/min/kg; </text>
<text top="106" left="481" width="120" height="17" font="13">capable of answering </text>
<text top="123" left="481" width="142" height="17" font="13">questions on HRQoL and </text>
<text top="140" left="481" width="140" height="17" font="13">psychological well-being. </text>
<text top="54" left="649" width="103" height="17" font="13">Severe pulmonary </text>
<text top="71" left="649" width="57" height="17" font="13">disorders; </text>
<text top="88" left="649" width="115" height="17" font="13">neurological deficits; </text>
<text top="106" left="649" width="130" height="17" font="13">cognitive disorders and </text>
<text top="123" left="649" width="143" height="17" font="13">physical disabilities which </text>
<text top="140" left="649" width="106" height="17" font="13">prevented pts from </text>
<text top="157" left="649" width="137" height="17" font="13">participating in a training </text>
<text top="174" left="649" width="53" height="17" font="13">program. </text>
<text top="54" left="815" width="38" height="17" font="13">LVEF, </text>
<text top="71" left="815" width="94" height="17" font="13">cardiopulmonary </text>
<text top="88" left="815" width="103" height="17" font="13">performance, QoL </text>
<text top="54" left="953" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1056" width="198" height="17" font="13">Women had a diagnosis of non-IHD </text>
<text top="71" left="1056" width="178" height="17" font="13">and valvular heart disease more </text>
<text top="88" left="1056" width="118" height="17" font="13">commonly than men. </text>
<text top="106" left="1056" width="3" height="17" font="13"> </text>
<text top="123" left="1056" width="94" height="17" font="13">LVEF increased: </text>
<text top="140" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="157" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="174" left="1056" width="3" height="17" font="13"> </text>
<text top="192" left="1056" width="108" height="17" font="13">LVEDV decreased: </text>
<text top="209" left="1056" width="103" height="17" font="13">Female: p&lt;0.05     </text>
<text top="226" left="1056" width="75" height="17" font="13">Male: p&lt;0.05 </text>
<text top="243" left="1056" width="3" height="17" font="13"> </text>
<text top="261" left="1056" width="47" height="17" font="13">LVESV: </text>
<text top="278" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="295" left="1056" width="85" height="17" font="13">Male: p&lt;0.001  </text>
<text top="312" left="1056" width="3" height="17" font="13"> </text>
<text top="329" left="1056" width="63" height="17" font="13">Peak VO2: </text>
<text top="347" left="1056" width="123" height="17" font="13">Female: p NS              </text>
<text top="364" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="381" left="1056" width="3" height="17" font="13"> </text>
<text top="398" left="1056" width="79" height="17" font="13">Wattmax (W): </text>
<text top="415" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="433" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="450" left="1056" width="3" height="17" font="13"> </text>
<text top="467" left="1056" width="65" height="17" font="13">6MWT (m): </text>
<text top="484" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="501" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="519" left="1056" width="3" height="17" font="13"> </text>
<text top="536" left="1056" width="137" height="17" font="13">Muscle strength training: </text>
<text top="553" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="570" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="588" left="1056" width="3" height="17" font="13"> </text>
<text top="605" left="1056" width="92" height="17" font="13">Physical Health: </text>
<text top="622" left="1056" width="106" height="17" font="13">Female: p&lt;0.001    </text>
<text top="639" left="1056" width="82" height="17" font="13">Male: p&lt;0.001 </text>
<text top="656" left="1056" width="3" height="17" font="13"> </text>
<text top="674" left="1056" width="83" height="17" font="13">Mental Health: </text>
<text top="691" left="1056" width="106" height="17" font="13">Female: p&lt;0.01      </text>
<text top="708" left="1056" width="75" height="17" font="13">Male: p&lt;0.05 </text>
<text top="54" left="1291" width="132" height="17" font="13">The results of our study </text>
<text top="71" left="1291" width="142" height="17" font="13">confirm the feasibility of a </text>
<text top="88" left="1291" width="142" height="17" font="13">combined endurance and </text>
<text top="106" left="1291" width="112" height="17" font="13">resistance program, </text>
<text top="123" left="1291" width="122" height="17" font="13">especially for women. </text>
<text top="140" left="1291" width="112" height="17" font="13">Our findings show a </text>
<text top="157" left="1291" width="120" height="17" font="13">considerably reduced </text>
<text top="174" left="1291" width="94" height="17" font="13">cardiopulmonary </text>
<text top="192" left="1291" width="135" height="17" font="13">performance, negatively </text>
<text top="209" left="1291" width="138" height="17" font="13">affecting physical health. </text>
<text top="226" left="1291" width="133" height="17" font="13">In contrast, no essential </text>
<text top="243" left="1291" width="142" height="17" font="13">restrictions were reported </text>
<text top="261" left="1291" width="134" height="17" font="13">by our groups regarding </text>
<text top="278" left="1291" width="107" height="17" font="13">mental health. This </text>
<text top="295" left="1291" width="81" height="17" font="13">underlines the </text>
<text top="312" left="1291" width="136" height="17" font="13">importance of a physical </text>
<text top="329" left="1291" width="133" height="17" font="13">training program and its </text>
<text top="347" left="1291" width="118" height="17" font="13">continuation at home </text>
<text top="364" left="1291" width="117" height="17" font="13">following the hospital </text>
<text top="381" left="1291" width="137" height="17" font="13">stay in order to influence </text>
<text top="398" left="1291" width="100" height="17" font="13">performance data </text>
<text top="415" left="1291" width="57" height="17" font="13">favorably. </text>
</page>
<page number="56" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">56</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="99" height="17" font="13">Long-term effects </text>
<text top="71" left="61" width="96" height="17" font="13">of a group-based </text>
<text top="88" left="61" width="76" height="17" font="13">high-intensity </text>
<text top="106" left="61" width="87" height="17" font="13">aerobic interval-</text>
<text top="123" left="61" width="93" height="17" font="13">training program </text>
<text top="140" left="61" width="58" height="17" font="13">in pts with </text>
<text top="157" left="61" width="66" height="17" font="13">chronic HF. </text>
<text top="174" left="61" width="92" height="17" font="13">Nilsson, Birgitta. </text>
<text top="192" left="61" width="31" height="17" font="13">2008 </text>
<text top="209" left="61" width="58" height="17" font="14">18940296 </text>
<text top="209" left="119" width="32" height="17" font="13">(137) </text>
<text top="54" left="174" width="116" height="17" font="13">To evaluate the long-</text>
<text top="71" left="174" width="103" height="17" font="13">term effects of a 4-</text>
<text top="88" left="174" width="100" height="17" font="13">mo, group-based, </text>
<text top="106" left="174" width="120" height="17" font="13">high-intensity aerobic </text>
<text top="123" left="174" width="87" height="17" font="13">interval training </text>
<text top="140" left="174" width="122" height="17" font="13">program on functional </text>
<text top="157" left="174" width="120" height="17" font="13">capacity and the QoL </text>
<text top="174" left="174" width="124" height="17" font="13">in pts with chronic HF. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="17" height="17" font="13">80 </text>
<text top="54" left="481" width="105" height="17" font="13">Stable chronic HF; </text>
<text top="71" left="481" width="74" height="17" font="13">NYHA II-IIIB; </text>
<text top="88" left="481" width="141" height="17" font="13">receiving optimal medical </text>
<text top="106" left="481" width="59" height="17" font="13">treatment; </text>
<text top="123" left="481" width="144" height="17" font="13">LVEF &lt;40% or &gt;40% with </text>
<text top="140" left="481" width="114" height="17" font="13">clinical symptoms of </text>
<text top="157" left="481" width="68" height="17" font="13">diastolic HF </text>
<text top="54" left="649" width="140" height="17" font="13">Acute MI within 4 wk; UA </text>
<text top="71" left="649" width="50" height="17" font="13">pectoris; </text>
<text top="88" left="649" width="84" height="17" font="13">serious rhythm </text>
<text top="106" left="649" width="70" height="17" font="13">disturbance; </text>
<text top="123" left="649" width="131" height="17" font="13">symptomatic peripheral </text>
<text top="140" left="649" width="98" height="17" font="13">vascular disease; </text>
<text top="157" left="649" width="103" height="17" font="13">severe obstructive </text>
<text top="174" left="649" width="110" height="17" font="13">pulmonary disease; </text>
<text top="192" left="649" width="88" height="17" font="13">6MWT &lt;550 m; </text>
<text top="209" left="649" width="122" height="17" font="13">workload on the cycle </text>
<text top="226" left="649" width="132" height="17" font="13">ergometer test &gt;110 W; </text>
<text top="243" left="649" width="134" height="17" font="13">significant comorbidities </text>
<text top="261" left="649" width="137" height="17" font="13">that would prevent study </text>
<text top="278" left="649" width="115" height="17" font="13">entry due to terminal </text>
<text top="295" left="649" width="135" height="17" font="13">disease or an inability to </text>
<text top="312" left="649" width="129" height="17" font="13">exercise In a long-term </text>
<text top="329" left="649" width="107" height="17" font="13">care establishment </text>
<text top="54" left="815" width="112" height="17" font="13">Functional capacity, </text>
<text top="71" left="815" width="107" height="17" font="13">evaluated by 6-min </text>
<text top="88" left="815" width="97" height="17" font="13">walking distance. </text>
<text top="54" left="953" width="27" height="17" font="13">QoL </text>
<text top="54" left="1056" width="185" height="17" font="13">After 4 mo, in the exercise group: </text>
<text top="71" left="1056" width="163" height="17" font="13">Functional capacity improved </text>
<text top="88" left="1056" width="60" height="17" font="13">(p&lt;0.001), </text>
<text top="106" left="1056" width="140" height="17" font="13">QoL improved (p&lt;0.001). </text>
<text top="123" left="1056" width="3" height="17" font="13"> </text>
<text top="140" left="1056" width="191" height="17" font="13">After 12 mo, in the exercise group: </text>
<text top="157" left="1056" width="184" height="17" font="13">Functional capacity still improved </text>
<text top="174" left="1056" width="60" height="17" font="13">(p&lt;0.001). </text>
<text top="192" left="1056" width="162" height="17" font="13">QoL still improved (p=0.003).<b> </b></text>
<text top="54" left="1291" width="109" height="17" font="13">The results support </text>
<text top="71" left="1291" width="131" height="17" font="13">the implementation of a </text>
<text top="88" left="1291" width="116" height="17" font="13">group-based aerobic </text>
<text top="106" left="1291" width="136" height="17" font="13">interval training program </text>
<text top="123" left="1291" width="116" height="17" font="13">to improve long-term </text>
<text top="140" left="1291" width="113" height="17" font="13">effects on functional </text>
<text top="157" left="1291" width="133" height="17" font="13">capacity and the QoL in </text>
<text top="174" left="1291" width="111" height="17" font="13">pts with chronic HF. </text>
<text top="358" left="61" width="70" height="17" font="13">Efficacy and </text>
<text top="375" left="61" width="99" height="17" font="13">safety of exercise </text>
<text top="392" left="61" width="76" height="17" font="13">training in pts </text>
<text top="409" left="61" width="92" height="17" font="13">with chronic HF. </text>
<text top="427" left="61" width="59" height="17" font="13">O'Connor, </text>
<text top="444" left="61" width="70" height="17" font="13">Christopher. </text>
<text top="461" left="61" width="31" height="17" font="13">2009 </text>
<text top="478" left="61" width="58" height="17" font="14">19351941 </text>
<text top="478" left="119" width="32" height="17" font="13">(138) </text>
<text top="358" left="174" width="107" height="17" font="13">To test the efficacy </text>
<text top="375" left="174" width="123" height="17" font="13">and safety of exercise </text>
<text top="392" left="174" width="105" height="17" font="13">training among pts </text>
<text top="409" left="174" width="49" height="17" font="13">with HF. </text>
<text top="358" left="312" width="178" height="17" font="13">RCT 2331 </text>
<text top="358" left="481" width="79" height="17" font="13">HF </text>
<text top="375" left="481" width="73" height="17" font="13">LVEF &lt;35%, </text>
<text top="392" left="481" width="150" height="17" font="13">NYHA II-IV,despite optimal </text>
<text top="409" left="481" width="154" height="17" font="13">HF therapy for at least 6 wk </text>
<text top="358" left="649" width="124" height="17" font="13">Major comorbidities or </text>
<text top="375" left="649" width="115" height="17" font="13">limitations that could </text>
<text top="392" left="649" width="123" height="17" font="13">interfere with exercise </text>
<text top="409" left="649" width="146" height="17" font="13">training, recent or planned </text>
<text top="427" left="649" width="109" height="17" font="13">major CV events or </text>
<text top="444" left="649" width="68" height="17" font="13">procedures, </text>
<text top="461" left="649" width="128" height="17" font="13">performance of regular </text>
<text top="478" left="649" width="96" height="17" font="13">exercise training, </text>
<text top="495" left="649" width="145" height="17" font="13">use of devices that limited </text>
<text top="513" left="649" width="150" height="17" font="13">the ability to achieve target </text>
<text top="530" left="649" width="66" height="17" font="13">heart rates. </text>
<text top="358" left="815" width="92" height="17" font="13">Composite of all-</text>
<text top="375" left="815" width="117" height="17" font="13">cause mortality or all-</text>
<text top="392" left="815" width="121" height="17" font="13">cause hospitalization. </text>
<text top="358" left="953" width="54" height="17" font="13">All-cause </text>
<text top="375" left="953" width="74" height="17" font="13">mortality, the </text>
<text top="392" left="953" width="59" height="17" font="13">composite </text>
<text top="409" left="953" width="84" height="17" font="13">of CV mortality </text>
<text top="427" left="953" width="35" height="17" font="13">or CV </text>
<text top="444" left="953" width="85" height="17" font="13">hospitalization, </text>
<text top="461" left="953" width="44" height="17" font="13">and the </text>
<text top="478" left="953" width="73" height="17" font="13">composite of </text>
<text top="495" left="953" width="70" height="17" font="13">CV mortality </text>
<text top="513" left="953" width="34" height="17" font="13">or HF </text>
<text top="530" left="953" width="85" height="17" font="13">hospitalization. </text>
<text top="358" left="1056" width="213" height="17" font="13">NS reductions in primary or secondary </text>
<text top="375" left="1056" width="60" height="17" font="13">endpoints. </text>
<text top="392" left="1056" width="3" height="17" font="13"> </text>
<text top="409" left="1056" width="174" height="17" font="13">In prespecificed supplementary </text>
<text top="427" left="1056" width="218" height="17" font="13">analyses adjusting for highly prognostic </text>
<text top="444" left="1056" width="193" height="17" font="13">baseline characteristics there were </text>
<text top="461" left="1056" width="222" height="17" font="13">reductions in the exercise training group </text>
<text top="478" left="1056" width="21" height="17" font="13">for: </text>
<text top="495" left="1056" width="203" height="17" font="13">All-cause mortality or hospitalization: </text>
<text top="513" left="1056" width="159" height="17" font="13">(p=0.03;  95% CI: 0.81-0.99)<b> </b></text>
<text top="530" left="1056" width="7" height="17" font="13">  </text>
<text top="547" left="1056" width="189" height="17" font="13">CV mortality or HF hospitalization: </text>
<text top="564" left="1056" width="159" height="17" font="13">(p=0.03;  95% CI: 0.74-0.99) </text>
<text top="581" left="1056" width="3" height="17" font="15"><b> </b></text>
<text top="599" left="1056" width="3" height="17" font="15"><b> </b></text>
<text top="358" left="1291" width="139" height="17" font="13">Regular exercise training </text>
<text top="375" left="1291" width="122" height="17" font="13">in pts with systolic HF </text>
<text top="392" left="1291" width="137" height="17" font="13">was safe. In the protocol-</text>
<text top="409" left="1291" width="96" height="17" font="13">specified primary </text>
<text top="427" left="1291" width="101" height="17" font="13">analysis, exercise </text>
<text top="444" left="1291" width="104" height="17" font="13">training resulted in </text>
<text top="461" left="1291" width="139" height="17" font="13">nonsignificant reductions </text>
<text top="478" left="1291" width="142" height="17" font="13">in the primary endpoint of </text>
<text top="495" left="1291" width="117" height="17" font="13">all-cause mortality or </text>
<text top="513" left="1291" width="118" height="17" font="13">hospitalization and in </text>
<text top="530" left="1291" width="120" height="17" font="13">secondary endpoints. </text>
<text top="547" left="1291" width="111" height="17" font="13">After adjustment for </text>
<text top="564" left="1291" width="96" height="17" font="13">highly prognostic </text>
<text top="581" left="1291" width="136" height="17" font="13">predictors of the primary </text>
<text top="599" left="1291" width="103" height="17" font="13">endpoint, exercise </text>
<text top="616" left="1291" width="131" height="17" font="13">training was associated </text>
<text top="633" left="1291" width="127" height="17" font="13">with modest significant </text>
<text top="650" left="1291" width="122" height="17" font="13">reductions for both all-</text>
<text top="668" left="1291" width="101" height="17" font="13">cause mortality or </text>
<text top="685" left="1291" width="126" height="17" font="13">hospitalization and CV </text>
<text top="702" left="1291" width="84" height="17" font="13">mortality or HF </text>
<text top="719" left="1291" width="85" height="17" font="13">hospitalization. </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">57</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="94" height="17" font="13">Exercise training </text>
<text top="71" left="61" width="93" height="17" font="13">meta-analysis of </text>
<text top="88" left="61" width="87" height="17" font="13">trials in pts with </text>
<text top="106" left="61" width="63" height="17" font="13">chronic HF </text>
<text top="123" left="61" width="92" height="17" font="13">(ExTraMATCH). </text>
<text top="140" left="61" width="75" height="17" font="13">Piepoli. 2004 </text>
<text top="157" left="61" width="58" height="17" font="14">14729656 </text>
<text top="157" left="119" width="32" height="17" font="13">(139) </text>
<text top="54" left="174" width="96" height="17" font="13">To determine the </text>
<text top="71" left="174" width="96" height="17" font="13">effect of exercise </text>
<text top="88" left="174" width="119" height="17" font="13">training on survival in </text>
<text top="106" left="174" width="121" height="17" font="13">pts with HF due to LV </text>
<text top="123" left="174" width="113" height="17" font="13">systolic dysfunction. </text>
<text top="54" left="312" width="65" height="17" font="13">Collaborativ</text>
<text top="71" left="312" width="42" height="17" font="13">e meta-</text>
<text top="88" left="312" width="48" height="17" font="13">analysis </text>
<text top="54" left="400" width="44" height="17" font="13">801 pts </text>
<text top="71" left="400" width="68" height="17" font="13">from 9 trials </text>
<text top="54" left="481" width="150" height="17" font="13">Randomized parallel group </text>
<text top="71" left="481" width="90" height="17" font="13">controlled trials, </text>
<text top="88" left="481" width="143" height="17" font="13">evaluate exercise training </text>
<text top="106" left="481" width="97" height="17" font="13">without any other </text>
<text top="123" left="481" width="146" height="17" font="13">simultaneous intervention, </text>
<text top="140" left="481" width="148" height="17" font="13">study pts with stable HF (3 </text>
<text top="157" left="481" width="152" height="17" font="13">mo or more of stability) due </text>
<text top="174" left="481" width="137" height="17" font="13">to left systolic ventricular </text>
<text top="192" left="481" width="147" height="17" font="13">dysfunction (LVEF &lt;50%), </text>
<text top="209" left="481" width="146" height="17" font="13">have an exercise program </text>
<text top="226" left="481" width="123" height="17" font="13">lasting 8 wks or more, </text>
<text top="243" left="481" width="143" height="17" font="13">utilize training involving at </text>
<text top="261" left="481" width="116" height="17" font="13">least both legs, have </text>
<text top="278" left="481" width="153" height="17" font="13">survival follow up of ≥3 mo. </text>
<text top="54" left="649" width="141" height="17" font="13">Trials of arm or single leg </text>
<text top="71" left="649" width="127" height="17" font="13">training were excluded </text>
<text top="54" left="815" width="82" height="17" font="13">Time to death. </text>
<text top="54" left="953" width="77" height="17" font="13">Death or time </text>
<text top="71" left="953" width="86" height="17" font="13">to admission to </text>
<text top="88" left="953" width="49" height="17" font="13">hospital. </text>
<text top="54" left="1056" width="202" height="17" font="13">Exercise training significantly reduce </text>
<text top="71" left="1056" width="219" height="17" font="13">mortality (p=0.0015; 95% CI: 0.46-0.92)<b> </b></text>
<text top="88" left="1056" width="3" height="17" font="13"> </text>
<text top="106" left="1056" width="209" height="17" font="13">Exercise training significantly reduced </text>
<text top="123" left="1056" width="219" height="17" font="13">death or admission to hospital (p=0.01   </text>
<text top="140" left="1056" width="110" height="17" font="13">95% CI: 0.56-0.93).<b> </b></text>
<text top="54" left="1291" width="93" height="17" font="13">Meta-analysis of </text>
<text top="71" left="1291" width="129" height="17" font="13">randomized trials gives </text>
<text top="88" left="1291" width="142" height="17" font="13">no evidence that properly </text>
<text top="106" left="1291" width="109" height="17" font="13">supervised medical </text>
<text top="123" left="1291" width="137" height="17" font="13">training programs for pts </text>
<text top="140" left="1291" width="96" height="17" font="13">with HF might be </text>
<text top="157" left="1291" width="129" height="17" font="13">dangerous, and indeed </text>
<text top="174" left="1291" width="140" height="17" font="13">there is clear evidence of </text>
<text top="192" left="1291" width="124" height="17" font="13">an overall reduction in </text>
<text top="209" left="1291" width="53" height="17" font="13">mortality. </text>
<text top="304" left="61" width="96" height="17" font="13">Randomized trial </text>
<text top="321" left="61" width="81" height="17" font="13">of progressive </text>
<text top="338" left="61" width="59" height="17" font="13">resistance </text>
<text top="355" left="61" width="57" height="17" font="13">training to </text>
<text top="373" left="61" width="81" height="17" font="13">counteract the </text>
<text top="390" left="61" width="70" height="17" font="13">myopathy of </text>
<text top="407" left="61" width="88" height="17" font="13">chronic HF. Pu, </text>
<text top="424" left="61" width="80" height="17" font="13">Charles. 2001 </text>
<text top="441" left="61" width="58" height="17" font="14">11356801 </text>
<text top="441" left="119" width="32" height="17" font="13">(140) </text>
<text top="304" left="174" width="115" height="17" font="13">To evaluate whether </text>
<text top="321" left="174" width="105" height="17" font="13">strength training in </text>
<text top="338" left="174" width="85" height="17" font="13">elderly pts with </text>
<text top="355" left="174" width="116" height="17" font="13">chronic HF would be </text>
<text top="373" left="174" width="100" height="17" font="13">well tolerated and </text>
<text top="390" left="174" width="101" height="17" font="13">result in improved </text>
<text top="407" left="174" width="89" height="17" font="13">overall exercise </text>
<text top="424" left="174" width="115" height="17" font="13">performance without </text>
<text top="441" left="174" width="103" height="17" font="13">changes in central </text>
<text top="459" left="174" width="93" height="17" font="13">cardiac function. </text>
<text top="304" left="312" width="29" height="17" font="13">RCT </text>
<text top="304" left="400" width="58" height="17" font="13">96 (16 HF </text>
<text top="321" left="400" width="62" height="17" font="13">80 control) </text>
<text top="304" left="481" width="118" height="17" font="13">Community-dwelling, </text>
<text top="321" left="481" width="44" height="17" font="13">female, </text>
<text top="338" left="481" width="48" height="17" font="13">age &gt;65 </text>
<text top="355" left="481" width="135" height="17" font="13">mild to moderate, stable </text>
<text top="373" left="481" width="67" height="17" font="13">systolic HF, </text>
<text top="390" left="481" width="62" height="17" font="13">NYHA I-III, </text>
<text top="407" left="481" width="110" height="17" font="13">resting LVEF &lt;45% </text>
<text top="304" left="649" width="87" height="17" font="13">NYHA class IV, </text>
<text top="321" left="649" width="86" height="17" font="13">MI within 6 mo, </text>
<text top="338" left="649" width="142" height="17" font="13">hospitalization for chronic </text>
<text top="355" left="649" width="89" height="17" font="13">HF within 2 mo, </text>
<text top="373" left="649" width="122" height="17" font="13">change of HF therapy </text>
<text top="390" left="649" width="69" height="17" font="13">within 1 mo, </text>
<text top="407" left="649" width="100" height="17" font="13">UA pectoris, fixed </text>
<text top="424" left="649" width="152" height="17" font="13">ventricular rate pacemaker, </text>
<text top="441" left="649" width="151" height="17" font="13">abdominal aortic aneurysm </text>
<text top="459" left="649" width="101" height="17" font="13">&gt;4 cm, major limb </text>
<text top="476" left="649" width="140" height="17" font="13">amputation, symptomatic </text>
<text top="493" left="649" width="120" height="17" font="13">abdominal or inguinal </text>
<text top="510" left="649" width="44" height="17" font="13">hernias </text>
<text top="527" left="649" width="143" height="17" font="13">Folstein mini-mental state </text>
<text top="545" left="649" width="131" height="17" font="13">examination score &lt;23, </text>
<text top="562" left="649" width="152" height="17" font="13">significant abnormalities on </text>
<text top="579" left="649" width="139" height="17" font="13">maximal treadmill testing </text>
<text top="596" left="649" width="119" height="17" font="13">or screening strength </text>
<text top="614" left="649" width="40" height="17" font="13">testing </text>
<text top="304" left="815" width="92" height="17" font="13">Overall exercise </text>
<text top="321" left="815" width="115" height="17" font="13">capacity (6-min walk </text>
<text top="338" left="815" width="120" height="17" font="13">distance) and muscle </text>
<text top="355" left="815" width="50" height="17" font="13">function. </text>
<text top="304" left="953" width="42" height="17" font="13">Muscle </text>
<text top="321" left="953" width="66" height="17" font="13">metabolism </text>
<text top="338" left="953" width="79" height="17" font="13">and histology, </text>
<text top="355" left="953" width="30" height="17" font="13">body </text>
<text top="373" left="953" width="72" height="17" font="13">composition, </text>
<text top="390" left="953" width="49" height="17" font="13">maximal </text>
<text top="407" left="953" width="43" height="17" font="13">oxygen </text>
<text top="424" left="953" width="76" height="17" font="13">consumption, </text>
<text top="441" left="953" width="67" height="17" font="13">and cardiac </text>
<text top="459" left="953" width="50" height="17" font="13">function, </text>
<text top="304" left="1056" width="158" height="17" font="13">Women with chronic HF had </text>
<text top="321" left="1056" width="217" height="17" font="13">significantly lower muscle strength than </text>
<text top="338" left="1056" width="215" height="17" font="13">women without chronic HF (p&lt;0.0001). </text>
<text top="355" left="1056" width="3" height="17" font="13"> </text>
<text top="373" left="1056" width="198" height="17" font="13">In resistance trainers (vs. controls):  </text>
<text top="390" left="1056" width="171" height="17" font="13">Strength improved (p&lt;0.0001); </text>
<text top="407" left="1056" width="158" height="17" font="13">Muscle endurance improved </text>
<text top="424" left="1056" width="67" height="17" font="13">(p&lt;0.0001); </text>
<text top="441" left="1056" width="185" height="17" font="13">6-minute walk distance increased </text>
<text top="459" left="1056" width="67" height="17" font="13">(p&lt;0.0003). </text>
<text top="476" left="1056" width="3" height="17" font="13"> </text>
<text top="493" left="1056" width="186" height="17" font="13">Increases in type 1 fiber area and </text>
<text top="510" left="1056" width="189" height="17" font="13">citrate synthase activity in skeletal </text>
<text top="527" left="1056" width="208" height="17" font="13">muscle were independently predictive </text>
<text top="545" left="1056" width="187" height="17" font="13">of improved 6-min walk distance (r</text>
<text top="546" left="1243" width="7" height="11" font="19">2 </text>
<text top="545" left="1250" width="11" height="17" font="13">= </text>
<text top="562" left="1056" width="93" height="17" font="13">0.78; p=0.0024). </text>
<text top="304" left="1291" width="78" height="17" font="13">High-intensity </text>
<text top="321" left="1291" width="126" height="17" font="13">progressive resistance </text>
<text top="338" left="1291" width="97" height="17" font="13">training improves </text>
<text top="355" left="1291" width="138" height="17" font="13">impaired skeletal muscle </text>
<text top="373" left="1291" width="106" height="17" font="13">characteristics and </text>
<text top="390" left="1291" width="89" height="17" font="13">overall exercise </text>
<text top="407" left="1291" width="116" height="17" font="13">performance in older </text>
<text top="424" left="1291" width="135" height="17" font="13">women with chronic HF. </text>
<text top="441" left="1291" width="131" height="17" font="13">These gains are largely </text>
<text top="459" left="1291" width="118" height="17" font="13">explained by skeletal </text>
<text top="476" left="1291" width="127" height="17" font="13">muscle and not resting </text>
<text top="493" left="1291" width="113" height="17" font="13">cardiac adaptations. </text>
</page>
<page number="58" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">58</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="78" height="17" font="13">The effects of </text>
<text top="71" left="61" width="92" height="17" font="13">physical training </text>
<text top="88" left="61" width="73" height="17" font="13">on workload, </text>
<text top="106" left="61" width="97" height="17" font="13">upper leg muscle </text>
<text top="123" left="61" width="70" height="17" font="13">function and </text>
<text top="140" left="61" width="89" height="17" font="13">muscle areas in </text>
<text top="157" left="61" width="88" height="17" font="13">pts with chronic </text>
<text top="174" left="61" width="99" height="17" font="13">HF. Senden, Jeff. </text>
<text top="192" left="61" width="31" height="17" font="13">2005 </text>
<text top="209" left="61" width="58" height="17" font="14">15823638 </text>
<text top="209" left="119" width="32" height="17" font="13">(141) </text>
<text top="54" left="174" width="101" height="17" font="13">To investigate the </text>
<text top="71" left="174" width="95" height="17" font="13">effect of physical </text>
<text top="88" left="174" width="116" height="17" font="13">training on upper leg </text>
<text top="106" left="174" width="116" height="17" font="13">muscle area, muscle </text>
<text top="123" left="174" width="114" height="17" font="13">strength and muscle </text>
<text top="140" left="174" width="122" height="17" font="13">endurance expressed </text>
<text top="157" left="174" width="113" height="17" font="13">as upper leg muscle </text>
<text top="174" left="174" width="117" height="17" font="13">function in relation to </text>
<text top="192" left="174" width="49" height="17" font="13">exercise </text>
<text top="209" left="174" width="76" height="17" font="13">performance. </text>
<text top="54" left="312" width="29" height="17" font="13">RCT </text>
<text top="54" left="400" width="17" height="17" font="13">77 </text>
<text top="54" left="481" width="137" height="17" font="13">Chronic HF for at least 6 </text>
<text top="71" left="481" width="24" height="17" font="13">mo, </text>
<text top="88" left="481" width="66" height="17" font="13">NYHA II-III, </text>
<text top="106" left="481" width="146" height="17" font="13">clinically stable for at least </text>
<text top="123" left="481" width="34" height="17" font="13">3 mo, </text>
<text top="140" left="481" width="139" height="17" font="13">received optimal medical </text>
<text top="157" left="481" width="48" height="17" font="13">therapy, </text>
<text top="174" left="481" width="142" height="17" font="13">physically able to visit the </text>
<text top="192" left="481" width="65" height="17" font="13">outpt clinic, </text>
<text top="209" left="481" width="69" height="17" font="13">LVEF &lt;35% </text>
<text top="54" left="649" width="150" height="17" font="13">Interfering disease such as </text>
<text top="71" left="649" width="42" height="17" font="13">COPD, </text>
<text top="88" left="649" width="113" height="17" font="13">fasting glucose &lt;7.0 </text>
<text top="106" left="649" width="78" height="17" font="13">mmol/L (DM), </text>
<text top="123" left="649" width="142" height="17" font="13">neuromuscular disorders, </text>
<text top="140" left="649" width="29" height="17" font="13">HTN </text>
<text top="157" left="649" width="3" height="17" font="13"> </text>
<text top="54" left="815" width="68" height="17" font="13">LVEF, body </text>
<text top="71" left="815" width="101" height="17" font="13">composition, daily </text>
<text top="88" left="815" width="92" height="17" font="13">physical activity, </text>
<text top="106" left="815" width="125" height="17" font="13">exercise performance, </text>
<text top="123" left="815" width="125" height="17" font="13">upper leg muscle area </text>
<text top="140" left="815" width="98" height="17" font="13">and isokinetic leg </text>
<text top="157" left="815" width="98" height="17" font="13">muscle variables. </text>
<text top="54" left="953" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1056" width="152" height="17" font="13">Workload and peak oxygen </text>
<text top="71" left="1056" width="208" height="17" font="13">consumption decreased in the control </text>
<text top="88" left="1056" width="193" height="17" font="13">group and increased in the training </text>
<text top="106" left="1056" width="88" height="17" font="13">group (p&lt;0.05). </text>
<text top="123" left="1056" width="3" height="17" font="13"> </text>
<text top="140" left="1056" width="188" height="17" font="13">Hamstrings area decreased in the </text>
<text top="157" left="1056" width="217" height="17" font="13">control group and did not change in the </text>
<text top="174" left="1056" width="132" height="17" font="13">training group (p&lt;0.05). </text>
<text top="192" left="1056" width="3" height="17" font="13"> </text>
<text top="209" left="1056" width="212" height="17" font="13">Upper leg muscle function improved in </text>
<text top="226" left="1056" width="220" height="17" font="13">the training group and did not change in </text>
<text top="243" left="1056" width="149" height="17" font="13">the control group (p&lt;0.05). </text>
<text top="261" left="1056" width="3" height="17" font="13"> </text>
<text top="278" left="1056" width="220" height="17" font="13">At baseline and after intervention nearly </text>
<text top="295" left="1056" width="174" height="17" font="13">60% of the variance in maximal </text>
<text top="312" left="1056" width="205" height="17" font="13">workload was explained by upper leg </text>
<text top="329" left="1056" width="219" height="17" font="13">muscle function and quadriceps muscle </text>
<text top="347" left="1056" width="32" height="17" font="13">area. </text>
<text top="54" left="1291" width="135" height="17" font="13">In chronic HF pts, home-</text>
<text top="71" left="1291" width="94" height="17" font="13">based training in </text>
<text top="88" left="1291" width="101" height="17" font="13">conjunction with a </text>
<text top="106" left="1291" width="135" height="17" font="13">supervised strength and </text>
<text top="123" left="1291" width="105" height="17" font="13">endurance training </text>
<text top="140" left="1291" width="137" height="17" font="13">program is safe, feasible </text>
<text top="157" left="1291" width="127" height="17" font="13">and effective and does </text>
<text top="174" left="1291" width="111" height="17" font="13">not require complex </text>
<text top="192" left="1291" width="108" height="17" font="13">training equipment. </text>
<text top="209" left="1291" width="93" height="17" font="13">Physical training </text>
<text top="226" left="1291" width="97" height="17" font="13">prevented loss of </text>
<text top="243" left="1291" width="139" height="17" font="13">hamstrings muscle mass </text>
<text top="261" left="1291" width="127" height="17" font="13">and improved exercise </text>
<text top="278" left="1291" width="89" height="17" font="13">performance by </text>
<text top="295" left="1291" width="102" height="17" font="13">enhancing muscle </text>
<text top="312" left="1291" width="137" height="17" font="13">strength and endurance. </text>
<text top="371" left="61" width="85" height="17" font="13">Antiremodeling </text>
<text top="388" left="61" width="74" height="17" font="13">effect of long-</text>
<text top="406" left="61" width="77" height="17" font="13">term exercise </text>
<text top="423" left="61" width="76" height="17" font="13">training in pts </text>
<text top="440" left="61" width="61" height="17" font="13">with stable </text>
<text top="457" left="61" width="66" height="17" font="13">chronic HF. </text>
<text top="474" left="61" width="61" height="17" font="13">Giannuzzi, </text>
<text top="492" left="61" width="86" height="17" font="13">Pantaleo. 2003 </text>
<text top="509" left="61" width="58" height="17" font="14">12860904 </text>
<text top="509" left="119" width="32" height="17" font="13">(127) </text>
<text top="526" left="61" width="3" height="17" font="13"> </text>
<text top="371" left="174" width="123" height="17" font="13">To determine whether </text>
<text top="388" left="174" width="105" height="17" font="13">long-term exercise </text>
<text top="406" left="174" width="123" height="17" font="13">training may influence </text>
<text top="423" left="174" width="85" height="17" font="13">LV volume and </text>
<text top="440" left="174" width="101" height="17" font="13">function in a large </text>
<text top="457" left="174" width="96" height="17" font="13">cohort of pts with </text>
<text top="474" left="174" width="68" height="17" font="13">stable CHF. </text>
<text top="371" left="312" width="29" height="17" font="13">RCT </text>
<text top="371" left="400" width="17" height="17" font="13">90 </text>
<text top="371" left="481" width="149" height="17" font="13">HF secondary to idiopathic </text>
<text top="388" left="481" width="120" height="17" font="13">DCM, IHD or valvular </text>
<text top="406" left="481" width="49" height="17" font="13">disease, </text>
<text top="423" left="481" width="128" height="17" font="13">LVEF &lt;35% by ECHO, </text>
<text top="440" left="481" width="156" height="17" font="13">clinical stability for at least 3 </text>
<text top="457" left="481" width="111" height="17" font="13">mo under optimized </text>
<text top="474" left="481" width="48" height="17" font="13">therapy, </text>
<text top="492" left="481" width="66" height="17" font="13">NYHA II-III, </text>
<text top="509" left="481" width="135" height="17" font="13">peak oxygen uptake (VO</text>
<text top="515" left="616" width="4" height="11" font="19">2</text>
<text top="509" left="620" width="8" height="17" font="13">) </text>
<text top="526" left="481" width="95" height="17" font="13">&lt;20mL/kg/min at </text>
<text top="543" left="481" width="89" height="17" font="13">ergospirometry, </text>
<text top="561" left="481" width="147" height="17" font="13">echocardiographic images </text>
<text top="578" left="481" width="125" height="17" font="13">of adequate quality for </text>
<text top="595" left="481" width="114" height="17" font="13">quantitative analysis </text>
<text top="371" left="649" width="122" height="17" font="13">Any systemic disease </text>
<text top="388" left="649" width="94" height="17" font="13">limiting exercise, </text>
<text top="406" left="649" width="71" height="17" font="13">hypertrophic </text>
<text top="423" left="649" width="94" height="17" font="13">cardiomyopathy, </text>
<text top="440" left="649" width="143" height="17" font="13">valvular disease requiring </text>
<text top="457" left="649" width="48" height="17" font="13">surgery, </text>
<text top="474" left="649" width="90" height="17" font="13">angina pectoris, </text>
<text top="492" left="649" width="116" height="17" font="13">sustained ventricular </text>
<text top="509" left="649" width="71" height="17" font="13">arrhythmias, </text>
<text top="526" left="649" width="72" height="17" font="13">severe HTN, </text>
<text top="543" left="649" width="145" height="17" font="13">excess variability &gt;10% at </text>
<text top="561" left="649" width="144" height="17" font="13">baseline cardiopulmonary </text>
<text top="578" left="649" width="72" height="17" font="13">exercise test </text>
<text top="371" left="815" width="97" height="17" font="13">Cardiopulmonary </text>
<text top="388" left="815" width="92" height="17" font="13">exercise testing, </text>
<text top="406" left="815" width="109" height="17" font="13">6MWT, ECHO, and </text>
<text top="423" left="815" width="30" height="17" font="13">QoL. </text>
<text top="371" left="953" width="27" height="17" font="13"> N/A </text>
<text top="371" left="1056" width="187" height="17" font="13">Differences from baseline to 6 mo </text>
<text top="388" left="1056" width="211" height="17" font="13">improved in the intervention group for: </text>
<text top="406" left="1056" width="79" height="17" font="13">EF (p&lt;0.001), </text>
<text top="423" left="1056" width="140" height="17" font="13">Work capacity (p&lt;0.001), </text>
<text top="440" left="1056" width="49" height="17" font="13">Peak VO</text>
<text top="446" left="1105" width="4" height="11" font="19">2</text>
<text top="440" left="1109" width="63" height="17" font="13"> (p&lt;0.006), </text>
<text top="457" left="1056" width="156" height="17" font="13">Walking distance (p&lt;0.001), </text>
<text top="474" left="1056" width="80" height="17" font="13">QoL (p&lt;0.01), </text>
<text top="492" left="1056" width="198" height="17" font="13">LV volumes (diminished) (p&lt;0.006), </text>
<text top="509" left="1056" width="176" height="17" font="13">Trend to fewer readmissions for </text>
<text top="526" left="1056" width="216" height="17" font="13">worsening dyspnea (EDV p&lt;0.05 ESV) </text>
<text top="543" left="1056" width="3" height="17" font="13"> </text>
<text top="561" left="1056" width="213" height="17" font="13">LV volumes increased in control group </text>
<text top="578" left="1056" width="117" height="17" font="13">(p&lt;0.0.01 EDV ESV)<b> </b></text>
<text top="371" left="1291" width="116" height="17" font="13">In stable chronic HF, </text>
<text top="388" left="1291" width="111" height="17" font="13">long-term moderate </text>
<text top="406" left="1291" width="133" height="17" font="13">exercise training has no </text>
<text top="423" left="1291" width="133" height="17" font="13">detrimental effect on LV </text>
<text top="440" left="1291" width="123" height="17" font="13">volumes and function; </text>
<text top="457" left="1291" width="109" height="17" font="13">rather, it attenuates </text>
<text top="474" left="1291" width="122" height="17" font="13">abnormal remodeling. </text>
<text top="492" left="1291" width="124" height="17" font="13">Furthermore, exercise </text>
<text top="509" left="1291" width="107" height="17" font="13">training is safe and </text>
<text top="526" left="1291" width="119" height="17" font="13">effective in improving </text>
<text top="543" left="1291" width="127" height="17" font="13">exercise tolerance and </text>
<text top="561" left="1291" width="30" height="17" font="13">QoL. </text>
</page>
<page number="59" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">59</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="61" width="94" height="17" font="13">Exercise training </text>
<text top="71" left="61" width="47" height="17" font="13">reduces </text>
<text top="88" left="61" width="59" height="17" font="13">circulating </text>
<text top="106" left="61" width="66" height="17" font="13">adiponectin </text>
<text top="123" left="61" width="93" height="17" font="13">levels in pts with </text>
<text top="140" left="61" width="92" height="17" font="13">chronic HF. Van </text>
<text top="157" left="61" width="79" height="17" font="13">Berendoncks, </text>
<text top="174" left="61" width="53" height="17" font="13">An. 2010 </text>
<text top="192" left="61" width="58" height="17" font="14">19656085 </text>
<text top="192" left="119" width="32" height="17" font="13">(142) </text>
<text top="209" left="61" width="3" height="17" font="13"> </text>
<text top="54" left="174" width="118" height="17" font="13">To assess circulating </text>
<text top="71" left="174" width="66" height="17" font="13">adiponectin </text>
<text top="88" left="174" width="96" height="17" font="13">concentrations in </text>
<text top="106" left="174" width="86" height="17" font="13">chronic HF pts, </text>
<text top="123" left="174" width="77" height="17" font="13">compare with </text>
<text top="140" left="174" width="124" height="17" font="13">controls, and evaluate </text>
<text top="157" left="174" width="116" height="17" font="13">the effects of a 4-mo </text>
<text top="174" left="174" width="93" height="17" font="13">exercise training </text>
<text top="192" left="174" width="53" height="17" font="13">program. </text>
<text top="54" left="312" width="71" height="17" font="13">Prospective, </text>
<text top="71" left="312" width="25" height="17" font="13">non-</text>
<text top="88" left="312" width="68" height="17" font="13">randomized </text>
<text top="106" left="312" width="23" height="17" font="13">trial </text>
<text top="54" left="400" width="179" height="17" font="13">80 LVEF </text>
<text top="54" left="515" width="103" height="17" font="13">&lt;30%, </text>
<text top="71" left="481" width="66" height="17" font="13">NYHA II-III, </text>
<text top="88" left="481" width="150" height="17" font="13">symptoms had been stable </text>
<text top="106" left="481" width="150" height="17" font="13">on medical treatment for at </text>
<text top="123" left="481" width="153" height="17" font="13">least 1 mo prior to inclusion </text>
<text top="54" left="649" width="85" height="17" font="13">Recent ACS or </text>
<text top="71" left="649" width="99" height="17" font="13">revascularization, </text>
<text top="88" left="649" width="143" height="17" font="13">valvular disease requiring </text>
<text top="106" left="649" width="48" height="17" font="13">surgery, </text>
<text top="123" left="649" width="96" height="17" font="13">exercise-induced </text>
<text top="140" left="649" width="129" height="17" font="13">myocardial ischemia or </text>
<text top="157" left="649" width="117" height="17" font="13">malignant ventricular </text>
<text top="174" left="649" width="98" height="17" font="13">arrhythmia, acute </text>
<text top="192" left="649" width="146" height="17" font="13">myocarditis or pericarditis, </text>
<text top="209" left="649" width="105" height="17" font="13">cerebrovascular or </text>
<text top="226" left="649" width="137" height="17" font="13">musculoskeletal disease </text>
<text top="243" left="649" width="150" height="17" font="13">preventing exercise testing </text>
<text top="261" left="649" width="62" height="17" font="13">or training, </text>
<text top="278" left="649" width="150" height="17" font="13">acute or chronic infections, </text>
<text top="295" left="649" width="107" height="17" font="13">allergies, cancer or </text>
<text top="312" left="649" width="149" height="17" font="13">inflammatory disease, DM. </text>
<text top="54" left="815" width="61" height="17" font="13">Circulating </text>
<text top="71" left="815" width="66" height="17" font="13">adiponectin </text>
<text top="88" left="815" width="87" height="17" font="13">concentrations, </text>
<text top="106" left="815" width="101" height="17" font="13">exercise capacity, </text>
<text top="123" left="815" width="113" height="17" font="13">anthropometric data </text>
<text top="140" left="815" width="91" height="17" font="13">and NT-proBNP </text>
<text top="157" left="815" width="38" height="17" font="13">levels. </text>
<text top="54" left="953" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1056" width="199" height="17" font="13">At baseline, adiponectin levels were </text>
<text top="71" left="1056" width="200" height="17" font="13">significantly higher in chronic HF pts </text>
<text top="88" left="1056" width="175" height="17" font="13">compared with healthy subjects </text>
<text top="106" left="1056" width="60" height="17" font="13">(p=0.015). </text>
<text top="123" left="1056" width="3" height="17" font="13"> </text>
<text top="140" left="1056" width="170" height="17" font="13">At baseline, stratification of pts </text>
<text top="157" left="1056" width="191" height="17" font="13">according to tertiles of NT-proBNP </text>
<text top="174" left="1056" width="197" height="17" font="13">revealed an increase in adiponectin </text>
<text top="192" left="1056" width="177" height="17" font="13">with disease severity (p&lt;0.001). </text>
<text top="209" left="1056" width="3" height="17" font="13"> </text>
<text top="226" left="1056" width="209" height="17" font="13">Exercise training significantly reduced </text>
<text top="243" left="1056" width="194" height="17" font="13">circulating adiponectin levels in the </text>
<text top="261" left="1056" width="215" height="17" font="13">trained chronic HF group (compared to </text>
<text top="278" left="1056" width="216" height="17" font="13">sedentary chronic HF group) (p=0.008)<b> </b></text>
<text top="54" left="1291" width="128" height="17" font="13">Circulating adiponectin </text>
<text top="71" left="1291" width="83" height="17" font="13">concentrations </text>
<text top="88" left="1291" width="135" height="17" font="13">are higher in chronic HF </text>
<text top="106" left="1291" width="103" height="17" font="13">pts compared with </text>
<text top="123" left="1291" width="116" height="17" font="13">healthy subjects and </text>
<text top="140" left="1291" width="121" height="17" font="13">increase with disease </text>
<text top="157" left="1291" width="49" height="17" font="13">severity. </text>
<text top="174" left="1291" width="122" height="17" font="13">Exercise training for 4 </text>
<text top="192" left="1291" width="118" height="17" font="13">mo lowers circulating </text>
<text top="209" left="1291" width="129" height="17" font="13">adiponectin levels. The </text>
<text top="226" left="1291" width="142" height="17" font="13">present findings, together </text>
<text top="243" left="1291" width="118" height="17" font="13">with those from other </text>
<text top="261" left="1291" width="116" height="17" font="13">studies, suggest that </text>
<text top="278" left="1291" width="111" height="17" font="13">dysregulation of the </text>
<text top="295" left="1291" width="116" height="17" font="13">adiponectin pathway </text>
<text top="312" left="1291" width="98" height="17" font="13">contributes to the </text>
<text top="329" left="1291" width="110" height="17" font="13">observed metabolic </text>
<text top="347" left="1291" width="140" height="17" font="13">impairment in chronic HF </text>
<text top="365" left="61" width="55" height="17" font="13">Effects of </text>
<text top="382" left="61" width="93" height="17" font="13">exercise training </text>
<text top="399" left="61" width="60" height="17" font="13">on cardiac </text>
<text top="416" left="61" width="76" height="17" font="13">performance, </text>
<text top="433" left="61" width="98" height="17" font="13">exercise capacity </text>
<text top="451" left="61" width="83" height="17" font="13">and QoL in pts </text>
<text top="468" left="61" width="98" height="17" font="13">with HF. Van Tol, </text>
<text top="485" left="61" width="73" height="17" font="13">Benno. 2006 </text>
<text top="502" left="61" width="58" height="17" font="14">16713337 </text>
<text top="502" left="119" width="32" height="17" font="13">(143) </text>
<text top="365" left="174" width="96" height="17" font="13">To determine the </text>
<text top="382" left="174" width="96" height="17" font="13">effect of exercise </text>
<text top="399" left="174" width="102" height="17" font="13">training in pts with </text>
<text top="416" left="174" width="123" height="17" font="13">chronic HF on cardiac </text>
<text top="433" left="174" width="76" height="17" font="13">performance, </text>
<text top="451" left="174" width="122" height="17" font="13">exercise capacity and </text>
<text top="468" left="174" width="48" height="17" font="13">HRQoL. </text>
<text top="365" left="312" width="31" height="17" font="13">Meta-</text>
<text top="382" left="312" width="61" height="17" font="13">analysis of </text>
<text top="399" left="312" width="35" height="17" font="13">RCTs </text>
<text top="365" left="400" width="47" height="17" font="13">35 trials </text>
<text top="365" left="481" width="38" height="17" font="13">RCTs, </text>
<text top="382" left="481" width="137" height="17" font="13">included pts with chronic </text>
<text top="399" left="481" width="151" height="17" font="13">HF in the control and in the </text>
<text top="416" left="481" width="102" height="17" font="13">intervention group </text>
<text top="433" left="481" width="96" height="17" font="13">(diagnosis based </text>
<text top="451" left="481" width="152" height="17" font="13">on clinical findings or LVEF </text>
<text top="468" left="481" width="145" height="17" font="13">&lt;40%), included at least 1 </text>
<text top="485" left="481" width="143" height="17" font="13">treatment group receiving </text>
<text top="502" left="481" width="127" height="17" font="13">exercise training and 1 </text>
<text top="519" left="481" width="110" height="17" font="13">control group which </text>
<text top="537" left="481" width="147" height="17" font="13">received standard medical </text>
<text top="554" left="481" width="134" height="17" font="13">treatment w/o additional </text>
<text top="571" left="481" width="96" height="17" font="13">exercise training, </text>
<text top="588" left="481" width="107" height="17" font="13">evaluated outcome </text>
<text top="606" left="481" width="118" height="17" font="13">measures in terms of </text>
<text top="623" left="481" width="119" height="17" font="13">cardiac performance, </text>
<text top="640" left="481" width="136" height="17" font="13">exercise capacity and/or </text>
<text top="657" left="481" width="141" height="17" font="13">HRQoL, exercise training </text>
<text top="674" left="481" width="147" height="17" font="13">had to include at least one </text>
<text top="692" left="481" width="129" height="17" font="13">of the following training </text>
<text top="709" left="481" width="151" height="17" font="13">modalities: walking, cycling </text>
<text top="726" left="481" width="120" height="17" font="13">or resistive training of </text>
<text top="743" left="481" width="110" height="17" font="13">peripheral muscles. </text>
<text top="365" left="649" width="118" height="17" font="13">Studies in which only </text>
<text top="382" left="649" width="148" height="17" font="13">respiratory muscles or one </text>
<text top="399" left="649" width="148" height="17" font="13">isolated muscle group was </text>
<text top="416" left="649" width="44" height="17" font="13">trained. </text>
<text top="365" left="815" width="122" height="17" font="13">Cardiac performance, </text>
<text top="382" left="815" width="122" height="17" font="13">exercise capacity and </text>
<text top="399" left="815" width="48" height="17" font="13">HRQoL. </text>
<text top="365" left="953" width="27" height="17" font="13"> N/A </text>
<text top="365" left="1056" width="200" height="17" font="13">During maximal exercise, significant </text>
<text top="382" left="1056" width="204" height="17" font="13">summary effect sizes were found for: </text>
<text top="399" left="1056" width="81" height="17" font="13">SBP (p=0.03), </text>
<text top="416" left="1056" width="118" height="17" font="13">Heart rate (p=0.011), </text>
<text top="433" left="1056" width="143" height="17" font="13">Cardiac output (p=0.004), </text>
<text top="451" left="1056" width="168" height="17" font="13">Peak oxygen uptake (p=0.00), </text>
<text top="468" left="1056" width="166" height="17" font="13">Anaerobic threshold (p=0.00), </text>
<text top="485" left="1056" width="93" height="17" font="13">6MWT (p=0.00). </text>
<text top="502" left="1056" width="3" height="17" font="13"> </text>
<text top="519" left="1056" width="220" height="17" font="13">The MLHFQ improved by an average of </text>
<text top="537" left="1056" width="110" height="17" font="13">9.7 points (p=0.00).<b> </b></text>
<text top="365" left="1291" width="118" height="17" font="13">Exercise training has </text>
<text top="382" left="1291" width="104" height="17" font="13">clinically important </text>
<text top="399" left="1291" width="106" height="17" font="13">effects on exercise </text>
<text top="416" left="1291" width="110" height="17" font="13">capacity and health-</text>
<text top="433" left="1291" width="140" height="17" font="13">related quality of life, and </text>
<text top="451" left="1291" width="134" height="17" font="13">may have small positive </text>
<text top="468" left="1291" width="100" height="17" font="13">effects on cardiac </text>
<text top="485" left="1291" width="110" height="17" font="13">performance during </text>
<text top="502" left="1291" width="53" height="17" font="13">exercise. </text>
<text top="764" left="54" width="1352" height="18" font="13">6MWT indicates 6 minute walk test; ACS acute coronary syndrome; AF, atrial fibrillation; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DCM, dilated cardiomyopathy; DM, diabetes mellitus; ECHO, </text>
<text top="781" left="54" width="1317" height="17" font="13">echocardiography; EF, ejection fraction; EXERT, Exercise Rehabilitation Trial; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fration; HRQoL, health related quality of life; HTN, </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">60</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="1349" height="17" font="13">hypertension; IHD, ischemic heart disease; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MI, </text>
<text top="71" left="54" width="1305" height="17" font="13">myocardial infarction; MLHFQ, Minnesota Living with Heart Failure Questionaire; N/A, not applicatble; NT-proBNP, N-terminal pro-B-Type natriuretic peptide; N/A, not applicable; NS, not significant; O2, oygen; pt, patient; QoL, quality of life; r</text>
<text top="72" left="1359" width="4" height="11" font="19">2</text>
<text top="71" left="1364" width="3" height="17" font="13">,</text>
<text top="72" left="1367" width="2" height="11" font="19"> </text>
<text top="71" left="1369" width="59" height="17" font="13">coefficient </text>
<text top="88" left="54" width="800" height="17" font="13">of determination; RCT, randomized control trial; SSW, Stead-state workload; UA, unstable angina; UK, United Kingdom; and VO2, oxygen volume. </text>
<text top="106" left="54" width="3" height="17" font="13"> </text>
<text top="132" left="54" width="687" height="21" font="8"><b>Data Supplement 17. Diuretics Versus Ultrafiltration in Acute Decompensated HF (Section 7.3.2.1) </b></text>
<text top="153" left="30" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="170" left="31" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="153" left="148" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="153" left="273" width="38" height="17" font="15"><b>Study </b></text>
<text top="170" left="276" width="32" height="17" font="15"><b>Type </b></text>
<text top="153" left="337" width="38" height="17" font="15"><b>Study </b></text>
<text top="170" left="342" width="28" height="17" font="15"><b>Size </b></text>
<text top="153" left="496" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="153" left="831" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="153" left="1040" width="171" height="17" font="15"><b>Statistical Analysis (Results) </b></text>
<text top="153" left="1282" width="38" height="17" font="15"><b>Study </b></text>
<text top="170" left="1267" width="69" height="17" font="15"><b>Limitations </b></text>
<text top="153" left="1380" width="58" height="17" font="15"><b>Findings/ </b></text>
<text top="170" left="1376" width="67" height="17" font="15"><b>Comments </b></text>
<text top="201" left="45" width="49" height="17" font="15"><b>Diuretic </b></text>
<text top="218" left="46" width="46" height="17" font="15"><b>studies </b></text>
<text top="201" left="186" width="3" height="17" font="13"> </text>
<text top="201" left="290" width="3" height="17" font="13"> </text>
<text top="201" left="354" width="3" height="17" font="13"> </text>
<text top="201" left="395" width="104" height="17" font="21"><i><b>Inclusion Criteria </b></i></text>
<text top="201" left="559" width="108" height="17" font="21"><i><b>Exclusion Criteria </b></i></text>
<text top="201" left="749" width="106" height="17" font="21"><i><b>Primary Endpoint </b></i></text>
<text top="201" left="914" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="218" left="918" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="201" left="1124" width="3" height="17" font="13"> </text>
<text top="201" left="1299" width="3" height="17" font="13"> </text>
<text top="201" left="1407" width="3" height="17" font="13"> </text>
<text top="239" left="28" width="71" height="17" font="15"><b>DOSE-AHF</b>, </text>
<text top="257" left="28" width="72" height="17" font="13">Felker, 2011 </text>
<text top="274" left="28" width="55" height="17" font="14">21366472</text>
<text top="274" left="83" width="3" height="17" font="13"> </text>
<text top="291" left="28" width="32" height="17" font="13">(144) </text>
<text top="239" left="123" width="120" height="17" font="13">To compare high and </text>
<text top="257" left="123" width="121" height="17" font="13">low doses of diuretics </text>
<text top="274" left="123" width="101" height="17" font="13">administered over </text>
<text top="291" left="123" width="103" height="17" font="13">longer and shorter </text>
<text top="308" left="123" width="98" height="17" font="13">periods of time to </text>
<text top="326" left="123" width="115" height="17" font="13">determine the safest </text>
<text top="343" left="123" width="103" height="17" font="13">and most effective </text>
<text top="360" left="123" width="77" height="17" font="13">combination.  </text>
<text top="239" left="265" width="196" height="17" font="13">RCT 308 Prior </text>
<text top="239" left="422" width="79" height="17" font="13">clinical </text>
<text top="257" left="393" width="89" height="17" font="13">diagnosis of HF </text>
<text top="274" left="393" width="91" height="17" font="13">that was treated </text>
<text top="291" left="393" width="105" height="17" font="13">with daily oral loop </text>
<text top="308" left="393" width="81" height="17" font="13">diuretics for at </text>
<text top="326" left="393" width="115" height="17" font="13">least 1 mo;                </text>
<text top="343" left="393" width="97" height="17" font="13">current diagnosis </text>
<text top="360" left="393" width="97" height="17" font="13">of HF, as defined </text>
<text top="377" left="393" width="105" height="17" font="13">by the presence of </text>
<text top="394" left="393" width="107" height="17" font="13">at least 1 symptom </text>
<text top="412" left="393" width="57" height="17" font="13">(dyspnea, </text>
<text top="429" left="393" width="77" height="17" font="13">orthopnea, or </text>
<text top="446" left="393" width="105" height="17" font="13">edema) and 1 sign </text>
<text top="463" left="393" width="51" height="17" font="13">(rales on </text>
<text top="480" left="393" width="72" height="17" font="13">auscultation, </text>
<text top="498" left="393" width="103" height="17" font="13">peripheral edema, </text>
<text top="515" left="393" width="106" height="17" font="13">ascites, pulmonary </text>
<text top="532" left="393" width="49" height="17" font="13">vascular </text>
<text top="549" left="393" width="80" height="17" font="13">congestion on </text>
<text top="567" left="393" width="33" height="17" font="13">chest </text>
<text top="584" left="393" width="113" height="17" font="13">radiography);            </text>
<text top="601" left="393" width="96" height="17" font="13">daily oral dose of </text>
<text top="618" left="393" width="103" height="17" font="13">furosemide 80 mg-</text>
<text top="635" left="393" width="63" height="17" font="13">240 mg (or </text>
<text top="653" left="393" width="115" height="17" font="13">equivalent);               </text>
<text top="670" left="393" width="105" height="17" font="13">identified within 24 </text>
<text top="687" left="393" width="70" height="17" font="13">h of hospital </text>
<text top="704" left="393" width="114" height="17" font="13">admission;                </text>
<text top="721" left="393" width="97" height="17" font="13">current treatment </text>
<text top="739" left="393" width="90" height="17" font="13">plan includes IV </text>
<text top="756" left="393" width="107" height="17" font="13">loop diuretics for at </text>
<text top="773" left="393" width="57" height="17" font="13">least 48 h </text>
<text top="239" left="514" width="182" height="17" font="13">BNP &lt;250 mg/mL or NT-proBNP </text>
<text top="257" left="514" width="159" height="17" font="13">&lt;1000 mg/mL; IV vasoactive </text>
<text top="274" left="514" width="185" height="17" font="13">treatment or ultrafiltration therapy </text>
<text top="291" left="514" width="193" height="17" font="13">since initial presentation; treatment </text>
<text top="308" left="514" width="152" height="17" font="13">plan includes IV vasoactive </text>
<text top="326" left="514" width="148" height="17" font="13">treatment or ultra-filtration; </text>
<text top="343" left="514" width="173" height="17" font="13">substantial diuretic response to </text>
<text top="360" left="514" width="181" height="17" font="13">prerandomization diuretic dosing </text>
<text top="377" left="514" width="190" height="17" font="13">such that higher doses of diuretics </text>
<text top="394" left="514" width="176" height="17" font="13">would be medically inadvisable; </text>
<text top="412" left="514" width="189" height="17" font="13">SBP &lt;90 mm Hg; SCr &gt;3.0 mg/dL </text>
<text top="429" left="514" width="193" height="17" font="13">at baseline or currently undergoing </text>
<text top="446" left="514" width="153" height="17" font="13">renal replacement therapy;  </text>
<text top="463" left="514" width="157" height="17" font="13">hemodynamically significant </text>
<text top="480" left="514" width="191" height="17" font="13">arrhythmias; ACS within 4 wk prior </text>
<text top="498" left="514" width="185" height="17" font="13">to study entry; active myocarditis; </text>
<text top="515" left="514" width="134" height="17" font="13">hypertrophic obstructive </text>
<text top="532" left="514" width="180" height="17" font="13">cardiomyopathy; severe stenotic </text>
<text top="549" left="514" width="165" height="17" font="13">valvular disease; restrictive or </text>
<text top="567" left="514" width="159" height="17" font="13">constrictive cardiomyopathy; </text>
<text top="584" left="514" width="189" height="17" font="13">complex congenital heart disease; </text>
<text top="601" left="514" width="159" height="17" font="13">constrictive pericarditis;. non-</text>
<text top="618" left="514" width="189" height="17" font="13">cardiac pulmonary edema; clinical </text>
<text top="635" left="514" width="184" height="17" font="13">evidence of digoxin toxicity; need </text>
<text top="653" left="514" width="163" height="17" font="13">for mechanical hemodynamic </text>
<text top="670" left="514" width="174" height="17" font="13">support; sepsis; terminal illness </text>
<text top="687" left="514" width="165" height="17" font="13">(other than HF) with expected </text>
<text top="704" left="514" width="169" height="17" font="13">survival time of &lt;1 y; history of </text>
<text top="721" left="514" width="161" height="17" font="13">adverse reaction to the study </text>
<text top="739" left="514" width="146" height="17" font="13">drugs;  use of IV iodinated </text>
<text top="756" left="514" width="184" height="17" font="13">radiocontrast material within 72 h </text>
<text top="773" left="514" width="167" height="17" font="13">prior to study entry or planned </text>
<text top="790" left="514" width="183" height="17" font="13">during hospitalization; enrollment </text>
<text top="239" left="724" width="94" height="17" font="13">Pt well-being, as </text>
<text top="257" left="724" width="113" height="17" font="13">determined by VAS; </text>
<text top="274" left="724" width="85" height="17" font="13">change in SCr  </text>
<text top="239" left="892" width="70" height="17" font="13">Weight loss; </text>
<text top="257" left="892" width="88" height="17" font="13">Proportion of pt </text>
<text top="274" left="892" width="105" height="17" font="13">free of congestion; </text>
<text top="291" left="892" width="77" height="17" font="13">change in the </text>
<text top="308" left="892" width="50" height="17" font="13">bivariate </text>
<text top="326" left="892" width="80" height="17" font="13">relationship of </text>
<text top="343" left="892" width="76" height="17" font="13">creatinine vs. </text>
<text top="360" left="892" width="68" height="17" font="13">weight loss; </text>
<text top="377" left="892" width="70" height="17" font="13">dyspnea, as </text>
<text top="394" left="892" width="81" height="17" font="13">determined by </text>
<text top="412" left="892" width="81" height="17" font="13">VAS; pt global </text>
<text top="429" left="892" width="89" height="17" font="13">assessment, as </text>
<text top="446" left="892" width="81" height="17" font="13">determined by </text>
<text top="463" left="892" width="88" height="17" font="13">VAS; change in </text>
<text top="480" left="892" width="88" height="17" font="13">SCr; Change in </text>
<text top="498" left="892" width="61" height="17" font="13">cystatin C; </text>
<text top="515" left="892" width="74" height="17" font="13">worsening or </text>
<text top="532" left="892" width="80" height="17" font="13">persistent HF, </text>
<text top="549" left="892" width="101" height="17" font="13">defined as a need </text>
<text top="567" left="892" width="109" height="17" font="13">for rescue therapy;  </text>
<text top="584" left="892" width="87" height="17" font="13">development of </text>
<text top="601" left="892" width="68" height="17" font="13">cardio-renal </text>
<text top="618" left="892" width="105" height="17" font="13">syndrome, defined </text>
<text top="635" left="892" width="96" height="17" font="13">as an increase in </text>
<text top="653" left="892" width="102" height="17" font="13">the SCr level &gt;0.3 </text>
<text top="670" left="892" width="87" height="17" font="13">mg/dL; net fluid </text>
<text top="687" left="892" width="83" height="17" font="13">loss; time from </text>
<text top="704" left="892" width="77" height="17" font="13">study entry to </text>
<text top="721" left="892" width="94" height="17" font="13">discharge during </text>
<text top="739" left="892" width="33" height="17" font="13">index </text>
<text top="756" left="892" width="85" height="17" font="13">hospitalization; </text>
<text top="773" left="892" width="105" height="17" font="13">death or total days </text>
<text top="790" left="892" width="86" height="17" font="13">hospitalized for </text>
<text top="239" left="1014" width="198" height="17" font="13">Comparison of bolus vs. continuous </text>
<text top="257" left="1014" width="195" height="17" font="13">infusion: no significant difference in </text>
<text top="274" left="1014" width="229" height="17" font="13">either                                                          </text>
<text top="291" left="1014" width="201" height="17" font="13">pts' global assessment of symptoms </text>
<text top="308" left="1014" width="219" height="17" font="13">(mean AUC, 4236±1440 in the bolus vs </text>
<text top="326" left="1014" width="184" height="17" font="13">4373±1404 in the infusion group, </text>
<text top="343" left="1014" width="230" height="17" font="13">p=0.47)                                                       </text>
<text top="360" left="1014" width="176" height="17" font="13">Mean change in creatinine level </text>
<text top="377" left="1014" width="176" height="17" font="13">(0.05±0.3 mg/dL in the bolus vs </text>
<text top="394" left="1014" width="208" height="17" font="13">0.07±0.3 mg/dL in the infusion group, </text>
<text top="412" left="1014" width="230" height="17" font="13">p=0.45)                                                       </text>
<text top="429" left="1014" width="201" height="17" font="13">Secondary Endpoints: No significant </text>
<text top="446" left="1014" width="213" height="17" font="13">differences, including SCr and cystatin </text>
<text top="463" left="1014" width="223" height="17" font="13">C levels during index hospitalization and </text>
<text top="480" left="1014" width="204" height="17" font="13">at 60 d. Comparison of high-dose vs. </text>
<text top="498" left="1014" width="179" height="17" font="13">low-dose strategy<b>:</b> no significant </text>
<text top="515" left="1014" width="215" height="17" font="13">difference in  pts' global assessment of </text>
<text top="532" left="1014" width="180" height="17" font="13">symptoms, although there was a </text>
<text top="549" left="1014" width="193" height="17" font="13">nonsignificant trend toward greater </text>
<text top="567" left="1014" width="200" height="17" font="13">improvement in the high-dose group </text>
<text top="584" left="1014" width="157" height="17" font="13">(mean AUC, 4430±1401 vs. </text>
<text top="601" left="1014" width="205" height="17" font="13">4171±1436; p=0.06; mean change in </text>
<text top="618" left="1014" width="205" height="17" font="13">creatinine level (0.08±0.3 mg/dL with </text>
<text top="635" left="1014" width="202" height="17" font="13">the high-dose strategy and 0.04±0.3 </text>
<text top="653" left="1014" width="187" height="17" font="13">mg/dL with the low-dose strategy, </text>
<text top="670" left="1014" width="217" height="17" font="13">p=0.21).                                Secondary </text>
<text top="687" left="1014" width="215" height="17" font="13">endpoints<b>:</b> The high-dose strategy was </text>
<text top="704" left="1014" width="200" height="17" font="13">associated with greater diuresis (net </text>
<text top="721" left="1014" width="210" height="17" font="13">fluid loss and weight loss) and greater </text>
<text top="739" left="1014" width="180" height="17" font="13">relief from dyspnea but also with </text>
<text top="756" left="1014" width="201" height="17" font="13">transient worsening of renal function </text>
<text top="773" left="1014" width="217" height="17" font="13">(occured in 23% of pts in the high-dose </text>
<text top="790" left="1014" width="231" height="17" font="13">vs 14% in the low-dose group, p=0.04)      </text>
<text top="239" left="1250" width="27" height="17" font="13"> N/A </text>
<text top="239" left="1365" width="27" height="17" font="13"> N/A </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="23" size="13" family="Times" color="#323232"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">61</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="514" width="181" height="17" font="13">or planned enrollment in another </text>
<text top="72" left="514" width="186" height="17" font="13">clinical trial during hospitalization; </text>
<text top="89" left="514" width="173" height="17" font="13">inability to comply with planned </text>
<text top="106" left="514" width="98" height="17" font="13">study procedures </text>
<text top="55" left="892" width="87" height="17" font="13">HF; death or re-</text>
<text top="72" left="892" width="109" height="17" font="13">hospitalization         </text>
<text top="55" left="1014" width="204" height="17" font="13">Clinical composite endpoint of death, </text>
<text top="72" left="1014" width="213" height="17" font="13">rehospitalization, or ED visit during the </text>
<text top="89" left="1014" width="168" height="17" font="13">60-d follow-up period: HR with </text>
<text top="106" left="1014" width="218" height="17" font="13">continuous infusion: 1.15; 95% CI: 0.83-</text>
<text top="124" left="1014" width="180" height="17" font="13">1.60; p=0.41, HR with high-dose </text>
<text top="141" left="1014" width="187" height="17" font="13">strategy, 0.83; 95% CI: 0.60-1.16; </text>
<text top="158" left="1014" width="41" height="17" font="13">p=0.28 </text>
<text top="176" left="28" width="66" height="17" font="15"><b>PROTECT</b>, </text>
<text top="193" left="28" width="77" height="17" font="13">Massie, 2010 </text>
<text top="210" left="28" width="55" height="17" font="14">20925544</text>
<text top="210" left="83" width="3" height="17" font="13"> </text>
<text top="228" left="28" width="32" height="17" font="13">(145) </text>
<text top="176" left="123" width="81" height="17" font="13">Rolofylline, an </text>
<text top="193" left="123" width="128" height="17" font="13">adenosine A1-receptor </text>
<text top="210" left="123" width="99" height="17" font="13">antagonist, would </text>
<text top="228" left="123" width="101" height="17" font="13">improve dyspnea, </text>
<text top="245" left="123" width="98" height="17" font="13">reduce the risk of </text>
<text top="262" left="123" width="109" height="17" font="13">WRF, and lead to a </text>
<text top="279" left="123" width="126" height="17" font="13">more favorable clinical </text>
<text top="296" left="123" width="126" height="17" font="13">course in pt with acute </text>
<text top="314" left="123" width="20" height="17" font="13">HF </text>
<text top="176" left="265" width="141" height="17" font="13">RCT 2,033 </text>
<text top="176" left="393" width="108" height="17" font="23">Persistent dyspnea </text>
<text top="193" left="393" width="77" height="17" font="23">at rest or with </text>
<text top="210" left="393" width="90" height="17" font="23">minimal activity, </text>
<text top="228" left="393" width="81" height="17" font="23">impaired renal </text>
<text top="245" left="393" width="68" height="17" font="23">function (an </text>
<text top="262" left="393" width="98" height="17" font="23">estimated CrCl of </text>
<text top="279" left="393" width="104" height="17" font="23">20-80 mL/min with </text>
<text top="296" left="393" width="78" height="17" font="23">the use of the </text>
<text top="314" left="393" width="92" height="17" font="23">Cockcroft−Gault </text>
<text top="331" left="393" width="97" height="17" font="23">equation), a BNP </text>
<text top="348" left="393" width="75" height="17" font="23">level of ≥500 </text>
<text top="365" left="393" width="98" height="17" font="23">pg/mL or more or </text>
<text top="382" left="393" width="102" height="17" font="23">an NT-pBNP level </text>
<text top="400" left="393" width="80" height="17" font="23">≥2000 pg/mL, </text>
<text top="417" left="393" width="90" height="17" font="23">ongoing IV loop-</text>
<text top="434" left="393" width="91" height="17" font="23">diuretic therapy, </text>
<text top="451" left="393" width="85" height="17" font="23">and enrollment </text>
<text top="469" left="393" width="90" height="17" font="23">within 24 h after </text>
<text top="486" left="393" width="62" height="17" font="23">admission. </text>
<text top="176" left="514" width="186" height="17" font="13">Pregnant or breast feeding; acute </text>
<text top="193" left="514" width="169" height="17" font="13">contrast induced nephropathy, </text>
<text top="210" left="514" width="139" height="17" font="13">sepsis, serum potassium </text>
<text top="228" left="514" width="190" height="17" font="13">&lt;3.5mEq/L; ongoing or planned IV </text>
<text top="245" left="514" width="186" height="17" font="13">therapy for acute HF with positive </text>
<text top="262" left="514" width="174" height="17" font="13">inotropic agents, vasopressors, </text>
<text top="279" left="514" width="152" height="17" font="13">vasodilators, or mechanical </text>
<text top="296" left="514" width="178" height="17" font="13">support, with the exception of IV </text>
<text top="314" left="514" width="169" height="17" font="13">nitrates, BNP&lt;500; ongoing or </text>
<text top="331" left="514" width="162" height="17" font="13">planned UF, hemofiltration or </text>
<text top="348" left="514" width="148" height="17" font="13">dialysis; severe pulmonary </text>
<text top="365" left="514" width="153" height="17" font="13">disease; significant stenotic </text>
<text top="382" left="514" width="184" height="17" font="13">valvular disease, heart transplant </text>
<text top="400" left="514" width="176" height="17" font="13">recipient or admitted for cardiac </text>
<text top="417" left="514" width="84" height="17" font="13">transplantation </text>
<text top="176" left="724" width="125" height="17" font="13">Primary end point was </text>
<text top="193" left="724" width="107" height="17" font="13">treatment success, </text>
<text top="210" left="724" width="127" height="17" font="13">treatment failure, or no </text>
<text top="228" left="724" width="155" height="17" font="13">change in the pt's condition. </text>
<text top="245" left="724" width="124" height="17" font="13">Success defined as pt-</text>
<text top="262" left="724" width="119" height="17" font="13">reported moderate or </text>
<text top="279" left="724" width="132" height="17" font="13">marked improvement in </text>
<text top="296" left="724" width="146" height="17" font="13">dyspnea both 24 and 48 h </text>
<text top="314" left="724" width="142" height="17" font="13">after administration of the </text>
<text top="331" left="724" width="148" height="17" font="13">study drug, in the absence </text>
<text top="348" left="724" width="142" height="17" font="13">of any criterion for failure. </text>
<text top="365" left="724" width="122" height="17" font="13">Failure defined as the </text>
<text top="382" left="724" width="135" height="17" font="13">occurrence of any of the </text>
<text top="400" left="724" width="103" height="17" font="13">following: death or </text>
<text top="417" left="724" width="153" height="17" font="13">readmission for HF through </text>
<text top="434" left="724" width="143" height="17" font="13">d 7, worsening symptoms </text>
<text top="451" left="724" width="144" height="17" font="13">and signs of HF occurring </text>
<text top="469" left="724" width="145" height="17" font="13">&gt;24 h after the initiation of </text>
<text top="486" left="724" width="133" height="17" font="13">the study drug requiring </text>
<text top="503" left="724" width="118" height="17" font="13">intervention by d 7 or </text>
<text top="520" left="724" width="130" height="17" font="13">discharge (if earlier), or </text>
<text top="537" left="724" width="152" height="17" font="13">persistent WRF, defined as </text>
<text top="555" left="724" width="154" height="17" font="13">an increase in the SCr level </text>
<text top="572" left="724" width="139" height="17" font="13">≥0.3 mg/dL (26.5 μmolL) </text>
<text top="589" left="724" width="146" height="17" font="13">from randomization to d 7, </text>
<text top="606" left="724" width="137" height="17" font="13">confirmed at d 14, or the </text>
<text top="623" left="724" width="154" height="17" font="13">initiation of hemofiltration or </text>
<text top="641" left="724" width="139" height="17" font="13">dialysis during the period </text>
<text top="658" left="724" width="144" height="17" font="13">from initiation of the study </text>
<text top="675" left="724" width="148" height="17" font="13">drug through d 7. Pts were </text>
<text top="692" left="724" width="110" height="17" font="13">classified as having </text>
<text top="710" left="724" width="156" height="17" font="13">unchanged treatment status </text>
<text top="727" left="724" width="122" height="17" font="13">if they met neither the </text>
<text top="744" left="724" width="114" height="17" font="13">criteria for treatment </text>
<text top="761" left="724" width="148" height="17" font="13">success nor the criteria for </text>
<text top="778" left="724" width="96" height="17" font="13">treatment failure. </text>
<text top="176" left="892" width="87" height="17" font="13">Two secondary </text>
<text top="193" left="892" width="87" height="17" font="13">outcomes were </text>
<text top="210" left="892" width="107" height="17" font="13">prespecified: death </text>
<text top="228" left="892" width="102" height="17" font="13">from any cause or </text>
<text top="245" left="892" width="92" height="17" font="13">rehospitalization </text>
<text top="262" left="892" width="101" height="17" font="13">for cardiovascular </text>
<text top="279" left="892" width="87" height="17" font="13">or renal causes </text>
<text top="296" left="892" width="96" height="17" font="13">through d 60 and </text>
<text top="314" left="892" width="93" height="17" font="13">the proportion of </text>
<text top="331" left="892" width="102" height="17" font="13">pts with persistent </text>
<text top="348" left="892" width="98" height="17" font="13">renal impairment, </text>
<text top="365" left="892" width="77" height="17" font="13">defined as an </text>
<text top="382" left="892" width="108" height="17" font="13">increase in the SCr </text>
<text top="400" left="892" width="95" height="17" font="13">level ≥0.3 mg/dL </text>
<text top="417" left="892" width="98" height="17" font="13">by d 7, confirmed </text>
<text top="434" left="892" width="65" height="17" font="13">at d 14; the </text>
<text top="451" left="892" width="62" height="17" font="13">initiation of </text>
<text top="469" left="892" width="92" height="17" font="13">hemofiltration or </text>
<text top="486" left="892" width="99" height="17" font="13">dialysis through d </text>
<text top="503" left="892" width="103" height="17" font="13">7; or death by d 7. </text>
<text top="176" left="1014" width="220" height="17" font="13">Rolofylline did not provide a benefit with </text>
<text top="193" left="1014" width="202" height="17" font="13">respect to the primary endpoint (OR: </text>
<text top="210" left="1014" width="186" height="17" font="13">0.92; 95% CI: 0.78-1.09; p=0.35). </text>
<text top="228" left="1014" width="213" height="17" font="13">Persistent renal impairment developed </text>
<text top="245" left="1014" width="222" height="17" font="13">in 15% of pts in the rolofylline group and </text>
<text top="262" left="1014" width="200" height="17" font="13">in 13.7% of pts in the placebo group </text>
<text top="279" left="1014" width="219" height="17" font="13">(OR: 1.11; 95% CI: 0.85-1.46; p=0.44).  </text>
<text top="296" left="1014" width="185" height="17" font="13">By 60 d, death or readmission for </text>
<text top="314" left="1014" width="194" height="17" font="13">cardiovascular or renal causes had </text>
<text top="331" left="1014" width="202" height="17" font="13">occurred in similar proportions of pts </text>
<text top="348" left="1014" width="213" height="17" font="13">assigned to rolofylline, 386 of 1356 pts </text>
<text top="365" left="1014" width="206" height="17" font="13">(Kaplan–Meier estimate, 30.7%; 95% </text>
<text top="382" left="1014" width="216" height="17" font="13">CI: 27.8-33.6) as compared with 195 of </text>
<text top="400" left="1014" width="206" height="17" font="13">677 pts assigned to placebo (Kaplan–</text>
<text top="417" left="1014" width="204" height="17" font="13">Meier estimate: 31.9%; 95% CI: 27.4-</text>
<text top="434" left="1014" width="197" height="17" font="13">36.4) (HR: 0.98; 95% CI: 0.83-1.17; </text>
<text top="451" left="1014" width="212" height="17" font="13">p=0.86). AE rates were similar overall; </text>
<text top="469" left="1014" width="223" height="17" font="13">however, only pts in the rolofylline group </text>
<text top="486" left="1014" width="223" height="17" font="13">had seizures, a known potential adverse </text>
<text top="503" left="1014" width="188" height="17" font="13">effect of A1-receptor antagonists1.</text>
<text top="503" left="1202" width="3" height="17" font="23"> </text>
<text top="176" left="1250" width="51" height="17" font="23">Post hoc </text>
<text top="193" left="1250" width="86" height="17" font="23">selection of the </text>
<text top="210" left="1250" width="81" height="17" font="23">best of 3 dose </text>
<text top="228" left="1250" width="90" height="17" font="23">groups from the </text>
<text top="245" left="1250" width="74" height="17" font="23">pilot trial with </text>
<text top="262" left="1250" width="78" height="17" font="23">multiple small </text>
<text top="279" left="1250" width="96" height="17" font="23">treatment groups </text>
<text top="296" left="1250" width="83" height="17" font="23">carries the risk </text>
<text top="314" left="1250" width="93" height="17" font="23">that an apparent </text>
<text top="331" left="1250" width="87" height="17" font="23">superiority may </text>
<text top="348" left="1250" width="77" height="17" font="23">be the play of </text>
<text top="365" left="1250" width="94" height="17" font="23">chance and may </text>
<text top="382" left="1250" width="90" height="17" font="23">have resulted in </text>
<text top="400" left="1250" width="79" height="17" font="23">the inability to </text>
<text top="417" left="1250" width="76" height="17" font="23">replicate pilot </text>
<text top="434" left="1250" width="92" height="17" font="23">study findings in </text>
<text top="451" left="1250" width="54" height="17" font="23">this more </text>
<text top="469" left="1250" width="90" height="17" font="23">definitive, larger </text>
<text top="486" left="1250" width="67" height="17" font="23">study. Also, </text>
<text top="503" left="1250" width="97" height="17" font="23">clinical relevance </text>
<text top="520" left="1250" width="94" height="17" font="23">of endpoints has </text>
<text top="537" left="1250" width="94" height="17" font="23">been questioned </text>
<text top="176" left="1365" width="80" height="17" font="13">Rolofylline did </text>
<text top="193" left="1365" width="61" height="17" font="13">not have a </text>
<text top="210" left="1365" width="87" height="17" font="13">favorable effect </text>
<text top="228" left="1365" width="83" height="17" font="13">with respect to </text>
<text top="245" left="1365" width="65" height="17" font="13">the primary </text>
<text top="262" left="1365" width="40" height="17" font="13">clinical </text>
<text top="279" left="1365" width="83" height="17" font="13">composite end </text>
<text top="296" left="1365" width="84" height="17" font="13">point, nor did it </text>
<text top="314" left="1365" width="78" height="17" font="13">improve renal </text>
<text top="331" left="1365" width="79" height="17" font="13">function or 60-</text>
<text top="348" left="1365" width="81" height="17" font="13">d outcomes. It </text>
<text top="365" left="1365" width="83" height="17" font="13">does not show </text>
<text top="382" left="1365" width="81" height="17" font="13">promise in the </text>
<text top="400" left="1365" width="69" height="17" font="13">treatment of </text>
<text top="417" left="1365" width="79" height="17" font="13">acute HF with </text>
<text top="434" left="1365" width="31" height="17" font="13">renal </text>
<text top="451" left="1365" width="66" height="17" font="13">dysfunction </text>
</page>
<page number="62" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">62</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="54" height="17" font="15"><b>DAD-HF</b>, </text>
<text top="72" left="28" width="65" height="17" font="13">Giamouzis, </text>
<text top="89" left="28" width="31" height="17" font="13">2010 </text>
<text top="106" left="28" width="55" height="17" font="14">21111980</text>
<text top="106" left="83" width="3" height="17" font="13"> </text>
<text top="124" left="28" width="32" height="17" font="13">(146) </text>
<text top="55" left="123" width="119" height="17" font="13">Evaluate the effect of </text>
<text top="72" left="123" width="110" height="17" font="13">low-dose dopamine </text>
<text top="89" left="123" width="105" height="17" font="13">and furosemide on </text>
<text top="106" left="123" width="100" height="17" font="13">diuresis and renal </text>
<text top="124" left="123" width="105" height="17" font="13">function in pts with </text>
<text top="141" left="123" width="124" height="17" font="13">acute decompensated </text>
<text top="158" left="123" width="20" height="17" font="13">HF </text>
<text top="55" left="265" width="29" height="17" font="13">RCT </text>
<text top="55" left="332" width="17" height="17" font="13">60 </text>
<text top="55" left="393" width="102" height="17" font="13">Age &gt;18 y; history </text>
<text top="72" left="393" width="116" height="17" font="13">of HF;                        </text>
<text top="89" left="393" width="109" height="17" font="13">deterioration of HF, </text>
<text top="106" left="393" width="73" height="17" font="13">symptoms of </text>
<text top="124" left="393" width="93" height="17" font="13">recent onset (&lt;6 </text>
<text top="141" left="393" width="81" height="17" font="13">h), dyspnea at </text>
<text top="158" left="393" width="90" height="17" font="13">rest, orthopnea, </text>
<text top="175" left="393" width="90" height="17" font="13">and paroxysmal </text>
<text top="192" left="393" width="107" height="17" font="13">nocturnal dyspnea, </text>
<text top="210" left="393" width="93" height="17" font="13">accompanied by </text>
<text top="227" left="393" width="46" height="17" font="13">signs of </text>
<text top="244" left="393" width="94" height="17" font="13">congestion (third </text>
<text top="261" left="393" width="72" height="17" font="13">heart sound, </text>
<text top="278" left="393" width="83" height="17" font="13">jugular venous </text>
<text top="296" left="393" width="62" height="17" font="13">distension, </text>
<text top="313" left="393" width="95" height="17" font="13">pulmonary rales) </text>
<text top="330" left="393" width="65" height="17" font="13">on physical </text>
<text top="347" left="393" width="108" height="17" font="13">examination; levels </text>
<text top="365" left="393" width="80" height="17" font="13">of serum BNP </text>
<text top="382" left="393" width="103" height="17" font="13">&gt;400 pg/mL or NT </text>
<text top="399" left="393" width="77" height="17" font="13">pBNP &gt;1,500 </text>
<text top="416" left="393" width="108" height="17" font="13">pg/mL; and oxygen </text>
<text top="433" left="393" width="93" height="17" font="13">saturation &lt;90% </text>
<text top="451" left="393" width="79" height="17" font="13">on admission. </text>
<text top="55" left="514" width="176" height="17" font="13">Acute de novo HF; severe renal </text>
<text top="72" left="514" width="156" height="17" font="13">failure (admission SCr &gt;215 </text>
<text top="89" left="514" width="184" height="17" font="13">mmol/L [2.5 mg/dL] or eGFR &lt;30 </text>
<text top="106" left="514" width="92" height="17" font="13">mL min 1 1.73 m</text>
<text top="108" left="606" width="4" height="11" font="19">2</text>
<text top="106" left="610" width="98" height="17" font="13">); admission SBP </text>
<text top="124" left="514" width="160" height="17" font="13">&lt;90 mm Hg;  severe valvular </text>
<text top="141" left="514" width="189" height="17" font="13">disease; known adverse reactions </text>
<text top="158" left="514" width="173" height="17" font="13">to furosemide or dopamine; HF </text>
<text top="175" left="514" width="165" height="17" font="13">secondary to congenital heart </text>
<text top="192" left="514" width="178" height="17" font="13">disease; a scheduled procedure </text>
<text top="210" left="514" width="183" height="17" font="13">with a need for IV contrast dye in </text>
<text top="227" left="514" width="184" height="17" font="13">the present hospitalization; and a </text>
<text top="244" left="514" width="192" height="17" font="13">scheduled cardiac surgery within 2 </text>
<text top="261" left="514" width="24" height="17" font="13">mo. </text>
<text top="55" left="724" width="139" height="17" font="13">Incidence of WRF during </text>
<text top="72" left="724" width="99" height="17" font="13">the first 24 h from </text>
<text top="89" left="724" width="98" height="17" font="13">randomization.  2 </text>
<text top="106" left="724" width="137" height="17" font="13">definitions were used for </text>
<text top="124" left="724" width="151" height="17" font="13">WRF: 1) &gt;0.3 mg/dL rise in </text>
<text top="141" left="724" width="144" height="17" font="13">SCr level from baseline to </text>
<text top="158" left="724" width="104" height="17" font="13">24 h; and 2) &gt;20% </text>
<text top="175" left="724" width="131" height="17" font="13">decrease in eGFR from </text>
<text top="192" left="724" width="107" height="17" font="13">baseline to 24 h      </text>
<text top="55" left="892" width="94" height="17" font="13">Changes in SCr, </text>
<text top="72" left="892" width="94" height="17" font="13">urea, potassium, </text>
<text top="89" left="892" width="98" height="17" font="13">and eGFR during </text>
<text top="106" left="892" width="99" height="17" font="13">the first 24 h from </text>
<text top="124" left="892" width="84" height="17" font="13">randomization; </text>
<text top="141" left="892" width="101" height="17" font="13">incidence of WRF </text>
<text top="158" left="892" width="102" height="17" font="13">over the course of </text>
<text top="175" left="892" width="85" height="17" font="13">hospitalization; </text>
<text top="192" left="892" width="107" height="17" font="13">total length of stay; </text>
<text top="210" left="892" width="102" height="17" font="13">and 60-d mortality </text>
<text top="227" left="892" width="107" height="17" font="13">or rehospitalization </text>
<text top="244" left="892" width="85" height="17" font="13">rate (all-cause, </text>
<text top="261" left="892" width="86" height="17" font="13">cardiovascular, </text>
<text top="278" left="892" width="97" height="17" font="13">and worsening of </text>
<text top="296" left="892" width="27" height="17" font="13">HF). </text>
<text top="55" left="1014" width="196" height="17" font="13">Mean hourly excreted urine volume </text>
<text top="72" left="1014" width="208" height="17" font="13">(272±149mL in high-dose furosemide </text>
<text top="89" left="1014" width="213" height="17" font="13">vs 278±186mL in LDFD plus low-dose </text>
<text top="106" left="1014" width="215" height="17" font="13">dopamine group; p=.965) and changes </text>
<text top="124" left="1014" width="212" height="17" font="13">in dyspnea score (Borg index: 4.4±2.1 </text>
<text top="141" left="1014" width="185" height="17" font="13">in high-dose furosemide group vs </text>
<text top="158" left="1014" width="216" height="17" font="13">4.7±2.0 in LDFD group; p=.575) during </text>
<text top="175" left="1014" width="187" height="17" font="13">the 8 h of protocol treatment were </text>
<text top="192" left="1014" width="196" height="17" font="13">similar in the two groups. WRF was </text>
<text top="210" left="1014" width="171" height="17" font="13">more frequent in the high-dose </text>
<text top="227" left="1014" width="189" height="17" font="13">furosemide (n=9; 30%) than in the </text>
<text top="244" left="1014" width="186" height="17" font="13">LDFD group (n=2; 6.7%; p=.042). </text>
<text top="261" left="1014" width="178" height="17" font="13">Serum potassium changed from </text>
<text top="278" left="1014" width="182" height="17" font="13">4.3±0.5 to 3.9±0.4mEq/L at 24 h </text>
<text top="296" left="1014" width="205" height="17" font="13">(p=.003) in the high-dose furosemide </text>
<text top="313" left="1014" width="143" height="17" font="13">group and from4.4±0.5 to </text>
<text top="330" left="1014" width="223" height="17" font="13">4.2±0.5mEq/L at 24 hours (p=.07) in the </text>
<text top="347" left="1014" width="207" height="17" font="13">LDFD group. Length of stay and 60-d </text>
<text top="365" left="1014" width="208" height="17" font="13">mortality or rehospitalization rates (all-</text>
<text top="382" left="1014" width="209" height="17" font="13">cause, cardiovascular, and worsening </text>
<text top="399" left="1014" width="27" height="17" font="13">HF). </text>
<text top="55" left="1250" width="89" height="17" font="13">Relatively small </text>
<text top="72" left="1250" width="87" height="17" font="13">study, 2 groups </text>
<text top="89" left="1250" width="83" height="17" font="13">did not receive </text>
<text top="106" left="1250" width="98" height="17" font="13">the same dose of </text>
<text top="124" left="1250" width="88" height="17" font="13">furosemide and </text>
<text top="141" left="1250" width="93" height="17" font="13">did not include a </text>
<text top="158" left="1250" width="53" height="17" font="13">low-dose </text>
<text top="175" left="1250" width="90" height="17" font="13">furosemide only </text>
<text top="192" left="1250" width="42" height="17" font="13">group.  </text>
<text top="55" left="1365" width="59" height="17" font="13">This study </text>
<text top="72" left="1365" width="62" height="17" font="13">shows that </text>
<text top="89" left="1365" width="87" height="17" font="13">LDFD infusions </text>
<text top="106" left="1365" width="87" height="17" font="13">are as effective </text>
<text top="124" left="1365" width="74" height="17" font="13">as high-dose </text>
<text top="141" left="1365" width="64" height="17" font="13">furosemide </text>
<text top="158" left="1365" width="65" height="17" font="13">infusions in </text>
<text top="175" left="1365" width="88" height="17" font="13">terms of clinical </text>
<text top="192" left="1365" width="67" height="17" font="13">and diuretic </text>
<text top="210" left="1365" width="87" height="17" font="13">response in pts </text>
<text top="227" left="1365" width="86" height="17" font="13">hospitalized for </text>
<text top="244" left="1365" width="33" height="17" font="13">acute </text>
<text top="261" left="1365" width="81" height="17" font="13">decompensate</text>
<text top="278" left="1365" width="34" height="17" font="13">d HF. </text>
<text top="296" left="1365" width="59" height="17" font="13">Moreover, </text>
<text top="313" left="1365" width="81" height="17" font="13">LDFD infusion </text>
<text top="330" left="1365" width="87" height="17" font="13">was associated </text>
<text top="347" left="1365" width="25" height="17" font="13">with </text>
<text top="365" left="1365" width="67" height="17" font="13">significantly </text>
<text top="382" left="1365" width="77" height="17" font="13">lower rates of </text>
<text top="399" left="1365" width="59" height="17" font="13">WRF than </text>
<text top="416" left="1365" width="57" height="17" font="13">high-dose </text>
<text top="433" left="1365" width="68" height="17" font="13">furosemide, </text>
<text top="451" left="1365" width="73" height="17" font="13">suggesting a </text>
<text top="468" left="1365" width="81" height="17" font="13">renoprotective </text>
<text top="485" left="1365" width="83" height="17" font="13">effect in this pt </text>
<text top="502" left="1365" width="64" height="17" font="13">population. </text>
</page>
<page number="63" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">63</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="30" height="17" font="15"><b>Pilot </b></text>
<text top="72" left="28" width="70" height="17" font="15"><b>continuous </b></text>
<text top="89" left="28" width="53" height="17" font="15"><b>vs bolus </b></text>
<text top="106" left="28" width="51" height="17" font="15"><b>infusion </b></text>
<text top="124" left="28" width="54" height="17" font="13">(Duke), L </text>
<text top="141" left="28" width="65" height="17" font="13">Allen, 2010 </text>
<text top="158" left="28" width="55" height="17" font="14">20538132</text>
<text top="158" left="83" width="3" height="17" font="13"> </text>
<text top="175" left="28" width="32" height="17" font="13">(147) </text>
<text top="55" left="123" width="74" height="17" font="13">Pilot study of </text>
<text top="72" left="123" width="81" height="17" font="13">furosemide by </text>
<text top="89" left="123" width="124" height="17" font="13">continuous infusion vs </text>
<text top="106" left="123" width="130" height="17" font="13">twice-d bolus injection.  </text>
<text top="124" left="123" width="88" height="17" font="13">Hypothesis that </text>
<text top="141" left="123" width="116" height="17" font="13">continuous dosing of </text>
<text top="158" left="123" width="79" height="17" font="13">IV furosemide </text>
<text top="175" left="123" width="94" height="17" font="13">provides gradual </text>
<text top="192" left="123" width="96" height="17" font="13">diuresis with less </text>
<text top="210" left="123" width="86" height="17" font="13">neurohormonal </text>
<text top="227" left="123" width="94" height="17" font="13">activation, which </text>
<text top="244" left="123" width="127" height="17" font="13">would manifest as less </text>
<text top="261" left="123" width="100" height="17" font="13">renal dysfunction, </text>
<text top="278" left="123" width="105" height="17" font="13">compared to bolus </text>
<text top="296" left="123" width="129" height="17" font="13">dosing in the treatment </text>
<text top="313" left="123" width="47" height="17" font="13">of acute </text>
<text top="330" left="123" width="111" height="17" font="13">decompensated HF </text>
<text top="347" left="123" width="119" height="17" font="13">with volume overload </text>
<text top="55" left="265" width="213" height="17" font="13">RCT 41  Primary </text>
<text top="55" left="439" width="94" height="17" font="13">diagnosis </text>
<text top="72" left="393" width="47" height="17" font="13">of acute </text>
<text top="89" left="393" width="91" height="17" font="13">decompensated </text>
<text top="106" left="393" width="90" height="17" font="13">HF; evidence of </text>
<text top="124" left="393" width="97" height="17" font="13">volume overload; </text>
<text top="141" left="393" width="50" height="17" font="13">could be </text>
<text top="158" left="393" width="102" height="17" font="13">randomized &lt;24 h </text>
<text top="175" left="393" width="74" height="17" font="13">from hospital </text>
<text top="192" left="393" width="71" height="17" font="13">presentation </text>
<text top="55" left="514" width="150" height="17" font="13">End-stage renal disease or </text>
<text top="72" left="514" width="142" height="17" font="13">anticipated need for renal </text>
<text top="89" left="514" width="170" height="17" font="13">replacement therapy; were not </text>
<text top="106" left="514" width="194" height="17" font="13">expected to survive hospitalization; </text>
<text top="124" left="514" width="52" height="17" font="13">pregnant </text>
<text top="55" left="724" width="112" height="17" font="13">Change in SCr from </text>
<text top="72" left="724" width="153" height="17" font="13">admission to hospital d 3 or </text>
<text top="89" left="724" width="103" height="17" font="13">hospital discharge </text>
<text top="55" left="892" width="96" height="17" font="13">Cumulative urine </text>
<text top="72" left="892" width="93" height="17" font="13">output and other </text>
<text top="89" left="892" width="59" height="17" font="13">electrolyte </text>
<text top="106" left="892" width="78" height="17" font="13">changes from </text>
<text top="124" left="892" width="72" height="17" font="13">admission to </text>
<text top="141" left="892" width="107" height="17" font="13">hospital d 3 as well </text>
<text top="158" left="892" width="99" height="17" font="13">as hospital length </text>
<text top="175" left="892" width="40" height="17" font="13">of stay </text>
<text top="55" left="1014" width="180" height="17" font="13">None of the outcomes showed a </text>
<text top="72" left="1014" width="178" height="17" font="13">statistically significant difference </text>
<text top="89" left="1014" width="209" height="17" font="13">between bolus and continuous dosing </text>
<text top="106" left="1014" width="170" height="17" font="13">from admission to hospital d 3. </text>
<text top="124" left="1014" width="153" height="17" font="13">Nonsignificant trend toward </text>
<text top="141" left="1014" width="209" height="17" font="13">improvement in the bolus dosing arm. </text>
<text top="158" left="1014" width="213" height="17" font="13">Decreases in serum potassium, serum </text>
<text top="175" left="1014" width="223" height="17" font="13">sodium, and SBP showed nonsignificant </text>
<text top="192" left="1014" width="204" height="17" font="13">trends in favor of continuous infusion </text>
<text top="210" left="1014" width="7" height="17" font="13">  </text>
<text top="55" left="1250" width="78" height="17" font="13">Smaller study </text>
<text top="55" left="1365" width="82" height="17" font="13">No statistically </text>
<text top="72" left="1365" width="58" height="17" font="13">significant </text>
<text top="89" left="1365" width="64" height="17" font="13">differences </text>
<text top="106" left="1365" width="84" height="17" font="13">noted between </text>
<text top="124" left="1365" width="57" height="17" font="13">bolus and </text>
<text top="141" left="1365" width="63" height="17" font="13">continuous </text>
<text top="158" left="1365" width="46" height="17" font="13">infusion </text>
<text top="371" left="28" width="30" height="17" font="15"><b>Pilot </b></text>
<text top="388" left="28" width="70" height="17" font="15"><b>continuous </b></text>
<text top="405" left="28" width="53" height="17" font="15"><b>vs bolus </b></text>
<text top="422" left="28" width="51" height="17" font="15"><b>infusion </b></text>
<text top="439" left="28" width="51" height="17" font="13">(MUSC)<b>,</b> </text>
<text top="457" left="28" width="58" height="17" font="13">Thomson, </text>
<text top="474" left="28" width="31" height="17" font="13">2010 </text>
<text top="491" left="28" width="55" height="17" font="14">20206891</text>
<text top="491" left="83" width="3" height="17" font="13"> </text>
<text top="508" left="28" width="32" height="17" font="13">(148) </text>
<text top="371" left="123" width="121" height="17" font="13">Pilot study comparing </text>
<text top="388" left="123" width="109" height="17" font="13">the effectiveness of </text>
<text top="405" left="123" width="103" height="17" font="13">continuous IV with </text>
<text top="422" left="123" width="125" height="17" font="13">intermittent IV infusion </text>
<text top="439" left="123" width="105" height="17" font="13">of furosemide in pt </text>
<text top="457" left="123" width="59" height="17" font="13">with acute </text>
<text top="474" left="123" width="111" height="17" font="13">decompensated HF </text>
<text top="371" left="265" width="227" height="17" font="13">RCT 56  Admission </text>
<text top="388" left="393" width="103" height="17" font="13">diagnosis of acute </text>
<text top="405" left="393" width="91" height="17" font="13">decompensated </text>
<text top="422" left="393" width="20" height="17" font="13">HF </text>
<text top="371" left="514" width="188" height="17" font="13">Pts who had received &gt;2 doses of </text>
<text top="388" left="514" width="118" height="17" font="13">IV fruosemide before </text>
<text top="405" left="514" width="81" height="17" font="13">randomization </text>
<text top="371" left="724" width="120" height="17" font="13">Net daily urine output </text>
<text top="371" left="892" width="82" height="17" font="13">Net daily urine </text>
<text top="388" left="892" width="101" height="17" font="13">output normalized </text>
<text top="405" left="892" width="76" height="17" font="13">for amount of </text>
<text top="422" left="892" width="64" height="17" font="13">furosemide </text>
<text top="439" left="892" width="80" height="17" font="13">received, total </text>
<text top="457" left="892" width="97" height="17" font="13">daily urine output </text>
<text top="474" left="892" width="81" height="17" font="13">normalized for </text>
<text top="491" left="892" width="58" height="17" font="13">amount of </text>
<text top="508" left="892" width="64" height="17" font="13">furosemide </text>
<text top="526" left="892" width="92" height="17" font="13">received, weight </text>
<text top="543" left="892" width="83" height="17" font="13">loss during the </text>
<text top="560" left="892" width="85" height="17" font="13">study, need for </text>
<text top="577" left="892" width="76" height="17" font="13">additional HF </text>
<text top="594" left="892" width="96" height="17" font="13">therapy, duration </text>
<text top="612" left="892" width="75" height="17" font="13">of study drug </text>
<text top="629" left="892" width="76" height="17" font="13">dministration, </text>
<text top="646" left="892" width="51" height="17" font="13">length of </text>
<text top="663" left="892" width="81" height="17" font="13">hospitalization </text>
<text top="371" left="1014" width="168" height="17" font="13">Mean urine output in 24 h was </text>
<text top="388" left="1014" width="173" height="17" font="13">2,098±1,132 mL in pt receiving </text>
<text top="405" left="1014" width="202" height="17" font="13">continuous vs 1,575±1100 mL in the </text>
<text top="422" left="1014" width="189" height="17" font="13">bolus group (p=0.086). Total urine </text>
<text top="439" left="1014" width="211" height="17" font="13">output was 3726±1121 mL/24 h in the </text>
<text top="457" left="1014" width="187" height="17" font="13">continuous group vs 2,955±1,267 </text>
<text top="474" left="1014" width="188" height="17" font="13">mL/24 h in bolus group (p=0.019). </text>
<text top="491" left="1014" width="221" height="17" font="13">Length of hospital stay was 6.9±3.7 d in </text>
<text top="508" left="1014" width="210" height="17" font="13">the continuous group vs 10.9±8.3 d in </text>
<text top="526" left="1014" width="145" height="17" font="13">the bolus group (p=0.006) </text>
<text top="543" left="1014" width="7" height="17" font="13">  </text>
<text top="371" left="1250" width="78" height="17" font="13">Smaller study </text>
<text top="371" left="1365" width="70" height="17" font="13">LOS shorter </text>
<text top="388" left="1365" width="58" height="17" font="13">and mean </text>
<text top="405" left="1365" width="68" height="17" font="13">urine output </text>
<text top="422" left="1365" width="76" height="17" font="13">greater in the </text>
<text top="439" left="1365" width="63" height="17" font="13">continuous </text>
<text top="457" left="1365" width="81" height="17" font="13">infusion group </text>
<text top="474" left="1365" width="83" height="17" font="13">vs bolus group </text>
<text top="681" left="28" width="59" height="17" font="15"><b>ADHERE</b>, </text>
<text top="698" left="28" width="54" height="17" font="13">Peacock, </text>
<text top="716" left="28" width="31" height="17" font="13">2008 </text>
<text top="733" left="28" width="55" height="17" font="14">18480204</text>
<text top="733" left="83" width="3" height="17" font="13"> </text>
<text top="750" left="28" width="32" height="17" font="13">(149) </text>
<text top="681" left="123" width="96" height="17" font="13">To determine the </text>
<text top="698" left="123" width="95" height="17" font="13">clinical and renal </text>
<text top="716" left="123" width="119" height="17" font="13">outcomes associated </text>
<text top="733" left="123" width="127" height="17" font="13">with lower vs higher IV </text>
<text top="750" left="123" width="113" height="17" font="13">loop diuretic dose in </text>
<text top="767" left="123" width="113" height="17" font="13">pts hospitalized with </text>
<text top="785" left="123" width="124" height="17" font="13">acute decompensated </text>
<text top="681" left="265" width="48" height="17" font="13">Registry </text>
<text top="681" left="332" width="115" height="17" font="13">82,540   Pts in the </text>
<text top="698" left="393" width="98" height="17" font="13">ADHERE registry </text>
<text top="716" left="393" width="91" height="17" font="13">who received IV </text>
<text top="733" left="393" width="97" height="17" font="13">diuretics during a </text>
<text top="750" left="393" width="99" height="17" font="13">hospitalization for </text>
<text top="767" left="393" width="33" height="17" font="13">acute </text>
<text top="785" left="393" width="91" height="17" font="13">decompensated </text>
<text top="681" left="514" width="184" height="17" font="13">Pts receiving vasoactive drugs or </text>
<text top="698" left="514" width="161" height="17" font="13">dialysis. Those who received </text>
<text top="716" left="514" width="191" height="17" font="13">multiple types of diuretics. Pts with </text>
<text top="733" left="514" width="133" height="17" font="13">SCr values &gt;6 mg/dL or </text>
<text top="750" left="514" width="169" height="17" font="13">hospitalizations with LOS &lt;4 h </text>
<text top="767" left="514" width="193" height="17" font="13">were excluded from the analysis of </text>
<text top="785" left="514" width="149" height="17" font="13">change in SCr and dialysis </text>
<text top="681" left="724" width="141" height="17" font="13">Increase from baseline to </text>
<text top="698" left="724" width="130" height="17" font="13">last available SCr &gt; 0.5 </text>
<text top="716" left="724" width="120" height="17" font="13">mg/dL;                        </text>
<text top="733" left="724" width="121" height="17" font="13">decrease in GFR &gt;10 </text>
<text top="750" left="724" width="135" height="17" font="13">mL/min from baseline to </text>
<text top="767" left="724" width="150" height="17" font="13">discharge;         initiation of </text>
<text top="785" left="724" width="81" height="17" font="13">dialysis during </text>
<text top="681" left="892" width="56" height="17" font="13">Inhospital </text>
<text top="698" left="892" width="78" height="17" font="13">mortality, ICU </text>
<text top="716" left="892" width="87" height="17" font="13">admission, ICU </text>
<text top="733" left="892" width="83" height="17" font="13">LOS &gt;3 d, and </text>
<text top="750" left="892" width="101" height="17" font="13">hospital LOS &gt;4 d </text>
<text top="681" left="1014" width="166" height="17" font="13">Both before and after risk and </text>
<text top="698" left="1014" width="213" height="17" font="13">propensity adjustments, an increase in </text>
<text top="716" left="1014" width="166" height="17" font="13">SCr &gt;0.5 mg/dL occurred less </text>
<text top="733" left="1014" width="207" height="17" font="13">frequently in LDD  admissions than in </text>
<text top="750" left="1014" width="214" height="17" font="13">HDD admissions (both p&lt;0.0001). The </text>
<text top="767" left="1014" width="223" height="17" font="13">prevalence of a &gt;10 mL/min decrease in </text>
<text top="785" left="1014" width="202" height="17" font="13">GFR from baseline to discharge was </text>
<text top="681" left="1250" width="98" height="17" font="13">ADHERE registry </text>
<text top="698" left="1250" width="58" height="17" font="13">data were </text>
<text top="716" left="1250" width="98" height="17" font="13">retrospective and </text>
<text top="733" left="1250" width="93" height="17" font="13">observational so </text>
<text top="750" left="1250" width="57" height="17" font="13">should be </text>
<text top="767" left="1250" width="69" height="17" font="13">regarded as </text>
<text top="785" left="1250" width="62" height="17" font="13">hypothesis </text>
<text top="681" left="1365" width="75" height="17" font="13">Among pts in </text>
<text top="698" left="1365" width="75" height="17" font="13">the ADHERE </text>
<text top="716" left="1365" width="77" height="17" font="13">registry, After </text>
<text top="733" left="1365" width="77" height="17" font="13">covariate and </text>
<text top="750" left="1365" width="60" height="17" font="13">propensity </text>
<text top="767" left="1365" width="73" height="17" font="13">adjustments, </text>
<text top="785" left="1365" width="76" height="17" font="13">the inhospital </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">64</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="123" width="83" height="17" font="13">HF. This study </text>
<text top="72" left="123" width="129" height="17" font="13">analyzed data from the </text>
<text top="89" left="123" width="112" height="17" font="13">ADHERE registry to </text>
<text top="106" left="123" width="114" height="17" font="13">look at the impact of </text>
<text top="124" left="123" width="127" height="17" font="13">diuretic dosing. 62,866 </text>
<text top="141" left="123" width="118" height="17" font="13">pt receiving &lt;160 mg </text>
<text top="158" left="123" width="117" height="17" font="13">and 19,674 pts ≥160 </text>
<text top="175" left="123" width="129" height="17" font="13">mg of furosemide were </text>
<text top="192" left="123" width="56" height="17" font="13">analyzed. </text>
<text top="55" left="393" width="23" height="17" font="13">HF. </text>
<text top="55" left="514" width="177" height="17" font="13">initiation.  Pt with SCr values &gt;6 </text>
<text top="72" left="514" width="188" height="17" font="13">mg/dL, GFR values &gt;200 mL/min, </text>
<text top="89" left="514" width="190" height="17" font="13">or hospitalizations with LOS &lt;24 h </text>
<text top="106" left="514" width="193" height="17" font="13">were excluded from the analysis of </text>
<text top="124" left="514" width="93" height="17" font="13">change in GFR.  </text>
<text top="55" left="724" width="88" height="17" font="13">hospitalization.  </text>
<text top="55" left="1014" width="187" height="17" font="13">significantly lower in LDD vs HDD </text>
<text top="72" left="1014" width="195" height="17" font="13">admissions (p &lt;0.0001). Significant </text>
<text top="89" left="1014" width="202" height="17" font="13">differences between cohorts present </text>
<text top="106" left="1014" width="208" height="17" font="13">after risk and propensity adjustments. </text>
<text top="124" left="1014" width="196" height="17" font="13">LDD treatment was associated with </text>
<text top="141" left="1014" width="221" height="17" font="13">lower prevalence of prolonged ICU LOS </text>
<text top="158" left="1014" width="229" height="17" font="13">(nonsignificant differences).                       </text>
<text top="175" left="1014" width="167" height="17" font="13">After covariate and propensity </text>
<text top="192" left="1014" width="219" height="17" font="13">adjustments: in-hospital mortality risk of </text>
<text top="210" left="1014" width="211" height="17" font="13">LDD was significantly lower compared </text>
<text top="227" left="1014" width="206" height="17" font="13">to HDD. AUC for adjusted model was </text>
<text top="244" left="1014" width="31" height="17" font="13">0.78. </text>
<text top="261" left="1014" width="222" height="17" font="13">Unadjusted mortality OR 0.875; 95% CI: </text>
<text top="278" left="1014" width="230" height="17" font="13">0.787–0.973; p =0.01.                                </text>
<text top="296" left="1014" width="223" height="17" font="13">After adjustment for covariates known to </text>
<text top="313" left="1014" width="192" height="17" font="13">be associated with mortality – age, </text>
<text top="330" left="1014" width="203" height="17" font="13">BUN, SBP, DBP, sodium, creatinine, </text>
<text top="347" left="1014" width="174" height="17" font="13">heart rate and dyspnea at rest –</text>
<text top="365" left="1014" width="219" height="17" font="13">adjusted OR was 0.888: 95% CI: 0.795–</text>
<text top="382" left="1014" width="96" height="17" font="13">0.993; p =0.0364 </text>
<text top="55" left="1250" width="65" height="17" font="13">generating. </text>
<text top="72" left="1250" width="90" height="17" font="13">Clinical reasons </text>
<text top="89" left="1250" width="95" height="17" font="13">for initiation of IV </text>
<text top="106" left="1250" width="95" height="17" font="13">diuretics was not </text>
<text top="124" left="1250" width="76" height="17" font="13">collected and </text>
<text top="141" left="1250" width="73" height="17" font="13">therefore not </text>
<text top="158" left="1250" width="76" height="17" font="13">considered in </text>
<text top="175" left="1250" width="55" height="17" font="13">analysis.  </text>
<text top="55" left="1365" width="86" height="17" font="13">mortality risk of </text>
<text top="72" left="1365" width="46" height="17" font="13">pts who </text>
<text top="89" left="1365" width="78" height="17" font="13">received LDD </text>
<text top="106" left="1365" width="25" height="17" font="13">was </text>
<text top="124" left="1365" width="67" height="17" font="13">significantly </text>
<text top="141" left="1365" width="33" height="17" font="13">lower </text>
<text top="158" left="1365" width="72" height="17" font="13">compared to </text>
<text top="175" left="1365" width="86" height="17" font="13">those receiving </text>
<text top="192" left="1365" width="33" height="17" font="13">HDD. </text>
<text top="400" left="28" width="80" height="17" font="15"><b>Cohort study </b></text>
<text top="417" left="28" width="74" height="17" font="15"><b>high vs. low </b></text>
<text top="434" left="28" width="32" height="17" font="15"><b>dose</b> </text>
<text top="451" left="28" width="77" height="17" font="13">(Brigham and </text>
<text top="469" left="28" width="58" height="17" font="13">Women's) </text>
<text top="486" left="28" width="64" height="17" font="13">Mielniczuk, </text>
<text top="503" left="28" width="31" height="17" font="13">2008 </text>
<text top="520" left="28" width="55" height="17" font="14">18514930</text>
<text top="520" left="83" width="3" height="17" font="13"> </text>
<text top="537" left="28" width="32" height="17" font="13">(150) </text>
<text top="400" left="123" width="95" height="17" font="13">This study was a </text>
<text top="417" left="123" width="66" height="17" font="13">prospective </text>
<text top="434" left="123" width="124" height="17" font="13">observational analysis </text>
<text top="451" left="123" width="120" height="17" font="13">of pts in an advanced </text>
<text top="469" left="123" width="114" height="17" font="13">HF clinic stratified at </text>
<text top="486" left="123" width="109" height="17" font="13">baseline by diuretic </text>
<text top="503" left="123" width="112" height="17" font="13">dose (low dose ≤80 </text>
<text top="520" left="123" width="125" height="17" font="13">mg, high dose &gt;80 mg </text>
<text top="537" left="123" width="128" height="17" font="13">furosemide equivalent) </text>
<text top="555" left="123" width="118" height="17" font="13">to evaluate the effect </text>
<text top="572" left="123" width="102" height="17" font="13">of high/low (or no) </text>
<text top="589" left="123" width="96" height="17" font="13">diuretic doses on </text>
<text top="606" left="123" width="60" height="17" font="13">outcomes. </text>
<text top="400" left="265" width="40" height="17" font="13">Cohort </text>
<text top="400" left="332" width="24" height="17" font="13">183 </text>
<text top="400" left="393" width="101" height="17" font="13">Eligible pts had to </text>
<text top="417" left="393" width="85" height="17" font="13">have a primary </text>
<text top="434" left="393" width="69" height="17" font="13">diagnosis of </text>
<text top="451" left="393" width="104" height="17" font="13">chronic HF and be </text>
<text top="469" left="393" width="75" height="17" font="13">followed by a </text>
<text top="486" left="393" width="77" height="17" font="13">specialist in a </text>
<text top="503" left="393" width="88" height="17" font="13">tertiary care HF </text>
<text top="520" left="393" width="81" height="17" font="13">clinic. Pts with </text>
<text top="537" left="393" width="107" height="17" font="13">either preserved or </text>
<text top="555" left="393" width="92" height="17" font="13">reduced systolic </text>
<text top="572" left="393" width="77" height="17" font="13">function were </text>
<text top="589" left="393" width="49" height="17" font="13">included </text>
<text top="400" left="514" width="189" height="17" font="13">Pts were excluded if they required </text>
<text top="417" left="514" width="184" height="17" font="13">renal replacement therapy, had a </text>
<text top="434" left="514" width="180" height="17" font="13">concurrent noncardiac diagnosis </text>
<text top="451" left="514" width="191" height="17" font="13">expected to limit life expectancy to </text>
<text top="469" left="514" width="174" height="17" font="13">less than 1 y, or were unable to </text>
<text top="486" left="514" width="152" height="17" font="13">participate in repeat clinical </text>
<text top="503" left="514" width="75" height="17" font="13">assessments </text>
<text top="400" left="724" width="144" height="17" font="13">All pts were followed for 1 </text>
<text top="417" left="724" width="150" height="17" font="13">y. The primary outcome for </text>
<text top="434" left="724" width="134" height="17" font="13">the analysis was time to </text>
<text top="451" left="724" width="110" height="17" font="13">first HF event of HF </text>
<text top="469" left="724" width="105" height="17" font="13">admission, cardiac </text>
<text top="486" left="724" width="144" height="17" font="13">transplant, MCS, or death </text>
<text top="400" left="892" width="62" height="17" font="13">Secondary </text>
<text top="417" left="892" width="106" height="17" font="13">outcomes included </text>
<text top="434" left="892" width="55" height="17" font="13">individual </text>
<text top="451" left="892" width="105" height="17" font="13">components of the </text>
<text top="469" left="892" width="103" height="17" font="13">HF composite and </text>
<text top="486" left="892" width="95" height="17" font="13">WRF, which was </text>
<text top="503" left="892" width="77" height="17" font="13">defined as an </text>
<text top="520" left="892" width="91" height="17" font="13">increase in SCr  </text>
<text top="537" left="892" width="93" height="17" font="13">&gt;0.3 mg/dL from </text>
<text top="555" left="892" width="49" height="17" font="13">baseline </text>
<text top="400" left="1014" width="218" height="17" font="13">Compared with pts taking LDD (113 pts </text>
<text top="417" left="1014" width="205" height="17" font="13">[62%]), pts taking HDD (70 pts[38%]) </text>
<text top="434" left="1014" width="174" height="17" font="13">had more markers of increased </text>
<text top="451" left="1014" width="195" height="17" font="13">cardiovascular risk (older, ischemic </text>
<text top="469" left="1014" width="197" height="17" font="13">cardiomyopathy, DM and HTN) and </text>
<text top="486" left="1014" width="200" height="17" font="13">were more likely to have a history of </text>
<text top="503" left="1014" width="206" height="17" font="13">recent instability (33% vs 4.4% in low </text>
<text top="520" left="1014" width="222" height="17" font="13">dose,  p&lt; .001).  SCr significantly higher </text>
<text top="537" left="1014" width="220" height="17" font="13">in pts receiving HDD vs. LDD (1.4 ± 0.5 </text>
<text top="555" left="1014" width="219" height="17" font="13">mg/dL vs 1.1 ± 0.5 mg/dL, respectively, </text>
<text top="572" left="1014" width="230" height="17" font="13">p &lt; .001).                                                    </text>
<text top="589" left="1014" width="166" height="17" font="13">1 y cumulative HF event rates </text>
<text top="606" left="1014" width="209" height="17" font="13">significantly greater in pts taking HDD </text>
<text top="624" left="1014" width="189" height="17" font="13">when to low-dose/no diuretics (HF </text>
<text top="641" left="1014" width="199" height="17" font="13">composite, 29% vs 4.5%, p&lt;.01; HF </text>
<text top="658" left="1014" width="205" height="17" font="13">hospitalization, 26% vs 4.5%, p&lt; .01; </text>
<text top="675" left="1014" width="210" height="17" font="13">MCS or transplant, 7.1% vs 2.7%, P = </text>
<text top="692" left="1014" width="220" height="17" font="13">.02; death, 2.9% vs 0.9%, p= .4; high vs </text>
<text top="710" left="1014" width="220" height="17" font="13">low dose for all).                                      </text>
<text top="727" left="1014" width="201" height="17" font="13">Among pts taking HDD, those with a </text>
<text top="744" left="1014" width="198" height="17" font="13">history of instability had significantly </text>
<text top="761" left="1014" width="195" height="17" font="13">greater HF event rates during a 1-y </text>
<text top="778" left="1014" width="204" height="17" font="13">period compared with pts with recent </text>
<text top="400" left="1250" width="81" height="17" font="13">Smaller study, </text>
<text top="417" left="1250" width="80" height="17" font="13">observational, </text>
<text top="434" left="1250" width="74" height="17" font="13">single-center </text>
<text top="400" left="1365" width="74" height="17" font="13">HDD may be </text>
<text top="417" left="1365" width="55" height="17" font="13">more of a </text>
<text top="434" left="1365" width="79" height="17" font="13">marker than a </text>
<text top="451" left="1365" width="50" height="17" font="13">cause of </text>
<text top="469" left="1365" width="69" height="17" font="13">instability. A </text>
<text top="486" left="1365" width="73" height="17" font="13">history of HF </text>
<text top="503" left="1365" width="82" height="17" font="13">stability during </text>
<text top="520" left="1365" width="78" height="17" font="13">the past 6 mo </text>
<text top="537" left="1365" width="74" height="17" font="13">is associated </text>
<text top="555" left="1365" width="70" height="17" font="13">with an 80% </text>
<text top="572" left="1365" width="86" height="17" font="13">lower risk of an </text>
<text top="589" left="1365" width="53" height="17" font="13">HF event </text>
<text top="606" left="1365" width="85" height="17" font="13">during the next </text>
<text top="624" left="1365" width="13" height="17" font="13">y, </text>
<text top="641" left="1365" width="80" height="17" font="13">independently </text>
<text top="658" left="1365" width="63" height="17" font="13">of baseline </text>
<text top="675" left="1365" width="77" height="17" font="13">diuretic dose. </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">65</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1014" width="215" height="17" font="13">clinical stability (HF composite, 47% vs </text>
<text top="72" left="1014" width="218" height="17" font="13">18%, p =.013) Independently of diuretic </text>
<text top="89" left="1014" width="183" height="17" font="13">dose, pts with a history of clinical </text>
<text top="106" left="1014" width="183" height="17" font="13">stability had an 80% lower risk of </text>
<text top="124" left="1014" width="211" height="17" font="13">developing an HF event . HDD were a </text>
<text top="141" left="1014" width="159" height="17" font="13">strong univariate predictor of </text>
<text top="158" left="1014" width="214" height="17" font="13">subsequent HF events (HR: 3.83, 95% </text>
<text top="175" left="1014" width="164" height="17" font="13">CI: 1.82-8.54); however, after </text>
<text top="192" left="1014" width="213" height="17" font="13">adjustment for clinical stability, diuretic </text>
<text top="210" left="1014" width="198" height="17" font="13">dose no longer remained significant </text>
<text top="227" left="1014" width="170" height="17" font="13">(HR: 1.53, 95% CI: 0.58-4.03). </text>
<text top="245" left="28" width="62" height="17" font="15"><b>PROTECT </b></text>
<text top="262" left="28" width="73" height="17" font="15"><b>pilot</b>, Cotter, </text>
<text top="279" left="28" width="31" height="17" font="13">2008 </text>
<text top="296" left="28" width="55" height="17" font="14">18926433</text>
<text top="296" left="83" width="3" height="17" font="13"> </text>
<text top="314" left="28" width="32" height="17" font="13">(151) </text>
<text top="245" left="123" width="85" height="17" font="13">Pilot study was </text>
<text top="262" left="123" width="126" height="17" font="13">designed to identify an </text>
<text top="279" left="123" width="123" height="17" font="13">efficacious dose while </text>
<text top="296" left="123" width="95" height="17" font="13">refining inclusion </text>
<text top="314" left="123" width="121" height="17" font="13">criteria and endpoints </text>
<text top="245" left="265" width="237" height="17" font="13">RCT 301 Hospitalized </text>
<text top="245" left="463" width="57" height="17" font="13">for </text>
<text top="262" left="393" width="96" height="17" font="13">acute HF with an </text>
<text top="279" left="393" width="98" height="17" font="13">estimated CrCl of </text>
<text top="296" left="393" width="103" height="17" font="13">20-80 mL/min and </text>
<text top="314" left="393" width="107" height="17" font="13">elevated natriuretic </text>
<text top="331" left="393" width="79" height="17" font="13">peptide levels </text>
<text top="348" left="393" width="77" height="17" font="13">were enrolled </text>
<text top="365" left="393" width="76" height="17" font="13">within 24 h of </text>
<text top="382" left="393" width="71" height="17" font="13">presentation </text>
<text top="245" left="514" width="175" height="17" font="13">SBP &lt;95 or &gt;160 mm Hg; fever </text>
<text top="262" left="514" width="170" height="17" font="13">&gt;38°C; acute contrast-induced </text>
<text top="279" left="514" width="125" height="17" font="13">nephropathy; resistant </text>
<text top="296" left="514" width="185" height="17" font="13">hypokalemia; ongoing or planned </text>
<text top="314" left="514" width="180" height="17" font="13">IV therapy with positive inotropic </text>
<text top="331" left="514" width="193" height="17" font="13">agents, vasopressors, vasodilators </text>
<text top="348" left="514" width="192" height="17" font="13">with the exception of IV nitrates, or </text>
<text top="365" left="514" width="176" height="17" font="13">mechanical support (intra-aortic </text>
<text top="382" left="514" width="155" height="17" font="13">balloon pump, endotracheal </text>
<text top="400" left="514" width="170" height="17" font="13">intubation, or ventricular assist </text>
<text top="417" left="514" width="148" height="17" font="13">device); severe pulmonary </text>
<text top="434" left="514" width="153" height="17" font="13">disease; significant stenotic </text>
<text top="451" left="514" width="176" height="17" font="13">valvular disease; previous heart </text>
<text top="469" left="514" width="191" height="17" font="13">transplant or admission for cardiac </text>
<text top="486" left="514" width="194" height="17" font="13">transplantation; clinical evidence of </text>
<text top="503" left="514" width="187" height="17" font="13">ACS <i>&lt;</i>2 wk before screening; and </text>
<text top="520" left="514" width="171" height="17" font="13">acute HF caused by significant </text>
<text top="537" left="514" width="167" height="17" font="13">arrhythmias; pts at high risk of </text>
<text top="555" left="514" width="49" height="17" font="13">seizures </text>
<text top="245" left="724" width="139" height="17" font="13">The prespecified primary </text>
<text top="262" left="724" width="151" height="17" font="13">analysis for this pilot phase </text>
<text top="279" left="724" width="109" height="17" font="13">was a trichotomous </text>
<text top="296" left="724" width="123" height="17" font="13">classification of pts as </text>
<text top="314" left="724" width="150" height="17" font="13">”success,” “unchanged,” or </text>
<text top="331" left="724" width="127" height="17" font="13">”failure” based on their </text>
<text top="348" left="724" width="146" height="17" font="13">changes in symptoms and </text>
<text top="365" left="724" width="133" height="17" font="13">renal function. This pilot </text>
<text top="382" left="724" width="147" height="17" font="13">phase was not powered to </text>
<text top="400" left="724" width="135" height="17" font="13">demonstrate statistically </text>
<text top="417" left="724" width="140" height="17" font="13">significant changes. The  </text>
<text top="434" left="724" width="125" height="17" font="13">major objective was to </text>
<text top="451" left="724" width="143" height="17" font="13">evaluate the performance </text>
<text top="469" left="724" width="144" height="17" font="13">of this novel endpoint and </text>
<text top="486" left="724" width="152" height="17" font="13">refine it on the basis of real-</text>
<text top="503" left="724" width="161" height="17" font="13">world experience.                   </text>
<text top="520" left="724" width="133" height="17" font="13">Treatment success was </text>
<text top="537" left="724" width="152" height="17" font="13">defined as an improvement </text>
<text top="555" left="724" width="153" height="17" font="13">in dyspnea (reported by the </text>
<text top="572" left="724" width="131" height="17" font="13">pt using a 7-point Likert </text>
<text top="589" left="724" width="127" height="17" font="13">scale as moderately or </text>
<text top="606" left="724" width="146" height="17" font="13">markedly better compared </text>
<text top="624" left="724" width="155" height="17" font="13">with study start) determined </text>
<text top="641" left="724" width="131" height="17" font="13">at 24 and 48 h after the </text>
<text top="658" left="724" width="150" height="17" font="13">start of study drug (d 2 and </text>
<text top="675" left="724" width="119" height="17" font="13">3) or d of discharge if </text>
<text top="692" left="724" width="154" height="17" font="13">earlier, as long as the pt did </text>
<text top="710" left="724" width="149" height="17" font="13">not meet any of the criteria </text>
<text top="727" left="724" width="114" height="17" font="13">for treatment failure. </text>
<text top="744" left="724" width="122" height="17" font="13">Treatment failure was </text>
<text top="761" left="724" width="148" height="17" font="13">defined as death, early HF </text>
<text top="778" left="724" width="128" height="17" font="13">readmission (occurring </text>
<text top="245" left="892" width="76" height="17" font="13">Composite of </text>
<text top="262" left="892" width="101" height="17" font="13">death or all-cause </text>
<text top="279" left="892" width="105" height="17" font="13">readmission within </text>
<text top="296" left="892" width="27" height="17" font="13">60 d </text>
<text top="245" left="1014" width="219" height="17" font="13">Pts treated with rolofylline more likely to </text>
<text top="262" left="1014" width="189" height="17" font="13">achieve success, as evidenced by<b> </b></text>
<text top="279" left="1014" width="208" height="17" font="13">improved dyspnea (52.7% vs 37.2%), </text>
<text top="296" left="1014" width="194" height="17" font="13">and less likely to experience failure </text>
<text top="314" left="1014" width="219" height="17" font="13">(manifested by worsening HF, death, or </text>
<text top="331" left="1014" width="202" height="17" font="13">renal impairment) compared with pts </text>
<text top="348" left="1014" width="217" height="17" font="13">treated with placebo (16.2% vs 28.2%). </text>
<text top="365" left="1014" width="197" height="17" font="13">By comparing rolofylline 30 mg with </text>
<text top="382" left="1014" width="198" height="17" font="13">placebo, the OR estimated from the </text>
<text top="400" left="1014" width="220" height="17" font="13">proportional odds model was 0.51 (95% </text>
<text top="417" left="1014" width="189" height="17" font="13">CI: 0.28–0.94). In the prespecified </text>
<text top="434" left="1014" width="209" height="17" font="13">subgroup of pts with higher natriuretic </text>
<text top="451" left="1014" width="213" height="17" font="13">peptide levels, pretreatment BNP level </text>
<text top="469" left="1014" width="200" height="17" font="13">≥500, or NT pro-BNP ≥2000 pg/mL, </text>
<text top="486" left="1014" width="204" height="17" font="13">most likely representing more severe </text>
<text top="503" left="1014" width="216" height="17" font="13">acute HF, the OR from the proportional </text>
<text top="520" left="1014" width="198" height="17" font="13">odds model was 0.59 (95% CI 0.30–</text>
<text top="537" left="1014" width="202" height="17" font="13">1.17). SCr increased in pts receiving </text>
<text top="555" left="1014" width="217" height="17" font="13">placebo and remained stable or tended </text>
<text top="572" left="1014" width="167" height="17" font="13">to decrease in those receiving </text>
<text top="589" left="1014" width="176" height="17" font="13">rolofylline. On d 14 the absolute </text>
<text top="606" left="1014" width="184" height="17" font="13">differences between placebo and </text>
<text top="624" left="1014" width="187" height="17" font="13">rolofylline for change in creatinine </text>
<text top="641" left="1014" width="197" height="17" font="13">increased with increasing rolofylline </text>
<text top="658" left="1014" width="206" height="17" font="13">dose, reflecting the lesser increase in </text>
<text top="675" left="1014" width="207" height="17" font="13">creatinine in rolofylline-treated pt (r = -</text>
<text top="692" left="1014" width="205" height="17" font="13">0.12, p=.030). Treatment with 30 mg, </text>
<text top="710" left="1014" width="210" height="17" font="13">the dose selected for the pivotal trials, </text>
<text top="727" left="1014" width="195" height="17" font="13">was associated with a trend toward </text>
<text top="744" left="1014" width="210" height="17" font="13">reduced 60-d mortality or readmission </text>
<text top="761" left="1014" width="211" height="17" font="13">for cardiovascular or renal cause (HR: </text>
<text top="778" left="1014" width="141" height="17" font="13">0.55; 95% CI: 0.28-1.04). </text>
<text top="245" left="1250" width="80" height="17" font="13">Limited by the </text>
<text top="262" left="1250" width="82" height="17" font="13">study size and </text>
<text top="279" left="1250" width="59" height="17" font="13">number of </text>
<text top="296" left="1250" width="100" height="17" font="13">treatment groups. </text>
<text top="314" left="1250" width="81" height="17" font="13">Study was not </text>
<text top="331" left="1250" width="64" height="17" font="13">powered to </text>
<text top="348" left="1250" width="75" height="17" font="13">quantitatively </text>
<text top="365" left="1250" width="61" height="17" font="13">distinguish </text>
<text top="382" left="1250" width="81" height="17" font="13">between the 3 </text>
<text top="400" left="1250" width="75" height="17" font="13">active doses, </text>
<text top="417" left="1250" width="88" height="17" font="13">although trends </text>
<text top="434" left="1250" width="52" height="17" font="13">emerged </text>
<text top="451" left="1250" width="73" height="17" font="13">suggesting a </text>
<text top="469" left="1250" width="72" height="17" font="13">dose-related </text>
<text top="486" left="1250" width="85" height="17" font="13">preservation of </text>
<text top="503" left="1250" width="101" height="17" font="13">renal function and </text>
<text top="520" left="1250" width="63" height="17" font="13">increase in </text>
<text top="537" left="1250" width="90" height="17" font="13">diuresis, as well </text>
<text top="555" left="1250" width="69" height="17" font="13">as a greater </text>
<text top="572" left="1250" width="71" height="17" font="13">effect on the </text>
<text top="589" left="1250" width="59" height="17" font="13">composite </text>
<text top="606" left="1250" width="102" height="17" font="13">endpoint at the 30 </text>
<text top="623" left="1250" width="54" height="17" font="13">mg dose. </text>
<text top="245" left="1365" width="25" height="17" font="13">The </text>
<text top="262" left="1365" width="85" height="17" font="13">preservation of </text>
<text top="279" left="1365" width="77" height="17" font="13">renal function </text>
<text top="296" left="1365" width="87" height="17" font="13">associated with </text>
<text top="314" left="1365" width="69" height="17" font="13">rolofylline, a </text>
<text top="331" left="1365" width="82" height="17" font="13">selective renal </text>
<text top="348" left="1365" width="79" height="17" font="13">vasodilator, is </text>
<text top="365" left="1365" width="44" height="17" font="13">the first </text>
<text top="382" left="1365" width="77" height="17" font="13">evidence that </text>
<text top="400" left="1365" width="84" height="17" font="13">an intervention </text>
<text top="417" left="1365" width="58" height="17" font="13">to prevent </text>
<text top="434" left="1365" width="31" height="17" font="13">renal </text>
<text top="451" left="1365" width="64" height="17" font="13">impairment </text>
<text top="469" left="1365" width="81" height="17" font="13">may positively </text>
<text top="486" left="1365" width="67" height="17" font="13">affect acute </text>
<text top="503" left="1365" width="83" height="17" font="13">symptoms and </text>
<text top="520" left="1365" width="79" height="17" font="13">60-d outcome </text>
<text top="537" left="1365" width="58" height="17" font="13">in pts with </text>
<text top="555" left="1365" width="57" height="17" font="13">acute HF; </text>
<text top="572" left="1365" width="53" height="17" font="13">however, </text>
<text top="589" left="1365" width="70" height="17" font="13">results were </text>
<text top="606" left="1365" width="78" height="17" font="13">not confirmed </text>
<text top="623" left="1365" width="84" height="17" font="13">in the phase III </text>
<text top="641" left="1365" width="27" height="17" font="13">trial. </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">66</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="724" width="130" height="17" font="13">within 7 d of study drug </text>
<text top="72" left="724" width="152" height="17" font="13">initiation), worsening HF as </text>
<text top="89" left="724" width="109" height="17" font="13">defined daily by the </text>
<text top="106" left="724" width="150" height="17" font="13">physician assessment by d </text>
<text top="124" left="724" width="116" height="17" font="13">7, or persistent renal </text>
<text top="141" left="724" width="124" height="17" font="13">impairment as defined </text>
<text top="158" left="724" width="40" height="17" font="13">above. </text>
<text top="175" left="724" width="116" height="17" font="13">Unchanged pts were </text>
<text top="192" left="724" width="144" height="17" font="13">classified as unchanged if </text>
<text top="210" left="724" width="147" height="17" font="13">neither criteria for success </text>
<text top="227" left="724" width="109" height="17" font="13">or failure were met. </text>
<text top="245" left="28" width="75" height="17" font="15"><b>DIG</b>, Ahmed, </text>
<text top="262" left="28" width="34" height="17" font="13">2008  </text>
<text top="279" left="28" width="55" height="17" font="14">17532064</text>
<text top="279" left="83" width="7" height="17" font="13">  </text>
<text top="296" left="28" width="32" height="17" font="13">(152) </text>
<text top="245" left="123" width="113" height="17" font="13">The objective of this </text>
<text top="262" left="123" width="111" height="17" font="13">propensity-matched </text>
<text top="279" left="123" width="72" height="17" font="13">study was to </text>
<text top="296" left="123" width="126" height="17" font="13">determine the effect of </text>
<text top="314" left="123" width="116" height="17" font="13">diuretics on mortality </text>
<text top="331" left="123" width="124" height="17" font="13">and hospitalizations in </text>
<text top="348" left="123" width="78" height="17" font="13">HF pts ≥65 y. </text>
<text top="245" left="265" width="49" height="17" font="13">Registry </text>
<text top="245" left="332" width="34" height="17" font="13">7,788 </text>
<text top="245" left="393" width="91" height="17" font="13">Pts who were at </text>
<text top="262" left="393" width="103" height="17" font="13">≥21 y of age were </text>
<text top="279" left="393" width="80" height="17" font="13">eligible for the </text>
<text top="296" left="393" width="89" height="17" font="13">main trial if they </text>
<text top="314" left="393" width="92" height="17" font="13">had HF, a LVEF </text>
<text top="331" left="393" width="83" height="17" font="13">≤45%, were in </text>
<text top="348" left="393" width="73" height="17" font="13">normal sinus </text>
<text top="365" left="393" width="88" height="17" font="13">rhythm, and did </text>
<text top="382" left="393" width="105" height="17" font="13">not meet any of 20 </text>
<text top="400" left="393" width="103" height="17" font="13">easily determined, </text>
<text top="417" left="393" width="57" height="17" font="13">not overly </text>
<text top="434" left="393" width="56" height="17" font="13">restrictive </text>
<text top="451" left="393" width="98" height="17" font="13">exclusion criteria  </text>
<text top="245" left="514" width="162" height="17" font="13">Age &lt;21 yrs; baseline EF not </text>
<text top="262" left="514" width="178" height="17" font="13">available; MI, cardiac surgery or </text>
<text top="279" left="514" width="167" height="17" font="13">PTCA within 4 wk; unstable or </text>
<text top="296" left="514" width="179" height="17" font="13">refractory angina &lt;1 month; II-III </text>
<text top="314" left="514" width="196" height="17" font="13">AV block without pacemaker; AF or </text>
<text top="331" left="514" width="187" height="17" font="13">flutter; cor pulmonale; constrictive </text>
<text top="348" left="514" width="169" height="17" font="13">pericarditis; acute myocarditis; </text>
<text top="365" left="514" width="165" height="17" font="13">hypertrophic cardiomyopathy; </text>
<text top="382" left="514" width="189" height="17" font="13">amyloid cardiomyopathy; complex </text>
<text top="400" left="514" width="180" height="17" font="13">CHD; tx with IV inotropic agents; </text>
<text top="417" left="514" width="183" height="17" font="13">K+ &lt; 3.2 mmol/L or &gt;5.5 mmol/L; </text>
<text top="434" left="514" width="191" height="17" font="13">on heart transplant list; noncardiac </text>
<text top="451" left="514" width="160" height="17" font="13">cause of HF; Creatinine &gt;3.0 </text>
<text top="469" left="514" width="167" height="17" font="13">mg/dL or severe liver disease; </text>
<text top="486" left="514" width="100" height="17" font="13">unlikely to comply </text>
<text top="245" left="724" width="144" height="17" font="13">All-cause mortality and all-</text>
<text top="262" left="724" width="155" height="17" font="13">cause hospitalization during </text>
<text top="279" left="724" width="141" height="17" font="13">36.7 mo of median follow-</text>
<text top="296" left="724" width="17" height="17" font="13">up </text>
<text top="245" left="892" width="74" height="17" font="13">Mortality and </text>
<text top="262" left="892" width="87" height="17" font="13">hospitalizations </text>
<text top="279" left="892" width="38" height="17" font="13">due to </text>
<text top="296" left="892" width="83" height="17" font="13">cardiovascular </text>
<text top="314" left="892" width="86" height="17" font="13">causes and HF </text>
<text top="245" left="1014" width="212" height="17" font="13">All-cause mortality occurred in 173 pts </text>
<text top="262" left="1014" width="190" height="17" font="13">not receiving diuretics and 208 pts </text>
<text top="279" left="1014" width="208" height="17" font="13">receiving diuretics respectively during </text>
<text top="296" left="1014" width="210" height="17" font="13">2,056 and 1,943 person-y of follow-up </text>
<text top="314" left="1014" width="218" height="17" font="13">(HR:1.36; 95% CI: 1.08-1.71; p=0.009). </text>
<text top="331" left="1014" width="206" height="17" font="13">All-cause hospitalizations occurred in </text>
<text top="348" left="1014" width="185" height="17" font="13">413 pts not receiving and 438 pts </text>
<text top="365" left="1014" width="208" height="17" font="13">receiving diuretics respectively during </text>
<text top="382" left="1014" width="210" height="17" font="13">1,255 and 1,144 person-y of follow-up </text>
<text top="400" left="1014" width="221" height="17" font="13">(HR: 1.18; 95% CI: 0.99-1.39; p=0.063). </text>
<text top="417" left="1014" width="181" height="17" font="13">Diuretic use was associated with </text>
<text top="434" left="1014" width="151" height="17" font="13">significant increased risk of </text>
<text top="451" left="1014" width="217" height="17" font="13">cardiovascular mortality (HR:1.50; 95% </text>
<text top="469" left="1014" width="171" height="17" font="13">CI:1.15-1.96; p=0.003) and HF </text>
<text top="486" left="1014" width="213" height="17" font="13">hospitalization (HR:1.48; 95% 95% CI: </text>
<text top="503" left="1014" width="115" height="17" font="13">1.13-1.94; p=0.005). </text>
<text top="245" left="1250" width="78" height="17" font="13">Beta blockers </text>
<text top="262" left="1250" width="51" height="17" font="13">were not </text>
<text top="279" left="1250" width="92" height="17" font="13">approved for HF </text>
<text top="296" left="1250" width="84" height="17" font="13">during the DIG </text>
<text top="314" left="1250" width="92" height="17" font="13">trial and data on </text>
<text top="331" left="1250" width="94" height="17" font="13">beta blocker use </text>
<text top="348" left="1250" width="51" height="17" font="13">were not </text>
<text top="365" left="1250" width="52" height="17" font="13">collected </text>
<text top="245" left="1365" width="68" height="17" font="13">Diuretic use </text>
<text top="262" left="1365" width="87" height="17" font="13">associated with </text>
<text top="279" left="1365" width="57" height="17" font="13">increased </text>
<text top="296" left="1365" width="50" height="17" font="13">mortality </text>
<text top="314" left="1365" width="81" height="17" font="13">among elderly </text>
<text top="331" left="1365" width="82" height="17" font="13">in the DIG trial </text>
<text top="521" left="28" width="68" height="17" font="15"><b>EVEREST,</b>  </text>
<text top="538" left="28" width="78" height="17" font="13">Gheorghiade, </text>
<text top="555" left="28" width="31" height="17" font="13">2007 </text>
<text top="573" left="28" width="55" height="17" font="14">17384438</text>
<text top="573" left="83" width="3" height="17" font="13"> </text>
<text top="590" left="28" width="32" height="17" font="13">(153) </text>
<text top="521" left="123" width="127" height="17" font="13">To evaluate short-term </text>
<text top="538" left="123" width="107" height="17" font="13">effects of tolvaptan </text>
<text top="555" left="123" width="84" height="17" font="13">when added to </text>
<text top="573" left="123" width="128" height="17" font="13">standard therapy in pts </text>
<text top="590" left="123" width="113" height="17" font="13">hospitalized with HF </text>
<text top="521" left="265" width="141" height="17" font="13">RCT 2,048 </text>
<text top="538" left="332" width="43" height="17" font="13">(trial A) </text>
<text top="555" left="332" width="24" height="17" font="13">and </text>
<text top="573" left="332" width="34" height="17" font="13">2,085 </text>
<text top="590" left="332" width="43" height="17" font="13">(trial B) </text>
<text top="521" left="393" width="96" height="17" font="13">Age ≥18 y with a </text>
<text top="538" left="393" width="96" height="17" font="13">history of chronic </text>
<text top="555" left="393" width="75" height="17" font="13">HF (requiring </text>
<text top="573" left="393" width="84" height="17" font="13">treatment for a </text>
<text top="590" left="393" width="94" height="17" font="13">minimum of 30 d </text>
<text top="607" left="393" width="38" height="17" font="13">before </text>
<text top="624" left="393" width="85" height="17" font="13">hospitalization) </text>
<text top="641" left="393" width="81" height="17" font="13">who had been </text>
<text top="659" left="393" width="68" height="17" font="13">hospitalized </text>
<text top="676" left="393" width="68" height="17" font="13">primarily for </text>
<text top="693" left="393" width="92" height="17" font="13">worsening  CHF </text>
<text top="710" left="393" width="92" height="17" font="13">and had a LVEF </text>
<text top="727" left="393" width="98" height="17" font="13">≤40% (measured </text>
<text top="745" left="393" width="102" height="17" font="13">at any point within </text>
<text top="762" left="393" width="100" height="17" font="13">1 y of admission). </text>
<text top="779" left="393" width="100" height="17" font="13">Entry required HF </text>
<text top="521" left="514" width="166" height="17" font="13">Cardiac surgery within 60 d of </text>
<text top="538" left="514" width="173" height="17" font="13">enrollment, cardiac mechanical </text>
<text top="555" left="514" width="182" height="17" font="13">support, biventricular pacemaker </text>
<text top="573" left="514" width="169" height="17" font="13">placement within the last 60 d, </text>
<text top="590" left="514" width="155" height="17" font="13">comorbid conditions with an </text>
<text top="607" left="514" width="175" height="17" font="13">expected survival of less than 6 </text>
<text top="624" left="514" width="149" height="17" font="13">mo, acute MI at the time of </text>
<text top="641" left="514" width="183" height="17" font="13">hospitalization, hemodynamically </text>
<text top="659" left="514" width="171" height="17" font="13">significant uncorrected primary </text>
<text top="676" left="514" width="193" height="17" font="13">cardiac valvular disease, refractory </text>
<text top="693" left="514" width="173" height="17" font="13">end-stage HF, hemofiltration or </text>
<text top="710" left="514" width="172" height="17" font="13">dialysis, supine systolic arterial </text>
<text top="727" left="514" width="192" height="17" font="13">blood pressure of less than 90 mm </text>
<text top="745" left="514" width="190" height="17" font="13">Hg, SCr concentration &gt;3.5 mg/dL </text>
<text top="762" left="514" width="190" height="17" font="13">(&gt;309.4 μmol/L), serum potassium </text>
<text top="779" left="514" width="175" height="17" font="13">concentration &gt; 5.5 mEq/L, and </text>
<text top="521" left="724" width="139" height="17" font="13">Composite of changes in </text>
<text top="538" left="724" width="150" height="17" font="13">global clinical status based </text>
<text top="555" left="724" width="135" height="17" font="13">on a visual analog scale </text>
<text top="573" left="724" width="142" height="17" font="13">and body weight at d 7 or </text>
<text top="590" left="724" width="104" height="17" font="13">discharge if earlier </text>
<text top="521" left="892" width="84" height="17" font="13">Dyspnea (d 1), </text>
<text top="538" left="892" width="77" height="17" font="13">global clinical </text>
<text top="555" left="892" width="75" height="17" font="13">status (d 7 or </text>
<text top="573" left="892" width="94" height="17" font="13">discharge), body </text>
<text top="590" left="892" width="98" height="17" font="13">weight (d 1 and 7 </text>
<text top="607" left="892" width="103" height="17" font="13">or discharge), and </text>
<text top="624" left="892" width="99" height="17" font="13">peripheral edema </text>
<text top="641" left="892" width="103" height="17" font="13">(d 7 or discharge). </text>
<text top="521" left="1014" width="200" height="17" font="13">Rank sum analysis of the composite </text>
<text top="538" left="1014" width="183" height="17" font="13">primary endpoint showed greater </text>
<text top="555" left="1014" width="215" height="17" font="13">improvement with tolvaptan vs placebo </text>
<text top="573" left="1014" width="219" height="17" font="13">(trial A, mean [+SD], 1.06 [0.43] vs 0.99 </text>
<text top="590" left="1014" width="204" height="17" font="13">[0.44]; and trial B, 1.07 [0.42] vs 0.97 </text>
<text top="607" left="1014" width="213" height="17" font="13">[0.43]; both trials p&lt;.001). Mean (+SD) </text>
<text top="624" left="1014" width="216" height="17" font="13">body weight reduction was greater with </text>
<text top="641" left="1014" width="211" height="17" font="13">tolvaptan on d 1 (trial A, 1.71 [1.80] vs </text>
<text top="659" left="1014" width="216" height="17" font="13">0.99 [1.83] kg; p&lt;.001; and trial B, 1.82 </text>
<text top="676" left="1014" width="201" height="17" font="13">[2.01] vs 0.95 [1.85] kg; p&lt;.001) and </text>
<text top="693" left="1014" width="209" height="17" font="13">day 7 or discharge (trial A, 3.35 [3.27] </text>
<text top="710" left="1014" width="204" height="17" font="13">vs 2.73 [3.34] kg; p&lt;.001; and trial B, </text>
<text top="727" left="1014" width="225" height="17" font="13">3.77 [3.59] vs 2.79 [3.46] kg; p&lt;.001).      </text>
<text top="745" left="1014" width="207" height="17" font="13">Improvements in global clinical status </text>
<text top="762" left="1014" width="227" height="17" font="13">were not different between groups.           </text>
<text top="779" left="1014" width="185" height="17" font="13">More pts receiving tolvaptan (684 </text>
<text top="521" left="1250" width="27" height="17" font="13"> N/A </text>
<text top="521" left="1365" width="33" height="17" font="13">In pts </text>
<text top="538" left="1365" width="68" height="17" font="13">hospitalized </text>
<text top="555" left="1365" width="73" height="17" font="13">with HF, oral </text>
<text top="573" left="1365" width="66" height="17" font="13">tolvaptan in </text>
<text top="590" left="1365" width="60" height="17" font="13">addition to </text>
<text top="607" left="1365" width="51" height="17" font="13">standard </text>
<text top="624" left="1365" width="44" height="17" font="13">therapy </text>
<text top="641" left="1365" width="52" height="17" font="13">including </text>
<text top="659" left="1365" width="49" height="17" font="13">diuretics </text>
<text top="676" left="1365" width="54" height="17" font="13">improved </text>
<text top="693" left="1365" width="78" height="17" font="13">many, though </text>
<text top="710" left="1365" width="59" height="17" font="13">not all, HF </text>
<text top="727" left="1365" width="56" height="17" font="13">signs and </text>
<text top="745" left="1365" width="63" height="17" font="13">symptoms, </text>
<text top="762" left="1365" width="85" height="17" font="13">without serious </text>
<text top="779" left="1365" width="23" height="17" font="13">AE. </text>
</page>
<page number="67" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">67</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="393" width="97" height="17" font="13">symptoms at rest </text>
<text top="72" left="393" width="107" height="17" font="13">or minimal exertion </text>
<text top="89" left="393" width="70" height="17" font="13">and signs of </text>
<text top="106" left="393" width="99" height="17" font="13">congestion (≥2 of </text>
<text top="124" left="393" width="75" height="17" font="13">the following: </text>
<text top="141" left="393" width="94" height="17" font="13">dyspnea, jugular </text>
<text top="158" left="393" width="103" height="17" font="13">venous distention, </text>
<text top="175" left="393" width="73" height="17" font="13">or peripheral </text>
<text top="192" left="393" width="99" height="17" font="13">edema) at time of </text>
<text top="210" left="393" width="84" height="17" font="13">randomization. </text>
<text top="55" left="514" width="128" height="17" font="13">hgb of less than 9 g/dL </text>
<text top="55" left="1014" width="215" height="17" font="13">[76.7%] and 678 [72.1%] for trial A and </text>
<text top="72" left="1014" width="199" height="17" font="13">trial B, respectively) vs pts receiving </text>
<text top="89" left="1014" width="216" height="17" font="13">placebo (646 [70.6%] and 597 [65.3%], </text>
<text top="106" left="1014" width="209" height="17" font="13">respectively) reported improvement in </text>
<text top="124" left="1014" width="194" height="17" font="13">dyspnea at d 1 (both trials p&lt;.001). </text>
<text top="141" left="1014" width="202" height="17" font="13">Edema at d 7 or discharge improved </text>
<text top="158" left="1014" width="208" height="17" font="13">significantly with tolvaptan in trial B (p </text>
<text top="175" left="1014" width="214" height="17" font="13">=0.02) but did not reach significance in </text>
<text top="192" left="1014" width="220" height="17" font="13">trial A (p=0.07). Serious AE frequencies </text>
<text top="210" left="1014" width="206" height="17" font="13">were similar between groups, without </text>
<text top="227" left="1014" width="193" height="17" font="13">excess renal failure or hypotension </text>
<text top="245" left="28" width="64" height="17" font="15"><b>EVEREST</b>, </text>
<text top="262" left="28" width="55" height="17" font="13">Konstam, </text>
<text top="279" left="28" width="31" height="17" font="13">2007 </text>
<text top="296" left="28" width="55" height="17" font="14">17384437</text>
<text top="296" left="83" width="3" height="17" font="13"> </text>
<text top="314" left="28" width="32" height="17" font="13">(154) </text>
<text top="245" left="123" width="101" height="17" font="13">To investigate the </text>
<text top="262" left="123" width="107" height="17" font="13">effects of tolvaptan </text>
<text top="279" left="123" width="79" height="17" font="13">initiated in pts </text>
<text top="296" left="123" width="113" height="17" font="13">hospitalized with HF </text>
<text top="245" left="265" width="140" height="17" font="13">RCT 4,133 </text>
<text top="245" left="393" width="60" height="17" font="13">Pts </text>
<text top="245" left="414" width="63" height="17" font="13">age </text>
<text top="245" left="438" width="60" height="17" font="13">≥18 y with </text>
<text top="262" left="393" width="82" height="17" font="13">reduced LVEF </text>
<text top="279" left="393" width="85" height="17" font="13">≤40%, signs of </text>
<text top="296" left="393" width="106" height="17" font="13">volume expansion, </text>
<text top="314" left="393" width="98" height="17" font="13">NYHA class III/IV </text>
<text top="331" left="393" width="87" height="17" font="13">symptoms, and </text>
<text top="348" left="393" width="99" height="17" font="13">hospitalization for </text>
<text top="365" left="393" width="87" height="17" font="13">exacerbation of </text>
<text top="382" left="393" width="80" height="17" font="13">chronic HF no </text>
<text top="400" left="393" width="86" height="17" font="13">more than 48 h </text>
<text top="417" left="393" width="68" height="17" font="13">earlier were </text>
<text top="434" left="393" width="80" height="17" font="13">eligible for the </text>
<text top="451" left="393" width="33" height="17" font="13">study </text>
<text top="245" left="514" width="166" height="17" font="13">Cardiac surgery within 60 d of </text>
<text top="262" left="514" width="173" height="17" font="13">enrollment, cardiac mechanical </text>
<text top="279" left="514" width="182" height="17" font="13">support, biventricular pacemaker </text>
<text top="296" left="514" width="169" height="17" font="13">placement within the last 60 d, </text>
<text top="314" left="514" width="155" height="17" font="13">comorbid conditions with an </text>
<text top="331" left="514" width="187" height="17" font="13">expected survival of &lt;6 mo, acute </text>
<text top="348" left="514" width="176" height="17" font="13">MI at the time of hospitalization, </text>
<text top="365" left="514" width="157" height="17" font="13">hemodynamically significant </text>
<text top="382" left="514" width="156" height="17" font="13">uncorrected primary cardiac </text>
<text top="400" left="514" width="175" height="17" font="13">valvular disease, refractory end-</text>
<text top="417" left="514" width="195" height="17" font="13">stage HF, hemofiltration or dialysis, </text>
<text top="434" left="514" width="193" height="17" font="13">supine systolic arterial bp &lt; 90 mm </text>
<text top="451" left="514" width="188" height="17" font="13">Hg, SCr &gt;3.5 mg/dL (309 μmol/L), </text>
<text top="469" left="514" width="180" height="17" font="13">K+ level greater than 5.5 mEq/L, </text>
<text top="486" left="514" width="96" height="17" font="13">and hgb &lt;9 g/dL. </text>
<text top="245" left="724" width="130" height="17" font="13">Dual primary endpoints </text>
<text top="262" left="724" width="132" height="17" font="13">were all-cause mortality </text>
<text top="279" left="724" width="88" height="17" font="13">(superiority and </text>
<text top="296" left="724" width="102" height="17" font="13">noninferiority) and </text>
<text top="314" left="724" width="131" height="17" font="13">cardiovascular death or </text>
<text top="331" left="724" width="119" height="17" font="13">hospitalization for HF </text>
<text top="348" left="724" width="94" height="17" font="13">(superiority only) </text>
<text top="245" left="892" width="76" height="17" font="13">Composite of </text>
<text top="262" left="892" width="83" height="17" font="13">cardiovascular </text>
<text top="279" left="892" width="64" height="17" font="13">mortality or </text>
<text top="296" left="892" width="83" height="17" font="13">cardiovascular </text>
<text top="314" left="892" width="85" height="17" font="13">hospitalization; </text>
<text top="331" left="892" width="69" height="17" font="13">incidence of </text>
<text top="348" left="892" width="83" height="17" font="13">cardiovascular </text>
<text top="365" left="892" width="77" height="17" font="13">mortality; and </text>
<text top="382" left="892" width="69" height="17" font="13">incidence of </text>
<text top="400" left="892" width="100" height="17" font="13">clinical worsening </text>
<text top="417" left="892" width="75" height="17" font="13">of HF (death, </text>
<text top="434" left="892" width="99" height="17" font="13">hospitalization for </text>
<text top="451" left="892" width="38" height="17" font="13">HF, or </text>
<text top="469" left="892" width="98" height="17" font="13">unscheduled visit </text>
<text top="486" left="892" width="103" height="17" font="13">for HF). Additional </text>
<text top="503" left="892" width="60" height="17" font="13">secondary </text>
<text top="520" left="892" width="106" height="17" font="13">endpoints included </text>
<text top="537" left="892" width="78" height="17" font="13">changes from </text>
<text top="555" left="892" width="92" height="17" font="13">baseline in body </text>
<text top="572" left="892" width="77" height="17" font="13">weight at d 1, </text>
<text top="589" left="892" width="81" height="17" font="13">serum sodium </text>
<text top="606" left="892" width="77" height="17" font="13">level at d 7 or </text>
<text top="623" left="892" width="89" height="17" font="13">discharge in pts </text>
<text top="641" left="892" width="85" height="17" font="13">with a baseline </text>
<text top="658" left="892" width="81" height="17" font="13">serum sodium </text>
<text top="675" left="892" width="74" height="17" font="13">&lt;134 mEq/L, </text>
<text top="692" left="892" width="98" height="17" font="13">edema score at d </text>
<text top="710" left="892" width="99" height="17" font="13">7 or discharge for </text>
<text top="727" left="892" width="100" height="17" font="13">those with edema </text>
<text top="744" left="892" width="81" height="17" font="13">at baseline, pt-</text>
<text top="761" left="892" width="105" height="17" font="13">assessed dyspnea </text>
<text top="778" left="892" width="86" height="17" font="13">at d 1 for those </text>
<text top="245" left="1014" width="204" height="17" font="13">During a median follow-up of 9.9 mo, </text>
<text top="262" left="1014" width="215" height="17" font="13">537 pts (25.9%) in tolvaptan group and </text>
<text top="279" left="1014" width="213" height="17" font="13">543 (26.3%) in placebo group died HR </text>
<text top="296" left="1014" width="208" height="17" font="13">for mortality: 0.98; 95% CI, 0.87-1.11; </text>
<text top="314" left="1014" width="188" height="17" font="13">p=.68). Kaplan-Meier estimates of </text>
<text top="331" left="1014" width="185" height="17" font="13">mortality at 1 y were 25.0% in the </text>
<text top="348" left="1014" width="184" height="17" font="13">tolvaptan group and 26.0% in the </text>
<text top="365" left="1014" width="228" height="17" font="13">placebo group.                                           </text>
<text top="382" left="1014" width="194" height="17" font="13">Composite cardiovascular death or </text>
<text top="400" left="1014" width="200" height="17" font="13">hospitalization for HF: 871 tolvaptan </text>
<text top="417" left="1014" width="211" height="17" font="13">group (42.0%) and 829 placebo group </text>
<text top="434" left="1014" width="211" height="17" font="13">(40.2%) HR: 1.04; 95% CI:  0.95-1.14; </text>
<text top="451" left="1014" width="220" height="17" font="13">p=.55).                                                     </text>
<text top="469" left="1014" width="206" height="17" font="13">Secondary endpoints of CV mortality, </text>
<text top="486" left="1014" width="178" height="17" font="13">CV death or hospitalization, and </text>
<text top="503" left="1014" width="231" height="17" font="13">worsening HF were also not different.        </text>
<text top="520" left="1014" width="178" height="17" font="13">Tolvaptan significantly improved </text>
<text top="537" left="1014" width="221" height="17" font="13">secondary endpoints of d 1 pt-assessed </text>
<text top="555" left="1014" width="201" height="17" font="13">dyspnea (p&lt;.001), with 74.3% of the </text>
<text top="572" left="1014" width="185" height="17" font="13">tolvaptan group and 68.0% of the </text>
<text top="589" left="1014" width="180" height="17" font="13">placebo group demonstrating an </text>
<text top="606" left="1014" width="215" height="17" font="13">improvement in dyspnea score, as well </text>
<text top="624" left="1014" width="212" height="17" font="13">as d 1 body weight, and d 7 edema. In </text>
<text top="641" left="1014" width="207" height="17" font="13">pts with hyponatremia, serum sodium </text>
<text top="658" left="1014" width="187" height="17" font="13">levels significantly increased. The </text>
<text top="675" left="1014" width="212" height="17" font="13">KCCQ overall summary score was not </text>
<text top="692" left="1014" width="220" height="17" font="13">improved at outpt wk 1, but body weight </text>
<text top="710" left="1014" width="198" height="17" font="13">and serum sodium effects persisted </text>
<text top="727" left="1014" width="115" height="17" font="13">long after discharge. </text>
<text top="245" left="1250" width="27" height="17" font="13"> N/A </text>
<text top="245" left="1365" width="57" height="17" font="13">Tolvaptan </text>
<text top="262" left="1365" width="64" height="17" font="13">initiated for </text>
<text top="279" left="1365" width="33" height="17" font="13">acute </text>
<text top="296" left="1365" width="69" height="17" font="13">treatment of </text>
<text top="314" left="1365" width="88" height="17" font="13">pts hospitalized </text>
<text top="331" left="1365" width="86" height="17" font="13">with HF had no </text>
<text top="348" left="1365" width="78" height="17" font="13">effect on long-</text>
<text top="365" left="1365" width="78" height="17" font="13">term mortality </text>
<text top="382" left="1365" width="76" height="17" font="13">or HF-related </text>
<text top="400" left="1365" width="57" height="17" font="13">morbidity. </text>
</page>
<page number="68" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">68</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="892" width="89" height="17" font="13">with dyspnea at </text>
<text top="72" left="892" width="77" height="17" font="13">baseline, and </text>
<text top="89" left="892" width="79" height="17" font="13">KCCQ overall </text>
<text top="106" left="892" width="101" height="17" font="13">summary score at </text>
<text top="124" left="892" width="63" height="17" font="13">outpt wk 1. </text>
<text top="419" left="28" width="71" height="17" font="15"><b>DIG</b>, Ahmed </text>
<text top="436" left="28" width="71" height="17" font="13">(UAB), 2006 </text>
<text top="453" left="28" width="55" height="17" font="14">16709595</text>
<text top="453" left="83" width="3" height="17" font="13"> </text>
<text top="471" left="28" width="32" height="17" font="13">(155) </text>
<text top="419" left="123" width="87" height="17" font="13">Non-potassium-</text>
<text top="436" left="123" width="114" height="17" font="13">sparing diuretics are </text>
<text top="453" left="123" width="126" height="17" font="13">commonly used in HF. </text>
<text top="471" left="123" width="97" height="17" font="13">They activate the </text>
<text top="488" left="123" width="86" height="17" font="13">neurohormonal </text>
<text top="505" left="123" width="91" height="17" font="13">system, and are </text>
<text top="522" left="123" width="107" height="17" font="13">potentially harmful. </text>
<text top="539" left="123" width="101" height="17" font="13">Yet, the long-term </text>
<text top="557" left="123" width="96" height="17" font="13">effects of chronic </text>
<text top="574" left="123" width="120" height="17" font="13">diuretic use in HF are </text>
<text top="591" left="123" width="122" height="17" font="13">largely unknown. This </text>
<text top="608" left="123" width="115" height="17" font="13">study retrospectively </text>
<text top="625" left="123" width="126" height="17" font="13">analysed the DIG data </text>
<text top="643" left="123" width="92" height="17" font="13">to determine the </text>
<text top="660" left="123" width="120" height="17" font="13">effects of diuretics on </text>
<text top="677" left="123" width="121" height="17" font="13">HF outcomes. Effects </text>
<text top="694" left="123" width="80" height="17" font="13">of diuretics on </text>
<text top="711" left="123" width="74" height="17" font="13">mortality and </text>
<text top="729" left="123" width="112" height="17" font="13">hospitalization at 40 </text>
<text top="746" left="123" width="113" height="17" font="13">mo of median follow-</text>
<text top="763" left="123" width="103" height="17" font="13">up were assessed </text>
<text top="780" left="123" width="109" height="17" font="13">using matched Cox </text>
<text top="419" left="265" width="49" height="17" font="13">Registry </text>
<text top="419" left="332" width="34" height="17" font="13">2,782 </text>
<text top="419" left="393" width="73" height="17" font="13">The DIG trial </text>
<text top="436" left="393" width="81" height="17" font="13">enrolled 7,788 </text>
<text top="453" left="393" width="107" height="17" font="13">ambulatory chronic </text>
<text top="471" left="393" width="82" height="17" font="13">systolic (LVEF </text>
<text top="488" left="393" width="89" height="17" font="13">≤45%; n=6800) </text>
<text top="505" left="393" width="72" height="17" font="13">and diastolic </text>
<text top="522" left="393" width="77" height="17" font="13">(LVEF &gt;45%; </text>
<text top="539" left="393" width="95" height="17" font="13">n=988) HF pts in </text>
<text top="557" left="393" width="73" height="17" font="13">normal sinus </text>
<text top="574" left="393" width="94" height="17" font="13">rhythm, of whom </text>
<text top="591" left="393" width="101" height="17" font="13">6,076 (78%) were </text>
<text top="608" left="393" width="105" height="17" font="13">receiving diuretics  </text>
<text top="419" left="514" width="131" height="17" font="13">Age &lt;21 y; baseline EF </text>
<text top="436" left="514" width="191" height="17" font="13">unavailable; MI, cardiac surgery or </text>
<text top="453" left="514" width="167" height="17" font="13">PTCA within 4 wk; unstable or </text>
<text top="471" left="514" width="182" height="17" font="13">refractory angina &lt;1 mo; II-III AV </text>
<text top="488" left="514" width="176" height="17" font="13">block without pacemaker; AF or </text>
<text top="505" left="514" width="187" height="17" font="13">flutter; cor pulmonale; constrictive </text>
<text top="522" left="514" width="169" height="17" font="13">pericarditis; acute myocarditis; </text>
<text top="539" left="514" width="165" height="17" font="13">hypertrophic cardiomyopathy; </text>
<text top="557" left="514" width="189" height="17" font="13">amyloid cardiomyopathy; complex </text>
<text top="574" left="514" width="180" height="17" font="13">CHD; tx with IV inotropic agents; </text>
<text top="591" left="514" width="186" height="17" font="13">K+ &lt; 3.2 mmol/L or &gt; 5.5 mmol/L; </text>
<text top="608" left="514" width="191" height="17" font="13">on heart transplant list; noncardiac </text>
<text top="625" left="514" width="164" height="17" font="13">cause of HF; Creatinine &gt; 3.0 </text>
<text top="643" left="514" width="167" height="17" font="13">mg/dL or severe liver disease; </text>
<text top="660" left="514" width="100" height="17" font="13">unlikely to comply </text>
<text top="419" left="724" width="104" height="17" font="13">All-cause mortality </text>
<text top="419" left="892" width="78" height="17" font="13">Mortality from </text>
<text top="436" left="892" width="107" height="17" font="13">worsening HF, and </text>
<text top="453" left="892" width="87" height="17" font="13">hospitalizations </text>
<text top="471" left="892" width="96" height="17" font="13">due to all causes </text>
<text top="488" left="892" width="103" height="17" font="13">and worsening HF </text>
<text top="419" left="1014" width="215" height="17" font="13">Propensity scores for diuretic use were </text>
<text top="436" left="1014" width="200" height="17" font="13">calculated for each of the 7,788 DIG </text>
<text top="453" left="1014" width="211" height="17" font="13">participants using a non-parsimonious </text>
<text top="471" left="1014" width="215" height="17" font="13">multivariable logistic regression model, </text>
<text top="488" left="1014" width="205" height="17" font="13">and were used to match 1,391 (81%) </text>
<text top="505" left="1014" width="230" height="17" font="13">no-diuretic pts with 1,391 diuretic pts.        </text>
<text top="522" left="1014" width="210" height="17" font="13">Mean survival times for diuretic vs. no-</text>
<text top="539" left="1014" width="217" height="17" font="13">diuretic pts: 47 (95% CI: 46–48) and 50 </text>
<text top="557" left="1014" width="230" height="17" font="13">(95% CI: 49–51) mo.                                  </text>
<text top="574" left="1014" width="193" height="17" font="13">All-cause mortality was 21% for no-</text>
<text top="591" left="1014" width="196" height="17" font="13">diuretic pts and 29% for diuretic pts </text>
<text top="608" left="1014" width="228" height="17" font="13">(HR: 1.31; 95% CI: 1.11-1.55; p=0.002).   </text>
<text top="625" left="1014" width="213" height="17" font="13">HF hospitalizations occurred in 18% of </text>
<text top="643" left="1014" width="209" height="17" font="13">no-diuretic pts and 23% of diuretic pts </text>
<text top="660" left="1014" width="221" height="17" font="13">(HR: 1.37; 95% CI: 1.13-1.65; p=0.001). </text>
<text top="677" left="1014" width="206" height="17" font="13">Mortality due to HF occurred in 6% of </text>
<text top="694" left="1014" width="208" height="17" font="13">pts in the no-diuretic group and 9% of </text>
<text top="711" left="1014" width="204" height="17" font="13">those in the diuretic group (HR: 1.36; </text>
<text top="729" left="1014" width="229" height="17" font="13">95% CI 0.99–1.87; p=0.056).                     </text>
<text top="746" left="1014" width="208" height="17" font="13">Compared with 8% deaths among pts </text>
<text top="763" left="1014" width="217" height="17" font="13">never receiving diuretics during the first </text>
<text top="780" left="1014" width="209" height="17" font="13">24 mo of follow-up, 19% of those who </text>
<text top="419" left="1250" width="80" height="17" font="13">Based on non-</text>
<text top="436" left="1250" width="68" height="17" font="13">randomized </text>
<text top="453" left="1250" width="49" height="17" font="13">findings, </text>
<text top="471" left="1250" width="77" height="17" font="13">retrospective. </text>
<text top="488" left="1250" width="79" height="17" font="13">Beta-blockers </text>
<text top="505" left="1250" width="51" height="17" font="13">were not </text>
<text top="522" left="1250" width="92" height="17" font="13">approved for HF </text>
<text top="539" left="1250" width="84" height="17" font="13">during the DIG </text>
<text top="557" left="1250" width="92" height="17" font="13">trial and data on </text>
<text top="574" left="1250" width="94" height="17" font="13">beta-blocker use </text>
<text top="591" left="1250" width="51" height="17" font="13">were not </text>
<text top="608" left="1250" width="52" height="17" font="13">collected </text>
<text top="419" left="1365" width="46" height="17" font="13">Chronic </text>
<text top="436" left="1365" width="66" height="17" font="13">diuretic use </text>
<text top="453" left="1365" width="87" height="17" font="13">was associated </text>
<text top="471" left="1365" width="82" height="17" font="13">with increased </text>
<text top="488" left="1365" width="55" height="17" font="13">long-term </text>
<text top="505" left="1365" width="74" height="17" font="13">mortality and </text>
<text top="522" left="1365" width="87" height="17" font="13">hospitalizations </text>
<text top="539" left="1365" width="52" height="17" font="13">in a wide </text>
<text top="557" left="1365" width="68" height="17" font="13">spectrum of </text>
<text top="574" left="1365" width="64" height="17" font="13">ambulatory </text>
<text top="591" left="1365" width="87" height="17" font="13">chronic systolic </text>
<text top="608" left="1365" width="72" height="17" font="13">and diastolic </text>
<text top="625" left="1365" width="40" height="17" font="13">HF pts </text>
</page>
<page number="69" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">69</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="123" width="104" height="17" font="13">regression models </text>
<text top="55" left="1014" width="198" height="17" font="13">always received diuretics during the </text>
<text top="72" left="1014" width="173" height="17" font="13">same time died from all causes </text>
<text top="89" left="1014" width="210" height="17" font="13">(multivariable adjusted HR: 1.81; 95% </text>
<text top="106" left="1014" width="140" height="17" font="13">CI 1.38–2.38; p&lt;0.0001). </text>
<text top="198" left="28" width="29" height="17" font="15"><b>DIG</b>, </text>
<text top="215" left="28" width="61" height="17" font="13">Domanski, </text>
<text top="232" left="28" width="34" height="17" font="13">2006  </text>
<text top="250" left="28" width="55" height="17" font="14">16762792</text>
<text top="250" left="83" width="3" height="17" font="13"> </text>
<text top="267" left="28" width="32" height="17" font="13">(156) </text>
<text top="198" left="123" width="83" height="17" font="13">Investigate the </text>
<text top="215" left="123" width="121" height="17" font="13">associations between </text>
<text top="232" left="123" width="120" height="17" font="13">death, cardiovascular </text>
<text top="250" left="123" width="100" height="17" font="13">death, death from </text>
<text top="267" left="123" width="116" height="17" font="13">worsening HF, SCD, </text>
<text top="284" left="123" width="125" height="17" font="13">and HF hospitalization </text>
<text top="301" left="123" width="121" height="17" font="13">among those taking a </text>
<text top="318" left="123" width="105" height="17" font="13">PSD, NPSD, or no </text>
<text top="336" left="123" width="125" height="17" font="13">diuretic in the DIG trial </text>
<text top="198" left="265" width="49" height="17" font="13">Registry </text>
<text top="198" left="332" width="34" height="17" font="13">6,797 </text>
<text top="198" left="393" width="81" height="17" font="13">HF and LVEF  </text>
<text top="215" left="393" width="96" height="17" font="13">≤45% enrolled in </text>
<text top="232" left="393" width="101" height="17" font="13">the DIG trial.  The </text>
<text top="250" left="393" width="79" height="17" font="13">DIG randomly </text>
<text top="267" left="393" width="103" height="17" font="13">assigned 6800 pts </text>
<text top="284" left="393" width="103" height="17" font="13">with HF and LVEF </text>
<text top="301" left="393" width="107" height="17" font="13">≤45% to digoxin or </text>
<text top="318" left="393" width="70" height="17" font="13">placebo in a </text>
<text top="336" left="393" width="84" height="17" font="13">double-blinded </text>
<text top="353" left="393" width="80" height="17" font="13">controlled trial </text>
<text top="198" left="514" width="151" height="17" font="13">Age &lt;21 y; baseline EF not </text>
<text top="215" left="514" width="178" height="17" font="13">available; MI, cardiac surgery or </text>
<text top="232" left="514" width="167" height="17" font="13">PTCA within 4 wk; unstable or </text>
<text top="250" left="514" width="182" height="17" font="13">refractory angina &lt;1 mo; II-III AV </text>
<text top="267" left="514" width="176" height="17" font="13">block without pacemaker; AF or </text>
<text top="284" left="514" width="187" height="17" font="13">flutter; cor pulmonale; constrictive </text>
<text top="301" left="514" width="169" height="17" font="13">pericarditis; acute myocarditis; </text>
<text top="318" left="514" width="165" height="17" font="13">hypertrophic cardiomyopathy; </text>
<text top="336" left="514" width="189" height="17" font="13">amyloid cardiomyopathy; complex </text>
<text top="353" left="514" width="180" height="17" font="13">CHD; tx with IV inotropic agents; </text>
<text top="370" left="514" width="186" height="17" font="13">K+ &lt; 3.2 mmol/L or &gt; 5.5 mmol/L; </text>
<text top="387" left="514" width="191" height="17" font="13">on heart transplant list; noncardiac </text>
<text top="404" left="514" width="164" height="17" font="13">cause of HF; Creatinine &gt; 3.0 </text>
<text top="422" left="514" width="167" height="17" font="13">mg/dL or severe liver disease; </text>
<text top="439" left="514" width="100" height="17" font="13">unlikely to comply </text>
<text top="198" left="724" width="92" height="17" font="13">All-cause death, </text>
<text top="215" left="724" width="155" height="17" font="13">cardiovascular death, death </text>
<text top="232" left="724" width="151" height="17" font="13">from progressive HF, SCD, </text>
<text top="250" left="724" width="125" height="17" font="13">and HF hospitalization </text>
<text top="198" left="892" width="24" height="17" font="13">N/A </text>
<text top="198" left="1014" width="217" height="17" font="13">For death from HF or SCD, the incident </text>
<text top="215" left="1014" width="196" height="17" font="13">rates were not significantly different </text>
<text top="232" left="1014" width="202" height="17" font="13">between the pts taking the PSD only </text>
<text top="250" left="1014" width="201" height="17" font="13">versus no-diuretic group (p=.06, and </text>
<text top="267" left="1014" width="187" height="17" font="13">p=.7, respectively); for the other 4 </text>
<text top="284" left="1014" width="210" height="17" font="13">events (hosp for HF, death from CVD, </text>
<text top="301" left="1014" width="202" height="17" font="13">death from all causes, hosp or death </text>
<text top="318" left="1014" width="208" height="17" font="13">from HF), the incidence rates were all </text>
<text top="336" left="1014" width="194" height="17" font="13">significantly lower in the no-diuretic </text>
<text top="353" left="1014" width="186" height="17" font="13">group than in the PSD-only group </text>
<text top="370" left="1014" width="187" height="17" font="13">(p≤.01).                            For all 6 </text>
<text top="387" left="1014" width="188" height="17" font="13">events, the incidence rates for the </text>
<text top="404" left="1014" width="195" height="17" font="13">NPSD only group were significantly </text>
<text top="422" left="1014" width="223" height="17" font="13">higher than the PSD-only group (p≤.02). </text>
<text top="439" left="1014" width="213" height="17" font="13">The incidence rates for the NPSD-only </text>
<text top="456" left="1014" width="201" height="17" font="13">group and both-diuretic groups were </text>
<text top="473" left="1014" width="179" height="17" font="13">comparable and not significantly </text>
<text top="490" left="1014" width="219" height="17" font="13">different with the p- values ranging from </text>
<text top="508" left="1014" width="228" height="17" font="13">.07 to .6 (date not shown).                         </text>
<text top="525" left="1014" width="210" height="17" font="13">After multivariate analysis, the risks of </text>
<text top="542" left="1014" width="202" height="17" font="13">all 6 endpoints were increased in pts </text>
<text top="559" left="1014" width="196" height="17" font="13">taking a NPSD, whether or not they </text>
<text top="577" left="1014" width="204" height="17" font="13">were taking a PSD after adjusting for </text>
<text top="594" left="1014" width="180" height="17" font="13">known covariates. There was no </text>
<text top="611" left="1014" width="222" height="17" font="13">significant difference in the risk of any of </text>
<text top="628" left="1014" width="202" height="17" font="13">these events for pts taking only PSD </text>
<text top="645" left="1014" width="229" height="17" font="13">and those taking no diuretics.                    </text>
<text top="663" left="1014" width="212" height="17" font="13">Compared with not taking diuretic, risk </text>
<text top="680" left="1014" width="216" height="17" font="13">of death (RR: 1.36, 95% CI: 1.17–1.59, </text>
<text top="697" left="1014" width="201" height="17" font="13">p&lt;.0001), cardiovascular death (RR: </text>
<text top="714" left="1014" width="195" height="17" font="13">1.38, 95% CI: 1.17–1.63; p=.0001), </text>
<text top="731" left="1014" width="209" height="17" font="13">progressive HF death (RR: 1.41, 95% </text>
<text top="749" left="1014" width="215" height="17" font="13">CI: 1.06–1.89, p= .02), SCD (RR: 1.67, </text>
<text top="766" left="1014" width="198" height="17" font="13">95% CI 1.23–2.27, p=.001), and HF </text>
<text top="783" left="1014" width="219" height="17" font="13">hospitalization (RR: 1.68, 95% CI: 1.41–</text>
<text top="198" left="1250" width="85" height="17" font="13">Post-hoc study </text>
<text top="215" left="1250" width="74" height="17" font="13">and doses of </text>
<text top="232" left="1250" width="100" height="17" font="13">diuretics were not </text>
<text top="250" left="1250" width="70" height="17" font="13">available for </text>
<text top="267" left="1250" width="102" height="17" font="13">analysis. Also, did </text>
<text top="284" left="1250" width="66" height="17" font="13">not analyze </text>
<text top="301" left="1250" width="53" height="17" font="13">effects of </text>
<text top="318" left="1250" width="83" height="17" font="13">treatment over </text>
<text top="336" left="1250" width="59" height="17" font="13">time. Beta-</text>
<text top="353" left="1250" width="100" height="17" font="13">blockers were not </text>
<text top="370" left="1250" width="92" height="17" font="13">approved for HF </text>
<text top="387" left="1250" width="84" height="17" font="13">during the DIG </text>
<text top="404" left="1250" width="92" height="17" font="13">trial and data on </text>
<text top="422" left="1250" width="94" height="17" font="13">beta blocker use </text>
<text top="439" left="1250" width="51" height="17" font="13">were not </text>
<text top="456" left="1250" width="52" height="17" font="13">collected </text>
<text top="198" left="1365" width="75" height="17" font="13">Among pts in </text>
<text top="215" left="1365" width="73" height="17" font="13">the DIG trial, </text>
<text top="232" left="1365" width="83" height="17" font="13">compared with </text>
<text top="250" left="1365" width="76" height="17" font="13">pts not taking </text>
<text top="267" left="1365" width="81" height="17" font="13">any diuretic or </text>
<text top="284" left="1365" width="79" height="17" font="13">taking a PSD, </text>
<text top="301" left="1365" width="81" height="17" font="13">pts taking non-</text>
<text top="318" left="1365" width="63" height="17" font="13">PSD had a </text>
<text top="336" left="1365" width="73" height="17" font="13">higher RR of </text>
<text top="353" left="1365" width="38" height="17" font="13">death. </text>
</page>
<page number="70" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">70</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1014" width="199" height="17" font="13">1.99, p&lt; .0001) were increased with </text>
<text top="72" left="1014" width="229" height="17" font="13">NPSD.                                                        </text>
<text top="89" left="1014" width="206" height="17" font="13">There was no significant difference in </text>
<text top="106" left="1014" width="202" height="17" font="13">any endpoint for pts taking only PSD </text>
<text top="124" left="1014" width="190" height="17" font="13">compared to no diuretic. PSD only </text>
<text top="141" left="1014" width="200" height="17" font="13">subjects were less likely than NPSD </text>
<text top="158" left="1014" width="214" height="17" font="13">subjects to be hospitalized for HF (RR: </text>
<text top="175" left="1014" width="182" height="17" font="13">0.71, 95% CI: 0.52–0.96, p=.02). </text>
<text top="193" left="28" width="80" height="17" font="15"><b>Cohort study </b></text>
<text top="210" left="28" width="74" height="17" font="15"><b>low vs. high </b></text>
<text top="228" left="28" width="79" height="17" font="15"><b>dose </b>(Cedars </text>
<text top="245" left="28" width="78" height="17" font="13">Sinai/ UCLA<b>)</b>, </text>
<text top="262" left="28" width="65" height="17" font="13">Eshaghian, </text>
<text top="279" left="28" width="31" height="17" font="13">2006 </text>
<text top="296" left="28" width="55" height="17" font="14">16765130</text>
<text top="296" left="83" width="3" height="17" font="13"> </text>
<text top="314" left="28" width="32" height="17" font="13">(157) </text>
<text top="193" left="123" width="114" height="17" font="13">This study sought to </text>
<text top="210" left="123" width="109" height="17" font="13">determine the dose-</text>
<text top="228" left="123" width="105" height="17" font="13">dependent relation </text>
<text top="245" left="123" width="120" height="17" font="13">between loop diuretic </text>
<text top="262" left="123" width="124" height="17" font="13">use and HF prognosis </text>
<text top="193" left="265" width="190" height="17" font="13">Cohort 1,354 Study </text>
<text top="193" left="428" width="87" height="17" font="13">population </text>
<text top="210" left="393" width="103" height="17" font="13">consisted of 1,354 </text>
<text top="228" left="393" width="88" height="17" font="13">consecutive pts </text>
<text top="245" left="393" width="82" height="17" font="13">with advanced </text>
<text top="262" left="393" width="64" height="17" font="13">systolic HF </text>
<text top="279" left="393" width="106" height="17" font="13">referred to a single </text>
<text top="296" left="393" width="101" height="17" font="13">university medical </text>
<text top="314" left="393" width="75" height="17" font="13">center for HF </text>
<text top="331" left="393" width="75" height="17" font="13">management </text>
<text top="348" left="393" width="96" height="17" font="13">and/or transplant </text>
<text top="365" left="393" width="87" height="17" font="13">evaluation from </text>
<text top="382" left="393" width="75" height="17" font="13">1985 to 2004 </text>
<text top="193" left="514" width="178" height="17" font="13">Pts with LVEF &gt;40%, those with </text>
<text top="210" left="514" width="176" height="17" font="13">HF due to valvular disease, and </text>
<text top="228" left="514" width="181" height="17" font="13">those aged &lt;18 y were excluded </text>
<text top="245" left="514" width="96" height="17" font="13">from the analysis </text>
<text top="193" left="724" width="104" height="17" font="13">All-cause mortality </text>
<text top="193" left="892" width="84" height="17" font="13">The composite </text>
<text top="210" left="892" width="98" height="17" font="13">endpoint of death </text>
<text top="228" left="892" width="53" height="17" font="13">or urgent </text>
<text top="245" left="892" width="98" height="17" font="13">transplant (status </text>
<text top="262" left="892" width="97" height="17" font="13">IA) was analyzed </text>
<text top="279" left="892" width="87" height="17" font="13">as a secondary </text>
<text top="296" left="892" width="51" height="17" font="13">endpoint </text>
<text top="193" left="1014" width="219" height="17" font="13"> Pts with HF in the highest diuretic dose </text>
<text top="210" left="1014" width="219" height="17" font="13">quartile were found to have significantly </text>
<text top="228" left="1014" width="212" height="17" font="13">impaired survival compared with pts in </text>
<text top="245" left="1014" width="229" height="17" font="13">the lowest quartile.                                     </text>
<text top="262" left="1014" width="198" height="17" font="13">Survival estimates at 1 y were 91%, </text>
<text top="279" left="1014" width="210" height="17" font="13">88%, 80%, and 69% for quartiles 1, 2, </text>
<text top="296" left="1014" width="231" height="17" font="13">3, and 4, respectively (p &lt;0.0001).             </text>
<text top="314" left="1014" width="198" height="17" font="13">Survival estimates at 2 y were 83%, </text>
<text top="331" left="1014" width="201" height="17" font="13">81%, 68%, and 53%, respectively (p </text>
<text top="348" left="1014" width="208" height="17" font="13">&lt;0.0001). Death from any cause: HR: </text>
<text top="365" left="1014" width="229" height="17" font="13">3.4, 95% CI: 2.4-4.7                                   </text>
<text top="382" left="1014" width="205" height="17" font="13">death and urgent transplantation: HR </text>
<text top="400" left="1014" width="229" height="17" font="13">2.7, 95% CI 2.0-3.5                                    </text>
<text top="417" left="1014" width="201" height="17" font="13">death from progressive HF: HR: 3.8; </text>
<text top="434" left="1014" width="229" height="17" font="13">95% CI 2.1-6.8                                           </text>
<text top="451" left="1014" width="222" height="17" font="13">sudden death: HR: 3.6; 95% CI: 1.9-6.8  </text>
<text top="469" left="1014" width="215" height="17" font="13">Univariate analysis- compared with the </text>
<text top="486" left="1014" width="215" height="17" font="13">lowest quartile, increasing loop diuretic </text>
<text top="503" left="1014" width="208" height="17" font="13">dose quartiles were associated with a </text>
<text top="520" left="1014" width="180" height="17" font="13">progressive increase in mortality </text>
<text top="537" left="1014" width="211" height="17" font="13">(second quartile, HR: 1.2; 95% CI: 0.8-</text>
<text top="555" left="1014" width="212" height="17" font="13">1.7; third quartile, HR: 2.1, 95% CI 1.5-</text>
<text top="572" left="1014" width="222" height="17" font="13">2.9; and fourth quartile, HR: 3.4; 95% CI </text>
<text top="589" left="1014" width="204" height="17" font="13">2.4-4.7). Diuretic dose quartiles were </text>
<text top="606" left="1014" width="194" height="17" font="13">associated with increased mortality </text>
<text top="624" left="1014" width="209" height="17" font="13">independent of other covariates. After </text>
<text top="641" left="1014" width="214" height="17" font="13">adjustment the highest diuretic quartile </text>
<text top="658" left="1014" width="188" height="17" font="13">remained a significant predictor of </text>
<text top="675" left="1014" width="221" height="17" font="13">increased mortality at 1 y (HR: 4.2; 95% </text>
<text top="692" left="1014" width="210" height="17" font="13">CI: 1.5-11.3) and at 2 y (HR: 4.0; 95% </text>
<text top="710" left="1014" width="65" height="17" font="13">CI 1.9-8.4)  </text>
<text top="727" left="1014" width="140" height="17" font="13">                                         </text>
<text top="193" left="1250" width="102" height="17" font="13">Possible selection </text>
<text top="210" left="1250" width="78" height="17" font="13">bias.  Diuretic </text>
<text top="228" left="1250" width="55" height="17" font="13">dose was </text>
<text top="245" left="1250" width="96" height="17" font="13">examined at only </text>
<text top="262" left="1250" width="89" height="17" font="13">a single point in </text>
<text top="279" left="1250" width="72" height="17" font="13">time, without </text>
<text top="296" left="1250" width="66" height="17" font="13">considering </text>
<text top="314" left="1250" width="99" height="17" font="13">chnages in doses </text>
<text top="331" left="1250" width="57" height="17" font="13">over time. </text>
<text top="348" left="1250" width="50" height="17" font="13">Baseline </text>
<text top="365" left="1250" width="82" height="17" font="13">characteristics </text>
<text top="382" left="1250" width="75" height="17" font="13">and other HF </text>
<text top="400" left="1250" width="62" height="17" font="13">treatments </text>
<text top="417" left="1250" width="89" height="17" font="13">different among </text>
<text top="434" left="1250" width="94" height="17" font="13">the diuretic dose </text>
<text top="451" left="1250" width="81" height="17" font="13">quartiles. With </text>
<text top="469" left="1250" width="81" height="17" font="13">adjustment for </text>
<text top="486" left="1250" width="46" height="17" font="13">multiple </text>
<text top="503" left="1250" width="98" height="17" font="13">covariates, larger </text>
<text top="520" left="1250" width="70" height="17" font="13">loop diuretic </text>
<text top="537" left="1250" width="90" height="17" font="13">doses could still </text>
<text top="555" left="1250" width="101" height="17" font="13">be a surrogate for </text>
<text top="572" left="1250" width="90" height="17" font="13">other measured </text>
<text top="589" left="1250" width="96" height="17" font="13">and unmeasured </text>
<text top="606" left="1250" width="77" height="17" font="13">variables that </text>
<text top="624" left="1250" width="68" height="17" font="13">reflect more </text>
<text top="641" left="1250" width="64" height="17" font="13">severe HF. </text>
<text top="658" left="1250" width="99" height="17" font="13">Serum potassium </text>
<text top="675" left="1250" width="91" height="17" font="13">and magnesium </text>
<text top="692" left="1250" width="93" height="17" font="13">level information </text>
<text top="710" left="1250" width="94" height="17" font="13">was unavailable. </text>
<text top="727" left="1250" width="61" height="17" font="13">Propensity </text>
<text top="744" left="1250" width="99" height="17" font="13">matching was not </text>
<text top="761" left="1250" width="102" height="17" font="13">performed. So the </text>
<text top="778" left="1250" width="94" height="17" font="13">relation between </text>
<text top="193" left="1365" width="59" height="17" font="13">This study </text>
<text top="210" left="1365" width="76" height="17" font="13">suggests that </text>
<text top="228" left="1365" width="58" height="17" font="13">in pts with </text>
<text top="245" left="1365" width="57" height="17" font="13">advanced </text>
<text top="262" left="1365" width="88" height="17" font="13">systolic HF, the </text>
<text top="279" left="1365" width="75" height="17" font="13">use of higher </text>
<text top="296" left="1365" width="77" height="17" font="13">doses of loop </text>
<text top="314" left="1365" width="61" height="17" font="13">diuretics is </text>
<text top="331" left="1365" width="87" height="17" font="13">associated with </text>
<text top="348" left="1365" width="67" height="17" font="13">significantly </text>
<text top="365" left="1365" width="73" height="17" font="13">increased all-</text>
<text top="382" left="1365" width="36" height="17" font="13">cause </text>
<text top="400" left="1365" width="53" height="17" font="13">mortality. </text>
<text top="417" left="1365" width="88" height="17" font="13">Although it may </text>
<text top="434" left="1365" width="87" height="17" font="13">appear obvious </text>
<text top="451" left="1365" width="69" height="17" font="13">that pts with </text>
<text top="469" left="1365" width="71" height="17" font="13">HF requiring </text>
<text top="486" left="1365" width="64" height="17" font="13">higher loop </text>
<text top="503" left="1365" width="79" height="17" font="13">diuretic doses </text>
<text top="520" left="1365" width="84" height="17" font="13">to prevent fluid </text>
<text top="537" left="1365" width="75" height="17" font="13">retention and </text>
<text top="555" left="1365" width="40" height="17" font="13">control </text>
<text top="572" left="1365" width="59" height="17" font="13">symptoms </text>
<text top="589" left="1365" width="86" height="17" font="13">might be sicker </text>
<text top="606" left="1365" width="47" height="17" font="13">than pts </text>
<text top="623" left="1365" width="85" height="17" font="13">receiving lower </text>
<text top="641" left="1365" width="60" height="17" font="13">doses, the </text>
<text top="658" left="1365" width="74" height="17" font="13">powerful and </text>
<text top="675" left="1365" width="71" height="17" font="13">independent </text>
<text top="692" left="1365" width="65" height="17" font="13">association </text>
<text top="710" left="1365" width="75" height="17" font="13">with mortality </text>
<text top="727" left="1365" width="51" height="17" font="13">warrants </text>
<text top="744" left="1365" width="39" height="17" font="13">further </text>
<text top="761" left="1365" width="80" height="17" font="13">consideration. </text>
</page>
<page number="71" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">71</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1250" width="100" height="17" font="13">loop diuretic dose </text>
<text top="72" left="1250" width="81" height="17" font="13">and increased </text>
<text top="89" left="1250" width="62" height="17" font="13">mortality is </text>
<text top="106" left="1250" width="59" height="17" font="13">causative. </text>
<text top="177" left="28" width="60" height="17" font="15"><b>Cochrane </b></text>
<text top="194" left="28" width="76" height="17" font="15"><b>review</b>, 2005 </text>
<text top="211" left="28" width="55" height="17" font="14">16034890</text>
<text top="211" left="83" width="3" height="17" font="13"> </text>
<text top="229" left="28" width="32" height="17" font="13">(158) </text>
<text top="177" left="123" width="90" height="17" font="13">To compare the </text>
<text top="194" left="123" width="111" height="17" font="13">effects and adverse </text>
<text top="211" left="123" width="116" height="17" font="13">effects of continuous </text>
<text top="229" left="123" width="101" height="17" font="13">IV infusion of loop </text>
<text top="246" left="123" width="122" height="17" font="13">diuretics with those of </text>
<text top="263" left="123" width="128" height="17" font="13">bolus IV administration </text>
<text top="280" left="123" width="106" height="17" font="13">among pts with HF </text>
<text top="297" left="123" width="61" height="17" font="13">class III-IV </text>
<text top="177" left="265" width="31" height="17" font="13">Meta-</text>
<text top="194" left="265" width="48" height="17" font="13">analysis </text>
<text top="177" left="332" width="132" height="17" font="13">254 RCTs </text>
<text top="177" left="428" width="98" height="17" font="13">comparing </text>
<text top="194" left="393" width="79" height="17" font="13">the efficacy of </text>
<text top="211" left="393" width="78" height="17" font="13">continuous IV </text>
<text top="229" left="393" width="85" height="17" font="13">infusion versus </text>
<text top="246" left="393" width="48" height="17" font="13">bolus IV </text>
<text top="263" left="393" width="94" height="17" font="13">administration of </text>
<text top="280" left="393" width="109" height="17" font="13">loop diuretics in HF </text>
<text top="297" left="393" width="74" height="17" font="13">in a total of 8 </text>
<text top="315" left="393" width="38" height="17" font="13">RCTs. </text>
<text top="177" left="514" width="24" height="17" font="13">N/A </text>
<text top="177" left="724" width="133" height="17" font="13">(7 studies) urine output, </text>
<text top="194" left="724" width="132" height="17" font="13">cc/24 h;                          </text>
<text top="211" left="724" width="134" height="17" font="13">Electrolyte disturbances </text>
<text top="229" left="724" width="80" height="17" font="13">(hypokalemia, </text>
<text top="246" left="724" width="155" height="17" font="13">hypomagnesemia); adverse </text>
<text top="263" left="724" width="154" height="17" font="13">effects (tinnitus and hearing </text>
<text top="280" left="724" width="131" height="17" font="13">loss);                  (single </text>
<text top="297" left="724" width="144" height="17" font="13">study) duration of hospital </text>
<text top="315" left="724" width="93" height="17" font="13">stay and cardiac </text>
<text top="332" left="724" width="130" height="17" font="13">mortality; (2 studies) all </text>
<text top="349" left="724" width="86" height="17" font="13">cause mortality </text>
<text top="177" left="892" width="24" height="17" font="13">N/A </text>
<text top="177" left="1014" width="211" height="17" font="13">Urine output: the output (as measured </text>
<text top="194" left="1014" width="206" height="17" font="13">in cc/24 h) was noted to be greater in </text>
<text top="211" left="1014" width="197" height="17" font="13">pts given continuous infusion with a </text>
<text top="229" left="1014" width="218" height="17" font="13">WMD of 271 cc/24 h (95%CI: 93.1-449; </text>
<text top="246" left="1014" width="171" height="17" font="13">p&lt;0.01).                   Electrolyte </text>
<text top="263" left="1014" width="191" height="17" font="13">disturbances were not significantly </text>
<text top="280" left="1014" width="104" height="17" font="13">different in the two </text>
<text top="297" left="1014" width="199" height="17" font="13">treatment groups : RR 1.47; 95%CI: </text>
<text top="315" left="1014" width="230" height="17" font="13">0.52-4.15; p=0.5.                                        </text>
<text top="332" left="1014" width="187" height="17" font="13">Less adverse effects (tinnitus and </text>
<text top="349" left="1014" width="163" height="17" font="13">hearing loss) were noted with </text>
<text top="366" left="1014" width="208" height="17" font="13">continuous infusion: RR 0.06; 95%CI: </text>
<text top="383" left="1014" width="230" height="17" font="13">0.01- 0.44; p=0.005.                                   </text>
<text top="401" left="1014" width="161" height="17" font="13">Duration of hospital stay was </text>
<text top="418" left="1014" width="198" height="17" font="13">significantly shortened by 3.1 d with </text>
<text top="435" left="1014" width="215" height="17" font="13">continuous infusion WMD -3.1; 95%CI -</text>
<text top="452" left="1014" width="209" height="17" font="13">4.06 to -2.20; p&lt;0.0001; while cardiac </text>
<text top="470" left="1014" width="203" height="17" font="13">mortality was significantly different in </text>
<text top="487" left="1014" width="198" height="17" font="13">the two treatment groups, RR: 0.47; </text>
<text top="504" left="1014" width="229" height="17" font="13">95% CI: 0.33 to 0.69; p&lt;0.0001.                </text>
<text top="521" left="1014" width="196" height="17" font="13">All-cause mortality was significantly </text>
<text top="538" left="1014" width="204" height="17" font="13">different in the two treatment groups, </text>
<text top="556" left="1014" width="223" height="17" font="13">RR: 0.52; 95% CI: 0.38- 0.71; p&lt;0.0001. </text>
<text top="177" left="1250" width="81" height="17" font="13">Available data </text>
<text top="194" left="1250" width="92" height="17" font="13">were insufficient </text>
<text top="211" left="1250" width="76" height="17" font="13">to confidently </text>
<text top="229" left="1250" width="99" height="17" font="13">assess the merits </text>
<text top="246" left="1250" width="95" height="17" font="13">of the 2 methods </text>
<text top="263" left="1250" width="64" height="17" font="13">of giving IV </text>
<text top="280" left="1250" width="77" height="17" font="13">diuretics. The </text>
<text top="297" left="1250" width="92" height="17" font="13">existing data did </text>
<text top="315" left="1250" width="52" height="17" font="13">not allow </text>
<text top="332" left="1250" width="52" height="17" font="13">definitive </text>
<text top="349" left="1250" width="101" height="17" font="13">recommendations </text>
<text top="366" left="1250" width="58" height="17" font="13">for clinical </text>
<text top="383" left="1250" width="50" height="17" font="13">practice  </text>
<text top="177" left="1365" width="87" height="17" font="13">Based on small </text>
<text top="194" left="1365" width="76" height="17" font="13">and relatively </text>
<text top="211" left="1365" width="85" height="17" font="13">heterogeneous </text>
<text top="229" left="1365" width="68" height="17" font="13">studies, this </text>
<text top="246" left="1365" width="85" height="17" font="13">review showed </text>
<text top="263" left="1365" width="88" height="17" font="13">greater diuresis </text>
<text top="280" left="1365" width="69" height="17" font="13">and a better </text>
<text top="297" left="1365" width="73" height="17" font="13">safety profile </text>
<text top="315" left="1365" width="59" height="17" font="13">when loop </text>
<text top="332" left="1365" width="79" height="17" font="13">diuretics were </text>
<text top="349" left="1365" width="49" height="17" font="13">given as </text>
<text top="366" left="1365" width="63" height="17" font="13">continuous </text>
<text top="383" left="1365" width="53" height="17" font="13">infusion.  </text>
<text top="574" left="28" width="49" height="17" font="15"><b>SOLVD</b>, </text>
<text top="591" left="28" width="61" height="17" font="13">Domanski, </text>
<text top="608" left="28" width="31" height="17" font="13">2003 </text>
<text top="625" left="28" width="55" height="17" font="14">12932605</text>
<text top="625" left="83" width="3" height="17" font="13"> </text>
<text top="642" left="28" width="32" height="17" font="13">(159) </text>
<text top="574" left="123" width="89" height="17" font="13">Study sought to </text>
<text top="591" left="123" width="105" height="17" font="13">determine whether </text>
<text top="608" left="123" width="127" height="17" font="13">NPSDs in the absence </text>
<text top="625" left="123" width="126" height="17" font="13">of a PSD may result in </text>
<text top="642" left="123" width="90" height="17" font="13">progressive HF. </text>
<text top="574" left="265" width="222" height="17" font="13">Registry 6,797  Symptomatic </text>
<text top="574" left="467" width="43" height="17" font="13">and </text>
<text top="591" left="393" width="99" height="17" font="13">asymptomatic pts </text>
<text top="608" left="393" width="70" height="17" font="13">with a LVEF </text>
<text top="625" left="393" width="108" height="17" font="13">fraction &lt;0.36 were </text>
<text top="642" left="393" width="107" height="17" font="13">randomly assigned </text>
<text top="660" left="393" width="98" height="17" font="13">to double-blinded </text>
<text top="677" left="393" width="81" height="17" font="13">treatment with </text>
<text top="694" left="393" width="64" height="17" font="13">enalapril or </text>
<text top="711" left="393" width="53" height="17" font="13">placebo.  </text>
<text top="574" left="514" width="184" height="17" font="13">Only drug class was ascertained; </text>
<text top="591" left="514" width="164" height="17" font="13">specific medications were not </text>
<text top="608" left="514" width="55" height="17" font="13">recorded. </text>
<text top="574" left="724" width="148" height="17" font="13">Rates of hospitalization for </text>
<text top="591" left="724" width="86" height="17" font="13">HF, death from </text>
<text top="608" left="724" width="132" height="17" font="13">cardiovascular disease, </text>
<text top="625" left="724" width="148" height="17" font="13">death from all causes, and </text>
<text top="642" left="724" width="130" height="17" font="13">either hospitalization or </text>
<text top="660" left="724" width="151" height="17" font="13">death due to worsening HF </text>
<text top="574" left="892" width="24" height="17" font="13">N/A </text>
<text top="574" left="1014" width="170" height="17" font="13">The risk of hospitalization from </text>
<text top="591" left="1014" width="201" height="17" font="13">worsening HF in those taking a PSD </text>
<text top="608" left="1014" width="216" height="17" font="13">relative to those taking only a non-PSD </text>
<text top="625" left="1014" width="214" height="17" font="13">was 0.74; 95% CI 0.55-0.99; p= 0.047. </text>
<text top="642" left="1014" width="206" height="17" font="13">The RR for cardiovascular death was </text>
<text top="660" left="1014" width="207" height="17" font="13">0.74; 95% CI 0.59-0.93; p=0.011), for </text>
<text top="677" left="1014" width="198" height="17" font="13">death from all causes 0.73; 95% CI: </text>
<text top="694" left="1014" width="156" height="17" font="13">0.59-0.90; p=0.004), and for </text>
<text top="711" left="1014" width="202" height="17" font="13">hospitalization for, or death from, HF </text>
<text top="728" left="1014" width="192" height="17" font="13">0.75; 95% CI: 0.58-0.97; p=0.030). </text>
<text top="746" left="1014" width="186" height="17" font="13">Compared with pts not taking any </text>
<text top="763" left="1014" width="199" height="17" font="13">diuretic, the risk of hospitalization or </text>
<text top="780" left="1014" width="220" height="17" font="13">death due to worsening HF in pts taking </text>
<text top="574" left="1250" width="72" height="17" font="13">This study is </text>
<text top="591" left="1250" width="101" height="17" font="13">retrospective and, </text>
<text top="608" left="1250" width="77" height="17" font="13">therefore, not </text>
<text top="625" left="1250" width="83" height="17" font="13">definitive proof </text>
<text top="642" left="1250" width="68" height="17" font="13">that NPSDs </text>
<text top="660" left="1250" width="36" height="17" font="13">cause </text>
<text top="677" left="1250" width="90" height="17" font="13">progressive HF. </text>
<text top="694" left="1250" width="72" height="17" font="13">Because the </text>
<text top="711" left="1250" width="87" height="17" font="13">diuretic dosage </text>
<text top="728" left="1250" width="101" height="17" font="13">was not available, </text>
<text top="746" left="1250" width="90" height="17" font="13">we cannot draw </text>
<text top="763" left="1250" width="102" height="17" font="13">conclusions about </text>
<text top="780" left="1250" width="95" height="17" font="13">a dose-response </text>
<text top="574" left="1365" width="59" height="17" font="13">This study </text>
<text top="591" left="1365" width="75" height="17" font="13">shows that in </text>
<text top="608" left="1365" width="45" height="17" font="13">pts with </text>
<text top="625" left="1365" width="70" height="17" font="13">moderate or </text>
<text top="642" left="1365" width="59" height="17" font="13">severe LV </text>
<text top="660" left="1365" width="69" height="17" font="13">dysfunction, </text>
<text top="677" left="1365" width="68" height="17" font="13">the use of a </text>
<text top="694" left="1365" width="41" height="17" font="13">PSD is </text>
<text top="711" left="1365" width="87" height="17" font="13">associated with </text>
<text top="728" left="1365" width="81" height="17" font="13">a reduced risk </text>
<text top="746" left="1365" width="62" height="17" font="13">of death or </text>
<text top="763" left="1365" width="81" height="17" font="13">hospitalization </text>
<text top="780" left="1365" width="38" height="17" font="13">due to </text>
</page>
<page number="72" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">72</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1014" width="185" height="17" font="13">non-PSDs alone was significantly </text>
<text top="72" left="1014" width="219" height="17" font="13">increased (RR:1.31: 95% CI: 1.09-1.57; </text>
<text top="89" left="1014" width="218" height="17" font="13">p=0.0004); this was not observed in pts </text>
<text top="106" left="1014" width="201" height="17" font="13">taking PSDs with or without a NPSD </text>
<text top="124" left="1014" width="214" height="17" font="13">(RR: 0.99; 95% CI: 0.76- 1.30; p=0.95).</text>
<text top="124" left="1228" width="3" height="17" font="23"> </text>
<text top="55" left="1250" width="101" height="17" font="13">relationship. Also, </text>
<text top="72" left="1250" width="77" height="17" font="13">baseline data </text>
<text top="89" left="1250" width="88" height="17" font="13">were used, and </text>
<text top="106" left="1250" width="98" height="17" font="13">diuretic treatment </text>
<text top="124" left="1250" width="93" height="17" font="13">status may have </text>
<text top="141" left="1250" width="78" height="17" font="13">changed over </text>
<text top="158" left="1250" width="27" height="17" font="13">time </text>
<text top="55" left="1365" width="67" height="17" font="13">progressive </text>
<text top="72" left="1365" width="80" height="17" font="13">HF, relative to </text>
<text top="89" left="1365" width="82" height="17" font="13">pts taking only </text>
<text top="106" left="1365" width="67" height="17" font="13">a non-PSD. </text>
<text top="190" left="28" width="53" height="17" font="15"><b>PRAISE</b>, </text>
<text top="207" left="28" width="54" height="17" font="13">Neuberg, </text>
<text top="224" left="28" width="31" height="17" font="13">2002 </text>
<text top="241" left="28" width="55" height="17" font="14">12094185</text>
<text top="241" left="83" width="3" height="17" font="13"> </text>
<text top="259" left="28" width="32" height="17" font="13">(152) </text>
<text top="190" left="123" width="85" height="17" font="13">The prognostic </text>
<text top="207" left="123" width="121" height="17" font="13">importance of diuretic </text>
<text top="224" left="123" width="80" height="17" font="13">resistance (as </text>
<text top="241" left="123" width="113" height="17" font="13">evidenced by a high-</text>
<text top="259" left="123" width="129" height="17" font="13">dose requirement) was </text>
<text top="276" left="123" width="83" height="17" font="13">retrospectively </text>
<text top="293" left="123" width="115" height="17" font="13">evaluated in pts with </text>
<text top="310" left="123" width="103" height="17" font="13">advanced HF who </text>
<text top="327" left="123" width="111" height="17" font="13">were enrolled in the </text>
<text top="345" left="123" width="52" height="17" font="13">PRAISE. </text>
<text top="190" left="265" width="49" height="17" font="13">Registry </text>
<text top="190" left="332" width="34" height="17" font="13">1,153 </text>
<text top="190" left="393" width="93" height="17" font="13">LVEF &lt;30% and </text>
<text top="207" left="393" width="94" height="17" font="13">NYHA functional </text>
<text top="224" left="393" width="87" height="17" font="13">class IIIb/IV HF </text>
<text top="241" left="393" width="105" height="17" font="13">despite mandatory </text>
<text top="259" left="393" width="68" height="17" font="13">background </text>
<text top="276" left="393" width="81" height="17" font="13">treatment with </text>
<text top="293" left="393" width="98" height="17" font="13">digoxin, diuretics, </text>
<text top="310" left="393" width="109" height="17" font="13">and ACE inhibitors. </text>
<text top="190" left="514" width="178" height="17" font="13">Pts were excluded if their serum </text>
<text top="207" left="514" width="183" height="17" font="13">potassium level was &lt;3.5 or &gt;5.5 </text>
<text top="224" left="514" width="183" height="17" font="13">mmol/L and if their SCr level was </text>
<text top="241" left="514" width="189" height="17" font="13">&gt;3.0 mg/dL (270 &gt;mol/L), and/or if </text>
<text top="259" left="514" width="188" height="17" font="13">they met other standard exclusion </text>
<text top="276" left="514" width="40" height="17" font="13">criteria </text>
<text top="190" left="724" width="97" height="17" font="13">Death or  cardiac </text>
<text top="207" left="724" width="88" height="17" font="13">transplantation  </text>
<text top="190" left="892" width="24" height="17" font="13">N/A </text>
<text top="190" left="1014" width="202" height="17" font="13">HDD were independently associated </text>
<text top="207" left="1014" width="218" height="17" font="13">with mortality, sudden death, and pump </text>
<text top="224" left="1014" width="218" height="17" font="13">failure death (aHR: 1.37 (p=.004), aHR: </text>
<text top="241" left="1014" width="216" height="17" font="13">1.39 (p=.042), and aHR: 1.51 (p=.034), </text>
<text top="259" left="1014" width="75" height="17" font="13">respectively.  </text>
<text top="276" left="1014" width="219" height="17" font="13">Use of metolazone was an independent </text>
<text top="293" left="1014" width="208" height="17" font="13">predictor of total mortality (aHR: 1.37; </text>
<text top="310" left="1014" width="181" height="17" font="13">p=.016) but not of cause-specific </text>
<text top="327" left="1014" width="200" height="17" font="13">mortality. In quartiles of loop diuretic </text>
<text top="345" left="1014" width="167" height="17" font="13">dose, total mortality increased </text>
<text top="362" left="1014" width="181" height="17" font="13">progressively without a clear risk </text>
<text top="379" left="1014" width="215" height="17" font="13">threshold, more than doubling from the </text>
<text top="396" left="1014" width="212" height="17" font="13">lowest-dose group to the highest-dose </text>
<text top="413" left="1014" width="207" height="17" font="13">group (p=.001).  Unadjusted mortality </text>
<text top="431" left="1014" width="187" height="17" font="13">rates were 20.7% (n=152), 30.7% </text>
<text top="448" left="1014" width="200" height="17" font="13">(n=313), 36.8% (n=304), and 44.8% </text>
<text top="465" left="1014" width="160" height="17" font="13">(n=84) for increasing dose of </text>
<text top="482" left="1014" width="210" height="17" font="13">furosemide (40 mg, 40-80 mg, 80-120 </text>
<text top="500" left="1014" width="211" height="17" font="13">mg, and  120 mg daily) or bumetanide </text>
<text top="517" left="1014" width="223" height="17" font="13">(1 mg, 1-2 mg, 2-3 mg, and  3 mg daily), </text>
<text top="534" left="1014" width="199" height="17" font="13">respectively. By proportional hazard </text>
<text top="551" left="1014" width="206" height="17" font="13">regression, high diuretic dose was an </text>
<text top="568" left="1014" width="213" height="17" font="13">independent predictor of total mortality </text>
<text top="586" left="1014" width="214" height="17" font="13">(aHR: 1.37; p=0.004), sudden death (a </text>
<text top="603" left="1014" width="206" height="17" font="13">HR: 1.39, p=0.042), and pump failure </text>
<text top="620" left="1014" width="156" height="17" font="13">death (aHR: 1.51, p=0.034). </text>
<text top="190" left="1250" width="98" height="17" font="13">Retrospectiveolde</text>
<text top="207" left="1250" width="77" height="17" font="13">r study as pts </text>
<text top="224" left="1250" width="60" height="17" font="13">enrolled in </text>
<text top="241" left="1250" width="99" height="17" font="13">PRAISE were not </text>
<text top="259" left="1250" width="97" height="17" font="13">on beta blockers. </text>
<text top="190" left="1365" width="62" height="17" font="13">Found that </text>
<text top="207" left="1365" width="77" height="17" font="13">high doses of </text>
<text top="224" left="1365" width="70" height="17" font="13">loop diuretic </text>
<text top="241" left="1365" width="59" height="17" font="13">(&gt;80mg of </text>
<text top="259" left="1365" width="79" height="17" font="13">furosemide or </text>
<text top="276" left="1365" width="48" height="17" font="13">&gt;2mg of </text>
<text top="293" left="1365" width="57" height="17" font="13">buetanide </text>
<text top="310" left="1365" width="63" height="17" font="13">daily) were </text>
<text top="327" left="1365" width="80" height="17" font="13">independently </text>
<text top="345" left="1365" width="87" height="17" font="13">associated with </text>
<text top="362" left="1365" width="83" height="17" font="13">mortality in pts </text>
<text top="379" left="1365" width="82" height="17" font="13">with advanced </text>
<text top="396" left="1365" width="62" height="17" font="13">HF.  When </text>
<text top="413" left="1365" width="55" height="17" font="13">degree of </text>
<text top="431" left="1365" width="88" height="17" font="13">congestion was </text>
<text top="448" left="1365" width="64" height="17" font="13">considered </text>
<text top="465" left="1365" width="74" height="17" font="13">together with </text>
<text top="482" left="1365" width="74" height="17" font="13">its treatment, </text>
<text top="500" left="1365" width="83" height="17" font="13">the associated </text>
<text top="517" left="1365" width="59" height="17" font="13">risks were </text>
<text top="534" left="1365" width="49" height="17" font="13">additive, </text>
<text top="551" left="1365" width="87" height="17" font="13">suggesting that </text>
<text top="568" left="1365" width="43" height="17" font="13">diuretic </text>
<text top="586" left="1365" width="59" height="17" font="13">resistance </text>
<text top="603" left="1365" width="57" height="17" font="13">should be </text>
<text top="620" left="1365" width="81" height="17" font="13">considered an </text>
<text top="637" left="1365" width="66" height="17" font="13">indicatior of </text>
<text top="654" left="1365" width="70" height="17" font="13">prognosis in </text>
<text top="672" left="1365" width="66" height="17" font="13">chronic HF. </text>
<text top="689" left="1365" width="55" height="17" font="13">However, </text>
<text top="706" left="1365" width="74" height="17" font="13">retrospective </text>
<text top="723" left="1365" width="78" height="17" font="13">analysis does </text>
<text top="740" left="1365" width="72" height="17" font="13">not establish </text>
<text top="758" left="1365" width="80" height="17" font="13">harm, nor rule </text>
<text top="775" left="1365" width="86" height="17" font="13">out a long-term </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">73</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1365" width="54" height="17" font="13">benefit of </text>
<text top="72" left="1365" width="43" height="17" font="13">diuretic </text>
<text top="89" left="1365" width="51" height="17" font="13">therapy.  </text>
<text top="109" left="28" width="81" height="17" font="15"><b>Ultrafiltration </b></text>
<text top="136" left="28" width="56" height="17" font="15"><b>UNLOAD </b></text>
<text top="154" left="28" width="58" height="17" font="15"><b>substudy </b></text>
<text top="171" left="28" width="66" height="17" font="13">(Maryland), </text>
<text top="188" left="28" width="47" height="17" font="13">Rogers, </text>
<text top="205" left="28" width="34" height="17" font="13">2008  </text>
<text top="222" left="28" width="55" height="17" font="14">18226766</text>
<text top="222" left="83" width="3" height="17" font="13"> </text>
<text top="240" left="28" width="32" height="17" font="13">(160) </text>
<text top="257" left="28" width="3" height="17" font="13"> </text>
<text top="136" left="116" width="85" height="17" font="13">This study was </text>
<text top="154" left="116" width="117" height="17" font="13">designed to evaluate </text>
<text top="171" left="116" width="117" height="17" font="13">the consequences of </text>
<text top="188" left="116" width="110" height="17" font="13">UF and standard IV </text>
<text top="205" left="116" width="116" height="17" font="13">diuretic (furosemide) </text>
<text top="222" left="116" width="115" height="17" font="13">therapy on GFR and </text>
<text top="240" left="116" width="132" height="17" font="13">renal plasma flow in pts </text>
<text top="257" left="116" width="59" height="17" font="13">with acute </text>
<text top="274" left="116" width="118" height="17" font="13">decompensated HF.  </text>
<text top="136" left="265" width="29" height="17" font="13">RCT </text>
<text top="136" left="332" width="17" height="17" font="13">19 </text>
<text top="136" left="393" width="141" height="17" font="13">Pts hospitalized for acute </text>
<text top="154" left="393" width="136" height="17" font="13">decompensated HF with </text>
<text top="171" left="393" width="114" height="17" font="13">an EF &lt;40% and ≥2 </text>
<text top="188" left="393" width="122" height="17" font="13">signs of hypervolemia </text>
<text top="205" left="393" width="142" height="17" font="13">based on at least 2 of the </text>
<text top="222" left="393" width="126" height="17" font="13">following findings: ≥2+ </text>
<text top="240" left="393" width="112" height="17" font="13">pitting edema of the </text>
<text top="257" left="393" width="139" height="17" font="13">lower extremities, jugular </text>
<text top="274" left="393" width="140" height="17" font="13">venous pressure ≥10 cm </text>
<text top="291" left="393" width="9" height="17" font="13">H</text>
<text top="297" left="402" width="4" height="11" font="19">2</text>
<text top="291" left="406" width="118" height="17" font="13">O, pulmonary edema </text>
<text top="309" left="393" width="118" height="17" font="13">or pleural effusion on </text>
<text top="326" left="393" width="95" height="17" font="13">chest radiograph </text>
<text top="343" left="393" width="84" height="17" font="13">consistent with </text>
<text top="360" left="393" width="91" height="17" font="13">decompensated </text>
<text top="377" left="393" width="131" height="17" font="13">congestive HF, ascites, </text>
<text top="395" left="393" width="120" height="17" font="13">paroxysmal nocturnal </text>
<text top="412" left="393" width="120" height="17" font="13">dyspnea, or ≥2 pillow </text>
<text top="429" left="393" width="62" height="17" font="13">orthopnea. </text>
<text top="136" left="548" width="131" height="17" font="13">Pts with ACS, SCr &gt;3.0 </text>
<text top="154" left="548" width="144" height="17" font="13">mg/dL, SBP ≤ 90 mm Hg, </text>
<text top="171" left="548" width="157" height="17" font="13">hematocrit &gt;45%, inability to </text>
<text top="188" left="548" width="139" height="17" font="13">obtain venous access, or </text>
<text top="205" left="548" width="139" height="17" font="13">clinical instability likely to </text>
<text top="222" left="548" width="160" height="17" font="13">require IV nitroprusside or IV </text>
<text top="240" left="548" width="107" height="17" font="13">pressors, history of </text>
<text top="257" left="548" width="158" height="17" font="13">administration of IV diuretics </text>
<text top="274" left="548" width="134" height="17" font="13">and/or vasoactive drugs </text>
<text top="291" left="548" width="103" height="17" font="13">during the present </text>
<text top="309" left="548" width="153" height="17" font="13">hospitalization (except for a </text>
<text top="326" left="548" width="144" height="17" font="13">single dose of IV diuretics </text>
<text top="343" left="548" width="128" height="17" font="13">administered in the ED </text>
<text top="360" left="548" width="150" height="17" font="13">before hospitalization), use </text>
<text top="377" left="548" width="142" height="17" font="13">of iodinated radiocontrast </text>
<text top="395" left="548" width="154" height="17" font="13">material, contraindication to </text>
<text top="412" left="548" width="147" height="17" font="13">the use of anticoagulation, </text>
<text top="429" left="548" width="118" height="17" font="13">systemic infection, or </text>
<text top="446" left="548" width="157" height="17" font="13">hemodialysis were excluded </text>
<text top="463" left="548" width="105" height="17" font="13">from the substudy. </text>
<text top="136" left="724" width="103" height="17" font="13">Urine output, GFR </text>
<text top="154" left="724" width="95" height="17" font="13">(as measured by </text>
<text top="171" left="724" width="98" height="17" font="13">iothalamate), and </text>
<text top="188" left="724" width="120" height="17" font="13">renal plasma flow (as </text>
<text top="205" left="724" width="103" height="17" font="13">measured by para-</text>
<text top="222" left="724" width="92" height="17" font="13">aminohippurate) </text>
<text top="240" left="724" width="85" height="17" font="13">were assessed </text>
<text top="257" left="724" width="111" height="17" font="13">before fluid removal </text>
<text top="274" left="724" width="83" height="17" font="13">and after 48 h. </text>
<text top="136" left="859" width="24" height="17" font="13">N/A </text>
<text top="136" left="1014" width="199" height="17" font="13">19 pts (59 +/- 16 y, 68% were male) </text>
<text top="154" left="1014" width="210" height="17" font="13">were randomized to receive UF (n= 9) </text>
<text top="171" left="1014" width="206" height="17" font="13">or IV diuretics (n= 10). The change in </text>
<text top="188" left="1014" width="199" height="17" font="13">GFR (-3.4 +/- 7.7 mL/min vs -3.6 +/- </text>
<text top="205" left="1014" width="201" height="17" font="13">11.5 mL/min; p= .966), renal plasma </text>
<text top="222" left="1014" width="207" height="17" font="13">flow (26.6 +/- 62.7 mL/min vs 16.1 +/- </text>
<text top="240" left="1014" width="197" height="17" font="13">42.0 mL/min; p= .669), and filtration </text>
<text top="257" left="1014" width="220" height="17" font="13">fraction (-6.9 +/- 13.6 mL/min vs -3.9 +/- </text>
<text top="274" left="1014" width="207" height="17" font="13">13.6 mL/min; p= .644) after treatment </text>
<text top="291" left="1014" width="215" height="17" font="13">were not significantly different between </text>
<text top="308" left="1014" width="184" height="17" font="13">the UF and furosemide treatment </text>
<text top="326" left="1014" width="221" height="17" font="13">groups.                              No significant </text>
<text top="343" left="1014" width="192" height="17" font="13">difference in net 48-h fluid removal </text>
<text top="360" left="1014" width="220" height="17" font="13">between the groups (-3211 +/- 2345 mL </text>
<text top="377" left="1014" width="184" height="17" font="13">for UF and -2725 +/- 2330 mL for </text>
<text top="395" left="1014" width="222" height="17" font="13">furosemide, p= .682). UF removed 3666 </text>
<text top="412" left="1014" width="210" height="17" font="13">+/- 2402 mL.                                         </text>
<text top="429" left="1014" width="161" height="17" font="13">Urine output during 48 h was </text>
<text top="446" left="1014" width="207" height="17" font="13">significantly greater in the furosemide </text>
<text top="463" left="1014" width="201" height="17" font="13">group (5786 +/- 2587 mL) compared </text>
<text top="481" left="1014" width="219" height="17" font="13">with the UF group (2286 +/- 915 mL, p&lt; </text>
<text top="498" left="1014" width="35" height="17" font="13">.001). </text>
<text top="136" left="1250" width="70" height="17" font="13">Small single </text>
<text top="154" left="1250" width="74" height="17" font="13">center study. </text>
<text top="171" left="1250" width="74" height="17" font="13">Pts receiving </text>
<text top="188" left="1250" width="75" height="17" font="13">UF tended to </text>
<text top="205" left="1250" width="66" height="17" font="13">have worse </text>
<text top="222" left="1250" width="43" height="17" font="13">GFR at </text>
<text top="240" left="1250" width="53" height="17" font="13">baseline. </text>
<text top="257" left="1250" width="36" height="17" font="13">Renal </text>
<text top="274" left="1250" width="80" height="17" font="13">hemodynamic </text>
<text top="291" left="1250" width="57" height="17" font="13">outcomes </text>
<text top="308" left="1250" width="30" height="17" font="13">were </text>
<text top="326" left="1250" width="58" height="17" font="13">measured </text>
<text top="343" left="1250" width="71" height="17" font="13">during acute </text>
<text top="360" left="1250" width="73" height="17" font="13">fluid removal </text>
<text top="377" left="1250" width="39" height="17" font="13">(48 h). </text>
<text top="395" left="1250" width="71" height="17" font="13">Unknown as </text>
<text top="412" left="1250" width="47" height="17" font="13">to when </text>
<text top="429" left="1250" width="63" height="17" font="13">changes in </text>
<text top="446" left="1250" width="72" height="17" font="13">GFR or RPF </text>
<text top="463" left="1250" width="62" height="17" font="13">occur. The </text>
<text top="481" left="1250" width="77" height="17" font="13">present study </text>
<text top="498" left="1250" width="51" height="17" font="13">does not </text>
<text top="515" left="1250" width="65" height="17" font="13">assess any </text>
<text top="532" left="1250" width="43" height="17" font="13">chronic </text>
<text top="550" left="1250" width="73" height="17" font="13">effects of UF </text>
<text top="567" left="1250" width="64" height="17" font="13">or diuresis. </text>
<text top="136" left="1345" width="78" height="17" font="13">During a 48-h </text>
<text top="154" left="1345" width="101" height="17" font="13">period, UF did not </text>
<text top="171" left="1345" width="59" height="17" font="13">cause any </text>
<text top="188" left="1345" width="58" height="17" font="13">significant </text>
<text top="205" left="1345" width="107" height="17" font="13">differences in renal </text>
<text top="222" left="1345" width="86" height="17" font="13">hemodynamics </text>
<text top="240" left="1345" width="104" height="17" font="13">compared with the </text>
<text top="257" left="1345" width="107" height="17" font="13">standard treatment </text>
<text top="274" left="1345" width="78" height="17" font="13">of IV diuretics </text>
<text top="603" left="28" width="59" height="17" font="15"><b>UNLOAD</b>, </text>
<text top="620" left="28" width="23" height="17" font="13">MR </text>
<text top="637" left="28" width="59" height="17" font="13">Costanzo, </text>
<text top="654" left="28" width="31" height="17" font="13">2007 </text>
<text top="671" left="28" width="55" height="17" font="14">17291932</text>
<text top="671" left="83" width="3" height="17" font="13"> </text>
<text top="689" left="28" width="32" height="17" font="13">(161) </text>
<text top="603" left="116" width="126" height="17" font="13">To compare the safety </text>
<text top="620" left="116" width="83" height="17" font="13">and efficacy of </text>
<text top="637" left="116" width="113" height="17" font="13">venovenous UF and </text>
<text top="654" left="116" width="109" height="17" font="13">standard IV diruetic </text>
<text top="671" left="116" width="62" height="17" font="13">therapy for </text>
<text top="689" left="116" width="116" height="17" font="13">hypervolemic HF pts </text>
<text top="603" left="265" width="188" height="17" font="13">RCT 200 Pts </text>
<text top="603" left="414" width="107" height="17" font="13">hospitalized </text>
<text top="603" left="482" width="64" height="17" font="13">with </text>
<text top="620" left="393" width="113" height="17" font="13">primary diagnosis of </text>
<text top="637" left="393" width="124" height="17" font="13">acute decompensated </text>
<text top="654" left="393" width="142" height="17" font="13">congestive HF;  evidence </text>
<text top="671" left="393" width="107" height="17" font="13">of fluid overload as </text>
<text top="689" left="393" width="109" height="17" font="13">indicated by: pitting </text>
<text top="706" left="393" width="113" height="17" font="13">edema (2+) of lower </text>
<text top="723" left="393" width="107" height="17" font="13">extremities; jugular </text>
<text top="740" left="393" width="105" height="17" font="13">venous distension; </text>
<text top="758" left="393" width="116" height="17" font="13">pulmonary edema or </text>
<text top="775" left="393" width="135" height="17" font="13">pleural effusion; ascites; </text>
<text top="603" left="548" width="148" height="17" font="13">ACS; creatinine &gt;3.0; SBP </text>
<text top="620" left="548" width="128" height="17" font="13">&lt;90 mmHg; hematocrit </text>
<text top="637" left="548" width="160" height="17" font="13">&gt;45%; prior administration of </text>
<text top="654" left="548" width="144" height="17" font="13">IV vasoactive drugs in the </text>
<text top="671" left="548" width="118" height="17" font="13">ED; clinical instability </text>
<text top="689" left="548" width="139" height="17" font="13">requiring pressors during </text>
<text top="706" left="548" width="159" height="17" font="13">hospitalization; recent use of </text>
<text top="723" left="548" width="151" height="17" font="13">iodinated contrast material; </text>
<text top="740" left="548" width="156" height="17" font="13">severe concomitant disease </text>
<text top="758" left="548" width="111" height="17" font="13">expected to prolong </text>
<text top="775" left="548" width="158" height="17" font="13">hospitalization; sepsis; on or </text>
<text top="603" left="724" width="95" height="17" font="13">Total weight loss </text>
<text top="620" left="724" width="92" height="17" font="13">during first 48 h; </text>
<text top="637" left="724" width="107" height="17" font="13">change in dyspnea </text>
<text top="654" left="724" width="111" height="17" font="13">score during first 48 </text>
<text top="671" left="724" width="17" height="17" font="13">h.  </text>
<text top="603" left="859" width="96" height="17" font="13">Change in global </text>
<text top="620" left="859" width="129" height="17" font="13">assessment; change in </text>
<text top="637" left="859" width="115" height="17" font="13">QoL (living with HF); </text>
<text top="654" left="859" width="95" height="17" font="13">changes in BNP; </text>
<text top="671" left="859" width="124" height="17" font="13">changes in 6 min walk </text>
<text top="689" left="859" width="142" height="17" font="13">test; total fluid loss during </text>
<text top="706" left="859" width="117" height="17" font="13">first 48 h; changes in </text>
<text top="723" left="859" width="114" height="17" font="13">BUN and creatinine; </text>
<text top="740" left="859" width="118" height="17" font="13">changes in renin and </text>
<text top="758" left="859" width="109" height="17" font="13">aldosterone; rate of </text>
<text top="775" left="859" width="112" height="17" font="13">hospitalizations and </text>
<text top="603" left="1014" width="230" height="17" font="13">Primary efficacy endpoints:                        </text>
<text top="620" left="1014" width="215" height="17" font="13">Weight loss was greater in the UF than </text>
<text top="637" left="1014" width="221" height="17" font="13">in the standard-care group (5.0 ± 3.1 kg </text>
<text top="654" left="1014" width="230" height="17" font="13">vs. 3.1 ± 3.5 kg; p=0.0001)                        </text>
<text top="671" left="1014" width="169" height="17" font="13">Dyspnea scores were similarly </text>
<text top="689" left="1014" width="211" height="17" font="13">improved in the UF and standard-care </text>
<text top="706" left="1014" width="230" height="17" font="13">group at both 8 and 48 h.                           </text>
<text top="723" left="1014" width="231" height="17" font="13">Primary safety endpoints:                           </text>
<text top="740" left="1014" width="203" height="17" font="13">Changes in SCr were similar in the 2 </text>
<text top="758" left="1014" width="208" height="17" font="13">groups throughout the study and % of </text>
<text top="775" left="1014" width="201" height="17" font="13">pts with rise in SCr &gt;0.3 mg/dL were </text>
<text top="603" left="1250" width="61" height="17" font="13">Population </text>
<text top="620" left="1250" width="21" height="17" font="13">not </text>
<text top="637" left="1250" width="81" height="17" font="13">representative </text>
<text top="654" left="1250" width="53" height="17" font="13">of HF pts </text>
<text top="671" left="1250" width="70" height="17" font="13">(better renal </text>
<text top="689" left="1250" width="74" height="17" font="13">function, and </text>
<text top="706" left="1250" width="72" height="17" font="13">excluded pts </text>
<text top="723" left="1250" width="25" height="17" font="13">with </text>
<text top="740" left="1250" width="78" height="17" font="13">hypotention);  </text>
<text top="758" left="1250" width="46" height="17" font="13">industry </text>
<text top="775" left="1250" width="64" height="17" font="13">sponsored; </text>
<text top="603" left="1345" width="98" height="17" font="13">While weight loss </text>
<text top="620" left="1345" width="92" height="17" font="13">was greater and </text>
<text top="637" left="1345" width="106" height="17" font="13">rehospitalization at </text>
<text top="654" left="1345" width="98" height="17" font="13">90 d was lower in </text>
<text top="671" left="1345" width="96" height="17" font="13">the UF arm, data </text>
<text top="689" left="1345" width="89" height="17" font="13">not available on </text>
<text top="706" left="1345" width="95" height="17" font="13">long-term effects </text>
<text top="723" left="1345" width="94" height="17" font="13">on renal function </text>
<text top="740" left="1345" width="66" height="17" font="13">or resource </text>
<text top="758" left="1345" width="103" height="17" font="13">utilization. The pts </text>
<text top="775" left="1345" width="105" height="17" font="13">in trial represented </text>
</page>
<page number="74" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">74</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="393" width="120" height="17" font="13">paroxysmal nocturnal </text>
<text top="72" left="393" width="109" height="17" font="13">dyspnea or 2-pillow </text>
<text top="89" left="393" width="62" height="17" font="13">orthopnea  </text>
<text top="106" left="393" width="7" height="17" font="13">  </text>
<text top="55" left="548" width="126" height="17" font="13">requires renal dialysis; </text>
<text top="72" left="548" width="157" height="17" font="13">history of cardiac transplant; </text>
<text top="89" left="548" width="91" height="17" font="13">heparin allergy.  </text>
<text top="55" left="859" width="128" height="17" font="13">unscheduled clinic and </text>
<text top="72" left="859" width="131" height="17" font="13">ED visits in the wk after </text>
<text top="89" left="859" width="79" height="17" font="13">inpt treatment </text>
<text top="55" left="1014" width="216" height="17" font="13">similar in both groups at 24 h, 48 h and </text>
<text top="72" left="1014" width="224" height="17" font="13">at discharge                                              </text>
<text top="89" left="1014" width="213" height="17" font="13">Serum potassium &lt;3.5 mEq/l occurred </text>
<text top="106" left="1014" width="189" height="17" font="13">in 1% of the UF group and 12% of </text>
<text top="124" left="1014" width="140" height="17" font="13">diuretics group (p=0.018) </text>
<text top="55" left="1250" width="59" height="17" font="13">small trial; </text>
<text top="72" left="1250" width="60" height="17" font="13">usual care </text>
<text top="89" left="1250" width="55" height="17" font="13">group not </text>
<text top="106" left="1250" width="27" height="17" font="13">very </text>
<text top="124" left="1250" width="72" height="17" font="13">aggressively </text>
<text top="141" left="1250" width="42" height="17" font="13">treated </text>
<text top="55" left="1345" width="98" height="17" font="13">hemodynamically </text>
<text top="72" left="1345" width="96" height="17" font="13">stable/congested </text>
<text top="89" left="1345" width="64" height="17" font="13">HF pts that </text>
<text top="106" left="1345" width="99" height="17" font="13">respond very well </text>
<text top="124" left="1345" width="87" height="17" font="13">to diuretics and </text>
<text top="141" left="1345" width="65" height="17" font="13">have better </text>
<text top="158" left="1345" width="96" height="17" font="13">outcomes vs. HF </text>
<text top="175" left="1345" width="73" height="17" font="13">population in </text>
<text top="192" left="1345" width="51" height="17" font="13">general.  </text>
<text top="210" left="28" width="73" height="17" font="15"><b>Case-series </b></text>
<text top="228" left="28" width="38" height="17" font="13">(Mayo </text>
<text top="245" left="28" width="38" height="17" font="13">clinic), </text>
<text top="262" left="28" width="68" height="17" font="13">Liang, 2006 </text>
<text top="279" left="28" width="55" height="17" font="14">17174232</text>
<text top="279" left="83" width="3" height="17" font="13"> </text>
<text top="296" left="28" width="32" height="17" font="13">(162) </text>
<text top="210" left="116" width="110" height="17" font="13">Present data on UF </text>
<text top="228" left="116" width="108" height="17" font="13">from a series of pts </text>
<text top="245" left="116" width="109" height="17" font="13">treated at the Mayo </text>
<text top="262" left="116" width="87" height="17" font="13">clinic who were </text>
<text top="279" left="116" width="113" height="17" font="13">generally sicker and </text>
<text top="296" left="116" width="125" height="17" font="13">had failed at least 1 IV </text>
<text top="314" left="116" width="59" height="17" font="13">treatment  </text>
<text top="210" left="265" width="33" height="17" font="13">Case-</text>
<text top="228" left="265" width="36" height="17" font="13">series </text>
<text top="210" left="332" width="17" height="17" font="13">11 </text>
<text top="210" left="393" width="137" height="17" font="13">HF pts admitted to Mayo </text>
<text top="228" left="393" width="133" height="17" font="13">clinic who have failed at </text>
<text top="245" left="393" width="100" height="17" font="13">least 1 IV diuresis </text>
<text top="262" left="393" width="59" height="17" font="13">treatment  </text>
<text top="210" left="548" width="126" height="17" font="13">Contraindication to UF </text>
<text top="210" left="724" width="120" height="17" font="13">Change in creatinine; </text>
<text top="228" left="724" width="120" height="17" font="13">fluid loss;                    </text>
<text top="245" left="724" width="106" height="17" font="13">complications from </text>
<text top="262" left="724" width="20" height="17" font="13">UF </text>
<text top="210" left="859" width="24" height="17" font="13">N/A </text>
<text top="210" left="1014" width="229" height="17" font="13">5 pts had significant rise in creatinine,       </text>
<text top="228" left="1014" width="177" height="17" font="13">5 required dialysis, overall 6-mo </text>
<text top="245" left="1014" width="155" height="17" font="13">mortality 55%, bleeding and </text>
<text top="262" left="1014" width="213" height="17" font="13">complications related to positional flow </text>
<text top="279" left="1014" width="84" height="17" font="13">were common. </text>
<text top="210" left="1250" width="70" height="17" font="13">Small study; </text>
<text top="228" left="1250" width="35" height="17" font="13">single </text>
<text top="245" left="1250" width="79" height="17" font="13">institution; pts </text>
<text top="262" left="1250" width="59" height="17" font="13">with much </text>
<text top="279" left="1250" width="36" height="17" font="13">worse </text>
<text top="296" left="1250" width="72" height="17" font="13">prognosis vs </text>
<text top="314" left="1250" width="64" height="17" font="13">general HF </text>
<text top="331" left="1250" width="60" height="17" font="13">population </text>
<text top="210" left="1345" width="63" height="17" font="13">In high risk </text>
<text top="228" left="1345" width="108" height="17" font="13">populations, (mean </text>
<text top="245" left="1345" width="108" height="17" font="13">GFR of 38 mL/min) </text>
<text top="262" left="1345" width="105" height="17" font="13">UF may not be the </text>
<text top="279" left="1345" width="96" height="17" font="13">most appropriate </text>
<text top="296" left="1345" width="42" height="17" font="13">choice. </text>
<text top="349" left="28" width="75" height="17" font="15"><b>RAPID-CHF</b>, </text>
<text top="366" left="28" width="60" height="17" font="13">Bart, 2005 </text>
<text top="383" left="28" width="55" height="17" font="14">16325039</text>
<text top="383" left="83" width="3" height="17" font="13"> </text>
<text top="400" left="28" width="32" height="17" font="13">(163) </text>
<text top="349" left="116" width="95" height="17" font="13">Pilot study which </text>
<text top="366" left="116" width="125" height="17" font="13">compared a single 8-h </text>
<text top="383" left="116" width="133" height="17" font="13">UF intervention to usual </text>
<text top="400" left="116" width="111" height="17" font="13">care in pts admitted </text>
<text top="418" left="116" width="116" height="17" font="13">with decompensated </text>
<text top="435" left="116" width="20" height="17" font="13">HF </text>
<text top="349" left="265" width="29" height="17" font="13">RCT </text>
<text top="349" left="332" width="17" height="17" font="13">40 </text>
<text top="349" left="393" width="140" height="17" font="13">Hospitalized with primary </text>
<text top="366" left="393" width="135" height="17" font="13">diagnosis of HF; at least </text>
<text top="383" left="393" width="126" height="17" font="13">2+ edema of the lower </text>
<text top="400" left="393" width="130" height="17" font="13">extremities and at least </text>
<text top="418" left="393" width="88" height="17" font="13">either JVP &gt;10, </text>
<text top="435" left="393" width="116" height="17" font="13">pulmonary edema or </text>
<text top="452" left="393" width="137" height="17" font="13">pleural effusion on CXR, </text>
<text top="469" left="393" width="94" height="17" font="13">pulmonary rales, </text>
<text top="487" left="393" width="115" height="17" font="13">pulmonary wedge or </text>
<text top="504" left="393" width="131" height="17" font="13">LVEDP &gt;20, ascites, or </text>
<text top="521" left="393" width="99" height="17" font="13">pre-sacral edema </text>
<text top="349" left="548" width="134" height="17" font="13">Severe stenotic valvular </text>
<text top="366" left="548" width="168" height="17" font="13">disease; ACS; SBP &lt;90;          </text>
<text top="383" left="548" width="168" height="17" font="13">hematocrit &gt;40%                      </text>
<text top="400" left="548" width="143" height="17" font="13">5. poor peripheral venous </text>
<text top="418" left="548" width="125" height="17" font="13">access; hemodynamic </text>
<text top="435" left="548" width="148" height="17" font="13">instability; use of iodinated </text>
<text top="452" left="548" width="150" height="17" font="13">radiocontrast within 72 h of </text>
<text top="469" left="548" width="154" height="17" font="13">consent or anticipated use;  </text>
<text top="487" left="548" width="156" height="17" font="13">severe concomitant disease </text>
<text top="349" left="724" width="270" height="17" font="13">24-h weight loss             Total volume removal at </text>
<text top="366" left="859" width="128" height="17" font="13">24 and 48 h; global HF </text>
<text top="383" left="859" width="74" height="17" font="13">and dyspnea </text>
<text top="400" left="859" width="116" height="17" font="13">assessments; serum </text>
<text top="418" left="859" width="130" height="17" font="13">electrolytes; and length </text>
<text top="435" left="859" width="85" height="17" font="13">of hospital stay </text>
<text top="349" left="1014" width="182" height="17" font="13">No difference in 24-h weight loss </text>
<text top="366" left="1014" width="184" height="17" font="13">(p=0.240), significantly more fluid </text>
<text top="383" left="1014" width="219" height="17" font="13">removal with UF (4,650 mL in UF group </text>
<text top="400" left="1014" width="185" height="17" font="13">vs. 2,838 mL in usual care group, </text>
<text top="418" left="1014" width="184" height="17" font="13">(p=0.001) and improved dyspnea </text>
<text top="435" left="1014" width="194" height="17" font="13">scores (p=0.039) and no change in </text>
<text top="452" left="1014" width="221" height="17" font="13">creatinine.  Trend toward greater weight </text>
<text top="469" left="1014" width="155" height="17" font="13">loss at 24 h in the UF group </text>
<text top="349" left="1250" width="70" height="17" font="13">Small study, </text>
<text top="366" left="1250" width="26" height="17" font="13">pilot </text>
<text top="349" left="1345" width="79" height="17" font="13">UF group had </text>
<text top="366" left="1345" width="57" height="17" font="13">more fluid </text>
<text top="383" left="1345" width="97" height="17" font="13">removed, with no </text>
<text top="400" left="1345" width="102" height="17" font="13">significant change </text>
<text top="418" left="1345" width="73" height="17" font="13">in creatinine, </text>
<text top="435" left="1345" width="67" height="17" font="13">however no </text>
<text top="452" left="1345" width="98" height="17" font="13">difference in 24 h </text>
<text top="469" left="1345" width="68" height="17" font="13">weight loss. </text>
<text top="541" left="28" width="72" height="17" font="15"><b>EUPHORIA</b>, </text>
<text top="558" left="28" width="59" height="17" font="13">Costanzo, </text>
<text top="575" left="28" width="31" height="17" font="13">2005 </text>
<text top="592" left="28" width="55" height="17" font="14">16325040</text>
<text top="592" left="83" width="3" height="17" font="13"> </text>
<text top="610" left="28" width="32" height="17" font="13">(164) </text>
<text top="627" left="28" width="3" height="17" font="13"> </text>
<text top="541" left="116" width="94" height="17" font="13">Compared UF to </text>
<text top="558" left="116" width="112" height="17" font="13">historical controls in </text>
<text top="575" left="116" width="113" height="17" font="13">order to determine if </text>
<text top="592" left="116" width="133" height="17" font="13">use of UF before any IV </text>
<text top="610" left="116" width="107" height="17" font="13">diuretics in pts with </text>
<text top="627" left="116" width="135" height="17" font="13">decompensated HF and </text>
<text top="644" left="116" width="75" height="17" font="13">modest renal </text>
<text top="661" left="116" width="66" height="17" font="13">dysfunction </text>
<text top="678" left="116" width="135" height="17" font="13">reestablishes euvolemia </text>
<text top="696" left="116" width="113" height="17" font="13">and permits hospital </text>
<text top="713" left="116" width="102" height="17" font="13">discharge in ≤3 d, </text>
<text top="730" left="116" width="126" height="17" font="13">without hypotension, a </text>
<text top="747" left="116" width="127" height="17" font="13">≥25% increase in SCr. </text>
<text top="765" left="116" width="75" height="17" font="13">or other AEs. </text>
<text top="541" left="265" width="50" height="17" font="13">Observat</text>
<text top="558" left="265" width="29" height="17" font="13">ional </text>
<text top="575" left="265" width="33" height="17" font="13">study </text>
<text top="541" left="332" width="150" height="17" font="13">20 Volume </text>
<text top="541" left="438" width="98" height="17" font="13">overload; </text>
<text top="558" left="393" width="130" height="17" font="13">modest degree of renal </text>
<text top="575" left="393" width="123" height="17" font="13">dysfunction or diuretic </text>
<text top="592" left="393" width="135" height="17" font="13">resistance (chronic daily </text>
<text top="610" left="393" width="135" height="17" font="13">PO furosemide ≥80 mg, </text>
<text top="627" left="393" width="135" height="17" font="13">or torsemide ≥ 40mg, or </text>
<text top="644" left="393" width="134" height="17" font="13">bumetamide ≥ 2mg and </text>
<text top="661" left="393" width="94" height="17" font="13">SCr ≥1.5 mg/dl), </text>
<text top="678" left="393" width="122" height="17" font="13">relatively high diuretic </text>
<text top="696" left="393" width="135" height="17" font="13">requirement at baseline; </text>
<text top="713" left="393" width="67" height="17" font="13">&lt;12 h since </text>
<text top="730" left="393" width="135" height="17" font="13">hospitalization, given no </text>
<text top="747" left="393" width="137" height="17" font="13">vasoactive drugs and &lt;1 </text>
<text top="765" left="393" width="88" height="17" font="13">dose IV diuretic </text>
<text top="541" left="548" width="130" height="17" font="13">Hematocrit &gt;40%;. end-</text>
<text top="558" left="548" width="161" height="17" font="13">stage renal disease requiring </text>
<text top="575" left="548" width="161" height="17" font="13">dialysis;  Hypercoagulability;  </text>
<text top="592" left="548" width="99" height="17" font="13">SBP &lt;85 mm Hg; </text>
<text top="610" left="548" width="107" height="17" font="13">Requirement for IV </text>
<text top="627" left="548" width="145" height="17" font="13">inotropes;  Participation in </text>
<text top="644" left="548" width="144" height="17" font="13">another research study or </text>
<text top="661" left="548" width="118" height="17" font="13">previously in this trial </text>
<text top="541" left="724" width="120" height="17" font="13">Weight loss;  hospital </text>
<text top="558" left="724" width="128" height="17" font="13">length of stay                </text>
<text top="541" left="859" width="120" height="17" font="13">Increase in creatinine </text>
<text top="558" left="859" width="140" height="17" font="13">&gt;25%, hypotension; BNP </text>
<text top="575" left="859" width="38" height="17" font="13">levels  </text>
<text top="541" left="1014" width="211" height="17" font="13">An average of 8,367 ± 4,232 mL were </text>
<text top="558" left="1014" width="223" height="17" font="13">removed with 2.6 ± 1.2, 8 h UF courses. </text>
<text top="575" left="1014" width="221" height="17" font="13">Of the 19 pts 12 (68%) were discharged </text>
<text top="592" left="1014" width="42" height="17" font="13">in ≤3 d </text>
<text top="541" left="1250" width="34" height="17" font="13">Small </text>
<text top="558" left="1250" width="76" height="17" font="13">observational </text>
<text top="575" left="1250" width="74" height="17" font="13">study; Single-</text>
<text top="592" left="1250" width="77" height="17" font="13">center series  </text>
<text top="541" left="1345" width="106" height="17" font="13">Concluded that UF </text>
<text top="558" left="1345" width="97" height="17" font="13">decreases length </text>
<text top="575" left="1345" width="64" height="17" font="13">of stay and </text>
<text top="592" left="1345" width="83" height="17" font="13">readmissions.  </text>
<text top="610" left="1345" width="79" height="17" font="13">compared the </text>
<text top="627" left="1345" width="93" height="17" font="13">treatment period </text>
<text top="644" left="1345" width="68" height="17" font="13">with the pre-</text>
<text top="661" left="1345" width="96" height="17" font="13">treatment period, </text>
<text top="678" left="1345" width="98" height="17" font="13">rather than with a </text>
<text top="696" left="1345" width="108" height="17" font="13">randomized control </text>
<text top="713" left="1345" width="44" height="17" font="13">cohort.  </text>
</page>
<page number="75" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">75</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="55" height="17" font="13">Agostoni, </text>
<text top="72" left="28" width="31" height="17" font="13">1994 </text>
<text top="89" left="28" width="48" height="17" font="14">8154506</text>
<text top="89" left="76" width="3" height="17" font="13"> </text>
<text top="106" left="28" width="32" height="17" font="13">(165) </text>
<text top="55" left="116" width="90" height="17" font="13">Investigated the </text>
<text top="72" left="116" width="134" height="17" font="13">mechanisms involved in </text>
<text top="89" left="116" width="114" height="17" font="13">the regulation of salt </text>
<text top="106" left="116" width="124" height="17" font="13">and water metabolism </text>
<text top="124" left="116" width="75" height="17" font="13">in pt with HF. </text>
<text top="141" left="116" width="129" height="17" font="13">Extracorporeal UF was </text>
<text top="158" left="116" width="68" height="17" font="13">utilized as a </text>
<text top="175" left="116" width="104" height="17" font="13">nonpharmacologic </text>
<text top="192" left="116" width="124" height="17" font="13">method for withdrawal </text>
<text top="210" left="116" width="77" height="17" font="13">of body fluid.  </text>
<text top="55" left="265" width="29" height="17" font="13">RCT </text>
<text top="55" left="332" width="17" height="17" font="13">16 </text>
<text top="55" left="393" width="81" height="17" font="13">Treated with a </text>
<text top="72" left="393" width="83" height="17" font="13">combination of </text>
<text top="89" left="393" width="137" height="17" font="13">digoxin, oral furosemide, </text>
<text top="106" left="393" width="99" height="17" font="13">and ACE inhibitor </text>
<text top="124" left="393" width="54" height="17" font="13">(captopril </text>
<text top="141" left="393" width="150" height="17" font="13">or enalapril) for chronic;      </text>
<text top="158" left="393" width="139" height="17" font="13">sinus rhythm; NYHA II-III </text>
<text top="55" left="548" width="136" height="17" font="13">Pts with acute MI (&lt;1 y), </text>
<text top="72" left="548" width="135" height="17" font="13">angina pectoris, primary </text>
<text top="89" left="548" width="159" height="17" font="13">valvular disease, intermittent </text>
<text top="106" left="548" width="126" height="17" font="13">claudication, fibrotic or </text>
<text top="124" left="548" width="120" height="17" font="13">primary vascular lung </text>
<text top="141" left="548" width="102" height="17" font="13">diseases, sinus or </text>
<text top="158" left="548" width="115" height="17" font="13">atrioventricular node </text>
<text top="175" left="548" width="148" height="17" font="13">dysfunction, effort-induced </text>
<text top="192" left="548" width="101" height="17" font="13">severe ventricular </text>
<text top="210" left="548" width="144" height="17" font="13">arrhythmias or an artificial </text>
<text top="227" left="548" width="64" height="17" font="13">pacemaker </text>
<text top="55" left="724" width="119" height="17" font="13">Scores of lung water; </text>
<text top="72" left="724" width="72" height="17" font="13">exercise test </text>
<text top="89" left="724" width="116" height="17" font="13">parameters;  plasma </text>
<text top="106" left="724" width="102" height="17" font="13">renin, aldosterone </text>
<text top="124" left="724" width="109" height="17" font="13">and norepinephrine </text>
<text top="55" left="859" width="7" height="17" font="13">  </text>
<text top="55" left="1014" width="175" height="17" font="13">3 mo after UF or IV diuretic, the </text>
<text top="72" left="1014" width="203" height="17" font="13">hemodynamic variables examined at </text>
<text top="89" left="1014" width="211" height="17" font="13">rest had returned to the control values </text>
<text top="106" left="1014" width="196" height="17" font="13">in the diuretic group, but not the UF </text>
<text top="124" left="1014" width="188" height="17" font="13">group. In the UF group, right atrial </text>
<text top="141" left="1014" width="202" height="17" font="13">pressure, pulmonary artery pressure </text>
<text top="158" left="1014" width="183" height="17" font="13">and wedge pressure were still as </text>
<text top="175" left="1014" width="201" height="17" font="13">reduced as they had been 24 h after </text>
<text top="192" left="1014" width="208" height="17" font="13">UF. (p&lt;0.01, only figures displayed).   </text>
<text top="55" left="1250" width="65" height="17" font="13">Small older </text>
<text top="72" left="1250" width="33" height="17" font="13">study </text>
<text top="55" left="1345" width="107" height="17" font="13">After UF, improved </text>
<text top="72" left="1345" width="105" height="17" font="13">functional capacity </text>
<text top="89" left="1345" width="105" height="17" font="13">continued for 3 mo </text>
<text top="106" left="1345" width="107" height="17" font="13">after the procedure </text>
<text top="245" left="28" width="62" height="17" font="13">Pepi, 1993 </text>
<text top="262" left="28" width="48" height="17" font="14">8038023</text>
<text top="262" left="76" width="3" height="17" font="13"> </text>
<text top="279" left="28" width="32" height="17" font="13">(166) </text>
<text top="245" left="116" width="101" height="17" font="13">To investigate the </text>
<text top="262" left="116" width="105" height="17" font="13">pathophysiological </text>
<text top="279" left="116" width="118" height="17" font="13">(cardiac function and </text>
<text top="296" left="116" width="124" height="17" font="13">physical performance) </text>
<text top="314" left="116" width="130" height="17" font="13">significance of clinically </text>
<text top="331" left="116" width="114" height="17" font="13">silent interstitial lung </text>
<text top="348" left="116" width="122" height="17" font="13">water accumulation in </text>
<text top="365" left="116" width="124" height="17" font="13">pts with moderate HF; </text>
<text top="382" left="116" width="129" height="17" font="13">to use isolated UF as a </text>
<text top="400" left="116" width="131" height="17" font="13">means of extravascular </text>
<text top="417" left="116" width="98" height="17" font="13">fluid reabsorption </text>
<text top="245" left="265" width="29" height="17" font="13">RCT </text>
<text top="245" left="332" width="17" height="17" font="13">24 </text>
<text top="245" left="393" width="136" height="17" font="13">NYHA functional class II-</text>
<text top="262" left="393" width="139" height="17" font="13">III HF and clinically silent </text>
<text top="279" left="393" width="134" height="17" font="13">by radiologically evident </text>
<text top="296" left="393" width="148" height="17" font="13">increased lung water;         </text>
<text top="314" left="393" width="116" height="17" font="13">sinus rhythm and EF </text>
<text top="331" left="393" width="35" height="17" font="13">&lt;35% </text>
<text top="245" left="548" width="139" height="17" font="13">Severe tricuspid or mitral </text>
<text top="262" left="548" width="119" height="17" font="13">regurgitation; pleural, </text>
<text top="279" left="548" width="135" height="17" font="13">pericardial or abdominal </text>
<text top="296" left="548" width="67" height="17" font="13">effusion       </text>
<text top="245" left="724" width="66" height="17" font="13">LVSF (from </text>
<text top="262" left="724" width="99" height="17" font="13">ultrasonography); </text>
<text top="279" left="724" width="120" height="17" font="13">Doppler evaluation of </text>
<text top="296" left="724" width="113" height="17" font="13">mitral, tricuspid, and </text>
<text top="314" left="724" width="113" height="17" font="13">aortic flow and echo-</text>
<text top="331" left="724" width="47" height="17" font="13">Doppler </text>
<text top="348" left="724" width="92" height="17" font="13">determination of </text>
<text top="365" left="724" width="84" height="17" font="13">cardiac output; </text>
<text top="382" left="724" width="113" height="17" font="13">radiological score of </text>
<text top="400" left="724" width="103" height="17" font="13">extravascular lung </text>
<text top="417" left="724" width="99" height="17" font="13">water; R/LV filling </text>
<text top="434" left="724" width="104" height="17" font="13">pressures; oxygen </text>
<text top="451" left="724" width="117" height="17" font="13">consumption at peak </text>
<text top="469" left="724" width="73" height="17" font="13">exercise and </text>
<text top="486" left="724" width="103" height="17" font="13">exercise tolerance </text>
<text top="503" left="724" width="40" height="17" font="13">time in </text>
<text top="520" left="724" width="94" height="17" font="13">cardiopulmonary </text>
<text top="537" left="724" width="36" height="17" font="13">tests.  </text>
<text top="245" left="859" width="7" height="17" font="13">  </text>
<text top="245" left="1014" width="193" height="17" font="13">UF decreased radiological score of </text>
<text top="262" left="1014" width="202" height="17" font="13">extravascular lung water (from 15(1)-</text>
<text top="279" left="1014" width="197" height="17" font="13">9(1)) and of right (from 7.1 (2.3)-2.3 </text>
<text top="296" left="1014" width="208" height="17" font="13">(1.7) mm Hg) and left (from 17.6 (8.8)-</text>
<text top="314" left="1014" width="188" height="17" font="13">9.5 (6.4) mm Hg) ventricular filling </text>
<text top="331" left="1014" width="184" height="17" font="13">pressures; an increase in oxygen </text>
<text top="348" left="1014" width="198" height="17" font="13">consumption at peak exercise (from </text>
<text top="365" left="1014" width="217" height="17" font="13">15.8 (3.3) to 17.6 (2) mL/min/kg) and of </text>
<text top="382" left="1014" width="206" height="17" font="13">tolerance time (from 444 (138) to 508 </text>
<text top="400" left="1014" width="170" height="17" font="13">(134) s); decrease in atrial and </text>
<text top="417" left="1014" width="209" height="17" font="13">ventricular dimensions; no changes in </text>
<text top="434" left="1014" width="218" height="17" font="13">the systolic function of the left ventricle; </text>
<text top="451" left="1014" width="197" height="17" font="13">a reduction of the early to late filling </text>
<text top="469" left="1014" width="221" height="17" font="13">ratio in both ventricles (mitral valve from </text>
<text top="486" left="1014" width="213" height="17" font="13">2 (2) to 1.1 (1.1)); (tricuspid valve from </text>
<text top="503" left="1014" width="221" height="17" font="13">1.3 (1.3) to 0.69 (0.18)) and an increase </text>
<text top="520" left="1014" width="202" height="17" font="13">in the deceleration time of mitral and </text>
<text top="537" left="1014" width="215" height="17" font="13">tricuspid flow, reflecting a redistribution </text>
<text top="555" left="1014" width="223" height="17" font="13">of filling to late diastole. Variations in the </text>
<text top="572" left="1014" width="197" height="17" font="13">ventricular filling pattern, lung water </text>
<text top="589" left="1014" width="200" height="17" font="13">content, and functional performance </text>
<text top="606" left="1014" width="213" height="17" font="13">persisted for 3mo in all cases. None of </text>
<text top="624" left="1014" width="193" height="17" font="13">these changes was detected in the </text>
<text top="641" left="1014" width="82" height="17" font="13">control group.  </text>
<text top="245" left="1250" width="65" height="17" font="13">Small older </text>
<text top="262" left="1250" width="72" height="17" font="13">study; single </text>
<text top="279" left="1250" width="55" height="17" font="13">institution </text>
<text top="245" left="1345" width="106" height="17" font="13">Pathophysiological </text>
<text top="262" left="1345" width="104" height="17" font="13">study involving UF </text>
<text top="279" left="1345" width="104" height="17" font="13">and hemodynamic </text>
<text top="296" left="1345" width="64" height="17" font="13">outcomes.  </text>
<text top="659" left="28" width="55" height="17" font="13">Agostoni, </text>
<text top="676" left="28" width="31" height="17" font="13">1993 </text>
<text top="693" left="28" width="51" height="17" font="14">8426008 </text>
<text top="710" left="28" width="32" height="17" font="13">(167) </text>
<text top="659" left="116" width="117" height="17" font="13">The aim of this study </text>
<text top="676" left="116" width="89" height="17" font="13">was to evaluate </text>
<text top="693" left="116" width="135" height="17" font="13">whether UF is beneficial </text>
<text top="710" left="116" width="114" height="17" font="13">in pts with moderate </text>
<text top="727" left="116" width="86" height="17" font="13">congestive HF. </text>
<text top="659" left="265" width="29" height="17" font="13">RCT </text>
<text top="659" left="332" width="17" height="17" font="13">36 </text>
<text top="659" left="393" width="138" height="17" font="13">NYHA functional classes </text>
<text top="676" left="393" width="128" height="17" font="13">II and III; stable clinical </text>
<text top="693" left="393" width="137" height="17" font="13">condition; receiving drug </text>
<text top="710" left="393" width="123" height="17" font="13">treatment (stable over </text>
<text top="727" left="393" width="127" height="17" font="13">last 6 mo) optimized to </text>
<text top="745" left="393" width="132" height="17" font="13">prevent development of </text>
<text top="762" left="393" width="125" height="17" font="13">edema and maintain a </text>
<text top="779" left="393" width="138" height="17" font="13">stable body weight (+/- 1 </text>
<text top="659" left="548" width="136" height="17" font="13">Pts with acute MI (&lt;1 y), </text>
<text top="676" left="548" width="135" height="17" font="13">angina pectoris, primary </text>
<text top="693" left="548" width="159" height="17" font="13">valvular disease, intermittent </text>
<text top="710" left="548" width="126" height="17" font="13">claudication, fibrotic or </text>
<text top="727" left="548" width="120" height="17" font="13">primary vascular lung </text>
<text top="745" left="548" width="102" height="17" font="13">diseases, sinus or </text>
<text top="762" left="548" width="115" height="17" font="13">atrioventricular node </text>
<text top="779" left="548" width="148" height="17" font="13">dysfunction, effort-induced </text>
<text top="659" left="724" width="60" height="17" font="13">Functional </text>
<text top="676" left="724" width="98" height="17" font="13">performance was </text>
<text top="693" left="724" width="81" height="17" font="13">assessed with </text>
<text top="710" left="724" width="94" height="17" font="13">cardiopulmonary </text>
<text top="727" left="724" width="96" height="17" font="13">exercise tests      </text>
<text top="659" left="859" width="130" height="17" font="13">Plasma norepinephrine </text>
<text top="676" left="859" width="35" height="17" font="13">levels </text>
<text top="659" left="1014" width="215" height="17" font="13">Significant reductions in UF group right </text>
<text top="676" left="1014" width="206" height="17" font="13">atrial pressure (from 8 ± 1 - 3.4 ± 0.7 </text>
<text top="693" left="1014" width="198" height="17" font="13">mm Hg, pulmonary wedge pressure </text>
<text top="710" left="1014" width="209" height="17" font="13">(from 18 ± 2.5 - 10 ± 1.9 mm Hg) and </text>
<text top="727" left="1014" width="214" height="17" font="13">cardiac index (from 2.8 ± 0.2 -2.3± 0.2 </text>
<text top="745" left="1014" width="198" height="17" font="13">L/min).  During the follow-up period, </text>
<text top="762" left="1014" width="207" height="17" font="13">lung function improved, extravascular </text>
<text top="779" left="1014" width="219" height="17" font="13">lung water (X-ray score) decreased and </text>
<text top="659" left="1250" width="65" height="17" font="13">Small older </text>
<text top="676" left="1250" width="40" height="17" font="13">study   </text>
<text top="659" left="1345" width="106" height="17" font="13">Pathophysiological </text>
<text top="676" left="1345" width="104" height="17" font="13">study involving UF </text>
<text top="693" left="1345" width="104" height="17" font="13">and hemodynamic </text>
<text top="710" left="1345" width="64" height="17" font="13">outcomes.  </text>
</page>
<page number="76" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">76</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="393" width="148" height="17" font="13">kg in last 6 mo);                  </text>
<text top="72" left="393" width="135" height="17" font="13">therapeutic digoxin level </text>
<text top="89" left="393" width="77" height="17" font="13">(if on digoxin) </text>
<text top="55" left="548" width="101" height="17" font="13">severe ventricular </text>
<text top="72" left="548" width="144" height="17" font="13">arrhythmias or an artificial </text>
<text top="89" left="548" width="64" height="17" font="13">pacemaker </text>
<text top="55" left="1014" width="215" height="17" font="13">peak oxygen consumption (mL/min per </text>
<text top="72" left="1014" width="201" height="17" font="13">kg) increased from 15.5 ± 1 (d -1) to </text>
<text top="89" left="1014" width="214" height="17" font="13">17.6 ± 0.9 (d 4), to 17.8 ±0.9 (d 30), to </text>
<text top="106" left="1014" width="211" height="17" font="13">18.9 ±1 (d 90) and to 19.1 ±1 (d 180). </text>
<text top="124" left="1014" width="190" height="17" font="13">Oxygen consumption at anaerobic </text>
<text top="141" left="1014" width="170" height="17" font="13">threshold (mL/min per kg) also </text>
<text top="158" left="1014" width="204" height="17" font="13">increased from 11.6 ±0.8 (d -1) to 13 </text>
<text top="175" left="1014" width="214" height="17" font="13">±0.7 (d 4), to 13.7 ± 0.5 (d 30), to 15.5 </text>
<text top="192" left="1014" width="211" height="17" font="13">± 0.8 (d 90) and to 15.2 ± 0.8 (d 180). </text>
<text top="210" left="1014" width="205" height="17" font="13">These changes were associated with </text>
<text top="227" left="1014" width="212" height="17" font="13">increased ventilation, tidal volume and </text>
<text top="244" left="1014" width="207" height="17" font="13">dead space/tidal volume ratio at peak </text>
<text top="261" left="1014" width="190" height="17" font="13">exercise. Improvement in exercise </text>
<text top="278" left="1014" width="196" height="17" font="13">performance was associated with a </text>
<text top="296" left="1014" width="204" height="17" font="13">decrease in norepinephrine at rest, a </text>
<text top="313" left="1014" width="185" height="17" font="13">downward shift of norepinephrine </text>
<text top="330" left="1014" width="217" height="17" font="13">kinetics at submaximal exercise and an </text>
<text top="347" left="1014" width="186" height="17" font="13">increase in norepinephrine during </text>
<text top="365" left="1014" width="209" height="17" font="13">orthostatic tilt. None of these changes </text>
<text top="382" left="1014" width="145" height="17" font="13">were recorded in group B. </text>
<text top="400" left="22" width="880" height="17" font="13">ACS indicates acute coronary syndrome; ADHERE, Acute Decompensated Heart Failure National Registry; AE, adverse event; AUC, area under the curve; BNP, </text>
<text top="400" left="902" width="545" height="17" font="23">B-Type natriuretic peptide; BUN, blood urea nitrogen; CHD, chronic heart disease; CHF, congestive </text>
<text top="417" left="22" width="1143" height="17" font="23">heart failure; CrCl, creatinine clearance; CV, cardiovascular; DAD-HF, Dopamine in Acute Decompensated Heart Failure; DBP, diastolic blood pressure; DIG, Digitalis Investigation Group; DM, diabetes mellitus; </text>
<text top="417" left="1165" width="258" height="17" font="13">ED, emergency department; eGFR, glomerular </text>
<text top="434" left="22" width="1427" height="17" font="13">filtration rate; EUPHORIA, Early Ultrafiltration Therapy in Patients with Decompensated Heart Failure and Observed Resistance to Intervention with Diuretic Agents; EVEREST, Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan; </text>
<text top="451" left="22" width="1422" height="17" font="13">HDD, high dose diuretics; HF, heart failure; Hgb, hemoglobin; HTN, hypertension; ICU, intensive care unit; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LDD, low dose diuretics; LDFD, low-dose furosemide; LOS, length of stay; LVEF, left </text>
<text top="469" left="22" width="669" height="17" font="13">ventricular ejection fraction; MCS, mechanical cardiac support; N/A, not applicable; NPSD, nonpotassium-sparing diuretics;</text>
<text top="469" left="690" width="737" height="17" font="23"> NT-pBNP, N-terminal pro-B-Type natriuretic peptide; PO, per oral;  PRAISE, Prospective Randomized Amlodipine Survival Evaluation; </text>
<text top="486" left="22" width="1369" height="17" font="23">PROTECT, Placebo-controlled Randomized study of the selective A(1) adenosine receptor antagonist rolofylline for patients hospitalized with acute heart failure and volume Overload to assess Treatment Effect on Congestion and renal function; PTCA, </text>
<text top="503" left="22" width="1431" height="17" font="23">percutaneous transluminal coronary angioplasty; PSD, potassium-sparing diuretics; pts, patients; RAPID-HF, Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure; RCT, randomized control trial; SBP, systolic blood pressure; </text>
<text top="520" left="22" width="618" height="17" font="23">SCD, sudden cardiac death; SCr, serum creatinine; SOLVD, Studies of left ventricular dysfunction; Tx, treatment; </text>
<text top="520" left="640" width="814" height="17" font="13">UF, ultrafiltration; UNLOAD, Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure; VAS, visual </text>
<text top="537" left="22" width="463" height="17" font="13">analog scale, WMD, weighted mean difference; and WRF, worsening renal function.  </text>
<text top="558" left="54" width="4" height="16" font="9"><b> </b></text>
<text top="593" left="27" width="372" height="21" font="8"><b>Data Supplement 18. ACE Inhibitors (Section 7.3.2.2) </b></text>
<text top="614" left="27" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="631" left="27" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="614" left="128" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="614" left="234" width="70" height="17" font="15"><b>Study Type </b></text>
<text top="614" left="339" width="75" height="17" font="15"><b>Background </b></text>
<text top="631" left="351" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="614" left="458" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="614" left="576" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="614" left="709" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="614" left="942" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="614" left="1095" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="614" left="1188" width="29" height="17" font="15"><b>Trial </b></text>
<text top="631" left="1176" width="54" height="17" font="15"><b>Duration </b></text>
<text top="649" left="1181" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="614" left="1246" width="56" height="17" font="15"><b>Absolute </b></text>
<text top="631" left="1252" width="45" height="17" font="15"><b>Benefit </b></text>
<text top="614" left="1331" width="115" height="17" font="15"><b>P Values &amp; 95% CI: </b></text>
<text top="667" left="62" width="7" height="17" font="13">  </text>
<text top="667" left="164" width="7" height="17" font="13">  </text>
<text top="667" left="265" width="7" height="17" font="13">  </text>
<text top="667" left="351" width="50" height="17" font="21"><i><b>Pre-trial </b></i></text>
<text top="684" left="349" width="55" height="17" font="21"><i><b>standard </b></i></text>
<text top="701" left="345" width="63" height="17" font="21"><i><b>treatment. </b></i></text>
<text top="667" left="464" width="53" height="17" font="21"><i><b>N (Total) </b></i></text>
<text top="684" left="441" width="100" height="17" font="21"><i><b>n (Experimental) </b></i></text>
<text top="701" left="458" width="66" height="17" font="21"><i><b>n (Control) </b></i></text>
<text top="667" left="573" width="84" height="17" font="21"><i><b>Ischemic/        </b></i></text>
<text top="684" left="560" width="84" height="17" font="21"><i><b>Non-Ischemic </b></i></text>
<text top="667" left="682" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="684" left="687" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="667" left="788" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="684" left="795" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="667" left="892" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="684" left="888" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="667" left="984" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="684" left="989" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="667" left="1097" width="51" height="17" font="21"><i><b>1st Year </b></i></text>
<text top="684" left="1095" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="667" left="1200" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="667" left="1271" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="667" left="1385" width="7" height="17" font="13">  </text>
</page>
<page number="77" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">77</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="81" height="17" font="13">CONSENSUS </text>
<text top="71" left="22" width="34" height="17" font="13">1987  </text>
<text top="88" left="22" width="51" height="17" font="14">2883575 </text>
<text top="88" left="73" width="32" height="17" font="13">(168) </text>
<text top="106" left="22" width="3" height="17" font="13"> </text>
<text top="54" left="123" width="69" height="17" font="13">To Evaluate </text>
<text top="71" left="123" width="66" height="17" font="13">influence of </text>
<text top="88" left="123" width="67" height="17" font="13">enalapril on </text>
<text top="106" left="123" width="70" height="17" font="13">prognosis of </text>
<text top="123" left="123" width="83" height="17" font="13">NYHA class lV </text>
<text top="140" left="123" width="20" height="17" font="13">HF </text>
<text top="54" left="225" width="224" height="17" font="13">RCT Diuretics </text>
<text top="71" left="325" width="87" height="17" font="13">(spironolactone </text>
<text top="88" left="325" width="96" height="17" font="13">53%, mean dose </text>
<text top="106" left="325" width="86" height="17" font="13">80mg), digitalis </text>
<text top="123" left="325" width="71" height="17" font="13">(93%), other </text>
<text top="140" left="325" width="72" height="17" font="13">vasodilators, </text>
<text top="157" left="325" width="89" height="17" font="13">except ACEI (ie </text>
<text top="174" left="325" width="76" height="17" font="13">nitrates 46%) </text>
<text top="54" left="440" width="75" height="17" font="13">253; 127;126 </text>
<text top="71" left="440" width="3" height="17" font="13"> </text>
<text top="54" left="555" width="57" height="17" font="13">CAD 73% </text>
<text top="54" left="663" width="42" height="17" font="13">Severe </text>
<text top="71" left="663" width="93" height="17" font="13">HF/symptoms at </text>
<text top="88" left="663" width="93" height="17" font="13">rest/NYHA class </text>
<text top="106" left="663" width="18" height="17" font="13">lV; </text>
<text top="123" left="663" width="89" height="17" font="13">Increased heart </text>
<text top="140" left="663" width="76" height="17" font="13">size &gt;600 ml; </text>
<text top="157" left="663" width="71" height="17" font="13">BP:  120/75; </text>
<text top="174" left="663" width="71" height="17" font="13">HR:  80;  AF </text>
<text top="192" left="663" width="28" height="17" font="13">50% </text>
<text top="54" left="771" width="31" height="17" font="13">APE; </text>
<text top="71" left="771" width="89" height="17" font="13">hemodynamicall</text>
<text top="88" left="771" width="47" height="17" font="13">y import </text>
<text top="106" left="771" width="55" height="17" font="13">aortic/MV </text>
<text top="123" left="771" width="52" height="17" font="13">stenosis; </text>
<text top="140" left="771" width="81" height="17" font="13">MI w/in prior 2 </text>
<text top="157" left="771" width="21" height="17" font="13">mo </text>
<text top="174" left="771" width="52" height="17" font="13">Unstable </text>
<text top="192" left="771" width="91" height="17" font="13">angina; planned </text>
<text top="209" left="771" width="91" height="17" font="13">cardiac surgery; </text>
<text top="226" left="771" width="81" height="17" font="13">right HF b/c of </text>
<text top="243" left="771" width="79" height="17" font="13">pulm disease; </text>
<text top="261" left="771" width="84" height="17" font="13">Cr&gt;300 umol/L </text>
<text top="54" left="879" width="50" height="17" font="13">Mortality </text>
<text top="54" left="967" width="98" height="17" font="13">Change in NYHA-</text>
<text top="71" left="967" width="87" height="17" font="13">FC, LV size, Cr </text>
<text top="88" left="967" width="29" height="17" font="13">level </text>
<text top="54" left="1081" width="74" height="17" font="13">52% placebo </text>
<text top="71" left="1081" width="59" height="17" font="13">group and </text>
<text top="88" left="1081" width="78" height="17" font="13">36% enalapril </text>
<text top="106" left="1081" width="73" height="17" font="13">group  (6 mo </text>
<text top="123" left="1081" width="57" height="17" font="13">mortality:  </text>
<text top="140" left="1081" width="41" height="17" font="13">26% in </text>
<text top="157" left="1081" width="78" height="17" font="13">enalpril group </text>
<text top="174" left="1081" width="65" height="17" font="13">and 44% in </text>
<text top="192" left="1081" width="46" height="17" font="13">placebo </text>
<text top="209" left="1081" width="39" height="17" font="13">group) </text>
<text top="54" left="1176" width="37" height="17" font="13">0.51 y </text>
<text top="54" left="1243" width="27" height="17" font="13"> N/A </text>
<text top="54" left="1318" width="138" height="17" font="13">Crude mortality at end of </text>
<text top="71" left="1318" width="137" height="17" font="13">6 mo (primary endpoint), </text>
<text top="88" left="1318" width="126" height="17" font="13">26% in enalapril group </text>
<text top="106" left="1318" width="112" height="17" font="13">and 44% in placebo </text>
<text top="123" left="1318" width="140" height="17" font="13">group—40% reduction (p </text>
<text top="140" left="1318" width="49" height="17" font="13">=0.002). </text>
<text top="157" left="1318" width="139" height="17" font="13">Mortality was reduced by </text>
<text top="174" left="1318" width="118" height="17" font="13">31% at 1 y (p=0.001) </text>
<text top="283" left="22" width="60" height="17" font="13">10 y FU of </text>
<text top="301" left="22" width="81" height="17" font="13">CONSENSUS </text>
<text top="318" left="22" width="34" height="17" font="13">1999  </text>
<text top="335" left="22" width="55" height="17" font="14">10099910</text>
<text top="335" left="76" width="3" height="17" font="13"> </text>
<text top="352" left="22" width="66" height="17" font="13">(169)           </text>
<text top="283" left="123" width="78" height="17" font="13">Report on the </text>
<text top="301" left="123" width="79" height="17" font="13">survival at the </text>
<text top="318" left="123" width="79" height="17" font="13">10-y follow up </text>
<text top="335" left="123" width="54" height="17" font="13">of the pts </text>
<text top="352" left="123" width="81" height="17" font="13">randomized in </text>
<text top="370" left="123" width="85" height="17" font="13">CONSENSUS. </text>
<text top="387" left="123" width="70" height="17" font="13">(1st study to </text>
<text top="404" left="123" width="32" height="17" font="13">show </text>
<text top="421" left="123" width="60" height="17" font="13">prognostic </text>
<text top="438" left="123" width="75" height="17" font="13">improvement </text>
<text top="456" left="123" width="69" height="17" font="13">by an ACEI. </text>
<text top="473" left="123" width="72" height="17" font="13">Pts in NYHA </text>
<text top="490" left="123" width="66" height="17" font="13">class IV HF </text>
<text top="507" left="123" width="67" height="17" font="13">treated with </text>
<text top="524" left="123" width="64" height="17" font="13">enalapril or </text>
<text top="542" left="123" width="79" height="17" font="13">placebo. After </text>
<text top="559" left="123" width="33" height="17" font="13">study </text>
<text top="576" left="123" width="79" height="17" font="13">completion all </text>
<text top="593" left="123" width="50" height="17" font="13">pts were </text>
<text top="611" left="123" width="73" height="17" font="13">offered open-</text>
<text top="628" left="123" width="79" height="17" font="13">label enalapril </text>
<text top="645" left="123" width="55" height="17" font="13">therapy).  </text>
<text top="283" left="225" width="59" height="17" font="13">10-y open-</text>
<text top="301" left="225" width="82" height="17" font="13">label follow-up </text>
<text top="318" left="225" width="56" height="17" font="13">study (via </text>
<text top="335" left="225" width="87" height="17" font="13">completion of a </text>
<text top="352" left="225" width="81" height="17" font="13">questionnaire) </text>
<text top="370" left="225" width="83" height="17" font="13">on the survival </text>
<text top="387" left="225" width="83" height="17" font="13">status of pts in </text>
<text top="404" left="225" width="81" height="17" font="13">CONSENSUS </text>
<text top="421" left="225" width="50" height="17" font="13">-a RCT.  </text>
<text top="283" left="325" width="67" height="17" font="13">All pts were </text>
<text top="301" left="325" width="73" height="17" font="13">offered open-</text>
<text top="318" left="325" width="79" height="17" font="13">label enalapril </text>
<text top="335" left="325" width="44" height="17" font="13">therapy </text>
<text top="283" left="440" width="65" height="17" font="13">315; 77; 58 </text>
<text top="283" left="555" width="7" height="17" font="13">  </text>
<text top="283" left="663" width="92" height="17" font="13">253 randomized </text>
<text top="301" left="663" width="82" height="17" font="13">pts included in </text>
<text top="318" left="663" width="88" height="17" font="13">analysis of time </text>
<text top="335" left="663" width="28" height="17" font="13">from </text>
<text top="352" left="663" width="94" height="17" font="13">randomization to </text>
<text top="370" left="663" width="38" height="17" font="13">death; </text>
<text top="387" left="663" width="87" height="17" font="13">Survivors (135) </text>
<text top="404" left="663" width="75" height="17" font="13">of the double-</text>
<text top="421" left="663" width="70" height="17" font="13">blind period  </text>
<text top="438" left="663" width="62" height="17" font="13">included in </text>
<text top="456" left="663" width="82" height="17" font="13">analysis of the </text>
<text top="473" left="663" width="92" height="17" font="13">time from end of </text>
<text top="490" left="663" width="70" height="17" font="13">double-blind </text>
<text top="507" left="663" width="89" height="17" font="13">period to death; </text>
<text top="524" left="663" width="83" height="17" font="13">Severe, NYHA </text>
<text top="542" left="663" width="14" height="17" font="13">lV </text>
<text top="283" left="771" width="7" height="17" font="13">  </text>
<text top="283" left="879" width="50" height="17" font="13">Mortality </text>
<text top="283" left="967" width="7" height="17" font="13">  </text>
<text top="283" left="1081" width="7" height="17" font="13">  </text>
<text top="283" left="1176" width="27" height="17" font="13">10 y </text>
<text top="283" left="1243" width="7" height="17" font="13">  </text>
<text top="283" left="1318" width="133" height="17" font="13">5 pts, all in the enalapril </text>
<text top="301" left="1318" width="124" height="17" font="13">group, were long-term </text>
<text top="318" left="1318" width="112" height="17" font="13">survivors (p=0.004). </text>
<text top="335" left="1318" width="127" height="17" font="13">Averaged over the trial </text>
<text top="352" left="1318" width="132" height="17" font="13">(double-blind plus open-</text>
<text top="370" left="1318" width="112" height="17" font="13">label extension) risk </text>
<text top="387" left="1318" width="107" height="17" font="13">reduction was 30% </text>
<text top="404" left="1318" width="135" height="17" font="13">(p=0.008), 95% CI: 11% </text>
<text top="421" left="1318" width="42" height="17" font="13">- 46%.  </text>
<text top="438" left="1318" width="123" height="17" font="13">At end of double-blind </text>
<text top="456" left="1318" width="124" height="17" font="13">study period, mortality </text>
<text top="473" left="1318" width="110" height="17" font="13">considerably higher </text>
<text top="490" left="1318" width="134" height="17" font="13">among pts not receiving </text>
<text top="507" left="1318" width="111" height="17" font="13">open ACEI therapy  </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">78</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="77" height="17" font="15"><b>SOLVD </b>1991 </text>
<text top="71" left="22" width="51" height="17" font="14">2057034 </text>
<text top="71" left="73" width="32" height="17" font="13">(170) </text>
<text top="54" left="123" width="89" height="17" font="13">Study the effect </text>
<text top="71" left="123" width="81" height="17" font="13">of enalapril on </text>
<text top="88" left="123" width="74" height="17" font="13">mortality and </text>
<text top="106" left="123" width="81" height="17" font="13">hospitalization </text>
<text top="123" left="123" width="58" height="17" font="13">in pts with </text>
<text top="140" left="123" width="87" height="17" font="13">chronic HF and </text>
<text top="157" left="123" width="58" height="17" font="13">EF &lt;35%  </text>
<text top="54" left="225" width="224" height="17" font="13">RCT Diuretics </text>
<text top="54" left="377" width="83" height="17" font="13">+ </text>
<text top="71" left="325" width="44" height="17" font="13">Digoxin </text>
<text top="54" left="440" width="198" height="17" font="13">2569; 1285; 1284  Ischemic heart </text>
<text top="71" left="555" width="74" height="17" font="13">disease 72% </text>
<text top="54" left="663" width="73" height="17" font="13">LVEF &lt;35%; </text>
<text top="71" left="663" width="101" height="17" font="13">Mild to severe       </text>
<text top="88" left="663" width="63" height="17" font="13">(11% class </text>
<text top="106" left="663" width="88" height="17" font="13">l/&lt;2% class lV); </text>
<text top="123" left="663" width="92" height="17" font="13">LVEF 25%; BP:  </text>
<text top="140" left="663" width="76" height="17" font="13">125/77;  HR:  </text>
<text top="157" left="663" width="85" height="17" font="13">80;  AF: 8-12% </text>
<text top="54" left="771" width="63" height="17" font="13">Age &gt;80 y; </text>
<text top="71" left="771" width="52" height="17" font="13">Unstable </text>
<text top="88" left="771" width="86" height="17" font="13">angina; MI w/in </text>
<text top="106" left="771" width="91" height="17" font="13">past mo; Cr&gt;2.0 </text>
<text top="123" left="771" width="38" height="17" font="13">mg/dL </text>
<text top="140" left="771" width="3" height="17" font="13"> </text>
<text top="54" left="879" width="219" height="17" font="13">Mortality Hospitalizations; </text>
<text top="71" left="967" width="90" height="17" font="13">Incidence of MI; </text>
<text top="88" left="967" width="66" height="17" font="13">Mortality by </text>
<text top="106" left="967" width="90" height="17" font="13">specific causes; </text>
<text top="123" left="967" width="59" height="17" font="13">Combined </text>
<text top="140" left="967" width="74" height="17" font="13">mortality and </text>
<text top="157" left="967" width="81" height="17" font="13">morbidity from </text>
<text top="174" left="967" width="27" height="17" font="13">both </text>
<text top="192" left="967" width="101" height="17" font="13">SOLVD+/SOLVD- </text>
<text top="54" left="1081" width="171" height="17" font="13">15.70% 3.45 </text>
<text top="54" left="1203" width="59" height="17" font="13">y </text>
<text top="54" left="1243" width="98" height="17" font="13">Treating </text>
<text top="71" left="1243" width="31" height="17" font="13">1000 </text>
<text top="88" left="1243" width="52" height="17" font="13">SOLVD+ </text>
<text top="106" left="1243" width="45" height="17" font="13">pts with </text>
<text top="123" left="1243" width="50" height="17" font="13">enalapril </text>
<text top="140" left="1243" width="45" height="17" font="13">for ~3 y </text>
<text top="157" left="1243" width="36" height="17" font="13">would </text>
<text top="174" left="1243" width="54" height="17" font="13">save ~50 </text>
<text top="192" left="1243" width="60" height="17" font="13">premature </text>
<text top="209" left="1243" width="40" height="17" font="13">deaths </text>
<text top="226" left="1243" width="48" height="17" font="13">and 350 </text>
<text top="243" left="1243" width="51" height="17" font="13">hospitaliz</text>
<text top="261" left="1243" width="40" height="17" font="13">ations. </text>
<text top="54" left="1318" width="119" height="17" font="13">Reduced mortality by </text>
<text top="71" left="1318" width="125" height="17" font="13">16%; (95% CI, 5-26%; </text>
<text top="88" left="1318" width="59" height="17" font="13">p=0.0036) </text>
<text top="304" left="22" width="80" height="17" font="15"><b>SOLVD </b>1992  </text>
<text top="322" left="22" width="51" height="17" font="14">1463530 </text>
<text top="322" left="73" width="25" height="17" font="13">(90) </text>
<text top="339" left="22" width="3" height="17" font="13"> </text>
<text top="304" left="123" width="82" height="17" font="13">Study effect of </text>
<text top="322" left="123" width="82" height="17" font="13">ACEIs on total </text>
<text top="339" left="123" width="74" height="17" font="13">mortality and </text>
<text top="356" left="123" width="78" height="17" font="13">mortality from </text>
<text top="373" left="123" width="87" height="17" font="13">CV causes, the </text>
<text top="391" left="123" width="87" height="17" font="13">development of </text>
<text top="408" left="123" width="47" height="17" font="13">HF, and </text>
<text top="425" left="123" width="81" height="17" font="13">hospitalization </text>
<text top="442" left="123" width="70" height="17" font="13">for HF in pts </text>
<text top="459" left="123" width="80" height="17" font="13">with EF &lt;35% </text>
<text top="304" left="225" width="192" height="17" font="13">RCT No </text>
<text top="304" left="345" width="100" height="17" font="13">drug </text>
<text top="322" left="325" width="93" height="17" font="13">treatment for HF </text>
<text top="304" left="440" width="170" height="17" font="13">4228; 2111; 2117  History of </text>
<text top="322" left="555" width="83" height="17" font="13">ischemic heart </text>
<text top="339" left="555" width="74" height="17" font="13">disease 85% </text>
<text top="304" left="663" width="58" height="17" font="13">EF &lt;35%; </text>
<text top="322" left="663" width="84" height="17" font="13">Asymptomatic; </text>
<text top="339" left="663" width="76" height="17" font="13">NYHA class I </text>
<text top="356" left="663" width="59" height="17" font="13">(67%) + ll; </text>
<text top="373" left="663" width="87" height="17" font="13">EF:  28%;  BP:  </text>
<text top="391" left="663" width="76" height="17" font="13">126/78;  HR:  </text>
<text top="408" left="663" width="68" height="17" font="13">75;  AF: 4% </text>
<text top="304" left="771" width="161" height="17" font="13">As per SOLVD+  Mortality; </text>
<text top="322" left="879" width="59" height="17" font="13">Combined </text>
<text top="339" left="879" width="74" height="17" font="13">mortality and </text>
<text top="356" left="879" width="21" height="17" font="13">the </text>
<text top="373" left="879" width="69" height="17" font="13">incidence of </text>
<text top="391" left="879" width="68" height="17" font="13">HF and rate </text>
<text top="408" left="879" width="14" height="17" font="13">of </text>
<text top="425" left="879" width="71" height="17" font="13">hospitalizatio</text>
<text top="442" left="879" width="48" height="17" font="13">n for HF </text>
<text top="304" left="967" width="90" height="17" font="13">Incidence of HF </text>
<text top="322" left="967" width="62" height="17" font="13">and rate of </text>
<text top="339" left="967" width="99" height="17" font="13">hospitalization for </text>
<text top="356" left="967" width="57" height="17" font="13">HF            </text>
<text top="304" left="1081" width="7" height="17" font="13">  </text>
<text top="304" left="1176" width="37" height="17" font="13">3.12 y </text>
<text top="304" left="1243" width="7" height="17" font="13">  </text>
<text top="304" left="1318" width="106" height="17" font="13">Reduced mortality: </text>
<text top="322" left="1318" width="138" height="17" font="13">p=0.30;  95% CI: -8-21% </text>
<text top="480" left="22" width="69" height="17" font="15"><b>SOLVD F/U </b></text>
<text top="497" left="22" width="34" height="17" font="15"><b>2003  </b></text>
<text top="514" left="22" width="58" height="17" font="14">12788569 </text>
<text top="514" left="80" width="25" height="17" font="13">(91) </text>
<text top="480" left="123" width="61" height="17" font="13">12-y FU of </text>
<text top="497" left="123" width="59" height="17" font="13">SOLVD to </text>
<text top="514" left="123" width="82" height="17" font="13">establish if the </text>
<text top="532" left="123" width="50" height="17" font="13">mortality </text>
<text top="549" left="123" width="79" height="17" font="13">reduction with </text>
<text top="566" left="123" width="50" height="17" font="13">enalapril </text>
<text top="583" left="123" width="86" height="17" font="13">among pts with </text>
<text top="600" left="123" width="45" height="17" font="13">HF was </text>
<text top="618" left="123" width="83" height="17" font="13">sustained, and </text>
<text top="635" left="123" width="57" height="17" font="13">whether a </text>
<text top="652" left="123" width="67" height="17" font="13">subsequent </text>
<text top="669" left="123" width="67" height="17" font="13">reduction in </text>
<text top="687" left="123" width="85" height="17" font="13">mortality would </text>
<text top="704" left="123" width="86" height="17" font="13">emerge among </text>
<text top="721" left="123" width="59" height="17" font="13">those with </text>
<text top="738" left="123" width="79" height="17" font="13">asymptomatic </text>
<text top="755" left="123" width="60" height="17" font="13">ventricular </text>
<text top="773" left="123" width="69" height="17" font="13">dysfunction. </text>
<text top="480" left="225" width="57" height="17" font="13">12 y f/u of </text>
<text top="497" left="225" width="35" height="17" font="13">RCTs </text>
<text top="514" left="225" width="80" height="17" font="13">[SOLVD+ and </text>
<text top="532" left="225" width="53" height="17" font="13">SOLVD-] </text>
<text top="480" left="325" width="27" height="17" font="13"> N/A </text>
<text top="480" left="440" width="142" height="17" font="13">6784; 3391; 3393   N/A </text>
<text top="480" left="663" width="84" height="17" font="13">Participation in </text>
<text top="497" left="663" width="76" height="17" font="13">SOLVD+ and </text>
<text top="514" left="663" width="49" height="17" font="13">SOLVD- </text>
<text top="532" left="663" width="94" height="17" font="13">Asymptomatic to </text>
<text top="549" left="663" width="75" height="17" font="13">severe;          </text>
<text top="566" left="663" width="59" height="17" font="13">NYHA l-lV </text>
<text top="480" left="771" width="27" height="17" font="13"> N/A </text>
<text top="480" left="879" width="50" height="17" font="13">Mortality </text>
<text top="480" left="967" width="24" height="17" font="13">N/A </text>
<text top="480" left="1081" width="24" height="17" font="13">N/A </text>
<text top="480" left="1176" width="24" height="17" font="13">N/A </text>
<text top="480" left="1243" width="51" height="17" font="13">Enalapril </text>
<text top="497" left="1243" width="54" height="17" font="13">extended </text>
<text top="514" left="1243" width="44" height="17" font="13">median </text>
<text top="532" left="1243" width="45" height="17" font="13">survival </text>
<text top="549" left="1243" width="57" height="17" font="13">by 9.4 mo </text>
<text top="566" left="1243" width="33" height="17" font="13">in the </text>
<text top="583" left="1243" width="57" height="17" font="13">combined </text>
<text top="600" left="1243" width="29" height="17" font="13">trials </text>
<text top="618" left="1243" width="51" height="17" font="13">(95% CI: </text>
<text top="635" left="1243" width="55" height="17" font="13">2.8–16.5, </text>
<text top="652" left="1243" width="56" height="17" font="13">p=0.004). </text>
<text top="480" left="1318" width="122" height="17" font="13">In the prevention trial, </text>
<text top="497" left="1318" width="122" height="17" font="13">50.9% of the enalapril </text>
<text top="514" left="1318" width="107" height="17" font="13">group had died c/w </text>
<text top="532" left="1318" width="119" height="17" font="13">56.4% of the placebo </text>
<text top="549" left="1318" width="95" height="17" font="13">group (p=0.001). </text>
<text top="566" left="1318" width="116" height="17" font="13">In the treatment trial, </text>
<text top="583" left="1318" width="122" height="17" font="13">79.8% of the enalapril </text>
<text top="600" left="1318" width="107" height="17" font="13">group had died c/w </text>
<text top="618" left="1318" width="119" height="17" font="13">80.8% of the placebo </text>
<text top="635" left="1318" width="91" height="17" font="13">group (p=0.01).  </text>
<text top="652" left="1318" width="120" height="17" font="13">Combined prevention </text>
<text top="669" left="1318" width="137" height="17" font="13">and treatment trials:  HR </text>
<text top="687" left="1318" width="123" height="17" font="13">for death was 0.90 for </text>
<text top="704" left="1318" width="127" height="17" font="13">the enalapril group c/w </text>
<text top="721" left="1318" width="133" height="17" font="13">placebo group (95% CI: </text>
<text top="738" left="1318" width="124" height="17" font="13">0.84–0.95, p=0.0003). </text>
<text top="755" left="1318" width="3" height="17" font="13"> </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">79</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="44" height="17" font="15"><b>ATLAS </b></text>
<text top="71" left="22" width="31" height="17" font="13">1999 </text>
<text top="88" left="22" width="58" height="17" font="14">10587334 </text>
<text top="106" left="22" width="32" height="17" font="13">(171) </text>
<text top="123" left="22" width="3" height="17" font="13"> </text>
<text top="54" left="123" width="69" height="17" font="13">To compare </text>
<text top="71" left="123" width="66" height="17" font="13">the efficacy </text>
<text top="88" left="123" width="74" height="17" font="13">and safety of </text>
<text top="106" left="123" width="72" height="17" font="13">low and high </text>
<text top="123" left="123" width="82" height="17" font="13">doses of ACEI </text>
<text top="140" left="123" width="74" height="17" font="13">on the risk of </text>
<text top="157" left="123" width="58" height="17" font="13">death and </text>
<text top="174" left="123" width="81" height="17" font="13">hospitalization </text>
<text top="192" left="123" width="79" height="17" font="13">in chronic HF. </text>
<text top="209" left="123" width="79" height="17" font="13">than the large </text>
<text top="226" left="123" width="60" height="17" font="13">doses that </text>
<text top="243" left="123" width="61" height="17" font="13">have been </text>
<text top="261" left="123" width="53" height="17" font="13">shown to </text>
<text top="278" left="123" width="41" height="17" font="13">reduce </text>
<text top="295" left="123" width="77" height="17" font="13">morbidity and </text>
<text top="312" left="123" width="83" height="17" font="13">mortality in pts </text>
<text top="329" left="123" width="52" height="17" font="13">with HF.  </text>
<text top="347" left="123" width="32" height="17" font="13">AIM:  </text>
<text top="364" left="123" width="72" height="17" font="13">Investigate if </text>
<text top="381" left="123" width="82" height="17" font="13">low doses and </text>
<text top="398" left="123" width="77" height="17" font="13">high doses of </text>
<text top="415" left="123" width="68" height="17" font="13">ACEIs have </text>
<text top="433" left="123" width="89" height="17" font="13">similar benefits. </text>
<text top="54" left="225" width="176" height="17" font="13">RCT  </text>
<text top="54" left="329" width="217" height="17" font="13">N/A  3164; </text>
<text top="71" left="440" width="88" height="17" font="13">1596 to the low-</text>
<text top="88" left="440" width="101" height="17" font="13">dose strategy and </text>
<text top="106" left="440" width="92" height="17" font="13">1568 to the high-</text>
<text top="123" left="440" width="81" height="17" font="13">dose strategy. </text>
<text top="140" left="440" width="7" height="17" font="13">  </text>
<text top="54" left="555" width="57" height="17" font="13">CAD 65% </text>
<text top="54" left="663" width="83" height="17" font="13">LVEF &lt;=30%;  </text>
<text top="71" left="663" width="83" height="17" font="13">NYHA class II, </text>
<text top="88" left="663" width="93" height="17" font="13">III, or IV, despite </text>
<text top="106" left="663" width="81" height="17" font="13">treatment with </text>
<text top="123" left="663" width="86" height="17" font="13">diuretics for ≥2 </text>
<text top="140" left="663" width="21" height="17" font="13">mo </text>
<text top="157" left="663" width="81" height="17" font="13">(Treatment for </text>
<text top="174" left="663" width="68" height="17" font="13">HF in ED or </text>
<text top="192" left="663" width="91" height="17" font="13">hospital within 6 </text>
<text top="209" left="663" width="87" height="17" font="13">mo required for </text>
<text top="226" left="663" width="89" height="17" font="13">pts in class II);   </text>
<text top="243" left="663" width="66" height="17" font="13">Prior use of </text>
<text top="261" left="663" width="89" height="17" font="13">digitalis, ACEIs, </text>
<text top="278" left="663" width="83" height="17" font="13">or vasodilators </text>
<text top="295" left="663" width="86" height="17" font="13">allowed but not </text>
<text top="312" left="663" width="62" height="17" font="13">mandated; </text>
<text top="329" left="663" width="61" height="17" font="13">NYHA ll-lV </text>
<text top="347" left="663" width="91" height="17" font="13">(mainly class ll); </text>
<text top="364" left="663" width="69" height="17" font="13">LVEF 23%;  </text>
<text top="381" left="663" width="98" height="17" font="13">SBP 126 mmHg;  </text>
<text top="398" left="663" width="83" height="17" font="13">HR 80;  NYHA </text>
<text top="415" left="663" width="85" height="17" font="13">class:  lll (few ll </text>
<text top="433" left="663" width="49" height="17" font="13">and lV)   </text>
<text top="54" left="771" width="86" height="17" font="13">Acute coronary </text>
<text top="71" left="771" width="85" height="17" font="13">ischemic event </text>
<text top="88" left="771" width="14" height="17" font="13">or </text>
<text top="106" left="771" width="85" height="17" font="13">revascularizatio</text>
<text top="123" left="771" width="69" height="17" font="13">n procedure </text>
<text top="140" left="771" width="69" height="17" font="13">within 2 mo; </text>
<text top="157" left="771" width="55" height="17" font="13">History of </text>
<text top="174" left="771" width="70" height="17" font="13">sustained or </text>
<text top="192" left="771" width="72" height="17" font="13">symptomatic </text>
<text top="209" left="771" width="60" height="17" font="13">ventricular </text>
<text top="226" left="771" width="70" height="17" font="13">tachycardia; </text>
<text top="243" left="771" width="68" height="17" font="13">Intolerant of </text>
<text top="261" left="771" width="42" height="17" font="13">ACEIs; </text>
<text top="278" left="771" width="90" height="17" font="13">SCr &gt;2.5 mg/dL </text>
<text top="54" left="879" width="50" height="17" font="13">Mortality </text>
<text top="71" left="879" width="44" height="17" font="13">from all </text>
<text top="88" left="879" width="42" height="17" font="13">causes </text>
<text top="54" left="967" width="96" height="17" font="13">Combined risk of </text>
<text top="71" left="967" width="53" height="17" font="13">all-cause </text>
<text top="88" left="967" width="74" height="17" font="13">mortality and </text>
<text top="106" left="967" width="99" height="17" font="13">hospitalization for </text>
<text top="123" left="967" width="92" height="17" font="13">any reason;        </text>
<text top="140" left="967" width="94" height="17" font="13">CV mortality, CV </text>
<text top="157" left="967" width="91" height="17" font="13">hospitalizations; </text>
<text top="174" left="967" width="54" height="17" font="13">All-cause </text>
<text top="192" left="967" width="50" height="17" font="13">mortality </text>
<text top="209" left="967" width="82" height="17" font="13">combined with </text>
<text top="226" left="967" width="21" height="17" font="13">CV </text>
<text top="243" left="967" width="91" height="17" font="13">hospitalizations; </text>
<text top="261" left="967" width="70" height="17" font="13">CV mortality </text>
<text top="278" left="967" width="82" height="17" font="13">combined with </text>
<text top="295" left="967" width="21" height="17" font="13">CV </text>
<text top="312" left="967" width="91" height="17" font="13">hospitalizations; </text>
<text top="329" left="967" width="96" height="17" font="13">Combined risk of </text>
<text top="347" left="967" width="98" height="17" font="13">fatal and nonfatal </text>
<text top="364" left="967" width="43" height="17" font="13">MI plus </text>
<text top="381" left="967" width="99" height="17" font="13">hospitalization for </text>
<text top="398" left="967" width="90" height="17" font="13">unstable angina </text>
<text top="415" left="967" width="3" height="17" font="13"> </text>
<text top="54" left="1081" width="7" height="17" font="13">  </text>
<text top="54" left="1176" width="20" height="17" font="13">5 y </text>
<text top="54" left="1243" width="7" height="17" font="13">  </text>
<text top="54" left="1318" width="139" height="17" font="13">High-dose group had 8% </text>
<text top="71" left="1318" width="122" height="17" font="13">lower risk of all-cause </text>
<text top="88" left="1318" width="130" height="17" font="13">mortality (p=0.128) and </text>
<text top="106" left="1318" width="118" height="17" font="13">10% lower risk of CV </text>
<text top="123" left="1318" width="134" height="17" font="13">mortality (p=0.073) than </text>
<text top="140" left="1318" width="149" height="17" font="13">low-dose group.                  </text>
<text top="157" left="1318" width="132" height="17" font="13">Death or hospitalization </text>
<text top="174" left="1318" width="113" height="17" font="13">for any reason, high-</text>
<text top="192" left="1318" width="117" height="17" font="13">dose group had 12% </text>
<text top="209" left="1318" width="135" height="17" font="13">lower risk than low-dose </text>
<text top="226" left="1318" width="90" height="17" font="13">group, p=0.002. </text>
<text top="243" left="1318" width="90" height="17" font="13">Total number of </text>
<text top="261" left="1318" width="122" height="17" font="13">hospitalizations:  high-</text>
<text top="278" left="1318" width="127" height="17" font="13">dose group 13% fewer </text>
<text top="295" left="1318" width="129" height="17" font="13">hospitalizations for any </text>
<text top="312" left="1318" width="129" height="17" font="13">reason (p=0.021), 16% </text>
<text top="329" left="1318" width="139" height="17" font="13">fewer hospitalizations for </text>
<text top="347" left="1318" width="138" height="17" font="13">CV reason (p=0.05), and </text>
<text top="364" left="1318" width="62" height="17" font="13">24% fewer </text>
<text top="381" left="1318" width="125" height="17" font="13">hospitalizations for HF </text>
<text top="398" left="1318" width="60" height="17" font="13">(p=0.002). </text>
<text top="459" left="22" width="107" height="17" font="15"><b>Post-MI ACEI Use </b></text>
</page>
<page number="80" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">80</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="74" height="17" font="13">SAVE, 1992  </text>
<text top="71" left="22" width="51" height="17" font="14">1386652 </text>
<text top="71" left="73" width="25" height="17" font="13">(89) </text>
<text top="88" left="22" width="48" height="17" font="13">              </text>
<text top="54" left="123" width="62" height="17" font="13">To test the </text>
<text top="71" left="123" width="86" height="17" font="13">hypothesis that </text>
<text top="88" left="123" width="76" height="17" font="13">the long-term </text>
<text top="106" left="123" width="80" height="17" font="13">administration </text>
<text top="123" left="123" width="77" height="17" font="13">of captopril to </text>
<text top="140" left="123" width="66" height="17" font="13">survivors of </text>
<text top="157" left="123" width="77" height="17" font="13">acute MI who </text>
<text top="174" left="123" width="73" height="17" font="13">had baseline </text>
<text top="192" left="123" width="84" height="17" font="13">LV dysfunction </text>
<text top="209" left="123" width="61" height="17" font="13">but did not </text>
<text top="226" left="123" width="81" height="17" font="13">have overt HF </text>
<text top="243" left="123" width="51" height="17" font="13">requiring </text>
<text top="261" left="123" width="63" height="17" font="13">vasodilator </text>
<text top="278" left="123" width="80" height="17" font="13">therapy would </text>
<text top="295" left="123" width="41" height="17" font="13">reduce </text>
<text top="312" left="123" width="53" height="17" font="13">mortality, </text>
<text top="329" left="123" width="39" height="17" font="13">lessen </text>
<text top="347" left="123" width="85" height="17" font="13">deterioration in </text>
<text top="364" left="123" width="43" height="17" font="13">cardiac </text>
<text top="381" left="123" width="76" height="17" font="13">performance, </text>
<text top="398" left="123" width="71" height="17" font="13">and improve </text>
<text top="415" left="123" width="40" height="17" font="13">clinical </text>
<text top="433" left="123" width="57" height="17" font="13">outcome.  </text>
<text top="54" left="225" width="32" height="17" font="13">RCT  </text>
<text top="54" left="298" width="79" height="17" font="13">Beta-blockers </text>
<text top="71" left="298" width="69" height="17" font="13">36%;            </text>
<text top="88" left="298" width="116" height="17" font="13">Digitalis 26%;            </text>
<text top="106" left="298" width="74" height="17" font="13">Nitrates 51% </text>
<text top="54" left="420" width="99" height="17" font="13">2231; 1115; 1116 </text>
<text top="54" left="555" width="52" height="17" font="13">Ischemic </text>
<text top="71" left="555" width="35" height="17" font="13">100% </text>
<text top="54" left="649" width="79" height="17" font="13">Alive 3 d after </text>
<text top="71" left="649" width="21" height="17" font="13">MI; </text>
<text top="88" left="649" width="73" height="17" font="13">LVEF &lt;40%; </text>
<text top="106" left="649" width="75" height="17" font="13">&gt;21 y of age, </text>
<text top="123" left="649" width="48" height="17" font="13">but &lt;80; </text>
<text top="140" left="649" width="83" height="17" font="13">Killip class I — </text>
<text top="157" left="649" width="83" height="17" font="13">60%                 </text>
<text top="174" left="649" width="83" height="17" font="13">(60% of the ps </text>
<text top="192" left="649" width="70" height="17" font="13">did not have </text>
<text top="209" left="649" width="81" height="17" font="13">even transient </text>
<text top="226" left="649" width="61" height="17" font="13">pulmonary </text>
<text top="243" left="649" width="77" height="17" font="13">congestion at </text>
<text top="261" left="649" width="70" height="17" font="13">baseline/the </text>
<text top="278" left="649" width="68" height="17" font="13">time of their </text>
<text top="295" left="649" width="54" height="17" font="13">acute MI; </text>
<text top="312" left="649" width="81" height="17" font="13">EF 31%;          </text>
<text top="329" left="649" width="102" height="17" font="13">BP 113/70;            </text>
<text top="347" left="649" width="100" height="17" font="13">HR 78;                  </text>
<text top="54" left="757" width="55" height="17" font="13">Failure to </text>
<text top="71" left="757" width="49" height="17" font="13">undergo </text>
<text top="88" left="757" width="81" height="17" font="13">randomization </text>
<text top="106" left="757" width="90" height="17" font="13">within 16 d after </text>
<text top="123" left="757" width="41" height="17" font="13">the MI; </text>
<text top="140" left="757" width="48" height="17" font="13">Relative </text>
<text top="157" left="757" width="89" height="17" font="13">contraindication </text>
<text top="174" left="757" width="88" height="17" font="13">to the use of an </text>
<text top="192" left="757" width="77" height="17" font="13">ACEIs  or the </text>
<text top="209" left="757" width="95" height="17" font="13">need for such an </text>
<text top="226" left="757" width="48" height="17" font="13">agent;    </text>
<text top="243" left="757" width="103" height="17" font="13">SCr &gt; 2.5 mg/dl     </text>
<text top="54" left="872" width="78" height="17" font="13">Mortality from </text>
<text top="71" left="872" width="58" height="17" font="13">all causes </text>
<text top="54" left="967" width="78" height="17" font="13">Mortality from </text>
<text top="71" left="967" width="66" height="17" font="13">CV causes; </text>
<text top="88" left="967" width="50" height="17" font="13">Mortality </text>
<text top="106" left="967" width="92" height="17" font="13">combined with a </text>
<text top="123" left="967" width="87" height="17" font="13">decrease in the </text>
<text top="140" left="967" width="86" height="17" font="13">EF of at least 9 </text>
<text top="157" left="967" width="94" height="17" font="13">units in surviving </text>
<text top="174" left="967" width="23" height="17" font="13">pts; </text>
<text top="192" left="967" width="74" height="17" font="13">CV morbidity </text>
<text top="209" left="967" width="92" height="17" font="13">(development of </text>
<text top="226" left="967" width="83" height="17" font="13">severe CHF or </text>
<text top="243" left="967" width="83" height="17" font="13">the recurrence </text>
<text top="261" left="967" width="38" height="17" font="13">of MI); </text>
<text top="278" left="967" width="86" height="17" font="13">Combination of </text>
<text top="295" left="967" width="94" height="17" font="13">CV mortality and </text>
<text top="312" left="967" width="60" height="17" font="13">morbidity;  </text>
<text top="329" left="967" width="81" height="17" font="13">2 endpoints of </text>
<text top="347" left="967" width="60" height="17" font="13">severe HF </text>
<text top="364" left="967" width="60" height="17" font="13">(treatment </text>
<text top="381" left="967" width="68" height="17" font="13">failure): 1st, </text>
<text top="398" left="967" width="87" height="17" font="13">development of </text>
<text top="415" left="967" width="51" height="17" font="13">overt HF </text>
<text top="433" left="967" width="75" height="17" font="13">necessitating </text>
<text top="450" left="967" width="81" height="17" font="13">treatment with </text>
<text top="467" left="967" width="83" height="17" font="13">ACEI and 2nd, </text>
<text top="484" left="967" width="95" height="17" font="13">hospitalization to </text>
<text top="501" left="967" width="61" height="17" font="13">treat CHD. </text>
<text top="54" left="1075" width="7" height="17" font="13">  </text>
<text top="54" left="1176" width="30" height="17" font="13">3.5 y </text>
<text top="54" left="1243" width="7" height="17" font="13">  </text>
<text top="54" left="1318" width="136" height="17" font="13">Mortality from all causes </text>
<text top="71" left="1318" width="140" height="17" font="13">was significantly reduced </text>
<text top="88" left="1318" width="118" height="17" font="13">in the captopril group </text>
<text top="106" left="1318" width="135" height="17" font="13">(228 deaths, or 20%) as </text>
<text top="123" left="1318" width="124" height="17" font="13">c/w the placebo group </text>
<text top="140" left="1318" width="142" height="17" font="13">(275 deaths, or 25%); the </text>
<text top="157" left="1318" width="111" height="17" font="13">RR:19% (95% CI, 3-</text>
<text top="174" left="1318" width="94" height="17" font="13">32%; p= 0.019).  </text>
<text top="192" left="1318" width="115" height="17" font="13">RR:21% (95% CI, 5 -</text>
<text top="209" left="1318" width="108" height="17" font="13">35%; p = 0.014) for </text>
<text top="226" left="1318" width="129" height="17" font="13">death from CV causes, </text>
<text top="243" left="1318" width="128" height="17" font="13">37% (95% CI, 20-50%; </text>
<text top="261" left="1318" width="91" height="17" font="13">p&lt;0.001) for the </text>
<text top="278" left="1318" width="128" height="17" font="13">development of severe </text>
<text top="295" left="1318" width="113" height="17" font="13">HF, 22% (95% CI, 4-</text>
<text top="312" left="1318" width="134" height="17" font="13">37%; p= 0.019) for CHF </text>
<text top="329" left="1318" width="136" height="17" font="13">requiring hospitalization, </text>
<text top="347" left="1318" width="114" height="17" font="13">and 25% (95% CI, 5-</text>
<text top="364" left="1318" width="105" height="17" font="13">40%; p= 0.015) for </text>
<text top="381" left="1318" width="73" height="17" font="13">recurrent MI. </text>
</page>
<page number="81" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">81</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="64" height="17" font="15"><b>AIRE 1993 </b></text>
<text top="71" left="22" width="51" height="17" font="14">8104270 </text>
<text top="71" left="73" width="32" height="17" font="13">(172) </text>
<text top="88" left="22" width="3" height="17" font="13"> </text>
<text top="54" left="123" width="70" height="17" font="13">Investigated </text>
<text top="71" left="123" width="68" height="17" font="13">the effect of </text>
<text top="88" left="123" width="70" height="17" font="13">therapy with </text>
<text top="106" left="123" width="79" height="17" font="13">ACEI ramipril, </text>
<text top="123" left="123" width="75" height="17" font="13">on survival in </text>
<text top="140" left="123" width="70" height="17" font="13">pts who had </text>
<text top="157" left="123" width="79" height="17" font="13">shown clinical </text>
<text top="174" left="123" width="86" height="17" font="13">evidence of HF </text>
<text top="192" left="123" width="64" height="17" font="13">at any time </text>
<text top="209" left="123" width="79" height="17" font="13">after an acute </text>
<text top="226" left="123" width="68" height="17" font="13">MI.  Also, to </text>
<text top="243" left="123" width="72" height="17" font="13">compare the </text>
<text top="261" left="123" width="75" height="17" font="13">incidences of </text>
<text top="278" left="123" width="81" height="17" font="13">progression to </text>
<text top="295" left="123" width="55" height="17" font="13">severe or </text>
<text top="312" left="123" width="73" height="17" font="13">resistant HF, </text>
<text top="329" left="123" width="62" height="17" font="13">nonfatal re-</text>
<text top="347" left="123" width="77" height="17" font="13">infarction and </text>
<text top="364" left="123" width="87" height="17" font="13">stroke between </text>
<text top="381" left="123" width="75" height="17" font="13">the 2 groups. </text>
<text top="54" left="225" width="29" height="17" font="13">RCT </text>
<text top="54" left="298" width="7" height="17" font="13">  </text>
<text top="54" left="420" width="92" height="17" font="13">2006; 1014; 992 </text>
<text top="54" left="555" width="7" height="17" font="13">  </text>
<text top="54" left="649" width="71" height="17" font="13">Aged ≥18 y, </text>
<text top="71" left="649" width="79" height="17" font="13">with a definite </text>
<text top="88" left="649" width="89" height="17" font="13">acute MI 3-10 d </text>
<text top="106" left="649" width="38" height="17" font="13">before </text>
<text top="123" left="649" width="87" height="17" font="13">randomization;  </text>
<text top="140" left="649" width="43" height="17" font="13">Clinical </text>
<text top="157" left="649" width="86" height="17" font="13">evidence of HF </text>
<text top="174" left="649" width="64" height="17" font="13">at any time </text>
<text top="192" left="649" width="83" height="17" font="13">since acute MI </text>
<text top="54" left="757" width="88" height="17" font="13">Use of an ACEI </text>
<text top="71" left="757" width="94" height="17" font="13">considered to be </text>
<text top="88" left="757" width="68" height="17" font="13">mandatory   </text>
<text top="54" left="872" width="78" height="17" font="13">Mortality from </text>
<text top="71" left="872" width="58" height="17" font="13">all causes </text>
<text top="54" left="967" width="7" height="17" font="13">  </text>
<text top="54" left="1075" width="7" height="17" font="13">  </text>
<text top="54" left="1176" width="30" height="17" font="13">1.3 y </text>
<text top="54" left="1243" width="7" height="17" font="13">  </text>
<text top="54" left="1318" width="136" height="17" font="13">Mortality from all causes </text>
<text top="71" left="1318" width="125" height="17" font="13">was significantly lower </text>
<text top="88" left="1318" width="98" height="17" font="13">for pts on ramipril </text>
<text top="106" left="1318" width="109" height="17" font="13">compared to pts on </text>
<text top="123" left="1318" width="134" height="17" font="13">placebo. RR: 27%; 95% </text>
<text top="140" left="1318" width="150" height="17" font="13">Cl: 11-40%; p = 0.002.        </text>
<text top="157" left="1318" width="131" height="17" font="13">Prespecified secondary </text>
<text top="174" left="1318" width="137" height="17" font="13">outcomes: risk reduction </text>
<text top="192" left="1318" width="100" height="17" font="13">of 19% for the 1st </text>
<text top="209" left="1318" width="112" height="17" font="13">validated outcome—</text>
<text top="226" left="1318" width="84" height="17" font="13">namely, death, </text>
<text top="243" left="1318" width="134" height="17" font="13">severe/resistant HF, MI, </text>
<text top="261" left="1318" width="131" height="17" font="13">or stroke (95% CI: 5% - </text>
<text top="278" left="1318" width="87" height="17" font="13">31%; p=0.008). </text>
<text top="418" left="22" width="77" height="17" font="15"><b>TRACE</b> 1995 </text>
<text top="436" left="22" width="48" height="17" font="14">7477219</text>
<text top="436" left="69" width="39" height="17" font="13">  (173) </text>
<text top="453" left="22" width="3" height="17" font="13"> </text>
<text top="418" left="123" width="76" height="17" font="13">To determine </text>
<text top="436" left="123" width="67" height="17" font="13">whether pts </text>
<text top="453" left="123" width="44" height="17" font="13">who LV </text>
<text top="470" left="123" width="66" height="17" font="13">dysfunction </text>
<text top="487" left="123" width="75" height="17" font="13">soon after MI </text>
<text top="505" left="123" width="68" height="17" font="13">benefit from </text>
<text top="522" left="123" width="79" height="17" font="13">long-term oral </text>
<text top="539" left="123" width="87" height="17" font="13">ACE inhibition.  </text>
<text top="418" left="225" width="29" height="17" font="13">RCT </text>
<text top="418" left="298" width="107" height="17" font="13">Beta blocker 16%;  </text>
<text top="436" left="298" width="108" height="17" font="13">Calcium antagonist </text>
<text top="453" left="298" width="80" height="17" font="13">28%;  Diuretic </text>
<text top="470" left="298" width="81" height="17" font="13">66%;  Nitrates </text>
<text top="487" left="298" width="79" height="17" font="13">53%;  Digoxin </text>
<text top="505" left="298" width="32" height="17" font="13">28%. </text>
<text top="418" left="420" width="85" height="17" font="13">1749; 876; 873 </text>
<text top="418" left="555" width="52" height="17" font="13">Ischemic </text>
<text top="436" left="555" width="35" height="17" font="13">100% </text>
<text top="418" left="649" width="91" height="17" font="13">Consecutive pts </text>
<text top="436" left="649" width="34" height="17" font="13">&gt;18 y </text>
<text top="453" left="649" width="94" height="17" font="13">hospitalized with </text>
<text top="470" left="649" width="21" height="17" font="13">MI; </text>
<text top="487" left="649" width="85" height="17" font="13">Criteria for MI:  </text>
<text top="505" left="649" width="74" height="17" font="13">chest pain or </text>
<text top="522" left="649" width="88" height="17" font="13">electrocardiogra</text>
<text top="539" left="649" width="79" height="17" font="13">phic changes, </text>
<text top="556" left="649" width="93" height="17" font="13">accompanied by </text>
<text top="573" left="649" width="88" height="17" font="13">&gt;2X increase in </text>
<text top="591" left="649" width="70" height="17" font="13">one or more </text>
<text top="608" left="649" width="43" height="17" font="13">cardiac </text>
<text top="625" left="649" width="56" height="17" font="13">enzymes; </text>
<text top="642" left="649" width="84" height="17" font="13">LV dysfunction </text>
<text top="659" left="649" width="69" height="17" font="13">(EF &lt;35%);  </text>
<text top="677" left="649" width="83" height="17" font="13">NYHA class 1 -</text>
<text top="694" left="649" width="35" height="17" font="13">41%;  </text>
<text top="711" left="649" width="92" height="17" font="13">BP  121/76;  HR </text>
<text top="728" left="649" width="17" height="17" font="13">81 </text>
<text top="418" left="757" width="92" height="17" font="13">Contraindication </text>
<text top="436" left="757" width="70" height="17" font="13">to ACEI or a </text>
<text top="453" left="757" width="92" height="17" font="13">definite need for </text>
<text top="470" left="757" width="34" height="17" font="13">them; </text>
<text top="487" left="757" width="46" height="17" font="13">Severe, </text>
<text top="505" left="757" width="96" height="17" font="13">uncontrolled DM; </text>
<text top="522" left="757" width="80" height="17" font="13">Hyponatremia </text>
<text top="539" left="757" width="86" height="17" font="13">(&lt;125 mmol/L); </text>
<text top="556" left="757" width="76" height="17" font="13">Elevated SCr </text>
<text top="573" left="757" width="95" height="17" font="13">level (2.3 mg/dL) </text>
<text top="418" left="872" width="64" height="17" font="13">Death from </text>
<text top="436" left="872" width="60" height="17" font="13">any cause </text>
<text top="418" left="967" width="95" height="17" font="13">Death from a CV </text>
<text top="436" left="967" width="83" height="17" font="13">cause, sudden </text>
<text top="453" left="967" width="38" height="17" font="13">death; </text>
<text top="470" left="967" width="83" height="17" font="13">Progression to </text>
<text top="487" left="967" width="60" height="17" font="13">severe HF </text>
<text top="505" left="967" width="50" height="17" font="13">(hospital </text>
<text top="522" left="967" width="77" height="17" font="13">admission for </text>
<text top="539" left="967" width="95" height="17" font="13">HF, death due to </text>
<text top="556" left="967" width="90" height="17" font="13">progressive HF, </text>
<text top="573" left="967" width="34" height="17" font="13">or HF </text>
<text top="591" left="967" width="75" height="17" font="13">necessitating </text>
<text top="608" left="967" width="61" height="17" font="13">open-label </text>
<text top="625" left="967" width="40" height="17" font="13">ACEI); </text>
<text top="642" left="967" width="58" height="17" font="13">Recurrent </text>
<text top="659" left="967" width="84" height="17" font="13">infarction (fatal </text>
<text top="677" left="967" width="69" height="17" font="13">or nonfatal); </text>
<text top="694" left="967" width="80" height="17" font="13">Change in the </text>
<text top="711" left="967" width="66" height="17" font="13">wall-motion </text>
<text top="728" left="967" width="60" height="17" font="13">index (EF) </text>
<text top="418" left="1075" width="74" height="17" font="13">The mortality </text>
<text top="436" left="1075" width="86" height="17" font="13">from all causes </text>
<text top="453" left="1075" width="59" height="17" font="13">at 1 y was </text>
<text top="470" left="1075" width="35" height="17" font="13">24%.  </text>
<text top="418" left="1176" width="7" height="17" font="13">  </text>
<text top="418" left="1243" width="45" height="17" font="13">24 lives </text>
<text top="436" left="1243" width="30" height="17" font="13">were </text>
<text top="453" left="1243" width="36" height="17" font="13">saved </text>
<text top="470" left="1243" width="52" height="17" font="13">after one </text>
<text top="487" left="1243" width="34" height="17" font="13">mo of </text>
<text top="505" left="1243" width="44" height="17" font="13">treating </text>
<text top="522" left="1243" width="51" height="17" font="13">1000 pts </text>
<text top="418" left="1318" width="134" height="17" font="13">During the study period, </text>
<text top="436" left="1318" width="141" height="17" font="13">304 pts in the trandolapril </text>
<text top="453" left="1318" width="128" height="17" font="13">group died (34.7%), as </text>
<text top="470" left="1318" width="124" height="17" font="13">did 369 in the placebo </text>
<text top="487" left="1318" width="137" height="17" font="13">group (42.3%). RR: 0.78 </text>
<text top="505" left="1318" width="117" height="17" font="13">(95% CI, 0.67 - 0.91; </text>
<text top="522" left="1318" width="148" height="17" font="13">p=0.001).                            </text>
<text top="539" left="1318" width="105" height="17" font="13">In every subgroup, </text>
<text top="556" left="1318" width="81" height="17" font="13">treatment with </text>
<text top="573" left="1318" width="90" height="17" font="13">trandolapril was </text>
<text top="591" left="1318" width="98" height="17" font="13">associated with a </text>
<text top="608" left="1318" width="93" height="17" font="13">reduction in risk. </text>
<text top="753" left="11" width="1449" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; AIRE, Acute Infarction Ramipril Efficacy; APE, acute pulmonary embolism; ATLAS, Assessment of Treatment with Lisinopril and Survival; BP, blood pressure; CAD, coronary artery disease; </text>
<text top="771" left="11" width="1445" height="17" font="13">CHD, chronic heart disease; CHF, congestive heart failure; CONSENSUS Cooperative North Scandinavian Enalapril Survival Study; Cr, creatinine; CV, cardiovascular; C/W, compared with; DM, diabetes mellitus; ED, emergency department; FU, follow-up; HF, heart </text>
</page>
<page number="82" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">82</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="11" width="1413" height="17" font="13">failure; HR, heart rate; LV, left ventricular; MI, myocardial infarction; MV, mitral valve; N/A, not applicable; NYHA, New York Heart Association; pts, patients; SAVE, survival and ventricular enlargement trial; SBP, systolic blood pressure; SOLVD, Studies Of Left </text>
<text top="71" left="11" width="680" height="17" font="13">Ventricular Dysfunction; RCT, randomized control trial; SCr, serum creatinine; and TRACE, Trandolapril Cardiac Evaluation.  </text>
<text top="97" left="34" width="310" height="21" font="8"><b>Data Supplement 19. ARBs (Section 7.3.2.3) </b></text>
<text top="119" left="44" width="38" height="17" font="15"><b>Study </b></text>
<text top="136" left="42" width="40" height="17" font="15"><b>Name, </b></text>
<text top="153" left="39" width="47" height="17" font="15"><b>Author, </b></text>
<text top="170" left="47" width="30" height="17" font="15"><b>Year </b></text>
<text top="153" left="124" width="42" height="17" font="15"><b>Aim of </b></text>
<text top="170" left="126" width="38" height="17" font="15"><b>Study </b></text>
<text top="153" left="200" width="38" height="17" font="15"><b>Study </b></text>
<text top="170" left="203" width="32" height="17" font="15"><b>Type </b></text>
<text top="153" left="261" width="75" height="17" font="15"><b>Background </b></text>
<text top="170" left="273" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="170" left="367" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="170" left="489" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="170" left="612" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="170" left="794" width="51" height="17" font="15"><b>Severity </b></text>
<text top="170" left="952" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="170" left="1119" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="136" left="1222" width="29" height="17" font="15"><b>Trial </b></text>
<text top="153" left="1210" width="54" height="17" font="15"><b>Duration </b></text>
<text top="170" left="1227" width="20" height="17" font="15"><b>(Y) </b></text>
<text top="170" left="1307" width="109" height="17" font="15"><b>Statistical Results </b></text>
<text top="188" left="274" width="50" height="17" font="21"><i><b>Pre-trial </b></i></text>
<text top="206" left="271" width="55" height="17" font="21"><i><b>standard </b></i></text>
<text top="223" left="267" width="63" height="17" font="21"><i><b>treatment. </b></i></text>
<text top="188" left="375" width="12" height="17" font="21"><i><b>N </b></i></text>
<text top="190" left="388" width="34" height="15" font="16"><i><b>(Total)</b></i></text>
<text top="188" left="421" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="206" left="354" width="11" height="17" font="21"><i><b>n </b></i></text>
<text top="207" left="365" width="77" height="15" font="16"><i><b>(Experimental)</b></i></text>
<text top="206" left="442" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="223" left="369" width="15" height="17" font="21"><i><b>n (</b></i></text>
<text top="224" left="384" width="43" height="15" font="16"><i><b>Control)</b></i></text>
<text top="223" left="427" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="206" left="485" width="90" height="17" font="21"><i><b>Ischemic/          </b></i></text>
<text top="223" left="473" width="84" height="17" font="21"><i><b>Non-Ischemic </b></i></text>
<text top="206" left="596" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="223" left="602" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="206" left="687" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="223" left="695" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="223" left="818" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="206" left="902" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="223" left="898" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="206" left="998" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="223" left="1003" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="223" left="1102" width="87" height="17" font="21"><i><b>1st Y Mortality </b></i></text>
<text top="241" left="28" width="49" height="17" font="13">CHARM </text>
<text top="258" left="28" width="65" height="17" font="13">Alternative; </text>
<text top="275" left="28" width="62" height="17" font="13">Granger et </text>
<text top="292" left="28" width="55" height="17" font="13">al; (2003) </text>
<text top="310" left="28" width="65" height="17" font="14">13678870   </text>
<text top="327" left="28" width="32" height="17" font="13">(174) </text>
<text top="241" left="109" width="51" height="17" font="13">Discover </text>
<text top="258" left="109" width="47" height="17" font="13">whether </text>
<text top="275" left="109" width="61" height="17" font="13">ARB could </text>
<text top="292" left="109" width="47" height="17" font="13">improve </text>
<text top="310" left="109" width="64" height="17" font="13">outcome in </text>
<text top="327" left="109" width="40" height="17" font="13">pts not </text>
<text top="344" left="109" width="53" height="17" font="13">taking an </text>
<text top="361" left="109" width="32" height="17" font="13">ACEI </text>
<text top="379" left="109" width="62" height="17" font="13">(intolerant) </text>
<text top="241" left="193" width="156" height="17" font="13">RCT Diuretics, </text>
<text top="258" left="258" width="79" height="17" font="13">Beta-blockers </text>
<text top="275" left="258" width="40" height="17" font="13">(55%), </text>
<text top="292" left="258" width="73" height="17" font="13">spironolacton</text>
<text top="310" left="258" width="42" height="17" font="13">e 24%, </text>
<text top="327" left="258" width="62" height="17" font="13">Digoxin 45-</text>
<text top="344" left="258" width="28" height="17" font="13">46% </text>
<text top="241" left="352" width="68" height="17" font="13">2028; 1013; </text>
<text top="258" left="352" width="31" height="17" font="13">1015 </text>
<text top="241" left="460" width="98" height="17" font="13">Ischemic 67-70% </text>
<text top="241" left="582" width="74" height="17" font="13">Symptomatic </text>
<text top="258" left="582" width="81" height="17" font="13">HF, EF &lt;40%, </text>
<text top="275" left="582" width="73" height="17" font="13">no ACEI (b/c </text>
<text top="292" left="582" width="81" height="17" font="13">of intolerance) </text>
<text top="241" left="681" width="7" height="17" font="13">  </text>
<text top="241" left="767" width="105" height="17" font="13">NYHA ll-lV; mild to </text>
<text top="258" left="767" width="104" height="17" font="13">severe (&lt;4% class </text>
<text top="275" left="767" width="102" height="17" font="13">lV); EF: 30%;  BP: </text>
<text top="292" left="767" width="87" height="17" font="13">130/70; HR: 74-</text>
<text top="310" left="767" width="89" height="17" font="13">75; AF: 25-26% </text>
<text top="241" left="886" width="76" height="17" font="13">Composite of </text>
<text top="258" left="886" width="69" height="17" font="13">CV death or </text>
<text top="275" left="886" width="46" height="17" font="13">hospital </text>
<text top="292" left="886" width="77" height="17" font="13">admission for </text>
<text top="310" left="886" width="29" height="17" font="13">CHF </text>
<text top="241" left="980" width="58" height="17" font="13">CV death, </text>
<text top="258" left="980" width="46" height="17" font="13">hospital </text>
<text top="275" left="980" width="77" height="17" font="13">admission for </text>
<text top="292" left="980" width="94" height="17" font="13">CHF or non-fatal </text>
<text top="310" left="980" width="79" height="17" font="13">MI; CV death, </text>
<text top="327" left="980" width="91" height="17" font="13">CHF admission, </text>
<text top="344" left="980" width="96" height="17" font="13">non-fatal MI, non-</text>
<text top="361" left="980" width="87" height="17" font="13">fatal stroke; CV </text>
<text top="379" left="980" width="66" height="17" font="13">death, CHF </text>
<text top="396" left="980" width="87" height="17" font="13">admission, non-</text>
<text top="413" left="980" width="98" height="17" font="13">fatal MI, non-fatal </text>
<text top="430" left="980" width="92" height="17" font="13">stroke, coronary </text>
<text top="447" left="980" width="99" height="17" font="13">revascularization; </text>
<text top="465" left="980" width="64" height="17" font="13">Death (any </text>
<text top="482" left="980" width="94" height="17" font="13">cause); New DM </text>
<text top="241" left="1095" width="7" height="17" font="13">  </text>
<text top="241" left="1210" width="30" height="17" font="13">2.8 y </text>
<text top="241" left="1277" width="163" height="17" font="13">Absolute reduction of 7 major </text>
<text top="258" left="1277" width="161" height="17" font="13">events per 100 pts threated - </text>
<text top="275" left="1277" width="155" height="17" font="13">NNT 14 pts to prevent 1 CV </text>
<text top="292" left="1277" width="133" height="17" font="13">death or hospitalization. </text>
<text top="313" left="1277" width="19" height="16" font="7">HR</text>
<text top="311" left="1296" width="149" height="17" font="13">: 0.77 (95% CI: 0.67-0.89); </text>
<text top="330" left="1277" width="55" height="17" font="13">p=0.0004 </text>
<text top="500" left="28" width="49" height="17" font="13">CHARM-</text>
<text top="517" left="28" width="50" height="17" font="13">ADDED; </text>
<text top="534" left="28" width="58" height="17" font="13">McMurray </text>
<text top="551" left="28" width="30" height="17" font="13">et al; </text>
<text top="569" left="28" width="39" height="17" font="13">(2003) </text>
<text top="586" left="28" width="58" height="17" font="14">13678869 </text>
<text top="603" left="28" width="32" height="17" font="13">(175) </text>
<text top="620" left="28" width="3" height="17" font="13"> </text>
<text top="500" left="109" width="18" height="17" font="13">To </text>
<text top="517" left="109" width="62" height="17" font="13">investigate </text>
<text top="534" left="109" width="49" height="17" font="13">if ARB + </text>
<text top="551" left="109" width="65" height="17" font="13">ACEI in pts </text>
<text top="569" left="109" width="68" height="17" font="13">with chronic </text>
<text top="586" left="109" width="67" height="17" font="13">HF improve </text>
<text top="603" left="109" width="38" height="17" font="13">clincal </text>
<text top="620" left="109" width="57" height="17" font="13">outcomes </text>
<text top="500" left="193" width="130" height="17" font="13">RCT Beta </text>
<text top="500" left="287" width="44" height="17" font="13">blocker-</text>
<text top="517" left="258" width="31" height="17" font="13">55%; </text>
<text top="534" left="258" width="73" height="17" font="13">spironolacton</text>
<text top="551" left="258" width="42" height="17" font="13">e 17%; </text>
<text top="569" left="258" width="62" height="17" font="13">Digoxin 58-</text>
<text top="586" left="258" width="28" height="17" font="13">59% </text>
<text top="500" left="352" width="68" height="17" font="13">2548; 1276; </text>
<text top="517" left="352" width="31" height="17" font="13">1272 </text>
<text top="500" left="460" width="98" height="17" font="13">Ischemic 62-63% </text>
<text top="500" left="582" width="74" height="17" font="13">Symptomatic </text>
<text top="517" left="582" width="81" height="17" font="13">HF; EF &lt;40%; </text>
<text top="534" left="582" width="85" height="17" font="13">Treatment with </text>
<text top="551" left="582" width="85" height="17" font="13">ACEI; Age &gt;18 </text>
<text top="569" left="582" width="10" height="17" font="13">y </text>
<text top="500" left="681" width="7" height="17" font="13">  </text>
<text top="500" left="767" width="96" height="17" font="13">NYHA class ll-lV; </text>
<text top="517" left="767" width="80" height="17" font="13">mild to severe </text>
<text top="534" left="767" width="89" height="17" font="13">(&lt;3% class lV) ; </text>
<text top="551" left="767" width="70" height="17" font="13">EF 28%; BP </text>
<text top="569" left="767" width="90" height="17" font="13">125/75; HR 74;  </text>
<text top="586" left="767" width="47" height="17" font="13">AF 27% </text>
<text top="500" left="886" width="76" height="17" font="13">Composite of </text>
<text top="517" left="886" width="69" height="17" font="13">CV death or </text>
<text top="534" left="886" width="46" height="17" font="13">hospital </text>
<text top="551" left="886" width="77" height="17" font="13">admission for </text>
<text top="569" left="886" width="29" height="17" font="13">CHF </text>
<text top="500" left="980" width="58" height="17" font="13">CV death, </text>
<text top="517" left="980" width="46" height="17" font="13">hospital </text>
<text top="534" left="980" width="77" height="17" font="13">admission for </text>
<text top="551" left="980" width="94" height="17" font="13">CHF or non-fatal </text>
<text top="569" left="980" width="79" height="17" font="13">MI; CV death, </text>
<text top="586" left="980" width="91" height="17" font="13">CHF admission, </text>
<text top="603" left="980" width="92" height="17" font="13">nonfatal MI, non-</text>
<text top="620" left="980" width="87" height="17" font="13">fatal stroke; CV </text>
<text top="637" left="980" width="66" height="17" font="13">death, CHF </text>
<text top="655" left="980" width="87" height="17" font="13">admission, non-</text>
<text top="672" left="980" width="98" height="17" font="13">fatal MI, non-fatal </text>
<text top="689" left="980" width="92" height="17" font="13">stroke, coronary </text>
<text top="706" left="980" width="99" height="17" font="13">revascularization; </text>
<text top="723" left="980" width="64" height="17" font="13">Death (any </text>
<text top="741" left="980" width="94" height="17" font="13">cause); New DM </text>
<text top="500" left="1095" width="7" height="17" font="13">  </text>
<text top="500" left="1210" width="30" height="17" font="13">3.4 y </text>
<text top="500" left="1277" width="159" height="17" font="13">Absolute reduction of 4.4 pts </text>
<text top="517" left="1277" width="130" height="17" font="13">with events per 100 pts </text>
<text top="534" left="1277" width="163" height="17" font="13">treated- NNT of 23 to prevent </text>
<text top="551" left="1277" width="150" height="17" font="13">1 first event of CV death or </text>
<text top="569" left="1277" width="113" height="17" font="13">CHF hospitalization. </text>
<text top="586" left="1277" width="166" height="17" font="13">RR: 0.85 (95% CI: 0.75-0.96); </text>
<text top="603" left="1277" width="48" height="17" font="13">p=0.011 </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">83</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="28" width="58" height="17" font="13">VALIANT; </text>
<text top="72" left="28" width="53" height="17" font="13">Pfeffer et </text>
<text top="89" left="28" width="55" height="17" font="13">al; (2003) </text>
<text top="106" left="28" width="58" height="17" font="14">14610160 </text>
<text top="124" left="28" width="32" height="17" font="13">(176) </text>
<text top="141" left="28" width="3" height="17" font="13"> </text>
<text top="55" left="109" width="54" height="17" font="13">Compare </text>
<text top="72" left="109" width="68" height="17" font="13">the effect of </text>
<text top="89" left="109" width="49" height="17" font="13">an ARB, </text>
<text top="106" left="109" width="60" height="17" font="13">ACEI  and </text>
<text top="124" left="109" width="21" height="17" font="13">the </text>
<text top="141" left="109" width="70" height="17" font="13">combination </text>
<text top="158" left="109" width="58" height="17" font="13">of the 2on </text>
<text top="175" left="109" width="50" height="17" font="13">mortality </text>
<text top="55" left="193" width="47" height="17" font="13">Random</text>
<text top="72" left="193" width="26" height="17" font="13">ized </text>
<text top="89" left="193" width="40" height="17" font="13">double </text>
<text top="106" left="193" width="29" height="17" font="13">blind </text>
<text top="124" left="193" width="46" height="17" font="13">multicen</text>
<text top="141" left="193" width="41" height="17" font="13">ter trial </text>
<text top="55" left="258" width="29" height="17" font="13">Beta-</text>
<text top="72" left="258" width="81" height="17" font="13">blockers; ASA </text>
<text top="55" left="352" width="41" height="17" font="13">14,703 </text>
<text top="72" left="352" width="100" height="17" font="13">Valsartan:4909     </text>
<text top="89" left="352" width="101" height="17" font="13">Captopril-: 4909    </text>
<text top="106" left="352" width="69" height="17" font="13">VAL + CAP: </text>
<text top="124" left="352" width="31" height="17" font="13">4885 </text>
<text top="141" left="352" width="7" height="17" font="13">  </text>
<text top="55" left="460" width="90" height="17" font="13">Ischemic 100%  </text>
<text top="72" left="460" width="72" height="17" font="13">(MI inclusion </text>
<text top="89" left="460" width="48" height="17" font="13">criteria)  </text>
<text top="55" left="582" width="63" height="17" font="13">Age &gt;18 y; </text>
<text top="72" left="582" width="52" height="17" font="13">Acute MI </text>
<text top="89" left="582" width="85" height="17" font="13">complicated by </text>
<text top="106" left="582" width="23" height="17" font="13">HF; </text>
<text top="124" left="582" width="62" height="17" font="13">LV systolic </text>
<text top="141" left="582" width="72" height="17" font="13">dysfunct (EF </text>
<text top="158" left="582" width="82" height="17" font="13">&lt;35%), (&lt;40% </text>
<text top="175" left="582" width="17" height="17" font="13">on </text>
<text top="192" left="582" width="70" height="17" font="13">radionuclide </text>
<text top="210" left="582" width="77" height="17" font="13">ventriculograp</text>
<text top="227" left="582" width="24" height="17" font="13">hy); </text>
<text top="244" left="582" width="63" height="17" font="13">SBP &gt; 100 </text>
<text top="261" left="582" width="70" height="17" font="13">mmHg; Cr &lt; </text>
<text top="278" left="582" width="58" height="17" font="13">2.5 mg/dL </text>
<text top="55" left="681" width="29" height="17" font="13">Prior </text>
<text top="72" left="681" width="64" height="17" font="13">intolerance </text>
<text top="89" left="681" width="53" height="17" font="13">or contra-</text>
<text top="106" left="681" width="69" height="17" font="13">indication to </text>
<text top="124" left="681" width="36" height="17" font="13">ACEI/ </text>
<text top="141" left="681" width="29" height="17" font="13">ARB </text>
<text top="55" left="767" width="62" height="17" font="13">NYHA l-lV; </text>
<text top="72" left="767" width="80" height="17" font="13">asymptomatic-</text>
<text top="89" left="767" width="44" height="17" font="13">severe, </text>
<text top="106" left="767" width="77" height="17" font="13">EF 35%;  BP: </text>
<text top="124" left="767" width="90" height="17" font="13">123/72;  HR: 76 </text>
<text top="55" left="886" width="64" height="17" font="13">Death from </text>
<text top="72" left="886" width="60" height="17" font="13">any cause </text>
<text top="55" left="980" width="7" height="17" font="13">  </text>
<text top="55" left="1095" width="96" height="17" font="13">12.5% VAL          </text>
<text top="72" left="1095" width="102" height="17" font="13">12.3% VAL--CAP  </text>
<text top="89" left="1095" width="108" height="17" font="13">13.2% CAP             </text>
<text top="55" left="1210" width="30" height="17" font="13">2.1 y </text>
<text top="55" left="1277" width="165" height="17" font="13">VAL and CAP:  1.0 (97.5% CI-</text>
<text top="72" left="1277" width="156" height="17" font="13">- 0.90-1.11); p= 0.98 ;           </text>
<text top="89" left="1277" width="146" height="17" font="13">VAL+CAP and CAP:  0.98 </text>
<text top="106" left="1277" width="147" height="17" font="13">(97.5% CI-- 0.89-1.09); p= </text>
<text top="124" left="1277" width="58" height="17" font="13">0.73          </text>
<text top="296" left="28" width="63" height="17" font="13">Val-HeFT;  </text>
<text top="314" left="28" width="66" height="17" font="13">Cohn et al;  </text>
<text top="331" left="28" width="39" height="17" font="13">(2001) </text>
<text top="348" left="28" width="58" height="17" font="14">11759645 </text>
<text top="365" left="28" width="32" height="17" font="13">(177) </text>
<text top="382" left="28" width="3" height="17" font="13"> </text>
<text top="296" left="109" width="51" height="17" font="13">Evaluate </text>
<text top="314" left="109" width="55" height="17" font="13">long term </text>
<text top="331" left="109" width="53" height="17" font="13">effects of </text>
<text top="348" left="109" width="69" height="17" font="13">adding ARB </text>
<text top="365" left="109" width="65" height="17" font="13">to standard </text>
<text top="382" left="109" width="62" height="17" font="13">therapy for </text>
<text top="400" left="109" width="20" height="17" font="13">HF </text>
<text top="296" left="193" width="156" height="17" font="13">RCT Diuretics; </text>
<text top="314" left="258" width="76" height="17" font="13">Digoxin 67%; </text>
<text top="331" left="258" width="72" height="17" font="13">Beta blocker </text>
<text top="348" left="258" width="64" height="17" font="13">35%; ACEI </text>
<text top="365" left="258" width="32" height="17" font="13">93%  </text>
<text top="296" left="352" width="68" height="17" font="13">5010; 2511; </text>
<text top="314" left="352" width="31" height="17" font="13">2499 </text>
<text top="296" left="460" width="80" height="17" font="13">Ischemic 57% </text>
<text top="296" left="582" width="59" height="17" font="13">Age&gt;18 y; </text>
<text top="314" left="582" width="80" height="17" font="13">NYHA ll, ll, lV; </text>
<text top="331" left="582" width="73" height="17" font="13">At least 2 wk </text>
<text top="348" left="582" width="81" height="17" font="13">of background </text>
<text top="365" left="582" width="85" height="17" font="13">meds including </text>
<text top="382" left="582" width="42" height="17" font="13">ACEIs; </text>
<text top="400" left="582" width="78" height="17" font="13">EF &lt;40% and </text>
<text top="417" left="582" width="59" height="17" font="13">LVID &gt;2.9 </text>
<text top="434" left="582" width="48" height="17" font="13">cm/BSA </text>
<text top="296" left="681" width="7" height="17" font="13">  </text>
<text top="296" left="767" width="76" height="17" font="13">NYHA ll-lll, lV </text>
<text top="314" left="767" width="90" height="17" font="13">(only ~2% class </text>
<text top="331" left="767" width="65" height="17" font="13">lV);  Mild to </text>
<text top="348" left="767" width="44" height="17" font="13">severe; </text>
<text top="365" left="767" width="74" height="17" font="13">EF 27%;  BP </text>
<text top="382" left="767" width="95" height="17" font="13">123/76;  AF 12% </text>
<text top="296" left="886" width="53" height="17" font="13">Mortality; </text>
<text top="314" left="886" width="59" height="17" font="13">Combined </text>
<text top="331" left="886" width="68" height="17" font="13">end point of </text>
<text top="348" left="886" width="74" height="17" font="13">mortality and </text>
<text top="365" left="886" width="57" height="17" font="13">morbidity  </text>
<text top="296" left="980" width="82" height="17" font="13">Change in EF; </text>
<text top="314" left="980" width="80" height="17" font="13">• NYHA class, </text>
<text top="331" left="980" width="73" height="17" font="13">QoL scores;  </text>
<text top="348" left="980" width="58" height="17" font="13">Signs and </text>
<text top="365" left="980" width="96" height="17" font="13">symptoms of  HF </text>
<text top="296" left="1095" width="7" height="17" font="13">  </text>
<text top="296" left="1210" width="37" height="17" font="13">1.92 y </text>
<text top="296" left="1277" width="137" height="17" font="13">Mortality similar for the 2 </text>
<text top="314" left="1277" width="158" height="17" font="13">treatment groups.                  </text>
<text top="331" left="1277" width="157" height="17" font="13">For the combined endpoint:  </text>
<text top="348" left="1277" width="141" height="17" font="13">RR: 0.87; 97.5% CI, 0.77-</text>
<text top="365" left="1277" width="79" height="17" font="13">0.97; p=0.009 </text>
<text top="452" left="28" width="44" height="17" font="13">HEAAL </text>
<text top="469" left="28" width="36" height="17" font="13">study; </text>
<text top="487" left="28" width="40" height="17" font="13">Lancet </text>
<text top="504" left="28" width="62" height="17" font="13">2009; 374: </text>
<text top="521" left="28" width="59" height="17" font="13">1840-48.   </text>
<text top="538" left="28" width="58" height="17" font="14">19922995 </text>
<text top="555" left="28" width="32" height="17" font="13">(178) </text>
<text top="573" left="28" width="3" height="17" font="13"> </text>
<text top="452" left="109" width="61" height="17" font="13">Compared </text>
<text top="469" left="109" width="60" height="17" font="13">the effects </text>
<text top="487" left="109" width="41" height="17" font="13">of high-</text>
<text top="504" left="109" width="46" height="17" font="13">dose vs </text>
<text top="521" left="109" width="53" height="17" font="13">low-dose </text>
<text top="538" left="109" width="64" height="17" font="13">losartan on </text>
<text top="555" left="109" width="40" height="17" font="13">clinical </text>
<text top="573" left="109" width="70" height="17" font="13">outcomes in </text>
<text top="590" left="109" width="68" height="17" font="13">pts with HF. </text>
<text top="452" left="193" width="146" height="17" font="13">RCT Diuretic </text>
<text top="452" left="303" width="70" height="17" font="13">drugs </text>
<text top="469" left="258" width="67" height="17" font="13">(77%), beta </text>
<text top="487" left="258" width="49" height="17" font="13">blockers </text>
<text top="504" left="258" width="64" height="17" font="13">(72%), and </text>
<text top="521" left="258" width="75" height="17" font="13">ARBs (38%). </text>
<text top="452" left="352" width="31" height="17" font="13">3846 </text>
<text top="469" left="352" width="92" height="17" font="13">losartan 150 mg </text>
<text top="487" left="352" width="84" height="17" font="13">(n=1927) or 50 </text>
<text top="504" left="352" width="49" height="17" font="13">mg daily </text>
<text top="521" left="352" width="56" height="17" font="13">(n=1919). </text>
<text top="538" left="352" width="7" height="17" font="13">  </text>
<text top="452" left="460" width="53" height="17" font="13">IHD 64% </text>
<text top="452" left="582" width="37" height="17" font="13">&gt;18 y; </text>
<text top="469" left="582" width="83" height="17" font="13">NYHA class II–</text>
<text top="487" left="582" width="53" height="17" font="13">IV; LVEF </text>
<text top="504" left="582" width="64" height="17" font="13">&lt;40%, with </text>
<text top="521" left="582" width="57" height="17" font="13">stable CV </text>
<text top="538" left="582" width="46" height="17" font="13">medical </text>
<text top="555" left="582" width="76" height="17" font="13">therapy for at </text>
<text top="573" left="582" width="62" height="17" font="13">least 2 wk; </text>
<text top="590" left="582" width="78" height="17" font="13">Intolerance to </text>
<text top="607" left="582" width="39" height="17" font="13">ACEI;  </text>
<text top="624" left="582" width="73" height="17" font="13">Investigators </text>
<text top="641" left="582" width="82" height="17" font="13">encouraged to </text>
<text top="659" left="582" width="55" height="17" font="13">start beta </text>
<text top="676" left="582" width="67" height="17" font="13">blocker and </text>
<text top="693" left="582" width="58" height="17" font="13">titrate to a </text>
<text top="710" left="582" width="60" height="17" font="13">maximum, </text>
<text top="727" left="582" width="57" height="17" font="13">whenever </text>
<text top="745" left="582" width="49" height="17" font="13">possible </text>
<text top="452" left="681" width="62" height="17" font="13">Pregnancy </text>
<text top="469" left="681" width="67" height="17" font="13">or lactation; </text>
<text top="487" left="681" width="39" height="17" font="13">known </text>
<text top="504" left="681" width="64" height="17" font="13">intolerance </text>
<text top="521" left="681" width="52" height="17" font="13">to ARBs; </text>
<text top="538" left="681" width="46" height="17" font="13">Systolic </text>
<text top="555" left="681" width="41" height="17" font="13">arterial </text>
<text top="573" left="681" width="33" height="17" font="13">blood </text>
<text top="590" left="681" width="51" height="17" font="13">pressure </text>
<text top="607" left="681" width="71" height="17" font="13">&lt;90 mm Hg; </text>
<text top="624" left="681" width="60" height="17" font="13">Significant </text>
<text top="641" left="681" width="46" height="17" font="13">stenotic </text>
<text top="659" left="681" width="46" height="17" font="13">valvular </text>
<text top="676" left="681" width="31" height="17" font="13">heart </text>
<text top="693" left="681" width="49" height="17" font="13">disease; </text>
<text top="710" left="681" width="37" height="17" font="13">Active </text>
<text top="727" left="681" width="69" height="17" font="13">myocarditis; </text>
<text top="745" left="681" width="35" height="17" font="13">active </text>
<text top="762" left="681" width="66" height="17" font="13">pericarditis; </text>
<text top="779" left="681" width="49" height="17" font="13">Planned </text>
<text top="452" left="767" width="94" height="17" font="13">NYHA ll-lV (70% </text>
<text top="469" left="767" width="97" height="17" font="13">ll); EF: 33%;  BP: </text>
<text top="487" left="767" width="96" height="17" font="13">124/77;  HR: 71;  </text>
<text top="504" left="767" width="51" height="17" font="13">AF; 28% </text>
<text top="521" left="767" width="3" height="17" font="13"> </text>
<text top="452" left="886" width="51" height="17" font="13">Death or </text>
<text top="469" left="886" width="77" height="17" font="13">admission for </text>
<text top="487" left="886" width="20" height="17" font="13">HF </text>
<text top="452" left="980" width="62" height="17" font="13">Composite </text>
<text top="469" left="980" width="98" height="17" font="13">endpoint of death </text>
<text top="487" left="980" width="101" height="17" font="13">or CV admission.  </text>
<text top="504" left="980" width="57" height="17" font="13">Additional </text>
<text top="521" left="980" width="70" height="17" font="13">prespecified </text>
<text top="538" left="980" width="57" height="17" font="13">outcomes </text>
<text top="555" left="980" width="90" height="17" font="13">included: death, </text>
<text top="573" left="980" width="101" height="17" font="13">death or all-cause </text>
<text top="590" left="980" width="83" height="17" font="13">admission, CV </text>
<text top="607" left="980" width="90" height="17" font="13">death, all-cause </text>
<text top="624" left="980" width="83" height="17" font="13">admission, CV </text>
<text top="641" left="980" width="62" height="17" font="13">admission, </text>
<text top="659" left="980" width="100" height="17" font="13">admission for HF, </text>
<text top="676" left="980" width="87" height="17" font="13">and changes in </text>
<text top="693" left="980" width="80" height="17" font="13">the severity of </text>
<text top="710" left="980" width="77" height="17" font="13">heart disease </text>
<text top="452" left="1095" width="7" height="17" font="13">  </text>
<text top="452" left="1210" width="30" height="17" font="13">4.7 y </text>
<text top="469" left="1210" width="44" height="17" font="13">median </text>
<text top="487" left="1210" width="17" height="17" font="13">f/u </text>
<text top="452" left="1277" width="168" height="17" font="13">Treating pts with 150 mg dose </text>
<text top="469" left="1277" width="160" height="17" font="13">instead of 50 mg dose would </text>
<text top="487" left="1277" width="159" height="17" font="13">result in 1 additional pt w/out </text>
<text top="504" left="1277" width="150" height="17" font="13">the primary event at 4 y for </text>
<text top="521" left="1277" width="116" height="17" font="13">every 31 pts treated. </text>
<text top="538" left="1277" width="162" height="17" font="13">Composite:  828 (43%) pts in </text>
<text top="555" left="1277" width="159" height="17" font="13">150 mg group vs. 889 (46%) </text>
<text top="573" left="1277" width="127" height="17" font="13">in 50 mg group died or </text>
<text top="590" left="1277" width="148" height="17" font="13">admitted for HF (HR: 0.90; </text>
<text top="607" left="1277" width="162" height="17" font="13">95% CI: 0.82-0.99; p=0.027)  </text>
<text top="624" left="1277" width="168" height="17" font="13">• Components:  635 pts in 150 </text>
<text top="641" left="1277" width="149" height="17" font="13">mg group vs. 665 in 50 mg </text>
<text top="659" left="1277" width="168" height="17" font="13">group died (HR: 0.94, 95% CI: </text>
<text top="676" left="1277" width="156" height="17" font="13">0.84-1.04; p=0.24), and 450 </text>
<text top="693" left="1277" width="151" height="17" font="13">vs. 503 pts admitted for HF </text>
<text top="710" left="1277" width="149" height="17" font="13">(0.87, 0.76–0.98; p=0.025) </text>
</page>
<page number="84" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">84</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="681" width="31" height="17" font="13">heart </text>
<text top="72" left="681" width="67" height="17" font="13">transplantati</text>
<text top="89" left="681" width="53" height="17" font="13">on w/in 6 </text>
<text top="106" left="681" width="24" height="17" font="13">mo; </text>
<text top="124" left="681" width="51" height="17" font="13">coronary </text>
<text top="141" left="681" width="69" height="17" font="13">angioplasty, </text>
<text top="158" left="681" width="42" height="17" font="13">CABG, </text>
<text top="175" left="681" width="54" height="17" font="13">acute MI, </text>
<text top="192" left="681" width="70" height="17" font="13">UA pectoris, </text>
<text top="210" left="681" width="67" height="17" font="13">cerebrovasc</text>
<text top="227" left="681" width="24" height="17" font="13">ular </text>
<text top="244" left="681" width="67" height="17" font="13">accident, or </text>
<text top="261" left="681" width="57" height="17" font="13">TIA within </text>
<text top="278" left="681" width="70" height="17" font="13">the previous </text>
<text top="296" left="681" width="39" height="17" font="13">12 wk; </text>
<text top="313" left="681" width="61" height="17" font="13">Suspected </text>
<text top="330" left="681" width="58" height="17" font="13">significant </text>
<text top="347" left="681" width="66" height="17" font="13">renal artery </text>
<text top="365" left="681" width="49" height="17" font="13">stenosis </text>
<text top="382" left="28" width="49" height="17" font="13">CHARM-</text>
<text top="400" left="28" width="46" height="17" font="13">Overall<b> </b> </text>
<text top="417" left="28" width="58" height="17" font="14">13678868 </text>
<text top="434" left="28" width="32" height="17" font="13">(179) </text>
<text top="382" left="109" width="52" height="17" font="13">Aimed to </text>
<text top="400" left="109" width="44" height="17" font="13">find out </text>
<text top="417" left="109" width="68" height="17" font="13">whether the </text>
<text top="434" left="109" width="54" height="17" font="13">use of an </text>
<text top="451" left="109" width="61" height="17" font="13">ARB could </text>
<text top="469" left="109" width="41" height="17" font="13">reduce </text>
<text top="486" left="109" width="50" height="17" font="13">mortality </text>
<text top="503" left="109" width="24" height="17" font="13">and </text>
<text top="520" left="109" width="57" height="17" font="13">morbidity. </text>
<text top="382" left="193" width="57" height="17" font="13">RCT-        </text>
<text top="400" left="193" width="46" height="17" font="13">parallel, </text>
<text top="417" left="193" width="44" height="17" font="13">randomi</text>
<text top="434" left="193" width="27" height="17" font="13">zed, </text>
<text top="451" left="193" width="41" height="17" font="13">double-</text>
<text top="469" left="193" width="36" height="17" font="13">blind,  </text>
<text top="382" left="258" width="89" height="17" font="13">Diuretics 83%    </text>
<text top="400" left="258" width="78" height="17" font="13">Beta blockers </text>
<text top="417" left="258" width="86" height="17" font="13">55%                  </text>
<text top="434" left="258" width="87" height="17" font="13">ACEI 43%         </text>
<text top="451" left="258" width="75" height="17" font="13">Spironolacton</text>
<text top="469" left="258" width="86" height="17" font="13">e 17%               </text>
<text top="486" left="258" width="72" height="17" font="13">Digoxin 43% </text>
<text top="382" left="352" width="78" height="17" font="13">7601 pts         </text>
<text top="400" left="352" width="95" height="17" font="13">(7599 with data)  </text>
<text top="417" left="352" width="31" height="17" font="13">3803 </text>
<text top="434" left="352" width="31" height="17" font="13">3796 </text>
<text top="382" left="460" width="7" height="17" font="13">  </text>
<text top="382" left="582" width="37" height="17" font="13">&gt;18 y; </text>
<text top="400" left="582" width="83" height="17" font="13">NYHA class II–</text>
<text top="417" left="582" width="86" height="17" font="13">IV for at least 4 </text>
<text top="434" left="582" width="22" height="17" font="13">wk; </text>
<text top="451" left="582" width="52" height="17" font="13">3 distinct </text>
<text top="469" left="582" width="73" height="17" font="13">populations:  </text>
<text top="486" left="582" width="79" height="17" font="13">pts with LVEF </text>
<text top="503" left="582" width="61" height="17" font="13">&lt;40% who </text>
<text top="520" left="582" width="51" height="17" font="13">were not </text>
<text top="537" left="582" width="53" height="17" font="13">receiving </text>
<text top="555" left="582" width="38" height="17" font="13">ACEIs </text>
<text top="572" left="582" width="54" height="17" font="13">(previous </text>
<text top="589" left="582" width="82" height="17" font="13">intolerance) or </text>
<text top="606" left="582" width="56" height="17" font="13">who were </text>
<text top="624" left="582" width="51" height="17" font="13">currently </text>
<text top="641" left="582" width="85" height="17" font="13">receiving ACE, </text>
<text top="658" left="582" width="69" height="17" font="13">and pts with </text>
<text top="675" left="582" width="69" height="17" font="13">LVEF &gt;40% </text>
<text top="382" left="681" width="59" height="17" font="13">SCr &gt; 265 </text>
<text top="400" left="681" width="44" height="17" font="13">μmol/L, </text>
<text top="417" left="681" width="38" height="17" font="13">serum </text>
<text top="434" left="681" width="59" height="17" font="13">potassium </text>
<text top="451" left="681" width="71" height="17" font="13">&gt;5.5 mmol/L </text>
<text top="469" left="681" width="48" height="17" font="13">Bilateral </text>
<text top="486" left="681" width="66" height="17" font="13">renal artery </text>
<text top="503" left="681" width="52" height="17" font="13">stenosis; </text>
<text top="520" left="681" width="72" height="17" font="13">symptomatic </text>
<text top="537" left="681" width="70" height="17" font="13">hypotension </text>
<text top="555" left="681" width="59" height="17" font="13">Women of </text>
<text top="572" left="681" width="70" height="17" font="13">childbearing </text>
<text top="589" left="681" width="70" height="17" font="13">potential not </text>
<text top="606" left="681" width="33" height="17" font="13">using </text>
<text top="624" left="681" width="55" height="17" font="13">adequate </text>
<text top="641" left="681" width="67" height="17" font="13">contraceptio</text>
<text top="658" left="681" width="55" height="17" font="13">n; Critical </text>
<text top="675" left="681" width="48" height="17" font="13">aortic or </text>
<text top="692" left="681" width="33" height="17" font="13">mitral </text>
<text top="710" left="681" width="52" height="17" font="13">stenosis; </text>
<text top="727" left="681" width="61" height="17" font="13">MI, stroke, </text>
<text top="744" left="681" width="46" height="17" font="13">or open-</text>
<text top="761" left="681" width="31" height="17" font="13">heart </text>
<text top="778" left="681" width="57" height="17" font="13">surgery in </text>
<text top="382" left="767" width="61" height="17" font="13">NYHA ll-lV </text>
<text top="400" left="767" width="113" height="17" font="13">NYHA ll-lV                </text>
<text top="417" left="767" width="96" height="17" font="13">Only 3% class lV </text>
<text top="382" left="886" width="69" height="17" font="13">The primary </text>
<text top="400" left="886" width="64" height="17" font="13">outcome of </text>
<text top="417" left="886" width="60" height="17" font="13">the overall </text>
<text top="434" left="886" width="69" height="17" font="13">program: all-</text>
<text top="451" left="886" width="36" height="17" font="13">cause </text>
<text top="469" left="886" width="53" height="17" font="13">mortality; </text>
<text top="486" left="886" width="58" height="17" font="13">For all the </text>
<text top="503" left="886" width="64" height="17" font="13">component </text>
<text top="520" left="886" width="57" height="17" font="13">trials:  CV </text>
<text top="537" left="886" width="49" height="17" font="13">death or </text>
<text top="555" left="886" width="46" height="17" font="13">hospital </text>
<text top="572" left="886" width="77" height="17" font="13">admission for </text>
<text top="589" left="886" width="32" height="17" font="13">CHF. </text>
<text top="382" left="980" width="7" height="17" font="13">  </text>
<text top="382" left="1095" width="85" height="17" font="13">The annual CV </text>
<text top="400" left="1095" width="100" height="17" font="13">death rate among </text>
<text top="417" left="1095" width="102" height="17" font="13">the placebo group </text>
<text top="434" left="1095" width="98" height="17" font="13">who had reduced </text>
<text top="451" left="1095" width="101" height="17" font="13">LVEF was around </text>
<text top="469" left="1095" width="96" height="17" font="13">9% and was only </text>
<text top="486" left="1095" width="101" height="17" font="13">4% in the placebo </text>
<text top="503" left="1095" width="98" height="17" font="13">group of CHARM-</text>
<text top="520" left="1095" width="66" height="17" font="13">Preserved.  </text>
<text top="382" left="1210" width="30" height="17" font="13">3.1 y </text>
<text top="382" left="1277" width="164" height="17" font="13">886 (23%) pts in candesartan </text>
<text top="400" left="1277" width="144" height="17" font="13">and 945 (25%) in placebo </text>
<text top="417" left="1277" width="154" height="17" font="13">group died (unadjusted HR: </text>
<text top="434" left="1277" width="139" height="17" font="13">0.91; 95% Cl: 0.83–1.00; </text>
<text top="451" left="1277" width="164" height="17" font="13">p=0.055; covariate aHR: 0.90 </text>
<text top="469" left="1277" width="166" height="17" font="13">95% CU: 0.82–0.99; p=0.032) </text>
<text top="486" left="1277" width="169" height="17" font="13">• Fewer CV deaths (691 [18%] </text>
<text top="503" left="1277" width="166" height="17" font="13">vs 769 [20%], unadjusted HR: </text>
<text top="520" left="1277" width="139" height="17" font="13">0.88; 95% Cl: 0.79–0.97; </text>
<text top="537" left="1277" width="167" height="17" font="13">p=0.012; covariate aHR: 0.87; </text>
<text top="555" left="1277" width="164" height="17" font="13">95% Cl: 0.78–0.96; p=0.006)  </text>
<text top="572" left="1277" width="167" height="17" font="13">• Hospital admissions for CHF </text>
<text top="589" left="1277" width="141" height="17" font="13">(757 [20%] vs 918 [24%], </text>
<text top="606" left="1277" width="59" height="17" font="13">p&lt;0.0001) </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">85</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="681" width="70" height="17" font="13">the previous </text>
<text top="72" left="681" width="71" height="17" font="13">4 wk; Use of </text>
<text top="89" left="681" width="59" height="17" font="13">an ARB in </text>
<text top="106" left="681" width="70" height="17" font="13">the previous </text>
<text top="124" left="681" width="29" height="17" font="13">2 wk </text>
<text top="142" left="22" width="1431" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blockers; ASA, aspirin; BP, blood pressure; BSA, body surface area; CABG, coronary artery bypass graft; CHARM, Candesartan in Heart Failure: Assessment </text>
<text top="159" left="22" width="1436" height="17" font="13">of Reduction in Mortality and Morbidity; CHD, chronic heart disease; CHF, congestive heart failure; Cr, creatinine; CV, cardiovascular; DM, diabetes mellitus; EF, ejection fraction; FU, follow-up; HEAAL study, effects of high-dose versus low-dose losartan on clinical </text>
<text top="176" left="22" width="1434" height="17" font="13">outcomes in patients with heart failure; HF, heart failure; HR, heart rate; IHD, ischemic heart disease; LV, left ventricular; LVD, left ventricular dilatation; MI, myocardial infarction; MV, mitral valve; N/A, not applicable; NNT, number needed to treat; NYHA, New York </text>
<text top="193" left="22" width="1428" height="17" font="13">Heart Association; QoL, quality of life; pts, patients; SBP, systolic blood pressure; RCT, randomized control trial; SCr, serum creatinine; TIA, transient ischemic attack; UA, unstable angina; Val-HeFT, Valsartan Heart Failure Trial; and VALIANT, Valsartan in Acute </text>
<text top="210" left="22" width="120" height="17" font="13">Myocardial Infarction. </text>
<text top="231" left="54" width="4" height="16" font="7"> </text>
<text top="266" left="54" width="369" height="21" font="8"><b>Data Supplement 20. Beta Blockers (Section 7.3.2.4) </b></text>
<text top="310" left="40" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="327" left="41" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="310" left="153" width="42" height="17" font="15"><b>Aim of </b></text>
<text top="327" left="155" width="38" height="17" font="15"><b>Study </b></text>
<text top="310" left="233" width="38" height="17" font="15"><b>Study </b></text>
<text top="327" left="235" width="32" height="17" font="15"><b>Type </b></text>
<text top="310" left="295" width="75" height="17" font="15"><b>Background </b></text>
<text top="327" left="307" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="327" left="401" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="327" left="506" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="327" left="643" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="327" left="851" width="51" height="17" font="15"><b>Severity </b></text>
<text top="327" left="999" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="327" left="1179" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="310" left="1303" width="29" height="17" font="15"><b>Trial </b></text>
<text top="327" left="1291" width="57" height="17" font="15"><b>Duration  </b></text>
<text top="310" left="1379" width="62" height="17" font="15"><b>Statistical </b></text>
<text top="327" left="1386" width="48" height="17" font="15"><b>Results </b></text>
<text top="345" left="409" width="12" height="17" font="21"><i><b>N </b></i></text>
<text top="347" left="421" width="34" height="15" font="16"><i><b>(Total)</b></i></text>
<text top="345" left="455" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="363" left="388" width="11" height="17" font="21"><i><b>n </b></i></text>
<text top="364" left="399" width="77" height="15" font="16"><i><b>(Experimental)</b></i></text>
<text top="363" left="476" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="380" left="403" width="11" height="17" font="21"><i><b>n </b></i></text>
<text top="381" left="414" width="47" height="15" font="16"><i><b>(Control)</b></i></text>
<text top="380" left="461" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="363" left="597" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="380" left="603" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="380" left="695" width="108" height="17" font="21"><i><b>Exclusion Criteria </b></i></text>
<text top="380" left="875" width="3" height="17" font="21"><i><b> </b></i></text>
<text top="363" left="955" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="380" left="952" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="363" left="1045" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="380" left="1050" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="363" left="1138" width="69" height="17" font="21"><i><b>Annualized </b></i></text>
<text top="380" left="1146" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="363" left="1234" width="33" height="17" font="21"><i><b>1st Y </b></i></text>
<text top="380" left="1223" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="398" left="35" width="82" height="17" font="15"><b>CIBIS ll</b> CIBIS </text>
<text top="415" left="35" width="81" height="17" font="13">ll investigators </text>
<text top="432" left="35" width="84" height="17" font="13">and committee </text>
<text top="449" left="35" width="55" height="17" font="13">members </text>
<text top="467" left="35" width="39" height="17" font="13">(1999) </text>
<text top="484" left="35" width="55" height="17" font="14">10023943</text>
<text top="484" left="90" width="3" height="17" font="13"> </text>
<text top="501" left="35" width="32" height="17" font="13">(180) </text>
<text top="398" left="136" width="63" height="17" font="13">Investigate </text>
<text top="415" left="136" width="66" height="17" font="13">the efficacy </text>
<text top="432" left="136" width="70" height="17" font="13">of bisoprolol </text>
<text top="449" left="136" width="13" height="17" font="13">in </text>
<text top="467" left="136" width="64" height="17" font="13">decreasing </text>
<text top="484" left="136" width="53" height="17" font="13">all-cause </text>
<text top="501" left="136" width="63" height="17" font="13">mortality in </text>
<text top="518" left="136" width="63" height="17" font="13">chronic HF </text>
<text top="398" left="224" width="33" height="17" font="13">RCT- </text>
<text top="415" left="224" width="49" height="17" font="13">multicent</text>
<text top="432" left="224" width="14" height="17" font="13">er </text>
<text top="449" left="224" width="41" height="17" font="13">double-</text>
<text top="467" left="224" width="29" height="17" font="13">blind </text>
<text top="484" left="224" width="47" height="17" font="13">randiomi</text>
<text top="501" left="224" width="23" height="17" font="13">sed </text>
<text top="518" left="224" width="46" height="17" font="13">placebo </text>
<text top="535" left="224" width="46" height="17" font="13">controlle</text>
<text top="553" left="224" width="33" height="17" font="13">d trial </text>
<text top="570" left="224" width="51" height="17" font="13">(Europe) </text>
<text top="398" left="292" width="62" height="17" font="13">Diuretics + </text>
<text top="415" left="292" width="39" height="17" font="13">ACEI;  </text>
<text top="432" left="292" width="72" height="17" font="13">[amiodarone </text>
<text top="449" left="292" width="68" height="17" font="13">allowed--14-</text>
<text top="467" left="292" width="34" height="17" font="13">l6%]   </text>
<text top="398" left="386" width="68" height="17" font="13">2647; 1327; </text>
<text top="415" left="386" width="31" height="17" font="13">1320 </text>
<text top="398" left="494" width="73" height="17" font="13">Documented </text>
<text top="415" left="494" width="52" height="17" font="13">Ischemic </text>
<text top="432" left="494" width="28" height="17" font="13">50% </text>
<text top="398" left="582" width="81" height="17" font="13">NYHA class lll </text>
<text top="415" left="582" width="29" height="17" font="13">or lV </text>
<text top="432" left="582" width="58" height="17" font="13">EF: &lt;35% </text>
<text top="449" left="582" width="71" height="17" font="13">18-80 y old   </text>
<text top="398" left="683" width="105" height="17" font="13">Uncontrolled HTN; </text>
<text top="415" left="683" width="123" height="17" font="13">MI/UA w/in previous 3 </text>
<text top="432" left="683" width="24" height="17" font="13">mo; </text>
<text top="449" left="683" width="100" height="17" font="13">PTCA/CABG w/in </text>
<text top="467" left="683" width="84" height="17" font="13">previous 6 mo; </text>
<text top="484" left="683" width="121" height="17" font="13">AV-block &gt;1st degree </text>
<text top="501" left="683" width="56" height="17" font="13">w/o PPM; </text>
<text top="518" left="683" width="117" height="17" font="13">Heart rate &lt; 60bpm;  </text>
<text top="535" left="683" width="68" height="17" font="13">resting SBP </text>
<text top="553" left="683" width="101" height="17" font="13">&lt;100mmHg; renal </text>
<text top="570" left="683" width="40" height="17" font="13">failure; </text>
<text top="587" left="683" width="109" height="17" font="13">Reversible obstruct </text>
<text top="604" left="683" width="115" height="17" font="13">lung disease; Use of </text>
<text top="621" left="683" width="77" height="17" font="13">beta blocker   </text>
<text top="398" left="828" width="69" height="17" font="13">Moderate to </text>
<text top="415" left="828" width="47" height="17" font="13">severe.  </text>
<text top="432" left="828" width="61" height="17" font="13">Mean BP:  </text>
<text top="449" left="828" width="82" height="17" font="13">130/80;  Mean </text>
<text top="467" left="828" width="86" height="17" font="13">HR:  80;  Mean </text>
<text top="484" left="828" width="95" height="17" font="13">EF:  28%;  Mean </text>
<text top="501" left="828" width="98" height="17" font="13">LVEDD:  6.7 cm;  </text>
<text top="518" left="828" width="51" height="17" font="13">AF: 20% </text>
<text top="398" left="939" width="54" height="17" font="13">All-cause </text>
<text top="415" left="939" width="50" height="17" font="13">mortality </text>
<text top="398" left="1034" width="54" height="17" font="13">All-cause </text>
<text top="415" left="1034" width="46" height="17" font="13">hospital </text>
<text top="432" left="1034" width="65" height="17" font="13">admissions </text>
<text top="449" left="1034" width="78" height="17" font="13">All CV deaths </text>
<text top="467" left="1034" width="59" height="17" font="13">Combined </text>
<text top="484" left="1034" width="57" height="17" font="13">endpoints </text>
<text top="501" left="1034" width="64" height="17" font="13">Permanent </text>
<text top="518" left="1034" width="55" height="17" font="13">treatment </text>
<text top="535" left="1034" width="61" height="17" font="13">withdrawal </text>
<text top="398" left="1135" width="38" height="17" font="13">13.2% </text>
<text top="415" left="1135" width="48" height="17" font="13">Placebo </text>
<text top="432" left="1135" width="79" height="17" font="13">group              </text>
<text top="449" left="1135" width="31" height="17" font="13">8.8% </text>
<text top="467" left="1135" width="48" height="17" font="13">Treatm't </text>
<text top="484" left="1135" width="38" height="17" font="13">group  </text>
<text top="398" left="1223" width="27" height="17" font="13"> N/A </text>
<text top="398" left="1291" width="34" height="17" font="13">1.3 y  </text>
<text top="398" left="1358" width="87" height="17" font="13"> HR: 0.66 (95% </text>
<text top="415" left="1358" width="82" height="17" font="13">CI: 0.54-0.81); </text>
<text top="432" left="1358" width="55" height="17" font="13">p&lt;0.0001 </text>
<text top="639" left="35" width="73" height="17" font="15"><b>MERIT-HF;   </b></text>
<text top="657" left="35" width="75" height="17" font="13">MERIT study </text>
<text top="674" left="35" width="83" height="17" font="13">Group;  (1999) </text>
<text top="691" left="35" width="55" height="17" font="14">10376614</text>
<text top="691" left="90" width="3" height="17" font="13"> </text>
<text top="708" left="35" width="32" height="17" font="13">(181) </text>
<text top="639" left="136" width="63" height="17" font="13">Investigate </text>
<text top="657" left="136" width="47" height="17" font="13">whether </text>
<text top="674" left="136" width="61" height="17" font="13">Metoprolol </text>
<text top="691" left="136" width="40" height="17" font="13">CR/XL </text>
<text top="708" left="136" width="47" height="17" font="13">lowered </text>
<text top="725" left="136" width="63" height="17" font="13">mortality in </text>
<text top="743" left="136" width="45" height="17" font="13">pts with </text>
<text top="760" left="136" width="61" height="17" font="13">decreased </text>
<text top="777" left="136" width="43" height="17" font="13">EF and </text>
<text top="639" left="224" width="34" height="17" font="13">RCT--</text>
<text top="657" left="224" width="49" height="17" font="13">multicent</text>
<text top="674" left="224" width="14" height="17" font="13">er </text>
<text top="691" left="224" width="41" height="17" font="13">double-</text>
<text top="708" left="224" width="29" height="17" font="13">blind </text>
<text top="725" left="224" width="47" height="17" font="13">randiomi</text>
<text top="743" left="224" width="23" height="17" font="13">sed </text>
<text top="760" left="224" width="46" height="17" font="13">placebo </text>
<text top="777" left="224" width="46" height="17" font="13">controlle</text>
<text top="639" left="292" width="62" height="17" font="13">Diuretics + </text>
<text top="657" left="292" width="63" height="17" font="13">ACEI          </text>
<text top="674" left="292" width="73" height="17" font="13">[Amiodarone </text>
<text top="691" left="292" width="78" height="17" font="13">NOT allowed] </text>
<text top="639" left="386" width="68" height="17" font="13">3991; 1991; </text>
<text top="657" left="386" width="31" height="17" font="13">2001 </text>
<text top="639" left="494" width="52" height="17" font="13">Ischemic </text>
<text top="657" left="494" width="28" height="17" font="13">65% </text>
<text top="639" left="582" width="65" height="17" font="13">NYHA ll-lV; </text>
<text top="657" left="582" width="68" height="17" font="13">40-80 y old; </text>
<text top="674" left="582" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="691" left="582" width="83" height="17" font="13">(36-40 if 6-min </text>
<text top="708" left="582" width="77" height="17" font="13">walk &lt;450m); </text>
<text top="725" left="582" width="73" height="17" font="13">HR &gt;68 bpm </text>
<text top="639" left="683" width="94" height="17" font="13">MI/UA w/in 28 d; </text>
<text top="657" left="683" width="111" height="17" font="13">Contra-indication or </text>
<text top="674" left="683" width="106" height="17" font="13">current use of beta </text>
<text top="691" left="683" width="47" height="17" font="13">blocker; </text>
<text top="708" left="683" width="131" height="17" font="13">PTCA/CABG w/in 4 mo </text>
<text top="725" left="683" width="120" height="17" font="13">Planned transplant or </text>
<text top="743" left="683" width="28" height="17" font="13">ICD; </text>
<text top="760" left="683" width="83" height="17" font="13">Heart block &gt; 1</text>
<text top="761" left="766" width="6" height="11" font="19">st</text>
<text top="760" left="772" width="3" height="17" font="13"> </text>
<text top="777" left="683" width="98" height="17" font="13">degree w/o PPM; </text>
<text top="639" left="828" width="83" height="17" font="13">Mild to severe. </text>
<text top="657" left="828" width="61" height="17" font="13">Mean BP:  </text>
<text top="674" left="828" width="79" height="17" font="13">130/78; Mean </text>
<text top="691" left="828" width="86" height="17" font="13">HR:  78;  Mean </text>
<text top="708" left="828" width="91" height="17" font="13">EF 28%;  AF 16-</text>
<text top="725" left="828" width="28" height="17" font="13">17% </text>
<text top="639" left="939" width="54" height="17" font="13">All-cause </text>
<text top="657" left="939" width="87" height="17" font="13">mortality            </text>
<text top="674" left="939" width="54" height="17" font="13">All-cause </text>
<text top="691" left="939" width="63" height="17" font="13">mortality in </text>
<text top="708" left="939" width="70" height="17" font="13">combination </text>
<text top="725" left="939" width="78" height="17" font="13">with all-cause </text>
<text top="743" left="939" width="72" height="17" font="13">admission to </text>
<text top="760" left="939" width="46" height="17" font="13">hospital </text>
<text top="639" left="1034" width="27" height="17" font="13"> N/A </text>
<text top="639" left="1135" width="38" height="17" font="13">11.0% </text>
<text top="657" left="1135" width="48" height="17" font="13">Placebo </text>
<text top="674" left="1135" width="79" height="17" font="13">group              </text>
<text top="691" left="1135" width="31" height="17" font="13">7.2% </text>
<text top="708" left="1135" width="48" height="17" font="13">Treatm't </text>
<text top="725" left="1135" width="38" height="17" font="13">group  </text>
<text top="639" left="1223" width="27" height="17" font="13"> N/A </text>
<text top="639" left="1291" width="23" height="17" font="13">1 y  </text>
<text top="639" left="1358" width="90" height="17" font="13">Treatment of 27 </text>
<text top="657" left="1358" width="75" height="17" font="13">pt for 1 y can </text>
<text top="674" left="1358" width="92" height="17" font="13">prevent 1 death. </text>
<text top="691" left="1358" width="79" height="17" font="13">0.66 (95% CI: </text>
<text top="708" left="1358" width="63" height="17" font="13">0.53-0.81); </text>
<text top="725" left="1358" width="62" height="17" font="13">p=0.00009 </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">86</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="136" width="73" height="17" font="13">symptoms of </text>
<text top="72" left="136" width="20" height="17" font="13">HF </text>
<text top="55" left="224" width="33" height="17" font="13">d trial </text>
<text top="72" left="224" width="47" height="17" font="13">(Europe </text>
<text top="89" left="224" width="43" height="17" font="13">+ USA) </text>
<text top="55" left="683" width="92" height="17" font="13">SBP&lt;100mmHg </text>
<text top="115" left="35" width="82" height="17" font="15"><b>COPERNICUS</b></text>
<text top="133" left="35" width="79" height="17" font="13">; Packer et al; </text>
<text top="150" left="35" width="39" height="17" font="13">(2002) </text>
<text top="167" left="35" width="58" height="17" font="14">12390947 </text>
<text top="167" left="93" width="3" height="17" font="13"> </text>
<text top="184" left="35" width="35" height="17" font="13">(182)  </text>
<text top="115" left="136" width="63" height="17" font="13">Investigate </text>
<text top="133" left="136" width="47" height="17" font="13">whether </text>
<text top="150" left="136" width="74" height="17" font="13">Carvadiolo is </text>
<text top="167" left="136" width="68" height="17" font="13">beneficial in </text>
<text top="184" left="136" width="60" height="17" font="13">severe HF </text>
<text top="115" left="224" width="34" height="17" font="13">RCT--</text>
<text top="133" left="224" width="40" height="17" font="13">double </text>
<text top="150" left="224" width="29" height="17" font="13">blind </text>
<text top="115" left="292" width="77" height="17" font="13">Diuretics (PO </text>
<text top="133" left="292" width="76" height="17" font="13">or IV) + ACEI </text>
<text top="150" left="292" width="62" height="17" font="13">(or ARB);   </text>
<text top="167" left="292" width="73" height="17" font="13">[Amiodarone </text>
<text top="184" left="292" width="63" height="17" font="13">allowed 17-</text>
<text top="202" left="292" width="31" height="17" font="13">18%] </text>
<text top="115" left="386" width="68" height="17" font="13">2289; 1156; </text>
<text top="133" left="386" width="31" height="17" font="13">1133 </text>
<text top="115" left="494" width="52" height="17" font="13">Ischemic </text>
<text top="133" left="494" width="28" height="17" font="13">67% </text>
<text top="115" left="582" width="60" height="17" font="13">Euvolumic </text>
<text top="133" left="582" width="87" height="17" font="13">NYHA class lV; </text>
<text top="150" left="582" width="73" height="17" font="13">LVEF &lt;25%; </text>
<text top="167" left="582" width="64" height="17" font="13">No positive </text>
<text top="184" left="582" width="68" height="17" font="13">inotropes or </text>
<text top="202" left="582" width="69" height="17" font="13">vasodilators </text>
<text top="219" left="582" width="46" height="17" font="13">w/in 4 d </text>
<text top="115" left="683" width="66" height="17" font="13">Pt requiring </text>
<text top="133" left="683" width="120" height="17" font="13">hospitalized intensive </text>
<text top="150" left="683" width="31" height="17" font="13">care; </text>
<text top="167" left="683" width="84" height="17" font="13">Use of positive </text>
<text top="184" left="683" width="87" height="17" font="13">inotropes or IV; </text>
<text top="202" left="683" width="119" height="17" font="13">vasodilators w/in 4-d; </text>
<text top="219" left="683" width="54" height="17" font="13">Coronary </text>
<text top="236" left="683" width="122" height="17" font="13">revascularization/MI/C</text>
<text top="253" left="683" width="124" height="17" font="13">VA/sign VT or VF w/in </text>
<text top="270" left="683" width="34" height="17" font="13">2 mo; </text>
<text top="288" left="683" width="99" height="17" font="13">SBP &lt; 85 mmHg, </text>
<text top="305" left="683" width="130" height="17" font="13">Heart rate &lt;68, Cr &gt;2.8 </text>
<text top="322" left="683" width="38" height="17" font="13">mg/dL </text>
<text top="115" left="828" width="42" height="17" font="13">Severe </text>
<text top="133" left="828" width="61" height="17" font="13">Mean BP:  </text>
<text top="150" left="828" width="48" height="17" font="13">123/76;  </text>
<text top="167" left="828" width="86" height="17" font="13">Mean HR:  83;  </text>
<text top="184" left="828" width="92" height="17" font="13">Mean EF 20%;   </text>
<text top="115" left="939" width="54" height="17" font="13">All-cause </text>
<text top="133" left="939" width="50" height="17" font="13">mortality </text>
<text top="115" left="1034" width="82" height="17" font="13">Combined risk </text>
<text top="133" left="1034" width="62" height="17" font="13">of death or </text>
<text top="150" left="1034" width="82" height="17" font="13">hospitalization-</text>
<text top="167" left="1034" width="68" height="17" font="13">any reason; </text>
<text top="184" left="1034" width="82" height="17" font="13">Combined risk </text>
<text top="202" left="1034" width="62" height="17" font="13">of death or </text>
<text top="219" left="1034" width="82" height="17" font="13">hospitalization-</text>
<text top="236" left="1034" width="69" height="17" font="13">-CV reason; </text>
<text top="253" left="1034" width="82" height="17" font="13">Combined risk </text>
<text top="270" left="1034" width="62" height="17" font="13">of death or </text>
<text top="288" left="1034" width="82" height="17" font="13">hospitalization-</text>
<text top="305" left="1034" width="68" height="17" font="13">-HF reason; </text>
<text top="322" left="1034" width="51" height="17" font="13">Pt global </text>
<text top="339" left="1034" width="69" height="17" font="13">assessment </text>
<text top="115" left="1135" width="38" height="17" font="13">19.7% </text>
<text top="133" left="1135" width="67" height="17" font="13">placebo       </text>
<text top="150" left="1135" width="74" height="17" font="13">[24.0% in pts </text>
<text top="167" left="1135" width="63" height="17" font="13">with recent </text>
<text top="184" left="1135" width="67" height="17" font="13">or recurrent </text>
<text top="202" left="1135" width="43" height="17" font="13">cardiac </text>
<text top="219" left="1135" width="70" height="17" font="13">decompensa</text>
<text top="236" left="1135" width="33" height="17" font="13">tions] </text>
<text top="115" left="1223" width="51" height="17" font="13">18.5% in </text>
<text top="133" left="1223" width="50" height="17" font="13">placebo  </text>
<text top="150" left="1223" width="62" height="17" font="13">group         </text>
<text top="167" left="1223" width="51" height="17" font="13">11.4% in </text>
<text top="184" left="1223" width="45" height="17" font="13">Carvedil</text>
<text top="202" left="1223" width="58" height="17" font="13">ol group    </text>
<text top="115" left="1291" width="48" height="17" font="13">10.4 mo </text>
<text top="115" left="1358" width="93" height="17" font="13">Treating 1000 pt </text>
<text top="133" left="1358" width="71" height="17" font="13">for 1 y led to </text>
<text top="150" left="1358" width="76" height="17" font="13">savings of 70 </text>
<text top="167" left="1358" width="100" height="17" font="13">premature deaths </text>
<text top="184" left="1358" width="55" height="17" font="13">p=0.0014 </text>
<text top="365" left="35" width="62" height="17" font="15"><b>SENIORS</b>; </text>
<text top="382" left="35" width="72" height="17" font="13">Flather et al; </text>
<text top="400" left="35" width="39" height="17" font="13">(2005) </text>
<text top="417" left="35" width="55" height="17" font="14">15642700</text>
<text top="417" left="90" width="3" height="17" font="13"> </text>
<text top="434" left="35" width="32" height="17" font="13">(183) </text>
<text top="365" left="136" width="43" height="17" font="13">Assess </text>
<text top="382" left="136" width="74" height="17" font="13">effects of the </text>
<text top="400" left="136" width="70" height="17" font="13">beta blocker </text>
<text top="417" left="136" width="67" height="17" font="13">Nebivolol in </text>
<text top="434" left="136" width="54" height="17" font="13">pts &gt;70 y </text>
<text top="451" left="136" width="74" height="17" font="13">regardless of </text>
<text top="469" left="136" width="23" height="17" font="13">EF. </text>
<text top="365" left="224" width="158" height="17" font="13">RCT Diuretics </text>
<text top="365" left="343" width="49" height="17" font="13">+ </text>
<text top="382" left="292" width="32" height="17" font="13">ACEI </text>
<text top="400" left="292" width="79" height="17" font="13">(+aldosterone </text>
<text top="417" left="292" width="73" height="17" font="13">antagonist in </text>
<text top="434" left="292" width="32" height="17" font="13">29%) </text>
<text top="365" left="386" width="68" height="17" font="13">2128; 1067; </text>
<text top="382" left="386" width="31" height="17" font="13">1061 </text>
<text top="365" left="494" width="50" height="17" font="13">Prior h/o </text>
<text top="382" left="494" width="70" height="17" font="13">CAD in 69% </text>
<text top="365" left="582" width="50" height="17" font="13">Age &gt;70 </text>
<text top="382" left="582" width="66" height="17" font="13">Chronic HF </text>
<text top="400" left="582" width="83" height="17" font="13">with one of the </text>
<text top="417" left="582" width="58" height="17" font="13">following:  </text>
<text top="434" left="582" width="81" height="17" font="13">hospitalization </text>
<text top="451" left="582" width="79" height="17" font="13">with CHF w/in </text>
<text top="469" left="582" width="71" height="17" font="13">a year or EF </text>
<text top="486" left="582" width="81" height="17" font="13">&lt;35% w/in the </text>
<text top="503" left="582" width="81" height="17" font="13">past 6 months </text>
<text top="365" left="683" width="128" height="17" font="13">New HF therapy w/in 6 </text>
<text top="382" left="683" width="118" height="17" font="13">wk or change in drug </text>
<text top="400" left="683" width="98" height="17" font="13">therapy w/in 2 wk </text>
<text top="417" left="683" width="110" height="17" font="13">Contra-indication to </text>
<text top="434" left="683" width="122" height="17" font="13">beta blockers, current </text>
<text top="451" left="683" width="113" height="17" font="13">use of beta blockers </text>
<text top="469" left="683" width="91" height="17" font="13">Significant renal </text>
<text top="486" left="683" width="66" height="17" font="13">dysfunction </text>
<text top="503" left="683" width="88" height="17" font="13">CVA w/in 3 mo. </text>
<text top="365" left="828" width="80" height="17" font="13">Mild to severe </text>
<text top="382" left="828" width="61" height="17" font="13">Mean BP:  </text>
<text top="400" left="828" width="48" height="17" font="13">139/81;  </text>
<text top="417" left="828" width="83" height="17" font="13">Mean HR:  79; </text>
<text top="434" left="828" width="81" height="17" font="13">Mean EF 36% </text>
<text top="451" left="828" width="69" height="17" font="13">(1/3 with EF </text>
<text top="469" left="828" width="50" height="17" font="13">&gt;35%);   </text>
<text top="365" left="939" width="76" height="17" font="13">Composite of </text>
<text top="382" left="939" width="53" height="17" font="13">all-cause </text>
<text top="400" left="939" width="64" height="17" font="13">mortality or </text>
<text top="417" left="939" width="66" height="17" font="13">CV hospital </text>
<text top="434" left="939" width="59" height="17" font="13">admission </text>
<text top="365" left="1034" width="54" height="17" font="13">All-cause </text>
<text top="382" left="1034" width="50" height="17" font="13">mortality </text>
<text top="400" left="1034" width="76" height="17" font="13">Composite of </text>
<text top="417" left="1034" width="53" height="17" font="13">all-cause </text>
<text top="434" left="1034" width="81" height="17" font="13">mortality or all-</text>
<text top="451" left="1034" width="82" height="17" font="13">cause hospital </text>
<text top="469" left="1034" width="65" height="17" font="13">admissions </text>
<text top="486" left="1034" width="53" height="17" font="13">All cause </text>
<text top="503" left="1034" width="46" height="17" font="13">hospital </text>
<text top="520" left="1034" width="65" height="17" font="13">admissions </text>
<text top="537" left="1034" width="66" height="17" font="13">CV hospital </text>
<text top="555" left="1034" width="65" height="17" font="13">admissions </text>
<text top="572" left="1034" width="70" height="17" font="13">CV mortality </text>
<text top="589" left="1034" width="76" height="17" font="13">Composite of </text>
<text top="606" left="1034" width="85" height="17" font="13">CV mortality or </text>
<text top="623" left="1034" width="66" height="17" font="13">CV hospital </text>
<text top="641" left="1034" width="65" height="17" font="13">admissions </text>
<text top="658" left="1034" width="69" height="17" font="13">NYHA class </text>
<text top="675" left="1034" width="83" height="17" font="13">assessment; 6 </text>
<text top="692" left="1034" width="33" height="17" font="13">MWT </text>
<text top="365" left="1135" width="27" height="17" font="13"> N/A </text>
<text top="365" left="1223" width="24" height="17" font="13">N/A </text>
<text top="365" left="1291" width="37" height="17" font="13">1.75 y </text>
<text top="365" left="1358" width="74" height="17" font="13">Absolute risk </text>
<text top="382" left="1358" width="92" height="17" font="13">reduction 4.2%;  </text>
<text top="400" left="1358" width="103" height="17" font="13">24 pts would need </text>
<text top="417" left="1358" width="90" height="17" font="13">to be treated for </text>
<text top="434" left="1358" width="84" height="17" font="13">21 mo to avoid </text>
<text top="451" left="1358" width="57" height="17" font="13">one event </text>
<text top="469" left="1358" width="103" height="17" font="13">RR: 0.86; 95% CI: </text>
<text top="486" left="1358" width="59" height="17" font="13">0.74-0.99; </text>
<text top="503" left="1358" width="48" height="17" font="13">p=0.039 </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">87</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="35" width="73" height="17" font="13">A Trial of the </text>
<text top="72" left="35" width="74" height="17" font="13">Beta-Blocker </text>
<text top="89" left="35" width="88" height="17" font="13">Bucindolol in Pt </text>
<text top="106" left="35" width="83" height="17" font="13">with Advanced </text>
<text top="124" left="35" width="66" height="17" font="13">Chronic HF </text>
<text top="141" left="35" width="54" height="17" font="13">The Beta-</text>
<text top="158" left="35" width="44" height="17" font="13">Blocker </text>
<text top="175" left="35" width="74" height="17" font="13">Evaluation of </text>
<text top="192" left="35" width="74" height="17" font="13">Survival Trial </text>
<text top="210" left="35" width="73" height="17" font="13">Investigators </text>
<text top="227" left="35" width="55" height="17" font="14">11386264</text>
<text top="227" left="90" width="3" height="17" font="13"> </text>
<text top="244" left="35" width="32" height="17" font="13">(184) </text>
<text top="55" left="136" width="69" height="17" font="13">Designed to </text>
<text top="72" left="136" width="58" height="17" font="13">determine </text>
<text top="89" left="136" width="47" height="17" font="13">whether </text>
<text top="106" left="136" width="59" height="17" font="13">bucindolol </text>
<text top="124" left="136" width="67" height="17" font="13">hydrochlorid</text>
<text top="141" left="136" width="24" height="17" font="13">e, a </text>
<text top="158" left="136" width="72" height="17" font="13">nonselective </text>
<text top="175" left="136" width="28" height="17" font="13">beta-</text>
<text top="192" left="136" width="62" height="17" font="13">adrenergic </text>
<text top="210" left="136" width="67" height="17" font="13">blocker and </text>
<text top="227" left="136" width="26" height="17" font="13">mild </text>
<text top="244" left="136" width="66" height="17" font="13">vasodilator, </text>
<text top="261" left="136" width="36" height="17" font="13">would </text>
<text top="278" left="136" width="62" height="17" font="13">reduce the </text>
<text top="296" left="136" width="73" height="17" font="13">rate of death </text>
<text top="313" left="136" width="51" height="17" font="13">from any </text>
<text top="330" left="136" width="36" height="17" font="13">cause </text>
<text top="347" left="136" width="55" height="17" font="13">among pt </text>
<text top="365" left="136" width="25" height="17" font="13">with </text>
<text top="382" left="136" width="57" height="17" font="13">advanced </text>
<text top="399" left="136" width="58" height="17" font="13">HF and to </text>
<text top="416" left="136" width="57" height="17" font="13">assess its </text>
<text top="433" left="136" width="46" height="17" font="13">effect in </text>
<text top="451" left="136" width="43" height="17" font="13">various </text>
<text top="468" left="136" width="61" height="17" font="13">subgroups </text>
<text top="485" left="136" width="60" height="17" font="13">defined by </text>
<text top="502" left="136" width="36" height="17" font="13">ethnic </text>
<text top="519" left="136" width="68" height="17" font="13">background </text>
<text top="537" left="136" width="24" height="17" font="13">and </text>
<text top="554" left="136" width="75" height="17" font="13">demographic </text>
<text top="571" left="136" width="56" height="17" font="13">criteria — </text>
<text top="588" left="136" width="63" height="17" font="13">specifically </text>
<text top="606" left="136" width="67" height="17" font="13">women and </text>
<text top="623" left="136" width="68" height="17" font="13">members of </text>
<text top="640" left="136" width="46" height="17" font="13">minority </text>
<text top="657" left="136" width="44" height="17" font="13">groups. </text>
<text top="55" left="224" width="145" height="17" font="13">RCT ACEIs </text>
<text top="55" left="330" width="52" height="17" font="13">(if </text>
<text top="72" left="292" width="55" height="17" font="13">tolerated) </text>
<text top="89" left="292" width="64" height="17" font="13">[91% ACE; </text>
<text top="106" left="292" width="75" height="17" font="13">7% ARB], for </text>
<text top="124" left="292" width="77" height="17" font="13">at least 1 mo. </text>
<text top="141" left="292" width="60" height="17" font="13">Before the </text>
<text top="158" left="292" width="76" height="17" font="13">publication of </text>
<text top="175" left="292" width="74" height="17" font="13">the results of </text>
<text top="192" left="292" width="73" height="17" font="13">the DIG trial, </text>
<text top="210" left="292" width="59" height="17" font="13">12 digoxin </text>
<text top="227" left="292" width="54" height="17" font="13">therapies </text>
<text top="244" left="292" width="30" height="17" font="13">were </text>
<text top="261" left="292" width="73" height="17" font="13">required, but </text>
<text top="278" left="292" width="72" height="17" font="13">thereafter its </text>
<text top="296" left="292" width="70" height="17" font="13">use became </text>
<text top="313" left="292" width="73" height="17" font="13">discretionary </text>
<text top="330" left="292" width="67" height="17" font="13">[DIG 94%].  </text>
<text top="55" left="386" width="68" height="17" font="13">2708; 1354; </text>
<text top="72" left="386" width="31" height="17" font="13">1354 </text>
<text top="55" left="494" width="52" height="17" font="13">Ischemic </text>
<text top="72" left="494" width="28" height="17" font="13">59% </text>
<text top="55" left="582" width="83" height="17" font="13">NYHA class III </text>
<text top="72" left="582" width="53" height="17" font="13">or IV HF  </text>
<text top="89" left="582" width="69" height="17" font="13">LVEF &lt;35% </text>
<text top="106" left="582" width="41" height="17" font="13"> &gt;18 y  </text>
<text top="55" left="683" width="131" height="17" font="13">Reversible cause of HF </text>
<text top="72" left="683" width="44" height="17" font="13">present </text>
<text top="89" left="683" width="115" height="17" font="13">Candidates for heart </text>
<text top="106" left="683" width="84" height="17" font="13">transplantation </text>
<text top="124" left="683" width="46" height="17" font="13">Cardiac </text>
<text top="141" left="683" width="96" height="17" font="13">revascularization </text>
<text top="158" left="683" width="114" height="17" font="13">procedure within the </text>
<text top="175" left="683" width="77" height="17" font="13">previous 60 d </text>
<text top="192" left="683" width="21" height="17" font="13">UA </text>
<text top="210" left="683" width="116" height="17" font="13">Heart rate &lt;50 beats </text>
<text top="227" left="683" width="93" height="17" font="13">per minute, SBP </text>
<text top="244" left="683" width="60" height="17" font="13">&lt;80mmHg </text>
<text top="261" left="683" width="116" height="17" font="13">Decompensated HF. </text>
<text top="55" left="828" width="78" height="17" font="13">NYHA lll or lV </text>
<text top="72" left="828" width="79" height="17" font="13">(92% class lll) </text>
<text top="89" left="828" width="54" height="17" font="13">EF 23%;  </text>
<text top="106" left="828" width="93" height="17" font="13">HR 82;                </text>
<text top="124" left="828" width="71" height="17" font="13">BP 117/71;   </text>
<text top="141" left="828" width="47" height="17" font="13">AF 12% </text>
<text top="55" left="939" width="64" height="17" font="13">Death from </text>
<text top="72" left="939" width="60" height="17" font="13">any cause </text>
<text top="55" left="1034" width="85" height="17" font="13">Death from CV </text>
<text top="72" left="1034" width="81" height="17" font="13">causes (death </text>
<text top="89" left="1034" width="72" height="17" font="13">due to pump </text>
<text top="106" left="1034" width="68" height="17" font="13">failure or an </text>
<text top="124" left="1034" width="85" height="17" font="13">ischemic event </text>
<text top="141" left="1034" width="58" height="17" font="13">or sudden </text>
<text top="158" left="1034" width="38" height="17" font="13">death) </text>
<text top="175" left="1034" width="83" height="17" font="13">Hospitalization </text>
<text top="192" left="1034" width="82" height="17" font="13">for any reason </text>
<text top="210" left="1034" width="83" height="17" font="13">Hospitalization </text>
<text top="227" left="1034" width="83" height="17" font="13">because of HF </text>
<text top="244" left="1034" width="76" height="17" font="13">Composite of </text>
<text top="261" left="1034" width="80" height="17" font="13">death or heart </text>
<text top="278" left="1034" width="80" height="17" font="13">tansplantation </text>
<text top="296" left="1034" width="82" height="17" font="13">LVEF at 3 and </text>
<text top="313" left="1034" width="38" height="17" font="13">12 mo </text>
<text top="330" left="1034" width="75" height="17" font="13">MI; QoL; and </text>
<text top="347" left="1034" width="80" height="17" font="13">any change in </text>
<text top="365" left="1034" width="69" height="17" font="13">the need for </text>
<text top="382" left="1034" width="70" height="17" font="13">concomitant </text>
<text top="399" left="1034" width="44" height="17" font="13">therapy </text>
<text top="55" left="1135" width="49" height="17" font="13">For pt in </text>
<text top="72" left="1135" width="38" height="17" font="13">NYHA </text>
<text top="89" left="1135" width="56" height="17" font="13">functional </text>
<text top="106" left="1135" width="69" height="17" font="13">class III, the </text>
<text top="124" left="1135" width="40" height="17" font="13">annual </text>
<text top="141" left="1135" width="75" height="17" font="13">mortality rate </text>
<text top="158" left="1135" width="66" height="17" font="13">was 16% in </text>
<text top="175" left="1135" width="67" height="17" font="13">the placebo </text>
<text top="192" left="1135" width="74" height="17" font="13">group; For pt </text>
<text top="210" left="1135" width="63" height="17" font="13">with NYHA </text>
<text top="227" left="1135" width="70" height="17" font="13">class IV, the </text>
<text top="244" left="1135" width="40" height="17" font="13">annual </text>
<text top="261" left="1135" width="75" height="17" font="13">mortality rate </text>
<text top="278" left="1135" width="33" height="17" font="13">in the </text>
<text top="296" left="1135" width="46" height="17" font="13">placebo </text>
<text top="313" left="1135" width="60" height="17" font="13">group was </text>
<text top="330" left="1135" width="28" height="17" font="13">28% </text>
<text top="347" left="1135" width="49" height="17" font="15"><b>Overall</b>: </text>
<text top="365" left="1135" width="40" height="17" font="13">annual </text>
<text top="382" left="1135" width="64" height="17" font="13">mortality of </text>
<text top="399" left="1135" width="44" height="17" font="13">17%  in </text>
<text top="416" left="1135" width="46" height="17" font="13">placebo </text>
<text top="433" left="1135" width="57" height="17" font="13">group c/w </text>
<text top="451" left="1135" width="61" height="17" font="13">15% in the </text>
<text top="468" left="1135" width="59" height="17" font="13">bucindolol </text>
<text top="485" left="1135" width="38" height="17" font="13">group. </text>
<text top="502" left="1135" width="7" height="17" font="13">  </text>
<text top="55" left="1223" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1291" width="27" height="17" font="13">~2 y </text>
<text top="55" left="1358" width="101" height="17" font="13"> 449 pt in placebo </text>
<text top="72" left="1358" width="101" height="17" font="13">group (33%) died, </text>
<text top="89" left="1358" width="57" height="17" font="13">411 in the </text>
<text top="106" left="1358" width="94" height="17" font="13">bucindolol group </text>
<text top="124" left="1358" width="91" height="17" font="13">(30%; HR: 0.90; </text>
<text top="141" left="1358" width="75" height="17" font="13">95% CI, 0.78-</text>
<text top="158" left="1358" width="94" height="17" font="13">1.02; unadjusted </text>
<text top="175" left="1358" width="95" height="17" font="13">p=0.10; adjusted </text>
<text top="192" left="1358" width="45" height="17" font="13">p=0.13) </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">88</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="35" width="51" height="17" font="15"><b>COMET</b>; </text>
<text top="72" left="35" width="76" height="17" font="13">Poole-Wilson </text>
<text top="89" left="35" width="69" height="17" font="13">et al; (2003) </text>
<text top="106" left="35" width="55" height="17" font="14">12853193</text>
<text top="106" left="90" width="3" height="17" font="13"> </text>
<text top="124" left="35" width="32" height="17" font="13">(185) </text>
<text top="55" left="136" width="69" height="17" font="13">To compare </text>
<text top="72" left="136" width="74" height="17" font="13">the effects of </text>
<text top="89" left="136" width="55" height="17" font="13">carvedilol </text>
<text top="106" left="136" width="24" height="17" font="13">and </text>
<text top="124" left="136" width="61" height="17" font="13">metoprolol </text>
<text top="141" left="136" width="57" height="17" font="13">on clinical </text>
<text top="158" left="136" width="64" height="17" font="13">outcome in </text>
<text top="175" left="136" width="65" height="17" font="13">pts with HF </text>
<text top="55" left="224" width="161" height="17" font="13">RCT Diuretics, </text>
<text top="72" left="292" width="38" height="17" font="13">ACEIs </text>
<text top="55" left="386" width="34" height="17" font="13">3029; </text>
<text top="72" left="386" width="100" height="17" font="13">1511 carvedilol;    </text>
<text top="89" left="386" width="92" height="17" font="13">1518 metoprolol </text>
<text top="106" left="386" width="42" height="17" font="13">tartrate </text>
<text top="124" left="386" width="7" height="17" font="13">  </text>
<text top="55" left="494" width="27" height="17" font="13"> N/A </text>
<text top="55" left="582" width="79" height="17" font="13">NYHA class ll-</text>
<text top="72" left="582" width="14" height="17" font="13">lV </text>
<text top="89" left="582" width="54" height="17" font="13">EF &lt;35% </text>
<text top="106" left="582" width="72" height="17" font="13">Previous CV </text>
<text top="124" left="582" width="59" height="17" font="13">admission </text>
<text top="55" left="683" width="27" height="17" font="13"> N/A </text>
<text top="55" left="828" width="80" height="17" font="13">Mild to severe </text>
<text top="72" left="828" width="7" height="17" font="13">  </text>
<text top="55" left="939" width="54" height="17" font="13">All-cause </text>
<text top="72" left="939" width="50" height="17" font="13">mortality </text>
<text top="89" left="939" width="62" height="17" font="13">Composite </text>
<text top="106" left="939" width="64" height="17" font="13">endpoint of </text>
<text top="124" left="939" width="53" height="17" font="13">all-cause </text>
<text top="141" left="939" width="68" height="17" font="13">mortality, or </text>
<text top="158" left="939" width="53" height="17" font="13">all-cause </text>
<text top="175" left="939" width="59" height="17" font="13">admission </text>
<text top="55" left="1034" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1135" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1223" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1291" width="30" height="17" font="13">4.8 y </text>
<text top="55" left="1358" width="54" height="17" font="13">All-cause </text>
<text top="72" left="1358" width="78" height="17" font="13">mortality 34% </text>
<text top="89" left="1358" width="79" height="17" font="13">carvedilol and </text>
<text top="106" left="1358" width="89" height="17" font="13">40% metoprolol </text>
<text top="124" left="1358" width="103" height="17" font="13">(HR: 0.83; 95% CI </text>
<text top="141" left="1358" width="59" height="17" font="13">0.74-0.93; </text>
<text top="158" left="1358" width="59" height="17" font="13">p=0.0017) </text>
<text top="193" left="35" width="68" height="17" font="15"><b>(CIBIS) III</b>;   </text>
<text top="210" left="35" width="38" height="17" font="13">2005   </text>
<text top="228" left="35" width="55" height="17" font="14">16143696</text>
<text top="228" left="90" width="3" height="17" font="13"> </text>
<text top="245" left="35" width="32" height="17" font="13">(186) </text>
<text top="193" left="136" width="54" height="17" font="13">Sufficient </text>
<text top="210" left="136" width="65" height="17" font="13">data do not </text>
<text top="228" left="136" width="51" height="17" font="13">currently </text>
<text top="245" left="136" width="42" height="17" font="13">exist to </text>
<text top="262" left="136" width="72" height="17" font="13">establish the </text>
<text top="279" left="136" width="51" height="17" font="13">optimum </text>
<text top="296" left="136" width="46" height="17" font="13">order of </text>
<text top="314" left="136" width="48" height="17" font="13">initiating </text>
<text top="331" left="136" width="63" height="17" font="13">chronic HF </text>
<text top="348" left="136" width="44" height="17" font="13">therapy </text>
<text top="365" left="136" width="55" height="17" font="13">(ACEI vs. </text>
<text top="382" left="136" width="27" height="17" font="13">beta </text>
<text top="400" left="136" width="54" height="17" font="13">blocker).  </text>
<text top="417" left="136" width="72" height="17" font="13">This was the </text>
<text top="434" left="136" width="66" height="17" font="13">objective of </text>
<text top="451" left="136" width="70" height="17" font="13">the CIBIS III </text>
<text top="469" left="136" width="41" height="17" font="13">trial-- it </text>
<text top="486" left="136" width="58" height="17" font="13">compared </text>
<text top="503" left="136" width="71" height="17" font="13">the effect on </text>
<text top="520" left="136" width="74" height="17" font="13">mortality and </text>
<text top="537" left="136" width="71" height="17" font="13">hospitalizatio</text>
<text top="555" left="136" width="55" height="17" font="13">n of initial </text>
<text top="572" left="136" width="66" height="17" font="13">monotherap</text>
<text top="589" left="136" width="69" height="17" font="13">y with either </text>
<text top="606" left="136" width="70" height="17" font="13">bisoprolol or </text>
<text top="624" left="136" width="68" height="17" font="13">enalapril for </text>
<text top="641" left="136" width="34" height="17" font="13">6 mo, </text>
<text top="658" left="136" width="65" height="17" font="13">followed by </text>
<text top="675" left="136" width="27" height="17" font="13">their </text>
<text top="692" left="136" width="70" height="17" font="13">combination </text>
<text top="710" left="136" width="59" height="17" font="13">for 6 to 24 </text>
<text top="727" left="136" width="24" height="17" font="13">mo. </text>
<text top="193" left="224" width="49" height="17" font="13">Multicent</text>
<text top="210" left="224" width="18" height="17" font="13">er, </text>
<text top="228" left="224" width="50" height="17" font="13">prospecti</text>
<text top="245" left="224" width="20" height="17" font="13">ve, </text>
<text top="262" left="224" width="51" height="17" font="13">randomiz</text>
<text top="279" left="224" width="21" height="17" font="13">ed, </text>
<text top="296" left="224" width="31" height="17" font="13">open-</text>
<text top="314" left="224" width="33" height="17" font="13">label, </text>
<text top="331" left="224" width="43" height="17" font="13">blinded </text>
<text top="348" left="224" width="54" height="17" font="13">end point </text>
<text top="365" left="224" width="49" height="17" font="13">evaluatio</text>
<text top="382" left="224" width="10" height="17" font="13">n </text>
<text top="400" left="224" width="55" height="17" font="13">(PROBE) </text>
<text top="417" left="224" width="40" height="17" font="13">trial,24 </text>
<text top="434" left="224" width="36" height="17" font="13">with 2 </text>
<text top="451" left="224" width="43" height="17" font="13">parallel </text>
<text top="469" left="224" width="44" height="17" font="13">groups. </text>
<text top="193" left="292" width="51" height="17" font="13">Diuretics </text>
<text top="210" left="292" width="76" height="17" font="13">84%; Digoxin </text>
<text top="228" left="292" width="28" height="17" font="13">32% </text>
<text top="193" left="386" width="31" height="17" font="13">1010 </text>
<text top="210" left="386" width="102" height="17" font="13">Bisoprolol 505;      </text>
<text top="228" left="386" width="75" height="17" font="13">Enalapril 505 </text>
<text top="245" left="386" width="7" height="17" font="13">  </text>
<text top="193" left="494" width="57" height="17" font="13">CAD 62% </text>
<text top="193" left="582" width="75" height="17" font="13">&gt;65 y, NYHA </text>
<text top="210" left="582" width="73" height="17" font="13">class II or III, </text>
<text top="228" left="582" width="58" height="17" font="13">and LVEF </text>
<text top="245" left="582" width="87" height="17" font="13">&lt;35% (By echo </text>
<text top="262" left="582" width="66" height="17" font="13">within the 3 </text>
<text top="279" left="582" width="28" height="17" font="13">mo)  </text>
<text top="296" left="582" width="88" height="17" font="13">Clinically stable </text>
<text top="314" left="582" width="66" height="17" font="13">HF (without </text>
<text top="331" left="582" width="49" height="17" font="13">clinically </text>
<text top="348" left="582" width="73" height="17" font="13">relevant fluid </text>
<text top="365" left="582" width="66" height="17" font="13">retention or </text>
<text top="382" left="582" width="43" height="17" font="13">diuretic </text>
<text top="400" left="582" width="64" height="17" font="13">adjustment </text>
<text top="417" left="582" width="59" height="17" font="13">within 7 d) </text>
<text top="193" left="683" width="102" height="17" font="13">Treatment with an </text>
<text top="210" left="683" width="109" height="17" font="13">ACEI, an ARB, or a </text>
<text top="228" left="683" width="116" height="17" font="13">beta blocker for &gt;7 d </text>
<text top="245" left="683" width="127" height="17" font="13">during the 3 mo before </text>
<text top="262" left="683" width="81" height="17" font="13">randomization </text>
<text top="279" left="683" width="120" height="17" font="13">Heart rate at rest &lt;60 </text>
<text top="296" left="683" width="109" height="17" font="13">beats/min without a </text>
<text top="314" left="683" width="127" height="17" font="13">functioning pacemaker </text>
<text top="331" left="683" width="125" height="17" font="13">Supine SBP &lt;100 mm </text>
<text top="348" left="683" width="57" height="17" font="13">Hg at rest </text>
<text top="365" left="683" width="96" height="17" font="13">SCr≥220 µmol/L </text>
<text top="382" left="683" width="122" height="17" font="13">AV block greater than </text>
<text top="400" left="683" width="118" height="17" font="13">first degree without a </text>
<text top="417" left="683" width="127" height="17" font="13">functioning pacemaker </text>
<text top="434" left="683" width="92" height="17" font="13">Obstructive lung </text>
<text top="451" left="683" width="46" height="17" font="13">disease </text>
<text top="469" left="683" width="89" height="17" font="13">contraindicating </text>
<text top="486" left="683" width="111" height="17" font="13">bisoprolol treatment </text>
<text top="193" left="828" width="79" height="17" font="13">NYHA ll or lll;  </text>
<text top="210" left="828" width="95" height="17" font="13">mild to moderate </text>
<text top="228" left="828" width="29" height="17" font="13">CHF </text>
<text top="245" left="828" width="72" height="17" font="13">LVEF 29%;   </text>
<text top="262" left="828" width="85" height="17" font="13">Heart rate 79;   </text>
<text top="279" left="828" width="59" height="17" font="13">SBP 134   </text>
<text top="193" left="939" width="69" height="17" font="13">The primary </text>
<text top="210" left="939" width="76" height="17" font="13">endpoint was </text>
<text top="228" left="939" width="63" height="17" font="13">time-to-the-</text>
<text top="245" left="939" width="71" height="17" font="13">first-event of </text>
<text top="262" left="939" width="73" height="17" font="13">combined all-</text>
<text top="279" left="939" width="36" height="17" font="13">cause </text>
<text top="296" left="939" width="64" height="17" font="13">mortality or </text>
<text top="314" left="939" width="53" height="17" font="13">all-cause </text>
<text top="331" left="939" width="81" height="17" font="13">hospitalization </text>
<text top="193" left="1034" width="83" height="17" font="13">Combined end </text>
<text top="210" left="1034" width="88" height="17" font="13">point at the end </text>
<text top="228" left="1034" width="34" height="17" font="13">of the </text>
<text top="245" left="1034" width="75" height="17" font="13">monotherapy </text>
<text top="262" left="1034" width="81" height="17" font="13">phase and the </text>
<text top="279" left="1034" width="55" height="17" font="13">individual </text>
<text top="296" left="1034" width="84" height="17" font="13">components of </text>
<text top="314" left="1034" width="65" height="17" font="13">the primary </text>
<text top="331" left="1034" width="71" height="17" font="13">end point, at </text>
<text top="348" left="1034" width="81" height="17" font="13">study end and </text>
<text top="365" left="1034" width="72" height="17" font="13">at the end of </text>
<text top="382" left="1034" width="21" height="17" font="13">the </text>
<text top="400" left="1034" width="75" height="17" font="13">monotherapy </text>
<text top="417" left="1034" width="40" height="17" font="13">phase. </text>
<text top="434" left="1034" width="58" height="17" font="13">CV death  </text>
<text top="451" left="1034" width="21" height="17" font="13">CV </text>
<text top="469" left="1034" width="85" height="17" font="13">hospitalization  </text>
<text top="193" left="1135" width="31" height="17" font="13">  N/A </text>
<text top="193" left="1223" width="31" height="17" font="13">  N/A </text>
<text top="193" left="1291" width="48" height="17" font="13">Mean of </text>
<text top="210" left="1291" width="49" height="17" font="13">1.22±0.4</text>
<text top="228" left="1291" width="20" height="17" font="13">2 y </text>
<text top="245" left="1291" width="47" height="17" font="13">(maximu</text>
<text top="262" left="1291" width="55" height="17" font="13">m of 2.10 </text>
<text top="279" left="1291" width="17" height="17" font="13">y). </text>
<text top="193" left="1358" width="103" height="17" font="13">In the ITT sample, </text>
<text top="210" left="1358" width="84" height="17" font="13">178 pt (35.2%) </text>
<text top="228" left="1358" width="80" height="17" font="13">with a primary </text>
<text top="245" left="1358" width="87" height="17" font="13">end point in the </text>
<text top="262" left="1358" width="80" height="17" font="13">bisoprolol-first </text>
<text top="279" left="1358" width="86" height="17" font="13">group, and 186 </text>
<text top="296" left="1358" width="80" height="17" font="13">(36.8%) in the </text>
<text top="314" left="1358" width="74" height="17" font="13">enalapril-first </text>
<text top="331" left="1358" width="89" height="17" font="13">group (absolute </text>
<text top="348" left="1358" width="96" height="17" font="13">difference -1.6%; </text>
<text top="365" left="1358" width="82" height="17" font="13">95% CI -7.6 to </text>
<text top="382" left="1358" width="90" height="17" font="13">4.4%; HR: 0.94; </text>
<text top="400" left="1358" width="85" height="17" font="13">95% CI 0.77 to </text>
<text top="417" left="1358" width="31" height="17" font="13">1.16; </text>
<text top="434" left="1358" width="92" height="17" font="13">noninferiority for </text>
<text top="451" left="1358" width="80" height="17" font="13">bisoprolol-first </text>
<text top="469" left="1358" width="90" height="17" font="13">versus enalapril-</text>
<text top="486" left="1358" width="82" height="17" font="13">first treatment, </text>
<text top="503" left="1358" width="52" height="17" font="13">p=0.019) </text>
<text top="745" left="22" width="1427" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; AV, atrioventricular; BP, blood pressure; CABG, coronary artery bypass graft; CHF, congestive heart failure; CIBIS II, Cardiac Insufficiency Bisoprolol </text>
<text top="762" left="22" width="1435" height="17" font="13">Study II; COMET, Carvedilol Or Metoprolol European Trial; COPERNICUS, carvedilol prospective randomized cumulative survival; Cr, creatinine; CR/XL, controlled release/extended release; CV, cardiovascular; CVA, cerebrovascular accident; c/w, compared with; </text>
<text top="779" left="22" width="1427" height="17" font="13">DIG, Digitalis Investigation Group; EF, ejection fraction; HF, heart failure; h/o, history of; HR, hazard ratio; ICD, ICD, implantable cardioverter defibrillator; ITT, intent to treat; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; </text>
</page>
<page number="89" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">89</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="22" width="1415" height="17" font="13">MI, myocardial infarction; MWT, minute walk test; NYHA, New York Heart Association; PPM, permanent pacemaker; PTCA, percutaneous transluminal coronary angioplasty; Pts, patients; QoL, quality of life; RCT, randomized control trial; RR, relative risk; SBP, </text>
<text top="71" left="22" width="940" height="17" font="13">systolic blood pressure; SCr, serum creatinine; UA, unstable angina; USA, United States of America; VF, ventricular fibrillation; VT, ventricular tachycardia; and w/o, without. </text>
<text top="88" left="54" width="3" height="15" font="6"> </text>
<text top="125" left="54" width="4" height="16" font="7"> </text>
<text top="159" left="54" width="394" height="21" font="8"><b>Data Supplement 21. Anticoagulation (Section 7.3.2.8.1) </b></text>
<text top="200" left="73" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="219" left="73" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="219" left="194" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="219" left="322" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="219" left="437" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="181" left="546" width="76" height="19" font="9"><b>Study Size  </b></text>
<text top="200" left="569" width="26" height="19" font="9"><b>(HF </b></text>
<text top="219" left="531" width="103" height="19" font="9"><b>Subpopulation) </b></text>
<text top="219" left="705" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="219" left="1017" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="219" left="1240" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="238" left="668" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="257" left="674" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="257" left="767" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="257" left="909" width="117" height="19" font="10"><i><b>Primary Endpoint </b></i></text>
<text top="257" left="1057" width="139" height="19" font="10"><i><b>Secondary  Endpoint </b></i></text>
<text top="277" left="61" width="107" height="17" font="15"><b>WARCEF</b> Pullicino </text>
<text top="294" left="61" width="34" height="17" font="13">2006, </text>
<text top="294" left="95" width="55" height="17" font="14">16500579</text>
<text top="294" left="150" width="7" height="17" font="13">; </text>
<text top="311" left="61" width="81" height="17" font="13">Homma 2012, </text>
<text top="329" left="61" width="58" height="17" font="14">22551105 </text>
<text top="346" left="61" width="32" height="17" font="13">(187) </text>
<text top="277" left="183" width="99" height="17" font="13">Compare efficacy </text>
<text top="294" left="183" width="90" height="17" font="13">of warfarin (INR </text>
<text top="311" left="183" width="87" height="17" font="13">2.75) vs aspirin </text>
<text top="329" left="183" width="96" height="17" font="13">(325 mg/d) in HF </text>
<text top="346" left="183" width="100" height="17" font="13">pt in sinus rhythm </text>
<text top="277" left="305" width="73" height="17" font="13">RCT, double </text>
<text top="294" left="305" width="70" height="17" font="13">blind/double </text>
<text top="311" left="305" width="47" height="17" font="13">dummy, </text>
<text top="329" left="305" width="110" height="17" font="13">multicenter, parallel </text>
<text top="346" left="305" width="35" height="17" font="13">group </text>
<text top="277" left="429" width="84" height="17" font="13">N=2305, mean </text>
<text top="294" left="429" width="83" height="17" font="13">f/u 3.5 y; (69% </text>
<text top="311" left="429" width="88" height="17" font="13">power to detect </text>
<text top="329" left="429" width="35" height="17" font="13">~18% </text>
<text top="346" left="429" width="54" height="17" font="13">reduction </text>
<text top="363" left="429" width="44" height="17" font="13">primary </text>
<text top="380" left="429" width="55" height="17" font="13">endpoint) </text>
<text top="277" left="531" width="212" height="17" font="13">N/A EF≤35%,NYHA I-</text>
<text top="294" left="646" width="88" height="17" font="13">IV, sinus rhytm, </text>
<text top="311" left="646" width="97" height="17" font="13">taking ACEI/ARB </text>
<text top="329" left="646" width="90" height="17" font="13">or H/N, planned </text>
<text top="346" left="646" width="81" height="17" font="13">treatment with </text>
<text top="363" left="646" width="70" height="17" font="13">beta blocker </text>
<text top="277" left="766" width="106" height="17" font="13">Contraindication to </text>
<text top="294" left="766" width="120" height="17" font="13">or absolute indication </text>
<text top="311" left="766" width="87" height="17" font="13">for 1 treatment; </text>
<text top="329" left="766" width="84" height="17" font="13">MI/PCI/cardiac </text>
<text top="346" left="766" width="86" height="17" font="13">surgery &lt;3 mo; </text>
<text top="363" left="766" width="114" height="17" font="13">decompensated HF, </text>
<text top="380" left="766" width="85" height="17" font="13">life expectancy </text>
<text top="397" left="766" width="106" height="17" font="13">otherwise &lt;5 y, HF </text>
<text top="415" left="766" width="116" height="17" font="13">admission or CEA or </text>
<text top="432" left="766" width="118" height="17" font="13">PPM insertion &lt;1 mo </text>
<text top="277" left="899" width="127" height="17" font="13">Efficacy: time to first of </text>
<text top="294" left="899" width="93" height="17" font="13">(death+ischemic </text>
<text top="311" left="899" width="112" height="17" font="13">stroke+intracerebral </text>
<text top="329" left="899" width="119" height="17" font="13">hemorrhage); Safety: </text>
<text top="346" left="899" width="104" height="17" font="13">major hemorrhage </text>
<text top="277" left="1048" width="94" height="17" font="13">Efficacy: primary </text>
<text top="294" left="1048" width="95" height="17" font="13">endpoint+MI+HF </text>
<text top="311" left="1048" width="155" height="17" font="13">hospitalization; components </text>
<text top="329" left="1048" width="121" height="17" font="13">of primary composite; </text>
<text top="346" left="1048" width="42" height="17" font="13">Safety: </text>
<text top="363" left="1048" width="139" height="17" font="13">intracerebral+intracranial </text>
<text top="380" left="1048" width="70" height="17" font="13">hemorrhage </text>
<text top="277" left="1218" width="218" height="17" font="13">Primary Efficacy: 7.47 events (warfarin) </text>
<text top="294" left="1218" width="216" height="17" font="13">vs. 7.93 events (aspirin) /100 person-y. </text>
<text top="311" left="1218" width="215" height="17" font="13">Secondary: ischemic stroke – warfarin, </text>
<text top="329" left="1218" width="201" height="17" font="13">HR: 0.52; Safety major hemorrhage: </text>
<text top="346" left="1218" width="222" height="17" font="13">Warafin 1.78 vs aspirin 0.87/100 person-</text>
<text top="363" left="1218" width="13" height="17" font="13">y. </text>
<text top="380" left="1218" width="228" height="17" font="13">Primary Endpoint: p=0.40: 95% CI: 0.79 - </text>
<text top="397" left="1218" width="225" height="17" font="13">1.10; ischemic stroke p=0.0005, 95% CI: </text>
<text top="415" left="1218" width="218" height="17" font="13">0.33 - 0.82; major hemorrhage p&lt;0.001 </text>
<text top="450" left="61" width="49" height="17" font="15"><b>HELAS</b>  </text>
<text top="467" left="61" width="85" height="17" font="13">Cokkinos 2006 </text>
<text top="484" left="61" width="58" height="17" font="14">16737850 </text>
<text top="501" left="61" width="32" height="17" font="13">(188) </text>
<text top="450" left="183" width="70" height="17" font="13">Determine if </text>
<text top="467" left="183" width="94" height="17" font="13">warfarin(INR 2.0-</text>
<text top="484" left="183" width="107" height="17" font="13">3.0) or aspirin (325 </text>
<text top="501" left="183" width="82" height="17" font="13">mg/d) reduces </text>
<text top="519" left="183" width="98" height="17" font="13">thromboemboli in </text>
<text top="536" left="183" width="20" height="17" font="13">HF </text>
<text top="450" left="305" width="99" height="17" font="13">RCT, multicenter, </text>
<text top="467" left="305" width="74" height="17" font="13">double-blind, </text>
<text top="484" left="305" width="107" height="17" font="13">placebo-controlled; </text>
<text top="501" left="305" width="101" height="17" font="13">(converted to pilot </text>
<text top="519" left="305" width="70" height="17" font="13">study due to </text>
<text top="536" left="305" width="64" height="17" font="13">inadequate </text>
<text top="553" left="305" width="65" height="17" font="13">enrollment) </text>
<text top="450" left="429" width="78" height="17" font="13">N=194, mean </text>
<text top="467" left="429" width="58" height="17" font="13">f/u 22 mo; </text>
<text top="484" left="429" width="52" height="17" font="13">Ischemic </text>
<text top="501" left="429" width="59" height="17" font="13">(aspirin vs </text>
<text top="519" left="429" width="55" height="17" font="13">warfarin), </text>
<text top="536" left="429" width="75" height="17" font="13">N=114; DCM </text>
<text top="553" left="429" width="70" height="17" font="13">(warfarin vs. </text>
<text top="570" left="429" width="87" height="17" font="13">placebo), N=80 </text>
<text top="588" left="429" width="86" height="17" font="13">(stopped at 4% </text>
<text top="605" left="429" width="73" height="17" font="13">target due to </text>
<text top="622" left="429" width="28" height="17" font="13">poor </text>
<text top="639" left="429" width="69" height="17" font="13">recruitment) </text>
<text top="450" left="531" width="24" height="17" font="13">N/A </text>
<text top="450" left="646" width="86" height="17" font="13">NYHA II-IV; EF </text>
<text top="467" left="646" width="39" height="17" font="13">&lt;35%; </text>
<text top="484" left="646" width="71" height="17" font="13">Prespecified </text>
<text top="501" left="646" width="64" height="17" font="13">subgroups: </text>
<text top="519" left="646" width="99" height="17" font="13">Ischemic vs DCM </text>
<text top="450" left="766" width="119" height="17" font="13">MI &lt;2 mo; &#34;reversible </text>
<text top="467" left="766" width="93" height="17" font="13">ischemia&#34;, mitral </text>
<text top="484" left="766" width="113" height="17" font="13">disease, HoCM, AF, </text>
<text top="501" left="766" width="77" height="17" font="13">LV thrombus, </text>
<text top="519" left="766" width="109" height="17" font="13">pregnancy, uncontr </text>
<text top="536" left="766" width="104" height="17" font="13">HTN, contra-ind to </text>
<text top="553" left="766" width="98" height="17" font="13">either study drug, </text>
<text top="570" left="766" width="83" height="17" font="13">otherwise &lt;2 y </text>
<text top="588" left="766" width="98" height="17" font="13">expected survival </text>
<text top="450" left="899" width="109" height="17" font="13">Efficacy: composite </text>
<text top="467" left="899" width="98" height="17" font="13">[nonfatal stroke + </text>
<text top="484" left="899" width="130" height="17" font="13">arterial TEE or PE + MI </text>
<text top="501" left="899" width="113" height="17" font="13">+ rehospitalization + </text>
<text top="519" left="899" width="103" height="17" font="13">worsened HF + all-</text>
<text top="536" left="899" width="135" height="17" font="13">cause mortality]; Safety: </text>
<text top="553" left="899" width="111" height="17" font="13">ICH + &#34;bleeding&#34; on </text>
<text top="570" left="899" width="55" height="17" font="13">treatment </text>
<text top="450" left="1048" width="102" height="17" font="13">Need for coronary </text>
<text top="467" left="1048" width="99" height="17" font="13">revascularization; </text>
<text top="484" left="1048" width="140" height="17" font="13">readmission for ischemia </text>
<text top="450" left="1218" width="219" height="17" font="13">Primary Efficacy (events/100 person-y): </text>
<text top="467" left="1218" width="217" height="17" font="13">Isch/aspirin (14.9), Isch/warfarin (15.7); </text>
<text top="484" left="1218" width="207" height="17" font="13">DCM/warfarin (6); DCM/placebo (10); </text>
<text top="501" left="1218" width="222" height="17" font="13">Safety: Isch/ warfarin (4), DCM/ warfarin </text>
<text top="519" left="1218" width="231" height="17" font="13">(3), others (0). 2.2 events/100 person-y (5 </text>
<text top="536" left="1218" width="198" height="17" font="13">stroke, 2 MI, no arterial TEE or PE). </text>
<text top="657" left="61" width="44" height="17" font="15"><b>WASH</b>  </text>
<text top="674" left="61" width="79" height="17" font="13">Cleland 2004  </text>
<text top="692" left="61" width="55" height="17" font="14">15215806</text>
<text top="692" left="116" width="3" height="17" font="13"> </text>
<text top="709" left="61" width="32" height="17" font="13">(189) </text>
<text top="657" left="183" width="66" height="17" font="13">Pilot Study: </text>
<text top="674" left="183" width="100" height="17" font="13">feasibility of study </text>
<text top="692" left="183" width="108" height="17" font="13">comparing warfarin </text>
<text top="709" left="183" width="107" height="17" font="13">(INR 2.5) to aspirin </text>
<text top="726" left="183" width="77" height="17" font="13">(300 mg/d) to </text>
<text top="743" left="183" width="47" height="17" font="13">placebo </text>
<text top="657" left="305" width="68" height="17" font="13">Prospective </text>
<text top="674" left="305" width="64" height="17" font="13">multicenter </text>
<text top="692" left="305" width="104" height="17" font="13">placebo-controlled </text>
<text top="709" left="305" width="103" height="17" font="13">RCT, 3-arm, open-</text>
<text top="726" left="305" width="76" height="17" font="13">label, blinded </text>
<text top="743" left="305" width="54" height="17" font="13">endpoint  </text>
<text top="657" left="429" width="63" height="17" font="13">N=279 pts, </text>
<text top="674" left="429" width="89" height="17" font="13">mean f/u 27 mo </text>
<text top="657" left="531" width="260" height="17" font="13">N/A Required </text>
<text top="657" left="699" width="144" height="17" font="13">diuretics; </text>
<text top="674" left="646" width="107" height="17" font="13">LVEDD &gt;55 mm or </text>
<text top="692" left="646" width="58" height="17" font="13">&gt;30 mm/m</text>
<text top="693" left="705" width="4" height="11" font="19">2</text>
<text top="692" left="709" width="37" height="17" font="13"> or EF </text>
<text top="709" left="646" width="40" height="17" font="13">≤35%; </text>
<text top="726" left="646" width="71" height="17" font="13">Prespecified </text>
<text top="743" left="646" width="64" height="17" font="13">subgroups: </text>
<text top="760" left="646" width="102" height="17" font="13">ischemic vs. DCM </text>
<text top="657" left="766" width="109" height="17" font="13">&#34;Definite&#34; indication </text>
<text top="674" left="766" width="79" height="17" font="13">for warfarin or </text>
<text top="692" left="766" width="103" height="17" font="13">aspirin, MI &lt; 4 wk, </text>
<text top="709" left="766" width="114" height="17" font="13">inpt status, contr-ind </text>
<text top="726" left="766" width="76" height="17" font="13">to either drug </text>
<text top="657" left="899" width="122" height="17" font="13">Time to first event (on </text>
<text top="674" left="899" width="132" height="17" font="13">treatment or within 10 d </text>
<text top="692" left="899" width="130" height="17" font="13">of stopping treatment):  </text>
<text top="709" left="899" width="108" height="17" font="13">composite [death + </text>
<text top="726" left="899" width="122" height="17" font="13">nonfatal MI + nonfatal </text>
<text top="743" left="899" width="40" height="17" font="13">stroke] </text>
<text top="657" left="1048" width="144" height="17" font="13">Prespecified: death or CV </text>
<text top="674" left="1048" width="150" height="17" font="13">hospitalization; death or all-</text>
<text top="692" left="1048" width="148" height="17" font="13">cause hospitalization; total </text>
<text top="709" left="1048" width="140" height="17" font="13">hospitalizations; death or </text>
<text top="726" left="1048" width="147" height="17" font="13">CV hospitalization or need </text>
<text top="743" left="1048" width="151" height="17" font="13">for increased diuretic dose; </text>
<text top="760" left="1048" width="144" height="17" font="13">worsening HF; MI; stroke; </text>
<text top="778" left="1048" width="107" height="17" font="13">major hemorrhage. </text>
<text top="657" left="1218" width="174" height="17" font="13">Both ITT an AT: &#34;no difference&#34; </text>
<text top="674" left="1218" width="227" height="17" font="13">PRIMARY ITT:  Placebo: 26% (HR: 0.96; </text>
<text top="692" left="1218" width="211" height="17" font="13">95% CI: 0.60-1.54); Aspirin: 32% (HR: </text>
<text top="709" left="1218" width="226" height="17" font="13">1.16; 95%  CI: 0.74-1.85); Warfarin: 26% </text>
<text top="726" left="1218" width="218" height="17" font="13">(HR: 0.88; 95% CI 0.54-1.43), p=0.22;   </text>
<text top="743" left="1218" width="205" height="17" font="13">AT: Placebo: 20% (HR: 1.08 95% CI: </text>
<text top="760" left="1218" width="219" height="17" font="13">0.65-1.89); Aspirin: 22% (HR: 1.02 95% </text>
<text top="778" left="1218" width="219" height="17" font="13">CI: 0.59-1.75); Warfarin: 18% (HR: 0.89 </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">90</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1218" width="211" height="17" font="13">95% CI: 0.50-1.16); Secondar ITT:  all-</text>
<text top="72" left="1218" width="223" height="17" font="13">cause hospitalizations (Placebo 48% vs. </text>
<text top="89" left="1218" width="208" height="17" font="13">Aspirin 64% vs. Warfarin 47%); Major </text>
<text top="106" left="1218" width="190" height="17" font="13">hemorrhage &#34;no difference&#34;; minor </text>
<text top="124" left="1218" width="231" height="17" font="13">hemorrhage (Placebo 5% vs. Aspirin 13% </text>
<text top="141" left="1218" width="153" height="17" font="13">vs. Warfarin 17%), p=0.033 </text>
<text top="159" left="61" width="53" height="17" font="15"><b>WATCH</b>  </text>
<text top="176" left="61" width="73" height="17" font="13">Massie 2009 </text>
<text top="193" left="61" width="58" height="17" font="14">19289640 </text>
<text top="210" left="61" width="32" height="17" font="13">(190) </text>
<text top="159" left="183" width="75" height="17" font="13">Hypotheses:  </text>
<text top="176" left="183" width="109" height="17" font="13">warfarin superior to </text>
<text top="193" left="183" width="64" height="17" font="13">aspirin and </text>
<text top="210" left="183" width="63" height="17" font="13">clopidogrel </text>
<text top="228" left="183" width="101" height="17" font="13">superior to aspirin </text>
<text top="245" left="183" width="77" height="17" font="13">for HF pt with </text>
<text top="262" left="183" width="95" height="17" font="13">reduced LVEF in </text>
<text top="279" left="183" width="73" height="17" font="13">sinus rhythm </text>
<text top="159" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="176" left="305" width="96" height="17" font="13">multicenter RCT, </text>
<text top="193" left="305" width="60" height="17" font="13">open label </text>
<text top="210" left="305" width="110" height="17" font="13">(warfarin) or double </text>
<text top="228" left="305" width="92" height="17" font="13">blind APT group </text>
<text top="245" left="305" width="101" height="17" font="13">comparing aspirin </text>
<text top="262" left="305" width="72" height="17" font="13">(162 mg) vs. </text>
<text top="279" left="305" width="105" height="17" font="13">clopidogrel (75 mg </text>
<text top="296" left="305" width="111" height="17" font="13">no load) vs warfarin </text>
<text top="314" left="305" width="88" height="17" font="13">(target INR 2.5) </text>
<text top="159" left="429" width="50" height="17" font="13">N=1587; </text>
<text top="176" left="429" width="84" height="17" font="13">treatment for 1 </text>
<text top="193" left="429" width="85" height="17" font="13">y; mean f/u 1.9 </text>
<text top="210" left="429" width="61" height="17" font="13">y (stopped </text>
<text top="228" left="429" width="68" height="17" font="13">early due to </text>
<text top="245" left="429" width="28" height="17" font="13">poor </text>
<text top="262" left="429" width="69" height="17" font="13">recruitment) </text>
<text top="159" left="531" width="24" height="17" font="13">N/A </text>
<text top="159" left="646" width="86" height="17" font="13">NYHA II-IV, EF </text>
<text top="176" left="646" width="72" height="17" font="13">≤35%; sinus </text>
<text top="193" left="646" width="92" height="17" font="13">rhythm on entry; </text>
<text top="210" left="646" width="90" height="17" font="13">on diuretics and </text>
<text top="228" left="646" width="83" height="17" font="13">ACE-I /ARB or </text>
<text top="245" left="646" width="25" height="17" font="13">H/N </text>
<text top="159" left="766" width="85" height="17" font="13">Reversible HF; </text>
<text top="176" left="766" width="101" height="17" font="13">contraindicated to </text>
<text top="193" left="766" width="87" height="17" font="13">any study drug; </text>
<text top="210" left="766" width="112" height="17" font="13">imminent procedure </text>
<text top="228" left="766" width="94" height="17" font="13">or surgery; other </text>
<text top="245" left="766" width="87" height="17" font="13">survival-limiting </text>
<text top="262" left="766" width="46" height="17" font="13">disease </text>
<text top="159" left="899" width="114" height="17" font="13">Efficacy: time to first </text>
<text top="176" left="899" width="107" height="17" font="13">event of composite </text>
<text top="193" left="899" width="123" height="17" font="13">[death + nonfatal MI + </text>
<text top="210" left="899" width="133" height="17" font="13">nonfatal stroke]; Safety: </text>
<text top="228" left="899" width="84" height="17" font="13">major bleeding </text>
<text top="159" left="1048" width="155" height="17" font="13">Death; nonfatal MI; nonfatal </text>
<text top="176" left="1048" width="140" height="17" font="13">stroke; hospitalization for </text>
<text top="193" left="1048" width="20" height="17" font="13">HF </text>
<text top="159" left="1218" width="205" height="17" font="13">Efficacy ITT:  Primary - No difference </text>
<text top="176" left="1218" width="188" height="17" font="13">warfarin vs. aspirin vs clopidogrel; </text>
<text top="193" left="1218" width="224" height="17" font="13">Secondary - A group with more total and </text>
<text top="210" left="1218" width="198" height="17" font="13">HF hospital admissions; Safety ITT: </text>
<text top="228" left="1218" width="212" height="17" font="13">warfarin=aspirin, both with more major </text>
<text top="245" left="1218" width="140" height="17" font="13">bleeding than clopidogrel </text>
<text top="262" left="1218" width="201" height="17" font="13">Efficacy PRIMARY: ITT: warfarin vs. </text>
<text top="279" left="1218" width="204" height="17" font="13">aspirin: HR: 0.98; 95% CI: 0.86-1.12; </text>
<text top="296" left="1218" width="222" height="17" font="13">p=0.77. clopidogrel vs. aspirin: HR: 1.08 </text>
<text top="314" left="1218" width="217" height="17" font="13">95% CI: 0.83-1.40; p=0.57. warfarin vs. </text>
<text top="331" left="1218" width="228" height="17" font="13">clopidogrel: HR: 0.89; 95% CI: 0.68-1.16; </text>
<text top="348" left="1218" width="219" height="17" font="13">p=0.39.  AT: warfarin superior to aspirin </text>
<text top="365" left="1218" width="175" height="17" font="13">(p=0.0095), warfarin superior to </text>
<text top="382" left="1218" width="214" height="17" font="13">clopidogrel (p=0.0031).  SECONDARY </text>
<text top="400" left="1218" width="207" height="17" font="13">endpoints: HF hospitalizations aspirin </text>
<text top="417" left="1218" width="214" height="17" font="13">(22.2%) vs. warfarin (16.5%), p=0.019; </text>
<text top="434" left="1218" width="206" height="17" font="13">Total HF admissions aspirin (218) vs. </text>
<text top="451" left="1218" width="176" height="17" font="13">warfarin (155), p &lt;0.001. Safety </text>
<text top="469" left="1218" width="194" height="17" font="13">PRIMARY: major bleeding warfarin </text>
<text top="486" left="1218" width="216" height="17" font="13">(5.2%) vs. clopidogrel (2.1%), p=0.007; </text>
<text top="503" left="1218" width="223" height="17" font="13">warfarin vs. aspirin (p=NS).  POST HOC </text>
<text top="520" left="1218" width="190" height="17" font="13">Ischemic group (N=1163): Strokes </text>
<text top="537" left="1218" width="201" height="17" font="13">warfarin (0) vs. aspirin (1.6), p=0.01; </text>
<text top="555" left="1218" width="191" height="17" font="13">warfarin (0) vs. clopidogrel (2.7%), </text>
<text top="572" left="1218" width="215" height="17" font="13">p=0.0009; Nonischemic group (N=424) </text>
<text top="589" left="1218" width="189" height="17" font="13">Major bleed clopidogrel (0.7%) vs. </text>
<text top="606" left="1218" width="222" height="17" font="13">warfarin (6.3%), p=0.0093.   AT analysis </text>
<text top="623" left="1218" width="211" height="17" font="13">(not prespecified): warfarin superior to </text>
<text top="641" left="1218" width="215" height="17" font="13">aspirin (p=0.0095); warfarin superior to </text>
<text top="658" left="1218" width="130" height="17" font="13">clopidogrel (p=0.0031). </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">91</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="49" height="17" font="15"><b>EPICAL</b> </text>
<text top="72" left="61" width="93" height="17" font="13">Echemann 2002 </text>
<text top="89" left="61" width="58" height="17" font="14">12413509 </text>
<text top="106" left="61" width="32" height="17" font="13">(191) </text>
<text top="55" left="183" width="101" height="17" font="13">Compare warfarin </text>
<text top="72" left="183" width="105" height="17" font="13">vs. aspirin vs. both </text>
<text top="89" left="183" width="104" height="17" font="13">on survival in CHF </text>
<text top="55" left="305" width="68" height="17" font="13">Prospective </text>
<text top="72" left="305" width="76" height="17" font="13">observational </text>
<text top="89" left="305" width="101" height="17" font="13">population-based, </text>
<text top="106" left="305" width="92" height="17" font="13">nonrandomized, </text>
<text top="124" left="305" width="68" height="17" font="13">consecutive </text>
<text top="141" left="305" width="98" height="17" font="13">hospital survivors </text>
<text top="158" left="305" width="98" height="17" font="13">of hospitalization, </text>
<text top="175" left="305" width="106" height="17" font="13">aspirin vs. warfarin </text>
<text top="192" left="305" width="59" height="17" font="13">at hospital </text>
<text top="210" left="305" width="57" height="17" font="13">discharge </text>
<text top="55" left="429" width="65" height="17" font="13">N=417 with </text>
<text top="72" left="429" width="84" height="17" font="13">complete data, </text>
<text top="89" left="429" width="82" height="17" font="13">mean f/u= 5 y; </text>
<text top="106" left="429" width="86" height="17" font="13">aspirin (30.9%) </text>
<text top="124" left="429" width="48" height="17" font="13">vs. OAT </text>
<text top="141" left="429" width="66" height="17" font="13">(28.3%) vs. </text>
<text top="158" left="429" width="70" height="17" font="13">both (2.4%)  </text>
<text top="55" left="531" width="210" height="17" font="13">N/A  </text>
<text top="55" left="650" width="103" height="17" font="13">≥ 1 hospitalization </text>
<text top="72" left="646" width="90" height="17" font="13">for HF, NYHA II-</text>
<text top="89" left="646" width="88" height="17" font="13">IV, EF ≤30% or </text>
<text top="106" left="646" width="97" height="17" font="13">CTR ≥ 0.60, plus </text>
<text top="124" left="646" width="84" height="17" font="13">hypotension or </text>
<text top="141" left="646" width="66" height="17" font="13">systemic or </text>
<text top="158" left="646" width="102" height="17" font="13">pulmonary edema </text>
<text top="55" left="766" width="85" height="17" font="13">Failure to meet </text>
<text top="72" left="766" width="92" height="17" font="13">inclusion criteria </text>
<text top="89" left="766" width="66" height="17" font="13">(systematic </text>
<text top="106" left="766" width="65" height="17" font="13">enrollment) </text>
<text top="55" left="899" width="111" height="17" font="13">Survival 1 y and 5 y </text>
<text top="72" left="899" width="61" height="17" font="13">from index </text>
<text top="89" left="899" width="135" height="17" font="13">hospitalization; stratified </text>
<text top="106" left="899" width="51" height="17" font="13">by LVEF </text>
<text top="55" left="1048" width="33" height="17" font="13">None </text>
<text top="55" left="1218" width="200" height="17" font="13">Both warfarin (RR=0.60) and aspirin </text>
<text top="72" left="1218" width="202" height="17" font="13">(RR=0.70) associated with improved </text>
<text top="89" left="1218" width="45" height="17" font="13">survival </text>
<text top="106" left="1218" width="221" height="17" font="13">Univariate survival: AC (1 y 77.7%; 95% </text>
<text top="124" left="1218" width="219" height="17" font="13">CI: 71.7-82.4), 3 y 55.1%; 95% CI: 48.7-</text>
<text top="141" left="1218" width="221" height="17" font="13">61.5), 5 y 40.4% [95% CI: 34.1-46.8] vs. </text>
<text top="158" left="1218" width="232" height="17" font="13">no AC (1 y 71.5% [95% CI: 64.9-78.1], 3 y </text>
<text top="175" left="1218" width="209" height="17" font="13">47.0% [95% CI: 39.6-54.3], 5 y 31.0% </text>
<text top="192" left="1218" width="222" height="17" font="13">[95% CI 24.0-38.0; p=0.01] for AC vs no </text>
<text top="210" left="1218" width="218" height="17" font="13">AC; Multivariate: OAT RR:0.60 [95% CI </text>
<text top="227" left="1218" width="226" height="17" font="13">0.4-0.8], aspirin RR: 0.7 [95% CI 0.5-0.9] </text>
<text top="245" left="61" width="101" height="17" font="13">Wojnicz 2006        </text>
<text top="262" left="61" width="58" height="17" font="14">16996844 </text>
<text top="279" left="61" width="32" height="17" font="13">(192) </text>
<text top="245" left="183" width="107" height="17" font="13">Pilot Study: LMWH </text>
<text top="262" left="183" width="97" height="17" font="13">effects on clinical </text>
<text top="279" left="183" width="70" height="17" font="13">endpoints in </text>
<text top="296" left="183" width="63" height="17" font="13">chronic HF </text>
<text top="314" left="183" width="105" height="17" font="13">secondary to DCM </text>
<text top="245" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="262" left="305" width="107" height="17" font="13">randomized, active </text>
<text top="279" left="305" width="99" height="17" font="13">treatment control, </text>
<text top="296" left="305" width="60" height="17" font="13">open label </text>
<text top="314" left="305" width="61" height="17" font="13">comparing </text>
<text top="331" left="305" width="85" height="17" font="13">enoxaparin 1.5 </text>
<text top="348" left="305" width="101" height="17" font="13">mg/kg BID x 14 d, </text>
<text top="365" left="305" width="86" height="17" font="13">then 1 daily x 3 </text>
<text top="382" left="305" width="27" height="17" font="13">mos </text>
<text top="245" left="429" width="61" height="17" font="13">N=102 (52 </text>
<text top="262" left="429" width="76" height="17" font="13">treatment, 50 </text>
<text top="279" left="429" width="44" height="17" font="13">control) </text>
<text top="296" left="429" width="78" height="17" font="13">enrolled, data </text>
<text top="314" left="429" width="68" height="17" font="13">on N=85 for </text>
<text top="331" left="429" width="82" height="17" font="13">analysis; f/u=1 </text>
<text top="348" left="429" width="10" height="17" font="13">y </text>
<text top="245" left="531" width="24" height="17" font="13">N/A </text>
<text top="245" left="646" width="105" height="17" font="13">Stable NYHA II-IV, </text>
<text top="262" left="646" width="99" height="17" font="13">EF ≤40%; cath to </text>
<text top="279" left="646" width="79" height="17" font="13">exclude CAD, </text>
<text top="296" left="646" width="40" height="17" font="13">Biopsy </text>
<text top="245" left="766" width="103" height="17" font="13">Contraindicated to </text>
<text top="262" left="766" width="112" height="17" font="13">any heparin, T1DM, </text>
<text top="279" left="766" width="108" height="17" font="13">valvular HD, recent </text>
<text top="296" left="766" width="102" height="17" font="13">heparin exposure, </text>
<text top="314" left="766" width="29" height="17" font="13">CAD </text>
<text top="245" left="899" width="126" height="17" font="13">Composite [mortality + </text>
<text top="262" left="899" width="127" height="17" font="13">urgent heart transplant </text>
<text top="279" left="899" width="133" height="17" font="13">+ hospital admission for </text>
<text top="296" left="899" width="131" height="17" font="13">worsening HF] at 6 and </text>
<text top="314" left="899" width="38" height="17" font="13">12 mo </text>
<text top="245" left="1048" width="149" height="17" font="13">Total survival, BNP, LVEF, </text>
<text top="262" left="1048" width="150" height="17" font="13">echo chamber parameters, </text>
<text top="279" left="1048" width="134" height="17" font="13">NYHA class change, VO</text>
<text top="285" left="1182" width="7" height="11" font="19">2 </text>
<text top="296" left="1048" width="57" height="17" font="13">max, QoL </text>
<text top="245" left="1218" width="124" height="17" font="13">Primary: no difference </text>
<text top="262" left="1218" width="200" height="17" font="13">Primary:  enoxaparin 4 vs. control 8, </text>
<text top="279" left="1218" width="227" height="17" font="13">p=NS; mortality: p=NS; Secondary:  BNP </text>
<text top="296" left="1218" width="230" height="17" font="13">reduction enoxaparin (1125-489) p&lt;0.001 </text>
<text top="314" left="1218" width="171" height="17" font="13">vs. no change in control; LVEF </text>
<text top="331" left="1218" width="227" height="17" font="13">improvement: enoxaparin increase 6.5%, </text>
<text top="348" left="1218" width="158" height="17" font="13">p=0.023; 95% CI: 1.01-8.17. </text>
<text top="400" left="61" width="44" height="17" font="15"><b>RE-LY</b>  </text>
<text top="418" left="61" width="82" height="17" font="13">Connolly 2009 </text>
<text top="435" left="61" width="58" height="17" font="14">19717844 </text>
<text top="452" left="61" width="32" height="17" font="13">(193) </text>
<text top="400" left="183" width="54" height="17" font="13">Compare </text>
<text top="418" left="183" width="81" height="17" font="13">dabigatran vs. </text>
<text top="435" left="183" width="104" height="17" font="13">warfarin effects on </text>
<text top="452" left="183" width="78" height="17" font="13">stroke/arterial </text>
<text top="469" left="183" width="98" height="17" font="13">emboli in pts with </text>
<text top="487" left="183" width="19" height="17" font="13">AF </text>
<text top="400" left="305" width="79" height="17" font="13">Noninferiority, </text>
<text top="418" left="305" width="67" height="17" font="13">multicenter, </text>
<text top="435" left="305" width="98" height="17" font="13">prospective RCT, </text>
<text top="452" left="305" width="109" height="17" font="13">blinded dab (110 or </text>
<text top="469" left="305" width="87" height="17" font="13">150 mg BID) or </text>
<text top="487" left="305" width="104" height="17" font="13">unblinded warfarin </text>
<text top="504" left="305" width="75" height="17" font="13">(INR 2.0-3.0) </text>
<text top="400" left="429" width="31" height="17" font="13">Total </text>
<text top="418" left="429" width="61" height="17" font="13">N=18,113; </text>
<text top="435" left="429" width="85" height="17" font="13">median f/u=2.0 </text>
<text top="452" left="429" width="10" height="17" font="13">y </text>
<text top="400" left="531" width="65" height="17" font="13">HF n=5793 </text>
<text top="418" left="531" width="80" height="17" font="13">(32%):  HF on </text>
<text top="435" left="531" width="68" height="17" font="13">dab 110 mg </text>
<text top="452" left="531" width="87" height="17" font="13">(n=1937/6015); </text>
<text top="469" left="531" width="85" height="17" font="13">HF on dab 150 </text>
<text top="487" left="531" width="87" height="17" font="13">(n=1934/6076); </text>
<text top="504" left="531" width="84" height="17" font="13">HF on warfarin </text>
<text top="521" left="531" width="87" height="17" font="13">(n=1922/6022). </text>
<text top="400" left="646" width="104" height="17" font="13">AF + ≥1 additional </text>
<text top="418" left="646" width="75" height="17" font="13">risk factor for </text>
<text top="435" left="646" width="85" height="17" font="13">stroke (median </text>
<text top="452" left="646" width="87" height="17" font="13">CHADS2 score </text>
<text top="469" left="646" width="68" height="17" font="13">2.1).  HF as </text>
<text top="487" left="646" width="96" height="17" font="13">qualifying criteria </text>
<text top="504" left="646" width="100" height="17" font="13">req'd LVEF &lt;40% </text>
<text top="521" left="646" width="98" height="17" font="13">or NYHA Class ≥ </text>
<text top="538" left="646" width="10" height="17" font="13">II </text>
<text top="400" left="766" width="109" height="17" font="13">Excessive bleeding </text>
<text top="418" left="766" width="98" height="17" font="13">risk, severe valve </text>
<text top="435" left="766" width="110" height="17" font="13">disease, stroke &lt;14 </text>
<text top="452" left="766" width="112" height="17" font="13">d/severe stroke &lt;60 </text>
<text top="469" left="766" width="109" height="17" font="13">mo, creat clear &lt;30 </text>
<text top="487" left="766" width="44" height="17" font="13">mL/min </text>
<text top="400" left="899" width="109" height="17" font="13">Efficacy: composite </text>
<text top="418" left="899" width="106" height="17" font="13">[stroke or systemic </text>
<text top="435" left="899" width="105" height="17" font="13">embolism]; Safety: </text>
<text top="452" left="899" width="132" height="17" font="13">Major hemorrhage (2 y) </text>
<text top="400" left="1048" width="153" height="17" font="13">Stroke, systemic embolism, </text>
<text top="418" left="1048" width="107" height="17" font="13">death, MI, PE, TIA, </text>
<text top="435" left="1048" width="81" height="17" font="13">hospitalization </text>
<text top="400" left="1218" width="228" height="17" font="13">ITT, noninferiority with Cox prop hazards. </text>
<text top="418" left="1218" width="199" height="17" font="13">Subsequent analyses for superiority </text>
<text top="435" left="1218" width="230" height="17" font="13">Symptomatic HF:  multivariate HR for dab </text>
<text top="452" left="1218" width="219" height="17" font="13">150 vs warfarin, p=0.33; 150 mg dab vs </text>
<text top="469" left="1218" width="224" height="17" font="13">warfarin: stroke 0.64; 95% CI: 0.51-0.81; </text>
<text top="487" left="1218" width="233" height="17" font="13">p&lt;0.001 (p&lt;0.05 for all stroke subgroups). </text>
<text top="504" left="1218" width="223" height="17" font="13">MI: RR: 1.38; 95% CI1.00-1.91; p=0.048 </text>
<text top="556" left="61" width="68" height="17" font="15"><b>ACTIVE-W</b>  </text>
<text top="573" left="61" width="34" height="17" font="13">2006  </text>
<text top="591" left="61" width="58" height="17" font="14">16765759 </text>
<text top="608" left="61" width="32" height="17" font="13">(194) </text>
<text top="556" left="183" width="72" height="17" font="13">Combination </text>
<text top="573" left="183" width="77" height="17" font="13">clopidogrel  + </text>
<text top="591" left="183" width="102" height="17" font="13">aspirin vs warfarin </text>
<text top="608" left="183" width="64" height="17" font="13">in reducing </text>
<text top="625" left="183" width="102" height="17" font="13">vascular events in </text>
<text top="642" left="183" width="19" height="17" font="13">AF </text>
<text top="556" left="305" width="98" height="17" font="13">Prospective open </text>
<text top="573" left="305" width="103" height="17" font="13">label noninferiority </text>
<text top="591" left="305" width="112" height="17" font="13">RCT of [clopidogrel  </text>
<text top="608" left="305" width="106" height="17" font="13">75 mg + aspirin 75-</text>
<text top="625" left="305" width="111" height="17" font="13">100 mg] vs warfarin </text>
<text top="642" left="305" width="75" height="17" font="13">(INR 2.0-3.0) </text>
<text top="556" left="429" width="78" height="17" font="13">Total N=6706 </text>
<text top="556" left="531" width="67" height="17" font="13">HF N=2031 </text>
<text top="573" left="531" width="36" height="17" font="13">(30%) </text>
<text top="556" left="646" width="92" height="17" font="13">AF, LVEF &lt;45% </text>
<text top="556" left="766" width="83" height="17" font="13">Other need for </text>
<text top="573" left="766" width="108" height="17" font="13">warfarin, excessive </text>
<text top="591" left="766" width="103" height="17" font="13">bleeding risk, prev </text>
<text top="608" left="766" width="117" height="17" font="13">ICH, platelets &lt;50 K, </text>
<text top="625" left="766" width="82" height="17" font="13">mitral stenosis </text>
<text top="556" left="899" width="124" height="17" font="13">Efficacy: First event of </text>
<text top="573" left="899" width="123" height="17" font="13">[stroke or arterial TEE </text>
<text top="591" left="899" width="136" height="17" font="13">or MI or vascular death]; </text>
<text top="608" left="899" width="76" height="17" font="13">Safety: Major </text>
<text top="625" left="899" width="70" height="17" font="13">hemorrhage </text>
<text top="556" left="1048" width="134" height="17" font="13">Efficacy: components of </text>
<text top="573" left="1048" width="124" height="17" font="13">primary; Safety: Minor </text>
<text top="591" left="1048" width="70" height="17" font="13">hemorrhage </text>
<text top="556" left="1218" width="152" height="17" font="13">KM log-rank (time to event) </text>
<text top="573" left="1218" width="231" height="17" font="13">Total Study: Primary Efficacy:  clopidogrel </text>
<text top="591" left="1218" width="220" height="17" font="13">+aspirin: 5.60 events/y vs. warfarin 3.93 </text>
<text top="608" left="1218" width="211" height="17" font="13">events/y; RR: 1.44; 95% CI 1.18-1.76; </text>
<text top="625" left="1218" width="226" height="17" font="13">p=0.0003; stroke RR: 1.72; 95% CI: 1.24-</text>
<text top="642" left="1218" width="79" height="17" font="13">2.37; p=0.001 </text>
<text top="660" left="61" width="73" height="17" font="15"><b>ARISTOTLE</b> </text>
<text top="677" left="61" width="79" height="17" font="13">Granger 2011 </text>
<text top="695" left="61" width="58" height="17" font="14">21870978 </text>
<text top="712" left="61" width="32" height="17" font="13">(195) </text>
<text top="660" left="183" width="107" height="17" font="13">Compare apixaban </text>
<text top="677" left="183" width="74" height="17" font="13">to warfarin in </text>
<text top="695" left="183" width="98" height="17" font="13">preventing stroke </text>
<text top="712" left="183" width="71" height="17" font="13">in pt with AF </text>
<text top="660" left="305" width="68" height="17" font="13">Prospective </text>
<text top="677" left="305" width="74" height="17" font="13">double-blind, </text>
<text top="695" left="305" width="85" height="17" font="13">double-dummy </text>
<text top="712" left="305" width="84" height="17" font="13">noninferiority + </text>
<text top="729" left="305" width="103" height="17" font="13">superiority RCT of </text>
<text top="746" left="305" width="88" height="17" font="13">AP 5 mg BID to </text>
<text top="763" left="305" width="93" height="17" font="13">warfarin INR 2-3 </text>
<text top="660" left="429" width="88" height="17" font="13">Total N=18,201 </text>
<text top="677" left="429" width="51" height="17" font="13">, median </text>
<text top="695" left="429" width="55" height="17" font="13">F/u=1.8 y </text>
<text top="660" left="531" width="65" height="17" font="13">HF n=6451 </text>
<text top="677" left="531" width="50" height="17" font="13">(35.5%), </text>
<text top="695" left="531" width="91" height="17" font="13">apixaban=3235, </text>
<text top="712" left="531" width="82" height="17" font="13">warfarin=3216 </text>
<text top="660" left="646" width="105" height="17" font="13">≥2 episodes AF or </text>
<text top="677" left="646" width="91" height="17" font="13">flutter, CHADS2 </text>
<text top="695" left="646" width="86" height="17" font="13">≥2 (HF criteria: </text>
<text top="712" left="646" width="92" height="17" font="13">symptomatic HF </text>
<text top="729" left="646" width="80" height="17" font="13">within 3 mo or </text>
<text top="746" left="646" width="74" height="17" font="13">LVEF ≤ 40% </text>
<text top="660" left="766" width="118" height="17" font="13">Reversible AF, mitral </text>
<text top="677" left="766" width="87" height="17" font="13">stenosis, orther </text>
<text top="695" left="766" width="73" height="17" font="13">indication for </text>
<text top="712" left="766" width="89" height="17" font="13">anticoagulation, </text>
<text top="729" left="766" width="109" height="17" font="13">recent stroke, need </text>
<text top="746" left="766" width="81" height="17" font="13">for antiplatelet </text>
<text top="763" left="766" width="115" height="17" font="13">therapy (beyond low-</text>
<text top="781" left="766" width="108" height="17" font="13">dose aspirin), creat </text>
<text top="660" left="899" width="79" height="17" font="13">Noninferiority: </text>
<text top="677" left="899" width="105" height="17" font="13">EFFICACY: stroke </text>
<text top="695" left="899" width="70" height="17" font="13">(ischemic or </text>
<text top="712" left="899" width="93" height="17" font="13">hemmorhagic) + </text>
<text top="729" left="899" width="111" height="17" font="13">systemic embolism; </text>
<text top="746" left="899" width="89" height="17" font="13">SAFETY: major </text>
<text top="763" left="899" width="50" height="17" font="13">bleeding </text>
<text top="660" left="1048" width="133" height="17" font="13">Superiority: EFFICACY: </text>
<text top="677" left="1048" width="107" height="17" font="13">stroke (ischemic or </text>
<text top="695" left="1048" width="144" height="17" font="13">hemmorhagic) + systemic </text>
<text top="712" left="1048" width="115" height="17" font="13">embolism;  all-cause </text>
<text top="729" left="1048" width="153" height="17" font="13">mortality; SAFETY: major + </text>
<text top="746" left="1048" width="145" height="17" font="13">clinical nonmajor bleeding </text>
<text top="660" left="1218" width="188" height="17" font="13">PRIMARY: ITT Efficacy: apixaban </text>
<text top="677" left="1218" width="166" height="17" font="13">1.27%/y vs warfarin 1.60%/y)  </text>
<text top="695" left="1218" width="221" height="17" font="13">Modified ITT Safety: apixaban 2.13% vs </text>
<text top="712" left="1218" width="230" height="17" font="13">warfarin 3.09%; mortality apixaban 3.52% </text>
<text top="729" left="1218" width="108" height="17" font="13">vs warfarin 3.94%.  </text>
<text top="746" left="1218" width="215" height="17" font="13">HF subgroup results not different (p for </text>
<text top="763" left="1218" width="92" height="17" font="13">interaction 0.50) </text>
<text top="781" left="1218" width="209" height="17" font="13">Efficacy: apixaban: HR: 0.79; 95% CI: </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">92</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="766" width="65" height="17" font="13">&gt;2.5 mg/dL </text>
<text top="55" left="1218" width="199" height="17" font="13">0.66-0.9;, p&lt;0.001 for noninferiority, </text>
<text top="72" left="1218" width="126" height="17" font="13">p=0.01 for superiority;  </text>
<text top="89" left="1218" width="209" height="17" font="13">Mortality apixaban: HR: 0.89: 95% CI: </text>
<text top="106" left="1218" width="114" height="17" font="13">0.80-0.99; p=0.047.  </text>
<text top="124" left="1218" width="229" height="17" font="13">Safety: apixaban: HR: 0.69; 95% CI: 0.60-</text>
<text top="141" left="1218" width="202" height="17" font="13">0.80; p&lt;0.001 (apixaban RRR: 27%) </text>
<text top="170" left="61" width="79" height="17" font="15"><b>ROCKET AF</b>  </text>
<text top="187" left="61" width="62" height="17" font="13">Patel 2011 </text>
<text top="205" left="61" width="58" height="17" font="14">21830957 </text>
<text top="222" left="61" width="32" height="17" font="13">(196) </text>
<text top="170" left="183" width="54" height="17" font="13">Compare </text>
<text top="187" left="183" width="81" height="17" font="13">rivaroxaban to </text>
<text top="205" left="183" width="60" height="17" font="13">warfarin in </text>
<text top="222" left="183" width="61" height="17" font="13">preventing </text>
<text top="239" left="183" width="107" height="17" font="13">ischemic strokes in </text>
<text top="256" left="183" width="105" height="17" font="13">pt with nonvalvular </text>
<text top="273" left="183" width="19" height="17" font="13">AF </text>
<text top="170" left="305" width="68" height="17" font="13">Prospective </text>
<text top="187" left="305" width="105" height="17" font="13">multicenter double-</text>
<text top="205" left="305" width="70" height="17" font="13">blind double-</text>
<text top="222" left="305" width="78" height="17" font="13">dummy event-</text>
<text top="239" left="305" width="111" height="17" font="13">driven noninferiority </text>
<text top="256" left="305" width="110" height="17" font="13">RCT of rivaroxaban </text>
<text top="273" left="305" width="99" height="17" font="13">20 mg/d (15 mg if </text>
<text top="291" left="305" width="66" height="17" font="13">Cr Cl 30-49 </text>
<text top="308" left="305" width="67" height="17" font="13">mL/min) vs. </text>
<text top="325" left="305" width="101" height="17" font="13">warfarin (INR 2-3) </text>
<text top="170" left="429" width="57" height="17" font="13">N=14,264 </text>
<text top="187" left="429" width="71" height="17" font="13">randomized, </text>
<text top="205" left="429" width="89" height="17" font="13">median f/u=707 </text>
<text top="222" left="429" width="10" height="17" font="13">d </text>
<text top="170" left="531" width="103" height="17" font="13">8909 (rivaroxaban </text>
<text top="187" left="531" width="81" height="17" font="13">4467, warfarin </text>
<text top="205" left="531" width="81" height="17" font="13">4441) (62.5%) </text>
<text top="170" left="646" width="91" height="17" font="13">Nonvalvular AF, </text>
<text top="187" left="646" width="95" height="17" font="13">CHADS2 ≥2; HF </text>
<text top="205" left="646" width="75" height="17" font="13">(clinical dx or </text>
<text top="222" left="646" width="78" height="17" font="13">LVEF ≤ 35%) </text>
<text top="170" left="766" width="85" height="17" font="13">Mitral stenosis, </text>
<text top="187" left="766" width="94" height="17" font="13">absolute non-AF </text>
<text top="205" left="766" width="97" height="17" font="13">indication for AC, </text>
<text top="222" left="766" width="67" height="17" font="13">high risk for </text>
<text top="239" left="766" width="86" height="17" font="13">anticoagulation </text>
<text top="170" left="899" width="94" height="17" font="13">Primary efficacy: </text>
<text top="187" left="899" width="129" height="17" font="13">composite [ischemic or </text>
<text top="205" left="899" width="112" height="17" font="13">hemorragic stroke + </text>
<text top="222" left="899" width="114" height="17" font="13">systemic embolism]; </text>
<text top="239" left="899" width="85" height="17" font="13">Primary safety: </text>
<text top="256" left="899" width="108" height="17" font="13">composite [major + </text>
<text top="273" left="899" width="104" height="17" font="13">nonmajor clinically </text>
<text top="291" left="899" width="101" height="17" font="13">relevant bleeding] </text>
<text top="170" left="1048" width="111" height="17" font="13">Secondary efficacy: </text>
<text top="187" left="1048" width="107" height="17" font="13">composite stroke + </text>
<text top="205" left="1048" width="138" height="17" font="13">systemic embolism + CV </text>
<text top="222" left="1048" width="156" height="17" font="13">mortality]; composite [stroke </text>
<text top="239" left="1048" width="149" height="17" font="13">+ systemic embolism + CV </text>
<text top="256" left="1048" width="139" height="17" font="13">mortality + MI]; individual </text>
<text top="273" left="1048" width="129" height="17" font="13">components of primary </text>
<text top="291" left="1048" width="125" height="17" font="13">composite. Secondary </text>
<text top="308" left="1048" width="36" height="17" font="13">safety </text>
<text top="170" left="1218" width="208" height="17" font="13">Active treatment analysis (by design): </text>
<text top="187" left="1218" width="196" height="17" font="13">rivaroxaban (1.7% per year events) </text>
<text top="205" left="1218" width="206" height="17" font="13">noninferior to warfarin (2.2% per year </text>
<text top="222" left="1218" width="177" height="17" font="13">events) for primary outcome; no </text>
<text top="239" left="1218" width="231" height="17" font="13">difference in safety endpoints; fewer CHN </text>
<text top="256" left="1218" width="183" height="17" font="13">hemorrhage and fatal bleeding in </text>
<text top="273" left="1218" width="232" height="17" font="13">rivaroxaban group. Findings consistent for </text>
<text top="291" left="1218" width="80" height="17" font="13">all subgroups. </text>
<text top="308" left="1218" width="215" height="17" font="13">Efficacy: Per protocol, rivaroxaban HR: </text>
<text top="325" left="1218" width="210" height="17" font="13">0.79; 95% CI: 0.66 - 0.96; p&lt;0.001 for </text>
<text top="342" left="1218" width="232" height="17" font="13">noninferiority;   HF subgroup ITT p=0.419. </text>
<text top="360" left="1218" width="221" height="17" font="13">Safety superiority of rivaroxaban p=0.02 </text>
<text top="378" left="61" width="92" height="17" font="13">Belch 1981         </text>
<text top="395" left="61" width="51" height="17" font="14">7291971 </text>
<text top="412" left="61" width="32" height="17" font="13">(197) </text>
<text top="378" left="183" width="101" height="17" font="13">Effect of low-dose </text>
<text top="395" left="183" width="84" height="17" font="13">SQ H on lower </text>
<text top="412" left="183" width="94" height="17" font="13">extremity DVT in </text>
<text top="429" left="183" width="109" height="17" font="13">pts with HF and pts </text>
<text top="446" left="183" width="58" height="17" font="13">with chest </text>
<text top="464" left="183" width="55" height="17" font="13">infections </text>
<text top="378" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="395" left="305" width="102" height="17" font="13">randomized, open </text>
<text top="412" left="305" width="89" height="17" font="13">label, controlled </text>
<text top="429" left="305" width="107" height="17" font="13">study SQ H 5000 u </text>
<text top="446" left="305" width="101" height="17" font="13">q8h x 14 d or until </text>
<text top="464" left="305" width="57" height="17" font="13">discharge </text>
<text top="378" left="429" width="71" height="17" font="13">Total N=100 </text>
<text top="378" left="531" width="91" height="17" font="13">HF subset n=38 </text>
<text top="395" left="531" width="97" height="17" font="13">(21 treatment, 17 </text>
<text top="412" left="531" width="44" height="17" font="13">control) </text>
<text top="378" left="646" width="87" height="17" font="13">HF NYHA II-IV, </text>
<text top="395" left="646" width="86" height="17" font="13">clinical signs of </text>
<text top="412" left="646" width="94" height="17" font="13">volume overload </text>
<text top="378" left="766" width="90" height="17" font="13">&#34;Definite&#34; risk of </text>
<text top="395" left="766" width="116" height="17" font="13">bleeding, DVT or PE </text>
<text top="412" left="766" width="107" height="17" font="13">on admission, &gt;2 d </text>
<text top="429" left="766" width="90" height="17" font="13">bed rest prior to </text>
<text top="446" left="766" width="59" height="17" font="13">admission </text>
<text top="378" left="899" width="136" height="17" font="13">DVT diagnosed by I-125 </text>
<text top="395" left="899" width="114" height="17" font="13">fribrinogen scanning </text>
<text top="412" left="899" width="94" height="17" font="13">every 2 d or until </text>
<text top="429" left="899" width="57" height="17" font="13">discharge </text>
<text top="378" left="1048" width="109" height="17" font="13">Clinical evidence of </text>
<text top="395" left="1048" width="50" height="17" font="13">bleeding </text>
<text top="378" left="1218" width="166" height="17" font="13">H reduced demonstrable DVT </text>
<text top="395" left="1218" width="211" height="17" font="13">Total group: DVT (Ctl 26% vs H 4% of </text>
<text top="412" left="1218" width="230" height="17" font="13">treated, p&lt;0.01); 20% had minor bleeding </text>
<text top="429" left="1218" width="194" height="17" font="13">(bruising at injection site), no major </text>
<text top="446" left="1218" width="50" height="17" font="13">bleeding </text>
<text top="493" left="61" width="62" height="17" font="15"><b>ARTEMIS</b>  </text>
<text top="510" left="61" width="115" height="17" font="13">Cohen 2006              </text>
<text top="527" left="61" width="58" height="17" font="14">16439370 </text>
<text top="545" left="61" width="32" height="17" font="13">(198) </text>
<text top="493" left="183" width="107" height="17" font="13">Safety and efficacy </text>
<text top="510" left="183" width="101" height="17" font="13">of fondaparinux in </text>
<text top="527" left="183" width="91" height="17" font="13">reducing VTE in </text>
<text top="545" left="183" width="90" height="17" font="13">older, moderate-</text>
<text top="562" left="183" width="95" height="17" font="13">high risk medical </text>
<text top="579" left="183" width="23" height="17" font="13">inpt </text>
<text top="493" left="305" width="76" height="17" font="13">Double-blind, </text>
<text top="510" left="305" width="107" height="17" font="13">placebo-controlled, </text>
<text top="527" left="305" width="103" height="17" font="13">block randomized, </text>
<text top="545" left="305" width="106" height="17" font="13">multicenter RCT of </text>
<text top="562" left="305" width="96" height="17" font="13">SQ fondaparinux </text>
<text top="579" left="305" width="107" height="17" font="13">2.5 mg/d for 6-14 d </text>
<text top="596" left="305" width="103" height="17" font="13">started within 48 h </text>
<text top="614" left="305" width="72" height="17" font="13">of admission </text>
<text top="493" left="429" width="86" height="17" font="13">N=849 medical </text>
<text top="510" left="429" width="61" height="17" font="13">inpt, mean </text>
<text top="527" left="429" width="52" height="17" font="13">f/u=1 mo </text>
<text top="493" left="531" width="61" height="17" font="13">HF  n=160 </text>
<text top="510" left="531" width="99" height="17" font="13">(fondaparinux 78, </text>
<text top="527" left="531" width="68" height="17" font="13">placebo 82) </text>
<text top="493" left="646" width="104" height="17" font="13">CHF (NYHA III-IV) </text>
<text top="510" left="646" width="48" height="17" font="13">or acute </text>
<text top="527" left="646" width="102" height="17" font="13">respiratory illness; </text>
<text top="545" left="646" width="101" height="17" font="13">expected bed rest </text>
<text top="562" left="646" width="79" height="17" font="13">&gt;4 d; age &gt;60 </text>
<text top="493" left="766" width="120" height="17" font="13">High bleeding risk&#34; or </text>
<text top="510" left="766" width="101" height="17" font="13">contraindicated to </text>
<text top="527" left="766" width="89" height="17" font="13">anticoagulation, </text>
<text top="545" left="766" width="102" height="17" font="13">Creat &gt;2.0 mg/dL, </text>
<text top="562" left="766" width="90" height="17" font="13">contrast allergy, </text>
<text top="579" left="766" width="117" height="17" font="13">mechanical vent &gt;24 </text>
<text top="596" left="766" width="104" height="17" font="13">h (total), indication </text>
<text top="614" left="766" width="118" height="17" font="13">for AC prophylaxis or </text>
<text top="631" left="766" width="67" height="17" font="13">therapy, life </text>
<text top="648" left="766" width="65" height="17" font="13">expectancy </text>
<text top="665" left="766" width="94" height="17" font="13">otherwise &lt;1 mo </text>
<text top="493" left="899" width="78" height="17" font="13">Efficacy: DVT </text>
<text top="510" left="899" width="124" height="17" font="13">diagnosed by contrast </text>
<text top="527" left="899" width="104" height="17" font="13">venogray (d 5-15), </text>
<text top="545" left="899" width="123" height="17" font="13">symptomatic VTE (inc </text>
<text top="562" left="899" width="128" height="17" font="13">PE by imaging or fatal) </text>
<text top="579" left="899" width="118" height="17" font="13">through d 15; Safety: </text>
<text top="596" left="899" width="84" height="17" font="13">major bleeding </text>
<text top="493" left="1048" width="144" height="17" font="13">Efficacy: composite [Total </text>
<text top="510" left="1048" width="157" height="17" font="13">VTE + bleeding + death at 1 </text>
<text top="527" left="1048" width="132" height="17" font="13">mo]; Safety:  composite </text>
<text top="545" left="1048" width="139" height="17" font="13">[death or minor bleeding] </text>
<text top="493" left="1218" width="224" height="17" font="13">ITT (efficacy): all pt with ≥1 dose of drug </text>
<text top="510" left="1218" width="214" height="17" font="13">(safety); HF pts=predefined subgroup.  </text>
<text top="527" left="1218" width="150" height="17" font="13">Fishers Exact and log-rank </text>
<text top="545" left="1218" width="209" height="17" font="13">HF subgroup:  Primary:  fondaparinux </text>
<text top="562" left="1218" width="203" height="17" font="13">7/78 (9%) vs placebo 10/82 (12.2%), </text>
<text top="579" left="1218" width="222" height="17" font="13">p=NS; Primary safety:  p=NS (1 bleed in </text>
<text top="596" left="1218" width="69" height="17" font="13">each group) </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">93</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="63" height="17" font="15"><b>CERTIFY</b>   </text>
<text top="72" left="61" width="117" height="17" font="13">Tebbe 2011               </text>
<text top="89" left="61" width="58" height="17" font="14">21315215 </text>
<text top="106" left="61" width="32" height="17" font="13">(199) </text>
<text top="55" left="183" width="109" height="17" font="13">Compare LMWH to </text>
<text top="72" left="183" width="89" height="17" font="13">heparin on VTE </text>
<text top="89" left="183" width="108" height="17" font="13">incidence in elderly </text>
<text top="106" left="183" width="33" height="17" font="13">HF pt </text>
<text top="55" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="72" left="305" width="74" height="17" font="13">double-blind, </text>
<text top="89" left="305" width="88" height="17" font="13">double dummy, </text>
<text top="106" left="305" width="79" height="17" font="13">active control, </text>
<text top="124" left="305" width="68" height="17" font="13">randomized </text>
<text top="141" left="305" width="107" height="17" font="13">noninferiority study </text>
<text top="158" left="305" width="103" height="17" font="13">of certoparin 3000 </text>
<text top="175" left="305" width="90" height="17" font="13">u/d vs H 5000 u </text>
<text top="192" left="305" width="68" height="17" font="13">TID SQ (HF </text>
<text top="210" left="305" width="62" height="17" font="13">predefined </text>
<text top="227" left="305" width="59" height="17" font="13">subgroup) </text>
<text top="55" left="429" width="81" height="17" font="13">Total N=3239, </text>
<text top="72" left="429" width="34" height="17" font="13">mean </text>
<text top="89" left="429" width="81" height="17" font="13">hospitalization </text>
<text top="106" left="429" width="76" height="17" font="13">12.2 +/-5.1 d, </text>
<text top="124" left="429" width="34" height="17" font="13">mean </text>
<text top="141" left="429" width="55" height="17" font="13">treatment </text>
<text top="158" left="429" width="69" height="17" font="13">period = 9 d </text>
<text top="55" left="531" width="85" height="17" font="13">HF n=470; 238 </text>
<text top="72" left="531" width="92" height="17" font="13">pts (cert) vs 232 </text>
<text top="89" left="531" width="44" height="17" font="13">pts (H), </text>
<text top="55" left="646" width="93" height="17" font="13">age ≥70, clinical </text>
<text top="72" left="646" width="106" height="17" font="13">diagnosis of HF on </text>
<text top="89" left="646" width="80" height="17" font="13">admission (no </text>
<text top="106" left="646" width="82" height="17" font="13">further details) </text>
<text top="55" left="766" width="103" height="17" font="13">Contraindicated to </text>
<text top="72" left="766" width="89" height="17" font="13">anticoagulation, </text>
<text top="89" left="766" width="107" height="17" font="13">History of DVT, PE </text>
<text top="106" left="766" width="102" height="17" font="13">or HIT2, stroke &lt;3 </text>
<text top="124" left="766" width="52" height="17" font="13">mo, &gt;3 d </text>
<text top="141" left="766" width="120" height="17" font="13">immobilization before </text>
<text top="158" left="766" width="110" height="17" font="13">randomization, cast </text>
<text top="175" left="766" width="107" height="17" font="13">or fracture, surgery </text>
<text top="192" left="766" width="80" height="17" font="13">&lt;3 wk, severe </text>
<text top="210" left="766" width="107" height="17" font="13">sepsis, mechanical </text>
<text top="227" left="766" width="85" height="17" font="13">ventilation, any </text>
<text top="244" left="766" width="72" height="17" font="13">heparin &lt;5 d </text>
<text top="55" left="899" width="109" height="17" font="13">Efficacy: composite </text>
<text top="72" left="899" width="136" height="17" font="13">[prox DVT (compression </text>
<text top="89" left="899" width="130" height="17" font="13">USG d 8-20) + nonfatal </text>
<text top="106" left="899" width="99" height="17" font="13">PE + VTE-related </text>
<text top="124" left="899" width="83" height="17" font="13">death]; Safety: </text>
<text top="141" left="899" width="97" height="17" font="13">composite [major </text>
<text top="158" left="899" width="95" height="17" font="13">bleeding + minor </text>
<text top="175" left="899" width="87" height="17" font="13">bleeding + HIT] </text>
<text top="55" left="1048" width="131" height="17" font="13">Prox DVT, nonfatal PE, </text>
<text top="72" left="1048" width="121" height="17" font="13">fatal VTE, distal DVT, </text>
<text top="89" left="1048" width="157" height="17" font="13">symptomatic DVT, all-cause </text>
<text top="106" left="1048" width="124" height="17" font="13">mortality, documented </text>
<text top="124" left="1048" width="103" height="17" font="13">symtpomatic VTE, </text>
<text top="141" left="1048" width="141" height="17" font="13">composite [nonfatal PE + </text>
<text top="158" left="1048" width="119" height="17" font="13">prox DVT + all-cause </text>
<text top="175" left="1048" width="53" height="17" font="13">mortality] </text>
<text top="55" left="1218" width="211" height="17" font="13">Active treatment only. No difference in </text>
<text top="72" left="1218" width="199" height="17" font="13">efficacy or safety endpoints in HF pt </text>
<text top="89" left="1218" width="214" height="17" font="13">based on treatment arm. Primary:  cert </text>
<text top="106" left="1218" width="224" height="17" font="13">3.78% vs heparin 4.74%, OR: 0.79; 95% </text>
<text top="124" left="1218" width="186" height="17" font="13">CI 0.32-1.94; p=NS; multivariate:  </text>
<text top="141" left="1218" width="226" height="17" font="13">insufficient to confirm noninferiority in HF </text>
<text top="158" left="1218" width="17" height="17" font="13">pt. </text>
<text top="262" left="61" width="78" height="17" font="15"><b>THE PRINCE</b> </text>
<text top="279" left="61" width="90" height="17" font="13">Kleber 2003       </text>
<text top="296" left="61" width="58" height="17" font="14">12679756 </text>
<text top="314" left="61" width="32" height="17" font="13">(200) </text>
<text top="262" left="183" width="90" height="17" font="13">Compare safety </text>
<text top="279" left="183" width="83" height="17" font="13">and efficacy of </text>
<text top="296" left="183" width="90" height="17" font="13">enoxaparin with </text>
<text top="314" left="183" width="103" height="17" font="13">UFH in preventing </text>
<text top="331" left="183" width="105" height="17" font="13">VTE in pts with HF </text>
<text top="348" left="183" width="55" height="17" font="13">or severe </text>
<text top="365" left="183" width="107" height="17" font="13">respiratory disease </text>
<text top="262" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="279" left="305" width="107" height="17" font="13">randomized, active </text>
<text top="296" left="305" width="83" height="17" font="13">control/parallel </text>
<text top="314" left="305" width="98" height="17" font="13">group open label, </text>
<text top="331" left="305" width="74" height="17" font="13">noninferiority </text>
<text top="348" left="305" width="67" height="17" font="13">comparison </text>
<text top="365" left="305" width="81" height="17" font="13">enoxaparin 40 </text>
<text top="382" left="305" width="91" height="17" font="13">mg/d vs heparin </text>
<text top="400" left="305" width="99" height="17" font="13">5000 u TID for 10 </text>
<text top="417" left="305" width="86" height="17" font="13">+/- 2 d. 1-sided </text>
<text top="434" left="305" width="107" height="17" font="13">equivalence, upper </text>
<text top="451" left="305" width="93" height="17" font="13">limit = 9% or 4% </text>
<text top="469" left="305" width="70" height="17" font="13">difference in </text>
<text top="486" left="305" width="48" height="17" font="13">efficacy. </text>
<text top="262" left="429" width="71" height="17" font="13">Total N=665 </text>
<text top="262" left="531" width="79" height="17" font="13">HF  n=333 for </text>
<text top="279" left="531" width="90" height="17" font="13">safety endpoint, </text>
<text top="296" left="531" width="101" height="17" font="13">n=206 for efficacy </text>
<text top="262" left="646" width="67" height="17" font="13">NYHA III-IV </text>
<text top="262" left="766" width="103" height="17" font="13">Contraindicated to </text>
<text top="279" left="766" width="59" height="17" font="13">heparin or </text>
<text top="296" left="766" width="89" height="17" font="13">anticoagulation, </text>
<text top="314" left="766" width="118" height="17" font="13">contrast allergy, DVT </text>
<text top="331" left="766" width="113" height="17" font="13">or PE on admission, </text>
<text top="348" left="766" width="103" height="17" font="13">immobilized &gt;24 h </text>
<text top="365" left="766" width="104" height="17" font="13">prior to admission, </text>
<text top="382" left="766" width="98" height="17" font="13">taking warfarin or </text>
<text top="400" left="766" width="116" height="17" font="13">&gt;low dose aspirin on </text>
<text top="417" left="766" width="59" height="17" font="13">admission </text>
<text top="262" left="899" width="117" height="17" font="13">Efficacy:  Comfirmed </text>
<text top="279" left="899" width="79" height="17" font="13">TEE (DVT  by </text>
<text top="296" left="899" width="132" height="17" font="13">venography or autopsy, </text>
<text top="314" left="899" width="110" height="17" font="13">PE by  V/Q, CXR/Q </text>
<text top="331" left="899" width="130" height="17" font="13">scan [plus confirmatory </text>
<text top="348" left="899" width="85" height="17" font="13">venogram if +], </text>
<text top="365" left="899" width="130" height="17" font="13">angiogram or autopsy)  </text>
<text top="382" left="899" width="132" height="17" font="13">within 1 d of completing </text>
<text top="400" left="899" width="135" height="17" font="13">treatment; Safety: Major </text>
<text top="417" left="899" width="53" height="17" font="13">bleeding  </text>
<text top="262" left="1048" width="144" height="17" font="13">Efficacy:  composite [TEE </text>
<text top="279" left="1048" width="52" height="17" font="13">or death] </text>
<text top="262" left="1218" width="218" height="17" font="13">No differences in primary, secondary or </text>
<text top="279" left="1218" width="93" height="17" font="13">safety endpoints </text>
<text top="296" left="1218" width="195" height="17" font="13">12.6% HF pt had events.  Primary:  </text>
<text top="314" left="1218" width="230" height="17" font="13">enoxaparin (9.7%) vs heparin (16.1%) [CI </text>
<text top="331" left="1218" width="198" height="17" font="13">-1.4 - +14.2], p=0.139.  Secondary:  </text>
<text top="348" left="1218" width="209" height="17" font="13">mortality: enoxaparin 5.3% vs heparin </text>
<text top="365" left="1218" width="226" height="17" font="13">6.4% (no statistical comparison); Saftey:  </text>
<text top="382" left="1218" width="202" height="17" font="13">no difference (1 bleed in entire study </text>
<text top="400" left="1218" width="64" height="17" font="13">population) </text>
<text top="504" left="61" width="69" height="17" font="15"><b>MEDENOX</b>  </text>
<text top="521" left="61" width="83" height="17" font="13">Samama 1999 </text>
<text top="538" left="61" width="55" height="17" font="14">10477777</text>
<text top="538" left="116" width="14" height="17" font="13">;   </text>
<text top="555" left="61" width="73" height="17" font="13">Turpie 2000  </text>
<text top="573" left="61" width="55" height="17" font="14">11206019</text>
<text top="573" left="116" width="10" height="17" font="13">;  </text>
<text top="590" left="61" width="74" height="17" font="13">Alikhan 2003 </text>
<text top="607" left="61" width="58" height="17" font="14">12945875 </text>
<text top="624" left="61" width="32" height="17" font="13">(201) </text>
<text top="504" left="183" width="90" height="17" font="13">Compare safety </text>
<text top="521" left="183" width="93" height="17" font="13">and efficacy of 2 </text>
<text top="538" left="183" width="50" height="17" font="13">doses of </text>
<text top="555" left="183" width="80" height="17" font="13">enoxaparin vs </text>
<text top="573" left="183" width="105" height="17" font="13">placebo to prevent </text>
<text top="590" left="183" width="100" height="17" font="13">VTE in medical pt </text>
<text top="607" left="183" width="104" height="17" font="13">hospitalized ≤14 d </text>
<text top="504" left="305" width="71" height="17" font="13">Prospective, </text>
<text top="521" left="305" width="71" height="17" font="13">randomized, </text>
<text top="538" left="305" width="74" height="17" font="13">double-blind, </text>
<text top="555" left="305" width="81" height="17" font="13">parallel arm of </text>
<text top="573" left="305" width="62" height="17" font="13">placebo vs </text>
<text top="590" left="305" width="81" height="17" font="13">enoxaparin 20 </text>
<text top="607" left="305" width="111" height="17" font="13">mg/d vs enoxaparin </text>
<text top="624" left="305" width="48" height="17" font="13">40 mg/d </text>
<text top="504" left="429" width="74" height="17" font="13">Total N=855; </text>
<text top="521" left="429" width="62" height="17" font="13">f/u = 110 d </text>
<text top="504" left="531" width="94" height="17" font="13">HF n=290 (34%) </text>
<text top="504" left="646" width="67" height="17" font="13">NYHA III-IV </text>
<text top="504" left="766" width="103" height="17" font="13">Contraindicated to </text>
<text top="521" left="766" width="101" height="17" font="13">anticoagulation or </text>
<text top="538" left="766" width="95" height="17" font="13">heparin, contrast </text>
<text top="555" left="766" width="120" height="17" font="13">allergy, thrombophilic </text>
<text top="573" left="766" width="60" height="17" font="13">disease or </text>
<text top="590" left="766" width="114" height="17" font="13">coagulopathy, Creat </text>
<text top="607" left="766" width="100" height="17" font="13">&gt;1.7,  mechanical </text>
<text top="624" left="766" width="106" height="17" font="13">ventilation, any AC </text>
<text top="641" left="766" width="94" height="17" font="13">for &gt;48 h prior to </text>
<text top="659" left="766" width="61" height="17" font="13">enrollment </text>
<text top="504" left="899" width="110" height="17" font="13">VTE (DVT [contrast </text>
<text top="521" left="899" width="75" height="17" font="13">venograpy or </text>
<text top="538" left="899" width="127" height="17" font="13">compression USG day </text>
<text top="555" left="899" width="105" height="17" font="13">6-14 or earlier with </text>
<text top="573" left="899" width="116" height="17" font="13">symptoms], PE [high </text>
<text top="590" left="899" width="135" height="17" font="13">prob V/Q, CTA or angio] </text>
<text top="607" left="899" width="84" height="17" font="13">or both) d 1-14 </text>
<text top="504" left="1048" width="124" height="17" font="13">VTE d 1-110; Major or </text>
<text top="521" left="1048" width="107" height="17" font="13">minor hemorrhage, </text>
<text top="538" left="1048" width="53" height="17" font="13">mortality, </text>
<text top="555" left="1048" width="128" height="17" font="13">thrombocytopenia, any </text>
<text top="573" left="1048" width="104" height="17" font="13">adverse event, lab </text>
<text top="590" left="1048" width="131" height="17" font="13">abnormalities (multiple) </text>
<text top="504" left="1218" width="218" height="17" font="13">Enoxaparin 20 mg = Placebo (excluded </text>
<text top="521" left="1218" width="211" height="17" font="13">from final analysis); lower incidence of </text>
<text top="538" left="1218" width="230" height="17" font="13">radiographic DVT in enoxaparin 40 mg vs </text>
<text top="555" left="1218" width="230" height="17" font="13">placebo. No difference in mortality or AEs </text>
<text top="573" left="1218" width="141" height="17" font="13">among treatment groups. </text>
<text top="590" left="1218" width="221" height="17" font="13">Primary: All HF pts: enoxaparin 4.0% vs </text>
<text top="607" left="1218" width="223" height="17" font="13">placebo 14.6%, (RR: 0.29; 95% CI: 0.10-</text>
<text top="624" left="1218" width="232" height="17" font="13">0.84; p-0.02); Class III HF pts: enoxaparin </text>
<text top="641" left="1218" width="223" height="17" font="13">5.1% vs. placebo 12.3% (RR: 0.42; 95% </text>
<text top="659" left="1218" width="219" height="17" font="13">CI: 0.13-1.29; p=0.20); Class IV HF pts: </text>
<text top="676" left="1218" width="193" height="17" font="13">enoxaparin 0% vs. placebo 21.7%, </text>
<text top="693" left="1218" width="210" height="17" font="13">(p=0.05); History of chronic HF as risk </text>
<text top="710" left="1218" width="200" height="17" font="13">(regardless of admission diagnosis): </text>
<text top="727" left="1218" width="228" height="17" font="13">enoxaparin 2.2% vs. placebo 12.1% (RR: </text>
<text top="745" left="1218" width="186" height="17" font="13">0.26; 95% CI: 0.08-0.92;  p=0.04) </text>
<text top="763" left="54" width="1389" height="17" font="13">AC indicates anticoagulant; ACEI, angiotensin-converting-enzyme inhibitor; ACT,  active control parallel; AE, adverse event; AP, apixaban; APT, antiplatelet therapy; AF, atrial fibrillation; ARB, angiotensin receptor blockers; AT, as treated; BID, twice a day; </text>
<text top="780" left="54" width="1399" height="17" font="13">BNP, brain natriuretic peptide; CAD, coronary artery disease; CHF, congestive heart failure; CrCl, creatinine clearance; CTA, computed tomography angiography; CTR, cardiothoracic ratio; CV, cardiovascular; CXR, chest x-ray; Dab, dabigitran; DCM, dilated </text>
</page>
<page number="94" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">94</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="1338" height="17" font="13">cardiomyopathy; DVT, deep venous thrombosis; EF, ejection fraction; f/u, follow-up; H, heparin; HD, heart disease; HF, heart failure; HIT2, heparin-induced thrombocytopenia; H/N, hydralazine and nitrates; HTN, hypertension; ICH, ischemia; INR, </text>
<text top="71" left="54" width="1347" height="17" font="13">international normalized ratio; ITT, intent to treat; KM, kaplan-meier; LMWH, low moleduclar weight heparin; LV, left ventricular; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, not </text>
<text top="88" left="54" width="1379" height="17" font="13">applicable; NS, not significant; NYHA, New York Heart Association; OAT, oral anticoagulant therapy; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PPM, pacemaker; pt, patient; QoL; quality of life; RCT, randomized control trial; SQ, </text>
<text top="107" left="54" width="538" height="17" font="13">subcutaneous; TEE, thromboembolic event; TIA, transient ischemic attack; TID, three times a day; </text>
<text top="106" left="591" width="174" height="19" font="7">UFH, unfractionated heparin;</text>
<text top="107" left="765" width="665" height="17" font="13"> USG, ultrasonography ; VO2, oxygen volume; V/Q, ventilation/perfusion scan; and VTE, venous thromboembolic disease. </text>
<text top="125" left="54" width="3" height="17" font="13"> </text>
<text top="151" left="54" width="385" height="21" font="8"><b>Data Supplement 22. Statin Therapy (Section 7.3.2.8.2) </b></text>
<text top="180" left="57" width="38" height="17" font="15"><b>Study </b></text>
<text top="197" left="55" width="40" height="17" font="15"><b>Name, </b></text>
<text top="214" left="52" width="47" height="17" font="15"><b>Author, </b></text>
<text top="231" left="61" width="30" height="17" font="15"><b>Year </b></text>
<text top="214" left="136" width="42" height="17" font="15"><b>Aim of </b></text>
<text top="231" left="138" width="38" height="17" font="15"><b>Study </b></text>
<text top="214" left="212" width="38" height="17" font="15"><b>Study </b></text>
<text top="231" left="215" width="32" height="17" font="15"><b>Type </b></text>
<text top="214" left="288" width="75" height="17" font="15"><b>Background </b></text>
<text top="231" left="300" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="231" left="411" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="231" left="516" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="231" left="611" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="231" left="766" width="51" height="17" font="15"><b>Severity </b></text>
<text top="231" left="878" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="231" left="1038" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="214" left="1161" width="29" height="17" font="15"><b>Trial </b></text>
<text top="231" left="1149" width="54" height="17" font="15"><b>Duration </b></text>
<text top="214" left="1219" width="56" height="17" font="15"><b>Absolute </b></text>
<text top="231" left="1225" width="45" height="17" font="15"><b>Benefit </b></text>
<text top="214" left="1297" width="62" height="17" font="15"><b>Statistical </b></text>
<text top="231" left="1304" width="48" height="17" font="15"><b>Results </b></text>
<text top="214" left="1401" width="38" height="17" font="15"><b>Study </b></text>
<text top="231" left="1385" width="69" height="17" font="15"><b>Limitations </b></text>
<text top="273" left="275" width="101" height="17" font="21"><i><b>Pretrial standard </b></i></text>
<text top="290" left="296" width="60" height="17" font="21"><i><b>treatment </b></i></text>
<text top="256" left="417" width="53" height="17" font="21"><i><b>N (Total) </b></i></text>
<text top="273" left="394" width="100" height="17" font="21"><i><b>n (Experimental) </b></i></text>
<text top="290" left="411" width="66" height="17" font="21"><i><b>n (Control) </b></i></text>
<text top="256" left="512" width="59" height="17" font="21"><i><b>Ischemic/ </b></i></text>
<text top="273" left="526" width="28" height="17" font="21"><i><b>Non-</b></i></text>
<text top="290" left="514" width="56" height="17" font="21"><i><b>Ischemic </b></i></text>
<text top="273" left="597" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="290" left="603" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="273" left="680" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="290" left="687" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="256" left="758" width="66" height="17" font="21"><i><b>Severity of </b></i></text>
<text top="273" left="781" width="20" height="17" font="21"><i><b>HF </b></i></text>
<text top="290" left="758" width="66" height="17" font="21"><i><b>Symptoms </b></i></text>
<text top="273" left="844" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="290" left="841" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="273" left="914" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="290" left="918" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="273" left="996" width="69" height="17" font="21"><i><b>Annualized </b></i></text>
<text top="290" left="1004" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="273" left="1083" width="51" height="17" font="21"><i><b>1st Year </b></i></text>
<text top="290" left="1081" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="308" left="42" width="62" height="17" font="13">Horwich et </text>
<text top="325" left="42" width="47" height="17" font="13">al, 2004 </text>
<text top="343" left="42" width="55" height="17" font="14">14975476</text>
<text top="343" left="97" width="7" height="17" font="13">  </text>
<text top="360" left="42" width="32" height="17" font="13">(202) </text>
<text top="308" left="122" width="18" height="17" font="13">To </text>
<text top="325" left="122" width="62" height="17" font="13">investigate </text>
<text top="343" left="122" width="60" height="17" font="13">the impact </text>
<text top="360" left="122" width="46" height="17" font="13">of statin </text>
<text top="377" left="122" width="57" height="17" font="13">therapy in </text>
<text top="394" left="122" width="45" height="17" font="13">pts with </text>
<text top="411" left="122" width="57" height="17" font="13">advanced </text>
<text top="429" left="122" width="66" height="17" font="13">HF referred </text>
<text top="446" left="122" width="18" height="17" font="13">for </text>
<text top="463" left="122" width="57" height="17" font="13">transplant </text>
<text top="480" left="122" width="59" height="17" font="13">evaluation </text>
<text top="498" left="122" width="53" height="17" font="13">at UCLA. </text>
<text top="308" left="204" width="40" height="17" font="13">Cohort </text>
<text top="325" left="204" width="33" height="17" font="13">study </text>
<text top="308" left="271" width="92" height="17" font="13">ACEI/ARB, beta-</text>
<text top="325" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="343" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="308" left="393" width="79" height="17" font="13">551; 248; 303 </text>
<text top="308" left="508" width="28" height="17" font="13">45% </text>
<text top="308" left="589" width="68" height="17" font="13">Pts referred </text>
<text top="325" left="589" width="18" height="17" font="13">for </text>
<text top="343" left="589" width="57" height="17" font="13">transplant </text>
<text top="360" left="589" width="59" height="17" font="13">evaluation </text>
<text top="377" left="589" width="50" height="17" font="13">between </text>
<text top="394" left="589" width="42" height="17" font="13">2000-2 </text>
<text top="308" left="676" width="34" height="17" font="13">LVEF </text>
<text top="325" left="676" width="39" height="17" font="13">&gt;40%, </text>
<text top="343" left="676" width="49" height="17" font="13">baseline </text>
<text top="360" left="676" width="27" height="17" font="13">data </text>
<text top="377" left="676" width="63" height="17" font="13">incomplete </text>
<text top="308" left="757" width="59" height="17" font="13">NYHA 3-4 </text>
<text top="308" left="838" width="51" height="17" font="13">Death or </text>
<text top="325" left="838" width="38" height="17" font="13">urgent </text>
<text top="343" left="838" width="57" height="17" font="13">transplant </text>
<text top="308" left="913" width="24" height="17" font="13">N/A </text>
<text top="308" left="994" width="31" height="17" font="13">  N/A </text>
<text top="308" left="1081" width="28" height="17" font="13">75% </text>
<text top="308" left="1149" width="20" height="17" font="13">2 y </text>
<text top="308" left="1216" width="28" height="17" font="13">14% </text>
<text top="308" left="1291" width="52" height="17" font="13">HR 0.44; </text>
<text top="325" left="1291" width="44" height="17" font="13">95% CI </text>
<text top="343" left="1291" width="59" height="17" font="13">0.30-0.67; </text>
<text top="360" left="1291" width="55" height="17" font="13">p&lt;0.0001 </text>
<text top="308" left="1378" width="79" height="17" font="13">Single-center, </text>
<text top="325" left="1378" width="25" height="17" font="13">non-</text>
<text top="343" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="360" left="1378" width="59" height="17" font="13">reason for </text>
<text top="377" left="1378" width="51" height="17" font="13">drug use </text>
<text top="394" left="1378" width="73" height="17" font="13">unclear, bias </text>
<text top="515" left="42" width="57" height="17" font="13">Mozaffaria</text>
<text top="533" left="42" width="40" height="17" font="13">n et al, </text>
<text top="550" left="42" width="31" height="17" font="13">2004 </text>
<text top="567" left="42" width="55" height="17" font="14">15110204</text>
<text top="567" left="97" width="7" height="17" font="13">  </text>
<text top="584" left="42" width="32" height="17" font="13">(203) </text>
<text top="515" left="122" width="68" height="17" font="13">To evaluate </text>
<text top="533" left="122" width="64" height="17" font="13">the relation </text>
<text top="550" left="122" width="46" height="17" font="13">of statin </text>
<text top="567" left="122" width="44" height="17" font="13">therapy </text>
<text top="584" left="122" width="66" height="17" font="13">with clinical </text>
<text top="601" left="122" width="57" height="17" font="13">outcomes </text>
<text top="619" left="122" width="53" height="17" font="13">in severe </text>
<text top="636" left="122" width="67" height="17" font="13">HF enrolled </text>
<text top="653" left="122" width="33" height="17" font="13">in the </text>
<text top="670" left="122" width="49" height="17" font="13">PRAISE </text>
<text top="688" left="122" width="33" height="17" font="13">study </text>
<text top="515" left="204" width="40" height="17" font="13">Cohort </text>
<text top="533" left="204" width="33" height="17" font="13">study </text>
<text top="515" left="271" width="64" height="17" font="13">ACEI/ARB, </text>
<text top="533" left="271" width="95" height="17" font="13">diuretics, digoxin </text>
<text top="515" left="393" width="143" height="17" font="13">1,153; 1,019; 134  63% </text>
<text top="515" left="589" width="66" height="17" font="13">Dyspnea or </text>
<text top="533" left="589" width="57" height="17" font="13">fatigue on </text>
<text top="550" left="589" width="47" height="17" font="13">exertion </text>
<text top="567" left="589" width="60" height="17" font="13">(NYHA 3b-</text>
<text top="584" left="589" width="52" height="17" font="13">4), LVEF </text>
<text top="601" left="589" width="36" height="17" font="13">≥30% </text>
<text top="515" left="676" width="176" height="17" font="13">N/A NYHA </text>
<text top="515" left="795" width="85" height="17" font="13">3b-4 </text>
<text top="515" left="838" width="111" height="17" font="13">All-cause </text>
<text top="533" left="838" width="50" height="17" font="13">mortality </text>
<text top="515" left="913" width="40" height="17" font="13">Cause-</text>
<text top="533" left="913" width="44" height="17" font="13">specific </text>
<text top="550" left="913" width="50" height="17" font="13">mortality </text>
<text top="567" left="913" width="37" height="17" font="13">(SCD, </text>
<text top="584" left="913" width="34" height="17" font="13">pump </text>
<text top="601" left="913" width="37" height="17" font="13">failure </text>
<text top="619" left="913" width="64" height="17" font="13">death, fatal </text>
<text top="636" left="913" width="21" height="17" font="13">MI) </text>
<text top="515" left="994" width="17" height="17" font="13">29 </text>
<text top="533" left="994" width="64" height="17" font="13">deaths/100 </text>
<text top="550" left="994" width="51" height="17" font="13">person-y </text>
<text top="515" left="1081" width="145" height="17" font="13">N/A Mean </text>
<text top="515" left="1183" width="64" height="17" font="13">1.5 </text>
<text top="533" left="1149" width="10" height="17" font="13">y </text>
<text top="515" left="1216" width="149" height="17" font="13">N/A HR: </text>
<text top="515" left="1315" width="81" height="17" font="13">0.38; </text>
<text top="533" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="550" left="1291" width="59" height="17" font="13">0.23-0.65; </text>
<text top="567" left="1291" width="62" height="17" font="13">Propensity-</text>
<text top="584" left="1291" width="51" height="17" font="13">matched </text>
<text top="601" left="1291" width="59" height="17" font="13">HR: 0.46.  </text>
<text top="619" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="636" left="1291" width="58" height="17" font="13">0.26–0.75 </text>
<text top="515" left="1378" width="52" height="17" font="13">Post-hoc </text>
<text top="533" left="1378" width="76" height="17" font="13">analysis from </text>
<text top="550" left="1378" width="64" height="17" font="13">clinical trial </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">95</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="42" width="55" height="17" font="13">Ray et al, </text>
<text top="72" left="42" width="31" height="17" font="13">2005 </text>
<text top="89" left="42" width="55" height="17" font="14">15642876</text>
<text top="89" left="97" width="7" height="17" font="13">  </text>
<text top="106" left="42" width="32" height="17" font="13">(204) </text>
<text top="124" left="42" width="3" height="17" font="13"> </text>
<text top="55" left="122" width="18" height="17" font="13">To </text>
<text top="72" left="122" width="58" height="17" font="13">determine </text>
<text top="89" left="122" width="47" height="17" font="13">whether </text>
<text top="106" left="122" width="68" height="17" font="13">statin use is </text>
<text top="124" left="122" width="62" height="17" font="13">associated </text>
<text top="141" left="122" width="25" height="17" font="13">with </text>
<text top="158" left="122" width="66" height="17" font="13">a lower risk </text>
<text top="175" left="122" width="48" height="17" font="13">of death </text>
<text top="192" left="122" width="58" height="17" font="13">and major </text>
<text top="210" left="122" width="29" height="17" font="13">CVD </text>
<text top="227" left="122" width="41" height="17" font="13">among </text>
<text top="244" left="122" width="36" height="17" font="13">adults </text>
<text top="261" left="122" width="35" height="17" font="13">newly </text>
<text top="278" left="122" width="60" height="17" font="13">diagnosed </text>
<text top="296" left="122" width="56" height="17" font="13">as having </text>
<text top="313" left="122" width="33" height="17" font="13">HF in </text>
<text top="330" left="122" width="44" height="17" font="13">Ontario </text>
<text top="347" left="122" width="44" height="17" font="13">registry </text>
<text top="55" left="204" width="40" height="17" font="13">Cohort </text>
<text top="72" left="204" width="33" height="17" font="13">study </text>
<text top="55" left="271" width="92" height="17" font="13">ACEI/ARB, beta-</text>
<text top="72" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="89" left="271" width="83" height="17" font="13">tone, diuretics, </text>
<text top="106" left="271" width="44" height="17" font="13">nitrates </text>
<text top="55" left="393" width="82" height="17" font="13">28,828; 1,146; </text>
<text top="72" left="393" width="41" height="17" font="13">27,682 </text>
<text top="55" left="508" width="38" height="17" font="13">11.3% </text>
<text top="72" left="508" width="53" height="17" font="13">history of </text>
<text top="89" left="508" width="17" height="17" font="13">MI </text>
<text top="55" left="589" width="68" height="17" font="13">Adults aged </text>
<text top="72" left="589" width="70" height="17" font="13">66 to 85 y in </text>
<text top="89" left="589" width="44" height="17" font="13">Ontario </text>
<text top="106" left="589" width="47" height="17" font="13">Canada </text>
<text top="124" left="589" width="35" height="17" font="13">newly </text>
<text top="141" left="589" width="68" height="17" font="13">hospitalized </text>
<text top="158" left="589" width="70" height="17" font="13">with primary </text>
<text top="175" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="192" left="589" width="70" height="17" font="13">HF between </text>
<text top="210" left="589" width="42" height="17" font="13">April 1, </text>
<text top="227" left="589" width="58" height="17" font="13">1995, and </text>
<text top="244" left="589" width="60" height="17" font="13">December </text>
<text top="261" left="589" width="51" height="17" font="13">31, 2001 </text>
<text top="278" left="589" width="73" height="17" font="13">and survived </text>
<text top="296" left="589" width="70" height="17" font="13">at least 90 d </text>
<text top="313" left="589" width="49" height="17" font="13">after the </text>
<text top="330" left="589" width="33" height="17" font="13">index </text>
<text top="347" left="589" width="20" height="17" font="13">HF </text>
<text top="365" left="589" width="71" height="17" font="13">hospitalizatio</text>
<text top="382" left="589" width="10" height="17" font="13">n </text>
<text top="55" left="676" width="21" height="17" font="13">Pts </text>
<text top="72" left="676" width="58" height="17" font="13">hospitalize</text>
<text top="89" left="676" width="62" height="17" font="13">d within 36 </text>
<text top="106" left="676" width="58" height="17" font="13">mo for HF </text>
<text top="124" left="676" width="54" height="17" font="13">or having </text>
<text top="141" left="676" width="55" height="17" font="13">diagnosis </text>
<text top="158" left="676" width="54" height="17" font="13">of cancer </text>
<text top="175" left="676" width="61" height="17" font="13">within past </text>
<text top="192" left="676" width="62" height="17" font="13">365 d prior </text>
<text top="210" left="676" width="66" height="17" font="13">to index HF </text>
<text top="227" left="676" width="64" height="17" font="13">hospitalizati</text>
<text top="244" left="676" width="17" height="17" font="13">on </text>
<text top="261" left="676" width="57" height="17" font="13">discharge </text>
<text top="278" left="676" width="31" height="17" font="13">date; </text>
<text top="296" left="676" width="59" height="17" font="13">dispensed </text>
<text top="313" left="676" width="67" height="17" font="13">statin 365 d </text>
<text top="330" left="676" width="42" height="17" font="13">prior to </text>
<text top="347" left="676" width="46" height="17" font="13">hospital </text>
<text top="365" left="676" width="60" height="17" font="13">discharge, </text>
<text top="382" left="676" width="51" height="17" font="13">length of </text>
<text top="399" left="676" width="64" height="17" font="13">stay &gt;60 d, </text>
<text top="416" left="676" width="33" height="17" font="13">direct </text>
<text top="433" left="676" width="59" height="17" font="13">transfer to </text>
<text top="451" left="676" width="43" height="17" font="13">chronic </text>
<text top="468" left="676" width="27" height="17" font="13">care </text>
<text top="485" left="676" width="49" height="17" font="13">hospital, </text>
<text top="502" left="676" width="40" height="17" font="13">cancer </text>
<text top="519" left="676" width="62" height="17" font="13">within 90 d </text>
<text top="537" left="676" width="51" height="17" font="13">following </text>
<text top="554" left="676" width="53" height="17" font="13">index HF </text>
<text top="571" left="676" width="64" height="17" font="13">hospitalizati</text>
<text top="588" left="676" width="17" height="17" font="13">on </text>
<text top="55" left="757" width="174" height="17" font="13">N/A Death </text>
<text top="72" left="838" width="51" height="17" font="13">from any </text>
<text top="89" left="838" width="40" height="17" font="13">cause, </text>
<text top="106" left="838" width="47" height="17" font="13">nonfatal </text>
<text top="124" left="838" width="54" height="17" font="13">acute MI, </text>
<text top="141" left="838" width="14" height="17" font="13">or </text>
<text top="158" left="838" width="47" height="17" font="13">nonfatal </text>
<text top="175" left="838" width="37" height="17" font="13">stroke </text>
<text top="55" left="913" width="169" height="17" font="13">N/A 9.9% </text>
<text top="55" left="1025" width="78" height="17" font="13">per </text>
<text top="72" left="994" width="66" height="17" font="13">100 person-</text>
<text top="89" left="994" width="64" height="17" font="13">y vs 19.1% </text>
<text top="106" left="994" width="45" height="17" font="13">per 100 </text>
<text top="124" left="994" width="51" height="17" font="13">person-y </text>
<text top="55" left="1081" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1149" width="48" height="17" font="13">16.6 mo </text>
<text top="72" left="1149" width="33" height="17" font="13">in the </text>
<text top="89" left="1149" width="33" height="17" font="13">statin </text>
<text top="106" left="1149" width="35" height="17" font="13">group </text>
<text top="124" left="1149" width="51" height="17" font="13">and 24.4 </text>
<text top="141" left="1149" width="54" height="17" font="13">mo in the </text>
<text top="158" left="1149" width="53" height="17" font="13">nonstatin </text>
<text top="175" left="1149" width="35" height="17" font="13">group </text>
<text top="55" left="1216" width="53" height="17" font="13">8.2% per </text>
<text top="72" left="1216" width="24" height="17" font="13">100 </text>
<text top="89" left="1216" width="51" height="17" font="13">person-y </text>
<text top="55" left="1291" width="55" height="17" font="13">HR: 0.62; </text>
<text top="72" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="89" left="1291" width="59" height="17" font="13">0.53-0.69; </text>
<text top="106" left="1291" width="66" height="17" font="13">aHR: 0.72;  </text>
<text top="124" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="141" left="1291" width="59" height="17" font="13">0.63-0.83. </text>
<text top="55" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="89" left="1378" width="25" height="17" font="13">non-</text>
<text top="106" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="124" left="1378" width="59" height="17" font="13">reason for </text>
<text top="141" left="1378" width="51" height="17" font="13">drug use </text>
<text top="158" left="1378" width="73" height="17" font="13">unclear, bias </text>
<text top="606" left="42" width="51" height="17" font="13">Foody et </text>
<text top="624" left="42" width="47" height="17" font="13">al, 2006 </text>
<text top="641" left="42" width="55" height="17" font="14">16490817</text>
<text top="641" left="97" width="7" height="17" font="13">  </text>
<text top="658" left="42" width="32" height="17" font="13">(205) </text>
<text top="606" left="122" width="68" height="17" font="13">To evaluate </text>
<text top="624" left="122" width="21" height="17" font="13">the </text>
<text top="641" left="122" width="65" height="17" font="13">association </text>
<text top="658" left="122" width="50" height="17" font="13">between </text>
<text top="675" left="122" width="56" height="17" font="13">statin use </text>
<text top="692" left="122" width="24" height="17" font="13">and </text>
<text top="710" left="122" width="45" height="17" font="13">survival </text>
<text top="727" left="122" width="51" height="17" font="13">among a </text>
<text top="744" left="122" width="46" height="17" font="13">national </text>
<text top="761" left="122" width="57" height="17" font="13">sample of </text>
<text top="778" left="122" width="40" height="17" font="13">elderly </text>
<text top="606" left="204" width="40" height="17" font="13">Cohort </text>
<text top="624" left="204" width="33" height="17" font="13">study </text>
<text top="606" left="271" width="92" height="17" font="13">ACEI/ARB, beta-</text>
<text top="624" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="641" left="271" width="83" height="17" font="13">tone, diuretics, </text>
<text top="658" left="271" width="44" height="17" font="13">nitrates </text>
<text top="606" left="393" width="82" height="17" font="13">54,960; 9,163; </text>
<text top="624" left="393" width="41" height="17" font="13">45,797 </text>
<text top="606" left="508" width="68" height="17" font="13">30% history </text>
<text top="624" left="508" width="31" height="17" font="13">of MI </text>
<text top="606" left="589" width="68" height="17" font="13">Sampling of </text>
<text top="624" left="589" width="54" height="17" font="13">Medicare </text>
<text top="641" left="589" width="40" height="17" font="13">fee-for-</text>
<text top="658" left="589" width="42" height="17" font="13">service </text>
<text top="675" left="589" width="72" height="17" font="13">beneficiaries </text>
<text top="692" left="589" width="68" height="17" font="13">hospitalized </text>
<text top="710" left="589" width="36" height="17" font="13">with a </text>
<text top="727" left="589" width="49" height="17" font="13">principal </text>
<text top="744" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="761" left="589" width="72" height="17" font="13">HF by ICD-9 </text>
<text top="778" left="589" width="30" height="17" font="13">code </text>
<text top="606" left="676" width="47" height="17" font="13">&lt;65 y of </text>
<text top="624" left="676" width="47" height="17" font="13">age, HF </text>
<text top="641" left="676" width="59" height="17" font="13">readmissio</text>
<text top="658" left="676" width="20" height="17" font="13">ns, </text>
<text top="675" left="676" width="63" height="17" font="13">transferred </text>
<text top="692" left="676" width="55" height="17" font="13">out of the </text>
<text top="710" left="676" width="49" height="17" font="13">hospital, </text>
<text top="727" left="676" width="68" height="17" font="13">left AMA, or </text>
<text top="744" left="676" width="24" height="17" font="13">had </text>
<text top="761" left="676" width="53" height="17" font="13">unknown </text>
<text top="778" left="676" width="57" height="17" font="13">discharge </text>
<text top="606" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="606" left="838" width="54" height="17" font="13">All-cause </text>
<text top="624" left="838" width="50" height="17" font="13">mortality </text>
<text top="606" left="913" width="31" height="17" font="13">  N/A </text>
<text top="606" left="994" width="28" height="17" font="13">20% </text>
<text top="606" left="1081" width="24" height="17" font="13">N/A </text>
<text top="606" left="1149" width="20" height="17" font="13">3 y </text>
<text top="606" left="1216" width="24" height="17" font="13">N/A </text>
<text top="606" left="1291" width="55" height="17" font="13">HR: 0.62; </text>
<text top="624" left="1291" width="44" height="17" font="13">95%CI: </text>
<text top="641" left="1291" width="62" height="17" font="13">0.59–0.65; </text>
<text top="658" left="1291" width="48" height="17" font="13">p&lt;0.001 </text>
<text top="675" left="1291" width="62" height="17" font="13">aHR: 0.80; </text>
<text top="692" left="1291" width="44" height="17" font="13">95%CI: </text>
<text top="710" left="1291" width="62" height="17" font="13">0.76–0.84; </text>
<text top="727" left="1291" width="48" height="17" font="13">p&lt;0.001 </text>
<text top="606" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="624" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="641" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="658" left="1378" width="25" height="17" font="13">non-</text>
<text top="675" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="692" left="1378" width="59" height="17" font="13">reason for </text>
<text top="710" left="1378" width="51" height="17" font="13">drug use </text>
<text top="727" left="1378" width="73" height="17" font="13">unclear, bias </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">96</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="122" width="54" height="17" font="13">Medicare </text>
<text top="72" left="122" width="63" height="17" font="13">beneficiarie</text>
<text top="89" left="122" width="10" height="17" font="13">s </text>
<text top="106" left="122" width="68" height="17" font="13">hospitalized </text>
<text top="124" left="122" width="45" height="17" font="13">with HF </text>
<text top="141" left="122" width="28" height="17" font="13">from </text>
<text top="158" left="122" width="49" height="17" font="13">National </text>
<text top="175" left="122" width="64" height="17" font="13">Heart Care </text>
<text top="192" left="122" width="45" height="17" font="13">Project. </text>
<text top="55" left="589" width="50" height="17" font="13">between </text>
<text top="72" left="589" width="55" height="17" font="13">4/98-3/99 </text>
<text top="89" left="589" width="52" height="17" font="13">and 7/00-</text>
<text top="106" left="589" width="31" height="17" font="13">6/01. </text>
<text top="55" left="676" width="65" height="17" font="13">disposition, </text>
<text top="72" left="676" width="64" height="17" font="13">died during </text>
<text top="89" left="676" width="64" height="17" font="13">hospitalizati</text>
<text top="106" left="676" width="62" height="17" font="13">on, had no </text>
<text top="124" left="676" width="41" height="17" font="13">date of </text>
<text top="141" left="676" width="34" height="17" font="13">death </text>
<text top="158" left="676" width="64" height="17" font="13">information </text>
<text top="175" left="676" width="59" height="17" font="13">available,  </text>
<text top="192" left="676" width="58" height="17" font="13">hospitalize</text>
<text top="210" left="676" width="53" height="17" font="13">d outside </text>
<text top="227" left="676" width="44" height="17" font="13">the US, </text>
<text top="244" left="676" width="64" height="17" font="13">discharged </text>
<text top="261" left="676" width="63" height="17" font="13">to hospice, </text>
<text top="278" left="676" width="59" height="17" font="13">contraindic</text>
<text top="296" left="676" width="50" height="17" font="13">ations to </text>
<text top="313" left="676" width="33" height="17" font="13">statin </text>
<text top="330" left="676" width="48" height="17" font="13">therapy, </text>
<text top="347" left="676" width="52" height="17" font="13">including </text>
<text top="365" left="676" width="33" height="17" font="13">statin </text>
<text top="382" left="676" width="54" height="17" font="13">allergy or </text>
<text top="399" left="676" width="26" height="17" font="13">liver </text>
<text top="416" left="676" width="62" height="17" font="13">dysfunction</text>
<text top="433" left="676" width="38" height="17" font="13">, or no </text>
<text top="451" left="676" width="59" height="17" font="13">medication</text>
<text top="468" left="676" width="62" height="17" font="13">s recorded </text>
<text top="485" left="676" width="17" height="17" font="13">on </text>
<text top="502" left="676" width="57" height="17" font="13">discharge </text>
<text top="520" left="42" width="66" height="17" font="13">Anker et al, </text>
<text top="537" left="42" width="31" height="17" font="13">2006 </text>
<text top="555" left="42" width="55" height="17" font="14">16846656</text>
<text top="555" left="97" width="3" height="17" font="13"> </text>
<text top="572" left="42" width="32" height="17" font="13">(206) </text>
<text top="520" left="122" width="59" height="17" font="13">To assess </text>
<text top="537" left="122" width="21" height="17" font="13">the </text>
<text top="555" left="122" width="66" height="17" font="13">relationship </text>
<text top="572" left="122" width="50" height="17" font="13">between </text>
<text top="589" left="122" width="56" height="17" font="13">statin use </text>
<text top="606" left="122" width="24" height="17" font="13">and </text>
<text top="624" left="122" width="58" height="17" font="13">survival in </text>
<text top="641" left="122" width="65" height="17" font="13">ELITE-II as </text>
<text top="658" left="122" width="62" height="17" font="13">well as a 5-</text>
<text top="675" left="122" width="38" height="17" font="13">center </text>
<text top="692" left="122" width="44" height="17" font="13">registry </text>
<text top="520" left="204" width="40" height="17" font="13">Cohort </text>
<text top="537" left="204" width="33" height="17" font="13">study </text>
<text top="520" left="271" width="109" height="17" font="13">ACEI or ARB (as in </text>
<text top="537" left="271" width="109" height="17" font="13">ELITE-2), diuretics, </text>
<text top="555" left="271" width="42" height="17" font="13">digoxin </text>
<text top="520" left="393" width="75" height="17" font="13">5,200; 1,103; </text>
<text top="537" left="393" width="34" height="17" font="13">4,097 </text>
<text top="520" left="508" width="186" height="17" font="13">67% ELITE-II: </text>
<text top="520" left="641" width="73" height="17" font="13">pts </text>
<text top="537" left="589" width="62" height="17" font="13">age ≥60 y; </text>
<text top="555" left="589" width="62" height="17" font="13">NYHA 2-4, </text>
<text top="572" left="589" width="77" height="17" font="13">LVEF ≥40%.  </text>
<text top="589" left="589" width="57" height="17" font="13">European </text>
<text top="606" left="589" width="47" height="17" font="13">registry: </text>
<text top="624" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="641" left="589" width="68" height="17" font="13">HF followed </text>
<text top="658" left="589" width="70" height="17" font="13">by HF clinic  </text>
<text top="520" left="676" width="178" height="17" font="13">NR NYHA </text>
<text top="520" left="795" width="81" height="17" font="13">2-4 </text>
<text top="520" left="838" width="114" height="17" font="13">All-cause </text>
<text top="537" left="838" width="50" height="17" font="13">mortality </text>
<text top="520" left="913" width="254" height="17" font="13">N/A NR  12% </text>
<text top="520" left="1149" width="91" height="17" font="13">mean </text>
<text top="520" left="1183" width="78" height="17" font="13">1.5 </text>
<text top="537" left="1149" width="10" height="17" font="13">y </text>
<text top="555" left="1149" width="42" height="17" font="13">(ELITE-</text>
<text top="572" left="1149" width="21" height="17" font="13">2);  </text>
<text top="589" left="1149" width="20" height="17" font="13">2 y </text>
<text top="606" left="1149" width="51" height="17" font="13">(Europea</text>
<text top="624" left="1149" width="10" height="17" font="13">n </text>
<text top="641" left="1149" width="48" height="17" font="13">registry) </text>
<text top="520" left="1216" width="179" height="17" font="13">NR ELITE-II: </text>
<text top="537" left="1291" width="59" height="17" font="13">aHR 0.61; </text>
<text top="555" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="572" left="1291" width="59" height="17" font="13">0.44-0.84; </text>
<text top="589" left="1291" width="55" height="17" font="13">p&lt;0.0028 </text>
<text top="606" left="1291" width="57" height="17" font="13">European </text>
<text top="624" left="1291" width="47" height="17" font="13">registry: </text>
<text top="641" left="1291" width="59" height="17" font="13">aHR 0.58; </text>
<text top="658" left="1291" width="40" height="17" font="13">95%CI </text>
<text top="675" left="1291" width="50" height="17" font="13">adjusted </text>
<text top="692" left="1291" width="59" height="17" font="13">0.44-0.77; </text>
<text top="710" left="1291" width="58" height="17" font="13">p&lt;0.0001; </text>
<text top="727" left="1291" width="3" height="17" font="13"> </text>
<text top="520" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="537" left="1378" width="70" height="17" font="13">cohort study </text>
<text top="555" left="1378" width="75" height="17" font="13">and post-hoc </text>
<text top="572" left="1378" width="51" height="17" font="13">analysis, </text>
<text top="589" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="606" left="1378" width="25" height="17" font="13">non-</text>
<text top="624" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="641" left="1378" width="59" height="17" font="13">reason for </text>
<text top="658" left="1378" width="51" height="17" font="13">drug use </text>
<text top="675" left="1378" width="73" height="17" font="13">unclear, bias </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">97</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="42" width="61" height="17" font="13">Folkeringa </text>
<text top="72" left="42" width="61" height="17" font="13">et al, 2006 </text>
<text top="89" left="42" width="55" height="17" font="14">16520262</text>
<text top="89" left="97" width="7" height="17" font="13">  </text>
<text top="106" left="42" width="32" height="17" font="13">(207) </text>
<text top="55" left="122" width="63" height="17" font="13">Investigate </text>
<text top="72" left="122" width="60" height="17" font="13">the effects </text>
<text top="89" left="122" width="53" height="17" font="13">of statins </text>
<text top="106" left="122" width="62" height="17" font="13">on survival </text>
<text top="124" left="122" width="62" height="17" font="13">in CHF pts </text>
<text top="141" left="122" width="43" height="17" font="13">using a </text>
<text top="158" left="122" width="51" height="17" font="13">matched </text>
<text top="175" left="122" width="30" height="17" font="13">case-</text>
<text top="192" left="122" width="57" height="17" font="13">controlled </text>
<text top="210" left="122" width="66" height="17" font="13">study in pts </text>
<text top="227" left="122" width="64" height="17" font="13">admitted to </text>
<text top="244" left="122" width="46" height="17" font="13">hospital </text>
<text top="261" left="122" width="64" height="17" font="13">because of </text>
<text top="278" left="122" width="40" height="17" font="13">severe </text>
<text top="296" left="122" width="57" height="17" font="13">CHF from </text>
<text top="313" left="122" width="21" height="17" font="13">the </text>
<text top="330" left="122" width="49" height="17" font="13">MARCH </text>
<text top="347" left="122" width="33" height="17" font="13">study </text>
<text top="55" left="204" width="33" height="17" font="13">Case-</text>
<text top="72" left="204" width="40" height="17" font="13">control </text>
<text top="89" left="204" width="33" height="17" font="13">study </text>
<text top="55" left="271" width="64" height="17" font="13">ACEI/ARB, </text>
<text top="72" left="271" width="95" height="17" font="13">diuretics, digoxin </text>
<text top="55" left="393" width="79" height="17" font="13">524; 262; 262 </text>
<text top="55" left="507" width="28" height="17" font="13">50% </text>
<text top="55" left="589" width="72" height="17" font="13">Pts admitted </text>
<text top="72" left="589" width="63" height="17" font="13">for HF with </text>
<text top="89" left="589" width="17" height="17" font="13">an </text>
<text top="106" left="589" width="66" height="17" font="13">uncomplicat</text>
<text top="124" left="589" width="62" height="17" font="13">ed survival </text>
<text top="141" left="589" width="71" height="17" font="13">for at least 1 </text>
<text top="158" left="589" width="49" height="17" font="13">mo after </text>
<text top="175" left="589" width="46" height="17" font="13">hospital </text>
<text top="192" left="589" width="60" height="17" font="13">discharge, </text>
<text top="210" left="589" width="64" height="17" font="13">group-wise </text>
<text top="227" left="589" width="51" height="17" font="13">matched </text>
<text top="244" left="589" width="50" height="17" font="13">between </text>
<text top="261" left="589" width="53" height="17" font="13">survivors </text>
<text top="278" left="589" width="49" height="17" font="13">and non-</text>
<text top="296" left="589" width="70" height="17" font="13">survivors on </text>
<text top="313" left="589" width="54" height="17" font="13">means of </text>
<text top="330" left="589" width="65" height="17" font="13">age, LVEF, </text>
<text top="347" left="589" width="31" height="17" font="13">renal </text>
<text top="365" left="589" width="74" height="17" font="13">function, and </text>
<text top="382" left="589" width="26" height="17" font="13">sex. </text>
<text top="55" left="676" width="178" height="17" font="13">NR NYHA </text>
<text top="55" left="795" width="81" height="17" font="13">3-4 </text>
<text top="55" left="838" width="114" height="17" font="13">All-cause </text>
<text top="72" left="838" width="50" height="17" font="13">mortality </text>
<text top="55" left="913" width="247" height="17" font="13">N/A NR  NR </text>
<text top="55" left="1149" width="91" height="17" font="13">Mean </text>
<text top="55" left="1183" width="78" height="17" font="13">2.6 </text>
<text top="72" left="1149" width="10" height="17" font="13">y </text>
<text top="55" left="1216" width="153" height="17" font="13">4% OR: </text>
<text top="55" left="1316" width="84" height="17" font="13">0.42; </text>
<text top="72" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="89" left="1291" width="58" height="17" font="13">0.26–0.69 </text>
<text top="106" left="1291" width="3" height="17" font="13"> </text>
<text top="55" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="89" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="106" left="1378" width="25" height="17" font="13">non-</text>
<text top="124" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="141" left="1378" width="59" height="17" font="13">reason for </text>
<text top="158" left="1378" width="51" height="17" font="13">drug use </text>
<text top="175" left="1378" width="73" height="17" font="13">unclear, bias </text>
<text top="400" left="42" width="50" height="17" font="13">Go et al, </text>
<text top="417" left="42" width="31" height="17" font="13">2006 </text>
<text top="434" left="42" width="55" height="17" font="14">17077375</text>
<text top="434" left="97" width="7" height="17" font="13">  </text>
<text top="451" left="42" width="32" height="17" font="13">(208) </text>
<text top="400" left="122" width="68" height="17" font="13">To evaluate </text>
<text top="417" left="122" width="21" height="17" font="13">the </text>
<text top="434" left="122" width="65" height="17" font="13">association </text>
<text top="451" left="122" width="50" height="17" font="13">between </text>
<text top="469" left="122" width="62" height="17" font="13">initiation of </text>
<text top="486" left="122" width="33" height="17" font="13">statin </text>
<text top="503" left="122" width="68" height="17" font="13">therapy and </text>
<text top="520" left="122" width="46" height="17" font="13">risks for </text>
<text top="537" left="122" width="58" height="17" font="13">death and </text>
<text top="555" left="122" width="64" height="17" font="13">hospitalizati</text>
<text top="572" left="122" width="58" height="17" font="13">on among </text>
<text top="589" left="122" width="61" height="17" font="13">adults with </text>
<text top="606" left="122" width="63" height="17" font="13">chronic HF </text>
<text top="624" left="122" width="33" height="17" font="13">in the </text>
<text top="641" left="122" width="38" height="17" font="13">Kaiser </text>
<text top="658" left="122" width="60" height="17" font="13">Permanent</text>
<text top="675" left="122" width="56" height="17" font="13">e Chronic </text>
<text top="692" left="122" width="57" height="17" font="13">HF cohort </text>
<text top="400" left="204" width="40" height="17" font="13">Cohort </text>
<text top="417" left="204" width="33" height="17" font="13">study </text>
<text top="400" left="271" width="64" height="17" font="13">ACEI/ARB, </text>
<text top="417" left="271" width="95" height="17" font="13">diuretics, digoxin </text>
<text top="400" left="393" width="89" height="17" font="13">24,598; 12,648; </text>
<text top="417" left="393" width="41" height="17" font="13">11,950 </text>
<text top="400" left="508" width="172" height="17" font="13">54% Adults </text>
<text top="400" left="626" width="81" height="17" font="13">(age </text>
<text top="417" left="589" width="39" height="17" font="13">≥20 y) </text>
<text top="434" left="589" width="60" height="17" font="13">diagnosed </text>
<text top="451" left="589" width="45" height="17" font="13">with HF </text>
<text top="469" left="589" width="62" height="17" font="13">1/96-12/04 </text>
<text top="486" left="589" width="44" height="17" font="13">with ≥1 </text>
<text top="503" left="589" width="71" height="17" font="13">hospitalizatio</text>
<text top="520" left="589" width="52" height="17" font="13">ns with a </text>
<text top="537" left="589" width="49" height="17" font="13">principal </text>
<text top="555" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="572" left="589" width="42" height="17" font="13">HF; ≥2 </text>
<text top="589" left="589" width="71" height="17" font="13">hospitalizatio</text>
<text top="606" left="589" width="52" height="17" font="13">ns with a </text>
<text top="624" left="589" width="60" height="17" font="13">secondary </text>
<text top="641" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="658" left="589" width="68" height="17" font="13">HF in which </text>
<text top="675" left="589" width="70" height="17" font="13">the principal </text>
<text top="692" left="589" width="68" height="17" font="13">diagnosis is </text>
<text top="710" left="589" width="44" height="17" font="13">cardiac-</text>
<text top="727" left="589" width="63" height="17" font="13">related; ≥3 </text>
<text top="744" left="589" width="71" height="17" font="13">hospitalizatio</text>
<text top="761" left="589" width="42" height="17" font="13">ns with </text>
<text top="778" left="589" width="60" height="17" font="13">secondary </text>
<text top="400" left="676" width="47" height="17" font="13">Pts who </text>
<text top="417" left="676" width="30" height="17" font="13">were </text>
<text top="434" left="676" width="53" height="17" font="13">receiving </text>
<text top="451" left="676" width="33" height="17" font="13">statin </text>
<text top="469" left="676" width="58" height="17" font="13">therapy at </text>
<text top="486" left="676" width="67" height="17" font="13">the study at </text>
<text top="503" left="676" width="62" height="17" font="13">entry date; </text>
<text top="520" left="676" width="56" height="17" font="13">who were </text>
<text top="537" left="676" width="62" height="17" font="13">not eligible </text>
<text top="555" left="676" width="18" height="17" font="13">for </text>
<text top="572" left="676" width="55" height="17" font="13">treatment </text>
<text top="589" left="676" width="54" height="17" font="13">based on </text>
<text top="606" left="676" width="46" height="17" font="13">national </text>
<text top="623" left="676" width="59" height="17" font="13">guidelines </text>
<text top="400" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="400" left="838" width="36" height="17" font="13">Death </text>
<text top="417" left="838" width="51" height="17" font="13">from any </text>
<text top="434" left="838" width="60" height="17" font="13">cause and </text>
<text top="451" left="838" width="51" height="17" font="13">hospitaliz</text>
<text top="469" left="838" width="48" height="17" font="13">ation for </text>
<text top="486" left="838" width="20" height="17" font="13">HF </text>
<text top="400" left="913" width="183" height="17" font="13">N/A 13.90% </text>
<text top="400" left="1081" width="78" height="17" font="13">NR </text>
<text top="400" left="1149" width="101" height="17" font="13">Median </text>
<text top="417" left="1149" width="30" height="17" font="13">2.4 y </text>
<text top="400" left="1216" width="159" height="17" font="13">NR aHR: </text>
<text top="400" left="1322" width="84" height="17" font="13">0.76; </text>
<text top="417" left="1291" width="44" height="17" font="13">95%CI: </text>
<text top="434" left="1291" width="55" height="17" font="13">0.72-0.80 </text>
<text top="451" left="1291" width="3" height="17" font="13"> </text>
<text top="400" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="417" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="434" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="451" left="1378" width="25" height="17" font="13">non-</text>
<text top="469" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="486" left="1378" width="59" height="17" font="13">reason for </text>
<text top="503" left="1378" width="51" height="17" font="13">drug use </text>
<text top="520" left="1378" width="73" height="17" font="13">unclear, bias </text>
</page>
<page number="98" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">98</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="589" width="69" height="17" font="13">diagnosis of </text>
<text top="72" left="589" width="42" height="17" font="13">HF; ≥2 </text>
<text top="89" left="589" width="57" height="17" font="13">outpatient </text>
<text top="106" left="589" width="63" height="17" font="13">diagnoses; </text>
<text top="124" left="589" width="64" height="17" font="13">≥3 ED visit </text>
<text top="141" left="589" width="63" height="17" font="13">diagnoses; </text>
<text top="158" left="589" width="33" height="17" font="13">or ≥2 </text>
<text top="175" left="589" width="50" height="17" font="13">inpatient </text>
<text top="192" left="589" width="60" height="17" font="13">secondary </text>
<text top="210" left="589" width="59" height="17" font="13">diagnoses </text>
<text top="227" left="589" width="36" height="17" font="13">plus 1 </text>
<text top="244" left="589" width="57" height="17" font="13">outpatient </text>
<text top="261" left="589" width="62" height="17" font="13">diagnosis.  </text>
<text top="279" left="42" width="63" height="17" font="13">Krum et al, </text>
<text top="296" left="42" width="31" height="17" font="13">2007 </text>
<text top="314" left="42" width="55" height="17" font="14">16960445</text>
<text top="314" left="97" width="7" height="17" font="13">  </text>
<text top="331" left="42" width="32" height="17" font="13">(209) </text>
<text top="279" left="122" width="68" height="17" font="13">To examine </text>
<text top="296" left="122" width="60" height="17" font="13">statin/beta </text>
<text top="314" left="122" width="43" height="17" font="13">blocker </text>
<text top="331" left="122" width="66" height="17" font="13">interactions </text>
<text top="348" left="122" width="55" height="17" font="13">within the </text>
<text top="365" left="122" width="67" height="17" font="13">context of a </text>
<text top="382" left="122" width="64" height="17" font="13">large-scale </text>
<text top="400" left="122" width="63" height="17" font="13">clinical trial </text>
<text top="417" left="122" width="59" height="17" font="13">of pts with </text>
<text top="434" left="122" width="44" height="17" font="13">systolic </text>
<text top="451" left="122" width="42" height="17" font="13">CHF in </text>
<text top="469" left="122" width="46" height="17" font="13">CIBIS-II </text>
<text top="279" left="204" width="40" height="17" font="13">Cohort </text>
<text top="296" left="204" width="33" height="17" font="13">study </text>
<text top="279" left="271" width="98" height="17" font="13">ACEIs/ARB, beta-</text>
<text top="296" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="314" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="279" left="393" width="143" height="17" font="13">2,647; 220; 2,421  59% </text>
<text top="279" left="589" width="68" height="17" font="13">Pts enrolled </text>
<text top="296" left="589" width="59" height="17" font="13">in CIBIS-II </text>
<text top="314" left="589" width="33" height="17" font="13">study </text>
<text top="279" left="676" width="31" height="17" font="13">  N/A </text>
<text top="279" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="279" left="838" width="36" height="17" font="13">Death </text>
<text top="279" left="913" width="61" height="17" font="13">CV deaths </text>
<text top="296" left="913" width="49" height="17" font="13">included </text>
<text top="314" left="913" width="21" height="17" font="13">the </text>
<text top="331" left="913" width="51" height="17" font="13">following </text>
<text top="348" left="913" width="44" height="17" font="13">specific </text>
<text top="365" left="913" width="46" height="17" font="13">causes: </text>
<text top="382" left="913" width="44" height="17" font="13">sudden </text>
<text top="400" left="913" width="38" height="17" font="13">death, </text>
<text top="417" left="913" width="34" height="17" font="13">pump </text>
<text top="434" left="913" width="57" height="17" font="13">failure, MI </text>
<text top="451" left="913" width="47" height="17" font="13">and any </text>
<text top="469" left="913" width="52" height="17" font="13">other CV </text>
<text top="486" left="913" width="53" height="17" font="13">condition </text>
<text top="503" left="913" width="53" height="17" font="13">not listed </text>
<text top="520" left="913" width="37" height="17" font="13">above </text>
<text top="537" left="913" width="55" height="17" font="13">which led </text>
<text top="555" left="913" width="56" height="17" font="13">to the pt's </text>
<text top="572" left="913" width="38" height="17" font="13">death. </text>
<text top="589" left="913" width="62" height="17" font="13">Worsening </text>
<text top="606" left="913" width="46" height="17" font="13">HF only </text>
<text top="624" left="913" width="25" height="17" font="13">was </text>
<text top="641" left="913" width="64" height="17" font="13">counted as </text>
<text top="658" left="913" width="68" height="17" font="13">an outcome </text>
<text top="675" left="913" width="64" height="17" font="13">endpoint in </text>
<text top="692" left="913" width="46" height="17" font="13">CIBIS II </text>
<text top="710" left="913" width="55" height="17" font="13">when this </text>
<text top="727" left="913" width="46" height="17" font="13">(critical) </text>
<text top="744" left="913" width="67" height="17" font="13">event led to </text>
<text top="761" left="913" width="21" height="17" font="13">the </text>
<text top="778" left="913" width="64" height="17" font="13">hospitalizati</text>
<text top="279" left="994" width="232" height="17" font="13">11.10% NR  Mean </text>
<text top="279" left="1183" width="63" height="17" font="13">1.3 </text>
<text top="296" left="1149" width="10" height="17" font="13">y </text>
<text top="279" left="1216" width="149" height="17" font="13">NR HR </text>
<text top="279" left="1312" width="84" height="17" font="13">0.57; </text>
<text top="296" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="314" left="1291" width="62" height="17" font="13">0.37–0.94; </text>
<text top="331" left="1291" width="59" height="17" font="13">aHR 0.60; </text>
<text top="348" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="365" left="1291" width="58" height="17" font="13">0.39–0.94 </text>
<text top="382" left="1291" width="3" height="17" font="13"> </text>
<text top="279" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="296" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="314" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="331" left="1378" width="25" height="17" font="13">non-</text>
<text top="348" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="365" left="1378" width="59" height="17" font="13">reason for </text>
<text top="382" left="1378" width="51" height="17" font="13">drug use </text>
<text top="400" left="1378" width="73" height="17" font="13">unclear, bias </text>
</page>
<page number="99" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="14" height="14" font="6">99</text>
<text top="810" left="824" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="913" width="51" height="17" font="13">on of the </text>
<text top="72" left="913" width="17" height="17" font="13">pt. </text>
<text top="223" left="42" width="63" height="17" font="13">Krum et al, </text>
<text top="241" left="42" width="31" height="17" font="13">2007 </text>
<text top="258" left="42" width="55" height="17" font="14">17049646</text>
<text top="258" left="97" width="7" height="17" font="13">  </text>
<text top="275" left="42" width="32" height="17" font="13">(209) </text>
<text top="223" left="122" width="59" height="17" font="13">To assess </text>
<text top="241" left="122" width="21" height="17" font="13">the </text>
<text top="258" left="122" width="64" height="17" font="13">outcome of </text>
<text top="275" left="122" width="67" height="17" font="13">pts enrolled </text>
<text top="292" left="122" width="35" height="17" font="13">in Val-</text>
<text top="310" left="122" width="34" height="17" font="13">HeFT </text>
<text top="327" left="122" width="57" height="17" font="13">according </text>
<text top="344" left="122" width="46" height="17" font="13">to statin </text>
<text top="361" left="122" width="57" height="17" font="13">use at the </text>
<text top="378" left="122" width="40" height="17" font="13">time of </text>
<text top="396" left="122" width="64" height="17" font="13">randomizati</text>
<text top="413" left="122" width="31" height="17" font="13">on to </text>
<text top="430" left="122" width="68" height="17" font="13">valsartan or </text>
<text top="447" left="122" width="50" height="17" font="13">placebo. </text>
<text top="223" left="204" width="40" height="17" font="13">Cohort </text>
<text top="241" left="204" width="33" height="17" font="13">study </text>
<text top="223" left="271" width="92" height="17" font="13">ACEI/ARB, beta-</text>
<text top="241" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="258" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="223" left="393" width="75" height="17" font="13">5,010; 1,602; </text>
<text top="241" left="393" width="34" height="17" font="13">3,408 </text>
<text top="223" left="508" width="155" height="17" font="13">57% Pts </text>
<text top="223" left="610" width="100" height="17" font="13">enrolled </text>
<text top="241" left="589" width="69" height="17" font="13">in Val-HeFT </text>
<text top="258" left="589" width="33" height="17" font="13">study </text>
<text top="223" left="676" width="31" height="17" font="13">  N/A </text>
<text top="223" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="223" left="838" width="54" height="17" font="13">All-cause </text>
<text top="241" left="838" width="50" height="17" font="13">mortality </text>
<text top="223" left="913" width="50" height="17" font="13">Mortality </text>
<text top="241" left="913" width="24" height="17" font="13">and </text>
<text top="258" left="913" width="53" height="17" font="13">morbidity </text>
<text top="275" left="913" width="47" height="17" font="13">(cardiac </text>
<text top="292" left="913" width="60" height="17" font="13">arrest with </text>
<text top="310" left="913" width="62" height="17" font="13">resuscitatio</text>
<text top="327" left="913" width="14" height="17" font="13">n, </text>
<text top="344" left="913" width="64" height="17" font="13">hospitalizati</text>
<text top="361" left="913" width="58" height="17" font="13">on for HF, </text>
<text top="378" left="913" width="14" height="17" font="13">or </text>
<text top="396" left="913" width="63" height="17" font="13">administrati</text>
<text top="413" left="913" width="31" height="17" font="13">on of </text>
<text top="430" left="913" width="61" height="17" font="13">IVinotropic </text>
<text top="447" left="913" width="14" height="17" font="13">or </text>
<text top="464" left="913" width="63" height="17" font="13">vasodilator </text>
<text top="482" left="913" width="62" height="17" font="13">drugs for 4 </text>
<text top="499" left="913" width="56" height="17" font="13">h or more </text>
<text top="516" left="913" width="42" height="17" font="13">without </text>
<text top="533" left="913" width="64" height="17" font="13">hospitalizati</text>
<text top="551" left="913" width="21" height="17" font="13">on) </text>
<text top="223" left="994" width="239" height="17" font="13">7.90% NR Mean </text>
<text top="223" left="1183" width="70" height="17" font="13">1.9 </text>
<text top="241" left="1149" width="10" height="17" font="13">y </text>
<text top="223" left="1216" width="131" height="17" font="13">7.20% HR </text>
<text top="223" left="1312" width="67" height="17" font="13">0.81: </text>
<text top="241" left="1291" width="71" height="17" font="13">95%CI 0.70–</text>
<text top="258" left="1291" width="31" height="17" font="13">0.94; </text>
<text top="275" left="1291" width="48" height="17" font="13">p=0.005 </text>
<text top="223" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="241" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="258" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="275" left="1378" width="25" height="17" font="13">non-</text>
<text top="292" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="310" left="1378" width="59" height="17" font="13">reason for </text>
<text top="327" left="1378" width="51" height="17" font="13">drug use </text>
<text top="344" left="1378" width="73" height="17" font="13">unclear, bias </text>
<text top="569" left="42" width="57" height="17" font="13">Dickinson </text>
<text top="586" left="42" width="61" height="17" font="13">et al, 2007 </text>
<text top="603" left="42" width="55" height="17" font="14">17383296</text>
<text top="603" left="97" width="7" height="17" font="13">  </text>
<text top="620" left="42" width="32" height="17" font="13">(210) </text>
<text top="569" left="122" width="68" height="17" font="13">To examine </text>
<text top="586" left="122" width="60" height="17" font="13">the effects </text>
<text top="603" left="122" width="59" height="17" font="13">of statin in </text>
<text top="620" left="122" width="51" height="17" font="13">reducing </text>
<text top="637" left="122" width="63" height="17" font="13">mortality in </text>
<text top="655" left="122" width="64" height="17" font="13">SCD-HeFT </text>
<text top="569" left="204" width="40" height="17" font="13">Cohort </text>
<text top="586" left="204" width="33" height="17" font="13">study </text>
<text top="569" left="271" width="92" height="17" font="13">ACEI/ARB, beta-</text>
<text top="586" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="603" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="569" left="393" width="143" height="17" font="13">2,521; 965; 1,556  52% </text>
<text top="569" left="588" width="52" height="17" font="13">Ischemic </text>
<text top="586" left="589" width="49" height="17" font="13">and non-</text>
<text top="603" left="589" width="51" height="17" font="13">ischemic </text>
<text top="620" left="589" width="70" height="17" font="13">cardiomyopa</text>
<text top="637" left="589" width="61" height="17" font="13">thy, NYHA </text>
<text top="655" left="589" width="45" height="17" font="13">2-3 HF, </text>
<text top="672" left="589" width="62" height="17" font="13">LVEF 35% </text>
<text top="689" left="589" width="40" height="17" font="13">or less </text>
<text top="569" left="676" width="31" height="17" font="13">  N/A </text>
<text top="569" left="757" width="59" height="17" font="13">NYHA 2-3 </text>
<text top="569" left="838" width="54" height="17" font="13">All-cause </text>
<text top="586" left="838" width="50" height="17" font="13">mortality </text>
<text top="569" left="913" width="247" height="17" font="13">N/A 6.80% NR </text>
<text top="569" left="1149" width="91" height="17" font="13">Mean </text>
<text top="569" left="1183" width="78" height="17" font="13">3.8 </text>
<text top="586" left="1149" width="10" height="17" font="13">y </text>
<text top="569" left="1216" width="21" height="17" font="13">NR </text>
<text top="569" left="1291" width="55" height="17" font="13">aHR 0.7;  </text>
<text top="586" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="603" left="1291" width="55" height="17" font="13">0.57-0.83 </text>
<text top="569" left="1378" width="79" height="17" font="13">Retrospective </text>
<text top="586" left="1378" width="74" height="17" font="13">cohort study, </text>
<text top="603" left="1378" width="56" height="17" font="13">sampling, </text>
<text top="620" left="1378" width="25" height="17" font="13">non-</text>
<text top="637" left="1378" width="71" height="17" font="13">randomized, </text>
<text top="655" left="1378" width="59" height="17" font="13">reason for </text>
<text top="672" left="1378" width="51" height="17" font="13">drug use </text>
<text top="689" left="1378" width="73" height="17" font="13">unclear, bias </text>
</page>
<page number="100" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">100</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="42" width="61" height="17" font="13">CORONA, </text>
<text top="72" left="42" width="67" height="17" font="13">Kjekshus et </text>
<text top="89" left="42" width="47" height="17" font="13">al, 2007 </text>
<text top="106" left="42" width="55" height="17" font="14">17984166</text>
<text top="106" left="97" width="3" height="17" font="13"> </text>
<text top="124" left="42" width="32" height="17" font="13">(211) </text>
<text top="55" left="122" width="18" height="17" font="13">To </text>
<text top="72" left="122" width="62" height="17" font="13">investigate </text>
<text top="89" left="122" width="21" height="17" font="13">the </text>
<text top="106" left="122" width="55" height="17" font="13">beneficial </text>
<text top="124" left="122" width="53" height="17" font="13">effects of </text>
<text top="141" left="122" width="59" height="17" font="13">rosuvastati</text>
<text top="158" left="122" width="27" height="17" font="13">n on </text>
<text top="175" left="122" width="57" height="17" font="13">improving </text>
<text top="192" left="122" width="48" height="17" font="13">survival, </text>
<text top="210" left="122" width="51" height="17" font="13">reducing </text>
<text top="227" left="122" width="57" height="17" font="13">morbidity, </text>
<text top="244" left="122" width="24" height="17" font="13">and </text>
<text top="261" left="122" width="59" height="17" font="13">increasing </text>
<text top="278" left="122" width="59" height="17" font="13">well-being </text>
<text top="296" left="122" width="58" height="17" font="13">in pts with </text>
<text top="313" left="122" width="46" height="17" font="13">chronic, </text>
<text top="330" left="122" width="63" height="17" font="13">symptomati</text>
<text top="347" left="122" width="60" height="17" font="13">c, systolic, </text>
<text top="365" left="122" width="51" height="17" font="13">ischemic </text>
<text top="382" left="122" width="23" height="17" font="13">HF. </text>
<text top="55" left="204" width="171" height="17" font="13">RCT ACEI/ARB, </text>
<text top="55" left="336" width="28" height="17" font="13">beta-</text>
<text top="72" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="89" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="55" left="393" width="75" height="17" font="13">5,011; 2,497; </text>
<text top="72" left="393" width="34" height="17" font="13">2,514 </text>
<text top="55" left="508" width="152" height="17" font="13">100% Age </text>
<text top="55" left="614" width="29" height="17" font="13">≥18, </text>
<text top="72" left="589" width="72" height="17" font="13">symptomatic </text>
<text top="89" left="589" width="68" height="17" font="13">HF NYHA 2-</text>
<text top="106" left="589" width="42" height="17" font="13">4, IHD, </text>
<text top="124" left="589" width="73" height="17" font="13">LVEF &lt;40%, </text>
<text top="141" left="589" width="51" height="17" font="13">does not </text>
<text top="158" left="589" width="64" height="17" font="13">need statin </text>
<text top="175" left="589" width="48" height="17" font="13">therapy, </text>
<text top="192" left="589" width="43" height="17" font="13">optimal </text>
<text top="210" left="589" width="46" height="17" font="13">medical </text>
<text top="227" left="589" width="62" height="17" font="13">therapy &gt;2 </text>
<text top="244" left="589" width="18" height="17" font="13">wk </text>
<text top="55" left="676" width="57" height="17" font="13">Myopathy </text>
<text top="72" left="676" width="14" height="17" font="13">or </text>
<text top="89" left="676" width="63" height="17" font="13">hypersensti</text>
<text top="106" left="676" width="35" height="17" font="13">vity to </text>
<text top="124" left="676" width="65" height="17" font="13">statin, ACS </text>
<text top="141" left="676" width="14" height="17" font="13">or </text>
<text top="158" left="676" width="59" height="17" font="13">revasculari</text>
<text top="175" left="676" width="54" height="17" font="13">zation &lt;1 </text>
<text top="192" left="676" width="24" height="17" font="13">mo, </text>
<text top="210" left="676" width="67" height="17" font="13">reduced life </text>
<text top="227" left="676" width="62" height="17" font="13">expectancy</text>
<text top="244" left="676" width="54" height="17" font="13">, planned </text>
<text top="261" left="676" width="62" height="17" font="13">surgery &lt;3 </text>
<text top="278" left="676" width="68" height="17" font="13">mo, Cr &gt;2.5 </text>
<text top="296" left="676" width="65" height="17" font="13">mg/dL, ,CK </text>
<text top="313" left="676" width="55" height="17" font="13">&gt;2x ULN, </text>
<text top="330" left="676" width="65" height="17" font="13">LFTs &gt;1.5x </text>
<text top="347" left="676" width="32" height="17" font="13">ULN, </text>
<text top="365" left="676" width="58" height="17" font="13">uncorrecte</text>
<text top="382" left="676" width="57" height="17" font="13">d valve or </text>
<text top="399" left="676" width="31" height="17" font="13">HCM </text>
<text top="55" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="55" left="838" width="52" height="17" font="13">Composit</text>
<text top="72" left="838" width="58" height="17" font="13">e of death </text>
<text top="89" left="838" width="28" height="17" font="13">from </text>
<text top="106" left="838" width="53" height="17" font="13">cardiovas</text>
<text top="124" left="838" width="30" height="17" font="13">cular </text>
<text top="141" left="838" width="46" height="17" font="13">causes, </text>
<text top="158" left="838" width="47" height="17" font="13">nonfatal </text>
<text top="175" left="838" width="44" height="17" font="13">MI, and </text>
<text top="192" left="838" width="47" height="17" font="13">nonfatal </text>
<text top="210" left="838" width="37" height="17" font="13">stroke </text>
<text top="55" left="913" width="64" height="17" font="13">Death from </text>
<text top="72" left="913" width="63" height="17" font="13">any cause, </text>
<text top="89" left="913" width="23" height="17" font="13">any </text>
<text top="106" left="913" width="51" height="17" font="13">coronary </text>
<text top="124" left="913" width="33" height="17" font="13">event </text>
<text top="141" left="913" width="48" height="17" font="13">(sudden </text>
<text top="158" left="913" width="64" height="17" font="13">death, fatal </text>
<text top="175" left="913" width="62" height="17" font="13">or nonfatal </text>
<text top="192" left="913" width="59" height="17" font="13">MI, PCI or </text>
<text top="210" left="913" width="42" height="17" font="13">CABG, </text>
<text top="227" left="913" width="60" height="17" font="13">ventricular </text>
<text top="244" left="913" width="59" height="17" font="13">defibrillatio</text>
<text top="261" left="913" width="44" height="17" font="13">n by an </text>
<text top="278" left="913" width="28" height="17" font="13">ICD, </text>
<text top="296" left="913" width="62" height="17" font="13">resuscitatio</text>
<text top="313" left="913" width="38" height="17" font="13">n after </text>
<text top="330" left="913" width="43" height="17" font="13">cardiac </text>
<text top="347" left="913" width="53" height="17" font="13">arrest, or </text>
<text top="365" left="913" width="64" height="17" font="13">hospitalizati</text>
<text top="382" left="913" width="63" height="17" font="13">on for UA), </text>
<text top="399" left="913" width="62" height="17" font="13">death from </text>
<text top="416" left="913" width="63" height="17" font="13">CV causes </text>
<text top="433" left="913" width="47" height="17" font="13">(with an </text>
<text top="451" left="913" width="56" height="17" font="13">additional </text>
<text top="468" left="913" width="61" height="17" font="13">analysis of </text>
<text top="485" left="913" width="37" height="17" font="13">cause-</text>
<text top="502" left="913" width="44" height="17" font="13">specific </text>
<text top="519" left="913" width="62" height="17" font="13">death from </text>
<text top="537" left="913" width="31" height="17" font="13">a CV </text>
<text top="554" left="913" width="68" height="17" font="13">cause), and </text>
<text top="571" left="913" width="66" height="17" font="13">the number </text>
<text top="588" left="913" width="14" height="17" font="13">of </text>
<text top="605" left="913" width="64" height="17" font="13">hospitalizati</text>
<text top="623" left="913" width="62" height="17" font="13">ons for CV </text>
<text top="640" left="913" width="46" height="17" font="13">causes, </text>
<text top="657" left="913" width="50" height="17" font="13">unstable </text>
<text top="674" left="913" width="58" height="17" font="13">angina, or </text>
<text top="692" left="913" width="59" height="17" font="13">worsening </text>
<text top="709" left="913" width="20" height="17" font="13">HF </text>
<text top="55" left="994" width="169" height="17" font="13">11% NR </text>
<text top="55" left="1149" width="103" height="17" font="13">Median </text>
<text top="72" left="1149" width="30" height="17" font="13">2.7 y </text>
<text top="55" left="1216" width="53" height="17" font="13">0.9% per </text>
<text top="72" left="1216" width="24" height="17" font="13">100 </text>
<text top="89" left="1216" width="51" height="17" font="13">patient-y </text>
<text top="55" left="1291" width="55" height="17" font="13">HR: 0.92; </text>
<text top="72" left="1291" width="47" height="17" font="13">95% CI: </text>
<text top="89" left="1291" width="59" height="17" font="13">0.83-1.02; </text>
<text top="106" left="1291" width="41" height="17" font="13">p=0.12 </text>
<text top="55" left="1378" width="31" height="17" font="13">  N/A </text>
<text top="727" left="42" width="60" height="17" font="13">GISSI-HF, </text>
<text top="744" left="42" width="59" height="17" font="13">Tavazzi et </text>
<text top="761" left="42" width="47" height="17" font="13">al, 2008 </text>
<text top="778" left="42" width="55" height="17" font="14">18757089</text>
<text top="778" left="97" width="7" height="17" font="13">  </text>
<text top="727" left="122" width="18" height="17" font="13">To </text>
<text top="744" left="122" width="62" height="17" font="13">investigate </text>
<text top="761" left="122" width="40" height="17" font="13">the effi </text>
<text top="778" left="122" width="53" height="17" font="13">cacy and </text>
<text top="727" left="204" width="171" height="17" font="13">RCT ACEI/ARB, </text>
<text top="727" left="336" width="28" height="17" font="13">beta-</text>
<text top="744" left="271" width="105" height="17" font="13">blockers,spironolac</text>
<text top="761" left="271" width="80" height="17" font="13">tone, diuretics </text>
<text top="727" left="393" width="75" height="17" font="13">4,574; 2,285; </text>
<text top="744" left="393" width="34" height="17" font="13">2,289 </text>
<text top="727" left="508" width="68" height="17" font="13">42% history </text>
<text top="744" left="508" width="31" height="17" font="13">of MI </text>
<text top="727" left="589" width="29" height="17" font="13">≥18, </text>
<text top="744" left="589" width="72" height="17" font="13">symptomatic </text>
<text top="761" left="589" width="68" height="17" font="13">HF NYHA 2-</text>
<text top="778" left="589" width="57" height="17" font="13">4, if LVEF </text>
<text top="727" left="676" width="62" height="17" font="13">Hypersenst</text>
<text top="744" left="676" width="38" height="17" font="13">ivity to </text>
<text top="761" left="676" width="36" height="17" font="13">statin, </text>
<text top="778" left="676" width="61" height="17" font="13">investigatio</text>
<text top="727" left="757" width="59" height="17" font="13">NYHA 2-4 </text>
<text top="727" left="838" width="20" height="17" font="13">Co-</text>
<text top="744" left="838" width="44" height="17" font="13">primary </text>
<text top="761" left="838" width="54" height="17" font="13">endpoint: </text>
<text top="778" left="838" width="40" height="17" font="13">time to </text>
<text top="727" left="913" width="64" height="17" font="13">Death for a </text>
<text top="744" left="913" width="60" height="17" font="13">CV cause; </text>
<text top="761" left="913" width="23" height="17" font="13">first </text>
<text top="778" left="913" width="46" height="17" font="13">hospital </text>
<text top="727" left="994" width="248" height="17" font="13">7.90% NR Median </text>
<text top="744" left="1149" width="30" height="17" font="13">3.9 y </text>
<text top="727" left="1216" width="148" height="17" font="13">-1% HR: </text>
<text top="727" left="1315" width="76" height="17" font="13">1.02 </text>
<text top="744" left="1291" width="47" height="17" font="13">99% CI: </text>
<text top="761" left="1291" width="73" height="17" font="13">0.923-1.130; </text>
<text top="778" left="1291" width="48" height="17" font="13">p=0.594 </text>
<text top="727" left="1378" width="27" height="17" font="13"> N/A </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="24" size="11" family="Times" color="#000000"/>
	<fontspec id="25" size="11" family="Times" color="#0000ff"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">101</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="42" width="165" height="17" font="13">(212) safety </text>
<text top="55" left="158" width="62" height="17" font="13">of </text>
<text top="72" left="122" width="53" height="17" font="13">the statin </text>
<text top="89" left="122" width="59" height="17" font="13">rosuvastati</text>
<text top="106" left="122" width="68" height="17" font="13">n in pts with </text>
<text top="124" left="122" width="23" height="17" font="13">HF. </text>
<text top="55" left="589" width="71" height="17" font="13">&gt;40% (10%) </text>
<text top="72" left="589" width="68" height="17" font="13">requires HF </text>
<text top="89" left="589" width="71" height="17" font="13">hospitalizatio</text>
<text top="106" left="589" width="62" height="17" font="13">n within 12 </text>
<text top="124" left="589" width="21" height="17" font="13">mo </text>
<text top="55" left="676" width="65" height="17" font="13">nal drug &lt;1 </text>
<text top="72" left="676" width="58" height="17" font="13">month, MI </text>
<text top="89" left="676" width="41" height="17" font="13">&lt;6 mo, </text>
<text top="106" left="676" width="43" height="17" font="13">ACS or </text>
<text top="124" left="676" width="59" height="17" font="13">revasculari</text>
<text top="141" left="676" width="54" height="17" font="13">zation &lt;3 </text>
<text top="158" left="676" width="24" height="17" font="13">mo, </text>
<text top="175" left="676" width="67" height="17" font="13">reduced life </text>
<text top="192" left="676" width="62" height="17" font="13">expectancy</text>
<text top="210" left="676" width="54" height="17" font="13">, planned </text>
<text top="227" left="676" width="64" height="17" font="13">surgery/dev</text>
<text top="244" left="676" width="61" height="17" font="13">ice &lt;3 mo, </text>
<text top="261" left="676" width="44" height="17" font="13">Cr &gt;2.5 </text>
<text top="278" left="676" width="41" height="17" font="13">mg/dL, </text>
<text top="296" left="676" width="65" height="17" font="13">LFTs &gt;1.5x </text>
<text top="313" left="676" width="32" height="17" font="13">ULN, </text>
<text top="330" left="676" width="52" height="17" font="13">pregnant </text>
<text top="55" left="838" width="38" height="17" font="13">death; </text>
<text top="72" left="838" width="40" height="17" font="13">time to </text>
<text top="89" left="838" width="34" height="17" font="13">death </text>
<text top="106" left="838" width="14" height="17" font="13">or </text>
<text top="124" left="838" width="59" height="17" font="13">admission </text>
<text top="141" left="838" width="18" height="17" font="13">for </text>
<text top="158" left="838" width="53" height="17" font="13">cardiovas</text>
<text top="175" left="838" width="30" height="17" font="13">cular </text>
<text top="192" left="838" width="47" height="17" font="13">reasons </text>
<text top="55" left="913" width="59" height="17" font="13">admission </text>
<text top="72" left="913" width="44" height="17" font="13">for any, </text>
<text top="89" left="913" width="58" height="17" font="13">CV, or HF </text>
<text top="106" left="913" width="64" height="17" font="13">cause; and </text>
<text top="124" left="913" width="21" height="17" font="13">the </text>
<text top="141" left="913" width="57" height="17" font="13">combined </text>
<text top="158" left="913" width="51" height="17" font="13">outcome </text>
<text top="175" left="913" width="65" height="17" font="13">measure of </text>
<text top="192" left="913" width="55" height="17" font="13">CV death </text>
<text top="210" left="913" width="14" height="17" font="13">or </text>
<text top="227" left="913" width="59" height="17" font="13">admission </text>
<text top="244" left="913" width="59" height="17" font="13">to hospital </text>
<text top="261" left="913" width="41" height="17" font="13">for any </text>
<text top="278" left="913" width="36" height="17" font="13">cause </text>
<text top="55" left="1291" width="62" height="17" font="13">aHR: 1.01; </text>
<text top="72" left="1291" width="44" height="17" font="13">99% CI </text>
<text top="89" left="1291" width="73" height="17" font="13">0.908-1.112, </text>
<text top="106" left="1291" width="55" height="17" font="13">p=0.903;  </text>
<text top="348" left="54" width="1349" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; AMA, against medical advice; ARB, angiotensin receptor blocker; CABG, coronary artery bypass surgery; CHF, congestive heart failure; CIBIS-II, The Cardiac </text>
<text top="365" left="54" width="1370" height="17" font="13">Insufficiency Bisoprolol Study II; CORONA, Controlled Rosuvastatin Multinational Trial in HF; CV, cardiovascular; ELITE-II, Losartan Heart Failure Survival Study; HF, heart failure; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto </text>
<text top="382" left="54" width="551" height="17" font="13">Miocardico; ICD, implantable cardioverter defibrillator; ICD-9, international classification of diseases 9</text>
<text top="384" left="605" width="7" height="11" font="19">th</text>
<text top="382" left="612" width="847" height="17" font="13"> edition; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; MARCH, Maastricht Registry of Congestive HF; MI, myocardial infarction; N/A, </text>
<text top="400" left="54" width="610" height="17" font="13">not applicable, NR, not reported; NYHA, New York Heart Association; PCI, Percutaneous coronary intervention; </text>
<text top="400" left="664" width="522" height="17" font="23">PRAISE, Prospective Randomized Amlodipine Survival Evaluation; SCD, sudden cardiac death;</text>
<text top="400" left="1185" width="249" height="17" font="13"> SCD-HeFT , Sudden Cardiac Death in Heart </text>
<text top="417" left="54" width="671" height="17" font="13">Failure Trial;UA, unstable angina; UCLA, University of California Los Angelos; and Val-HeFT, Valsartan Heart Failure Trial. </text>
<text top="434" left="54" width="3" height="15" font="6"> </text>
<text top="459" left="54" width="428" height="21" font="8"><b>Data Supplement 23. Omega 3 Fatty Acids (Section 7.3.2.8.3) </b></text>
<text top="480" left="65" width="34" height="15" font="24"><b>Study </b></text>
<text top="495" left="64" width="36" height="15" font="24"><b>Name, </b></text>
<text top="511" left="61" width="42" height="15" font="24"><b>Author, </b></text>
<text top="526" left="68" width="27" height="15" font="24"><b>Year </b></text>
<text top="511" left="135" width="37" height="15" font="24"><b>Aim of </b></text>
<text top="526" left="137" width="34" height="15" font="24"><b>Study </b></text>
<text top="511" left="208" width="34" height="15" font="24"><b>Study </b></text>
<text top="526" left="210" width="29" height="15" font="24"><b>Type </b></text>
<text top="511" left="267" width="68" height="15" font="24"><b>Background </b></text>
<text top="526" left="278" width="46" height="15" font="24"><b>Therapy </b></text>
<text top="526" left="366" width="59" height="15" font="24"><b>Study Size </b></text>
<text top="526" left="461" width="47" height="15" font="24"><b>Etiology </b></text>
<text top="526" left="555" width="100" height="15" font="24"><b>Patient Population </b></text>
<text top="526" left="720" width="46" height="15" font="24"><b>Severity </b></text>
<text top="526" left="839" width="57" height="15" font="24"><b>Endpoints </b></text>
<text top="526" left="985" width="49" height="15" font="24"><b>Mortality </b></text>
<text top="495" left="1099" width="26" height="15" font="24"><b>Trial </b></text>
<text top="511" left="1091" width="39" height="15" font="24"><b>Duratio</b></text>
<text top="526" left="1107" width="13" height="15" font="24"><b>n  </b></text>
<text top="511" left="1158" width="104" height="15" font="24"><b>Statistical Anaylsis </b></text>
<text top="526" left="1185" width="50" height="15" font="24"><b>(Results) </b></text>
<text top="511" left="1301" width="34" height="15" font="24"><b>Study </b></text>
<text top="526" left="1287" width="62" height="15" font="24"><b>Limitations </b></text>
<text top="511" left="1372" width="82" height="15" font="24"><b>Complications/ </b></text>
<text top="526" left="1370" width="86" height="15" font="24"><b>Adverse Events </b></text>
<text top="574" left="372" width="48" height="15" font="16"><i><b>N (Total) </b></i></text>
<text top="589" left="351" width="90" height="15" font="16"><i><b>n (Experimental) </b></i></text>
<text top="605" left="366" width="60" height="15" font="16"><i><b>n (Control) </b></i></text>
<text top="589" left="536" width="52" height="15" font="16"><i><b>Inclusion </b></i></text>
<text top="605" left="541" width="42" height="15" font="16"><i><b>Criteria </b></i></text>
<text top="589" left="617" width="55" height="15" font="16"><i><b>Exclusion </b></i></text>
<text top="605" left="624" width="42" height="15" font="16"><i><b>Criteria </b></i></text>
<text top="558" left="696" width="37" height="15" font="16"><i><b>Severit</b></i></text>
<text top="574" left="696" width="40" height="15" font="16"><i><b>y of HF </b></i></text>
<text top="589" left="697" width="34" height="15" font="16"><i><b>Sympt</b></i></text>
<text top="605" left="703" width="26" height="15" font="16"><i><b>oms </b></i></text>
<text top="543" left="754" width="34" height="15" font="16"><i><b>Study </b></i></text>
<text top="558" left="755" width="31" height="15" font="16"><i><b>Entry </b></i></text>
<text top="574" left="751" width="40" height="15" font="16"><i><b>Sverity </b></i></text>
<text top="589" left="753" width="33" height="15" font="16"><i><b>Criteri</b></i></text>
<text top="605" left="766" width="9" height="15" font="16"><i><b>a </b></i></text>
<text top="589" left="809" width="44" height="15" font="16"><i><b>Primary </b></i></text>
<text top="605" left="805" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="589" left="871" width="63" height="15" font="16"><i><b>Secondary  </b></i></text>
<text top="605" left="875" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="589" left="945" width="62" height="15" font="16"><i><b>Annualized </b></i></text>
<text top="605" left="951" width="49" height="15" font="16"><i><b>Mortality </b></i></text>
<text top="589" left="1025" width="46" height="15" font="16"><i><b>1st Year </b></i></text>
<text top="605" left="1023" width="49" height="15" font="16"><i><b>Mortality </b></i></text>
<text top="621" left="54" width="54" height="15" font="6">GISSI-HF, </text>
<text top="636" left="54" width="36" height="15" font="6">Lancet </text>
<text top="652" left="54" width="28" height="15" font="6">2008 </text>
<text top="667" left="54" width="49" height="15" font="25">18757090</text>
<text top="683" left="54" width="29" height="15" font="6">(213) </text>
<text top="621" left="123" width="16" height="15" font="6">To </text>
<text top="636" left="123" width="56" height="15" font="6">investigate </text>
<text top="652" left="123" width="42" height="15" font="6">whether </text>
<text top="667" left="123" width="47" height="15" font="6">omega-3 </text>
<text top="683" left="123" width="47" height="15" font="6">fatty acid </text>
<text top="698" left="123" width="57" height="15" font="6">supplement</text>
<text top="714" left="123" width="57" height="15" font="6">ation could </text>
<text top="729" left="123" width="42" height="15" font="6">improve </text>
<text top="745" left="123" width="48" height="15" font="6">morbidity </text>
<text top="760" left="123" width="21" height="15" font="6">and </text>
<text top="776" left="123" width="57" height="15" font="6">mortality in </text>
<text top="791" left="123" width="37" height="15" font="6">a large </text>
<text top="621" left="197" width="50" height="15" font="6">Randomis</text>
<text top="636" left="197" width="18" height="15" font="6">ed, </text>
<text top="652" left="197" width="37" height="15" font="6">double-</text>
<text top="667" left="197" width="29" height="15" font="6">blind, </text>
<text top="683" left="197" width="42" height="15" font="6">placebo-</text>
<text top="698" left="197" width="51" height="15" font="6">controlled </text>
<text top="714" left="197" width="52" height="15" font="6">trial  (2x2, </text>
<text top="729" left="197" width="42" height="15" font="6">factorial </text>
<text top="745" left="197" width="39" height="15" font="6">design, </text>
<text top="760" left="197" width="51" height="15" font="6">rosuvastat</text>
<text top="776" left="197" width="15" height="15" font="6">in) </text>
<text top="621" left="265" width="71" height="15" font="6">All treatments </text>
<text top="636" left="265" width="49" height="15" font="6">of proven </text>
<text top="652" left="265" width="56" height="15" font="6">efficacy for </text>
<text top="667" left="265" width="57" height="15" font="6">chronic HF </text>
<text top="683" left="265" width="60" height="15" font="6">(eg, ACEIs, </text>
<text top="698" left="265" width="72" height="15" font="6">beta blockers, </text>
<text top="714" left="265" width="73" height="15" font="6">diuretic drugs, </text>
<text top="729" left="265" width="28" height="15" font="6">italis, </text>
<text top="745" left="265" width="66" height="15" font="6">spironolacton</text>
<text top="760" left="265" width="40" height="15" font="6">e) were </text>
<text top="776" left="265" width="49" height="15" font="6">positively </text>
<text top="791" left="265" width="65" height="15" font="6">recommende</text>
<text top="621" left="351" width="65" height="15" font="6">7,046; 3494; </text>
<text top="636" left="351" width="80" height="15" font="6">3,481 (placebo) </text>
<text top="621" left="454" width="34" height="15" font="6">49.6% </text>
<text top="636" left="454" width="52" height="15" font="6">ischemic/5</text>
<text top="652" left="454" width="50" height="15" font="6">0.4% non-</text>
<text top="667" left="454" width="47" height="15" font="6">ischemic-</text>
<text top="683" left="454" width="28" height="15" font="6">other </text>
<text top="621" left="528" width="34" height="15" font="6">≥18 y, </text>
<text top="636" left="528" width="36" height="15" font="6">clinical </text>
<text top="652" left="528" width="60" height="15" font="6">evidence of </text>
<text top="667" left="528" width="51" height="15" font="6">HF of any </text>
<text top="683" left="528" width="33" height="15" font="6">cause </text>
<text top="698" left="528" width="63" height="15" font="6">classified as </text>
<text top="714" left="528" width="62" height="15" font="6">the ESC GL </text>
<text top="729" left="528" width="62" height="15" font="6">NYHA class </text>
<text top="745" left="528" width="29" height="15" font="6">II–IV, </text>
<text top="760" left="528" width="67" height="15" font="6">provided that </text>
<text top="776" left="528" width="53" height="15" font="6">LVEF was </text>
<text top="791" left="528" width="52" height="15" font="6">measured </text>
<text top="621" left="609" width="42" height="15" font="6">Specific </text>
<text top="636" left="609" width="63" height="15" font="6">indication or </text>
<text top="652" left="609" width="65" height="15" font="6">contraindicati</text>
<text top="667" left="609" width="47" height="15" font="6">on to n-3 </text>
<text top="683" left="609" width="71" height="15" font="6">PUFA; known </text>
<text top="698" left="609" width="67" height="15" font="6">hypersensitivi</text>
<text top="714" left="609" width="53" height="15" font="6">ty to study </text>
<text top="729" left="609" width="58" height="15" font="6">treatments; </text>
<text top="745" left="609" width="61" height="15" font="6">presence of </text>
<text top="760" left="609" width="43" height="15" font="6">any non-</text>
<text top="776" left="609" width="39" height="15" font="6">cardiac </text>
<text top="791" left="609" width="60" height="15" font="6">comorbidity </text>
<text top="621" left="694" width="40" height="15" font="6">Class II </text>
<text top="636" left="694" width="41" height="15" font="6">63%, III </text>
<text top="652" left="694" width="42" height="15" font="6">34%, IV </text>
<text top="667" left="694" width="19" height="15" font="6">3% </text>
<text top="621" left="751" width="34" height="15" font="6">NYHA </text>
<text top="636" left="751" width="31" height="15" font="6">Class </text>
<text top="652" left="751" width="23" height="15" font="6">II-IV </text>
<text top="667" left="751" width="18" height="15" font="6">HF </text>
<text top="621" left="805" width="25" height="15" font="6">2 co-</text>
<text top="636" left="805" width="40" height="15" font="6">primary </text>
<text top="652" left="805" width="48" height="15" font="6">endpoints</text>
<text top="667" left="805" width="42" height="15" font="6">: time to </text>
<text top="683" left="805" width="34" height="15" font="6">death, </text>
<text top="698" left="805" width="46" height="15" font="6">and time </text>
<text top="714" left="805" width="43" height="15" font="6">to death </text>
<text top="729" left="805" width="13" height="15" font="6">or </text>
<text top="745" left="805" width="44" height="15" font="6">admissio</text>
<text top="760" left="805" width="21" height="15" font="6">n to </text>
<text top="776" left="805" width="41" height="15" font="6">hospital </text>
<text top="791" left="805" width="16" height="15" font="6">for </text>
<text top="621" left="870" width="55" height="15" font="6">Cardiovasc</text>
<text top="636" left="870" width="21" height="15" font="6">ular </text>
<text top="652" left="870" width="48" height="15" font="6">mortality, </text>
<text top="667" left="870" width="53" height="15" font="6">cardiovasc</text>
<text top="683" left="870" width="21" height="15" font="6">ular </text>
<text top="698" left="870" width="58" height="15" font="6">mortality or </text>
<text top="714" left="870" width="53" height="15" font="6">admission </text>
<text top="729" left="870" width="37" height="15" font="6">for any </text>
<text top="745" left="870" width="40" height="15" font="6">reason, </text>
<text top="760" left="870" width="39" height="15" font="6">sudden </text>
<text top="776" left="870" width="39" height="15" font="6">cardiac </text>
<text top="791" left="870" width="34" height="15" font="6">death, </text>
<text top="621" left="944" width="22" height="15" font="6">7%  </text>
<text top="621" left="1021" width="28" height="15" font="6">7.0% </text>
<text top="636" left="1021" width="45" height="15" font="6">(estimate</text>
<text top="652" left="1021" width="54" height="15" font="6">d from KM </text>
<text top="667" left="1021" width="39" height="15" font="6">curves) </text>
<text top="621" left="1088" width="30" height="15" font="6">4.5 y, </text>
<text top="636" left="1088" width="39" height="15" font="6">median </text>
<text top="652" left="1088" width="42" height="15" font="6">f/u 3.9 y </text>
<text top="621" left="1149" width="118" height="15" font="6">1.8% absolute mortality </text>
<text top="636" left="1149" width="114" height="15" font="6">reduction (95% CI 0·3–</text>
<text top="652" left="1149" width="118" height="15" font="6">3·9%). Absolute benefit </text>
<text top="667" left="1149" width="74" height="15" font="6">for mortality or </text>
<text top="683" left="1149" width="69" height="15" font="6">admission for </text>
<text top="698" left="1149" width="117" height="15" font="6">cardiovascular reasons </text>
<text top="714" left="1149" width="117" height="15" font="6">was 2·3% (95% CI 0·0–</text>
<text top="729" left="1149" width="117" height="15" font="6">4·6%).  NNT for benefit </text>
<text top="745" left="1149" width="100" height="15" font="6">is 56 pts need to be </text>
<text top="760" left="1149" width="116" height="15" font="6">treated to avoid 1death </text>
<text top="776" left="1149" width="105" height="15" font="6">and 44 pts treated to </text>
<text top="791" left="1149" width="116" height="15" font="6">avoid 1event like death </text>
<text top="621" left="1284" width="56" height="15" font="6">By the end </text>
<text top="636" left="1284" width="63" height="15" font="6">of the study, </text>
<text top="652" left="1284" width="60" height="15" font="6">1004 (29%) </text>
<text top="667" left="1284" width="60" height="15" font="6">of pts in the </text>
<text top="683" left="1284" width="63" height="15" font="6">omega 3 FA </text>
<text top="698" left="1284" width="53" height="15" font="6">group and </text>
<text top="714" left="1284" width="60" height="15" font="6">1029 (30%) </text>
<text top="729" left="1284" width="30" height="15" font="6">in the </text>
<text top="745" left="1284" width="42" height="15" font="6">placebo </text>
<text top="760" left="1284" width="58" height="15" font="6">group were </text>
<text top="776" left="1284" width="49" height="15" font="6">no longer </text>
<text top="791" left="1284" width="62" height="15" font="6">taking study </text>
<text top="621" left="1365" width="75" height="15" font="6">The rate of pts </text>
<text top="636" left="1365" width="45" height="15" font="6">who had </text>
<text top="652" left="1365" width="64" height="15" font="6">permanently </text>
<text top="667" left="1365" width="65" height="15" font="6">discontinued </text>
<text top="683" left="1365" width="81" height="15" font="6">taking the study </text>
<text top="698" left="1365" width="83" height="15" font="6">drug because of </text>
<text top="714" left="1365" width="90" height="15" font="6">adverse reactions </text>
<text top="729" left="1365" width="71" height="15" font="6">was much the </text>
<text top="745" left="1365" width="60" height="15" font="6">same in the </text>
<text top="760" left="1365" width="85" height="15" font="6">omega 3 FA and </text>
<text top="776" left="1365" width="72" height="15" font="6">in the placebo </text>
<text top="791" left="1365" width="87" height="15" font="6">groups (102 [3%] </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">102</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="123" width="54" height="15" font="6">population </text>
<text top="70" left="123" width="53" height="15" font="6">of pts with </text>
<text top="86" left="123" width="57" height="15" font="6">symptomati</text>
<text top="101" left="123" width="60" height="15" font="6">c HF of any </text>
<text top="117" left="123" width="36" height="15" font="6">cause. </text>
<text top="55" left="265" width="15" height="15" font="6">d.  </text>
<text top="70" left="265" width="62" height="15" font="6">Background </text>
<text top="86" left="265" width="50" height="15" font="6">treatment </text>
<text top="101" left="265" width="40" height="15" font="6">rates of </text>
<text top="117" left="265" width="55" height="15" font="6">ACEI/ARB </text>
<text top="132" left="265" width="53" height="15" font="6">93%, beta </text>
<text top="147" left="265" width="73" height="15" font="6">blockers 65%, </text>
<text top="163" left="265" width="61" height="15" font="6">aldosterone </text>
<text top="178" left="265" width="60" height="15" font="6">antagonists </text>
<text top="194" left="265" width="52" height="15" font="6">40%, loop </text>
<text top="210" left="265" width="69" height="15" font="6">durietics 90% </text>
<text top="55" left="528" width="59" height="15" font="6">within 3 mo </text>
<text top="70" left="528" width="34" height="15" font="6">before </text>
<text top="86" left="528" width="58" height="15" font="6">enrollment. </text>
<text top="101" left="528" width="63" height="15" font="6">When LVEF </text>
<text top="117" left="528" width="57" height="15" font="6">was &gt;40%, </text>
<text top="132" left="528" width="65" height="15" font="6">the pt had to </text>
<text top="147" left="528" width="55" height="15" font="6">have been </text>
<text top="163" left="528" width="58" height="15" font="6">admitted at </text>
<text top="178" left="528" width="36" height="15" font="6">least 1 </text>
<text top="194" left="528" width="57" height="15" font="6">hospital for </text>
<text top="210" left="528" width="48" height="15" font="6">HF in the </text>
<text top="225" left="528" width="60" height="15" font="6">preceding y </text>
<text top="240" left="528" width="58" height="15" font="6">to meet the </text>
<text top="256" left="528" width="46" height="15" font="6">inclusion </text>
<text top="271" left="528" width="39" height="15" font="6">criteria. </text>
<text top="55" left="609" width="62" height="15" font="6">(eg, cancer) </text>
<text top="70" left="609" width="65" height="15" font="6">incompatible </text>
<text top="86" left="609" width="56" height="15" font="6">with a long </text>
<text top="101" left="609" width="68" height="15" font="6">f/u; treatment </text>
<text top="117" left="609" width="72" height="15" font="6">with any other </text>
<text top="132" left="609" width="68" height="15" font="6">investigationa</text>
<text top="147" left="609" width="68" height="15" font="6">l agent within </text>
<text top="163" left="609" width="62" height="15" font="6">1 mo before </text>
<text top="178" left="609" width="63" height="15" font="6">randomisatio</text>
<text top="194" left="609" width="51" height="15" font="6">n; ACS or </text>
<text top="210" left="609" width="68" height="15" font="6">revascularisat</text>
<text top="225" left="609" width="71" height="15" font="6">ion procedure </text>
<text top="240" left="609" width="50" height="15" font="6">within the </text>
<text top="256" left="609" width="61" height="15" font="6">preceding 1 </text>
<text top="271" left="609" width="64" height="15" font="6">mo; planned </text>
<text top="287" left="609" width="39" height="15" font="6">cardiac </text>
<text top="302" left="609" width="43" height="15" font="6">surgery, </text>
<text top="318" left="609" width="60" height="15" font="6">expected to </text>
<text top="333" left="609" width="43" height="15" font="6">be done </text>
<text top="349" left="609" width="59" height="15" font="6">within 3 mo </text>
<text top="364" left="609" width="25" height="15" font="6">after </text>
<text top="380" left="609" width="63" height="15" font="6">randomisatio</text>
<text top="395" left="609" width="65" height="15" font="6">n; significant </text>
<text top="411" left="609" width="68" height="15" font="6">liver disease; </text>
<text top="426" left="609" width="22" height="15" font="6">and </text>
<text top="442" left="609" width="60" height="15" font="6">pregnant or </text>
<text top="457" left="609" width="44" height="15" font="6">lactating </text>
<text top="473" left="609" width="52" height="15" font="6">women or </text>
<text top="488" left="609" width="51" height="15" font="6">women of </text>
<text top="504" left="609" width="63" height="15" font="6">childbearing </text>
<text top="519" left="609" width="68" height="15" font="6">potential who </text>
<text top="535" left="609" width="45" height="15" font="6">were not </text>
<text top="550" left="609" width="57" height="15" font="6">adequately </text>
<text top="566" left="609" width="49" height="15" font="6">protected </text>
<text top="581" left="609" width="39" height="15" font="6">against </text>
<text top="597" left="609" width="51" height="15" font="6">becoming </text>
<text top="612" left="609" width="50" height="15" font="6">pregnant. </text>
<text top="55" left="805" width="47" height="15" font="6">cardiovas</text>
<text top="70" left="805" width="27" height="15" font="6">cular </text>
<text top="86" left="805" width="46" height="15" font="6">reasons. </text>
<text top="55" left="870" width="53" height="15" font="6">admission </text>
<text top="70" left="870" width="37" height="15" font="6">for any </text>
<text top="86" left="870" width="40" height="15" font="6">reason, </text>
<text top="101" left="870" width="53" height="15" font="6">admission </text>
<text top="117" left="870" width="16" height="15" font="6">for </text>
<text top="132" left="870" width="53" height="15" font="6">cardiovasc</text>
<text top="148" left="870" width="21" height="15" font="6">ular </text>
<text top="163" left="870" width="45" height="15" font="6">reasons, </text>
<text top="178" left="870" width="53" height="15" font="6">admission </text>
<text top="194" left="870" width="55" height="15" font="6">for HF, MI, </text>
<text top="210" left="870" width="58" height="15" font="6">and stroke. </text>
<text top="55" left="1149" width="66" height="15" font="6">or admission </text>
<text top="70" left="1149" width="90" height="15" font="6">for cardiovascular </text>
<text top="86" left="1149" width="107" height="15" font="6">reason for nearly 4 y. </text>
<text top="101" left="1149" width="105" height="15" font="6">Mortality: aHR: 0·91; </text>
<text top="117" left="1149" width="118" height="15" font="6">95·5% CI 0·833–0·998; </text>
<text top="132" left="1149" width="108" height="15" font="6">p=0·041.  Mortality or </text>
<text top="148" left="1149" width="85" height="15" font="6">were admitted to </text>
<text top="163" left="1149" width="57" height="15" font="6">hospital for </text>
<text top="178" left="1149" width="117" height="15" font="6">cardiovascular reasons </text>
<text top="194" left="1149" width="100" height="15" font="6">(aHR: 0·92; 99% CI </text>
<text top="210" left="1149" width="120" height="15" font="6">0·849–0·999; p=0·009). </text>
<text top="225" left="1149" width="101" height="15" font="6">Mortality: aHR 0.91  </text>
<text top="240" left="1149" width="76" height="15" font="6">Mortality of CV </text>
<text top="256" left="1149" width="100" height="15" font="6">Hospitalization aHR </text>
<text top="271" left="1149" width="25" height="15" font="6">0.92 </text>
<text top="55" left="1284" width="41" height="15" font="6">drug for </text>
<text top="70" left="1284" width="39" height="15" font="6">various </text>
<text top="86" left="1284" width="49" height="15" font="6">reasons.  </text>
<text top="101" left="1284" width="26" height="15" font="6">Only </text>
<text top="117" left="1284" width="60" height="15" font="6">evaluated a </text>
<text top="132" left="1284" width="65" height="15" font="6">single dose.  </text>
<text top="148" left="1284" width="31" height="15" font="6">Study </text>
<text top="163" left="1284" width="66" height="15" font="6">conducted in </text>
<text top="178" left="1284" width="57" height="15" font="6">Italy where </text>
<text top="194" left="1284" width="39" height="15" font="6">there is </text>
<text top="210" left="1284" width="47" height="15" font="6">relatively </text>
<text top="225" left="1284" width="64" height="15" font="6">high amount </text>
<text top="240" left="1284" width="49" height="15" font="6">of dietary </text>
<text top="256" left="1284" width="45" height="15" font="6">intake of </text>
<text top="271" left="1284" width="46" height="15" font="6">omega 3 </text>
<text top="287" left="1284" width="56" height="15" font="6">fatty acids. </text>
<text top="302" left="1284" width="45" height="15" font="6">(p=0·45; </text>
<text top="318" left="1284" width="43" height="15" font="6">table 5). </text>
<text top="55" left="1365" width="64" height="15" font="6">vs 104 [3%], </text>
<text top="70" left="1365" width="93" height="15" font="6">p=0·87). Very well </text>
<text top="86" left="1365" width="66" height="15" font="6">tolerated. No </text>
<text top="101" left="1365" width="95" height="15" font="6">safety issues other </text>
<text top="117" left="1365" width="63" height="15" font="6">than a slight </text>
<text top="132" left="1365" width="50" height="15" font="6">excess of </text>
<text top="148" left="1365" width="82" height="15" font="6">cerebrovascular </text>
<text top="163" left="1365" width="93" height="15" font="6">events, which was </text>
<text top="178" left="1365" width="92" height="15" font="6">a similar finding to </text>
<text top="194" left="1365" width="96" height="15" font="6">that reported in the </text>
<text top="210" left="1365" width="33" height="15" font="6">GISSI-</text>
<text top="225" left="1365" width="89" height="15" font="6">Prevenzione trial. </text>
<text top="240" left="1365" width="84" height="15" font="6">This excess was </text>
<text top="256" left="1365" width="81" height="15" font="6">distributed fairly </text>
<text top="271" left="1365" width="80" height="15" font="6">evenly between </text>
<text top="287" left="1365" width="74" height="15" font="6">ischaemic and </text>
<text top="302" left="1365" width="71" height="15" font="6">haemorrhagic </text>
<text top="318" left="1365" width="77" height="15" font="6">cases. No drug </text>
<text top="333" left="1365" width="94" height="15" font="6">interactions noted. </text>
<text top="349" left="1365" width="23" height="15" font="6">with </text>
<text top="364" left="1365" width="95" height="15" font="6">gastrointestinal dis </text>
<text top="380" left="1365" width="95" height="15" font="6">turbance being the </text>
<text top="395" left="1365" width="71" height="15" font="6">most frequent </text>
<text top="411" left="1365" width="69" height="15" font="6">cause in both </text>
<text top="426" left="1365" width="84" height="15" font="6">groups (table 5). </text>
<text top="628" left="54" width="33" height="15" font="6">GISSI-</text>
<text top="644" left="54" width="47" height="15" font="6">Preventio</text>
<text top="659" left="54" width="12" height="15" font="6">n, </text>
<text top="675" left="54" width="55" height="15" font="6">Macchia A </text>
<text top="690" left="54" width="27" height="15" font="6">et al. </text>
<text top="706" left="54" width="31" height="15" font="6">EJHF </text>
<text top="721" left="54" width="28" height="15" font="6">2005 </text>
<text top="737" left="54" width="53" height="15" font="6">(subgroup </text>
<text top="752" left="54" width="47" height="15" font="6">analysis) </text>
<text top="768" left="54" width="49" height="15" font="25">16087142</text>
<text top="768" left="103" width="3" height="15" font="6"> </text>
<text top="783" left="54" width="29" height="15" font="6">(214) </text>
<text top="628" left="123" width="61" height="15" font="6">To evaluate </text>
<text top="644" left="123" width="61" height="15" font="6">the effect of </text>
<text top="659" left="123" width="46" height="15" font="6">omega 3 </text>
<text top="675" left="123" width="47" height="15" font="6">fatty acid </text>
<text top="690" left="123" width="57" height="15" font="6">supplement</text>
<text top="706" left="123" width="39" height="15" font="6">ation in </text>
<text top="721" left="123" width="57" height="15" font="6">post MI pts </text>
<text top="737" left="123" width="50" height="15" font="6">with LVD. </text>
<text top="628" left="197" width="50" height="15" font="6">Randomiz</text>
<text top="644" left="197" width="18" height="15" font="6">ed, </text>
<text top="659" left="197" width="50" height="15" font="6">multicente</text>
<text top="675" left="197" width="38" height="15" font="6">r, open-</text>
<text top="690" left="197" width="29" height="15" font="6">label, </text>
<text top="706" left="197" width="36" height="15" font="6">clinical </text>
<text top="721" left="197" width="21" height="15" font="6">trial </text>
<text top="737" left="197" width="23" height="15" font="6">with </text>
<text top="752" left="197" width="39" height="15" font="6">blinded </text>
<text top="768" left="197" width="50" height="15" font="6">validation </text>
<text top="783" left="197" width="51" height="15" font="6">of events. </text>
<text top="628" left="265" width="48" height="15" font="6">Standard </text>
<text top="644" left="265" width="61" height="15" font="6">background </text>
<text top="659" left="265" width="56" height="15" font="6">therapy for </text>
<text top="675" left="265" width="60" height="15" font="6">pts who are </text>
<text top="690" left="265" width="47" height="15" font="6">post AMI </text>
<text top="628" left="351" width="86" height="15" font="6">11323 pts ; 4324 </text>
<text top="644" left="351" width="57" height="15" font="6">(with LVEF </text>
<text top="659" left="351" width="36" height="15" font="6">≤50%) </text>
<text top="675" left="351" width="6" height="15" font="6">  </text>
<text top="690" left="351" width="6" height="15" font="6">  </text>
<text top="628" left="454" width="31" height="15" font="6">100% </text>
<text top="644" left="454" width="46" height="15" font="6">ischemic </text>
<text top="628" left="528" width="60" height="15" font="6">Patient with </text>
<text top="644" left="528" width="60" height="15" font="6">AMI in prior </text>
<text top="659" left="528" width="31" height="15" font="6">3 mo. </text>
<text top="675" left="528" width="60" height="15" font="6">Irrespective </text>
<text top="690" left="528" width="29" height="15" font="6">of LV </text>
<text top="706" left="528" width="62" height="15" font="6">function. No </text>
<text top="721" left="528" width="53" height="15" font="6">age limits. </text>
<text top="628" left="609" width="68" height="15" font="6">Contraindicati</text>
<text top="644" left="609" width="52" height="15" font="6">ons to the </text>
<text top="659" left="609" width="36" height="15" font="6">dietary </text>
<text top="675" left="609" width="66" height="15" font="6">supplements </text>
<text top="690" left="609" width="53" height="15" font="6">(ie, known </text>
<text top="706" left="609" width="48" height="15" font="6">allergy to </text>
<text top="721" left="609" width="71" height="15" font="6">omega-3 fatty </text>
<text top="737" left="609" width="36" height="15" font="6">acids). </text>
<text top="752" left="609" width="63" height="15" font="6">Unfavorable </text>
<text top="768" left="609" width="53" height="15" font="6">short-term </text>
<text top="783" left="609" width="61" height="15" font="6">outlook (eg, </text>
<text top="628" left="694" width="35" height="15" font="6">No HF </text>
<text top="644" left="694" width="13" height="15" font="6">or </text>
<text top="659" left="694" width="34" height="15" font="6">NYHA </text>
<text top="675" left="694" width="40" height="15" font="6">Class I, </text>
<text top="690" left="694" width="40" height="15" font="6">subgrou</text>
<text top="706" left="694" width="9" height="15" font="6">p </text>
<text top="721" left="694" width="43" height="15" font="6">analysis </text>
<text top="737" left="694" width="30" height="15" font="6">in pts </text>
<text top="752" left="694" width="23" height="15" font="6">with </text>
<text top="768" left="694" width="31" height="15" font="6">LVEF </text>
<text top="783" left="694" width="33" height="15" font="6">≤50% </text>
<text top="628" left="751" width="6" height="15" font="6">  </text>
<text top="628" left="805" width="40" height="15" font="6">Time to </text>
<text top="644" left="805" width="34" height="15" font="6">death, </text>
<text top="659" left="805" width="46" height="15" font="6">and time </text>
<text top="675" left="805" width="43" height="15" font="6">to death </text>
<text top="690" left="805" width="13" height="15" font="6">or </text>
<text top="706" left="805" width="44" height="15" font="6">admissio</text>
<text top="721" left="805" width="21" height="15" font="6">n to </text>
<text top="737" left="805" width="41" height="15" font="6">hospital </text>
<text top="752" left="805" width="16" height="15" font="6">for </text>
<text top="768" left="805" width="47" height="15" font="6">cardiovas</text>
<text top="783" left="805" width="27" height="15" font="6">cular </text>
<text top="628" left="870" width="41" height="15" font="6">Sudden </text>
<text top="644" left="870" width="31" height="15" font="6">death </text>
<text top="628" left="944" width="47" height="15" font="6">4% per y </text>
<text top="628" left="1021" width="19" height="15" font="6">4% </text>
<text top="628" left="1088" width="27" height="15" font="6">3.5 y </text>
<text top="628" left="1149" width="95" height="15" font="6">Treatment with n-3 </text>
<text top="644" left="1149" width="100" height="15" font="6">PUFA reduced total </text>
<text top="659" left="1149" width="119" height="15" font="6">mortality in pts with and </text>
<text top="675" left="1149" width="77" height="15" font="6">without systolic </text>
<text top="690" left="1149" width="117" height="15" font="6">dysfunction, 24% (40%-</text>
<text top="706" left="1149" width="113" height="15" font="6">4%, p =0.02) and 19% </text>
<text top="721" left="1149" width="85" height="15" font="6">(41% to +10%, p </text>
<text top="737" left="1149" width="99" height="15" font="6">=0.17), respectively </text>
<text top="752" left="1149" width="95" height="15" font="6">(heterogeneity test </text>
<text top="768" left="1149" width="127" height="15" font="6">p=0.55).                            </text>
<text top="783" left="1149" width="86" height="15" font="6">The effect on SD </text>
<text top="628" left="1284" width="60" height="15" font="6">Open label. </text>
<text top="644" left="1284" width="67" height="15" font="6">Excluded pts </text>
<text top="659" left="1284" width="47" height="15" font="6">with over </text>
<text top="675" left="1284" width="21" height="15" font="6">HF. </text>
<text top="628" left="1365" width="74" height="15" font="6">Well tolerated. </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">103</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="197" width="51" height="15" font="6">Subgroup </text>
<text top="70" left="197" width="43" height="15" font="6">analysis </text>
<text top="86" left="197" width="42" height="15" font="6">of those </text>
<text top="101" left="197" width="41" height="15" font="6">pts with </text>
<text top="117" left="197" width="39" height="15" font="6">post MI </text>
<text top="132" left="197" width="25" height="15" font="6">LVD </text>
<text top="55" left="609" width="57" height="15" font="6">overt CHF, </text>
<text top="70" left="609" width="69" height="15" font="6">cancers, etc). </text>
<text top="55" left="805" width="42" height="15" font="6">reasons </text>
<text top="55" left="1149" width="71" height="15" font="6">reduction was </text>
<text top="70" left="1149" width="103" height="15" font="6">asymmetrical, with a </text>
<text top="86" left="1149" width="121" height="15" font="6">greater effect in pts with </text>
<text top="101" left="1149" width="119" height="15" font="6">LVSD (RRR: 58%; 95% </text>
<text top="117" left="1149" width="84" height="15" font="6">CI: 74%-33%;  p </text>
<text top="132" left="1149" width="114" height="15" font="6">=0.0003) as compared </text>
<text top="147" left="1149" width="105" height="15" font="6">to pts with preserved </text>
<text top="163" left="1149" width="115" height="15" font="6">systolic function (RRR: </text>
<text top="178" left="1149" width="100" height="15" font="6">11%; 95% CI: 54% -</text>
<text top="194" left="1149" width="78" height="15" font="6">69%;  p =0.71), </text>
<text top="210" left="1149" width="64" height="15" font="6">although the </text>
<text top="225" left="1149" width="114" height="15" font="6">heterogeneity test was </text>
<text top="240" left="1149" width="75" height="15" font="6">not statistically </text>
<text top="256" left="1149" width="100" height="15" font="6">significant (p=0.07). </text>
<text top="271" left="1149" width="105" height="15" font="6">LVD subgroup (0.60–</text>
<text top="287" left="1149" width="69" height="15" font="6">0.96) p=0.02) </text>
<text top="302" left="1149" width="100" height="15" font="6">RR 0.76  (subgroup </text>
<text top="318" left="1149" width="51" height="15" font="6">with LVD) </text>
<text top="334" left="54" width="49" height="15" font="6">Omega 3 </text>
<text top="350" left="54" width="53" height="15" font="6">fatty acids </text>
<text top="365" left="54" width="43" height="15" font="6">in DCM, </text>
<text top="381" left="54" width="39" height="15" font="6">Nodari, </text>
<text top="396" left="54" width="35" height="15" font="6">JACC, </text>
<text top="412" left="54" width="22" height="15" font="6">201 </text>
<text top="427" left="54" width="49" height="15" font="25">21215550</text>
<text top="427" left="103" width="3" height="15" font="6"> </text>
<text top="443" left="54" width="29" height="15" font="6">(215) </text>
<text top="334" left="123" width="53" height="15" font="6">This study </text>
<text top="350" left="123" width="23" height="15" font="6">was </text>
<text top="365" left="123" width="60" height="15" font="6">designed to </text>
<text top="381" left="123" width="39" height="15" font="6">test the </text>
<text top="396" left="123" width="57" height="15" font="6">effects of 3 </text>
<text top="412" left="123" width="53" height="15" font="6">PUFAs on </text>
<text top="427" left="123" width="24" height="15" font="6">(LV) </text>
<text top="443" left="123" width="39" height="15" font="6">systolic </text>
<text top="458" left="123" width="53" height="15" font="6">function in </text>
<text top="474" left="123" width="57" height="15" font="6">chronic HF </text>
<text top="489" left="123" width="34" height="15" font="6">due to </text>
<text top="505" left="123" width="31" height="15" font="6">NICM </text>
<text top="334" left="197" width="50" height="15" font="6">Randomiz</text>
<text top="350" left="197" width="50" height="15" font="6">ed, single </text>
<text top="365" left="197" width="34" height="15" font="6">center </text>
<text top="381" left="197" width="36" height="15" font="6">double </text>
<text top="396" left="197" width="29" height="15" font="6">blind, </text>
<text top="412" left="197" width="36" height="15" font="6">clinical </text>
<text top="427" left="197" width="21" height="15" font="6">trial </text>
<text top="443" left="197" width="23" height="15" font="6">with </text>
<text top="458" left="197" width="39" height="15" font="6">blinded </text>
<text top="474" left="197" width="50" height="15" font="6">validation </text>
<text top="489" left="197" width="51" height="15" font="6">of events. </text>
<text top="505" left="197" width="51" height="15" font="6">Subgroup </text>
<text top="520" left="197" width="43" height="15" font="6">analysis </text>
<text top="535" left="197" width="42" height="15" font="6">of those </text>
<text top="551" left="197" width="41" height="15" font="6">pts with </text>
<text top="567" left="197" width="39" height="15" font="6">post MI </text>
<text top="582" left="197" width="25" height="15" font="6">LVD </text>
<text top="334" left="265" width="49" height="15" font="6">Evidence </text>
<text top="350" left="265" width="51" height="15" font="6">based HF </text>
<text top="365" left="265" width="43" height="15" font="6">therapy  </text>
<text top="381" left="265" width="52" height="15" font="6">ACE/ARB </text>
<text top="396" left="265" width="59" height="15" font="6">100%, beta </text>
<text top="412" left="265" width="44" height="15" font="6">blockers </text>
<text top="427" left="265" width="34" height="15" font="6">100%, </text>
<text top="443" left="265" width="61" height="15" font="6">aldosterone </text>
<text top="458" left="265" width="60" height="15" font="6">antagonists </text>
<text top="474" left="265" width="52" height="15" font="6">60%, loop </text>
<text top="489" left="265" width="44" height="15" font="6">diuretics </text>
<text top="505" left="265" width="31" height="15" font="6">100% </text>
<text top="334" left="351" width="95" height="15" font="6">133;                        </text>
<text top="350" left="351" width="85" height="15" font="6">67 experimental; </text>
<text top="365" left="351" width="52" height="15" font="6">66 control </text>
<text top="334" left="454" width="53" height="15" font="6">100% non-</text>
<text top="350" left="454" width="46" height="15" font="6">ischemic </text>
<text top="334" left="528" width="63" height="15" font="6">Pts aged 18-</text>
<text top="350" left="528" width="56" height="15" font="6">75 y with a </text>
<text top="365" left="528" width="62" height="15" font="6">diagnosis of </text>
<text top="381" left="528" width="66" height="15" font="6">NICM, LVSD </text>
<text top="396" left="528" width="58" height="15" font="6">(defined as </text>
<text top="412" left="528" width="33" height="15" font="6">an EF </text>
<text top="427" left="528" width="60" height="15" font="6">&lt;45%), and </text>
<text top="443" left="528" width="32" height="15" font="6">stable </text>
<text top="458" left="528" width="36" height="15" font="6">clinical </text>
<text top="474" left="528" width="53" height="15" font="6">conditions </text>
<text top="489" left="528" width="64" height="15" font="6">with minimal </text>
<text top="505" left="528" width="28" height="15" font="6">or no </text>
<text top="520" left="528" width="53" height="15" font="6">symptoms </text>
<text top="535" left="528" width="64" height="15" font="6">for at least 3 </text>
<text top="551" left="528" width="34" height="15" font="6">mo on </text>
<text top="567" left="528" width="48" height="15" font="6">evidence-</text>
<text top="582" left="528" width="33" height="15" font="6">based </text>
<text top="598" left="528" width="41" height="15" font="6">medical </text>
<text top="613" left="528" width="62" height="15" font="6">treatment at </text>
<text top="628" left="528" width="51" height="15" font="6">maximum </text>
<text top="644" left="528" width="46" height="15" font="6">tolerated </text>
<text top="659" left="528" width="64" height="15" font="6">target doses </text>
<text top="675" left="528" width="64" height="15" font="6">for at least 6 </text>
<text top="690" left="528" width="22" height="15" font="6">mo. </text>
<text top="334" left="609" width="61" height="15" font="6">presence of </text>
<text top="350" left="609" width="66" height="15" font="6">symptoms or </text>
<text top="365" left="609" width="60" height="15" font="6">evidence of </text>
<text top="381" left="609" width="26" height="15" font="6">CAD </text>
<text top="396" left="609" width="54" height="15" font="6">diagnosed </text>
<text top="412" left="609" width="41" height="15" font="6">through </text>
<text top="427" left="609" width="61" height="15" font="6">noninvasive </text>
<text top="443" left="609" width="58" height="15" font="6">tests, PAD, </text>
<text top="458" left="609" width="61" height="15" font="6">presence of </text>
<text top="474" left="609" width="66" height="15" font="6">congenital or </text>
<text top="489" left="609" width="69" height="15" font="6">primary VHD, </text>
<text top="505" left="609" width="71" height="15" font="6">persistent AF, </text>
<text top="520" left="609" width="52" height="15" font="6">inability to </text>
<text top="536" left="609" width="41" height="15" font="6">perform </text>
<text top="551" left="609" width="37" height="15" font="6">bicycle </text>
<text top="567" left="609" width="69" height="15" font="6">ergometry for </text>
<text top="582" left="609" width="57" height="15" font="6">noncardiac </text>
<text top="598" left="609" width="41" height="15" font="6">causes, </text>
<text top="613" left="609" width="61" height="15" font="6">moderately  </text>
<text top="628" left="609" width="44" height="15" font="6">severely </text>
<text top="644" left="609" width="43" height="15" font="6">reduced </text>
<text top="659" left="609" width="50" height="15" font="6">functional </text>
<text top="675" left="609" width="47" height="15" font="6">capacity, </text>
<text top="690" left="609" width="62" height="15" font="6">NYHA class </text>
<text top="706" left="609" width="42" height="15" font="6">IV, poor </text>
<text top="721" left="609" width="44" height="15" font="6">acoustic </text>
<text top="737" left="609" width="45" height="15" font="6">windows </text>
<text top="752" left="609" width="56" height="15" font="6">limiting the </text>
<text top="768" left="609" width="44" height="15" font="6">ability to </text>
<text top="783" left="609" width="65" height="15" font="6">assess echo </text>
<text top="334" left="694" width="26" height="15" font="6">Mild, </text>
<text top="350" left="694" width="40" height="15" font="6">Class I, </text>
<text top="365" left="694" width="28" height="15" font="6">15%, </text>
<text top="381" left="694" width="40" height="15" font="6">Class II </text>
<text top="396" left="694" width="32" height="15" font="6">85%.  </text>
<text top="334" left="751" width="23" height="15" font="6">Mild </text>
<text top="350" left="751" width="33" height="15" font="6">severit</text>
<text top="365" left="751" width="24" height="15" font="6">y on </text>
<text top="381" left="751" width="36" height="15" font="6">medica</text>
<text top="396" left="751" width="6" height="15" font="6">l </text>
<text top="412" left="751" width="40" height="15" font="6">therapy </text>
<text top="334" left="805" width="42" height="15" font="6">Change </text>
<text top="350" left="805" width="43" height="15" font="6">in LVEF </text>
<text top="334" left="870" width="54" height="15" font="6">Peak V02, </text>
<text top="350" left="870" width="55" height="15" font="6">hospitalizat</text>
<text top="365" left="870" width="23" height="15" font="6">ions </text>
<text top="334" left="944" width="19" height="15" font="6">0% </text>
<text top="334" left="1021" width="19" height="15" font="6">0% </text>
<text top="334" left="1088" width="34" height="15" font="6">12 mo </text>
<text top="334" left="1149" width="97" height="15" font="6">LVEF increased by </text>
<text top="350" left="1149" width="108" height="15" font="6">10.4% n-3 PUFA and </text>
<text top="365" left="1149" width="121" height="15" font="6">decreased by 5.0% with </text>
<text top="381" left="1149" width="92" height="15" font="6">placebo, p&lt;.0001, </text>
<text top="396" left="1149" width="107" height="15" font="6">peak VO2 (increased </text>
<text top="412" left="1149" width="119" height="15" font="6">by 6.2% and decreased </text>
<text top="427" left="1149" width="114" height="15" font="6">by 4.5%, respectively); </text>
<text top="443" left="1149" width="87" height="15" font="6">exercise duration </text>
<text top="458" left="1149" width="116" height="15" font="6">increased by 7.5% and </text>
<text top="474" left="1149" width="101" height="15" font="6">decreased by 4.8%; </text>
<text top="489" left="1149" width="114" height="15" font="6">and mean NYHA class </text>
<text top="505" left="1149" width="121" height="15" font="6">decreased from 1.88 +/- </text>
<text top="520" left="1149" width="102" height="15" font="6">0.33 to 1.61 +/- 0.49 </text>
<text top="535" left="1149" width="98" height="15" font="6">and increased from </text>
<text top="551" left="1149" width="119" height="15" font="6">1.83 +/- 0.38 to 2.14 +/- </text>
<text top="567" left="1149" width="50" height="15" font="6">0.65. The </text>
<text top="582" left="1149" width="117" height="15" font="6">hospitalization rates for </text>
<text top="597" left="1149" width="113" height="15" font="6">HF were 6% in the n-3 </text>
<text top="613" left="1149" width="115" height="15" font="6">PUFAs and 30% in the </text>
<text top="628" left="1149" width="96" height="15" font="6">placebo group (p = </text>
<text top="644" left="1149" width="44" height="15" font="6">0.0002). </text>
<text top="334" left="1284" width="34" height="15" font="6">Single </text>
<text top="350" left="1284" width="37" height="15" font="6">center, </text>
<text top="365" left="1284" width="47" height="15" font="6">small, no </text>
<text top="381" left="1284" width="39" height="15" font="6">deaths. </text>
<text top="334" left="1365" width="30" height="15" font="6">None </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">104</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="609" width="68" height="15" font="6">measurement</text>
<text top="70" left="609" width="50" height="15" font="6">s, chronic </text>
<text top="86" left="609" width="68" height="15" font="6">lung disease, </text>
<text top="101" left="609" width="51" height="15" font="6">advanced </text>
<text top="117" left="609" width="69" height="15" font="6">renal disease </text>
<text top="132" left="609" width="58" height="15" font="6">(eGFR &lt;30 </text>
<text top="147" left="609" width="60" height="15" font="6">ml/min/1.73 </text>
<text top="163" left="609" width="25" height="15" font="6">m2), </text>
<text top="178" left="609" width="51" height="15" font="6">advanced </text>
<text top="194" left="609" width="68" height="15" font="6">liver disease; </text>
<text top="210" left="609" width="62" height="15" font="6">any disease </text>
<text top="225" left="609" width="55" height="15" font="6">limiting life </text>
<text top="240" left="609" width="71" height="15" font="6">expectancy to </text>
<text top="256" left="609" width="27" height="15" font="6">&lt;1 y, </text>
<text top="271" left="609" width="65" height="15" font="6">contraindicati</text>
<text top="287" left="609" width="63" height="15" font="6">ons to study </text>
<text top="302" left="609" width="55" height="15" font="6">drugs, and </text>
<text top="318" left="609" width="63" height="15" font="6">concomitant </text>
<text top="333" left="609" width="63" height="15" font="6">participation </text>
<text top="349" left="609" width="40" height="15" font="6">in other </text>
<text top="364" left="609" width="46" height="15" font="6">research </text>
<text top="380" left="609" width="41" height="15" font="6">studies. </text>
<text top="396" left="43" width="1392" height="15" font="6">ACEI indicates angiotensin-converting-enzyme inhibitor;  ACS, acute coronary syndrome; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CV, cardiovascular; EF, ejection fraction;  eGFR, estimated glomerular filtration rate; ESC GL, </text>
<text top="412" left="43" width="1379" height="15" font="6">European Society for Cardiology guidelines; f/u, follow-up; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico; HF, heart failure; KM, Kaplan-Meier; LVD, left ventricular dysfunction; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic </text>
<text top="427" left="43" width="1133" height="15" font="6">dysfunction;  MI, myocardial infarction; NICM, nonischemic cardiomyopathy; NNT, number needed to treat; NYHA, New York Heart Association; PAD, peripheral arterial disease; PUFA, polyunsaturated fatty acids; SD, sudden death </text>
<text top="443" left="54" width="4" height="19" font="9"><b> </b></text>
<text top="480" left="54" width="488" height="21" font="8"><b>Data Supplement 24. Antiarrhythmic Agents to Avoid in HF (7.3.2.9.2) </b></text>
<text top="526" left="114" width="36" height="17" font="15"><b>Trials </b></text>
<text top="502" left="347" width="38" height="17" font="15"><b>Study </b></text>
<text top="502" left="623" width="107" height="17" font="15"><b>Study Drug Effect </b></text>
<text top="526" left="858" width="103" height="17" font="15"><b>Other Comments </b></text>
<text top="536" left="222" width="44" height="17" font="15"><b>Design </b></text>
<text top="536" left="306" width="32" height="17" font="15"><b>Drug </b></text>
<text top="536" left="373" width="47" height="17" font="15"><b>Control </b></text>
<text top="536" left="449" width="51" height="17" font="15"><b>Patients </b></text>
<text top="536" left="528" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="536" left="608" width="63" height="17" font="15"><b>CV events </b></text>
<text top="528" left="701" width="66" height="17" font="15"><b>Functional </b></text>
<text top="545" left="707" width="55" height="17" font="15"><b>Capacity </b></text>
<text top="522" left="791" width="28" height="17" font="15"><b>QoL </b></text>
<text top="570" left="54" width="166" height="17" font="15"><b>Class I  Na Channel Blocker </b></text>
<text top="590" left="54" width="36" height="17" font="13">CAST </text>
<text top="608" left="54" width="48" height="17" font="14">2473403</text>
<text top="608" left="102" width="7" height="17" font="13">  </text>
<text top="625" left="54" width="32" height="17" font="13">(216) </text>
<text top="590" left="230" width="29" height="17" font="13">RCT </text>
<text top="608" left="243" width="3" height="17" font="13"> </text>
<text top="625" left="243" width="3" height="17" font="13"> </text>
<text top="590" left="292" width="61" height="17" font="13">Encainide/ </text>
<text top="608" left="291" width="63" height="17" font="13">Flecainide/ </text>
<text top="625" left="293" width="59" height="17" font="13">Moricizine </text>
<text top="590" left="391" width="12" height="17" font="13">P </text>
<text top="608" left="395" width="3" height="17" font="13"> </text>
<text top="590" left="451" width="46" height="17" font="13">Post-MI </text>
<text top="608" left="456" width="36" height="17" font="13">NSVT </text>
<text top="625" left="473" width="3" height="17" font="13"> </text>
<text top="590" left="550" width="11" height="17" font="13">↑ </text>
<text top="608" left="543" width="25" height="17" font="13">with </text>
<text top="625" left="525" width="59" height="17" font="13">encainide, </text>
<text top="642" left="527" width="55" height="17" font="13">flecainide </text>
<text top="659" left="534" width="42" height="17" font="13">RR 2.5 </text>
<text top="590" left="628" width="24" height="17" font="13">N/A </text>
<text top="590" left="722" width="24" height="17" font="13">N/A </text>
<text top="590" left="793" width="24" height="17" font="13">N/A </text>
<text top="590" left="845" width="130" height="17" font="13">Study terminated early. </text>
<text top="679" left="54" width="169" height="17" font="15"><b>Class III K Channel Blockers </b></text>
<text top="699" left="54" width="51" height="17" font="13">SWORD </text>
<text top="717" left="54" width="48" height="17" font="14">8691967</text>
<text top="717" left="102" width="7" height="17" font="13">  </text>
<text top="734" left="54" width="32" height="17" font="13">(217) </text>
<text top="699" left="230" width="29" height="17" font="13">RCT </text>
<text top="699" left="296" width="52" height="17" font="13">d-Sotalol </text>
<text top="699" left="391" width="12" height="17" font="13">P </text>
<text top="699" left="451" width="46" height="17" font="13">Post-MI </text>
<text top="717" left="441" width="66" height="17" font="13">LVEF&lt;40% </text>
<text top="699" left="550" width="11" height="17" font="13">↑ </text>
<text top="717" left="531" width="49" height="17" font="13">RR 1.65 </text>
<text top="699" left="628" width="24" height="17" font="13">N/A </text>
<text top="699" left="722" width="24" height="17" font="13">N/A </text>
<text top="699" left="793" width="24" height="17" font="13">N/A </text>
<text top="699" left="845" width="130" height="17" font="13">Study terminated early. </text>
</page>
<page number="105" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">105</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="56" left="54" width="148" height="17" font="13">Dronedarone Study Group </text>
<text top="73" left="54" width="55" height="17" font="14">18565860</text>
<text top="73" left="109" width="7" height="17" font="13">  </text>
<text top="90" left="54" width="32" height="17" font="13">(218) </text>
<text top="56" left="230" width="29" height="17" font="13">RCT </text>
<text top="56" left="285" width="75" height="17" font="13">Dronedarone </text>
<text top="56" left="391" width="12" height="17" font="13">P </text>
<text top="56" left="442" width="64" height="17" font="13">NYHA II-IV </text>
<text top="73" left="441" width="66" height="17" font="13">LVEF&lt;35% </text>
<text top="90" left="440" width="68" height="17" font="13">hospitalized </text>
<text top="56" left="550" width="11" height="17" font="13">↑ </text>
<text top="73" left="531" width="49" height="17" font="13">HR 2.13 </text>
<text top="56" left="634" width="11" height="17" font="13">↑ </text>
<text top="73" left="618" width="44" height="17" font="13">first CV </text>
<text top="90" left="596" width="88" height="17" font="13">hospitalizations </text>
<text top="56" left="722" width="24" height="17" font="13">N/A </text>
<text top="56" left="793" width="24" height="17" font="13">N/A </text>
<text top="56" left="843" width="134" height="17" font="13">No difference in primary </text>
<text top="73" left="853" width="114" height="17" font="13">composite endpoint. </text>
<text top="120" left="54" width="924" height="15" font="6">CAST indicates Cardiac Arrhythmia Suppression Trial; CV, cardiovascular; K, potassium; LVEF, left ventricular ejection fraction; MI, myocardial infarction; Na, sodium; NSVT, nonsustained  </text>
<text top="136" left="54" width="915" height="15" font="6">ventricular tachycardia; N/A, not applicable; NYHA, New York Heart Association; P, placebo; QoL, quality of life; RCT, randomized control trial; and SWORD, Survival With Oral d-Sotalol.  </text>
<text top="151" left="54" width="4" height="19" font="7"> </text>
<text top="188" left="54" width="573" height="21" font="8"><b>Data Supplement 25. Calcium Channel Blockers to Avoid in HF (Section 7.3.2.9.3) </b></text>
<text top="229" left="109" width="36" height="17" font="15"><b>Trials </b></text>
<text top="211" left="316" width="38" height="17" font="15"><b>Study</b> </text>
<text top="211" left="572" width="107" height="17" font="15"><b>Study Drug Effect</b> </text>
<text top="229" left="828" width="103" height="17" font="15"><b>Other Comments</b> </text>
<text top="239" left="204" width="44" height="17" font="15"><b>Design </b></text>
<text top="239" left="269" width="32" height="17" font="15"><b>Drug </b></text>
<text top="239" left="322" width="47" height="17" font="15"><b>Control </b></text>
<text top="239" left="395" width="51" height="17" font="15"><b>Patients </b></text>
<text top="239" left="474" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="239" left="561" width="63" height="17" font="15"><b>CV events </b></text>
<text top="231" left="654" width="66" height="17" font="15"><b>Functional </b></text>
<text top="248" left="659" width="55" height="17" font="15"><b>Capacity </b></text>
<text top="239" left="740" width="28" height="17" font="15"><b>QoL </b></text>
<text top="268" left="54" width="120" height="17" font="15"><b>Nondihydropyridine </b></text>
<text top="288" left="54" width="45" height="17" font="13">MDPIT  </text>
<text top="305" left="54" width="48" height="17" font="14">2899840</text>
<text top="305" left="102" width="3" height="17" font="13"> </text>
<text top="323" left="54" width="32" height="17" font="13">(219) </text>
<text top="288" left="212" width="29" height="17" font="13">RCT </text>
<text top="288" left="258" width="54" height="17" font="13">Diltiazem </text>
<text top="288" left="340" width="12" height="17" font="13">P </text>
<text top="288" left="397" width="46" height="17" font="13">Post-MI </text>
<text top="288" left="491" width="21" height="17" font="13">NS </text>
<text top="288" left="587" width="11" height="17" font="13">↑ </text>
<text top="305" left="563" width="59" height="17" font="13">In pts with </text>
<text top="323" left="537" width="110" height="17" font="13">LVEF&lt;40% or pulm </text>
<text top="340" left="538" width="109" height="17" font="13">congestion on CXR </text>
<text top="357" left="568" width="49" height="17" font="13">HR 1.41 </text>
<text top="288" left="675" width="24" height="17" font="13">N/A </text>
<text top="288" left="742" width="24" height="17" font="13">N/A </text>
<text top="288" left="785" width="33" height="17" font="13">None </text>
<text top="377" left="54" width="42" height="17" font="13">MDPIT </text>
<text top="394" left="54" width="48" height="17" font="14">1984898</text>
<text top="394" left="102" width="7" height="17" font="13">  </text>
<text top="412" left="54" width="32" height="17" font="13">(220) </text>
<text top="377" left="210" width="102" height="17" font="13">Retro  Diltiazem </text>
<text top="377" left="340" width="12" height="17" font="13">P </text>
<text top="377" left="397" width="46" height="17" font="13">Post-MI </text>
<text top="377" left="500" width="3" height="17" font="13"> </text>
<text top="377" left="587" width="11" height="17" font="13">↑ </text>
<text top="394" left="553" width="78" height="17" font="13">HF in pts with </text>
<text top="412" left="550" width="84" height="17" font="13">EF&lt;40%, pulm </text>
<text top="429" left="552" width="81" height="17" font="13">congestion, or </text>
<text top="446" left="550" width="85" height="17" font="13">anterolateral Q </text>
<text top="463" left="568" width="49" height="17" font="13">wave MI </text>
<text top="377" left="675" width="24" height="17" font="13">N/A </text>
<text top="377" left="742" width="24" height="17" font="13">N/A </text>
<text top="377" left="785" width="33" height="17" font="13">None </text>
<text top="483" left="54" width="27" height="17" font="13">DiDi </text>
<text top="500" left="54" width="48" height="17" font="14">8759075</text>
<text top="500" left="102" width="3" height="17" font="13"> </text>
<text top="518" left="54" width="32" height="17" font="13">(221) </text>
<text top="483" left="212" width="29" height="17" font="13">RCT </text>
<text top="483" left="258" width="54" height="17" font="13">Diltiazem </text>
<text top="483" left="340" width="12" height="17" font="13">P </text>
<text top="483" left="392" width="56" height="17" font="13">Idiopathic </text>
<text top="500" left="404" width="31" height="17" font="13">DCM </text>
<text top="518" left="389" width="62" height="17" font="13">NYHA II-III </text>
<text top="483" left="491" width="21" height="17" font="13">NS </text>
<text top="500" left="500" width="3" height="17" font="13"> </text>
<text top="483" left="580" width="24" height="17" font="13">N/A </text>
<text top="483" left="675" width="24" height="17" font="13">N/A </text>
<text top="483" left="742" width="24" height="17" font="13">N/A </text>
<text top="483" left="785" width="174" height="17" font="13">18% of pts did not finish study.  </text>
<text top="500" left="785" width="172" height="17" font="13">No difference in transplant-free </text>
<text top="518" left="785" width="148" height="17" font="13">survival (85.2% vs. 80.4%, </text>
<text top="535" left="785" width="49" height="17" font="13">p=0.44). </text>
<text top="555" left="54" width="51" height="17" font="13">DAVIT-II </text>
<text top="572" left="54" width="48" height="17" font="14">2220572</text>
<text top="572" left="102" width="7" height="17" font="13">  </text>
<text top="589" left="54" width="32" height="17" font="13">(222) </text>
<text top="555" left="212" width="102" height="17" font="13">RCT  Verapamil </text>
<text top="555" left="340" width="12" height="17" font="13">P </text>
<text top="555" left="376" width="88" height="17" font="13">Hospitalized for </text>
<text top="572" left="408" width="25" height="17" font="13">AMI </text>
<text top="555" left="491" width="21" height="17" font="13">NS </text>
<text top="555" left="580" width="24" height="17" font="13">N/A </text>
<text top="555" left="675" width="24" height="17" font="13">N/A </text>
<text top="555" left="742" width="24" height="17" font="13">N/A </text>
<text top="555" left="785" width="160" height="17" font="13">HF pts had worse outcomes  </text>
<text top="609" left="54" width="98" height="17" font="15"><b>Dihydropyridine </b></text>
<text top="629" left="54" width="124" height="17" font="13">Elkayam U <i>Circulation</i> </text>
<text top="647" left="54" width="31" height="17" font="13">1990 </text>
<text top="664" left="54" width="48" height="17" font="14">2242521</text>
<text top="664" left="102" width="7" height="17" font="13">  </text>
<text top="681" left="54" width="32" height="17" font="13">(223) </text>
<text top="629" left="212" width="150" height="17" font="13">RCT  Nifedipine  ISDN </text>
<text top="629" left="389" width="62" height="17" font="13">NYHA II-III </text>
<text top="647" left="385" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="629" left="489" width="24" height="17" font="13">N/A </text>
<text top="629" left="587" width="11" height="17" font="13">↑ </text>
<text top="647" left="542" width="101" height="17" font="13">HF hospitalization </text>
<text top="664" left="536" width="113" height="17" font="13">(nifedipine vs ISDN) </text>
<text top="681" left="587" width="11" height="17" font="13">↑ </text>
<text top="698" left="553" width="79" height="17" font="13">worsening HF </text>
<text top="715" left="536" width="112" height="17" font="13">(nifedipine+ISDN vs </text>
<text top="733" left="556" width="72" height="17" font="13">either alone) </text>
<text top="629" left="677" width="21" height="17" font="13">NS </text>
<text top="629" left="742" width="24" height="17" font="13">N/A </text>
<text top="629" left="785" width="33" height="17" font="13">None </text>
<text top="753" left="54" width="116" height="17" font="13">Felodipine UK Study </text>
<text top="770" left="54" width="38" height="17" font="13">Group </text>
<text top="787" left="54" width="48" height="17" font="14">7786657</text>
<text top="787" left="102" width="3" height="17" font="13"> </text>
<text top="753" left="212" width="103" height="17" font="13">RCT  Felodipine </text>
<text top="753" left="340" width="12" height="17" font="13">P </text>
<text top="753" left="389" width="62" height="17" font="13">NYHA II-III </text>
<text top="770" left="385" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="787" left="393" width="54" height="17" font="13">76% ICM </text>
<text top="753" left="489" width="24" height="17" font="13">N/A </text>
<text top="753" left="587" width="11" height="17" font="13">↑ </text>
<text top="770" left="553" width="79" height="17" font="13">worsening HF </text>
<text top="753" left="677" width="21" height="17" font="13">NS </text>
<text top="753" left="742" width="24" height="17" font="13">N/A </text>
<text top="753" left="785" width="33" height="17" font="13">None </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">106</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="56" left="54" width="32" height="17" font="13">(224) </text>
<text top="76" left="54" width="60" height="17" font="13">V-HeFT III </text>
<text top="93" left="54" width="48" height="17" font="14">9264493</text>
<text top="93" left="102" width="7" height="17" font="13">  </text>
<text top="110" left="54" width="32" height="17" font="13">(225) </text>
<text top="76" left="212" width="103" height="17" font="13">RCT  Felodipine </text>
<text top="76" left="340" width="12" height="17" font="13">P </text>
<text top="76" left="389" width="62" height="17" font="13">NYHA II-III </text>
<text top="93" left="385" width="69" height="17" font="13">LVEF &lt;45% </text>
<text top="110" left="393" width="54" height="17" font="13">55% ICM </text>
<text top="76" left="491" width="21" height="17" font="13">NS </text>
<text top="76" left="582" width="21" height="17" font="13">NS </text>
<text top="76" left="677" width="21" height="17" font="13">NS </text>
<text top="76" left="744" width="21" height="17" font="13">NS </text>
<text top="76" left="785" width="181" height="17" font="13">More edema AE with felodipine.  </text>
<text top="93" left="785" width="173" height="17" font="13">Not powered to study mortality. </text>
<text top="130" left="54" width="64" height="17" font="13">PRAISE-2* </text>
<text top="148" left="54" width="55" height="17" font="14">15921795</text>
<text top="148" left="109" width="3" height="17" font="13"> </text>
<text top="165" left="54" width="32" height="17" font="13">(226) </text>
<text top="130" left="212" width="105" height="17" font="13">RCT  Amlodipine </text>
<text top="130" left="340" width="12" height="17" font="13">P </text>
<text top="130" left="403" width="35" height="17" font="13">NICM </text>
<text top="148" left="387" width="67" height="17" font="13">NYHA III-IV </text>
<text top="165" left="387" width="66" height="17" font="13">LVEF&lt;30% </text>
<text top="130" left="491" width="21" height="17" font="13">NS </text>
<text top="130" left="582" width="21" height="17" font="13">NS </text>
<text top="130" left="675" width="24" height="17" font="13">N/A </text>
<text top="130" left="742" width="24" height="17" font="13">N/A </text>
<text top="130" left="785" width="33" height="17" font="13">None </text>
<text top="185" left="54" width="142" height="17" font="13">Amlodipine Exercise Trial </text>
<text top="202" left="54" width="55" height="17" font="14">10689266</text>
<text top="202" left="109" width="3" height="17" font="13"> </text>
<text top="219" left="54" width="32" height="17" font="13">(227) </text>
<text top="185" left="212" width="105" height="17" font="13">RCT  Amlodipine </text>
<text top="185" left="340" width="12" height="17" font="13">P </text>
<text top="185" left="388" width="64" height="17" font="13">NYHA II-IV </text>
<text top="202" left="385" width="69" height="17" font="13">LVEF &lt;35% </text>
<text top="219" left="393" width="54" height="17" font="13">53% ICM </text>
<text top="185" left="489" width="24" height="17" font="13">N/A </text>
<text top="185" left="580" width="24" height="17" font="13">N/A </text>
<text top="185" left="677" width="21" height="17" font="13">NS </text>
<text top="185" left="744" width="21" height="17" font="13">NS </text>
<text top="185" left="785" width="33" height="17" font="13">None </text>
<text top="238" left="54" width="899" height="15" font="6">AE indicates adverse event; AMI, acute myocardial infarction; CV, cardiovascular; CXR, chest x-ray; DAVIT-II, Danish Verapamil Infarction Trial II; DCM, dilated cardiomyopathy; DiDi,  </text>
<text top="254" left="54" width="967" height="15" font="6">Diltiazem in Dilated Cardiomyopathy Trial; EF, ejection fraction; HF, heart failure; HR, hazard ratio; ICM, ischemic cardiomyopathy; ISDN, isosorbide dinitrate; LVEF, left ventricular ejection fraction;  </text>
<text top="269" left="54" width="1045" height="15" font="6">MDPIT, Multicenter Diltiazem Postinfarction Trial; MI, myocardial infarction; NICM, nonishemic cardiomyopathy; N/A, not applicable; NS, no statistically significant difference; NYHA, New York Heart Association; P,  </text>
<text top="285" left="54" width="941" height="15" font="6">placebo; PRAISE-II, second Prospective Randomized Amlodipine Survival Evaluation; pts, patients; QoL, quality of life; RCT, randomized control trial; Retro, retrospective analysis; UK, United  </text>
<text top="300" left="54" width="270" height="15" font="6">Kingdom; and V-HeFT, Vasodilator-Heart Failure Trial. </text>
<text top="316" left="54" width="4" height="19" font="9"><b> </b></text>
<text top="353" left="54" width="409" height="21" font="8"><b>Data Supplement 26. NSAIDs Use in HF (Section 7.3.2.9.4) </b></text>
<text top="394" left="67" width="118" height="17" font="15"><b>Cohort Populations </b></text>
<text top="375" left="361" width="38" height="17" font="15"><b>Study </b></text>
<text top="375" left="730" width="48" height="17" font="15"><b>Results </b></text>
<text top="394" left="990" width="103" height="17" font="15"><b>Other Comments </b></text>
<text top="404" left="216" width="44" height="17" font="15"><b>Design </b></text>
<text top="395" left="295" width="81" height="17" font="15"><b>Experimental </b></text>
<text top="412" left="326" width="19" height="17" font="15"><b>(n) </b></text>
<text top="395" left="407" width="47" height="17" font="15"><b>Control </b></text>
<text top="412" left="421" width="19" height="17" font="15"><b>(n) </b></text>
<text top="404" left="489" width="51" height="17" font="15"><b>Patients </b></text>
<text top="404" left="612" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="404" left="800" width="63" height="17" font="15"><b>CV events </b></text>
<text top="432" left="61" width="131" height="17" font="13">Netherlands  PHARMO </text>
<text top="449" left="61" width="48" height="17" font="14">9605782</text>
<text top="449" left="109" width="7" height="17" font="13">  </text>
<text top="467" left="61" width="32" height="17" font="13">(228) </text>
<text top="432" left="225" width="26" height="17" font="13">Obs </text>
<text top="432" left="302" width="67" height="17" font="13">NSAID plus </text>
<text top="449" left="310" width="51" height="17" font="13">Diuretics </text>
<text top="432" left="405" width="51" height="17" font="13">Diuretics </text>
<text top="449" left="414" width="33" height="17" font="13">alone </text>
<text top="432" left="485" width="59" height="17" font="13">Age &gt;55 y </text>
<text top="432" left="628" width="24" height="17" font="13">N/A </text>
<text top="432" left="776" width="112" height="17" font="13">↑ HF hospitalization </text>
<text top="449" left="808" width="49" height="17" font="13">aRR 1.8 </text>
<text top="432" left="947" width="124" height="17" font="13">Data presented in pt-y </text>
<text top="487" left="61" width="111" height="17" font="13">New South Whales  </text>
<text top="504" left="61" width="55" height="17" font="14">10737277</text>
<text top="504" left="115" width="3" height="17" font="13"> </text>
<text top="521" left="61" width="32" height="17" font="13">(229) </text>
<text top="487" left="220" width="33" height="17" font="13">Case-</text>
<text top="504" left="210" width="57" height="17" font="13">controlled </text>
<text top="521" left="219" width="38" height="17" font="13">cohort </text>
<text top="487" left="280" width="173" height="17" font="13">HF admission (365)  Non-HF </text>
<text top="504" left="401" width="59" height="17" font="13">admission </text>
<text top="521" left="414" width="32" height="17" font="13">(658) </text>
<text top="487" left="472" width="85" height="17" font="13">Mean age 76 y </text>
<text top="487" left="628" width="24" height="17" font="13">N/A </text>
<text top="487" left="787" width="90" height="17" font="13">↑ HF admission </text>
<text top="504" left="761" width="142" height="17" font="13">with non-ASA NSAID use </text>
<text top="521" left="811" width="42" height="17" font="13">OR 2.1 </text>
<text top="538" left="781" width="14" height="17" font="13">↑1</text>
<text top="540" left="795" width="6" height="11" font="19">st</text>
<text top="538" left="801" width="82" height="17" font="13"> HF admission </text>
<text top="556" left="721" width="221" height="17" font="13">in pts with h/o heart disease and NSAID </text>
<text top="573" left="723" width="219" height="17" font="13">use vs no h/o heart disease and NSAID </text>
<text top="590" left="820" width="23" height="17" font="13">use </text>
<text top="487" left="947" width="33" height="17" font="13">None </text>
<text top="610" left="61" width="99" height="17" font="13">Rotterdam Study  </text>
<text top="627" left="61" width="55" height="17" font="14">11822918</text>
<text top="627" left="115" width="7" height="17" font="13">  </text>
<text top="644" left="61" width="32" height="17" font="13">(230) </text>
<text top="610" left="218" width="40" height="17" font="13">Cohort </text>
<text top="610" left="290" width="92" height="17" font="13">No history of HF </text>
<text top="627" left="287" width="98" height="17" font="13">admission (7277) </text>
<text top="610" left="414" width="33" height="17" font="13">None </text>
<text top="610" left="485" width="59" height="17" font="13">Age &gt;55 y </text>
<text top="627" left="489" width="51" height="17" font="13">FS&gt;30% </text>
<text top="610" left="628" width="24" height="17" font="13">N/A </text>
<text top="610" left="782" width="100" height="17" font="13">↑ HF readmission </text>
<text top="627" left="743" width="177" height="17" font="13">during concurrent use of NSAID </text>
<text top="644" left="808" width="49" height="17" font="13">aRR 9.9 </text>
<text top="610" left="947" width="33" height="17" font="13">None </text>
<text top="665" left="61" width="116" height="17" font="13">Ontario Drug Benefit </text>
<text top="682" left="61" width="51" height="17" font="13">Program </text>
<text top="699" left="61" width="55" height="17" font="14">15172772</text>
<text top="699" left="115" width="7" height="17" font="13">  </text>
<text top="716" left="61" width="32" height="17" font="13">(231) </text>
<text top="665" left="221" width="33" height="17" font="13">Retro </text>
<text top="682" left="218" width="40" height="17" font="13">Cohort </text>
<text top="665" left="282" width="107" height="17" font="13">Rofecoxib (14,583) </text>
<text top="682" left="282" width="107" height="17" font="13">Celecoxib (18,908) </text>
<text top="699" left="297" width="78" height="17" font="13">Non-selective </text>
<text top="716" left="294" width="83" height="17" font="13">NSAID (5,391) </text>
<text top="665" left="400" width="60" height="17" font="13">No NSAID </text>
<text top="682" left="402" width="56" height="17" font="13">(100,000) </text>
<text top="665" left="485" width="59" height="17" font="13">Age &gt;66 y </text>
<text top="682" left="488" width="53" height="17" font="13">12% IHD </text>
<text top="665" left="628" width="24" height="17" font="13">N/A </text>
<text top="665" left="776" width="112" height="17" font="13">↑ HF hospitalization </text>
<text top="682" left="754" width="156" height="17" font="13">relative to non-NSAID users </text>
<text top="699" left="779" width="107" height="17" font="13">Rofecoxib aRR 1.8 </text>
<text top="716" left="777" width="110" height="17" font="13">NS NSAID aRR 1.4 </text>
<text top="665" left="947" width="154" height="17" font="13">No increased risk seen with </text>
<text top="682" left="947" width="177" height="17" font="13">celecoxib relative to non-NSAID </text>
<text top="699" left="947" width="33" height="17" font="13">users </text>
<text top="736" left="61" width="47" height="17" font="13">Quebec </text>
<text top="753" left="61" width="55" height="17" font="14">15947399</text>
<text top="753" left="115" width="7" height="17" font="13">  </text>
<text top="771" left="61" width="32" height="17" font="13">(232) </text>
<text top="736" left="221" width="33" height="17" font="13">Retro </text>
<text top="753" left="218" width="40" height="17" font="13">Cohort </text>
<text top="736" left="291" width="90" height="17" font="13">Rofecoxib (869) </text>
<text top="753" left="297" width="78" height="17" font="13">Non-selective </text>
<text top="771" left="298" width="77" height="17" font="13">NSAID  (280) </text>
<text top="736" left="402" width="57" height="17" font="13">Celecoxib </text>
<text top="753" left="414" width="32" height="17" font="13">(717) </text>
<text top="736" left="485" width="59" height="17" font="13">Age &gt;66 y </text>
<text top="753" left="488" width="53" height="17" font="13">Index HF </text>
<text top="771" left="485" width="59" height="17" font="13">admission </text>
<text top="736" left="634" width="11" height="17" font="13">↑ </text>
<text top="753" left="583" width="114" height="17" font="13">NS NSAID  HR 1.54 </text>
<text top="771" left="586" width="107" height="17" font="13">Rofecoxib HR 1.44 </text>
<text top="736" left="719" width="225" height="17" font="13">↑Recurrent HF ER visit or hospitalization </text>
<text top="753" left="749" width="167" height="17" font="13">NS NSAID HR 1.21 (0.92-1.6) </text>
<text top="771" left="747" width="170" height="17" font="13">Rofecoxib HR 1.17 (0.96-1.42) </text>
<text top="736" left="947" width="168" height="17" font="13">Combined endpoint significant </text>
<text top="753" left="947" width="187" height="17" font="13">risk with NS NSAID and rofecoxib </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">107</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="56" left="61" width="132" height="17" font="13">Danish National Patient </text>
<text top="73" left="61" width="52" height="17" font="13">Registry  </text>
<text top="90" left="61" width="55" height="17" font="14">19171810</text>
<text top="90" left="115" width="7" height="17" font="13">  </text>
<text top="107" left="61" width="32" height="17" font="13">(233) </text>
<text top="56" left="221" width="33" height="17" font="13">Retro </text>
<text top="73" left="218" width="40" height="17" font="13">Cohort </text>
<text top="56" left="287" width="97" height="17" font="13">Rofecoxib (6116) </text>
<text top="73" left="288" width="96" height="17" font="13">Celecoxib (5734) </text>
<text top="90" left="285" width="101" height="17" font="13">Ibuprofen (16875) </text>
<text top="107" left="286" width="100" height="17" font="13">Diclofenac (9377) </text>
<text top="125" left="290" width="92" height="17" font="13">Naproxen(2176) </text>
<text top="142" left="298" width="75" height="17" font="13">Other NSAID </text>
<text top="159" left="313" width="46" height="17" font="13">(11488) </text>
<text top="56" left="400" width="60" height="17" font="13">No NSAID </text>
<text top="73" left="407" width="46" height="17" font="13">(70738) </text>
<text top="56" left="485" width="59" height="17" font="13">Age &gt;30 y </text>
<text top="73" left="488" width="53" height="17" font="13">Index HF </text>
<text top="90" left="485" width="59" height="17" font="13">admission </text>
<text top="107" left="482" width="66" height="17" font="13">13% h/o MI </text>
<text top="56" left="634" width="11" height="17" font="13">↑ </text>
<text top="73" left="590" width="100" height="17" font="13">Rofecoxib HR 1.7 </text>
<text top="90" left="587" width="106" height="17" font="13">Celecoxib HR 1.75 </text>
<text top="107" left="588" width="104" height="17" font="13">Ibuprofen HR 1.31 </text>
<text top="125" left="585" width="109" height="17" font="13">Diclofenac HR 2.08 </text>
<text top="142" left="587" width="105" height="17" font="13">Naproxen HR 1.22 </text>
<text top="159" left="598" width="83" height="17" font="13">Other HR 1.28 </text>
<text top="56" left="778" width="109" height="17" font="13">↑HF hospitalization </text>
<text top="73" left="782" width="100" height="17" font="13">Rofecoxib HR 1.4 </text>
<text top="90" left="779" width="106" height="17" font="13">Celecoxib HR 1.24 </text>
<text top="107" left="780" width="104" height="17" font="13">Ibuprofen HR 1.16 </text>
<text top="125" left="777" width="109" height="17" font="13">Diclofenac HR 1.35 </text>
<text top="142" left="779" width="105" height="17" font="13">Naproxen HR 1.18 </text>
<text top="159" left="770" width="124" height="17" font="13">Other NSAID HR 1.27 </text>
<text top="56" left="947" width="179" height="17" font="13">Increased risk with higher doses </text>
<text top="73" left="947" width="127" height="17" font="13">of NSAIDs for all types </text>
<text top="178" left="54" width="1100" height="15" font="6">aRR indicates adjusted relative risk; ASA, aspirin; ER, emergency room; FS, fractional shortening; HF, heart failure; h/o, history of; IHD, HR, hazard ratio; ischemic heart disease; MI, myocardial infarction; N/A, not applicable;  </text>
<text top="193" left="54" width="907" height="15" font="6">NS, not statistically significant; NSAID, non-selective nonsteroidal anti-inflammatory drug; Obs, observational study; OR, odds ratio; pt-y, patient years; and Retro, retrospective analysis. </text>
<text top="194" left="961" width="4" height="16" font="7"> </text>
<text top="209" left="54" width="4" height="19" font="7"> </text>
<text top="246" left="54" width="456" height="21" font="8"><b>Data Supplement 27. Thiazolidinediones in HF (Section 7.3.2.9.5) </b></text>
<text top="287" left="87" width="77" height="17" font="15"><b>Cohort /Trial </b></text>
<text top="268" left="405" width="38" height="17" font="15"><b>Study </b></text>
<text top="268" left="869" width="48" height="17" font="15"><b>Results </b></text>
<text top="297" left="206" width="44" height="17" font="15"><b>Design </b></text>
<text top="288" left="275" width="81" height="17" font="15"><b>Experimental </b></text>
<text top="306" left="306" width="19" height="17" font="15"><b>(n) </b></text>
<text top="288" left="403" width="47" height="17" font="15"><b>Control </b></text>
<text top="306" left="417" width="19" height="17" font="15"><b>(n) </b></text>
<text top="297" left="540" width="51" height="17" font="15"><b>Patients </b></text>
<text top="297" left="690" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="297" left="929" width="63" height="17" font="15"><b>CV events </b></text>
<text top="326" left="61" width="75" height="17" font="15"><b>Pharmetrics </b></text>
<text top="343" left="61" width="126" height="17" font="15"><b>Integrated Outcomes </b></text>
<text top="360" left="61" width="61" height="17" font="15"><b>Database  </b></text>
<text top="377" left="61" width="55" height="17" font="14">14578227</text>
<text top="377" left="115" width="36" height="17" font="13"> (234) </text>
<text top="326" left="211" width="34" height="17" font="13">Retro </text>
<text top="343" left="208" width="40" height="17" font="13">Cohort </text>
<text top="326" left="302" width="27" height="17" font="13">TZD </text>
<text top="343" left="296" width="39" height="17" font="13">(5441) </text>
<text top="326" left="404" width="46" height="17" font="13">No TZD </text>
<text top="343" left="402" width="49" height="17" font="13">(28,103) </text>
<text top="326" left="546" width="39" height="17" font="13">No HF </text>
<text top="343" left="536" width="59" height="17" font="13">Age &gt;18 y </text>
<text top="360" left="549" width="33" height="17" font="13">DM II </text>
<text top="377" left="497" width="136" height="17" font="13">oral hypoglycemic agent </text>
<text top="326" left="705" width="24" height="17" font="13">N/A </text>
<text top="326" left="910" width="100" height="17" font="13">↑ incidence of HF </text>
<text top="343" left="926" width="69" height="17" font="13">TZD HR 1.7 </text>
<text top="397" left="61" width="68" height="17" font="15"><b>PROactive  </b></text>
<text top="415" left="61" width="55" height="17" font="14">16214598</text>
<text top="415" left="115" width="3" height="17" font="13"> </text>
<text top="432" left="61" width="32" height="17" font="13">(235)<b> </b></text>
<text top="397" left="213" width="29" height="17" font="13">RCT </text>
<text top="397" left="261" width="210" height="17" font="13">Pioglitazone (2065)  Placebo (2633) </text>
<text top="397" left="533" width="64" height="17" font="13">NYHA I HF </text>
<text top="415" left="530" width="70" height="17" font="13">Age 35-75 y </text>
<text top="432" left="549" width="33" height="17" font="13">DM II </text>
<text top="449" left="501" width="129" height="17" font="13">Macrovascular disease </text>
<text top="397" left="707" width="21" height="17" font="13">NS </text>
<text top="397" left="955" width="11" height="17" font="13">↓ </text>
<text top="415" left="790" width="341" height="17" font="13">Composite all-cause mortality, non-fatal MI, and CVA HR 0.84 </text>
<text top="432" left="888" width="144" height="17" font="13">95% CI 0.72-0.98; p=0.27 </text>
<text top="449" left="955" width="11" height="17" font="13">↑ </text>
<text top="466" left="930" width="59" height="17" font="13">HF events </text>
<text top="483" left="839" width="242" height="17" font="13">11% Pioglitazone vs 8% placebo, P&lt;0.0001 </text>
<text top="503" left="61" width="132" height="17" font="15"><b>Dargie HJ <i>JACC</i></b><b> 2007  </b></text>
<text top="521" left="61" width="55" height="17" font="14">17448371</text>
<text top="521" left="115" width="3" height="17" font="13"> </text>
<text top="538" left="61" width="32" height="17" font="13">(236)<b> </b></text>
<text top="503" left="213" width="29" height="17" font="13">RCT </text>
<text top="503" left="261" width="109" height="17" font="13">Rosiglitazone (110) </text>
<text top="503" left="403" width="48" height="17" font="13">Placebo </text>
<text top="521" left="411" width="32" height="17" font="13">(114) </text>
<text top="503" left="528" width="75" height="17" font="13">NYHA I-II HF </text>
<text top="521" left="531" width="69" height="17" font="13">LVEF &lt;45% </text>
<text top="538" left="549" width="36" height="17" font="13">DM II  </text>
<text top="555" left="497" width="136" height="17" font="13">oral hypoglycemic agent </text>
<text top="503" left="707" width="21" height="17" font="13">NS </text>
<text top="503" left="947" width="27" height="17" font="13">N.S. </text>
<text top="575" left="61" width="125" height="17" font="15"><b>Lipscombe LL <i>JAMA</i></b><b> </b></text>
<text top="592" left="61" width="31" height="17" font="15"><b>2007 </b></text>
<text top="610" left="61" width="55" height="17" font="14">18073359</text>
<text top="610" left="115" width="3" height="17" font="13"> </text>
<text top="627" left="54" width="36" height="17" font="13"> (237)<b> </b></text>
<text top="575" left="211" width="34" height="17" font="13">Retro </text>
<text top="592" left="208" width="44" height="17" font="13">Cohort  </text>
<text top="575" left="302" width="27" height="17" font="13">TZD </text>
<text top="575" left="398" width="58" height="17" font="13">Other oral </text>
<text top="592" left="388" width="78" height="17" font="13">hypoglycemic </text>
<text top="575" left="534" width="63" height="17" font="13">Age &gt; 66 y </text>
<text top="592" left="551" width="33" height="17" font="13">DMII  </text>
<text top="610" left="497" width="136" height="17" font="13">oral hypoglycemic agent </text>
<text top="575" left="712" width="11" height="17" font="13">↑ </text>
<text top="592" left="693" width="49" height="17" font="13">RR 1.29 </text>
<text top="610" left="664" width="106" height="17" font="13"> 95% CI 1.02-1.62; </text>
<text top="627" left="697" width="41" height="17" font="13">p=0.03 </text>
<text top="575" left="955" width="11" height="17" font="13">↑ </text>
<text top="592" left="901" width="122" height="17" font="13">HF adjusted RR 1.60  </text>
<text top="610" left="888" width="144" height="17" font="13">95% CI 1.21-2.10; p&lt;.001 </text>
<text top="627" left="955" width="11" height="17" font="13">↑ </text>
<text top="644" left="923" width="74" height="17" font="13">AMI RR 1.40 </text>
<text top="661" left="890" width="141" height="17" font="13">95% CI, 1.05-1.86; p=.02 </text>
<text top="681" left="61" width="57" height="17" font="15"><b>RECORD </b></text>
<text top="698" left="61" width="55" height="17" font="14">19501900</text>
<text top="698" left="115" width="7" height="17" font="13">, </text>
<text top="698" left="122" width="55" height="17" font="14">20118174</text>
<text top="698" left="177" width="3" height="17" font="13"> </text>
<text top="716" left="61" width="59" height="17" font="13"> (238,239)<b> </b></text>
<text top="681" left="213" width="29" height="17" font="13">RCT </text>
<text top="681" left="263" width="102" height="17" font="13">Rosiglitazone add-</text>
<text top="698" left="307" width="17" height="17" font="13">on </text>
<text top="716" left="296" width="39" height="17" font="13">(2220) </text>
<text top="681" left="390" width="74" height="17" font="13">MET and SU </text>
<text top="698" left="407" width="39" height="17" font="13">(2227) </text>
<text top="681" left="546" width="39" height="17" font="13">No HF </text>
<text top="698" left="551" width="33" height="17" font="13">DMII  </text>
<text top="716" left="521" width="88" height="17" font="13">oral MET or SU </text>
<text top="733" left="564" width="3" height="17" font="13"> </text>
<text top="681" left="707" width="21" height="17" font="13">NS </text>
<text top="681" left="955" width="11" height="17" font="13">↑ </text>
<text top="698" left="929" width="65" height="17" font="13">HF HR 2.1  </text>
<text top="716" left="885" width="151" height="17" font="13">95% CI 1.35-3.27, p=0.001 </text>
<text top="733" left="951" width="18" height="17" font="13">↔ </text>
<text top="750" left="923" width="74" height="17" font="13">AMI HR 1.14 </text>
<text top="767" left="892" width="137" height="17" font="13">95% CI 0.8-1.63, p=0.47 </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">108</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="56" left="61" width="123" height="17" font="15"><b>Giles TD <i>Congestive </i></b></text>
<text top="73" left="61" width="113" height="17" font="21"><i><b>Heart Failure</b></i><b> 2010  </b></text>
<text top="90" left="61" width="55" height="17" font="14">20557330</text>
<text top="90" left="115" width="3" height="17" font="13"> </text>
<text top="107" left="61" width="32" height="17" font="13">(240)<b> </b></text>
<text top="56" left="213" width="29" height="17" font="13">RCT </text>
<text top="56" left="264" width="103" height="17" font="13">Pioglitazone (151) </text>
<text top="56" left="399" width="59" height="17" font="13">Glyburide  </text>
<text top="73" left="411" width="32" height="17" font="13">(149) </text>
<text top="56" left="543" width="44" height="17" font="13">NYHA I </text>
<text top="73" left="508" width="115" height="17" font="13">Mild cardiac disease </text>
<text top="90" left="549" width="33" height="17" font="13">DM II </text>
<text top="56" left="707" width="21" height="17" font="13">NS </text>
<text top="56" left="950" width="21" height="17" font="13">NS </text>
<text top="73" left="889" width="142" height="17" font="13">exercise capacity, HbA1c </text>
<text top="126" left="54" width="1057" height="15" font="6">AMI, acute myocardial infarction; CVA, cerebral vascular accident; DM II, type 2 diabetes mellitus; HbA1c, hemoglobin A1c; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MET, metformin;  </text>
<text top="142" left="54" width="1069" height="15" font="6">MI, myocardial infarction; N/A, not applicable; NS, no statistically significant difference; NYHA, New York Heart Association; PROactive, Prospective pioglitazone Clinical Trial In Macrovascular Events;RCT, randomized  </text>
<text top="157" left="54" width="1101" height="15" font="6">control trial; RECORD, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes; Retro, retrospective analysis; RR, relative risk; SU, sulfonylurea; and TZD, thiazolidinediones. </text>
<text top="173" left="54" width="4" height="19" font="7"> </text>
<text top="210" left="54" width="449" height="21" font="8"><b>Data Supplement 28. Device-Based Management (Section 7.3.4) </b></text>
<text top="249" left="77" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="267" left="78" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="267" left="215" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="267" left="345" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="249" left="460" width="41" height="19" font="9"><b>Study </b></text>
<text top="267" left="465" width="31" height="19" font="9"><b>Size </b></text>
<text top="267" left="538" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="267" left="753" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="267" left="937" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="267" left="1222" width="117" height="19" font="9"><b>Study Limitations </b></text>
<text top="325" left="597" width="4" height="19" font="10"><i><b> </b></i></text>
<text top="313" left="708" width="44" height="15" font="16"><i><b>Primary </b></i></text>
<text top="328" left="705" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="313" left="812" width="63" height="15" font="16"><i><b>Secondary  </b></i></text>
<text top="328" left="816" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="287" left="1029" width="4" height="19" font="7"> </text>
<text top="306" left="1029" width="4" height="19" font="7"> </text>
<text top="325" left="1029" width="4" height="19" font="7"> </text>
<text top="345" left="54" width="129" height="17" font="13">COMPASS, Bourge et  </text>
<text top="362" left="54" width="83" height="17" font="13">al. 2008 JACC </text>
<text top="379" left="54" width="55" height="17" font="14">18342224</text>
<text top="379" left="109" width="3" height="17" font="13"> </text>
<text top="396" left="54" width="32" height="17" font="13">(241) </text>
<text top="345" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="362" left="199" width="99" height="17" font="13">clinician knowing  </text>
<text top="379" left="199" width="66" height="17" font="13">continuous  </text>
<text top="396" left="199" width="92" height="17" font="13">ambulatory right </text>
<text top="414" left="199" width="89" height="17" font="13">heart pressures </text>
<text top="345" left="332" width="96" height="17" font="13">Single blind RCT </text>
<text top="345" left="447" width="27" height="17" font="13"> 274 </text>
<text top="345" left="528" width="89" height="17" font="13">Class III-IV with </text>
<text top="362" left="528" width="131" height="17" font="13">hospitalization/6 mo, all </text>
<text top="379" left="528" width="19" height="17" font="13">EF </text>
<text top="396" left="528" width="7" height="17" font="13">  </text>
<text top="345" left="683" width="63" height="17" font="13"> HF events </text>
<text top="345" left="791" width="101" height="17" font="13">HF hospitalization </text>
<text top="362" left="791" width="58" height="17" font="13">(post hoc) </text>
<text top="345" left="906" width="245" height="17" font="13">Failed primary, with 21% reduction (p=0.33). </text>
<text top="362" left="906" width="232" height="17" font="13">HF hospilization 36% reduction (HR: 0.64: </text>
<text top="379" left="906" width="45" height="17" font="13">p=0.03) </text>
<text top="345" left="1169" width="180" height="17" font="13">Both groups high clinical contact </text>
<text top="362" left="1169" width="209" height="17" font="13">(0.95/wk). No protocol for response to </text>
<text top="379" left="1169" width="68" height="17" font="13">information. </text>
<text top="432" left="54" width="122" height="17" font="13">COMPASS –Diastolic </text>
<text top="449" left="54" width="106" height="17" font="13">HF, substudy. Zile, </text>
<text top="466" left="54" width="109" height="17" font="13">2008 J Cardiac Fail </text>
<text top="483" left="54" width="55" height="17" font="14">19041044</text>
<text top="483" left="109" width="3" height="17" font="13"> </text>
<text top="500" left="54" width="32" height="17" font="13">(242) </text>
<text top="432" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="449" left="199" width="99" height="17" font="13">clinician knowing  </text>
<text top="466" left="199" width="66" height="17" font="13">continuous  </text>
<text top="483" left="199" width="92" height="17" font="13">ambulatory right </text>
<text top="500" left="199" width="89" height="17" font="13">heart pressures </text>
<text top="432" left="332" width="29" height="17" font="13">RCT </text>
<text top="432" left="447" width="21" height="17" font="13"> 70 </text>
<text top="432" left="528" width="122" height="17" font="13">Class III-IV, EF ≥50% </text>
<text top="432" left="683" width="63" height="17" font="13"> HF events </text>
<text top="432" left="791" width="24" height="17" font="13">N/A </text>
<text top="432" left="906" width="229" height="17" font="13">20% reduction (p=0.66). HF hopsitlization </text>
<text top="449" left="906" width="132" height="17" font="13">29% reduction (p=0.43) </text>
<text top="432" left="1169" width="180" height="17" font="13">Both groups high clinical contact </text>
<text top="449" left="1169" width="209" height="17" font="13">(0.95/wk). No protocol for response to </text>
<text top="466" left="1169" width="163" height="17" font="13">information. Small subgroup.  </text>
<text top="518" left="54" width="76" height="17" font="13">REDUCE-HF </text>
<text top="536" left="54" width="120" height="17" font="13">Adamson,Congestive </text>
<text top="553" left="54" width="105" height="17" font="13">Heart Failure 2011 </text>
<text top="570" left="54" width="55" height="17" font="14">21906250</text>
<text top="570" left="109" width="3" height="17" font="13"> </text>
<text top="587" left="54" width="32" height="17" font="13">(243) </text>
<text top="518" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="536" left="199" width="120" height="17" font="13">clinician knowing and </text>
<text top="553" left="199" width="87" height="17" font="13">acting on home </text>
<text top="570" left="199" width="57" height="17" font="13">pressures </text>
<text top="518" left="332" width="96" height="17" font="13">Single blind RCT </text>
<text top="518" left="447" width="41" height="17" font="13"> 400 of </text>
<text top="536" left="447" width="31" height="17" font="13">1200 </text>
<text top="553" left="447" width="43" height="17" font="13">(target) </text>
<text top="518" left="528" width="58" height="17" font="13">Class II/III </text>
<text top="536" left="528" width="7" height="17" font="13">  </text>
<text top="518" left="683" width="63" height="17" font="13">HF events  </text>
<text top="518" left="791" width="27" height="17" font="13"> N/A </text>
<text top="518" left="906" width="112" height="17" font="13"> No trend for benefit </text>
<text top="518" left="1169" width="182" height="17" font="13">Trial stopped for anticipated lead </text>
<text top="536" left="1169" width="54" height="17" font="13">problems </text>
<text top="605" left="54" width="66" height="17" font="13">SENSE-HF </text>
<text top="622" left="54" width="120" height="17" font="13">Conraads 2011 Eur J </text>
<text top="640" left="54" width="32" height="17" font="13">Echo </text>
<text top="657" left="54" width="55" height="17" font="14">21362703</text>
<text top="657" left="109" width="3" height="17" font="13"> </text>
<text top="674" left="54" width="32" height="17" font="13">(244) </text>
<text top="605" left="199" width="116" height="17" font="13">Determine predictive </text>
<text top="622" left="199" width="110" height="17" font="13">value of impedance </text>
<text top="640" left="199" width="50" height="17" font="13">changes </text>
<text top="605" left="332" width="83" height="17" font="13">Observational, </text>
<text top="622" left="332" width="82" height="17" font="13">Doubleblinded </text>
<text top="640" left="332" width="49" height="17" font="13">Phase I, </text>
<text top="657" left="332" width="95" height="17" font="13">unblinded Phase </text>
<text top="674" left="332" width="10" height="17" font="13">II </text>
<text top="605" left="447" width="27" height="17" font="13"> 501 </text>
<text top="605" left="528" width="27" height="17" font="13"> N/A </text>
<text top="605" left="683" width="90" height="17" font="13">Predictive value </text>
<text top="622" left="683" width="84" height="17" font="13">of impendance </text>
<text top="640" left="683" width="50" height="17" font="13">changes </text>
<text top="605" left="791" width="24" height="17" font="13">N/A </text>
<text top="605" left="906" width="243" height="17" font="13">PPV for HF hosp increased from 4.7 to 38% </text>
<text top="622" left="906" width="70" height="17" font="13">during study </text>
<text top="605" left="1169" width="24" height="17" font="13">N/A </text>
<text top="692" left="54" width="35" height="17" font="13">FAST </text>
<text top="709" left="54" width="84" height="17" font="13">Abraham 2011 </text>
<text top="726" left="54" width="68" height="17" font="13">Cong H Fail </text>
<text top="744" left="54" width="55" height="17" font="14">21449992</text>
<text top="744" left="109" width="3" height="17" font="13"> </text>
<text top="761" left="54" width="32" height="17" font="13">(245) </text>
<text top="692" left="199" width="118" height="17" font="13">Compare impedance </text>
<text top="709" left="199" width="95" height="17" font="13">Changes to daily </text>
<text top="726" left="199" width="63" height="17" font="13">weights for </text>
<text top="744" left="199" width="61" height="17" font="13">monitoring </text>
<text top="692" left="332" width="78" height="17" font="13">RCT (Pts and </text>
<text top="709" left="332" width="64" height="17" font="13">study team </text>
<text top="726" left="332" width="57" height="17" font="13">blinded to </text>
<text top="744" left="332" width="95" height="17" font="13">impedance data) </text>
<text top="692" left="447" width="172" height="17" font="13">156 Class </text>
<text top="692" left="562" width="86" height="17" font="13">III-IV </text>
<text top="709" left="528" width="102" height="17" font="13">With ICD or CRT,  </text>
<text top="726" left="528" width="74" height="17" font="13">LVEF  ≤35% </text>
<text top="744" left="528" width="7" height="17" font="13">  </text>
<text top="692" left="683" width="61" height="17" font="13">Number of </text>
<text top="709" left="683" width="54" height="17" font="13">threshold </text>
<text top="726" left="683" width="50" height="17" font="13">changes </text>
<text top="744" left="683" width="87" height="17" font="13">associated with </text>
<text top="761" left="683" width="88" height="17" font="13">HF event within </text>
<text top="778" left="683" width="27" height="17" font="13">30 d </text>
<text top="692" left="791" width="27" height="17" font="13"> N/A </text>
<text top="692" left="906" width="239" height="17" font="13">Greater sensitivity for impedance than daily </text>
<text top="709" left="906" width="49" height="17" font="13">weights: </text>
<text top="726" left="906" width="128" height="17" font="13">76% vs 23% (p=0.001) </text>
<text top="744" left="906" width="140" height="17" font="13">Unexplained change rate </text>
<text top="761" left="906" width="84" height="17" font="13">1.9 vs 4.3/pt-y. </text>
<text top="778" left="906" width="234" height="17" font="13">1 in 7 impedance changes associated with </text>
<text top="692" left="1169" width="216" height="17" font="13">Weight changes defined as 3 lbs/1 d or </text>
<text top="709" left="1169" width="201" height="17" font="13">5 lbs in 3 d. Unknown relationship of </text>
<text top="726" left="1169" width="191" height="17" font="13">weight changes to therapy change </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">109</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="906" width="97" height="17" font="13">event (p=0.0001) </text>
<text top="78" left="54" width="70" height="17" font="13">CHAMPION </text>
<text top="95" left="54" width="53" height="17" font="13">Abraham </text>
<text top="112" left="54" width="71" height="17" font="13">Lancet 2011 </text>
<text top="130" left="54" width="55" height="17" font="14">21315441</text>
<text top="130" left="109" width="3" height="17" font="13"> </text>
<text top="147" left="54" width="32" height="17" font="13">(246) </text>
<text top="78" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="95" left="199" width="92" height="17" font="13">PAP information </text>
<text top="112" left="199" width="76" height="17" font="13">from wireless </text>
<text top="130" left="199" width="44" height="17" font="13">monitor </text>
<text top="78" left="332" width="96" height="17" font="13">Single blind RCT </text>
<text top="78" left="447" width="24" height="17" font="13">550 </text>
<text top="78" left="528" width="92" height="17" font="13">Class III HF and </text>
<text top="95" left="528" width="118" height="17" font="13">hospitalized in past y </text>
<text top="112" left="528" width="7" height="17" font="13">  </text>
<text top="78" left="683" width="20" height="17" font="13">HF </text>
<text top="95" left="683" width="83" height="17" font="13">hospitilizations </text>
<text top="78" left="791" width="92" height="17" font="13">AUC 6 mo PAP, </text>
<text top="95" left="791" width="65" height="17" font="13">% admitted </text>
<text top="112" left="791" width="42" height="17" font="13">DAOH, </text>
<text top="130" left="791" width="37" height="17" font="13">MLHF </text>
<text top="78" left="906" width="235" height="17" font="13"> 39% reduction in HF hospitalizations (HR: </text>
<text top="95" left="906" width="90" height="17" font="13">0.7; p=0.0001),  </text>
<text top="112" left="906" width="186" height="17" font="13">More reduction in PAP (p=0.008), </text>
<text top="130" left="906" width="232" height="17" font="13">Lower % pts with HF hospitalizations (HR: </text>
<text top="147" left="906" width="73" height="17" font="13">0.7; p=0.02), </text>
<text top="164" left="906" width="95" height="17" font="13">DAOH, (p=0.02), </text>
<text top="181" left="906" width="123" height="17" font="13">Better MLHF (p=0.02) </text>
<text top="78" left="1169" width="148" height="17" font="13"> 7 procedure-related SAEs </text>
<text top="199" left="54" width="87" height="17" font="13">CHAMPION      </text>
<text top="216" left="54" width="59" height="17" font="13">EF  ≥40% </text>
<text top="234" left="54" width="55" height="17" font="14">21315441</text>
<text top="234" left="109" width="3" height="17" font="13"> </text>
<text top="251" left="54" width="32" height="17" font="13">(246) </text>
<text top="199" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="216" left="199" width="92" height="17" font="13">PAP information </text>
<text top="234" left="199" width="76" height="17" font="13">from wireless </text>
<text top="251" left="199" width="44" height="17" font="13">monitor </text>
<text top="199" left="332" width="96" height="17" font="13">Single blind RCT </text>
<text top="199" left="447" width="27" height="17" font="13"> 119 </text>
<text top="199" left="528" width="92" height="17" font="13">Class III HF and </text>
<text top="216" left="528" width="118" height="17" font="13">hospitalized in past y </text>
<text top="234" left="528" width="7" height="17" font="13">  </text>
<text top="199" left="683" width="20" height="17" font="13">HF </text>
<text top="216" left="683" width="83" height="17" font="13">hospitilizations </text>
<text top="199" left="791" width="27" height="17" font="13"> N/A </text>
<text top="199" left="906" width="194" height="17" font="13">HF hosp reduced from 0.33 to 0.16 </text>
<text top="216" left="906" width="63" height="17" font="13">(p=0.0001) </text>
<text top="234" left="906" width="3" height="17" font="13"> </text>
<text top="251" left="906" width="7" height="17" font="13">  </text>
<text top="199" left="1169" width="157" height="17" font="13">Subgroup small, same trend </text>
<text top="269" left="54" width="94" height="17" font="13">HOMEOSTASIS </text>
<text top="286" left="54" width="113" height="17" font="13">Ritzema, Circulation </text>
<text top="303" left="54" width="31" height="17" font="13">2011 </text>
<text top="320" left="54" width="55" height="17" font="14">20176990</text>
<text top="320" left="109" width="3" height="17" font="13"> </text>
<text top="338" left="54" width="32" height="17" font="13">(247) </text>
<text top="269" left="199" width="105" height="17" font="13">Feasibility study of </text>
<text top="286" left="199" width="116" height="17" font="13">daily LAP monitoring </text>
<text top="303" left="199" width="113" height="17" font="13">to inform pt-directed </text>
<text top="320" left="199" width="44" height="17" font="13">therapy </text>
<text top="269" left="332" width="64" height="17" font="13">Open-label </text>
<text top="286" left="332" width="52" height="17" font="13">Registry, </text>
<text top="303" left="332" width="70" height="17" font="13">uncontrolled </text>
<text top="269" left="447" width="21" height="17" font="13"> 40 </text>
<text top="269" left="528" width="70" height="17" font="13">Class  III-IV; </text>
<text top="286" left="528" width="121" height="17" font="13">hospitalized in past y  </text>
<text top="303" left="528" width="35" height="17" font="13">all EF </text>
<text top="320" left="528" width="7" height="17" font="13">  </text>
<text top="269" left="683" width="27" height="17" font="13"> N/A </text>
<text top="269" left="791" width="27" height="17" font="13"> N/A </text>
<text top="269" left="906" width="214" height="17" font="13">LAP declined  17.6 to 14.8 (p=0.0003); </text>
<text top="286" left="906" width="192" height="17" font="13">% over 15 declined 67% (p=0.001) </text>
<text top="303" left="906" width="246" height="17" font="13">Beta blocker/ACE-I doses increased 40/37% </text>
<text top="320" left="906" width="56" height="17" font="13">(p=0.001) </text>
<text top="338" left="906" width="206" height="17" font="13">Loop doses decreased 27% (p=0.15) </text>
<text top="269" left="1169" width="178" height="17" font="13">Pilot observational, no controls.  </text>
<text top="269" left="1385" width="3" height="17" font="13"> </text>
<text top="286" left="1169" width="140" height="17" font="13">key concepts: physiology </text>
<text top="286" left="1331" width="3" height="17" font="13"> </text>
<text top="303" left="1169" width="111" height="17" font="13">reduce diuretics.   </text>
<text top="320" left="1169" width="90" height="17" font="13">Pt responsibility </text>
<text top="320" left="1277" width="3" height="17" font="13"> </text>
<text top="356" left="54" width="77" height="17" font="13">DOT-HF trial, </text>
<text top="373" left="54" width="55" height="17" font="14">21931078</text>
<text top="373" left="109" width="3" height="17" font="13"> </text>
<text top="390" left="54" width="55" height="17" font="13">[5816 /id} </text>
<text top="407" left="54" width="3" height="17" font="13"> </text>
<text top="356" left="199" width="113" height="17" font="13">Determine impact of </text>
<text top="373" left="199" width="112" height="17" font="13">knowing impedance </text>
<text top="390" left="199" width="68" height="17" font="13">information  </text>
<text top="356" left="332" width="96" height="17" font="13">Single blind RCT </text>
<text top="356" left="447" width="27" height="17" font="13"> N/A </text>
<text top="356" left="528" width="27" height="17" font="13"> N/A </text>
<text top="356" left="683" width="31" height="17" font="13">  N/A </text>
<text top="356" left="791" width="27" height="17" font="13"> N/A </text>
<text top="356" left="906" width="198" height="17" font="13">Monitoring increased hospilizations, </text>
<text top="373" left="906" width="65" height="17" font="13">clinic visits, </text>
<text top="390" left="906" width="136" height="17" font="13">No decrease in mortality </text>
<text top="356" left="1169" width="27" height="17" font="13"> N/A </text>
<text top="425" left="43" width="1291" height="17" font="13">AUC, area under the curve; CHAMPION, CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients; COMPASS-HF, Chronicle Offers Management to Patients with Advanced </text>
<text top="442" left="43" width="1242" height="17" font="13">Signs and Symptoms of Heart Failure; CRT, cardiac resynchronization therapy; DOT-HF, Diagnostic Outcome Trial in Heart Failure; EF, ejection fraction; FAST, Fluid Accumulation Status Trial; HF, heart failure; HOMEOSTASIS; </text>
<text top="460" left="43" width="1275" height="17" font="13">Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients; ICD; implantable cardioverter-defibrillator; LAP, left atrial pressure; lbs, pounds; LVEF, left ventricular ejection fraction; MLHF, Minnesota Living with Heart </text>
<text top="477" left="43" width="1235" height="17" font="13">Failure Questionnaire; N/A, not applicable; PAP, pulmonary artery pressure; PPV, positive predictive value; pt, patient; pt-y, patient years; RCT, randomized control trial; REDUCE-HF, Reducing Decompensation Events Utilizing </text>
<text top="494" left="43" width="973" height="17" font="13">Intracardiac Pressures in Patients With Chronic Heart Failure; SAE, serious adverse event; SENSE-HF, Sensitivity of the InSync Sentry feature for the Prediction of Heart Failure.  </text>
<text top="515" left="54" width="4" height="16" font="7"> </text>
<text top="549" left="54" width="300" height="21" font="8"><b>Data Supplement 29. CRT (Section 7.3.4.2) </b></text>
<text top="623" left="63" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="640" left="64" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="640" left="171" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="623" left="287" width="38" height="17" font="15"><b>Study </b></text>
<text top="640" left="289" width="32" height="17" font="15"><b>Type </b></text>
<text top="571" left="374" width="45" height="17" font="15"><b>Patient </b></text>
<text top="588" left="359" width="78" height="17" font="15"><b>Population -  </b></text>
<text top="605" left="372" width="50" height="17" font="15"><b>N (total) </b></text>
<text top="623" left="347" width="98" height="17" font="15"><b>n (experimental) </b></text>
<text top="640" left="364" width="64" height="17" font="15"><b>n (control) </b></text>
<text top="623" left="470" width="63" height="17" font="15"><b>Follow-Up </b></text>
<text top="640" left="486" width="30" height="17" font="15"><b>(mo) </b></text>
<text top="623" left="579" width="54" height="17" font="15"><b>Baseline </b></text>
<text top="640" left="574" width="63" height="17" font="15"><b>Treatment </b></text>
<text top="640" left="670" width="75" height="17" font="15"><b>NYHA Class </b></text>
<text top="640" left="771" width="42" height="17" font="15"><b>EF (%) </b></text>
<text top="588" left="844" width="30" height="17" font="15"><b>QRS </b></text>
<text top="605" left="840" width="34" height="17" font="15"><b>durati</b></text>
<text top="623" left="850" width="19" height="17" font="15"><b>on </b></text>
<text top="640" left="844" width="29" height="17" font="15"><b>(ms) </b></text>
<text top="640" left="910" width="108" height="17" font="15"><b>Exclusion Criteria </b></text>
<text top="588" left="1074" width="30" height="17" font="15"><b>QRS </b></text>
<text top="605" left="1055" width="68" height="17" font="15"><b>Subgroups </b></text>
<text top="623" left="1054" width="71" height="17" font="15"><b>by duration </b></text>
<text top="640" left="1074" width="29" height="17" font="15"><b>(ms) </b></text>
<text top="588" left="1157" width="67" height="17" font="15"><b>Composite </b></text>
<text top="605" left="1150" width="81" height="17" font="15"><b>Endpoint (for </b></text>
<text top="623" left="1175" width="30" height="17" font="15"><b>QRS </b></text>
<text top="640" left="1155" width="71" height="17" font="15"><b>subgroups) </b></text>
<text top="640" left="1324" width="48" height="17" font="15"><b>Results </b></text>
<text top="658" left="61" width="90" height="17" font="15"><b>COMPANION    </b></text>
<text top="675" left="61" width="77" height="17" font="15"><b>N</b> Engl J Med </text>
<text top="692" left="61" width="75" height="17" font="13">2004;350:214</text>
<text top="709" left="61" width="32" height="17" font="13">0-50. </text>
<text top="726" left="61" width="55" height="17" font="14">15152059</text>
<text top="726" left="116" width="3" height="17" font="13"> </text>
<text top="744" left="61" width="32" height="17" font="13">(248) </text>
<text top="658" left="157" width="100" height="17" font="13">Aim of trial was to </text>
<text top="675" left="157" width="94" height="17" font="13">compare optimal </text>
<text top="692" left="157" width="83" height="17" font="13">pharmacologic </text>
<text top="709" left="157" width="99" height="17" font="13">therapy plus CRT </text>
<text top="726" left="157" width="103" height="17" font="13">with a pacemaker, </text>
<text top="744" left="157" width="43" height="17" font="13">optimal </text>
<text top="761" left="157" width="83" height="17" font="13">pharmacologic </text>
<text top="778" left="157" width="99" height="17" font="13">therapy plus CRT </text>
<text top="658" left="278" width="141" height="17" font="13">RCT 1520; </text>
<text top="658" left="380" width="66" height="17" font="13">617; </text>
<text top="675" left="346" width="102" height="17" font="13">medical therapy*:  </text>
<text top="692" left="346" width="51" height="17" font="13">308;        </text>
<text top="709" left="346" width="65" height="17" font="13">pacemaker-</text>
<text top="726" left="346" width="91" height="17" font="13">defibrillator: 595 </text>
<text top="658" left="460" width="88" height="17" font="13">16.2 (CRT),       </text>
<text top="675" left="460" width="81" height="17" font="13">11.9 (medical) </text>
<text top="658" left="555" width="73" height="17" font="13">ACE-Is, beta </text>
<text top="675" left="555" width="77" height="17" font="13">blockers, and </text>
<text top="692" left="555" width="83" height="17" font="13">spironolactone </text>
<text top="658" left="670" width="35" height="17" font="13">3 or 4 </text>
<text top="658" left="757" width="28" height="17" font="13">&lt; 35 </text>
<text top="658" left="838" width="35" height="17" font="13">&gt; 120 </text>
<text top="658" left="892" width="107" height="17" font="13">• non- randomized  </text>
<text top="675" left="892" width="129" height="17" font="13">• no-CRT control group </text>
<text top="692" left="892" width="80" height="17" font="13">• enabled ICD </text>
<text top="709" left="892" width="133" height="17" font="13">implantation only in one </text>
<text top="726" left="892" width="83" height="17" font="13">study arm only </text>
<text top="744" left="892" width="141" height="17" font="13">• cross-over study design </text>
<text top="761" left="892" width="104" height="17" font="13">• did not report the </text>
<text top="778" left="892" width="111" height="17" font="13">clinical outcomes of </text>
<text top="658" left="1048" width="63" height="17" font="13">120-147 (n </text>
<text top="675" left="1048" width="56" height="17" font="13">324); 148-</text>
<text top="692" left="1048" width="88" height="17" font="13">*168 (n 314);     </text>
<text top="709" left="1048" width="74" height="17" font="13">&gt;168 (n 287) </text>
<text top="658" left="1143" width="53" height="17" font="13">All cause </text>
<text top="675" left="1143" width="64" height="17" font="13">mortality or </text>
<text top="692" left="1143" width="88" height="17" font="13">hospitalizations </text>
<text top="658" left="1250" width="189" height="17" font="13">CRT with a pacemaker decreased </text>
<text top="675" left="1250" width="176" height="17" font="13">the risk of the primary end point </text>
<text top="692" left="1250" width="29" height="17" font="13">(HR: </text>
<text top="709" left="1250" width="86" height="17" font="13">0.81; p=0.014), </text>
<text top="726" left="1250" width="195" height="17" font="13">CRT with a pacemaker–defibrillator </text>
<text top="744" left="1250" width="182" height="17" font="13">decreased the risk of the primary </text>
<text top="761" left="1250" width="156" height="17" font="13">endpoint (HR: 0.80; p=0.01) </text>
<text top="778" left="1250" width="3" height="17" font="13"> </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">110</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="157" width="103" height="17" font="13">with a pacemaker–</text>
<text top="72" left="157" width="91" height="17" font="13">defibrillator, and </text>
<text top="89" left="157" width="43" height="17" font="13">optimal </text>
<text top="106" left="157" width="83" height="17" font="13">pharmacologic </text>
<text top="124" left="157" width="101" height="17" font="13">therapy alone in a </text>
<text top="141" left="157" width="85" height="17" font="13">population with </text>
<text top="158" left="157" width="101" height="17" font="13">advanced HF and </text>
<text top="175" left="157" width="84" height="17" font="13">intraventricular </text>
<text top="192" left="157" width="105" height="17" font="13">conduction delays. </text>
<text top="55" left="892" width="47" height="17" font="13">interest  </text>
<text top="72" left="892" width="97" height="17" font="13">• reported clinical </text>
<text top="89" left="892" width="122" height="17" font="13">outcomes without any </text>
<text top="106" left="892" width="141" height="17" font="13">relation to specific limited </text>
<text top="124" left="892" width="71" height="17" font="13">QRS ranges </text>
<text top="55" left="1250" width="183" height="17" font="13">Risk of the combined endpoint of </text>
<text top="72" left="1250" width="176" height="17" font="13">death from or hospitalization for </text>
<text top="89" left="1250" width="167" height="17" font="13">HFwas reduced by 34% in the </text>
<text top="106" left="1250" width="196" height="17" font="13">pacemaker group (p&lt;0.002) and by </text>
<text top="124" left="1250" width="196" height="17" font="13">40 % in the pacemaker–defibrillator </text>
<text top="141" left="1250" width="193" height="17" font="13">group (p&lt;0.001 for the comparison </text>
<text top="158" left="1250" width="174" height="17" font="13">with the pharmacologic-therapy </text>
<text top="175" left="1250" width="42" height="17" font="13">group). </text>
<text top="192" left="1250" width="191" height="17" font="13">Pacemaker reduced the risk of the </text>
<text top="210" left="1250" width="187" height="17" font="13">secondary endpoint of death from </text>
<text top="227" left="1250" width="188" height="17" font="13">any cause by 24% (p=0.059), and </text>
<text top="244" left="1250" width="189" height="17" font="13">a pacemaker–defibrillator reduced </text>
<text top="261" left="1250" width="147" height="17" font="13">the risk by 36% (p=0.003). </text>
<text top="279" left="61" width="90" height="17" font="15"><b>CARE-HF</b>          </text>
<text top="296" left="61" width="77" height="17" font="13">N Engl J Med </text>
<text top="314" left="61" width="75" height="17" font="13">2005;352:153</text>
<text top="331" left="61" width="32" height="17" font="13">9-49. </text>
<text top="348" left="61" width="55" height="17" font="14">15753115</text>
<text top="348" left="116" width="3" height="17" font="13"> </text>
<text top="365" left="61" width="29" height="17" font="13">(249)</text>
<text top="364" left="90" width="4" height="19" font="7"> </text>
<text top="279" left="157" width="84" height="17" font="13">To analyze the </text>
<text top="296" left="157" width="96" height="17" font="13">effects of cardiac </text>
<text top="314" left="157" width="100" height="17" font="13">resynchronization </text>
<text top="331" left="157" width="74" height="17" font="13">on the risk of </text>
<text top="348" left="157" width="102" height="17" font="13">complications and </text>
<text top="365" left="157" width="95" height="17" font="13">death among pts </text>
<text top="382" left="157" width="109" height="17" font="13">who were receiving </text>
<text top="400" left="157" width="97" height="17" font="13">standard medical </text>
<text top="417" left="157" width="62" height="17" font="13">therapy for </text>
<text top="434" left="157" width="70" height="17" font="13">moderate or </text>
<text top="451" left="157" width="84" height="17" font="13">severe HF and </text>
<text top="469" left="157" width="43" height="17" font="13">cardiac </text>
<text top="486" left="157" width="82" height="17" font="13">dyssynchrony. </text>
<text top="279" left="278" width="29" height="17" font="13">RCT </text>
<text top="279" left="346" width="58" height="17" font="13">813; 409;  </text>
<text top="296" left="346" width="98" height="17" font="13">medical therapy*: </text>
<text top="314" left="346" width="24" height="17" font="13">404 </text>
<text top="279" left="460" width="207" height="17" font="13">29.4 ACE-Is, </text>
<text top="279" left="601" width="28" height="17" font="13">beta-</text>
<text top="296" left="555" width="77" height="17" font="13">blockers, and </text>
<text top="314" left="555" width="83" height="17" font="13">spironolactone </text>
<text top="279" left="670" width="35" height="17" font="13">3 or 4 </text>
<text top="279" left="757" width="24" height="17" font="13">&lt;35 </text>
<text top="279" left="838" width="31" height="17" font="13">&gt;120 </text>
<text top="279" left="892" width="96" height="17" font="13">• not randomized </text>
<text top="296" left="892" width="140" height="17" font="13">• lacked non-CRT control </text>
<text top="314" left="892" width="35" height="17" font="13">group </text>
<text top="331" left="892" width="80" height="17" font="13">• enabled ICD </text>
<text top="348" left="892" width="133" height="17" font="13">implantation only in one </text>
<text top="365" left="892" width="61" height="17" font="13">study arm  </text>
<text top="382" left="892" width="125" height="17" font="13">• had cross-over study </text>
<text top="400" left="892" width="43" height="17" font="13">design  </text>
<text top="417" left="892" width="104" height="17" font="13">• did not report the </text>
<text top="434" left="892" width="111" height="17" font="13">clinical outcomes of </text>
<text top="451" left="892" width="73" height="17" font="13">interest such </text>
<text top="469" left="892" width="97" height="17" font="13">• reported clinical </text>
<text top="486" left="892" width="122" height="17" font="13">outcomes without any </text>
<text top="503" left="892" width="141" height="17" font="13">relation to specific limited </text>
<text top="520" left="892" width="74" height="17" font="13">QRS ranges. </text>
<text top="279" left="1048" width="63" height="17" font="13">120-159 (n </text>
<text top="296" left="1048" width="77" height="17" font="13">290); &gt;159 (n </text>
<text top="314" left="1048" width="28" height="17" font="13">505) </text>
<text top="279" left="1143" width="53" height="17" font="13">All cause </text>
<text top="296" left="1143" width="64" height="17" font="13">mortality or </text>
<text top="314" left="1143" width="87" height="17" font="13">hospitalizations </text>
<text top="331" left="1143" width="73" height="17" font="13">for major CV </text>
<text top="348" left="1143" width="85" height="17" font="13">event including </text>
<text top="365" left="1143" width="20" height="17" font="13">HF </text>
<text top="382" left="1143" width="81" height="17" font="13">hospitalization </text>
<text top="279" left="1250" width="186" height="17" font="13">Primary endpoint was reached by </text>
<text top="296" left="1250" width="121" height="17" font="13">159 pts in the cardiac-</text>
<text top="314" left="1250" width="155" height="17" font="13">resynchronization group, as </text>
<text top="331" left="1250" width="161" height="17" font="13">compared with 224 pts in the </text>
<text top="348" left="1250" width="180" height="17" font="13">medical-therapy group (39 % vs. </text>
<text top="365" left="1250" width="196" height="17" font="13">55%; HR: 0.63; 95 % CI: 0.51-0.77; </text>
<text top="382" left="1250" width="59" height="17" font="13">p&lt;0.001).  </text>
<text top="400" left="1250" width="3" height="17" font="13"> </text>
<text top="417" left="1250" width="156" height="17" font="13">There were 82 deaths in the </text>
<text top="434" left="1250" width="182" height="17" font="13">cardiac-resynchronization group, </text>
<text top="451" left="1250" width="157" height="17" font="13">as compared with 120 in the </text>
<text top="469" left="1250" width="177" height="17" font="13">medical-therapy group (20% vs. </text>
<text top="486" left="1250" width="193" height="17" font="13">30%; HR: 0.64; 95 %CI: 0.48-0.85; </text>
<text top="503" left="1250" width="59" height="17" font="13">p&lt;0.002).  </text>
<text top="520" left="1250" width="3" height="17" font="13"> </text>
<text top="537" left="1250" width="195" height="17" font="13">As compared with medical therapy, </text>
<text top="555" left="1250" width="191" height="17" font="13">cardiac resynchronization reduced </text>
<text top="572" left="1250" width="170" height="17" font="13">the interventricular mechanical </text>
<text top="589" left="1250" width="168" height="17" font="13">delay, the end-systolic volume </text>
<text top="606" left="1250" width="176" height="17" font="13">index, and the area of the mitral </text>
<text top="624" left="1250" width="159" height="17" font="13">regurgitant jet; increased the </text>
<text top="641" left="1250" width="175" height="17" font="13">LVEF; and improved symptoms </text>
<text top="658" left="1250" width="150" height="17" font="13">and the QoL (p&lt;0.01 for all </text>
<text top="675" left="1250" width="81" height="17" font="13">comparisons). </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">111</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="62" height="17" font="15"><b>REVERSE </b></text>
<text top="72" left="61" width="55" height="17" font="14">19038680</text>
<text top="72" left="116" width="3" height="17" font="13"> </text>
<text top="89" left="61" width="32" height="17" font="13">(223) </text>
<text top="55" left="157" width="96" height="17" font="13">To determine the </text>
<text top="72" left="157" width="95" height="17" font="13">effects of CRT in </text>
<text top="89" left="157" width="94" height="17" font="13">NYHA functional </text>
<text top="106" left="157" width="85" height="17" font="13">class II HF and </text>
<text top="124" left="157" width="94" height="17" font="13">NYHA functional </text>
<text top="141" left="157" width="100" height="17" font="13">class I (ACC/AHA </text>
<text top="158" left="157" width="95" height="17" font="13">stage C) pts with </text>
<text top="175" left="157" width="70" height="17" font="13">previous HF </text>
<text top="192" left="157" width="63" height="17" font="13">symptoms. </text>
<text top="55" left="278" width="29" height="17" font="13">RCT </text>
<text top="55" left="346" width="58" height="17" font="13">610; 419;  </text>
<text top="72" left="346" width="77" height="17" font="13">CRT-off : 191 </text>
<text top="55" left="460" width="218" height="17" font="13">12 ACE-Is, </text>
<text top="55" left="601" width="105" height="17" font="13">beta </text>
<text top="72" left="555" width="77" height="17" font="13">blockers, and </text>
<text top="89" left="555" width="83" height="17" font="13">spironolactone </text>
<text top="55" left="670" width="35" height="17" font="13">1 or 2 </text>
<text top="55" left="757" width="24" height="17" font="13">&lt;40 </text>
<text top="55" left="838" width="31" height="17" font="13">&gt;120 </text>
<text top="55" left="892" width="96" height="17" font="13">• not randomized </text>
<text top="72" left="892" width="140" height="17" font="13">• lacked non-CRT control </text>
<text top="89" left="892" width="35" height="17" font="13">group </text>
<text top="106" left="892" width="80" height="17" font="13">• enabled ICD </text>
<text top="124" left="892" width="133" height="17" font="13">implantation only in one </text>
<text top="141" left="892" width="61" height="17" font="13">study arm  </text>
<text top="158" left="892" width="125" height="17" font="13">• had cross-over study </text>
<text top="175" left="892" width="43" height="17" font="13">design  </text>
<text top="192" left="892" width="104" height="17" font="13">• did not report the </text>
<text top="210" left="892" width="111" height="17" font="13">clinical outcomes of </text>
<text top="227" left="892" width="73" height="17" font="13">interest such </text>
<text top="244" left="892" width="97" height="17" font="13">• reported clinical </text>
<text top="261" left="892" width="122" height="17" font="13">outcomes without any </text>
<text top="278" left="892" width="141" height="17" font="13">relation to specific limited </text>
<text top="296" left="892" width="74" height="17" font="13">QRS ranges. </text>
<text top="55" left="1048" width="63" height="17" font="13">120-151 (n </text>
<text top="72" left="1048" width="35" height="17" font="13">303);  </text>
<text top="89" left="1048" width="74" height="17" font="13">&gt;151 (n 307) </text>
<text top="55" left="1143" width="53" height="17" font="13">All cause </text>
<text top="72" left="1143" width="84" height="17" font="13">mortality or HF </text>
<text top="89" left="1143" width="81" height="17" font="13">hospitalization </text>
<text top="106" left="1143" width="91" height="17" font="13">or worsened HF </text>
<text top="124" left="1143" width="63" height="17" font="13">resulting in </text>
<text top="141" left="1143" width="75" height="17" font="13">cross-over or </text>
<text top="158" left="1143" width="53" height="17" font="13">drop-out  </text>
<text top="175" left="1143" width="57" height="17" font="13">worsened </text>
<text top="192" left="1143" width="83" height="17" font="13">NYHA class or </text>
<text top="210" left="1143" width="82" height="17" font="13">moderately  or </text>
<text top="227" left="1143" width="53" height="17" font="13">markedly </text>
<text top="244" left="1143" width="77" height="17" font="13">worsened HF </text>
<text top="261" left="1143" width="60" height="17" font="13">symptoms </text>
<text top="55" left="1250" width="144" height="17" font="13">The HF clinical composite </text>
<text top="72" left="1250" width="143" height="17" font="13">response endpoint, which </text>
<text top="89" left="1250" width="149" height="17" font="13">compared only the percent </text>
<text top="106" left="1250" width="141" height="17" font="13">worsened, indicated 16% </text>
<text top="124" left="1250" width="179" height="17" font="13">worsened in CRT-ON compared </text>
<text top="141" left="1250" width="180" height="17" font="13">with 21% in CRT-OFF (p =0.10). </text>
<text top="158" left="1250" width="139" height="17" font="13">Pts assigned to CRT-ON </text>
<text top="175" left="1250" width="123" height="17" font="13">experienced a greater </text>
<text top="192" left="1250" width="174" height="17" font="13">improvement in LV end-systolic </text>
<text top="210" left="1250" width="186" height="17" font="13">volume index (-18.4 + 29.5 ml/m2 </text>
<text top="227" left="1250" width="185" height="17" font="13">vs. -1.3 +23.4 ml/m2, p &lt; 0.0001) </text>
<text top="244" left="1250" width="145" height="17" font="13">and other measures of LV </text>
<text top="261" left="1250" width="157" height="17" font="13">remodeling. Time-to-first HF </text>
<text top="278" left="1250" width="174" height="17" font="13">hospitalization was significantly </text>
<text top="296" left="1250" width="170" height="17" font="13">delayed in CRT-ON (HR: 0.47; </text>
<text top="313" left="1250" width="49" height="17" font="13">p=0.03). </text>
<text top="348" left="61" width="72" height="17" font="15"><b>MADIT-CRT </b></text>
<text top="365" left="61" width="55" height="17" font="14">19723701</text>
<text top="365" left="116" width="3" height="17" font="13"> </text>
<text top="382" left="61" width="32" height="17" font="13">(250) </text>
<text top="348" left="157" width="100" height="17" font="13">Aim of trial was to </text>
<text top="365" left="157" width="105" height="17" font="13">determine whether </text>
<text top="382" left="157" width="29" height="17" font="13">CRT </text>
<text top="400" left="157" width="95" height="17" font="13">with biventricular </text>
<text top="417" left="157" width="75" height="17" font="13">pacing would </text>
<text top="434" left="157" width="98" height="17" font="13">reduce the risk of </text>
<text top="451" left="157" width="108" height="17" font="13">death or HF events </text>
<text top="468" left="157" width="13" height="17" font="13">in </text>
<text top="486" left="157" width="71" height="17" font="13">pts with mild </text>
<text top="503" left="157" width="106" height="17" font="13">cardiac symptoms, </text>
<text top="520" left="157" width="105" height="17" font="13">a reduced EF, and </text>
<text top="537" left="157" width="69" height="17" font="13">a wide QRS </text>
<text top="555" left="157" width="53" height="17" font="13">complex. </text>
<text top="348" left="278" width="137" height="17" font="13">RCT 1800 </text>
<text top="365" left="346" width="31" height="17" font="13">1089 </text>
<text top="382" left="346" width="98" height="17" font="13">medical therapy*: </text>
<text top="400" left="346" width="24" height="17" font="13">731 </text>
<text top="348" left="460" width="207" height="17" font="13">28.8 ACE-Is, </text>
<text top="348" left="601" width="28" height="17" font="13">beta-</text>
<text top="365" left="555" width="77" height="17" font="13">blockers, and </text>
<text top="382" left="555" width="83" height="17" font="13">spironolactone </text>
<text top="348" left="670" width="35" height="17" font="13">1 or 2 </text>
<text top="348" left="757" width="24" height="17" font="13">&lt;30 </text>
<text top="348" left="838" width="31" height="17" font="13">&gt;130 </text>
<text top="348" left="892" width="96" height="17" font="13">• not randomized </text>
<text top="365" left="892" width="140" height="17" font="13">• lacked non-CRT control </text>
<text top="382" left="892" width="35" height="17" font="13">group </text>
<text top="400" left="892" width="80" height="17" font="13">• enabled ICD </text>
<text top="417" left="892" width="133" height="17" font="13">implantation only in one </text>
<text top="434" left="892" width="61" height="17" font="13">study arm  </text>
<text top="451" left="892" width="125" height="17" font="13">• had cross-over study </text>
<text top="468" left="892" width="43" height="17" font="13">design  </text>
<text top="486" left="892" width="104" height="17" font="13">• did not report the </text>
<text top="503" left="892" width="111" height="17" font="13">clinical outcomes of </text>
<text top="520" left="892" width="73" height="17" font="13">interest such </text>
<text top="537" left="892" width="97" height="17" font="13">• reported clinical </text>
<text top="555" left="892" width="122" height="17" font="13">outcomes without any </text>
<text top="572" left="892" width="141" height="17" font="13">relation to specific limited </text>
<text top="589" left="892" width="74" height="17" font="13">QRS ranges. </text>
<text top="348" left="1048" width="63" height="17" font="13">130-149 (n </text>
<text top="365" left="1048" width="77" height="17" font="13">645); &gt;149 (n </text>
<text top="382" left="1048" width="35" height="17" font="13">1175) </text>
<text top="348" left="1143" width="53" height="17" font="13">All cause </text>
<text top="365" left="1143" width="84" height="17" font="13">mortality or HF </text>
<text top="382" left="1143" width="58" height="17" font="13">event (HF </text>
<text top="400" left="1143" width="81" height="17" font="13">hospitalization </text>
<text top="417" left="1143" width="72" height="17" font="13">or outpatient </text>
<text top="434" left="1143" width="67" height="17" font="13">intravenous </text>
<text top="451" left="1143" width="92" height="17" font="13">diuretic therapy) </text>
<text top="348" left="1250" width="164" height="17" font="13">Primary end point occurred in </text>
<text top="365" left="1250" width="188" height="17" font="13">17.2% of the CRT–ICD group and </text>
<text top="382" left="1250" width="175" height="17" font="13">in 25.3% of the ICD-only group. </text>
<text top="400" left="1250" width="194" height="17" font="13">CRT–ICD group HR: 0.66; 95% CI: </text>
<text top="417" left="1250" width="110" height="17" font="13">0.52-0.84; p=0.001. </text>
<text top="434" left="1250" width="136" height="17" font="13">The benefit did not differ </text>
<text top="451" left="1250" width="162" height="17" font="13">significantly between pts with </text>
<text top="468" left="1250" width="165" height="17" font="13">ischemic cardiomyopathy and </text>
<text top="486" left="1250" width="131" height="17" font="13">those with nonischemic </text>
<text top="503" left="1250" width="186" height="17" font="13">cardiomyopathy. CRT superiority  </text>
<text top="520" left="1250" width="184" height="17" font="13">was driven by a 41% reduction in </text>
<text top="537" left="1250" width="159" height="17" font="13">the risk of HF events evident </text>
<text top="555" left="1250" width="143" height="17" font="13">primarily in a prespecified </text>
<text top="572" left="1250" width="154" height="17" font="13">subgroup of pts with a QRS </text>
<text top="589" left="1250" width="170" height="17" font="13">duration ≥150 msec. CRT was </text>
<text top="606" left="1250" width="156" height="17" font="13">associated with a significant </text>
<text top="623" left="1250" width="159" height="17" font="13">reduction in LV volumes and </text>
<text top="641" left="1250" width="191" height="17" font="13">improvement in the EF. There was </text>
<text top="658" left="1250" width="183" height="17" font="13">no significant difference between </text>
<text top="675" left="1250" width="193" height="17" font="13">the two groups in the overall risk of </text>
<text top="692" left="1250" width="185" height="17" font="13">death, with a 3% annual mortality </text>
<text top="709" left="1250" width="196" height="17" font="13">rate in each treatment group. SAEs </text>
<text top="727" left="1250" width="176" height="17" font="13">were infrequent in the 2 groups. </text>
</page>
<page number="112" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">112</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="36" height="17" font="15"><b>RAFT </b></text>
<text top="72" left="61" width="55" height="17" font="14">21073365</text>
<text top="72" left="116" width="3" height="17" font="13"> </text>
<text top="89" left="61" width="32" height="17" font="13">(251) </text>
<text top="55" left="157" width="100" height="17" font="13">Aim of trial was to </text>
<text top="72" left="157" width="97" height="17" font="13">evaluate whether </text>
<text top="89" left="157" width="40" height="17" font="13">adding </text>
<text top="106" left="157" width="108" height="17" font="13">CRT to an ICD and </text>
<text top="124" left="157" width="89" height="17" font="13">optimal medical </text>
<text top="141" left="157" width="78" height="17" font="13">therapy might </text>
<text top="158" left="157" width="91" height="17" font="13">reduce mortality </text>
<text top="175" left="157" width="77" height="17" font="13">and morbidity </text>
<text top="192" left="157" width="94" height="17" font="13">among such pts. </text>
<text top="55" left="278" width="29" height="17" font="13">RCT </text>
<text top="55" left="346" width="65" height="17" font="13">1800; 894;  </text>
<text top="72" left="346" width="75" height="17" font="13">No CRT: 904 </text>
<text top="55" left="460" width="204" height="17" font="13">40 ACE, </text>
<text top="55" left="587" width="28" height="17" font="13">beta-</text>
<text top="72" left="555" width="77" height="17" font="13">blockers, and </text>
<text top="89" left="555" width="83" height="17" font="13">spironolactone </text>
<text top="55" left="670" width="35" height="17" font="13">2 or 3 </text>
<text top="55" left="757" width="24" height="17" font="13">&lt;30 </text>
<text top="55" left="838" width="31" height="17" font="13">&gt;120 </text>
<text top="55" left="892" width="96" height="17" font="13">• not randomized </text>
<text top="72" left="892" width="140" height="17" font="13">• lacked non-CRT control </text>
<text top="89" left="892" width="35" height="17" font="13">group </text>
<text top="106" left="892" width="80" height="17" font="13">• enabled ICD </text>
<text top="124" left="892" width="133" height="17" font="13">implantation only in one </text>
<text top="141" left="892" width="61" height="17" font="13">study arm  </text>
<text top="158" left="892" width="125" height="17" font="13">• had cross-over study </text>
<text top="175" left="892" width="43" height="17" font="13">design  </text>
<text top="192" left="892" width="104" height="17" font="13">• did not report the </text>
<text top="210" left="892" width="111" height="17" font="13">clinical outcomes of </text>
<text top="227" left="892" width="73" height="17" font="13">interest such </text>
<text top="244" left="892" width="97" height="17" font="13">• reported clinical </text>
<text top="261" left="892" width="122" height="17" font="13">outcomes without any </text>
<text top="278" left="892" width="141" height="17" font="13">relation to specific limited </text>
<text top="296" left="892" width="74" height="17" font="13">QRS ranges. </text>
<text top="55" left="1048" width="63" height="17" font="13">120-149 (n </text>
<text top="72" left="1048" width="77" height="17" font="13">627); &gt;149 (n </text>
<text top="89" left="1048" width="35" height="17" font="13">1036) </text>
<text top="55" left="1143" width="53" height="17" font="13">All casue </text>
<text top="72" left="1143" width="84" height="17" font="13">mortality or HF </text>
<text top="89" left="1143" width="81" height="17" font="13">hospitalization </text>
<text top="55" left="1250" width="161" height="17" font="13">Primary outcome occurred in </text>
<text top="72" left="1250" width="187" height="17" font="13">33.2% in the ICD–CRT group and </text>
<text top="89" left="1250" width="192" height="17" font="13">40.3% in the ICD group; ICD–CRT </text>
<text top="106" left="1250" width="169" height="17" font="13">group HR: 0.75; 95% CI: 0.64- </text>
<text top="124" left="1250" width="86" height="17" font="13">0.87; p&lt;0.001.  </text>
<text top="141" left="1250" width="173" height="17" font="13">In the ICD–CRT group, 186 pts </text>
<text top="158" left="1250" width="187" height="17" font="13">died, as compared with 236 in the </text>
<text top="175" left="1250" width="166" height="17" font="13">ICD group (HR: 0.75; 95% CI: </text>
<text top="192" left="1250" width="182" height="17" font="13">0.62-0.91; p=0.003), and 174 pts </text>
<text top="210" left="1250" width="156" height="17" font="13">were hospitalized for HF, as </text>
<text top="227" left="1250" width="166" height="17" font="13">compared with 236 in the ICD </text>
<text top="244" left="1250" width="169" height="17" font="13">group (HR: 0.68; 95% CI: 0.56-</text>
<text top="261" left="1250" width="181" height="17" font="13">0.83; p&lt;0.001). 30 d after device </text>
<text top="278" left="1250" width="187" height="17" font="13">implantation, AEs had occurred in </text>
<text top="296" left="1250" width="186" height="17" font="13">124 pts in the ICD-CRT group, as </text>
<text top="313" left="1250" width="193" height="17" font="13">compared with 58 in the ICD group </text>
<text top="330" left="1250" width="60" height="17" font="13">(p&lt;0.001). </text>
<text top="352" left="61" width="88" height="17" font="15"><b>PROSPECT      </b></text>
<text top="369" left="61" width="65" height="17" font="13">Circulation. </text>
<text top="386" left="61" width="58" height="17" font="13">2008;117: </text>
<text top="403" left="61" width="66" height="17" font="13">2608-2616. </text>
<text top="421" left="61" width="55" height="17" font="14">18458170</text>
<text top="421" left="116" width="3" height="17" font="13"> </text>
<text top="438" left="61" width="32" height="17" font="13">(252)<b> </b></text>
<text top="352" left="157" width="100" height="17" font="13">Aim of trial was to </text>
<text top="369" left="157" width="103" height="17" font="13">evaluate selected, </text>
<text top="386" left="157" width="62" height="17" font="13">predefined </text>
<text top="403" left="157" width="49" height="17" font="13">baseline </text>
<text top="421" left="157" width="104" height="17" font="13">echocardiographic </text>
<text top="438" left="157" width="84" height="17" font="13">parameters for </text>
<text top="455" left="157" width="76" height="17" font="13">their ability to </text>
<text top="472" left="157" width="105" height="17" font="13">predict clinical and </text>
<text top="489" left="157" width="104" height="17" font="13">echocardiographic </text>
<text top="507" left="157" width="100" height="17" font="13">response to CRT. </text>
<text top="352" left="278" width="50" height="17" font="13">prospecti</text>
<text top="369" left="278" width="20" height="17" font="13">ve, </text>
<text top="386" left="278" width="49" height="17" font="13">multicent</text>
<text top="403" left="278" width="18" height="17" font="13">er, </text>
<text top="421" left="278" width="45" height="17" font="13">nonrand</text>
<text top="438" left="278" width="43" height="17" font="13">omized </text>
<text top="455" left="278" width="33" height="17" font="13">study </text>
<text top="472" left="278" width="51" height="17" font="13">(observat</text>
<text top="489" left="278" width="34" height="17" font="13">ional) </text>
<text top="352" left="346" width="75" height="17" font="13">498-enrolled; </text>
<text top="369" left="346" width="85" height="17" font="13">467-implanted; </text>
<text top="386" left="346" width="81" height="17" font="13">Not applicable </text>
<text top="352" left="460" width="224" height="17" font="13">6 Medical </text>
<text top="352" left="601" width="132" height="17" font="13">therapy, </text>
<text top="369" left="555" width="39" height="17" font="13">unless </text>
<text top="386" left="555" width="90" height="17" font="13">contraindicated, </text>
<text top="403" left="555" width="98" height="17" font="13">was to include an </text>
<text top="421" left="555" width="97" height="17" font="13">ACE-I or ARB for </text>
<text top="438" left="555" width="74" height="17" font="13">at least 1 mo </text>
<text top="455" left="555" width="99" height="17" font="13">before enrollment </text>
<text top="472" left="555" width="34" height="17" font="13">and a </text>
<text top="489" left="555" width="70" height="17" font="13">beta blocker </text>
<text top="507" left="555" width="94" height="17" font="13">started at least 3 </text>
<text top="524" left="555" width="83" height="17" font="13">mo before and </text>
<text top="541" left="555" width="96" height="17" font="13">unchanged for at </text>
<text top="558" left="555" width="98" height="17" font="13">least 1 mo before </text>
<text top="575" left="555" width="61" height="17" font="13">enrollment </text>
<text top="352" left="670" width="35" height="17" font="13">3 or 4 </text>
<text top="352" left="757" width="24" height="17" font="13">&lt;35 </text>
<text top="352" left="838" width="31" height="17" font="13">&gt;130 </text>
<text top="352" left="892" width="290" height="17" font="13">N/A  </text>
<text top="352" left="1051" width="155" height="17" font="13">N/A </text>
<text top="352" left="1143" width="148" height="17" font="13">12 </text>
<text top="369" left="1143" width="85" height="17" font="13">echocardiograp</text>
<text top="386" left="1143" width="85" height="17" font="13">hic parameters </text>
<text top="403" left="1143" width="14" height="17" font="13">of </text>
<text top="421" left="1143" width="82" height="17" font="13">dyssynchrony, </text>
<text top="438" left="1143" width="81" height="17" font="13">based on both </text>
<text top="455" left="1143" width="72" height="17" font="13">conventional </text>
<text top="472" left="1143" width="59" height="17" font="13">and tissue </text>
<text top="489" left="1143" width="84" height="17" font="13">Doppler-based </text>
<text top="507" left="1143" width="84" height="17" font="13">methods, were </text>
<text top="524" left="1143" width="85" height="17" font="13">evaluated after </text>
<text top="541" left="1143" width="79" height="17" font="13">site training in </text>
<text top="558" left="1143" width="61" height="17" font="13">acquisition </text>
<text top="575" left="1143" width="75" height="17" font="13">methods and </text>
<text top="593" left="1143" width="70" height="17" font="13">blinded core </text>
<text top="610" left="1143" width="58" height="17" font="13">laboratory </text>
<text top="627" left="1143" width="51" height="17" font="13">analysis. </text>
<text top="352" left="1250" width="161" height="17" font="13">Clinical composite score was </text>
<text top="369" left="1250" width="156" height="17" font="13">improved in 69% of 426 pts, </text>
<text top="386" left="1250" width="50" height="17" font="13">whereas </text>
<text top="403" left="1250" width="194" height="17" font="13">LV end-systolic volume decreased  </text>
<text top="421" left="1250" width="159" height="17" font="13">&gt;15% in 56% of 286 pts with </text>
<text top="438" left="1250" width="179" height="17" font="13">paired data. The ability of the 12 </text>
<text top="455" left="1250" width="190" height="17" font="13">echo parameters to predict clinical </text>
<text top="472" left="1250" width="184" height="17" font="13">composite score response varied </text>
<text top="489" left="1250" width="196" height="17" font="13">widely, with sensitivity ranging from </text>
<text top="507" left="1250" width="178" height="17" font="13">6%- 74% and specificity ranging </text>
<text top="524" left="1250" width="166" height="17" font="13">from 35%- 91%; for predicting </text>
<text top="541" left="1250" width="157" height="17" font="13">LVESV response, sensitivity </text>
<text top="558" left="1250" width="144" height="17" font="13">ranged from 9%-77% and </text>
<text top="575" left="1250" width="182" height="17" font="13">specificity from 31%-93%. For all </text>
<text top="593" left="1250" width="193" height="17" font="13">the parameters, the area under the </text>
<text top="610" left="1250" width="182" height="17" font="13">ROC curve for positive clinical or </text>
<text top="627" left="1250" width="168" height="17" font="13">volume response to CRT was  </text>
<text top="644" left="1250" width="184" height="17" font="13">&lt;0.62. There was large variability </text>
<text top="662" left="1250" width="194" height="17" font="13">in the analysis of the dyssynchrony </text>
<text top="679" left="1250" width="69" height="17" font="13">parameters. </text>
<text top="709" left="61" width="88" height="17" font="15"><b>CONNECT        </b></text>
<text top="727" left="61" width="56" height="17" font="13">J Am Coll </text>
<text top="744" left="61" width="42" height="17" font="13">Cardiol </text>
<text top="761" left="61" width="75" height="17" font="13">2011;57:1181</text>
<text top="778" left="61" width="17" height="17" font="13">–9 </text>
<text top="709" left="157" width="85" height="17" font="13">To determine if </text>
<text top="727" left="157" width="90" height="17" font="13">wireless remote </text>
<text top="744" left="157" width="86" height="17" font="13">monitoring with </text>
<text top="761" left="157" width="104" height="17" font="13">automatic clinician </text>
<text top="778" left="157" width="101" height="17" font="13">alerts reduces the </text>
<text top="709" left="278" width="49" height="17" font="13">multicent</text>
<text top="727" left="278" width="18" height="17" font="13">er, </text>
<text top="744" left="278" width="50" height="17" font="13">prospecti</text>
<text top="761" left="278" width="20" height="17" font="13">ve, </text>
<text top="778" left="278" width="51" height="17" font="13">randomiz</text>
<text top="709" left="346" width="34" height="17" font="13">1,997 </text>
<text top="727" left="346" width="90" height="17" font="13">REMOTE ARM: </text>
<text top="744" left="346" width="109" height="17" font="13">1014                        </text>
<text top="761" left="346" width="74" height="17" font="13">All automatic </text>
<text top="778" left="346" width="81" height="17" font="13">clinician alerts </text>
<text top="709" left="460" width="180" height="17" font="13">15  </text>
<text top="709" left="561" width="241" height="17" font="13">N/A  Inclusion </text>
<text top="727" left="670" width="58" height="17" font="13">criteria: 1) </text>
<text top="744" left="670" width="60" height="17" font="13">being able </text>
<text top="761" left="670" width="74" height="17" font="13">and willing to </text>
<text top="778" left="670" width="44" height="17" font="13">replace </text>
<text top="709" left="757" width="27" height="17" font="13"> N/A </text>
<text top="709" left="838" width="27" height="17" font="13"> N/A </text>
<text top="709" left="892" width="150" height="17" font="13">permanent AF                     </text>
<text top="727" left="892" width="148" height="17" font="13">chronic warfarin therapy     </text>
<text top="744" left="892" width="107" height="17" font="13">previous ICD, CRT </text>
<text top="761" left="892" width="148" height="17" font="13">device, or pacemaker         </text>
<text top="778" left="892" width="150" height="17" font="13">age  &lt;18 y                           </text>
<text top="709" left="1048" width="27" height="17" font="13"> N/A </text>
<text top="709" left="1143" width="27" height="17" font="13"> N/A </text>
<text top="709" left="1250" width="163" height="17" font="13">The median time from clinical </text>
<text top="727" left="1250" width="196" height="17" font="13">event to clinical decision per pt was </text>
<text top="744" left="1250" width="183" height="17" font="13">reduced from 22 d in the in-office </text>
<text top="761" left="1250" width="169" height="17" font="13">arm to 4.6 d in the remote arm </text>
<text top="778" left="1250" width="149" height="17" font="13">(p&lt;0.001). The health care </text>
</page>
<page number="113" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">113</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="55" height="17" font="14">21255955</text>
<text top="55" left="116" width="3" height="17" font="13"> </text>
<text top="72" left="61" width="32" height="17" font="13">(252)<b> </b></text>
<text top="55" left="157" width="105" height="17" font="13">time from a clinical </text>
<text top="72" left="157" width="98" height="17" font="13">event to a clinical </text>
<text top="89" left="157" width="62" height="17" font="13">decision in </text>
<text top="106" left="157" width="68" height="17" font="13">response to </text>
<text top="124" left="157" width="92" height="17" font="13">arrhythmias, CV </text>
<text top="141" left="157" width="46" height="17" font="13">disease </text>
<text top="158" left="157" width="71" height="17" font="13">progression, </text>
<text top="175" left="157" width="101" height="17" font="13">and device issues </text>
<text top="192" left="157" width="92" height="17" font="13">compared to pts </text>
<text top="210" left="157" width="104" height="17" font="13">receiving standard </text>
<text top="227" left="157" width="89" height="17" font="13">in-office care. A </text>
<text top="244" left="157" width="60" height="17" font="13">secondary </text>
<text top="261" left="157" width="91" height="17" font="13">objective was to </text>
<text top="278" left="157" width="102" height="17" font="13">compare the rates </text>
<text top="296" left="157" width="98" height="17" font="13">of CV health care </text>
<text top="313" left="157" width="105" height="17" font="13">utilization between </text>
<text top="330" left="157" width="95" height="17" font="13">pts in the remote </text>
<text top="347" left="157" width="105" height="17" font="13">and in-office arms. </text>
<text top="55" left="278" width="17" height="17" font="13">ed </text>
<text top="72" left="278" width="49" height="17" font="13">evaluatio</text>
<text top="89" left="278" width="10" height="17" font="13">n </text>
<text top="55" left="346" width="95" height="17" font="13">were enabled for </text>
<text top="72" left="346" width="95" height="17" font="13">pts in the remote </text>
<text top="89" left="346" width="86" height="17" font="13">arm. Audible pt </text>
<text top="106" left="346" width="64" height="17" font="13">alerts were </text>
<text top="124" left="346" width="95" height="17" font="13">disabled with the </text>
<text top="141" left="346" width="70" height="17" font="13">exception of </text>
<text top="158" left="346" width="88" height="17" font="13">those related to </text>
<text top="175" left="346" width="51" height="17" font="13">lead and </text>
<text top="192" left="346" width="89" height="17" font="13">device integrity. </text>
<text top="210" left="346" width="99" height="17" font="13">IN-OFFICE ARM: </text>
<text top="227" left="346" width="41" height="17" font="13">983      </text>
<text top="244" left="346" width="85" height="17" font="13">Only audible pt </text>
<text top="261" left="346" width="96" height="17" font="13">alerts associated </text>
<text top="278" left="346" width="76" height="17" font="13">with lead and </text>
<text top="296" left="346" width="85" height="17" font="13">device integrity </text>
<text top="313" left="346" width="95" height="17" font="13">were enabled for </text>
<text top="330" left="346" width="53" height="17" font="13">pts in the </text>
<text top="347" left="346" width="71" height="17" font="13">in-office arm </text>
<text top="365" left="346" width="98" height="17" font="13">because they are </text>
<text top="382" left="346" width="92" height="17" font="13">nominal settings </text>
<text top="399" left="346" width="87" height="17" font="13">and considered </text>
<text top="416" left="346" width="92" height="17" font="13">standard of care </text>
<text top="55" left="670" width="51" height="17" font="13">regularly </text>
<text top="72" left="670" width="59" height="17" font="13">scheduled </text>
<text top="89" left="670" width="46" height="17" font="13">in-office </text>
<text top="106" left="670" width="59" height="17" font="13">follow-ups </text>
<text top="124" left="670" width="67" height="17" font="13">with remote </text>
<text top="141" left="670" width="58" height="17" font="13">followups; </text>
<text top="158" left="670" width="72" height="17" font="13">and 2) being </text>
<text top="175" left="670" width="40" height="17" font="13">able to </text>
<text top="192" left="670" width="53" height="17" font="13">attend all </text>
<text top="210" left="670" width="49" height="17" font="13">required </text>
<text top="227" left="670" width="53" height="17" font="13">follow-up </text>
<text top="244" left="670" width="82" height="17" font="13">visits.               </text>
<text top="261" left="670" width="55" height="17" font="13">No HF as </text>
<text top="278" left="670" width="41" height="17" font="13">well as </text>
<text top="296" left="670" width="59" height="17" font="13">NYHA 1-4 </text>
<text top="313" left="670" width="30" height="17" font="13">were </text>
<text top="330" left="670" width="62" height="17" font="13">included in </text>
<text top="347" left="670" width="33" height="17" font="13">study </text>
<text top="55" left="892" width="135" height="17" font="13">having a life expectancy </text>
<text top="72" left="892" width="45" height="17" font="13">&lt;15 mo </text>
<text top="55" left="1250" width="143" height="17" font="13">utilization data revealed a </text>
<text top="72" left="1250" width="178" height="17" font="13">decrease in mean length of stay </text>
<text top="89" left="1250" width="196" height="17" font="13">per CV hospitalization visit from 4.0 </text>
<text top="106" left="1250" width="193" height="17" font="13">d in the in-office arm to 3.3 d in the </text>
<text top="124" left="1250" width="66" height="17" font="13">remote arm </text>
<text top="141" left="1250" width="60" height="17" font="13">(p=0.002). </text>
<text top="434" left="61" width="88" height="17" font="15"><b>SMART AV       </b></text>
<text top="451" left="61" width="65" height="17" font="13">Circulation. </text>
<text top="469" left="61" width="75" height="17" font="13">2010;122:266</text>
<text top="486" left="61" width="42" height="17" font="13">0-2668 </text>
<text top="503" left="61" width="55" height="17" font="14">21098426</text>
<text top="503" left="116" width="3" height="17" font="13"> </text>
<text top="520" left="61" width="32" height="17" font="13">(253)<b> </b></text>
<text top="434" left="157" width="100" height="17" font="13">Aim of trial was to </text>
<text top="451" left="157" width="62" height="17" font="13">compare 3 </text>
<text top="469" left="157" width="60" height="17" font="13">alternative </text>
<text top="486" left="157" width="101" height="17" font="13">techniques and to </text>
<text top="503" left="157" width="62" height="17" font="13">assess the </text>
<text top="520" left="157" width="90" height="17" font="13">hypotheses that </text>
<text top="537" left="157" width="81" height="17" font="13">systematic AV </text>
<text top="555" left="157" width="102" height="17" font="13">delay optimization </text>
<text top="572" left="157" width="25" height="17" font="13">with </text>
<text top="589" left="157" width="101" height="17" font="13">echocardiography </text>
<text top="606" left="157" width="79" height="17" font="13">and/or the SD </text>
<text top="624" left="157" width="66" height="17" font="13">algorithm is </text>
<text top="641" left="157" width="101" height="17" font="13">superior to a fixed </text>
<text top="658" left="157" width="99" height="17" font="13">nominal AV delay </text>
<text top="675" left="157" width="95" height="17" font="13">as demonstrated </text>
<text top="692" left="157" width="89" height="17" font="13">by improved LV </text>
<text top="710" left="157" width="93" height="17" font="13">geometry after 6 </text>
<text top="727" left="157" width="68" height="17" font="13">mo and that </text>
<text top="744" left="157" width="76" height="17" font="13">programming </text>
<text top="761" left="157" width="103" height="17" font="13">according to SD is </text>
<text top="778" left="157" width="108" height="17" font="13">noninferior to using </text>
<text top="434" left="278" width="51" height="17" font="13">randomiz</text>
<text top="451" left="278" width="21" height="17" font="13">ed, </text>
<text top="469" left="278" width="49" height="17" font="13">multicent</text>
<text top="486" left="278" width="18" height="17" font="13">er, </text>
<text top="503" left="278" width="41" height="17" font="13">double-</text>
<text top="520" left="278" width="46" height="17" font="13">blinded, </text>
<text top="537" left="278" width="49" height="17" font="13">3-armed </text>
<text top="555" left="278" width="23" height="17" font="13">trial </text>
<text top="434" left="346" width="86" height="17" font="13">1014; 332 SD;  </text>
<text top="451" left="346" width="83" height="17" font="13">323-Echo; 325 </text>
<text top="469" left="346" width="100" height="17" font="13">Fixed nominal AV </text>
<text top="486" left="346" width="33" height="17" font="13">delay </text>
<text top="434" left="460" width="238" height="17" font="13">6 Diuretics, </text>
<text top="434" left="612" width="114" height="17" font="13">beta </text>
<text top="451" left="557" width="77" height="17" font="13">blockers, and </text>
<text top="469" left="557" width="67" height="17" font="13">angiotensin-</text>
<text top="486" left="557" width="60" height="17" font="13">converting </text>
<text top="503" left="557" width="99" height="17" font="13">enzyme inhibitors </text>
<text top="520" left="557" width="81" height="17" font="13">or angiotensin </text>
<text top="537" left="557" width="49" height="17" font="13">receptor </text>
<text top="555" left="557" width="53" height="17" font="13">blockers, </text>
<text top="434" left="670" width="35" height="17" font="13">3 or 4 </text>
<text top="434" left="757" width="42" height="17" font="13">&lt;35%,  </text>
<text top="434" left="838" width="31" height="17" font="13">&gt;120 </text>
<text top="434" left="892" width="131" height="17" font="13">• Complete heart block, </text>
<text top="451" left="892" width="118" height="17" font="13">or who otherwise are </text>
<text top="469" left="892" width="138" height="17" font="13">unable to tolerate pacing </text>
<text top="486" left="892" width="142" height="17" font="13">at VVI-40-RV for up to 14 </text>
<text top="503" left="892" width="10" height="17" font="13">d </text>
<text top="520" left="892" width="118" height="17" font="13">• Previously received </text>
<text top="537" left="892" width="29" height="17" font="13">CRT </text>
<text top="555" left="892" width="82" height="17" font="13">• Upgrade of a </text>
<text top="572" left="892" width="134" height="17" font="13">pacemaker or ICD  and  </text>
<text top="589" left="892" width="138" height="17" font="13">unable to tolerate pacing </text>
<text top="606" left="892" width="142" height="17" font="13">at VVI-40-RV for up to 14 </text>
<text top="624" left="892" width="10" height="17" font="13">d </text>
<text top="641" left="892" width="136" height="17" font="13">• Heart transplant during </text>
<text top="658" left="892" width="128" height="17" font="13">the course of the study </text>
<text top="675" left="892" width="122" height="17" font="13">• Cardiac surgeries or </text>
<text top="692" left="892" width="112" height="17" font="13">procedures planned </text>
<text top="710" left="892" width="91" height="17" font="13">during the study </text>
<text top="727" left="892" width="120" height="17" font="13">• Have or are likely to </text>
<text top="744" left="892" width="135" height="17" font="13">receive a tricuspid valve </text>
<text top="761" left="892" width="129" height="17" font="13">prosthesis (mechanical </text>
<text top="778" left="892" width="64" height="17" font="13">right valve) </text>
<text top="434" left="1048" width="27" height="17" font="13"> N/A </text>
<text top="434" left="1143" width="69" height="17" font="13">The primary </text>
<text top="451" left="1143" width="76" height="17" font="13">endpoint was </text>
<text top="469" left="1143" width="87" height="17" font="13">LV end-systolic </text>
<text top="486" left="1143" width="46" height="17" font="13">volume. </text>
<text top="503" left="1143" width="62" height="17" font="13">Secondary </text>
<text top="520" left="1143" width="57" height="17" font="13">endpoints </text>
<text top="537" left="1143" width="87" height="17" font="13">included NYHA </text>
<text top="555" left="1143" width="61" height="17" font="13">class, QoL </text>
<text top="572" left="1143" width="71" height="17" font="13">score, 6-min </text>
<text top="589" left="1143" width="81" height="17" font="13">walk distance, </text>
<text top="606" left="1143" width="91" height="17" font="13">LV end-diastolic </text>
<text top="624" left="1143" width="70" height="17" font="13">volume, and </text>
<text top="641" left="1143" width="38" height="17" font="13">LVEF. </text>
<text top="434" left="1250" width="195" height="17" font="13">The medians (quartiles 1 and 3) for </text>
<text top="451" left="1250" width="187" height="17" font="13">change in LV end-systolic volume </text>
<text top="469" left="1250" width="154" height="17" font="13">at 6 mo for the SmartDelay, </text>
<text top="486" left="1250" width="189" height="17" font="13">echocardiography, and fixed arms </text>
<text top="503" left="1250" width="196" height="17" font="13">were  21 mL (45 and 6 mL),  19 mL </text>
<text top="520" left="1250" width="193" height="17" font="13">(45 and 6 mL), and  15 mL (41 and </text>
<text top="537" left="1250" width="187" height="17" font="13">6 mL), respectively. No difference </text>
<text top="555" left="1250" width="180" height="17" font="13">in improvement in left ventricular </text>
<text top="572" left="1250" width="179" height="17" font="13">end-systolic volume at 6 months </text>
<text top="589" left="1250" width="150" height="17" font="13">was observed between the </text>
<text top="606" left="1250" width="193" height="17" font="13">SmartDelay and echocardiography </text>
<text top="624" left="1250" width="183" height="17" font="13">arms (p=0.52) or the SmartDelay </text>
<text top="641" left="1250" width="53" height="17" font="13">and fixed </text>
<text top="658" left="1250" width="170" height="17" font="13">arms (p=0.66). Secondary end </text>
<text top="675" left="1250" width="193" height="17" font="13">points, including structural (LV end-</text>
<text top="692" left="1250" width="177" height="17" font="13">diastolic volume and LVEF) and </text>
<text top="710" left="1250" width="180" height="17" font="13">functional (6-min walk, QoL, and </text>
<text top="727" left="1250" width="115" height="17" font="13">NYHA classification) </text>
<text top="744" left="1250" width="178" height="17" font="13">measures, were not significantly </text>
<text top="761" left="1250" width="132" height="17" font="13">different between arms. </text>
</page>
<page number="114" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">114</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="157" width="102" height="17" font="13">echocardiography-</text>
<text top="72" left="157" width="85" height="17" font="13">determined AV </text>
<text top="89" left="157" width="33" height="17" font="13">delay </text>
<text top="106" left="157" width="72" height="17" font="13">optimization. </text>
<text top="55" left="892" width="98" height="17" font="13">• Neuromuscular, </text>
<text top="72" left="892" width="110" height="17" font="13">orthopedic, or other </text>
<text top="89" left="892" width="140" height="17" font="13">noncardiac condition that </text>
<text top="106" left="892" width="95" height="17" font="13">prevents normal, </text>
<text top="124" left="892" width="120" height="17" font="13">unsupported walking  </text>
<text top="141" left="892" width="139" height="17" font="13">• Pregnant or planning to </text>
<text top="158" left="892" width="103" height="17" font="13">become pregnant  </text>
<text top="175" left="892" width="114" height="17" font="13">• Enrolled in another </text>
<text top="192" left="892" width="129" height="17" font="13">investigational study or </text>
<text top="210" left="892" width="103" height="17" font="13">registry that would </text>
<text top="227" left="892" width="103" height="17" font="13">directly impact the </text>
<text top="244" left="892" width="75" height="17" font="13">current study </text>
<text top="291" left="54" width="258" height="15" font="6">*diuretics, ACEIs, beta-blockers, and spironolactone </text>
<text top="306" left="54" width="303" height="15" font="6">ACEI indicates angiotensin-converting-enzyme inhibitor; ARB,</text>
<text top="307" left="357" width="4" height="16" font="7"> </text>
<text top="306" left="361" width="1095" height="15" font="6">angiotensin receptor blocker; AV, atrioventricular;CARE-HF, Cardiac resynchronization in heart failure; COMPANION, comparisons of medical therapy, pacing, and defibrillation in heart failure; CONNECT, Clinical Evaluation </text>
<text top="322" left="54" width="1381" height="15" font="6">of Remote Notification to Reduce Time to Clinical Decision; CRT, cardiac resynchronization therapy; EF, Ejection Fraction; HCU; Health Care Utilization; HF, heart failure; HM, home monitoring; ICD, implantable cardioverter defibrillator; LVES left ventricular end-systolic; LVESV, left </text>
<text top="337" left="54" width="1403" height="15" font="6">ventricular end-systolic volume; MADIT-CRT, multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy; N/A, not applicable; NYHA, New York Heart Association; PROSPECT, Predictors of Response to CRT; Pt, patient; REVERSE, resynchronization reverses </text>
<text top="353" left="54" width="1402" height="16" font="6">remodeling in systolic left ventricular dysfunction, RAFT, resynchronation-defibrillation for ambulatoryheart failure trial; ROC curve, receiver-operating characteristics curve; SMART-AV, SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac </text>
<text top="368" left="54" width="596" height="15" font="6">Resynchronization Therapy; SD, SmartDelay™, TRUST, The Lumos-T Safely Reduces Routine Office Device Follow-Up; </text>
<text top="384" left="54" width="3" height="15" font="6"> </text>
<text top="399" left="54" width="3" height="15" font="6"> </text>
<text top="424" left="54" width="515" height="21" font="8"><b>Data Supplement 30. Therapies, Important Considerations (Section 7.4.2) </b></text>
<text top="446" left="60" width="125" height="17" font="15"><b>Study Name, Author, </b></text>
<text top="463" left="106" width="33" height="17" font="15"><b>Yearl </b></text>
<text top="463" left="215" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="463" left="325" width="70" height="17" font="15"><b>Study Type </b></text>
<text top="463" left="414" width="66" height="17" font="15"><b>Study Size </b></text>
<text top="463" left="587" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="463" left="946" width="48" height="17" font="15"><b>Results </b></text>
<text top="446" left="1156" width="67" height="17" font="15"><b>P Values &amp; </b></text>
<text top="463" left="1166" width="48" height="17" font="15"><b>95% CI: </b></text>
<text top="463" left="1249" width="76" height="17" font="15"><b>OR: HR: RR: </b></text>
<text top="446" left="1375" width="38" height="17" font="15"><b>Study </b></text>
<text top="463" left="1359" width="69" height="17" font="15"><b>Limitations </b></text>
<text top="483" left="520" width="104" height="17" font="21"><i><b>Inclusion Criteria </b></i></text>
<text top="483" left="673" width="108" height="17" font="21"><i><b>Exclusion Criteria </b></i></text>
<text top="501" left="54" width="299" height="17" font="15"><b>Hemodynamic Assessment of Hospitalized Patient </b></text>
<text top="501" left="494" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="501" left="663" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="501" left="805" width="7" height="17" font="15"><b>  </b></text>
<text top="501" left="1149" width="7" height="17" font="15"><b>  </b></text>
<text top="501" left="1243" width="7" height="17" font="15"><b>  </b></text>
<text top="501" left="1345" width="7" height="17" font="15"><b>  </b></text>
<text top="522" left="54" width="121" height="17" font="13">Binanay C, Califf RM, </text>
<text top="539" left="54" width="106" height="17" font="13">Hasselblad V et al. </text>
<text top="557" left="54" width="107" height="17" font="13">Evaluation study of </text>
<text top="574" left="54" width="106" height="17" font="13">congestive HF and </text>
<text top="591" left="54" width="96" height="17" font="13">pulmonary artery </text>
<text top="608" left="54" width="83" height="17" font="13">catheterization </text>
<text top="625" left="54" width="99" height="17" font="13">effectiveness: the </text>
<text top="643" left="54" width="116" height="17" font="13">ESCAPE trial. JAMA </text>
<text top="660" left="54" width="78" height="17" font="13">2005 October </text>
<text top="677" left="54" width="108" height="17" font="13">5;294(13):1625-33. </text>
<text top="694" left="54" width="58" height="17" font="14">16204662 </text>
<text top="694" left="112" width="32" height="17" font="13">(254) </text>
<text top="522" left="204" width="76" height="17" font="13">To determine </text>
<text top="539" left="204" width="99" height="17" font="13">whether PAC use </text>
<text top="557" left="204" width="63" height="17" font="13">is safe and </text>
<text top="574" left="204" width="94" height="17" font="13">improves clinical </text>
<text top="591" left="204" width="89" height="17" font="13">outcomes in pts </text>
<text top="608" left="204" width="94" height="17" font="13">hospitalized with </text>
<text top="625" left="204" width="40" height="17" font="13">severe </text>
<text top="643" left="204" width="96" height="17" font="13">symptomatic and </text>
<text top="660" left="204" width="72" height="17" font="13">recurrent HF </text>
<text top="522" left="319" width="29" height="17" font="13">RCT </text>
<text top="522" left="413" width="24" height="17" font="13">433 </text>
<text top="522" left="494" width="87" height="17" font="13">Pts with severe </text>
<text top="539" left="494" width="135" height="17" font="13">symptomatic HF despite </text>
<text top="557" left="494" width="154" height="17" font="13">recommended therapies. 1) </text>
<text top="574" left="494" width="154" height="17" font="13">hospitalization for HF within </text>
<text top="591" left="494" width="155" height="17" font="13">the past y; (2) urgent visit to </text>
<text top="608" left="494" width="133" height="17" font="13">the ED; or (3) treatment </text>
<text top="625" left="494" width="136" height="17" font="13">during the preceding mo </text>
<text top="643" left="494" width="155" height="17" font="13">with &gt;160 mg of furosemide </text>
<text top="660" left="494" width="148" height="17" font="13">daily (or equivalent). LVEF </text>
<text top="677" left="494" width="140" height="17" font="13">≤30%, SBP ≤125mmHg, </text>
<text top="694" left="494" width="137" height="17" font="13">and at least 1 sign and 1 </text>
<text top="712" left="494" width="137" height="17" font="13">symptom of congestion.  </text>
<text top="522" left="663" width="110" height="17" font="13">Exclusion criteria to </text>
<text top="539" left="663" width="122" height="17" font="13">minimize confounding </text>
<text top="557" left="663" width="129" height="17" font="13">comorbidities or urgent </text>
<text top="574" left="663" width="106" height="17" font="13">crossover included </text>
<text top="591" left="663" width="107" height="17" font="13">Crlevel &gt;3.5 mg/dL </text>
<text top="608" left="663" width="104" height="17" font="13">(309.4 μmol/ L), or </text>
<text top="625" left="663" width="65" height="17" font="13">prior use of </text>
<text top="643" left="663" width="82" height="17" font="13">dobutamine or </text>
<text top="660" left="663" width="75" height="17" font="13">dopamine &gt;3 </text>
<text top="677" left="663" width="126" height="17" font="13">μg/kg/min, or any prior </text>
<text top="694" left="663" width="128" height="17" font="13">use of milrinone during </text>
<text top="712" left="663" width="62" height="17" font="13">the current </text>
<text top="729" left="663" width="88" height="17" font="13">hospitalization.  </text>
<text top="522" left="805" width="309" height="17" font="23">PAC did not significantly affect the primary endpoint of d </text>
<text top="539" left="805" width="319" height="17" font="23">alive and out of the hospital during the first 6 mo (133 d vs </text>
<text top="557" left="805" width="312" height="17" font="23">135 d; HR: 1.00; 95% CI: 0.82-1.21; p=.99), mortality (43 </text>
<text top="574" left="805" width="301" height="17" font="23">pts [10%] vs 38 pts [9%]; OR: 1.26; 95% CI: 0.78-2.03; </text>
<text top="591" left="805" width="303" height="17" font="23">p=.35), or the number of d hospitalized (8.7 vs 8.3; HR: </text>
<text top="608" left="805" width="306" height="17" font="23">1.04; 95% CI: 0.86-1.27; p=.67). HR: 1.0 d alive outside </text>
<text top="625" left="805" width="292" height="17" font="23">hospital, HR: 1.26 for mortality (p=0.35), h 1.04 For d </text>
<text top="643" left="805" width="314" height="17" font="23">hospitalized.19 % mortality at 6 mo (dead at 180 d= 43 in </text>
<text top="660" left="805" width="327" height="17" font="23">PAC, 38 in CAG). Annualized mortality 36%. Inhospital AEs </text>
<text top="677" left="805" width="291" height="17" font="23">were more common among pts in the PAC group (47 </text>
<text top="694" left="805" width="292" height="17" font="23">[21.9%] vs 25 [11.5%]; p=.04). There were no deaths </text>
<text top="712" left="805" width="312" height="17" font="23">related to PAC use, and no difference for in-hospital plus </text>
<text top="729" left="805" width="315" height="17" font="23">30-d mortality (10 [4.7%] vs 11 [5.0%]; OR: 0.97; 95% CI, </text>
<text top="746" left="805" width="93" height="17" font="23">0.38-2.22; p=.97 </text>
<text top="522" left="1149" width="41" height="17" font="13">p=0.35 </text>
<text top="522" left="1243" width="27" height="17" font="13">1.26 </text>
<text top="522" left="1345" width="96" height="17" font="13">Use of inotropes, </text>
<text top="539" left="1345" width="55" height="17" font="13">variability </text>
<text top="557" left="1345" width="97" height="17" font="13">between centers, </text>
<text top="574" left="1345" width="99" height="17" font="13">generalizabiity of  </text>
<text top="591" left="1345" width="51" height="17" font="13">stringent </text>
<text top="608" left="1345" width="80" height="17" font="13">hemodynamic </text>
<text top="625" left="1345" width="41" height="17" font="13">targets </text>
<text top="643" left="1345" width="81" height="17" font="13">,individualized </text>
<text top="660" left="1345" width="62" height="17" font="13">targets not </text>
<text top="677" left="1345" width="43" height="17" font="13">applied </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">115</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="128" height="17" font="13">Drazner MH, Hellkamp </text>
<text top="72" left="54" width="105" height="17" font="13">AS, Leier CV et al. </text>
<text top="89" left="54" width="96" height="17" font="13">Value of clinician </text>
<text top="106" left="54" width="83" height="17" font="13">assessment of </text>
<text top="124" left="54" width="99" height="17" font="13">hemodynamics in </text>
<text top="141" left="54" width="101" height="17" font="13">advanced HF: the </text>
<text top="158" left="54" width="105" height="17" font="13">ESCAPE trial. Circ </text>
<text top="175" left="54" width="88" height="17" font="13">Heart Fail 2008 </text>
<text top="192" left="54" width="127" height="17" font="13">September;1(3):170-7. </text>
<text top="210" left="54" width="58" height="17" font="14">19675681 </text>
<text top="210" left="112" width="25" height="17" font="13">(31) </text>
<text top="55" left="204" width="76" height="17" font="13">To determine </text>
<text top="72" left="204" width="51" height="17" font="13">whether  </text>
<text top="89" left="204" width="57" height="17" font="13">estimated </text>
<text top="106" left="204" width="86" height="17" font="13">hemodynamics </text>
<text top="124" left="204" width="92" height="17" font="13">from history and </text>
<text top="141" left="204" width="48" height="17" font="13">physical </text>
<text top="158" left="204" width="73" height="17" font="13">examination  </text>
<text top="175" left="204" width="85" height="17" font="13">reflect invasive </text>
<text top="192" left="204" width="85" height="17" font="13">measurements </text>
<text top="210" left="204" width="64" height="17" font="13">and predict </text>
<text top="227" left="204" width="70" height="17" font="13">outcomes in </text>
<text top="244" left="204" width="80" height="17" font="13">advanced HF  </text>
<text top="55" left="319" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="319" width="48" height="17" font="13">analysis </text>
<text top="55" left="413" width="199" height="17" font="13">194 Compared </text>
<text top="55" left="555" width="86" height="17" font="13">H&amp;P </text>
<text top="55" left="584" width="113" height="17" font="13">estimates </text>
<text top="72" left="494" width="126" height="17" font="13">of filling pressures and </text>
<text top="89" left="494" width="149" height="17" font="13">cardiac index with invasive </text>
<text top="106" left="494" width="154" height="17" font="13">measurements in 194 pts in </text>
<text top="124" left="494" width="129" height="17" font="13">the ESCAPE trial. H&amp;P </text>
<text top="141" left="494" width="144" height="17" font="13">estimates were compared </text>
<text top="158" left="494" width="150" height="17" font="13">with 6-mo outcomes in 388 </text>
<text top="175" left="494" width="140" height="17" font="13">pts enrolled in ESCAPE.  </text>
<text top="55" left="663" width="107" height="17" font="13">Crlevel &gt;3.5 mg/dL </text>
<text top="72" left="663" width="129" height="17" font="13">(309.4 μmol/L), or prior </text>
<text top="89" left="663" width="119" height="17" font="13">use of dobutamine or </text>
<text top="106" left="663" width="75" height="17" font="13">dopamine &gt;3 </text>
<text top="124" left="663" width="126" height="17" font="13">μg/kg/min, or any prior </text>
<text top="141" left="663" width="128" height="17" font="13">use of milrinone during </text>
<text top="158" left="663" width="62" height="17" font="13">the current </text>
<text top="175" left="663" width="88" height="17" font="13">hospitalization.  </text>
<text top="55" left="805" width="328" height="17" font="13">RAP was &lt;8 mm Hg in 82% of pts with RAP estimated from </text>
<text top="72" left="805" width="324" height="17" font="13">jugular veins as &lt;8 mm Hg, and was &gt;12 mm Hg in 70% of </text>
<text top="89" left="805" width="307" height="17" font="13">pts when estimated as &gt;12 mm Hg. From the H&amp;P, only </text>
<text top="106" left="805" width="283" height="17" font="13">estimated RAP ≥12 mm Hg (OR: 4.6; p&lt;0.001) and </text>
<text top="124" left="805" width="309" height="17" font="13">orthopnea ≥2 pillows (OR: 3.6; p&lt;0.05) were associated </text>
<text top="141" left="805" width="312" height="17" font="13">with PCWP ≥30 mm Hg. Estimated cardiac index did not </text>
<text top="158" left="805" width="321" height="17" font="13">reliably reflect measured cardiac index (p=0.09), but &#34;cold&#34; </text>
<text top="175" left="805" width="308" height="17" font="13">versus &#34;warm&#34; profile was associated with lower median </text>
<text top="192" left="805" width="326" height="17" font="13">measured cardiac index (1.75 vs. 2.0 L/min/m(2); p=0.004). </text>
<text top="210" left="805" width="325" height="17" font="13">In Cox regression analysis, discharge &#34;cold&#34; or &#34;wet&#34; profile </text>
<text top="227" left="805" width="236" height="17" font="13">conveyed a 50% increased risk of death or </text>
<text top="244" left="805" width="281" height="17" font="13">rehospitalization.  In advanced HF, the presence of </text>
<text top="261" left="805" width="325" height="17" font="13">orthopnea and elevated jugular venous pressure are useful </text>
<text top="278" left="805" width="297" height="17" font="13">to detect elevated PCWP, and a global assessment of </text>
<text top="296" left="805" width="297" height="17" font="13">inadequate perfusion (&#34;cold&#34; profile) is useful to detect </text>
<text top="313" left="805" width="309" height="17" font="13">reduced cardiac index. Hemodynamic profiles estimated </text>
<text top="330" left="805" width="303" height="17" font="13">from the discharge H&amp;P identify pts at increased risk of </text>
<text top="347" left="805" width="73" height="17" font="13">early events. </text>
<text top="55" left="1149" width="205" height="17" font="13">p&lt;0.05 Estimated </text>
<text top="55" left="1301" width="82" height="17" font="13">RAP </text>
<text top="72" left="1243" width="49" height="17" font="13">OR: 4.6, </text>
<text top="89" left="1243" width="84" height="17" font="13">orthopnea OR: </text>
<text top="106" left="1243" width="21" height="17" font="13">3.6 </text>
<text top="55" left="1345" width="82" height="17" font="13">posthoc, small </text>
<text top="72" left="1345" width="43" height="17" font="13">sample </text>
<text top="365" left="54" width="137" height="17" font="13">Shah MR, Hasselblad V, </text>
<text top="382" left="54" width="114" height="17" font="13">Stevenson LW et al. </text>
<text top="400" left="54" width="135" height="17" font="13">Impact of the pulmonary </text>
<text top="417" left="54" width="96" height="17" font="13">artery catheter in </text>
<text top="434" left="54" width="113" height="17" font="13">critically ill pts: meta-</text>
<text top="451" left="54" width="129" height="17" font="13">analysis of randomized </text>
<text top="469" left="54" width="109" height="17" font="13">clinical trials. <i>JAMA</i> </text>
<text top="486" left="54" width="78" height="17" font="13">2005 October </text>
<text top="503" left="54" width="105" height="17" font="13">5;294(13):1664-70 </text>
<text top="520" left="54" width="58" height="17" font="14">16204666 </text>
<text top="520" left="112" width="32" height="17" font="13">(255) </text>
<text top="365" left="204" width="88" height="17" font="13">To estimate the </text>
<text top="382" left="204" width="74" height="17" font="13">impact of the </text>
<text top="400" left="204" width="81" height="17" font="13">PAC device in </text>
<text top="417" left="204" width="85" height="17" font="13">critically ill pts.  </text>
<text top="365" left="319" width="125" height="17" font="13">Meta-analysis  5051 </text>
<text top="365" left="494" width="152" height="17" font="13">MEDLINE (1985-2005), the </text>
<text top="382" left="494" width="150" height="17" font="13">Cochrane Controlled Trials </text>
<text top="400" left="494" width="143" height="17" font="13">Registry (1988-2005), the </text>
<text top="417" left="494" width="154" height="17" font="13">National Institutes of Health </text>
<text top="434" left="494" width="154" height="17" font="13">ClinicalTrials.gov database, </text>
<text top="451" left="494" width="150" height="17" font="13">and the US Food and Drug </text>
<text top="469" left="494" width="150" height="17" font="13">Administration Web site for </text>
<text top="486" left="494" width="133" height="17" font="13">RCTs in which pts were </text>
<text top="503" left="494" width="149" height="17" font="13">randomly assigned to PAC </text>
<text top="520" left="494" width="148" height="17" font="13">or no PAC were searched. </text>
<text top="537" left="494" width="146" height="17" font="13">Results from the ESCAPE </text>
<text top="555" left="494" width="142" height="17" font="13">trial of pts with severe HF </text>
<text top="572" left="494" width="151" height="17" font="13">were also included. Search </text>
<text top="589" left="494" width="144" height="17" font="13">terms included pulmonary </text>
<text top="606" left="494" width="145" height="17" font="13">artery catheter, right heart </text>
<text top="624" left="494" width="127" height="17" font="13">catheter, catheter, and </text>
<text top="641" left="494" width="74" height="17" font="13">Swan-Ganz.  </text>
<text top="365" left="663" width="27" height="17" font="13"> N/A </text>
<text top="365" left="805" width="302" height="17" font="23">HR for mortality 1.04. In critically ill pts, use of the PAC </text>
<text top="382" left="805" width="292" height="17" font="23">neither increased overall mortality or d in hospital nor </text>
<text top="400" left="805" width="303" height="17" font="23">conferred benefit. Despite almost 20 y of RCTs, a clear </text>
<text top="417" left="805" width="321" height="17" font="23">strategy leading to improved survival with the PAC has not </text>
<text top="434" left="805" width="279" height="17" font="23">been devised. The neutrality of the PAC for clinical </text>
<text top="451" left="805" width="278" height="17" font="23">outcomes may result from the absence of effective </text>
<text top="469" left="805" width="325" height="17" font="23">evidence-based treatments to use in combination with PAC </text>
<text top="486" left="805" width="330" height="17" font="23">information across the spectrum of critically ill pts.Use of the </text>
<text top="503" left="805" width="310" height="17" font="23">PAC was associated with a higher use of inotropes (OR: </text>
<text top="520" left="805" width="323" height="17" font="23">1.58; 95% CI: 1.19-2.12; p= .002) and IV vasodilators (OR: </text>
<text top="537" left="805" width="186" height="17" font="23">2.35; 95% CI: 1.75-3.15; p&lt;.001). </text>
<text top="365" left="1149" width="172" height="17" font="13">p=0.53 The </text>
<text top="365" left="1268" width="110" height="17" font="13">combined </text>
<text top="382" left="1243" width="40" height="17" font="13">OR for </text>
<text top="400" left="1243" width="75" height="17" font="13">mortality was </text>
<text top="417" left="1243" width="79" height="17" font="13">1.04 (95% CI: </text>
<text top="434" left="1243" width="59" height="17" font="13">0.90-1.20; </text>
<text top="451" left="1243" width="67" height="17" font="13">p=.59). The </text>
<text top="469" left="1243" width="70" height="17" font="13">difference in </text>
<text top="486" left="1243" width="55" height="17" font="13">the mean </text>
<text top="503" left="1243" width="69" height="17" font="13">number of d </text>
<text top="520" left="1243" width="86" height="17" font="13">hospitalized for </text>
<text top="537" left="1243" width="85" height="17" font="13">PAC minus the </text>
<text top="555" left="1243" width="69" height="17" font="13">mean for no </text>
<text top="572" left="1243" width="81" height="17" font="13">PAC was 0.11 </text>
<text top="589" left="1243" width="83" height="17" font="13">(95% CI: -0.51-</text>
<text top="606" left="1243" width="80" height="17" font="13">0.74; p=.73).   </text>
<text top="365" left="1345" width="85" height="17" font="13">heterogenity of </text>
<text top="382" left="1345" width="42" height="17" font="13">studies </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">116</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="118" height="17" font="13">Allen LA, Rogers JG, </text>
<text top="72" left="54" width="129" height="17" font="13">Warnica JW et al. High </text>
<text top="89" left="54" width="92" height="17" font="13">mortality without </text>
<text top="106" left="54" width="135" height="17" font="13">ESCAPE: the registry of </text>
<text top="124" left="54" width="92" height="17" font="13">HF pts receiving </text>
<text top="141" left="54" width="96" height="17" font="13">pulmonary artery </text>
<text top="158" left="54" width="96" height="17" font="13">catheters without </text>
<text top="175" left="54" width="124" height="17" font="13">randomization. J Card </text>
<text top="192" left="54" width="54" height="17" font="13">Fail 2008 </text>
<text top="210" left="54" width="114" height="17" font="13">October;14(8):661-9 </text>
<text top="227" left="54" width="58" height="17" font="14">18926438 </text>
<text top="227" left="112" width="32" height="17" font="13">(256) </text>
<text top="55" left="204" width="88" height="17" font="13">To characterize </text>
<text top="72" left="204" width="80" height="17" font="13">pts enrolled in </text>
<text top="89" left="204" width="53" height="17" font="13">ESCAPE </text>
<text top="106" left="204" width="49" height="17" font="13">Registry </text>
<text top="55" left="319" width="48" height="17" font="13">Registry </text>
<text top="55" left="413" width="24" height="17" font="13">439 </text>
<text top="55" left="494" width="153" height="17" font="13">ESCAPE sites enrolled 439 </text>
<text top="72" left="494" width="144" height="17" font="13">pts receiving PAC without </text>
<text top="89" left="494" width="104" height="17" font="13">randomization in a </text>
<text top="106" left="494" width="113" height="17" font="13">prospective registry. </text>
<text top="124" left="494" width="136" height="17" font="13">Baseline characteristics, </text>
<text top="141" left="494" width="129" height="17" font="13">pertinent trial exclusion </text>
<text top="158" left="494" width="137" height="17" font="13">criteria, reasons for PAC </text>
<text top="175" left="494" width="140" height="17" font="13">use, hemodynamics, and </text>
<text top="192" left="494" width="108" height="17" font="13">complications were </text>
<text top="210" left="494" width="128" height="17" font="13">collected. Survival was </text>
<text top="227" left="494" width="113" height="17" font="13">determined from the </text>
<text top="244" left="494" width="142" height="17" font="13">National Death Index and </text>
<text top="261" left="494" width="148" height="17" font="13">the Alberta Registry. Much </text>
<text top="278" left="494" width="136" height="17" font="13">sicker pts than ESCAPE </text>
<text top="55" left="663" width="27" height="17" font="13"> N/A </text>
<text top="55" left="805" width="318" height="17" font="13">Registry pts had longer hospitalization (13 vs 6 d, p&lt;.001) </text>
<text top="72" left="805" width="318" height="17" font="13">and higher 6-mo mortality (34% vs 20%, p&lt;.001) than trial </text>
<text top="89" left="805" width="303" height="17" font="13">pts. On average, registry pts had lower blood pressure, </text>
<text top="106" left="805" width="288" height="17" font="13">worse renal function, less neurohormonal antagonist </text>
<text top="124" left="805" width="322" height="17" font="13">therapy, and higher use of IV inotropes compared with trial </text>
<text top="141" left="805" width="316" height="17" font="13">pts. Although clinical assessment anticipated less volume </text>
<text top="158" left="805" width="303" height="17" font="13">overload and greater hypoperfusion among the registry </text>
<text top="175" left="805" width="288" height="17" font="13">population, measured filling pressures were similarly </text>
<text top="192" left="805" width="306" height="17" font="13">elevated in the registry and trial pts, whereas measured </text>
<text top="210" left="805" width="297" height="17" font="13">perfusion was slightly higher among registry pts. 6 mo </text>
<text top="227" left="805" width="78" height="17" font="13">mortality 34% </text>
<text top="55" left="1149" width="41" height="17" font="13">p&lt;0.05 </text>
<text top="55" left="1243" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1345" width="27" height="17" font="13"> N/A </text>
<text top="296" left="54" width="224" height="17" font="15"><b>Positive Pressure Ventilation Studies  </b></text>
<text top="317" left="54" width="118" height="17" font="13">Gray A, Goodacre S, </text>
<text top="335" left="54" width="129" height="17" font="13">Newby DE, Masson M, </text>
<text top="352" left="54" width="123" height="17" font="13">Sampson F, Nicholl J. </text>
<text top="369" left="54" width="129" height="17" font="13">Noninvasive ventilation </text>
<text top="386" left="54" width="113" height="17" font="13">in acute cardiogenic </text>
<text top="404" left="54" width="121" height="17" font="13">pulmonary edema. <i> N </i></text>
<text top="421" left="54" width="121" height="17" font="22"><i>Engl J Med</i> 2008 July </text>
<text top="438" left="54" width="101" height="17" font="13">10;359(2):142-51. </text>
<text top="455" left="54" width="58" height="17" font="14">18614781 </text>
<text top="455" left="112" width="32" height="17" font="13">(257) </text>
<text top="317" left="204" width="70" height="17" font="13">Noninvasive </text>
<text top="335" left="204" width="96" height="17" font="13">ventilation CPAP </text>
<text top="352" left="204" width="55" height="17" font="13">or NIPPV </text>
<text top="369" left="204" width="92" height="17" font="13">appears to be of </text>
<text top="386" left="204" width="74" height="17" font="13">benefit in the </text>
<text top="404" left="204" width="60" height="17" font="13">immediate </text>
<text top="421" left="204" width="89" height="17" font="13">treatment of pts </text>
<text top="438" left="204" width="59" height="17" font="13">with acute </text>
<text top="455" left="204" width="66" height="17" font="13">cardiogenic </text>
<text top="472" left="204" width="61" height="17" font="13">pulmonary </text>
<text top="490" left="204" width="92" height="17" font="13">edema and may </text>
<text top="507" left="204" width="94" height="17" font="13">reduce mortality. </text>
<text top="524" left="204" width="76" height="17" font="13">To determine </text>
<text top="541" left="204" width="47" height="17" font="13">whether </text>
<text top="558" left="204" width="68" height="17" font="13">noninvasive </text>
<text top="576" left="204" width="59" height="17" font="13">ventilation </text>
<text top="593" left="204" width="97" height="17" font="13">reduces mortality </text>
<text top="610" left="204" width="71" height="17" font="13">and whether </text>
<text top="627" left="204" width="53" height="17" font="13">there are </text>
<text top="644" left="204" width="55" height="17" font="13">important </text>
<text top="662" left="204" width="77" height="17" font="13">differences in </text>
<text top="679" left="204" width="51" height="17" font="13">outcome </text>
<text top="696" left="204" width="87" height="17" font="13">associated with </text>
<text top="713" left="204" width="79" height="17" font="13">the method of </text>
<text top="731" left="204" width="96" height="17" font="13">treatment (CPAP </text>
<text top="748" left="204" width="66" height="17" font="13">or NIPPV).  </text>
<text top="317" left="319" width="190" height="17" font="13">RCT 1069 </text>
<text top="335" left="413" width="65" height="17" font="13">(trandomize</text>
<text top="352" left="413" width="24" height="17" font="13">d to </text>
<text top="369" left="413" width="51" height="17" font="13">standard </text>
<text top="386" left="413" width="43" height="17" font="13">oxygen </text>
<text top="404" left="413" width="63" height="17" font="13">therapy, (n-</text>
<text top="421" left="413" width="68" height="17" font="13">367) versus </text>
<text top="438" left="413" width="65" height="17" font="13">CPAP (5 to </text>
<text top="455" left="413" width="51" height="17" font="13">15 cm of </text>
<text top="472" left="413" width="38" height="17" font="13">water) </text>
<text top="490" left="413" width="68" height="17" font="13">(n=346) OR </text>
<text top="507" left="413" width="40" height="17" font="13">NIPPV </text>
<text top="524" left="413" width="64" height="17" font="13">(inspiratory </text>
<text top="541" left="413" width="65" height="17" font="13">pressure, 8 </text>
<text top="558" left="413" width="64" height="17" font="13">to 20 cm of </text>
<text top="576" left="413" width="37" height="17" font="13">water; </text>
<text top="593" left="413" width="57" height="17" font="13">expiratory </text>
<text top="610" left="413" width="65" height="17" font="13">pressure, 4 </text>
<text top="627" left="413" width="64" height="17" font="13">to 10 cm of </text>
<text top="644" left="413" width="38" height="17" font="13">water) </text>
<text top="662" left="413" width="53" height="17" font="13">(n=356).  </text>
<text top="317" left="494" width="106" height="17" font="13">Age &gt; 16 y, clinical </text>
<text top="335" left="494" width="103" height="17" font="13">diagnosis of acute </text>
<text top="352" left="494" width="126" height="17" font="13">cardiogenic PE, PE on </text>
<text top="369" left="494" width="98" height="17" font="13">chest radiograph, </text>
<text top="386" left="494" width="110" height="17" font="13">respiratory rate &gt;20 </text>
<text top="404" left="494" width="136" height="17" font="13">breaths/min, and arterial </text>
<text top="421" left="494" width="75" height="17" font="13">hydrogen ion </text>
<text top="438" left="494" width="142" height="17" font="13">concentration &gt;45 nmol/L </text>
<text top="455" left="494" width="69" height="17" font="13">(pH &lt;7.35).  </text>
<text top="317" left="649" width="27" height="17" font="13"> N/A </text>
<text top="317" left="805" width="327" height="17" font="13">There was no significant difference in 7-d mortality between </text>
<text top="335" left="805" width="308" height="17" font="13">pts receiving standard oxygen therapy (9.8%) and those </text>
<text top="352" left="805" width="317" height="17" font="13">undergoing noninvasive ventilation (9.5%, P=0.87). There </text>
<text top="369" left="805" width="313" height="17" font="13">was no significant difference in the combined endpoint of </text>
<text top="386" left="805" width="328" height="17" font="13">death or intubation within 7 d between the two groups of pts </text>
<text top="404" left="805" width="313" height="17" font="13">undergoing noninvasive ventilation (11.7% for CPAP and </text>
<text top="421" left="805" width="311" height="17" font="13">11.1% for NIPPV, p=0.81).  In pts with acute cardiogenic </text>
<text top="438" left="805" width="269" height="17" font="13">PE, noninvasive ventilation induces a more rapid </text>
<text top="455" left="805" width="275" height="17" font="13">improvement in respiratory distress and metabolic </text>
<text top="472" left="805" width="324" height="17" font="13">disturbance than does standard oxygen therapy but has no </text>
<text top="490" left="805" width="302" height="17" font="13">effect on short-term mortality. CPAP or NIPPV MAY be </text>
<text top="507" left="805" width="315" height="17" font="13">considered as adjunctive therapy in pts with severe acute </text>
<text top="524" left="805" width="317" height="17" font="13">cardiogenic pulmonary oedema in the presence of severe </text>
<text top="541" left="805" width="306" height="17" font="13">respiratory distress or when there is a failure to improve </text>
<text top="558" left="805" width="315" height="17" font="13">with pharmacological therapy.As compared with standard </text>
<text top="576" left="805" width="331" height="17" font="13">oxygen therapy, noninvasive ventilation was associated with </text>
<text top="593" left="805" width="310" height="17" font="13">greater mean improvements at 1 h after the beginning of </text>
<text top="610" left="805" width="323" height="17" font="13">treatment in pt-reported dyspnea (treatment difference, 0.7 </text>
<text top="627" left="805" width="313" height="17" font="13">on a visual-analogue scale ranging from 1 to 10; 95% CI: </text>
<text top="644" left="805" width="287" height="17" font="13">0.2-1.3; p=0.008), heart rate (treatment difference, 4 </text>
<text top="662" left="805" width="295" height="17" font="13">beats/min; 95% CI; 1-6; p=0.004), acidosis (treatment </text>
<text top="679" left="805" width="296" height="17" font="13">difference, pH 0.03; 95% CI: 0.02-0.04; p&lt;0.001), and </text>
<text top="696" left="805" width="310" height="17" font="13">hypercapnia (treatment difference, 0.7 kPa [5.2 mm Hg]; </text>
<text top="713" left="805" width="148" height="17" font="13">95% CI: 0.4-0.9; p&lt;0.001). </text>
<text top="317" left="1149" width="41" height="17" font="13">p=0.87 </text>
<text top="317" left="1243" width="27" height="17" font="13"> N/A </text>
<text top="317" left="1345" width="27" height="17" font="13"> N/A </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">117</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="106" height="17" font="13">Masip J, Roque M, </text>
<text top="72" left="54" width="129" height="17" font="13">Sanchez B, Fernandez </text>
<text top="89" left="54" width="136" height="17" font="13">R, Subirana M, Exposito </text>
<text top="106" left="54" width="92" height="17" font="13">JA. Noninvasive </text>
<text top="124" left="54" width="105" height="17" font="13">ventilation in acute </text>
<text top="141" left="54" width="127" height="17" font="13">cardiogenic pulmonary </text>
<text top="158" left="54" width="106" height="17" font="13">edema: systematic </text>
<text top="175" left="54" width="94" height="17" font="13">review and meta-</text>
<text top="192" left="54" width="118" height="17" font="13">analysis. <i>JAMA</i> 2005 </text>
<text top="210" left="54" width="60" height="17" font="13">December </text>
<text top="227" left="54" width="111" height="17" font="13">28;294(24):3124-30 </text>
<text top="244" left="54" width="58" height="17" font="14">16380593 </text>
<text top="244" left="112" width="32" height="17" font="13">(258) </text>
<text top="55" left="204" width="98" height="17" font="13">To systematically </text>
<text top="72" left="204" width="63" height="17" font="13">review and </text>
<text top="89" left="204" width="75" height="17" font="13">quantitatively </text>
<text top="106" left="204" width="82" height="17" font="13">synthesize the </text>
<text top="124" left="204" width="93" height="17" font="13">short-term effect </text>
<text top="141" left="204" width="82" height="17" font="13">of noninvasive </text>
<text top="158" left="204" width="76" height="17" font="13">ventilation on </text>
<text top="175" left="204" width="74" height="17" font="13">major clinical </text>
<text top="192" left="204" width="60" height="17" font="13">outcomes. </text>
<text top="55" left="319" width="126" height="17" font="13">Meta-analysis 15 </text>
<text top="55" left="430" width="44" height="17" font="13">trials </text>
<text top="72" left="413" width="61" height="17" font="13">comparing </text>
<text top="89" left="413" width="68" height="17" font="13">noninvasive </text>
<text top="106" left="413" width="59" height="17" font="13">ventilation </text>
<text top="124" left="413" width="27" height="17" font="13">to to </text>
<text top="141" left="413" width="59" height="17" font="13">convention</text>
<text top="158" left="413" width="56" height="17" font="13">al oxygen </text>
<text top="55" left="494" width="105" height="17" font="13">Acute PE, relevant </text>
<text top="72" left="494" width="124" height="17" font="13">randomized controlled </text>
<text top="89" left="494" width="115" height="17" font="13">trials and systematic </text>
<text top="106" left="494" width="129" height="17" font="13">reviews published from </text>
<text top="124" left="494" width="119" height="17" font="13">1988-2005.  Included </text>
<text top="141" left="494" width="118" height="17" font="13">trials were all parallel </text>
<text top="158" left="494" width="103" height="17" font="13">studies comparing </text>
<text top="175" left="494" width="141" height="17" font="13">noninvasive ventilation to </text>
<text top="192" left="494" width="116" height="17" font="13">conventional oxygen </text>
<text top="210" left="494" width="136" height="17" font="13">therapy in pts with acute </text>
<text top="227" left="494" width="113" height="17" font="13">PE. Comparisons of </text>
<text top="244" left="494" width="114" height="17" font="13">different techniques, </text>
<text top="261" left="494" width="123" height="17" font="13">either CPAP or bilevel </text>
<text top="278" left="494" width="100" height="17" font="13">NIPSV, were also </text>
<text top="296" left="494" width="49" height="17" font="13">included </text>
<text top="55" left="649" width="27" height="17" font="13"> N/A </text>
<text top="55" left="805" width="308" height="17" font="13">Overall, noninvasive ventilation significantly reduced the </text>
<text top="72" left="805" width="312" height="17" font="13">mortality rate by nearly 45% compared with conventional </text>
<text top="89" left="805" width="262" height="17" font="13">therapy (RR: 0.55; 95% CI; 0.40-0.78; p=.72 for </text>
<text top="106" left="805" width="321" height="17" font="13">heterogeneity). The results were significant for CPAP (RR: </text>
<text top="124" left="805" width="316" height="17" font="13">0.53; 95% CI: 0.35-0.81; p= .44 for heterogeneity) but not </text>
<text top="141" left="805" width="276" height="17" font="13">for NIPSV (RR: 0.60; 95% CI, 0.34-1.05; p=.76 for </text>
<text top="158" left="805" width="307" height="17" font="13">heterogeneity), although there were fewer studies in the </text>
<text top="175" left="805" width="323" height="17" font="13">latter. Both modalities showed a significant decrease in the </text>
<text top="192" left="805" width="329" height="17" font="13">&#34;need to intubate&#34; rate compared with conventional therapy: </text>
<text top="210" left="805" width="255" height="17" font="13">CPAP (RR: 0.40; 95% CI: 0.27-0.58; p=.21 for </text>
<text top="227" left="805" width="326" height="17" font="13">heterogeneity), NIPSV (RR, 0.48; 95% CI: 0.30-0.76; p=.24 </text>
<text top="244" left="805" width="310" height="17" font="13">for heterogeneity), and together (RR: 0.43; 95% CI: 0.32-</text>
<text top="261" left="805" width="328" height="17" font="13">0.57; p=.20 for heterogeneity). There were no differences in </text>
<text top="278" left="805" width="289" height="17" font="13">intubation or mortality rates in the analysis of studies </text>
<text top="296" left="805" width="291" height="17" font="13">comparing CPAP and NIPSV.Noninvasive ventilation </text>
<text top="313" left="805" width="305" height="17" font="13">reduces the need for intubation and mortality in pts with </text>
<text top="330" left="805" width="320" height="17" font="13">acute cardiogenic pulmonary edema. Although the level of </text>
<text top="347" left="805" width="289" height="17" font="13">evidence is higher for CPAP, there are no significant </text>
<text top="365" left="805" width="323" height="17" font="13">differences in clinical outcomes when comparing CPAP vs. </text>
<text top="382" left="805" width="44" height="17" font="13">NIPSV. </text>
<text top="55" left="1149" width="59" height="17" font="13">p&lt;0.05 for </text>
<text top="72" left="1149" width="50" height="17" font="13">mortality </text>
<text top="89" left="1149" width="79" height="17" font="13">reduction with </text>
<text top="106" left="1149" width="68" height="17" font="13">noninvasive </text>
<text top="124" left="1149" width="59" height="17" font="13">ventilation </text>
<text top="55" left="1243" width="52" height="17" font="13">RR: 0.55 </text>
<text top="55" left="1345" width="27" height="17" font="13"> N/A </text>
<text top="400" left="54" width="555" height="17" font="15"><b>Severe Cardiogenic Shock  Patient, Role of PVADs to Bridge to Recovery or Bridge/Transplant </b></text>
<text top="400" left="649" width="7" height="17" font="15"><b>  </b></text>
<text top="400" left="805" width="7" height="17" font="15"><b>  </b></text>
<text top="400" left="1149" width="7" height="17" font="15"><b>  </b></text>
<text top="400" left="1243" width="7" height="17" font="15"><b>  </b></text>
<text top="400" left="1345" width="7" height="17" font="15"><b>  </b></text>
<text top="421" left="54" width="107" height="17" font="13">Kar B, Gregoric ID, </text>
<text top="438" left="54" width="131" height="17" font="13">Basra SS, Idelchik GM, </text>
<text top="455" left="54" width="85" height="17" font="13">Loyalka P. The </text>
<text top="472" left="54" width="78" height="17" font="13">percutaneous </text>
<text top="490" left="54" width="134" height="17" font="13">ventricular assist device </text>
<text top="507" left="54" width="109" height="17" font="13">in severe refractory </text>
<text top="524" left="54" width="137" height="17" font="13">cardiogenic shock. <i>J Am </i></text>
<text top="541" left="54" width="98" height="17" font="22"><i>Coll Cardiol</i> 2011 </text>
<text top="558" left="54" width="120" height="17" font="13">February 8;57(6):688-</text>
<text top="576" left="54" width="27" height="17" font="13">696. </text>
<text top="593" left="54" width="58" height="17" font="14">20950980 </text>
<text top="593" left="112" width="32" height="17" font="13">(259) </text>
<text top="421" left="204" width="96" height="17" font="13">To determine the </text>
<text top="438" left="204" width="69" height="17" font="13">efficacy and </text>
<text top="455" left="204" width="70" height="17" font="13">safety of the </text>
<text top="472" left="204" width="81" height="17" font="13">pVAD in pts in </text>
<text top="490" left="204" width="81" height="17" font="13">SRCS despite </text>
<text top="507" left="204" width="62" height="17" font="13">intra-aortic </text>
<text top="524" left="204" width="77" height="17" font="13">balloon pump </text>
<text top="541" left="204" width="96" height="17" font="13">and/or high-dose </text>
<text top="558" left="204" width="70" height="17" font="13">vasopressor </text>
<text top="576" left="204" width="48" height="17" font="13">support. </text>
<text top="421" left="319" width="68" height="17" font="13">Prospective </text>
<text top="438" left="319" width="40" height="17" font="13">Cohort </text>
<text top="421" left="413" width="24" height="17" font="13">117 </text>
<text top="421" left="494" width="124" height="17" font="13">Cardiogenic shock pts </text>
<text top="438" left="494" width="122" height="17" font="13">with a SBP of  90 mm </text>
<text top="455" left="494" width="126" height="17" font="13">Hg, a cardiac index of  </text>
<text top="472" left="494" width="103" height="17" font="13">2.0 l/(min·m2) and </text>
<text top="490" left="494" width="126" height="17" font="13">evidence of end-organ </text>
<text top="507" left="494" width="80" height="17" font="13">failure despite </text>
<text top="524" left="494" width="132" height="17" font="13">IABP/pressor support.A </text>
<text top="541" left="494" width="109" height="17" font="13">total of 117 pts with </text>
<text top="558" left="494" width="120" height="17" font="13">SRCS implanted with </text>
<text top="576" left="494" width="114" height="17" font="13">TandemHeart pVAD </text>
<text top="593" left="494" width="127" height="17" font="13">were studied, of whom </text>
<text top="610" left="494" width="83" height="17" font="13">56 pts (47.9%) </text>
<text top="627" left="494" width="96" height="17" font="13">underwent active </text>
<text top="644" left="494" width="94" height="17" font="13">cardiopulmonary </text>
<text top="662" left="494" width="142" height="17" font="13">resuscitation immediately </text>
<text top="679" left="494" width="127" height="17" font="13">before or at the time of </text>
<text top="696" left="494" width="70" height="17" font="13">implantation </text>
<text top="421" left="649" width="27" height="17" font="13"> N/A </text>
<text top="421" left="805" width="324" height="17" font="13">56 (47.9%) of the 117 pts (41 of 80 [51.2%] with ICM; 15 of </text>
<text top="438" left="805" width="324" height="17" font="13">37 [40.5%] with NICM) were undergoing CPR during pVAD </text>
<text top="455" left="805" width="264" height="17" font="13">placement.The average time from CPR onset to </text>
<text top="472" left="805" width="327" height="17" font="13">TandemHeart implantation was 65.6+/-41.3 min. 80 pts had </text>
<text top="490" left="805" width="326" height="17" font="13">ischemic and 37 pts had nonischemic cardiomyopathy. The </text>
<text top="507" left="805" width="316" height="17" font="13">average duration of support was 5.8 d. After implantation, </text>
<text top="524" left="805" width="321" height="17" font="13">the cardiac index improved from median 0.52 (interquartile </text>
<text top="541" left="805" width="304" height="17" font="13">range [IQR]: 0.8) l/(min·m2) to 3.0 (IQR: 0.9) l/(min·m2) </text>
<text top="558" left="805" width="316" height="17" font="13">(p=0.001). The SBP and mixed venous oxygen saturation </text>
<text top="576" left="805" width="330" height="17" font="13">increased from 75 (IQR: 15) mm Hg to 100 (IQR: 15)mm Hg </text>
<text top="593" left="805" width="323" height="17" font="13">(p   0.001) and 49 (IQR: 11.5) to 69.3 (IQR: 10) (p   0.001), </text>
<text top="610" left="805" width="295" height="17" font="13">respectively. The PCWP, lactic acid level, and Crlevel </text>
<text top="627" left="805" width="337" height="17" font="13">decreased, respectively, from 31.53 to 10.2 mm Hg to 17.29   </text>
<text top="644" left="805" width="303" height="17" font="13">10.82 mm Hg (p   0.001), 24.5 (IQR: 74.25) mg/dl to 11 </text>
<text top="662" left="805" width="324" height="17" font="13">(IQR: 92) mg/dl (p=0.001), and 1.5 (IQR: 0.95) mg/dl to 1.2 </text>
<text top="679" left="805" width="324" height="17" font="13">(IQR: 0.9) mg/dl (p   0.009). The mortality rates at 30 d and </text>
<text top="696" left="805" width="237" height="17" font="13">6 mo were 40.2% and 45.3%, respectively. </text>
<text top="421" left="1149" width="31" height="17" font="13">  N/A </text>
<text top="421" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="421" left="1345" width="31" height="17" font="13">  N/A </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">118</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="103" height="17" font="13">Thiele H, Lauer B, </text>
<text top="72" left="54" width="129" height="17" font="13">Hambrecht R, Boudriot </text>
<text top="89" left="54" width="124" height="17" font="13">E, Cohen HA, Schuler </text>
<text top="106" left="54" width="82" height="17" font="13">G. Reversal of </text>
<text top="124" left="54" width="118" height="17" font="13">cardiogenic shock by </text>
<text top="141" left="54" width="129" height="17" font="13">percutaneous left atrial-</text>
<text top="158" left="54" width="100" height="17" font="13">to-femoral arterial </text>
<text top="175" left="54" width="107" height="17" font="13">bypass assistance. </text>
<text top="192" left="54" width="92" height="17" font="22"><i>Circulation</i> 2001 </text>
<text top="210" left="54" width="60" height="17" font="13">December </text>
<text top="227" left="54" width="129" height="17" font="13">11;104(24):2917-2922. </text>
<text top="244" left="54" width="58" height="17" font="14">11739306 </text>
<text top="244" left="112" width="32" height="17" font="13">(260) </text>
<text top="55" left="204" width="88" height="17" font="13">To characterize </text>
<text top="72" left="204" width="88" height="17" font="13">whether  PVAD </text>
<text top="89" left="204" width="55" height="17" font="13">may offer </text>
<text top="106" left="204" width="49" height="17" font="13">effective </text>
<text top="124" left="204" width="73" height="17" font="13">treatment for </text>
<text top="141" left="204" width="66" height="17" font="13">cardiogenic </text>
<text top="158" left="204" width="39" height="17" font="13">shock  </text>
<text top="55" left="319" width="70" height="17" font="13">Case Series </text>
<text top="55" left="413" width="17" height="17" font="13">18 </text>
<text top="55" left="494" width="135" height="17" font="13">VADs were implanted in </text>
<text top="72" left="494" width="131" height="17" font="13">18 consecutive pts who </text>
<text top="89" left="494" width="126" height="17" font="13">had cardiogenic shock </text>
<text top="106" left="494" width="52" height="17" font="13">after MI.  </text>
<text top="55" left="649" width="31" height="17" font="13">  N/A </text>
<text top="55" left="805" width="331" height="17" font="13">Mean duration of cardiac assistance was 4+/-3 d. Mean flow </text>
<text top="72" left="805" width="308" height="17" font="13">of the VAD was 3.2+/-0.6 L/min. Before support, cardiac </text>
<text top="89" left="805" width="317" height="17" font="13">index was 1.7+/-0.3 L/min per m(2) and improved to 2.4+/-</text>
<text top="106" left="805" width="283" height="17" font="13">0.6 L/min per m(2) (p&lt;0.001). Mean blood pressure </text>
<text top="124" left="805" width="322" height="17" font="13">increased from 63+/-8 mm Hg to 80+/-9 mm Hg (p&lt;0.001). </text>
<text top="141" left="805" width="301" height="17" font="13">PCWP, central venous pressure, and pulmonary artery </text>
<text top="158" left="805" width="328" height="17" font="13">pressure were reduced from 21+/-4, 13+/-4, and 31+/-8 mm </text>
<text top="175" left="805" width="291" height="17" font="13">Hg to 14+/-4, 9+/-3, and 23+/-6 mm Hg (all p&lt;0.001), </text>
<text top="192" left="805" width="277" height="17" font="13">respectively. Overall 30-d mortality rate was 44%.  </text>
<text top="55" left="1149" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1345" width="31" height="17" font="13">  N/A </text>
<text top="262" left="54" width="137" height="17" font="13">Idelchik GM, Simpson L, </text>
<text top="279" left="54" width="131" height="17" font="13">Civitello AB, Loyalka P, </text>
<text top="296" left="54" width="135" height="17" font="13">Gregoric ID, Delgado R, </text>
<text top="314" left="54" width="114" height="17" font="13">III, Kar B. Use of the </text>
<text top="331" left="54" width="98" height="17" font="13">percutaneous left </text>
<text top="348" left="54" width="134" height="17" font="13">ventricular assist device </text>
<text top="365" left="54" width="98" height="17" font="13">in pts with severe </text>
<text top="382" left="54" width="122" height="17" font="13">refractory cardiogenic </text>
<text top="400" left="54" width="113" height="17" font="13">shock as a bridge to </text>
<text top="417" left="54" width="135" height="17" font="13">long-term left ventricular </text>
<text top="434" left="54" width="74" height="17" font="13">assist device </text>
<text top="451" left="54" width="116" height="17" font="13">implantation. <i>J Heart </i></text>
<text top="469" left="54" width="123" height="17" font="22"><i>Lung Transplant</i> 2008 </text>
<text top="486" left="54" width="131" height="17" font="13">January;27(1):106-111. </text>
<text top="503" left="54" width="58" height="17" font="14">18187095 </text>
<text top="503" left="112" width="32" height="17" font="13">(261) </text>
<text top="262" left="204" width="88" height="17" font="13">To evaluate the </text>
<text top="279" left="204" width="69" height="17" font="13">efficacy of a </text>
<text top="296" left="204" width="101" height="17" font="13">PVAD as a bridge </text>
<text top="314" left="204" width="49" height="17" font="13">to LVAD </text>
<text top="331" left="204" width="83" height="17" font="13">implantation in </text>
<text top="348" left="204" width="99" height="17" font="13">pts in cardiogenic </text>
<text top="365" left="204" width="91" height="17" font="13">shock refractory </text>
<text top="382" left="204" width="69" height="17" font="13">to IABP and </text>
<text top="400" left="204" width="92" height="17" font="13">pressor support. </text>
<text top="262" left="319" width="70" height="17" font="13">Case Series </text>
<text top="262" left="413" width="17" height="17" font="13">18 </text>
<text top="262" left="494" width="137" height="17" font="13">18 pts in SRCS received </text>
<text top="279" left="494" width="125" height="17" font="13">a PVAD as a bridge to </text>
<text top="296" left="494" width="110" height="17" font="13">LVAD placement or </text>
<text top="314" left="494" width="89" height="17" font="13">orthotopic heart </text>
<text top="331" left="494" width="142" height="17" font="13">transplantation. 6 pts had </text>
<text top="348" left="494" width="51" height="17" font="13">ischemic </text>
<text top="365" left="494" width="135" height="17" font="13">cardiomyopathy, and 12 </text>
<text top="382" left="494" width="96" height="17" font="13">had nonischemic </text>
<text top="400" left="494" width="129" height="17" font="13">cardiomyopathy. At the </text>
<text top="417" left="494" width="141" height="17" font="13">time of PVAD placement, </text>
<text top="434" left="494" width="131" height="17" font="13">17 were receiving IABP </text>
<text top="451" left="494" width="119" height="17" font="13">support, and 10 were </text>
<text top="469" left="494" width="65" height="17" font="13">undergoing </text>
<text top="486" left="494" width="94" height="17" font="13">cardiopulmonary </text>
<text top="503" left="494" width="72" height="17" font="13">resuscitation </text>
<text top="262" left="649" width="31" height="17" font="13">  N/A </text>
<text top="262" left="805" width="300" height="17" font="13">The mean duration of PVAD support was 4.2 +/- 2.5 d. </text>
<text top="279" left="805" width="316" height="17" font="13">During this time, the cardiac index improved from 0.86 +/- </text>
<text top="296" left="805" width="282" height="17" font="13">0.66 to 2.50 +/- 0.93 liters/min/m2 (p &lt; 0.001), SBP </text>
<text top="314" left="805" width="327" height="17" font="13">improved from 72 +/- 11 to 98 +/- 15 mm Hg (p=0.001), and </text>
<text top="331" left="805" width="328" height="17" font="13">systemic mixed venous oxygenation improved from 37 +/- 7 </text>
<text top="348" left="805" width="329" height="17" font="13">to 62 +/- 6 mm Hg (p &lt; 0.001). We terminated life support in </text>
<text top="365" left="805" width="266" height="17" font="13">4 of the 18 pts before LVAD placement; 14 were </text>
<text top="382" left="805" width="321" height="17" font="13">successfully bridged to LVAD or heart transplantation. The </text>
<text top="400" left="805" width="304" height="17" font="13">mortality rate was 27% at 30 d and 33% at 6 mo. There </text>
<text top="417" left="805" width="313" height="17" font="13">were no PVAD-associated deaths. CONCLUSION: In pts </text>
<text top="434" left="805" width="315" height="17" font="13">with terminal hemodynamic collapse, PVAD support is an </text>
<text top="451" left="805" width="303" height="17" font="13">effective bridging therapy to LVAD and appears to be a </text>
<text top="469" left="805" width="298" height="17" font="13">viable alternative to other invasive methods of support </text>
<text top="262" left="1149" width="31" height="17" font="13">  N/A </text>
<text top="262" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="262" left="1345" width="31" height="17" font="13">  N/A </text>
<text top="521" left="54" width="128" height="17" font="13">Cheng JM, den Uil CA, </text>
<text top="538" left="54" width="131" height="17" font="13">Hoeks SE, van der EM, </text>
<text top="555" left="54" width="89" height="17" font="13">Jewbali LS, van </text>
<text top="573" left="54" width="123" height="17" font="13">Domburg RT, Serruys </text>
<text top="590" left="54" width="126" height="17" font="13">PW. Percutaneous left </text>
<text top="607" left="54" width="95" height="17" font="13">ventricular assist </text>
<text top="624" left="54" width="126" height="17" font="13">devices vs. intra-aortic </text>
<text top="641" left="54" width="77" height="17" font="13">balloon pump </text>
<text top="659" left="54" width="112" height="17" font="13">counterpulsation for </text>
<text top="676" left="54" width="135" height="17" font="13">treatment of cardiogenic </text>
<text top="693" left="54" width="128" height="17" font="13">shock: a meta-analysis </text>
<text top="710" left="54" width="126" height="17" font="13">of controlled trials. <i>Eur </i></text>
<text top="727" left="54" width="74" height="17" font="22"><i>Heart J</i> 2009 </text>
<text top="745" left="54" width="134" height="17" font="13">September;30(17):2102-</text>
<text top="762" left="54" width="31" height="17" font="13">2108 </text>
<text top="779" left="54" width="58" height="17" font="14">19617601 </text>
<text top="779" left="112" width="32" height="17" font="13">(262) </text>
<text top="521" left="204" width="91" height="17" font="13">A meta-analysis </text>
<text top="538" left="204" width="100" height="17" font="13">of controlled trials </text>
<text top="555" left="204" width="76" height="17" font="13">of PVADs vs. </text>
<text top="573" left="204" width="62" height="17" font="13">intra-aortic </text>
<text top="590" left="204" width="77" height="17" font="13">balloon pump </text>
<text top="607" left="204" width="94" height="17" font="13">counterpulsation </text>
<text top="624" left="204" width="87" height="17" font="13">for treatment of </text>
<text top="641" left="204" width="66" height="17" font="13">cardiogenic </text>
<text top="659" left="204" width="81" height="17" font="13">shock for 30 d </text>
<text top="676" left="204" width="50" height="17" font="13">mortality </text>
<text top="521" left="319" width="101" height="17" font="13">Meta-Analysis    </text>
<text top="521" left="494" width="117" height="17" font="13">2 trials evaluated the </text>
<text top="538" left="494" width="113" height="17" font="13">TandemHeart and a </text>
<text top="555" left="494" width="111" height="17" font="13">recent trial used the </text>
<text top="573" left="494" width="82" height="17" font="13">Impella device </text>
<text top="521" left="649" width="31" height="17" font="13">  N/A </text>
<text top="521" left="805" width="299" height="17" font="13">After device implantation, percutaneous LVAD pts had </text>
<text top="538" left="805" width="321" height="17" font="13">higher CI (MD 0.35 L/min/m(2), 95% CI: 0.09-0.61), higher </text>
<text top="555" left="805" width="327" height="17" font="13">MAP (MD 12.8 mmHg, 95% CI: 3.6-22.0), and lower PCWP </text>
<text top="573" left="805" width="327" height="17" font="13">(MD -5.3 mm Hg, 95% CI: -9.4 to -1.2) compared with IABP </text>
<text top="590" left="805" width="321" height="17" font="13">pts. Similar 30-day mortality (RR: 1.06; 95% CI: 0.68-1.66) </text>
<text top="607" left="805" width="309" height="17" font="13">was observed using percutaneous LVAD compared with </text>
<text top="624" left="805" width="331" height="17" font="13">IABP. No significant difference was observed in incidence of </text>
<text top="641" left="805" width="258" height="17" font="13">leg ischaemia (RR: 2.59, 95% CI: 0.75-8.97) in </text>
<text top="659" left="805" width="323" height="17" font="13">percutaneous LVAD pts compared with IABP pts. Bleeding </text>
<text top="676" left="805" width="290" height="17" font="13">(RR: 2.35, 95% CI: 1.40-3.93) was significantly more </text>
<text top="693" left="805" width="310" height="17" font="13">observed in TandemHeart pts compared with pts treated </text>
<text top="710" left="805" width="320" height="17" font="13">with IABP.Although percutaneous LVAD provides superior </text>
<text top="727" left="805" width="291" height="17" font="13">haemodynamic support in pts with cardiogenic shock </text>
<text top="745" left="805" width="290" height="17" font="13">compared with IABP, the use of these more powerful </text>
<text top="762" left="805" width="326" height="17" font="13">devices did not improve early survival. These results do not </text>
<text top="779" left="805" width="325" height="17" font="13">yet support percutaneous LVAD as first-choice approach in </text>
<text top="521" left="1149" width="31" height="17" font="13">  N/A </text>
<text top="521" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="521" left="1345" width="31" height="17" font="13">  N/A </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">119</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="805" width="280" height="17" font="13">the mechanical management of cardiogenic shock. </text>
<text top="224" left="54" width="126" height="17" font="13">Seyfarth M, Sibbing D, </text>
<text top="241" left="54" width="110" height="17" font="13">Bauer I, Frohlich G, </text>
<text top="259" left="54" width="128" height="17" font="13">Bott-Flugel L, Byrne R, </text>
<text top="276" left="54" width="124" height="17" font="13">Dirschinger J, Kastrati </text>
<text top="293" left="54" width="93" height="17" font="13">A, Schomig A. A </text>
<text top="310" left="54" width="131" height="17" font="13">randomized clinical trial </text>
<text top="327" left="54" width="120" height="17" font="13">to evaluate the safety </text>
<text top="345" left="54" width="93" height="17" font="13">and efficacy of a </text>
<text top="362" left="54" width="98" height="17" font="13">percutaneous left </text>
<text top="379" left="54" width="134" height="17" font="13">ventricular assist device </text>
<text top="396" left="54" width="101" height="17" font="13">versus intra-aortic </text>
<text top="414" left="54" width="112" height="17" font="13">balloon pumping for </text>
<text top="431" left="54" width="135" height="17" font="13">treatment of cardiogenic </text>
<text top="448" left="54" width="95" height="17" font="13">shock caused by </text>
<text top="465" left="54" width="129" height="17" font="13">myocardial infarction. <i>J </i></text>
<text top="482" left="54" width="120" height="17" font="22"><i>Am Coll Cardiol</i> 2008 </text>
<text top="500" left="54" width="60" height="17" font="13">November </text>
<text top="517" left="54" width="111" height="17" font="13">4;52(19):1584-1588 </text>
<text top="534" left="54" width="58" height="17" font="14">19007597 </text>
<text top="534" left="112" width="32" height="17" font="13">(263) </text>
<text top="224" left="204" width="88" height="17" font="13">To test whether </text>
<text top="241" left="204" width="99" height="17" font="13">the LVAD Impella </text>
<text top="259" left="204" width="85" height="17" font="13">LP2.5 provides </text>
<text top="276" left="204" width="48" height="17" font="13">superior </text>
<text top="293" left="204" width="80" height="17" font="13">hemodynamic </text>
<text top="310" left="204" width="44" height="17" font="13">support </text>
<text top="327" left="204" width="83" height="17" font="13">compared with </text>
<text top="345" left="204" width="55" height="17" font="13">the IABP. </text>
<text top="224" left="319" width="66" height="17" font="13">RCT (ISAR-</text>
<text top="241" left="319" width="78" height="17" font="13">SHOCK Trial) </text>
<text top="224" left="413" width="17" height="17" font="13">26 </text>
<text top="224" left="494" width="131" height="17" font="13">Cardiogenic shock post </text>
<text top="241" left="494" width="25" height="17" font="13">AMI </text>
<text top="224" left="649" width="31" height="17" font="13">  N/A </text>
<text top="224" left="805" width="307" height="17" font="13">In 25 pts the allocated device (n=13 IABP, n=12 Impella </text>
<text top="241" left="805" width="330" height="17" font="13">LP2.5) could be safely placed. 1 pt died before implantation. </text>
<text top="259" left="805" width="329" height="17" font="13">The CI after 30 min of support was significantly increased in </text>
<text top="276" left="805" width="304" height="17" font="13">pts with the Impella LP2.5 compared with pts with IABP </text>
<text top="293" left="805" width="330" height="17" font="13">(Impella: DeltaCI = 0.49 +/- 0.46 l/min/m(2); IABP: DeltaCI = </text>
<text top="310" left="805" width="310" height="17" font="13">0.11 +/- 0.31 l/min/m(2); p = 0.02). Overall 30-d mortality </text>
<text top="327" left="805" width="297" height="17" font="13">was 46% in both groups.percutaneously placed LVAD </text>
<text top="345" left="805" width="324" height="17" font="13">(Impella LP 2.5) is feasible and safe, and provides superior </text>
<text top="362" left="805" width="314" height="17" font="13">hemodynamic support compared with standard treatment </text>
<text top="379" left="805" width="85" height="17" font="13">using an IABP. </text>
<text top="224" left="1149" width="67" height="17" font="13">mortality p= </text>
<text top="241" left="1149" width="16" height="17" font="13">ns </text>
<text top="224" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="224" left="1345" width="31" height="17" font="13">  N/A </text>
<text top="552" left="54" width="120" height="17" font="13">Burkhoff D, Cohen H, </text>
<text top="569" left="54" width="124" height="17" font="13">Brunckhorst C, O'Neill </text>
<text top="586" left="54" width="109" height="17" font="13">WW. A randomized </text>
<text top="604" left="54" width="137" height="17" font="13">multicenter clinical study </text>
<text top="621" left="54" width="120" height="17" font="13">to evaluate the safety </text>
<text top="638" left="54" width="103" height="17" font="13">and efficacy of the </text>
<text top="655" left="54" width="79" height="17" font="13">TandemHeart </text>
<text top="672" left="54" width="78" height="17" font="13">percutaneous </text>
<text top="690" left="54" width="134" height="17" font="13">ventricular assist device </text>
<text top="707" left="54" width="112" height="17" font="13">versus conventional </text>
<text top="724" left="54" width="127" height="17" font="13">therapy with intraaortic </text>
<text top="741" left="54" width="112" height="17" font="13">balloon pumping for </text>
<text top="759" left="54" width="135" height="17" font="13">treatment of cardiogenic </text>
<text top="776" left="54" width="135" height="17" font="13">shock. <i>Am Heart J</i> 2006 </text>
<text top="552" left="204" width="62" height="17" font="13">To test the </text>
<text top="569" left="204" width="86" height="17" font="13">hypothesis that </text>
<text top="586" left="204" width="99" height="17" font="13">the TandemHeart </text>
<text top="604" left="204" width="95" height="17" font="13">(PVAD) provides </text>
<text top="621" left="204" width="48" height="17" font="13">superior </text>
<text top="638" left="204" width="80" height="17" font="13">hemodynamic </text>
<text top="655" left="204" width="44" height="17" font="13">support </text>
<text top="672" left="204" width="83" height="17" font="13">compared with </text>
<text top="690" left="204" width="35" height="17" font="13">IABP. </text>
<text top="552" left="319" width="81" height="17" font="13">RCT (Tandem </text>
<text top="569" left="319" width="51" height="17" font="13">vs IABP) </text>
<text top="552" left="413" width="17" height="17" font="13">42 </text>
<text top="552" left="494" width="110" height="17" font="13">Pts from 12 centers </text>
<text top="569" left="494" width="137" height="17" font="13">presenting within 24 h of </text>
<text top="586" left="494" width="129" height="17" font="13">developing cardiogenic </text>
<text top="604" left="494" width="117" height="17" font="13">shock.randomized to </text>
<text top="621" left="494" width="112" height="17" font="13">treatment with IABP </text>
<text top="638" left="494" width="132" height="17" font="13">(n=14) or TandemHeart </text>
<text top="655" left="494" width="134" height="17" font="13">PVAD (n=19). Thirty pts </text>
<text top="672" left="494" width="117" height="17" font="13">(71%) had persistent </text>
<text top="690" left="494" width="135" height="17" font="13">shock despite having an </text>
<text top="707" left="494" width="138" height="17" font="13">IABP in place at the time </text>
<text top="724" left="494" width="111" height="17" font="13">of study enrollment. </text>
<text top="552" left="649" width="31" height="17" font="13">  N/A </text>
<text top="552" left="805" width="304" height="17" font="13">Cardiogenic shock was due to MI in 70% of the pts and </text>
<text top="569" left="805" width="328" height="17" font="13">decompensated HF in most of the remaining pts. The mean </text>
<text top="586" left="805" width="307" height="17" font="13">duration of support was 2.5 d. Compared with IABP, the </text>
<text top="604" left="805" width="278" height="17" font="13">TandemHeart PVAD achieved significantly greater </text>
<text top="621" left="805" width="329" height="17" font="13">increases in cardiac index and mean arterial blood pressure </text>
<text top="638" left="805" width="310" height="17" font="13">and significantly greater decreases in PCWP. Overall 30-</text>
<text top="655" left="805" width="325" height="17" font="13">dsurvival and SAEs were not significantly different between </text>
<text top="672" left="805" width="72" height="17" font="13">the 2 groups </text>
<text top="552" left="1149" width="74" height="17" font="13">Mortality =ns </text>
<text top="552" left="1243" width="31" height="17" font="13">  N/A </text>
<text top="552" left="1345" width="31" height="17" font="13">  N/A </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">120</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="137" height="17" font="13">September;152(3):469-8 </text>
<text top="72" left="54" width="58" height="17" font="14">16923414 </text>
<text top="72" left="112" width="32" height="17" font="13">(264) </text>
<text top="191" left="54" width="1355" height="15" font="6">AMI indicates, acute myocardial infarction; CPAP, continuous positive airway pressure; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device;  N/A, not applicable; NIPPV, noninvasive intermittent positive-pressure ventilation; NIPSV  noninvasive pressure support </text>
<text top="207" left="54" width="1281" height="15" font="6">ventilation; PAC, pulmonary artery catheter; PCWP, pulmonary capillary wedge pressure; PE, pulmonary edema; PVAD; percutaneous ventricular assist device; RAP, right atrial pressure; SBP, systolic blood pressure; SRCS, severe refractory cardiogenic shock; </text>
<text top="222" left="54" width="3" height="15" font="6"> </text>
<text top="238" left="54" width="3" height="15" font="6"> </text>
<text top="253" left="54" width="3" height="15" font="6"> </text>
<text top="278" left="54" width="381" height="21" font="8"><b>Data Supplement 31. Sildenafil (Section Section 7.4.2) </b></text>
<text top="322" left="74" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="340" left="74" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="340" left="203" width="78" height="17" font="15"><b>Aim of study </b></text>
<text top="322" left="321" width="38" height="17" font="15"><b>Study </b></text>
<text top="340" left="324" width="32" height="17" font="15"><b>Type </b></text>
<text top="322" left="374" width="38" height="17" font="15"><b>Study </b></text>
<text top="340" left="379" width="28" height="17" font="15"><b>Size </b></text>
<text top="340" left="444" width="52" height="17" font="15"><b>Etiology </b></text>
<text top="340" left="646" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="340" left="903" width="51" height="17" font="15"><b>Severity </b></text>
<text top="340" left="1006" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="322" left="1115" width="83" height="17" font="15"><b>Trial Duration </b></text>
<text top="340" left="1134" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="340" left="1238" width="101" height="17" font="15"><b>Absolute Benefit </b></text>
<text top="322" left="1383" width="67" height="17" font="15"><b>P Values &amp; </b></text>
<text top="340" left="1392" width="48" height="17" font="15"><b>95% CI: </b></text>
<text top="375" left="426" width="84" height="17" font="21"><i><b>Ischemic/Non-</b></i></text>
<text top="392" left="442" width="56" height="17" font="21"><i><b>Ischemic </b></i></text>
<text top="392" left="550" width="104" height="17" font="21"><i><b>Inclusion Criteria </b></i></text>
<text top="392" left="729" width="108" height="17" font="21"><i><b>Exclusion Criteria </b></i></text>
<text top="358" left="895" width="66" height="17" font="21"><i><b>Severity of </b></i></text>
<text top="375" left="918" width="20" height="17" font="21"><i><b>HF </b></i></text>
<text top="392" left="895" width="66" height="17" font="21"><i><b>Symptoms </b></i></text>
<text top="392" left="985" width="106" height="17" font="21"><i><b>Primary Endpoint </b></i></text>
<text top="410" left="61" width="88" height="17" font="13">PDE5 Inhibition </text>
<text top="427" left="61" width="81" height="17" font="13">With Sildenafil </text>
<text top="444" left="61" width="92" height="17" font="13">Improves LVDF, </text>
<text top="462" left="61" width="46" height="17" font="13">Cardiac </text>
<text top="479" left="61" width="85" height="17" font="13">Geometry, and </text>
<text top="496" left="61" width="94" height="17" font="13">Clinical Status in </text>
<text top="513" left="61" width="87" height="17" font="13">Pts With Stable </text>
<text top="530" left="61" width="69" height="17" font="13">Systolic HF, </text>
<text top="548" left="61" width="90" height="17" font="13">Guazzi M, 2011 </text>
<text top="565" left="61" width="58" height="17" font="14">21036891 </text>
<text top="565" left="119" width="32" height="17" font="13">(265) </text>
<text top="410" left="178" width="115" height="17" font="13">To test the effects of </text>
<text top="427" left="178" width="87" height="17" font="13">PDE5 inhibition </text>
<text top="444" left="178" width="114" height="17" font="13">(sildenafil) on LVEF, </text>
<text top="462" left="178" width="81" height="17" font="13">LVDF, cardiac </text>
<text top="479" left="178" width="122" height="17" font="13">geometry, and clinical </text>
<text top="496" left="178" width="36" height="17" font="13">status </text>
<text top="410" left="319" width="29" height="17" font="13">RCT </text>
<text top="410" left="374" width="17" height="17" font="13">45 </text>
<text top="410" left="425" width="54" height="17" font="13">50% ICM </text>
<text top="410" left="527" width="148" height="17" font="13">NYHA II-III HF with clinical </text>
<text top="427" left="527" width="139" height="17" font="13">stable conditions defined </text>
<text top="444" left="527" width="116" height="17" font="13">as no changes in HF </text>
<text top="462" left="527" width="150" height="17" font="13">regimens or hospitalization </text>
<text top="479" left="527" width="134" height="17" font="13">since 6 mo before study </text>
<text top="496" left="527" width="140" height="17" font="13">entry;                                </text>
<text top="513" left="527" width="137" height="17" font="13">Negative exercise stress </text>
<text top="530" left="527" width="108" height="17" font="13">test before study;    </text>
<text top="548" left="527" width="159" height="17" font="13">FEV1/FVC &gt;70%;                  </text>
<text top="565" left="527" width="158" height="17" font="13">LVEF &lt;40%                           </text>
<text top="582" left="527" width="135" height="17" font="13">Presence of LV diastolic </text>
<text top="599" left="527" width="147" height="17" font="13">dysfunction determined by </text>
<text top="616" left="527" width="120" height="17" font="13">Doppler analysis with </text>
<text top="634" left="527" width="149" height="17" font="13">documen- tation of a mitral </text>
<text top="651" left="527" width="143" height="17" font="13">inflow early (E) velocity to </text>
<text top="668" left="527" width="110" height="17" font="13">mitral annulus early </text>
<text top="685" left="527" width="94" height="17" font="13">velocity (E') &gt;10. </text>
<text top="410" left="691" width="169" height="17" font="13">Unable to complete a maximal </text>
<text top="427" left="691" width="184" height="17" font="13">exercise test;  Resting SBP &lt;110 </text>
<text top="444" left="691" width="157" height="17" font="13">mm Hg;  therapy with nitrate </text>
<text top="462" left="691" width="175" height="17" font="13">preparations; LVADs;                 </text>
<text top="479" left="691" width="191" height="17" font="13">History of sildenafil intolerance;      </text>
<text top="496" left="691" width="145" height="17" font="13">significant lung or valvular </text>
<text top="513" left="691" width="140" height="17" font="13">diseases, neuromuscular </text>
<text top="530" left="691" width="179" height="17" font="13">disorders, or peripheral vascular </text>
<text top="548" left="691" width="111" height="17" font="13">disease; Diabetic pt </text>
<text top="410" left="889" width="72" height="17" font="13">100% NYHA </text>
<text top="427" left="889" width="83" height="17" font="13">II-III                  </text>
<text top="444" left="889" width="70" height="17" font="13">(42% NYHA </text>
<text top="462" left="889" width="76" height="17" font="13">II/58% NYHA </text>
<text top="479" left="889" width="52" height="17" font="13">III)           </text>
<text top="496" left="889" width="58" height="17" font="13">peak VO2 </text>
<text top="513" left="889" width="27" height="17" font="13">12.8 </text>
<text top="530" left="889" width="77" height="17" font="13">ml/min/kg       </text>
<text top="548" left="889" width="57" height="17" font="13">VE/VCO2 </text>
<text top="565" left="889" width="60" height="17" font="13">slope 35.3 </text>
<text top="410" left="981" width="66" height="17" font="13">LV diastolic </text>
<text top="427" left="981" width="101" height="17" font="13">function, chamber </text>
<text top="444" left="981" width="93" height="17" font="13">dimensions, and </text>
<text top="462" left="981" width="33" height="17" font="13">mass </text>
<text top="410" left="1107" width="20" height="17" font="13">1 y </text>
<text top="410" left="1219" width="147" height="17" font="13">D Mitral E/A @ 1yr             </text>
<text top="427" left="1219" width="146" height="17" font="13">placebo 0 vs SIL -0.19       </text>
<text top="444" left="1219" width="124" height="17" font="13">D IVRT @ 1y               </text>
<text top="462" left="1219" width="119" height="17" font="13">placebo +1.4 vs SIL  -</text>
<text top="479" left="1219" width="146" height="17" font="13">6.0   D E/E', lat @ 1yr        </text>
<text top="496" left="1219" width="112" height="17" font="13">placebo -0.8 vs. SIL </text>
<text top="513" left="1219" width="139" height="17" font="13">+3.7    D LVEDD (mm)@ </text>
<text top="530" left="1219" width="136" height="17" font="13">1y  placebo +0.9 vs SIL -</text>
<text top="548" left="1219" width="146" height="17" font="13">4.2d  D LVMI @ 1yr           </text>
<text top="565" left="1219" width="133" height="17" font="13">placebo no change, SIL </text>
<text top="582" left="1219" width="111" height="17" font="13">decrease (value not </text>
<text top="599" left="1219" width="65" height="17" font="13">provided)    </text>
<text top="616" left="1219" width="144" height="17" font="13">D peak VO2   @ 1y           </text>
<text top="634" left="1219" width="112" height="17" font="13">placebo +0.3 vs SIL </text>
<text top="651" left="1219" width="107" height="17" font="13">+2.7    D VE/VCO2 </text>
<text top="668" left="1219" width="143" height="17" font="13">Slope at 1y placebo +0.4  </text>
<text top="685" left="1219" width="111" height="17" font="13">vs SIL -6.0;  D QOL </text>
<text top="703" left="1219" width="131" height="17" font="13">(breathlessness, fatige, </text>
<text top="720" left="1219" width="107" height="17" font="13">emotional function) </text>
<text top="410" left="1371" width="75" height="17" font="13">p&lt;0.01 for all </text>
<text top="427" left="1371" width="66" height="17" font="13">parameters </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">121</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="90" height="17" font="13">PDE5A inhibitor </text>
<text top="72" left="61" width="69" height="17" font="13">treatment of </text>
<text top="89" left="61" width="57" height="17" font="13">persistent </text>
<text top="106" left="61" width="61" height="17" font="13">pulmonary </text>
<text top="124" left="61" width="102" height="17" font="13">hypertension after </text>
<text top="141" left="61" width="66" height="17" font="13">mechanical </text>
<text top="158" left="61" width="59" height="17" font="13">circulatory </text>
<text top="175" left="61" width="94" height="17" font="13">support, Tedford </text>
<text top="192" left="61" width="53" height="17" font="13">RJ, 2008 </text>
<text top="210" left="61" width="58" height="17" font="14">19808294 </text>
<text top="210" left="119" width="32" height="17" font="13">(266) </text>
<text top="55" left="178" width="124" height="17" font="13">To test the hypothesis </text>
<text top="72" left="178" width="123" height="17" font="13">that when PH persists </text>
<text top="89" left="178" width="101" height="17" font="13">after adequate LV </text>
<text top="106" left="178" width="114" height="17" font="13">unloading via recent </text>
<text top="124" left="178" width="83" height="17" font="13">LVAD therapy, </text>
<text top="141" left="178" width="107" height="17" font="13">phosphodiesterase </text>
<text top="158" left="178" width="97" height="17" font="13">type 5A inhibition </text>
<text top="175" left="178" width="123" height="17" font="13">would decrease PH in </text>
<text top="192" left="178" width="86" height="17" font="13">this population. </text>
<text top="55" left="319" width="34" height="17" font="13">Open </text>
<text top="72" left="319" width="29" height="17" font="13">label </text>
<text top="89" left="319" width="40" height="17" font="13">clinical </text>
<text top="106" left="319" width="23" height="17" font="13">trial </text>
<text top="55" left="374" width="17" height="17" font="13">58 </text>
<text top="55" left="425" width="54" height="17" font="13">56% ICM </text>
<text top="55" left="527" width="146" height="17" font="13">Advanced LV dysfunction, </text>
<text top="72" left="527" width="116" height="17" font="13">treatment with LVAD </text>
<text top="89" left="527" width="97" height="17" font="13">implantation, and </text>
<text top="106" left="527" width="141" height="17" font="13">persistent PH (defined by </text>
<text top="124" left="527" width="147" height="17" font="13">a PVR &gt;3 Wood Units 7 to </text>
<text top="141" left="527" width="91" height="17" font="13">14 d after LVAD </text>
<text top="158" left="527" width="117" height="17" font="13">implantation) despite </text>
<text top="175" left="527" width="118" height="17" font="13">normalization of their </text>
<text top="192" left="527" width="121" height="17" font="13">PCWP to a value &lt;15 </text>
<text top="210" left="527" width="148" height="17" font="13">mmHg were consented for </text>
<text top="227" left="527" width="129" height="17" font="13">and received treatment </text>
<text top="244" left="527" width="151" height="17" font="13">with sildenafil in an attempt </text>
<text top="261" left="527" width="122" height="17" font="13">to reduce PVR before </text>
<text top="278" left="527" width="127" height="17" font="13">cardiac transplantation </text>
<text top="55" left="691" width="181" height="17" font="13">Combined LVAD and RVAD; Pts </text>
<text top="72" left="691" width="143" height="17" font="13">receiving chronic inotrope </text>
<text top="89" left="691" width="44" height="17" font="13">therapy </text>
<text top="55" left="889" width="185" height="17" font="13">N/A The </text>
<text top="55" left="1005" width="113" height="17" font="13">primary </text>
<text top="72" left="981" width="102" height="17" font="13">endpoint of the 12 </text>
<text top="89" left="981" width="106" height="17" font="13">to 15 wk change in </text>
<text top="106" left="981" width="29" height="17" font="13">PVR </text>
<text top="124" left="981" width="85" height="17" font="13">andcontractility </text>
<text top="141" left="981" width="115" height="17" font="13">index (dP/dtmax/IP)  </text>
<text top="55" left="1107" width="94" height="17" font="13">Enrollment 1999-</text>
<text top="72" left="1107" width="88" height="17" font="13">2007; 12-15 wk </text>
<text top="89" left="1107" width="65" height="17" font="13">of sildenafil </text>
<text top="106" left="1107" width="91" height="17" font="13">treatment/follow-</text>
<text top="124" left="1107" width="21" height="17" font="13">up; </text>
<text top="55" left="1219" width="124" height="17" font="13">Lowering of PVR from </text>
<text top="72" left="1219" width="131" height="17" font="13">5.87+1.93 to 2.96+0.92 </text>
<text top="89" left="1219" width="118" height="17" font="13">Wood Units (mm Hg/ </text>
<text top="106" left="1219" width="126" height="17" font="13">L/min;) after 2- 4 wk of </text>
<text top="124" left="1219" width="135" height="17" font="13">sildenafil therapy; vs. no </text>
<text top="141" left="1219" width="134" height="17" font="13">change in PVR in LVAD </text>
<text top="158" left="1219" width="95" height="17" font="13">only group. Also, </text>
<text top="175" left="1219" width="132" height="17" font="13">marked improvement in </text>
<text top="192" left="1219" width="136" height="17" font="13">RV systolic and diastolic </text>
<text top="210" left="1219" width="124" height="17" font="13">function, as measured </text>
<text top="227" left="1219" width="135" height="17" font="13">by RV contractility index </text>
<text top="244" left="1219" width="136" height="17" font="13">(dP/dtmax/IP; 8.69+1.78 </text>
<text top="261" left="1219" width="129" height="17" font="13">to 13.1+3.3) in LVAD + </text>
<text top="278" left="1219" width="86" height="17" font="13">sildenafil group </text>
<text top="55" left="1371" width="59" height="17" font="13">Change in </text>
<text top="72" left="1371" width="84" height="17" font="13">PVR,  p&lt;0.001 </text>
<text top="89" left="1371" width="53" height="17" font="13">for LVAD </text>
<text top="106" left="1371" width="58" height="17" font="13">+sildenafil </text>
<text top="124" left="1371" width="76" height="17" font="13">group             </text>
<text top="141" left="1371" width="80" height="17" font="13">Change in RV </text>
<text top="158" left="1371" width="65" height="17" font="13">contractility </text>
<text top="175" left="1371" width="51" height="17" font="13">index for </text>
<text top="192" left="1371" width="91" height="17" font="13">LVAD+sildefanil </text>
<text top="210" left="1371" width="42" height="17" font="13">group,  </text>
<text top="227" left="1371" width="55" height="17" font="13">p&lt;0.0001 </text>
<text top="296" left="61" width="53" height="17" font="13">Sildenafil </text>
<text top="314" left="61" width="54" height="17" font="13">Improves </text>
<text top="331" left="61" width="102" height="17" font="13">Exercise Capacity </text>
<text top="348" left="61" width="103" height="17" font="13">and Quality of Life </text>
<text top="365" left="61" width="62" height="17" font="13">in Pts With </text>
<text top="382" left="61" width="90" height="17" font="13">Systolic HF and </text>
<text top="400" left="61" width="62" height="17" font="13">Secondary </text>
<text top="417" left="61" width="62" height="17" font="13">Pulmonary </text>
<text top="434" left="61" width="79" height="17" font="13">Hypertension, </text>
<text top="451" left="61" width="91" height="17" font="13">Lewis GD, 2007 </text>
<text top="469" left="61" width="55" height="17" font="14">17785618</text>
<text top="469" left="116" width="36" height="17" font="13"> (267) </text>
<text top="296" left="178" width="124" height="17" font="13">To test the hypothesis </text>
<text top="314" left="178" width="96" height="17" font="13">that sildenafil, an </text>
<text top="331" left="178" width="112" height="17" font="13">effective therapy for </text>
<text top="348" left="178" width="102" height="17" font="13">pulmonary arterial </text>
<text top="365" left="178" width="113" height="17" font="13">hypertension, would </text>
<text top="382" left="178" width="94" height="17" font="13">lower pulmonary </text>
<text top="400" left="178" width="109" height="17" font="13">vascular resistance </text>
<text top="417" left="178" width="120" height="17" font="13">and improve exercise </text>
<text top="434" left="178" width="127" height="17" font="13">capacity in pts with HF </text>
<text top="451" left="178" width="106" height="17" font="13">complicated by PH </text>
<text top="296" left="319" width="29" height="17" font="13">RCT </text>
<text top="296" left="374" width="17" height="17" font="13">34 </text>
<text top="296" left="425" width="54" height="17" font="13">50% ICM </text>
<text top="296" left="527" width="75" height="17" font="13">&gt;18 y of age, </text>
<text top="314" left="527" width="130" height="17" font="13">LVEF&lt;40%,NYHA II-IV </text>
<text top="331" left="527" width="106" height="17" font="13">chronic HF despite </text>
<text top="348" left="527" width="156" height="17" font="13">standard HF therapies          </text>
<text top="365" left="527" width="144" height="17" font="13">Pts were required to have </text>
<text top="382" left="527" width="141" height="17" font="13">secondary PH as defined </text>
<text top="400" left="527" width="122" height="17" font="13">by a mean pulmonary </text>
<text top="417" left="527" width="141" height="17" font="13">arterial pressure &gt;25 mm </text>
<text top="434" left="527" width="19" height="17" font="13">Hg </text>
<text top="296" left="691" width="172" height="17" font="13">Pts with a noncardiac limitation </text>
<text top="314" left="691" width="130" height="17" font="13">to exercise, provocable </text>
<text top="331" left="691" width="135" height="17" font="13">ischemia, hemodynamic </text>
<text top="348" left="691" width="157" height="17" font="13">instability, or ongoing nitrate </text>
<text top="365" left="691" width="130" height="17" font="13">therapy were excluded. </text>
<text top="382" left="691" width="152" height="17" font="13">Additional exclusion criteria </text>
<text top="400" left="691" width="127" height="17" font="13">included concentric LV </text>
<text top="417" left="691" width="143" height="17" font="13">hypertrophy, critical aortic </text>
<text top="434" left="691" width="159" height="17" font="13">stenosis, or long-term use of </text>
<text top="451" left="691" width="128" height="17" font="13">medications that inhibit </text>
<text top="469" left="691" width="128" height="17" font="13">cytochrome P450 3A4. </text>
<text top="296" left="889" width="72" height="17" font="13">100% NYHA </text>
<text top="314" left="889" width="84" height="17" font="13">II-IV                  </text>
<text top="331" left="889" width="70" height="17" font="13">(53% NYHA </text>
<text top="348" left="889" width="45" height="17" font="13">II / 38% </text>
<text top="365" left="889" width="62" height="17" font="13">NYHA III/   </text>
<text top="382" left="889" width="85" height="17" font="13">9% NYHA IV)   </text>
<text top="400" left="889" width="62" height="17" font="13">peak VO2  </text>
<text top="417" left="889" width="27" height="17" font="13">11.1 </text>
<text top="434" left="889" width="56" height="17" font="13">ml/kg/min </text>
<text top="296" left="981" width="83" height="17" font="13">No predefinied </text>
<text top="314" left="981" width="105" height="17" font="13">primary endpoints; </text>
<text top="331" left="981" width="107" height="17" font="13">measured exercise </text>
<text top="348" left="981" width="100" height="17" font="13">capacity, invasive </text>
<text top="365" left="981" width="87" height="17" font="13">hemodyanamic </text>
<text top="382" left="981" width="99" height="17" font="13">parameters, QoL, </text>
<text top="400" left="981" width="88" height="17" font="13">and biomarkers </text>
<text top="296" left="1107" width="59" height="17" font="13">12 wk trial </text>
<text top="296" left="1219" width="116" height="17" font="13">Peak VO2 increased </text>
<text top="314" left="1219" width="93" height="17" font="13">from 12.2+0.7 to </text>
<text top="331" left="1219" width="128" height="17" font="13">13.9+1.0 mL/ kg/min in </text>
<text top="348" left="1219" width="107" height="17" font="13">the sildenafil group </text>
<text top="365" left="1219" width="114" height="17" font="13">(p=0.02) and did not </text>
<text top="382" left="1219" width="124" height="17" font="13">change in the placebo </text>
<text top="400" left="1219" width="117" height="17" font="13">group.                        </text>
<text top="417" left="1219" width="118" height="17" font="13">Change in peak VO2 </text>
<text top="434" left="1219" width="138" height="17" font="13">from baseline among pts </text>
<text top="451" left="1219" width="118" height="17" font="13">treated with sildenafil </text>
<text top="469" left="1219" width="121" height="17" font="13">(1.8+0.7 mL/· kg/min) </text>
<text top="486" left="1219" width="115" height="17" font="13">was greater than the </text>
<text top="503" left="1219" width="124" height="17" font="13">change in the placebo </text>
<text top="520" left="1219" width="134" height="17" font="13">group (-0.27 mL/kg/min; </text>
<text top="537" left="1219" width="110" height="17" font="13">p=0.02).                   </text>
<text top="555" left="1219" width="139" height="17" font="13">Sildenafil treated pts had </text>
<text top="572" left="1219" width="137" height="17" font="13">improvement in RVEF at </text>
<text top="589" left="1219" width="126" height="17" font="13">rest and with exercise; </text>
<text top="606" left="1219" width="116" height="17" font="13">control group had no </text>
<text top="624" left="1219" width="144" height="17" font="13">improvement in RVEF.      </text>
<text top="641" left="1219" width="114" height="17" font="13">Mean MLHFQ score </text>
<text top="658" left="1219" width="118" height="17" font="13">decreased (reflecting </text>
<text top="675" left="1219" width="126" height="17" font="13">improvement) by 13+5 </text>
<text top="692" left="1219" width="121" height="17" font="13">and 16+5 at wk 6 and </text>
<text top="710" left="1219" width="133" height="17" font="13">12, respectively, among </text>
<text top="727" left="1219" width="124" height="17" font="13">pts receiving sildenafil </text>
<text top="744" left="1219" width="121" height="17" font="13">(p=0.007) and did not </text>
<text top="761" left="1219" width="129" height="17" font="13">change in pts receiving </text>
<text top="778" left="1219" width="50" height="17" font="13">placebo. </text>
<text top="296" left="1371" width="7" height="17" font="13">  </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">122</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="96" height="17" font="13">Long-term use of </text>
<text top="72" left="61" width="85" height="17" font="13">sildenafil in the </text>
<text top="89" left="61" width="64" height="17" font="13">therapeutic </text>
<text top="106" left="61" width="89" height="17" font="13">management of </text>
<text top="124" left="61" width="82" height="17" font="13">HF, Guazzi M, </text>
<text top="141" left="61" width="34" height="17" font="13">2007  </text>
<text top="158" left="61" width="55" height="17" font="14">18036451</text>
<text top="158" left="116" width="36" height="17" font="13"> (268) </text>
<text top="55" left="178" width="118" height="17" font="13">To test the functional </text>
<text top="72" left="178" width="122" height="17" font="13">exercise capacity and </text>
<text top="89" left="178" width="122" height="17" font="13">endothelial function in </text>
<text top="106" left="178" width="110" height="17" font="13">a cohort of CHF pts </text>
<text top="124" left="178" width="110" height="17" font="13">treated with chronic </text>
<text top="141" left="178" width="37" height="17" font="13">type 5 </text>
<text top="158" left="178" width="107" height="17" font="13">phosphodiesterase </text>
<text top="175" left="178" width="90" height="17" font="13">(PDE5) inhibitor </text>
<text top="55" left="326" width="29" height="17" font="13">RCT </text>
<text top="55" left="385" width="17" height="17" font="13">46 </text>
<text top="55" left="443" width="54" height="17" font="13">ICM 46% </text>
<text top="55" left="527" width="157" height="17" font="13">Stable NHYA II-III CHF ;       </text>
<text top="72" left="527" width="135" height="17" font="13">negative exercise stress </text>
<text top="89" left="527" width="101" height="17" font="13">test prior to study; </text>
<text top="106" left="527" width="159" height="17" font="13">FEV1/FVC &gt;70%;                  </text>
<text top="124" left="527" width="138" height="17" font="13">LVEF &lt;45%, determined </text>
<text top="141" left="527" width="121" height="17" font="13">by echocardiography. </text>
<text top="55" left="691" width="169" height="17" font="13">Unable to complete a maximal </text>
<text top="72" left="691" width="184" height="17" font="13">exercise test;  SBP &gt;140 or &lt;110 </text>
<text top="89" left="691" width="150" height="17" font="13">mm Hg;  DM; Therapy with </text>
<text top="106" left="691" width="148" height="17" font="13">nitrate; History of sildenafil </text>
<text top="124" left="691" width="168" height="17" font="13">intolerance; Significant lung or </text>
<text top="141" left="691" width="101" height="17" font="13">valvular diseases, </text>
<text top="158" left="691" width="165" height="17" font="13">neuromuscular disorders, AF, </text>
<text top="175" left="691" width="144" height="17" font="13">claudication, or peripheral </text>
<text top="192" left="691" width="95" height="17" font="13">vascular disease </text>
<text top="55" left="889" width="86" height="17" font="13">NYHA II-III        </text>
<text top="72" left="889" width="75" height="17" font="13">peak VO2 15 </text>
<text top="89" left="889" width="56" height="17" font="13">ml/min/kg </text>
<text top="55" left="981" width="81" height="17" font="13">No predefined </text>
<text top="72" left="981" width="119" height="17" font="13">primary endpoint;       </text>
<text top="89" left="981" width="103" height="17" font="13">assessments (at 3 </text>
<text top="106" left="981" width="73" height="17" font="13">and 6 mo) of </text>
<text top="124" left="981" width="109" height="17" font="13">endothelial function </text>
<text top="141" left="981" width="98" height="17" font="13">by brachial artery </text>
<text top="158" left="981" width="34" height="17" font="13">FMD, </text>
<text top="175" left="981" width="94" height="17" font="13">cardiopulmonary </text>
<text top="192" left="981" width="96" height="17" font="13">exercise testing,  </text>
<text top="210" left="981" width="58" height="17" font="13">ergoreflex </text>
<text top="227" left="981" width="81" height="17" font="13">response, and </text>
<text top="244" left="981" width="107" height="17" font="13">QOL questionnaire </text>
<text top="261" left="981" width="67" height="17" font="13">(CHF) were </text>
<text top="278" left="981" width="59" height="17" font="13">performed </text>
<text top="55" left="1107" width="48" height="17" font="13">6 mo f/u </text>
<text top="55" left="1219" width="120" height="17" font="13">In the sildenafil group </text>
<text top="72" left="1219" width="112" height="17" font="13">only, at 3 and 6 mo, </text>
<text top="89" left="1219" width="133" height="17" font="13">systolic PAP decreased </text>
<text top="106" left="1219" width="120" height="17" font="13">from 33.7 to 25.2 mm </text>
<text top="124" left="1219" width="122" height="17" font="13">Hg and then 23.9 mm </text>
<text top="141" left="1219" width="131" height="17" font="13">Hg, ergoreflex effect on </text>
<text top="158" left="1219" width="120" height="17" font="13">ventilation decreased </text>
<text top="175" left="1219" width="130" height="17" font="13">from 6.9 to 2.3/min and </text>
<text top="192" left="1219" width="111" height="17" font="13">1.9L/min, VE/VCO2 </text>
<text top="210" left="1219" width="130" height="17" font="13">decreased from 35.5 to </text>
<text top="227" left="1219" width="106" height="17" font="13">32.1 and 29.8, and </text>
<text top="244" left="1219" width="128" height="17" font="13">breathlessness (score) </text>
<text top="261" left="1219" width="120" height="17" font="13">from 23.6 to 16.6 and </text>
<text top="278" left="1219" width="121" height="17" font="13">17.2,  FMD increased </text>
<text top="296" left="1219" width="135" height="17" font="13">from 8.5% to 13.4% and </text>
<text top="313" left="1219" width="128" height="17" font="13">14.2%, peak VO2 from </text>
<text top="330" left="1219" width="124" height="17" font="13">14.8 to 18.5 ml/min/kg </text>
<text top="347" left="1219" width="135" height="17" font="13">and 18.7 ml/min/kg, and </text>
<text top="365" left="1219" width="137" height="17" font="13">ratio of VO2 to work rate </text>
<text top="382" left="1219" width="133" height="17" font="13">changes from 7.7 to 9.3 </text>
<text top="399" left="1219" width="48" height="17" font="13">and 10.  </text>
<text top="55" left="1371" width="75" height="17" font="13">p&lt;0.01 for all </text>
<text top="72" left="1371" width="50" height="17" font="13">changes </text>
<text top="417" left="61" width="94" height="17" font="13">Sildenafil Effects </text>
<text top="434" left="61" width="71" height="17" font="13">on Exercise, </text>
<text top="451" left="61" width="88" height="17" font="13">Neurohormonal </text>
<text top="469" left="61" width="60" height="17" font="13">Activation, </text>
<text top="486" left="61" width="68" height="17" font="13">and Erectile </text>
<text top="503" left="61" width="81" height="17" font="13">Dysfunction in </text>
<text top="520" left="61" width="88" height="17" font="13">Congestive HF, </text>
<text top="537" left="61" width="87" height="17" font="13">Bocci EA, 2002 </text>
<text top="555" left="61" width="58" height="17" font="14">12196335 </text>
<text top="555" left="119" width="25" height="17" font="13">(94) </text>
<text top="417" left="178" width="101" height="17" font="13">To investigate the </text>
<text top="434" left="178" width="87" height="17" font="13">acute effects of </text>
<text top="451" left="178" width="121" height="17" font="13">sildenafil on exercise, </text>
<text top="469" left="178" width="86" height="17" font="13">neurohormonal </text>
<text top="486" left="178" width="123" height="17" font="13">activation, and clinical </text>
<text top="503" left="178" width="131" height="17" font="13">status of CHF pts with   </text>
<text top="520" left="178" width="124" height="17" font="13">(ED).  To evaluate the </text>
<text top="537" left="178" width="119" height="17" font="13">efficacy and safety of </text>
<text top="555" left="178" width="90" height="17" font="13">sildenafil for ED </text>
<text top="572" left="178" width="110" height="17" font="13">treatment in a 1-mo </text>
<text top="589" left="178" width="56" height="17" font="13">follow-up  </text>
<text top="417" left="326" width="29" height="17" font="13">RCT </text>
<text top="417" left="385" width="17" height="17" font="13">23 </text>
<text top="417" left="443" width="54" height="17" font="13">ICM 22% </text>
<text top="417" left="527" width="148" height="17" font="13">CHF outpatients who were </text>
<text top="434" left="527" width="140" height="17" font="13">referred for ED treatment </text>
<text top="451" left="527" width="131" height="17" font="13">(ED was defined as the </text>
<text top="469" left="527" width="118" height="17" font="13">inability to achieve or </text>
<text top="486" left="527" width="114" height="17" font="13">maintain an erection </text>
<text top="503" left="527" width="103" height="17" font="13">sufficient to permit </text>
<text top="520" left="527" width="105" height="17" font="13">satisfactory sexual </text>
<text top="537" left="527" width="113" height="17" font="13">intercourse);             </text>
<text top="555" left="527" width="130" height="17" font="13">History of ED x &gt; 4 mo, </text>
<text top="572" left="527" width="148" height="17" font="13">present interest in sex and </text>
<text top="589" left="527" width="157" height="17" font="13">in a stable relationship;         </text>
<text top="606" left="527" width="98" height="17" font="13">Concomitant new </text>
<text top="624" left="527" width="105" height="17" font="13">symptoms of CHF, </text>
<text top="641" left="527" width="133" height="17" font="13">worsening of HF clinical </text>
<text top="658" left="527" width="121" height="17" font="13">status, or a change in </text>
<text top="675" left="527" width="125" height="17" font="13">specific medication for </text>
<text top="692" left="527" width="32" height="17" font="13">CHF; </text>
<text top="710" left="527" width="116" height="17" font="13">All pts were in stable </text>
<text top="727" left="527" width="135" height="17" font="13">clinical condition without </text>
<text top="744" left="527" width="111" height="17" font="13">required changes in </text>
<text top="761" left="527" width="144" height="17" font="13">treatment within the last 3 </text>
<text top="778" left="527" width="27" height="17" font="13">mo.  </text>
<text top="417" left="691" width="158" height="17" font="13">ED considered secondary to </text>
<text top="434" left="691" width="140" height="17" font="13">causes other than CHF;   </text>
<text top="451" left="691" width="179" height="17" font="13">Previous therapy for ED,             </text>
<text top="469" left="691" width="171" height="17" font="13">Recent use of PDE inhibitors;   </text>
<text top="486" left="691" width="178" height="17" font="13">Severe systemic disease, visual </text>
<text top="503" left="691" width="152" height="17" font="13">disturbances, psychiatric or </text>
<text top="520" left="691" width="190" height="17" font="13">psychological disorder;                   </text>
<text top="537" left="691" width="167" height="17" font="13">UA or MI within the previous 3 </text>
<text top="555" left="691" width="85" height="17" font="13">mo;,                  </text>
<text top="572" left="691" width="164" height="17" font="13">Syncope,                                 </text>
<text top="589" left="691" width="165" height="17" font="13">Angina,                                    </text>
<text top="606" left="691" width="126" height="17" font="13">HR &lt;55 bpm, high-risk </text>
<text top="624" left="691" width="127" height="17" font="13">arrhythmias, new atrial </text>
<text top="641" left="691" width="170" height="17" font="13">tachycardia/fibrillation/flutter or </text>
<text top="658" left="691" width="157" height="17" font="13">uncontrolled high ventricular </text>
<text top="675" left="691" width="180" height="17" font="13">response, new or high degree of </text>
<text top="692" left="691" width="168" height="17" font="13">AV block                                   </text>
<text top="710" left="691" width="158" height="17" font="13">HCM                                      </text>
<text top="727" left="691" width="172" height="17" font="13">Valvular disease,                       </text>
<text top="744" left="691" width="159" height="17" font="13">Symptomatic hypotension or </text>
<text top="761" left="691" width="167" height="17" font="13">SBP &lt;85 mm Hg                      </text>
<text top="778" left="691" width="157" height="17" font="13">Unstable CHF, low systemic </text>
<text top="417" left="889" width="70" height="17" font="13">  NYHA II-IV </text>
<text top="417" left="981" width="111" height="17" font="13">First phase: 6MWT, </text>
<text top="434" left="981" width="120" height="17" font="13">exercise test               </text>
<text top="451" left="981" width="85" height="17" font="13">Second phase: </text>
<text top="469" left="981" width="110" height="17" font="13">efficacy of sildenafil </text>
<text top="486" left="981" width="59" height="17" font="13">in ED was </text>
<text top="503" left="981" width="111" height="17" font="13">evaluated by the 15 </text>
<text top="520" left="981" width="90" height="17" font="13">questions of the </text>
<text top="537" left="981" width="103" height="17" font="13">IIEF; adverse side </text>
<text top="555" left="981" width="40" height="17" font="13">effects </text>
<text top="417" left="1107" width="31" height="17" font="13">1 mo </text>
<text top="417" left="1219" width="144" height="17" font="13">Peak VO2 (ml/kg/min)       </text>
<text top="434" left="1219" width="145" height="17" font="13">placebo 16.6+3.4 vs          </text>
<text top="451" left="1219" width="144" height="17" font="13">sildenafil 17.7+3.4             </text>
<text top="469" left="1219" width="146" height="17" font="13">Ve/VCO2 slope                  </text>
<text top="486" left="1219" width="146" height="17" font="13">placebo 33+8                     </text>
<text top="503" left="1219" width="93" height="17" font="13">sildenafil 31+5    </text>
<text top="417" left="1371" width="96" height="17" font="13">p=0.025               </text>
<text top="434" left="1371" width="48" height="17" font="13">p=0.027 </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="26" size="16" family="Times" color="#000000"/>
	<fontspec id="27" size="9" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">123</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="691" width="129" height="17" font="13">perfusion, or venous or </text>
<text top="72" left="691" width="127" height="17" font="13">pulmonary congestion. </text>
<text top="235" left="54" width="1395" height="15" font="6">6MWT indicates 6 minute walk test; AF, atrial fibrillation; AV, atrioventricular; CHF, congestive heart failure; D, Doppler; DM, diabetes mellitus; ED, erectile dysfunction; EF, ejection fraction; FEV, forced expiratory volume; FMD, flow-mediated dilatation; FVC, forced vital capacity; HCM, </text>
<text top="251" left="54" width="685" height="15" font="6">hypertrophic cardiomyopathy; HF, heart failure; HR, heart rate; ICM, ischemic cardiomyopathy; IIEF, International Index of Erectile Function;</text>
<text top="251" left="739" width="4" height="16" font="7"> </text>
<text top="251" left="743" width="706" height="15" font="6">LVAD, left ventricular assist device; LVDF, left ventricular diastolic function; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular </text>
<text top="266" left="54" width="1373" height="15" font="6">ejection fraction; LVMI, left ventricular mass index; Mitral E/A, Mitral early-to-late velocity; MLHFQ, Minnesota Living with Heart Failure Questionaire; MI, myocardial infarction; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge </text>
<text top="282" left="54" width="470" height="15" font="6">pressure; PDE5A, phosphodiesterase type 5A; PH, pulmonary hypertension; pts, patients; PVR;</text>
<text top="282" left="524" width="4" height="16" font="7"> </text>
<text top="282" left="527" width="931" height="15" font="6">pulmonary vascular resistance; QoL, quality of life; RCT, randomized control trial; RVAD, right ventricular assist device; RVEF, right ventricular ejection fraction; SBP, systolic blood pressure; </text>
<text top="297" left="54" width="416" height="15" font="6">SIL, sildenafil; UA, unstable angina; VE/VCO2, ventilation efficiency ventilation to CO</text>
<text top="302" left="470" width="4" height="10" font="19">2</text>
<text top="297" left="474" width="199" height="15" font="6"> production slope; VO2, oxygen volume. </text>
<text top="316" left="54" width="4" height="16" font="7"> </text>
<text top="354" left="54" width="4" height="16" font="7"> </text>
<text top="393" left="54" width="4" height="16" font="7"> </text>
<text top="431" left="54" width="4" height="16" font="7"> </text>
<text top="469" left="54" width="4" height="16" font="7"> </text>
<text top="507" left="54" width="4" height="16" font="7"> </text>
<text top="542" left="54" width="4" height="21" font="26"> </text>
<text top="581" left="54" width="325" height="21" font="8"><b>Data Supplement 32. Inotropes (Section 7.4.4) </b></text>
<text top="602" left="70" width="38" height="17" font="15"><b>Study </b></text>
<text top="619" left="68" width="40" height="17" font="15"><b>Name, </b></text>
<text top="636" left="65" width="47" height="17" font="15"><b>Author, </b></text>
<text top="654" left="73" width="30" height="17" font="15"><b>Year </b></text>
<text top="602" left="135" width="42" height="17" font="15"><b>Aim of </b></text>
<text top="619" left="138" width="36" height="17" font="15"><b>study </b></text>
<text top="602" left="198" width="27" height="17" font="15"><b>Stud</b></text>
<text top="619" left="208" width="10" height="17" font="15"><b>y </b></text>
<text top="636" left="197" width="32" height="17" font="15"><b>Type </b></text>
<text top="602" left="245" width="57" height="17" font="15"><b>Backgrou</b></text>
<text top="619" left="265" width="19" height="17" font="15"><b>nd </b></text>
<text top="636" left="249" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="602" left="320" width="132" height="17" font="15"><b>Study Size  Etiology </b></text>
<text top="602" left="474" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="602" left="641" width="51" height="17" font="15"><b>Severity </b></text>
<text top="602" left="780" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="602" left="933" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="602" left="1043" width="29" height="17" font="15"><b>Trial </b></text>
<text top="619" left="1035" width="43" height="17" font="15"><b>Duratio</b></text>
<text top="636" left="1053" width="11" height="17" font="15"><b>n </b></text>
<text top="654" left="1036" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="602" left="1108" width="56" height="17" font="15"><b>Absolute </b></text>
<text top="619" left="1105" width="61" height="17" font="15"><b>Benefit or </b></text>
<text top="636" left="1118" width="36" height="17" font="15"><b>Major </b></text>
<text top="654" left="1112" width="48" height="17" font="15"><b>Finding </b></text>
<text top="602" left="1213" width="62" height="17" font="15"><b>Statistical </b></text>
<text top="619" left="1217" width="54" height="17" font="15"><b>Analysis </b></text>
<text top="636" left="1216" width="56" height="17" font="15"><b>(Results) </b></text>
<text top="602" left="1321" width="41" height="17" font="15"><b> Study </b></text>
<text top="619" left="1314" width="51" height="17" font="15"><b>Limitatio</b></text>
<text top="636" left="1333" width="18" height="17" font="15"><b>ns </b></text>
<text top="602" left="1386" width="70" height="17" font="15"><b>Complicatio</b></text>
<text top="619" left="1388" width="70" height="17" font="15"><b>ns/Adverse </b></text>
<text top="636" left="1401" width="44" height="17" font="15"><b>Events </b></text>
<text top="672" left="85" width="7" height="17" font="13">  </text>
<text top="672" left="153" width="7" height="17" font="13">  </text>
<text top="672" left="210" width="7" height="17" font="13">  </text>
<text top="671" left="256" width="37" height="14" font="27"><i><b>Pretrial </b></i></text>
<text top="685" left="252" width="44" height="14" font="27"><i><b>standard </b></i></text>
<text top="699" left="251" width="48" height="14" font="27"><i><b>treatment </b></i></text>
<text top="671" left="331" width="43" height="14" font="27"><i><b>N (Total) </b></i></text>
<text top="685" left="348" width="9" height="14" font="27"><i><b>n </b></i></text>
<text top="699" left="321" width="63" height="14" font="27"><i><b>(Experiment) </b></i></text>
<text top="713" left="326" width="53" height="14" font="27"><i><b>n (Control) </b></i></text>
<text top="671" left="401" width="45" height="14" font="27"><i><b>Ischemic/</b></i></text>
<text top="685" left="412" width="22" height="14" font="27"><i><b>Non-</b></i></text>
<text top="699" left="403" width="45" height="14" font="27"><i><b>Ischemic </b></i></text>
<text top="671" left="471" width="46" height="14" font="27"><i><b>Inclusion </b></i></text>
<text top="685" left="475" width="37" height="14" font="27"><i><b>Criteria </b></i></text>
<text top="671" left="542" width="49" height="14" font="27"><i><b>Exclusion </b></i></text>
<text top="685" left="548" width="37" height="14" font="27"><i><b>Criteria </b></i></text>
<text top="671" left="610" width="53" height="14" font="27"><i><b>Severity of </b></i></text>
<text top="685" left="628" width="16" height="14" font="27"><i><b>HF </b></i></text>
<text top="699" left="610" width="53" height="14" font="27"><i><b>Symptoms </b></i></text>
<text top="671" left="685" width="30" height="14" font="27"><i><b>Study </b></i></text>
<text top="685" left="686" width="28" height="14" font="27"><i><b>Entry </b></i></text>
<text top="699" left="682" width="35" height="14" font="27"><i><b>Sverity </b></i></text>
<text top="713" left="681" width="37" height="14" font="27"><i><b>Criteria </b></i></text>
<text top="671" left="747" width="39" height="14" font="27"><i><b>Primary </b></i></text>
<text top="685" left="744" width="45" height="14" font="27"><i><b>Endpoint </b></i></text>
<text top="671" left="822" width="56" height="14" font="27"><i><b>Secondary  </b></i></text>
<text top="685" left="826" width="45" height="14" font="27"><i><b>Endpoint </b></i></text>
<text top="671" left="902" width="55" height="14" font="27"><i><b>Annualized </b></i></text>
<text top="685" left="908" width="44" height="14" font="27"><i><b>Mortality </b></i></text>
<text top="671" left="977" width="41" height="14" font="27"><i><b>1st Year </b></i></text>
<text top="685" left="975" width="44" height="14" font="27"><i><b>Mortality </b></i></text>
<text top="672" left="1055" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="672" left="1132" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="672" left="1240" width="7" height="17" font="13">  </text>
<text top="689" left="1240" width="7" height="17" font="13">  </text>
<text top="672" left="1338" width="7" height="17" font="13">  </text>
<text top="672" left="1420" width="7" height="17" font="13">  </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="28" size="9" family="Times" color="#0000ff"/>
	<fontspec id="29" size="5" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">124</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="52" height="14" font="5">Intermittent </text>
<text top="68" left="61" width="43" height="14" font="5">6-mo low-</text>
<text top="82" left="61" width="24" height="14" font="5">dose </text>
<text top="96" left="61" width="54" height="14" font="5">dobutamine </text>
<text top="110" left="61" width="47" height="14" font="5">infusion in </text>
<text top="123" left="61" width="51" height="14" font="5">severe HF: </text>
<text top="137" left="61" width="26" height="14" font="5">DICE </text>
<text top="151" left="61" width="51" height="14" font="5">Multicenter </text>
<text top="165" left="61" width="50" height="14" font="5">Trial, Oliva </text>
<text top="178" left="61" width="36" height="14" font="5">F, 1999 </text>
<text top="192" left="61" width="46" height="14" font="28">10426835 </text>
<text top="206" left="61" width="26" height="14" font="5">(269) </text>
<text top="55" left="129" width="47" height="14" font="5">To reduce </text>
<text top="68" left="129" width="49" height="14" font="5">hospitalizat</text>
<text top="82" left="129" width="35" height="14" font="5">ions for </text>
<text top="96" left="129" width="48" height="14" font="5">worsening </text>
<text top="110" left="129" width="47" height="14" font="5">of CHF by </text>
<text top="123" left="129" width="47" height="14" font="5">administeri</text>
<text top="137" left="129" width="14" height="14" font="5">ng </text>
<text top="151" left="129" width="51" height="14" font="5">intermittent </text>
<text top="165" left="129" width="42" height="14" font="5">low-dose </text>
<text top="178" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="192" left="129" width="28" height="14" font="5">e (2.5-</text>
<text top="206" left="129" width="54" height="14" font="5">5mg/kg/min </text>
<text top="220" left="129" width="28" height="14" font="5">for 48-</text>
<text top="234" left="129" width="45" height="14" font="5">72hrs/wk) </text>
<text top="55" left="196" width="23" height="14" font="5">RCT </text>
<text top="55" left="243" width="67" height="14" font="5">ACEI 82%        </text>
<text top="68" left="243" width="69" height="14" font="5">Digoxin 95%     </text>
<text top="82" left="243" width="57" height="14" font="5">Furosemide  </text>
<text top="96" left="243" width="69" height="14" font="5">95%                  </text>
<text top="110" left="243" width="67" height="14" font="5">Nitrates  63%   </text>
<text top="123" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="137" left="243" width="42" height="14" font="5">39%        </text>
<text top="55" left="319" width="30" height="14" font="5">38; 19 </text>
<text top="68" left="319" width="63" height="14" font="5">(dobutamine); </text>
<text top="82" left="319" width="52" height="14" font="5">19 (control) </text>
<text top="55" left="399" width="43" height="14" font="5">47% ICM </text>
<text top="55" left="464" width="66" height="14" font="5">Age &gt;18 y;       </text>
<text top="68" left="464" width="53" height="14" font="5">NYHA III-IV </text>
<text top="82" left="464" width="67" height="14" font="5">CHF ;               </text>
<text top="96" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="110" left="464" width="56" height="14" font="5">for CHF and </text>
<text top="123" left="464" width="56" height="14" font="5">administratio</text>
<text top="137" left="464" width="31" height="14" font="5">n of IV </text>
<text top="151" left="464" width="54" height="14" font="5">inotropes in </text>
<text top="165" left="464" width="41" height="14" font="5">the 6 mo </text>
<text top="178" left="464" width="47" height="14" font="5">before the </text>
<text top="192" left="464" width="67" height="14" font="5">evaluation;       </text>
<text top="206" left="464" width="41" height="14" font="5">&gt; 48 h of </text>
<text top="220" left="464" width="32" height="14" font="5">clinical </text>
<text top="234" left="464" width="49" height="14" font="5">stability on </text>
<text top="247" left="464" width="66" height="14" font="5">oral therapy.    </text>
<text top="261" left="464" width="35" height="14" font="5">CI &lt;2.2 </text>
<text top="275" left="464" width="65" height="14" font="5">L/min/m2         </text>
<text top="289" left="464" width="47" height="14" font="5">6. LVEF &lt; </text>
<text top="302" left="464" width="25" height="14" font="5">30%. </text>
<text top="55" left="537" width="44" height="14" font="5">History of </text>
<text top="68" left="537" width="57" height="14" font="5">documented </text>
<text top="82" left="537" width="45" height="14" font="5">malignant </text>
<text top="96" left="537" width="54" height="14" font="5">arrhythmias </text>
<text top="110" left="537" width="48" height="14" font="5">without an </text>
<text top="123" left="537" width="45" height="14" font="5">automatic </text>
<text top="137" left="537" width="51" height="14" font="5">defibrillator </text>
<text top="151" left="537" width="64" height="14" font="5">in place;          </text>
<text top="165" left="537" width="49" height="14" font="5">Neoplastic </text>
<text top="178" left="537" width="52" height="14" font="5">or systemic </text>
<text top="192" left="537" width="37" height="14" font="5">disease </text>
<text top="206" left="537" width="40" height="14" font="5">affecting </text>
<text top="220" left="537" width="48" height="14" font="5">short-term </text>
<text top="234" left="537" width="64" height="14" font="5">prognosis        </text>
<text top="247" left="537" width="19" height="14" font="5">UA, </text>
<text top="261" left="537" width="52" height="14" font="5">angiographi</text>
<text top="275" left="537" width="22" height="14" font="5">cally </text>
<text top="289" left="537" width="57" height="14" font="5">documented </text>
<text top="302" left="537" width="39" height="14" font="5">effective </text>
<text top="316" left="537" width="41" height="14" font="5">coronary </text>
<text top="330" left="537" width="66" height="14" font="5">stenosis           </text>
<text top="344" left="537" width="45" height="14" font="5">Surgically </text>
<text top="357" left="537" width="35" height="14" font="5">curable </text>
<text top="371" left="537" width="37" height="14" font="5">valvular </text>
<text top="385" left="537" width="25" height="14" font="5">heart </text>
<text top="399" left="537" width="37" height="14" font="5">disease </text>
<text top="55" left="609" width="28" height="14" font="5">100% </text>
<text top="68" left="609" width="62" height="14" font="5">NYHA III-IV    </text>
<text top="82" left="609" width="39" height="14" font="5">6MWTD </text>
<text top="96" left="609" width="27" height="14" font="5">298m </text>
<text top="55" left="677" width="41" height="14" font="5">NYHA III-</text>
<text top="68" left="677" width="12" height="14" font="5">IV </text>
<text top="82" left="677" width="40" height="14" font="5">symptom</text>
<text top="96" left="677" width="51" height="14" font="5">s,                </text>
<text top="110" left="677" width="13" height="14" font="5">CI </text>
<text top="123" left="677" width="38" height="14" font="5">&lt;2.2L/mi</text>
<text top="137" left="677" width="25" height="14" font="5">n/m2 </text>
<text top="55" left="736" width="58" height="14" font="5">Reduction of </text>
<text top="68" left="736" width="57" height="14" font="5">hospitalizatio</text>
<text top="82" left="736" width="27" height="14" font="5">ns for </text>
<text top="96" left="736" width="58" height="14" font="5">worsening of </text>
<text top="110" left="736" width="23" height="14" font="5">CHF </text>
<text top="55" left="811" width="53" height="14" font="5">Changes in </text>
<text top="68" left="811" width="30" height="14" font="5">NYHA </text>
<text top="82" left="811" width="73" height="14" font="5">functional class, </text>
<text top="96" left="811" width="63" height="14" font="5">6-min walking </text>
<text top="110" left="811" width="40" height="14" font="5">test, and </text>
<text top="123" left="811" width="67" height="14" font="5">mortality rates. </text>
<text top="55" left="899" width="19" height="14" font="5">N/A </text>
<text top="55" left="973" width="19" height="14" font="5">N/A </text>
<text top="55" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="68" left="1034" width="35" height="14" font="5">t 18 mo </text>
<text top="82" left="1034" width="26" height="14" font="5">(7/94-</text>
<text top="96" left="1034" width="41" height="14" font="5">12/95); 6 </text>
<text top="110" left="1034" width="30" height="14" font="5">mo f/u </text>
<text top="55" left="1095" width="58" height="14" font="5">No benefit in </text>
<text top="68" left="1095" width="68" height="14" font="5">hospitalization, </text>
<text top="82" left="1095" width="76" height="14" font="5">functional status, </text>
<text top="96" left="1095" width="74" height="14" font="5">or mortality rate. </text>
<text top="55" left="1189" width="98" height="14" font="5">Time to first CV death </text>
<text top="68" left="1189" width="91" height="14" font="5">or hospitalization for </text>
<text top="82" left="1189" width="83" height="14" font="5">any cause, p=0.91 </text>
<text top="96" left="1189" width="5" height="14" font="5">  </text>
<text top="55" left="1311" width="27" height="14" font="5">Small </text>
<text top="68" left="1311" width="68" height="14" font="5">sample size      </text>
<text top="55" left="1385" width="22" height="14" font="5"> N/A </text>
<text top="413" left="61" width="48" height="14" font="5">Levosimen</text>
<text top="427" left="61" width="19" height="14" font="5">dan </text>
<text top="441" left="61" width="37" height="14" font="5">Infusion </text>
<text top="455" left="61" width="32" height="14" font="5">versus </text>
<text top="468" left="61" width="48" height="14" font="5">Dobutamin</text>
<text top="482" left="61" width="36" height="14" font="5">e Study </text>
<text top="496" left="61" width="35" height="14" font="5">(LIDO), </text>
<text top="510" left="61" width="44" height="14" font="5">Follath F, </text>
<text top="523" left="61" width="25" height="14" font="5">2002 </text>
<text top="537" left="61" width="46" height="14" font="28">12133653 </text>
<text top="551" left="61" width="26" height="14" font="5">(270) </text>
<text top="413" left="129" width="14" height="14" font="5">To </text>
<text top="427" left="129" width="47" height="14" font="5">compared </text>
<text top="441" left="129" width="48" height="14" font="5">the effects </text>
<text top="455" left="129" width="11" height="14" font="5">of </text>
<text top="468" left="129" width="50" height="14" font="5">levosimend</text>
<text top="482" left="129" width="33" height="14" font="5">an and </text>
<text top="496" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="510" left="129" width="22" height="14" font="5">e on </text>
<text top="523" left="129" width="46" height="14" font="5">haemodyn</text>
<text top="537" left="129" width="24" height="14" font="5">amic </text>
<text top="551" left="129" width="50" height="14" font="5">performanc</text>
<text top="565" left="129" width="8" height="14" font="5">e </text>
<text top="578" left="129" width="51" height="14" font="5">and clinical </text>
<text top="592" left="129" width="51" height="14" font="5">outcome in </text>
<text top="606" left="129" width="36" height="14" font="5">pts with </text>
<text top="620" left="129" width="48" height="14" font="5">low-output </text>
<text top="634" left="129" width="16" height="14" font="5">HF </text>
<text top="413" left="202" width="23" height="14" font="5">RCT </text>
<text top="413" left="243" width="69" height="14" font="5">Digoxin 75%,    </text>
<text top="427" left="243" width="41" height="14" font="5">Diuretics </text>
<text top="441" left="243" width="69" height="14" font="5">53%,                 </text>
<text top="455" left="243" width="67" height="14" font="5">ACEI 89%,       </text>
<text top="468" left="243" width="45" height="14" font="5">bblockers </text>
<text top="482" left="243" width="69" height="14" font="5">38%,                 </text>
<text top="496" left="243" width="54" height="14" font="5">oral nitrates </text>
<text top="510" left="243" width="69" height="14" font="5">41%,                 </text>
<text top="523" left="243" width="59" height="14" font="5">anticoagulant</text>
<text top="537" left="243" width="68" height="14" font="5">s 43%,              </text>
<text top="551" left="243" width="38" height="14" font="5">Class III </text>
<text top="565" left="243" width="60" height="14" font="5">antiarrhthmic </text>
<text top="578" left="243" width="57" height="14" font="5">agents 15%, </text>
<text top="592" left="243" width="68" height="14" font="5">CCB 4%,          </text>
<text top="606" left="243" width="50" height="14" font="5">antiplatelet </text>
<text top="620" left="243" width="49" height="14" font="5">agents 1% </text>
<text top="413" left="319" width="25" height="14" font="5">203;  </text>
<text top="427" left="319" width="19" height="14" font="5">103 </text>
<text top="441" left="319" width="69" height="14" font="5">levosimendan;  </text>
<text top="455" left="319" width="19" height="14" font="5">100 </text>
<text top="468" left="319" width="54" height="14" font="5">dobutamine </text>
<text top="413" left="414" width="22" height="14" font="5">48% </text>
<text top="427" left="404" width="41" height="14" font="5">Ischemic </text>
<text top="413" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="427" left="464" width="38" height="14" font="5">with low-</text>
<text top="441" left="464" width="49" height="14" font="5">output HF, </text>
<text top="455" left="464" width="41" height="14" font="5">requiring </text>
<text top="468" left="464" width="51" height="14" font="5">haemodyna</text>
<text top="482" left="464" width="54" height="14" font="5">mic monitor-</text>
<text top="496" left="464" width="35" height="14" font="5">ing and </text>
<text top="510" left="464" width="44" height="14" font="5">treatment </text>
<text top="523" left="464" width="32" height="14" font="5">with IV </text>
<text top="537" left="464" width="40" height="14" font="5">inotropic </text>
<text top="551" left="464" width="41" height="14" font="5">agent. a) </text>
<text top="565" left="464" width="57" height="14" font="5">deterioration </text>
<text top="578" left="464" width="43" height="14" font="5">of severe </text>
<text top="592" left="464" width="50" height="14" font="5">chronic HF </text>
<text top="606" left="464" width="34" height="14" font="5">despite </text>
<text top="620" left="464" width="40" height="14" font="5">optimum </text>
<text top="634" left="464" width="55" height="14" font="5">oral therapy </text>
<text top="647" left="464" width="20" height="14" font="5">with </text>
<text top="661" left="464" width="55" height="14" font="5">vasodilators </text>
<text top="675" left="464" width="19" height="14" font="5">and </text>
<text top="689" left="464" width="42" height="14" font="5">diuretics, </text>
<text top="702" left="464" width="42" height="14" font="5">including </text>
<text top="716" left="464" width="27" height="14" font="5">those </text>
<text top="730" left="464" width="39" height="14" font="5">awaiting </text>
<text top="744" left="464" width="34" height="14" font="5">cardiac </text>
<text top="758" left="464" width="54" height="14" font="5">transplantati</text>
<text top="771" left="464" width="28" height="14" font="5">on; b) </text>
<text top="785" left="464" width="32" height="14" font="5">severe </text>
<text top="413" left="537" width="66" height="14" font="5">Age &lt;21 y        </text>
<text top="427" left="537" width="58" height="14" font="5">Childbearing </text>
<text top="441" left="537" width="64" height="14" font="5">potential          </text>
<text top="455" left="537" width="46" height="14" font="5">HF due to </text>
<text top="468" left="537" width="56" height="14" font="5">restrictive or </text>
<text top="482" left="537" width="57" height="14" font="5">hypertrophic </text>
<text top="496" left="537" width="51" height="14" font="5">cardiomyop</text>
<text top="510" left="537" width="44" height="14" font="5">athy or to </text>
<text top="523" left="537" width="55" height="14" font="5">uncorrected </text>
<text top="537" left="537" width="37" height="14" font="5">stenotic </text>
<text top="551" left="537" width="37" height="14" font="5">valvular </text>
<text top="565" left="537" width="64" height="14" font="5">disease;          </text>
<text top="578" left="537" width="50" height="14" font="5">Chest pain </text>
<text top="592" left="537" width="49" height="14" font="5">at the time </text>
<text top="606" left="537" width="11" height="14" font="5">of </text>
<text top="620" left="537" width="51" height="14" font="5">randomisati</text>
<text top="634" left="537" width="16" height="14" font="5">on; </text>
<text top="647" left="537" width="47" height="14" font="5">Sustained </text>
<text top="661" left="537" width="58" height="14" font="5">VT/VF within </text>
<text top="675" left="537" width="59" height="14" font="5">prior 2 wk;     </text>
<text top="689" left="537" width="52" height="14" font="5">AVB of 2nd </text>
<text top="702" left="537" width="17" height="14" font="5">or 3</text>
<text top="704" left="554" width="5" height="9" font="29">rd</text>
<text top="702" left="559" width="3" height="14" font="5"> </text>
<text top="716" left="537" width="66" height="14" font="5">degree;            </text>
<text top="730" left="537" width="42" height="14" font="5">HR &gt;120 </text>
<text top="744" left="537" width="66" height="14" font="5">bpm at rest;     </text>
<text top="757" left="537" width="42" height="14" font="5">SBP&lt; 85 </text>
<text top="771" left="537" width="64" height="14" font="5">mm Hg;           </text>
<text top="785" left="537" width="58" height="14" font="5">Severe renal </text>
<text top="413" left="609" width="38" height="14" font="5">Severity </text>
<text top="427" left="609" width="52" height="14" font="5">determined </text>
<text top="441" left="609" width="51" height="14" font="5">by invasive </text>
<text top="455" left="609" width="46" height="14" font="5">hemodyna</text>
<text top="468" left="609" width="18" height="14" font="5">mic </text>
<text top="482" left="609" width="51" height="14" font="5">monitoring, </text>
<text top="496" left="609" width="16" height="14" font="5">not </text>
<text top="510" left="609" width="48" height="14" font="5">symptomat</text>
<text top="523" left="609" width="26" height="14" font="5">ology </text>
<text top="413" left="677" width="37" height="14" font="5">CI &lt; 2.5 </text>
<text top="427" left="677" width="51" height="14" font="5">L/min/m2    </text>
<text top="441" left="677" width="27" height="14" font="5">Mean </text>
<text top="455" left="677" width="41" height="14" font="5">PCWP &gt; </text>
<text top="468" left="677" width="33" height="14" font="5">15 mm </text>
<text top="482" left="677" width="15" height="14" font="5">Hg </text>
<text top="413" left="736" width="59" height="14" font="5">Proportion of </text>
<text top="427" left="736" width="36" height="14" font="5">pts with </text>
<text top="441" left="736" width="51" height="14" font="5">haemodyna</text>
<text top="455" left="736" width="18" height="14" font="5">mic </text>
<text top="468" left="736" width="60" height="14" font="5">improvement </text>
<text top="482" left="736" width="51" height="14" font="5">(defined as </text>
<text top="496" left="736" width="54" height="14" font="5">an increase </text>
<text top="510" left="736" width="45" height="14" font="5">of 30% or </text>
<text top="523" left="736" width="53" height="14" font="5">more in CO </text>
<text top="537" left="736" width="27" height="14" font="5">and a </text>
<text top="551" left="736" width="54" height="14" font="5">decrease of </text>
<text top="565" left="736" width="59" height="14" font="5">25% or more </text>
<text top="578" left="736" width="57" height="14" font="5">in PCWP) at </text>
<text top="592" left="736" width="25" height="14" font="5">24 h. </text>
<text top="413" left="811" width="64" height="14" font="5">Changes from </text>
<text top="427" left="811" width="50" height="14" font="5">baseline in </text>
<text top="441" left="811" width="73" height="14" font="5">haemo-dynamic </text>
<text top="455" left="811" width="67" height="14" font="5">variables other </text>
<text top="468" left="811" width="58" height="14" font="5">than CO and </text>
<text top="482" left="811" width="67" height="14" font="5">PCWP (eg, CI, </text>
<text top="496" left="811" width="67" height="14" font="5">stroke volume, </text>
<text top="510" left="811" width="60" height="14" font="5">PADP, mean </text>
<text top="523" left="811" width="61" height="14" font="5">RAP, BP, HR </text>
<text top="537" left="811" width="60" height="14" font="5">and total peri-</text>
<text top="551" left="811" width="30" height="14" font="5">pheral </text>
<text top="565" left="811" width="62" height="14" font="5">resistance) at </text>
<text top="578" left="811" width="82" height="14" font="5">24 h;                      </text>
<text top="592" left="811" width="64" height="14" font="5">Changes from </text>
<text top="606" left="811" width="72" height="14" font="5">baseline to 24 h </text>
<text top="620" left="811" width="74" height="14" font="5">in HF symptoms </text>
<text top="634" left="811" width="68" height="14" font="5">(dyspnoea and </text>
<text top="647" left="811" width="66" height="14" font="5">fatigue) on a 4-</text>
<text top="661" left="811" width="54" height="14" font="5">grade scale </text>
<text top="675" left="811" width="61" height="14" font="5">(much better, </text>
<text top="689" left="811" width="63" height="14" font="5">slightly better, </text>
<text top="702" left="811" width="51" height="14" font="5">no change, </text>
<text top="716" left="811" width="81" height="14" font="5">worse);                  </text>
<text top="730" left="811" width="59" height="14" font="5">Proportion of </text>
<text top="744" left="811" width="66" height="14" font="5">pts needing IV </text>
<text top="757" left="811" width="68" height="14" font="5">rescue therapy </text>
<text top="771" left="811" width="56" height="14" font="5">with positive </text>
<text top="785" left="811" width="40" height="14" font="5">inotropic </text>
<text top="413" left="920" width="19" height="14" font="5">N/A </text>
<text top="413" left="987" width="19" height="14" font="5">N/A </text>
<text top="413" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="427" left="1034" width="28" height="14" font="5">t 1/97-</text>
<text top="441" left="1034" width="27" height="14" font="5">11/98 </text>
<text top="455" left="1034" width="37" height="14" font="5">(23mo); </text>
<text top="468" left="1034" width="26" height="14" font="5">study </text>
<text top="482" left="1034" width="22" height="14" font="5">drug </text>
<text top="496" left="1034" width="37" height="14" font="5">infusion </text>
<text top="510" left="1034" width="38" height="14" font="5">up to 24 </text>
<text top="523" left="1034" width="47" height="14" font="5">hrs, follow </text>
<text top="537" left="1034" width="41" height="14" font="5">up out to </text>
<text top="551" left="1034" width="27" height="14" font="5">180 d </text>
<text top="413" left="1095" width="55" height="14" font="5">The primary </text>
<text top="427" left="1095" width="70" height="14" font="5">haemodynamic </text>
<text top="441" left="1095" width="61" height="14" font="5">endpoint was </text>
<text top="455" left="1095" width="75" height="14" font="5">achieved in 28% </text>
<text top="468" left="1095" width="64" height="14" font="5">levosimendan-</text>
<text top="482" left="1095" width="63" height="14" font="5">group pts and </text>
<text top="496" left="1095" width="49" height="14" font="5">15% in the </text>
<text top="510" left="1095" width="54" height="14" font="5">dobutamine </text>
<text top="523" left="1095" width="88" height="14" font="5">group.                      </text>
<text top="537" left="1095" width="69" height="14" font="5">Secondary end </text>
<text top="551" left="1095" width="87" height="14" font="5">point:                       </text>
<text top="565" left="1095" width="64" height="14" font="5">At 180 d, 26% </text>
<text top="578" left="1095" width="64" height="14" font="5">levosimendan </text>
<text top="592" left="1095" width="63" height="14" font="5">group pts had </text>
<text top="606" left="1095" width="71" height="14" font="5">died, compared </text>
<text top="620" left="1095" width="69" height="14" font="5">with 38% in the </text>
<text top="634" left="1095" width="54" height="14" font="5">dobutamine </text>
<text top="647" left="1095" width="31" height="14" font="5">group  </text>
<text top="413" left="1189" width="115" height="14" font="5">Primary endpoint:              </text>
<text top="427" left="1189" width="91" height="14" font="5">HR; 1.9; 95% CI 1.1-</text>
<text top="441" left="1189" width="115" height="14" font="5">3.3; p=0.022;                     </text>
<text top="455" left="1189" width="93" height="14" font="5">Secondary endpoint: </text>
<text top="468" left="1189" width="80" height="14" font="5">HR 0.57; p=0.029 </text>
<text top="482" left="1242" width="3" height="14" font="5"> </text>
<text top="413" left="1311" width="53" height="14" font="5">No placebo </text>
<text top="427" left="1311" width="68" height="14" font="5">control              </text>
<text top="441" left="1311" width="54" height="14" font="5">Small study </text>
<text top="455" left="1311" width="67" height="14" font="5">size                  </text>
<text top="468" left="1311" width="15" height="14" font="5">No </text>
<text top="482" left="1311" width="51" height="14" font="5">information </text>
<text top="496" left="1311" width="30" height="14" font="5">on the </text>
<text top="510" left="1311" width="49" height="14" font="5">duration of </text>
<text top="523" left="1311" width="48" height="14" font="5">infusion of </text>
<text top="537" left="1311" width="55" height="14" font="5">levosimenda</text>
<text top="551" left="1311" width="58" height="14" font="5">n needed for </text>
<text top="565" left="1311" width="40" height="14" font="5">optimum </text>
<text top="578" left="1311" width="57" height="14" font="5">benefit or on </text>
<text top="592" left="1311" width="53" height="14" font="5">how often it </text>
<text top="606" left="1311" width="35" height="14" font="5">may be </text>
<text top="620" left="1311" width="52" height="14" font="5">repeated in </text>
<text top="634" left="1311" width="50" height="14" font="5">pts who do </text>
<text top="647" left="1311" width="55" height="14" font="5">not respond </text>
<text top="661" left="1311" width="44" height="14" font="5">initially or </text>
<text top="675" left="1311" width="56" height="14" font="5">who relapse </text>
<text top="689" left="1311" width="36" height="14" font="5">after an </text>
<text top="702" left="1311" width="25" height="14" font="5">initial </text>
<text top="716" left="1311" width="68" height="14" font="5">response.         </text>
<text top="730" left="1311" width="56" height="14" font="5">Exclusion of </text>
<text top="744" left="1311" width="36" height="14" font="5">pts with </text>
<text top="757" left="1311" width="53" height="14" font="5">cardiogenic </text>
<text top="771" left="1311" width="67" height="14" font="5">shock.              </text>
<text top="785" left="1311" width="49" height="14" font="5">Short-term </text>
<text top="413" left="1385" width="62" height="14" font="5">Angina, chest </text>
<text top="427" left="1385" width="35" height="14" font="5">pain, or </text>
<text top="441" left="1385" width="48" height="14" font="5">myocardia </text>
<text top="455" left="1385" width="67" height="14" font="5">ischaemia (7% </text>
<text top="468" left="1385" width="67" height="14" font="5">dobutamine vs </text>
<text top="482" left="1385" width="17" height="14" font="5">0% </text>
<text top="496" left="1385" width="66" height="14" font="5">levosimendan, </text>
<text top="510" left="1385" width="50" height="14" font="5">p=0.013);   </text>
<text top="523" left="1385" width="55" height="14" font="5">Arrhythmias </text>
<text top="537" left="1385" width="26" height="14" font="5">(13% </text>
<text top="551" left="1385" width="67" height="14" font="5">dobutamine vs </text>
<text top="565" left="1385" width="17" height="14" font="5">4% </text>
<text top="578" left="1385" width="66" height="14" font="5">levosimendan, </text>
<text top="592" left="1385" width="39" height="14" font="5">p=0.023 </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">125</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="464" width="38" height="14" font="5">HF after </text>
<text top="68" left="464" width="34" height="14" font="5">cardiac </text>
<text top="82" left="464" width="50" height="14" font="5">surgery; or </text>
<text top="96" left="464" width="54" height="14" font="5">c) acute HF </text>
<text top="110" left="464" width="52" height="14" font="5">related to a </text>
<text top="123" left="464" width="46" height="14" font="5">cardiac or </text>
<text top="137" left="464" width="54" height="14" font="5">non-cardiac </text>
<text top="151" left="464" width="49" height="14" font="5">disorder of </text>
<text top="165" left="464" width="30" height="14" font="5">recent </text>
<text top="178" left="464" width="30" height="14" font="5">onset. </text>
<text top="192" left="464" width="53" height="14" font="5">LVEF&lt;35% </text>
<text top="206" left="464" width="52" height="14" font="5">(by echo or </text>
<text top="220" left="464" width="59" height="14" font="5">radio-nuclide </text>
<text top="234" left="464" width="56" height="14" font="5">ventriculogra</text>
<text top="247" left="464" width="47" height="14" font="5">phy w/in 1 </text>
<text top="261" left="464" width="54" height="14" font="5">mo of study </text>
<text top="275" left="464" width="66" height="14" font="5">enrolment)       </text>
<text top="289" left="464" width="37" height="14" font="5">CI &lt; 2.5 </text>
<text top="302" left="464" width="65" height="14" font="5">L/min/m2         </text>
<text top="316" left="464" width="27" height="14" font="5">Mean </text>
<text top="330" left="464" width="52" height="14" font="5">PCWP &gt;15 </text>
<text top="344" left="464" width="37" height="14" font="5">mm Hg. </text>
<text top="55" left="537" width="52" height="14" font="5">failure (SCr </text>
<text top="68" left="537" width="28" height="14" font="5">&gt;450  </text>
<text top="82" left="537" width="35" height="14" font="5">mol/L);  </text>
<text top="96" left="537" width="36" height="14" font="5">Hepatic </text>
<text top="110" left="537" width="65" height="14" font="5">failure              </text>
<text top="123" left="537" width="37" height="14" font="5">Cardiac </text>
<text top="137" left="537" width="66" height="14" font="5">tamponade;     </text>
<text top="151" left="537" width="66" height="14" font="5">ARDS;             </text>
<text top="165" left="537" width="30" height="14" font="5">Septic </text>
<text top="178" left="537" width="31" height="14" font="5">shock. </text>
<text top="55" left="811" width="30" height="14" font="5">drugs, </text>
<text top="68" left="811" width="69" height="14" font="5">vasodilators, or </text>
<text top="82" left="811" width="69" height="14" font="5">diuretics during </text>
<text top="96" left="811" width="64" height="14" font="5">the infusion of </text>
<text top="110" left="811" width="81" height="14" font="5">study drug;            </text>
<text top="123" left="811" width="60" height="14" font="5">No. of d alive </text>
<text top="137" left="811" width="46" height="14" font="5">and out of </text>
<text top="151" left="811" width="72" height="14" font="5">hospital and not </text>
<text top="165" left="811" width="54" height="14" font="5">receiving IV </text>
<text top="178" left="811" width="74" height="14" font="5">drugs during the </text>
<text top="192" left="811" width="81" height="14" font="5">1st mo;                  </text>
<text top="206" left="811" width="35" height="14" font="5">Time to </text>
<text top="220" left="811" width="70" height="14" font="5">development of </text>
<text top="234" left="811" width="63" height="14" font="5">worsening HF </text>
<text top="247" left="811" width="42" height="14" font="5">or death. </text>
<text top="261" left="811" width="31" height="14" font="5">Safety </text>
<text top="275" left="811" width="60" height="14" font="5">endpoints: a) </text>
<text top="289" left="811" width="35" height="14" font="5">AEs, b) </text>
<text top="302" left="811" width="47" height="14" font="5">laboratory </text>
<text top="316" left="811" width="52" height="14" font="5">safety tests </text>
<text top="330" left="811" width="49" height="14" font="5">(blood and </text>
<text top="344" left="811" width="61" height="14" font="5">urine), and c) </text>
<text top="357" left="811" width="42" height="14" font="5">all-cause </text>
<text top="371" left="811" width="73" height="14" font="5">mortality at 31 d </text>
<text top="385" left="811" width="69" height="14" font="5">and 180 d after </text>
<text top="399" left="811" width="70" height="14" font="5">randomization.  </text>
<text top="55" left="1311" width="56" height="14" font="5">hemodynami</text>
<text top="68" left="1311" width="8" height="14" font="5">c </text>
<text top="82" left="1311" width="66" height="14" font="5">assessment     </text>
<text top="96" left="1311" width="58" height="14" font="5">Not powered </text>
<text top="110" left="1311" width="44" height="14" font="5">to assess </text>
<text top="123" left="1311" width="40" height="14" font="5">mortality </text>
<text top="413" left="61" width="41" height="14" font="5">OPTIME-</text>
<text top="427" left="61" width="52" height="14" font="5">CHF, Cuffe </text>
<text top="441" left="61" width="45" height="14" font="5">MS, 2002 </text>
<text top="455" left="61" width="49" height="14" font="28">11911756\ </text>
<text top="468" left="61" width="26" height="14" font="5">(271) </text>
<text top="482" left="61" width="3" height="14" font="5"> </text>
<text top="413" left="129" width="14" height="14" font="5">To </text>
<text top="427" left="129" width="50" height="14" font="5">prospective</text>
<text top="441" left="129" width="28" height="14" font="5">ly test </text>
<text top="455" left="129" width="46" height="14" font="5">whether a </text>
<text top="468" left="129" width="38" height="14" font="5">strategy </text>
<text top="482" left="129" width="19" height="14" font="5">that </text>
<text top="496" left="129" width="39" height="14" font="5">includes </text>
<text top="510" left="129" width="48" height="14" font="5">short-term </text>
<text top="523" left="129" width="29" height="14" font="5">use of </text>
<text top="537" left="129" width="53" height="14" font="5">milrinone in </text>
<text top="551" left="129" width="48" height="14" font="5">addition to </text>
<text top="565" left="129" width="41" height="14" font="5">standard </text>
<text top="578" left="129" width="36" height="14" font="5">therapy </text>
<text top="592" left="129" width="19" height="14" font="5">can </text>
<text top="606" left="129" width="38" height="14" font="5">improve </text>
<text top="620" left="129" width="32" height="14" font="5">clinical </text>
<text top="634" left="129" width="45" height="14" font="5">outcomes </text>
<text top="647" left="129" width="27" height="14" font="5">of pts </text>
<text top="661" left="129" width="46" height="14" font="5">hospitalize</text>
<text top="675" left="129" width="42" height="14" font="5">d with an </text>
<text top="689" left="129" width="51" height="14" font="5">exacerbatio</text>
<text top="702" left="129" width="54" height="14" font="5">n of chronic </text>
<text top="716" left="129" width="16" height="14" font="5">HF </text>
<text top="413" left="196" width="23" height="14" font="5">RCT </text>
<text top="413" left="243" width="51" height="14" font="5">ACEI 70%, </text>
<text top="427" left="243" width="67" height="14" font="5">ARB 12%,        </text>
<text top="441" left="243" width="40" height="14" font="5">bblocker </text>
<text top="455" left="243" width="69" height="14" font="5">22%,                 </text>
<text top="468" left="243" width="69" height="14" font="5">Diuretic 90%,    </text>
<text top="482" left="243" width="69" height="14" font="5">Digoxin 73%,    </text>
<text top="496" left="243" width="46" height="14" font="5">CCB 11% </text>
<text top="510" left="243" width="45" height="14" font="5">placebo v </text>
<text top="523" left="243" width="22" height="14" font="5">16% </text>
<text top="537" left="243" width="48" height="14" font="5">milrinone   </text>
<text top="551" left="243" width="69" height="14" font="5">ASA 46%          </text>
<text top="565" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="578" left="243" width="22" height="14" font="5">15% </text>
<text top="413" left="319" width="41" height="14" font="5">949; 477 </text>
<text top="427" left="319" width="52" height="14" font="5">(milrinone); </text>
<text top="441" left="319" width="63" height="14" font="5">472 (placebo) </text>
<text top="413" left="399" width="43" height="14" font="5">ICM 51% </text>
<text top="413" left="464" width="47" height="14" font="5">Age &gt;18 y </text>
<text top="427" left="464" width="55" height="14" font="5">LVEF &lt;40% </text>
<text top="441" left="464" width="44" height="14" font="5">within the </text>
<text top="455" left="464" width="56" height="14" font="5">past y.          </text>
<text top="468" left="464" width="33" height="14" font="5">Known </text>
<text top="482" left="464" width="35" height="14" font="5">systolic </text>
<text top="496" left="464" width="53" height="14" font="5">chronic HF  </text>
<text top="510" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="523" left="464" width="14" height="14" font="5">for </text>
<text top="537" left="464" width="59" height="14" font="5">exacerbation </text>
<text top="551" left="464" width="45" height="14" font="5">of chronic </text>
<text top="565" left="464" width="43" height="14" font="5">HF &lt;48 h </text>
<text top="578" left="464" width="33" height="14" font="5">earlier. </text>
<text top="413" left="537" width="44" height="14" font="5">If treating </text>
<text top="427" left="537" width="44" height="14" font="5">physician </text>
<text top="441" left="537" width="51" height="14" font="5">judged that </text>
<text top="455" left="537" width="50" height="14" font="5">IV inotrope </text>
<text top="468" left="537" width="20" height="14" font="5">was </text>
<text top="482" left="537" width="42" height="14" font="5">essential </text>
<text top="496" left="537" width="34" height="14" font="5">(eg, for </text>
<text top="510" left="537" width="31" height="14" font="5">shock, </text>
<text top="523" left="537" width="45" height="14" font="5">metabolic </text>
<text top="537" left="537" width="52" height="14" font="5">acidosis, or </text>
<text top="551" left="537" width="32" height="14" font="5">severe </text>
<text top="565" left="537" width="53" height="14" font="5">hypotension</text>
<text top="578" left="537" width="42" height="14" font="5">).             </text>
<text top="592" left="537" width="30" height="14" font="5">Active </text>
<text top="606" left="537" width="50" height="14" font="5">myocardial </text>
<text top="620" left="537" width="42" height="14" font="5">ischemia </text>
<text top="634" left="537" width="44" height="14" font="5">within the </text>
<text top="647" left="537" width="65" height="14" font="5">past 3 mo        </text>
<text top="661" left="537" width="25" height="14" font="5">Atrial </text>
<text top="675" left="537" width="44" height="14" font="5">fibrillation </text>
<text top="689" left="537" width="43" height="14" font="5">with poor </text>
<text top="702" left="537" width="48" height="14" font="5">ventricular </text>
<text top="716" left="537" width="52" height="14" font="5">rate control </text>
<text top="730" left="537" width="66" height="14" font="5">(&gt;110/min)       </text>
<text top="744" left="537" width="47" height="14" font="5">Sustained </text>
<text top="757" left="537" width="48" height="14" font="5">ventricular </text>
<text top="771" left="537" width="53" height="14" font="5">tachycardia </text>
<text top="785" left="537" width="11" height="14" font="5">or </text>
<text top="413" left="609" width="28" height="14" font="5">100% </text>
<text top="427" left="609" width="62" height="14" font="5">NYHA II-IV     </text>
<text top="441" left="609" width="47" height="14" font="5">7% NYHA </text>
<text top="455" left="609" width="60" height="14" font="5">II                    </text>
<text top="468" left="609" width="52" height="14" font="5">46% NYHA </text>
<text top="482" left="609" width="60" height="14" font="5">III                   </text>
<text top="496" left="609" width="52" height="14" font="5">47% NYHA </text>
<text top="510" left="609" width="12" height="14" font="5">IV </text>
<text top="413" left="677" width="39" height="14" font="5">NYHA II-</text>
<text top="427" left="677" width="12" height="14" font="5">IV </text>
<text top="441" left="677" width="40" height="14" font="5">symptom</text>
<text top="455" left="677" width="8" height="14" font="5">s </text>
<text top="413" left="736" width="61" height="14" font="5">Total number </text>
<text top="427" left="736" width="19" height="14" font="5">of d </text>
<text top="441" left="736" width="55" height="14" font="5">hospitalized </text>
<text top="455" left="736" width="30" height="14" font="5">for CV </text>
<text top="468" left="736" width="57" height="14" font="5">causes (or d </text>
<text top="482" left="736" width="49" height="14" font="5">deceased) </text>
<text top="496" left="736" width="58" height="14" font="5">within the 60 </text>
<text top="510" left="736" width="30" height="14" font="5">d after </text>
<text top="523" left="736" width="56" height="14" font="5">randomizatio</text>
<text top="537" left="736" width="57" height="14" font="5">n. Hospital d </text>
<text top="551" left="736" width="59" height="14" font="5">were defined </text>
<text top="565" left="736" width="13" height="14" font="5">as </text>
<text top="578" left="736" width="46" height="14" font="5">inpt d and </text>
<text top="592" left="736" width="16" height="14" font="5">ED </text>
<text top="606" left="736" width="31" height="14" font="5">visit d. </text>
<text top="413" left="811" width="72" height="14" font="5">Main secondary </text>
<text top="427" left="811" width="41" height="14" font="5">outcome </text>
<text top="441" left="811" width="56" height="14" font="5">included the </text>
<text top="455" left="811" width="58" height="14" font="5">proportion of </text>
<text top="468" left="811" width="57" height="14" font="5">cases failing </text>
<text top="482" left="811" width="36" height="14" font="5">therapy </text>
<text top="496" left="811" width="67" height="14" font="5">because of AE </text>
<text top="510" left="811" width="59" height="14" font="5">or worsening </text>
<text top="523" left="811" width="60" height="14" font="5">HF 48 h after </text>
<text top="537" left="811" width="50" height="14" font="5">initiation of </text>
<text top="551" left="811" width="82" height="14" font="5">therapy.                 </text>
<text top="565" left="811" width="27" height="14" font="5">Other </text>
<text top="578" left="811" width="48" height="14" font="5">secondary </text>
<text top="592" left="811" width="45" height="14" font="5">outcomes </text>
<text top="606" left="811" width="56" height="14" font="5">included the </text>
<text top="620" left="811" width="74" height="14" font="5">proportion of pts </text>
<text top="634" left="811" width="72" height="14" font="5">achieving target </text>
<text top="647" left="811" width="66" height="14" font="5">doses of ACEI </text>
<text top="661" left="811" width="55" height="14" font="5">therapy and </text>
<text top="675" left="811" width="69" height="14" font="5">time to achieve </text>
<text top="689" left="811" width="55" height="14" font="5">target dose, </text>
<text top="702" left="811" width="50" height="14" font="5">symptoms, </text>
<text top="716" left="811" width="70" height="14" font="5">improvement in </text>
<text top="730" left="811" width="45" height="14" font="5">HF score, </text>
<text top="744" left="811" width="66" height="14" font="5">length of initial </text>
<text top="758" left="811" width="68" height="14" font="5">hospitalization, </text>
<text top="771" left="811" width="19" height="14" font="5">d of </text>
<text top="785" left="811" width="65" height="14" font="5">hospitalization </text>
<text top="413" left="899" width="19" height="14" font="5">N/A </text>
<text top="413" left="973" width="19" height="14" font="5">N/A </text>
<text top="413" left="1034" width="39" height="14" font="5">Recruitm</text>
<text top="427" left="1034" width="39" height="14" font="5">ent 7/97-</text>
<text top="441" left="1034" width="44" height="14" font="5">11/99 (29 </text>
<text top="455" left="1034" width="22" height="14" font="5">mo); </text>
<text top="468" left="1034" width="28" height="14" font="5">Study </text>
<text top="482" left="1034" width="22" height="14" font="5">drug </text>
<text top="496" left="1034" width="44" height="14" font="5">treatment </text>
<text top="510" left="1034" width="39" height="14" font="5">for up to </text>
<text top="523" left="1034" width="42" height="14" font="5">72 h with </text>
<text top="537" left="1034" width="32" height="14" font="5">60 day </text>
<text top="551" left="1034" width="42" height="14" font="5">follow-up </text>
<text top="565" left="1034" width="30" height="14" font="5">period </text>
<text top="578" left="1034" width="44" height="14" font="5">from time </text>
<text top="592" left="1034" width="11" height="14" font="5">of </text>
<text top="606" left="1034" width="40" height="14" font="5">randomiz</text>
<text top="620" left="1034" width="24" height="14" font="5">ation </text>
<text top="413" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="427" left="1095" width="72" height="14" font="5">primary efficacy </text>
<text top="441" left="1095" width="87" height="14" font="5">end point                 </text>
<text top="455" left="1095" width="63" height="14" font="5">Milrinone was </text>
<text top="468" left="1095" width="70" height="14" font="5">associated with </text>
<text top="482" left="1095" width="61" height="14" font="5">higher rate of </text>
<text top="496" left="1095" width="74" height="14" font="5">treatment failure </text>
<text top="510" left="1095" width="79" height="14" font="5">at 48 h due to AE </text>
<text top="523" left="1095" width="75" height="14" font="5">(12.6% vs 2.1%) </text>
<text top="413" left="1189" width="55" height="14" font="5">p=0.71, d of </text>
<text top="427" left="1189" width="96" height="14" font="5">hospitalization for CV </text>
<text top="441" left="1189" width="114" height="14" font="5">causes within 60 d            </text>
<text top="455" left="1189" width="75" height="14" font="5">p=0.92, death or </text>
<text top="468" left="1189" width="114" height="14" font="5">readmission within 60 d    </text>
<text top="482" left="1189" width="97" height="14" font="5">p&lt;0.001 for treatment </text>
<text top="496" left="1189" width="75" height="14" font="5">failure due to AE </text>
<text top="413" left="1311" width="34" height="14" font="5">Did not </text>
<text top="427" left="1311" width="34" height="14" font="5">directly </text>
<text top="441" left="1311" width="38" height="14" font="5">address </text>
<text top="455" left="1311" width="36" height="14" font="5">pts with </text>
<text top="468" left="1311" width="44" height="14" font="5">ADHF for </text>
<text top="482" left="1311" width="29" height="14" font="5">whom </text>
<text top="496" left="1311" width="40" height="14" font="5">inotropic </text>
<text top="510" left="1311" width="56" height="14" font="5">therapy was </text>
<text top="523" left="1311" width="41" height="14" font="5">felt to be </text>
<text top="537" left="1311" width="42" height="14" font="5">essential </text>
<text top="551" left="1311" width="37" height="14" font="5">(eg, low </text>
<text top="565" left="1311" width="34" height="14" font="5">cardiac </text>
<text top="578" left="1311" width="54" height="14" font="5">output state </text>
<text top="592" left="1311" width="49" height="14" font="5">with tissue </text>
<text top="606" left="1311" width="56" height="14" font="5">hypoperfusio</text>
<text top="620" left="1311" width="32" height="14" font="5">n), Not </text>
<text top="634" left="1311" width="57" height="14" font="5">structured to </text>
<text top="647" left="1311" width="49" height="14" font="5">assess pts </text>
<text top="661" left="1311" width="54" height="14" font="5">for NSVT, a </text>
<text top="675" left="1311" width="31" height="14" font="5">known </text>
<text top="689" left="1311" width="38" height="14" font="5">adverse </text>
<text top="702" left="1311" width="38" height="14" font="5">effect of </text>
<text top="716" left="1311" width="67" height="14" font="5">milrinone.         </text>
<text top="730" left="1311" width="59" height="14" font="5">Inadequately </text>
<text top="744" left="1311" width="51" height="14" font="5">powered to </text>
<text top="757" left="1311" width="40" height="14" font="5">evaluate </text>
<text top="771" left="1311" width="43" height="14" font="5">mortality. </text>
<text top="413" left="1385" width="47" height="14" font="5">Sustained </text>
<text top="427" left="1385" width="59" height="14" font="5">hypotension, </text>
<text top="441" left="1385" width="64" height="14" font="5">(SBP&lt; 80 mm </text>
<text top="455" left="1385" width="55" height="14" font="5">Hg for more </text>
<text top="468" left="1385" width="57" height="14" font="5">than 30 min, </text>
<text top="482" left="1385" width="41" height="14" font="5">requiring </text>
<text top="496" left="1385" width="65" height="14" font="5">intervention);   </text>
<text top="510" left="1385" width="51" height="14" font="5">10.7% with </text>
<text top="523" left="1385" width="70" height="14" font="5">milrinone, 3.2% </text>
<text top="537" left="1385" width="63" height="14" font="5">with placebo,  </text>
<text top="551" left="1385" width="82" height="14" font="5">p&lt;0.001                 </text>
<text top="565" left="1385" width="72" height="14" font="5">Significant atrial </text>
<text top="578" left="1385" width="54" height="14" font="5">arrhythmias </text>
<text top="592" left="1385" width="56" height="14" font="5">during index </text>
<text top="606" left="1385" width="68" height="14" font="5">hospitalization; </text>
<text top="620" left="1385" width="70" height="14" font="5">4.6% milrinone, </text>
<text top="634" left="1385" width="65" height="14" font="5">1.5% placebo, </text>
<text top="647" left="1385" width="39" height="14" font="5">p=0.004 </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">126</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="537" width="48" height="14" font="5">ventricular </text>
<text top="68" left="537" width="66" height="14" font="5">fibrillation.        </text>
<text top="82" left="537" width="41" height="14" font="5">Baseline </text>
<text top="96" left="537" width="42" height="14" font="5">SBP&lt; 80 </text>
<text top="110" left="537" width="64" height="14" font="5">mm Hg            </text>
<text top="123" left="537" width="51" height="14" font="5">SCr level &gt; </text>
<text top="137" left="537" width="44" height="14" font="5">3.0mg/dL </text>
<text top="55" left="811" width="62" height="14" font="5">for CV events </text>
<text top="68" left="811" width="47" height="14" font="5">from initial </text>
<text top="82" left="811" width="37" height="14" font="5">hospital </text>
<text top="96" left="811" width="70" height="14" font="5">discharge to 60 </text>
<text top="110" left="811" width="30" height="14" font="5">d, d of </text>
<text top="123" left="811" width="65" height="14" font="5">hospitalization </text>
<text top="137" left="811" width="62" height="14" font="5">for CV events </text>
<text top="151" left="811" width="72" height="14" font="5">within 30 d after </text>
<text top="165" left="811" width="67" height="14" font="5">randomization, </text>
<text top="178" left="811" width="42" height="14" font="5">all-cause </text>
<text top="192" left="811" width="71" height="14" font="5">hospitaliz-ation, </text>
<text top="206" left="811" width="62" height="14" font="5">and mortality. </text>
<text top="221" left="61" width="54" height="14" font="5">HF Etiology </text>
<text top="234" left="61" width="19" height="14" font="5">and </text>
<text top="248" left="61" width="47" height="14" font="5">Response </text>
<text top="262" left="61" width="54" height="14" font="5">to Milrinone </text>
<text top="276" left="61" width="10" height="14" font="5">in </text>
<text top="289" left="61" width="48" height="14" font="5">Decompen</text>
<text top="303" left="61" width="43" height="14" font="5">sated HF </text>
<text top="317" left="61" width="50" height="14" font="5">(subanalysi</text>
<text top="331" left="61" width="18" height="14" font="5">s of </text>
<text top="344" left="61" width="41" height="14" font="5">OPTIME-</text>
<text top="358" left="61" width="29" height="14" font="5">CHF), </text>
<text top="372" left="61" width="51" height="14" font="5">Felker GM, </text>
<text top="386" left="61" width="25" height="14" font="5">2003 </text>
<text top="400" left="61" width="46" height="14" font="28">12651048 </text>
<text top="413" left="61" width="26" height="14" font="5">(272) </text>
<text top="221" left="129" width="48" height="14" font="5">To assess </text>
<text top="234" left="129" width="16" height="14" font="5">the </text>
<text top="248" left="129" width="48" height="14" font="5">interaction </text>
<text top="262" left="129" width="40" height="14" font="5">between </text>
<text top="276" left="129" width="52" height="14" font="5">HF etiology </text>
<text top="289" left="129" width="19" height="14" font="5">and </text>
<text top="303" left="129" width="43" height="14" font="5">response </text>
<text top="317" left="129" width="54" height="14" font="5">to milrinone </text>
<text top="331" left="129" width="10" height="14" font="5">in </text>
<text top="344" left="129" width="51" height="14" font="5">decompens</text>
<text top="358" left="129" width="38" height="14" font="5">ated HF </text>
<text top="221" left="196" width="23" height="14" font="5">Post-</text>
<text top="234" left="196" width="19" height="14" font="5">hoc </text>
<text top="248" left="196" width="31" height="14" font="5">analysi</text>
<text top="262" left="196" width="8" height="14" font="5">s </text>
<text top="221" left="243" width="67" height="14" font="5">ACEI 70%,       </text>
<text top="234" left="243" width="40" height="14" font="5">bblocker </text>
<text top="248" left="243" width="69" height="14" font="5">23%,                 </text>
<text top="262" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="276" left="243" width="69" height="14" font="5">15%,                 </text>
<text top="289" left="243" width="63" height="14" font="5">Digoxin 73%,  </text>
<text top="221" left="319" width="52" height="14" font="5">949 (total);  </text>
<text top="234" left="319" width="19" height="14" font="5">477 </text>
<text top="248" left="319" width="57" height="14" font="5">(randomized </text>
<text top="262" left="319" width="59" height="14" font="5">to milrinone); </text>
<text top="276" left="319" width="46" height="14" font="5">242 (ICM, </text>
<text top="289" left="319" width="51" height="14" font="5">milrinone) ; </text>
<text top="303" left="319" width="53" height="14" font="5">235 (NICM, </text>
<text top="317" left="319" width="49" height="14" font="5">milrinone); </text>
<text top="331" left="319" width="46" height="14" font="5">243 (ICM, </text>
<text top="344" left="319" width="62" height="14" font="5">placebo); 229 </text>
<text top="358" left="319" width="34" height="14" font="5">(NICM, </text>
<text top="372" left="319" width="40" height="14" font="5">placebo) </text>
<text top="221" left="399" width="40" height="14" font="5">485 ICM </text>
<text top="234" left="399" width="37" height="14" font="5">(51% of </text>
<text top="248" left="399" width="52" height="14" font="5">total)           </text>
<text top="262" left="399" width="47" height="14" font="5">464 NICM </text>
<text top="276" left="399" width="37" height="14" font="5">(49% of </text>
<text top="289" left="399" width="25" height="14" font="5">total) </text>
<text top="221" left="464" width="47" height="14" font="5">Age &gt;18 y </text>
<text top="234" left="464" width="58" height="14" font="5">LVEF &lt; 40% </text>
<text top="248" left="464" width="44" height="14" font="5">within the </text>
<text top="262" left="464" width="65" height="14" font="5">past year.        </text>
<text top="276" left="464" width="33" height="14" font="5">Known </text>
<text top="289" left="464" width="35" height="14" font="5">systolic </text>
<text top="303" left="464" width="53" height="14" font="5">chronic HF  </text>
<text top="317" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="331" left="464" width="14" height="14" font="5">for </text>
<text top="344" left="464" width="59" height="14" font="5">exacerbation </text>
<text top="358" left="464" width="45" height="14" font="5">of chronic </text>
<text top="372" left="464" width="46" height="14" font="5">HF &lt; 48 h </text>
<text top="386" left="464" width="33" height="14" font="5">earlier. </text>
<text top="221" left="537" width="44" height="14" font="5">If treating </text>
<text top="234" left="537" width="44" height="14" font="5">physician </text>
<text top="248" left="537" width="51" height="14" font="5">judged that </text>
<text top="262" left="537" width="50" height="14" font="5">IV inotrope </text>
<text top="276" left="537" width="20" height="14" font="5">was </text>
<text top="289" left="537" width="42" height="14" font="5">essential </text>
<text top="303" left="537" width="34" height="14" font="5">(eg, for </text>
<text top="317" left="537" width="31" height="14" font="5">shock, </text>
<text top="331" left="537" width="45" height="14" font="5">metabolic </text>
<text top="344" left="537" width="52" height="14" font="5">acidosis, or </text>
<text top="358" left="537" width="32" height="14" font="5">severe </text>
<text top="372" left="537" width="53" height="14" font="5">hypotension</text>
<text top="386" left="537" width="39" height="14" font="5">).            </text>
<text top="400" left="537" width="30" height="14" font="5">Active </text>
<text top="413" left="537" width="50" height="14" font="5">myocardial </text>
<text top="427" left="537" width="42" height="14" font="5">ischemia </text>
<text top="441" left="537" width="44" height="14" font="5">within the </text>
<text top="455" left="537" width="65" height="14" font="5">past 3 mo        </text>
<text top="468" left="537" width="25" height="14" font="5">Atrial </text>
<text top="482" left="537" width="44" height="14" font="5">fibrillation </text>
<text top="496" left="537" width="43" height="14" font="5">with poor </text>
<text top="510" left="537" width="48" height="14" font="5">ventricular </text>
<text top="523" left="537" width="52" height="14" font="5">rate control </text>
<text top="537" left="537" width="66" height="14" font="5">(&gt;110/min)       </text>
<text top="551" left="537" width="47" height="14" font="5">Sustained </text>
<text top="565" left="537" width="48" height="14" font="5">ventricular </text>
<text top="578" left="537" width="53" height="14" font="5">tachycardia </text>
<text top="592" left="537" width="11" height="14" font="5">or </text>
<text top="606" left="537" width="48" height="14" font="5">ventricular </text>
<text top="620" left="537" width="66" height="14" font="5">fibrillation.        </text>
<text top="634" left="537" width="41" height="14" font="5">Baseline </text>
<text top="647" left="537" width="42" height="14" font="5">SBP&lt; 80 </text>
<text top="661" left="537" width="64" height="14" font="5">mm Hg            </text>
<text top="675" left="537" width="51" height="14" font="5">SCr level &gt; </text>
<text top="689" left="537" width="44" height="14" font="5">3.0mg/dL </text>
<text top="221" left="609" width="28" height="14" font="5">100% </text>
<text top="234" left="609" width="62" height="14" font="5">NYHA II-IV     </text>
<text top="248" left="609" width="47" height="14" font="5">7% NYHA </text>
<text top="262" left="609" width="60" height="14" font="5">II                    </text>
<text top="276" left="609" width="52" height="14" font="5">46% NYHA </text>
<text top="289" left="609" width="60" height="14" font="5">III                   </text>
<text top="303" left="609" width="52" height="14" font="5">47% NYHA </text>
<text top="317" left="609" width="12" height="14" font="5">IV </text>
<text top="221" left="677" width="39" height="14" font="5">NYHA II-</text>
<text top="234" left="677" width="12" height="14" font="5">IV </text>
<text top="248" left="677" width="40" height="14" font="5">symptom</text>
<text top="262" left="677" width="8" height="14" font="5">s </text>
<text top="221" left="736" width="10" height="14" font="5">D </text>
<text top="234" left="736" width="55" height="14" font="5">hospitalized </text>
<text top="248" left="736" width="30" height="14" font="5">for CV </text>
<text top="262" left="736" width="45" height="14" font="5">causes or </text>
<text top="276" left="736" width="55" height="14" font="5">death within </text>
<text top="289" left="736" width="44" height="14" font="5">60 d after </text>
<text top="303" left="736" width="56" height="14" font="5">randomizatio</text>
<text top="317" left="736" width="8" height="14" font="5">n </text>
<text top="221" left="811" width="72" height="14" font="5">Main secondary </text>
<text top="234" left="811" width="41" height="14" font="5">outcome </text>
<text top="248" left="811" width="56" height="14" font="5">included the </text>
<text top="262" left="811" width="58" height="14" font="5">proportion of </text>
<text top="276" left="811" width="57" height="14" font="5">cases failing </text>
<text top="289" left="811" width="36" height="14" font="5">therapy </text>
<text top="303" left="811" width="51" height="14" font="5">because of </text>
<text top="317" left="811" width="69" height="14" font="5">adverse events </text>
<text top="331" left="811" width="59" height="14" font="5">or worsening </text>
<text top="344" left="811" width="63" height="14" font="5">HF 48 hr after </text>
<text top="358" left="811" width="50" height="14" font="5">initiation of </text>
<text top="372" left="811" width="82" height="14" font="5">therapy.                 </text>
<text top="386" left="811" width="27" height="14" font="5">Other </text>
<text top="400" left="811" width="48" height="14" font="5">secondary </text>
<text top="413" left="811" width="45" height="14" font="5">outcomes </text>
<text top="427" left="811" width="56" height="14" font="5">included the </text>
<text top="441" left="811" width="74" height="14" font="5">proportion of pts </text>
<text top="455" left="811" width="72" height="14" font="5">achieving target </text>
<text top="468" left="811" width="66" height="14" font="5">doses of ACEI </text>
<text top="482" left="811" width="55" height="14" font="5">therapy and </text>
<text top="496" left="811" width="69" height="14" font="5">time to achieve </text>
<text top="510" left="811" width="55" height="14" font="5">target dose, </text>
<text top="523" left="811" width="50" height="14" font="5">symptoms, </text>
<text top="537" left="811" width="70" height="14" font="5">improvement in </text>
<text top="551" left="811" width="45" height="14" font="5">HF score, </text>
<text top="565" left="811" width="66" height="14" font="5">length of initial </text>
<text top="578" left="811" width="68" height="14" font="5">hospitalization, </text>
<text top="592" left="811" width="19" height="14" font="5">d of </text>
<text top="606" left="811" width="65" height="14" font="5">hospitalization </text>
<text top="620" left="811" width="62" height="14" font="5">for CV events </text>
<text top="634" left="811" width="47" height="14" font="5">from initial </text>
<text top="647" left="811" width="37" height="14" font="5">hospital </text>
<text top="661" left="811" width="70" height="14" font="5">discharge to 60 </text>
<text top="675" left="811" width="30" height="14" font="5">d, d of </text>
<text top="689" left="811" width="65" height="14" font="5">hospitalization </text>
<text top="702" left="811" width="62" height="14" font="5">for CV events </text>
<text top="716" left="811" width="72" height="14" font="5">within 30 d after </text>
<text top="730" left="811" width="67" height="14" font="5">randomization, </text>
<text top="744" left="811" width="42" height="14" font="5">all-cause </text>
<text top="758" left="811" width="71" height="14" font="5">hospitaliz-ation, </text>
<text top="771" left="811" width="62" height="14" font="5">and mortality. </text>
<text top="221" left="899" width="19" height="14" font="5">N/A </text>
<text top="221" left="973" width="19" height="14" font="5">N/A </text>
<text top="221" left="1034" width="39" height="14" font="5">Recruitm</text>
<text top="234" left="1034" width="39" height="14" font="5">ent 7/97-</text>
<text top="248" left="1034" width="27" height="14" font="5">11/99 </text>
<text top="262" left="1034" width="37" height="14" font="5">(29mo); </text>
<text top="276" left="1034" width="28" height="14" font="5">Study </text>
<text top="289" left="1034" width="22" height="14" font="5">drug </text>
<text top="303" left="1034" width="44" height="14" font="5">treatment </text>
<text top="317" left="1034" width="39" height="14" font="5">for up to </text>
<text top="331" left="1034" width="42" height="14" font="5">72 h with </text>
<text top="344" left="1034" width="35" height="14" font="5">60 d f/u </text>
<text top="358" left="1034" width="30" height="14" font="5">period </text>
<text top="372" left="1034" width="44" height="14" font="5">from time </text>
<text top="386" left="1034" width="11" height="14" font="5">of </text>
<text top="400" left="1034" width="40" height="14" font="5">randomiz</text>
<text top="413" left="1034" width="24" height="14" font="5">ation </text>
<text top="221" left="1095" width="79" height="14" font="5">D hospitalized for </text>
<text top="234" left="1095" width="62" height="14" font="5">CV causes or </text>
<text top="248" left="1095" width="67" height="14" font="5">death w/in 60d </text>
<text top="262" left="1095" width="22" height="14" font="5">after </text>
<text top="276" left="1095" width="65" height="14" font="5">randomization </text>
<text top="289" left="1095" width="73" height="14" font="5">was 13.0+14.2d </text>
<text top="303" left="1095" width="71" height="14" font="5">for ischemic HF </text>
<text top="317" left="1095" width="71" height="14" font="5">pts, 11.7+13.9d </text>
<text top="331" left="1095" width="72" height="14" font="5">for nonischemic </text>
<text top="344" left="1095" width="37" height="14" font="5">HF pts   </text>
<text top="358" left="1095" width="62" height="14" font="5">60 d mortality </text>
<text top="372" left="1095" width="68" height="14" font="5">was greater for </text>
<text top="386" left="1095" width="78" height="14" font="5">ischemic (11.6%) </text>
<text top="400" left="1095" width="56" height="14" font="5">than for non-</text>
<text top="413" left="1095" width="57" height="14" font="5">ischemic pts </text>
<text top="427" left="1095" width="86" height="14" font="5">(7.5%).                    </text>
<text top="441" left="1095" width="67" height="14" font="5">Combined end </text>
<text top="455" left="1095" width="74" height="14" font="5">point of death or </text>
<text top="468" left="1095" width="74" height="14" font="5">rehospitalization </text>
<text top="482" left="1095" width="53" height="14" font="5">at 60 d was </text>
<text top="496" left="1095" width="41" height="14" font="5">38.7% in </text>
<text top="510" left="1095" width="76" height="14" font="5">ischemic pts and </text>
<text top="523" left="1095" width="57" height="14" font="5">31.5% in the </text>
<text top="537" left="1095" width="87" height="14" font="5">nonischemic pts.     </text>
<text top="551" left="1095" width="61" height="14" font="5">More pts with </text>
<text top="565" left="1095" width="73" height="14" font="5">nonischemic HF </text>
<text top="578" left="1095" width="56" height="14" font="5">were able to </text>
<text top="592" left="1095" width="55" height="14" font="5">reach target </text>
<text top="606" left="1095" width="79" height="14" font="5">dosing of ACEI at </text>
<text top="620" left="1095" width="37" height="14" font="5">hospital </text>
<text top="634" left="1095" width="77" height="14" font="5">discharge (49%)  </text>
<text top="647" left="1095" width="47" height="14" font="5">compared </text>
<text top="661" left="1095" width="67" height="14" font="5">w/ischemic HF </text>
<text top="675" left="1095" width="48" height="14" font="5">pts (36%). </text>
<text top="689" left="1095" width="77" height="14" font="5">Treatment failure </text>
<text top="702" left="1095" width="55" height="14" font="5">while on the </text>
<text top="716" left="1095" width="69" height="14" font="5">study drug was </text>
<text top="730" left="1095" width="79" height="14" font="5">similar btwn the 2 </text>
<text top="744" left="1095" width="81" height="14" font="5">groups (14.2% for </text>
<text top="758" left="1095" width="59" height="14" font="5">ischemic  vs. </text>
<text top="771" left="1095" width="45" height="14" font="5">15.2% for </text>
<text top="785" left="1095" width="87" height="14" font="5">nonischemic pts).    </text>
<text top="221" left="1189" width="116" height="14" font="5">Primary endpoint, p=0.2    </text>
<text top="234" left="1189" width="115" height="14" font="5">60d mortality, P=0.03        </text>
<text top="248" left="1189" width="91" height="14" font="5">Combined endpoint, </text>
<text top="262" left="1189" width="82" height="14" font="5">p=0,02                   </text>
<text top="276" left="1189" width="89" height="14" font="5">Able to reach target </text>
<text top="289" left="1189" width="116" height="14" font="5">ACEI dose, p=0.001          </text>
<text top="303" left="1189" width="91" height="14" font="5">Treatment failure on </text>
<text top="317" left="1189" width="79" height="14" font="5">study drug, p=0.7 </text>
<text top="331" left="1189" width="5" height="14" font="5">  </text>
<text top="221" left="1311" width="55" height="14" font="5">Retrospectiv</text>
<text top="234" left="1311" width="67" height="14" font="5">e study;            </text>
<text top="248" left="1311" width="37" height="14" font="5">No data </text>
<text top="262" left="1311" width="55" height="14" font="5">collected on </text>
<text top="276" left="1311" width="50" height="14" font="5">the level of </text>
<text top="289" left="1311" width="57" height="14" font="5">care that pts </text>
<text top="303" left="1311" width="40" height="14" font="5">received </text>
<text top="317" left="1311" width="57" height="14" font="5">(i.e., ICU vs. </text>
<text top="331" left="1311" width="46" height="14" font="5">monitored </text>
<text top="344" left="1311" width="53" height="14" font="5">bed), which </text>
<text top="358" left="1311" width="47" height="14" font="5">potentially </text>
<text top="372" left="1311" width="50" height="14" font="5">could have </text>
<text top="386" left="1311" width="54" height="14" font="5">affected the </text>
<text top="400" left="1311" width="43" height="14" font="5">results of </text>
<text top="413" left="1311" width="67" height="14" font="5">study;               </text>
<text top="427" left="1311" width="54" height="14" font="5">Imbalanced </text>
<text top="441" left="1311" width="42" height="14" font="5">follow up </text>
<text top="455" left="1311" width="24" height="14" font="5">btwn </text>
<text top="468" left="1311" width="39" height="14" font="5">etiologic </text>
<text top="482" left="1311" width="60" height="14" font="5">groups (4 pts </text>
<text top="496" left="1311" width="51" height="14" font="5">in ischemic </text>
<text top="510" left="1311" width="51" height="14" font="5">group vs. 8 </text>
<text top="523" left="1311" width="26" height="14" font="5">pts in </text>
<text top="537" left="1311" width="58" height="14" font="5">nonischemic </text>
<text top="551" left="1311" width="57" height="14" font="5">group lost to </text>
<text top="565" left="1311" width="45" height="14" font="5">follow-up) </text>
<text top="221" left="1385" width="47" height="14" font="5">In pts with </text>
<text top="234" left="1385" width="60" height="14" font="5">ischemic HF, </text>
<text top="248" left="1385" width="75" height="14" font="5">milrinone tended </text>
<text top="262" left="1385" width="74" height="14" font="5">to be associated </text>
<text top="276" left="1385" width="67" height="14" font="5">with prolonged </text>
<text top="289" left="1385" width="65" height="14" font="5">hospitalization </text>
<text top="303" left="1385" width="49" height="14" font="5">and higher </text>
<text top="317" left="1385" width="43" height="14" font="5">mortality. </text>
<text top="331" left="1385" width="61" height="14" font="5">Composite of </text>
<text top="344" left="1385" width="39" height="14" font="5">death or </text>
<text top="358" left="1385" width="74" height="14" font="5">rehospitalization </text>
<text top="372" left="1385" width="75" height="14" font="5">at 60 d was 42% </text>
<text top="386" left="1385" width="71" height="14" font="5">for ischemic pts </text>
<text top="400" left="1385" width="54" height="14" font="5">treated with </text>
<text top="413" left="1385" width="62" height="14" font="5">milrinone and </text>
<text top="427" left="1385" width="64" height="14" font="5">36% for those </text>
<text top="441" left="1385" width="33" height="14" font="5">treated </text>
<text top="455" left="1385" width="47" height="14" font="5">w/placebo </text>
<text top="468" left="1385" width="50" height="14" font="5">(p=0.01 for </text>
<text top="482" left="1385" width="37" height="14" font="5">etiology-</text>
<text top="496" left="1385" width="44" height="14" font="5">treatment </text>
<text top="510" left="1385" width="66" height="14" font="5">interaction). In-</text>
<text top="523" left="1385" width="37" height="14" font="5">hospital </text>
<text top="537" left="1385" width="54" height="14" font="5">mortality for </text>
<text top="551" left="1385" width="43" height="14" font="5">milrinone-</text>
<text top="565" left="1385" width="69" height="14" font="5">treated pts with </text>
<text top="578" left="1385" width="57" height="14" font="5">ischemic HF </text>
<text top="592" left="1385" width="61" height="14" font="5">was 5.0% vs. </text>
<text top="606" left="1385" width="39" height="14" font="5">1.6% for </text>
<text top="620" left="1385" width="49" height="14" font="5">placebo (p </text>
<text top="634" left="1385" width="42" height="14" font="5">=0.04 for </text>
<text top="647" left="1385" width="37" height="14" font="5">etiology-</text>
<text top="661" left="1385" width="44" height="14" font="5">treatment </text>
<text top="675" left="1385" width="73" height="14" font="5">interaction), and </text>
<text top="689" left="1385" width="62" height="14" font="5">60 d mortality </text>
<text top="702" left="1385" width="65" height="14" font="5">was 13.3% for </text>
<text top="716" left="1385" width="55" height="14" font="5">milrinone vs </text>
<text top="730" left="1385" width="74" height="14" font="5">10% for placebo </text>
<text top="744" left="1385" width="39" height="14" font="5">(p= 0.21 </text>
<text top="758" left="1385" width="51" height="14" font="5">for etiology-</text>
<text top="771" left="1385" width="44" height="14" font="5">treatment </text>
<text top="785" left="1385" width="54" height="14" font="5">interaction). </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="30" size="9" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">127</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1095" width="62" height="14" font="5">Baseline QoL </text>
<text top="68" left="1095" width="81" height="14" font="5">data did not differ  </text>
<text top="82" left="1095" width="56" height="14" font="5">between the </text>
<text top="96" left="1095" width="41" height="14" font="5">2groups. </text>
<text top="115" left="61" width="45" height="14" font="5">Inhospital </text>
<text top="129" left="61" width="50" height="14" font="5">mortality in </text>
<text top="143" left="61" width="36" height="14" font="5">pts with </text>
<text top="157" left="61" width="27" height="14" font="5">acute </text>
<text top="170" left="61" width="51" height="14" font="5">decompens</text>
<text top="184" left="61" width="38" height="14" font="5">ated HF </text>
<text top="198" left="61" width="41" height="14" font="5">requiring </text>
<text top="212" left="61" width="54" height="14" font="5">intravenous </text>
<text top="225" left="61" width="49" height="14" font="5">vasoactive </text>
<text top="239" left="61" width="48" height="14" font="5">medication</text>
<text top="253" left="61" width="24" height="14" font="5">s: an </text>
<text top="267" left="61" width="38" height="14" font="5">analysis </text>
<text top="281" left="61" width="39" height="14" font="5">from the </text>
<text top="294" left="61" width="28" height="14" font="5">Acute </text>
<text top="308" left="61" width="48" height="14" font="5">Decompen</text>
<text top="322" left="61" width="43" height="14" font="5">sated HF </text>
<text top="336" left="61" width="39" height="14" font="5">National </text>
<text top="349" left="61" width="39" height="14" font="5">Registry </text>
<text top="363" left="61" width="53" height="14" font="5">(ADHERE), </text>
<text top="377" left="61" width="43" height="14" font="5">Abraham </text>
<text top="391" left="61" width="50" height="14" font="5">WR, JACC </text>
<text top="404" left="61" width="25" height="14" font="5">2005 </text>
<text top="418" left="61" width="46" height="14" font="28">15992636 </text>
<text top="432" left="61" width="26" height="14" font="5">(273) </text>
<text top="115" left="129" width="14" height="14" font="5">To </text>
<text top="129" left="129" width="51" height="14" font="5">compare in </text>
<text top="143" left="129" width="37" height="14" font="5">hospital </text>
<text top="157" left="129" width="50" height="14" font="5">mortality in </text>
<text top="170" left="129" width="36" height="14" font="5">pts with </text>
<text top="184" left="129" width="27" height="14" font="5">acute </text>
<text top="198" left="129" width="51" height="14" font="5">decompens</text>
<text top="212" left="129" width="38" height="14" font="5">ated HF </text>
<text top="225" left="129" width="42" height="14" font="5">receiving </text>
<text top="239" left="129" width="44" height="14" font="5">treatment </text>
<text top="253" left="129" width="47" height="14" font="5">with 1 of 4 </text>
<text top="267" left="129" width="49" height="14" font="5">vasoactive </text>
<text top="281" left="129" width="27" height="14" font="5">meds </text>
<text top="294" left="129" width="29" height="14" font="5">(NTG, </text>
<text top="308" left="129" width="45" height="14" font="5">nesiritide, </text>
<text top="322" left="129" width="45" height="14" font="5">milrinone, </text>
<text top="336" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="349" left="129" width="11" height="14" font="5">e) </text>
<text top="115" left="196" width="28" height="14" font="5">Regist</text>
<text top="129" left="196" width="11" height="14" font="5">ry </text>
<text top="115" left="243" width="57" height="14" font="5">Beta blocker </text>
<text top="129" left="243" width="69" height="14" font="5">50%                  </text>
<text top="143" left="243" width="67" height="14" font="5">ACEI 43%        </text>
<text top="157" left="243" width="67" height="14" font="5">ARB 12%         </text>
<text top="170" left="243" width="55" height="14" font="5">Spironolacto</text>
<text top="184" left="243" width="36" height="14" font="5">ne 15% </text>
<text top="198" left="243" width="33" height="14" font="5">(varied </text>
<text top="212" left="243" width="41" height="14" font="5">amongst </text>
<text top="225" left="243" width="58" height="14" font="5">subgroups 7-</text>
<text top="239" left="243" width="26" height="14" font="5">24%) </text>
<text top="115" left="319" width="60" height="14" font="5">65180;  6549 </text>
<text top="129" left="319" width="66" height="14" font="5">(NTG);  5220 ; </text>
<text top="143" left="319" width="54" height="14" font="5">(nesiritide) ; </text>
<text top="157" left="319" width="25" height="14" font="5">2021 </text>
<text top="170" left="319" width="68" height="14" font="5">(milrinone) ;      </text>
<text top="184" left="319" width="25" height="14" font="5">4226 </text>
<text top="198" left="319" width="66" height="14" font="5">(dobutamine) ; </text>
<text top="212" left="319" width="46" height="14" font="5">49950 (all </text>
<text top="225" left="319" width="33" height="14" font="5">others) </text>
<text top="115" left="399" width="43" height="14" font="5">56% ICM </text>
<text top="115" left="464" width="51" height="14" font="5">admitted to </text>
<text top="129" left="464" width="8" height="14" font="5">a </text>
<text top="143" left="464" width="56" height="14" font="5">participating </text>
<text top="157" left="464" width="49" height="14" font="5">acute care </text>
<text top="170" left="464" width="56" height="14" font="5">hospital and </text>
<text top="184" left="464" width="34" height="14" font="5">given a </text>
<text top="198" left="464" width="45" height="14" font="5">discharge </text>
<text top="212" left="464" width="55" height="14" font="5">diagnosis of </text>
<text top="225" left="464" width="16" height="14" font="5">HF </text>
<text top="115" left="537" width="58" height="14" font="5">HF is not the </text>
<text top="129" left="537" width="39" height="14" font="5">principal </text>
<text top="143" left="537" width="37" height="14" font="5">focus of </text>
<text top="157" left="537" width="56" height="14" font="5">diagnosis or </text>
<text top="170" left="537" width="44" height="14" font="5">treatment </text>
<text top="184" left="537" width="46" height="14" font="5">during the </text>
<text top="198" left="537" width="58" height="14" font="5">admission or </text>
<text top="212" left="537" width="29" height="14" font="5">if their </text>
<text top="225" left="537" width="37" height="14" font="5">medical </text>
<text top="239" left="537" width="31" height="14" font="5">record </text>
<text top="253" left="537" width="46" height="14" font="5">cannot be </text>
<text top="267" left="537" width="58" height="14" font="5">accessed for </text>
<text top="281" left="537" width="55" height="14" font="5">administrativ</text>
<text top="294" left="537" width="46" height="14" font="5">e reasons </text>
<text top="115" left="609" width="42" height="14" font="5">NYHA IV </text>
<text top="129" left="609" width="22" height="14" font="5">45% </text>
<text top="143" left="609" width="45" height="14" font="5">(dyspneic </text>
<text top="157" left="609" width="33" height="14" font="5">at rest) </text>
<text top="115" left="677" width="145" height="14" font="5">N/A Inhospital </text>
<text top="129" left="736" width="40" height="14" font="5">mortality </text>
<text top="115" left="811" width="72" height="14" font="5">Total LOS,  ICU </text>
<text top="129" left="811" width="22" height="14" font="5">LOS </text>
<text top="115" left="899" width="22" height="14" font="5"> N/A </text>
<text top="115" left="973" width="40" height="14" font="5">Inpatient </text>
<text top="129" left="973" width="54" height="14" font="5">mortality      </text>
<text top="143" left="973" width="54" height="14" font="5">Milrinone:    </text>
<text top="157" left="973" width="50" height="14" font="5">12.3%        </text>
<text top="170" left="973" width="42" height="14" font="5">Dobutami</text>
<text top="184" left="973" width="52" height="14" font="5">ne: 13.9%   </text>
<text top="198" left="973" width="26" height="14" font="5">NTG: </text>
<text top="212" left="973" width="52" height="14" font="5">4.7%           </text>
<text top="225" left="973" width="46" height="14" font="5">Nesiritide: </text>
<text top="239" left="973" width="52" height="14" font="5">7.1%           </text>
<text top="253" left="973" width="46" height="14" font="5">All others: </text>
<text top="267" left="973" width="25" height="14" font="5">3.1% </text>
<text top="115" left="1034" width="28" height="14" font="5">10/01-</text>
<text top="129" left="1034" width="22" height="14" font="5">7/03 </text>
<text top="115" left="1095" width="71" height="14" font="5">Worse inpatient </text>
<text top="129" left="1095" width="59" height="14" font="5">mortality and </text>
<text top="143" left="1095" width="73" height="14" font="5">longer LOS with </text>
<text top="157" left="1095" width="55" height="14" font="5">IV inotropes </text>
<text top="170" left="1095" width="69" height="14" font="5">compared to IV </text>
<text top="184" left="1095" width="67" height="14" font="5">vasodilators or </text>
<text top="198" left="1095" width="36" height="14" font="5">neither. </text>
<text top="115" left="1189" width="105" height="14" font="5">Inhospital Mortality Dob </text>
<text top="129" left="1189" width="103" height="14" font="5">vs Milrinone: OR: 1.24;<b> </b></text>
<text top="143" left="1189" width="85" height="14" font="5">95% CI: 1.03-1.55: </text>
<text top="157" left="1189" width="90" height="14" font="5">p=0.027                    </text>
<text top="170" left="1189" width="114" height="14" font="5">NTG vs Dobutamine:        </text>
<text top="184" left="1189" width="97" height="14" font="5">OR: 0.46; 95% CI:.37-</text>
<text top="198" left="1189" width="110" height="14" font="5">0.57, p&lt;0.005                  </text>
<text top="212" left="1189" width="102" height="14" font="5">NTG vs Milrinone: OR: </text>
<text top="225" left="1189" width="107" height="14" font="5">0.69; 95% CI:0.53-0.89; </text>
<text top="239" left="1189" width="41" height="14" font="5">p&lt;0.005  </text>
<text top="253" left="1189" width="3" height="14" font="5"> </text>
<text top="115" left="1311" width="53" height="14" font="5">Observation</text>
<text top="129" left="1311" width="68" height="14" font="5">al analysis        </text>
<text top="143" left="1311" width="55" height="14" font="5">Retrospectiv</text>
<text top="157" left="1311" width="68" height="14" font="5">e analysis         </text>
<text top="170" left="1311" width="40" height="14" font="5">Clinician </text>
<text top="184" left="1311" width="49" height="14" font="5">judgement </text>
<text top="198" left="1311" width="51" height="14" font="5">for medical </text>
<text top="212" left="1311" width="58" height="14" font="5">management</text>
<text top="225" left="1311" width="57" height="14" font="5">/choice of IV </text>
<text top="239" left="1311" width="68" height="14" font="5">med                  </text>
<text top="253" left="1311" width="21" height="14" font="5">Non-</text>
<text top="267" left="1311" width="68" height="14" font="5">randomized      </text>
<text top="280" left="1311" width="52" height="14" font="5">Differences </text>
<text top="294" left="1311" width="43" height="14" font="5">in clinical </text>
<text top="308" left="1311" width="37" height="14" font="5">severity </text>
<text top="322" left="1311" width="40" height="14" font="5">between </text>
<text top="336" left="1311" width="49" height="14" font="5">subgroups </text>
<text top="115" left="1385" width="19" height="14" font="5">N/A </text>
<text top="447" left="61" width="49" height="14" font="5">Survival of </text>
<text top="460" left="61" width="37" height="14" font="5">Pts with </text>
<text top="474" left="61" width="54" height="14" font="5">Acute HF in </text>
<text top="488" left="61" width="37" height="14" font="5">Need of </text>
<text top="502" left="61" width="54" height="14" font="5">Intravenous </text>
<text top="515" left="61" width="40" height="14" font="5">Inotropic </text>
<text top="529" left="61" width="37" height="14" font="5">Support </text>
<text top="543" left="61" width="50" height="14" font="5">(SURVIVE)</text>
<text top="557" left="61" width="49" height="14" font="5">, Mebazaa </text>
<text top="570" left="61" width="37" height="14" font="5">A, 2007 </text>
<text top="584" left="61" width="46" height="14" font="28">17473298 </text>
<text top="598" left="61" width="26" height="14" font="5">(274) </text>
<text top="612" left="61" width="3" height="14" font="5"> </text>
<text top="447" left="129" width="48" height="14" font="5">To assess </text>
<text top="460" left="129" width="43" height="14" font="5">the effect </text>
<text top="474" left="129" width="44" height="14" font="5">of a short-</text>
<text top="488" left="129" width="34" height="14" font="5">term IV </text>
<text top="502" left="129" width="48" height="14" font="5">infusion of </text>
<text top="515" left="129" width="50" height="14" font="5">levosimend</text>
<text top="529" left="129" width="14" height="14" font="5">an </text>
<text top="543" left="129" width="11" height="14" font="5">or </text>
<text top="557" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="570" left="129" width="44" height="14" font="5">e on long-</text>
<text top="584" left="129" width="22" height="14" font="5">term </text>
<text top="598" left="129" width="36" height="14" font="5">survival </text>
<text top="447" left="196" width="94" height="14" font="5">RCT Beta </text>
<text top="447" left="266" width="59" height="14" font="5">blocker </text>
<text top="460" left="243" width="69" height="14" font="5">51%                  </text>
<text top="474" left="243" width="51" height="14" font="5">ACEI/ARB  </text>
<text top="488" left="243" width="69" height="14" font="5">69%                  </text>
<text top="502" left="243" width="55" height="14" font="5">Aldosterone </text>
<text top="515" left="243" width="51" height="14" font="5">antagonist  </text>
<text top="529" left="243" width="69" height="14" font="5">53%                  </text>
<text top="543" left="243" width="51" height="14" font="5">IV diuretics </text>
<text top="557" left="243" width="69" height="14" font="5">79%                  </text>
<text top="570" left="243" width="47" height="14" font="5">IV nitrates </text>
<text top="584" left="243" width="69" height="14" font="5">37%                  </text>
<text top="598" left="243" width="58" height="14" font="5">IV dopamine </text>
<text top="612" left="243" width="17" height="14" font="5">6% </text>
<text top="447" left="319" width="46" height="14" font="5">1327; 664 </text>
<text top="460" left="319" width="64" height="14" font="5">(levosimendan</text>
<text top="474" left="319" width="28" height="14" font="5">); 663 </text>
<text top="488" left="319" width="61" height="14" font="5">(dobutamine) </text>
<text top="447" left="399" width="22" height="14" font="5">76% </text>
<text top="447" left="464" width="66" height="14" font="5">Age &gt;18 y        </text>
<text top="460" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="474" left="464" width="66" height="14" font="5">with ADHF.      </text>
<text top="488" left="464" width="55" height="14" font="5">LVEF &lt;30% </text>
<text top="502" left="464" width="50" height="14" font="5">within prior </text>
<text top="515" left="464" width="33" height="14" font="5">12 mo  </text>
<text top="529" left="464" width="55" height="14" font="5">Required IV </text>
<text top="543" left="464" width="40" height="14" font="5">inotropic </text>
<text top="557" left="464" width="38" height="14" font="5">support, </text>
<text top="570" left="464" width="13" height="14" font="5">as </text>
<text top="584" left="464" width="48" height="14" font="5">evidenced </text>
<text top="598" left="464" width="27" height="14" font="5">by an </text>
<text top="612" left="464" width="49" height="14" font="5">insufficient </text>
<text top="625" left="464" width="54" height="14" font="5">response to </text>
<text top="639" left="464" width="51" height="14" font="5">IV diuretics </text>
<text top="653" left="464" width="31" height="14" font="5">and/or </text>
<text top="667" left="464" width="58" height="14" font="5">vasodilators, </text>
<text top="681" left="464" width="44" height="14" font="5">and &gt;1 of </text>
<text top="694" left="464" width="57" height="14" font="5">the following </text>
<text top="708" left="464" width="59" height="14" font="5">at screening: </text>
<text top="722" left="464" width="55" height="14" font="5">(a) dyspnea </text>
<text top="736" left="464" width="41" height="14" font="5">at rest or </text>
<text top="749" left="464" width="53" height="14" font="5">mechanical </text>
<text top="763" left="464" width="47" height="14" font="5">ventilation </text>
<text top="777" left="464" width="46" height="14" font="5">for ADHF; </text>
<text top="791" left="464" width="49" height="14" font="5">(b) oliguria </text>
<text top="447" left="537" width="34" height="14" font="5">Severe </text>
<text top="460" left="537" width="48" height="14" font="5">ventricular </text>
<text top="474" left="537" width="34" height="14" font="5">outflow </text>
<text top="488" left="537" width="64" height="14" font="5">obstruction;     </text>
<text top="502" left="537" width="22" height="14" font="5">SBP </text>
<text top="515" left="537" width="53" height="14" font="5">persistently </text>
<text top="529" left="537" width="65" height="14" font="5">&lt;85 mm Hg     </text>
<text top="543" left="537" width="17" height="14" font="5">HR </text>
<text top="557" left="537" width="53" height="14" font="5">persistently </text>
<text top="570" left="537" width="66" height="14" font="5">&gt; 130 bpm;      </text>
<text top="584" left="537" width="50" height="14" font="5">IV inotrope </text>
<text top="598" left="537" width="49" height="14" font="5">use during </text>
<text top="612" left="537" width="43" height="14" font="5">the index </text>
<text top="625" left="537" width="51" height="14" font="5">hospitalizati</text>
<text top="639" left="537" width="49" height="14" font="5">on (except </text>
<text top="653" left="537" width="54" height="14" font="5">dopamine 2 </text>
<text top="667" left="537" width="57" height="14" font="5">μg/kg/min or </text>
<text top="681" left="537" width="66" height="14" font="5">digitalis);          </text>
<text top="694" left="537" width="44" height="14" font="5">History of </text>
<text top="708" left="537" width="49" height="14" font="5">torsade de </text>
<text top="722" left="537" width="64" height="14" font="5">pointes;           </text>
<text top="736" left="537" width="42" height="14" font="5">SCr&gt; 5.1 </text>
<text top="749" left="537" width="52" height="14" font="5">mg/dL (450 </text>
<text top="763" left="537" width="47" height="14" font="5">μmol/L) or </text>
<text top="777" left="537" width="51" height="14" font="5">on dialysis. </text>
<text top="447" left="609" width="52" height="14" font="5">86% NYHA </text>
<text top="460" left="609" width="12" height="14" font="5">IV </text>
<text top="447" left="677" width="21" height="14" font="5">Low-</text>
<text top="460" left="677" width="30" height="14" font="5">output </text>
<text top="474" left="677" width="30" height="14" font="5">ADHF </text>
<text top="447" left="736" width="43" height="14" font="5">All-cause </text>
<text top="460" left="736" width="40" height="14" font="5">mortality </text>
<text top="474" left="736" width="46" height="14" font="5">during the </text>
<text top="488" left="736" width="27" height="14" font="5">180 d </text>
<text top="502" left="736" width="41" height="14" font="5">following </text>
<text top="515" left="736" width="56" height="14" font="5">randomizatio</text>
<text top="529" left="736" width="14" height="14" font="5">n.  </text>
<text top="447" left="811" width="43" height="14" font="5">All-cause </text>
<text top="460" left="811" width="70" height="14" font="5">mortality during </text>
<text top="474" left="811" width="70" height="14" font="5">31 d, change in </text>
<text top="488" left="811" width="68" height="14" font="5">BNP level from </text>
<text top="502" left="811" width="64" height="14" font="5">baseline to 24 </text>
<text top="515" left="811" width="71" height="14" font="5">h; No. of d alive </text>
<text top="529" left="811" width="63" height="14" font="5">and out of the </text>
<text top="543" left="811" width="67" height="14" font="5">hospital during </text>
<text top="557" left="811" width="82" height="14" font="5">the 180 d;              </text>
<text top="570" left="811" width="56" height="14" font="5">change in pt </text>
<text top="584" left="811" width="44" height="14" font="5">assessed </text>
<text top="598" left="811" width="64" height="14" font="5">dyspnea at 24 </text>
<text top="612" left="811" width="67" height="14" font="5">h; Pt assessed </text>
<text top="625" left="811" width="29" height="14" font="5">global </text>
<text top="639" left="811" width="66" height="14" font="5">assessment at </text>
<text top="653" left="811" width="41" height="14" font="5">24 h; CV </text>
<text top="667" left="811" width="40" height="14" font="5">mortality </text>
<text top="681" left="811" width="36" height="14" font="5">through </text>
<text top="694" left="811" width="30" height="14" font="5">180 d. </text>
<text top="447" left="899" width="19" height="14" font="5">N/A </text>
<text top="447" left="973" width="19" height="14" font="5">N/A </text>
<text top="447" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="460" left="1034" width="28" height="14" font="5">t 3/03-</text>
<text top="474" left="1034" width="27" height="14" font="5">12/04 </text>
<text top="488" left="1034" width="39" height="14" font="5">(22mo),  </text>
<text top="502" left="1034" width="26" height="14" font="5">study </text>
<text top="515" left="1034" width="22" height="14" font="5">drug </text>
<text top="529" left="1034" width="37" height="14" font="5">infusion </text>
<text top="543" left="1034" width="14" height="14" font="5">for </text>
<text top="557" left="1034" width="43" height="14" font="5">minimum </text>
<text top="570" left="1034" width="33" height="14" font="5">of 24 h </text>
<text top="584" left="1034" width="40" height="14" font="5">and total </text>
<text top="598" left="1034" width="38" height="14" font="5">duration </text>
<text top="612" left="1034" width="11" height="14" font="5">of </text>
<text top="625" left="1034" width="42" height="14" font="5">unknown </text>
<text top="639" left="1034" width="33" height="14" font="5">period, </text>
<text top="653" left="1034" width="42" height="14" font="5">follow up </text>
<text top="667" left="1034" width="41" height="14" font="5">at 180 d, </text>
<text top="447" left="1095" width="75" height="14" font="5">During the 180 d </text>
<text top="460" left="1095" width="71" height="14" font="5">after study drug </text>
<text top="474" left="1095" width="64" height="14" font="5">infusion, there </text>
<text top="488" left="1095" width="75" height="14" font="5">were 173 deaths </text>
<text top="502" left="1095" width="56" height="14" font="5">(26%) in the </text>
<text top="515" left="1095" width="64" height="14" font="5">levosimendan </text>
<text top="529" left="1095" width="66" height="14" font="5">group and 185 </text>
<text top="543" left="1095" width="59" height="14" font="5">deaths in the </text>
<text top="557" left="1095" width="54" height="14" font="5">dobutamine </text>
<text top="570" left="1095" width="60" height="14" font="5">group (28%). </text>
<text top="584" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="598" left="1095" width="48" height="14" font="5">secondary </text>
<text top="612" left="1095" width="80" height="14" font="5">endpoints, except </text>
<text top="625" left="1095" width="73" height="14" font="5">in mean change </text>
<text top="639" left="1095" width="66" height="14" font="5">in BNP at 24 h </text>
<text top="653" left="1095" width="68" height="14" font="5">from baseline (-</text>
<text top="667" left="1095" width="19" height="14" font="5">631 </text>
<text top="681" left="1095" width="76" height="14" font="5">levosimendan vs </text>
<text top="694" left="1095" width="80" height="14" font="5">-397 dobutamine) </text>
<text top="447" left="1189" width="115" height="14" font="5">Primary endpoint:              </text>
<text top="460" left="1189" width="99" height="14" font="5">HR 0.91; 95% CI 0.74-</text>
<text top="474" left="1189" width="112" height="14" font="5">1.13; p=0.40                     </text>
<text top="488" left="1189" width="90" height="14" font="5">Secondary endpoint </text>
<text top="502" left="1189" width="78" height="14" font="5">(DBNP): p&lt;0.001 </text>
<text top="515" left="1189" width="3" height="14" font="5"> </text>
<text top="447" left="1311" width="26" height="14" font="5">Short </text>
<text top="460" left="1311" width="49" height="14" font="5">duration of </text>
<text top="474" left="1311" width="52" height="14" font="5">treatment.   </text>
<text top="488" left="1311" width="39" height="14" font="5">Detail of </text>
<text top="502" left="1311" width="49" height="14" font="5">duration of </text>
<text top="515" left="1311" width="56" height="14" font="5">infusion and </text>
<text top="529" left="1311" width="35" height="14" font="5">dose of </text>
<text top="543" left="1311" width="49" height="14" font="5">study drug </text>
<text top="557" left="1311" width="50" height="14" font="5">used is not </text>
<text top="570" left="1311" width="68" height="14" font="5">provided.          </text>
<text top="584" left="1311" width="15" height="14" font="5">No </text>
<text top="598" left="1311" width="51" height="14" font="5">information </text>
<text top="612" left="1311" width="44" height="14" font="5">regarding </text>
<text top="625" left="1311" width="32" height="14" font="5">clinical </text>
<text top="639" left="1311" width="56" height="14" font="5">symptomatol</text>
<text top="653" left="1311" width="29" height="14" font="5">ogy at </text>
<text top="667" left="1311" width="42" height="14" font="5">baseline. </text>
<text top="447" left="1385" width="60" height="14" font="5">Hypokalemia </text>
<text top="460" left="1385" width="28" height="14" font="5">(9.4% </text>
<text top="474" left="1385" width="71" height="14" font="5">levosimedan vs </text>
<text top="488" left="1385" width="25" height="14" font="5">5.9% </text>
<text top="502" left="1385" width="57" height="14" font="5">dobutamine, </text>
<text top="515" left="1385" width="69" height="14" font="5">p=0.02)             </text>
<text top="529" left="1385" width="44" height="14" font="5">AF (9.1% </text>
<text top="543" left="1385" width="71" height="14" font="5">levosimedan vs </text>
<text top="557" left="1385" width="25" height="14" font="5">6.1% </text>
<text top="570" left="1385" width="57" height="14" font="5">dobutamine, </text>
<text top="584" left="1385" width="53" height="14" font="5">p=0.05),      </text>
<text top="598" left="1385" width="48" height="14" font="5">Headache </text>
<text top="612" left="1385" width="28" height="14" font="5">(8.3% </text>
<text top="625" left="1385" width="71" height="14" font="5">levosimedan vs </text>
<text top="639" left="1385" width="25" height="14" font="5">4.7% </text>
<text top="653" left="1385" width="57" height="14" font="5">dobutamine, </text>
<text top="667" left="1385" width="53" height="14" font="5">p=0.01)       </text>
<text top="681" left="1385" width="56" height="14" font="5">PVCs (6.1% </text>
<text top="694" left="1385" width="71" height="14" font="5">levosimedan vs </text>
<text top="708" left="1385" width="25" height="14" font="5">3.6% </text>
<text top="722" left="1385" width="57" height="14" font="5">dobutamine, </text>
<text top="736" left="1385" width="75" height="14" font="5">p=0.05)               </text>
<text top="749" left="1385" width="69" height="14" font="5">Agitation (1.1% </text>
<text top="763" left="1385" width="71" height="14" font="5">levosimedan vs </text>
<text top="777" left="1385" width="74" height="14" font="5">0% dobutamine, </text>
<text top="791" left="1385" width="36" height="14" font="5">p=0.02) </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="31" size="9" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">128</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="464" width="38" height="14" font="5">not as a </text>
<text top="68" left="464" width="38" height="14" font="5">result of </text>
<text top="82" left="464" width="55" height="14" font="5">hypovolemia</text>
<text top="96" left="464" width="31" height="14" font="5">; or (c) </text>
<text top="110" left="464" width="52" height="14" font="5">PCWP &gt;18 </text>
<text top="123" left="464" width="34" height="14" font="5">mm Hg </text>
<text top="137" left="464" width="52" height="14" font="5">and/or CI <i>&lt;</i> </text>
<text top="151" left="464" width="16" height="14" font="5">2.2 </text>
<text top="165" left="464" width="46" height="14" font="5">L/min/m2. </text>
<text top="179" left="61" width="52" height="14" font="5">Enoximone </text>
<text top="193" left="61" width="10" height="14" font="5">in </text>
<text top="207" left="61" width="54" height="14" font="5">Intravenous </text>
<text top="221" left="61" width="39" height="14" font="5">Inotrope-</text>
<text top="234" left="61" width="51" height="14" font="5">Dependent </text>
<text top="248" left="61" width="41" height="14" font="5">Subjects </text>
<text top="262" left="61" width="28" height="14" font="5">Study </text>
<text top="276" left="61" width="47" height="14" font="5">(EMOTE), </text>
<text top="289" left="61" width="41" height="14" font="5">Feldman </text>
<text top="303" left="61" width="45" height="14" font="5">AM, 2007 </text>
<text top="317" left="61" width="46" height="14" font="28">17967591 </text>
<text top="331" left="61" width="26" height="14" font="5">(275) </text>
<text top="179" left="129" width="14" height="14" font="5">To </text>
<text top="193" left="129" width="46" height="14" font="5">determine </text>
<text top="207" left="129" width="38" height="14" font="5">whether </text>
<text top="221" left="129" width="42" height="14" font="5">low-dose </text>
<text top="234" left="129" width="19" height="14" font="5">oral </text>
<text top="248" left="129" width="51" height="14" font="5">enoximone </text>
<text top="262" left="129" width="53" height="14" font="5">could wean </text>
<text top="276" left="129" width="36" height="14" font="5">pts with </text>
<text top="289" left="129" width="22" height="14" font="5">ultra-</text>
<text top="303" left="129" width="45" height="14" font="5">advanced </text>
<text top="317" left="129" width="36" height="14" font="5">HF (UA-</text>
<text top="331" left="129" width="41" height="14" font="5">HF) from </text>
<text top="344" left="129" width="54" height="14" font="5">intravenous </text>
<text top="358" left="129" width="19" height="14" font="5">(IV) </text>
<text top="372" left="129" width="40" height="14" font="5">inotropic </text>
<text top="386" left="129" width="36" height="14" font="5">support </text>
<text top="179" left="196" width="23" height="14" font="5">RCT </text>
<text top="179" left="243" width="69" height="14" font="5">Diuretic 88%,    </text>
<text top="193" left="243" width="51" height="14" font="5">ACEI 62%, </text>
<text top="207" left="243" width="67" height="14" font="5">ARB 18%,        </text>
<text top="221" left="243" width="40" height="14" font="5">bblocker </text>
<text top="234" left="243" width="69" height="14" font="5">40%,                 </text>
<text top="248" left="243" width="67" height="14" font="5">digoxin 70%,    </text>
<text top="262" left="243" width="57" height="14" font="5">antiarrhythmi</text>
<text top="276" left="243" width="68" height="14" font="5">c 37%,              </text>
<text top="289" left="243" width="69" height="14" font="5">ICD 42%,          </text>
<text top="303" left="243" width="43" height="14" font="5">Milrinone </text>
<text top="317" left="243" width="69" height="14" font="5">62%,                 </text>
<text top="331" left="243" width="54" height="14" font="5">dobutamine </text>
<text top="344" left="243" width="69" height="14" font="5">36%,                 </text>
<text top="358" left="243" width="22" height="14" font="5">both </text>
<text top="372" left="243" width="54" height="14" font="5">dobutamine </text>
<text top="386" left="243" width="62" height="14" font="5">and milrinone </text>
<text top="400" left="243" width="17" height="14" font="5">3% </text>
<text top="413" left="243" width="53" height="14" font="5">Continuous </text>
<text top="427" left="243" width="50" height="14" font="5">IV inotrope </text>
<text top="441" left="243" width="22" height="14" font="5">74% </text>
<text top="179" left="319" width="41" height="14" font="5">201; 101 </text>
<text top="193" left="319" width="60" height="14" font="5">(enoximone); </text>
<text top="207" left="319" width="63" height="14" font="5">100 (placebo) </text>
<text top="179" left="399" width="43" height="14" font="5">61% ICM </text>
<text top="179" left="464" width="66" height="14" font="5">Age &gt; 18 y       </text>
<text top="193" left="464" width="52" height="14" font="5">NYHA III or </text>
<text top="207" left="464" width="65" height="14" font="5">IV CHF            </text>
<text top="221" left="464" width="40" height="14" font="5">Ongoing </text>
<text top="234" left="464" width="55" height="14" font="5">need for &gt; 5 </text>
<text top="248" left="464" width="19" height="14" font="5">d of </text>
<text top="262" left="464" width="50" height="14" font="5">continuous </text>
<text top="276" left="464" width="52" height="14" font="5">IV inotropic </text>
<text top="289" left="464" width="47" height="14" font="5">therapy or </text>
<text top="303" left="464" width="55" height="14" font="5">the need for </text>
<text top="317" left="464" width="51" height="14" font="5">intermittent </text>
<text top="331" left="464" width="52" height="14" font="5">IV inotropic </text>
<text top="344" left="464" width="56" height="14" font="5">therapy with </text>
<text top="358" left="464" width="27" height="14" font="5">either </text>
<text top="372" left="464" width="54" height="14" font="5">dobutamine </text>
<text top="386" left="464" width="18" height="14" font="5">(≥2 </text>
<text top="400" left="464" width="49" height="14" font="5">μg/kg/min) </text>
<text top="413" left="464" width="54" height="14" font="5">or milrinone </text>
<text top="427" left="464" width="37" height="14" font="5">(≥0.125 </text>
<text top="441" left="464" width="49" height="14" font="5">μg/kg/min) </text>
<text top="455" left="464" width="56" height="14" font="5">for ≥6 h at a </text>
<text top="468" left="464" width="57" height="14" font="5">frequency of </text>
<text top="482" left="464" width="58" height="14" font="5">&gt;1x/ wk, and </text>
<text top="496" left="464" width="66" height="14" font="5">for ≥4 wk.        </text>
<text top="510" left="464" width="38" height="14" font="5">LVEF of </text>
<text top="523" left="464" width="42" height="14" font="5">≤25% by </text>
<text top="537" left="464" width="56" height="14" font="5">radionuclide </text>
<text top="551" left="464" width="56" height="14" font="5">ventriculogra</text>
<text top="565" left="464" width="59" height="14" font="5">phy or ≤30% </text>
<text top="578" left="464" width="22" height="14" font="5">by 2-</text>
<text top="592" left="464" width="55" height="14" font="5">dimensional </text>
<text top="606" left="464" width="54" height="14" font="5">echocardiog</text>
<text top="620" left="464" width="66" height="14" font="5">raphy               </text>
<text top="634" left="464" width="37" height="14" font="5">Cardiac </text>
<text top="647" left="464" width="42" height="14" font="5">dilatation </text>
<text top="661" left="464" width="39" height="14" font="5">(LVEDD </text>
<text top="675" left="464" width="55" height="14" font="5">≥2.7 cm/m2 </text>
<text top="689" left="464" width="50" height="14" font="5">or ≥5.4 cm </text>
<text top="702" left="464" width="13" height="14" font="5">as </text>
<text top="716" left="464" width="47" height="14" font="5">measured </text>
<text top="730" left="464" width="22" height="14" font="5">by 2-</text>
<text top="744" left="464" width="55" height="14" font="5">dimensional </text>
<text top="758" left="464" width="54" height="14" font="5">echocardiog</text>
<text top="771" left="464" width="27" height="14" font="5">raphy </text>
<text top="785" left="464" width="56" height="14" font="5">within 26 wk </text>
<text top="179" left="537" width="52" height="14" font="5">Received a </text>
<text top="193" left="537" width="36" height="14" font="5">positive </text>
<text top="207" left="537" width="40" height="14" font="5">inotropic </text>
<text top="221" left="537" width="52" height="14" font="5">agent other </text>
<text top="234" left="537" width="58" height="14" font="5">than digoxin, </text>
<text top="248" left="537" width="57" height="14" font="5">dobutamine, </text>
<text top="262" left="537" width="54" height="14" font="5">or milrinone </text>
<text top="276" left="537" width="50" height="14" font="5">within 12 h </text>
<text top="289" left="537" width="11" height="14" font="5">of </text>
<text top="303" left="537" width="51" height="14" font="5">randomizati</text>
<text top="317" left="537" width="66" height="14" font="5">on                    </text>
<text top="331" left="537" width="34" height="14" font="5">Trough </text>
<text top="344" left="537" width="34" height="14" font="5">digoxin </text>
<text top="358" left="537" width="52" height="14" font="5">levels were </text>
<text top="372" left="537" width="58" height="14" font="5">&gt;1.0 ng/mL.  </text>
<text top="386" left="537" width="44" height="14" font="5">ICD firing </text>
<text top="400" left="537" width="52" height="14" font="5">within 90 d. </text>
<text top="179" left="609" width="28" height="14" font="5">100% </text>
<text top="193" left="609" width="62" height="14" font="5">NYHA III-IV    </text>
<text top="207" left="609" width="26" height="14" font="5">(56% </text>
<text top="221" left="609" width="45" height="14" font="5">NYHA IV) </text>
<text top="179" left="677" width="21" height="14" font="5">Low-</text>
<text top="193" left="677" width="30" height="14" font="5">output </text>
<text top="207" left="677" width="30" height="14" font="5">ADHF </text>
<text top="179" left="736" width="40" height="14" font="5">Ability to </text>
<text top="193" left="736" width="26" height="14" font="5">wean </text>
<text top="207" left="736" width="61" height="14" font="5">subjects from </text>
<text top="221" left="736" width="52" height="14" font="5">IV inotropic </text>
<text top="234" left="736" width="38" height="14" font="5">support. </text>
<text top="248" left="736" width="45" height="14" font="5">Assessed </text>
<text top="262" left="736" width="43" height="14" font="5">using the </text>
<text top="276" left="736" width="56" height="14" font="5">prespecified </text>
<text top="289" left="736" width="46" height="14" font="5">CMH test, </text>
<text top="303" left="736" width="54" height="14" font="5">adjusted for </text>
<text top="317" left="736" width="56" height="14" font="5">cardiomyopa</text>
<text top="331" left="736" width="55" height="14" font="5">thy etiology. </text>
<text top="344" left="736" width="55" height="14" font="5">The primary </text>
<text top="358" left="736" width="36" height="14" font="5">efficacy </text>
<text top="372" left="736" width="57" height="14" font="5">variable was </text>
<text top="386" left="736" width="21" height="14" font="5">also </text>
<text top="400" left="736" width="57" height="14" font="5">assessed as </text>
<text top="413" left="736" width="46" height="14" font="5">a protocol </text>
<text top="427" left="736" width="19" height="14" font="5">and </text>
<text top="441" left="736" width="43" height="14" font="5">statistical </text>
<text top="455" left="736" width="38" height="14" font="5">analysis </text>
<text top="468" left="736" width="24" height="14" font="5">plan–</text>
<text top="482" left="736" width="56" height="14" font="5">prespecified </text>
<text top="496" left="736" width="48" height="14" font="5">secondary </text>
<text top="510" left="736" width="43" height="14" font="5">end point </text>
<text top="523" left="736" width="48" height="14" font="5">using time-</text>
<text top="537" left="736" width="38" height="14" font="5">to-event </text>
<text top="551" left="736" width="37" height="14" font="5">(Kaplan-</text>
<text top="565" left="736" width="31" height="14" font="5">Meier) </text>
<text top="578" left="736" width="51" height="14" font="5">curves and </text>
<text top="592" left="736" width="55" height="14" font="5">the log-rank </text>
<text top="606" left="736" width="60" height="14" font="5">statistic, over </text>
<text top="620" left="736" width="44" height="14" font="5">the entire </text>
<text top="634" left="736" width="54" height="14" font="5">182 d study </text>
<text top="647" left="736" width="33" height="14" font="5">period. </text>
<text top="179" left="811" width="35" height="14" font="5">Time to </text>
<text top="193" left="811" width="70" height="14" font="5">reinitiation of IV </text>
<text top="207" left="811" width="52" height="14" font="5">inotrope      </text>
<text top="221" left="811" width="72" height="14" font="5">Total number of </text>
<text top="234" left="811" width="80" height="14" font="5">d on IV inotrope    </text>
<text top="248" left="811" width="72" height="14" font="5">Total number of </text>
<text top="262" left="811" width="73" height="14" font="5">hospitalization d </text>
<text top="276" left="811" width="58" height="14" font="5">for all cause, </text>
<text top="289" left="811" width="38" height="14" font="5">CV, and </text>
<text top="303" left="811" width="56" height="14" font="5">CV/vascular </text>
<text top="317" left="811" width="78" height="14" font="5">events;                 </text>
<text top="331" left="811" width="68" height="14" font="5">Measurements </text>
<text top="344" left="811" width="58" height="14" font="5">of symptoms </text>
<text top="358" left="811" width="54" height="14" font="5">(SAS scale, </text>
<text top="372" left="811" width="63" height="14" font="5">NYHA) and pt </text>
<text top="386" left="811" width="47" height="14" font="5">well-being </text>
<text top="400" left="811" width="66" height="14" font="5">(Visual Analog </text>
<text top="413" left="811" width="59" height="14" font="5">Scale, global </text>
<text top="427" left="811" width="63" height="14" font="5">assessments) </text>
<text top="441" left="811" width="69" height="14" font="5">at 4 and 26 wk. </text>
<text top="179" left="899" width="19" height="14" font="5">N/A </text>
<text top="179" left="973" width="19" height="14" font="5">N/A </text>
<text top="179" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="193" left="1034" width="28" height="14" font="5">t 7/00-</text>
<text top="207" left="1034" width="22" height="14" font="5">2/04 </text>
<text top="221" left="1034" width="37" height="14" font="5">(44mo); </text>
<text top="234" left="1034" width="47" height="14" font="5">26 wk trial </text>
<text top="179" left="1095" width="44" height="14" font="5">30 d after </text>
<text top="193" left="1095" width="75" height="14" font="5">weaning, 51% of </text>
<text top="207" left="1095" width="72" height="14" font="5">placebo pts and </text>
<text top="221" left="1095" width="31" height="14" font="5">61.4% </text>
<text top="234" left="1095" width="67" height="14" font="5">enoximone pts </text>
<text top="248" left="1095" width="66" height="14" font="5">were alive and </text>
<text top="262" left="1095" width="43" height="14" font="5">free of IV </text>
<text top="276" left="1095" width="86" height="14" font="5">inotropic therapy     </text>
<text top="289" left="1095" width="79" height="14" font="5">At 60 d, the wean </text>
<text top="303" left="1095" width="75" height="14" font="5">rate was 30% in  </text>
<text top="317" left="1095" width="65" height="14" font="5">placebo group </text>
<text top="331" left="1095" width="63" height="14" font="5">and 46.5% in  </text>
<text top="344" left="1095" width="87" height="14" font="5">enoximone group    </text>
<text top="358" left="1095" width="61" height="14" font="5">Kaplan-Meier </text>
<text top="372" left="1095" width="32" height="14" font="5">curves </text>
<text top="386" left="1095" width="71" height="14" font="5">demonstrated a </text>
<text top="400" left="1095" width="66" height="14" font="5">trend toward a </text>
<text top="413" left="1095" width="70" height="14" font="5">decrease in the </text>
<text top="427" left="1095" width="71" height="14" font="5">time to death or </text>
<text top="441" left="1095" width="70" height="14" font="5">reinitiation of IV </text>
<text top="455" left="1095" width="75" height="14" font="5">inotropic therapy </text>
<text top="468" left="1095" width="77" height="14" font="5">over the 182-day </text>
<text top="482" left="1095" width="26" height="14" font="5">study </text>
<text top="496" left="1095" width="57" height="14" font="5">period and a </text>
<text top="510" left="1095" width="76" height="14" font="5">reduction at 60 d </text>
<text top="523" left="1095" width="63" height="14" font="5">and 90 d after </text>
<text top="537" left="1095" width="66" height="14" font="5">weaning in the </text>
<text top="551" left="1095" width="51" height="14" font="5">enoximone </text>
<text top="565" left="1095" width="31" height="14" font="5">group. </text>
<text top="179" left="1189" width="107" height="14" font="5">Unadjusted primary end </text>
<text top="193" left="1189" width="100" height="14" font="5">point p=0.14, adjusted </text>
<text top="207" left="1189" width="114" height="14" font="5">for etiology p= 0.17           </text>
<text top="221" left="1189" width="65" height="14" font="5">60d wean rate </text>
<text top="234" left="1189" width="114" height="14" font="5">unadjusted p=0.016          </text>
<text top="248" left="1189" width="65" height="14" font="5">Time to death/ </text>
<text top="262" left="1189" width="70" height="14" font="5">reinitiation of IV </text>
<text top="276" left="1189" width="98" height="14" font="5">inotrope: 95% CI 0.55-</text>
<text top="289" left="1189" width="87" height="14" font="5">1.04                         </text>
<text top="303" left="1189" width="102" height="14" font="5">Reduction at 60d, 95% </text>
<text top="317" left="1189" width="115" height="14" font="5">CI 0.43-0.89, p = 0.009     </text>
<text top="331" left="1189" width="104" height="14" font="5">Reduction @ 90d, 95% </text>
<text top="344" left="1189" width="99" height="14" font="5">CI 0.49-0.97, P = .031 </text>
<text top="358" left="1189" width="65" height="14" font="5">Time to death/ </text>
<text top="372" left="1189" width="70" height="14" font="5">reinitiation of IV </text>
<text top="386" left="1189" width="115" height="14" font="5">inotrope: HR 0.76              </text>
<text top="400" left="1189" width="93" height="14" font="5">Reduction @60d HR </text>
<text top="413" left="1189" width="27" height="14" font="5">0.62   </text>
<text top="427" left="1189" width="93" height="14" font="5">Reduction @90d HR </text>
<text top="441" left="1189" width="22" height="14" font="5">0.69 </text>
<text top="179" left="1311" width="27" height="14" font="5">Small </text>
<text top="193" left="1311" width="68" height="14" font="5">sample size.     </text>
<text top="207" left="1311" width="61" height="14" font="5">Not designed </text>
<text top="221" left="1311" width="52" height="14" font="5">or powered </text>
<text top="234" left="1311" width="53" height="14" font="5">as mortality </text>
<text top="248" left="1311" width="26" height="14" font="5">study </text>
<text top="179" left="1385" width="71" height="14" font="5">Exacerbation of </text>
<text top="193" left="1385" width="56" height="14" font="5">CHF in 54% </text>
<text top="207" left="1385" width="64" height="14" font="5">enoximone vs </text>
<text top="221" left="1385" width="62" height="14" font="5">52% placebo, </text>
<text top="234" left="1385" width="82" height="14" font="5">NS                         </text>
<text top="248" left="1385" width="61" height="14" font="5">Dyspnea, 5% </text>
<text top="262" left="1385" width="64" height="14" font="5">enoximone vs </text>
<text top="276" left="1385" width="57" height="14" font="5">0% placebo, </text>
<text top="289" left="1385" width="34" height="14" font="5">P&lt;0.05 </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">129</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="464" width="27" height="14" font="5">of the </text>
<text top="68" left="464" width="39" height="14" font="5">baseline </text>
<text top="82" left="464" width="64" height="14" font="5">visit).               </text>
<text top="96" left="464" width="59" height="14" font="5">Ongoing and </text>
<text top="110" left="464" width="52" height="14" font="5">stable (&gt;30 </text>
<text top="123" left="464" width="47" height="14" font="5">d) therapy </text>
<text top="137" left="464" width="55" height="14" font="5">with optimal </text>
<text top="151" left="464" width="48" height="14" font="5">and stable </text>
<text top="165" left="464" width="40" height="14" font="5">doses of </text>
<text top="178" left="464" width="58" height="14" font="5">conventional </text>
<text top="192" left="464" width="55" height="14" font="5">medications </text>
<text top="207" left="61" width="39" height="14" font="5">Use and </text>
<text top="221" left="61" width="43" height="14" font="5">impact of </text>
<text top="234" left="61" width="43" height="14" font="5">inotropes </text>
<text top="248" left="61" width="19" height="14" font="5">and </text>
<text top="262" left="61" width="50" height="14" font="5">vasodilator </text>
<text top="276" left="61" width="36" height="14" font="5">therapy </text>
<text top="289" left="61" width="10" height="14" font="5">in </text>
<text top="303" left="61" width="46" height="14" font="5">hospitalize</text>
<text top="317" left="61" width="44" height="14" font="5">d pts with </text>
<text top="331" left="61" width="48" height="14" font="5">severe HF </text>
<text top="344" left="61" width="52" height="14" font="5">(ESCAPE), </text>
<text top="358" left="61" width="53" height="14" font="5">Elkayam U, </text>
<text top="372" left="61" width="52" height="14" font="5">Am Heart J </text>
<text top="386" left="61" width="25" height="14" font="5">2007 </text>
<text top="400" left="61" width="46" height="14" font="28">17174645 </text>
<text top="413" left="61" width="26" height="14" font="5">(276) </text>
<text top="427" left="61" width="3" height="14" font="5"> </text>
<text top="207" left="129" width="14" height="14" font="5">To </text>
<text top="221" left="129" width="46" height="14" font="5">determine </text>
<text top="234" left="129" width="48" height="14" font="5">6-mo risks </text>
<text top="248" left="129" width="53" height="14" font="5">of all-cause </text>
<text top="262" left="129" width="40" height="14" font="5">mortality </text>
<text top="276" left="129" width="32" height="14" font="5">and all-</text>
<text top="289" left="129" width="29" height="14" font="5">cause </text>
<text top="303" left="129" width="40" height="14" font="5">mortality </text>
<text top="317" left="129" width="21" height="14" font="5">plus </text>
<text top="331" left="129" width="50" height="14" font="5">rehospitaliz</text>
<text top="344" left="129" width="24" height="14" font="5">ation </text>
<text top="358" left="129" width="50" height="14" font="5">associated </text>
<text top="372" left="129" width="37" height="14" font="5">with the </text>
<text top="386" left="129" width="29" height="14" font="5">use of </text>
<text top="400" left="129" width="48" height="14" font="5">vasodilator</text>
<text top="413" left="129" width="10" height="14" font="5">s, </text>
<text top="427" left="129" width="46" height="14" font="5">inotropes, </text>
<text top="441" left="129" width="41" height="14" font="5">and their </text>
<text top="455" left="129" width="48" height="14" font="5">combinatio</text>
<text top="468" left="129" width="8" height="14" font="5">n </text>
<text top="207" left="196" width="23" height="14" font="5">Post-</text>
<text top="221" left="196" width="19" height="14" font="5">hoc </text>
<text top="234" left="196" width="31" height="14" font="5">analysi</text>
<text top="248" left="196" width="18" height="14" font="5">s of </text>
<text top="262" left="196" width="23" height="14" font="5">RCT </text>
<text top="207" left="243" width="67" height="14" font="5">ACEI 79%        </text>
<text top="221" left="243" width="41" height="14" font="5">Diuretics </text>
<text top="234" left="243" width="69" height="14" font="5">98%                  </text>
<text top="248" left="243" width="41" height="14" font="5">bBlocker </text>
<text top="262" left="243" width="69" height="14" font="5">62%                  </text>
<text top="276" left="243" width="50" height="14" font="5">IV inotrope </text>
<text top="289" left="243" width="69" height="14" font="5">42%                  </text>
<text top="303" left="243" width="12" height="14" font="5">IV </text>
<text top="317" left="243" width="50" height="14" font="5">vasodilator </text>
<text top="331" left="243" width="69" height="14" font="5">28%                  </text>
<text top="207" left="319" width="36" height="14" font="5">433; 75 </text>
<text top="221" left="319" width="62" height="14" font="5">(vasodilator);  </text>
<text top="234" left="319" width="34" height="14" font="5">133 (IV </text>
<text top="248" left="319" width="61" height="14" font="5">inotrope);  47 </text>
<text top="262" left="319" width="50" height="14" font="5">(both); 178 </text>
<text top="276" left="319" width="36" height="14" font="5">(neither </text>
<text top="289" left="319" width="59" height="14" font="5">inotrope/vaso</text>
<text top="303" left="319" width="33" height="14" font="5">dilator) </text>
<text top="207" left="399" width="43" height="14" font="5">50% ICM </text>
<text top="207" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="221" left="464" width="46" height="14" font="5">for severe </text>
<text top="234" left="464" width="65" height="14" font="5">ADHF              </text>
<text top="248" left="464" width="66" height="14" font="5">Age&gt;18 y;        </text>
<text top="262" left="464" width="56" height="14" font="5">Hx of HF for </text>
<text top="276" left="464" width="66" height="14" font="5">&gt;3 mo;             </text>
<text top="289" left="464" width="41" height="14" font="5">On ACEI </text>
<text top="303" left="464" width="59" height="14" font="5">and diuretics </text>
<text top="317" left="464" width="49" height="14" font="5">for z3 mo;. </text>
<text top="331" left="464" width="53" height="14" font="5">LVEF&lt;30% </text>
<text top="344" left="464" width="57" height="14" font="5">in the 12 mo </text>
<text top="358" left="464" width="31" height="14" font="5">before </text>
<text top="372" left="464" width="56" height="14" font="5">randomizatio</text>
<text top="386" left="464" width="66" height="14" font="5">n;                     </text>
<text top="400" left="464" width="47" height="14" font="5">SBP &lt;125 </text>
<text top="413" left="464" width="64" height="14" font="5">mm Hg;           </text>
<text top="427" left="464" width="55" height="14" font="5">elevated LV </text>
<text top="441" left="464" width="25" height="14" font="5">filling </text>
<text top="455" left="464" width="54" height="14" font="5">pressure as </text>
<text top="468" left="464" width="55" height="14" font="5">indicated by </text>
<text top="482" left="464" width="43" height="14" font="5">at least 1 </text>
<text top="496" left="464" width="38" height="14" font="5">physical </text>
<text top="510" left="464" width="48" height="14" font="5">sign and 1 </text>
<text top="523" left="464" width="64" height="14" font="5">symptom;        </text>
<text top="537" left="464" width="44" height="14" font="5">At least 1 </text>
<text top="551" left="464" width="22" height="14" font="5">prior </text>
<text top="565" left="464" width="47" height="14" font="5">admission </text>
<text top="578" left="464" width="44" height="14" font="5">for ADHF </text>
<text top="592" left="464" width="46" height="14" font="5">during the </text>
<text top="606" left="464" width="54" height="14" font="5">previous 12 </text>
<text top="620" left="464" width="28" height="14" font="5">mo or </text>
<text top="634" left="464" width="50" height="14" font="5">aggressive </text>
<text top="647" left="464" width="46" height="14" font="5">outpatient </text>
<text top="661" left="464" width="50" height="14" font="5">therapy for </text>
<text top="675" left="464" width="51" height="14" font="5">at least the </text>
<text top="689" left="464" width="62" height="14" font="5">previous mo.  </text>
<text top="207" left="537" width="150" height="14" font="5"> N/A Mean </text>
<text top="207" left="636" width="74" height="14" font="5">peak </text>
<text top="221" left="609" width="61" height="14" font="5">VO2 10.0       </text>
<text top="234" left="609" width="27" height="14" font="5">mean </text>
<text top="248" left="609" width="39" height="14" font="5">6MWTD </text>
<text top="262" left="609" width="27" height="14" font="5">414 ft </text>
<text top="207" left="677" width="19" height="14" font="5">N/A </text>
<text top="207" left="736" width="46" height="14" font="5">All- cause </text>
<text top="221" left="736" width="40" height="14" font="5">mortality </text>
<text top="207" left="811" width="67" height="14" font="5">Combined end </text>
<text top="221" left="811" width="48" height="14" font="5">point of all-</text>
<text top="234" left="811" width="69" height="14" font="5">cause mortality </text>
<text top="248" left="811" width="21" height="14" font="5">plus </text>
<text top="262" left="811" width="74" height="14" font="5">rehospitalization </text>
<text top="207" left="899" width="22" height="14" font="5"> N/A </text>
<text top="207" left="973" width="25" height="14" font="5">6 mo </text>
<text top="221" left="973" width="40" height="14" font="5">mortality </text>
<text top="207" left="1034" width="19" height="14" font="5">N/A </text>
<text top="207" left="1095" width="56" height="14" font="5">Worse 6 mo </text>
<text top="221" left="1095" width="45" height="14" font="5">outcomes </text>
<text top="234" left="1095" width="62" height="14" font="5">(mortality and </text>
<text top="248" left="1095" width="27" height="14" font="5">either </text>
<text top="262" left="1095" width="75" height="14" font="5">mortality/rehospit</text>
<text top="276" left="1095" width="62" height="14" font="5">alization) with </text>
<text top="289" left="1095" width="43" height="14" font="5">inotropes </text>
<text top="303" left="1095" width="79" height="14" font="5">(whether alone or </text>
<text top="317" left="1095" width="74" height="14" font="5">with vasodilator) </text>
<text top="207" left="1189" width="64" height="14" font="5">6 mo mortality </text>
<text top="221" left="1189" width="114" height="14" font="5">(adjusted), p, 95% CI        </text>
<text top="234" left="1189" width="86" height="14" font="5">Inotrope 1.10-4.15, </text>
<text top="248" left="1189" width="115" height="14" font="5">p=0.024                             </text>
<text top="262" left="1189" width="98" height="14" font="5">Both ino &amp; vasodilator </text>
<text top="276" left="1189" width="116" height="14" font="5">2.34-9.90, p&lt;0.001            </text>
<text top="289" left="1189" width="106" height="14" font="5">6mo mortality or rehosp </text>
<text top="303" left="1189" width="107" height="14" font="5">(adjusted)                       </text>
<text top="317" left="1189" width="86" height="14" font="5">Inotrope 1.37-2.82, </text>
<text top="331" left="1189" width="115" height="14" font="5">p&lt;0.001                             </text>
<text top="344" left="1189" width="98" height="14" font="5">Both ino &amp; vasodilator </text>
<text top="358" left="1189" width="88" height="14" font="5">1.88-4.48, p&lt;0.001  </text>
<text top="372" left="1189" width="81" height="14" font="5">6 mo mortality HR </text>
<text top="386" left="1189" width="84" height="14" font="5">adjusted                 </text>
<text top="400" left="1189" width="115" height="14" font="5">Inotrope 2.14                     </text>
<text top="413" left="1189" width="80" height="14" font="5">Both inotrope and </text>
<text top="427" left="1189" width="110" height="14" font="5">vasodilator 4.81               </text>
<text top="441" left="1189" width="76" height="14" font="5">6 mo mortality or </text>
<text top="455" left="1189" width="115" height="14" font="5">rehosp HR (adjusted)        </text>
<text top="468" left="1189" width="115" height="14" font="5">Inotrope 1.96                     </text>
<text top="482" left="1189" width="98" height="14" font="5">Both ino &amp; vasodilator </text>
<text top="496" left="1189" width="22" height="14" font="5">2.90 </text>
<text top="207" left="1311" width="34" height="14" font="5">Severe </text>
<text top="221" left="1311" width="68" height="14" font="5">ADHF               </text>
<text top="234" left="1311" width="50" height="14" font="5">Conducted </text>
<text top="248" left="1311" width="29" height="14" font="5">by HF </text>
<text top="262" left="1311" width="59" height="14" font="5">specialists at </text>
<text top="276" left="1311" width="45" height="14" font="5">academic </text>
<text top="289" left="1311" width="37" height="14" font="5">medical </text>
<text top="303" left="1311" width="68" height="14" font="5">centers             </text>
<text top="317" left="1311" width="54" height="14" font="5">Small study </text>
<text top="331" left="1311" width="67" height="14" font="5">size                  </text>
<text top="344" left="1311" width="21" height="14" font="5">Non-</text>
<text top="358" left="1311" width="68" height="14" font="5">randomized      </text>
<text top="372" left="1311" width="55" height="14" font="5">Retrospectiv</text>
<text top="386" left="1311" width="68" height="14" font="5">e analysis         </text>
<text top="207" left="1385" width="19" height="14" font="5">N/A </text>
<text top="703" left="61" width="54" height="14" font="5">Prospective </text>
<text top="717" left="61" width="50" height="14" font="5">Randomize</text>
<text top="731" left="61" width="51" height="14" font="5">d Milrinone </text>
<text top="745" left="61" width="38" height="14" font="5">Survival </text>
<text top="758" left="61" width="49" height="14" font="5">Evaluation </text>
<text top="772" left="61" width="49" height="14" font="5">(PROMISE</text>
<text top="786" left="61" width="45" height="14" font="5">),  Packer </text>
<text top="703" left="129" width="14" height="14" font="5">To </text>
<text top="717" left="129" width="46" height="14" font="5">determine </text>
<text top="731" left="129" width="43" height="14" font="5">the effect </text>
<text top="745" left="129" width="30" height="14" font="5">of oral </text>
<text top="758" left="129" width="43" height="14" font="5">milrinone </text>
<text top="772" left="129" width="30" height="14" font="5">on the </text>
<text top="786" left="129" width="51" height="14" font="5">mortality of </text>
<text top="703" left="196" width="23" height="14" font="5">RCT </text>
<text top="703" left="243" width="67" height="14" font="5">Nitrates  58%   </text>
<text top="717" left="243" width="58" height="14" font="5">Antiarrhythmi</text>
<text top="731" left="243" width="68" height="14" font="5">cs 25%             </text>
<text top="745" left="243" width="58" height="14" font="5">Digoxin level </text>
<text top="758" left="243" width="43" height="14" font="5">1.5nmol/l </text>
<text top="703" left="319" width="46" height="14" font="5">1088; 561 </text>
<text top="717" left="319" width="52" height="14" font="5">(milrinone); </text>
<text top="731" left="319" width="63" height="14" font="5">527 (placebo) </text>
<text top="703" left="399" width="43" height="14" font="5">54% ICM </text>
<text top="703" left="464" width="53" height="14" font="5">NYHA III-IV </text>
<text top="717" left="464" width="66" height="14" font="5">CHF x &gt;3mo    </text>
<text top="731" left="464" width="66" height="14" font="5">LVEF &lt; 35%    </text>
<text top="745" left="464" width="37" height="14" font="5">Medical </text>
<text top="758" left="464" width="49" height="14" font="5">regimen of </text>
<text top="772" left="464" width="37" height="14" font="5">digoxin, </text>
<text top="786" left="464" width="42" height="14" font="5">diuretics, </text>
<text top="703" left="537" width="53" height="14" font="5">Obstructive </text>
<text top="717" left="537" width="37" height="14" font="5">valvular </text>
<text top="731" left="537" width="64" height="14" font="5">disease           </text>
<text top="745" left="537" width="30" height="14" font="5">Active </text>
<text top="758" left="537" width="66" height="14" font="5">myocarditis      </text>
<text top="772" left="537" width="37" height="14" font="5">HCM or </text>
<text top="786" left="537" width="34" height="14" font="5">cardiac </text>
<text top="703" left="609" width="28" height="14" font="5">100% </text>
<text top="717" left="609" width="62" height="14" font="5">NYHA III-IV    </text>
<text top="731" left="609" width="52" height="14" font="5">58% NYHA </text>
<text top="745" left="609" width="36" height="14" font="5">III /42% </text>
<text top="758" left="609" width="61" height="14" font="5">NYHA IV        </text>
<text top="703" left="677" width="41" height="14" font="5">NYHA III-</text>
<text top="717" left="677" width="12" height="14" font="5">IV </text>
<text top="703" left="736" width="43" height="14" font="5">All cause </text>
<text top="717" left="736" width="40" height="14" font="5">mortality </text>
<text top="703" left="811" width="81" height="14" font="5">CV mortality,         </text>
<text top="717" left="811" width="29" height="14" font="5">No. of </text>
<text top="731" left="811" width="81" height="14" font="5">hospitalizations,    </text>
<text top="745" left="811" width="49" height="14" font="5">Addition of </text>
<text top="758" left="811" width="69" height="14" font="5">vasodilators for </text>
<text top="772" left="811" width="55" height="14" font="5">treatment of </text>
<text top="786" left="811" width="80" height="14" font="5">worsening hf,        </text>
<text top="703" left="899" width="19" height="14" font="5">N/A </text>
<text top="703" left="973" width="19" height="14" font="5">N/A </text>
<text top="703" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="717" left="1034" width="33" height="14" font="5">t 22mo </text>
<text top="731" left="1034" width="26" height="14" font="5">(1/89-</text>
<text top="745" left="1034" width="33" height="14" font="5">10/90); </text>
<text top="758" left="1034" width="38" height="14" font="5">stopped </text>
<text top="772" left="1034" width="24" height="14" font="5">early </text>
<text top="786" left="1034" width="40" height="14" font="5">because </text>
<text top="703" left="1095" width="46" height="14" font="5">Increased </text>
<text top="717" left="1095" width="60" height="14" font="5">mortality with </text>
<text top="731" left="1095" width="68" height="14" font="5">milrinone (30% </text>
<text top="745" left="1095" width="78" height="14" font="5">milrinone vs 24% </text>
<text top="758" left="1095" width="84" height="14" font="5">placebo);                </text>
<text top="772" left="1095" width="63" height="14" font="5">Log-rank test, </text>
<text top="786" left="1095" width="43" height="14" font="5">milrinone </text>
<text top="703" left="1189" width="86" height="14" font="5">All-cause mortality: </text>
<text top="717" left="1189" width="105" height="14" font="5">nominal P=0.038,  95% </text>
<text top="731" left="1189" width="100" height="14" font="5">CI 0.01-0.61; adjusted </text>
<text top="745" left="1189" width="75" height="14" font="5">P=0.06,               </text>
<text top="758" left="1189" width="94" height="14" font="5">CV mortality: 95% CI </text>
<text top="772" left="1189" width="84" height="14" font="5">0.06-0.69, nominal </text>
<text top="786" left="1189" width="82" height="14" font="5">P=0.016; adjusted </text>
<text top="703" left="1311" width="55" height="14" font="5">Background </text>
<text top="717" left="1311" width="37" height="14" font="5">medical </text>
<text top="731" left="1311" width="60" height="14" font="5">management </text>
<text top="745" left="1311" width="51" height="14" font="5">is outdated </text>
<text top="758" left="1311" width="19" height="14" font="5">and </text>
<text top="772" left="1311" width="67" height="14" font="5">suboptimal       </text>
<text top="703" left="1385" width="66" height="14" font="5">Stopped study </text>
<text top="717" left="1385" width="52" height="14" font="5">drug due to </text>
<text top="731" left="1385" width="66" height="14" font="5">worsening HF, </text>
<text top="745" left="1385" width="75" height="14" font="5">1.8% milrinone v </text>
<text top="758" left="1385" width="62" height="14" font="5">0.9% placebo </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">130</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="38" height="14" font="5">M, 1991 </text>
<text top="68" left="61" width="41" height="14" font="28">1944425 </text>
<text top="82" left="61" width="26" height="14" font="5">(277) </text>
<text top="55" left="129" width="36" height="14" font="5">pts with </text>
<text top="68" left="129" width="32" height="14" font="5">severe </text>
<text top="82" left="129" width="50" height="14" font="5">chronic HF </text>
<text top="96" left="129" width="21" height="14" font="5">who </text>
<text top="110" left="129" width="44" height="14" font="5">remained </text>
<text top="123" left="129" width="50" height="14" font="5">symptomati</text>
<text top="137" left="129" width="42" height="14" font="5">c despite </text>
<text top="151" left="129" width="48" height="14" font="5">convention</text>
<text top="165" left="129" width="46" height="14" font="5">al therapy </text>
<text top="55" left="464" width="59" height="14" font="5">and ACEI for </text>
<text top="68" left="464" width="29" height="14" font="5">&gt; 4wk </text>
<text top="55" left="537" width="64" height="14" font="5">amyloid           </text>
<text top="68" left="537" width="56" height="14" font="5">Uncorrected </text>
<text top="82" left="537" width="32" height="14" font="5">thyroid </text>
<text top="96" left="537" width="64" height="14" font="5">disease           </text>
<text top="110" left="537" width="52" height="14" font="5">Malfunctioni</text>
<text top="123" left="537" width="50" height="14" font="5">ng artificial </text>
<text top="137" left="537" width="54" height="14" font="5">heart valve  </text>
<text top="55" left="811" width="82" height="14" font="5">Symptoms,            </text>
<text top="68" left="811" width="39" height="14" font="5">Adverse </text>
<text top="82" left="811" width="43" height="14" font="5">reactions </text>
<text top="55" left="1034" width="11" height="14" font="5">of </text>
<text top="68" left="1034" width="38" height="14" font="5">adverse </text>
<text top="82" left="1034" width="38" height="14" font="5">effect of </text>
<text top="96" left="1034" width="45" height="14" font="5">milrinone; </text>
<text top="110" left="1034" width="35" height="14" font="5">median </text>
<text top="123" left="1034" width="38" height="14" font="5">duration </text>
<text top="137" left="1034" width="39" height="14" font="5">of follow-</text>
<text top="151" left="1034" width="46" height="14" font="5">up, 6.1mo </text>
<text top="55" left="1095" width="70" height="14" font="5">associated with </text>
<text top="68" left="1095" width="73" height="14" font="5">28% increase in </text>
<text top="82" left="1095" width="86" height="14" font="5">mortality;                 </text>
<text top="96" left="1095" width="63" height="14" font="5">Log-rank test, </text>
<text top="110" left="1095" width="43" height="14" font="5">milrinone </text>
<text top="123" left="1095" width="70" height="14" font="5">associated with </text>
<text top="137" left="1095" width="73" height="14" font="5">34% increase in </text>
<text top="151" left="1095" width="56" height="14" font="5">CV mortality </text>
<text top="55" left="1189" width="40" height="14" font="5">P=0.037 </text>
<text top="68" left="1189" width="5" height="14" font="5">  </text>
<text top="179" left="61" width="53" height="14" font="5">Continuous </text>
<text top="193" left="61" width="54" height="14" font="5">intravenous </text>
<text top="207" left="61" width="54" height="14" font="5">dobutamine </text>
<text top="221" left="61" width="10" height="14" font="5">is </text>
<text top="234" left="61" width="50" height="14" font="5">associated </text>
<text top="248" left="61" width="34" height="14" font="5">with an </text>
<text top="262" left="61" width="45" height="14" font="5">increased </text>
<text top="276" left="61" width="29" height="14" font="5">risk of </text>
<text top="289" left="61" width="54" height="14" font="5">death in pts </text>
<text top="303" left="61" width="20" height="14" font="5">with </text>
<text top="317" left="61" width="45" height="14" font="5">advanced </text>
<text top="331" left="61" width="19" height="14" font="5">HF: </text>
<text top="344" left="61" width="37" height="14" font="5">Insights </text>
<text top="358" left="61" width="39" height="14" font="5">from the </text>
<text top="372" left="61" width="30" height="14" font="5">Flolan </text>
<text top="386" left="61" width="46" height="14" font="5">Internation</text>
<text top="400" left="61" width="10" height="14" font="5">al </text>
<text top="413" left="61" width="50" height="14" font="5">Randomize</text>
<text top="427" left="61" width="46" height="14" font="5">d Survival </text>
<text top="441" left="61" width="22" height="14" font="5">Trial </text>
<text top="455" left="61" width="40" height="14" font="5">(FIRST), </text>
<text top="468" left="61" width="45" height="14" font="5">O'Connor </text>
<text top="482" left="61" width="45" height="14" font="5">CM, 1999 </text>
<text top="496" left="61" width="46" height="14" font="28">10385768 </text>
<text top="510" left="61" width="26" height="14" font="5">(278) </text>
<text top="523" left="61" width="3" height="14" font="5"> </text>
<text top="179" left="129" width="14" height="14" font="5">To </text>
<text top="193" left="129" width="40" height="14" font="5">evaluate </text>
<text top="207" left="129" width="32" height="14" font="5">clinical </text>
<text top="221" left="129" width="51" height="14" font="5">characterist</text>
<text top="234" left="129" width="34" height="14" font="5">ics and </text>
<text top="248" left="129" width="45" height="14" font="5">outcomes </text>
<text top="262" left="129" width="47" height="14" font="5">of pts with </text>
<text top="276" left="129" width="45" height="14" font="5">advanced </text>
<text top="289" left="129" width="16" height="14" font="5">HF </text>
<text top="303" left="129" width="42" height="14" font="5">receiving </text>
<text top="317" left="129" width="54" height="14" font="5">intravenous </text>
<text top="331" left="129" width="50" height="14" font="5">continuous </text>
<text top="344" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="358" left="129" width="35" height="14" font="5">e in the </text>
<text top="372" left="129" width="53" height="14" font="5">FIRST Trial </text>
<text top="386" left="129" width="33" height="14" font="5">(Flolan </text>
<text top="400" left="129" width="46" height="14" font="5">Internation</text>
<text top="413" left="129" width="10" height="14" font="5">al </text>
<text top="427" left="129" width="50" height="14" font="5">Randomize</text>
<text top="441" left="129" width="46" height="14" font="5">d Survival </text>
<text top="455" left="129" width="28" height="14" font="5">Trial). </text>
<text top="179" left="196" width="23" height="14" font="5">Post-</text>
<text top="193" left="196" width="19" height="14" font="5">hoc </text>
<text top="207" left="196" width="31" height="14" font="5">analysi</text>
<text top="221" left="196" width="8" height="14" font="5">s </text>
<text top="179" left="243" width="153" height="14" font="5">N/A 471; </text>
<text top="179" left="341" width="70" height="14" font="5">80 </text>
<text top="193" left="319" width="63" height="14" font="5">(dobutamine); </text>
<text top="207" left="319" width="36" height="14" font="5">391 (no </text>
<text top="221" left="319" width="57" height="14" font="5">dobutamine) </text>
<text top="179" left="399" width="22" height="14" font="5">67% </text>
<text top="193" left="399" width="41" height="14" font="5">Ischemic </text>
<text top="179" left="464" width="59" height="14" font="5">NYHA IIIB or </text>
<text top="193" left="464" width="56" height="14" font="5">IV HF for &gt;1 </text>
<text top="207" left="464" width="41" height="14" font="5">mo while </text>
<text top="221" left="464" width="50" height="14" font="5">receiving a </text>
<text top="234" left="464" width="38" height="14" font="5">regimen </text>
<text top="248" left="464" width="50" height="14" font="5">including a </text>
<text top="262" left="464" width="58" height="14" font="5">loop diuretic, </text>
<text top="276" left="464" width="35" height="14" font="5">digitalis </text>
<text top="289" left="464" width="47" height="14" font="5">glycoside, </text>
<text top="303" left="464" width="33" height="14" font="5">and an </text>
<text top="317" left="464" width="28" height="14" font="5">ACEI, </text>
<text top="331" left="464" width="34" height="14" font="5">unless  </text>
<text top="344" left="464" width="56" height="14" font="5">contraindicat</text>
<text top="358" left="464" width="66" height="14" font="5">ed.                   </text>
<text top="372" left="464" width="55" height="14" font="5">LVEF &lt;25% </text>
<text top="386" left="464" width="21" height="14" font="5">by a </text>
<text top="400" left="464" width="48" height="14" font="5">multigated </text>
<text top="413" left="464" width="56" height="14" font="5">angiocardiog</text>
<text top="427" left="464" width="56" height="14" font="5">ram within 3 </text>
<text top="441" left="464" width="27" height="14" font="5">mo of </text>
<text top="455" left="464" width="51" height="14" font="5">enrollment, </text>
<text top="468" left="464" width="58" height="14" font="5">unless the pt </text>
<text top="482" left="464" width="20" height="14" font="5">was </text>
<text top="496" left="464" width="27" height="14" font="5">being </text>
<text top="510" left="464" width="54" height="14" font="5">treated with </text>
<text top="523" left="464" width="26" height="14" font="5">an IV </text>
<text top="537" left="464" width="40" height="14" font="5">inotropic </text>
<text top="551" left="464" width="40" height="14" font="5">agent, in </text>
<text top="565" left="464" width="51" height="14" font="5">which case </text>
<text top="578" left="464" width="55" height="14" font="5">LVEF &lt;30% </text>
<text top="592" left="464" width="20" height="14" font="5">was </text>
<text top="606" left="464" width="45" height="14" font="5">accepted. </text>
<text top="620" left="464" width="59" height="14" font="5">Pts receiving </text>
<text top="634" left="464" width="12" height="14" font="5">IV </text>
<text top="647" left="464" width="49" height="14" font="5">vasoactive </text>
<text top="661" left="464" width="55" height="14" font="5">medications </text>
<text top="675" left="464" width="24" height="14" font="5">were </text>
<text top="689" left="464" width="50" height="14" font="5">required to </text>
<text top="702" left="464" width="40" height="14" font="5">have not </text>
<text top="716" left="464" width="49" height="14" font="5">responded </text>
<text top="730" left="464" width="25" height="14" font="5">to an </text>
<text top="744" left="464" width="47" height="14" font="5">attempt to </text>
<text top="758" left="464" width="49" height="14" font="5">wean from </text>
<text top="771" left="464" width="16" height="14" font="5">the </text>
<text top="785" left="464" width="47" height="14" font="5">medicines </text>
<text top="179" left="537" width="58" height="14" font="5">SBP&lt;80 mm </text>
<text top="193" left="537" width="64" height="14" font="5">Hg;                  </text>
<text top="207" left="537" width="48" height="14" font="5">Significant </text>
<text top="221" left="537" width="37" height="14" font="5">valvular </text>
<text top="234" left="537" width="66" height="14" font="5">stenosis;          </text>
<text top="248" left="537" width="51" height="14" font="5">Anticipated </text>
<text top="262" left="537" width="53" height="14" font="5">revasculariz</text>
<text top="276" left="537" width="35" height="14" font="5">ation or </text>
<text top="289" left="537" width="37" height="14" font="5">valvular </text>
<text top="303" left="537" width="66" height="14" font="5">surgery;           </text>
<text top="317" left="537" width="50" height="14" font="5">MI within 3 </text>
<text top="331" left="537" width="66" height="14" font="5">mo;                  </text>
<text top="344" left="537" width="58" height="14" font="5">Uncontrolled </text>
<text top="358" left="537" width="54" height="14" font="5">tachyarrhyth</text>
<text top="372" left="537" width="64" height="14" font="5">mias;               </text>
<text top="386" left="537" width="53" height="14" font="5">Unstable or </text>
<text top="400" left="537" width="43" height="14" font="5">symptom-</text>
<text top="413" left="537" width="33" height="14" font="5">limiting </text>
<text top="427" left="537" width="65" height="14" font="5">angina;            </text>
<text top="441" left="537" width="54" height="14" font="5">Requiremen</text>
<text top="455" left="537" width="28" height="14" font="5">t for a </text>
<text top="468" left="537" width="53" height="14" font="5">mechanical </text>
<text top="482" left="537" width="28" height="14" font="5">assist </text>
<text top="496" left="537" width="42" height="14" font="5">device to </text>
<text top="510" left="537" width="66" height="14" font="5">maintain life;    </text>
<text top="523" left="537" width="27" height="14" font="5">Major </text>
<text top="537" left="537" width="57" height="14" font="5">change in IV </text>
<text top="551" left="537" width="49" height="14" font="5">vasoactive </text>
<text top="565" left="537" width="59" height="14" font="5">medicat-ions </text>
<text top="578" left="537" width="53" height="14" font="5">within 12 hr </text>
<text top="592" left="537" width="11" height="14" font="5">of </text>
<text top="606" left="537" width="51" height="14" font="5">randomizati</text>
<text top="620" left="537" width="66" height="14" font="5">on;                   </text>
<text top="634" left="537" width="57" height="14" font="5">CHF caused </text>
<text top="647" left="537" width="13" height="14" font="5">by </text>
<text top="661" left="537" width="56" height="14" font="5">uncontrolled </text>
<text top="675" left="537" width="32" height="14" font="5">thyroid </text>
<text top="689" left="537" width="39" height="14" font="5">disease, </text>
<text top="702" left="537" width="55" height="14" font="5">myocarditis, </text>
<text top="716" left="537" width="51" height="14" font="5">high output </text>
<text top="730" left="537" width="44" height="14" font="5">failure, or </text>
<text top="744" left="537" width="44" height="14" font="5">infiltrative </text>
<text top="758" left="537" width="30" height="14" font="5">cardio-</text>
<text top="771" left="537" width="64" height="14" font="5">myopathy;       </text>
<text top="785" left="537" width="48" height="14" font="5">Significant </text>
<text top="179" left="609" width="15" height="14" font="5">No </text>
<text top="193" left="609" width="51" height="14" font="5">dobutamine</text>
<text top="207" left="609" width="60" height="14" font="5">:                     </text>
<text top="221" left="609" width="52" height="14" font="5">47% NYHA </text>
<text top="234" left="609" width="60" height="14" font="5">III                   </text>
<text top="248" left="609" width="52" height="14" font="5">53% NYHA </text>
<text top="262" left="609" width="61" height="14" font="5">IV                   </text>
<text top="276" left="609" width="48" height="14" font="5">Dobutamin</text>
<text top="289" left="609" width="60" height="14" font="5">e:                   </text>
<text top="303" left="609" width="52" height="14" font="5">11% NYHA </text>
<text top="317" left="609" width="60" height="14" font="5">III                   </text>
<text top="331" left="609" width="52" height="14" font="5">89% NYHA </text>
<text top="344" left="609" width="12" height="14" font="5">IV </text>
<text top="179" left="677" width="30" height="14" font="5">NYHA </text>
<text top="193" left="677" width="30" height="14" font="5">IIIB-IV </text>
<text top="179" left="736" width="54" height="14" font="5">Occurrence </text>
<text top="193" left="736" width="43" height="14" font="5">of clinical </text>
<text top="207" left="736" width="54" height="14" font="5">events from </text>
<text top="221" left="736" width="47" height="14" font="5">the FIRST </text>
<text top="234" left="736" width="21" height="14" font="5">trial, </text>
<text top="248" left="736" width="42" height="14" font="5">including </text>
<text top="262" left="736" width="48" height="14" font="5">worsening </text>
<text top="276" left="736" width="57" height="14" font="5">HF, need for </text>
<text top="289" left="736" width="53" height="14" font="5">mechanical </text>
<text top="303" left="736" width="28" height="14" font="5">assist </text>
<text top="317" left="736" width="34" height="14" font="5">device, </text>
<text top="331" left="736" width="58" height="14" font="5">resuscitation </text>
<text top="344" left="736" width="57" height="14" font="5">from sudden </text>
<text top="358" left="736" width="34" height="14" font="5">cardiac </text>
<text top="372" left="736" width="46" height="14" font="5">death, MI, </text>
<text top="386" left="736" width="46" height="14" font="5">and death </text>
<text top="179" left="811" width="65" height="14" font="5">QoL meaures  </text>
<text top="179" left="899" width="19" height="14" font="5">N/A </text>
<text top="179" left="973" width="19" height="14" font="5">N/A </text>
<text top="179" left="1034" width="19" height="14" font="5">N/A </text>
<text top="179" left="1095" width="74" height="14" font="5">The dobutamine </text>
<text top="193" left="1095" width="55" height="14" font="5">group had a </text>
<text top="207" left="1095" width="30" height="14" font="5">higher </text>
<text top="221" left="1095" width="81" height="14" font="5">occurrence of first </text>
<text top="234" left="1095" width="73" height="14" font="5">event (85.3% vs </text>
<text top="248" left="1095" width="61" height="14" font="5">64.5%) and a </text>
<text top="262" left="1095" width="70" height="14" font="5">higher mortality </text>
<text top="276" left="1095" width="66" height="14" font="5">rate (70.5% vs </text>
<text top="289" left="1095" width="80" height="14" font="5">37.1%) compared </text>
<text top="303" left="1095" width="50" height="14" font="5">with the no </text>
<text top="317" left="1095" width="54" height="14" font="5">dobutamine </text>
<text top="331" left="1095" width="77" height="14" font="5">group.                  </text>
<text top="344" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="358" left="1095" width="63" height="14" font="5">QOL between </text>
<text top="372" left="1095" width="36" height="14" font="5">groups. </text>
<text top="179" left="1189" width="96" height="14" font="5">Primary endpt       1st </text>
<text top="193" left="1189" width="115" height="14" font="5">event p=0.0006                 </text>
<text top="207" left="1189" width="84" height="14" font="5">mortality p=0.0001 </text>
<text top="221" left="1189" width="5" height="14" font="5">  </text>
<text top="179" left="1311" width="53" height="14" font="5">Observation</text>
<text top="193" left="1311" width="68" height="14" font="5">al analysis        </text>
<text top="207" left="1311" width="46" height="14" font="5">No details </text>
<text top="221" left="1311" width="41" height="14" font="5">provided </text>
<text top="234" left="1311" width="44" height="14" font="5">regarding </text>
<text top="248" left="1311" width="57" height="14" font="5">duration and </text>
<text top="262" left="1311" width="35" height="14" font="5">dose of </text>
<text top="276" left="1311" width="54" height="14" font="5">dobutamine </text>
<text top="179" left="1385" width="72" height="14" font="5">At 6 mo              </text>
<text top="193" left="1385" width="49" height="14" font="5">First event </text>
<text top="207" left="1385" width="31" height="14" font="5">85.3% </text>
<text top="221" left="1385" width="67" height="14" font="5">dobutamine vs </text>
<text top="234" left="1385" width="44" height="14" font="5">64.5% no </text>
<text top="248" left="1385" width="60" height="14" font="5">dobutamine , </text>
<text top="262" left="1385" width="77" height="14" font="5">p=0.0006             </text>
<text top="276" left="1385" width="60" height="14" font="5">Death 70.5% </text>
<text top="289" left="1385" width="67" height="14" font="5">dobutamine vs </text>
<text top="303" left="1385" width="44" height="14" font="5">37.1% no </text>
<text top="317" left="1385" width="57" height="14" font="5">dobutamine, </text>
<text top="331" left="1385" width="44" height="14" font="5">p=0.0001 </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">131</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="464" width="51" height="14" font="5">within 1 wk </text>
<text top="68" left="464" width="11" height="14" font="5">of </text>
<text top="82" left="464" width="65" height="14" font="5">enrollment.      </text>
<text top="96" left="464" width="48" height="14" font="5">Ineligibility </text>
<text top="110" left="464" width="49" height="14" font="5">for cardiac </text>
<text top="123" left="464" width="46" height="14" font="5">transplant-</text>
<text top="137" left="464" width="43" height="14" font="5">ation and </text>
<text top="151" left="464" width="54" height="14" font="5">eligibility for </text>
<text top="165" left="464" width="44" height="14" font="5">long-term </text>
<text top="178" left="464" width="19" height="14" font="5">oral </text>
<text top="192" left="464" width="55" height="14" font="5">anticoagulati</text>
<text top="206" left="464" width="49" height="14" font="5">on therapy </text>
<text top="220" left="464" width="45" height="14" font="5">were also </text>
<text top="234" left="464" width="42" height="14" font="5">required. </text>
<text top="55" left="537" width="48" height="14" font="5">congenital </text>
<text top="68" left="537" width="25" height="14" font="5">heart </text>
<text top="82" left="537" width="57" height="14" font="5">disease with </text>
<text top="96" left="537" width="34" height="14" font="5">shunts, </text>
<text top="110" left="537" width="48" height="14" font="5">valvular or </text>
<text top="123" left="537" width="39" height="14" font="5">vascular </text>
<text top="137" left="537" width="64" height="14" font="5">obstruction;     </text>
<text top="151" left="537" width="49" height="14" font="5">Substance </text>
<text top="165" left="537" width="45" height="14" font="5">or alcohol </text>
<text top="178" left="537" width="50" height="14" font="5">abuse w/in </text>
<text top="192" left="537" width="30" height="14" font="5">1year; </text>
<text top="206" left="537" width="56" height="14" font="5">Moderate or </text>
<text top="220" left="537" width="54" height="14" font="5">severe lung </text>
<text top="234" left="537" width="64" height="14" font="5">disease;          </text>
<text top="247" left="537" width="27" height="14" font="5">Other </text>
<text top="261" left="537" width="43" height="14" font="5">comorbid </text>
<text top="275" left="537" width="47" height="14" font="5">conditions </text>
<text top="289" left="537" width="35" height="14" font="5">likely to </text>
<text top="302" left="537" width="36" height="14" font="5">shorten </text>
<text top="316" left="537" width="66" height="14" font="5">survival;           </text>
<text top="330" left="537" width="54" height="14" font="5">Current use </text>
<text top="344" left="537" width="47" height="14" font="5">of another </text>
<text top="357" left="537" width="55" height="14" font="5">investigation</text>
<text top="371" left="537" width="44" height="14" font="5">al drug or </text>
<text top="385" left="537" width="34" height="14" font="5">device. </text>
<text top="400" left="61" width="24" height="14" font="5">Care </text>
<text top="413" left="61" width="48" height="14" font="5">processes </text>
<text top="427" left="61" width="51" height="14" font="5">and clinical </text>
<text top="441" left="61" width="45" height="14" font="5">outcomes </text>
<text top="455" left="61" width="11" height="14" font="5">of </text>
<text top="468" left="61" width="50" height="14" font="5">continuous </text>
<text top="482" left="61" width="46" height="14" font="5">outpatient </text>
<text top="496" left="61" width="36" height="14" font="5">support </text>
<text top="510" left="61" width="20" height="14" font="5">with </text>
<text top="523" left="61" width="43" height="14" font="5">inotropes </text>
<text top="537" left="61" width="44" height="14" font="5">(COSI) in </text>
<text top="551" left="61" width="36" height="14" font="5">pts with </text>
<text top="565" left="61" width="44" height="14" font="5">refractory </text>
<text top="578" left="61" width="43" height="14" font="5">endstage </text>
<text top="592" left="61" width="19" height="14" font="5">HF, </text>
<text top="606" left="61" width="51" height="14" font="5">Hershberge</text>
<text top="620" left="61" width="33" height="14" font="5">r RE, J </text>
<text top="634" left="61" width="37" height="14" font="5">Cardiac </text>
<text top="647" left="61" width="33" height="14" font="5">Failure </text>
<text top="661" left="61" width="25" height="14" font="5">2003 </text>
<text top="675" left="61" width="46" height="14" font="28">12815567 </text>
<text top="689" left="61" width="26" height="14" font="5">(279) </text>
<text top="400" left="129" width="48" height="14" font="5">To assess </text>
<text top="413" left="129" width="16" height="14" font="5">the </text>
<text top="427" left="129" width="45" height="14" font="5">outcomes </text>
<text top="441" left="129" width="45" height="14" font="5">of chronic </text>
<text top="455" left="129" width="27" height="14" font="5">home </text>
<text top="468" left="129" width="40" height="14" font="5">inotropic </text>
<text top="482" left="129" width="46" height="14" font="5">support in </text>
<text top="496" left="129" width="38" height="14" font="5">Stage D </text>
<text top="510" left="129" width="32" height="14" font="5">HF pts </text>
<text top="400" left="196" width="32" height="14" font="5">Cohort </text>
<text top="413" left="196" width="28" height="14" font="5">Study </text>
<text top="400" left="243" width="51" height="14" font="5">ACEI/ARB  </text>
<text top="413" left="243" width="69" height="14" font="5">72%                  </text>
<text top="427" left="243" width="56" height="14" font="5">Dobutamine </text>
<text top="441" left="243" width="69" height="14" font="5">100%                </text>
<text top="455" left="243" width="50" height="14" font="5">Dopamine  </text>
<text top="468" left="243" width="69" height="14" font="5">22%                  </text>
<text top="482" left="243" width="56" height="14" font="5">Milrinone      </text>
<text top="496" left="243" width="69" height="14" font="5">11%                  </text>
<text top="400" left="319" width="14" height="14" font="5">36 </text>
<text top="413" left="319" width="5" height="14" font="5">  </text>
<text top="427" left="319" width="5" height="14" font="5">  </text>
<text top="400" left="399" width="43" height="14" font="5">47% ICM </text>
<text top="400" left="464" width="56" height="14" font="5">Hospitalized </text>
<text top="413" left="464" width="45" height="14" font="5">advanced </text>
<text top="427" left="464" width="47" height="14" font="5">end-stage </text>
<text top="441" left="464" width="64" height="14" font="5">HF pts             </text>
<text top="455" left="464" width="41" height="14" font="5">Declined </text>
<text top="468" left="464" width="34" height="14" font="5">cardiac </text>
<text top="482" left="464" width="54" height="14" font="5">transplantati</text>
<text top="496" left="464" width="25" height="14" font="5">on or </text>
<text top="510" left="464" width="55" height="14" font="5">ineligible for </text>
<text top="523" left="464" width="34" height="14" font="5">cardiac </text>
<text top="537" left="464" width="54" height="14" font="5">transplantati</text>
<text top="551" left="464" width="14" height="14" font="5">on </text>
<text top="400" left="537" width="132" height="14" font="5"> N/A N/A                </text>
<text top="413" left="609" width="54" height="14" font="5">presumably </text>
<text top="427" left="609" width="47" height="14" font="5">NYHA IIIb-</text>
<text top="441" left="609" width="12" height="14" font="5">IV </text>
<text top="400" left="677" width="138" height="14" font="5">N/A Survival </text>
<text top="400" left="774" width="63" height="14" font="5">after </text>
<text top="413" left="736" width="37" height="14" font="5">hospital </text>
<text top="427" left="736" width="45" height="14" font="5">discharge </text>
<text top="400" left="811" width="25" height="14" font="5">Total </text>
<text top="413" left="811" width="73" height="14" font="5">hospitalizations, </text>
<text top="427" left="811" width="48" height="14" font="5">causes for </text>
<text top="441" left="811" width="71" height="14" font="5">rehospitalization</text>
<text top="455" left="811" width="73" height="14" font="5">, cause of death </text>
<text top="400" left="899" width="22" height="14" font="5"> N/A </text>
<text top="400" left="973" width="16" height="14" font="5">1 y </text>
<text top="413" left="973" width="40" height="14" font="5">mortality </text>
<text top="427" left="973" width="42" height="14" font="5">94%        </text>
<text top="441" left="973" width="25" height="14" font="5">6 mo </text>
<text top="455" left="973" width="40" height="14" font="5">mortality </text>
<text top="468" left="973" width="22" height="14" font="5">74% </text>
<text top="400" left="1034" width="22" height="14" font="5"> N/A </text>
<text top="400" left="1095" width="14" height="14" font="5">&gt;2 </text>
<text top="413" left="1095" width="76" height="14" font="5">rehospitalizations</text>
<text top="427" left="1095" width="74" height="14" font="5">: 36%                  </text>
<text top="441" left="1095" width="17" height="14" font="5">0-1 </text>
<text top="455" left="1095" width="77" height="14" font="5">rehospitalization: </text>
<text top="468" left="1095" width="74" height="14" font="5">64%                    </text>
<text top="482" left="1095" width="33" height="14" font="5">30% of </text>
<text top="496" left="1095" width="79" height="14" font="5">rehospitalizations </text>
<text top="510" left="1095" width="89" height="14" font="5">2/2 worse HF           </text>
<text top="523" left="1095" width="89" height="14" font="5">Cause of death        </text>
<text top="537" left="1095" width="66" height="14" font="5">Worsening HF </text>
<text top="551" left="1095" width="88" height="14" font="5">80%                         </text>
<text top="565" left="1095" width="87" height="14" font="5">SCD 14%                </text>
<text top="578" left="1095" width="61" height="14" font="5">Unknown 6% </text>
<text top="400" left="1189" width="25" height="14" font="5">  N/A </text>
<text top="400" left="1311" width="58" height="14" font="5">Lack of QOL </text>
<text top="413" left="1311" width="66" height="14" font="5">assessment     </text>
<text top="427" left="1311" width="55" height="14" font="5">Lack of cost </text>
<text top="441" left="1311" width="67" height="14" font="5">evaluation        </text>
<text top="455" left="1311" width="54" height="14" font="5">Small study </text>
<text top="468" left="1311" width="67" height="14" font="5">size                  </text>
<text top="482" left="1311" width="55" height="14" font="5">Retrospectiv</text>
<text top="496" left="1311" width="8" height="14" font="5">e </text>
<text top="400" left="1385" width="21" height="14" font="5">Line </text>
<text top="413" left="1385" width="70" height="14" font="5">infection/sepsis </text>
<text top="427" left="1385" width="37" height="14" font="5">(15% of </text>
<text top="441" left="1385" width="71" height="14" font="5">rehospitalization</text>
<text top="455" left="1385" width="11" height="14" font="5">s) </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">132</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="47" height="14" font="5">Prognosis </text>
<text top="68" left="61" width="48" height="14" font="5">on chronic </text>
<text top="82" left="61" width="54" height="14" font="5">dobutamine </text>
<text top="96" left="61" width="54" height="14" font="5">or milrinone </text>
<text top="110" left="61" width="42" height="14" font="5">infusions </text>
<text top="123" left="61" width="51" height="14" font="5">for stage D </text>
<text top="137" left="61" width="19" height="14" font="5">HF, </text>
<text top="151" left="61" width="48" height="14" font="5">Gorodeski </text>
<text top="165" left="61" width="54" height="14" font="5">EZ, Circ HF </text>
<text top="178" left="61" width="25" height="14" font="5">2009 </text>
<text top="192" left="61" width="46" height="14" font="28">19808355 </text>
<text top="206" left="61" width="26" height="14" font="5">(280) </text>
<text top="55" left="129" width="14" height="14" font="5">To </text>
<text top="68" left="129" width="50" height="14" font="5">investigate </text>
<text top="82" left="129" width="16" height="14" font="5">the </text>
<text top="96" left="129" width="53" height="14" font="5">relationship </text>
<text top="110" left="129" width="40" height="14" font="5">between </text>
<text top="123" left="129" width="42" height="14" font="5">choice of </text>
<text top="137" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="151" left="129" width="20" height="14" font="5">e or </text>
<text top="165" left="129" width="43" height="14" font="5">milrinone </text>
<text top="178" left="129" width="19" height="14" font="5">and </text>
<text top="192" left="129" width="50" height="14" font="5">mortality in </text>
<text top="206" left="129" width="39" height="14" font="5">inotrope-</text>
<text top="220" left="129" width="49" height="14" font="5">dependent </text>
<text top="234" left="129" width="52" height="14" font="5">stage D HF </text>
<text top="247" left="129" width="16" height="14" font="5">pts </text>
<text top="55" left="196" width="26" height="14" font="5">Case-</text>
<text top="68" left="196" width="30" height="14" font="5">control</text>
<text top="82" left="196" width="16" height="14" font="5">led </text>
<text top="55" left="243" width="69" height="14" font="5">ASA 39%          </text>
<text top="68" left="243" width="56" height="14" font="5">beta blocker </text>
<text top="82" left="243" width="50" height="14" font="5">5% (dob) v </text>
<text top="96" left="243" width="69" height="14" font="5">34% (mil)          </text>
<text top="110" left="243" width="67" height="14" font="5">ACEI 43%        </text>
<text top="123" left="243" width="67" height="14" font="5">ARB 5%           </text>
<text top="137" left="243" width="55" height="14" font="5">Aldosterone </text>
<text top="151" left="243" width="68" height="14" font="5">blocker 52%     </text>
<text top="165" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="178" left="243" width="69" height="14" font="5">50%                  </text>
<text top="192" left="243" width="55" height="14" font="5">Furosemide </text>
<text top="206" left="243" width="69" height="14" font="5">78%                  </text>
<text top="220" left="243" width="62" height="14" font="5">Other diuretic </text>
<text top="234" left="243" width="22" height="14" font="5">17% </text>
<text top="55" left="319" width="36" height="14" font="5">112; 56 </text>
<text top="68" left="319" width="63" height="14" font="5">(dobutamine); </text>
<text top="82" left="319" width="63" height="14" font="5">56 (milrinone) </text>
<text top="55" left="399" width="43" height="14" font="5">41% ICM </text>
<text top="55" left="464" width="54" height="14" font="5">Stage D HF </text>
<text top="68" left="464" width="54" height="14" font="5">pts deemed </text>
<text top="82" left="464" width="38" height="14" font="5">inotrope </text>
<text top="96" left="464" width="49" height="14" font="5">dependent </text>
<text top="55" left="537" width="132" height="14" font="5"> N/A N/A                </text>
<text top="68" left="609" width="54" height="14" font="5">presumably </text>
<text top="82" left="609" width="47" height="14" font="5">NYHA IIIb-</text>
<text top="96" left="609" width="12" height="14" font="5">IV </text>
<text top="55" left="677" width="39" height="14" font="5">Inotrope </text>
<text top="68" left="677" width="38" height="14" font="5">depende</text>
<text top="82" left="677" width="11" height="14" font="5">nt </text>
<text top="55" left="736" width="38" height="14" font="5">Survival </text>
<text top="55" left="811" width="22" height="14" font="5"> N/A </text>
<text top="55" left="899" width="22" height="14" font="5"> N/A </text>
<text top="55" left="973" width="25" height="14" font="5">6 mo </text>
<text top="68" left="973" width="40" height="14" font="5">mortality </text>
<text top="82" left="973" width="44" height="14" font="5">(propensit</text>
<text top="96" left="973" width="8" height="14" font="5">y </text>
<text top="110" left="973" width="55" height="14" font="5">matched)     </text>
<text top="123" left="973" width="42" height="14" font="5">Dobutami</text>
<text top="137" left="973" width="39" height="14" font="5">ne  60% </text>
<text top="151" left="973" width="43" height="14" font="5">Milrinone </text>
<text top="165" left="973" width="52" height="14" font="5">54%            </text>
<text top="178" left="973" width="16" height="14" font="5">1yr </text>
<text top="192" left="973" width="54" height="14" font="5">mortality      </text>
<text top="206" left="973" width="42" height="14" font="5">Dobutami</text>
<text top="220" left="973" width="52" height="14" font="5">ne 69%       </text>
<text top="234" left="973" width="43" height="14" font="5">Milrinone </text>
<text top="247" left="973" width="22" height="14" font="5">63% </text>
<text top="55" left="1034" width="22" height="14" font="5"> N/A </text>
<text top="55" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="68" left="1095" width="80" height="14" font="5">mortality between </text>
<text top="82" left="1095" width="60" height="14" font="5">inotrope type </text>
<text top="96" left="1095" width="56" height="14" font="5">(multivariate </text>
<text top="110" left="1095" width="69" height="14" font="5">analysis)           </text>
<text top="55" left="1189" width="90" height="14" font="5">Propensity matched </text>
<text top="68" left="1189" width="111" height="14" font="5">mortality,                          </text>
<text top="82" left="1189" width="74" height="14" font="5">log-rank p= 0.74 </text>
<text top="96" left="1189" width="5" height="14" font="5">  </text>
<text top="55" left="1311" width="55" height="14" font="5">Retrospectiv</text>
<text top="68" left="1311" width="68" height="14" font="5">e analysis         </text>
<text top="82" left="1311" width="60" height="14" font="5">Single center </text>
<text top="96" left="1311" width="67" height="14" font="5">study                </text>
<text top="110" left="1311" width="54" height="14" font="5">Small study </text>
<text top="123" left="1311" width="67" height="14" font="5">size                  </text>
<text top="137" left="1311" width="58" height="14" font="5">Lack of QOL </text>
<text top="151" left="1311" width="66" height="14" font="5">assessment     </text>
<text top="55" left="1385" width="19" height="14" font="5">N/A </text>
<text top="262" left="61" width="20" height="14" font="5">The </text>
<text top="276" left="61" width="46" height="14" font="5">Studies of </text>
<text top="289" left="61" width="21" height="14" font="5">Oral </text>
<text top="303" left="61" width="52" height="14" font="5">Enoximone </text>
<text top="317" left="61" width="49" height="14" font="5">Therapy in </text>
<text top="331" left="61" width="47" height="14" font="5">Advanced </text>
<text top="344" left="61" width="16" height="14" font="5">HF </text>
<text top="358" left="61" width="45" height="14" font="5">(ESSENTI</text>
<text top="372" left="61" width="49" height="14" font="5">AL), Metra </text>
<text top="386" left="61" width="38" height="14" font="5">M, 2009 </text>
<text top="400" left="61" width="46" height="14" font="28">19700774 </text>
<text top="413" left="61" width="26" height="14" font="5">(281) </text>
<text top="427" left="61" width="3" height="14" font="5"> </text>
<text top="262" left="129" width="14" height="14" font="5">To </text>
<text top="276" left="129" width="50" height="14" font="5">investigate </text>
<text top="289" left="129" width="48" height="14" font="5">the effects </text>
<text top="303" left="129" width="28" height="14" font="5">of low </text>
<text top="317" left="129" width="40" height="14" font="5">doses of </text>
<text top="331" left="129" width="52" height="14" font="5">the positive </text>
<text top="344" left="129" width="38" height="14" font="5">inotrope </text>
<text top="358" left="129" width="51" height="14" font="5">enoximone </text>
<text top="372" left="129" width="14" height="14" font="5">on </text>
<text top="386" left="129" width="50" height="14" font="5">symptoms, </text>
<text top="400" left="129" width="39" height="14" font="5">exercise </text>
<text top="413" left="129" width="42" height="14" font="5">capacity, </text>
<text top="427" left="129" width="46" height="14" font="5">and major </text>
<text top="441" left="129" width="32" height="14" font="5">clinical </text>
<text top="455" left="129" width="45" height="14" font="5">outcomes </text>
<text top="468" left="129" width="46" height="14" font="5">in pts with </text>
<text top="482" left="129" width="45" height="14" font="5">advanced </text>
<text top="496" left="129" width="37" height="14" font="5">HF who </text>
<text top="510" left="129" width="45" height="14" font="5">were also </text>
<text top="523" left="129" width="54" height="14" font="5">treated with </text>
<text top="537" left="129" width="22" height="14" font="5">beta </text>
<text top="551" left="129" width="39" height="14" font="5">blockers </text>
<text top="565" left="129" width="44" height="14" font="5">and other </text>
<text top="578" left="129" width="43" height="14" font="5">guideline-</text>
<text top="592" left="129" width="46" height="14" font="5">recommen</text>
<text top="606" left="129" width="19" height="14" font="5">ded </text>
<text top="620" left="129" width="46" height="14" font="5">backgroun</text>
<text top="634" left="129" width="44" height="14" font="5">d therapy </text>
<text top="262" left="196" width="105" height="14" font="5">RCT ESSENTIAL-</text>
<text top="276" left="243" width="68" height="14" font="5">I                        </text>
<text top="289" left="243" width="61" height="14" font="5">beta blockers </text>
<text top="303" left="243" width="69" height="14" font="5">83%,                 </text>
<text top="317" left="243" width="54" height="14" font="5">ACEI/ARBs </text>
<text top="331" left="243" width="69" height="14" font="5">94%,                 </text>
<text top="344" left="243" width="55" height="14" font="5">Aldosterone </text>
<text top="358" left="243" width="48" height="14" font="5">antagonist </text>
<text top="372" left="243" width="69" height="14" font="5">62%                  </text>
<text top="386" left="243" width="41" height="14" font="5">Diuretics </text>
<text top="400" left="243" width="69" height="14" font="5">95%,                 </text>
<text top="413" left="243" width="38" height="14" font="5">DIgitalis </text>
<text top="427" left="243" width="49" height="14" font="5">glycosides </text>
<text top="441" left="243" width="69" height="14" font="5">69%                  </text>
<text top="455" left="243" width="40" height="14" font="5">Warfarin </text>
<text top="468" left="243" width="69" height="14" font="5">31%                  </text>
<text top="482" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="496" left="243" width="69" height="14" font="5">22%                  </text>
<text top="510" left="243" width="69" height="14" font="5">ICD 21%           </text>
<text top="523" left="243" width="57" height="14" font="5">ESSENTIAL-</text>
<text top="537" left="243" width="68" height="14" font="5">II                       </text>
<text top="551" left="243" width="40" height="14" font="5">bblocker </text>
<text top="565" left="243" width="69" height="14" font="5">90%                  </text>
<text top="578" left="243" width="54" height="14" font="5">ACEI/ARBs </text>
<text top="592" left="243" width="69" height="14" font="5">99%                  </text>
<text top="606" left="243" width="55" height="14" font="5">Aldosterone </text>
<text top="620" left="243" width="48" height="14" font="5">antagonist </text>
<text top="634" left="243" width="69" height="14" font="5">54%                  </text>
<text top="647" left="243" width="37" height="14" font="5">Digitalis </text>
<text top="661" left="243" width="49" height="14" font="5">glycosides </text>
<text top="675" left="243" width="69" height="14" font="5">46%                  </text>
<text top="689" left="243" width="68" height="14" font="5">Warfarin 8%     </text>
<text top="702" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="716" left="243" width="69" height="14" font="5">14%                  </text>
<text top="730" left="243" width="37" height="14" font="5">ICD 5% </text>
<text top="262" left="319" width="66" height="14" font="5">ESSENTIAL-I: </text>
<text top="276" left="319" width="63" height="14" font="5">904                 </text>
<text top="289" left="319" width="57" height="14" font="5">ESSENTIAL-</text>
<text top="303" left="319" width="30" height="14" font="5">II: 950 </text>
<text top="317" left="319" width="73" height="14" font="5">enoximone         </text>
<text top="331" left="319" width="63" height="14" font="5">ESSENTIAL-I </text>
<text top="344" left="319" width="19" height="14" font="5">454 </text>
<text top="358" left="319" width="66" height="14" font="5">ESSENTIAL-II </text>
<text top="372" left="319" width="19" height="14" font="5">472 </text>
<text top="386" left="319" width="73" height="14" font="5">placebo              </text>
<text top="400" left="319" width="63" height="14" font="5">ESSENTIAL-I </text>
<text top="413" left="319" width="74" height="14" font="5">450                     </text>
<text top="427" left="319" width="66" height="14" font="5">ESSENTIAL-II </text>
<text top="441" left="319" width="19" height="14" font="5">478 </text>
<text top="262" left="399" width="42" height="14" font="5">ESSENTI</text>
<text top="276" left="399" width="43" height="14" font="5">AL-I 52% </text>
<text top="289" left="399" width="40" height="14" font="5">ICM        </text>
<text top="303" left="399" width="42" height="14" font="5">ESSENTI</text>
<text top="317" left="399" width="46" height="14" font="5">AL-II 59% </text>
<text top="331" left="399" width="21" height="14" font="5">ICM </text>
<text top="262" left="464" width="66" height="14" font="5">Age &gt;18 y        </text>
<text top="276" left="464" width="50" height="14" font="5">HF caused </text>
<text top="289" left="464" width="13" height="14" font="5">by </text>
<text top="303" left="464" width="58" height="14" font="5">ischaemic or </text>
<text top="317" left="464" width="55" height="14" font="5">nonischaemi</text>
<text top="331" left="464" width="8" height="14" font="5">c </text>
<text top="344" left="464" width="56" height="14" font="5">cardiomyopa</text>
<text top="358" left="464" width="54" height="14" font="5">thy               </text>
<text top="372" left="464" width="36" height="14" font="5">LVEF &lt; </text>
<text top="386" left="464" width="66" height="14" font="5">30%,                </text>
<text top="400" left="464" width="44" height="14" font="5">LVEDD &gt; </text>
<text top="413" left="464" width="49" height="14" font="5">3.2 cm/m2 </text>
<text top="427" left="464" width="55" height="14" font="5">or 6.0 cm;    </text>
<text top="441" left="464" width="56" height="14" font="5">NYHA III–IV </text>
<text top="455" left="464" width="66" height="14" font="5">for &gt;2 mo         </text>
<text top="468" left="464" width="14" height="14" font="5">&gt;1 </text>
<text top="482" left="464" width="51" height="14" font="5">hospitalizati</text>
<text top="496" left="464" width="33" height="14" font="5">on or 2 </text>
<text top="510" left="464" width="46" height="14" font="5">outpatient </text>
<text top="523" left="464" width="25" height="14" font="5">visits </text>
<text top="537" left="464" width="53" height="14" font="5">requiring IV </text>
<text top="551" left="464" width="46" height="14" font="5">diuretic or </text>
<text top="565" left="464" width="50" height="14" font="5">vasodilator </text>
<text top="578" left="464" width="56" height="14" font="5">therapy w/in </text>
<text top="592" left="464" width="30" height="14" font="5">12 mo </text>
<text top="606" left="464" width="31" height="14" font="5">before </text>
<text top="620" left="464" width="64" height="14" font="5">screening;       </text>
<text top="634" left="464" width="37" height="14" font="5">Optimal </text>
<text top="647" left="464" width="37" height="14" font="5">medical </text>
<text top="661" left="464" width="36" height="14" font="5">therapy </text>
<text top="675" left="464" width="42" height="14" font="5">including </text>
<text top="689" left="464" width="42" height="14" font="5">diuretics, </text>
<text top="702" left="464" width="22" height="14" font="5">beta-</text>
<text top="716" left="464" width="42" height="14" font="5">blockers, </text>
<text top="730" left="464" width="50" height="14" font="5">and ACEIs </text>
<text top="744" left="464" width="39" height="14" font="5">or ARBs </text>
<text top="758" left="464" width="31" height="14" font="5">unless </text>
<text top="771" left="464" width="55" height="14" font="5">intolerant or </text>
<text top="785" left="464" width="56" height="14" font="5">contraindicat</text>
<text top="262" left="537" width="52" height="14" font="5">Acute MI in </text>
<text top="276" left="537" width="54" height="14" font="5">previous 90 </text>
<text top="289" left="537" width="66" height="14" font="5">d,                     </text>
<text top="303" left="537" width="52" height="14" font="5">CV surgery </text>
<text top="317" left="537" width="57" height="14" font="5">in prior 60 d, </text>
<text top="331" left="537" width="52" height="14" font="5">Symptomati</text>
<text top="344" left="537" width="56" height="14" font="5">c ventricular </text>
<text top="358" left="537" width="54" height="14" font="5">arrhythmias </text>
<text top="372" left="537" width="55" height="14" font="5">or ICD firing </text>
<text top="386" left="537" width="66" height="14" font="5">in prior 90 d     </text>
<text top="400" left="537" width="32" height="14" font="5">Serum </text>
<text top="413" left="537" width="48" height="14" font="5">potassium </text>
<text top="427" left="537" width="56" height="14" font="5">&lt;4.0 or &gt;5.5 </text>
<text top="441" left="537" width="34" height="14" font="5">mEq/L, </text>
<text top="455" left="537" width="36" height="14" font="5">Digoxin </text>
<text top="468" left="537" width="50" height="14" font="5">levels &gt;1.2 </text>
<text top="482" left="537" width="66" height="14" font="5">ng/mL              </text>
<text top="496" left="537" width="54" height="14" font="5">Magnesium </text>
<text top="510" left="537" width="50" height="14" font="5">levels &lt;1.0 </text>
<text top="523" left="537" width="64" height="14" font="5">mEq/L             </text>
<text top="537" left="537" width="42" height="14" font="5">SCr&gt; 2.0 </text>
<text top="551" left="537" width="66" height="14" font="5">mg/dL              </text>
<text top="565" left="537" width="32" height="14" font="5">Serum </text>
<text top="578" left="537" width="45" height="14" font="5">bilirubin &gt; </text>
<text top="592" left="537" width="49" height="14" font="5">3.0 mg/dL. </text>
<text top="262" left="609" width="52" height="14" font="5">91% NYHA </text>
<text top="276" left="609" width="60" height="14" font="5">III                   </text>
<text top="289" left="609" width="47" height="14" font="5">8% NYHA </text>
<text top="303" left="609" width="61" height="14" font="5">IV                   </text>
<text top="317" left="609" width="32" height="14" font="5">6MWT </text>
<text top="331" left="609" width="27" height="14" font="5">274m </text>
<text top="344" left="609" width="45" height="14" font="5">(ESSENTI</text>
<text top="358" left="609" width="60" height="14" font="5">AL-I)              </text>
<text top="372" left="609" width="32" height="14" font="5">6MWT </text>
<text top="386" left="609" width="27" height="14" font="5">293m </text>
<text top="400" left="609" width="45" height="14" font="5">(ESSENTI</text>
<text top="413" left="609" width="27" height="14" font="5">AL-II) </text>
<text top="262" left="677" width="41" height="14" font="5">NYHA III-</text>
<text top="276" left="677" width="36" height="14" font="5">IV x &gt; 2 </text>
<text top="289" left="677" width="16" height="14" font="5">mo </text>
<text top="262" left="736" width="35" height="14" font="5">First co-</text>
<text top="276" left="736" width="36" height="14" font="5">primary </text>
<text top="289" left="736" width="41" height="14" font="5">endpoint </text>
<text top="303" left="736" width="49" height="14" font="5">(time to all-</text>
<text top="317" left="736" width="29" height="14" font="5">cause </text>
<text top="331" left="736" width="51" height="14" font="5">mortality or </text>
<text top="344" left="736" width="16" height="14" font="5">CV </text>
<text top="358" left="736" width="57" height="14" font="5">hospitalizatio</text>
<text top="372" left="736" width="50" height="14" font="5">ns) and for </text>
<text top="386" left="736" width="45" height="14" font="5">safety (all-</text>
<text top="400" left="736" width="29" height="14" font="5">cause </text>
<text top="413" left="736" width="43" height="14" font="5">mortality) </text>
<text top="427" left="736" width="57" height="14" font="5">(ESSENTIAL</text>
<text top="441" left="736" width="39" height="14" font="5">-I and II, </text>
<text top="455" left="736" width="68" height="14" font="5">combined)        </text>
<text top="468" left="736" width="51" height="14" font="5">Co-primary </text>
<text top="482" left="736" width="41" height="14" font="5">endpoint </text>
<text top="496" left="736" width="39" height="14" font="5">6MWTD </text>
<text top="510" left="736" width="57" height="14" font="5">(ESSENTIAL</text>
<text top="523" left="736" width="20" height="14" font="5">-I,-II </text>
<text top="537" left="736" width="68" height="14" font="5">separately)       </text>
<text top="551" left="736" width="51" height="14" font="5">Co-primary </text>
<text top="565" left="736" width="41" height="14" font="5">endpoint </text>
<text top="578" left="736" width="33" height="14" font="5">Patient </text>
<text top="592" left="736" width="31" height="14" font="5">Global </text>
<text top="606" left="736" width="59" height="14" font="5">Assessment, </text>
<text top="620" left="736" width="57" height="14" font="5">(ESSENTIAL</text>
<text top="634" left="736" width="42" height="14" font="5">-I and -II, </text>
<text top="647" left="736" width="51" height="14" font="5">separately) </text>
<text top="262" left="811" width="22" height="14" font="5"> N/A </text>
<text top="262" left="899" width="19" height="14" font="5">N/A </text>
<text top="262" left="973" width="19" height="14" font="5">N/A </text>
<text top="262" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="276" left="1034" width="28" height="14" font="5">t 2/02-</text>
<text top="289" left="1034" width="22" height="14" font="5">5/04 </text>
<text top="303" left="1034" width="37" height="14" font="5">(28mo); </text>
<text top="317" left="1034" width="35" height="14" font="5">Median </text>
<text top="331" left="1034" width="42" height="14" font="5">follow-up </text>
<text top="344" left="1034" width="38" height="14" font="5">duration </text>
<text top="358" left="1034" width="38" height="14" font="5">16.6 mo </text>
<text top="262" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="276" left="1095" width="68" height="14" font="5">first co-primary </text>
<text top="289" left="1095" width="56" height="14" font="5">endpoint: all-</text>
<text top="303" left="1095" width="71" height="14" font="5">cause mortality, </text>
<text top="317" left="1095" width="42" height="14" font="5">all-cause </text>
<text top="331" left="1095" width="75" height="14" font="5">mortality and CV </text>
<text top="344" left="1095" width="86" height="14" font="5">hospitalizations       </text>
<text top="358" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="372" left="1095" width="45" height="14" font="5">change in </text>
<text top="386" left="1095" width="88" height="14" font="5">6MWTD                   </text>
<text top="400" left="1095" width="72" height="14" font="5">No difference in </text>
<text top="413" left="1095" width="63" height="14" font="5">PGA changes </text>
<text top="262" left="1189" width="86" height="14" font="5">All-cause mortality, </text>
<text top="276" left="1189" width="96" height="14" font="5">p=0.73, 95% CI: 0.80-</text>
<text top="289" left="1189" width="115" height="14" font="5">1.17                                   </text>
<text top="303" left="1189" width="102" height="14" font="5">All-cause mortality and </text>
<text top="317" left="1189" width="89" height="14" font="5">CV hospitalizations, </text>
<text top="331" left="1189" width="93" height="14" font="5">p=0.71, 95% CI 0.86-</text>
<text top="344" left="1189" width="115" height="14" font="5">1.11                                   </text>
<text top="358" left="1189" width="89" height="14" font="5">Change in 6MWTD, </text>
<text top="372" left="1189" width="105" height="14" font="5">p=0.16 (ESSENTIAL-I), </text>
<text top="386" left="1189" width="113" height="14" font="5">p=0.57 (ESSENTIAL-II)    </text>
<text top="400" left="1189" width="107" height="14" font="5">Change in PGA, p=0.79 </text>
<text top="413" left="1189" width="105" height="14" font="5">(ESSENTIAL-I), p=0,11 </text>
<text top="427" left="1189" width="72" height="14" font="5">(ESSENTIAL-II) </text>
<text top="441" left="1189" width="102" height="14" font="5">All cause mortality, HR </text>
<text top="455" left="1189" width="55" height="14" font="5">0.97             </text>
<text top="468" left="1189" width="102" height="14" font="5">All-cause mortality and </text>
<text top="482" left="1189" width="106" height="14" font="5">CV hospitalizations, HR </text>
<text top="496" left="1189" width="22" height="14" font="5">0.98 </text>
<text top="262" left="1311" width="58" height="14" font="5">Crude global </text>
<text top="276" left="1311" width="55" height="14" font="5">assessment </text>
<text top="289" left="1311" width="68" height="14" font="5">for QOL;           </text>
<text top="303" left="1311" width="53" height="14" font="5">6MWT may </text>
<text top="317" left="1311" width="30" height="14" font="5">not be </text>
<text top="331" left="1311" width="41" height="14" font="5">sensitive </text>
<text top="344" left="1311" width="46" height="14" font="5">enough to </text>
<text top="358" left="1311" width="30" height="14" font="5">detect </text>
<text top="372" left="1311" width="57" height="14" font="5">improvement</text>
<text top="386" left="1311" width="57" height="14" font="5">s in exercise </text>
<text top="400" left="1311" width="57" height="14" font="5">capacity/func</text>
<text top="413" left="1311" width="55" height="14" font="5">tional status </text>
<text top="262" left="1385" width="74" height="14" font="5">1Worsening HF, </text>
<text top="276" left="1385" width="73" height="14" font="5">39% enoximone </text>
<text top="289" left="1385" width="75" height="14" font="5">vs 39% placebo, </text>
<text top="303" left="1385" width="82" height="14" font="5">p=0.88                   </text>
<text top="317" left="1385" width="66" height="14" font="5">Diarrhea, 12% </text>
<text top="331" left="1385" width="64" height="14" font="5">enoximone vs </text>
<text top="344" left="1385" width="57" height="14" font="5">7% placebo, </text>
<text top="358" left="1385" width="82" height="14" font="5">p=0.0001,              </text>
<text top="372" left="1385" width="70" height="14" font="5">Palpitations 8% </text>
<text top="386" left="1385" width="64" height="14" font="5">enoximone vs </text>
<text top="400" left="1385" width="57" height="14" font="5">5% placebo, </text>
<text top="413" left="1385" width="33" height="14" font="5">p=0.01 </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">133</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="464" width="14" height="14" font="5">ed </text>
<text top="268" left="61" width="9" height="14" font="5">A </text>
<text top="282" left="61" width="54" height="14" font="5">Prospective </text>
<text top="295" left="61" width="39" height="14" font="5">Sutdy of </text>
<text top="309" left="61" width="53" height="14" font="5">Continuous </text>
<text top="323" left="61" width="54" height="14" font="5">Intravenous </text>
<text top="337" left="61" width="43" height="14" font="5">Milrinone </text>
<text top="351" left="61" width="53" height="14" font="5">Therapy for </text>
<text top="364" left="61" width="43" height="14" font="5">Status IB </text>
<text top="378" left="61" width="17" height="14" font="5">Pts </text>
<text top="392" left="61" width="40" height="14" font="5">Awaiting </text>
<text top="406" left="61" width="27" height="14" font="5">Heart </text>
<text top="419" left="61" width="49" height="14" font="5">Transplant </text>
<text top="433" left="61" width="43" height="14" font="5">at Home, </text>
<text top="447" left="61" width="39" height="14" font="5">Brozena </text>
<text top="461" left="61" width="44" height="14" font="5">SC, 2003 </text>
<text top="474" left="61" width="46" height="14" font="28">15454175 </text>
<text top="488" left="61" width="26" height="14" font="5">(282) </text>
<text top="268" left="129" width="14" height="14" font="5">To </text>
<text top="282" left="129" width="46" height="14" font="5">determine </text>
<text top="295" left="129" width="16" height="14" font="5">the </text>
<text top="309" left="129" width="43" height="14" font="5">feasibility </text>
<text top="323" left="129" width="48" height="14" font="5">and safety </text>
<text top="337" left="129" width="11" height="14" font="5">of </text>
<text top="351" left="129" width="50" height="14" font="5">continuous </text>
<text top="364" left="129" width="12" height="14" font="5">IV </text>
<text top="378" left="129" width="43" height="14" font="5">milrinone </text>
<text top="392" left="129" width="36" height="14" font="5">therapy </text>
<text top="406" left="129" width="51" height="14" font="5">administere</text>
<text top="419" left="129" width="46" height="14" font="5">d at home </text>
<text top="433" left="129" width="52" height="14" font="5">in pts listed </text>
<text top="447" left="129" width="44" height="14" font="5">as Status </text>
<text top="461" left="129" width="51" height="14" font="5">IB for heart </text>
<text top="474" left="129" width="46" height="14" font="5">transplant </text>
<text top="268" left="196" width="32" height="14" font="5">Cohort </text>
<text top="282" left="196" width="26" height="14" font="5">study </text>
<text top="268" left="243" width="36" height="14" font="5">Digoxin </text>
<text top="282" left="243" width="31" height="14" font="5">96.6% </text>
<text top="295" left="243" width="59" height="14" font="5">Loop diuretic </text>
<text top="309" left="243" width="31" height="14" font="5">88.3% </text>
<text top="323" left="243" width="40" height="14" font="5">Warfarin </text>
<text top="337" left="243" width="31" height="14" font="5">83.3% </text>
<text top="351" left="243" width="58" height="14" font="5">Beta-blocker </text>
<text top="364" left="243" width="31" height="14" font="5">73.3% </text>
<text top="378" left="243" width="60" height="14" font="5">ACE-I 66.6% </text>
<text top="392" left="243" width="28" height="14" font="5">Statin </text>
<text top="406" left="243" width="36" height="14" font="5">therapy </text>
<text top="419" left="243" width="31" height="14" font="5">63.3% </text>
<text top="433" left="243" width="33" height="14" font="5">Aspirin </text>
<text top="447" left="243" width="31" height="14" font="5">63.3% </text>
<text top="461" left="243" width="55" height="14" font="5">Spironolacto</text>
<text top="474" left="243" width="44" height="14" font="5">ne 41.6% </text>
<text top="488" left="243" width="56" height="14" font="5">Amiodarone </text>
<text top="502" left="243" width="31" height="14" font="5">28.3% </text>
<text top="516" left="243" width="54" height="14" font="5">ARB 25.0% </text>
<text top="530" left="243" width="55" height="14" font="5">Hydralazine/</text>
<text top="543" left="243" width="61" height="14" font="5">nitrate 13.3% </text>
<text top="268" left="319" width="30" height="14" font="5">60; 60 </text>
<text top="282" left="319" width="52" height="14" font="5">(milrinone); </text>
<text top="295" left="319" width="25" height="14" font="5">none </text>
<text top="268" left="399" width="31" height="14" font="5">66.6% </text>
<text top="282" left="399" width="21" height="14" font="5">ICM </text>
<text top="268" left="464" width="43" height="14" font="5">Milrinone </text>
<text top="282" left="464" width="49" height="14" font="5">dose  &lt;0.5 </text>
<text top="295" left="464" width="62" height="14" font="5">mg/kg/min;     </text>
<text top="309" left="464" width="55" height="14" font="5">Stable dose </text>
<text top="323" left="464" width="56" height="14" font="5">of diuretic to </text>
<text top="337" left="464" width="56" height="14" font="5">maintain dry </text>
<text top="351" left="464" width="34" height="14" font="5">weight; </text>
<text top="364" left="464" width="48" height="14" font="5">Long-term </text>
<text top="378" left="464" width="35" height="14" font="5">venous </text>
<text top="392" left="464" width="66" height="14" font="5">access;            </text>
<text top="406" left="464" width="64" height="14" font="5">AICD;              </text>
<text top="419" left="464" width="45" height="14" font="5">Adequate </text>
<text top="433" left="464" width="28" height="14" font="5">social </text>
<text top="447" left="464" width="36" height="14" font="5">support </text>
<text top="461" left="464" width="47" height="14" font="5">system as </text>
<text top="474" left="464" width="57" height="14" font="5">assessed by </text>
<text top="488" left="464" width="54" height="14" font="5">a transplant </text>
<text top="502" left="464" width="28" height="14" font="5">social </text>
<text top="516" left="464" width="65" height="14" font="5">worker;            </text>
<text top="530" left="464" width="48" height="14" font="5">Functional </text>
<text top="543" left="464" width="25" height="14" font="5">class </text>
<text top="557" left="464" width="48" height="14" font="5">&lt;NYHA IV </text>
<text top="571" left="464" width="49" height="14" font="5">on therapy </text>
<text top="268" left="537" width="58" height="14" font="5">Uncontrolled </text>
<text top="282" left="537" width="52" height="14" font="5">arrhythmia; </text>
<text top="295" left="537" width="58" height="14" font="5">SBP&lt;80 mm </text>
<text top="309" left="537" width="64" height="14" font="5">Hg;                  </text>
<text top="323" left="537" width="46" height="14" font="5">Recurrent </text>
<text top="337" left="537" width="48" height="14" font="5">electrolyte </text>
<text top="351" left="537" width="64" height="14" font="5">abnormality;    </text>
<text top="364" left="537" width="40" height="14" font="5">Infection </text>
<text top="378" left="537" width="53" height="14" font="5">requiring IV </text>
<text top="392" left="537" width="44" height="14" font="5">antibiotic; </text>
<text top="406" left="537" width="54" height="14" font="5">Requiremen</text>
<text top="419" left="537" width="34" height="14" font="5">t for &gt;1 </text>
<text top="433" left="537" width="40" height="14" font="5">inotropic </text>
<text top="447" left="537" width="33" height="14" font="5">agent;  </text>
<text top="461" left="537" width="52" height="14" font="5">Acute renal </text>
<text top="474" left="537" width="65" height="14" font="5">failure;             </text>
<text top="488" left="537" width="36" height="14" font="5">Hepatic </text>
<text top="502" left="537" width="54" height="14" font="5">transaminas</text>
<text top="516" left="537" width="32" height="14" font="5">es &gt;2x </text>
<text top="530" left="537" width="33" height="14" font="5">normal </text>
<text top="268" left="609" width="61" height="14" font="5">NYHA II-III     </text>
<text top="282" left="609" width="48" height="14" font="5">Peak VO2 </text>
<text top="295" left="609" width="22" height="14" font="5">11.4 </text>
<text top="309" left="609" width="45" height="14" font="5">ml/kg/min </text>
<text top="268" left="677" width="39" height="14" font="5">NYHA II-</text>
<text top="282" left="677" width="11" height="14" font="5">III </text>
<text top="268" left="736" width="49" height="14" font="5">Survival to </text>
<text top="282" left="736" width="46" height="14" font="5">transplant </text>
<text top="268" left="811" width="69" height="14" font="5">Hospitalizations</text>
<text top="282" left="811" width="5" height="14" font="5">, </text>
<text top="295" left="811" width="81" height="14" font="5">QoL measures      </text>
<text top="309" left="811" width="21" height="14" font="5">cost </text>
<text top="268" left="899" width="19" height="14" font="5">N/A </text>
<text top="268" left="973" width="19" height="14" font="5">N/A </text>
<text top="268" left="1034" width="44" height="14" font="5">43 mo f/u </text>
<text top="268" left="1095" width="57" height="14" font="5">88.3% of pts </text>
<text top="282" left="1095" width="72" height="14" font="5">underwent OHT </text>
<text top="295" left="1095" width="77" height="14" font="5">3.2% died before </text>
<text top="309" left="1095" width="87" height="14" font="5">transplant                </text>
<text top="323" left="1095" width="86" height="14" font="5">1.6% LVAD             </text>
<text top="337" left="1095" width="87" height="14" font="5">3.2% BIVAD            </text>
<text top="351" left="1095" width="65" height="14" font="5">QoL improved </text>
<text top="364" left="1095" width="67" height="14" font="5">(MLHFQ score </text>
<text top="378" left="1095" width="65" height="14" font="5">decreased by -</text>
<text top="392" left="1095" width="87" height="14" font="5">13.3+3.4 points)      </text>
<text top="268" left="1189" width="87" height="14" font="5">QOL/MLHFQ score </text>
<text top="282" left="1189" width="100" height="14" font="5">change from baseline, </text>
<text top="295" left="1189" width="44" height="14" font="5">p=0.0061 </text>
<text top="309" left="1189" width="5" height="14" font="5">  </text>
<text top="268" left="1311" width="18" height="14" font="5">Not </text>
<text top="282" left="1311" width="68" height="14" font="5">randomized;     </text>
<text top="295" left="1311" width="67" height="14" font="5">No control;       </text>
<text top="309" left="1311" width="55" height="14" font="5">Limited cost </text>
<text top="323" left="1311" width="68" height="14" font="5">data;                 </text>
<text top="337" left="1311" width="54" height="14" font="5">Small study </text>
<text top="351" left="1311" width="20" height="14" font="5">size </text>
<text top="268" left="1385" width="72" height="14" font="5">8% hospitalized </text>
<text top="282" left="1385" width="44" height="14" font="5">for IV line </text>
<text top="295" left="1385" width="83" height="14" font="5">infection                 </text>
<text top="309" left="1385" width="22" height="14" font="5">65% </text>
<text top="323" left="1385" width="63" height="14" font="5">rehospitalized </text>
<text top="337" left="1385" width="74" height="14" font="5">for ADHF during </text>
<text top="351" left="1385" width="56" height="14" font="5">study period </text>
<text top="585" left="61" width="48" height="14" font="5">Compariso</text>
<text top="599" left="61" width="19" height="14" font="5">n of </text>
<text top="613" left="61" width="54" height="14" font="5">dobutamine </text>
<text top="627" left="61" width="32" height="14" font="5">versus </text>
<text top="640" left="61" width="43" height="14" font="5">milrinone </text>
<text top="654" left="61" width="46" height="14" font="5">therapy in </text>
<text top="668" left="61" width="46" height="14" font="5">hospitalize</text>
<text top="682" left="61" width="24" height="14" font="5">d pts </text>
<text top="695" left="61" width="39" height="14" font="5">awaiting </text>
<text top="709" left="61" width="34" height="14" font="5">cardiac </text>
<text top="723" left="61" width="48" height="14" font="5">trnsplantati</text>
<text top="737" left="61" width="51" height="14" font="5">on, Aranda </text>
<text top="751" left="61" width="43" height="14" font="5">JM, 2003 </text>
<text top="764" left="61" width="46" height="14" font="28">12595851 </text>
<text top="778" left="61" width="26" height="14" font="5">(283) </text>
<text top="585" left="129" width="14" height="14" font="5">To </text>
<text top="599" left="129" width="41" height="14" font="5">compare </text>
<text top="613" left="129" width="32" height="14" font="5">clinical </text>
<text top="627" left="129" width="45" height="14" font="5">outcomes </text>
<text top="640" left="129" width="45" height="14" font="5">and costs </text>
<text top="654" left="129" width="50" height="14" font="5">associated </text>
<text top="668" left="129" width="37" height="14" font="5">with the </text>
<text top="682" left="129" width="29" height="14" font="5">use of </text>
<text top="695" left="129" width="46" height="14" font="5">dobutamin</text>
<text top="709" left="129" width="20" height="14" font="5">e or </text>
<text top="723" left="129" width="53" height="14" font="5">milrinone in </text>
<text top="737" left="129" width="46" height="14" font="5">hospitalize</text>
<text top="751" left="129" width="24" height="14" font="5">d pts </text>
<text top="764" left="129" width="39" height="14" font="5">awaiting </text>
<text top="778" left="129" width="34" height="14" font="5">cardiac </text>
<text top="792" left="129" width="49" height="14" font="5">transplanta</text>
<text top="585" left="196" width="90" height="14" font="5">RCT N/A </text>
<text top="585" left="319" width="40" height="14" font="5">36; </text>
<text top="585" left="335" width="38" height="14" font="5">19 </text>
<text top="599" left="319" width="66" height="14" font="5">(dobutamine);  </text>
<text top="613" left="319" width="63" height="14" font="5">17 (milrinone) </text>
<text top="585" left="399" width="43" height="14" font="5">56% ICM </text>
<text top="585" left="464" width="66" height="14" font="5">Age &gt;18 y;       </text>
<text top="599" left="464" width="23" height="14" font="5">Prior </text>
<text top="613" left="464" width="55" height="14" font="5">approval for </text>
<text top="627" left="464" width="34" height="14" font="5">cardiac </text>
<text top="640" left="464" width="49" height="14" font="5">transplant; </text>
<text top="654" left="464" width="52" height="14" font="5">Exacerbatio</text>
<text top="668" left="464" width="51" height="14" font="5">n of HF not </text>
<text top="682" left="464" width="21" height="14" font="5">only </text>
<text top="695" left="464" width="52" height="14" font="5">necessitatin</text>
<text top="709" left="464" width="8" height="14" font="5">g </text>
<text top="723" left="464" width="51" height="14" font="5">hospitalizati</text>
<text top="737" left="464" width="30" height="14" font="5">on but </text>
<text top="751" left="464" width="51" height="14" font="5">demonstrati</text>
<text top="764" left="464" width="54" height="14" font="5">ng inotropic </text>
<text top="778" left="464" width="59" height="14" font="5">dependency. </text>
<text top="585" left="537" width="51" height="14" font="5">Any history </text>
<text top="599" left="537" width="11" height="14" font="5">of </text>
<text top="613" left="537" width="51" height="14" font="5">intolerance </text>
<text top="627" left="537" width="38" height="14" font="5">to either </text>
<text top="640" left="537" width="54" height="14" font="5">dobutamine </text>
<text top="654" left="537" width="65" height="14" font="5">or milrinone,    </text>
<text top="668" left="537" width="56" height="14" font="5">Hemodynam</text>
<text top="682" left="537" width="53" height="14" font="5">ic instability </text>
<text top="695" left="537" width="43" height="14" font="5">at time of </text>
<text top="709" left="537" width="36" height="14" font="5">random </text>
<text top="723" left="537" width="53" height="14" font="5">assignment </text>
<text top="737" left="537" width="41" height="14" font="5">requiring </text>
<text top="751" left="537" width="53" height="14" font="5">mechanical </text>
<text top="764" left="537" width="34" height="14" font="5">cardiac </text>
<text top="778" left="537" width="36" height="14" font="5">support </text>
<text top="792" left="537" width="40" height="14" font="5">(IABP or </text>
<text top="585" left="609" width="18" height="14" font="5">Not </text>
<text top="599" left="609" width="60" height="14" font="5">presented      </text>
<text top="613" left="609" width="49" height="14" font="5">(presumabl</text>
<text top="627" left="609" width="38" height="14" font="5">y NYHA </text>
<text top="640" left="609" width="32" height="14" font="5">IIIb-IV) </text>
<text top="585" left="677" width="16" height="14" font="5">not </text>
<text top="599" left="677" width="38" height="14" font="5">presente</text>
<text top="613" left="677" width="8" height="14" font="5">d </text>
<text top="585" left="736" width="58" height="14" font="5">Hemodynami</text>
<text top="599" left="736" width="8" height="14" font="5">c </text>
<text top="613" left="736" width="56" height="14" font="5">decompensa</text>
<text top="627" left="736" width="19" height="14" font="5">tion </text>
<text top="640" left="736" width="61" height="14" font="5">(assessed by </text>
<text top="654" left="736" width="59" height="14" font="5">periodic right </text>
<text top="668" left="736" width="25" height="14" font="5">heart </text>
<text top="682" left="736" width="58" height="14" font="5">catheterizatio</text>
<text top="695" left="736" width="69" height="14" font="5">n),                     </text>
<text top="709" left="736" width="52" height="14" font="5">occurrence </text>
<text top="723" left="736" width="59" height="14" font="5">of ventricular </text>
<text top="737" left="736" width="54" height="14" font="5">arrhythmias </text>
<text top="751" left="736" width="41" height="14" font="5">requiring </text>
<text top="764" left="736" width="45" height="14" font="5">increased </text>
<text top="778" left="736" width="57" height="14" font="5">antiarrhythmi</text>
<text top="792" left="736" width="46" height="14" font="5">c therapy, </text>
<text top="585" left="811" width="82" height="14" font="5">death,                    </text>
<text top="599" left="811" width="39" height="14" font="5">need for </text>
<text top="613" left="811" width="53" height="14" font="5">mechanical </text>
<text top="627" left="811" width="81" height="14" font="5">cardiac support,    </text>
<text top="640" left="811" width="25" height="14" font="5">heart </text>
<text top="654" left="811" width="70" height="14" font="5">transplantation, </text>
<text top="668" left="811" width="82" height="14" font="5">and                        </text>
<text top="682" left="811" width="66" height="14" font="5">need to add or </text>
<text top="695" left="811" width="59" height="14" font="5">cross over to </text>
<text top="709" left="811" width="64" height="14" font="5">the alternative </text>
<text top="723" left="811" width="67" height="14" font="5">inotropic agent </text>
<text top="585" left="899" width="19" height="14" font="5">N/A </text>
<text top="585" left="973" width="19" height="14" font="5">N/A </text>
<text top="585" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="599" left="1034" width="33" height="14" font="5">t 17mo </text>
<text top="613" left="1034" width="26" height="14" font="5">(1/99-</text>
<text top="627" left="1034" width="31" height="14" font="5">5/00);  </text>
<text top="585" left="1095" width="61" height="14" font="5">No difference </text>
<text top="599" left="1095" width="40" height="14" font="5">between </text>
<text top="613" left="1095" width="62" height="14" font="5">milrinone and </text>
<text top="627" left="1095" width="74" height="14" font="5">dobutamine with </text>
<text top="640" left="1095" width="78" height="14" font="5">respect to clinical </text>
<text top="654" left="1095" width="57" height="14" font="5">outcomes or </text>
<text top="668" left="1095" width="64" height="14" font="5">hemodynamic </text>
<text top="682" left="1095" width="46" height="14" font="5">measures </text>
<text top="585" left="1189" width="279" height="14" font="5">N/A Background </text>
<text top="599" left="1311" width="37" height="14" font="5">medical </text>
<text top="613" left="1311" width="60" height="14" font="5">management </text>
<text top="627" left="1311" width="56" height="14" font="5">not included </text>
<text top="640" left="1311" width="10" height="14" font="5">in </text>
<text top="654" left="1311" width="67" height="14" font="5">manuscript.      </text>
<text top="668" left="1311" width="40" height="14" font="5">Data not </text>
<text top="682" left="1311" width="61" height="14" font="5">presented for </text>
<text top="695" left="1311" width="59" height="14" font="5">beta-blocked </text>
<text top="709" left="1311" width="29" height="14" font="5">use in </text>
<text top="723" left="1311" width="43" height="14" font="5">milrinone </text>
<text top="737" left="1311" width="66" height="14" font="5">arm.                 </text>
<text top="751" left="1311" width="54" height="14" font="5">Small study </text>
<text top="764" left="1311" width="67" height="14" font="5">size                  </text>
<text top="778" left="1311" width="55" height="14" font="5">No report of </text>
<text top="792" left="1311" width="56" height="14" font="5">SAE/complic</text>
<text top="585" left="1385" width="19" height="14" font="5">N/A </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">134</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="129" width="19" height="14" font="5">tion </text>
<text top="55" left="537" width="64" height="14" font="5">LVAD),            </text>
<text top="68" left="537" width="49" height="14" font="5">Normal LV </text>
<text top="82" left="537" width="25" height="14" font="5">filling </text>
<text top="96" left="537" width="46" height="14" font="5">pressures </text>
<text top="110" left="537" width="31" height="14" font="5">(mean </text>
<text top="123" left="537" width="54" height="14" font="5">PCWP &lt; 15 </text>
<text top="137" left="537" width="65" height="14" font="5">mm Hg),          </text>
<text top="151" left="537" width="55" height="14" font="5">Developmen</text>
<text top="165" left="537" width="16" height="14" font="5">t of </text>
<text top="178" left="537" width="51" height="14" font="5">noncardiac </text>
<text top="192" left="537" width="37" height="14" font="5">medical </text>
<text top="206" left="537" width="30" height="14" font="5">illness </text>
<text top="220" left="537" width="52" height="14" font="5">sufficient to </text>
<text top="234" left="537" width="51" height="14" font="5">remove pts </text>
<text top="247" left="537" width="39" height="14" font="5">from the </text>
<text top="261" left="537" width="34" height="14" font="5">cardiac </text>
<text top="275" left="537" width="46" height="14" font="5">transplant </text>
<text top="289" left="537" width="48" height="14" font="5">waiting list </text>
<text top="55" left="736" width="68" height="14" font="5">and                   </text>
<text top="68" left="736" width="39" height="14" font="5">need for </text>
<text top="82" left="736" width="45" height="14" font="5">additional </text>
<text top="96" left="736" width="50" height="14" font="5">vasodilator </text>
<text top="110" left="736" width="51" height="14" font="5">or inotropic </text>
<text top="123" left="736" width="36" height="14" font="5">therapy </text>
<text top="137" left="736" width="54" height="14" font="5">(nitroprussid</text>
<text top="151" left="736" width="20" height="14" font="5">e or </text>
<text top="165" left="736" width="52" height="14" font="5">dopamine). </text>
<text top="55" left="1311" width="51" height="14" font="5">ations from </text>
<text top="68" left="1311" width="50" height="14" font="5">continuous </text>
<text top="82" left="1311" width="61" height="14" font="5">inotrope (e.g. </text>
<text top="96" left="1311" width="18" height="14" font="5">line </text>
<text top="110" left="1311" width="47" height="14" font="5">infections, </text>
<text top="123" left="1311" width="19" height="14" font="5">etc) </text>
<text top="303" left="61" width="42" height="14" font="5">LVAD as </text>
<text top="317" left="61" width="52" height="14" font="5">Destination </text>
<text top="331" left="61" width="30" height="14" font="5">for pts </text>
<text top="344" left="61" width="52" height="14" font="5">undergoing </text>
<text top="358" left="61" width="54" height="14" font="5">intravenous </text>
<text top="372" left="61" width="40" height="14" font="5">inotropic </text>
<text top="386" left="61" width="46" height="14" font="5">therapy: a </text>
<text top="400" left="61" width="32" height="14" font="5">subset </text>
<text top="413" left="61" width="38" height="14" font="5">analysis </text>
<text top="427" left="61" width="22" height="14" font="5">from </text>
<text top="441" left="61" width="54" height="14" font="5">REMATCH, </text>
<text top="455" left="61" width="49" height="14" font="5">Stevenson </text>
<text top="468" left="61" width="45" height="14" font="5">LW, 2004 </text>
<text top="482" left="61" width="46" height="14" font="28">15313942 </text>
<text top="496" left="61" width="26" height="14" font="5">(284) </text>
<text top="303" left="129" width="51" height="14" font="5">To analyze </text>
<text top="317" left="129" width="45" height="14" font="5">outcomes </text>
<text top="331" left="129" width="26" height="14" font="5">in pts </text>
<text top="344" left="129" width="52" height="14" font="5">undergoing </text>
<text top="358" left="129" width="40" height="14" font="5">inotropic </text>
<text top="372" left="129" width="52" height="14" font="5">infusions at </text>
<text top="386" left="129" width="51" height="14" font="5">randomizati</text>
<text top="400" left="129" width="28" height="14" font="5">on for </text>
<text top="413" left="129" width="28" height="14" font="5">LVAD </text>
<text top="427" left="129" width="50" height="14" font="5">destination </text>
<text top="441" left="129" width="36" height="14" font="5">therapy </text>
<text top="303" left="196" width="23" height="14" font="5">Post-</text>
<text top="317" left="196" width="19" height="14" font="5">hoc </text>
<text top="331" left="196" width="31" height="14" font="5">analysi</text>
<text top="344" left="196" width="8" height="14" font="5">s </text>
<text top="303" left="243" width="69" height="14" font="5">Diuretic 95%     </text>
<text top="317" left="243" width="50" height="14" font="5">&gt;1 Diuretic </text>
<text top="331" left="243" width="69" height="14" font="5">52%                  </text>
<text top="344" left="243" width="40" height="14" font="5">bblocker </text>
<text top="358" left="243" width="69" height="14" font="5">20%                  </text>
<text top="372" left="243" width="51" height="14" font="5">ACE-I 55% </text>
<text top="303" left="319" width="31" height="14" font="5">91 (on </text>
<text top="317" left="319" width="49" height="14" font="5">inotrope at </text>
<text top="331" left="319" width="62" height="14" font="5">randomization</text>
<text top="344" left="319" width="9" height="14" font="5">); </text>
<text top="358" left="319" width="51" height="14" font="5">45 (LVAD); </text>
<text top="372" left="319" width="47" height="14" font="5">46 (OMM) </text>
<text top="303" left="399" width="19" height="14" font="5">N/A </text>
<text top="303" left="464" width="56" height="14" font="5">LVEF &lt;25% </text>
<text top="317" left="464" width="42" height="14" font="5">NYHA IV </text>
<text top="331" left="464" width="48" height="14" font="5">symptoms </text>
<text top="344" left="464" width="52" height="14" font="5">for 60 of 90 </text>
<text top="358" left="464" width="43" height="14" font="5">d despite </text>
<text top="372" left="464" width="46" height="14" font="5">attempted </text>
<text top="386" left="464" width="56" height="14" font="5">therapy with </text>
<text top="400" left="464" width="33" height="14" font="5">ACEIs, </text>
<text top="413" left="464" width="42" height="14" font="5">diuretics, </text>
<text top="427" left="464" width="67" height="14" font="5">and digoxin.     </text>
<text top="441" left="464" width="48" height="14" font="5">Peak VO2 </text>
<text top="455" left="464" width="34" height="14" font="5">&lt;12-14 </text>
<text top="468" left="464" width="51" height="14" font="5">mL/kg/min  </text>
<text top="482" left="464" width="20" height="14" font="5">with </text>
<text top="496" left="464" width="53" height="14" font="5">evidence of </text>
<text top="510" left="464" width="46" height="14" font="5">anaerobic </text>
<text top="523" left="464" width="67" height="14" font="5">metabolism,     </text>
<text top="537" left="464" width="59" height="14" font="5">Dependence </text>
<text top="551" left="464" width="26" height="14" font="5">on IV </text>
<text top="565" left="464" width="40" height="14" font="5">inotropic </text>
<text top="578" left="464" width="32" height="14" font="5">agents </text>
<text top="592" left="464" width="47" height="14" font="5">supported </text>
<text top="606" left="464" width="13" height="14" font="5">by </text>
<text top="620" left="464" width="50" height="14" font="5">completion </text>
<text top="634" left="464" width="59" height="14" font="5">of a weaning </text>
<text top="647" left="464" width="58" height="14" font="5">failure form.  </text>
<text top="303" left="537" width="47" height="14" font="5">Advanced </text>
<text top="317" left="537" width="66" height="14" font="5">age,                 </text>
<text top="331" left="537" width="40" height="14" font="5">diabetes </text>
<text top="344" left="537" width="40" height="14" font="5">with end-</text>
<text top="358" left="537" width="28" height="14" font="5">organ </text>
<text top="372" left="537" width="66" height="14" font="5">damage,          </text>
<text top="386" left="537" width="39" height="14" font="5">SCr&gt;2.5 </text>
<text top="400" left="537" width="44" height="14" font="5">mg/dL for </text>
<text top="413" left="537" width="30" height="14" font="5">&gt;90 d, </text>
<text top="303" left="609" width="42" height="14" font="5">NYHA IV </text>
<text top="303" left="677" width="25" height="14" font="5">Peak </text>
<text top="317" left="677" width="42" height="14" font="5">VO2 &lt;14 </text>
<text top="331" left="677" width="40" height="14" font="5">mL/kg/mi</text>
<text top="344" left="677" width="11" height="14" font="5">n  </text>
<text top="358" left="677" width="5" height="14" font="5">  </text>
<text top="303" left="736" width="43" height="14" font="5">All-cause </text>
<text top="317" left="736" width="40" height="14" font="5">mortality </text>
<text top="331" left="736" width="46" height="14" font="5">during the </text>
<text top="344" left="736" width="27" height="14" font="5">180 d </text>
<text top="358" left="736" width="41" height="14" font="5">following </text>
<text top="372" left="736" width="56" height="14" font="5">randomizatio</text>
<text top="386" left="736" width="14" height="14" font="5">n.  </text>
<text top="303" left="811" width="48" height="14" font="5">QoL at 1 y </text>
<text top="303" left="899" width="19" height="14" font="5">N/A </text>
<text top="303" left="973" width="19" height="14" font="5">N/A </text>
<text top="303" left="1034" width="44" height="14" font="5">Enrollmen</text>
<text top="317" left="1034" width="28" height="14" font="5">t 5/98-</text>
<text top="331" left="1034" width="27" height="14" font="5">7/01;  </text>
<text top="303" left="1095" width="79" height="14" font="5">In pts undergoing </text>
<text top="317" left="1095" width="75" height="14" font="5">inotropic therapy </text>
<text top="331" left="1095" width="78" height="14" font="5">at randomization, </text>
<text top="344" left="1095" width="72" height="14" font="5">1 y survival with </text>
<text top="358" left="1095" width="71" height="14" font="5">LVAD was 49% </text>
<text top="372" left="1095" width="79" height="14" font="5">vs. 24% for OMM </text>
<text top="386" left="1095" width="73" height="14" font="5">and by 2 y, 28% </text>
<text top="400" left="1095" width="67" height="14" font="5">were alive with </text>
<text top="413" left="1095" width="56" height="14" font="5">LVAD group </text>
<text top="427" left="1095" width="67" height="14" font="5">compared with </text>
<text top="441" left="1095" width="59" height="14" font="5">11% in OMM </text>
<text top="455" left="1095" width="28" height="14" font="5">group </text>
<text top="303" left="1189" width="44" height="14" font="5">p=0.0014 </text>
<text top="317" left="1189" width="5" height="14" font="5">  </text>
<text top="303" left="1311" width="34" height="14" font="5">Did not </text>
<text top="317" left="1311" width="36" height="14" font="5">capture </text>
<text top="331" left="1311" width="40" height="14" font="5">inotropic </text>
<text top="344" left="1311" width="56" height="14" font="5">dependency </text>
<text top="358" left="1311" width="52" height="14" font="5">status in all </text>
<text top="372" left="1311" width="21" height="14" font="5">pts.  </text>
<text top="386" left="1311" width="44" height="14" font="5">Post-hoc, </text>
<text top="400" left="1311" width="44" height="14" font="5">subgroup </text>
<text top="413" left="1311" width="60" height="14" font="5">analysis.        </text>
<text top="427" left="1311" width="43" height="14" font="5">Outdated </text>
<text top="441" left="1311" width="61" height="14" font="5">LVAD model. </text>
<text top="303" left="1385" width="22" height="14" font="5"> N/A </text>
<text top="662" left="54" width="1392" height="14" font="5">ACEI indicates angiotensin-converting-enzyme inhibitor; ADHF, acute decompensated heart failure; AE, adverse event; AICD, automated implantable cardioverter defibrillator; ARDS, acute respiratory distress syndrome; ASA, aspirin; AVB, atrioventricular block; BIVAD, biventricular assist device; BNP, B-type natriuretic </text>
<text top="676" left="54" width="1389" height="14" font="5">peptide; BP, blood pressure; CCB, calcium channel blockers; CHF, congestive heart failure; CMH, Cochran-Mantel-Haenszel; CO, cardiac output; CrCl, creatinine clearance; CV, cardiovascular; ED, emergency department; F/U, follow-up; HCM, hypertrophic cardiomyopathy; HF, heart failure; HR, heart rate; IABP, intra-</text>
<text top="689" left="54" width="1374" height="14" font="5">aortic balloon pump; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy; ICU, intensive care unit; IV, intravenous; LOS, length of stay; LVAD, left ventricular assist device; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; MLHFQ, Minnesota Living with Heart </text>
<text top="703" left="54" width="1406" height="14" font="5">Failure Questionaire;  MWTD, minute walk test distance; N/A, not applicable; NSVT, non-sustained ventricular tachycardia; NTG, nitroglycerin; NYHA, New York Heart Association; OHT, orthotopic heart transplantation; OMM, optimal medical management; OPTIME_CHF, the Outcomes of a Prospective Trial of Intravenous </text>
<text top="717" left="54" width="1399" height="14" font="5">Milrinone for Exacerbations of Chronic Heart Failure study; PADP, pulmonary artery diastolic pressure; PCWP, pulmonary capillary wedge pressure; PGA, polyglycolide; pts, patients; PVC, premature ventricular contraction; QoL, quality of life; RAP, right atrial pressure; RCT, randomized control trial; SAE, serious adverse </text>
<text top="731" left="54" width="941" height="14" font="5">event; SAS, specific activity scale; SBP, systolic blood pressure; SCD, sudden cardiac death; SCr, serum creatinine; UA, unstable angina; UAHF, ultra-advanced; VF, ventricular fibrillation; VT, ventricular tachycardia. </text>
<text top="748" left="54" width="4" height="16" font="7"> </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">135</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="416" height="21" font="8"><b>Data Supplement 33. Inotropic Agents in HF (Section 7.4.4) </b></text>
<text top="75" left="114" width="38" height="17" font="15"><b>Study </b></text>
<text top="75" left="361" width="38" height="17" font="15"><b>Study </b></text>
<text top="75" left="757" width="48" height="17" font="15"><b>Results </b></text>
<text top="111" left="222" width="44" height="17" font="15"><b>Design </b></text>
<text top="111" left="300" width="32" height="17" font="15"><b>Drug </b></text>
<text top="111" left="371" width="51" height="17" font="15"><b>Support </b></text>
<text top="131" left="370" width="54" height="17" font="15"><b>Duration </b></text>
<text top="111" left="469" width="51" height="17" font="15"><b>Patients </b></text>
<text top="111" left="565" width="38" height="17" font="15"><b>Hemo-</b></text>
<text top="131" left="555" width="60" height="17" font="15"><b>dynamics </b></text>
<text top="111" left="627" width="66" height="17" font="15"><b>Functional </b></text>
<text top="131" left="632" width="55" height="17" font="15"><b>Capacity </b></text>
<text top="111" left="723" width="28" height="17" font="15"><b>QoL </b></text>
<text top="111" left="783" width="91" height="17" font="15"><b>Hospitalization </b></text>
<text top="111" left="921" width="51" height="17" font="15"><b>Survival </b></text>
<text top="166" left="56" width="63" height="17" font="13">PROMISE  </text>
<text top="183" left="56" width="48" height="17" font="14">1944425</text>
<text top="183" left="104" width="36" height="17" font="13"> (277) </text>
<text top="166" left="211" width="29" height="17" font="13">RCT </text>
<text top="166" left="279" width="44" height="17" font="13">M vs. P </text>
<text top="166" left="353" width="46" height="17" font="13">Chronic </text>
<text top="166" left="441" width="67" height="17" font="13">NYHA III-IV </text>
<text top="201" left="441" width="69" height="17" font="13">LVEF &lt;35% </text>
<text top="166" left="549" width="304" height="17" font="13">N/A N/A N/A  N/A </text>
<text top="166" left="880" width="11" height="17" font="13">↓ </text>
<text top="237" left="56" width="98" height="17" font="13">Aranda JM 2003* </text>
<text top="254" left="56" width="55" height="17" font="14">12595851</text>
<text top="254" left="111" width="36" height="17" font="13"> (283) </text>
<text top="237" left="211" width="123" height="17" font="13">RCT M, </text>
<text top="237" left="296" width="227" height="17" font="13">D  Chronic  Txplt-C </text>
<text top="237" left="549" width="14" height="17" font="13">M </text>
<text top="237" left="563" width="24" height="18" font="13">≅ D</text>
<text top="237" left="623" width="229" height="17" font="13">N/A N/A  N/A </text>
<text top="237" left="880" width="14" height="17" font="13">M </text>
<text top="237" left="893" width="27" height="18" font="13">≅ D </text>
<text top="273" left="56" width="42" height="17" font="13">FIRST  </text>
<text top="290" left="56" width="55" height="17" font="14">10385768</text>
<text top="290" left="111" width="36" height="17" font="13"> (278) </text>
<text top="273" left="211" width="32" height="17" font="13">RCT  </text>
<text top="307" left="211" width="59" height="17" font="13">(post-hoc) </text>
<text top="273" left="279" width="120" height="17" font="13">D vs. none  Chronic </text>
<text top="273" left="441" width="67" height="17" font="13">NYHA III-IV </text>
<text top="307" left="441" width="87" height="17" font="13">LVEF &lt;25-30% </text>
<text top="342" left="441" width="46" height="17" font="13">Txplt-IE </text>
<text top="273" left="549" width="304" height="17" font="13">N/A N/A N/A  N/A </text>
<text top="273" left="880" width="11" height="17" font="13">↓ </text>
<text top="378" left="56" width="37" height="17" font="13">COSI  </text>
<text top="395" left="56" width="55" height="17" font="14">12815567</text>
<text top="395" left="111" width="36" height="17" font="13"> (279) </text>
<text top="378" left="211" width="40" height="17" font="13">Cohort </text>
<text top="412" left="211" width="3" height="17" font="13"> </text>
<text top="378" left="279" width="29" height="17" font="13">M, D </text>
<text top="412" left="279" width="3" height="17" font="13"> </text>
<text top="378" left="353" width="46" height="17" font="13">Chronic </text>
<text top="412" left="353" width="3" height="17" font="13"> </text>
<text top="378" left="441" width="74" height="17" font="13">Hospitalized  </text>
<text top="412" left="441" width="46" height="17" font="13">Txplt-IE </text>
<text top="378" left="549" width="24" height="17" font="13">N/A </text>
<text top="378" left="623" width="24" height="17" font="13">N/A </text>
<text top="378" left="697" width="21" height="17" font="13">NS </text>
<text top="378" left="778" width="24" height="17" font="13">N/A </text>
<text top="378" left="880" width="57" height="17" font="13">6% @ 1 y </text>
<text top="412" left="880" width="75" height="17" font="13">26% @ 6 mo </text>
<text top="448" left="56" width="109" height="17" font="13">Brozena SC 2004*  </text>
<text top="465" left="56" width="55" height="17" font="14">15454175</text>
<text top="465" left="111" width="39" height="17" font="13">  (282) </text>
<text top="448" left="211" width="108" height="17" font="13">Cohort M </text>
<text top="448" left="353" width="158" height="17" font="13">Chronic  Txplt-C </text>
<text top="448" left="484" width="116" height="17" font="13">(1B)  N/A </text>
<text top="448" left="623" width="51" height="17" font="13">N/A </text>
<text top="448" left="697" width="276" height="17" font="13">↑ N/A  N/A </text>
<text top="484" left="56" width="109" height="17" font="13">Gorodeski EZ 2009 </text>
<text top="501" left="56" width="58" height="17" font="14">19808355 </text>
<text top="501" left="114" width="32" height="17" font="13">(280) </text>
<text top="483" left="211" width="32" height="17" font="13">Case </text>
<text top="503" left="211" width="43" height="17" font="13">Control </text>
<text top="483" left="279" width="45" height="17" font="13">M vs. D </text>
<text top="483" left="353" width="46" height="17" font="13">Chronic </text>
<text top="483" left="441" width="46" height="17" font="13">stage D </text>
<text top="518" left="441" width="48" height="17" font="13">ino-dpdt </text>
<text top="483" left="549" width="308" height="17" font="13">N/A N/A N/A  65% </text>
<text top="484" left="880" width="14" height="17" font="13">M </text>
<text top="484" left="893" width="27" height="18" font="13">≅ D </text>
<text top="519" left="880" width="93" height="17" font="13">31%-37% @ 1 y </text>
<text top="554" left="56" width="83" height="17" font="13">OPTIME-CHF  </text>
<text top="572" left="56" width="55" height="17" font="14">11911756</text>
<text top="572" left="111" width="39" height="17" font="13">  (271) </text>
<text top="554" left="211" width="29" height="17" font="13">RCT </text>
<text top="554" left="279" width="44" height="17" font="13">M vs. P </text>
<text top="554" left="353" width="61" height="17" font="13">Short-term </text>
<text top="589" left="353" width="43" height="17" font="13">(&lt;72 h) </text>
<text top="554" left="441" width="88" height="17" font="13">Hospitalized for </text>
<text top="574" left="441" width="90" height="17" font="13">HF, NYHA II-IV, </text>
<text top="594" left="441" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="554" left="549" width="24" height="17" font="13">N/A </text>
<text top="589" left="549" width="3" height="17" font="13"> </text>
<text top="624" left="549" width="3" height="17" font="13"> </text>
<text top="554" left="623" width="226" height="17" font="13">N/A NS  NS </text>
<text top="554" left="880" width="71" height="17" font="13">NS </text>
<text top="660" left="56" width="57" height="17" font="13">ESCAPE  </text>
<text top="677" left="56" width="58" height="17" font="14">17174645 </text>
<text top="677" left="114" width="32" height="17" font="13">(276) </text>
<text top="659" left="211" width="32" height="17" font="13">RCT  </text>
<text top="694" left="211" width="59" height="17" font="13">(post-hoc) </text>
<text top="659" left="279" width="26" height="17" font="13">M,D </text>
<text top="694" left="279" width="3" height="17" font="13"> </text>
<text top="659" left="353" width="184" height="17" font="13">Short-term Hospitalized </text>
<text top="659" left="511" width="44" height="17" font="13">for </text>
<text top="679" left="441" width="93" height="17" font="13">HF, LVEF &lt;30% </text>
<text top="659" left="549" width="240" height="17" font="13">N/A N/A N/A  ↑ </text>
<text top="659" left="880" width="11" height="17" font="13">↓ </text>
<text top="730" left="56" width="58" height="17" font="13">ADHERE  </text>
<text top="747" left="56" width="58" height="17" font="14">15992636 </text>
<text top="747" left="114" width="32" height="17" font="13">(273) </text>
<text top="730" left="211" width="33" height="17" font="13">Retro </text>
<text top="765" left="211" width="26" height="17" font="13">Obs </text>
<text top="730" left="279" width="29" height="17" font="13">M, D </text>
<text top="730" left="353" width="61" height="17" font="13">Short-term </text>
<text top="730" left="441" width="88" height="17" font="13">Hospitalized for </text>
<text top="750" left="441" width="20" height="17" font="13">HF </text>
<text top="730" left="549" width="240" height="17" font="13">N/A N/A N/A  ↑ </text>
<text top="765" left="778" width="28" height="17" font="13">LOS </text>
<text top="730" left="880" width="11" height="17" font="13">↓ </text>
<text top="765" left="880" width="44" height="17" font="13">in-hosp </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">136</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="56" width="36" height="17" font="13">DICE  </text>
<text top="72" left="56" width="55" height="17" font="14">10426835</text>
<text top="72" left="111" width="39" height="17" font="13">  (269) </text>
<text top="55" left="211" width="119" height="17" font="13">RCT D </text>
<text top="55" left="353" width="104" height="17" font="13">Intermittent </text>
<text top="74" left="353" width="77" height="17" font="13">(48-72 h/wk x </text>
<text top="94" left="353" width="35" height="17" font="13">6 mo) </text>
<text top="55" left="441" width="70" height="17" font="13">Hospitalized </text>
<text top="89" left="441" width="67" height="17" font="13">NYHA III-IV </text>
<text top="124" left="441" width="101" height="17" font="13">LVEF &lt;30%, prior </text>
<text top="144" left="441" width="40" height="17" font="13">h/o ino </text>
<text top="55" left="549" width="300" height="17" font="13">N/A NS  N/A  NS </text>
<text top="55" left="880" width="71" height="17" font="13">NS </text>
<text top="179" left="54" width="286" height="15" font="6">*Study limited to patients awaiting cardiac transplantation.<b> </b></text>
<text top="195" left="54" width="906" height="15" font="6">1B indicates UNOS Status 1B; ADHERE, Acute Decompensated HF National Registry;  ADHF, acute decompensated heart failure; COSI, continuous outpatient support with inotropes;   </text>
<text top="210" left="54" width="962" height="15" font="6">D, dobutamine; DICE, Dobutamina nell’Insufficienza Cardiaca Estrema; ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; FIRST, Flolan  </text>
<text top="226" left="54" width="975" height="15" font="6">International Randomized Survival Trial;  in-hosp, in-hospital mortality; ino-dpdt, inotrope-dependent; LOS, length of stay; LVEF, left ventricular ejection fraction; M, milrinone; N/A, not applicable; NS,  </text>
<text top="241" left="54" width="1014" height="15" font="6">no significant benefit; NYHA, New York Heart Association; OPTIME-CHF, the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure study; P, placebo; Post-hoc  </text>
<text top="257" left="54" width="980" height="15" font="6">(RCT), post-hoc analysis of an RCT; PROMISE, PROspective Imaging Study for Evaluation of Chest Pain; RCT, randomized, controlled clinical trial; RetroObs, retrospective observational study; QoL,  </text>
<text top="272" left="54" width="469" height="15" font="6">quality of life; Txplt-C, cardiac transplantation candidate; and Txplt-IE, transplantation ineligible. </text>
<text top="288" left="54" width="4" height="19" font="7"> </text>
<text top="325" left="54" width="480" height="21" font="8"><b>Data Supplement 34. Mechanical Circulatory Support (Section 7.4.5) </b></text>
<text top="349" left="127" width="38" height="17" font="15"><b>Study </b></text>
<text top="349" left="479" width="38" height="17" font="15"><b>Study</b> </text>
<text top="349" left="881" width="118" height="17" font="15"><b>Evidence of Benefit</b> </text>
<text top="349" left="1152" width="96" height="17" font="15"><b>Adverse Events </b></text>
<text top="349" left="1342" width="67" height="17" font="15"><b>Comments </b></text>
<text top="381" left="249" width="44" height="17" font="15"><b>Design </b></text>
<text top="381" left="358" width="43" height="17" font="15"><b>Device </b></text>
<text top="398" left="370" width="19" height="17" font="15"><b>(n) </b></text>
<text top="381" left="476" width="47" height="17" font="15"><b>Control </b></text>
<text top="398" left="490" width="19" height="17" font="15"><b>(n) </b></text>
<text top="381" left="602" width="51" height="17" font="15"><b>Patients </b></text>
<text top="381" left="720" width="30" height="17" font="15"><b>DOS </b></text>
<text top="381" left="791" width="51" height="17" font="15"><b>Survival </b></text>
<text top="381" left="874" width="72" height="17" font="15"><b>HD Support </b></text>
<text top="381" left="976" width="55" height="17" font="15"><b>Function </b></text>
<text top="381" left="1065" width="28" height="17" font="15"><b>QoL </b></text>
<text top="422" left="65" width="68" height="17" font="13">REMATCH  </text>
<text top="439" left="65" width="55" height="17" font="14">11794191</text>
<text top="439" left="120" width="7" height="17" font="13">, </text>
<text top="439" left="127" width="55" height="17" font="14">15313942</text>
<text top="439" left="181" width="3" height="17" font="13"> </text>
<text top="456" left="65" width="56" height="17" font="13">(284,285) </text>
<text top="422" left="226" width="29" height="17" font="13">RCT </text>
<text top="422" left="316" width="76" height="17" font="13">HM XVE (68) </text>
<text top="422" left="442" width="59" height="17" font="13">OMM (61) </text>
<text top="422" left="556" width="46" height="17" font="13">Txplt-IE </text>
<text top="439" left="556" width="54" height="17" font="13">74% ICM </text>
<text top="456" left="556" width="48" height="17" font="13">71% ino </text>
<text top="422" left="699" width="12" height="17" font="13">P </text>
<text top="422" left="769" width="11" height="17" font="13">+ </text>
<text top="422" left="862" width="24" height="17" font="13">N/A </text>
<text top="422" left="956" width="3" height="17" font="13"> </text>
<text top="439" left="956" width="24" height="17" font="13">N/A </text>
<text top="422" left="1049" width="11" height="17" font="13">+ </text>
<text top="439" left="1049" width="3" height="17" font="13"> </text>
<text top="422" left="1108" width="88" height="17" font="13">Bleeding Neuro </text>
<text top="439" left="1108" width="27" height="17" font="13">SVT </text>
<text top="456" left="1108" width="40" height="17" font="13">Sepsis </text>
<text top="422" left="1290" width="118" height="17" font="13">1 y Mortality RR 0.52 </text>
<text top="439" left="1290" width="93" height="17" font="13">No benefit at 2 y </text>
<text top="482" left="65" width="59" height="17" font="13">INTrEPID  </text>
<text top="499" left="65" width="55" height="17" font="14">17707178</text>
<text top="499" left="120" width="36" height="17" font="13"> (286) </text>
<text top="482" left="226" width="44" height="17" font="13">pNRCT </text>
<text top="482" left="316" width="77" height="17" font="13">NovaCor (37) </text>
<text top="482" left="442" width="59" height="17" font="13">OMM (18) </text>
<text top="482" left="556" width="46" height="17" font="13">Txplt-IE </text>
<text top="499" left="556" width="109" height="17" font="13">38% ICM 100% ino </text>
<text top="482" left="699" width="12" height="17" font="13">P </text>
<text top="482" left="769" width="11" height="17" font="13">+ </text>
<text top="482" left="862" width="24" height="17" font="13">N/A </text>
<text top="482" left="956" width="24" height="17" font="13">N/A </text>
<text top="482" left="1049" width="24" height="17" font="13">N/A </text>
<text top="482" left="1108" width="37" height="17" font="13">Neuro </text>
<text top="499" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="482" left="1290" width="155" height="17" font="13">1 y Survival 27% (NovaCor) </text>
<text top="499" left="1290" width="89" height="17" font="13">vs. 11% (OMM) </text>
<text top="520" left="65" width="53" height="17" font="13">HMII-DT  </text>
<text top="537" left="65" width="55" height="17" font="14">19920051</text>
<text top="537" left="120" width="36" height="17" font="13"> (287) </text>
<text top="520" left="226" width="29" height="17" font="13">RCT </text>
<text top="520" left="316" width="61" height="17" font="13">HMII (134) </text>
<text top="520" left="442" width="76" height="17" font="13">HM XVE (66) </text>
<text top="520" left="556" width="46" height="17" font="13">Txplt-IE </text>
<text top="537" left="556" width="54" height="17" font="13">67% ICM </text>
<text top="520" left="699" width="12" height="17" font="13">P </text>
<text top="520" left="769" width="11" height="17" font="13">+ </text>
<text top="520" left="862" width="24" height="17" font="13">N/A </text>
<text top="520" left="956" width="11" height="17" font="13">+ </text>
<text top="537" left="956" width="7" height="17" font="13">+</text>
<text top="539" left="963" width="9" height="11" font="19">21</text>
<text top="537" left="972" width="3" height="17" font="13"> </text>
<text top="520" left="1049" width="11" height="17" font="13">+ </text>
<text top="537" left="1049" width="7" height="17" font="13">+</text>
<text top="539" left="1056" width="9" height="11" font="19">21</text>
<text top="537" left="1065" width="3" height="17" font="13"> </text>
<text top="520" left="1108" width="150" height="17" font="13">PumpRplt Sepsis RespFail </text>
<text top="537" left="1108" width="145" height="17" font="13">RenalFail RV Fail Rehosp </text>
<text top="520" left="1290" width="152" height="17" font="13">2 y Survival 58% (HMII) vs. </text>
<text top="537" left="1290" width="87" height="17" font="13">24% (HM XVE) </text>
<text top="555" left="1290" width="136" height="17" font="13">Lower AE rate with HMII </text>
<text top="576" left="65" width="60" height="17" font="13">HMII-BTT  </text>
<text top="593" left="65" width="55" height="17" font="14">17761592</text>
<text top="593" left="120" width="7" height="17" font="13">, </text>
<text top="593" left="127" width="55" height="17" font="14">19608028</text>
<text top="593" left="181" width="3" height="17" font="13"> </text>
<text top="610" left="65" width="56" height="17" font="13">(288,289) </text>
<text top="576" left="226" width="40" height="17" font="13">Cohort </text>
<text top="576" left="316" width="61" height="17" font="13">HMII (281) </text>
<text top="593" left="316" width="3" height="17" font="13"> </text>
<text top="576" left="442" width="33" height="17" font="22"><i>None </i></text>
<text top="576" left="556" width="43" height="17" font="13">Txplt-C </text>
<text top="593" left="556" width="54" height="17" font="13">43% ICM </text>
<text top="576" left="699" width="11" height="17" font="13">T </text>
<text top="576" left="769" width="11" height="17" font="13">+ </text>
<text top="576" left="862" width="24" height="17" font="13">N/A </text>
<text top="576" left="956" width="7" height="17" font="13">+</text>
<text top="577" left="963" width="18" height="11" font="19">8, 21</text>
<text top="576" left="981" width="3" height="17" font="13"> </text>
<text top="576" left="1049" width="7" height="17" font="13">+</text>
<text top="577" left="1056" width="18" height="11" font="19">8, 21</text>
<text top="576" left="1074" width="3" height="17" font="13"> </text>
<text top="576" left="1108" width="162" height="17" font="13">Bleeding RespFail Infxn (NV) </text>
<text top="593" left="1108" width="19" height="17" font="13">VT </text>
<text top="610" left="1108" width="40" height="17" font="13">Sepsis </text>
<text top="627" left="1108" width="44" height="17" font="13">RV Fail </text>
<text top="576" left="1290" width="50" height="17" font="13">Mortality </text>
<text top="593" left="1290" width="135" height="17" font="13">12mo: 27%; 18mo: 28% </text>
<text top="649" left="65" width="59" height="17" font="13">EuroHMII  </text>
<text top="666" left="65" width="55" height="17" font="14">19616963</text>
<text top="666" left="120" width="36" height="17" font="13"> (290) </text>
<text top="649" left="226" width="49" height="17" font="13">Registry </text>
<text top="649" left="316" width="61" height="17" font="13">HMII (411) </text>
<text top="649" left="442" width="33" height="17" font="22"><i>None</i> </text>
<text top="649" left="556" width="74" height="17" font="13">21% Txplt-IE </text>
<text top="666" left="556" width="71" height="17" font="13">73% Txplt-C </text>
<text top="683" left="556" width="54" height="17" font="13">70% ICM </text>
<text top="700" left="556" width="55" height="17" font="13">100% ino </text>
<text top="649" left="699" width="40" height="17" font="13">21% P </text>
<text top="666" left="699" width="39" height="17" font="13">79% T </text>
<text top="649" left="769" width="11" height="17" font="13">+ </text>
<text top="649" left="862" width="24" height="17" font="13">N/A </text>
<text top="649" left="956" width="24" height="17" font="13">N/A </text>
<text top="649" left="1049" width="24" height="17" font="13">N/A </text>
<text top="649" left="1108" width="31" height="17" font="13">MOF </text>
<text top="666" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="683" left="1108" width="44" height="17" font="13">RV Fail </text>
<text top="700" left="1108" width="51" height="17" font="13">Bleeding </text>
<text top="717" left="1108" width="19" height="17" font="13">VT </text>
<text top="735" left="1108" width="37" height="17" font="13">Neuro </text>
<text top="649" left="1290" width="108" height="17" font="13">1 y mortality 28.5% </text>
<text top="756" left="65" width="79" height="17" font="13">INTERMACS  </text>
<text top="773" left="65" width="55" height="17" font="14">21545946</text>
<text top="773" left="120" width="60" height="17" font="13"> (291,292) </text>
<text top="756" left="226" width="44" height="17" font="13">pNRCT </text>
<text top="756" left="316" width="61" height="17" font="13">HMII (169) </text>
<text top="756" left="442" width="101" height="17" font="13">HM XVE (135) Th-</text>
<text top="773" left="442" width="57" height="17" font="13">IVAD (34) </text>
<text top="756" left="556" width="43" height="17" font="13">Txplt-C </text>
<text top="773" left="556" width="66" height="17" font="13">80-89% ino </text>
<text top="756" left="699" width="11" height="17" font="13">T </text>
<text top="756" left="769" width="11" height="17" font="13">+ </text>
<text top="756" left="862" width="24" height="17" font="13">N/A </text>
<text top="756" left="956" width="24" height="17" font="13">N/A </text>
<text top="756" left="1049" width="24" height="17" font="13">N/A </text>
<text top="756" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="773" left="1108" width="51" height="17" font="13">Bleeding </text>
<text top="756" left="1290" width="67" height="17" font="13">1 y Survival </text>
<text top="773" left="1290" width="81" height="17" font="13">85% (HMII) vs </text>
<text top="790" left="1290" width="70" height="17" font="13">70% (comp) </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">137</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="1290" width="165" height="17" font="13">Lower rate of infxns with HMII </text>
<text top="94" left="65" width="52" height="17" font="13">Grady K, </text>
<text top="112" left="65" width="131" height="17" font="22"><i>Ann Thorac Surg</i> 2004  </text>
<text top="129" left="65" width="58" height="17" font="14">15063260 </text>
<text top="129" left="123" width="35" height="17" font="13">(293)  </text>
<text top="94" left="226" width="44" height="17" font="13">pNRCT </text>
<text top="94" left="316" width="76" height="17" font="13">HM XVE (78) </text>
<text top="94" left="442" width="33" height="17" font="22"><i>None </i></text>
<text top="94" left="556" width="43" height="17" font="13">Txplt-C </text>
<text top="94" left="699" width="11" height="17" font="13">T </text>
<text top="94" left="769" width="3" height="17" font="13"> </text>
<text top="94" left="862" width="24" height="17" font="13">N/A </text>
<text top="94" left="956" width="18" height="17" font="13">+/- </text>
<text top="94" left="1049" width="18" height="17" font="13">+/- </text>
<text top="94" left="1108" width="21" height="17" font="13">n/a </text>
<text top="94" left="1290" width="24" height="17" font="13">N/A </text>
<text top="150" left="65" width="63" height="17" font="13">ADVANCE </text>
<text top="150" left="226" width="44" height="17" font="13">pNRCT </text>
<text top="150" left="316" width="98" height="17" font="13">Heart Ware (137) </text>
<text top="150" left="442" width="157" height="17" font="13">INTER MACS (499)  Txplt-C </text>
<text top="167" left="556" width="54" height="17" font="13">41% ICM </text>
<text top="184" left="556" width="48" height="17" font="13">82% ino </text>
<text top="150" left="699" width="11" height="17" font="13">T </text>
<text top="150" left="769" width="11" height="17" font="13">+ </text>
<text top="150" left="862" width="24" height="17" font="13">N/A </text>
<text top="150" left="956" width="11" height="17" font="13">+ </text>
<text top="150" left="1049" width="11" height="17" font="13">+ </text>
<text top="150" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="167" left="1108" width="51" height="17" font="13">Bleeding </text>
<text top="184" left="1108" width="37" height="17" font="13">Neuro </text>
<text top="150" left="1290" width="169" height="17" font="13">HeartWare is NON-INFERIOR </text>
<text top="167" left="1290" width="54" height="17" font="13">to control </text>
<text top="184" left="1290" width="152" height="17" font="13">Lower AE rate for bleeding, </text>
<text top="202" left="1290" width="29" height="17" font="13">infxn </text>
<text top="223" left="65" width="72" height="17" font="13">Elhenawy A, </text>
<text top="240" left="65" width="100" height="17" font="22"><i>J Card Surg</i> 2011 </text>
<text top="257" left="65" width="58" height="17" font="14">21883463 </text>
<text top="257" left="123" width="32" height="17" font="13">(294) </text>
<text top="223" left="226" width="43" height="17" font="13">ObsRS </text>
<text top="223" left="316" width="53" height="17" font="13">BTC (22) </text>
<text top="240" left="316" width="3" height="17" font="13"> </text>
<text top="257" left="316" width="113" height="17" font="13">NovaCor 6, HMXVE </text>
<text top="274" left="316" width="60" height="17" font="13">11, HMII 5 </text>
<text top="223" left="442" width="52" height="17" font="13">BTT (15) </text>
<text top="240" left="442" width="3" height="17" font="13"> </text>
<text top="257" left="442" width="113" height="17" font="13">NovaCor 1, HMXVE </text>
<text top="274" left="442" width="57" height="17" font="13">7, HMII 7, </text>
<text top="223" left="556" width="71" height="17" font="13">41% Txplt-C </text>
<text top="240" left="556" width="74" height="17" font="13">59% Txplt-IE </text>
<text top="257" left="556" width="54" height="17" font="13">27% ICM </text>
<text top="223" left="699" width="11" height="17" font="13">T </text>
<text top="223" left="769" width="11" height="17" font="13">+ </text>
<text top="223" left="862" width="24" height="17" font="13">N/A </text>
<text top="223" left="956" width="24" height="17" font="13">N/A </text>
<text top="223" left="1049" width="24" height="17" font="13">N/A </text>
<text top="223" left="1108" width="74" height="17" font="13">Infxn/ Sepsis </text>
<text top="240" left="1108" width="38" height="17" font="13">RVAD </text>
<text top="257" left="1108" width="31" height="17" font="13">MOF </text>
<text top="223" left="1290" width="163" height="17" font="13">No difference in BTC vs. BTT </text>
<text top="240" left="1290" width="103" height="17" font="13">Post-OHT survival </text>
<text top="257" left="1290" width="105" height="17" font="13">1 y: 67% vs. 100% </text>
<text top="274" left="1290" width="122" height="17" font="13">2 y: 67% vs. 90% and </text>
<text top="292" left="1290" width="98" height="17" font="13">3 y: 64% vs. 87% </text>
<text top="313" left="65" width="43" height="17" font="13">Alba A, </text>
<text top="330" left="65" width="64" height="17" font="22"><i>JHLT</i> 2010 </text>
<text top="347" left="65" width="58" height="17" font="14">20620083 </text>
<text top="347" left="123" width="32" height="17" font="13">(295) </text>
<text top="313" left="226" width="26" height="17" font="13">Obs </text>
<text top="313" left="316" width="94" height="17" font="13">Fixed pHTN (22) </text>
<text top="330" left="316" width="113" height="17" font="13">NovaCor 2, HMXVE </text>
<text top="347" left="316" width="60" height="17" font="13">14, HMII 6 </text>
<text top="313" left="442" width="80" height="17" font="13">No pHTN (32) </text>
<text top="330" left="442" width="113" height="17" font="13">NovaCor 4, HMXVE </text>
<text top="347" left="442" width="60" height="17" font="13">19, HMII 9 </text>
<text top="313" left="556" width="43" height="17" font="13">Txplt-C </text>
<text top="330" left="556" width="54" height="17" font="13">22% ICM </text>
<text top="313" left="699" width="11" height="17" font="13">T </text>
<text top="313" left="769" width="18" height="17" font="13">+/- </text>
<text top="330" left="769" width="3" height="17" font="13"> </text>
<text top="313" left="862" width="24" height="17" font="13">N/A </text>
<text top="313" left="956" width="24" height="17" font="13">N/A </text>
<text top="313" left="1049" width="24" height="17" font="13">N/A </text>
<text top="313" left="1108" width="21" height="17" font="13">n/a </text>
<text top="313" left="1290" width="127" height="17" font="13">Comparable post-OHT </text>
<text top="330" left="1290" width="144" height="17" font="13">survival 1 y: 93% vs. 96% </text>
<text top="347" left="1290" width="98" height="17" font="13">5 y: 77% vs. 86% </text>
<text top="364" left="1290" width="156" height="17" font="13">Higher peri-OHT mortality in </text>
<text top="382" left="1290" width="137" height="17" font="13">fixed pHTN: 18% vs. 0% </text>
<text top="403" left="65" width="41" height="17" font="13">Nair P, </text>
<text top="420" left="65" width="64" height="17" font="22"><i>JHLT</i> 2010 </text>
<text top="437" left="65" width="58" height="17" font="14">20113910 </text>
<text top="437" left="123" width="32" height="17" font="13">(296) </text>
<text top="403" left="226" width="26" height="17" font="13">Obs </text>
<text top="403" left="316" width="61" height="17" font="13">pHTN (14) </text>
<text top="420" left="316" width="3" height="17" font="13"> </text>
<text top="437" left="316" width="113" height="17" font="13">NovaCor, Th-LVAD, </text>
<text top="454" left="316" width="105" height="17" font="13">Th-IVAD, HM XVE </text>
<text top="403" left="442" width="80" height="17" font="13">No pHTN (44) </text>
<text top="420" left="442" width="113" height="17" font="13">NovaCor, Th-LVAD, </text>
<text top="437" left="442" width="105" height="17" font="13">Th-IVAD, HM XVE </text>
<text top="403" left="556" width="43" height="17" font="13">Txplt-C </text>
<text top="420" left="556" width="55" height="17" font="13">100% ino </text>
<text top="437" left="556" width="54" height="17" font="13">40% ICM </text>
<text top="403" left="699" width="11" height="17" font="13">T </text>
<text top="403" left="769" width="11" height="17" font="13">+ </text>
<text top="420" left="769" width="3" height="17" font="13"> </text>
<text top="403" left="862" width="11" height="17" font="13">+ </text>
<text top="420" left="862" width="3" height="17" font="13"> </text>
<text top="403" left="956" width="24" height="17" font="13">N/A </text>
<text top="403" left="1049" width="24" height="17" font="13">N/A </text>
<text top="403" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="403" left="1290" width="150" height="17" font="13">Comparable post-VAD and </text>
<text top="420" left="1290" width="102" height="17" font="13">post-OHT survival </text>
<text top="437" left="1290" width="125" height="17" font="13">Early ↓TPG with VAD, </text>
<text top="454" left="1290" width="127" height="17" font="13">sustained ↓mPAP with </text>
<text top="472" left="1290" width="78" height="17" font="13">ongoing MCS </text>
<text top="493" left="65" width="81" height="17" font="13">MOMENTUM  </text>
<text top="510" left="65" width="58" height="17" font="14">18765394 </text>
<text top="510" left="123" width="32" height="17" font="13">(297) </text>
<text top="493" left="226" width="29" height="17" font="13">RCT </text>
<text top="493" left="316" width="185" height="17" font="13">Orqis Cancion (109)  OMM (59) </text>
<text top="493" left="556" width="37" height="17" font="13">ADHF </text>
<text top="510" left="556" width="132" height="17" font="13">100% ino or vasodilator </text>
<text top="527" left="556" width="54" height="17" font="13">47% ICM </text>
<text top="493" left="699" width="11" height="17" font="13">T </text>
<text top="493" left="769" width="24" height="17" font="13">N.S </text>
<text top="493" left="862" width="21" height="17" font="13">NS </text>
<text top="493" left="956" width="24" height="17" font="13">N/A </text>
<text top="493" left="1049" width="21" height="17" font="13">NS </text>
<text top="493" left="1108" width="51" height="17" font="13">Bleeding </text>
<text top="510" left="1108" width="30" height="17" font="13">Infxn </text>
<text top="493" left="1290" width="156" height="17" font="13">65d mortality 33.9% (pVAD) </text>
<text top="510" left="1290" width="99" height="17" font="13">vs. 32.2% (OMM) </text>
<text top="548" left="65" width="66" height="17" font="13">Seyfarth M, </text>
<text top="566" left="65" width="66" height="17" font="22"><i>JACC</i> 2008 </text>
<text top="583" left="65" width="58" height="17" font="14">19007597 </text>
<text top="583" left="123" width="32" height="17" font="13">(263) </text>
<text top="548" left="226" width="29" height="17" font="13">RCT </text>
<text top="548" left="316" width="68" height="17" font="13">Impella (12) </text>
<text top="548" left="442" width="57" height="17" font="13">IABP (13) </text>
<text top="548" left="556" width="66" height="17" font="13">Post-MI CS </text>
<text top="548" left="699" width="11" height="17" font="13">T </text>
<text top="548" left="769" width="24" height="17" font="13">N/A </text>
<text top="548" left="862" width="11" height="17" font="13">+ </text>
<text top="548" left="956" width="24" height="17" font="13">N/A </text>
<text top="548" left="1049" width="24" height="17" font="13">N/A </text>
<text top="548" left="1108" width="21" height="17" font="13">n/a </text>
<text top="548" left="1290" width="135" height="17" font="13">No difference in MOF or </text>
<text top="566" left="1290" width="38" height="17" font="13">sepsis </text>
<text top="604" left="65" width="126" height="17" font="13">Burkhoff D, <i>AHJ</i> 2006  </text>
<text top="621" left="65" width="58" height="17" font="14">16923414 </text>
<text top="621" left="123" width="32" height="17" font="13">(264) </text>
<text top="604" left="226" width="29" height="17" font="13">RCT </text>
<text top="604" left="316" width="104" height="17" font="13">TandemHeart (19) </text>
<text top="604" left="442" width="57" height="17" font="13">IABP (14) </text>
<text top="604" left="556" width="21" height="17" font="13">CS </text>
<text top="604" left="699" width="11" height="17" font="13">T </text>
<text top="604" left="769" width="24" height="17" font="13">N/A </text>
<text top="604" left="862" width="11" height="17" font="13">+ </text>
<text top="604" left="956" width="24" height="17" font="13">N/A </text>
<text top="604" left="1049" width="24" height="17" font="13">N/A </text>
<text top="604" left="1108" width="63" height="17" font="13">Arrhythmia </text>
<text top="621" left="1108" width="51" height="17" font="13">Bleeding </text>
<text top="639" left="1108" width="37" height="17" font="13">Neuro </text>
<text top="656" left="1108" width="29" height="17" font="13">(NS) </text>
<text top="604" left="1290" width="154" height="17" font="13">Not powered to fully assess </text>
<text top="621" left="1290" width="134" height="17" font="13">hemodynamic effects or </text>
<text top="639" left="1290" width="97" height="17" font="13">clinical outcomes </text>
<text top="677" left="65" width="53" height="17" font="13">Thiele H, </text>
<text top="694" left="65" width="57" height="17" font="22"><i>EHJ </i>2005 </text>
<text top="711" left="65" width="58" height="17" font="14">15734771 </text>
<text top="711" left="123" width="32" height="17" font="13">(298) </text>
<text top="677" left="226" width="29" height="17" font="13">RCT </text>
<text top="677" left="316" width="107" height="17" font="13">Tandem Heart (21) </text>
<text top="677" left="442" width="57" height="17" font="13">IABP (20) </text>
<text top="677" left="556" width="66" height="17" font="13">Post-MI CS </text>
<text top="677" left="699" width="11" height="17" font="13">T </text>
<text top="677" left="769" width="21" height="17" font="13">NS </text>
<text top="677" left="862" width="11" height="17" font="13">+ </text>
<text top="677" left="956" width="24" height="17" font="13">N/A </text>
<text top="677" left="1049" width="24" height="17" font="13">N/A </text>
<text top="677" left="1108" width="70" height="17" font="13">Infxn/Sepsis </text>
<text top="694" left="1108" width="61" height="17" font="13">DIC (VAD) </text>
<text top="677" left="1290" width="124" height="17" font="13">Not powered to detect </text>
<text top="694" left="1290" width="90" height="17" font="13">mortality benefit </text>
<text top="729" left="54" width="1380" height="15" font="6">+ indicates survival benefit; ADHF, hospitalized for acute decompensated heart failure; AE, adverse event; BTC, bridge to candidacy; BTT, bridge to transplantation; DOS, duration of support; Expt, Experimental group; HMII, HeartMate II; HIMI-BTT, HeartMate II bridge to transplant; </text>
<text top="745" left="54" width="1402" height="15" font="6">HIMI-DT, HeartMate II destination therapy; HM XVE, HeartMate XVE; IABP, intra-aortic balloon pump; ICM, ischemic cardiomyopathy; ino, inotrope-dependent at time of randomization/implantation; Infx, infection; Infxn (NV), non-VAD related infection; INTERMACS, Interagency Registry </text>
<text top="760" left="54" width="1355" height="15" font="6">for Mechanically Assisted Circulatory Support; INTREPID, Investigation of Nontransplant-Eligible Patients Who Are Inotrope Dependent; MCS, mechanical circulatory support; MOF, multi-organ failure; MOMENTUM, Multicenter Trial of the Orqis Medical Cancion System for the </text>
<text top="776" left="54" width="1384" height="15" font="6">Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy; mPAP, mean pulmonary artery pressure; N/A, not applicable; Neuro, neurological complication (e.g. stroke); NS, no significant difference; Obs, Observational study; OHT, orthotopic heart transplantation; OMM, </text>
<text top="791" left="54" width="1381" height="15" font="6">optimal medical management; P, permanent; pNRCT, prospective non-randomized clinical trial; post-MI CS, post-myocardial infarction cardiogenic shock; PumpRplt, pump replacement; RCT, randomized clinical trial; Rehosp, rehospitalization; REMATCH, Randomized Evaluation of </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">138</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="1406" height="15" font="6">Mechanical Assistance in Treatment of Chronic Heart Failure; RenalFail, renal failure; RespFail, respiratory failure; RV Fail, right ventricular failure requiring inotropic support; RVAD, need for right ventricular assist device; RR, relative risk; SVT, supraventricular tachycardia; T, temporary; </text>
<text top="69" left="54" width="1039" height="15" font="6">Th-IVAD, Thoratec implantable ventricular assist device; Th-LVAD, extracorporeal VAD; TPG, transpulmonary gradient; Txplt-C, transplant candidate; Txplt-IE, transplant ineligible; and VT, ventricular tachycardia. </text>
<text top="85" left="54" width="4" height="19" font="7"> </text>
<text top="122" left="54" width="306" height="21" font="8"><b>Data Supplement 35. LVADs (Section 7.4.5) </b></text>
<text top="185" left="61" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="202" left="62" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="202" left="170" width="79" height="17" font="15"><b>Aim of Study </b></text>
<text top="185" left="278" width="38" height="17" font="15"><b>Study </b></text>
<text top="202" left="281" width="32" height="17" font="15"><b>Type </b></text>
<text top="185" left="349" width="38" height="17" font="15"><b>Study </b></text>
<text top="202" left="354" width="28" height="17" font="15"><b>Size </b></text>
<text top="202" left="516" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="202" left="800" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="202" left="953" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="168" left="1065" width="29" height="17" font="15"><b>Trial </b></text>
<text top="185" left="1053" width="54" height="17" font="15"><b>Duration </b></text>
<text top="202" left="1057" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="185" left="1139" width="117" height="17" font="15"><b>Absolute Benefit or </b></text>
<text top="202" left="1133" width="129" height="17" font="15"><b>Major Study Findings </b></text>
<text top="185" left="1319" width="92" height="17" font="15"><b>Complications/ </b></text>
<text top="202" left="1317" width="96" height="17" font="15"><b>Adverse Events </b></text>
<text top="224" left="346" width="44" height="15" font="16"><i><b>N (Total </b></i></text>
<text top="240" left="337" width="63" height="15" font="16"><i><b>Study Size) </b></i></text>
<text top="240" left="439" width="94" height="15" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="240" left="603" width="97" height="15" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="224" left="762" width="44" height="15" font="16"><i><b>Primary </b></i></text>
<text top="240" left="759" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="224" left="849" width="63" height="15" font="16"><i><b>Secondary  </b></i></text>
<text top="240" left="853" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="240" left="933" width="95" height="15" font="16"><i><b>1st Year Mortality </b></i></text>
<text top="256" left="54" width="208" height="17" font="15"><b>SELECTION OF VAD CANDIDATES </b></text>
<text top="256" left="1277" width="7" height="17" font="13">  </text>
<text top="277" left="54" width="43" height="17" font="13">Clinical </text>
<text top="294" left="54" width="75" height="17" font="13">outcomes for </text>
<text top="311" left="54" width="89" height="17" font="13">continuous-flow </text>
<text top="329" left="54" width="55" height="17" font="13">LVAD pts </text>
<text top="346" left="54" width="88" height="17" font="13">stratified by pre-</text>
<text top="363" left="54" width="54" height="17" font="13">operative </text>
<text top="380" left="54" width="76" height="17" font="13">INTERMACS </text>
<text top="398" left="54" width="76" height="17" font="13">classification, </text>
<text top="415" left="54" width="88" height="17" font="13">Boyle AJ, JHLT </text>
<text top="432" left="54" width="31" height="17" font="13">2011 </text>
<text top="449" left="54" width="58" height="17" font="14">21168346 </text>
<text top="449" left="112" width="32" height="17" font="13">(299) </text>
<text top="277" left="160" width="69" height="17" font="13">To compare </text>
<text top="294" left="160" width="70" height="17" font="13">post-implant </text>
<text top="311" left="160" width="96" height="17" font="13">outcomes across </text>
<text top="329" left="160" width="48" height="17" font="13">different </text>
<text top="346" left="160" width="76" height="17" font="13">INTERMACS </text>
<text top="363" left="160" width="73" height="17" font="13">classification </text>
<text top="380" left="160" width="38" height="17" font="13">levels. </text>
<text top="277" left="271" width="33" height="17" font="13">Case-</text>
<text top="294" left="271" width="46" height="17" font="13">controlle</text>
<text top="311" left="271" width="10" height="17" font="13">d </text>
<text top="277" left="336" width="24" height="17" font="13">101 </text>
<text top="277" left="413" width="120" height="17" font="13">Pts implanted with an </text>
<text top="294" left="413" width="135" height="17" font="13">LVAD prior to 8/27/07 at </text>
<text top="311" left="413" width="135" height="17" font="13">University of Minnesota, </text>
<text top="329" left="413" width="133" height="17" font="13">University of Pittsburgh, </text>
<text top="346" left="413" width="137" height="17" font="13">and Columbia University </text>
<text top="363" left="413" width="142" height="17" font="13">with either a VentraAssist </text>
<text top="380" left="413" width="121" height="17" font="13">or HM II, classified by </text>
<text top="398" left="413" width="145" height="17" font="13">INTERMACS level at time </text>
<text top="415" left="413" width="108" height="17" font="13">of implant (Goup 1: </text>
<text top="432" left="413" width="126" height="17" font="13">INTERMACS profile 1; </text>
<text top="449" left="413" width="127" height="17" font="13">Group 2: INTERMACS </text>
<text top="466" left="413" width="119" height="17" font="13">profiles 2-3; Group 3: </text>
<text top="484" left="413" width="144" height="17" font="13">INTERMACS profiles 4-7) </text>
<text top="277" left="572" width="27" height="17" font="13"> N/A </text>
<text top="277" left="744" width="61" height="17" font="13">Survival to </text>
<text top="294" left="744" width="60" height="17" font="13">discharge, </text>
<text top="311" left="744" width="56" height="17" font="13">LOS after </text>
<text top="329" left="744" width="29" height="17" font="13">VAD </text>
<text top="346" left="744" width="73" height="17" font="13">implantation, </text>
<text top="363" left="744" width="50" height="17" font="13">actuarial </text>
<text top="380" left="744" width="77" height="17" font="13">survival while </text>
<text top="398" left="744" width="48" height="17" font="13">on MCS </text>
<text top="277" left="838" width="27" height="17" font="13"> N/A </text>
<text top="277" left="932" width="27" height="17" font="13"> N/A </text>
<text top="277" left="1042" width="27" height="17" font="13">~2 y </text>
<text top="277" left="1130" width="141" height="17" font="13">Actuarial survival              </text>
<text top="294" left="1130" width="141" height="17" font="13">Group 3:  95.8%,              </text>
<text top="311" left="1130" width="96" height="17" font="13">Group 2:  68.8%, </text>
<text top="329" left="1130" width="115" height="17" font="13">p=0.065 vs Group 3  </text>
<text top="346" left="1130" width="96" height="17" font="13">Group 1:  51.1%, </text>
<text top="363" left="1130" width="139" height="17" font="13">p=0.011 vs Group 3         </text>
<text top="380" left="1130" width="140" height="17" font="13">survival to discharge        </text>
<text top="398" left="1130" width="93" height="17" font="13">Group 3: 95.8%, </text>
<text top="415" left="1130" width="139" height="17" font="13">p=0.02 vs Group 1           </text>
<text top="432" left="1130" width="93" height="17" font="13">Group 2: 93.8%, </text>
<text top="449" left="1130" width="139" height="17" font="13">p=0.009 vs Group 1         </text>
<text top="466" left="1130" width="93" height="17" font="13">Group 1: 70.4%  </text>
<text top="484" left="1130" width="7" height="17" font="13">  </text>
<text top="277" left="1277" width="27" height="17" font="13"> N/A </text>
<text top="507" left="54" width="73" height="17" font="15"><b>VAD AS DT</b> <b> </b></text>
<text top="530" left="54" width="72" height="17" font="13">Randomized </text>
<text top="547" left="54" width="74" height="17" font="13">Evaluation of </text>
<text top="564" left="54" width="66" height="17" font="13">Mechanical </text>
<text top="581" left="54" width="81" height="17" font="13">Assistance for </text>
<text top="599" left="54" width="80" height="17" font="13">the Treatment </text>
<text top="616" left="54" width="42" height="17" font="13">of CHF </text>
<text top="633" left="54" width="68" height="17" font="13">REMATCH, </text>
<text top="650" left="54" width="78" height="17" font="13">Rose E, 2001 </text>
<text top="668" left="54" width="58" height="17" font="14">11794191 </text>
<text top="668" left="112" width="32" height="17" font="13">(285) </text>
<text top="530" left="160" width="88" height="17" font="13">To evaluate the </text>
<text top="547" left="160" width="68" height="17" font="13">suitability of </text>
<text top="564" left="160" width="66" height="17" font="13">implantable </text>
<text top="581" left="160" width="81" height="17" font="13">LVAD for their </text>
<text top="599" left="160" width="97" height="17" font="13">ultimate intended </text>
<text top="616" left="160" width="81" height="17" font="13">use as a long- </text>
<text top="633" left="160" width="92" height="17" font="13">term myocardial-</text>
<text top="650" left="160" width="71" height="17" font="13">replacement </text>
<text top="668" left="160" width="82" height="17" font="13">therapy for pts </text>
<text top="685" left="160" width="98" height="17" font="13">who are ineligible </text>
<text top="702" left="160" width="61" height="17" font="13">for cardiac </text>
<text top="719" left="160" width="84" height="17" font="13">transplantation </text>
<text top="530" left="271" width="29" height="17" font="13">RCT </text>
<text top="530" left="336" width="24" height="17" font="13">129 </text>
<text top="530" left="413" width="131" height="17" font="13">Adults with chronic end-</text>
<text top="547" left="413" width="53" height="17" font="13">stage HF </text>
<text top="564" left="413" width="133" height="17" font="13">and contraindications to </text>
<text top="581" left="413" width="144" height="17" font="13">transplantation.  NYHA IV </text>
<text top="599" left="413" width="103" height="17" font="13">HF for &gt;60 of 90 d </text>
<text top="616" left="413" width="146" height="17" font="13">despite attempted therapy </text>
<text top="633" left="413" width="137" height="17" font="13">with ACEI, diuretics, and </text>
<text top="650" left="413" width="152" height="17" font="13">digoxin;                                </text>
<text top="668" left="413" width="73" height="17" font="13">LVEF &lt; 25% </text>
<text top="685" left="413" width="84" height="17" font="13">Peak VO2 &lt;12-</text>
<text top="702" left="413" width="94" height="17" font="13">14ml/kg/min or a </text>
<text top="719" left="413" width="120" height="17" font="13">continued need for IV </text>
<text top="736" left="413" width="144" height="17" font="13">inotropic therapy owing to </text>
<text top="754" left="413" width="146" height="17" font="13">symptomatic hypotension, </text>
<text top="771" left="413" width="144" height="17" font="13">decreasing renal function, </text>
<text top="788" left="413" width="135" height="17" font="13">or worsening pulmonary </text>
<text top="530" left="572" width="147" height="17" font="13">HF due to thyroid disease, </text>
<text top="547" left="572" width="63" height="17" font="13">obstructive </text>
<text top="564" left="572" width="150" height="17" font="13">cardiomyopathy,pericardial </text>
<text top="581" left="572" width="135" height="17" font="13">disease, amyloidosis, or </text>
<text top="599" left="572" width="101" height="17" font="13">active myocarditis </text>
<text top="616" left="572" width="135" height="17" font="13">Technical obstacles that </text>
<text top="633" left="572" width="140" height="17" font="13">pose an inordinately high </text>
<text top="650" left="572" width="72" height="17" font="13">surgical risk  </text>
<text top="668" left="572" width="136" height="17" font="13">INR &gt;1.3 or PT &gt;15 sec  </text>
<text top="685" left="572" width="66" height="17" font="13">BSA &lt;1.5 m</text>
<text top="686" left="638" width="4" height="11" font="19">2</text>
<text top="685" left="642" width="3" height="17" font="13"> </text>
<text top="702" left="572" width="76" height="17" font="13">BMI &gt;40 kg/m</text>
<text top="703" left="648" width="4" height="11" font="19">2</text>
<text top="702" left="652" width="3" height="17" font="13"> </text>
<text top="719" left="572" width="137" height="17" font="13">Severe COPD (FEV&lt;1.5 </text>
<text top="736" left="572" width="38" height="17" font="13">L/min) </text>
<text top="754" left="572" width="145" height="17" font="13">Positive serum pregnancy </text>
<text top="771" left="572" width="23" height="17" font="13">test </text>
<text top="788" left="572" width="140" height="17" font="13">Fixed pHTN with PVR&gt; 8 </text>
<text top="530" left="744" width="69" height="17" font="13">The primary </text>
<text top="547" left="744" width="79" height="17" font="13">end point was </text>
<text top="564" left="744" width="62" height="17" font="13">death from </text>
<text top="581" left="744" width="59" height="17" font="13">any cause </text>
<text top="599" left="744" width="49" height="17" font="13">and was </text>
<text top="616" left="744" width="58" height="17" font="13">compared </text>
<text top="633" left="744" width="50" height="17" font="13">between </text>
<text top="650" left="744" width="66" height="17" font="13">groups with </text>
<text top="668" left="744" width="78" height="17" font="13">the use of the </text>
<text top="685" left="744" width="48" height="17" font="13">log-rank </text>
<text top="702" left="744" width="48" height="17" font="13">statistic. </text>
<text top="530" left="838" width="62" height="17" font="13">Secondary </text>
<text top="547" left="838" width="57" height="17" font="13">endpoints </text>
<text top="564" left="838" width="70" height="17" font="13">included the </text>
<text top="581" left="838" width="69" height="17" font="13">incidence of </text>
<text top="599" left="838" width="79" height="17" font="13">SAEs, the no. </text>
<text top="616" left="838" width="38" height="17" font="13">of d of </text>
<text top="633" left="838" width="71" height="17" font="13">hospitalizatio</text>
<text top="650" left="838" width="68" height="17" font="13">n, the QoL,  </text>
<text top="668" left="838" width="73" height="17" font="13">symptoms of </text>
<text top="685" left="838" width="67" height="17" font="13">depression, </text>
<text top="702" left="838" width="80" height="17" font="13">and functional </text>
<text top="719" left="838" width="40" height="17" font="13">status. </text>
<text top="530" left="932" width="104" height="17" font="13">1 y Mortality:          </text>
<text top="547" left="932" width="105" height="17" font="13">LVAD 48%             </text>
<text top="564" left="932" width="103" height="17" font="13">OMM 75%             </text>
<text top="581" left="932" width="103" height="17" font="13">p=0.002                 </text>
<text top="599" left="932" width="105" height="17" font="13">2yr Mortality:          </text>
<text top="616" left="932" width="105" height="17" font="13">LVAD 77%             </text>
<text top="633" left="932" width="103" height="17" font="13">OMM  92%            </text>
<text top="650" left="932" width="41" height="17" font="13">p=0.09 </text>
<text top="530" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="547" left="1042" width="55" height="17" font="13">5/98-7/01 </text>
<text top="564" left="1042" width="49" height="17" font="13">(39mo);  </text>
<text top="530" left="1130" width="117" height="17" font="13">Reduction of 48 % in </text>
<text top="547" left="1130" width="57" height="17" font="13">the risk of </text>
<text top="564" left="1130" width="122" height="17" font="13">death from any cause </text>
<text top="581" left="1130" width="131" height="17" font="13">— the primary endpoint </text>
<text top="599" left="1130" width="119" height="17" font="13">— in LVAD group, as </text>
<text top="616" left="1130" width="130" height="17" font="13">compared with medical-</text>
<text top="633" left="1130" width="142" height="17" font="13">therapy group (OMM)       </text>
<text top="650" left="1130" width="129" height="17" font="13">QoL suggested greater </text>
<text top="668" left="1130" width="123" height="17" font="13">improvement in LVAD </text>
<text top="685" left="1130" width="116" height="17" font="13">group, though not all </text>
<text top="702" left="1130" width="105" height="17" font="13">measures reached </text>
<text top="719" left="1130" width="125" height="17" font="13">statistical significance. </text>
<text top="736" left="1130" width="103" height="17" font="13">(RR 0.52; 95% CI: </text>
<text top="754" left="1130" width="138" height="17" font="13">0.34-0.78; p=0.001)         </text>
<text top="530" left="1277" width="182" height="17" font="13">Sepsis (Rate Ratio 2.03)              </text>
<text top="547" left="1277" width="170" height="17" font="13">Non-neurologic bleeding (Rate </text>
<text top="564" left="1277" width="132" height="17" font="13">Ratio 9.47)                     </text>
<text top="581" left="1277" width="161" height="17" font="13">Neurologic dysfunction (Rate </text>
<text top="599" left="1277" width="166" height="17" font="13">Ratio 4.35)                       SVT </text>
<text top="616" left="1277" width="148" height="17" font="13">(Rate Ratio 3.92)                </text>
<text top="633" left="1277" width="141" height="17" font="13">Suspected malfunction of </text>
<text top="650" left="1277" width="120" height="17" font="13">LVAD (0.75 rate/pt-y) </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">139</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="413" width="66" height="17" font="13">congestion. </text>
<text top="72" left="413" width="123" height="17" font="13">NYHA III-IV for &gt; 28 d </text>
<text top="89" left="413" width="137" height="17" font="13">and who had received at </text>
<text top="106" left="413" width="140" height="17" font="13">least 14 d of support with </text>
<text top="124" left="413" width="81" height="17" font="13">IABP or with a </text>
<text top="141" left="413" width="103" height="17" font="13">dependence on IV </text>
<text top="158" left="413" width="129" height="17" font="13">inotropic agents, with 2 </text>
<text top="175" left="413" width="82" height="17" font="13">failed weaning </text>
<text top="192" left="413" width="54" height="17" font="13">attempts. </text>
<text top="55" left="572" width="65" height="17" font="13">Wood units </text>
<text top="72" left="572" width="119" height="17" font="13">Candidate for CABG, </text>
<text top="89" left="572" width="103" height="17" font="13">valvular repair, LV </text>
<text top="106" left="572" width="72" height="17" font="13">reduction, or </text>
<text top="124" left="572" width="92" height="17" font="13">cardiomyoplasty </text>
<text top="141" left="572" width="75" height="17" font="13">Hx of cardiac </text>
<text top="158" left="572" width="106" height="17" font="13">transplantation, LV </text>
<text top="175" left="572" width="68" height="17" font="13">reduction or </text>
<text top="192" left="572" width="92" height="17" font="13">cardiomyoplasty </text>
<text top="210" left="572" width="150" height="17" font="13">Mechanical AV that will not </text>
<text top="227" left="572" width="88" height="17" font="13">be converted to </text>
<text top="244" left="572" width="79" height="17" font="13">bioprosthesis  </text>
<text top="261" left="572" width="156" height="17" font="13">AST, ALT, TBili &gt; 5x normal </text>
<text top="278" left="572" width="121" height="17" font="13">or biopsy-proved liver </text>
<text top="296" left="572" width="49" height="17" font="13">cirrhosis </text>
<text top="313" left="572" width="103" height="17" font="13">Stroke w/in 90d or </text>
<text top="330" left="572" width="143" height="17" font="13">cerebrovascular dz with &gt; </text>
<text top="347" left="572" width="147" height="17" font="13">80% extracranial stenosis  </text>
<text top="365" left="572" width="153" height="17" font="13">Impaired cognitive function, </text>
<text top="382" left="572" width="154" height="17" font="13">Alzheimer’s disease and/or  </text>
<text top="399" left="572" width="156" height="17" font="13">other irreversible dementia,  </text>
<text top="416" left="572" width="126" height="17" font="13"> Untreated AAA &gt;5 cm </text>
<text top="433" left="572" width="111" height="17" font="13">Suspected or active </text>
<text top="451" left="572" width="104" height="17" font="13">systemic infection  </text>
<text top="468" left="572" width="119" height="17" font="13">Platelet count &lt;50x10</text>
<text top="469" left="690" width="4" height="11" font="19">3</text>
<text top="468" left="695" width="24" height="17" font="13">/mm</text>
<text top="469" left="719" width="4" height="11" font="19">3</text>
<text top="468" left="723" width="7" height="17" font="13">  </text>
<text top="485" left="572" width="148" height="17" font="13">SCr &gt;3.5 mg/dL or dialysis </text>
<text top="502" left="572" width="154" height="17" font="13">Peripheral vascular disease </text>
<text top="519" left="572" width="152" height="17" font="13">with rest claudication or leg </text>
<text top="537" left="572" width="57" height="17" font="13">ulceration </text>
<text top="554" left="572" width="154" height="17" font="13">CCB (except amlodipine) or </text>
<text top="571" left="572" width="88" height="17" font="13">type I or type III </text>
<text top="588" left="572" width="122" height="17" font="13">antiarrhythmic agent.  </text>
<text top="606" left="572" width="116" height="17" font="13">Abdominal operation </text>
<text top="623" left="572" width="47" height="17" font="13">planned </text>
<text top="640" left="572" width="109" height="17" font="13">Psychiatric disease </text>
<text top="657" left="572" width="102" height="17" font="13">/Substance abuse </text>
<text top="674" left="572" width="129" height="17" font="13">Participating in another </text>
<text top="692" left="572" width="73" height="17" font="13">clinical study </text>
<text top="709" left="572" width="157" height="17" font="13">Other condition with survival </text>
<text top="726" left="572" width="30" height="17" font="13">&lt; 3 y </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">140</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="52" height="17" font="13">LVAD as </text>
<text top="72" left="54" width="83" height="17" font="13">Destination for </text>
<text top="89" left="54" width="85" height="17" font="13">pts undergoing </text>
<text top="106" left="54" width="67" height="17" font="13">intravenous </text>
<text top="124" left="54" width="50" height="17" font="13">inotropic </text>
<text top="141" left="54" width="58" height="17" font="13">therapy: a </text>
<text top="158" left="54" width="87" height="17" font="13">subset analysis </text>
<text top="175" left="54" width="28" height="17" font="13">from </text>
<text top="192" left="54" width="68" height="17" font="13">REMATCH, </text>
<text top="210" left="54" width="87" height="17" font="13">Stevenson LW, </text>
<text top="227" left="54" width="31" height="17" font="13">2004 </text>
<text top="244" left="54" width="58" height="17" font="14">15313942 </text>
<text top="244" left="112" width="32" height="17" font="13">(284) </text>
<text top="55" left="160" width="64" height="17" font="13">To analyze </text>
<text top="72" left="160" width="89" height="17" font="13">outcomes in pts </text>
<text top="89" left="160" width="65" height="17" font="13">undergoing </text>
<text top="106" left="160" width="50" height="17" font="13">inotropic </text>
<text top="124" left="160" width="66" height="17" font="13">infusions at </text>
<text top="141" left="160" width="98" height="17" font="13">randomization for </text>
<text top="158" left="160" width="98" height="17" font="13">LVAD destination </text>
<text top="175" left="160" width="44" height="17" font="13">therapy </text>
<text top="55" left="271" width="29" height="17" font="13">Post-</text>
<text top="72" left="271" width="23" height="17" font="13">hoc </text>
<text top="89" left="271" width="48" height="17" font="13">analysis </text>
<text top="55" left="336" width="38" height="17" font="13">91 (on </text>
<text top="72" left="336" width="62" height="17" font="13">inotrope at </text>
<text top="89" left="336" width="61" height="17" font="13">randomizat</text>
<text top="106" left="336" width="24" height="17" font="13">ion) </text>
<text top="55" left="413" width="69" height="17" font="13">LVEF &lt;25% </text>
<text top="72" left="413" width="130" height="17" font="13">NYHA IV symptoms for </text>
<text top="89" left="413" width="101" height="17" font="13">60 of 90 d despite </text>
<text top="106" left="413" width="128" height="17" font="13">attempted therapy with </text>
<text top="124" left="413" width="112" height="17" font="13">ACEI, diuretics, and </text>
<text top="141" left="413" width="142" height="17" font="13">digoxin.                    Peak </text>
<text top="158" left="413" width="134" height="17" font="13">VO2 &lt;12-14 mL/kg/min  </text>
<text top="175" left="413" width="92" height="17" font="13">with evidence of </text>
<text top="192" left="413" width="151" height="17" font="13">anaerobic metabolism,        </text>
<text top="210" left="413" width="105" height="17" font="13">Dependence on IV </text>
<text top="227" left="413" width="90" height="17" font="13">inotropic agents </text>
<text top="244" left="413" width="137" height="17" font="13">supported by completion </text>
<text top="261" left="413" width="73" height="17" font="13">of a weaning </text>
<text top="278" left="413" width="72" height="17" font="13">failure form.  </text>
<text top="55" left="572" width="164" height="17" font="13">Advanced age,                        </text>
<text top="72" left="572" width="137" height="17" font="13">Diabetes with end-organ </text>
<text top="89" left="572" width="164" height="17" font="13">damage,                                  </text>
<text top="106" left="572" width="142" height="17" font="13">SCr &gt;2.5 mg/dL for &gt;90 d </text>
<text top="55" left="744" width="54" height="17" font="13">All-cause </text>
<text top="72" left="744" width="50" height="17" font="13">mortality </text>
<text top="89" left="744" width="58" height="17" font="13">during the </text>
<text top="106" left="744" width="34" height="17" font="13">180 d </text>
<text top="124" left="744" width="51" height="17" font="13">following </text>
<text top="141" left="744" width="77" height="17" font="13">randomization</text>
<text top="158" left="744" width="10" height="17" font="13">.  </text>
<text top="55" left="838" width="60" height="17" font="13">QoL at 1 y </text>
<text top="55" left="932" width="73" height="17" font="13">1 y Mortality: </text>
<text top="72" left="932" width="105" height="17" font="13">LVAD 51%             </text>
<text top="89" left="932" width="103" height="17" font="13">OMM 76%             </text>
<text top="106" left="932" width="103" height="17" font="13">p=0.0014               </text>
<text top="124" left="932" width="105" height="17" font="13">2yr Mortality:          </text>
<text top="141" left="932" width="105" height="17" font="13">LVAD 72%             </text>
<text top="158" left="932" width="103" height="17" font="13">OMM  89%            </text>
<text top="55" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="72" left="1042" width="62" height="17" font="13">5/98-7/01;  </text>
<text top="55" left="1130" width="98" height="17" font="13">In pts undergoing </text>
<text top="72" left="1130" width="108" height="17" font="13">inotropic therapy at </text>
<text top="89" left="1130" width="104" height="17" font="13">randomization, 1 y </text>
<text top="106" left="1130" width="131" height="17" font="13">survival with LVAD was </text>
<text top="124" left="1130" width="123" height="17" font="13">49% vs 24% for OMM </text>
<text top="141" left="1130" width="122" height="17" font="13">and by 2 y, 28% were </text>
<text top="158" left="1130" width="124" height="17" font="13">alive with LVAD group </text>
<text top="175" left="1130" width="124" height="17" font="13">compared with 11% in </text>
<text top="192" left="1130" width="68" height="17" font="13">OMM group </text>
<text top="210" left="1130" width="67" height="17" font="13">(p=0.0014). </text>
<text top="227" left="1130" width="7" height="17" font="13">  </text>
<text top="55" left="1277" width="24" height="17" font="13">N/A </text>
<text top="296" left="54" width="86" height="17" font="13">Investigation of </text>
<text top="314" left="54" width="81" height="17" font="13">Nontransplant-</text>
<text top="331" left="54" width="93" height="17" font="13">Eligible Pts Who </text>
<text top="348" left="54" width="71" height="17" font="13">Are Inotrope </text>
<text top="365" left="54" width="64" height="17" font="13">Dependent </text>
<text top="382" left="54" width="60" height="17" font="13">(INTrEPID </text>
<text top="400" left="54" width="78" height="17" font="13">Trial), Rogers </text>
<text top="417" left="54" width="53" height="17" font="13">JG, 2007 </text>
<text top="434" left="54" width="58" height="17" font="14">17707178 </text>
<text top="434" left="112" width="32" height="17" font="13">(286) </text>
<text top="296" left="160" width="88" height="17" font="13">To evaluate the </text>
<text top="314" left="160" width="89" height="17" font="13">impact of LVAD </text>
<text top="331" left="160" width="62" height="17" font="13">support on </text>
<text top="348" left="160" width="96" height="17" font="13">survival and QoL </text>
<text top="365" left="160" width="62" height="17" font="13">in inotrope-</text>
<text top="382" left="160" width="81" height="17" font="13">dependent HF </text>
<text top="400" left="160" width="89" height="17" font="13">pts ineligible for </text>
<text top="417" left="160" width="43" height="17" font="13">cardiac </text>
<text top="434" left="160" width="84" height="17" font="13">transplantation </text>
<text top="296" left="271" width="45" height="17" font="13">Prospec</text>
<text top="314" left="271" width="44" height="17" font="13">tivenonr</text>
<text top="331" left="271" width="46" height="17" font="13">andomiz</text>
<text top="348" left="271" width="17" height="17" font="13">ed </text>
<text top="365" left="271" width="40" height="17" font="13">clinical </text>
<text top="382" left="271" width="23" height="17" font="13">trial </text>
<text top="296" left="336" width="17" height="17" font="13">55 </text>
<text top="296" left="413" width="111" height="17" font="13">Adults with inotrope-</text>
<text top="314" left="413" width="131" height="17" font="13">dependent stage D HF; </text>
<text top="331" left="413" width="151" height="17" font="13">LVEF &lt; 25%,                       </text>
<text top="348" left="413" width="141" height="17" font="13">NYHA IV symptoms for &gt; </text>
<text top="365" left="413" width="130" height="17" font="13">3 mo before enrollment </text>
<text top="382" left="413" width="137" height="17" font="13">and were not candidates </text>
<text top="400" left="413" width="152" height="17" font="13">for cardiac transplantation   </text>
<text top="417" left="413" width="129" height="17" font="13">Treated with maximally </text>
<text top="434" left="413" width="137" height="17" font="13">tolerated doses of ACEI, </text>
<text top="451" left="413" width="126" height="17" font="13">beta-blockers, digoxin, </text>
<text top="469" left="413" width="122" height="17" font="13">diuretics, and/or other </text>
<text top="486" left="413" width="76" height="17" font="13">vasodilators.  </text>
<text top="296" left="572" width="165" height="17" font="13">BSA &lt;1.5 m2                           </text>
<text top="314" left="572" width="149" height="17" font="13">Contraindication to chronic </text>
<text top="331" left="572" width="165" height="17" font="13">anticoagulation                        </text>
<text top="348" left="572" width="145" height="17" font="13">Presence of a mechanical </text>
<text top="365" left="572" width="146" height="17" font="13">aortic valve constituted an </text>
<text top="382" left="572" width="155" height="17" font="13">exclusion criterion for LVAD </text>
<text top="400" left="572" width="164" height="17" font="13">support                                    </text>
<text top="417" left="572" width="131" height="17" font="13">CVA or TIA within 6 mo </text>
<text top="434" left="572" width="144" height="17" font="13">before enrollment, a  70% </text>
<text top="451" left="572" width="124" height="17" font="13">carotid stenosis, or an </text>
<text top="469" left="572" width="165" height="17" font="13">ulcerated carotid plaque.         </text>
<text top="486" left="572" width="150" height="17" font="13">Unresolved drug or alcohol </text>
<text top="503" left="572" width="166" height="17" font="13">dependency                             </text>
<text top="520" left="572" width="165" height="17" font="13">Active systemic infection         </text>
<text top="537" left="572" width="165" height="17" font="13">SCr &gt;5.0 mg/dL,                      </text>
<text top="555" left="572" width="166" height="17" font="13">Tbilli &gt;5.0 mg/dL                      </text>
<text top="572" left="572" width="125" height="17" font="13">Mechanical ventilatory </text>
<text top="589" left="572" width="158" height="17" font="13">support for &gt;48 h at the time </text>
<text top="606" left="572" width="167" height="17" font="13">of enrollment                            </text>
<text top="624" left="572" width="155" height="17" font="13">Comorbid medical condition </text>
<text top="641" left="572" width="157" height="17" font="13">limiting life expectancy &lt; 2 y </text>
<text top="296" left="744" width="54" height="17" font="13">All-cause </text>
<text top="314" left="744" width="74" height="17" font="13">mortality at 6 </text>
<text top="331" left="744" width="21" height="17" font="13">mo </text>
<text top="296" left="838" width="87" height="17" font="13">AEs,                  </text>
<text top="314" left="838" width="56" height="17" font="13">functional </text>
<text top="331" left="838" width="86" height="17" font="13">capacity            </text>
<text top="348" left="838" width="44" height="17" font="13">HRQoL </text>
<text top="296" left="932" width="103" height="17" font="13">1st y mortality        </text>
<text top="314" left="932" width="105" height="17" font="13">73% (LVAD) vs      </text>
<text top="331" left="932" width="105" height="17" font="13">89% (OMT)            </text>
<text top="348" left="932" width="105" height="17" font="13">6mo mortality:        </text>
<text top="365" left="932" width="105" height="17" font="13">54% (LVAD) vs      </text>
<text top="382" left="932" width="67" height="17" font="13">78% (OMT) </text>
<text top="296" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="314" left="1042" width="70" height="17" font="13">39 mo (3/00-</text>
<text top="331" left="1042" width="73" height="17" font="13">5/03); 12 mo </text>
<text top="348" left="1042" width="53" height="17" font="13">follow-up </text>
<text top="296" left="1130" width="141" height="17" font="13">6 mo survival                    </text>
<text top="314" left="1130" width="115" height="17" font="13">46% (LVAD) vs 22% </text>
<text top="331" left="1130" width="42" height="17" font="13">(OMT)  </text>
<text top="348" left="1130" width="128" height="17" font="13">(HR 0.47; 95% CI 0.23-</text>
<text top="365" left="1130" width="141" height="17" font="13">0.93; p=0.03)                    </text>
<text top="382" left="1130" width="140" height="17" font="13">1 y survival                       </text>
<text top="400" left="1130" width="115" height="17" font="13">27% (LVAD) vs 11% </text>
<text top="417" left="1130" width="142" height="17" font="13">(OMT)                               </text>
<text top="434" left="1130" width="129" height="17" font="13">Absolute reduction of 1 </text>
<text top="451" left="1130" width="129" height="17" font="13">y mortality by 16% with </text>
<text top="469" left="1130" width="39" height="17" font="13">LVAD  </text>
<text top="486" left="1130" width="107" height="17" font="13">(HR: 0.48; 95% CI: </text>
<text top="503" left="1130" width="104" height="17" font="13">0.25-0.85; p=0.02) </text>
<text top="296" left="1277" width="183" height="17" font="13">CVA   34.5%                                 </text>
<text top="314" left="1277" width="78" height="17" font="13">Infection 24% </text>
<text top="331" left="1277" width="3" height="17" font="13"> </text>
<text top="659" left="54" width="78" height="17" font="13">Advanced HF </text>
<text top="676" left="54" width="67" height="17" font="13">treated with </text>
<text top="693" left="54" width="89" height="17" font="13">continuous-flow </text>
<text top="710" left="54" width="39" height="17" font="13">LVAD, </text>
<text top="727" left="54" width="72" height="17" font="13">(HeartMateII </text>
<text top="745" left="54" width="84" height="17" font="13">DT), Slaughter </text>
<text top="762" left="54" width="56" height="17" font="13">MS, 2009 </text>
<text top="779" left="54" width="58" height="17" font="14">19920051 </text>
<text top="779" left="112" width="32" height="17" font="13">(287) </text>
<text top="659" left="160" width="90" height="17" font="13">To compare the </text>
<text top="676" left="160" width="90" height="17" font="13">outcomes of pts </text>
<text top="693" left="160" width="69" height="17" font="13">ineligible for </text>
<text top="710" left="160" width="43" height="17" font="13">cardiac </text>
<text top="727" left="160" width="84" height="17" font="13">transplantation </text>
<text top="745" left="160" width="74" height="17" font="13">with pulsatile </text>
<text top="762" left="160" width="40" height="17" font="13">versus </text>
<text top="779" left="160" width="88" height="17" font="13">continuous flow </text>
<text top="659" left="271" width="29" height="17" font="13">RCT </text>
<text top="659" left="336" width="24" height="17" font="13">200 </text>
<text top="659" left="413" width="63" height="17" font="13">Age  &gt;18 y </text>
<text top="676" left="413" width="132" height="17" font="13">BSA &gt; 1.5m2 for a pt to </text>
<text top="693" left="413" width="143" height="17" font="13">be randomized HM XVE - </text>
<text top="710" left="413" width="106" height="17" font="13">HM II. If BSA &lt; 1.5 </text>
<text top="727" left="413" width="130" height="17" font="13">m2and &gt; 1.2 m2, the pt </text>
<text top="745" left="413" width="139" height="17" font="13">must meet the remaining </text>
<text top="762" left="413" width="105" height="17" font="13">criteria and can be </text>
<text top="779" left="413" width="142" height="17" font="13">enrolled in the Small Size </text>
<text top="659" left="572" width="138" height="17" font="13">HF is due to uncorrected </text>
<text top="676" left="572" width="152" height="17" font="13">thyroid disease, obstructive </text>
<text top="693" left="572" width="154" height="17" font="13">cardiomyopathy, pericardial </text>
<text top="710" left="572" width="156" height="17" font="13">disease, amyloidosis, active </text>
<text top="727" left="572" width="115" height="17" font="13">myocarditis or RCM. </text>
<text top="745" left="572" width="150" height="17" font="13">Technical obstacles, which </text>
<text top="762" left="572" width="140" height="17" font="13">pose an inordinately high </text>
<text top="779" left="572" width="105" height="17" font="13">surgical risk, in the </text>
<text top="659" left="744" width="69" height="17" font="13">The primary </text>
<text top="676" left="744" width="59" height="17" font="13">composite </text>
<text top="693" left="744" width="79" height="17" font="13">endpoint was, </text>
<text top="710" left="744" width="37" height="17" font="13">at 2 y, </text>
<text top="727" left="744" width="70" height="17" font="13">survival free </text>
<text top="745" left="744" width="80" height="17" font="13">from disabling </text>
<text top="762" left="744" width="61" height="17" font="13">stroke and </text>
<text top="779" left="744" width="79" height="17" font="13">reoperation to </text>
<text top="659" left="838" width="62" height="17" font="13">Secondary </text>
<text top="676" left="838" width="57" height="17" font="13">endpoints </text>
<text top="693" left="838" width="49" height="17" font="13">included </text>
<text top="710" left="838" width="48" height="17" font="13">survival, </text>
<text top="727" left="838" width="71" height="17" font="13">frequency of </text>
<text top="745" left="838" width="74" height="17" font="13">AE, the QoL, </text>
<text top="762" left="838" width="80" height="17" font="13">and functional </text>
<text top="779" left="838" width="52" height="17" font="13">capacity. </text>
<text top="659" left="932" width="83" height="17" font="13">1st y mortality: </text>
<text top="676" left="932" width="95" height="17" font="13">32% (continuous </text>
<text top="693" left="932" width="81" height="17" font="13">flow LVAD) vs </text>
<text top="710" left="932" width="81" height="17" font="13">42% (pulsatile </text>
<text top="727" left="932" width="65" height="17" font="13">flow LVAD) </text>
<text top="659" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="676" left="1042" width="70" height="17" font="13">5/05-5/07 (2 </text>
<text top="693" left="1042" width="41" height="17" font="13">y)         </text>
<text top="710" left="1042" width="74" height="17" font="13">Follow-up &gt;2 </text>
<text top="727" left="1042" width="50" height="17" font="13">y or until </text>
<text top="745" left="1042" width="38" height="17" font="13">death, </text>
<text top="762" left="1042" width="43" height="17" font="13">cardiac </text>
<text top="779" left="1042" width="75" height="17" font="13">transplant, or </text>
<text top="659" left="1130" width="128" height="17" font="13">The primary composite </text>
<text top="676" left="1130" width="128" height="17" font="13">endpoint was achieved </text>
<text top="693" left="1130" width="131" height="17" font="13">in more pts assigned to </text>
<text top="710" left="1130" width="117" height="17" font="13">receive a continuous-</text>
<text top="727" left="1130" width="101" height="17" font="13">flow LVAD than in </text>
<text top="745" left="1130" width="100" height="17" font="13">those assigned to </text>
<text top="762" left="1130" width="128" height="17" font="13">receive a pulsatile-flow </text>
<text top="779" left="1130" width="139" height="17" font="13">LVAD (46% vs. 11%)       </text>
<text top="659" left="1277" width="161" height="17" font="13">Higher complication rate with </text>
<text top="676" left="1277" width="182" height="17" font="13">pulsatile LVAD (p&lt;0.001)             </text>
<text top="693" left="1277" width="182" height="17" font="13">Pump replacement                       </text>
<text top="710" left="1277" width="150" height="17" font="13">Sepsis                                 </text>
<text top="727" left="1277" width="155" height="17" font="13">Respiratory failure                </text>
<text top="745" left="1277" width="165" height="17" font="13">Renal failure                            </text>
<text top="762" left="1277" width="163" height="17" font="13">RV failure requiring extended </text>
<text top="779" left="1277" width="145" height="17" font="13">inotrope Rehospitalization </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">141</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="3" height="17" font="13"> </text>
<text top="72" left="54" width="3" height="17" font="13"> </text>
<text top="55" left="160" width="98" height="17" font="13">LVAD destination </text>
<text top="72" left="160" width="44" height="17" font="13">therapy </text>
<text top="55" left="413" width="44" height="17" font="13">Cohort. </text>
<text top="72" left="413" width="143" height="17" font="13">NYHA IIIB or IV HF and 1 </text>
<text top="89" left="413" width="68" height="17" font="13">of following: </text>
<text top="106" left="413" width="118" height="17" font="13">i. On OMM, including </text>
<text top="124" left="413" width="123" height="17" font="13">dietary salt restriction, </text>
<text top="141" left="413" width="128" height="17" font="13">diuretics, digitalis, beta </text>
<text top="158" left="413" width="136" height="17" font="13">blockers, spironolactone </text>
<text top="175" left="413" width="143" height="17" font="13">and ACE-I, for &gt; 45 out of </text>
<text top="192" left="413" width="133" height="17" font="13">the last 60 d and  failing </text>
<text top="210" left="413" width="68" height="17" font="13">to respond;  </text>
<text top="227" left="413" width="141" height="17" font="13">ii. NYHA III-IV HF for &gt;14 </text>
<text top="244" left="413" width="144" height="17" font="13">d and dependent on IABP </text>
<text top="261" left="413" width="131" height="17" font="13">for 7 d and/or inotropes </text>
<text top="278" left="413" width="56" height="17" font="13">for &gt;14 d  </text>
<text top="296" left="413" width="137" height="17" font="13">iii. Treated with ACE-I or </text>
<text top="313" left="413" width="132" height="17" font="13">beta blockers for &gt; 30 d </text>
<text top="330" left="413" width="89" height="17" font="13">and found to be </text>
<text top="347" left="413" width="57" height="17" font="13">intolerant. </text>
<text top="365" left="413" width="78" height="17" font="13">Female pts of </text>
<text top="382" left="413" width="120" height="17" font="13">childbearing potential </text>
<text top="399" left="413" width="102" height="17" font="13">must agree to use </text>
<text top="416" left="413" width="135" height="17" font="13">adequate contraception  </text>
<text top="433" left="413" width="113" height="17" font="13">Ineligible for cardiac </text>
<text top="451" left="413" width="61" height="17" font="13">transplant. </text>
<text top="468" left="413" width="139" height="17" font="13">VO2max &lt; 14 mL/kg/min </text>
<text top="485" left="413" width="117" height="17" font="13">or &lt;50% of predicted </text>
<text top="502" left="413" width="137" height="17" font="13">VO2max with attainment </text>
<text top="519" left="413" width="138" height="17" font="13">of anaerobic threshold, if </text>
<text top="537" left="413" width="145" height="17" font="13">not contraindicated due to </text>
<text top="554" left="413" width="127" height="17" font="13">IV inotropes, angina or </text>
<text top="571" left="413" width="102" height="17" font="13">physical disability. </text>
<text top="588" left="413" width="89" height="17" font="13">LVEF is &lt; 25%. </text>
<text top="55" left="572" width="158" height="17" font="13">judgment of the investigator. </text>
<text top="72" left="572" width="115" height="17" font="13">Ongoing mechanical </text>
<text top="89" left="572" width="135" height="17" font="13">circulatory support other </text>
<text top="106" left="572" width="62" height="17" font="13">than IABP. </text>
<text top="124" left="572" width="165" height="17" font="13">BMI &gt;40 kg/m2.                       </text>
<text top="141" left="572" width="134" height="17" font="13">Positive pregnancy test  </text>
<text top="158" left="572" width="154" height="17" font="13">Presence of mechanical AV </text>
<text top="175" left="572" width="153" height="17" font="13">that will not be converted to </text>
<text top="192" left="572" width="90" height="17" font="13">a bioprosthesis  </text>
<text top="210" left="572" width="156" height="17" font="13">History of cardiac transplant </text>
<text top="227" left="572" width="165" height="17" font="13">or cardiomyoplasty.                 </text>
<text top="244" left="572" width="164" height="17" font="13">Platelet count &lt; 50,000           </text>
<text top="261" left="572" width="159" height="17" font="13">Untreated aortic aneurysm &gt; </text>
<text top="278" left="572" width="33" height="17" font="13">5cm.  </text>
<text top="296" left="572" width="112" height="17" font="13">Psychiatric disease, </text>
<text top="313" left="572" width="115" height="17" font="13">irreversible cognitive </text>
<text top="330" left="572" width="143" height="17" font="13">dysfunction, psychosocial </text>
<text top="347" left="572" width="128" height="17" font="13">issues that are likely to </text>
<text top="365" left="572" width="106" height="17" font="13">impair compliance  </text>
<text top="382" left="572" width="111" height="17" font="13">Active, uncontrolled </text>
<text top="399" left="572" width="53" height="17" font="13">infection. </text>
<text top="416" left="572" width="154" height="17" font="13">Intolerance to anticoagulant </text>
<text top="433" left="572" width="146" height="17" font="13">or antiplatelet therapies or </text>
<text top="451" left="572" width="105" height="17" font="13">any other peri/post </text>
<text top="468" left="572" width="149" height="17" font="13">operative therapy that may </text>
<text top="485" left="572" width="66" height="17" font="13">be required </text>
<text top="502" left="572" width="141" height="17" font="13">INR &gt; 2.5, not due to anti-</text>
<text top="519" left="572" width="155" height="17" font="13">coagulant therapy, or Plavix </text>
<text top="537" left="572" width="75" height="17" font="13">within 5 days </text>
<text top="554" left="572" width="150" height="17" font="13"> AST, ALT, or total bilirubin </text>
<text top="571" left="572" width="121" height="17" font="13">&gt; 5x normal or biopsy </text>
<text top="588" left="572" width="116" height="17" font="13">proven liver cirrhosis </text>
<text top="606" left="572" width="152" height="17" font="13">Severe COPD or restrictive </text>
<text top="623" left="572" width="76" height="17" font="13">lung disease. </text>
<text top="640" left="572" width="151" height="17" font="13">Fixed pHTN with a PVR &gt;8 </text>
<text top="657" left="572" width="68" height="17" font="13">Wood units  </text>
<text top="674" left="572" width="157" height="17" font="13">Stroke w/in 90 d, or cerebral </text>
<text top="692" left="572" width="155" height="17" font="13">vascular disease with &gt;80% </text>
<text top="709" left="572" width="122" height="17" font="13">extra cranial stenosis. </text>
<text top="726" left="572" width="117" height="17" font="13">SCr &gt;3.5 mg/dl or on </text>
<text top="743" left="572" width="44" height="17" font="13">dialysis </text>
<text top="760" left="572" width="118" height="17" font="13">Significant peripheral </text>
<text top="778" left="572" width="144" height="17" font="13">vascular disease with rest </text>
<text top="55" left="744" width="49" height="17" font="13">repair or </text>
<text top="72" left="744" width="64" height="17" font="13">replace the </text>
<text top="89" left="744" width="42" height="17" font="13">device. </text>
<text top="55" left="1042" width="57" height="17" font="13">explant of </text>
<text top="72" left="1042" width="36" height="17" font="13">LVAD </text>
<text top="55" left="1130" width="124" height="17" font="13">On the basis of the as-</text>
<text top="72" left="1130" width="113" height="17" font="13">treated analysis, the </text>
<text top="89" left="1130" width="129" height="17" font="13">Kaplan–Meier estimate </text>
<text top="106" left="1130" width="134" height="17" font="13">of actuarial survival was </text>
<text top="124" left="1130" width="120" height="17" font="13">significantly better for </text>
<text top="141" left="1130" width="80" height="17" font="13">pts who had a </text>
<text top="158" left="1130" width="128" height="17" font="13">continuous- flow LVAD </text>
<text top="175" left="1130" width="133" height="17" font="13">as compared with those </text>
<text top="192" left="1130" width="110" height="17" font="13">with a pulsatile-flow </text>
<text top="210" left="1130" width="142" height="17" font="13">LVAD                                </text>
<text top="227" left="1130" width="94" height="17" font="13">Improvements in </text>
<text top="244" left="1130" width="109" height="17" font="13">functional status by </text>
<text top="261" left="1130" width="96" height="17" font="13">NYHA Class and </text>
<text top="278" left="1130" width="111" height="17" font="13">6MWT did not differ </text>
<text top="296" left="1130" width="93" height="17" font="13">between the two </text>
<text top="313" left="1130" width="44" height="17" font="13">groups. </text>
<text top="330" left="1130" width="3" height="17" font="13"> </text>
<text top="347" left="1130" width="105" height="17" font="13">Primary composite </text>
<text top="365" left="1130" width="57" height="17" font="13">endpoint:  </text>
<text top="382" left="1130" width="123" height="17" font="13">HR 0.38; 95%CI: 0.27 </text>
<text top="399" left="1130" width="141" height="17" font="13">to 0.54; p&lt;0.001               </text>
<text top="416" left="1130" width="124" height="17" font="13">Actuarial survival, RR: </text>
<text top="433" left="1130" width="27" height="17" font="13">0.54 </text>
<text top="451" left="1130" width="119" height="17" font="13">95% CI, 0.34 to 0.86; </text>
<text top="468" left="1130" width="48" height="17" font="13">p=0.008 </text>
<text top="485" left="1130" width="3" height="17" font="13"> </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">142</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="572" width="101" height="17" font="13">pain or ulceration. </text>
<text top="72" left="572" width="131" height="17" font="13">Moderate to severe AIy </text>
<text top="89" left="572" width="154" height="17" font="13">without plans for correction  </text>
<text top="106" left="572" width="139" height="17" font="13">Participation in any other </text>
<text top="124" left="572" width="116" height="17" font="13">clinical investigation  </text>
<text top="141" left="572" width="158" height="17" font="13">CCB (except amlodipine), or </text>
<text top="158" left="572" width="135" height="17" font="13">Type I /III antiarrhythmic </text>
<text top="175" left="572" width="151" height="17" font="13">(except amiodarone) within </text>
<text top="192" left="572" width="133" height="17" font="13">28 d prior to enrollment. </text>
<text top="210" left="572" width="134" height="17" font="13">Any condition that could </text>
<text top="227" left="572" width="114" height="17" font="13">limit survival to &lt;3 y. </text>
<text top="245" left="54" width="27" height="17" font="15"><b>BTT </b></text>
<text top="268" left="54" width="49" height="17" font="13">Use of a </text>
<text top="285" left="54" width="89" height="17" font="13">continuous-flow </text>
<text top="302" left="54" width="72" height="17" font="13">device in pts </text>
<text top="320" left="54" width="80" height="17" font="13">awaiting heart </text>
<text top="337" left="54" width="84" height="17" font="13">transplantation </text>
<text top="354" left="54" width="68" height="17" font="13">(HMII BTT), </text>
<text top="371" left="54" width="89" height="17" font="13">Miller LW, 2007 </text>
<text top="389" left="54" width="58" height="17" font="14">17761592 </text>
<text top="389" left="112" width="32" height="17" font="13">(289) </text>
<text top="268" left="160" width="80" height="17" font="13">To assess the </text>
<text top="285" left="160" width="59" height="17" font="13">efficacy of </text>
<text top="302" left="160" width="89" height="17" font="13">continuous-flow </text>
<text top="320" left="160" width="53" height="17" font="13">LVAD for </text>
<text top="337" left="160" width="53" height="17" font="13">providing </text>
<text top="354" left="160" width="80" height="17" font="13">hemodynamic </text>
<text top="371" left="160" width="72" height="17" font="13">support of at </text>
<text top="389" left="160" width="94" height="17" font="13">least 6 mo to pts </text>
<text top="406" left="160" width="80" height="17" font="13">awaiting heart </text>
<text top="423" left="160" width="84" height="17" font="13">transplantation </text>
<text top="268" left="271" width="44" height="17" font="13">Cohort  </text>
<text top="268" left="336" width="24" height="17" font="13">133 </text>
<text top="268" left="413" width="97" height="17" font="13">Transplant listed. </text>
<text top="285" left="413" width="83" height="17" font="13">BSA &gt; 1.2 m2. </text>
<text top="302" left="413" width="135" height="17" font="13">NYHA IV HF symptoms. </text>
<text top="320" left="413" width="148" height="17" font="13">Female pts of childbearing </text>
<text top="337" left="413" width="129" height="17" font="13">potential must agree to </text>
<text top="354" left="413" width="78" height="17" font="13">use adequate </text>
<text top="371" left="413" width="77" height="17" font="13">contraception </text>
<text top="389" left="413" width="127" height="17" font="13">On inotropic support, if </text>
<text top="406" left="413" width="55" height="17" font="13">tolerated. </text>
<text top="423" left="413" width="139" height="17" font="13">Despite medical therapy, </text>
<text top="440" left="413" width="133" height="17" font="13">the pt must meet one of </text>
<text top="457" left="413" width="116" height="17" font="13">the following criteria: </text>
<text top="475" left="413" width="140" height="17" font="13">a. No contraindication for </text>
<text top="492" left="413" width="95" height="17" font="13">Status 1A listing  </text>
<text top="509" left="413" width="140" height="17" font="13">b. No contraindication for </text>
<text top="526" left="413" width="95" height="17" font="13">Status 1B listing  </text>
<text top="543" left="413" width="111" height="17" font="13">PCWP or PAD &gt; 20 </text>
<text top="561" left="413" width="156" height="17" font="13">mmHg,                                  </text>
<text top="578" left="413" width="147" height="17" font="13">CI  &lt; 2.2 L/min/m2 or SBP </text>
<text top="595" left="413" width="67" height="17" font="13">&lt; 90 mmHg </text>
<text top="268" left="575" width="126" height="17" font="13">HF due to uncorrected </text>
<text top="285" left="575" width="89" height="17" font="13">thyroid disease, </text>
<text top="302" left="575" width="119" height="17" font="13">obstructive/restrictive </text>
<text top="320" left="575" width="154" height="17" font="13">cardiomyopathy, pericardial </text>
<text top="337" left="575" width="135" height="17" font="13">disease, or amyloidosis. </text>
<text top="354" left="575" width="150" height="17" font="13">Technical obstacles, which </text>
<text top="371" left="575" width="140" height="17" font="13">pose an inordinately high </text>
<text top="389" left="575" width="72" height="17" font="13">surgical risk. </text>
<text top="406" left="575" width="115" height="17" font="13">Ongoing mechanical </text>
<text top="423" left="575" width="135" height="17" font="13">circulatory support other </text>
<text top="440" left="575" width="59" height="17" font="13">than IABP </text>
<text top="457" left="575" width="93" height="17" font="13">BMI &gt; 40 kg/m2. </text>
<text top="475" left="575" width="134" height="17" font="13">Positive pregnancy test  </text>
<text top="492" left="575" width="155" height="17" font="13">Mechanical aortic valve that </text>
<text top="509" left="575" width="140" height="17" font="13">will not be converted to a </text>
<text top="526" left="575" width="79" height="17" font="13">bioprosthesis  </text>
<text top="543" left="575" width="136" height="17" font="13">Hx of cardiac transplant. </text>
<text top="561" left="575" width="164" height="17" font="13">Platelet count &lt;50,000/mL.     </text>
<text top="578" left="575" width="148" height="17" font="13">Untreated aortic aneurysm </text>
<text top="595" left="575" width="41" height="17" font="13">&gt; 5cm. </text>
<text top="612" left="575" width="143" height="17" font="13">Psychiatric dz irreversible </text>
<text top="630" left="575" width="121" height="17" font="13">cognitive dysfunction, </text>
<text top="647" left="575" width="109" height="17" font="13">psychosocial issue  </text>
<text top="664" left="575" width="107" height="17" font="13">Active uncontrolled </text>
<text top="681" left="575" width="53" height="17" font="13">infection. </text>
<text top="698" left="575" width="154" height="17" font="13">Intolerance to anticoagulant </text>
<text top="716" left="575" width="146" height="17" font="13">or antiplatelet therapies or </text>
<text top="733" left="575" width="105" height="17" font="13">any other peri/post </text>
<text top="750" left="575" width="149" height="17" font="13">operative therapy that may </text>
<text top="767" left="575" width="66" height="17" font="13">be required </text>
<text top="784" left="575" width="134" height="17" font="13">Any one of the following </text>
<text top="268" left="744" width="74" height="17" font="13">The principal </text>
<text top="285" left="744" width="57" height="17" font="13">outcomes </text>
<text top="302" left="744" width="51" height="17" font="13">were the </text>
<text top="320" left="744" width="79" height="17" font="13">proportions of </text>
<text top="337" left="744" width="63" height="17" font="13">pts who, at </text>
<text top="354" left="744" width="62" height="17" font="13">180 d, had </text>
<text top="371" left="744" width="62" height="17" font="13">undergone </text>
<text top="389" left="744" width="74" height="17" font="13">transplantatio</text>
<text top="406" left="744" width="38" height="17" font="13">n, had </text>
<text top="423" left="744" width="62" height="17" font="13">undergone </text>
<text top="440" left="744" width="70" height="17" font="13">explantation </text>
<text top="457" left="744" width="73" height="17" font="13">of the device </text>
<text top="475" left="744" width="64" height="17" font="13">because of </text>
<text top="492" left="744" width="64" height="17" font="13">recovery of </text>
<text top="509" left="744" width="60" height="17" font="13">ventricular </text>
<text top="526" left="744" width="50" height="17" font="13">function, </text>
<text top="543" left="744" width="38" height="17" font="13">or had </text>
<text top="561" left="744" width="47" height="17" font="13">ongoing </text>
<text top="578" left="744" width="66" height="17" font="13">mechanical </text>
<text top="595" left="744" width="68" height="17" font="13">support and </text>
<text top="612" left="744" width="55" height="17" font="13">remained </text>
<text top="630" left="744" width="59" height="17" font="13">eligible for </text>
<text top="647" left="744" width="74" height="17" font="13">transplantatio</text>
<text top="664" left="744" width="68" height="17" font="13">n (i.e., were </text>
<text top="681" left="744" width="72" height="17" font="13">not removed </text>
<text top="698" left="744" width="49" height="17" font="13">from the </text>
<text top="716" left="744" width="60" height="17" font="13">waiting list </text>
<text top="733" left="744" width="49" height="17" font="13">owing to </text>
<text top="750" left="744" width="64" height="17" font="13">irreversible </text>
<text top="767" left="744" width="78" height="17" font="13">complications </text>
<text top="784" left="744" width="55" height="17" font="13">or clinical </text>
<text top="268" left="838" width="62" height="17" font="13">Secondary </text>
<text top="285" left="838" width="57" height="17" font="13">outcomes </text>
<text top="302" left="838" width="49" height="17" font="13">included </text>
<text top="320" left="838" width="40" height="17" font="13">overall </text>
<text top="337" left="838" width="48" height="17" font="13">survival, </text>
<text top="354" left="838" width="77" height="17" font="13">survival while </text>
<text top="371" left="838" width="53" height="17" font="13">receiving </text>
<text top="389" left="838" width="39" height="17" font="13">device </text>
<text top="406" left="838" width="48" height="17" font="13">support, </text>
<text top="423" left="838" width="73" height="17" font="13">survival after </text>
<text top="440" left="838" width="74" height="17" font="13">transplantatio</text>
<text top="457" left="838" width="14" height="17" font="13">n, </text>
<text top="475" left="838" width="71" height="17" font="13">frequency of </text>
<text top="492" left="838" width="29" height="17" font="13">AEs, </text>
<text top="509" left="838" width="69" height="17" font="13">assessment </text>
<text top="526" left="838" width="70" height="17" font="13">of functional </text>
<text top="543" left="838" width="69" height="17" font="13">class by a 6-</text>
<text top="561" left="838" width="78" height="17" font="13">min walk test, </text>
<text top="578" left="838" width="71" height="17" font="13">independent </text>
<text top="595" left="838" width="73" height="17" font="13">evaluation of </text>
<text top="612" left="838" width="38" height="17" font="13">NYHA </text>
<text top="630" left="838" width="56" height="17" font="13">functional </text>
<text top="647" left="838" width="58" height="17" font="13">class by a </text>
<text top="664" left="838" width="58" height="17" font="13">physician, </text>
<text top="681" left="838" width="54" height="17" font="13">and QoL. </text>
<text top="268" left="932" width="70" height="17" font="13">1 y mortality </text>
<text top="285" left="932" width="28" height="17" font="13">32% </text>
<text top="268" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="285" left="1042" width="55" height="17" font="13">3/05-5/06 </text>
<text top="302" left="1042" width="46" height="17" font="13">(15mo); </text>
<text top="320" left="1042" width="53" height="17" font="13">follow-up </text>
<text top="337" left="1042" width="79" height="17" font="13">through  180d </text>
<text top="268" left="1136" width="125" height="17" font="13">75% reached principal </text>
<text top="285" left="1136" width="115" height="17" font="13">outcomes                  </text>
<text top="302" left="1136" width="103" height="17" font="13">18.8% died before </text>
<text top="320" left="1136" width="89" height="17" font="13">180d of support </text>
<text top="268" left="1277" width="152" height="17" font="13">Bleeding requiring pRBCs   </text>
<text top="285" left="1277" width="156" height="17" font="13">Local infection, non-LVAD    </text>
<text top="302" left="1277" width="181" height="17" font="13">Ventricular arrhythmias                </text>
<text top="320" left="1277" width="160" height="17" font="13">Sepsis                                    </text>
<text top="337" left="1277" width="79" height="17" font="13">Right HF         </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">143</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="575" width="105" height="17" font="13">risk factors for and </text>
<text top="72" left="575" width="135" height="17" font="13">indicators of severe end-</text>
<text top="89" left="575" width="155" height="17" font="13">organ dysfunction or failure: </text>
<text top="106" left="575" width="125" height="17" font="13">a) INR &gt;2.5 not due to </text>
<text top="124" left="575" width="135" height="17" font="13">anticoagulant therapy or </text>
<text top="141" left="575" width="98" height="17" font="13">Plavix  within 5 d. </text>
<text top="158" left="575" width="145" height="17" font="13">b) Total bilirubin &gt; 5mg/dl, </text>
<text top="175" left="575" width="137" height="17" font="13">or shock liver (AST, ALT </text>
<text top="192" left="575" width="143" height="17" font="13">&gt;2,000), or biopsy proven </text>
<text top="210" left="575" width="79" height="17" font="13">liver cirrhosis. </text>
<text top="227" left="575" width="150" height="17" font="13">c) Severe COPD or severe </text>
<text top="244" left="575" width="132" height="17" font="13">restrictive lung disease. </text>
<text top="261" left="575" width="109" height="17" font="13">d) Fixed pulmonary </text>
<text top="278" left="575" width="150" height="17" font="13">hypertension, with a recent </text>
<text top="296" left="575" width="115" height="17" font="13">PVR &gt;6 Wood units, </text>
<text top="313" left="575" width="131" height="17" font="13">e) Unresolved stroke or </text>
<text top="330" left="575" width="78" height="17" font="13">uncorrectable </text>
<text top="347" left="575" width="140" height="17" font="13">cerebrovascular disease. </text>
<text top="365" left="575" width="136" height="17" font="13">f) SCr &gt;3.5 mg/dL or the </text>
<text top="382" left="575" width="139" height="17" font="13">need for chronic dialysis. </text>
<text top="399" left="575" width="133" height="17" font="13">g) Significant peripheral </text>
<text top="416" left="575" width="144" height="17" font="13">vascular disease with rest </text>
<text top="433" left="575" width="98" height="17" font="13">pain or ulceration </text>
<text top="451" left="575" width="143" height="17" font="13">Moderate to severe aortic </text>
<text top="468" left="575" width="146" height="17" font="13">insufficiency without plans </text>
<text top="485" left="575" width="47" height="17" font="13">for AVR </text>
<text top="502" left="575" width="139" height="17" font="13">Participation in any other </text>
<text top="519" left="575" width="116" height="17" font="13">clinical investigation  </text>
<text top="55" left="744" width="76" height="17" font="13">deterioration) </text>
<text top="537" left="54" width="55" height="17" font="13">Extended </text>
<text top="555" left="54" width="66" height="17" font="13">Mechanical </text>
<text top="572" left="54" width="62" height="17" font="13">Circulatory </text>
<text top="589" left="54" width="82" height="17" font="13">Support with a </text>
<text top="606" left="54" width="66" height="17" font="13">Continuous-</text>
<text top="624" left="54" width="69" height="17" font="13">Flow Rotary </text>
<text top="641" left="54" width="69" height="17" font="13">LVAD (HMII </text>
<text top="658" left="54" width="76" height="17" font="13">BTT), Pagani </text>
<text top="675" left="54" width="54" height="17" font="13">FD, 2009 </text>
<text top="692" left="54" width="58" height="17" font="14">19608028 </text>
<text top="692" left="112" width="32" height="17" font="13">(288) </text>
<text top="537" left="160" width="88" height="17" font="13">To evaluate the </text>
<text top="555" left="160" width="47" height="17" font="13">use of a </text>
<text top="572" left="160" width="89" height="17" font="13">continuous-flow </text>
<text top="589" left="160" width="97" height="17" font="13">rotary LVAD as a </text>
<text top="606" left="160" width="83" height="17" font="13">bridge to heart </text>
<text top="624" left="160" width="84" height="17" font="13">transplantation </text>
<text top="641" left="160" width="98" height="17" font="13">over an extended </text>
<text top="658" left="160" width="89" height="17" font="13">period, up to 18 </text>
<text top="675" left="160" width="21" height="17" font="13">mo </text>
<text top="537" left="271" width="40" height="17" font="13">Cohort </text>
<text top="555" left="271" width="35" height="17" font="13">Study </text>
<text top="537" left="336" width="24" height="17" font="13">281 </text>
<text top="537" left="413" width="122" height="17" font="13">Same as above (HMII </text>
<text top="555" left="413" width="39" height="17" font="13">Study) </text>
<text top="537" left="575" width="122" height="17" font="13">Same as above (HMII </text>
<text top="555" left="575" width="39" height="17" font="13">Study) </text>
<text top="537" left="744" width="71" height="17" font="13">Survival and </text>
<text top="555" left="744" width="74" height="17" font="13">transplantatio</text>
<text top="572" left="744" width="71" height="17" font="13">n rates were </text>
<text top="589" left="744" width="69" height="17" font="13">assessed at </text>
<text top="606" left="744" width="41" height="17" font="13">18 mo. </text>
<text top="537" left="838" width="51" height="17" font="13">Pts were </text>
<text top="555" left="838" width="73" height="17" font="13">assessed for </text>
<text top="572" left="838" width="26" height="17" font="13">AEs </text>
<text top="589" left="838" width="62" height="17" font="13">throughout </text>
<text top="606" left="838" width="77" height="17" font="13">the study and </text>
<text top="624" left="838" width="18" height="17" font="13">for </text>
<text top="641" left="838" width="30" height="17" font="13">QoL, </text>
<text top="658" left="838" width="56" height="17" font="13">functional </text>
<text top="675" left="838" width="64" height="17" font="13">status, and </text>
<text top="692" left="838" width="35" height="17" font="13">organ </text>
<text top="710" left="838" width="75" height="17" font="13">function for 6 </text>
<text top="727" left="838" width="24" height="17" font="13">mo. </text>
<text top="537" left="932" width="81" height="17" font="13">6 mo Mortality </text>
<text top="555" left="932" width="79" height="17" font="13">18% (95% CI: </text>
<text top="572" left="932" width="50" height="17" font="13">77-87%) </text>
<text top="589" left="932" width="104" height="17" font="13">1 y Mortality           </text>
<text top="606" left="932" width="79" height="17" font="13">27% (95% CI: </text>
<text top="624" left="932" width="87" height="17" font="13">66-80%) 18 Mo </text>
<text top="641" left="932" width="81" height="17" font="13">Mortality  28% </text>
<text top="658" left="932" width="69" height="17" font="13">(95% CI: 65-</text>
<text top="675" left="932" width="36" height="17" font="13">79%)  </text>
<text top="537" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="555" left="1042" width="77" height="17" font="13">3/05-4/08 (38 </text>
<text top="572" left="1042" width="66" height="17" font="13">mo); 18 mo </text>
<text top="589" left="1042" width="53" height="17" font="13">follow-up </text>
<text top="537" left="1136" width="97" height="17" font="13">79% of LVAD pts </text>
<text top="555" left="1136" width="92" height="17" font="13">reached primary </text>
<text top="572" left="1136" width="105" height="17" font="13">outcome measure, </text>
<text top="589" left="1136" width="84" height="17" font="13">either received </text>
<text top="606" left="1136" width="71" height="17" font="13">a transplant, </text>
<text top="624" left="1136" width="101" height="17" font="13">recovered cardiac </text>
<text top="641" left="1136" width="70" height="17" font="13">function and </text>
<text top="658" left="1136" width="100" height="17" font="13">underwent device </text>
<text top="675" left="1136" width="87" height="17" font="13">explantation, or </text>
<text top="692" left="1136" width="109" height="17" font="13">remained alive with </text>
<text top="710" left="1136" width="83" height="17" font="13">ongoing LVAD </text>
<text top="727" left="1136" width="96" height="17" font="13">support at 18-mo </text>
<text top="744" left="1136" width="53" height="17" font="13">follow-up </text>
<text top="537" left="1277" width="183" height="17" font="13">Bleeding requiring pRBCs            </text>
<text top="555" left="1277" width="161" height="17" font="13">Respiratory failure                  </text>
<text top="572" left="1277" width="156" height="17" font="13">Local infection, non-LVAD    </text>
<text top="589" left="1277" width="181" height="17" font="13">Ventricular arrhythmias                </text>
<text top="606" left="1277" width="160" height="17" font="13">Sepsis                                    </text>
<text top="624" left="1277" width="157" height="17" font="13">Right HF requiring extended </text>
<text top="641" left="1277" width="118" height="17" font="13">inotropic support        </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">144</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="72" height="17" font="13">Evaluate the </text>
<text top="72" left="54" width="62" height="17" font="13">Safety and </text>
<text top="89" left="54" width="70" height="17" font="13">Efficacy of a </text>
<text top="106" left="54" width="79" height="17" font="13">Percutaneous </text>
<text top="124" left="54" width="86" height="17" font="13">LVAD vs. IABP </text>
<text top="141" left="54" width="91" height="17" font="13">for Treatment of </text>
<text top="158" left="54" width="69" height="17" font="13">Cardiogenic </text>
<text top="175" left="54" width="83" height="17" font="13">Shock Caused </text>
<text top="192" left="54" width="79" height="17" font="13">by Myocardial </text>
<text top="210" left="54" width="57" height="17" font="13">Infarction, </text>
<text top="227" left="54" width="66" height="17" font="13">Seyfarth M, </text>
<text top="244" left="54" width="31" height="17" font="13">2008 </text>
<text top="261" left="54" width="58" height="17" font="14">19007597 </text>
<text top="261" left="112" width="32" height="17" font="13">(263) </text>
<text top="55" left="160" width="88" height="17" font="13">To test whether </text>
<text top="72" left="160" width="98" height="17" font="13">the percutaneous </text>
<text top="89" left="160" width="79" height="17" font="13">LVAD Impella </text>
<text top="106" left="160" width="85" height="17" font="13">LP2.5 provides </text>
<text top="124" left="160" width="48" height="17" font="13">superior </text>
<text top="141" left="160" width="80" height="17" font="13">hemodynamic </text>
<text top="158" left="160" width="44" height="17" font="13">support </text>
<text top="175" left="160" width="83" height="17" font="13">compared with </text>
<text top="192" left="160" width="31" height="17" font="13">IABP </text>
<text top="55" left="271" width="29" height="17" font="13">RCT </text>
<text top="55" left="336" width="17" height="17" font="13">26 </text>
<text top="55" left="413" width="132" height="17" font="13">Pts with acute MI within </text>
<text top="72" left="413" width="118" height="17" font="13">48 h and cardiogenic </text>
<text top="89" left="413" width="156" height="17" font="13">shock within 24 h                  </text>
<text top="106" left="413" width="121" height="17" font="13">CI &lt; 2.2 l/min/m2 and </text>
<text top="124" left="413" width="139" height="17" font="13">PCWP &gt;15 mm Hg <i>or</i> an </text>
<text top="141" left="413" width="92" height="17" font="13">angiographically </text>
<text top="158" left="413" width="127" height="17" font="13">measured LVEF &lt;30% </text>
<text top="175" left="413" width="135" height="17" font="13">and LVEDP &gt;20 mm Hg </text>
<text top="55" left="575" width="162" height="17" font="13">Age &lt;18 y;                              </text>
<text top="72" left="575" width="132" height="17" font="13">Prolonged resuscitation </text>
<text top="89" left="575" width="162" height="17" font="13">(&gt;30 min)                                </text>
<text top="106" left="575" width="161" height="17" font="13">HCM;                                      </text>
<text top="124" left="575" width="162" height="17" font="13">LV thrombus;                          </text>
<text top="141" left="575" width="146" height="17" font="13">Treatment with intra-aortic </text>
<text top="158" left="575" width="163" height="17" font="13">balloon pump;                         </text>
<text top="175" left="575" width="148" height="17" font="13">Severe valvular disease or </text>
<text top="192" left="575" width="163" height="17" font="13">mechanical heart valve;          </text>
<text top="210" left="575" width="148" height="17" font="13">Cardiogenic shock caused </text>
<text top="227" left="575" width="82" height="17" font="13">by mechanical </text>
<text top="244" left="575" width="146" height="17" font="13">complications of AMI such </text>
<text top="261" left="575" width="153" height="17" font="13">as ventricular septal defect, </text>
<text top="278" left="575" width="139" height="17" font="13">acute mitral regurgitation </text>
<text top="296" left="575" width="113" height="17" font="13">greater than second </text>
<text top="313" left="575" width="136" height="17" font="13">degree, or rupture of the </text>
<text top="330" left="575" width="162" height="17" font="13">ventricle;                                 </text>
<text top="347" left="575" width="145" height="17" font="13">Predominant RV failure or </text>
<text top="365" left="575" width="161" height="17" font="13">the need for a RVAD;             </text>
<text top="382" left="575" width="163" height="17" font="13">Sepsis;                                    </text>
<text top="399" left="575" width="162" height="17" font="13">Known cerebral disease;        </text>
<text top="416" left="575" width="134" height="17" font="13">bleeding with a need for </text>
<text top="433" left="575" width="164" height="17" font="13">surgical intervention;               </text>
<text top="451" left="575" width="137" height="17" font="13">Allergy to heparin or any </text>
<text top="468" left="575" width="163" height="17" font="13">known coagulopathy;              </text>
<text top="485" left="575" width="162" height="17" font="13">Moderate to severe AI;           </text>
<text top="502" left="575" width="161" height="17" font="13">Pregnancy;                             </text>
<text top="519" left="575" width="143" height="17" font="13">Inclusion in another study </text>
<text top="537" left="575" width="38" height="17" font="13">or trial </text>
<text top="55" left="744" width="25" height="17" font="13">The </text>
<text top="72" left="744" width="80" height="17" font="13">hemodynamic </text>
<text top="89" left="744" width="75" height="17" font="13">improvement </text>
<text top="106" left="744" width="54" height="17" font="13">at 30 min </text>
<text top="124" left="744" width="28" height="17" font="13">after </text>
<text top="141" left="744" width="70" height="17" font="13">implantation </text>
<text top="158" left="744" width="81" height="17" font="13">defined as the </text>
<text top="175" left="744" width="72" height="17" font="13">change in CI </text>
<text top="192" left="744" width="81" height="17" font="13">from baseline. </text>
<text top="55" left="838" width="72" height="17" font="13">Hemodynami</text>
<text top="72" left="838" width="33" height="17" font="13">c and </text>
<text top="89" left="838" width="56" height="17" font="13">metabolic </text>
<text top="106" left="838" width="69" height="17" font="13">parameters; </text>
<text top="124" left="838" width="54" height="17" font="13">All-cause </text>
<text top="141" left="838" width="81" height="17" font="13">mortality at 30 </text>
<text top="158" left="838" width="79" height="17" font="13">d;                    </text>
<text top="175" left="838" width="42" height="17" font="13">Device-</text>
<text top="192" left="838" width="41" height="17" font="13">related </text>
<text top="210" left="838" width="78" height="17" font="13">complications </text>
<text top="227" left="838" width="52" height="17" font="13">including </text>
<text top="244" left="838" width="61" height="17" font="13">hemolysis, </text>
<text top="261" left="838" width="34" height="17" font="13">major </text>
<text top="278" left="838" width="53" height="17" font="13">bleeding, </text>
<text top="296" left="838" width="71" height="17" font="13">cerebrovasc-</text>
<text top="313" left="838" width="67" height="17" font="13">ular events, </text>
<text top="330" left="838" width="26" height="17" font="13">limb </text>
<text top="347" left="838" width="79" height="17" font="13">ischemia, and </text>
<text top="365" left="838" width="46" height="17" font="13">multiple-</text>
<text top="382" left="838" width="35" height="17" font="13">organ </text>
<text top="399" left="838" width="66" height="17" font="13">dysfunction </text>
<text top="416" left="838" width="81" height="17" font="13">scores at 30 d </text>
<text top="433" left="838" width="73" height="17" font="13">using MODS </text>
<text top="451" left="838" width="61" height="17" font="13">and SOFA </text>
<text top="468" left="838" width="44" height="17" font="13">criteria. </text>
<text top="55" left="932" width="226" height="17" font="13">n/a N/A; </text>
<text top="55" left="1069" width="142" height="17" font="13">follow-up </text>
<text top="72" left="1042" width="38" height="17" font="13">of 30d </text>
<text top="55" left="1136" width="122" height="17" font="13">The CI after 30 min of </text>
<text top="72" left="1136" width="70" height="17" font="13">support was </text>
<text top="89" left="1136" width="124" height="17" font="13">significantly increased </text>
<text top="106" left="1136" width="58" height="17" font="13">in pts with </text>
<text top="124" left="1136" width="99" height="17" font="13">the Impella LP2.5 </text>
<text top="141" left="1136" width="103" height="17" font="13">compared with pts </text>
<text top="158" left="1136" width="129" height="17" font="13">with IABP                      </text>
<text top="175" left="1136" width="124" height="17" font="13">(Impella:DCI=0.49+0.4</text>
<text top="192" left="1136" width="102" height="17" font="13">6 l/min/m2; IABP:  </text>
<text top="210" left="1136" width="90" height="17" font="13">DCI=0.11+ 0.31 </text>
<text top="227" left="1136" width="57" height="17" font="13">l/min/m2). </text>
<text top="244" left="1136" width="45" height="17" font="13">p= 0.02 </text>
<text top="261" left="1136" width="7" height="17" font="13">  </text>
<text top="55" left="1277" width="137" height="17" font="13">No difference in adverse </text>
<text top="72" left="1277" width="156" height="17" font="13">effects between pLVAD and </text>
<text top="89" left="1277" width="31" height="17" font="13">IABP </text>
<text top="555" left="54" width="54" height="17" font="13">Impact of </text>
<text top="572" left="54" width="85" height="17" font="13">Center Volume </text>
<text top="589" left="54" width="90" height="17" font="13">on Outcomes of </text>
<text top="606" left="54" width="36" height="17" font="13">LVAD </text>
<text top="624" left="54" width="87" height="17" font="13">Implantation as </text>
<text top="641" left="54" width="86" height="17" font="13">DT: Analysis of </text>
<text top="658" left="54" width="73" height="17" font="13">the Thoratec </text>
<text top="675" left="54" width="61" height="17" font="13">HeartMate </text>
<text top="692" left="54" width="83" height="17" font="13">Registry, 1998 </text>
<text top="710" left="54" width="92" height="17" font="13">to 2005, Lietz K, </text>
<text top="727" left="54" width="31" height="17" font="13">2009 </text>
<text top="744" left="54" width="58" height="17" font="14">19808309 </text>
<text top="744" left="112" width="32" height="17" font="13">(300) </text>
<text top="555" left="160" width="88" height="17" font="13">To examine the </text>
<text top="572" left="160" width="89" height="17" font="13">impact of LVAD </text>
<text top="589" left="160" width="98" height="17" font="13">center volume on </text>
<text top="606" left="160" width="91" height="17" font="13">the outcomes of </text>
<text top="624" left="160" width="20" height="17" font="13">DT </text>
<text top="555" left="271" width="45" height="17" font="13">Registry</text>
<text top="572" left="271" width="58" height="17" font="13">;                </text>
<text top="589" left="271" width="43" height="17" font="13">Retrosp</text>
<text top="606" left="271" width="35" height="17" font="13">ective </text>
<text top="624" left="271" width="48" height="17" font="13">analysis </text>
<text top="555" left="336" width="24" height="17" font="13">351 </text>
<text top="555" left="413" width="141" height="17" font="13">NYHA IV symptoms for &gt; </text>
<text top="572" left="413" width="133" height="17" font="13">60 d despite maximized </text>
<text top="589" left="413" width="83" height="17" font="13">oral therapy or </text>
<text top="606" left="413" width="133" height="17" font="13">requirement of inotropic </text>
<text top="624" left="413" width="137" height="17" font="13">support               LVEF &lt; </text>
<text top="641" left="413" width="155" height="17" font="13">25%                                      </text>
<text top="658" left="413" width="144" height="17" font="13">Peak VO2 &lt;12 mL/kg/min </text>
<text top="675" left="413" width="136" height="17" font="13">or documented failure to </text>
<text top="692" left="413" width="156" height="17" font="13">wean IV inotropic therapy;    </text>
<text top="710" left="413" width="126" height="17" font="13">Contraindication to HT </text>
<text top="727" left="413" width="139" height="17" font="13">attributable to age &gt;65 y, </text>
<text top="744" left="413" width="148" height="17" font="13">insulin-dependent DM with </text>
<text top="761" left="413" width="110" height="17" font="13">end organ damage, </text>
<text top="778" left="413" width="129" height="17" font="13">chronic renal failure, or </text>
<text top="555" left="575" width="135" height="17" font="13">Not specifically outlined; </text>
<text top="572" left="575" width="117" height="17" font="13">similar to REMATCH </text>
<text top="555" left="744" width="65" height="17" font="13">1 y survival </text>
<text top="572" left="744" width="45" height="17" font="13">with DT </text>
<text top="555" left="838" width="7" height="17" font="13">  </text>
<text top="555" left="932" width="104" height="17" font="13">1 y Mortality           </text>
<text top="572" left="932" width="89" height="17" font="13">low volume:       </text>
<text top="589" left="932" width="90" height="17" font="13">52.2%                </text>
<text top="606" left="932" width="47" height="17" font="13">medium </text>
<text top="624" left="932" width="102" height="17" font="13">volume:42.8%       </text>
<text top="641" left="932" width="90" height="17" font="13">high volume:      </text>
<text top="658" left="932" width="38" height="17" font="13">32.6% </text>
<text top="555" left="1042" width="66" height="17" font="13">Enrollment: </text>
<text top="572" left="1042" width="62" height="17" font="13">5/98-12/05 </text>
<text top="589" left="1042" width="76" height="17" font="13">(92 mo); total </text>
<text top="606" left="1042" width="62" height="17" font="13">duration of </text>
<text top="624" left="1042" width="70" height="17" font="13">observation: </text>
<text top="641" left="1042" width="48" height="17" font="13">102 mo; </text>
<text top="658" left="1042" width="44" height="17" font="13">median </text>
<text top="675" left="1042" width="53" height="17" font="13">follow-up </text>
<text top="692" left="1042" width="79" height="17" font="13">period 9.5mo  </text>
<text top="555" left="1136" width="109" height="17" font="13">High volume center </text>
<text top="572" left="1136" width="105" height="17" font="13">compared with low </text>
<text top="589" left="1136" width="121" height="17" font="13">volume center has an </text>
<text top="606" left="1136" width="104" height="17" font="13">absolute benefit of </text>
<text top="624" left="1136" width="105" height="17" font="13">19.6% reduction in </text>
<text top="641" left="1136" width="104" height="17" font="13">mortality at 1 y (1y </text>
<text top="658" left="1136" width="117" height="17" font="13">mortality of 32.6% vs </text>
<text top="675" left="1136" width="42" height="17" font="13">52.2%) </text>
<text top="692" left="1136" width="111" height="17" font="13">OR 0.4; 95% CI 0.2-</text>
<text top="710" left="1136" width="110" height="17" font="13">0.7; p=0.006;           </text>
<text top="555" left="1277" width="164" height="17" font="13">Sepsis                                     </text>
<text top="572" left="1277" width="183" height="17" font="13">Multiorgan failure                          </text>
<text top="589" left="1277" width="179" height="17" font="13">Stroke                                          </text>
<text top="606" left="1277" width="182" height="17" font="13">Right HF                                       </text>
<text top="624" left="1277" width="150" height="17" font="13">LVAD failure/complications </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">145</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="413" width="111" height="17" font="13">other comorbidities. </text>
<text top="252" left="54" width="72" height="17" font="13">Predictors of </text>
<text top="270" left="54" width="58" height="17" font="13">death and </text>
<text top="287" left="54" width="90" height="17" font="13">transplant in pts </text>
<text top="304" left="54" width="36" height="17" font="13">with a </text>
<text top="321" left="54" width="66" height="17" font="13">mechanical </text>
<text top="338" left="54" width="59" height="17" font="13">circulatory </text>
<text top="356" left="54" width="87" height="17" font="13">support device: </text>
<text top="373" left="54" width="40" height="17" font="13">a multi-</text>
<text top="390" left="54" width="65" height="17" font="13">institutional </text>
<text top="407" left="54" width="33" height="17" font="13">study </text>
<text top="425" left="54" width="88" height="17" font="13">(INTERMACS), </text>
<text top="442" left="54" width="71" height="17" font="13">Holman WL, </text>
<text top="459" left="54" width="31" height="17" font="13">2009 </text>
<text top="476" left="54" width="58" height="17" font="14">19134530 </text>
<text top="476" left="112" width="32" height="17" font="13">(301) </text>
<text top="252" left="160" width="60" height="17" font="13">To identify </text>
<text top="270" left="160" width="75" height="17" font="13">predictors for </text>
<text top="287" left="160" width="58" height="17" font="13">death and </text>
<text top="304" left="160" width="84" height="17" font="13">transplantation </text>
<text top="321" left="160" width="85" height="17" font="13">based on initial </text>
<text top="338" left="160" width="68" height="17" font="13">results from </text>
<text top="356" left="160" width="76" height="17" font="13">INTERMACS </text>
<text top="252" left="271" width="89" height="17" font="13">Registry  420 </text>
<text top="252" left="413" width="146" height="17" font="13">Pt underwent implantation </text>
<text top="270" left="413" width="139" height="17" font="13">of mechanical circulatory </text>
<text top="287" left="413" width="83" height="17" font="13">support device </text>
<text top="304" left="413" width="128" height="17" font="13">(INTERMACS registry) </text>
<text top="252" left="575" width="122" height="17" font="13">Not specifically stated </text>
<text top="252" left="744" width="65" height="17" font="13">1 y survival </text>
<text top="270" left="744" width="62" height="17" font="13">post LVAD </text>
<text top="287" left="744" width="70" height="17" font="13">implantation </text>
<text top="252" left="838" width="172" height="17" font="13">AEs 1 </text>
<text top="252" left="943" width="94" height="17" font="13">y Mortality           </text>
<text top="270" left="932" width="103" height="17" font="13">DT: 37%                </text>
<text top="287" left="932" width="62" height="17" font="13">BTT: 24%  </text>
<text top="252" left="1042" width="79" height="17" font="13">19 mo, 12 mo </text>
<text top="270" left="1042" width="53" height="17" font="13">follow-up </text>
<text top="252" left="1136" width="133" height="17" font="13">Risk factors for death     </text>
<text top="270" left="1136" width="118" height="17" font="13">1. INTERMACS level </text>
<text top="287" left="1136" width="135" height="17" font="13">1 (p=0.02)                       </text>
<text top="304" left="1136" width="117" height="17" font="13">2. Older age (&gt; 60yr) </text>
<text top="321" left="1136" width="135" height="17" font="13">(p&lt;0.01)                          </text>
<text top="338" left="1136" width="131" height="17" font="13">3. Presence of ascites   </text>
<text top="356" left="1136" width="135" height="17" font="13">(p=0.003)                        </text>
<text top="373" left="1136" width="92" height="17" font="13">4. Elevated total </text>
<text top="390" left="1136" width="135" height="17" font="13">bilirubin                           </text>
<text top="407" left="1136" width="50" height="17" font="13">(p=0.05) </text>
<text top="425" left="1136" width="134" height="17" font="13">5. BiVAD (p=0.002)        </text>
<text top="442" left="1136" width="121" height="17" font="13">6. Total artificial heart </text>
<text top="459" left="1136" width="121" height="17" font="13">(p=0.03)                      </text>
<text top="476" left="1136" width="123" height="17" font="13">                                    </text>
<text top="493" left="1136" width="123" height="17" font="13">                                    </text>
<text top="511" left="1136" width="62" height="17" font="13">                  </text>
<text top="252" left="1277" width="161" height="17" font="13">CNS events                            </text>
<text top="270" left="1277" width="50" height="17" font="13">Infection </text>
<text top="528" left="54" width="57" height="17" font="13">European </text>
<text top="546" left="54" width="75" height="17" font="13">results with a </text>
<text top="563" left="54" width="89" height="17" font="13">continuous-flow </text>
<text top="580" left="54" width="47" height="17" font="13">VAD for </text>
<text top="597" left="54" width="77" height="17" font="13">advanced HF </text>
<text top="615" left="54" width="78" height="17" font="13">pts, Lahpor J, </text>
<text top="632" left="54" width="31" height="17" font="13">2010 </text>
<text top="649" left="54" width="58" height="17" font="14">19616963 </text>
<text top="649" left="112" width="35" height="17" font="13">(290)  </text>
<text top="528" left="160" width="91" height="17" font="13">To report on the </text>
<text top="546" left="160" width="57" height="17" font="13">European </text>
<text top="563" left="160" width="89" height="17" font="13">experience with </text>
<text top="580" left="160" width="95" height="17" font="13">the Heart Mate II </text>
<text top="597" left="160" width="36" height="17" font="13">LVAD </text>
<text top="528" left="271" width="89" height="17" font="13">Registry   411 </text>
<text top="528" left="413" width="121" height="17" font="13">NYHA IIIB-IV CHF on </text>
<text top="546" left="413" width="102" height="17" font="13">maximum medical </text>
<text top="563" left="413" width="122" height="17" font="13">treatment including IV </text>
<text top="580" left="413" width="146" height="17" font="13">inotropic support                </text>
<text top="597" left="413" width="80" height="17" font="13">At least LVAD </text>
<text top="615" left="413" width="143" height="17" font="13">implantation took place at </text>
<text top="632" left="413" width="144" height="17" font="13">least 6 mo prior to closing </text>
<text top="649" left="413" width="74" height="17" font="13">date of study </text>
<text top="528" left="575" width="122" height="17" font="13">Not specifically stated </text>
<text top="528" left="744" width="75" height="17" font="13">6 mo and 1 y </text>
<text top="546" left="744" width="45" height="17" font="13">survival </text>
<text top="528" left="838" width="26" height="17" font="13">AEs </text>
<text top="528" left="932" width="91" height="17" font="13">6 mo mortality:   </text>
<text top="546" left="932" width="103" height="17" font="13">26%                       </text>
<text top="563" left="932" width="83" height="17" font="13">1st y mortality: </text>
<text top="580" left="932" width="32" height="17" font="13">8.5% </text>
<text top="528" left="1042" width="66" height="17" font="13">52mo (3/04-</text>
<text top="546" left="1042" width="32" height="17" font="13">8/08) </text>
<text top="528" left="1136" width="101" height="17" font="13">Overall survival to </text>
<text top="546" left="1136" width="87" height="17" font="13">transplantation, </text>
<text top="563" left="1136" width="105" height="17" font="13">recovery of natural </text>
<text top="580" left="1136" width="103" height="17" font="13">heart function with </text>
<text top="597" left="1136" width="97" height="17" font="13">evice removal, or </text>
<text top="615" left="1136" width="86" height="17" font="13">ongoing device </text>
<text top="632" left="1136" width="96" height="17" font="13">support at end of </text>
<text top="649" left="1136" width="68" height="17" font="13">study: 69%  </text>
<text top="666" left="1136" width="7" height="17" font="13">  </text>
<text top="528" left="1277" width="183" height="17" font="13">Multiorgan failure                          </text>
<text top="546" left="1277" width="155" height="17" font="13">Infections (sepsis, local non-</text>
<text top="563" left="1277" width="164" height="17" font="13">VAD related, drive line)           </text>
<text top="580" left="1277" width="183" height="17" font="13">Right heart failure                         </text>
<text top="597" left="1277" width="178" height="17" font="13">Bleeding                                      </text>
<text top="615" left="1277" width="181" height="17" font="13">Ventricular arrhythmias                </text>
<text top="632" left="1277" width="140" height="17" font="13">Neurologic complications </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">146</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="74" height="17" font="13">Post–cardiac </text>
<text top="72" left="54" width="57" height="17" font="13">transplant </text>
<text top="89" left="54" width="73" height="17" font="13">survival after </text>
<text top="106" left="54" width="80" height="17" font="13">support with a </text>
<text top="124" left="54" width="89" height="17" font="13">continuous-flow </text>
<text top="141" left="54" width="93" height="17" font="13">LVAD: Impact of </text>
<text top="158" left="54" width="62" height="17" font="13">duration of </text>
<text top="175" left="54" width="80" height="17" font="13">LVAD support </text>
<text top="192" left="54" width="55" height="17" font="13">and other </text>
<text top="210" left="54" width="86" height="17" font="13">variables, John </text>
<text top="227" left="54" width="47" height="17" font="13">R, 2010 </text>
<text top="244" left="54" width="58" height="17" font="14">20447659 </text>
<text top="244" left="112" width="32" height="17" font="13">(302) </text>
<text top="261" left="54" width="3" height="17" font="13"> </text>
<text top="55" left="160" width="76" height="17" font="13">To determine </text>
<text top="72" left="160" width="95" height="17" font="13">factors related to </text>
<text top="89" left="160" width="81" height="17" font="13">posttransplant </text>
<text top="106" left="160" width="78" height="17" font="13">survival in pts </text>
<text top="124" left="160" width="83" height="17" font="13">supported with </text>
<text top="141" left="160" width="89" height="17" font="13">continuous-flow </text>
<text top="158" left="160" width="42" height="17" font="13">LVADs </text>
<text top="55" left="271" width="89" height="17" font="13">Registry  468 </text>
<text top="55" left="413" width="135" height="17" font="13">Adult pts with end-stage </text>
<text top="72" left="413" width="125" height="17" font="13">HF and listed for heart </text>
<text top="89" left="413" width="118" height="17" font="13">transplantation           </text>
<text top="106" left="413" width="118" height="17" font="13">(SAME AS HMII BTT </text>
<text top="124" left="413" width="61" height="17" font="13">STUDIES) </text>
<text top="55" left="575" width="155" height="17" font="13">Severe renal, pulmonary, or </text>
<text top="72" left="575" width="112" height="17" font="13">hepatic dysfunction, </text>
<text top="89" left="575" width="107" height="17" font="13">Active uncontrolled </text>
<text top="106" left="575" width="162" height="17" font="13">infection                                  </text>
<text top="124" left="575" width="145" height="17" font="13">Mechanical aortic valve or </text>
<text top="141" left="575" width="107" height="17" font="13">aortic insufficiency, </text>
<text top="158" left="575" width="164" height="17" font="13">Aortic aneurysm,                     </text>
<text top="175" left="575" width="128" height="17" font="13">Other MCS (other than </text>
<text top="192" left="575" width="142" height="17" font="13">IABP)                                </text>
<text top="210" left="575" width="156" height="17" font="13">Technical obstacles thought </text>
<text top="227" left="575" width="118" height="17" font="13">to pose an increased </text>
<text top="244" left="575" width="164" height="17" font="13">surgical risk                             </text>
<text top="55" left="744" width="75" height="17" font="13">1 mo and 1 y </text>
<text top="72" left="744" width="89" height="17" font="13">survival;             </text>
<text top="89" left="744" width="73" height="17" font="13">survival after </text>
<text top="106" left="744" width="74" height="17" font="13">transplantatio</text>
<text top="124" left="744" width="10" height="17" font="13">n </text>
<text top="55" left="838" width="7" height="17" font="13">  </text>
<text top="55" left="932" width="62" height="17" font="13">Overall 1 y </text>
<text top="72" left="932" width="102" height="17" font="13">mortality: 13%       </text>
<text top="55" left="1042" width="79" height="17" font="13">Enrollment 38 </text>
<text top="72" left="1042" width="53" height="17" font="13">mo (3/05-</text>
<text top="89" left="1042" width="70" height="17" font="13">4/08); follow-</text>
<text top="106" left="1042" width="55" height="17" font="13">up for 1 y </text>
<text top="124" left="1042" width="27" height="17" font="13">post-</text>
<text top="141" left="1042" width="57" height="17" font="13">transplant </text>
<text top="158" left="1042" width="79" height="17" font="13">and for 18 mo </text>
<text top="175" left="1042" width="72" height="17" font="13">post-LVAD if </text>
<text top="192" left="1042" width="21" height="17" font="13">not </text>
<text top="210" left="1042" width="71" height="17" font="13">transplanted </text>
<text top="55" left="1136" width="86" height="17" font="13">Post-transplant </text>
<text top="72" left="1136" width="133" height="17" font="13">survival at 1y:                 </text>
<text top="89" left="1136" width="118" height="17" font="13">&lt;30 d LVAD support: </text>
<text top="106" left="1136" width="134" height="17" font="13">94%                                </text>
<text top="124" left="1136" width="81" height="17" font="13">30-89 d LVAD </text>
<text top="141" left="1136" width="134" height="17" font="13">support: 93%                  </text>
<text top="158" left="1136" width="88" height="17" font="13">90-179 d LVAD </text>
<text top="175" left="1136" width="134" height="17" font="13">support: 84%                  </text>
<text top="192" left="1136" width="125" height="17" font="13">&gt;180 d LVAD support: </text>
<text top="210" left="1136" width="28" height="17" font="13">81% </text>
<text top="227" left="1136" width="50" height="17" font="13">(p=0.18) </text>
<text top="244" left="1136" width="7" height="17" font="13">  </text>
<text top="55" left="1277" width="145" height="17" font="13">Bleeding requiring pRBCs </text>
<text top="282" left="54" width="79" height="17" font="13">Results of the </text>
<text top="299" left="54" width="85" height="17" font="13">Post-U.S. FDA-</text>
<text top="317" left="54" width="87" height="17" font="13">Approval Study </text>
<text top="334" left="54" width="38" height="17" font="13">With a </text>
<text top="351" left="54" width="66" height="17" font="13">Continuous </text>
<text top="368" left="54" width="92" height="17" font="13">Flow LVAD as a </text>
<text top="385" left="54" width="86" height="17" font="13">Bridge to Heart </text>
<text top="403" left="54" width="88" height="17" font="13">Transplantation </text>
<text top="420" left="54" width="88" height="17" font="13">(INTERMACS), </text>
<text top="437" left="54" width="70" height="17" font="13">Starling RC, </text>
<text top="454" left="54" width="66" height="17" font="13">JACC 2011 </text>
<text top="472" left="54" width="58" height="17" font="14">21545946 </text>
<text top="472" left="112" width="32" height="17" font="13">(291) </text>
<text top="282" left="160" width="76" height="17" font="13">To determine </text>
<text top="299" left="160" width="87" height="17" font="13">whether results </text>
<text top="317" left="160" width="75" height="17" font="13">with the HMII </text>
<text top="334" left="160" width="59" height="17" font="13">LVAD in a </text>
<text top="351" left="160" width="66" height="17" font="13">commercial </text>
<text top="368" left="160" width="61" height="17" font="13">setting are </text>
<text top="385" left="160" width="81" height="17" font="13">comparable to </text>
<text top="403" left="160" width="83" height="17" font="13">other available </text>
<text top="420" left="160" width="83" height="17" font="13">devices for the </text>
<text top="437" left="160" width="89" height="17" font="13">same indication </text>
<text top="282" left="271" width="105" height="17" font="13">Registry 338 </text>
<text top="282" left="413" width="92" height="17" font="13">INTERMACS </text>
<text top="282" left="489" width="63" height="17" font="13">registry, </text>
<text top="299" left="413" width="80" height="17" font="13">LVAD for BTT </text>
<text top="282" left="575" width="7" height="17" font="13">  </text>
<text top="282" left="744" width="47" height="17" font="13">Survival </text>
<text top="299" left="744" width="76" height="17" font="13">(transplant or </text>
<text top="317" left="744" width="38" height="17" font="13">death) </text>
<text top="282" left="838" width="81" height="17" font="13">30 d mortality, </text>
<text top="299" left="838" width="55" height="17" font="13">inhospital </text>
<text top="317" left="838" width="53" height="17" font="13">mortality, </text>
<text top="334" left="838" width="64" height="17" font="13">LOS, QOL, </text>
<text top="351" left="838" width="20" height="17" font="13">AE </text>
<text top="282" left="932" width="98" height="17" font="13">12 mo mortality    </text>
<text top="299" left="932" width="77" height="17" font="13">13% HMII vs. </text>
<text top="317" left="932" width="85" height="17" font="13">22%COMP       </text>
<text top="282" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="299" left="1042" width="73" height="17" font="13">9/07-2/09; at </text>
<text top="317" left="1042" width="67" height="17" font="13">least 12 mo </text>
<text top="334" left="1042" width="79" height="17" font="13">follow-up post </text>
<text top="351" left="1042" width="29" height="17" font="13">VAD </text>
<text top="282" left="1136" width="134" height="17" font="13">12 mo survival:               </text>
<text top="299" left="1136" width="101" height="17" font="13">85% HMII vs 70% </text>
<text top="317" left="1136" width="133" height="17" font="13">COMP                            </text>
<text top="334" left="1136" width="124" height="17" font="13">no difference between </text>
<text top="351" left="1136" width="119" height="17" font="13">INTERMACS profiles </text>
<text top="368" left="1136" width="100" height="17" font="13">within each group </text>
<text top="385" left="1136" width="134" height="17" font="13">12 mo survival:               </text>
<text top="403" left="1136" width="95" height="17" font="13">log rank p&lt;0.001 </text>
<text top="420" left="1136" width="7" height="17" font="13">  </text>
<text top="282" left="1277" width="181" height="17" font="13">Bleeding event rate/pt-y               </text>
<text top="299" left="1277" width="137" height="17" font="13">1.44 HMII v 1.79 COMP, </text>
<text top="317" left="1277" width="182" height="17" font="13">p=0.19                                          </text>
<text top="334" left="1277" width="183" height="17" font="13">Infection event rate/pt-y                </text>
<text top="351" left="1277" width="131" height="17" font="13">1.0 HMII v 2.12 COMP, </text>
<text top="368" left="1277" width="182" height="17" font="13">p&lt;0.0001                                      </text>
<text top="489" left="54" width="42" height="17" font="15"><b>BIVAD </b></text>
<text top="513" left="54" width="75" height="17" font="13">Survival after </text>
<text top="530" left="54" width="70" height="17" font="13">biventricular </text>
<text top="547" left="54" width="74" height="17" font="13">assist device </text>
<text top="564" left="54" width="92" height="17" font="13">implantation: An </text>
<text top="582" left="54" width="61" height="17" font="13">analysis of </text>
<text top="599" left="54" width="76" height="17" font="13">INTERMACS </text>
<text top="616" left="54" width="57" height="17" font="13">database, </text>
<text top="633" left="54" width="80" height="17" font="13">Cleveland JC, </text>
<text top="650" left="54" width="31" height="17" font="13">2011 </text>
<text top="668" left="54" width="58" height="17" font="14">21621423 </text>
<text top="668" left="112" width="32" height="17" font="13">(303) </text>
<text top="513" left="160" width="81" height="17" font="13">To identify the </text>
<text top="530" left="160" width="82" height="17" font="13">underlying pre-</text>
<text top="547" left="160" width="43" height="17" font="13">implant </text>
<text top="564" left="160" width="96" height="17" font="13">characteristics of </text>
<text top="582" left="160" width="81" height="17" font="13">the population </text>
<text top="599" left="160" width="91" height="17" font="13">requiring BiVAD </text>
<text top="616" left="160" width="68" height="17" font="13">support that </text>
<text top="633" left="160" width="71" height="17" font="13">contribute to </text>
<text top="650" left="160" width="96" height="17" font="13">reduced survival, </text>
<text top="668" left="160" width="80" height="17" font="13">and to identify </text>
<text top="685" left="160" width="77" height="17" font="13">differences in </text>
<text top="702" left="160" width="77" height="17" font="13">postoperative </text>
<text top="719" left="160" width="82" height="17" font="13">outcomes with </text>
<text top="737" left="160" width="83" height="17" font="13">respect to AEs </text>
<text top="754" left="160" width="83" height="17" font="13">compared with </text>
<text top="771" left="160" width="78" height="17" font="13">pts supported </text>
<text top="788" left="160" width="98" height="17" font="13">with LVAD alone. </text>
<text top="513" left="271" width="112" height="17" font="13">Registry 1852 </text>
<text top="513" left="413" width="92" height="17" font="13">INTERMACS </text>
<text top="513" left="489" width="63" height="17" font="13">registry, </text>
<text top="530" left="413" width="90" height="17" font="13">LVAD or BiVAD </text>
<text top="547" left="413" width="70" height="17" font="13">implantation </text>
<text top="513" left="575" width="24" height="17" font="13">N/A </text>
<text top="513" left="710" width="51" height="17" font="13">Survival  </text>
<text top="513" left="831" width="26" height="17" font="13">AEs </text>
<text top="513" left="932" width="101" height="17" font="13">6 mo mortality       </text>
<text top="530" left="932" width="102" height="17" font="13">BiVAD: 44%          </text>
<text top="547" left="932" width="101" height="17" font="13">LVAD: 14%           </text>
<text top="564" left="932" width="55" height="17" font="13">p&lt;0.0001 </text>
<text top="513" left="1042" width="70" height="17" font="13">15 mo (6/06-</text>
<text top="530" left="1042" width="32" height="17" font="13">9/09) </text>
<text top="513" left="1136" width="120" height="17" font="13">Risk factors for death </text>
<text top="530" left="1136" width="144" height="17" font="13">with BiVAD                        </text>
<text top="547" left="1136" width="146" height="17" font="13">Older age                           </text>
<text top="564" left="1136" width="146" height="17" font="13">Higher BSA                        </text>
<text top="582" left="1136" width="146" height="17" font="13">Presence of Ascites           </text>
<text top="599" left="1136" width="146" height="17" font="13">Elevated creatinine            </text>
<text top="616" left="1136" width="144" height="17" font="13">Elevated total bilirubin       </text>
<text top="633" left="1136" width="144" height="17" font="13">Elevated INR                     </text>
<text top="650" left="1136" width="146" height="17" font="13">History of valve surgery     </text>
<text top="668" left="1136" width="116" height="17" font="13">Failure to wean from </text>
<text top="685" left="1136" width="42" height="17" font="13">bypass </text>
<text top="702" left="1136" width="7" height="17" font="13">  </text>
<text top="513" left="1288" width="171" height="17" font="13">Bleeding                                    </text>
<text top="530" left="1288" width="50" height="17" font="13">Infection </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">147</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="136" height="17" font="15"><b>PERCUTANEOUS VAD</b> </text>
<text top="78" left="54" width="91" height="17" font="13">Multicenter Trial </text>
<text top="95" left="54" width="67" height="17" font="13">of the Orqis </text>
<text top="112" left="54" width="46" height="17" font="13">Medical </text>
<text top="130" left="54" width="93" height="17" font="13">Cancion System </text>
<text top="147" left="54" width="38" height="17" font="13">for the </text>
<text top="164" left="54" width="59" height="17" font="13">Enhanced </text>
<text top="181" left="54" width="93" height="17" font="13">Treatment of HF </text>
<text top="198" left="54" width="92" height="17" font="13">Unresponsive to </text>
<text top="216" left="54" width="46" height="17" font="13">Medical </text>
<text top="233" left="54" width="49" height="17" font="13">Therapy </text>
<text top="250" left="54" width="89" height="17" font="13">(MOMENTUM), </text>
<text top="267" left="54" width="77" height="17" font="13">Greenberg B, </text>
<text top="285" left="54" width="31" height="17" font="13">2008 </text>
<text top="302" left="54" width="58" height="17" font="14">18765394 </text>
<text top="302" left="112" width="32" height="17" font="13">(297) </text>
<text top="78" left="160" width="69" height="17" font="13">To compare </text>
<text top="95" left="160" width="78" height="17" font="13">percutaneous </text>
<text top="112" left="160" width="96" height="17" font="13">continuous aortic </text>
<text top="130" left="160" width="25" height="17" font="13">flow </text>
<text top="147" left="160" width="78" height="17" font="13">augmentation </text>
<text top="164" left="160" width="98" height="17" font="13">(flow&lt;.5 L/min for </text>
<text top="181" left="160" width="88" height="17" font="13">up to 96 h) plus </text>
<text top="198" left="160" width="90" height="17" font="13">medical therapy </text>
<text top="216" left="160" width="65" height="17" font="13">vs. medical </text>
<text top="233" left="160" width="78" height="17" font="13">therapy alone </text>
<text top="78" left="271" width="29" height="17" font="13">RCT </text>
<text top="78" left="336" width="24" height="17" font="13">168 </text>
<text top="78" left="413" width="155" height="17" font="13">LVEF&lt;35%                           </text>
<text top="95" left="413" width="102" height="17" font="13">Persistent clinical, </text>
<text top="112" left="413" width="83" height="17" font="13">hemodynamic, </text>
<text top="130" left="413" width="131" height="17" font="13">and renal derangement </text>
<text top="147" left="413" width="118" height="17" font="13">despite standard oral </text>
<text top="164" left="413" width="142" height="17" font="13">medication and treatment </text>
<text top="181" left="413" width="133" height="17" font="13">for &gt; 24 h with &gt;1 of the </text>
<text top="198" left="413" width="99" height="17" font="13">following drugs at </text>
<text top="216" left="413" width="137" height="17" font="13">minimum dosage (stable </text>
<text top="233" left="413" width="156" height="17" font="13">for &gt;6 h):                               </text>
<text top="250" left="413" width="103" height="17" font="13">a) dobutamine 2.5 </text>
<text top="267" left="413" width="156" height="17" font="13">mg/kg/min                             </text>
<text top="285" left="413" width="155" height="17" font="13">b) milrinone 0.3mg/kg/min    </text>
<text top="302" left="413" width="148" height="17" font="13">c) dopamine 5 mg/kg/min , </text>
<text top="319" left="413" width="67" height="17" font="13">d) nesiritide </text>
<text top="336" left="413" width="156" height="17" font="13">0.01mg/kg/min                      </text>
<text top="353" left="413" width="88" height="17" font="13">e) nitroprusside </text>
<text top="371" left="413" width="105" height="17" font="13">0.25mg/kg/min , or </text>
<text top="388" left="413" width="87" height="17" font="13">f) nitroglycerine </text>
<text top="405" left="413" width="156" height="17" font="13">0.25mg/kg/min                      </text>
<text top="422" left="413" width="108" height="17" font="13">PCWP &gt;18 mm Hg </text>
<text top="439" left="413" width="141" height="17" font="13">continuously for 12 h and </text>
<text top="457" left="413" width="121" height="17" font="13">&gt;20 mm Hg at time of </text>
<text top="474" left="413" width="156" height="17" font="13">randomization;                      </text>
<text top="491" left="413" width="156" height="17" font="13">CI &lt; 2.4 L/min/m 2;               </text>
<text top="508" left="413" width="119" height="17" font="13">SCr &gt;1.2 mg/dL or IV </text>
<text top="525" left="413" width="129" height="17" font="13">furosemide dose  &gt;120 </text>
<text top="543" left="413" width="108" height="17" font="13">mg/d or equivalent. </text>
<text top="78" left="575" width="120" height="17" font="13">Recent Q-wave MI or </text>
<text top="95" left="575" width="43" height="17" font="13">cardaic </text>
<text top="112" left="575" width="130" height="17" font="13">revascularization;          </text>
<text top="130" left="575" width="129" height="17" font="13">Severe lung disease;    </text>
<text top="147" left="575" width="121" height="17" font="13">Primary liver disease; </text>
<text top="164" left="575" width="121" height="17" font="13">SCr &gt;4.0 mg/dL or on </text>
<text top="181" left="575" width="129" height="17" font="13">dialysis;                         </text>
<text top="198" left="575" width="68" height="17" font="13">CRT device </text>
<text top="216" left="575" width="129" height="17" font="13">implanted within 14 d;   </text>
<text top="233" left="575" width="130" height="17" font="13">SBP &lt;80 mm Hg;          </text>
<text top="250" left="575" width="94" height="17" font="13">Need for cardiac </text>
<text top="267" left="575" width="127" height="17" font="13">mechanical support;     </text>
<text top="285" left="575" width="81" height="17" font="13">Platelet count  </text>
<text top="302" left="575" width="127" height="17" font="13">&lt;50 000/ L;                   </text>
<text top="319" left="575" width="89" height="17" font="13">INR &gt; 1.5 in the </text>
<text top="336" left="575" width="64" height="17" font="13">absence of </text>
<text top="353" left="575" width="90" height="17" font="13">anticoagulation; </text>
<text top="371" left="575" width="130" height="17" font="13">Systemic infection;        </text>
<text top="388" left="575" width="111" height="17" font="13">CVA or TIA within 3 </text>
<text top="405" left="575" width="130" height="17" font="13">mo;                                </text>
<text top="422" left="575" width="111" height="17" font="13">Active status on the </text>
<text top="439" left="575" width="43" height="17" font="13">cardiac </text>
<text top="457" left="575" width="103" height="17" font="13">transplantation list </text>
<text top="474" left="575" width="122" height="17" font="13">unless transplant was </text>
<text top="491" left="575" width="108" height="17" font="13">considered unlikely </text>
<text top="508" left="575" width="76" height="17" font="13">within 65 d;    </text>
<text top="525" left="575" width="109" height="17" font="13">Peripheral vascular </text>
<text top="543" left="575" width="111" height="17" font="13">disease with absent </text>
<text top="560" left="575" width="81" height="17" font="13">pedal pulse or </text>
<text top="577" left="575" width="66" height="17" font="13">evidence of </text>
<text top="594" left="575" width="129" height="17" font="13">limb ischemia;               </text>
<text top="612" left="575" width="60" height="17" font="13">Significant </text>
<text top="629" left="575" width="113" height="17" font="13">uncorrected primary </text>
<text top="646" left="575" width="95" height="17" font="13">valvular disease. </text>
<text top="78" left="710" width="90" height="17" font="13">Overall success </text>
<text top="95" left="710" width="96" height="17" font="13">composite based </text>
<text top="112" left="710" width="69" height="17" font="13">on technical </text>
<text top="130" left="710" width="78" height="17" font="13">(device group </text>
<text top="147" left="710" width="33" height="17" font="13">only), </text>
<text top="164" left="710" width="107" height="17" font="13">hemodynamic, and </text>
<text top="181" left="710" width="88" height="17" font="13">clinical success </text>
<text top="198" left="710" width="105" height="17" font="13">defined as follows: </text>
<text top="216" left="710" width="100" height="17" font="13">technical success </text>
<text top="233" left="710" width="78" height="17" font="13">(device group </text>
<text top="250" left="710" width="107" height="17" font="13">only), insertion and </text>
<text top="267" left="710" width="100" height="17" font="13">attainment of flow </text>
<text top="285" left="710" width="107" height="17" font="13">&gt;1 L/min for &gt;24 h; </text>
<text top="302" left="710" width="80" height="17" font="13">hemodynamic </text>
<text top="319" left="710" width="85" height="17" font="13">success, mean </text>
<text top="336" left="710" width="94" height="17" font="13">PCWP decrease </text>
<text top="353" left="710" width="105" height="17" font="13">from baseline of  5 </text>
<text top="371" left="710" width="98" height="17" font="13">mmHg calculated </text>
<text top="388" left="710" width="98" height="17" font="13">as the average of </text>
<text top="405" left="710" width="101" height="17" font="13">values at 72-96 h; </text>
<text top="422" left="710" width="64" height="17" font="13">and clinical </text>
<text top="439" left="710" width="100" height="17" font="13">success, from d 1-</text>
<text top="457" left="710" width="45" height="17" font="13">35 after </text>
<text top="474" left="710" width="107" height="17" font="13">randomization, any </text>
<text top="491" left="710" width="89" height="17" font="13">of the following: </text>
<text top="508" left="710" width="103" height="17" font="13">&gt;10 consecutive d </text>
<text top="525" left="710" width="63" height="17" font="13">alive out of </text>
<text top="543" left="710" width="66" height="17" font="13">hospital, no </text>
<text top="560" left="710" width="60" height="17" font="13">alternative </text>
<text top="577" left="710" width="66" height="17" font="13">mechanical </text>
<text top="594" left="710" width="98" height="17" font="13">support, absence </text>
<text top="612" left="710" width="75" height="17" font="13">of death, and </text>
<text top="629" left="710" width="64" height="17" font="13">absence of </text>
<text top="646" left="710" width="107" height="17" font="13">readmission for HF </text>
<text top="78" left="831" width="84" height="17" font="13">Change in SCr </text>
<text top="95" left="831" width="81" height="17" font="13">at d 3 Change </text>
<text top="112" left="831" width="82" height="17" font="13">in body weight </text>
<text top="130" left="831" width="96" height="17" font="13">at d 4                   </text>
<text top="147" left="831" width="75" height="17" font="13">Change in CI </text>
<text top="164" left="831" width="53" height="17" font="13">(72- 96 h </text>
<text top="181" left="831" width="55" height="17" font="13">average), </text>
<text top="198" left="831" width="80" height="17" font="13">Change in NT-</text>
<text top="216" left="831" width="94" height="17" font="13">proBNP at d 3;    </text>
<text top="233" left="831" width="59" height="17" font="13">Change in </text>
<text top="250" left="831" width="81" height="17" font="13">KCCQ Overall </text>
<text top="267" left="831" width="56" height="17" font="13">Summary </text>
<text top="285" left="831" width="76" height="17" font="13">score at 2 wk </text>
<text top="302" left="831" width="55" height="17" font="13">and 35 d. </text>
<text top="78" left="932" width="77" height="17" font="13">65 d mortality </text>
<text top="95" left="932" width="74" height="17" font="13">pVAD 33.9% </text>
<text top="112" left="932" width="82" height="17" font="13">control 32.2%  </text>
<text top="130" left="932" width="56" height="17" font="13">(HR:1.05; </text>
<text top="147" left="932" width="69" height="17" font="13">p=0.87)        </text>
<text top="78" left="1042" width="62" height="17" font="13">Enrollment </text>
<text top="95" left="1042" width="55" height="17" font="13">9/04-8/07 </text>
<text top="112" left="1042" width="79" height="17" font="13">(3y), out to 64 </text>
<text top="130" left="1042" width="42" height="17" font="13">d since </text>
<text top="147" left="1042" width="81" height="17" font="13">randomization </text>
<text top="78" left="1136" width="91" height="17" font="13">Primary efficacy </text>
<text top="95" left="1136" width="98" height="17" font="13">endpoint success </text>
<text top="112" left="1136" width="108" height="17" font="13">(hemodynamic and </text>
<text top="130" left="1136" width="133" height="17" font="13">clinical success for both </text>
<text top="147" left="1136" width="119" height="17" font="13">groups plus technical </text>
<text top="164" left="1136" width="61" height="17" font="13">success in </text>
<text top="181" left="1136" width="124" height="17" font="13">the device group) was </text>
<text top="198" left="1136" width="116" height="17" font="13">seen in 13.6% of the </text>
<text top="216" left="1136" width="137" height="17" font="13">control group and 17.4% </text>
<text top="233" left="1136" width="128" height="17" font="13">of the device group pts </text>
<text top="250" left="1136" width="145" height="17" font="13">(p=0.45)                             </text>
<text top="267" left="1136" width="135" height="17" font="13">No significant difference </text>
<text top="285" left="1136" width="121" height="17" font="13">was found in SCr, NT-</text>
<text top="302" left="1136" width="137" height="17" font="13">proBNP, or body weight. </text>
<text top="319" left="1136" width="137" height="17" font="13">KCCQ Overall Summary </text>
<text top="336" left="1136" width="24" height="17" font="13">and </text>
<text top="353" left="1136" width="139" height="17" font="13">Clinical Summary scores </text>
<text top="371" left="1136" width="122" height="17" font="13">increased more in the </text>
<text top="388" left="1136" width="123" height="17" font="13">device group (p=0.10) </text>
<text top="405" left="1136" width="136" height="17" font="13">than in the control group </text>
<text top="422" left="1136" width="136" height="17" font="13">(p=0.095), but treatment </text>
<text top="439" left="1136" width="114" height="17" font="13">differences were not </text>
<text top="457" left="1136" width="62" height="17" font="13">significant  </text>
<text top="474" left="1136" width="7" height="17" font="13">  </text>
<text top="78" left="1288" width="155" height="17" font="13">Any bleed (40.4% device vs </text>
<text top="95" left="1288" width="141" height="17" font="13">13.6% control, p=0.0004) </text>
<text top="672" left="54" width="30" height="17" font="15"><b>QOL </b></text>
</page>
<page number="148" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">148</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="70" height="17" font="13">Longitudinal </text>
<text top="72" left="54" width="86" height="17" font="13">Change in QoL </text>
<text top="89" left="54" width="81" height="17" font="13">and Impact on </text>
<text top="106" left="54" width="77" height="17" font="13">Survival After </text>
<text top="124" left="54" width="36" height="17" font="13">LVAD </text>
<text top="141" left="54" width="74" height="17" font="13">Implantation, </text>
<text top="158" left="54" width="90" height="17" font="13">Grady KL, 2004 </text>
<text top="175" left="54" width="58" height="17" font="14">15063260 </text>
<text top="175" left="112" width="32" height="17" font="13">(293) </text>
<text top="55" left="160" width="68" height="17" font="13">To describe </text>
<text top="72" left="160" width="96" height="17" font="13">change with time </text>
<text top="89" left="160" width="97" height="17" font="13">(from 1mo to 1 y) </text>
<text top="106" left="160" width="59" height="17" font="13">in pts who </text>
<text top="124" left="160" width="94" height="17" font="13">received a Heart </text>
<text top="141" left="160" width="71" height="17" font="13">Mate vented </text>
<text top="158" left="160" width="91" height="17" font="13">elecric LVAD as </text>
<text top="175" left="160" width="64" height="17" font="13">BTT and to </text>
<text top="192" left="160" width="72" height="17" font="13">identify QOL </text>
<text top="210" left="160" width="75" height="17" font="13">(predictors of </text>
<text top="227" left="160" width="73" height="17" font="13">survival after </text>
<text top="244" left="160" width="36" height="17" font="13">LVAD </text>
<text top="261" left="160" width="74" height="17" font="13">implantation) </text>
<text top="55" left="271" width="40" height="17" font="13">Cohort </text>
<text top="72" left="271" width="35" height="17" font="13">Study </text>
<text top="55" left="336" width="192" height="17" font="13">78 Received </text>
<text top="55" left="468" width="94" height="17" font="13">either </text>
<text top="72" left="413" width="131" height="17" font="13">HeartMate VE LVAD or </text>
<text top="89" left="413" width="134" height="17" font="13">Heart Mate implantatble </text>
<text top="106" left="413" width="146" height="17" font="13">pneumatic LVAD between </text>
<text top="124" left="413" width="144" height="17" font="13">8/1/94 and 8/31/99 at 1 of </text>
<text top="141" left="413" width="133" height="17" font="13">9 medical centers in US </text>
<text top="158" left="413" width="144" height="17" font="13">and one medical center in </text>
<text top="175" left="413" width="156" height="17" font="13">Australia as BTT                   </text>
<text top="192" left="413" width="155" height="17" font="13">Age &gt; 18 y                            </text>
<text top="210" left="413" width="123" height="17" font="13">Able to read and write </text>
<text top="227" left="413" width="153" height="17" font="13">English                                 </text>
<text top="244" left="413" width="98" height="17" font="13">Physically able to </text>
<text top="261" left="413" width="112" height="17" font="13">participate                </text>
<text top="55" left="575" width="27" height="17" font="13"> N/A </text>
<text top="55" left="710" width="29" height="17" font="13">QOL </text>
<text top="72" left="710" width="87" height="17" font="13">questionnaires: </text>
<text top="89" left="710" width="105" height="17" font="13">QOL Index, Rating </text>
<text top="106" left="710" width="108" height="17" font="13">Question Form, HF </text>
<text top="124" left="710" width="55" height="17" font="13">Symptom </text>
<text top="141" left="710" width="81" height="17" font="13">Checklist, and </text>
<text top="158" left="710" width="93" height="17" font="13">Sickness Impact </text>
<text top="175" left="710" width="38" height="17" font="13">Profile </text>
<text top="55" left="831" width="27" height="17" font="13"> N/A </text>
<text top="55" left="932" width="24" height="17" font="13">N/A </text>
<text top="55" left="1042" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1136" width="114" height="17" font="13">QoL outcomes were </text>
<text top="72" left="1136" width="120" height="17" font="13">fairly good and stable </text>
<text top="89" left="1136" width="120" height="17" font="13">from 1 mo to 1 y after </text>
<text top="106" left="1136" width="109" height="17" font="13">LVAD implantation. </text>
<text top="124" left="1136" width="94" height="17" font="13">Overall QoL was </text>
<text top="141" left="1136" width="118" height="17" font="13">unchanged, however </text>
<text top="158" left="1136" width="96" height="17" font="13">both positive and </text>
<text top="175" left="1136" width="113" height="17" font="13">negative changes in </text>
<text top="192" left="1136" width="125" height="17" font="13">subareas of QoL were </text>
<text top="210" left="1136" width="118" height="17" font="13">noted. Pt satisfaction </text>
<text top="227" left="1136" width="111" height="17" font="13">with life improved in </text>
<text top="244" left="1136" width="42" height="17" font="13">area of </text>
<text top="261" left="1136" width="120" height="17" font="13">health/functioning but </text>
<text top="278" left="1136" width="135" height="17" font="13">worsened in satisfaction </text>
<text top="296" left="1136" width="124" height="17" font="13">with significant others. </text>
<text top="313" left="1136" width="100" height="17" font="13">Cardiopulmonary, </text>
<text top="330" left="1136" width="64" height="17" font="13">neurologic, </text>
<text top="347" left="1136" width="105" height="17" font="13">psychological, and </text>
<text top="365" left="1136" width="101" height="17" font="13">physical symptom </text>
<text top="382" left="1136" width="103" height="17" font="13">distress improved. </text>
<text top="399" left="1136" width="136" height="17" font="13">Functional disability with </text>
<text top="416" left="1136" width="90" height="17" font="13">respect to work, </text>
<text top="433" left="1136" width="138" height="17" font="13">sleep/rest, self-care, and </text>
<text top="451" left="1136" width="98" height="17" font="13">physical disability </text>
<text top="468" left="1136" width="111" height="17" font="13">improved over time. </text>
<text top="485" left="1136" width="111" height="17" font="13">However, functional </text>
<text top="502" left="1136" width="133" height="17" font="13">disability with respect to </text>
<text top="519" left="1136" width="133" height="17" font="13">home management and </text>
<text top="537" left="1136" width="95" height="17" font="13">social interaction </text>
<text top="554" left="1136" width="60" height="17" font="13">worsened. </text>
<text top="55" left="1288" width="27" height="17" font="13"> N/A </text>
<text top="574" left="54" width="66" height="17" font="13">Continuous </text>
<text top="592" left="54" width="65" height="17" font="13">Flow LVAD </text>
<text top="609" left="54" width="54" height="17" font="13">Improves </text>
<text top="626" left="54" width="60" height="17" font="13">Functional </text>
<text top="643" left="54" width="75" height="17" font="13">Capacity and </text>
<text top="661" left="54" width="40" height="17" font="13">QoL of </text>
<text top="678" left="54" width="78" height="17" font="13">Advanced HF </text>
<text top="695" left="54" width="90" height="17" font="13">Pts, Rogers JG, </text>
<text top="712" left="54" width="31" height="17" font="13">2010 </text>
<text top="729" left="54" width="58" height="17" font="14">20413033 </text>
<text top="729" left="112" width="32" height="17" font="13">(304) </text>
<text top="574" left="160" width="80" height="17" font="13">To assess the </text>
<text top="592" left="160" width="53" height="17" font="13">impact of </text>
<text top="609" left="160" width="88" height="17" font="13">continuous flow </text>
<text top="626" left="160" width="59" height="17" font="13">LVADs on </text>
<text top="643" left="160" width="56" height="17" font="13">functional </text>
<text top="661" left="160" width="93" height="17" font="13">capacity and HF-</text>
<text top="678" left="160" width="68" height="17" font="13">related QoL </text>
<text top="574" left="271" width="40" height="17" font="13">Cohort </text>
<text top="592" left="271" width="35" height="17" font="13">Study </text>
<text top="574" left="336" width="24" height="17" font="13">655 </text>
<text top="574" left="413" width="148" height="17" font="13">Pts enrolled in either HM II </text>
<text top="592" left="413" width="131" height="17" font="13">BTT or DT clinical trials </text>
<text top="574" left="575" width="27" height="17" font="13"> N/A </text>
<text top="574" left="710" width="98" height="17" font="13">NYHA Functional </text>
<text top="592" left="710" width="92" height="17" font="13">Class assess by </text>
<text top="609" left="710" width="116" height="17" font="13">clinician                     </text>
<text top="626" left="710" width="105" height="17" font="13">Pt reported activity </text>
<text top="643" left="710" width="105" height="17" font="13">levels (METS) and </text>
<text top="661" left="710" width="115" height="17" font="13">6MWT                       </text>
<text top="678" left="710" width="71" height="17" font="13">Heart failure-</text>
<text top="695" left="710" width="87" height="17" font="13">related QOL by </text>
<text top="712" left="710" width="73" height="17" font="13">MLWHF and </text>
<text top="729" left="710" width="39" height="17" font="13">KCCQ </text>
<text top="574" left="831" width="24" height="17" font="13">N/A </text>
<text top="574" left="932" width="24" height="17" font="13">N/A </text>
<text top="574" left="1042" width="24" height="17" font="13">N/A </text>
<text top="574" left="1136" width="134" height="17" font="13">LVAD pts demonstrated </text>
<text top="592" left="1136" width="110" height="17" font="13">early and sustained </text>
<text top="609" left="1136" width="94" height="17" font="13">improvements in </text>
<text top="626" left="1136" width="116" height="17" font="13">functional status and </text>
<text top="643" left="1136" width="126" height="17" font="13">QOL. NYHA functional </text>
<text top="661" left="1136" width="114" height="17" font="13">class improved from </text>
<text top="678" left="1136" width="136" height="17" font="13">class IV to class I or II in </text>
<text top="695" left="1136" width="118" height="17" font="13">majority of pts (about </text>
<text top="712" left="1136" width="130" height="17" font="13">80%). Improved 6MWT </text>
<text top="729" left="1136" width="107" height="17" font="13">distance as well as </text>
<text top="747" left="1136" width="112" height="17" font="13">MLWHF and KCCQ </text>
<text top="764" left="1136" width="47" height="17" font="13">scores.  </text>
<text top="574" left="1288" width="24" height="17" font="13">N/A </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">149</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="53" height="17" font="13">QOL and </text>
<text top="72" left="54" width="92" height="17" font="13">functional status </text>
<text top="89" left="54" width="85" height="17" font="13">in pts surviving </text>
<text top="106" left="54" width="66" height="17" font="13">12 mo after </text>
<text top="124" left="54" width="36" height="17" font="13">LVAD </text>
<text top="141" left="54" width="73" height="17" font="13">implantation, </text>
<text top="158" left="54" width="84" height="17" font="13">Allen JG, 2010 </text>
<text top="175" left="54" width="58" height="17" font="14">19837607 </text>
<text top="175" left="112" width="32" height="17" font="13">(305) </text>
<text top="192" left="54" width="3" height="17" font="13"> </text>
<text top="55" left="160" width="96" height="17" font="13">To review QoL in </text>
<text top="72" left="160" width="66" height="17" font="13">pt on LVAD </text>
<text top="89" left="160" width="93" height="17" font="13">support for &gt;1 y  </text>
<text top="55" left="271" width="43" height="17" font="13">Retrosp</text>
<text top="72" left="271" width="35" height="17" font="13">ective </text>
<text top="89" left="271" width="48" height="17" font="13">analysis </text>
<text top="55" left="336" width="17" height="17" font="13">30 </text>
<text top="55" left="413" width="137" height="17" font="13">Pts who underwent HMII </text>
<text top="72" left="413" width="146" height="17" font="13">or HMI LVAD implantation </text>
<text top="89" left="413" width="126" height="17" font="13">between 2000-2008 at </text>
<text top="106" left="413" width="132" height="17" font="13">Johns Hopkins Hospital </text>
<text top="55" left="575" width="101" height="17" font="13">Pt transplanted or </text>
<text top="72" left="575" width="113" height="17" font="13">died before 365 d of </text>
<text top="89" left="575" width="31" height="17" font="13">MCS </text>
<text top="55" left="710" width="92" height="17" font="13">6MWT distance, </text>
<text top="72" left="710" width="87" height="17" font="13">MET tolerance, </text>
<text top="89" left="710" width="88" height="17" font="13">MLHFQ, NYHA </text>
<text top="106" left="710" width="88" height="17" font="13">functional class </text>
<text top="55" left="831" width="48" height="17" font="13">Hospital </text>
<text top="72" left="831" width="79" height="17" font="13">readmissions, </text>
<text top="89" left="831" width="55" height="17" font="13">infectious </text>
<text top="106" left="831" width="78" height="17" font="13">complications </text>
<text top="55" left="932" width="24" height="17" font="13">N/A </text>
<text top="55" left="1042" width="7" height="17" font="13">  </text>
<text top="55" left="1136" width="113" height="17" font="13">LVAD pts spend the </text>
<text top="72" left="1136" width="130" height="17" font="13">majority of time outside </text>
<text top="89" left="1136" width="126" height="17" font="13">the hospital enjoying a </text>
<text top="106" left="1136" width="57" height="17" font="13">good QoL </text>
<text top="124" left="1136" width="7" height="17" font="13">  </text>
<text top="141" left="1136" width="7" height="17" font="13">  </text>
<text top="55" left="1288" width="132" height="17" font="13">90% of pts experienced </text>
<text top="72" left="1288" width="150" height="17" font="13">hospital readmissions, with </text>
<text top="89" left="1288" width="144" height="17" font="13">mean no. of readmissions </text>
<text top="106" left="1288" width="142" height="17" font="13">per year of 2.9 with mean </text>
<text top="124" left="1288" width="159" height="17" font="13">length of stay of 13.8 d. 43% </text>
<text top="141" left="1288" width="138" height="17" font="13">of readmissions were for </text>
<text top="158" left="1288" width="165" height="17" font="13">infectious complications. 77% </text>
<text top="175" left="1288" width="118" height="17" font="13">of LVAD pts required </text>
<text top="192" left="1288" width="135" height="17" font="13">additional operations for </text>
<text top="210" left="1288" width="108" height="17" font="13">various indications. </text>
<text top="237" left="43" width="1360" height="16" font="6">AAA indicates abdominal aortic aneurysm; ACEI, angiotensin-converting-enzyme inhibitor; AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AV, atrioventricular; AVR, aortic valve replacement; BMI, body mass index; BSA, body surface area; </text>
<text top="252" left="43" width="1363" height="16" font="6">BTT, bridge to transplantation; CABG, coronary artery bypass surgery; CCB, calcium channel blocker; CHF, congestive heart failure; Cl, clearance; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; DT, destination therapy; dz, </text>
<text top="268" left="43" width="1346" height="15" font="6">disease; FEV, forced expiratory volume; HCM, hypertrophic cardiomyopathy; HF, heart failure; HM II, HeartMate II; HM XVE, HeartMate XVE; HT, heart transplantation; hx, history; IABP, intra-aortic balloon pump; INR, international normalized ratio; INTERMACS, Interagency </text>
<text top="283" left="43" width="1352" height="16" font="6">Registry for Mechanically Assisted Circulatory Support; IV, intravenous; KCCQ, Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; LV, left ventricle;  LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; </text>
<text top="299" left="43" width="1369" height="15" font="6">METS, metabolic equivalents; MLWHF, Minnesota Living with Heart Failure; MWT, minute walk test; MODS, multiple organ dysfunction scores;  N/A, not applicable; NT-proBNP, N-terminal pro-B-Type natriuretic peptide; NYHA, New York Heart Association; OMM, optimal medical </text>
<text top="314" left="43" width="1370" height="15" font="6">management; PAD, peripheral arterial disease; pRBC, packed red blood cells; PCWP, pulmonary capillary wedge pressure; pHTN, pulmonary hypertension; pts, patients; PVR, peripheral vascular resistance; QoL, quality of life; RCM, Restrictive cardiomyopathy; RCT, randomized </text>
<text top="330" left="43" width="1383" height="15" font="6">control trial; RV, right ventricule; SAE, serious adverse event; SBP, systolic blood pressure; SCr, serum creatinine; SOFA, sequential organ failure assessment; SVT, supraventricular tachycardia; Tbilli, total bilirubin; TIA, transient ischaemic attack; VAD, ventricular assist device; and </text>
<text top="345" left="43" width="109" height="15" font="6">VO2, oxygen volume. </text>
<text top="361" left="54" width="4" height="19" font="7"> </text>
<text top="398" left="54" width="368" height="21" font="8"><b>Data Supplement 36. Transplantation (Section 7.4.6) </b></text>
<text top="419" left="78" width="78" height="17" font="15"><b>Study Name, </b></text>
<text top="436" left="78" width="77" height="17" font="15"><b>Author, Year </b></text>
<text top="419" left="195" width="78" height="17" font="15"><b>Aim of study </b></text>
<text top="419" left="300" width="70" height="17" font="15"><b>Study Type </b></text>
<text top="419" left="388" width="126" height="17" font="15"><b>Background Therapy </b></text>
<text top="419" left="543" width="38" height="17" font="15"><b>Study </b></text>
<text top="436" left="548" width="28" height="17" font="15"><b>Size </b></text>
<text top="419" left="654" width="111" height="17" font="15"><b>Patient Population </b></text>
<text top="419" left="833" width="51" height="17" font="15"><b>Severity </b></text>
<text top="419" left="922" width="64" height="17" font="15"><b>Endpoints </b></text>
<text top="419" left="1037" width="55" height="17" font="15"><b>Mortality </b></text>
<text top="419" left="1136" width="29" height="17" font="15"><b>Trial </b></text>
<text top="436" left="1127" width="43" height="17" font="15"><b>Duratio</b></text>
<text top="453" left="1145" width="11" height="17" font="15"><b>n </b></text>
<text top="471" left="1128" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="419" left="1204" width="122" height="17" font="15"><b>Absolute Benefit       </b></text>
<text top="436" left="1204" width="100" height="17" font="15"><b>or Major Finding </b></text>
<text top="419" left="1335" width="67" height="17" font="15"><b>P Values &amp; </b></text>
<text top="436" left="1345" width="48" height="17" font="15"><b>95% CI: </b></text>
<text top="489" left="113" width="7" height="17" font="13">  </text>
<text top="489" left="231" width="7" height="17" font="13">  </text>
<text top="489" left="331" width="7" height="17" font="13">  </text>
<text top="489" left="401" width="101" height="17" font="21"><i><b>Pretrial standard </b></i></text>
<text top="506" left="420" width="63" height="17" font="21"><i><b>treatment. </b></i></text>
<text top="489" left="537" width="49" height="17" font="21"><i><b>N (Total </b></i></text>
<text top="506" left="543" width="38" height="17" font="21"><i><b>Study </b></i></text>
<text top="523" left="546" width="32" height="17" font="21"><i><b>Size) </b></i></text>
<text top="489" left="625" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="506" left="630" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="489" left="732" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="506" left="740" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="489" left="825" width="66" height="17" font="21"><i><b>Severity of </b></i></text>
<text top="506" left="849" width="20" height="17" font="21"><i><b>HF </b></i></text>
<text top="523" left="825" width="66" height="17" font="21"><i><b>Symptoms </b></i></text>
<text top="489" left="930" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="506" left="926" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="489" left="1038" width="51" height="17" font="21"><i><b>1st Year </b></i></text>
<text top="506" left="1037" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="489" left="1147" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="489" left="1251" width="7" height="17" font="21"><i><b>  </b></i></text>
<text top="489" left="1365" width="7" height="17" font="13">  </text>
<text top="546" left="61" width="130" height="17" font="15"><b>PATIENT SELECTION </b></text>
<text top="564" left="61" width="79" height="17" font="13">Value of peak </text>
<text top="582" left="61" width="92" height="17" font="13">exercise oxygen </text>
<text top="599" left="61" width="91" height="17" font="13">consumption for </text>
<text top="616" left="61" width="93" height="17" font="13">optimal timing of </text>
<text top="633" left="61" width="43" height="17" font="13">cardiac </text>
<text top="650" left="61" width="97" height="17" font="13">transplantation in </text>
<text top="668" left="61" width="109" height="17" font="13">ambulatory pts with </text>
<text top="685" left="61" width="95" height="17" font="13">HF, Mancini DM, </text>
<text top="702" left="61" width="96" height="17" font="13">Circulation, 1991 </text>
<text top="719" left="61" width="51" height="17" font="14">1999029 </text>
<text top="719" left="112" width="25" height="17" font="13">(27) </text>
<text top="564" left="185" width="76" height="17" font="13">To determine </text>
<text top="582" left="185" width="47" height="17" font="13">whether </text>
<text top="599" left="185" width="92" height="17" font="13">measurement of </text>
<text top="616" left="185" width="96" height="17" font="13">peak VO2 during </text>
<text top="633" left="185" width="98" height="17" font="13">maximal exercise </text>
<text top="650" left="185" width="80" height="17" font="13">testing can be </text>
<text top="668" left="185" width="86" height="17" font="13">used to identify </text>
<text top="685" left="185" width="69" height="17" font="13">pts in whom </text>
<text top="702" left="185" width="84" height="17" font="13">transplantation </text>
<text top="719" left="185" width="76" height="17" font="13">can be safely </text>
<text top="736" left="185" width="49" height="17" font="13">deferred </text>
<text top="564" left="296" width="228" height="17" font="13">Case-control  ACEI 95%                        </text>
<text top="582" left="386" width="137" height="17" font="13">Diuretics 100%                </text>
<text top="599" left="386" width="137" height="17" font="13">Digoxin 100%                  </text>
<text top="616" left="386" width="137" height="17" font="13">Vasodilators 98%            </text>
<text top="633" left="386" width="137" height="17" font="13">PDE3 inhibitors 13%       </text>
<text top="650" left="386" width="137" height="17" font="13">Antiarrhythmics 10%       </text>
<text top="668" left="386" width="46" height="17" font="13">ICD 1% </text>
<text top="564" left="530" width="195" height="17" font="13">122 Ambulatory </text>
<text top="564" left="672" width="72" height="17" font="13">HF </text>
<text top="582" left="606" width="78" height="17" font="13">pt referred for </text>
<text top="599" left="606" width="43" height="17" font="13">cardiac </text>
<text top="616" left="606" width="84" height="17" font="13">transplantation </text>
<text top="633" left="606" width="59" height="17" font="13">evaluation </text>
<text top="564" left="713" width="81" height="17" font="13">Dependent on </text>
<text top="582" left="713" width="62" height="17" font="13">inotrope or </text>
<text top="599" left="713" width="66" height="17" font="13">mechanical </text>
<text top="616" left="713" width="106" height="17" font="13">support;                  </text>
<text top="633" left="713" width="56" height="17" font="13">Unable to </text>
<text top="650" left="713" width="46" height="17" font="13">achieve </text>
<text top="668" left="713" width="57" height="17" font="13">anaerobic </text>
<text top="685" left="713" width="71" height="17" font="13">threshold on </text>
<text top="702" left="713" width="29" height="17" font="13">CPX </text>
<text top="564" left="825" width="48" height="17" font="13">NYHA II </text>
<text top="582" left="825" width="72" height="17" font="13">13%              </text>
<text top="599" left="825" width="51" height="17" font="13">NYHA III </text>
<text top="616" left="825" width="72" height="17" font="13">70%              </text>
<text top="633" left="825" width="53" height="17" font="13">NYHA IV </text>
<text top="650" left="825" width="28" height="17" font="13">17% </text>
<text top="564" left="905" width="40" height="17" font="13">Death  </text>
<text top="564" left="1017" width="101" height="17" font="13">1 y mortality          </text>
<text top="582" left="1017" width="86" height="17" font="13">peak VO2 &lt;14, </text>
<text top="599" left="1017" width="71" height="17" font="13">accepted for </text>
<text top="616" left="1017" width="103" height="17" font="13">transplant: 30%     </text>
<text top="633" left="1017" width="86" height="17" font="13">peak VO2 &gt;14: </text>
<text top="650" left="1017" width="100" height="17" font="13">6%                        </text>
<text top="668" left="1017" width="86" height="17" font="13">peak VO2 &lt;14, </text>
<text top="685" left="1017" width="65" height="17" font="13">rejected for </text>
<text top="702" left="1017" width="89" height="17" font="13">transplant: 53% </text>
<text top="564" left="1124" width="14" height="17" font="13">3  </text>
<text top="564" left="1189" width="105" height="17" font="13">Pts with preserved </text>
<text top="582" left="1189" width="98" height="17" font="13">exercise capacity </text>
<text top="599" left="1189" width="124" height="17" font="13">despite severe resting </text>
<text top="616" left="1189" width="80" height="17" font="13">hemodynamic </text>
<text top="633" left="1189" width="94" height="17" font="13">impairment have </text>
<text top="650" left="1189" width="69" height="17" font="13">survival and </text>
<text top="668" left="1189" width="105" height="17" font="13">functional capacity </text>
<text top="685" left="1189" width="129" height="17" font="13">equal to those afforded </text>
<text top="702" left="1189" width="60" height="17" font="13">by cardiac </text>
<text top="719" left="1189" width="84" height="17" font="13">transplantation </text>
<text top="564" left="1332" width="27" height="17" font="13"> N/A </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">150</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="105" height="17" font="13">Predicting Survival </text>
<text top="72" left="61" width="100" height="17" font="13">in Ambulatory Pts </text>
<text top="89" left="61" width="107" height="17" font="13">With Severe HF on </text>
<text top="106" left="61" width="73" height="17" font="13">Beta Blocker </text>
<text top="124" left="61" width="105" height="17" font="13">Therapy, Lund LH, </text>
<text top="141" left="61" width="105" height="17" font="13">Am J Cardiol 2003 </text>
<text top="158" left="61" width="58" height="17" font="14">14636921 </text>
<text top="158" left="119" width="32" height="17" font="13">(306) </text>
<text top="55" left="185" width="88" height="17" font="13">To examine the </text>
<text top="72" left="185" width="89" height="17" font="13">predictive value </text>
<text top="89" left="185" width="96" height="17" font="13">of peak VO2 and </text>
<text top="106" left="185" width="90" height="17" font="13">the HFSS in pts </text>
<text top="124" left="185" width="64" height="17" font="13">referred for </text>
<text top="141" left="185" width="43" height="17" font="13">cardiac </text>
<text top="158" left="185" width="97" height="17" font="13">transplantation in </text>
<text top="175" left="185" width="91" height="17" font="13">the beta blocker </text>
<text top="192" left="185" width="21" height="17" font="13">era </text>
<text top="55" left="296" width="195" height="17" font="13">Case-control  Beta blockers 65% </text>
<text top="55" left="530" width="24" height="17" font="13">221 </text>
<text top="55" left="606" width="85" height="17" font="13">Ambulatory HF </text>
<text top="72" left="606" width="84" height="17" font="13">pts referred for </text>
<text top="89" left="606" width="89" height="17" font="13">heart transplant </text>
<text top="106" left="606" width="59" height="17" font="13">evaluation </text>
<text top="55" left="713" width="27" height="17" font="13"> N/A </text>
<text top="55" left="825" width="24" height="17" font="13">N/A </text>
<text top="55" left="905" width="96" height="17" font="13">Outcome events: </text>
<text top="72" left="905" width="73" height="17" font="13">death before </text>
<text top="89" left="905" width="96" height="17" font="13">transplant, LVAD </text>
<text top="106" left="905" width="73" height="17" font="13">implantation, </text>
<text top="124" left="905" width="49" height="17" font="13">inotrope-</text>
<text top="141" left="905" width="62" height="17" font="13">dependent </text>
<text top="158" left="905" width="88" height="17" font="13">transplantation  </text>
<text top="55" left="1017" width="79" height="17" font="13">1 y event-free </text>
<text top="72" left="1017" width="100" height="17" font="13">survival:                </text>
<text top="89" left="1017" width="70" height="17" font="13">beta blocker </text>
<text top="106" left="1017" width="100" height="17" font="13">75%                      </text>
<text top="124" left="1017" width="88" height="17" font="13">no beta blocker </text>
<text top="141" left="1017" width="100" height="17" font="13">56%                      </text>
<text top="55" left="1124" width="14" height="17" font="13">6  </text>
<text top="55" left="1189" width="109" height="17" font="13">No difference in 1 y </text>
<text top="72" left="1189" width="104" height="17" font="13">event-free survival </text>
<text top="89" left="1189" width="121" height="17" font="13">amongst beta blocker </text>
<text top="106" left="1189" width="108" height="17" font="13">users by peak VO2 </text>
<text top="124" left="1189" width="136" height="17" font="13">statum;                            </text>
<text top="141" left="1189" width="111" height="17" font="13">however, significant </text>
<text top="158" left="1189" width="110" height="17" font="13">difference by HFSS </text>
<text top="175" left="1189" width="47" height="17" font="13">statum   </text>
<text top="55" left="1332" width="63" height="17" font="13">Survival by </text>
<text top="72" left="1332" width="40" height="17" font="13">HFSS, </text>
<text top="89" left="1332" width="55" height="17" font="13">p&lt;0.0002 </text>
<text top="106" left="1332" width="31" height="17" font="13">(total </text>
<text top="124" left="1332" width="45" height="17" font="13">cohort), </text>
<text top="141" left="1332" width="73" height="17" font="13">p&lt;0.02 (beta </text>
<text top="158" left="1332" width="81" height="17" font="13">blocker pts)     </text>
<text top="175" left="1332" width="63" height="17" font="13">Survival by </text>
<text top="192" left="1332" width="66" height="17" font="13">VO2, p=0.3 </text>
<text top="210" left="1332" width="31" height="17" font="13">(total </text>
<text top="227" left="1332" width="45" height="17" font="13">cohort), </text>
<text top="244" left="1332" width="73" height="17" font="13">p=0.29 (beta </text>
<text top="261" left="1332" width="67" height="17" font="13">blocker pts) </text>
<text top="279" left="61" width="107" height="17" font="13">Selection of Pts for </text>
<text top="296" left="61" width="34" height="17" font="13">Heart </text>
<text top="314" left="61" width="101" height="17" font="13">Transplantation in </text>
<text top="331" left="61" width="101" height="17" font="13">the Current Era of </text>
<text top="348" left="61" width="107" height="17" font="13">HF Therapy, Butler </text>
<text top="365" left="61" width="79" height="17" font="13">J, JACC 2004 </text>
<text top="382" left="61" width="58" height="17" font="14">14998618 </text>
<text top="382" left="119" width="32" height="17" font="13">(307) </text>
<text top="279" left="185" width="80" height="17" font="13">To assess the </text>
<text top="296" left="185" width="66" height="17" font="13">relationship </text>
<text top="314" left="185" width="50" height="17" font="13">between </text>
<text top="331" left="185" width="79" height="17" font="13">survival, peak </text>
<text top="348" left="185" width="92" height="17" font="13">exercise oxygen </text>
<text top="365" left="185" width="73" height="17" font="13">consumption </text>
<text top="382" left="185" width="84" height="17" font="13">(VO2), and HF </text>
<text top="400" left="185" width="79" height="17" font="13">survival score </text>
<text top="417" left="185" width="78" height="17" font="13">(HFSS) in the </text>
<text top="434" left="185" width="96" height="17" font="13">current era of HF </text>
<text top="451" left="185" width="72" height="17" font="13">(HF) therapy </text>
<text top="279" left="296" width="228" height="17" font="13">Case-control   ACEI 92%                        </text>
<text top="296" left="386" width="138" height="17" font="13">Diuretic 96%                    </text>
<text top="314" left="386" width="137" height="17" font="13">Digoxin 94%                    </text>
<text top="331" left="386" width="98" height="17" font="13">beta blocker 10% </text>
<text top="348" left="386" width="82" height="17" font="13">(past) vs. 72% </text>
<text top="365" left="386" width="87" height="17" font="13">(current)            </text>
<text top="382" left="386" width="107" height="17" font="13">Spironolactone 2% </text>
<text top="400" left="386" width="82" height="17" font="13">(past) vs. 41% </text>
<text top="417" left="386" width="139" height="17" font="13">(current)                           </text>
<text top="434" left="386" width="137" height="17" font="13">Antiarrhythmic 13%         </text>
<text top="451" left="386" width="105" height="17" font="13">AICD 11% (past) v </text>
<text top="469" left="386" width="78" height="17" font="13">19% (current) </text>
<text top="279" left="530" width="24" height="17" font="13">507 </text>
<text top="279" left="606" width="65" height="17" font="13">HF pts with </text>
<text top="296" left="606" width="100" height="17" font="13">LVEF &lt;40%;         </text>
<text top="314" left="606" width="92" height="17" font="13">Underwent CPX </text>
<text top="331" left="606" width="75" height="17" font="13">in 1994-1997 </text>
<text top="348" left="606" width="70" height="17" font="13">(past era) or </text>
<text top="365" left="606" width="66" height="17" font="13">1999-2001; </text>
<text top="382" left="606" width="102" height="17" font="13">(current era)          </text>
<text top="400" left="606" width="92" height="17" font="13">Underwent OHT </text>
<text top="417" left="606" width="99" height="17" font="13">in 1993-2000        </text>
<text top="279" left="713" width="105" height="17" font="13">On inotrope;           </text>
<text top="296" left="713" width="56" height="17" font="13">Angina or </text>
<text top="314" left="713" width="93" height="17" font="13">orthopedic issue </text>
<text top="331" left="713" width="57" height="17" font="13">restricting </text>
<text top="348" left="713" width="49" height="17" font="13">exercise </text>
<text top="365" left="713" width="107" height="17" font="13">capacity;                 </text>
<text top="382" left="713" width="60" height="17" font="13">Significant </text>
<text top="400" left="713" width="105" height="17" font="13">valvular stenosis;   </text>
<text top="417" left="713" width="58" height="17" font="13">Exertional </text>
<text top="434" left="713" width="43" height="17" font="13">oxygen </text>
<text top="451" left="713" width="71" height="17" font="13">desaturation </text>
<text top="279" left="825" width="52" height="17" font="13">NYHA III-</text>
<text top="296" left="825" width="43" height="17" font="13">IV 84% </text>
<text top="279" left="905" width="79" height="17" font="13">1 y event-free </text>
<text top="296" left="905" width="92" height="17" font="13">survival (without </text>
<text top="314" left="905" width="98" height="17" font="13">need for LVAD or </text>
<text top="331" left="905" width="81" height="17" font="13">urgent- Status </text>
<text top="348" left="905" width="23" height="17" font="13">1A- </text>
<text top="365" left="905" width="88" height="17" font="13">transplantation) </text>
<text top="382" left="905" width="105" height="17" font="13">for HF pts;              </text>
<text top="400" left="905" width="63" height="17" font="13">Overall 1-y </text>
<text top="417" left="905" width="63" height="17" font="13">survival for </text>
<text top="434" left="905" width="91" height="17" font="13">transplanted pts </text>
<text top="279" left="1017" width="60" height="17" font="13">Overal 1-y </text>
<text top="296" left="1017" width="100" height="17" font="13">survival                 </text>
<text top="314" left="1017" width="79" height="17" font="13">Transplanted: </text>
<text top="331" left="1017" width="100" height="17" font="13">88%                      </text>
<text top="348" left="1017" width="89" height="17" font="13">Current era HF: </text>
<text top="365" left="1017" width="100" height="17" font="13">88%                      </text>
<text top="382" left="1017" width="73" height="17" font="13">Past era HF: </text>
<text top="400" left="1017" width="28" height="17" font="13">78% </text>
<text top="279" left="1124" width="27" height="17" font="13"> N/A </text>
<text top="279" left="1189" width="109" height="17" font="13">No difference in 1 y </text>
<text top="296" left="1189" width="117" height="17" font="13">event-free survival in </text>
<text top="314" left="1189" width="111" height="17" font="13">current era by initial </text>
<text top="331" left="1189" width="93" height="17" font="13">peak VO2; trend </text>
<text top="348" left="1189" width="117" height="17" font="13">towards difference in </text>
<text top="365" left="1189" width="128" height="17" font="13">survival when stratified </text>
<text top="382" left="1189" width="53" height="17" font="13">by HFSS </text>
<text top="279" left="1332" width="27" height="17" font="13"> N/A </text>
<text top="487" left="61" width="83" height="17" font="13">Peak VO2 and </text>
<text top="504" left="61" width="103" height="17" font="13">VE/VCO2 slope in </text>
<text top="521" left="61" width="79" height="17" font="13">pts with HF: a </text>
<text top="538" left="61" width="60" height="17" font="13">prognostic </text>
<text top="555" left="61" width="107" height="17" font="13">comparison, Arena </text>
<text top="573" left="61" width="84" height="17" font="13">R, Am Heart J, </text>
<text top="590" left="61" width="31" height="17" font="13">2004 </text>
<text top="607" left="61" width="58" height="17" font="14">14760336 </text>
<text top="607" left="119" width="32" height="17" font="13">(308) </text>
<text top="487" left="185" width="88" height="17" font="13">To examine the </text>
<text top="504" left="185" width="79" height="17" font="13">ability of peak </text>
<text top="521" left="185" width="52" height="17" font="13">VO2 and </text>
<text top="538" left="185" width="90" height="17" font="13">VE/VCO2 slope </text>
<text top="555" left="185" width="54" height="17" font="13">to predict </text>
<text top="573" left="185" width="85" height="17" font="13">cardiac-related </text>
<text top="590" left="185" width="74" height="17" font="13">mortality and </text>
<text top="607" left="185" width="81" height="17" font="13">hospitalization </text>
<text top="487" left="296" width="68" height="17" font="13">Retrospectiv</text>
<text top="504" left="296" width="58" height="17" font="13">e analysis </text>
<text top="487" left="386" width="139" height="17" font="13">ACEI 70%                        </text>
<text top="504" left="386" width="136" height="17" font="13">Digitalis 57%                   </text>
<text top="521" left="386" width="138" height="17" font="13">Diuretic  63%                   </text>
<text top="538" left="386" width="137" height="17" font="13">Oral nitrate  29%             </text>
<text top="555" left="386" width="136" height="17" font="13">beta blocker    42%         </text>
<text top="573" left="386" width="136" height="17" font="13">CCB   15%                      </text>
<text top="590" left="386" width="139" height="17" font="13">anticoagulant   35%         </text>
<text top="607" left="386" width="110" height="17" font="13">Antiarrhythmic 15% </text>
<text top="487" left="550" width="109" height="17" font="13">213 HF </text>
<text top="487" left="626" width="79" height="17" font="13">diagnosis;       </text>
<text top="504" left="606" width="86" height="17" font="13">Evidence of LV </text>
<text top="521" left="606" width="44" height="17" font="13">systolic </text>
<text top="538" left="606" width="82" height="17" font="13">dysfunction by </text>
<text top="555" left="606" width="92" height="17" font="13">echocardiogram </text>
<text top="573" left="606" width="57" height="17" font="13">or cardiac </text>
<text top="590" left="606" width="83" height="17" font="13">catheterization </text>
<text top="487" left="713" width="7" height="17" font="13">  </text>
<text top="487" left="825" width="24" height="17" font="13">N/A </text>
<text top="487" left="905" width="88" height="17" font="13">Cardiac-related </text>
<text top="504" left="905" width="74" height="17" font="13">mortality and </text>
<text top="521" left="905" width="92" height="17" font="13">hospitalization 1-</text>
<text top="538" left="905" width="87" height="17" font="13">y after exercise </text>
<text top="555" left="905" width="59" height="17" font="13">testing via </text>
<text top="573" left="905" width="77" height="17" font="13">medical chart </text>
<text top="590" left="905" width="83" height="17" font="13">review and the </text>
<text top="607" left="905" width="85" height="17" font="13">Social Security </text>
<text top="624" left="905" width="70" height="17" font="13">Death Index </text>
<text top="487" left="1017" width="101" height="17" font="13">1 year mortality     </text>
<text top="504" left="1017" width="102" height="17" font="13">VE/VCO2 &lt; 34:     </text>
<text top="521" left="1017" width="100" height="17" font="13">0.8%                     </text>
<text top="538" left="1017" width="102" height="17" font="13">VE/VCO2 &gt;34:      </text>
<text top="555" left="1017" width="38" height="17" font="13">16.9% </text>
<text top="487" left="1124" width="34" height="17" font="13">8 y, 7 </text>
<text top="504" left="1124" width="21" height="17" font="13">mo </text>
<text top="521" left="1124" width="33" height="17" font="13">(CPX </text>
<text top="538" left="1124" width="28" height="17" font="13">from </text>
<text top="555" left="1124" width="28" height="17" font="13">4/93-</text>
<text top="573" left="1124" width="42" height="17" font="13">10/01), </text>
<text top="590" left="1124" width="46" height="17" font="13">plus 1 y </text>
<text top="607" left="1124" width="17" height="17" font="13">f/u </text>
<text top="487" left="1189" width="88" height="17" font="13">Peak VO2 (&lt;14 </text>
<text top="504" left="1189" width="85" height="17" font="13">ml/kg/min) was </text>
<text top="521" left="1189" width="67" height="17" font="13">revealed by </text>
<text top="538" left="1189" width="92" height="17" font="13">multivariate Cox </text>
<text top="555" left="1189" width="122" height="17" font="13">regression analysis to </text>
<text top="573" left="1189" width="125" height="17" font="13">add significantly to the </text>
<text top="590" left="1189" width="122" height="17" font="13">VE/VCO2 slope (&gt;34) </text>
<text top="607" left="1189" width="90" height="17" font="13">in predicting 1-y </text>
<text top="624" left="1189" width="85" height="17" font="13">cardiac-related </text>
<text top="641" left="1189" width="81" height="17" font="13">hospitalization </text>
<text top="659" left="1189" width="59" height="17" font="13">(residual X</text>
<text top="660" left="1248" width="4" height="11" font="19">2</text>
<text top="659" left="1253" width="35" height="17" font="13"> =6.5; </text>
<text top="676" left="1189" width="120" height="17" font="13">p=0.01). The addition </text>
<text top="693" left="1189" width="92" height="17" font="13">of peak VO2 did </text>
<text top="710" left="1189" width="120" height="17" font="13">not provide additional </text>
<text top="727" left="1189" width="124" height="17" font="13">value to the VE/VCO2 </text>
<text top="745" left="1189" width="103" height="17" font="13">slope in predicting </text>
<text top="762" left="1189" width="124" height="17" font="13">overall cardiac-related </text>
<text top="779" left="1189" width="100" height="17" font="13">mortality (residual </text>
<text top="487" left="1332" width="63" height="17" font="13">1 y cardiac </text>
<text top="504" left="1332" width="81" height="17" font="13">mortality          </text>
<text top="521" left="1332" width="57" height="17" font="13">VE/VCO2 </text>
<text top="538" left="1332" width="71" height="17" font="13">slope &gt;34, p </text>
<text top="555" left="1332" width="48" height="17" font="13">&lt;0.0001 </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">151</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1189" width="116" height="17" font="13"> X2 = 0.2; p=0.89) or </text>
<text top="72" left="1189" width="123" height="17" font="13">1-year cardiac-related </text>
<text top="89" left="1189" width="129" height="17" font="13">mortality (residual  X2= </text>
<text top="106" left="1189" width="73" height="17" font="13">1.5; p=0.29). </text>
<text top="138" left="61" width="61" height="17" font="13">Prognostic </text>
<text top="155" left="61" width="96" height="17" font="13">usefulness of the </text>
<text top="172" left="61" width="100" height="17" font="13">functional aerobic </text>
<text top="189" left="61" width="103" height="17" font="13">reserve in pts with </text>
<text top="206" left="61" width="111" height="17" font="13">HF, Chase P, Am H </text>
<text top="224" left="61" width="44" height="17" font="13">J, 2010 </text>
<text top="241" left="61" width="58" height="17" font="14">21095281 </text>
<text top="241" left="119" width="32" height="17" font="13">(309) </text>
<text top="258" left="61" width="7" height="17" font="13">  </text>
<text top="138" left="185" width="75" height="17" font="13">To develop a </text>
<text top="155" left="185" width="97" height="17" font="13">prognostic model </text>
<text top="172" left="185" width="88" height="17" font="13">using FAR as a </text>
<text top="189" left="185" width="63" height="17" font="13">continuous </text>
<text top="206" left="185" width="70" height="17" font="13">variable that </text>
<text top="224" left="185" width="91" height="17" font="13">incorporates pts </text>
<text top="241" left="185" width="42" height="17" font="13">with an </text>
<text top="258" left="185" width="103" height="17" font="13">undetectable VT.   </text>
<text top="275" left="185" width="85" height="17" font="13">Secondarily, to </text>
<text top="292" left="185" width="79" height="17" font="13">determine the </text>
<text top="310" left="185" width="97" height="17" font="13">prognostic power </text>
<text top="327" left="185" width="88" height="17" font="13">of the FAR with </text>
<text top="344" left="185" width="79" height="17" font="13">that of VO2pk </text>
<text top="361" left="185" width="44" height="17" font="13">and the </text>
<text top="379" left="185" width="90" height="17" font="13">VE/VCO2 slope </text>
<text top="396" left="185" width="78" height="17" font="13">in pts with HF </text>
<text top="138" left="296" width="210" height="17" font="13">Case-control  Beta blocker 86% (no </text>
<text top="155" left="386" width="139" height="17" font="13">VT) vs 75% (VT)              </text>
<text top="172" left="386" width="139" height="17" font="13">ACEI 76%                        </text>
<text top="189" left="386" width="136" height="17" font="13">CCB 7%                          </text>
<text top="206" left="386" width="118" height="17" font="13">Diuretic 90% (no VT) </text>
<text top="224" left="386" width="71" height="17" font="13">vs 70% (VT) </text>
<text top="138" left="530" width="24" height="17" font="13">874 </text>
<text top="138" left="606" width="91" height="17" font="13">Chronic HF with </text>
<text top="155" left="606" width="56" height="17" font="13">stable HF </text>
<text top="172" left="606" width="83" height="17" font="13">symptoms and </text>
<text top="189" left="606" width="87" height="17" font="13">medications for </text>
<text top="206" left="606" width="74" height="17" font="13">at least 1 mo </text>
<text top="224" left="606" width="87" height="17" font="13">before exercise </text>
<text top="241" left="606" width="101" height="17" font="13">testing,                  </text>
<text top="258" left="606" width="66" height="17" font="13">LVEF&lt;45% </text>
<text top="138" left="713" width="238" height="17" font="13">N/A NYHA </text>
<text top="138" left="863" width="14" height="17" font="13">III-</text>
<text top="155" left="825" width="73" height="17" font="13">IV                  </text>
<text top="172" left="825" width="49" height="17" font="13">89% (no </text>
<text top="189" left="825" width="42" height="17" font="13">VT) vs. </text>
<text top="206" left="825" width="55" height="17" font="13">45% (VT) </text>
<text top="138" left="905" width="78" height="17" font="13">Major cardiac-</text>
<text top="155" left="905" width="81" height="17" font="13">related events </text>
<text top="172" left="905" width="36" height="17" font="13">(heart </text>
<text top="189" left="905" width="88" height="17" font="13">transplantation, </text>
<text top="206" left="905" width="36" height="17" font="13">LVAD </text>
<text top="224" left="905" width="97" height="17" font="13">implantation, and </text>
<text top="241" left="905" width="85" height="17" font="13">cardiac-related </text>
<text top="258" left="905" width="76" height="17" font="13">death) for 2 y </text>
<text top="275" left="905" width="96" height="17" font="13">after CPX testing </text>
<text top="138" left="1017" width="79" height="17" font="13">2 y event-free </text>
<text top="155" left="1017" width="82" height="17" font="13">survival based </text>
<text top="172" left="1017" width="59" height="17" font="13">upon CPX </text>
<text top="189" left="1017" width="73" height="17" font="13">responses--- </text>
<text top="206" left="1017" width="54" height="17" font="13">favorable </text>
<text top="224" left="1017" width="60" height="17" font="13">responses </text>
<text top="241" left="1017" width="60" height="17" font="13">defined as </text>
<text top="258" left="1017" width="85" height="17" font="13">VE/VCO2 &lt;36, </text>
<text top="275" left="1017" width="89" height="17" font="13">VO2pk &gt; 10 mL </text>
<text top="292" left="1017" width="91" height="17" font="13">O2/kg/min, FAR </text>
<text top="310" left="1017" width="74" height="17" font="13">&gt; 3ml O2/kg/ </text>
<text top="327" left="1017" width="103" height="17" font="13">min)                       </text>
<text top="344" left="1017" width="71" height="17" font="13">All favorable </text>
<text top="361" left="1017" width="70" height="17" font="13">responses:   </text>
<text top="379" left="1017" width="83" height="17" font="13">95%                 </text>
<text top="396" left="1017" width="81" height="17" font="13">1 unfavorable: </text>
<text top="413" left="1017" width="100" height="17" font="13">83.1%                   </text>
<text top="430" left="1017" width="81" height="17" font="13">2 unfavorable: </text>
<text top="447" left="1017" width="100" height="17" font="13">76.0%                   </text>
<text top="465" left="1017" width="88" height="17" font="13">All unfavorable: </text>
<text top="482" left="1017" width="38" height="17" font="13">58.3% </text>
<text top="138" left="1124" width="27" height="17" font="13">11 y </text>
<text top="155" left="1124" width="33" height="17" font="13">(CPX </text>
<text top="172" left="1124" width="50" height="17" font="13">between </text>
<text top="189" left="1124" width="32" height="17" font="13">5/97- </text>
<text top="206" left="1124" width="45" height="17" font="13">5/08); 2 </text>
<text top="224" left="1124" width="42" height="17" font="13">yfollow-</text>
<text top="241" left="1124" width="17" height="17" font="13">up </text>
<text top="138" left="1189" width="74" height="17" font="13">Pts without a </text>
<text top="155" left="1189" width="103" height="17" font="13">detectable VT had </text>
<text top="172" left="1189" width="137" height="17" font="13">worse prognosis.             </text>
<text top="189" left="1189" width="122" height="17" font="13">VE/VCO2 slope (&gt;36) </text>
<text top="206" left="1189" width="126" height="17" font="13">is the strongest overall </text>
<text top="224" left="1189" width="81" height="17" font="13">univariate and </text>
<text top="241" left="1189" width="121" height="17" font="13">multivariate predictor; </text>
<text top="258" left="1189" width="130" height="17" font="13">FAR (&lt;3 ml O2/kg/min) </text>
<text top="275" left="1189" width="123" height="17" font="13">and peak VO2 (&lt;10ml </text>
<text top="292" left="1189" width="85" height="17" font="13">O2/kg/min) are </text>
<text top="310" left="1189" width="80" height="17" font="13">additive to the </text>
<text top="327" left="1189" width="90" height="17" font="13">VE/VCO2 slope </text>
<text top="138" left="1332" width="54" height="17" font="13">No VT vs </text>
<text top="155" left="1332" width="81" height="17" font="13">VT:                  </text>
<text top="172" left="1332" width="52" height="17" font="13">p&lt;0.001, </text>
<text top="189" left="1332" width="65" height="17" font="13">95% CI 2.3-</text>
<text top="206" left="1332" width="79" height="17" font="13">4.8                  </text>
<text top="224" left="1332" width="61" height="17" font="13">Prognostic </text>
<text top="241" left="1332" width="80" height="17" font="13">classification   </text>
<text top="258" left="1332" width="48" height="17" font="13">p&lt;0.001 </text>
<text top="500" left="61" width="61" height="17" font="13">Ventilatory </text>
<text top="517" left="61" width="101" height="17" font="13">Efficiency and the </text>
<text top="534" left="61" width="107" height="17" font="13">Selection of Pts for </text>
<text top="551" left="61" width="34" height="17" font="13">Heart </text>
<text top="569" left="61" width="92" height="17" font="13">Transplantation, </text>
<text top="586" left="61" width="72" height="17" font="13">Ferreira AM, </text>
<text top="603" left="61" width="85" height="17" font="13">Circulation HF, </text>
<text top="620" left="61" width="31" height="17" font="13">2010 </text>
<text top="638" left="61" width="58" height="17" font="14">20176714 </text>
<text top="638" left="119" width="32" height="17" font="13">(310) </text>
<text top="500" left="185" width="59" height="17" font="13">To assess </text>
<text top="517" left="185" width="47" height="17" font="13">whether </text>
<text top="534" left="185" width="88" height="17" font="13">Ve/VCO2 slope </text>
<text top="551" left="185" width="78" height="17" font="13">would identify </text>
<text top="569" left="185" width="92" height="17" font="13">individuals likely </text>
<text top="586" left="185" width="82" height="17" font="13">to benefit from </text>
<text top="603" left="185" width="89" height="17" font="13">heart transplant </text>
<text top="620" left="185" width="91" height="17" font="13">more accurately </text>
<text top="638" left="185" width="69" height="17" font="13">than current </text>
<text top="655" left="185" width="89" height="17" font="13">exercise criteria </text>
<text top="672" left="185" width="53" height="17" font="13">for listing </text>
<text top="500" left="298" width="112" height="17" font="13">Case-control  N/A </text>
<text top="500" left="530" width="24" height="17" font="13">663 </text>
<text top="500" left="606" width="66" height="17" font="13">HF pts who </text>
<text top="517" left="606" width="61" height="17" font="13">underwent </text>
<text top="534" left="606" width="94" height="17" font="13">cardiopulmonary </text>
<text top="551" left="606" width="64" height="17" font="13">testing at 4 </text>
<text top="569" left="606" width="98" height="17" font="13">laboratories;         </text>
<text top="586" left="606" width="101" height="17" font="13">NYHA II-IV;           </text>
<text top="603" left="606" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="500" left="713" width="78" height="17" font="13">Primary valve </text>
<text top="517" left="713" width="49" height="17" font="13">disease; </text>
<text top="534" left="713" width="94" height="17" font="13">Congenital heart </text>
<text top="551" left="713" width="49" height="17" font="13">disease; </text>
<text top="569" left="713" width="49" height="17" font="13">Planned </text>
<text top="586" left="713" width="55" height="17" font="13">coronary; </text>
<text top="603" left="713" width="106" height="17" font="13">revascularization;   </text>
<text top="620" left="713" width="92" height="17" font="13">Planned cardiac </text>
<text top="638" left="713" width="89" height="17" font="13">surgery;             </text>
<text top="655" left="713" width="104" height="17" font="13">Age &lt;18 y;             </text>
<text top="672" left="713" width="46" height="17" font="13">Primary </text>
<text top="689" left="713" width="61" height="17" font="13">pulmonary </text>
<text top="706" left="713" width="53" height="17" font="13">disease;  </text>
<text top="724" left="713" width="94" height="17" font="13">Previous cardiac </text>
<text top="741" left="713" width="105" height="17" font="13">transplantation;      </text>
<text top="758" left="713" width="71" height="17" font="13">Submaximal </text>
<text top="775" left="713" width="92" height="17" font="13">CPX (peak RER </text>
<text top="500" left="825" width="161" height="17" font="13">NYHA II-IV  Death or heart </text>
<text top="517" left="905" width="57" height="17" font="13">transplant </text>
<text top="500" left="1017" width="92" height="17" font="13">During follow-up </text>
<text top="517" left="1017" width="103" height="17" font="13">period,                   </text>
<text top="534" left="1017" width="38" height="17" font="13">15.2% </text>
<text top="551" left="1017" width="61" height="17" font="13">underwent </text>
<text top="569" left="1017" width="102" height="17" font="13">transplant              </text>
<text top="586" left="1017" width="65" height="17" font="13">13,7% died </text>
<text top="500" left="1124" width="44" height="17" font="13">Median </text>
<text top="517" left="1124" width="34" height="17" font="13">f/u 26 </text>
<text top="534" left="1124" width="21" height="17" font="13">mo </text>
<text top="500" left="1189" width="136" height="17" font="13">Ve/VCO2 slope &lt;43,       </text>
<text top="517" left="1189" width="137" height="17" font="13">1y survival 97%               </text>
<text top="534" left="1189" width="137" height="17" font="13">3y survival 89.4%            </text>
<text top="551" left="1189" width="136" height="17" font="13">Ve/VCO2 slope &gt;43        </text>
<text top="569" left="1189" width="137" height="17" font="13">1y survival 77.8%            </text>
<text top="586" left="1189" width="100" height="17" font="13">3y survival 55.1% </text>
<text top="500" left="1332" width="55" height="17" font="13">Ve/VCO2 </text>
<text top="517" left="1332" width="78" height="17" font="13">slope &lt;43,      </text>
<text top="534" left="1332" width="65" height="17" font="13">1y survival: </text>
<text top="551" left="1332" width="47" height="17" font="13">95% CI: </text>
<text top="569" left="1332" width="72" height="17" font="13">95.4-98.6,  y </text>
<text top="586" left="1332" width="48" height="17" font="13">survival: </text>
<text top="603" left="1332" width="47" height="17" font="13">95% CI: </text>
<text top="620" left="1332" width="69" height="17" font="13">85.8-93.0     </text>
<text top="638" left="1332" width="79" height="17" font="13">p&lt;0.001          </text>
<text top="655" left="1332" width="55" height="17" font="13">Ve/VCO2 </text>
<text top="672" left="1332" width="78" height="17" font="13">slope &gt;43       </text>
<text top="689" left="1332" width="68" height="17" font="13">1 y survival: </text>
<text top="706" left="1332" width="47" height="17" font="13">95% CI: </text>
<text top="724" left="1332" width="70" height="17" font="13">71.3-84.3%, </text>
<text top="741" left="1332" width="68" height="17" font="13">3 y survival: </text>
<text top="758" left="1332" width="47" height="17" font="13">95% CI: </text>
<text top="775" left="1332" width="66" height="17" font="13">45.2-65.0    </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">152</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="713" width="69" height="17" font="13">ratio &lt;1.05). </text>
<text top="150" left="61" width="92" height="17" font="13">The HF Survival </text>
<text top="167" left="61" width="105" height="17" font="13">Score outperforms </text>
<text top="184" left="61" width="94" height="17" font="13">the peak oxygen </text>
<text top="202" left="61" width="91" height="17" font="13">consumption for </text>
<text top="219" left="61" width="31" height="17" font="13">heart </text>
<text top="236" left="61" width="84" height="17" font="13">transplantation </text>
<text top="253" left="61" width="107" height="17" font="13">selection in the era </text>
<text top="270" left="61" width="101" height="17" font="13">of device therapy, </text>
<text top="288" left="61" width="81" height="17" font="13">Goda A, JHLT </text>
<text top="305" left="61" width="31" height="17" font="13">2011 </text>
<text top="322" left="61" width="58" height="17" font="14">21093299 </text>
<text top="322" left="119" width="32" height="17" font="13">(311) </text>
<text top="339" left="61" width="3" height="17" font="13"> </text>
<text top="150" left="185" width="98" height="17" font="13">To evaluate peak </text>
<text top="167" left="185" width="88" height="17" font="13">VO2 and HFSS </text>
<text top="184" left="185" width="76" height="17" font="13">as prognostic </text>
<text top="202" left="185" width="87" height="17" font="13">tools in pts with </text>
<text top="219" left="185" width="66" height="17" font="13">and without </text>
<text top="236" left="185" width="88" height="17" font="13">CRT-D referred </text>
<text top="253" left="185" width="49" height="17" font="13">for heart </text>
<text top="270" left="185" width="57" height="17" font="13">transplant </text>
<text top="288" left="185" width="59" height="17" font="13">evaluation </text>
<text top="150" left="298" width="224" height="17" font="13">Case-control  ACEI/ARB 80%               </text>
<text top="167" left="386" width="103" height="17" font="13">b-blocker 64% (no </text>
<text top="184" left="386" width="108" height="17" font="13">device) v 76% (any </text>
<text top="202" left="386" width="43" height="17" font="13">device) </text>
<text top="150" left="530" width="24" height="17" font="13">715 </text>
<text top="150" left="606" width="79" height="17" font="13">Systolic HF pt </text>
<text top="167" left="606" width="64" height="17" font="13">referred for </text>
<text top="184" left="606" width="89" height="17" font="13">heart transplant </text>
<text top="202" left="606" width="59" height="17" font="13">evaluation </text>
<text top="150" left="713" width="74" height="17" font="13">Excluded pts </text>
<text top="167" left="713" width="54" height="17" font="13">unable to </text>
<text top="184" left="713" width="90" height="17" font="13">exercise for any </text>
<text top="202" left="713" width="41" height="17" font="13">reason </text>
<text top="150" left="825" width="34" height="17" font="13">mean </text>
<text top="167" left="825" width="38" height="17" font="13">NYHA </text>
<text top="184" left="825" width="59" height="17" font="13">class 2.82 </text>
<text top="202" left="825" width="59" height="17" font="13">(total), 2.7 </text>
<text top="219" left="825" width="64" height="17" font="13">(no device) </text>
<text top="236" left="825" width="64" height="17" font="13">vs 2.9 (any </text>
<text top="253" left="825" width="43" height="17" font="13">device) </text>
<text top="150" left="905" width="93" height="17" font="13">Outcome events </text>
<text top="167" left="905" width="90" height="17" font="13">were defined as </text>
<text top="184" left="905" width="76" height="17" font="13">death, urgent </text>
<text top="202" left="905" width="84" height="17" font="13">transplantation </text>
<text top="219" left="905" width="99" height="17" font="13">(UNOS Status 1), </text>
<text top="236" left="905" width="84" height="17" font="13">or implantation </text>
<text top="253" left="905" width="74" height="17" font="13">of LVAD. Pts </text>
<text top="270" left="905" width="87" height="17" font="13">who underwent </text>
<text top="288" left="905" width="74" height="17" font="13">transplant as </text>
<text top="305" left="905" width="63" height="17" font="13">non-urgent </text>
<text top="322" left="905" width="94" height="17" font="13">(UNOS status 2) </text>
<text top="339" left="905" width="84" height="17" font="13">were censored </text>
<text top="357" left="905" width="94" height="17" font="13">alive on the date </text>
<text top="374" left="905" width="95" height="17" font="13">of the transplant. </text>
<text top="150" left="1017" width="79" height="17" font="13">1 y event-free </text>
<text top="167" left="1017" width="70" height="17" font="13">survival with </text>
<text top="184" left="1017" width="86" height="17" font="13">peak VO2 10.1-</text>
<text top="202" left="1017" width="103" height="17" font="13">14                          </text>
<text top="219" left="1017" width="72" height="17" font="13">Total cohort: </text>
<text top="236" left="1017" width="100" height="17" font="13">77%                      </text>
<text top="253" left="1017" width="68" height="17" font="13">CRT+/-ICD: </text>
<text top="270" left="1017" width="100" height="17" font="13">84%                      </text>
<text top="288" left="1017" width="75" height="17" font="13">ICD +/- CRT: </text>
<text top="305" left="1017" width="100" height="17" font="13">80%                      </text>
<text top="322" left="1017" width="102" height="17" font="13">Any device: 80%   </text>
<text top="339" left="1017" width="72" height="17" font="13">1 year event-</text>
<text top="357" left="1017" width="95" height="17" font="13">free survival with </text>
<text top="374" left="1017" width="100" height="17" font="13">peak VO2 &lt; 10     </text>
<text top="391" left="1017" width="72" height="17" font="13">Total cohort: </text>
<text top="408" left="1017" width="100" height="17" font="13">65%                      </text>
<text top="425" left="1017" width="68" height="17" font="13">CRT+/-ICD: </text>
<text top="443" left="1017" width="100" height="17" font="13">52%                      </text>
<text top="460" left="1017" width="75" height="17" font="13">ICD +/- CRT: </text>
<text top="477" left="1017" width="100" height="17" font="13">59%                      </text>
<text top="494" left="1017" width="102" height="17" font="13">Any device: 58%   </text>
<text top="150" left="1124" width="27" height="17" font="13"> N/A </text>
<text top="150" left="1189" width="103" height="17" font="13">HFSS significantly </text>
<text top="167" left="1189" width="125" height="17" font="13">discriminates between </text>
<text top="184" left="1189" width="127" height="17" font="13">the 3 risk strata across </text>
<text top="202" left="1189" width="99" height="17" font="13">all device groups, </text>
<text top="219" left="1189" width="108" height="17" font="13">whereas peak VO2 </text>
<text top="236" left="1189" width="125" height="17" font="13">&lt;10 only discriminates </text>
<text top="253" left="1189" width="77" height="17" font="13">high risk from </text>
<text top="270" left="1189" width="95" height="17" font="13">low/medium risk. </text>
<text top="150" left="1332" width="51" height="17" font="13">1y event-</text>
<text top="167" left="1332" width="73" height="17" font="13">free survival, </text>
<text top="184" left="1332" width="51" height="17" font="13">amongst </text>
<text top="202" left="1332" width="65" height="17" font="13">CRT+/-ICD </text>
<text top="219" left="1332" width="78" height="17" font="13">pts                  </text>
<text top="236" left="1332" width="44" height="17" font="13">low risk </text>
<text top="253" left="1332" width="78" height="17" font="13">HFSS 90%,    </text>
<text top="270" left="1332" width="70" height="17" font="13">medium risk </text>
<text top="288" left="1332" width="78" height="17" font="13">HFSS 72%,    </text>
<text top="305" left="1332" width="49" height="17" font="13">high risk </text>
<text top="322" left="1332" width="64" height="17" font="13">HFSS 56% </text>
<text top="517" left="61" width="183" height="17" font="15"><b>FUNCTIONAL/QOL OUTCOME  </b></text>
<text top="535" left="61" width="88" height="17" font="13">Improvement in </text>
<text top="553" left="61" width="106" height="17" font="13">QoL in Pts with HF </text>
<text top="570" left="61" width="77" height="17" font="13">who Undergo </text>
<text top="587" left="61" width="92" height="17" font="13">Transplantation, </text>
<text top="604" left="61" width="90" height="17" font="13">Grady KL, 1996 </text>
<text top="622" left="61" width="51" height="17" font="14">8878757 </text>
<text top="622" left="112" width="32" height="17" font="13">(312) </text>
<text top="535" left="185" width="96" height="17" font="13">To compare QoL </text>
<text top="553" left="185" width="92" height="17" font="13">of pts with HF at </text>
<text top="570" left="185" width="82" height="17" font="13">time of loisting </text>
<text top="587" left="185" width="60" height="17" font="13">for a heart </text>
<text top="604" left="185" width="83" height="17" font="13">transplant with </text>
<text top="622" left="185" width="72" height="17" font="13">that 1 y after </text>
<text top="639" left="185" width="84" height="17" font="13">transplantation </text>
<text top="535" left="296" width="44" height="17" font="13">Cohort  </text>
<text top="535" left="386" width="86" height="17" font="13">Post-transplant </text>
<text top="553" left="386" width="74" height="17" font="13">maintanence </text>
<text top="570" left="386" width="113" height="17" font="13">immunosuppression </text>
<text top="587" left="386" width="124" height="17" font="13">included cyclosporine, </text>
<text top="604" left="386" width="88" height="17" font="13">prednisone and </text>
<text top="622" left="386" width="109" height="17" font="13">azathioprine. Some </text>
<text top="639" left="386" width="126" height="17" font="13">received induction anti-</text>
<text top="656" left="386" width="81" height="17" font="13">T-cell therapy. </text>
<text top="535" left="530" width="192" height="17" font="13">148 Underwent </text>
<text top="553" left="606" width="43" height="17" font="13">cardiac </text>
<text top="570" left="606" width="84" height="17" font="13">transplantation </text>
<text top="587" left="606" width="53" height="17" font="13">at Loyola </text>
<text top="604" left="606" width="71" height="17" font="13">University of </text>
<text top="622" left="606" width="94" height="17" font="13">Chicago Medical </text>
<text top="639" left="606" width="55" height="17" font="13">Center or </text>
<text top="656" left="606" width="71" height="17" font="13">University of </text>
<text top="673" left="606" width="66" height="17" font="13">Alabama at </text>
<text top="690" left="606" width="69" height="17" font="13">Birmingham </text>
<text top="535" left="713" width="27" height="17" font="13"> N/A </text>
<text top="535" left="825" width="24" height="17" font="13">N/A </text>
<text top="535" left="905" width="65" height="17" font="13">Symptoms, </text>
<text top="553" left="905" width="37" height="17" font="13">health </text>
<text top="570" left="905" width="64" height="17" font="13">perception, </text>
<text top="587" left="905" width="96" height="17" font="13">functional status, </text>
<text top="604" left="905" width="83" height="17" font="13">stress, coping, </text>
<text top="622" left="905" width="87" height="17" font="13">life satisfaction, </text>
<text top="639" left="905" width="90" height="17" font="13">and overall QoL </text>
<text top="656" left="905" width="91" height="17" font="13">as measured by </text>
<text top="673" left="905" width="41" height="17" font="13">6 point-</text>
<text top="690" left="905" width="60" height="17" font="13">completed </text>
<text top="708" left="905" width="70" height="17" font="13">instruments. </text>
<text top="725" left="905" width="77" height="17" font="13">Demographic </text>
<text top="742" left="905" width="92" height="17" font="13">and clinical data </text>
<text top="759" left="905" width="59" height="17" font="13">from chart </text>
<text top="776" left="905" width="42" height="17" font="13">review. </text>
<text top="535" left="1017" width="216" height="17" font="13">N/A N/A </text>
<text top="535" left="1189" width="115" height="17" font="13">Total </text>
<text top="535" left="1220" width="137" height="17" font="13">symptom </text>
<text top="553" left="1189" width="107" height="17" font="13">distress decreased </text>
<text top="570" left="1189" width="60" height="17" font="13">after heart </text>
<text top="587" left="1189" width="87" height="17" font="13">transplantation. </text>
<text top="604" left="1189" width="85" height="17" font="13">Overall level of </text>
<text top="622" left="1189" width="107" height="17" font="13">functional disability </text>
<text top="639" left="1189" width="114" height="17" font="13">improved after heart </text>
<text top="656" left="1189" width="129" height="17" font="13">transplantation, though </text>
<text top="673" left="1189" width="80" height="17" font="13">remained low. </text>
<text top="535" left="1332" width="27" height="17" font="13"> N/A </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">153</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="98" height="17" font="13">A Controlled Trial </text>
<text top="72" left="61" width="64" height="17" font="13">of Exercise </text>
<text top="89" left="61" width="107" height="17" font="13">Rehabilitation After </text>
<text top="106" left="61" width="34" height="17" font="13">Heart </text>
<text top="124" left="61" width="92" height="17" font="13">Transplantation, </text>
<text top="141" left="61" width="98" height="17" font="13">Kobashigawa JA, </text>
<text top="158" left="61" width="31" height="17" font="13">1999 </text>
<text top="175" left="61" width="51" height="17" font="14">9920951 </text>
<text top="175" left="112" width="32" height="17" font="13">(313) </text>
<text top="192" left="61" width="3" height="17" font="13"> </text>
<text top="55" left="185" width="80" height="17" font="13">To assess the </text>
<text top="72" left="185" width="53" height="17" font="13">effects of </text>
<text top="89" left="185" width="89" height="17" font="13">structured 6 mo </text>
<text top="106" left="185" width="44" height="17" font="13">training </text>
<text top="124" left="185" width="98" height="17" font="13">(cardiopulmonary </text>
<text top="141" left="185" width="94" height="17" font="13">rehabilitation) on </text>
<text top="158" left="185" width="87" height="17" font="13">the capacity for </text>
<text top="175" left="185" width="79" height="17" font="13">exercise early </text>
<text top="192" left="185" width="71" height="17" font="13">after cardiac </text>
<text top="210" left="185" width="84" height="17" font="13">transplantation </text>
<text top="55" left="296" width="29" height="17" font="13">RCT </text>
<text top="55" left="386" width="109" height="17" font="13">All pts were treated </text>
<text top="72" left="386" width="84" height="17" font="13">with triple-drug </text>
<text top="89" left="386" width="122" height="17" font="13">immunosuppression-- </text>
<text top="106" left="386" width="75" height="17" font="13">cyclosporine, </text>
<text top="124" left="386" width="98" height="17" font="13">azathioprine, and </text>
<text top="141" left="386" width="71" height="17" font="13">prednisone.  </text>
<text top="55" left="530" width="199" height="17" font="13">27 Underwent </text>
<text top="72" left="606" width="43" height="17" font="13">cardiac </text>
<text top="89" left="606" width="84" height="17" font="13">transplantation </text>
<text top="55" left="713" width="92" height="17" font="13">Multiple medical </text>
<text top="72" left="713" width="80" height="17" font="13">issues limiting </text>
<text top="89" left="713" width="48" height="17" font="13">ability to </text>
<text top="106" left="713" width="73" height="17" font="13">participate in </text>
<text top="124" left="713" width="93" height="17" font="13">exercise training </text>
<text top="55" left="825" width="27" height="17" font="13"> N/A </text>
<text top="55" left="905" width="79" height="17" font="13">Differences in </text>
<text top="72" left="905" width="53" height="17" font="13">results of </text>
<text top="89" left="905" width="94" height="17" font="13">cardiopulmonary </text>
<text top="106" left="905" width="85" height="17" font="13">exercise stress </text>
<text top="124" left="905" width="95" height="17" font="13">testing at 1-  and </text>
<text top="141" left="905" width="63" height="17" font="13">6- mo after </text>
<text top="158" left="905" width="84" height="17" font="13">transplantation </text>
<text top="55" left="1017" width="27" height="17" font="13"> N/A </text>
<text top="55" left="1124" width="49" height="17" font="13">Enrollme</text>
<text top="72" left="1124" width="31" height="17" font="13">nt 11 </text>
<text top="89" left="1124" width="34" height="17" font="13">mo; 6 </text>
<text top="106" left="1124" width="21" height="17" font="13">mo </text>
<text top="124" left="1124" width="49" height="17" font="13">followup </text>
<text top="141" left="1124" width="31" height="17" font="13">(total </text>
<text top="158" left="1124" width="38" height="17" font="13">17mo) </text>
<text top="55" left="1189" width="135" height="17" font="13">6 mo D peak VO2:          </text>
<text top="72" left="1189" width="78" height="17" font="13">+4.4 L/min/kg </text>
<text top="89" left="1189" width="105" height="17" font="13">(exercise)               </text>
<text top="106" left="1189" width="126" height="17" font="13">+1.9 L/min/kg (control) </text>
<text top="55" left="1332" width="41" height="17" font="13">p=0.01 </text>
<text top="228" left="61" width="99" height="17" font="13">Predictors of QoL </text>
<text top="245" left="61" width="97" height="17" font="13">in Pts at 1 y After </text>
<text top="262" left="61" width="34" height="17" font="13">Heart </text>
<text top="279" left="61" width="92" height="17" font="13">Transplantation, </text>
<text top="296" left="61" width="90" height="17" font="13">Grady KL, 1999 </text>
<text top="314" left="61" width="58" height="17" font="14">10328145 </text>
<text top="314" left="119" width="32" height="17" font="13">(314) </text>
<text top="228" left="185" width="98" height="17" font="13">To describe QoL, </text>
<text top="245" left="185" width="50" height="17" font="13">examine </text>
<text top="262" left="185" width="72" height="17" font="13">relationships </text>
<text top="279" left="185" width="89" height="17" font="13">between quality </text>
<text top="296" left="185" width="57" height="17" font="13">of life and </text>
<text top="314" left="185" width="78" height="17" font="13">demographic, </text>
<text top="331" left="185" width="75" height="17" font="13">physical, and </text>
<text top="348" left="185" width="74" height="17" font="13">psychosocial </text>
<text top="365" left="185" width="80" height="17" font="13">variables, and </text>
<text top="382" left="185" width="42" height="17" font="13">identify </text>
<text top="400" left="185" width="98" height="17" font="13">predictors of Q0L </text>
<text top="417" left="185" width="80" height="17" font="13">in pts 1 y post-</text>
<text top="434" left="185" width="57" height="17" font="13">transplant </text>
<text top="228" left="296" width="195" height="17" font="13">Cohort study  Some pt receieved </text>
<text top="245" left="386" width="112" height="17" font="13">induction anti-T celll </text>
<text top="262" left="386" width="122" height="17" font="13">therapy with HATG or </text>
<text top="279" left="386" width="116" height="17" font="13">OKT3, some did not. </text>
<text top="296" left="386" width="84" height="17" font="13">All pts were on </text>
<text top="314" left="386" width="74" height="17" font="13">maintenance </text>
<text top="331" left="386" width="124" height="17" font="13">immmunosuppression </text>
<text top="348" left="386" width="72" height="17" font="13">consisting of </text>
<text top="365" left="386" width="75" height="17" font="13">cyclosporine, </text>
<text top="382" left="386" width="92" height="17" font="13">prednisone, and </text>
<text top="400" left="386" width="74" height="17" font="13">azathioprine. </text>
<text top="417" left="386" width="130" height="17" font="13">Prednisone was rapidly </text>
<text top="434" left="386" width="123" height="17" font="13">tapered to 0.1mg/kg/d </text>
<text top="451" left="386" width="89" height="17" font="13">by 1 y post-OH. </text>
<text top="228" left="530" width="150" height="17" font="13">232 Pts </text>
<text top="228" left="627" width="78" height="17" font="13">who </text>
<text top="245" left="606" width="83" height="17" font="13">survived to 1 y </text>
<text top="262" left="606" width="70" height="17" font="13">post-cardiac </text>
<text top="279" left="606" width="81" height="17" font="13">transplant and </text>
<text top="296" left="606" width="81" height="17" font="13">completed the </text>
<text top="314" left="606" width="76" height="17" font="13">study booklet </text>
<text top="228" left="713" width="27" height="17" font="13"> N/A </text>
<text top="228" left="825" width="24" height="17" font="13">N/A </text>
<text top="228" left="905" width="77" height="17" font="13">QoL domains </text>
<text top="245" left="905" width="70" height="17" font="13">and multiple </text>
<text top="262" left="905" width="93" height="17" font="13">subscales within </text>
<text top="279" left="905" width="87" height="17" font="13">these domains: </text>
<text top="296" left="905" width="46" height="17" font="13">somatic </text>
<text top="314" left="905" width="59" height="17" font="13">sensation, </text>
<text top="331" left="905" width="77" height="17" font="13">psychological </text>
<text top="348" left="905" width="81" height="17" font="13">state, physical </text>
<text top="365" left="905" width="96" height="17" font="13">and occupational </text>
<text top="382" left="905" width="85" height="17" font="13">function, social </text>
<text top="400" left="905" width="60" height="17" font="13">interaction </text>
<text top="228" left="1017" width="27" height="17" font="13"> N/A </text>
<text top="228" left="1124" width="46" height="17" font="13">Recruite</text>
<text top="245" left="1124" width="30" height="17" font="13">d pts </text>
<text top="262" left="1124" width="50" height="17" font="13">listed for </text>
<text top="279" left="1124" width="29" height="17" font="13">OHT </text>
<text top="296" left="1124" width="28" height="17" font="13">from </text>
<text top="314" left="1124" width="28" height="17" font="13">3/88-</text>
<text top="331" left="1124" width="27" height="17" font="13">8/96 </text>
<text top="228" left="1189" width="107" height="17" font="13">Predictors of better </text>
<text top="245" left="1189" width="117" height="17" font="13">QoL at 1 y post-OHT </text>
<text top="262" left="1189" width="125" height="17" font="13">were: less total stress, </text>
<text top="279" left="1189" width="111" height="17" font="13">more helpfulness of </text>
<text top="296" left="1189" width="103" height="17" font="13">information, better </text>
<text top="314" left="1189" width="101" height="17" font="13">health perception, </text>
<text top="331" left="1189" width="126" height="17" font="13">better compliance with </text>
<text top="348" left="1189" width="109" height="17" font="13">transplant regimen, </text>
<text top="365" left="1189" width="124" height="17" font="13">more effective coping, </text>
<text top="382" left="1189" width="126" height="17" font="13">more functional ability, </text>
<text top="400" left="1189" width="128" height="17" font="13">less symptom distress, </text>
<text top="417" left="1189" width="92" height="17" font="13">older age, fewer </text>
<text top="434" left="1189" width="95" height="17" font="13">complications      </text>
<text top="451" left="1189" width="112" height="17" font="13">Predictors of POOR </text>
<text top="469" left="1189" width="81" height="17" font="13">outcome were </text>
<text top="486" left="1189" width="127" height="17" font="13">primarily psychological </text>
<text top="228" left="1332" width="62" height="17" font="13">p&lt;0.00001 </text>
<text top="245" left="1332" width="34" height="17" font="13">for all </text>
<text top="504" left="61" width="99" height="17" font="13">Lifestyle and QoL </text>
<text top="521" left="61" width="80" height="17" font="13">in Long- Term </text>
<text top="538" left="61" width="107" height="17" font="13">Cardiac Transplant </text>
<text top="555" left="61" width="103" height="17" font="13">Recipients, Salyer </text>
<text top="573" left="61" width="44" height="17" font="13">J, 2003 </text>
<text top="590" left="61" width="58" height="17" font="14">12633699 </text>
<text top="590" left="119" width="32" height="17" font="13">(315) </text>
<text top="504" left="185" width="68" height="17" font="13">To describe </text>
<text top="521" left="185" width="91" height="17" font="13">long-term (&gt;1 y) </text>
<text top="538" left="185" width="43" height="17" font="13">cardiac </text>
<text top="555" left="185" width="57" height="17" font="13">transplant </text>
<text top="573" left="185" width="59" height="17" font="13">recipients’ </text>
<text top="590" left="185" width="81" height="17" font="13">perceptions of </text>
<text top="607" left="185" width="59" height="17" font="13">barriers to </text>
<text top="624" left="185" width="96" height="17" font="13">health-promoting </text>
<text top="641" left="185" width="95" height="17" font="13">behaviors; ability </text>
<text top="659" left="185" width="89" height="17" font="13">to manage their </text>
<text top="676" left="185" width="78" height="17" font="13">health, health-</text>
<text top="693" left="185" width="58" height="17" font="13">promoting </text>
<text top="710" left="185" width="85" height="17" font="13">lifestyle, health </text>
<text top="727" left="185" width="90" height="17" font="13">status and QoL; </text>
<text top="745" left="185" width="82" height="17" font="13">and determine </text>
<text top="762" left="185" width="71" height="17" font="13">predictors of </text>
<text top="779" left="185" width="30" height="17" font="13">QoL. </text>
<text top="504" left="296" width="36" height="17" font="13">Cross-</text>
<text top="521" left="296" width="52" height="17" font="13">sectional </text>
<text top="538" left="296" width="33" height="17" font="13">study </text>
<text top="504" left="386" width="27" height="17" font="13"> N/A </text>
<text top="504" left="530" width="17" height="17" font="13">93 </text>
<text top="504" left="606" width="46" height="17" font="13">Cardiac </text>
<text top="521" left="606" width="57" height="17" font="13">transplant </text>
<text top="538" left="606" width="82" height="17" font="13">recipients who </text>
<text top="555" left="606" width="86" height="17" font="13">were: (1) &gt;18 y </text>
<text top="573" left="606" width="72" height="17" font="13">of age at the </text>
<text top="590" left="606" width="40" height="17" font="13">time of </text>
<text top="607" left="606" width="79" height="17" font="13">transplant; (2) </text>
<text top="624" left="606" width="85" height="17" font="13">could read and </text>
<text top="641" left="606" width="77" height="17" font="13">write English; </text>
<text top="659" left="606" width="87" height="17" font="13">and (3) had the </text>
<text top="676" left="606" width="84" height="17" font="13">visual acuity to </text>
<text top="693" left="606" width="52" height="17" font="13">read and </text>
<text top="710" left="606" width="62" height="17" font="13">respond to </text>
<text top="727" left="606" width="40" height="17" font="13">written </text>
<text top="745" left="606" width="87" height="17" font="13">questionnaires. </text>
<text top="504" left="713" width="31" height="17" font="13">  N/A </text>
<text top="504" left="825" width="27" height="17" font="13"> N/A </text>
<text top="504" left="905" width="61" height="17" font="13">Self-report </text>
<text top="521" left="905" width="77" height="17" font="13">questionnaire </text>
<text top="538" left="905" width="96" height="17" font="13">incorporating: (1) </text>
<text top="555" left="905" width="99" height="17" font="13">pt characteristics; </text>
<text top="573" left="905" width="77" height="17" font="13">(2) barriers to </text>
<text top="590" left="905" width="98" height="17" font="13">health promotion, </text>
<text top="607" left="905" width="94" height="17" font="13">perceived health </text>
<text top="624" left="905" width="94" height="17" font="13">competence and </text>
<text top="641" left="905" width="96" height="17" font="13">health-promoting </text>
<text top="659" left="905" width="66" height="17" font="13">lifestyle; (3) </text>
<text top="676" left="905" width="94" height="17" font="13">perceived health </text>
<text top="693" left="905" width="82" height="17" font="13">status; and (4) </text>
<text top="710" left="905" width="30" height="17" font="13">QoL. </text>
<text top="504" left="1017" width="27" height="17" font="13"> N/A </text>
<text top="504" left="1124" width="34" height="17" font="13">Mean </text>
<text top="521" left="1124" width="27" height="17" font="13">time </text>
<text top="538" left="1124" width="32" height="17" font="13">since </text>
<text top="555" left="1124" width="44" height="17" font="13">transpla</text>
<text top="573" left="1124" width="39" height="17" font="13">nt was </text>
<text top="590" left="1124" width="34" height="17" font="13">101.4 </text>
<text top="607" left="1124" width="45" height="17" font="13">mo (SD </text>
<text top="624" left="1124" width="34" height="17" font="13">49.44 </text>
<text top="641" left="1124" width="24" height="17" font="13">mo, </text>
<text top="659" left="1124" width="35" height="17" font="13">range </text>
<text top="676" left="1124" width="42" height="17" font="13">12-188 </text>
<text top="693" left="1124" width="25" height="17" font="13">mo) </text>
<text top="504" left="1189" width="85" height="17" font="13">Despite having </text>
<text top="521" left="1189" width="129" height="17" font="13">multiple co-morbidities, </text>
<text top="538" left="1189" width="89" height="17" font="13">heart transplant </text>
<text top="555" left="1189" width="106" height="17" font="13">recipients evaluate </text>
<text top="573" left="1189" width="135" height="17" font="13">their health as good.       </text>
<text top="590" left="1189" width="122" height="17" font="13">QoL in recipients who </text>
<text top="607" left="1189" width="123" height="17" font="13">are, on average, 8.5 y </text>
<text top="624" left="1189" width="109" height="17" font="13">post-transplant and </text>
<text top="641" left="1189" width="99" height="17" font="13">demonstrate that, </text>
<text top="659" left="1189" width="91" height="17" font="13">overall, they are </text>
<text top="676" left="1189" width="113" height="17" font="13">moderately satisfied </text>
<text top="693" left="1189" width="129" height="17" font="13">with their lives               </text>
<text top="710" left="1189" width="107" height="17" font="13">Predictors of better </text>
<text top="727" left="1189" width="107" height="17" font="13">perceptions of QoL </text>
<text top="745" left="1189" width="74" height="17" font="13">included less </text>
<text top="762" left="1189" width="124" height="17" font="13">education, longer time </text>
<text top="779" left="1189" width="93" height="17" font="13">since transplant, </text>
<text top="504" left="1332" width="27" height="17" font="13"> N/A </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">154</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1189" width="111" height="17" font="13">ischemic etiology of </text>
<text top="72" left="1189" width="105" height="17" font="13">HF, fewer barriers, </text>
<text top="89" left="1189" width="94" height="17" font="13">higher perceived </text>
<text top="106" left="1189" width="107" height="17" font="13">health competence </text>
<text top="124" left="1189" width="72" height="17" font="13">and a health-</text>
<text top="141" left="1189" width="116" height="17" font="13">promoting lifestyle (R</text>
<text top="142" left="1305" width="4" height="11" font="19">2</text>
<text top="141" left="1309" width="3" height="17" font="13"> </text>
<text top="158" left="1189" width="90" height="17" font="13">=0.51; F=14.77; </text>
<text top="175" left="1189" width="56" height="17" font="13">p=0.001). </text>
<text top="193" left="61" width="66" height="17" font="13">Changes in </text>
<text top="210" left="61" width="101" height="17" font="13">exercise capacity, </text>
<text top="228" left="61" width="86" height="17" font="13">ventilation, and </text>
<text top="245" left="61" width="69" height="17" font="13">body weight </text>
<text top="262" left="61" width="83" height="17" font="13">following heart </text>
<text top="279" left="61" width="87" height="17" font="13">transplantation, </text>
<text top="296" left="61" width="106" height="17" font="13">Habedank D, 2007 </text>
<text top="314" left="61" width="58" height="17" font="14">17023206 </text>
<text top="314" left="119" width="32" height="17" font="13">(316) </text>
<text top="193" left="185" width="93" height="17" font="13">To prospectively </text>
<text top="210" left="185" width="50" height="17" font="13">examine </text>
<text top="228" left="185" width="93" height="17" font="13">changes in peak </text>
<text top="245" left="185" width="52" height="17" font="13">VO2 and </text>
<text top="262" left="185" width="59" height="17" font="13">ventilatory </text>
<text top="279" left="185" width="55" height="17" font="13">efficiency </text>
<text top="296" left="185" width="98" height="17" font="13">(VE/VCO2 slope) </text>
<text top="314" left="185" width="65" height="17" font="13">over 24 mo </text>
<text top="331" left="185" width="83" height="17" font="13">following heart </text>
<text top="348" left="185" width="84" height="17" font="13">transplantation </text>
<text top="365" left="185" width="94" height="17" font="13">and evaluate the </text>
<text top="382" left="185" width="59" height="17" font="13">potentially </text>
<text top="400" left="185" width="70" height="17" font="13">confounding </text>
<text top="417" left="185" width="92" height="17" font="13">effects of weight </text>
<text top="434" left="185" width="27" height="17" font="13">gain </text>
<text top="193" left="296" width="152" height="17" font="13">Case control   In txplt pts  </text>
<text top="210" left="386" width="118" height="17" font="13">Immunosuppression: </text>
<text top="228" left="386" width="131" height="17" font="13">cyclosporine/tacrolimus </text>
<text top="245" left="386" width="131" height="17" font="13">100%                             </text>
<text top="262" left="386" width="136" height="17" font="13">prenisolone 100%           </text>
<text top="279" left="386" width="102" height="17" font="13">azathioprine/MMF </text>
<text top="296" left="386" width="73" height="17" font="13">100%            </text>
<text top="314" left="386" width="124" height="17" font="13">ACE-I/ARB 99%          </text>
<text top="331" left="386" width="109" height="17" font="13">CCB   93%              </text>
<text top="348" left="386" width="100" height="17" font="13">Diuretics  92%      </text>
<text top="365" left="386" width="139" height="17" font="13">alpha blocker 17%           </text>
<text top="382" left="386" width="102" height="17" font="13">beta blocker  12% </text>
<text top="193" left="530" width="192" height="17" font="13">125 Underwent </text>
<text top="210" left="606" width="43" height="17" font="13">cardiac </text>
<text top="228" left="606" width="84" height="17" font="13">transplantation </text>
<text top="245" left="606" width="77" height="17" font="13">between 9/97 </text>
<text top="262" left="606" width="65" height="17" font="13">and 1/02 at </text>
<text top="279" left="606" width="81" height="17" font="13">German Heart </text>
<text top="296" left="606" width="102" height="17" font="13">Institute, Berlin;     </text>
<text top="314" left="606" width="45" height="17" font="13">Healthy </text>
<text top="331" left="606" width="60" height="17" font="13">volunteers </text>
<text top="193" left="713" width="31" height="17" font="13">  N/A </text>
<text top="193" left="825" width="24" height="17" font="13">N/A </text>
<text top="193" left="905" width="63" height="17" font="13">Peak VO2, </text>
<text top="210" left="905" width="88" height="17" font="13">Ve/VCO2 slope </text>
<text top="193" left="1017" width="24" height="17" font="13">N/A </text>
<text top="193" left="1124" width="31" height="17" font="13">  N/A </text>
<text top="193" left="1189" width="88" height="17" font="13">Ve/VCO2 slope </text>
<text top="210" left="1189" width="123" height="17" font="13">improved (decreased) </text>
<text top="228" left="1189" width="123" height="17" font="13">at 6 mo and remained </text>
<text top="245" left="1189" width="126" height="17" font="13">improved at 12, 24 mo </text>
<text top="262" left="1189" width="112" height="17" font="13">post-txplt compared </text>
<text top="279" left="1189" width="106" height="17" font="13">with pre-txplt value </text>
<text top="296" left="1189" width="116" height="17" font="13">and no different than </text>
<text top="314" left="1189" width="116" height="17" font="13">matched normal at 6 </text>
<text top="331" left="1189" width="127" height="17" font="13">mo.                               </text>
<text top="348" left="1189" width="127" height="17" font="13">Peak VO2 improved at </text>
<text top="365" left="1189" width="109" height="17" font="13">6 mo and remained </text>
<text top="382" left="1189" width="126" height="17" font="13">improved at 12, 24 mo </text>
<text top="400" left="1189" width="125" height="17" font="13">post-txplt compared to </text>
<text top="417" left="1189" width="118" height="17" font="13">pre-txplt baseline but </text>
<text top="434" left="1189" width="115" height="17" font="13">remained lower than </text>
<text top="451" left="1189" width="92" height="17" font="13">normal matched </text>
<text top="469" left="1189" width="50" height="17" font="13">controls. </text>
<text top="193" left="1332" width="59" height="17" font="13">Ve/VCO2, </text>
<text top="210" left="1332" width="67" height="17" font="13">p&lt;0.001 vs. </text>
<text top="228" left="1332" width="53" height="17" font="13">baseline, </text>
<text top="245" left="1332" width="57" height="17" font="13">p=0.12 vs </text>
<text top="262" left="1332" width="51" height="17" font="13">matched </text>
<text top="279" left="1332" width="78" height="17" font="13">normals          </text>
<text top="296" left="1332" width="63" height="17" font="13">Peak VO2, </text>
<text top="314" left="1332" width="57" height="17" font="13">p&lt;0.01 vs </text>
<text top="331" left="1332" width="53" height="17" font="13">baseline, </text>
<text top="348" left="1332" width="71" height="17" font="13">p&lt;0.0001 vs </text>
<text top="365" left="1332" width="51" height="17" font="13">matched </text>
<text top="382" left="1332" width="51" height="17" font="13">normals  </text>
<text top="487" left="61" width="73" height="17" font="13">Patterns and </text>
<text top="504" left="61" width="99" height="17" font="13">Predictors of QoL </text>
<text top="521" left="61" width="96" height="17" font="13">at 5 to 10 Y After </text>
<text top="538" left="61" width="34" height="17" font="13">Heart </text>
<text top="555" left="61" width="92" height="17" font="13">Transplantation, </text>
<text top="573" left="61" width="90" height="17" font="13">Grady KL, 2007 </text>
<text top="590" left="61" width="58" height="17" font="14">18022086 </text>
<text top="590" left="119" width="32" height="17" font="13">(317) </text>
<text top="487" left="185" width="94" height="17" font="13">To describe QoL </text>
<text top="504" left="185" width="78" height="17" font="13">over time and </text>
<text top="521" left="185" width="42" height="17" font="13">identify </text>
<text top="538" left="185" width="98" height="17" font="13">predictors of QoL </text>
<text top="555" left="185" width="74" height="17" font="13">longitudinally </text>
<text top="573" left="185" width="94" height="17" font="13">from 5-10 y after </text>
<text top="590" left="185" width="31" height="17" font="13">heart </text>
<text top="607" left="185" width="84" height="17" font="13">transplantation </text>
<text top="487" left="296" width="162" height="17" font="13">Cohort N/A </text>
<text top="487" left="530" width="201" height="17" font="13">555  Transplanted </text>
<text top="504" left="606" width="91" height="17" font="13">between 7/1990 </text>
<text top="521" left="606" width="68" height="17" font="13">and 6/1999; </text>
<text top="538" left="606" width="89" height="17" font="13">Survived 5-10 y </text>
<text top="555" left="606" width="102" height="17" font="13">post-transplant      </text>
<text top="573" left="606" width="77" height="17" font="13">Completed pt </text>
<text top="590" left="606" width="40" height="17" font="13">survey </text>
<text top="607" left="606" width="102" height="17" font="13">pamphlet;              </text>
<text top="624" left="606" width="100" height="17" font="13">Age &gt;21y;             </text>
<text top="641" left="606" width="57" height="17" font="13">Literate in </text>
<text top="659" left="606" width="44" height="17" font="13">English </text>
<text top="487" left="713" width="31" height="17" font="13">  N/A </text>
<text top="487" left="825" width="31" height="17" font="13">  N/A </text>
<text top="487" left="905" width="31" height="17" font="13">  N/A </text>
<text top="487" left="1017" width="31" height="17" font="13">  N/A </text>
<text top="487" left="1124" width="31" height="17" font="13">  N/A </text>
<text top="487" left="1189" width="108" height="17" font="13">QoL is positive and </text>
<text top="504" left="1189" width="129" height="17" font="13">stable at 5 to 10 y after </text>
<text top="521" left="1189" width="119" height="17" font="13">heart transplantation. </text>
<text top="538" left="1189" width="96" height="17" font="13">Bio-psychosocial </text>
<text top="555" left="1189" width="107" height="17" font="13">variables predicted </text>
<text top="573" left="1189" width="90" height="17" font="13">satisfaction with </text>
<text top="590" left="1189" width="90" height="17" font="13">overall QoL and </text>
<text top="607" left="1189" width="48" height="17" font="13">HRQoL. </text>
<text top="487" left="1332" width="31" height="17" font="13">  N/A </text>
<text top="677" left="61" width="140" height="17" font="15"><b>SURVIVAL OUTCOMES </b></text>
<text top="700" left="61" width="104" height="17" font="13">Long-term Results </text>
<text top="717" left="61" width="59" height="17" font="13">of Cardiac </text>
<text top="734" left="61" width="101" height="17" font="13">Transplantation in </text>
<text top="751" left="61" width="99" height="17" font="13">Pts Older than 60 </text>
<text top="769" left="61" width="18" height="17" font="13">Y,  </text>
<text top="786" left="61" width="79" height="17" font="13">Bull DA, 1996 </text>
<text top="700" left="185" width="88" height="17" font="13">To examine the </text>
<text top="717" left="185" width="95" height="17" font="13">long-term results </text>
<text top="734" left="185" width="57" height="17" font="13">of cardiac </text>
<text top="751" left="185" width="97" height="17" font="13">transplantation in </text>
<text top="769" left="185" width="54" height="17" font="13">pts &gt;60 y </text>
<text top="700" left="298" width="73" height="17" font="13">Case-control </text>
<text top="700" left="439" width="24" height="17" font="13">N/A </text>
<text top="700" left="550" width="24" height="17" font="13">527 </text>
<text top="700" left="606" width="72" height="17" font="13">NYHA IV HF </text>
<text top="717" left="606" width="78" height="17" font="13">unremedial to </text>
<text top="734" left="606" width="46" height="17" font="13">surgical </text>
<text top="751" left="606" width="87" height="17" font="13">treatment other </text>
<text top="769" left="606" width="70" height="17" font="13">than cardiac </text>
<text top="786" left="606" width="102" height="17" font="13">replacement,         </text>
<text top="700" left="713" width="78" height="17" font="13">Severe pHTN </text>
<text top="717" left="713" width="86" height="17" font="13">(PVR &gt;6 Wood </text>
<text top="734" left="713" width="33" height="17" font="13">units, </text>
<text top="751" left="713" width="105" height="17" font="13">irreversible)            </text>
<text top="769" left="713" width="42" height="17" font="13">Severe </text>
<text top="786" left="713" width="64" height="17" font="13">irreversible </text>
<text top="700" left="825" width="56" height="17" font="13">NYHA IV  </text>
<text top="700" left="905" width="75" height="17" font="13">Survival after </text>
<text top="717" left="905" width="57" height="17" font="13">transplant </text>
<text top="700" left="1017" width="101" height="17" font="13">6 y mortality          </text>
<text top="717" left="1017" width="100" height="17" font="13">&gt;60y/o:   46%       </text>
<text top="734" left="1017" width="100" height="17" font="13">&lt;60y/o:   28%       </text>
<text top="700" left="1124" width="20" height="17" font="13">9 y </text>
<text top="700" left="1189" width="64" height="17" font="13">18% worse </text>
<text top="717" left="1189" width="83" height="17" font="13">survival/higher </text>
<text top="734" left="1189" width="111" height="17" font="13">mortality at 6 y post-</text>
<text top="751" left="1189" width="95" height="17" font="13">transplant for pts </text>
<text top="769" left="1189" width="119" height="17" font="13">transplanted at age &gt; </text>
<text top="786" left="1189" width="98" height="17" font="13">60 y.                     </text>
<text top="700" left="1332" width="20" height="17" font="13">6-y </text>
<text top="717" left="1332" width="53" height="17" font="13">mortality: </text>
<text top="734" left="1332" width="79" height="17" font="13">p&lt;0.05            </text>
<text top="751" left="1332" width="64" height="17" font="13">Death from </text>
<text top="769" left="1332" width="70" height="17" font="13">infection:      </text>
<text top="786" left="1332" width="79" height="17" font="13">p&lt;0.003          </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">155</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="51" height="17" font="14">8583816 </text>
<text top="55" left="112" width="32" height="17" font="13">(318) </text>
<text top="72" left="61" width="3" height="17" font="13"> </text>
<text top="55" left="606" width="62" height="17" font="13">Limited life </text>
<text top="72" left="606" width="89" height="17" font="13">expectancy, 1-y </text>
<text top="89" left="606" width="99" height="17" font="13">mortality &gt;50%     </text>
<text top="106" left="606" width="100" height="17" font="13">Age &lt;65 y;            </text>
<text top="124" left="606" width="70" height="17" font="13">No systemic </text>
<text top="141" left="606" width="69" height="17" font="13">illness other </text>
<text top="158" left="606" width="27" height="17" font="13">than </text>
<text top="175" left="606" width="76" height="17" font="13">abnormalities </text>
<text top="192" left="606" width="102" height="17" font="13">related to HF,        </text>
<text top="210" left="606" width="58" height="17" font="13">Emotional </text>
<text top="227" left="606" width="99" height="17" font="13">stability,                </text>
<text top="244" left="606" width="75" height="17" font="13">Strong family </text>
<text top="261" left="606" width="90" height="17" font="13">support system. </text>
<text top="55" left="713" width="92" height="17" font="13">hepatic, renal or </text>
<text top="72" left="713" width="61" height="17" font="13">pulmonary </text>
<text top="89" left="713" width="104" height="17" font="13">disease,                 </text>
<text top="106" left="713" width="88" height="17" font="13">Active systemic </text>
<text top="124" left="713" width="75" height="17" font="13">or pulmonary </text>
<text top="141" left="713" width="104" height="17" font="13">infection,                </text>
<text top="158" left="713" width="42" height="17" font="13">Recent </text>
<text top="175" left="713" width="61" height="17" font="13">pulmonary </text>
<text top="192" left="713" width="60" height="17" font="13">infarction,  </text>
<text top="210" left="713" width="82" height="17" font="13">Uncontrollable </text>
<text top="227" left="713" width="73" height="17" font="13">HTN,             </text>
<text top="244" left="713" width="80" height="17" font="13">Uncorrectable </text>
<text top="261" left="713" width="58" height="17" font="13">peripheral </text>
<text top="278" left="713" width="105" height="17" font="13">vascular disease,   </text>
<text top="296" left="713" width="73" height="17" font="13">Active peptic </text>
<text top="313" left="713" width="107" height="17" font="13">ulcer disease,         </text>
<text top="330" left="713" width="55" height="17" font="13">History of </text>
<text top="347" left="713" width="96" height="17" font="13">substance abuse </text>
<text top="365" left="713" width="56" height="17" font="13">(including </text>
<text top="382" left="713" width="61" height="17" font="13">alcohol) or </text>
<text top="399" left="713" width="99" height="17" font="13">behavior problem </text>
<text top="416" left="713" width="59" height="17" font="13">that would </text>
<text top="433" left="713" width="74" height="17" font="13">interfere with </text>
<text top="451" left="713" width="46" height="17" font="13">medical </text>
<text top="468" left="713" width="66" height="17" font="13">compliance </text>
<text top="55" left="1189" width="91" height="17" font="13">Older transplant </text>
<text top="72" left="1189" width="99" height="17" font="13">recipient (&gt;60y/o) </text>
<text top="89" left="1189" width="127" height="17" font="13">more likely to die of an </text>
<text top="106" left="1189" width="127" height="17" font="13">infectious complication </text>
<text top="124" left="1189" width="136" height="17" font="13">after transplantation.       </text>
<text top="141" left="1189" width="91" height="17" font="13">Older transplant </text>
<text top="158" left="1189" width="99" height="17" font="13">recipient (&gt;60y/o) </text>
<text top="175" left="1189" width="109" height="17" font="13">more likely to die of </text>
<text top="192" left="1189" width="103" height="17" font="13">malignant disease </text>
<text top="210" left="1189" width="136" height="17" font="13">after transplantation.       </text>
<text top="227" left="1189" width="126" height="17" font="13">Older pts (&gt;60y/o) had </text>
<text top="244" left="1189" width="101" height="17" font="13">significantly fewer </text>
<text top="261" left="1189" width="124" height="17" font="13">rejection episodes per </text>
<text top="278" left="1189" width="102" height="17" font="13">pt than those &lt; 60 </text>
<text top="296" left="1189" width="47" height="17" font="13">years at </text>
<text top="313" left="1189" width="84" height="17" font="13">transplantation </text>
<text top="330" left="1189" width="117" height="17" font="13">(1.9+1.3 vs 2.6 +1.8) </text>
<text top="55" left="1332" width="64" height="17" font="13">Death from </text>
<text top="72" left="1332" width="64" height="17" font="13">cancer:       </text>
<text top="89" left="1332" width="79" height="17" font="13">p=0.015          </text>
<text top="106" left="1332" width="55" height="17" font="13">Rejection </text>
<text top="124" left="1332" width="70" height="17" font="13">episodes:     </text>
<text top="141" left="1332" width="48" height="17" font="13">p=0.009 </text>
<text top="486" left="61" width="73" height="17" font="13">Comparative </text>
<text top="503" left="61" width="77" height="17" font="13">Outcome and </text>
<text top="520" left="61" width="101" height="17" font="13">Clinical Profiles in </text>
<text top="537" left="61" width="88" height="17" font="13">Transplantation </text>
<text top="555" left="61" width="96" height="17" font="13">(COCPIT) Study, </text>
<text top="572" left="61" width="90" height="17" font="13">Deng MC, 2000 </text>
<text top="589" left="61" width="58" height="17" font="14">10968814 </text>
<text top="589" left="119" width="32" height="17" font="13">(319) </text>
<text top="486" left="185" width="76" height="17" font="13">To determine </text>
<text top="503" left="185" width="91" height="17" font="13">whether there is </text>
<text top="520" left="185" width="96" height="17" font="13">a survival benefit </text>
<text top="537" left="185" width="87" height="17" font="13">associated with </text>
<text top="555" left="185" width="43" height="17" font="13">cardiac </text>
<text top="572" left="185" width="97" height="17" font="13">transplantation in </text>
<text top="589" left="185" width="57" height="17" font="13">Germany. </text>
<text top="486" left="296" width="68" height="17" font="13">Prospective </text>
<text top="503" left="296" width="76" height="17" font="13">observational </text>
<text top="520" left="296" width="41" height="17" font="13">cohort  </text>
<text top="486" left="386" width="24" height="17" font="13">N/A </text>
<text top="486" left="530" width="24" height="17" font="13">889 </text>
<text top="486" left="606" width="63" height="17" font="13">Age &gt;16 y, </text>
<text top="503" left="606" width="93" height="17" font="13">listed for cardiac </text>
<text top="520" left="606" width="84" height="17" font="13">transplantation </text>
<text top="486" left="713" width="238" height="17" font="13">N/A NYHA </text>
<text top="486" left="863" width="103" height="17" font="13">IV </text>
<text top="486" left="905" width="141" height="17" font="13">Mortality, </text>
<text top="503" left="905" width="86" height="17" font="13">stratified by HF </text>
<text top="520" left="905" width="49" height="17" font="13">severity. </text>
<text top="486" left="1017" width="70" height="17" font="13">1 y mortality </text>
<text top="503" left="1017" width="77" height="17" font="13">after listing:    </text>
<text top="520" left="1017" width="101" height="17" font="13">high risk: 51%       </text>
<text top="537" left="1017" width="73" height="17" font="13">medium risk: </text>
<text top="555" left="1017" width="93" height="17" font="13">32%                    </text>
<text top="572" left="1017" width="100" height="17" font="13">low risk: 29%        </text>
<text top="589" left="1017" width="100" height="17" font="13">p &lt;0.0001             </text>
<text top="606" left="1017" width="70" height="17" font="13">1y  mortality </text>
<text top="624" left="1017" width="90" height="17" font="13">while waiting on </text>
<text top="641" left="1017" width="100" height="17" font="13">transplant list:       </text>
<text top="658" left="1017" width="101" height="17" font="13">high risk: 32%       </text>
<text top="675" left="1017" width="73" height="17" font="13">medium risk: </text>
<text top="692" left="1017" width="93" height="17" font="13">20%                    </text>
<text top="710" left="1017" width="100" height="17" font="13">low risk: 19%        </text>
<text top="727" left="1017" width="76" height="17" font="13">p &lt;0.0003 for </text>
<text top="744" left="1017" width="49" height="17" font="13">high risk </text>
<text top="761" left="1017" width="83" height="17" font="13">compared with </text>
<text top="778" left="1017" width="100" height="17" font="13">low/medium          </text>
<text top="486" left="1124" width="31" height="17" font="13">  N/A </text>
<text top="486" left="1189" width="107" height="17" font="13">For the total cohort </text>
<text top="503" left="1189" width="119" height="17" font="13">there was no survival </text>
<text top="520" left="1189" width="68" height="17" font="13">benefit from </text>
<text top="537" left="1189" width="87" height="17" font="13">transplantation. </text>
<text top="555" left="1189" width="122" height="17" font="13">However, for high risk </text>
<text top="572" left="1189" width="106" height="17" font="13">pts, a mortality risk </text>
<text top="589" left="1189" width="79" height="17" font="13">reduction was </text>
<text top="606" left="1189" width="118" height="17" font="13">observed within 2 wk </text>
<text top="624" left="1189" width="123" height="17" font="13">of transplantation (RR </text>
<text top="641" left="1189" width="102" height="17" font="13">&lt;1.0). This benefit </text>
<text top="658" left="1189" width="129" height="17" font="13">disappeared after eight </text>
<text top="675" left="1189" width="47" height="17" font="13">months. </text>
<text top="486" left="1332" width="41" height="17" font="13">p=0.04 </text>
<text top="503" left="1332" width="54" height="17" font="13">(mortality </text>
<text top="520" left="1332" width="22" height="17" font="13">risk </text>
<text top="537" left="1332" width="72" height="17" font="13">reduction for </text>
<text top="555" left="1332" width="80" height="17" font="13">high risk pts)   </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">156</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1017" width="86" height="17" font="13">1y mortality s/p </text>
<text top="72" left="1017" width="64" height="17" font="13">transplant   </text>
<text top="89" left="1017" width="101" height="17" font="13">high risk: 64%       </text>
<text top="106" left="1017" width="73" height="17" font="13">medium risk: </text>
<text top="124" left="1017" width="93" height="17" font="13">76%                    </text>
<text top="141" left="1017" width="100" height="17" font="13">low risk: 75%        </text>
<text top="158" left="1017" width="100" height="17" font="13">p=0.2                    </text>
<text top="176" left="61" width="61" height="17" font="13">Reversible </text>
<text top="193" left="61" width="103" height="17" font="13">pulmonary HTN in </text>
<text top="210" left="61" width="89" height="17" font="13">heart transplant </text>
<text top="228" left="61" width="75" height="17" font="13">candidates— </text>
<text top="245" left="61" width="75" height="17" font="13">pretransplant </text>
<text top="262" left="61" width="83" height="17" font="13">evaluation and </text>
<text top="279" left="61" width="79" height="17" font="13">outcome after </text>
<text top="296" left="61" width="109" height="17" font="13">OHT, Klotz S, 2003 </text>
<text top="314" left="61" width="58" height="17" font="14">14607204 </text>
<text top="314" left="119" width="32" height="17" font="13">(320) </text>
<text top="176" left="185" width="80" height="17" font="13">To assess the </text>
<text top="193" left="185" width="46" height="17" font="13">value of </text>
<text top="210" left="185" width="96" height="17" font="13">prostaglandin E1 </text>
<text top="228" left="185" width="66" height="17" font="13">(PG-E1) for </text>
<text top="245" left="185" width="96" height="17" font="13">reduction of PHT </text>
<text top="262" left="185" width="78" height="17" font="13">and to predict </text>
<text top="279" left="185" width="98" height="17" font="13">the postoperative </text>
<text top="296" left="185" width="54" height="17" font="13">outcome, </text>
<text top="314" left="185" width="92" height="17" font="13">compared to pts </text>
<text top="331" left="185" width="70" height="17" font="13">without PHT </text>
<text top="176" left="296" width="228" height="17" font="13">Case-control  ACEI 81%                        </text>
<text top="193" left="386" width="136" height="17" font="13">Digitalis 74%                   </text>
<text top="210" left="386" width="137" height="17" font="13">Diuretics 75%                  </text>
<text top="228" left="386" width="105" height="17" font="13">beta blockers 38% </text>
<text top="176" left="530" width="180" height="17" font="13">151 Referred </text>
<text top="176" left="658" width="70" height="17" font="13">for </text>
<text top="193" left="606" width="89" height="17" font="13">heart transplant </text>
<text top="210" left="606" width="73" height="17" font="13">evaluation at </text>
<text top="228" left="606" width="48" height="17" font="13">Munster </text>
<text top="245" left="606" width="57" height="17" font="13">University </text>
<text top="262" left="606" width="78" height="17" font="13">between 3/98-</text>
<text top="279" left="606" width="27" height="17" font="13">4/01 </text>
<text top="176" left="713" width="46" height="17" font="13">Pts with </text>
<text top="193" left="713" width="97" height="17" font="13">implanted MADs; </text>
<text top="210" left="713" width="40" height="17" font="13">clinical </text>
<text top="228" left="713" width="94" height="17" font="13">decompensation </text>
<text top="245" left="713" width="65" height="17" font="13">or inotropic-</text>
<text top="262" left="713" width="89" height="17" font="13">support at initial </text>
<text top="279" left="713" width="59" height="17" font="13">evaluation </text>
<text top="176" left="825" width="60" height="17" font="13">NYHA IIIB-</text>
<text top="193" left="825" width="15" height="17" font="13">IV </text>
<text top="176" left="905" width="47" height="17" font="13">1 y post-</text>
<text top="193" left="905" width="57" height="17" font="13">transplant </text>
<text top="210" left="905" width="50" height="17" font="13">Mortality </text>
<text top="176" left="1017" width="70" height="17" font="13">1y post-txplt </text>
<text top="193" left="1017" width="101" height="17" font="13">mortality                </text>
<text top="210" left="1017" width="66" height="17" font="13">Non-pHTN: </text>
<text top="228" left="1017" width="100" height="17" font="13">14.8%                   </text>
<text top="245" left="1017" width="61" height="17" font="13">Reversible </text>
<text top="262" left="1017" width="101" height="17" font="13">pHTN: 22%           </text>
<text top="279" left="1017" width="46" height="17" font="13">Wait list </text>
<text top="296" left="1017" width="101" height="17" font="13">mortality                </text>
<text top="314" left="1017" width="69" height="17" font="13">Non-pHTN:  </text>
<text top="331" left="1017" width="100" height="17" font="13">17%                      </text>
<text top="348" left="1017" width="61" height="17" font="13">Reversible </text>
<text top="365" left="1017" width="101" height="17" font="13">pHTN:  17%          </text>
<text top="382" left="1017" width="70" height="17" font="13">Non-wait list </text>
<text top="400" left="1017" width="101" height="17" font="13">Mortality                </text>
<text top="417" left="1017" width="100" height="17" font="13">Non-pHTN: 7%     </text>
<text top="434" left="1017" width="61" height="17" font="13">Reversible </text>
<text top="451" left="1017" width="88" height="17" font="13">pHTN: 13%, p= </text>
<text top="469" left="1017" width="103" height="17" font="13">0.39                       </text>
<text top="486" left="1017" width="64" height="17" font="13">Irreversible </text>
<text top="503" left="1017" width="70" height="17" font="13">pHTN: 50%, </text>
<text top="520" left="1017" width="41" height="17" font="13">p&lt;0.05 </text>
<text top="176" left="1124" width="27" height="17" font="13">&gt;3 y </text>
<text top="176" left="1189" width="121" height="17" font="13">Non-wait list, wait list, </text>
<text top="193" left="1189" width="94" height="17" font="13">and 1y post-txplt </text>
<text top="210" left="1189" width="102" height="17" font="13">mortality rates are </text>
<text top="228" left="1189" width="102" height="17" font="13">similar for pts with </text>
<text top="245" left="1189" width="109" height="17" font="13">reversible pHTN as </text>
<text top="262" left="1189" width="118" height="17" font="13">those without pHTN.  </text>
<text top="176" left="1332" width="31" height="17" font="13">  N/A </text>
<text top="538" left="61" width="101" height="17" font="13">Evolving trends in </text>
<text top="555" left="61" width="89" height="17" font="13">risk profiles and </text>
<text top="573" left="61" width="90" height="17" font="13">causes of death </text>
<text top="590" left="61" width="60" height="17" font="13">after heart </text>
<text top="607" left="61" width="99" height="17" font="13">transplantation: A </text>
<text top="624" left="61" width="57" height="17" font="13">10 y multi-</text>
<text top="641" left="61" width="101" height="17" font="13">institutional study, </text>
<text top="659" left="61" width="89" height="17" font="13">Kirklin JK, 2003 </text>
<text top="676" left="61" width="58" height="17" font="14">12698152 </text>
<text top="676" left="119" width="32" height="17" font="13">(321) </text>
<text top="538" left="185" width="68" height="17" font="13">To examine </text>
<text top="555" left="185" width="77" height="17" font="13">differences in </text>
<text top="573" left="185" width="73" height="17" font="13">risk-adjusted </text>
<text top="590" left="185" width="93" height="17" font="13">expected versus </text>
<text top="607" left="185" width="54" height="17" font="13">observed </text>
<text top="624" left="185" width="50" height="17" font="13">actuarial </text>
<text top="641" left="185" width="70" height="17" font="13">outcomes of </text>
<text top="659" left="185" width="43" height="17" font="13">cardiac </text>
<text top="676" left="185" width="84" height="17" font="13">transplantation </text>
<text top="693" left="185" width="78" height="17" font="13">over time at a </text>
<text top="710" left="185" width="91" height="17" font="13">single institution </text>
<text top="538" left="296" width="47" height="17" font="13">Cohort,  </text>
<text top="555" left="296" width="49" height="17" font="13">Registry </text>
<text top="538" left="386" width="295" height="17" font="13">N/A 7290 </text>
<text top="538" left="606" width="151" height="17" font="13">7290 </text>
<text top="538" left="637" width="140" height="17" font="13">pts </text>
<text top="555" left="606" width="65" height="17" font="13">undergoing </text>
<text top="573" left="606" width="78" height="17" font="13">cardiac trans- </text>
<text top="590" left="606" width="87" height="17" font="13">plantation at 42 </text>
<text top="607" left="606" width="89" height="17" font="13">institutions over </text>
<text top="624" left="606" width="75" height="17" font="13">a 10-y period </text>
<text top="641" left="606" width="70" height="17" font="13">(1990-2000) </text>
<text top="538" left="713" width="31" height="17" font="13">  N/A </text>
<text top="538" left="825" width="24" height="17" font="13">N/A </text>
<text top="538" left="905" width="93" height="17" font="13">The primary end </text>
<text top="555" left="905" width="99" height="17" font="13">point of this study </text>
<text top="573" left="905" width="88" height="17" font="13">was death from </text>
<text top="590" left="905" width="65" height="17" font="13">all causes.  </text>
<text top="538" left="1017" width="70" height="17" font="13">1y post-txplt </text>
<text top="555" left="1017" width="81" height="17" font="13">mortality 1990-</text>
<text top="573" left="1017" width="100" height="17" font="13">1992: 16%            </text>
<text top="590" left="1017" width="101" height="17" font="13">1993-1995: 15%   </text>
<text top="607" left="1017" width="101" height="17" font="13">1996-1999: 15%   </text>
<text top="624" left="1017" width="73" height="17" font="13">3 y post-txplt </text>
<text top="641" left="1017" width="101" height="17" font="13">mortality                </text>
<text top="659" left="1017" width="101" height="17" font="13">1990-1992: 24%   </text>
<text top="676" left="1017" width="101" height="17" font="13">1993-1995: 21%   </text>
<text top="693" left="1017" width="94" height="17" font="13">1996-1999: 21% </text>
<text top="538" left="1124" width="27" height="17" font="13">10 y </text>
<text top="555" left="1124" width="44" height="17" font="13">registry </text>
<text top="573" left="1124" width="30" height="17" font="13">+ 3 y </text>
<text top="590" left="1124" width="36" height="17" font="13">follow-</text>
<text top="607" left="1124" width="47" height="17" font="13">up, 13 y </text>
<text top="624" left="1124" width="47" height="17" font="13">observat</text>
<text top="641" left="1124" width="20" height="17" font="13">ion </text>
<text top="659" left="1124" width="38" height="17" font="13">period </text>
<text top="538" left="1189" width="116" height="17" font="13">Later transplantation </text>
<text top="555" left="1189" width="126" height="17" font="13">date reduced late post-</text>
<text top="573" left="1189" width="111" height="17" font="13">transplant mortality, </text>
<text top="590" left="1189" width="124" height="17" font="13">particularly that due to </text>
<text top="607" left="1189" width="102" height="17" font="13">rejection and graft </text>
<text top="624" left="1189" width="79" height="17" font="13">vasculopathy, </text>
<text top="641" left="1189" width="113" height="17" font="13">refelcting increasing </text>
<text top="659" left="1189" width="122" height="17" font="13">institutional expertise, </text>
<text top="676" left="1189" width="53" height="17" font="13">changing </text>
<text top="693" left="1189" width="113" height="17" font="13">immunosuppression </text>
<text top="710" left="1189" width="57" height="17" font="13">regimens. </text>
<text top="538" left="1332" width="31" height="17" font="13">  N/A </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">157</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="100" height="17" font="13">Retransplantation </text>
<text top="72" left="61" width="93" height="17" font="13">in 7,290 Primary </text>
<text top="89" left="61" width="98" height="17" font="13">Transplant Pts: A </text>
<text top="106" left="61" width="29" height="17" font="13">10-Y </text>
<text top="124" left="61" width="96" height="17" font="13">Multi-Institutional </text>
<text top="141" left="61" width="85" height="17" font="13">Study (Cardiac </text>
<text top="158" left="61" width="62" height="17" font="13">Transplant </text>
<text top="175" left="61" width="56" height="17" font="13">Research </text>
<text top="192" left="61" width="101" height="17" font="13">Database Group), </text>
<text top="210" left="61" width="96" height="17" font="13">Radovancevic B, </text>
<text top="227" left="61" width="31" height="17" font="13">2003 </text>
<text top="244" left="61" width="58" height="17" font="14">12909465 </text>
<text top="244" left="119" width="32" height="17" font="13">(322) </text>
<text top="55" left="185" width="76" height="17" font="13">To determine </text>
<text top="72" left="185" width="97" height="17" font="13">subsets of pts for </text>
<text top="89" left="185" width="79" height="17" font="13">whom cardiac </text>
<text top="106" left="185" width="95" height="17" font="13">retransplantation </text>
<text top="124" left="185" width="78" height="17" font="13">is appropriate </text>
<text top="141" left="185" width="44" height="17" font="13">therapy </text>
<text top="55" left="296" width="47" height="17" font="13">Cohort,  </text>
<text top="72" left="296" width="49" height="17" font="13">Registry </text>
<text top="55" left="386" width="24" height="17" font="13">N/A </text>
<text top="55" left="530" width="31" height="17" font="13">7290 </text>
<text top="55" left="606" width="72" height="17" font="13">Pts in CTRD </text>
<text top="72" left="606" width="85" height="17" font="13">that underwent </text>
<text top="89" left="606" width="53" height="17" font="13">a second </text>
<text top="106" left="606" width="43" height="17" font="13">cardiac </text>
<text top="124" left="606" width="84" height="17" font="13">transplantation </text>
<text top="141" left="606" width="50" height="17" font="13">between </text>
<text top="158" left="606" width="78" height="17" font="13">January 1990 </text>
<text top="175" left="606" width="84" height="17" font="13">and December </text>
<text top="192" left="606" width="31" height="17" font="13">1999 </text>
<text top="55" left="713" width="7" height="17" font="13">  </text>
<text top="55" left="825" width="60" height="17" font="13">NYHA IIIB-</text>
<text top="72" left="825" width="15" height="17" font="13">IV </text>
<text top="55" left="905" width="81" height="17" font="13">Freedom from </text>
<text top="72" left="905" width="40" height="17" font="13">events </text>
<text top="89" left="905" width="99" height="17" font="13">(retransplantation </text>
<text top="106" left="905" width="24" height="17" font="13">and </text>
<text top="124" left="905" width="67" height="17" font="13">subsequent </text>
<text top="141" left="905" width="91" height="17" font="13">death, rejection, </text>
<text top="158" left="905" width="77" height="17" font="13">and infection) </text>
<text top="55" left="1017" width="20" height="17" font="13">1 y </text>
<text top="72" left="1017" width="95" height="17" font="13">retransplantation </text>
<text top="89" left="1017" width="101" height="17" font="13">rate: 0.8%             </text>
<text top="106" left="1017" width="27" height="17" font="13">10 y </text>
<text top="124" left="1017" width="95" height="17" font="13">retransplantation </text>
<text top="141" left="1017" width="101" height="17" font="13">rate: 3.2%             </text>
<text top="158" left="1017" width="101" height="17" font="13">1y mortality           </text>
<text top="175" left="1017" width="79" height="17" font="13">15% after first </text>
<text top="192" left="1017" width="88" height="17" font="13">transplant          </text>
<text top="210" left="1017" width="63" height="17" font="13">46% after 2</text>
<text top="211" left="1079" width="9" height="11" font="19">nd</text>
<text top="210" left="1088" width="3" height="17" font="13"> </text>
<text top="227" left="1017" width="92" height="17" font="13">transplant           </text>
<text top="244" left="1017" width="66" height="17" font="13">1y mortality </text>
<text top="261" left="1017" width="34" height="17" font="13">post-2</text>
<text top="262" left="1051" width="9" height="11" font="19">nd</text>
<text top="261" left="1060" width="46" height="17" font="13"> txplt by </text>
<text top="278" left="1017" width="88" height="17" font="13">indication for re-</text>
<text top="296" left="1017" width="101" height="17" font="13">txplt                       </text>
<text top="313" left="1017" width="61" height="17" font="13">68% acute </text>
<text top="330" left="1017" width="101" height="17" font="13">rejection                </text>
<text top="347" left="1017" width="86" height="17" font="13">50% early graft </text>
<text top="365" left="1017" width="37" height="17" font="13">failure </text>
<text top="55" left="1124" width="27" height="17" font="13">10 y </text>
<text top="55" left="1189" width="113" height="17" font="13">Major indications for </text>
<text top="72" left="1189" width="43" height="17" font="13">cardiac </text>
<text top="89" left="1189" width="136" height="17" font="13">retransplantation:            </text>
<text top="106" left="1189" width="136" height="17" font="13">1. Acute rejection            </text>
<text top="124" left="1189" width="138" height="17" font="13">2. Early graft failure         </text>
<text top="141" left="1189" width="62" height="17" font="13">3. Allograft </text>
<text top="158" left="1189" width="130" height="17" font="13">vasculopathy                 </text>
<text top="175" left="1189" width="126" height="17" font="13">Improved survival post </text>
<text top="192" left="1189" width="95" height="17" font="13">re-txplt if primary </text>
<text top="210" left="1189" width="101" height="17" font="13">reason is allograft </text>
<text top="227" left="1189" width="99" height="17" font="13">vasculopathy, not </text>
<text top="244" left="1189" width="128" height="17" font="13">acute rejection or early </text>
<text top="261" left="1189" width="113" height="17" font="13">graft failure; survival </text>
<text top="278" left="1189" width="110" height="17" font="13">similar to that of pts </text>
<text top="296" left="1189" width="109" height="17" font="13">undergoing primary </text>
<text top="313" left="1189" width="29" height="17" font="13">OHT </text>
<text top="55" left="1332" width="55" height="17" font="13">Improved </text>
<text top="72" left="1332" width="45" height="17" font="13">survival </text>
<text top="89" left="1332" width="64" height="17" font="13">post-retxplt </text>
<text top="106" left="1332" width="58" height="17" font="13">if done for </text>
<text top="124" left="1332" width="32" height="17" font="13">CAV, </text>
<text top="141" left="1332" width="79" height="17" font="13">p=0.02            </text>
<text top="158" left="1332" width="66" height="17" font="13">Post-retxplt </text>
<text top="175" left="1332" width="63" height="17" font="13">survival for </text>
<text top="192" left="1332" width="46" height="17" font="13">CAV no </text>
<text top="210" left="1332" width="48" height="17" font="13">different </text>
<text top="227" left="1332" width="69" height="17" font="13">than that for </text>
<text top="244" left="1332" width="70" height="17" font="13">primary txplt </text>
<text top="261" left="1332" width="37" height="17" font="13">of any </text>
<text top="278" left="1332" width="40" height="17" font="13">cause, </text>
<text top="296" left="1332" width="41" height="17" font="13">p=0.67 </text>
<text top="382" left="61" width="66" height="17" font="13">Outcome in </text>
<text top="400" left="61" width="107" height="17" font="13">Cardiac Recipients </text>
<text top="417" left="61" width="90" height="17" font="13">of Donor Hearts </text>
<text top="434" left="61" width="104" height="17" font="13">With Increased LV </text>
<text top="451" left="61" width="90" height="17" font="13">WT, Kuppahally </text>
<text top="469" left="61" width="54" height="17" font="13">SS, 2007 </text>
<text top="486" left="61" width="58" height="17" font="14">17845572 </text>
<text top="486" left="119" width="32" height="17" font="13">(323) </text>
<text top="503" left="61" width="3" height="17" font="13"> </text>
<text top="382" left="185" width="88" height="17" font="13">To evaluate the </text>
<text top="400" left="185" width="64" height="17" font="13">outcome in </text>
<text top="417" left="185" width="70" height="17" font="13">recipients of </text>
<text top="434" left="185" width="98" height="17" font="13">donor hearts with </text>
<text top="451" left="185" width="94" height="17" font="13">increased LVWT </text>
<text top="469" left="185" width="28" height="17" font="13">&gt;1.2 </text>
<text top="382" left="296" width="180" height="17" font="13">Case-control Cyclosporine </text>
<text top="382" left="460" width="44" height="17" font="13">58% </text>
<text top="382" left="488" width="20" height="17" font="13"> </text>
<text top="382" left="492" width="31" height="17" font="13">         </text>
<text top="400" left="386" width="136" height="17" font="13">Tacrolimus 41%              </text>
<text top="417" left="386" width="127" height="17" font="13">Sirolimus 31%              </text>
<text top="434" left="386" width="118" height="17" font="13">Mycophenolate  69% </text>
<text top="382" left="530" width="150" height="17" font="13">157 Pts </text>
<text top="382" left="627" width="124" height="17" font="13">transplanted </text>
<text top="400" left="606" width="77" height="17" font="13">between 1/01 </text>
<text top="417" left="606" width="72" height="17" font="13">and 12/04 at </text>
<text top="434" left="606" width="50" height="17" font="13">Stanford </text>
<text top="451" left="606" width="57" height="17" font="13">University </text>
<text top="469" left="606" width="86" height="17" font="13">Medical Center </text>
<text top="486" left="606" width="94" height="17" font="13">and the affiliated </text>
<text top="503" left="606" width="51" height="17" font="13">Northern </text>
<text top="520" left="606" width="94" height="17" font="13">California Kaiser </text>
<text top="537" left="606" width="70" height="17" font="13">Permanente </text>
<text top="555" left="606" width="89" height="17" font="13">heart transplant </text>
<text top="572" left="606" width="55" height="17" font="13">programs </text>
<text top="382" left="713" width="105" height="17" font="13">Pediatric pts,          </text>
<text top="400" left="713" width="81" height="17" font="13">multiple organ </text>
<text top="417" left="713" width="80" height="17" font="13">recipients,       </text>
<text top="434" left="713" width="82" height="17" font="13">recipients who </text>
<text top="451" left="713" width="82" height="17" font="13">died within 3 d </text>
<text top="469" left="713" width="28" height="17" font="13">after </text>
<text top="486" left="713" width="84" height="17" font="13">transplantation </text>
<text top="382" left="825" width="190" height="17" font="13">N/A Incidence </text>
<text top="382" left="961" width="69" height="17" font="13">of </text>
<text top="400" left="905" width="93" height="17" font="13">cardiac recipient </text>
<text top="417" left="905" width="92" height="17" font="13">death or cardiac </text>
<text top="434" left="905" width="95" height="17" font="13">retransplantation </text>
<text top="382" left="1017" width="92" height="17" font="13">Overall mortality </text>
<text top="400" left="1017" width="79" height="17" font="13">(mean 3 y f/u) </text>
<text top="417" left="1017" width="62" height="17" font="13">donor LVH </text>
<text top="434" left="1017" width="102" height="17" font="13">(&gt;1.2): 21.3%        </text>
<text top="451" left="1017" width="76" height="17" font="13">donor normal </text>
<text top="469" left="1017" width="100" height="17" font="13">LVWT: 20%          </text>
<text top="486" left="1017" width="62" height="17" font="13">donor LVH </text>
<text top="503" left="1017" width="102" height="17" font="13">(&gt;1.4): 50%           </text>
<text top="520" left="1017" width="68" height="17" font="13">total: 20.4% </text>
<text top="382" left="1124" width="31" height="17" font="13">  N/A </text>
<text top="382" left="1189" width="68" height="17" font="13">Donor heart </text>
<text top="400" left="1189" width="78" height="17" font="13">LVWT&gt;1.4cm </text>
<text top="417" left="1189" width="83" height="17" font="13">increases post-</text>
<text top="434" left="1189" width="107" height="17" font="13">transplant mortality </text>
<text top="451" left="1189" width="107" height="17" font="13">and risk of allograft </text>
<text top="469" left="1189" width="79" height="17" font="13">vasculopathy  </text>
<text top="382" left="1332" width="57" height="17" font="13">Increased </text>
<text top="400" left="1332" width="50" height="17" font="13">mortality </text>
<text top="417" left="1332" width="60" height="17" font="13">with donor </text>
<text top="434" left="1332" width="79" height="17" font="13">LVWT&gt;1.4,     </text>
<text top="451" left="1332" width="52" height="17" font="13">p=0.003, </text>
<text top="469" left="1332" width="65" height="17" font="13">95% CI 1.8-</text>
<text top="486" left="1332" width="79" height="17" font="13">21.5                </text>
<text top="503" left="1332" width="79" height="17" font="13">VAD BTT,       </text>
<text top="520" left="1332" width="73" height="17" font="13">p=0.04, 95% </text>
<text top="537" left="1332" width="78" height="17" font="13">CI 1.02-6.85   </text>
<text top="590" left="61" width="60" height="17" font="13">Long-term </text>
<text top="607" left="61" width="70" height="17" font="13">outcomes of </text>
<text top="624" left="61" width="43" height="17" font="13">cardiac </text>
<text top="641" left="61" width="102" height="17" font="13">transplantation for </text>
<text top="659" left="61" width="53" height="17" font="13">PPCM: a </text>
<text top="676" left="61" width="91" height="17" font="13">multiinstitutional </text>
<text top="693" left="61" width="107" height="17" font="13">analysis (CTRDG), </text>
<text top="710" left="61" width="92" height="17" font="13">Rasmusson KD, </text>
<text top="727" left="61" width="31" height="17" font="13">2007 </text>
<text top="745" left="61" width="58" height="17" font="14">18022074 </text>
<text top="745" left="119" width="32" height="17" font="13">(324) </text>
<text top="762" left="61" width="3" height="17" font="13"> </text>
<text top="590" left="185" width="59" height="17" font="13">To assess </text>
<text top="607" left="185" width="80" height="17" font="13">outcomes in a </text>
<text top="624" left="185" width="83" height="17" font="13">relatively large </text>
<text top="641" left="185" width="87" height="17" font="13">group of PPCM </text>
<text top="659" left="185" width="47" height="17" font="13">allograft </text>
<text top="676" left="185" width="81" height="17" font="13">recipients with </text>
<text top="693" left="185" width="91" height="17" font="13">long-term follow-</text>
<text top="710" left="185" width="17" height="17" font="13">up </text>
<text top="590" left="296" width="48" height="17" font="13">Registry </text>
<text top="590" left="386" width="118" height="17" font="13">Induction cytolytic rx  </text>
<text top="607" left="386" width="117" height="17" font="13">31%                           </text>
<text top="624" left="386" width="118" height="17" font="13">Steroids (at 1y): 88% </text>
<text top="590" left="530" width="24" height="17" font="13">671 </text>
<text top="590" left="606" width="87" height="17" font="13">1. Age &lt;40 y at </text>
<text top="607" left="606" width="83" height="17" font="13">time of cardiac </text>
<text top="624" left="606" width="102" height="17" font="13">transplant              </text>
<text top="641" left="606" width="74" height="17" font="13">2. Etiology of </text>
<text top="659" left="606" width="77" height="17" font="13">HF: PPCM or </text>
<text top="676" left="606" width="35" height="17" font="13">IDCM </text>
<text top="590" left="713" width="224" height="17" font="13">N/A N/A </text>
<text top="590" left="905" width="146" height="17" font="13">Rejection, </text>
<text top="607" left="905" width="96" height="17" font="13">infection, cardiac </text>
<text top="624" left="905" width="47" height="17" font="13">allograft </text>
<text top="641" left="905" width="79" height="17" font="13">vasculopathy, </text>
<text top="659" left="905" width="69" height="17" font="13">and survival </text>
<text top="590" left="1017" width="209" height="17" font="13">N/A 15 </text>
<text top="590" left="1141" width="93" height="17" font="13">y </text>
<text top="607" left="1124" width="44" height="17" font="13">registry </text>
<text top="590" left="1189" width="119" height="17" font="13">PPCM recipients had </text>
<text top="607" left="1189" width="94" height="17" font="13">similar long-term </text>
<text top="624" left="1189" width="127" height="17" font="13">survival as male IDCM </text>
<text top="641" left="1189" width="98" height="17" font="13">recipients; PPCM </text>
<text top="659" left="1189" width="101" height="17" font="13">recipients trended </text>
<text top="676" left="1189" width="126" height="17" font="13">towards better survival </text>
<text top="693" left="1189" width="124" height="17" font="13">compared with female </text>
<text top="710" left="1189" width="127" height="17" font="13">IDCM, +h/o pregnancy </text>
<text top="727" left="1189" width="135" height="17" font="13">recipients;                       </text>
<text top="745" left="1189" width="95" height="17" font="13">PPCM recipients </text>
<text top="762" left="1189" width="99" height="17" font="13">appeared to have </text>
<text top="779" left="1189" width="107" height="17" font="13">better survival than </text>
<text top="590" left="1332" width="42" height="17" font="13">Overall </text>
<text top="607" left="1332" width="79" height="17" font="13">survival           </text>
<text top="624" left="1332" width="46" height="17" font="13">PPM vs </text>
<text top="641" left="1332" width="79" height="17" font="13">male IDCM,    </text>
<text top="659" left="1332" width="79" height="17" font="13">p=0.9              </text>
<text top="676" left="1332" width="68" height="17" font="13">PPM vs +P, </text>
<text top="693" left="1332" width="80" height="17" font="13">P=0.05            </text>
<text top="710" left="1332" width="65" height="17" font="13">PPM vs -P, </text>
<text top="727" left="1332" width="41" height="17" font="13">p=0.07 </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">158</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1189" width="127" height="17" font="13">femail idiopathic DCM, </text>
<text top="72" left="1189" width="95" height="17" font="13">never pregnancy </text>
<text top="89" left="1189" width="97" height="17" font="13">recipients but not </text>
<text top="106" left="1189" width="124" height="17" font="13">statistically significant. </text>
<text top="171" left="61" width="100" height="17" font="13">Clinical outcomes </text>
<text top="189" left="61" width="71" height="17" font="13">after cardiac </text>
<text top="206" left="61" width="97" height="17" font="13">transplantation in </text>
<text top="223" left="61" width="110" height="17" font="13">muscular dystrophy </text>
<text top="240" left="61" width="100" height="17" font="13">pts (CTRDG), Wu </text>
<text top="257" left="61" width="55" height="17" font="13">RS, 2010 </text>
<text top="275" left="61" width="58" height="17" font="14">19864165 </text>
<text top="275" left="119" width="32" height="17" font="13">(325) </text>
<text top="292" left="61" width="3" height="17" font="13"> </text>
<text top="171" left="185" width="80" height="17" font="13">To investigate </text>
<text top="189" left="185" width="82" height="17" font="13">the clinical out-</text>
<text top="206" left="185" width="96" height="17" font="13">comes of cardiac </text>
<text top="223" left="185" width="97" height="17" font="13">transplantation in </text>
<text top="240" left="185" width="53" height="17" font="13">muscular </text>
<text top="257" left="185" width="76" height="17" font="13">dystrophy pts </text>
<text top="275" left="185" width="96" height="17" font="13">with an extended </text>
<text top="292" left="185" width="90" height="17" font="13">follow-up period </text>
<text top="309" left="185" width="79" height="17" font="13">and to assess </text>
<text top="326" left="185" width="90" height="17" font="13">the outcomes in </text>
<text top="344" left="185" width="92" height="17" font="13">comparison with </text>
<text top="361" left="185" width="92" height="17" font="13">an age-matched </text>
<text top="378" left="185" width="78" height="17" font="13">control cohort </text>
<text top="171" left="296" width="33" height="17" font="13">Case-</text>
<text top="189" left="296" width="57" height="17" font="13">controlled </text>
<text top="171" left="386" width="138" height="17" font="13">Calcineurin inhibitors       </text>
<text top="189" left="386" width="137" height="17" font="13">Cyclosporine 87%           </text>
<text top="206" left="386" width="136" height="17" font="13">Tacrolimus      9%           </text>
<text top="223" left="386" width="137" height="17" font="13">Unknown         4%           </text>
<text top="240" left="386" width="137" height="17" font="13">Azathioprine     61%        </text>
<text top="257" left="386" width="139" height="17" font="13">Mycophenolate 33%        </text>
<text top="275" left="386" width="137" height="17" font="13">Uknown             6%         </text>
<text top="292" left="386" width="118" height="17" font="13">Steroids (@1yr) 25% </text>
<text top="171" left="530" width="182" height="17" font="13">304 Muscular </text>
<text top="189" left="606" width="76" height="17" font="13">dystrophy pts </text>
<text top="206" left="606" width="87" height="17" font="13">who underwent </text>
<text top="223" left="606" width="43" height="17" font="13">cardiac </text>
<text top="240" left="606" width="84" height="17" font="13">transplantation </text>
<text top="257" left="606" width="75" height="17" font="13">and matched-</text>
<text top="275" left="606" width="92" height="17" font="13">control cohort of </text>
<text top="292" left="606" width="55" height="17" font="13">IDCM pts </text>
<text top="309" left="606" width="71" height="17" font="13">(matched by </text>
<text top="326" left="606" width="56" height="17" font="13">age, BMI, </text>
<text top="344" left="606" width="69" height="17" font="13">gender, and </text>
<text top="361" left="606" width="31" height="17" font="13">race) </text>
<text top="171" left="713" width="224" height="17" font="13">N/A N/A </text>
<text top="171" left="905" width="135" height="17" font="13">Survival </text>
<text top="171" left="952" width="116" height="17" font="13">after </text>
<text top="189" left="905" width="57" height="17" font="13">transplant </text>
<text top="171" left="1017" width="70" height="17" font="13">1y post-txplt </text>
<text top="189" left="1017" width="101" height="17" font="13">mortality:               </text>
<text top="206" left="1017" width="53" height="17" font="13">Muscular </text>
<text top="223" left="1017" width="102" height="17" font="13">dystrophy 11%      </text>
<text top="240" left="1017" width="102" height="17" font="13">Matched-control    </text>
<text top="257" left="1017" width="86" height="17" font="13">9%                    </text>
<text top="275" left="1017" width="73" height="17" font="13">5 y post-txplt </text>
<text top="292" left="1017" width="101" height="17" font="13">mortality:               </text>
<text top="309" left="1017" width="53" height="17" font="13">Muscular </text>
<text top="326" left="1017" width="102" height="17" font="13">dystrophy 17%      </text>
<text top="344" left="1017" width="102" height="17" font="13">Matched-control    </text>
<text top="361" left="1017" width="100" height="17" font="13">21%                      </text>
<text top="378" left="1017" width="79" height="17" font="13">p=0.5              </text>
<text top="171" left="1124" width="27" height="17" font="13">15 y </text>
<text top="189" left="1124" width="44" height="17" font="13">registry </text>
<text top="171" left="1189" width="296" height="17" font="13">N/A p=0.5 </text>
<text top="171" left="1366" width="31" height="17" font="13">(post-</text>
<text top="189" left="1332" width="26" height="17" font="13">txplt </text>
<text top="206" left="1332" width="54" height="17" font="13">mortality) </text>
<text top="396" left="61" width="72" height="17" font="13">The effect of </text>
<text top="413" left="61" width="95" height="17" font="13">transplant center </text>
<text top="430" left="61" width="105" height="17" font="13">volume on survival </text>
<text top="447" left="61" width="60" height="17" font="13">after heart </text>
<text top="465" left="61" width="99" height="17" font="13">transplantation: A </text>
<text top="482" left="61" width="100" height="17" font="13">multicenter study, </text>
<text top="499" left="61" width="81" height="17" font="13">Shuhaiber JH, </text>
<text top="516" left="61" width="31" height="17" font="13">2010 </text>
<text top="534" left="61" width="58" height="17" font="14">20138635 </text>
<text top="534" left="119" width="32" height="17" font="13">(326) </text>
<text top="551" left="61" width="3" height="17" font="13"> </text>
<text top="396" left="185" width="91" height="17" font="13">To elucidate the </text>
<text top="413" left="185" width="47" height="17" font="13">effect of </text>
<text top="430" left="185" width="95" height="17" font="13">transplant center </text>
<text top="447" left="185" width="81" height="17" font="13">volume on 1-y </text>
<text top="465" left="185" width="50" height="17" font="13">mortality </text>
<text top="396" left="296" width="130" height="17" font="13">Case-control N/A </text>
<text top="396" left="530" width="40" height="17" font="13">147 </text>
<text top="413" left="530" width="57" height="17" font="13">transplant </text>
<text top="430" left="530" width="47" height="17" font="13">centers/ </text>
<text top="447" left="530" width="38" height="17" font="13">13230 </text>
<text top="465" left="530" width="31" height="17" font="13">heart </text>
<text top="482" left="530" width="64" height="17" font="13">transplants </text>
<text top="396" left="606" width="78" height="17" font="13">Data from the </text>
<text top="413" left="606" width="53" height="17" font="13">Scientific </text>
<text top="430" left="606" width="62" height="17" font="13">Registry of </text>
<text top="447" left="606" width="62" height="17" font="13">Transplant </text>
<text top="465" left="606" width="74" height="17" font="13">Recipients of </text>
<text top="482" left="606" width="31" height="17" font="13">heart </text>
<text top="499" left="606" width="90" height="17" font="13">transplantations </text>
<text top="516" left="606" width="88" height="17" font="13">between 1/1/99 </text>
<text top="534" left="606" width="68" height="17" font="13">and 5/31/05 </text>
<text top="396" left="713" width="24" height="17" font="13">N/A </text>
<text top="396" left="825" width="24" height="17" font="13">N/A </text>
<text top="396" left="905" width="70" height="17" font="13">1 y mortality </text>
<text top="396" left="1017" width="7" height="17" font="13">1</text>
<text top="397" left="1023" width="6" height="11" font="19">st</text>
<text top="396" left="1030" width="40" height="17" font="13"> y post-</text>
<text top="413" left="1017" width="57" height="17" font="13">transplant </text>
<text top="430" left="1017" width="50" height="17" font="13">mortality </text>
<text top="447" left="1017" width="67" height="17" font="13">significantly </text>
<text top="465" left="1017" width="78" height="17" font="13">higher at very </text>
<text top="482" left="1017" width="66" height="17" font="13">low-volume </text>
<text top="499" left="1017" width="57" height="17" font="13">transplant </text>
<text top="516" left="1017" width="44" height="17" font="13">centers </text>
<text top="534" left="1017" width="83" height="17" font="13">compared with </text>
<text top="551" left="1017" width="62" height="17" font="13">low to high </text>
<text top="568" left="1017" width="43" height="17" font="13">volume </text>
<text top="585" left="1017" width="57" height="17" font="13">transplant </text>
<text top="602" left="1017" width="47" height="17" font="13">centers. </text>
<text top="396" left="1124" width="30" height="17" font="13">5.5 y </text>
<text top="413" left="1124" width="44" height="17" font="13">registry </text>
<text top="396" left="1189" width="108" height="17" font="13">Low-, medium, and </text>
<text top="413" left="1189" width="128" height="17" font="13">high-volume transplant </text>
<text top="430" left="1189" width="123" height="17" font="13">centers have lower 1y </text>
<text top="447" left="1189" width="85" height="17" font="13">post-transplant </text>
<text top="465" left="1189" width="126" height="17" font="13">mortality than very-low </text>
<text top="482" left="1189" width="101" height="17" font="13">volume transplant </text>
<text top="499" left="1189" width="54" height="17" font="13">centers.   </text>
<text top="396" left="1332" width="66" height="17" font="13">p&lt;0.001 for </text>
<text top="413" left="1332" width="65" height="17" font="13">each group </text>
<text top="430" left="1332" width="58" height="17" font="13">compared </text>
<text top="447" left="1332" width="53" height="17" font="13">with very-</text>
<text top="465" left="1332" width="65" height="17" font="13">low volume </text>
<text top="482" left="1332" width="38" height="17" font="13">center </text>
<text top="499" left="1332" width="79" height="17" font="13">group,             </text>
<text top="516" left="1332" width="78" height="17" font="13">95% CI:          </text>
<text top="534" left="1332" width="69" height="17" font="13">Low volume </text>
<text top="551" left="1332" width="79" height="17" font="13">0.62-0.82        </text>
<text top="568" left="1332" width="70" height="17" font="13">Med volume </text>
<text top="585" left="1332" width="79" height="17" font="13">0.56-0.74        </text>
<text top="602" left="1332" width="72" height="17" font="13">High volume </text>
<text top="620" left="1332" width="55" height="17" font="13">0.48-0.65 </text>
<text top="637" left="54" width="1351" height="15" font="6">ACEI indicates angiotensin-converting-enzyme inhibitor; AICD, automatic internal cardiac defibrillator; BMI, body mass index; BTT, bridge to transplant; CAV, cardiac allograft vasculopathy; CCB, calcium channel blocker; COCPIT, Comparative Outcome and Clinical Profiles in </text>
<text top="653" left="54" width="1360" height="15" font="6">Transplantation; CPX, cardiopulmonary stress testing; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; CTRD, Cardiac Transplant Research Database; DCM, dilated cardiomyopathy; FAR, functional aerobic reserve; f/u, follow-up;  </text>
<text top="668" left="54" width="1367" height="15" font="6">HATG, anti-T cell therapy; HF, heart failure; HFSS, heart failure survival score; h/o, history of; HTN, hypertension; ICD, implantable cardioverter defibrillator; IDCM, idiopathic dilated cardiomyopathy; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; </text>
<text top="684" left="54" width="1339" height="15" font="6">LVWT, left ventricular wall thickness; MAD, mechanical assist device; N/A, not applicable; NYHA, New York Heart Association; OH, organ harvest; OHT, orthotopic heart transplantation; OKT3, Othoclone; PG-E1, prostaglandin E1; PDE3, phosphodiesterase enzyme; pHTN, </text>
<text top="699" left="54" width="1346" height="15" font="6">pulmonary hypertension; PPCM, peripartum cardiomyopathy; PVR, pulmonary vascular resistance; QoL, quality of life; RCT, randomized controlled trial; RER, espiratory exchange ratio; SD, standard deviation; txplt, transplant; UNOS, United Network for Organ Sharing; VAD, </text>
<text top="715" left="54" width="612" height="15" font="6">ventricular assist device; VE/VCO2, carbon dioxide production; VO2, oxygen consumption; and VT, ventricular tachychardia. </text>
<text top="730" left="54" width="3" height="15" font="6"> </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">159</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="537" height="21" font="8"><b>Data Supplement 37. Comorbidities in the Hospitalized Patient (Section 8.1)  </b></text>
<text top="75" left="71" width="138" height="19" font="9"><b>Study Name, Author, </b></text>
<text top="94" left="123" width="33" height="19" font="9"><b>Year </b></text>
<text top="75" left="238" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="75" left="363" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="366" width="35" height="19" font="9"><b>Type </b></text>
<text top="75" left="443" width="83" height="19" font="9"><b>Background </b></text>
<text top="94" left="456" width="56" height="19" font="9"><b>Therapy </b></text>
<text top="75" left="550" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="75" left="658" width="57" height="19" font="9"><b>Etiology </b></text>
<text top="75" left="803" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="75" left="995" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="75" left="1085" width="62" height="19" font="9"><b>Absolute </b></text>
<text top="94" left="1091" width="50" height="19" font="9"><b>Benefit </b></text>
<text top="75" left="1173" width="74" height="19" font="9"><b>P Values &amp; </b></text>
<text top="94" left="1184" width="53" height="19" font="9"><b>95% CI: </b></text>
<text top="75" left="1290" width="84" height="19" font="9"><b>OR: HR: RR: </b></text>
<text top="134" left="136" width="8" height="19" font="7">  </text>
<text top="134" left="278" width="8" height="19" font="7">  </text>
<text top="134" left="379" width="8" height="19" font="7">  </text>
<text top="133" left="439" width="91" height="15" font="16"><i><b>Pretrial standard </b></i></text>
<text top="149" left="456" width="57" height="15" font="16"><i><b>treatment. </b></i></text>
<text top="133" left="563" width="44" height="15" font="16"><i><b>N (Total </b></i></text>
<text top="149" left="554" width="63" height="15" font="16"><i><b>Study Size) </b></i></text>
<text top="133" left="647" width="76" height="15" font="16"><i><b>Ischemic/Non-</b></i></text>
<text top="149" left="661" width="51" height="15" font="16"><i><b>Ischemic </b></i></text>
<text top="133" left="755" width="94" height="15" font="16"><i><b>Inclusion Criteria </b></i></text>
<text top="133" left="873" width="97" height="15" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="133" left="1008" width="44" height="15" font="16"><i><b>Primary </b></i></text>
<text top="149" left="1004" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="134" left="1112" width="8" height="19" font="10"><i><b>  </b></i></text>
<text top="134" left="1206" width="8" height="19" font="7">  </text>
<text top="134" left="1328" width="8" height="19" font="7">  </text>
<text top="169" left="61" width="188" height="19" font="9"><b>Diabetes and Hyperglycemia </b></text>
<text top="189" left="61" width="147" height="17" font="13">Intensive vs. Conventional </text>
<text top="206" left="61" width="154" height="17" font="13">Glucose Control in Critically </text>
<text top="224" left="61" width="142" height="17" font="13">Ill Pts: The NICE-SUGAR </text>
<text top="241" left="61" width="148" height="17" font="13">Investigators. NEJM 2009; </text>
<text top="258" left="61" width="108" height="17" font="13">360: 1283-97 (327) </text>
<text top="275" left="61" width="55" height="17" font="14">19318384</text>
<text top="275" left="116" width="3" height="17" font="13"> </text>
<text top="189" left="231" width="99" height="17" font="13">Randomization of </text>
<text top="206" left="231" width="58" height="17" font="13">ICU pts to </text>
<text top="224" left="231" width="71" height="17" font="13">intensive vs. </text>
<text top="241" left="231" width="72" height="17" font="13">conventional </text>
<text top="258" left="231" width="90" height="17" font="13">glucose control  </text>
<text top="189" left="346" width="178" height="17" font="13">RCT Tight </text>
<text top="189" left="464" width="105" height="17" font="13">glucose </text>
<text top="206" left="433" width="40" height="17" font="13">control </text>
<text top="224" left="433" width="98" height="17" font="13">recommended by </text>
<text top="241" left="433" width="33" height="17" font="13">some </text>
<text top="189" left="548" width="31" height="17" font="13">6104 </text>
<text top="189" left="636" width="24" height="17" font="13">N/A </text>
<text top="189" left="751" width="90" height="17" font="13">Hospitalized pts </text>
<text top="189" left="863" width="27" height="17" font="13"> N/A </text>
<text top="189" left="991" width="36" height="17" font="13">Death </text>
<text top="189" left="1082" width="42" height="17" font="13">-2.60% </text>
<text top="189" left="1162" width="82" height="17" font="13">95% CI: 1.02 - </text>
<text top="206" left="1162" width="77" height="17" font="13">1.28 (p=0.02) </text>
<text top="189" left="1270" width="114" height="17" font="13">OR:1.02 death at 90 </text>
<text top="206" left="1270" width="10" height="17" font="13">d </text>
<text top="299" left="61" width="111" height="17" font="13">Elevated Admission </text>
<text top="316" left="61" width="135" height="17" font="13">Glucose and Mortality in </text>
<text top="334" left="61" width="132" height="17" font="13">Elderly Pts Hospitalized </text>
<text top="351" left="61" width="124" height="17" font="13">with HF. Kosiborod M, </text>
<text top="368" left="61" width="139" height="17" font="13">Inzucchi SE, Spertus JA, </text>
<text top="385" left="61" width="123" height="17" font="13">Wang Y, Masoudi FA, </text>
<text top="402" left="61" width="135" height="17" font="13">Havranek EP, Krumholz </text>
<text top="420" left="61" width="149" height="17" font="13">HM. Circulation 2009; 119: </text>
<text top="437" left="61" width="98" height="17" font="13">1899-1907. (328) </text>
<text top="454" left="61" width="55" height="17" font="14">19332465</text>
<text top="454" left="116" width="3" height="17" font="13"> </text>
<text top="299" left="231" width="101" height="17" font="13">To investigate the </text>
<text top="316" left="231" width="65" height="17" font="13">association </text>
<text top="334" left="231" width="50" height="17" font="13">between </text>
<text top="351" left="231" width="59" height="17" font="13">admission </text>
<text top="368" left="231" width="70" height="17" font="13">glucose and </text>
<text top="385" left="231" width="63" height="17" font="13">mortality in </text>
<text top="402" left="231" width="59" height="17" font="13">elderly pts </text>
<text top="420" left="231" width="94" height="17" font="13">hospitalized with </text>
<text top="437" left="231" width="20" height="17" font="13">HF </text>
<text top="299" left="346" width="44" height="17" font="13">Cohort  </text>
<text top="299" left="433" width="76" height="17" font="13">Tight glucose </text>
<text top="316" left="433" width="40" height="17" font="13">control </text>
<text top="334" left="433" width="98" height="17" font="13">recommended by </text>
<text top="351" left="433" width="33" height="17" font="13">some </text>
<text top="299" left="548" width="41" height="17" font="13">50,532 </text>
<text top="299" left="636" width="89" height="17" font="13">59.7% ischemic </text>
<text top="299" left="751" width="90" height="17" font="13">Hospitalized pts </text>
<text top="299" left="863" width="27" height="17" font="13"> N/A </text>
<text top="299" left="991" width="36" height="17" font="13">Death </text>
<text top="299" left="1082" width="24" height="17" font="13">N/A </text>
<text top="299" left="1162" width="41" height="17" font="13">p=0.64 </text>
<text top="299" left="1270" width="110" height="17" font="13">0.998 fully adjusted </text>
<text top="316" left="1270" width="113" height="17" font="13">model per 10 mg/dL </text>
<text top="334" left="1270" width="122" height="17" font="13">increase in admission </text>
<text top="351" left="1270" width="46" height="17" font="13">glucose </text>
<text top="475" left="61" width="151" height="17" font="13">Seven-Year mortality in HF </text>
<text top="492" left="61" width="145" height="17" font="13">pts with undiagnosed DM: </text>
<text top="509" left="61" width="133" height="17" font="13">an observational study.  </text>
<text top="526" left="61" width="132" height="17" font="13">Flores-LeRoux JA et al. </text>
<text top="543" left="61" width="148" height="17" font="13">Cardiovasc Diabetol 2011; </text>
<text top="561" left="61" width="66" height="17" font="13">10:39 (329) </text>
<text top="578" left="61" width="55" height="17" font="14">21569580</text>
<text top="578" left="116" width="3" height="17" font="13"> </text>
<text top="475" left="231" width="80" height="17" font="13">To assess the </text>
<text top="492" left="231" width="70" height="17" font="13">prognosis of </text>
<text top="509" left="231" width="83" height="17" font="13">hyperglycemia </text>
<text top="526" left="231" width="63" height="17" font="13">(previously </text>
<text top="543" left="231" width="101" height="17" font="13">undiagnosed DM) </text>
<text top="561" left="231" width="97" height="17" font="13">in pts admitted to </text>
<text top="578" left="231" width="92" height="17" font="13">the hospital with </text>
<text top="595" left="231" width="20" height="17" font="13">HF </text>
<text top="475" left="346" width="44" height="17" font="13">Cohort  </text>
<text top="475" left="433" width="27" height="17" font="13"> N/A </text>
<text top="475" left="548" width="24" height="17" font="13">400 </text>
<text top="475" left="636" width="79" height="17" font="13">43% ischemic </text>
<text top="475" left="751" width="55" height="17" font="13">Acute HF </text>
<text top="492" left="751" width="59" height="17" font="13">admission </text>
<text top="475" left="863" width="93" height="17" font="13">Lost to follow-up </text>
<text top="475" left="991" width="31" height="17" font="13">Total </text>
<text top="492" left="991" width="50" height="17" font="13">mortality </text>
<text top="475" left="1082" width="31" height="17" font="13">  N/A </text>
<text top="475" left="1162" width="82" height="17" font="13">95% CI: 1.17 - </text>
<text top="492" left="1162" width="87" height="17" font="13">2.46 (p=0.006); </text>
<text top="509" left="1162" width="82" height="17" font="13">95% CI: 1.10 - </text>
<text top="526" left="1162" width="84" height="17" font="13">1.99 (p=0.009) </text>
<text top="475" left="1270" width="103" height="17" font="13">aHR unknown DM </text>
<text top="492" left="1270" width="91" height="17" font="13">1.69 (ACM); HR </text>
<text top="509" left="1270" width="90" height="17" font="13">clinical DM 1.48 </text>
<text top="526" left="1270" width="39" height="17" font="13">(ACM) </text>
<text top="613" left="61" width="157" height="17" font="13">Berry C, Brett M, Stevenson </text>
<text top="630" left="61" width="150" height="17" font="13">K, McMurray JJV, Norrie J. </text>
<text top="648" left="61" width="124" height="17" font="13">Nature and prognostic </text>
<text top="665" left="61" width="133" height="17" font="13">importance of abnormal </text>
<text top="682" left="61" width="124" height="17" font="13">glucose tolerance and </text>
<text top="699" left="61" width="153" height="17" font="13">diabetes in acute HF. Heart </text>
<text top="716" left="61" width="132" height="17" font="13">2008;94:296-304. (330) </text>
<text top="734" left="61" width="55" height="17" font="14">17664189</text>
<text top="734" left="116" width="3" height="17" font="13"> </text>
<text top="613" left="231" width="101" height="17" font="13">To investigate the </text>
<text top="630" left="231" width="62" height="17" font="13">nature and </text>
<text top="648" left="231" width="78" height="17" font="13">importance of </text>
<text top="665" left="231" width="79" height="17" font="13">blood glucose </text>
<text top="682" left="231" width="89" height="17" font="13">abnormalities in </text>
<text top="699" left="231" width="100" height="17" font="13">an unselected HF </text>
<text top="716" left="231" width="60" height="17" font="13">population </text>
<text top="613" left="346" width="44" height="17" font="13">Cohort  </text>
<text top="613" left="433" width="31" height="17" font="13">  N/A </text>
<text top="613" left="548" width="24" height="17" font="13">454 </text>
<text top="613" left="636" width="31" height="17" font="13">  N/A </text>
<text top="613" left="751" width="31" height="17" font="13">  N/A </text>
<text top="613" left="863" width="31" height="17" font="13">  N/A </text>
<text top="613" left="991" width="56" height="17" font="13">Inhospital </text>
<text top="630" left="991" width="50" height="17" font="13">mortality </text>
<text top="613" left="1082" width="31" height="17" font="13">  N/A </text>
<text top="613" left="1162" width="91" height="17" font="13">p=0.0023; (95% </text>
<text top="630" left="1162" width="79" height="17" font="13">CI: 1.03-1.13) </text>
<text top="613" left="1270" width="90" height="17" font="13">1.08, aHR per 2 </text>
<text top="630" left="1270" width="107" height="17" font="13">mmol/L increase in </text>
<text top="648" left="1270" width="46" height="17" font="13">glucose </text>
<text top="770" left="61" width="48" height="17" font="15"><b>Anemia </b></text>
</page>
<page number="160" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">160</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="61" width="127" height="17" font="13">Blood Transfusions for </text>
<text top="72" left="61" width="151" height="17" font="13">Acute Decompensated HF: </text>
<text top="89" left="61" width="148" height="17" font="13">Friend or Foe? Garty et al. </text>
<text top="106" left="61" width="144" height="17" font="13">Am Heart J 2009;158:653-</text>
<text top="124" left="61" width="46" height="17" font="13">8. (331) </text>
<text top="124" left="107" width="55" height="17" font="14">19781427</text>
<text top="124" left="161" width="3" height="17" font="13"> </text>
<text top="55" left="231" width="80" height="17" font="13">To assess the </text>
<text top="72" left="231" width="87" height="17" font="13">impact of blood </text>
<text top="89" left="231" width="64" height="17" font="13">transfusion </text>
<text top="106" left="231" width="86" height="17" font="13">among pts with </text>
<text top="124" left="231" width="40" height="17" font="13">ADHF  </text>
<text top="55" left="346" width="61" height="17" font="13">Propensity </text>
<text top="72" left="346" width="33" height="17" font="13">score </text>
<text top="89" left="346" width="51" height="17" font="13">analysis, </text>
<text top="106" left="346" width="66" height="17" font="13">national HF </text>
<text top="124" left="346" width="40" height="17" font="13">survey </text>
<text top="55" left="433" width="298" height="17" font="13">Unknown 2335 ~85% </text>
<text top="55" left="671" width="111" height="17" font="13">ischemic </text>
<text top="55" left="751" width="218" height="17" font="13">ADHF  Chronic </text>
<text top="55" left="909" width="80" height="17" font="13">HF </text>
<text top="72" left="863" width="114" height="17" font="13">admitted for another </text>
<text top="89" left="863" width="41" height="17" font="13">reason </text>
<text top="55" left="991" width="53" height="17" font="13">Mortality; </text>
<text top="72" left="991" width="46" height="17" font="13">39.6 vs. </text>
<text top="89" left="991" width="70" height="17" font="13">28.5% in BT </text>
<text top="106" left="991" width="75" height="17" font="13">vs. no BT pts </text>
<text top="55" left="1082" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1162" width="71" height="17" font="13">In hosp 0.08 </text>
<text top="72" left="1162" width="79" height="17" font="13">(95% CI: 0.21-</text>
<text top="89" left="1162" width="90" height="17" font="13">1.11); 30 d 0.02 </text>
<text top="106" left="1162" width="79" height="17" font="13">(95% CI: 0.13-</text>
<text top="124" left="1162" width="82" height="17" font="13">0.64); 1 y 0.12 </text>
<text top="141" left="1162" width="79" height="17" font="13">(95% CI: 0.50-</text>
<text top="158" left="1162" width="82" height="17" font="13">1.09); 4 y 0.29 </text>
<text top="175" left="1162" width="79" height="17" font="13">(95% CI: 0.64-</text>
<text top="192" left="1162" width="32" height="17" font="13">1.14) </text>
<text top="55" left="1270" width="100" height="17" font="13">aOR for BT: 0.48; </text>
<text top="72" left="1270" width="89" height="17" font="13">0.29; 0.74; 0.86 </text>
<text top="219" left="61" width="39" height="17" font="15"><b>COPD </b></text>
<text top="237" left="61" width="144" height="17" font="13">Bronchodilator Therapy in </text>
<text top="254" left="61" width="124" height="17" font="13">ADHF in Pts without a </text>
<text top="271" left="61" width="101" height="17" font="13">History of Chronic </text>
<text top="288" left="61" width="128" height="17" font="13">Obstructive Pulmonary </text>
<text top="305" left="61" width="138" height="17" font="13">Disease. Singer AJ et al. </text>
<text top="323" left="61" width="147" height="17" font="13">Ann Emerg Med. 2008;51: </text>
<text top="340" left="61" width="71" height="17" font="13">25-34. (332) </text>
<text top="340" left="131" width="55" height="17" font="14">17949853</text>
<text top="340" left="186" width="3" height="17" font="13"> </text>
<text top="237" left="231" width="89" height="17" font="13">The association </text>
<text top="254" left="231" width="93" height="17" font="13">between inhaled </text>
<text top="271" left="231" width="87" height="17" font="13">bronchodilators </text>
<text top="288" left="231" width="89" height="17" font="13">and HF pts with </text>
<text top="305" left="231" width="66" height="17" font="13">and without </text>
<text top="323" left="231" width="39" height="17" font="13">COPD </text>
<text top="237" left="346" width="73" height="17" font="13">Registry (AD </text>
<text top="254" left="346" width="68" height="17" font="13">HF National </text>
<text top="271" left="346" width="49" height="17" font="13">Registry </text>
<text top="288" left="346" width="66" height="17" font="13">Emergency </text>
<text top="305" left="346" width="44" height="17" font="13">Module </text>
<text top="323" left="346" width="48" height="17" font="13">registry) </text>
<text top="237" left="433" width="31" height="17" font="13">  N/A </text>
<text top="237" left="548" width="41" height="17" font="13">10,978 </text>
<text top="237" left="636" width="24" height="17" font="13">N/A </text>
<text top="237" left="751" width="77" height="17" font="13">ED discharge </text>
<text top="254" left="751" width="69" height="17" font="13">diagnosis of </text>
<text top="271" left="751" width="64" height="17" font="13">ADHF as a </text>
<text top="288" left="751" width="44" height="17" font="13">primary </text>
<text top="305" left="751" width="90" height="17" font="13">condition, adult  </text>
<text top="237" left="863" width="31" height="17" font="13">  N/A </text>
<text top="237" left="991" width="50" height="17" font="13">Mortality </text>
<text top="254" left="991" width="64" height="17" font="13">(inhospital) </text>
<text top="237" left="1082" width="31" height="17" font="13">  N/A </text>
<text top="237" left="1162" width="84" height="17" font="13">For pts without </text>
<text top="254" left="1162" width="39" height="17" font="13">COPD </text>
<text top="271" left="1162" width="81" height="17" font="13">bronchodilator </text>
<text top="288" left="1162" width="85" height="17" font="13">use associated </text>
<text top="305" left="1162" width="75" height="17" font="13">with mortality </text>
<text top="323" left="1162" width="82" height="17" font="13">(95% CI: 0.67–</text>
<text top="340" left="1162" width="35" height="17" font="13">1.56); </text>
<text top="357" left="1162" width="66" height="17" font="13">mechanical </text>
<text top="374" left="1162" width="91" height="17" font="13">ventilation (95% </text>
<text top="391" left="1162" width="81" height="17" font="13">CI: 1.21–2.37) </text>
<text top="409" left="1162" width="57" height="17" font="13">[adjusted, </text>
<text top="426" left="1162" width="61" height="17" font="13">propensity-</text>
<text top="443" left="1162" width="84" height="17" font="13">scored model]. </text>
<text top="460" left="1162" width="67" height="17" font="13">For pts with </text>
<text top="478" left="1162" width="60" height="17" font="13">COPD, no </text>
<text top="495" left="1162" width="58" height="17" font="13">significant </text>
<text top="512" left="1162" width="57" height="17" font="13">difference </text>
<text top="237" left="1270" width="62" height="17" font="13">1.02; 1.69  </text>
<text top="530" left="61" width="156" height="17" font="13">Should acute treatment with </text>
<text top="547" left="61" width="137" height="17" font="13">inhaled beta agonists be </text>
<text top="564" left="61" width="148" height="17" font="13">withheld from patients with </text>
<text top="582" left="61" width="133" height="17" font="13">dyspnea who may have </text>
<text top="599" left="61" width="143" height="17" font="13">heart failure? Maak CA et </text>
<text top="616" left="61" width="127" height="17" font="13">al. J Emerg Med. 2011 </text>
<text top="633" left="61" width="134" height="17" font="13">Feb;40(2):135-45. (333) </text>
<text top="650" left="61" width="55" height="17" font="14">18572345</text>
<text top="650" left="116" width="3" height="17" font="13"> </text>
<text top="530" left="231" width="96" height="17" font="13">To determine the </text>
<text top="547" left="231" width="60" height="17" font="13">safety and </text>
<text top="564" left="231" width="92" height="17" font="13">efficacy of acute </text>
<text top="582" left="231" width="94" height="17" font="13">administration of </text>
<text top="599" left="231" width="81" height="17" font="13">inhaled beta-2 </text>
<text top="616" left="231" width="83" height="17" font="13">agonists to pts </text>
<text top="633" left="231" width="45" height="17" font="13">with HF </text>
<text top="530" left="346" width="47" height="17" font="13">Review; </text>
<text top="547" left="346" width="53" height="17" font="13">evidence </text>
<text top="564" left="346" width="55" height="17" font="13">synthesis </text>
<text top="582" left="346" width="28" height="17" font="13">from </text>
<text top="599" left="346" width="58" height="17" font="13">MEDLINE </text>
<text top="616" left="346" width="24" height="17" font="13">and </text>
<text top="633" left="346" width="55" height="17" font="13">EMBASE </text>
<text top="650" left="346" width="53" height="17" font="13">searches </text>
<text top="530" left="433" width="31" height="17" font="13">  N/A </text>
<text top="530" left="548" width="31" height="17" font="13">  N/A </text>
<text top="530" left="636" width="31" height="17" font="13">  N/A </text>
<text top="530" left="751" width="31" height="17" font="13">  N/A </text>
<text top="530" left="863" width="31" height="17" font="13">  N/A </text>
<text top="530" left="991" width="31" height="17" font="13">  N/A </text>
<text top="530" left="1082" width="31" height="17" font="13">  N/A </text>
<text top="530" left="1162" width="31" height="17" font="13">  N/A </text>
<text top="530" left="1270" width="31" height="17" font="13">  N/A </text>
<text top="678" left="54" width="1396" height="17" font="13">ACM indicates all cause mortality; ADHF, acute decompensated heart failure; BT, blood transfusion; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ED, emergency department; EMBASE, Excerpta Medica Database; HF, heart failure; </text>
<text top="696" left="54" width="1348" height="17" font="13">ICU, intensive care unit; MEDLINE, Medical Literature Analysis and Retrieval System Online; N/A, not applicable; NICE-SUGAR, Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation; pt, patient; and RCT, </text>
<text top="713" left="54" width="135" height="17" font="13">randomized control trial. </text>
<text top="733" left="54" width="4" height="16" font="7"> </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">161</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="715" height="21" font="8"><b>Data Supplement 38. Worsening Renal Function, Mortality and Readmission in Acute HF (Section 8.5) </b></text>
<text top="75" left="54" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="52" width="44" height="19" font="9"><b>Name, </b></text>
<text top="113" left="48" width="52" height="19" font="9"><b>Author, </b></text>
<text top="132" left="58" width="33" height="19" font="9"><b>Year </b></text>
<text top="104" left="131" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="104" left="249" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="104" left="367" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="104" left="572" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="104" left="942" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="104" left="1210" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="155" left="71" width="7" height="17" font="13">  </text>
<text top="155" left="171" width="7" height="17" font="13">  </text>
<text top="155" left="284" width="7" height="17" font="13">  </text>
<text top="155" left="399" width="7" height="17" font="13">  </text>
<text top="155" left="493" width="104" height="17" font="21"><i><b>Inclusion Criteria </b></i></text>
<text top="155" left="656" width="108" height="17" font="21"><i><b>Exclusion Criteria </b></i></text>
<text top="155" left="833" width="106" height="17" font="21"><i><b>Primary Endpoint </b></i></text>
<text top="155" left="1002" width="126" height="17" font="21"><i><b>Secondary  Endpoint </b></i></text>
<text top="155" left="1301" width="7" height="17" font="13">  </text>
<text top="175" left="42" width="46" height="17" font="13">Damien </text>
<text top="192" left="42" width="49" height="17" font="13">Logeart, </text>
<text top="210" left="42" width="63" height="17" font="13">2008 (334) </text>
<text top="227" left="42" width="55" height="17" font="14">17651843</text>
<text top="227" left="97" width="3" height="17" font="13"> </text>
<text top="244" left="42" width="3" height="17" font="13"> </text>
<text top="175" left="119" width="102" height="17" font="13">Study prevalence, </text>
<text top="192" left="119" width="66" height="17" font="13">causes and </text>
<text top="210" left="119" width="96" height="17" font="13">consequences of </text>
<text top="227" left="119" width="69" height="17" font="13">WRF during </text>
<text top="244" left="119" width="99" height="17" font="13">hospitalization for </text>
<text top="261" left="119" width="53" height="17" font="13">acute HF </text>
<text top="175" left="242" width="79" height="17" font="13">Observational </text>
<text top="175" left="345" width="116" height="17" font="13">416 pts admitted for  </text>
<text top="192" left="345" width="53" height="17" font="13">acute HF </text>
<text top="175" left="474" width="141" height="17" font="13">Pts hospitalized for acute </text>
<text top="192" left="474" width="20" height="17" font="13">HF </text>
<text top="175" left="629" width="141" height="17" font="13">Chronic and severe renal </text>
<text top="192" left="629" width="156" height="17" font="13">failure (admission SCr &gt;230 </text>
<text top="210" left="629" width="130" height="17" font="13">μmol/lol/L); cardiogenic </text>
<text top="227" left="629" width="150" height="17" font="13">shock or severe low output </text>
<text top="244" left="629" width="141" height="17" font="13">requiring inotropic agents </text>
<text top="261" left="629" width="143" height="17" font="13">during the hospitalization; </text>
<text top="278" left="629" width="90" height="17" font="13">inhospital death </text>
<text top="175" left="805" width="120" height="17" font="13">Combined death; first </text>
<text top="192" left="805" width="161" height="17" font="13">unscheduled readmission for </text>
<text top="210" left="805" width="162" height="17" font="13">HF Outcome during the 6 mo </text>
<text top="227" left="805" width="110" height="17" font="13">after discharge was </text>
<text top="244" left="805" width="161" height="17" font="13">determined by contacting the </text>
<text top="261" left="805" width="106" height="17" font="13">pts or their general </text>
<text top="278" left="805" width="151" height="17" font="13">practitioners by telephone.  </text>
<text top="175" left="980" width="27" height="17" font="13"> N/A </text>
<text top="175" left="1162" width="258" height="17" font="13">WRF occurred in 152 cases (37%), 5±3 d after </text>
<text top="192" left="1162" width="275" height="17" font="13">admission. Old age, DM, HTN and acute coronary </text>
<text top="210" left="1162" width="268" height="17" font="13">syndromes increased the risk of WRF. Inhospital </text>
<text top="227" left="1162" width="270" height="17" font="13">furosemide doses as well as discharge treatment </text>
<text top="244" left="1162" width="250" height="17" font="13">were similar in WRF and no-WRF pts. Serum </text>
<text top="261" left="1162" width="237" height="17" font="13">Crelevation was the strongest independent </text>
<text top="278" left="1162" width="262" height="17" font="13">determinant of a longer hospital stay (p=0.001). </text>
<text top="296" left="1162" width="264" height="17" font="13">AEs occurred in 158 pts (38%) during follow-up, </text>
<text top="313" left="1162" width="283" height="17" font="13">with 23 deaths and 135 readmissions. Cox analysis </text>
<text top="330" left="1162" width="236" height="17" font="13">showed that WRF, transient or not, was an </text>
<text top="347" left="1162" width="241" height="17" font="13">independent predictor of the risk of death or </text>
<text top="364" left="1162" width="280" height="17" font="13">readmission (HR: 1.74 95%CI: 1.14–2.68; p=0.01). </text>
<text top="382" left="42" width="51" height="17" font="13">Grace L. </text>
<text top="400" left="42" width="38" height="17" font="13">Smith, </text>
<text top="417" left="42" width="63" height="17" font="13">2006 (335) </text>
<text top="434" left="42" width="55" height="17" font="14">16697315</text>
<text top="434" left="97" width="3" height="17" font="13"> </text>
<text top="451" left="42" width="3" height="17" font="13"> </text>
<text top="382" left="119" width="51" height="17" font="13">Estimate </text>
<text top="400" left="119" width="108" height="17" font="13">prevalence of renal </text>
<text top="417" left="119" width="97" height="17" font="13">impairment in HF </text>
<text top="434" left="119" width="64" height="17" font="13">pts and the </text>
<text top="451" left="119" width="75" height="17" font="13">magnitude of </text>
<text top="468" left="119" width="62" height="17" font="13">associated </text>
<text top="486" left="119" width="105" height="17" font="13">mortality risk using </text>
<text top="503" left="119" width="72" height="17" font="13">a systematic </text>
<text top="520" left="119" width="109" height="17" font="13">review of published </text>
<text top="537" left="119" width="46" height="17" font="13">studies. </text>
<text top="382" left="242" width="167" height="17" font="13">Meta-analysis 80,098 </text>
<text top="382" left="386" width="92" height="17" font="13">hospitalized </text>
<text top="400" left="345" width="49" height="17" font="13">and non-</text>
<text top="417" left="345" width="111" height="17" font="13">hospitalized HF pts. </text>
<text top="382" left="474" width="107" height="17" font="13">Cohort studies and </text>
<text top="400" left="474" width="126" height="17" font="13">secondary analyses of </text>
<text top="417" left="474" width="85" height="17" font="13">several RCTs.  </text>
<text top="382" left="629" width="160" height="17" font="13">Studies with &lt;6 mo follow-up </text>
<text top="400" left="629" width="135" height="17" font="13">and a study that defined </text>
<text top="417" left="629" width="153" height="17" font="13">renal impairment using ICD-</text>
<text top="434" left="629" width="149" height="17" font="13">9 code but no direct serum </text>
<text top="451" left="629" width="57" height="17" font="13">measures </text>
<text top="382" left="805" width="132" height="17" font="13">All-cause mortality risks </text>
<text top="400" left="805" width="141" height="17" font="13">associated with any renal </text>
<text top="417" left="805" width="150" height="17" font="13">impairment (Cr&gt;1.0 mg/dL, </text>
<text top="434" left="805" width="160" height="17" font="13">CrCl or estimated eGFR &lt;90 </text>
<text top="451" left="805" width="107" height="17" font="13">mL/min, or cystatin-</text>
<text top="468" left="805" width="143" height="17" font="13">clopidogrel  &gt;1.03 mg/dL) </text>
<text top="486" left="805" width="133" height="17" font="13">and moderate to severe </text>
<text top="503" left="805" width="156" height="17" font="13">impairment (Cr≥1.5, CrCl or </text>
<text top="520" left="805" width="124" height="17" font="13">eGFR &lt;53, or cystatin-</text>
<text top="537" left="805" width="106" height="17" font="13">clopidogrel  ≥1.56) </text>
<text top="382" left="980" width="155" height="17" font="13">Cardiovascular mortality (all </text>
<text top="400" left="980" width="156" height="17" font="13">cardiovascular mortality and </text>
<text top="417" left="980" width="159" height="17" font="13">HF or pump failure mortality) </text>
<text top="434" left="980" width="139" height="17" font="13">and functional decline by </text>
<text top="451" left="980" width="145" height="17" font="13">validated functional status </text>
<text top="468" left="980" width="122" height="17" font="13">scales such as NYHA </text>
<text top="486" left="980" width="166" height="17" font="13">functional class or activities of </text>
<text top="503" left="980" width="133" height="17" font="13">daily living assessment  </text>
<text top="382" left="1162" width="283" height="17" font="13">A total of 63% of pts had any renal impairment, and </text>
<text top="400" left="1162" width="259" height="17" font="13">29% had moderate to severe impairment. After </text>
<text top="417" left="1162" width="225" height="17" font="13">follow-up ≥1 y, 38% of pts with any renal </text>
<text top="434" left="1162" width="251" height="17" font="13">impairment and 51% with moderate to severe </text>
<text top="451" left="1162" width="248" height="17" font="13">impairment died vs 24% without. Adjusted all-</text>
<text top="468" left="1162" width="281" height="17" font="13">cause mortality was increased with any impairment </text>
<text top="486" left="1162" width="252" height="17" font="13">(aHR: 1.56; 95% CI: 1.53-1.60, p &lt;0.001) and </text>
<text top="503" left="1162" width="268" height="17" font="13">moderate to severe impairment (aHR: 2.31; 95% </text>
<text top="520" left="1162" width="240" height="17" font="13">CI: 2.18-2.44, p&lt;0.001). Mortality worsened </text>
<text top="537" left="1162" width="265" height="17" font="13">incrementally across the range of renal function, </text>
<text top="555" left="1162" width="262" height="17" font="13">with 15% (95% CI: 14%-17%) increased risk for </text>
<text top="572" left="1162" width="264" height="17" font="13">every 0.5 mg/dL increase in Crand 7% (95% CI: </text>
<text top="589" left="1162" width="245" height="17" font="13">4%-10%) increased risk for every 10 mL/min </text>
<text top="606" left="1162" width="107" height="17" font="13">decrease in eGFR. </text>
<text top="624" left="42" width="38" height="17" font="13">Marco </text>
<text top="641" left="42" width="38" height="17" font="13">Metra, </text>
<text top="659" left="42" width="63" height="17" font="13">2008 (336) </text>
<text top="676" left="42" width="55" height="17" font="14">18279773</text>
<text top="676" left="97" width="3" height="17" font="13"> </text>
<text top="693" left="42" width="3" height="17" font="13"> </text>
<text top="624" left="119" width="66" height="17" font="13">Association </text>
<text top="641" left="119" width="50" height="17" font="13">between </text>
<text top="659" left="119" width="105" height="17" font="13">hospitalizations for </text>
<text top="676" left="119" width="109" height="17" font="13">acute HF and WRF </text>
<text top="624" left="242" width="79" height="17" font="13">Observational </text>
<text top="624" left="345" width="112" height="17" font="13">318 consecutive pts </text>
<text top="641" left="345" width="105" height="17" font="13">admitted for  acute </text>
<text top="659" left="345" width="27" height="17" font="13">HF.  </text>
<text top="624" left="474" width="128" height="17" font="13">Diagnosis of acute HF, </text>
<text top="641" left="474" width="119" height="17" font="13">as established by the </text>
<text top="659" left="474" width="91" height="17" font="13">ESC guidelines; </text>
<text top="676" left="474" width="113" height="17" font="13">treatment with an IV </text>
<text top="693" left="474" width="137" height="17" font="13">agent, which in all cases </text>
<text top="710" left="474" width="139" height="17" font="13">included furosemide with </text>
<text top="727" left="474" width="88" height="17" font="13">or without other </text>
<text top="745" left="474" width="137" height="17" font="13">vasoactive medications.  </text>
<text top="624" left="629" width="136" height="17" font="13">Inability to give informed </text>
<text top="641" left="629" width="129" height="17" font="13">consent and those with </text>
<text top="659" left="629" width="132" height="17" font="13">evidence of ACS, acute </text>
<text top="676" left="629" width="134" height="17" font="13">arrhythmia, myocarditis, </text>
<text top="693" left="629" width="127" height="17" font="13">valve stenosis, cardiac </text>
<text top="710" left="629" width="102" height="17" font="13">tamponade, aortic </text>
<text top="727" left="629" width="122" height="17" font="13">dissection, pulmonary </text>
<text top="745" left="629" width="124" height="17" font="13">embolism, high output </text>
<text top="762" left="629" width="138" height="17" font="13">syndrome or evidence of </text>
<text top="779" left="629" width="148" height="17" font="13">non-cardiovascular factors </text>
<text top="624" left="805" width="146" height="17" font="13">Cardiac death and urgent, </text>
<text top="641" left="805" width="148" height="17" font="13">unplanned hospitalizations </text>
<text top="624" left="980" width="27" height="17" font="13"> N/A </text>
<text top="624" left="1162" width="214" height="17" font="13">53 pts (17%) died and 132 (41%) were </text>
<text top="641" left="1162" width="280" height="17" font="13">rehospitalized for HF. WRF-Abs-% occurred in 107 </text>
<text top="659" left="1162" width="274" height="17" font="13">(34%) pts. In multivariable survival analysis, WRF-</text>
<text top="676" left="1162" width="267" height="17" font="13">Abs-% was an independent predictor of death or </text>
<text top="693" left="1162" width="284" height="17" font="13">HF rehospitalization (aHR: 1.47; 95%CI: 1.13–1.81; </text>
<text top="710" left="1162" width="280" height="17" font="13">p=0.024). The independent predictors of WRF-Abs-</text>
<text top="727" left="1162" width="221" height="17" font="13">%, evaluated using multivariable logistic </text>
<text top="745" left="1162" width="276" height="17" font="13">regression, were history of chronic kidney disease </text>
<text top="762" left="1162" width="277" height="17" font="13">(p=0.002), LVEF (p=0.012), furosemide daily dose </text>
<text top="779" left="1162" width="275" height="17" font="13">(p=0.03) and NYHA class (p=0.05) on admission.  </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">162</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="629" width="156" height="17" font="13">as main cause of symptoms </text>
<text top="72" left="629" width="91" height="17" font="13">development of  </text>
<text top="89" left="629" width="157" height="17" font="13">complications or undergoing </text>
<text top="106" left="629" width="126" height="17" font="13">procedures which may </text>
<text top="124" left="629" width="157" height="17" font="13">cause a rise in Cr during the </text>
<text top="141" left="629" width="81" height="17" font="13">hospitalization </text>
<text top="213" left="42" width="64" height="17" font="13">Cowie MR, </text>
<text top="230" left="42" width="31" height="17" font="13">2006 </text>
<text top="247" left="42" width="55" height="17" font="14">16624834</text>
<text top="247" left="97" width="3" height="17" font="13"> </text>
<text top="265" left="42" width="32" height="17" font="13">(337) </text>
<text top="213" left="119" width="96" height="17" font="13">To determine the </text>
<text top="230" left="119" width="110" height="17" font="13">prevalence and risk </text>
<text top="247" left="119" width="90" height="17" font="13">factors for WRF </text>
<text top="265" left="119" width="61" height="17" font="13">among pts </text>
<text top="282" left="119" width="86" height="17" font="13">hospitalized for </text>
<text top="299" left="119" width="91" height="17" font="13">decompensated </text>
<text top="316" left="119" width="64" height="17" font="13">HF and the </text>
<text top="333" left="119" width="90" height="17" font="13">association with </text>
<text top="351" left="119" width="67" height="17" font="13">subsequent </text>
<text top="368" left="119" width="92" height="17" font="13">rehospitalization </text>
<text top="385" left="119" width="77" height="17" font="13">and mortality. </text>
<text top="213" left="242" width="79" height="17" font="13">Observational </text>
<text top="213" left="345" width="27" height="17" font="13">299  </text>
<text top="213" left="474" width="134" height="17" font="13">Age &gt;20 y, documented </text>
<text top="230" left="474" width="116" height="17" font="13">history of chronic HF </text>
<text top="247" left="474" width="135" height="17" font="13">defined according to the </text>
<text top="265" left="474" width="72" height="17" font="13">ESC criteria; </text>
<text top="282" left="474" width="137" height="17" font="13">documented evidence of </text>
<text top="299" left="474" width="105" height="17" font="13">impaired LVSF, as </text>
<text top="316" left="474" width="135" height="17" font="13">demonstrated by an EF  </text>
<text top="333" left="474" width="118" height="17" font="13">40% on TTE or other </text>
<text top="351" left="474" width="141" height="17" font="13">imaging technique on the </text>
<text top="368" left="474" width="141" height="17" font="13">index admission or within </text>
<text top="385" left="474" width="109" height="17" font="13">the preceding 6 mo </text>
<text top="213" left="629" width="161" height="17" font="13">Pts with a planned discharge </text>
<text top="230" left="629" width="155" height="17" font="13">within 24 h of admission; an </text>
<text top="247" left="629" width="150" height="17" font="13">investigator-defined history </text>
<text top="265" left="629" width="159" height="17" font="13">of ACS or cardiogenic shock </text>
<text top="282" left="629" width="161" height="17" font="13">within 1 mo prior to the index </text>
<text top="299" left="629" width="151" height="17" font="13">admission; receiving a new </text>
<text top="316" left="629" width="143" height="17" font="13">prescription for potentially </text>
<text top="333" left="629" width="156" height="17" font="13">nephrotoxic drugs within 2 d </text>
<text top="351" left="629" width="144" height="17" font="13">prior to admission; severe </text>
<text top="368" left="629" width="131" height="17" font="13">aortic stenosis, valvular </text>
<text top="385" left="629" width="122" height="17" font="13">disease anticipated to </text>
<text top="402" left="629" width="155" height="17" font="13">require surgery within 6 mo, </text>
<text top="420" left="629" width="153" height="17" font="13">‘high output’ cardiac failure, </text>
<text top="437" left="629" width="156" height="17" font="13">or those undergoing chronic </text>
<text top="454" left="629" width="161" height="17" font="13">renal replacement therapy or </text>
<text top="471" left="629" width="122" height="17" font="13">cancer chemotherapy </text>
<text top="213" left="805" width="162" height="17" font="13">All-cause mortality during the </text>
<text top="230" left="805" width="137" height="17" font="13">initial hospitalization and </text>
<text top="247" left="805" width="35" height="17" font="13">within </text>
<text top="265" left="805" width="148" height="17" font="13">30+7 d and 180+7 d of the </text>
<text top="282" left="805" width="145" height="17" font="13">index hospitalization; date </text>
<text top="299" left="805" width="141" height="17" font="13">and cause of subsequent </text>
<text top="316" left="805" width="126" height="17" font="13">hospital re-admissions </text>
<text top="333" left="805" width="111" height="17" font="13">were also recorded. </text>
<text top="213" left="980" width="27" height="17" font="13"> N/A </text>
<text top="213" left="1162" width="268" height="17" font="13">1/3 of pts [72 of 248 pts, 29% (95% CI: 26-32%)] </text>
<text top="230" left="1162" width="275" height="17" font="13">developed WRF during hospitalization. The risk of </text>
<text top="247" left="1162" width="284" height="17" font="13">WRF was independently associated with SCr levels </text>
<text top="265" left="1162" width="246" height="17" font="13">on admission (OR: 3.02, 95% CI: 1.58-5.76), </text>
<text top="282" left="1162" width="264" height="17" font="13">pulmonary edema OR: 3.35, 95% CI: 1.79-6.27, </text>
<text top="299" left="1162" width="269" height="17" font="13">and a history of AF: OR 0.35: 95% CI: 0.18-0.67. </text>
<text top="316" left="1162" width="233" height="17" font="13">Although the mortality of WRF pts was not </text>
<text top="333" left="1162" width="270" height="17" font="13">increased significantly, the length of stay was 2 d </text>
<text top="351" left="1162" width="267" height="17" font="13">longer [median 11 d (90% range (4-41) vs 9 d (4-</text>
<text top="368" left="1162" width="246" height="17" font="13">34), p=0.006]. The rehospitalization rate was </text>
<text top="385" left="1162" width="124" height="17" font="13">similar in both groups. </text>
<text top="489" left="42" width="51" height="17" font="13">Komukai </text>
<text top="506" left="42" width="46" height="17" font="13">K, 2008 </text>
<text top="524" left="42" width="55" height="17" font="14">18577827</text>
<text top="524" left="97" width="3" height="17" font="13"> </text>
<text top="541" left="42" width="32" height="17" font="13">(338) </text>
<text top="558" left="42" width="3" height="17" font="13"> </text>
<text top="489" left="119" width="80" height="17" font="13">To investigate </text>
<text top="506" left="119" width="78" height="17" font="13">whether renal </text>
<text top="524" left="119" width="78" height="17" font="13">dysfunction is </text>
<text top="541" left="119" width="87" height="17" font="13">associated with </text>
<text top="558" left="119" width="110" height="17" font="13">rehospitalization for </text>
<text top="575" left="119" width="57" height="17" font="13">CHF after </text>
<text top="592" left="119" width="61" height="17" font="13">successful </text>
<text top="610" left="119" width="57" height="17" font="13">discharge </text>
<text top="489" left="242" width="79" height="17" font="13">Observational </text>
<text top="489" left="345" width="44" height="17" font="13">109 pts </text>
<text top="489" left="474" width="125" height="17" font="13">Pts with CHF who had </text>
<text top="506" left="474" width="105" height="17" font="13">been admitted and </text>
<text top="524" left="474" width="94" height="17" font="13">followed up after </text>
<text top="541" left="474" width="91" height="17" font="13">discharge at the </text>
<text top="558" left="474" width="118" height="17" font="13">outpatient clinic were </text>
<text top="575" left="474" width="110" height="17" font="13">reviewed. CHF was </text>
<text top="592" left="474" width="95" height="17" font="13">diagnosed by ≥2 </text>
<text top="610" left="474" width="141" height="17" font="13">cardiologists on the basis </text>
<text top="627" left="474" width="107" height="17" font="13">of the Framingham </text>
<text top="644" left="474" width="40" height="17" font="13">criteria </text>
<text top="489" left="629" width="159" height="17" font="13">HF complicated by acute MI, </text>
<text top="506" left="629" width="123" height="17" font="13">undergoing or starting </text>
<text top="524" left="629" width="155" height="17" font="13">dialysis during the follow-up </text>
<text top="541" left="629" width="127" height="17" font="13">period, or undergoning </text>
<text top="558" left="629" width="146" height="17" font="13">cardiac surgery during the </text>
<text top="575" left="629" width="90" height="17" font="13">follow-up period </text>
<text top="489" left="805" width="135" height="17" font="13">Rehospitalization for HF </text>
<text top="506" left="805" width="85" height="17" font="13">after discharge </text>
<text top="489" left="980" width="27" height="17" font="13"> N/A </text>
<text top="489" left="1162" width="275" height="17" font="13">Pts with decreased renal function (estimated GFR </text>
<text top="506" left="1162" width="242" height="17" font="13">on admission &lt;45ml Emin.1 E1.73m2) were </text>
<text top="524" left="1162" width="271" height="17" font="13">rehospitalized more frequently than were pts with </text>
<text top="541" left="1162" width="243" height="17" font="13">preserved renal function (estimated GFR on </text>
<text top="558" left="1162" width="271" height="17" font="13">admission .45). Pts with decreased renal function </text>
<text top="575" left="1162" width="269" height="17" font="13">were older and had higher rates of anemia, WRF </text>
<text top="592" left="1162" width="216" height="17" font="13">during hospitalization, and previous HF </text>
<text top="610" left="1162" width="228" height="17" font="13">hospitalization. Independent predictors of </text>
<text top="627" left="1162" width="274" height="17" font="13">rehospitalization for HF identified with multivariate </text>
<text top="644" left="1162" width="278" height="17" font="13">analysis were age, previous hospitalization for HF, </text>
<text top="661" left="1162" width="276" height="17" font="13">decreased renal function, and non-use of an ACEI </text>
<text top="678" left="1162" width="46" height="17" font="13">or ARB. </text>
<text top="696" left="42" width="39" height="17" font="13">Akhter </text>
<text top="714" left="42" width="59" height="17" font="13">MW, 2004 </text>
<text top="731" left="42" width="58" height="17" font="14">15464689 </text>
<text top="748" left="42" width="32" height="17" font="13">(339) </text>
<text top="696" left="119" width="72" height="17" font="13">Evaluate the </text>
<text top="714" left="119" width="94" height="17" font="13">relation between </text>
<text top="731" left="119" width="88" height="17" font="13">elevated SCr at </text>
<text top="748" left="119" width="110" height="17" font="13">baseline, as well as </text>
<text top="765" left="119" width="69" height="17" font="13">WRF during </text>
<text top="782" left="119" width="109" height="17" font="13">hospitalization, and </text>
<text top="696" left="242" width="62" height="17" font="13">Secondary </text>
<text top="714" left="242" width="82" height="17" font="13">analysis of the </text>
<text top="731" left="242" width="62" height="17" font="13">VMAC trial </text>
<text top="696" left="345" width="116" height="17" font="13">481 (215 had RI and </text>
<text top="714" left="345" width="68" height="17" font="13">266 did not) </text>
<text top="696" left="474" width="137" height="17" font="13">Patients with dyspnea at </text>
<text top="714" left="474" width="140" height="17" font="13">rest caused by acute HF  </text>
<text top="696" left="629" width="31" height="17" font="13">  N/A </text>
<text top="696" left="805" width="157" height="17" font="13">Length of hospitalization, 30 </text>
<text top="714" left="805" width="162" height="17" font="13">d readmission rate as well as </text>
<text top="731" left="805" width="133" height="17" font="13">30-d and 6-mo mortality </text>
<text top="696" left="980" width="31" height="17" font="13">  N/A </text>
<text top="696" left="1162" width="280" height="17" font="13">Elevated baseline Cr was associated with length of </text>
<text top="714" left="1162" width="266" height="17" font="13">hospital stay (median 6 vs 7 d, p=0.003). RI was </text>
<text top="731" left="1162" width="217" height="17" font="13">associated with a 59% increase in 30-d </text>
<text top="748" left="1162" width="270" height="17" font="13">readmissions (17% vs 27%, p=0.016).  Higher Cr </text>
<text top="765" left="1162" width="269" height="17" font="13">on admission was associated with both morbidity </text>
<text top="782" left="1162" width="282" height="17" font="13">and mortality. All-cause mortality at 6 mo increased </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">163</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="119" width="76" height="17" font="13">outcomes pts </text>
<text top="72" left="119" width="86" height="17" font="13">hospitalized for </text>
<text top="89" left="119" width="91" height="17" font="13">decompensated </text>
<text top="106" left="119" width="92" height="17" font="13">HF in the VMAC </text>
<text top="124" left="119" width="27" height="17" font="13">trial  </text>
<text top="55" left="1162" width="275" height="17" font="13">(37.4% vs 12.3%, p &lt;0.0001). Baseline RI was an </text>
<text top="72" left="1162" width="278" height="17" font="13">independent predictor of 6-mo mortality with a RR: </text>
<text top="89" left="1162" width="195" height="17" font="13">2.72; 95% CI 1.76-4.21; p=0.0001.  </text>
<text top="168" left="42" width="55" height="17" font="13">Nohria A, </text>
<text top="185" left="42" width="31" height="17" font="13">2008 </text>
<text top="202" left="42" width="55" height="17" font="14">18371557</text>
<text top="202" left="97" width="3" height="17" font="13"> </text>
<text top="220" left="42" width="32" height="17" font="13">(340) </text>
<text top="237" left="42" width="3" height="17" font="13"> </text>
<text top="168" left="119" width="72" height="17" font="13">Examine the </text>
<text top="185" left="119" width="57" height="17" font="13">ESCAPE  </text>
<text top="202" left="119" width="109" height="17" font="13">database to assess </text>
<text top="220" left="119" width="105" height="17" font="13">the impact of renal </text>
<text top="237" left="119" width="79" height="17" font="13">dysfunction in </text>
<text top="254" left="119" width="105" height="17" font="13">patients with acute </text>
<text top="271" left="119" width="20" height="17" font="13">HF </text>
<text top="168" left="242" width="62" height="17" font="13">Secondary </text>
<text top="185" left="242" width="82" height="17" font="13">analysis of the </text>
<text top="202" left="242" width="77" height="17" font="13">ESCAPE trial </text>
<text top="168" left="345" width="96" height="17" font="13">A total of 433 pts </text>
<text top="185" left="345" width="108" height="17" font="13">were enrolled at 26 </text>
<text top="202" left="345" width="29" height="17" font="13">sites </text>
<text top="168" left="474" width="111" height="17" font="13">LVEF ≤30%, recent </text>
<text top="185" left="474" width="96" height="17" font="13">hospitalization or </text>
<text top="202" left="474" width="130" height="17" font="13">escalation of outpatient </text>
<text top="220" left="474" width="115" height="17" font="13">diuretic therapy, and </text>
<text top="237" left="474" width="129" height="17" font="13">SBP ≤125 mm Hg who </text>
<text top="254" left="474" width="115" height="17" font="13">were admitted to the </text>
<text top="271" left="474" width="124" height="17" font="13">hospital with at least 1 </text>
<text top="288" left="474" width="127" height="17" font="13">sign and 1 symptom of </text>
<text top="306" left="474" width="121" height="17" font="13">HF, despite adequate </text>
<text top="323" left="474" width="119" height="17" font="13">treatment with ACEIs </text>
<text top="340" left="474" width="73" height="17" font="13">and diuretics </text>
<text top="168" left="629" width="149" height="17" font="13">Creatinine &gt;3.5 mg/dL, the </text>
<text top="185" left="629" width="162" height="17" font="13">use of dobutamine/dopamine </text>
<text top="202" left="629" width="142" height="17" font="13">&gt;3 μg/kg/min or milrinone </text>
<text top="220" left="629" width="146" height="17" font="13">before randomization, and </text>
<text top="237" left="629" width="144" height="17" font="13">requirement for early right </text>
<text top="254" left="629" width="118" height="17" font="13">heart catheterization. </text>
<text top="168" left="805" width="120" height="17" font="13">D alive and out of the </text>
<text top="185" left="805" width="122" height="17" font="13">hospital for 6 mo after </text>
<text top="202" left="805" width="81" height="17" font="13">randomization </text>
<text top="168" left="980" width="152" height="17" font="13">30-d mortality and length of </text>
<text top="185" left="980" width="26" height="17" font="13">stay </text>
<text top="168" left="1162" width="256" height="17" font="13">Baseline and discharge RI, but not WRF, were </text>
<text top="185" left="1162" width="256" height="17" font="13">associated with an increased risk of death and </text>
<text top="202" left="1162" width="207" height="17" font="13">death or rehospitalization. Among the </text>
<text top="220" left="1162" width="236" height="17" font="13">hemodynamic parameters measured in pts </text>
<text top="237" left="1162" width="258" height="17" font="13">randomized to the PAC arm (n=194), only right </text>
<text top="254" left="1162" width="280" height="17" font="13">atrial pressure correlated weakly with baseline SCr </text>
<text top="271" left="1162" width="241" height="17" font="13">(r=0.165; p=0.03). There was no correlation </text>
<text top="288" left="1162" width="256" height="17" font="13">between baseline hemodynamics or change in </text>
<text top="306" left="1162" width="273" height="17" font="13">hemodynamics and WRF. A PAC-guided strategy </text>
<text top="323" left="1162" width="269" height="17" font="13">was associated with less average increase in Cr, </text>
<text top="340" left="1162" width="280" height="17" font="13">but did not decrease the incidence of defined WRF </text>
<text top="357" left="1162" width="272" height="17" font="13">during hospitalization or affect renal function after </text>
<text top="375" left="1162" width="260" height="17" font="13">discharge relative to clinical assessment alone. </text>
<text top="392" left="42" width="49" height="17" font="13">Owan et </text>
<text top="410" left="42" width="51" height="17" font="13">al., 2006 </text>
<text top="427" left="42" width="55" height="17" font="14">16679257</text>
<text top="427" left="97" width="3" height="17" font="13"> </text>
<text top="444" left="42" width="7" height="17" font="13">  </text>
<text top="392" left="119" width="70" height="17" font="13">Whether the </text>
<text top="410" left="119" width="90" height="17" font="13">severity of renal </text>
<text top="427" left="119" width="89" height="17" font="13">dysfunction, the </text>
<text top="444" left="119" width="101" height="17" font="13">incidence of WRF </text>
<text top="461" left="119" width="94" height="17" font="13">or outcomes has </text>
<text top="479" left="119" width="105" height="17" font="13">changed over time </text>
<text top="496" left="119" width="102" height="17" font="13">(secular trends) in </text>
<text top="513" left="119" width="106" height="17" font="13">pts hospitalized for </text>
<text top="530" left="119" width="68" height="17" font="13">HF therapy. </text>
<text top="392" left="242" width="79" height="17" font="13">Observational </text>
<text top="392" left="345" width="31" height="17" font="13">6440 </text>
<text top="392" left="474" width="125" height="17" font="13">All consecutive HF pts </text>
<text top="410" left="474" width="131" height="17" font="13">admitted to Mayo Clinic </text>
<text top="427" left="474" width="128" height="17" font="13">hospitals in Rochester, </text>
<text top="444" left="474" width="137" height="17" font="13">MN, between January 1, </text>
<text top="461" left="474" width="139" height="17" font="13">1987, and December 31, </text>
<text top="479" left="474" width="31" height="17" font="13">2002 </text>
<text top="392" left="629" width="31" height="17" font="13">  N/A </text>
<text top="392" left="805" width="149" height="17" font="13">Change in the incidence of </text>
<text top="410" left="805" width="156" height="17" font="13">WRF or outcomes over time </text>
<text top="392" left="980" width="31" height="17" font="13">  N/A </text>
<text top="392" left="1162" width="269" height="17" font="13">The incidence of WRF, defined as an increase in </text>
<text top="410" left="1162" width="270" height="17" font="13">Crof &gt;0.3 mg/dL increased slightly over the study </text>
<text top="427" left="1162" width="216" height="17" font="13">period (p=0.01). Renal dysfunction and </text>
<text top="444" left="1162" width="237" height="17" font="13">development of WRF were associated with </text>
<text top="461" left="1162" width="240" height="17" font="13">mortality. When adjusted for the changes in </text>
<text top="479" left="1162" width="273" height="17" font="13">baseline characteristics, later admission year was </text>
<text top="496" left="1162" width="278" height="17" font="13">associated with lower 3-mo (aOR: 0.98 per y; 95% </text>
<text top="513" left="1162" width="275" height="17" font="13">CI: 0.96–0.99; p=0.008) and overall mortality (HR: </text>
<text top="530" left="1162" width="219" height="17" font="13">0.99 per y; 95% CI 0.98–1.00; p 0.002). </text>
<text top="548" left="42" width="59" height="17" font="13">Krumholz, </text>
<text top="565" left="42" width="31" height="17" font="13">2000 </text>
<text top="583" left="42" width="55" height="17" font="14">10781761</text>
<text top="583" left="97" width="3" height="17" font="13"> </text>
<text top="600" left="42" width="32" height="17" font="13">(341) </text>
<text top="617" left="42" width="3" height="17" font="13"> </text>
<text top="548" left="119" width="96" height="17" font="13">To determine the </text>
<text top="565" left="119" width="79" height="17" font="13">incidence and </text>
<text top="583" left="119" width="83" height="17" font="13">identify factors </text>
<text top="600" left="119" width="108" height="17" font="13">associated with the </text>
<text top="617" left="119" width="87" height="17" font="13">development of </text>
<text top="634" left="119" width="90" height="17" font="13">worsening renal </text>
<text top="651" left="119" width="99" height="17" font="13">function in elderly </text>
<text top="669" left="119" width="105" height="17" font="13">patients with acute </text>
<text top="686" left="119" width="107" height="17" font="13">HF and to examine </text>
<text top="703" left="119" width="105" height="17" font="13">the impact of WRF </text>
<text top="720" left="119" width="81" height="17" font="13">on clinical and </text>
<text top="737" left="119" width="56" height="17" font="13">economic </text>
<text top="755" left="119" width="60" height="17" font="13">outcomes. </text>
<text top="548" left="242" width="83" height="17" font="13">Retrospecrive  </text>
<text top="548" left="345" width="99" height="17" font="13">1,681 pts from 18 </text>
<text top="565" left="345" width="68" height="17" font="13">Connecticut </text>
<text top="583" left="345" width="55" height="17" font="13">hospitals  </text>
<text top="548" left="474" width="120" height="17" font="13">Age ≥65 y; discharge </text>
<text top="565" left="474" width="127" height="17" font="13">with HF without having </text>
<text top="583" left="474" width="114" height="17" font="13">clear precipitants for </text>
<text top="600" left="474" width="96" height="17" font="13">renal dysfunction </text>
<text top="548" left="629" width="155" height="17" font="13">Pts &lt;65 y of age; pts whose </text>
<text top="565" left="629" width="126" height="17" font="13">diagnosis could not be </text>
<text top="583" left="629" width="153" height="17" font="13">validated by medical record </text>
<text top="600" left="629" width="161" height="17" font="13">review, pts with severe aortic </text>
<text top="617" left="629" width="126" height="17" font="13">stenosis, severe mitral </text>
<text top="634" left="629" width="160" height="17" font="13">stenosis, or HF secondary to </text>
<text top="651" left="629" width="125" height="17" font="13">a medical illness (e.g., </text>
<text top="669" left="629" width="158" height="17" font="13">sepsis); major complications </text>
<text top="686" left="629" width="134" height="17" font="13">(stroke, acute MI shock, </text>
<text top="703" left="629" width="143" height="17" font="13">heart arrest, hypotension, </text>
<text top="720" left="629" width="159" height="17" font="13">pneumonia, and infection) or </text>
<text top="737" left="629" width="114" height="17" font="13">underwent a cardiac </text>
<text top="755" left="629" width="157" height="17" font="13">procedure requiring contrast </text>
<text top="772" left="629" width="145" height="17" font="13">(cardiac catheterization or </text>
<text top="789" left="629" width="126" height="17" font="13">angioplasty) or bypass </text>
<text top="548" left="805" width="160" height="17" font="13">The outcome variable for the </text>
<text top="565" left="805" width="152" height="17" font="13">first phase of the study was </text>
<text top="583" left="805" width="140" height="17" font="13">worsening renal function, </text>
<text top="600" left="805" width="131" height="17" font="13">defined as in the ELITE </text>
<text top="617" left="805" width="154" height="17" font="13">study as an increase in SCr </text>
<text top="634" left="805" width="161" height="17" font="13">level during hospitalization of </text>
<text top="651" left="805" width="155" height="17" font="13">&gt;0.3 mg/dL from admission. </text>
<text top="669" left="805" width="148" height="17" font="13">The principal endpoints for </text>
<text top="686" left="805" width="148" height="17" font="13">the 2nd phase of the study </text>
<text top="703" left="805" width="139" height="17" font="13">were inhospital mortality, </text>
<text top="720" left="805" width="158" height="17" font="13">length of stay and cost, 30-d </text>
<text top="737" left="805" width="147" height="17" font="13">mortality and readmission, </text>
<text top="755" left="805" width="129" height="17" font="13">and 6-mo mortality and </text>
<text top="772" left="805" width="70" height="17" font="13">readmission </text>
<text top="548" left="980" width="31" height="17" font="13">  N/A </text>
<text top="548" left="1162" width="245" height="17" font="13">WRF occurred in 28% of the cohort and was </text>
<text top="565" left="1162" width="279" height="17" font="13">associated with male gender, HTN, rales &gt; basilar, </text>
<text top="583" left="1162" width="254" height="17" font="13">pulse &gt;100 beats/min, SBP &gt;200 mm Hg, and </text>
<text top="600" left="1162" width="275" height="17" font="13">admission Cr&gt;1.5 mg/dL. Based on the number of </text>
<text top="617" left="1162" width="245" height="17" font="13">these factors, a pt’s risk for developing WRF </text>
<text top="634" left="1162" width="255" height="17" font="13">ranged between 16% (≤1 factor) and 53% (≥5 </text>
<text top="651" left="1162" width="261" height="17" font="13">factors). After adjusting for confounding effects, </text>
<text top="669" left="1162" width="259" height="17" font="13">WRF was associated with a significantly longer </text>
<text top="686" left="1162" width="262" height="17" font="13">length of stay by 2.3 d, higher inhospital cost by </text>
<text top="703" left="1162" width="284" height="17" font="13">$1,758, and an increased risk of inhospital mortality </text>
<text top="720" left="1162" width="167" height="17" font="13">(aOR:2.72; 95% CI:1.62-4.58) </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">164</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="629" width="82" height="17" font="13">surgery during </text>
<text top="72" left="629" width="81" height="17" font="13">hospitalization </text>
<text top="303" left="42" width="53" height="17" font="13">Forman , </text>
<text top="320" left="42" width="31" height="17" font="13">2004 </text>
<text top="337" left="42" width="55" height="17" font="14">14715185</text>
<text top="337" left="97" width="3" height="17" font="13"> </text>
<text top="355" left="42" width="32" height="17" font="13">(342) </text>
<text top="372" left="42" width="3" height="17" font="13"> </text>
<text top="303" left="119" width="96" height="17" font="13">To determine the </text>
<text top="320" left="119" width="109" height="17" font="13">prevalence of WRF </text>
<text top="337" left="119" width="109" height="17" font="13">among hospitalized </text>
<text top="355" left="119" width="83" height="17" font="13">HF pts, clinical </text>
<text top="372" left="119" width="106" height="17" font="13">predictors of WRF, </text>
<text top="389" left="119" width="70" height="17" font="13">and hospital </text>
<text top="406" left="119" width="57" height="17" font="13">outcomes </text>
<text top="423" left="119" width="87" height="17" font="13">associated with </text>
<text top="441" left="119" width="35" height="17" font="13">WRF. </text>
<text top="303" left="242" width="40" height="17" font="13">Cohort </text>
<text top="320" left="242" width="82" height="17" font="13">(retrospective) </text>
<text top="303" left="345" width="38" height="17" font="13">1,004  </text>
<text top="303" left="474" width="108" height="17" font="13">HF pts hospitalized </text>
<text top="320" left="474" width="123" height="17" font="13">between July 1, 1997, </text>
<text top="337" left="474" width="139" height="17" font="13">and June 30, 1998, at 11 </text>
<text top="355" left="474" width="102" height="17" font="13">academic medical </text>
<text top="372" left="474" width="51" height="17" font="13">centers.  </text>
<text top="303" left="629" width="141" height="17" font="13">Pts were excluded if their </text>
<text top="320" left="629" width="153" height="17" font="13">hospitalizations were for an </text>
<text top="337" left="629" width="135" height="17" font="13">elective procedure (e.g., </text>
<text top="355" left="629" width="148" height="17" font="13">percutaneous transluminal </text>
<text top="372" left="629" width="120" height="17" font="13">coronary angioplasty, </text>
<text top="389" left="629" width="163" height="17" font="13">pacemaker, or cardioversion) </text>
<text top="406" left="629" width="148" height="17" font="13">or if their hospital length of </text>
<text top="423" left="629" width="117" height="17" font="13">stay was &lt;2 d. Other </text>
<text top="441" left="629" width="144" height="17" font="13">exclusion criteria included </text>
<text top="458" left="629" width="126" height="17" font="13">severe aortic stenosis, </text>
<text top="475" left="629" width="106" height="17" font="13">anticipated cardiac </text>
<text top="492" left="629" width="161" height="17" font="13">transplantation, transfer from </text>
<text top="510" left="629" width="144" height="17" font="13">another inhospital setting, </text>
<text top="527" left="629" width="156" height="17" font="13">chronic dialysis, use of a LV </text>
<text top="544" left="629" width="142" height="17" font="13">assist device, high-output </text>
<text top="561" left="629" width="154" height="17" font="13">HF, age &lt;20 y, concomitant </text>
<text top="578" left="629" width="135" height="17" font="13">use of an investigational </text>
<text top="596" left="629" width="125" height="17" font="13">product or device, and </text>
<text top="613" left="629" width="99" height="17" font="13">patients receiving </text>
<text top="630" left="629" width="135" height="17" font="13">chemotherapy. Subjects </text>
<text top="647" left="629" width="118" height="17" font="13">were also excluded if </text>
<text top="664" left="629" width="103" height="17" font="13">Crvalues were not </text>
<text top="682" left="629" width="147" height="17" font="13">documented at admission. </text>
<text top="303" left="805" width="150" height="17" font="13">The principal outcome was </text>
<text top="320" left="805" width="162" height="17" font="13">WRF, defined as an increase </text>
<text top="337" left="805" width="148" height="17" font="13">in SCr of &gt;0.3 mg/dL (26.5 </text>
<text top="355" left="805" width="135" height="17" font="13">μmol/L) from admission, </text>
<text top="372" left="805" width="127" height="17" font="13">consistent with several </text>
<text top="389" left="805" width="131" height="17" font="13">previous investigations; </text>
<text top="406" left="805" width="126" height="17" font="13">hospital length of stay, </text>
<text top="423" left="805" width="133" height="17" font="13">inhospital mortality, and </text>
<text top="441" left="805" width="160" height="17" font="13">complications occurring after </text>
<text top="458" left="805" width="117" height="17" font="13">the rise in creatinine. </text>
<text top="475" left="805" width="155" height="17" font="13">Complications were defined </text>
<text top="492" left="805" width="150" height="17" font="13">as shock, MI, stroke, major </text>
<text top="510" left="805" width="140" height="17" font="13">infection/sepsis, clinically </text>
<text top="527" left="805" width="155" height="17" font="13">significant hypotension, and </text>
<text top="544" left="805" width="104" height="17" font="13">new onset AF with </text>
<text top="561" left="805" width="122" height="17" font="13">ventricular rates &gt;100 </text>
<text top="578" left="805" width="60" height="17" font="13">beats/min. </text>
<text top="303" left="980" width="31" height="17" font="13">  N/A </text>
<text top="303" left="1162" width="267" height="17" font="13">Among 1,004 HF pts studied, WRF developed in </text>
<text top="320" left="1162" width="282" height="17" font="13">27%. In the majority of cases, WRF occurred within </text>
<text top="337" left="1162" width="271" height="17" font="13">3 d of admission. History of HF or DM, admission </text>
<text top="355" left="1162" width="273" height="17" font="13">Cr≥1.5 mg/dL (132.6 μmol/L), and SBP &gt;160 mm </text>
<text top="372" left="1162" width="277" height="17" font="13">Hg were independently associated with higher risk </text>
<text top="389" left="1162" width="211" height="17" font="13">of WRF. A point score based on these </text>
<text top="406" left="1162" width="276" height="17" font="13">characteristics and their RR ratios predicted those </text>
<text top="423" left="1162" width="280" height="17" font="13">at risk for WRF. Hospital deaths aRR: 7.5; 95% CI: </text>
<text top="441" left="1162" width="262" height="17" font="13">2.9-19.3), complications (aRR: 2.1; 95% CI: 1.5-</text>
<text top="458" left="1162" width="284" height="17" font="13">3.0), and length of hospitalizations &gt;10 d (aRR: 3.2, </text>
<text top="475" left="1162" width="283" height="17" font="13">95% CI: 2.2-4.9) were greater among pts with WRF </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">165</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="42" width="34" height="17" font="13">Klein, </text>
<text top="72" left="42" width="31" height="17" font="13">2008 </text>
<text top="89" left="42" width="55" height="17" font="14">19808267</text>
<text top="89" left="97" width="3" height="17" font="13"> </text>
<text top="106" left="42" width="32" height="17" font="13">(343) </text>
<text top="55" left="119" width="101" height="17" font="13">To investigate the </text>
<text top="72" left="119" width="94" height="17" font="13">relation between </text>
<text top="89" left="119" width="98" height="17" font="13">admission values </text>
<text top="106" left="119" width="87" height="17" font="13">and changes in </text>
<text top="124" left="119" width="90" height="17" font="13">BUN and eGFR </text>
<text top="141" left="119" width="96" height="17" font="13">and rate of death </text>
<text top="158" left="119" width="72" height="17" font="13">by 60 d after </text>
<text top="175" left="119" width="57" height="17" font="13">discharge </text>
<text top="55" left="242" width="79" height="17" font="13">Retrospective </text>
<text top="72" left="242" width="61" height="17" font="13">analysis of </text>
<text top="89" left="242" width="80" height="17" font="13">OPTIME-CHF </text>
<text top="106" left="242" width="71" height="17" font="13">(multicenter, </text>
<text top="124" left="242" width="71" height="17" font="13">randomized, </text>
<text top="141" left="242" width="74" height="17" font="13">double-blind, </text>
<text top="158" left="242" width="47" height="17" font="13">placebo-</text>
<text top="175" left="242" width="84" height="17" font="13">controlled trial) </text>
<text top="55" left="345" width="27" height="17" font="13">949  </text>
<text top="55" left="474" width="105" height="17" font="13">Pts &gt;18 y who had </text>
<text top="72" left="474" width="127" height="17" font="13">known systolic HF and </text>
<text top="89" left="474" width="141" height="17" font="13">had been hospitalized for </text>
<text top="106" left="474" width="136" height="17" font="13">exacerbation of no more </text>
<text top="124" left="474" width="96" height="17" font="13">than 48 h earlier  </text>
<text top="55" left="629" width="152" height="17" font="13">Active myocardial ischemia </text>
<text top="72" left="629" width="161" height="17" font="13">within the past 3 mo, AF with </text>
<text top="89" left="629" width="153" height="17" font="13">poor ventricular rate control </text>
<text top="106" left="629" width="122" height="17" font="13">(&gt;110/min), sustained </text>
<text top="124" left="629" width="141" height="17" font="13">ventricular tachycardia or </text>
<text top="141" left="629" width="119" height="17" font="13">ventricular fibrillation, </text>
<text top="158" left="629" width="159" height="17" font="13">baseline SBP &lt;80 mm Hg or </text>
<text top="175" left="629" width="147" height="17" font="13">SCr level &gt;3.0 mg/dL (265 </text>
<text top="192" left="629" width="50" height="17" font="13">µmol/L)  </text>
<text top="55" left="805" width="161" height="17" font="13">Total no. of d hospitalized for </text>
<text top="72" left="805" width="160" height="17" font="13">cardiovascular causes within </text>
<text top="89" left="805" width="160" height="17" font="13">60 d of randomization. D lost </text>
<text top="106" left="805" width="157" height="17" font="13">to follow-up and d deceased </text>
<text top="124" left="805" width="154" height="17" font="13">were prospectively included </text>
<text top="141" left="805" width="142" height="17" font="13">in the primary endpoint to </text>
<text top="158" left="805" width="154" height="17" font="13">avoid bias toward a therapy </text>
<text top="175" left="805" width="161" height="17" font="13">with an increased death rate. </text>
<text top="55" left="980" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1162" width="269" height="17" font="13">Although both lower admission eGFR and higher </text>
<text top="72" left="1162" width="280" height="17" font="13">admission BUN were associated with higher risk of </text>
<text top="89" left="1162" width="239" height="17" font="13">death by 60 d after discharge, multivariable </text>
<text top="106" left="1162" width="263" height="17" font="13">proportional-hazards analysis showed that BUN </text>
<text top="124" left="1162" width="280" height="17" font="13">was a stronger predictor of death by 60 d than was </text>
<text top="141" left="1162" width="47" height="17" font="13">eGFR (χ</text>
<text top="142" left="1209" width="4" height="11" font="19">2</text>
<text top="141" left="1214" width="193" height="17" font="13"> =11.6 and 0.6 for BUN and eGFR, </text>
<text top="158" left="1162" width="271" height="17" font="13">respectively). Independently of admission values, </text>
<text top="175" left="1162" width="224" height="17" font="13">an increase of ≥10 mg/dL in BUN during </text>
<text top="192" left="1162" width="258" height="17" font="13">hospitalization was associated with worse 60-d </text>
<text top="210" left="1162" width="265" height="17" font="13">survival rate: BUN (per 5-mg/dL increase) had a </text>
<text top="227" left="1162" width="271" height="17" font="13">HR: 1.08; 95% CI: 1.01-1.16). Although milrinone </text>
<text top="244" left="1162" width="252" height="17" font="13">treatment led to a minor improvement in renal </text>
<text top="261" left="1162" width="233" height="17" font="13">function by discharge, the 60-d  death and </text>
<text top="278" left="1162" width="240" height="17" font="13">readmission rates were similar between the </text>
<text top="296" left="1162" width="165" height="17" font="13">milrinone and placebo groups </text>
<text top="313" left="32" width="1420" height="15" font="6">ACEI indicates angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; AE, adverse event; AF, atrial fibrillation; BUN, blood urea nitrogen; CHF, congestive heart failure; Cr, creatinine; CrCL, creatinine clearance; DM, diabetes mellitus; eGFR, estimated glomerular filtration </text>
<text top="329" left="32" width="1376" height="15" font="6">rate; ELITE, Evaluation of Losartan in the Elderly; ESC, European Society of Cardiology; ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness; HTN, hypertension; ICD-9, international classification of diseases – 9th edition; IV, </text>
<text top="344" left="32" width="1416" height="15" font="6">intravenous; LVSF, left ventricular systolic function; MI, myocardial infarction; NYHA, New York Heart Association; OPTIME-CHF, the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure study ; Pts, patients; RCT, randomized clinical trial; RI, </text>
<text top="360" left="32" width="1093" height="15" font="6">renal insufficiency; SBP, systolic blood pressure; SCr, serum creatinine; TTE, transthoracic echocardiography; VMAC, Vasodilation in the Management of Acute Congestive Heart Failure; and WRF, worsening renal function. </text>
<text top="375" left="54" width="3" height="15" font="6"> </text>
<text top="391" left="54" width="3" height="15" font="6"> </text>
<text top="406" left="54" width="3" height="15" font="6"> </text>
<text top="431" left="54" width="313" height="21" font="8"><b>Data Supplement 39. Nesiritide (Section 8.7) </b></text>
<text top="453" left="71" width="38" height="17" font="15"><b>Study </b></text>
<text top="470" left="70" width="40" height="17" font="15"><b>Name, </b></text>
<text top="487" left="67" width="47" height="17" font="15"><b>Author, </b></text>
<text top="504" left="75" width="30" height="17" font="15"><b>Year </b></text>
<text top="487" left="157" width="42" height="17" font="15"><b>Aim of </b></text>
<text top="504" left="159" width="36" height="17" font="15"><b>study </b></text>
<text top="487" left="229" width="38" height="17" font="15"><b>Study </b></text>
<text top="504" left="231" width="32" height="17" font="15"><b>Type </b></text>
<text top="470" left="283" width="57" height="17" font="15"><b>Backgrou</b></text>
<text top="487" left="304" width="19" height="17" font="15"><b>nd </b></text>
<text top="504" left="287" width="51" height="17" font="15"><b>Therapy </b></text>
<text top="504" left="377" width="66" height="17" font="15"><b>Study Size<i> </i></b></text>
<text top="504" left="482" width="52" height="17" font="15"><b>Etiology<i> </i></b></text>
<text top="504" left="600" width="83" height="17" font="15"><b>Pt Population<i> </i></b></text>
<text top="504" left="791" width="51" height="17" font="15"><b>Severity<i> </i></b></text>
<text top="504" left="944" width="64" height="17" font="15"><b>Endpoints<i> </i></b></text>
<text top="504" left="1062" width="55" height="17" font="15"><b>Mortality<i> </i></b></text>
<text top="470" left="1143" width="29" height="17" font="15"><b>Trial </b></text>
<text top="487" left="1131" width="54" height="17" font="15"><b>Duration </b></text>
<text top="504" left="1136" width="45" height="17" font="15"><b>(Years) </b></text>
<text top="470" left="1205" width="62" height="17" font="15"><b>Statistical </b></text>
<text top="487" left="1209" width="54" height="17" font="15"><b>Analysis </b></text>
<text top="504" left="1208" width="56" height="17" font="15"><b>(Results) </b></text>
<text top="487" left="1304" width="38" height="17" font="15"><b>Study </b></text>
<text top="504" left="1288" width="69" height="17" font="15"><b>Limitations </b></text>
<text top="487" left="1373" width="85" height="17" font="15"><b>Complications</b></text>
<text top="504" left="1401" width="31" height="17" font="15"><b>/AEs </b></text>
<text top="539" left="288" width="50" height="17" font="21"><i><b>Pre-trial </b></i></text>
<text top="557" left="285" width="55" height="17" font="21"><i><b>standard </b></i></text>
<text top="574" left="281" width="63" height="17" font="21"><i><b>treatment. </b></i></text>
<text top="539" left="383" width="53" height="17" font="21"><i><b>N (Total) </b></i></text>
<text top="557" left="360" width="100" height="17" font="21"><i><b>n (Experimental) </b></i></text>
<text top="574" left="377" width="66" height="17" font="21"><i><b>n (Control) </b></i></text>
<text top="539" left="478" width="56" height="17" font="21"><i><b>Ischemic/</b></i></text>
<text top="557" left="492" width="28" height="17" font="21"><i><b>Non-</b></i></text>
<text top="574" left="480" width="56" height="17" font="21"><i><b>Ischemic </b></i></text>
<text top="557" left="564" width="58" height="17" font="21"><i><b>Inclusion </b></i></text>
<text top="574" left="570" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="557" left="656" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="574" left="664" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="539" left="744" width="66" height="17" font="21"><i><b>Severity of </b></i></text>
<text top="557" left="767" width="20" height="17" font="21"><i><b>HF </b></i></text>
<text top="574" left="744" width="66" height="17" font="21"><i><b>Symptoms </b></i></text>
<text top="522" left="839" width="38" height="17" font="21"><i><b>Study </b></i></text>
<text top="539" left="841" width="35" height="17" font="21"><i><b>Entry </b></i></text>
<text top="557" left="836" width="44" height="17" font="21"><i><b>Sverity </b></i></text>
<text top="574" left="835" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="557" left="915" width="49" height="17" font="21"><i><b>Primary </b></i></text>
<text top="574" left="911" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="539" left="989" width="56" height="17" font="21"><i><b>Secondar</b></i></text>
<text top="557" left="1013" width="10" height="17" font="21"><i><b>y </b></i></text>
<text top="574" left="990" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="557" left="1064" width="51" height="17" font="21"><i><b>1st Year </b></i></text>
<text top="574" left="1062" width="55" height="17" font="21"><i><b>Mortality </b></i></text>
<text top="592" left="54" width="55" height="17" font="13">Nesiritide </text>
<text top="609" left="54" width="35" height="17" font="13">Study </text>
<text top="626" left="54" width="38" height="17" font="13">Group </text>
<text top="643" left="54" width="49" height="17" font="13">(NSGT), </text>
<text top="661" left="54" width="70" height="17" font="13">Colucci WS, </text>
<text top="678" left="54" width="34" height="17" font="13">2000. </text>
<text top="695" left="54" width="55" height="17" font="14">10911006</text>
<text top="695" left="109" width="3" height="17" font="13"> </text>
<text top="712" left="54" width="32" height="17" font="13">(344) </text>
<text top="729" left="54" width="3" height="17" font="13"> </text>
<text top="592" left="139" width="60" height="17" font="13">Determine </text>
<text top="609" left="139" width="72" height="17" font="13">efficacy/clinic</text>
<text top="626" left="139" width="50" height="17" font="13">al use of </text>
<text top="643" left="139" width="70" height="17" font="13">nesiritide for </text>
<text top="661" left="139" width="59" height="17" font="13">short term </text>
<text top="678" left="139" width="69" height="17" font="13">treatment of </text>
<text top="695" left="139" width="40" height="17" font="13">ADHF. </text>
<text top="592" left="229" width="118" height="17" font="13">RCT Chronic </text>
<text top="609" left="279" width="63" height="17" font="13">medication </text>
<text top="626" left="279" width="48" height="17" font="13">regimen </text>
<text top="643" left="279" width="66" height="17" font="13">N/A; any IV </text>
<text top="661" left="279" width="63" height="17" font="13">medication </text>
<text top="678" left="279" width="62" height="17" font="13">(dobutamin</text>
<text top="695" left="279" width="14" height="17" font="13">e, </text>
<text top="712" left="279" width="57" height="17" font="13">milrinone, </text>
<text top="729" left="279" width="61" height="17" font="13">dopamine, </text>
<text top="747" left="279" width="14" height="17" font="13">or </text>
<text top="764" left="279" width="67" height="17" font="13">vasodilator) </text>
<text top="781" left="279" width="25" height="17" font="13">was </text>
<text top="592" left="359" width="101" height="17" font="13">Efficacy trial: 127  </text>
<text top="609" left="359" width="100" height="17" font="13">Comparative trial: </text>
<text top="626" left="359" width="27" height="17" font="13">305. </text>
<text top="643" left="359" width="3" height="17" font="13"> </text>
<text top="661" left="359" width="96" height="17" font="13">NESIRITIDE        </text>
<text top="678" left="359" width="107" height="17" font="13">Efficacy trial:           </text>
<text top="695" left="359" width="55" height="17" font="13">43 (0.015 </text>
<text top="712" left="359" width="75" height="17" font="13">g/kg/min), 42 </text>
<text top="729" left="359" width="106" height="17" font="13">(0.03 mg/kg/min)    </text>
<text top="747" left="359" width="100" height="17" font="13">Comparative trial: </text>
<text top="764" left="359" width="24" height="17" font="13">103 </text>
<text top="781" left="359" width="96" height="17" font="13">(0.015mg/kg/min)</text>
<text top="592" left="473" width="46" height="17" font="13">Efficacy </text>
<text top="609" left="473" width="55" height="17" font="13">trial: 46% </text>
<text top="626" left="473" width="29" height="17" font="13">ICM, </text>
<text top="643" left="473" width="63" height="17" font="13">Comparativ</text>
<text top="661" left="473" width="65" height="17" font="13">e trial: 54% </text>
<text top="678" left="473" width="29" height="17" font="13">ICM. </text>
<text top="592" left="554" width="74" height="17" font="13">Symptomatic </text>
<text top="609" left="554" width="20" height="17" font="13">HF </text>
<text top="626" left="554" width="61" height="17" font="13">warranting </text>
<text top="643" left="554" width="71" height="17" font="13">hospitalizatio</text>
<text top="661" left="554" width="61" height="17" font="13">n for &gt;1 IV </text>
<text top="678" left="554" width="76" height="17" font="13">medication in </text>
<text top="695" left="554" width="60" height="17" font="13">addition to </text>
<text top="712" left="554" width="53" height="17" font="13">diuretics. </text>
<text top="729" left="554" width="73" height="17" font="13">Efficacy trial: </text>
<text top="747" left="554" width="65" height="17" font="13">PCWP &gt;18 </text>
<text top="764" left="554" width="62" height="17" font="13">mmHg, CI, </text>
<text top="781" left="554" width="75" height="17" font="13">&lt;2.7L/min/m, </text>
<text top="592" left="644" width="72" height="17" font="13">MI/UA within </text>
<text top="609" left="644" width="59" height="17" font="13">prior 48 h. </text>
<text top="626" left="644" width="52" height="17" font="13">Clinically </text>
<text top="643" left="644" width="55" height="17" font="13">important </text>
<text top="661" left="644" width="46" height="17" font="13">valvular </text>
<text top="678" left="644" width="83" height="17" font="13">stenosis, HCM </text>
<text top="695" left="644" width="49" height="17" font="13">or RCM, </text>
<text top="712" left="644" width="65" height="17" font="13">constrictive </text>
<text top="729" left="644" width="66" height="17" font="13">pericarditis, </text>
<text top="747" left="644" width="83" height="17" font="13">primary pHTN, </text>
<text top="764" left="644" width="50" height="17" font="13">or active </text>
<text top="781" left="644" width="69" height="17" font="13">myocarditis. </text>
<text top="592" left="742" width="46" height="17" font="13">Efficacy </text>
<text top="609" left="742" width="55" height="17" font="13">trial: 98% </text>
<text top="626" left="742" width="67" height="17" font="13">NYHA III-IV </text>
<text top="643" left="742" width="34" height="17" font="13">mean </text>
<text top="661" left="742" width="57" height="17" font="13">PCWP 28 </text>
<text top="678" left="742" width="50" height="17" font="13">mmHg,   </text>
<text top="695" left="742" width="50" height="17" font="13">mean CI </text>
<text top="712" left="742" width="21" height="17" font="13">1.9 </text>
<text top="729" left="742" width="57" height="17" font="13">L/min/m2, </text>
<text top="747" left="742" width="62" height="17" font="13">mean SBP </text>
<text top="764" left="742" width="67" height="17" font="13">116 mmHg. </text>
<text top="781" left="742" width="63" height="17" font="13">Comparativ</text>
<text top="592" left="825" width="62" height="17" font="13">Symptomat</text>
<text top="609" left="825" width="49" height="17" font="13">ic ADHF </text>
<text top="626" left="825" width="51" height="17" font="13">requiring </text>
<text top="643" left="825" width="17" height="17" font="13">&gt;1 </text>
<text top="661" left="825" width="57" height="17" font="13">intravenou</text>
<text top="678" left="825" width="10" height="17" font="13">s </text>
<text top="695" left="825" width="63" height="17" font="13">medication </text>
<text top="712" left="825" width="59" height="17" font="13">in addition </text>
<text top="729" left="825" width="14" height="17" font="13">to </text>
<text top="747" left="825" width="53" height="17" font="13">diuretics. </text>
<text top="592" left="904" width="50" height="17" font="13">Efficacy: </text>
<text top="609" left="904" width="72" height="17" font="13">change from </text>
<text top="626" left="904" width="49" height="17" font="13">baseline </text>
<text top="643" left="904" width="67" height="17" font="13">PCWP @ 6 </text>
<text top="661" left="904" width="38" height="17" font="13">h after </text>
<text top="678" left="904" width="55" height="17" font="13">treatment </text>
<text top="695" left="904" width="63" height="17" font="13">Comparativ</text>
<text top="712" left="904" width="14" height="17" font="13">e: </text>
<text top="729" left="904" width="39" height="17" font="13">Global </text>
<text top="747" left="904" width="40" height="17" font="13">clinical </text>
<text top="764" left="904" width="36" height="17" font="13">status </text>
<text top="781" left="904" width="68" height="17" font="13">(independen</text>
<text top="592" left="988" width="46" height="17" font="13">Efficacy </text>
<text top="609" left="988" width="64" height="17" font="13">trial:            </text>
<text top="626" left="988" width="39" height="17" font="13">Global </text>
<text top="643" left="988" width="40" height="17" font="13">clinical </text>
<text top="661" left="988" width="40" height="17" font="13">status. </text>
<text top="678" left="988" width="43" height="17" font="13">Clinical </text>
<text top="695" left="988" width="56" height="17" font="13">symptoms</text>
<text top="712" left="988" width="27" height="17" font="13">.       </text>
<text top="729" left="988" width="34" height="17" font="13">Other </text>
<text top="747" left="988" width="51" height="17" font="13">hemodyn</text>
<text top="764" left="988" width="29" height="17" font="13">amic </text>
<text top="781" left="988" width="48" height="17" font="13">measure</text>
<text top="592" left="1061" width="139" height="17" font="13">N/A &lt;1y </text>
<text top="592" left="1154" width="67" height="17" font="13">(10 </text>
<text top="609" left="1131" width="21" height="17" font="13">mo </text>
<text top="626" left="1131" width="47" height="17" font="13">enrollme</text>
<text top="643" left="1131" width="49" height="17" font="13">nt 10/96-</text>
<text top="661" left="1131" width="35" height="17" font="13">7/97); </text>
<text top="678" left="1131" width="51" height="17" font="13">Compara</text>
<text top="695" left="1131" width="53" height="17" font="13">tive trial:  </text>
<text top="712" left="1131" width="46" height="17" font="13">68-73% </text>
<text top="729" left="1131" width="39" height="17" font="13">rx with </text>
<text top="747" left="1131" width="53" height="17" font="13">nesiritide </text>
<text top="764" left="1131" width="41" height="17" font="13">x 1-2 d </text>
<text top="781" left="1131" width="46" height="17" font="13">14-21% </text>
<text top="592" left="1198" width="80" height="17" font="13">Efficacy trial:   </text>
<text top="609" left="1198" width="48" height="17" font="13">PCWP - </text>
<text top="626" left="1198" width="63" height="17" font="13">6.0±7.2mm</text>
<text top="643" left="1198" width="73" height="17" font="13">Hg (@ 0.015 </text>
<text top="661" left="1198" width="73" height="17" font="13">g/kg/min) vs. </text>
<text top="678" left="1198" width="8" height="17" font="13">- </text>
<text top="695" left="1198" width="63" height="17" font="13">9.6±6.2mm</text>
<text top="712" left="1198" width="67" height="17" font="13">Hg (@ 0.03 </text>
<text top="729" left="1198" width="73" height="17" font="13">g/kg/min) vs. </text>
<text top="747" left="1198" width="70" height="17" font="13">+2.0±7.2mm</text>
<text top="764" left="1198" width="81" height="17" font="13">Hg (placebo)   </text>
<text top="781" left="1198" width="73" height="17" font="13">Comparative </text>
<text top="592" left="1286" width="60" height="17" font="13">Subjective </text>
<text top="609" left="1286" width="65" height="17" font="13">measureme</text>
<text top="626" left="1286" width="70" height="17" font="13">nts of global </text>
<text top="643" left="1286" width="40" height="17" font="13">clinical </text>
<text top="661" left="1286" width="60" height="17" font="13">status and </text>
<text top="678" left="1286" width="40" height="17" font="13">clinical </text>
<text top="695" left="1286" width="63" height="17" font="13">symptoms. </text>
<text top="712" left="1286" width="69" height="17" font="13">Background </text>
<text top="729" left="1286" width="46" height="17" font="13">medical </text>
<text top="747" left="1286" width="65" height="17" font="13">therapy not </text>
<text top="764" left="1286" width="80" height="17" font="13">reported.         </text>
<text top="781" left="1286" width="73" height="17" font="13">3. Change in </text>
<text top="592" left="1372" width="81" height="17" font="13">Asymptomatic/</text>
<text top="609" left="1372" width="35" height="17" font="13">mildly </text>
<text top="626" left="1372" width="72" height="17" font="13">symptomatic </text>
<text top="643" left="1372" width="83" height="17" font="13">hypotension.    </text>
<text top="661" left="1372" width="36" height="17" font="13">NSVT </text>
<text top="678" left="1372" width="77" height="17" font="13">(Comparative </text>
<text top="695" left="1372" width="31" height="17" font="13">trial). </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">166</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="279" width="62" height="17" font="13">discontinue</text>
<text top="72" left="279" width="63" height="17" font="13">d; diuretics </text>
<text top="89" left="279" width="67" height="17" font="13">were held 4 </text>
<text top="106" left="279" width="52" height="17" font="13">h before, </text>
<text top="124" left="279" width="65" height="17" font="13">during, and </text>
<text top="141" left="279" width="49" height="17" font="13">6 h after </text>
<text top="158" left="279" width="61" height="17" font="13">study drug </text>
<text top="175" left="279" width="59" height="17" font="13">infusion in </text>
<text top="192" left="279" width="46" height="17" font="13">Efficacy </text>
<text top="210" left="279" width="27" height="17" font="13">trial. </text>
<text top="55" left="359" width="62" height="17" font="13">, 100 (0.03 </text>
<text top="72" left="359" width="68" height="17" font="13">mg/kg/min). </text>
<text top="89" left="359" width="3" height="17" font="13"> </text>
<text top="106" left="359" width="90" height="17" font="13">Efficacy trial: 42 </text>
<text top="124" left="359" width="50" height="17" font="13">placebo, </text>
<text top="141" left="359" width="73" height="17" font="13">Comparative </text>
<text top="158" left="359" width="55" height="17" font="13">Trial: 102 </text>
<text top="175" left="359" width="65" height="17" font="13">standard rx </text>
<text top="192" left="359" width="70" height="17" font="13">(investigator </text>
<text top="210" left="359" width="94" height="17" font="13">choice of up to 2 </text>
<text top="227" left="359" width="68" height="17" font="13">IV agents--- </text>
<text top="244" left="359" width="57" height="17" font="13">milrinone, </text>
<text top="261" left="359" width="71" height="17" font="13">dobutamine, </text>
<text top="278" left="359" width="87" height="17" font="13">nitroglycerin, or </text>
<text top="296" left="359" width="77" height="17" font="13">nitroprusside, </text>
<text top="313" left="359" width="59" height="17" font="13">along with </text>
<text top="330" left="359" width="73" height="17" font="13">diuretics and </text>
<text top="347" left="359" width="75" height="17" font="13">other oral HF </text>
<text top="365" left="359" width="77" height="17" font="13">medications). </text>
<text top="55" left="554" width="69" height="17" font="13">2, SBP, &gt;90 </text>
<text top="72" left="554" width="43" height="17" font="13">mmHg. </text>
<text top="55" left="742" width="42" height="17" font="13">e: 92% </text>
<text top="72" left="742" width="52" height="17" font="13">NYHA III-</text>
<text top="89" left="742" width="18" height="17" font="13">IV. </text>
<text top="55" left="904" width="7" height="17" font="13">t </text>
<text top="72" left="904" width="69" height="17" font="13">assessment </text>
<text top="89" left="904" width="54" height="17" font="13">by pt and </text>
<text top="106" left="904" width="70" height="17" font="13">investigator, </text>
<text top="124" left="904" width="41" height="17" font="13">5-point </text>
<text top="141" left="904" width="35" height="17" font="13">scale: </text>
<text top="158" left="904" width="53" height="17" font="13">markedly </text>
<text top="175" left="904" width="38" height="17" font="13">better, </text>
<text top="192" left="904" width="55" height="17" font="13">better, no </text>
<text top="210" left="904" width="47" height="17" font="13">change, </text>
<text top="227" left="904" width="54" height="17" font="13">worse, or </text>
<text top="244" left="904" width="53" height="17" font="13">markedly </text>
<text top="261" left="904" width="44" height="17" font="13">worse). </text>
<text top="278" left="904" width="43" height="17" font="13">Clinical </text>
<text top="296" left="904" width="59" height="17" font="13">symptoms </text>
<text top="313" left="904" width="54" height="17" font="13">(dyspnea </text>
<text top="330" left="904" width="68" height="17" font="13">and fatigue, </text>
<text top="347" left="904" width="48" height="17" font="13">jointly pt </text>
<text top="365" left="904" width="24" height="17" font="13">and </text>
<text top="382" left="904" width="66" height="17" font="13">investigator </text>
<text top="399" left="904" width="66" height="17" font="13">assessment</text>
<text top="416" left="904" width="47" height="17" font="13">, 3 point </text>
<text top="433" left="904" width="35" height="17" font="13">scale: </text>
<text top="451" left="904" width="57" height="17" font="13">improved, </text>
<text top="468" left="904" width="64" height="17" font="13">no change, </text>
<text top="485" left="904" width="58" height="17" font="13">or worse). </text>
<text top="55" left="988" width="253" height="17" font="13">ments. x </text>
<text top="55" left="1140" width="133" height="17" font="13">3-5d, </text>
<text top="72" left="1131" width="48" height="17" font="13">9-14% x </text>
<text top="89" left="1131" width="21" height="17" font="13">5d. </text>
<text top="55" left="1198" width="61" height="17" font="13">trial: none. </text>
<text top="72" left="1198" width="3" height="17" font="13"> </text>
<text top="89" left="1198" width="73" height="17" font="13">Efficacy trial: </text>
<text top="106" left="1198" width="48" height="17" font="13">p&lt;0.001 </text>
<text top="124" left="1198" width="53" height="17" font="13">(pairwise </text>
<text top="141" left="1198" width="25" height="17" font="13">with </text>
<text top="158" left="1198" width="54" height="17" font="13">placebo). </text>
<text top="175" left="1198" width="3" height="17" font="13"> </text>
<text top="192" left="1198" width="3" height="17" font="13"> </text>
<text top="55" left="1286" width="63" height="17" font="13">PCWP is a </text>
<text top="72" left="1286" width="55" height="17" font="13">surrogate </text>
<text top="89" left="1286" width="54" height="17" font="13">outcome. </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">167</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="70" height="17" font="13">Vasodilation </text>
<text top="72" left="54" width="33" height="17" font="13">in the </text>
<text top="89" left="54" width="68" height="17" font="13">Managemen</text>
<text top="106" left="54" width="55" height="17" font="13">t of Acute </text>
<text top="124" left="54" width="29" height="17" font="13">CHF </text>
<text top="141" left="54" width="51" height="17" font="13">(VMAC), </text>
<text top="158" left="54" width="34" height="17" font="13">2002. </text>
<text top="175" left="54" width="55" height="17" font="14">11911755</text>
<text top="175" left="109" width="3" height="17" font="13"> </text>
<text top="192" left="54" width="32" height="17" font="13">(345) </text>
<text top="55" left="139" width="69" height="17" font="13">To compare </text>
<text top="72" left="139" width="66" height="17" font="13">the efficacy </text>
<text top="89" left="139" width="74" height="17" font="13">and safety of </text>
<text top="106" left="139" width="67" height="17" font="13">intravenous </text>
<text top="124" left="139" width="56" height="17" font="13">nesiritide, </text>
<text top="141" left="139" width="67" height="17" font="13">intravenous </text>
<text top="158" left="139" width="73" height="17" font="13">nitroglycerin, </text>
<text top="175" left="139" width="74" height="17" font="13">and placebo. </text>
<text top="55" left="229" width="123" height="17" font="13">RCT Diuretics </text>
<text top="72" left="279" width="55" height="17" font="13">86%,        </text>
<text top="89" left="279" width="63" height="17" font="13">ACEI 60%, </text>
<text top="106" left="279" width="60" height="17" font="13">ARB 11%, </text>
<text top="124" left="279" width="27" height="17" font="13">beta </text>
<text top="141" left="279" width="49" height="17" font="13">blockers </text>
<text top="158" left="279" width="55" height="17" font="13">33%, oral </text>
<text top="175" left="279" width="44" height="17" font="13">nitrates </text>
<text top="192" left="279" width="61" height="17" font="13">35%, CCB </text>
<text top="210" left="279" width="31" height="17" font="13">14%, </text>
<text top="227" left="279" width="42" height="17" font="13">digoxin </text>
<text top="244" left="279" width="31" height="17" font="13">60%, </text>
<text top="261" left="279" width="47" height="17" font="13">warfarin </text>
<text top="278" left="279" width="59" height="17" font="13">33%, ASA </text>
<text top="296" left="279" width="31" height="17" font="13">45%, </text>
<text top="313" left="279" width="39" height="17" font="13">statins </text>
<text top="330" left="279" width="32" height="17" font="13">25%. </text>
<text top="55" left="359" width="24" height="17" font="13">489 </text>
<text top="72" left="359" width="3" height="17" font="13"> </text>
<text top="89" left="359" width="81" height="17" font="13">204(nesiritide) </text>
<text top="106" left="359" width="3" height="17" font="13"> </text>
<text top="124" left="359" width="24" height="17" font="13">143 </text>
<text top="141" left="359" width="105" height="17" font="13">(nitroglycerin)         </text>
<text top="158" left="359" width="79" height="17" font="13">142 (placebo) </text>
<text top="55" left="473" width="52" height="17" font="13">Ischemic </text>
<text top="72" left="473" width="28" height="17" font="13">55% </text>
<text top="55" left="554" width="66" height="17" font="13">Dyspena at </text>
<text top="72" left="554" width="62" height="17" font="13">rest due to </text>
<text top="89" left="554" width="74" height="17" font="13">decompensat</text>
<text top="106" left="554" width="46" height="17" font="13">ed CHF </text>
<text top="124" left="554" width="42" height="17" font="13">Severe </text>
<text top="141" left="554" width="44" height="17" font="13">enough </text>
<text top="158" left="554" width="64" height="17" font="13">dyspnea to </text>
<text top="175" left="554" width="42" height="17" font="13">require </text>
<text top="192" left="554" width="71" height="17" font="13">hospitalizatio</text>
<text top="210" left="554" width="37" height="17" font="13">n &amp; IV </text>
<text top="227" left="554" width="82" height="17" font="13">therapy.           </text>
<text top="244" left="554" width="55" height="17" font="13">A cardiac </text>
<text top="261" left="554" width="64" height="17" font="13">etiology for </text>
<text top="278" left="554" width="75" height="17" font="13">dyspnea was </text>
<text top="296" left="554" width="66" height="17" font="13">established </text>
<text top="313" left="554" width="73" height="17" font="13">by estimated </text>
<text top="330" left="554" width="73" height="17" font="13">or measured </text>
<text top="347" left="554" width="66" height="17" font="13">elevation of </text>
<text top="365" left="554" width="74" height="17" font="13">cardiac filling </text>
<text top="382" left="554" width="57" height="17" font="13">pressures </text>
<text top="399" left="554" width="69" height="17" font="13">(PCWP &gt;20 </text>
<text top="416" left="554" width="56" height="17" font="13">mm Hg in </text>
<text top="433" left="554" width="70" height="17" font="13">catheterized </text>
<text top="451" left="554" width="69" height="17" font="13">pts) and &gt; 2 </text>
<text top="468" left="554" width="34" height="17" font="13">of the </text>
<text top="485" left="554" width="73" height="17" font="13">following: (a) </text>
<text top="502" left="554" width="49" height="17" font="13">JVD, (b) </text>
<text top="519" left="554" width="55" height="17" font="13">PND or 2-</text>
<text top="537" left="554" width="34" height="17" font="13">pillow </text>
<text top="554" left="554" width="59" height="17" font="13">orthopnea </text>
<text top="571" left="554" width="62" height="17" font="13">within 72 h </text>
<text top="588" left="554" width="71" height="17" font="13">before study </text>
<text top="606" left="554" width="52" height="17" font="13">entry, (c) </text>
<text top="623" left="554" width="60" height="17" font="13">abdominal </text>
<text top="640" left="554" width="60" height="17" font="13">discomfort </text>
<text top="657" left="554" width="38" height="17" font="13">due to </text>
<text top="674" left="554" width="64" height="17" font="13">mesenteric </text>
<text top="692" left="554" width="66" height="17" font="13">congestion, </text>
<text top="709" left="554" width="73" height="17" font="13">or (d) a CXR </text>
<text top="726" left="554" width="59" height="17" font="13">consistent </text>
<text top="743" left="554" width="25" height="17" font="13">with </text>
<text top="760" left="554" width="74" height="17" font="13">decompensat</text>
<text top="778" left="554" width="53" height="17" font="13">ed CHF.  </text>
<text top="55" left="644" width="76" height="17" font="13">SBP &lt;90 mm </text>
<text top="72" left="644" width="23" height="17" font="13">Hg, </text>
<text top="89" left="644" width="66" height="17" font="13">cardiogenic </text>
<text top="106" left="644" width="50" height="17" font="13">shock or </text>
<text top="124" left="644" width="43" height="17" font="13">volume </text>
<text top="141" left="644" width="80" height="17" font="13">depletion, any </text>
<text top="158" left="644" width="76" height="17" font="13">condition that </text>
<text top="175" left="644" width="36" height="17" font="13">would </text>
<text top="192" left="644" width="80" height="17" font="13">contraindicate </text>
<text top="210" left="644" width="32" height="17" font="13">an IV </text>
<text top="227" left="644" width="66" height="17" font="13">vasodilator, </text>
<text top="244" left="644" width="42" height="17" font="13">acutely </text>
<text top="261" left="644" width="50" height="17" font="13">unstable </text>
<text top="278" left="644" width="77" height="17" font="13">clinical status </text>
<text top="296" left="644" width="80" height="17" font="13">that would not </text>
<text top="313" left="644" width="68" height="17" font="13">permit a 3 h </text>
<text top="330" left="644" width="46" height="17" font="13">placebo </text>
<text top="347" left="644" width="78" height="17" font="13">period, use of </text>
<text top="365" left="644" width="15" height="17" font="13">IV </text>
<text top="382" left="644" width="70" height="17" font="13">nitroglycerin </text>
<text top="399" left="644" width="77" height="17" font="13">that could not </text>
<text top="416" left="644" width="69" height="17" font="13">be withheld, </text>
<text top="433" left="644" width="66" height="17" font="13">mechanical </text>
<text top="451" left="644" width="62" height="17" font="13">ventilation, </text>
<text top="468" left="644" width="24" height="17" font="13">and </text>
<text top="485" left="644" width="63" height="17" font="13">anticipated </text>
<text top="502" left="644" width="59" height="17" font="13">survival of </text>
<text top="519" left="644" width="59" height="17" font="13">&lt;30-35 d.  </text>
<text top="55" left="742" width="35" height="17" font="13">100% </text>
<text top="72" left="742" width="66" height="17" font="13">NYHA IV at </text>
<text top="89" left="742" width="40" height="17" font="13">time of </text>
<text top="106" left="742" width="61" height="17" font="13">presentatio</text>
<text top="124" left="742" width="69" height="17" font="13">n/entry or at </text>
<text top="141" left="742" width="29" height="17" font="13">least </text>
<text top="158" left="742" width="66" height="17" font="13">dyspneic at </text>
<text top="175" left="742" width="55" height="17" font="13">rest, 84% </text>
<text top="192" left="742" width="43" height="17" font="13">chronic </text>
<text top="210" left="742" width="67" height="17" font="13">NYHA III-IV </text>
<text top="227" left="742" width="46" height="17" font="13">(prior to </text>
<text top="244" left="742" width="64" height="17" font="13">decompens</text>
<text top="261" left="742" width="66" height="17" font="13">ation), 19% </text>
<text top="278" left="742" width="28" height="17" font="13">SBP </text>
<text top="296" left="742" width="64" height="17" font="13">&lt;100mmHg</text>
<text top="313" left="742" width="7" height="17" font="13">. </text>
<text top="55" left="825" width="53" height="17" font="13">NYHA IV </text>
<text top="72" left="825" width="14" height="17" font="13">at </text>
<text top="89" left="825" width="61" height="17" font="13">presentatio</text>
<text top="106" left="825" width="64" height="17" font="13">n (dyspnea </text>
<text top="124" left="825" width="45" height="17" font="13">at rest). </text>
<text top="55" left="904" width="78" height="17" font="13">PCWP            </text>
<text top="72" left="904" width="38" height="17" font="13">Pt self-</text>
<text top="89" left="904" width="69" height="17" font="13">assessment </text>
<text top="106" left="904" width="64" height="17" font="13">of dyspnea </text>
<text top="124" left="904" width="50" height="17" font="13">@ 3 h of </text>
<text top="141" left="904" width="61" height="17" font="13">study drug </text>
<text top="158" left="904" width="60" height="17" font="13">infusion (3 </text>
<text top="175" left="904" width="66" height="17" font="13">point scale: </text>
<text top="192" left="904" width="57" height="17" font="13">improved, </text>
<text top="210" left="904" width="64" height="17" font="13">no change, </text>
<text top="227" left="904" width="44" height="17" font="13">worse). </text>
<text top="55" left="988" width="53" height="17" font="13">Comparis</text>
<text top="72" left="988" width="23" height="17" font="13">ons </text>
<text top="89" left="988" width="50" height="17" font="13">between </text>
<text top="106" left="988" width="53" height="17" font="13">nesiritide </text>
<text top="124" left="988" width="24" height="17" font="13">and </text>
<text top="141" left="988" width="53" height="17" font="13">nitroglyce</text>
<text top="158" left="988" width="55" height="17" font="13">rin:           </text>
<text top="175" left="988" width="50" height="17" font="13">Onset of </text>
<text top="192" left="988" width="51" height="17" font="13">effect on </text>
<text top="210" left="988" width="47" height="17" font="13">PCWP.  </text>
<text top="227" left="988" width="52" height="17" font="13">Effect on </text>
<text top="244" left="988" width="56" height="17" font="13">PCWP @ </text>
<text top="261" left="988" width="60" height="17" font="13">24 hr after </text>
<text top="278" left="988" width="41" height="17" font="13">start of </text>
<text top="296" left="988" width="33" height="17" font="13">study </text>
<text top="313" left="988" width="35" height="17" font="13">drug.  </text>
<text top="330" left="988" width="25" height="17" font="13">Self-</text>
<text top="347" left="988" width="55" height="17" font="13">assessed </text>
<text top="365" left="988" width="50" height="17" font="13">dyspnea </text>
<text top="382" left="988" width="24" height="17" font="13">and </text>
<text top="399" left="988" width="36" height="17" font="13">global </text>
<text top="416" left="988" width="40" height="17" font="13">clinical </text>
<text top="433" left="988" width="40" height="17" font="13">status. </text>
<text top="451" left="988" width="42" height="17" font="13">Overall </text>
<text top="468" left="988" width="36" height="17" font="13">safety </text>
<text top="485" left="988" width="44" height="17" font="13">profile.  </text>
<text top="502" left="988" width="39" height="17" font="13">Use of </text>
<text top="519" left="988" width="47" height="17" font="13">other IV </text>
<text top="537" left="988" width="51" height="17" font="13">vasoactiv</text>
<text top="554" left="988" width="10" height="17" font="13">e </text>
<text top="571" left="988" width="55" height="17" font="13">agents or </text>
<text top="588" left="988" width="66" height="17" font="13">diuretics.     </text>
<text top="606" left="988" width="58" height="17" font="13">Effects on </text>
<text top="623" left="988" width="32" height="17" font="13">other </text>
<text top="640" left="988" width="51" height="17" font="13">hemodyn</text>
<text top="657" left="988" width="29" height="17" font="13">amic </text>
<text top="674" left="988" width="56" height="17" font="13">variables. </text>
<text top="55" left="1061" width="118" height="17" font="13">N/A Enrollme</text>
<text top="72" left="1131" width="14" height="17" font="13">nt </text>
<text top="89" left="1131" width="47" height="17" font="13">October </text>
<text top="106" left="1131" width="55" height="17" font="13">1999 and </text>
<text top="124" left="1131" width="25" height="17" font="13">July </text>
<text top="141" left="1131" width="52" height="17" font="13">2000 (10 </text>
<text top="158" left="1131" width="28" height="17" font="13">mo); </text>
<text top="175" left="1131" width="33" height="17" font="13">study </text>
<text top="192" left="1131" width="28" height="17" font="13">drug </text>
<text top="210" left="1131" width="49" height="17" font="13">infusion, </text>
<text top="227" left="1131" width="44" height="17" font="13">median </text>
<text top="244" left="1131" width="44" height="17" font="13">time 24-</text>
<text top="261" left="1131" width="31" height="17" font="13">25 h. </text>
<text top="55" left="1198" width="75" height="17" font="13">PCWP at 3 h </text>
<text top="72" left="1198" width="81" height="17" font="13">(mean (SD))    </text>
<text top="89" left="1198" width="58" height="17" font="13">Nesiritide: </text>
<text top="106" left="1198" width="57" height="17" font="13">−5.8 (6.5) </text>
<text top="124" left="1198" width="72" height="17" font="13">mmHg*         </text>
<text top="141" left="1198" width="68" height="17" font="13">Nitroglycerin</text>
<text top="158" left="1198" width="63" height="17" font="13">: −3.8 (5.3) </text>
<text top="175" left="1198" width="81" height="17" font="13">mmHg             </text>
<text top="192" left="1198" width="69" height="17" font="13">Placebo: −2 </text>
<text top="210" left="1198" width="82" height="17" font="13">(4.2) mmHg     </text>
<text top="227" left="1198" width="69" height="17" font="13">ABSOLUTE </text>
<text top="244" left="1198" width="71" height="17" font="13">BENEFIT IN </text>
<text top="261" left="1198" width="40" height="17" font="13">PCWP </text>
<text top="278" left="1198" width="71" height="17" font="13">Nesiritde vs. </text>
<text top="296" left="1198" width="59" height="17" font="13">Placebo : -</text>
<text top="313" left="1198" width="64" height="17" font="13">3.8 mmHg. </text>
<text top="330" left="1198" width="3" height="17" font="13"> </text>
<text top="347" left="1198" width="46" height="17" font="13">*p&lt;0.05 </text>
<text top="365" left="1198" width="62" height="17" font="13">(compared </text>
<text top="382" left="1198" width="25" height="17" font="13">with </text>
<text top="399" left="1198" width="50" height="17" font="13">placebo, </text>
<text top="416" left="1198" width="58" height="17" font="13">compared </text>
<text top="433" left="1198" width="25" height="17" font="13">with </text>
<text top="451" left="1198" width="70" height="17" font="13">nitroglycerin)</text>
<text top="468" left="1198" width="7" height="17" font="13">. </text>
<text top="485" left="1198" width="3" height="17" font="13"> </text>
<text top="502" left="1198" width="24" height="17" font="13">N/A </text>
<text top="55" left="1286" width="60" height="17" font="13">Subjective </text>
<text top="72" left="1286" width="65" height="17" font="13">measureme</text>
<text top="89" left="1286" width="70" height="17" font="13">nts of global </text>
<text top="106" left="1286" width="40" height="17" font="13">clinical </text>
<text top="124" left="1286" width="60" height="17" font="13">status and </text>
<text top="141" left="1286" width="40" height="17" font="13">clinical </text>
<text top="158" left="1286" width="66" height="17" font="13">symptoms.  </text>
<text top="175" left="1286" width="59" height="17" font="13">Change in </text>
<text top="192" left="1286" width="63" height="17" font="13">PCWP is a </text>
<text top="210" left="1286" width="55" height="17" font="13">surrogate </text>
<text top="227" left="1286" width="54" height="17" font="13">outcome. </text>
<text top="55" left="1372" width="70" height="17" font="13">Generalized </text>
<text top="72" left="1372" width="83" height="17" font="13">headache (8% </text>
<text top="89" left="1372" width="87" height="17" font="13">nesiritide group </text>
<text top="106" left="1372" width="47" height="17" font="13">vs. 20% </text>
<text top="124" left="1372" width="70" height="17" font="13">nitroglycerin </text>
<text top="141" left="1372" width="60" height="17" font="13">group)       </text>
<text top="158" left="1372" width="81" height="17" font="13">Asymptomatic </text>
<text top="175" left="1372" width="53" height="17" font="13">(8%) and </text>
<text top="192" left="1372" width="72" height="17" font="13">symptomatic </text>
<text top="210" left="1372" width="29" height="17" font="13">(4%) </text>
<text top="227" left="1372" width="83" height="17" font="13">hypotension in </text>
<text top="244" left="1372" width="53" height="17" font="13">nesiritide </text>
<text top="261" left="1372" width="38" height="17" font="13">group. </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">168</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="68" height="17" font="13">Prospective </text>
<text top="72" left="54" width="62" height="17" font="13">Randomize</text>
<text top="89" left="54" width="70" height="17" font="13">d Outcomes </text>
<text top="106" left="54" width="49" height="17" font="13">Study of </text>
<text top="124" left="54" width="44" height="17" font="13">Acutely </text>
<text top="141" left="54" width="66" height="17" font="13">Decompens</text>
<text top="158" left="54" width="27" height="17" font="13">ated </text>
<text top="175" left="54" width="65" height="17" font="13">Congestive </text>
<text top="192" left="54" width="66" height="17" font="13">HF Treated </text>
<text top="210" left="54" width="57" height="17" font="13">Initially as </text>
<text top="227" left="54" width="68" height="17" font="13">Outpts With </text>
<text top="244" left="54" width="55" height="17" font="13">Nesiritide </text>
<text top="261" left="54" width="68" height="17" font="13">(PROACTIO</text>
<text top="278" left="54" width="70" height="17" font="13">N), Peacock </text>
<text top="296" left="54" width="41" height="17" font="13">IV WF, </text>
<text top="313" left="54" width="34" height="17" font="13">2005. </text>
<text top="330" left="54" width="55" height="17" font="14">16183441</text>
<text top="330" left="109" width="3" height="17" font="13"> </text>
<text top="347" left="54" width="32" height="17" font="13">(346) </text>
<text top="55" left="139" width="68" height="17" font="13">To evaluate </text>
<text top="72" left="139" width="57" height="17" font="13">the safety </text>
<text top="89" left="139" width="69" height="17" font="13">and efficacy </text>
<text top="106" left="139" width="75" height="17" font="13">of a standard </text>
<text top="124" left="139" width="27" height="17" font="13">care </text>
<text top="141" left="139" width="55" height="17" font="13">treatment </text>
<text top="158" left="139" width="73" height="17" font="13">regimen with </text>
<text top="175" left="139" width="67" height="17" font="13">the addition </text>
<text top="192" left="139" width="48" height="17" font="13">of either </text>
<text top="210" left="139" width="67" height="17" font="13">nesiritide or </text>
<text top="227" left="139" width="59" height="17" font="13">placebo in </text>
<text top="244" left="139" width="62" height="17" font="13">ED/OU pts </text>
<text top="261" left="139" width="25" height="17" font="13">with </text>
<text top="278" left="139" width="70" height="17" font="13">decompensa</text>
<text top="296" left="139" width="44" height="17" font="13">ted HF. </text>
<text top="55" left="229" width="123" height="17" font="13">RCT Diuretics </text>
<text top="72" left="279" width="55" height="17" font="13">77%,        </text>
<text top="89" left="279" width="63" height="17" font="13">ACEI 58%, </text>
<text top="106" left="279" width="60" height="17" font="13">ARB 14%, </text>
<text top="124" left="279" width="27" height="17" font="13">beta </text>
<text top="141" left="279" width="49" height="17" font="13">blockers </text>
<text top="158" left="279" width="31" height="17" font="13">46%, </text>
<text top="175" left="279" width="57" height="17" font="13">aldosteron</text>
<text top="192" left="279" width="10" height="17" font="13">e </text>
<text top="210" left="279" width="60" height="17" font="13">antagonist </text>
<text top="227" left="279" width="61" height="17" font="13">14%, CCB </text>
<text top="244" left="279" width="59" height="17" font="13">22%,         </text>
<text top="261" left="279" width="42" height="17" font="13">digoxin </text>
<text top="278" left="279" width="28" height="17" font="13">48% </text>
<text top="296" left="279" width="66" height="17" font="13">placebo vs. </text>
<text top="313" left="279" width="28" height="17" font="13">34% </text>
<text top="330" left="279" width="70" height="17" font="13">nesiritide,     </text>
<text top="347" left="279" width="44" height="17" font="13">nitrates </text>
<text top="365" left="279" width="59" height="17" font="13">45%,         </text>
<text top="382" left="279" width="39" height="17" font="13">statins </text>
<text top="399" left="279" width="66" height="17" font="13">29%,           </text>
<text top="416" left="279" width="60" height="17" font="13">ASA 46%. </text>
<text top="55" left="359" width="24" height="17" font="13">237 </text>
<text top="72" left="359" width="3" height="17" font="13"> </text>
<text top="89" left="359" width="24" height="17" font="13">120 </text>
<text top="106" left="359" width="3" height="17" font="13"> </text>
<text top="124" left="359" width="24" height="17" font="13">117 </text>
<text top="55" left="473" width="152" height="17" font="13">N/A 1. </text>
<text top="55" left="568" width="72" height="17" font="13">Pt </text>
<text top="72" left="554" width="72" height="17" font="13">presented to </text>
<text top="89" left="554" width="56" height="17" font="13">ED with a </text>
<text top="106" left="554" width="64" height="17" font="13">medical Hx </text>
<text top="124" left="554" width="49" height="17" font="13">with HF, </text>
<text top="141" left="554" width="59" height="17" font="13">along with </text>
<text top="158" left="554" width="76" height="17" font="13">fluid overload </text>
<text top="175" left="554" width="64" height="17" font="13">or elevated </text>
<text top="192" left="554" width="74" height="17" font="13">cardiac filling </text>
<text top="210" left="554" width="74" height="17" font="13">pressures by </text>
<text top="227" left="554" width="40" height="17" font="13">clinical </text>
<text top="244" left="554" width="72" height="17" font="13">assessment, </text>
<text top="261" left="554" width="64" height="17" font="13">dyspnea at </text>
<text top="278" left="554" width="64" height="17" font="13">rest or with </text>
<text top="296" left="554" width="46" height="17" font="13">minimal </text>
<text top="313" left="554" width="47" height="17" font="13">exertion </text>
<text top="330" left="554" width="64" height="17" font="13">(defined as </text>
<text top="347" left="554" width="61" height="17" font="13">walking 20 </text>
<text top="365" left="554" width="42" height="17" font="13">ft), and </text>
<text top="382" left="554" width="54" height="17" font="13">judged to </text>
<text top="399" left="554" width="76" height="17" font="13">require &gt;12 h </text>
<text top="416" left="554" width="59" height="17" font="13">of hospital </text>
<text top="433" left="554" width="62" height="17" font="13">therapy for </text>
<text top="451" left="554" width="27" height="17" font="13">HF.  </text>
<text top="468" left="554" width="68" height="17" font="13">2. Evidence </text>
<text top="485" left="554" width="50" height="17" font="13">of HF as </text>
<text top="502" left="554" width="44" height="17" font="13">primary </text>
<text top="519" left="554" width="59" height="17" font="13">etiology of </text>
<text top="537" left="554" width="70" height="17" font="13">the dyspnea </text>
<text top="554" left="554" width="66" height="17" font="13">required &gt;2 </text>
<text top="571" left="554" width="34" height="17" font="13">of the </text>
<text top="588" left="554" width="69" height="17" font="13">following: a) </text>
<text top="606" left="554" width="55" height="17" font="13">PND or 2-</text>
<text top="623" left="554" width="34" height="17" font="13">pillow </text>
<text top="640" left="554" width="59" height="17" font="13">orthopnea </text>
<text top="657" left="554" width="62" height="17" font="13">within 72 h </text>
<text top="674" left="554" width="59" height="17" font="13">before the </text>
<text top="692" left="554" width="74" height="17" font="13">start of study </text>
<text top="709" left="554" width="76" height="17" font="13">drug; b) JVD; </text>
<text top="726" left="554" width="74" height="17" font="13">c) abdominal </text>
<text top="743" left="554" width="63" height="17" font="13">symptoms, </text>
<text top="760" left="554" width="66" height="17" font="13">as manifest </text>
<text top="778" left="554" width="16" height="17" font="13">by </text>
<text top="55" left="644" width="60" height="17" font="13">1. Pt not a </text>
<text top="72" left="644" width="75" height="17" font="13">candidate for </text>
<text top="89" left="644" width="67" height="17" font="13">observation </text>
<text top="106" left="644" width="31" height="17" font="13">(e.g., </text>
<text top="124" left="644" width="83" height="17" font="13">presented with </text>
<text top="141" left="644" width="76" height="17" font="13">any condition </text>
<text top="158" left="644" width="79" height="17" font="13">that obviously </text>
<text top="175" left="644" width="58" height="17" font="13">mandated </text>
<text top="192" left="644" width="46" height="17" font="13">hospital </text>
<text top="210" left="644" width="62" height="17" font="13">admission, </text>
<text top="227" left="644" width="79" height="17" font="13">such as acute </text>
<text top="244" left="644" width="35" height="17" font="13">MI, or </text>
<text top="261" left="644" width="69" height="17" font="13">requirement </text>
<text top="278" left="644" width="66" height="17" font="13">for invasive </text>
<text top="296" left="644" width="75" height="17" font="13">monitoring or </text>
<text top="313" left="644" width="66" height="17" font="13">mechanical </text>
<text top="330" left="644" width="62" height="17" font="13">ventilation, </text>
<text top="347" left="644" width="52" height="17" font="13">including </text>
<text top="365" left="644" width="47" height="17" font="13">BPAP);  </text>
<text top="382" left="644" width="66" height="17" font="13">2. SBP &lt;90 </text>
<text top="399" left="644" width="46" height="17" font="13">mmHg;  </text>
<text top="416" left="644" width="79" height="17" font="13">3. Admitted to </text>
<text top="433" left="644" width="41" height="17" font="13">the ED </text>
<text top="451" left="644" width="78" height="17" font="13">primarily for a </text>
<text top="468" left="644" width="59" height="17" font="13">diagnostic </text>
<text top="485" left="644" width="59" height="17" font="13">evaluation </text>
<text top="502" left="644" width="76" height="17" font="13">(e.g., rule out </text>
<text top="519" left="644" width="40" height="17" font="13">ACS);  </text>
<text top="537" left="644" width="71" height="17" font="13">4. Receiving </text>
<text top="554" left="644" width="43" height="17" font="13">chronic </text>
<text top="571" left="644" width="51" height="17" font="13">dialysis;  </text>
<text top="588" left="644" width="83" height="17" font="13">5. Had cardiac </text>
<text top="606" left="644" width="48" height="17" font="13">markers </text>
<text top="623" left="644" width="68" height="17" font="13">indicative of </text>
<text top="640" left="644" width="63" height="17" font="13">myocardial </text>
<text top="657" left="644" width="56" height="17" font="13">necrosis;  </text>
<text top="674" left="644" width="59" height="17" font="13">6. Medical </text>
<text top="692" left="644" width="69" height="17" font="13">condition so </text>
<text top="709" left="644" width="81" height="17" font="13">severe that 30 </text>
<text top="726" left="644" width="81" height="17" font="13">d survival was </text>
<text top="743" left="644" width="51" height="17" font="13">unlikely;  </text>
<text top="760" left="644" width="59" height="17" font="13">7. Medical </text>
<text top="778" left="644" width="53" height="17" font="13">condition </text>
<text top="55" left="742" width="66" height="17" font="13">61% NYHA </text>
<text top="72" left="742" width="43" height="17" font="13">III-IV at </text>
<text top="89" left="742" width="53" height="17" font="13">baseline. </text>
<text top="55" left="825" width="66" height="17" font="13">Dyspnea at </text>
<text top="72" left="825" width="64" height="17" font="13">rest or with </text>
<text top="89" left="825" width="48" height="17" font="13">&lt;20 feet </text>
<text top="106" left="825" width="60" height="17" font="13">ambulation</text>
<text top="124" left="825" width="7" height="17" font="13">. </text>
<text top="55" left="904" width="41" height="17" font="13">No pre-</text>
<text top="72" left="904" width="44" height="17" font="13">defined </text>
<text top="89" left="904" width="44" height="17" font="13">primary </text>
<text top="106" left="904" width="77" height="17" font="13">endpoints.      </text>
<text top="124" left="904" width="46" height="17" font="13">Efficacy </text>
<text top="141" left="904" width="57" height="17" font="13">measures </text>
<text top="158" left="904" width="49" height="17" font="13">included </text>
<text top="175" left="904" width="59" height="17" font="13">admission </text>
<text top="192" left="904" width="34" height="17" font="13">to the </text>
<text top="210" left="904" width="46" height="17" font="13">hospital </text>
<text top="227" left="904" width="49" height="17" font="13">after the </text>
<text top="244" left="904" width="61" height="17" font="13">index visit, </text>
<text top="261" left="904" width="70" height="17" font="13">readmission </text>
<text top="278" left="904" width="62" height="17" font="13">within 30 d </text>
<text top="296" left="904" width="41" height="17" font="13">for any </text>
<text top="313" left="904" width="44" height="17" font="13">reason, </text>
<text top="330" left="904" width="51" height="17" font="13">length of </text>
<text top="347" left="904" width="59" height="17" font="13">stay in the </text>
<text top="365" left="904" width="49" height="17" font="13">hospital, </text>
<text top="382" left="904" width="69" height="17" font="13">assessment </text>
<text top="399" left="904" width="67" height="17" font="13">of dyspnea, </text>
<text top="416" left="904" width="24" height="17" font="13">and </text>
<text top="433" left="904" width="51" height="17" font="13">resource </text>
<text top="451" left="904" width="79" height="17" font="13">utilization.       </text>
<text top="468" left="904" width="38" height="17" font="13">Safety </text>
<text top="485" left="904" width="57" height="17" font="13">measures </text>
<text top="502" left="904" width="53" height="17" font="13">included: </text>
<text top="519" left="904" width="61" height="17" font="13">vital signs, </text>
<text top="537" left="904" width="26" height="17" font="13">AEs </text>
<text top="554" left="904" width="64" height="17" font="13">(defined as </text>
<text top="571" left="904" width="45" height="17" font="13">any pre-</text>
<text top="588" left="904" width="45" height="17" font="13">existing </text>
<text top="606" left="904" width="46" height="17" font="13">medical </text>
<text top="623" left="904" width="57" height="17" font="13">event that </text>
<text top="640" left="904" width="71" height="17" font="13">worsened or </text>
<text top="657" left="904" width="49" height="17" font="13">any new </text>
<text top="674" left="904" width="46" height="17" font="13">medical </text>
<text top="692" left="904" width="57" height="17" font="13">event that </text>
<text top="709" left="904" width="51" height="17" font="13">occurred </text>
<text top="726" left="904" width="38" height="17" font="13">during </text>
<text top="743" left="904" width="63" height="17" font="13">administrati</text>
<text top="760" left="904" width="64" height="17" font="13">on of study </text>
<text top="778" left="904" width="32" height="17" font="13">drug, </text>
<text top="55" left="988" width="208" height="17" font="13">N/A N/A 11 </text>
<text top="55" left="1148" width="69" height="17" font="13">mo </text>
<text top="72" left="1131" width="47" height="17" font="13">enrollme</text>
<text top="89" left="1131" width="51" height="17" font="13">nt period </text>
<text top="106" left="1131" width="32" height="17" font="13">(3/01-</text>
<text top="124" left="1131" width="35" height="17" font="13">1/02); </text>
<text top="141" left="1131" width="34" height="17" font="13">mean </text>
<text top="158" left="1131" width="33" height="17" font="13">study </text>
<text top="175" left="1131" width="28" height="17" font="13">drug </text>
<text top="192" left="1131" width="46" height="17" font="13">infusion </text>
<text top="210" left="1131" width="51" height="17" font="13">time ~20 </text>
<text top="227" left="1131" width="48" height="17" font="13">h (same </text>
<text top="244" left="1131" width="45" height="17" font="13">for both </text>
<text top="261" left="1131" width="49" height="17" font="13">groups); </text>
<text top="278" left="1131" width="24" height="17" font="13">30d </text>
<text top="296" left="1131" width="53" height="17" font="13">follow-up </text>
<text top="313" left="1131" width="41" height="17" font="13">period. </text>
<text top="55" left="1198" width="31" height="17" font="13">Total </text>
<text top="72" left="1198" width="74" height="17" font="13">hospital LOS </text>
<text top="89" left="1198" width="45" height="17" font="13">through </text>
<text top="106" left="1198" width="58" height="17" font="13">study Day </text>
<text top="124" left="1198" width="72" height="17" font="13">30 excluding </text>
<text top="141" left="1198" width="57" height="17" font="13">index visit </text>
<text top="158" left="1198" width="38" height="17" font="13">(days) </text>
<text top="175" left="1198" width="79" height="17" font="13">Mean + SD:    </text>
<text top="192" left="1198" width="59" height="17" font="13">7.1 + 4.25 </text>
<text top="210" left="1198" width="61" height="17" font="13">(placebo + </text>
<text top="227" left="1198" width="51" height="17" font="13">standard </text>
<text top="244" left="1198" width="71" height="17" font="13">care) vs. 3.1 </text>
<text top="261" left="1198" width="38" height="17" font="13">+ 2.20 </text>
<text top="278" left="1198" width="67" height="17" font="13">(nesiritide + </text>
<text top="296" left="1198" width="51" height="17" font="13">standard </text>
<text top="313" left="1198" width="49" height="17" font="13">care); 2. </text>
<text top="330" left="1198" width="50" height="17" font="13">Subjects </text>
<text top="347" left="1198" width="62" height="17" font="13">readmitted </text>
<text top="365" left="1198" width="61" height="17" font="13">after index </text>
<text top="382" left="1198" width="71" height="17" font="13">hospitalizatio</text>
<text top="399" left="1198" width="69" height="17" font="13">n, excluding </text>
<text top="416" left="1198" width="59" height="17" font="13">those who </text>
<text top="433" left="1198" width="71" height="17" font="13">died or were </text>
<text top="451" left="1198" width="36" height="17" font="13">lost to </text>
<text top="468" left="1198" width="59" height="17" font="13">follow- up: </text>
<text top="485" left="1198" width="28" height="17" font="13">23% </text>
<text top="502" left="1198" width="61" height="17" font="13">(placebo + </text>
<text top="519" left="1198" width="51" height="17" font="13">standard </text>
<text top="537" left="1198" width="72" height="17" font="13">care) vs. 9% </text>
<text top="554" left="1198" width="67" height="17" font="13">(nesiritide + </text>
<text top="571" left="1198" width="51" height="17" font="13">standard </text>
<text top="588" left="1198" width="35" height="17" font="13">care). </text>
<text top="606" left="1198" width="3" height="17" font="13"> </text>
<text top="623" left="1198" width="79" height="17" font="13">1. p=0.032      </text>
<text top="640" left="1198" width="62" height="17" font="13">2. p=0.049 </text>
<text top="657" left="1198" width="3" height="17" font="13"> </text>
<text top="674" left="1198" width="24" height="17" font="13">N/A </text>
<text top="55" left="1286" width="44" height="17" font="13"> No pre-</text>
<text top="72" left="1286" width="44" height="17" font="13">defined </text>
<text top="89" left="1286" width="69" height="17" font="13">primary end-</text>
<text top="106" left="1286" width="43" height="17" font="13">points;  </text>
<text top="124" left="1286" width="61" height="17" font="13">49% of pts </text>
<text top="141" left="1286" width="68" height="17" font="13">were NYHA </text>
<text top="158" left="1286" width="32" height="17" font="13">I-II or </text>
<text top="175" left="1286" width="66" height="17" font="13">without any </text>
<text top="192" left="1286" width="55" height="17" font="13">Hx of HF. </text>
<text top="55" left="1372" width="81" height="17" font="13">Asymptomatic </text>
<text top="72" left="1372" width="70" height="17" font="13">hypotension </text>
<text top="89" left="1372" width="57" height="17" font="13">(10% with </text>
<text top="106" left="1372" width="68" height="17" font="13">nesiritide vs </text>
<text top="124" left="1372" width="46" height="17" font="13">3% with </text>
<text top="141" left="1372" width="50" height="17" font="13">placebo, </text>
<text top="158" left="1372" width="49" height="17" font="13">p=0.03). </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">169</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="554" width="64" height="17" font="13">discomfort, </text>
<text top="72" left="554" width="61" height="17" font="13">decreased </text>
<text top="89" left="554" width="65" height="17" font="13">appetite, or </text>
<text top="106" left="554" width="44" height="17" font="13">nausea </text>
<text top="124" left="554" width="71" height="17" font="13">attributed by </text>
<text top="141" left="554" width="21" height="17" font="13">the </text>
<text top="158" left="554" width="66" height="17" font="13">investigator </text>
<text top="175" left="554" width="68" height="17" font="13">to be due to </text>
<text top="192" left="554" width="73" height="17" font="13">hepatosplanc</text>
<text top="210" left="554" width="26" height="17" font="13">hnic </text>
<text top="227" left="554" width="66" height="17" font="13">congestion; </text>
<text top="244" left="554" width="41" height="17" font="13">d) &gt;5lb </text>
<text top="261" left="554" width="66" height="17" font="13">weight gain </text>
<text top="278" left="554" width="34" height="17" font="13">in the </text>
<text top="296" left="554" width="50" height="17" font="13">previous </text>
<text top="313" left="554" width="55" height="17" font="13">month; e) </text>
<text top="330" left="554" width="55" height="17" font="13">CXR with </text>
<text top="347" left="554" width="46" height="17" font="13">findings </text>
<text top="365" left="554" width="68" height="17" font="13">indicative of </text>
<text top="382" left="554" width="49" height="17" font="13">HF; or f) </text>
<text top="399" left="554" width="61" height="17" font="13">pulmonary </text>
<text top="416" left="554" width="33" height="17" font="13">rales. </text>
<text top="55" left="644" width="50" height="17" font="13">(such as </text>
<text top="72" left="644" width="66" height="17" font="13">cardiogenic </text>
<text top="89" left="644" width="50" height="17" font="13">shock or </text>
<text top="106" left="644" width="43" height="17" font="13">volume </text>
<text top="124" left="644" width="81" height="17" font="13">depletion) that </text>
<text top="141" left="644" width="77" height="17" font="13">contraindicate</text>
<text top="158" left="644" width="62" height="17" font="13">d use of IV </text>
<text top="175" left="644" width="89" height="17" font="13">vasodilatators.   </text>
<text top="192" left="644" width="79" height="17" font="13">8. If within 2 h </text>
<text top="210" left="644" width="59" height="17" font="13">before the </text>
<text top="227" left="644" width="74" height="17" font="13">start of study </text>
<text top="244" left="644" width="28" height="17" font="13">drug </text>
<text top="261" left="644" width="80" height="17" font="13">administration </text>
<text top="278" left="644" width="79" height="17" font="13">pt received IV </text>
<text top="296" left="644" width="79" height="17" font="13">vasodilatators </text>
<text top="313" left="644" width="74" height="17" font="13">or oral ACEI; </text>
<text top="330" left="644" width="71" height="17" font="13">or they were </text>
<text top="347" left="644" width="76" height="17" font="13">anticipated to </text>
<text top="365" left="644" width="76" height="17" font="13">require either </text>
<text top="382" left="644" width="84" height="17" font="13">IV vasodilators </text>
<text top="399" left="644" width="81" height="17" font="13">during the first </text>
<text top="416" left="644" width="69" height="17" font="13">3 h after the </text>
<text top="433" left="644" width="74" height="17" font="13">start of study </text>
<text top="451" left="644" width="66" height="17" font="13">drug or oral </text>
<text top="468" left="644" width="70" height="17" font="13">ACEI during </text>
<text top="485" left="644" width="84" height="17" font="13">the first 30 min </text>
<text top="502" left="644" width="76" height="17" font="13">after the start </text>
<text top="519" left="644" width="78" height="17" font="13">of study drug. </text>
<text top="55" left="904" width="62" height="17" font="13">whether or </text>
<text top="72" left="904" width="62" height="17" font="13">not related </text>
<text top="89" left="904" width="46" height="17" font="13">to study </text>
<text top="106" left="904" width="60" height="17" font="13">drug), and </text>
<text top="124" left="904" width="34" height="17" font="13">SAEs </text>
<text top="141" left="904" width="64" height="17" font="13">(defined as </text>
<text top="158" left="904" width="50" height="17" font="13">AEs that </text>
<text top="175" left="904" width="50" height="17" font="13">were life-</text>
<text top="192" left="904" width="68" height="17" font="13">threatening, </text>
<text top="210" left="904" width="60" height="17" font="13">resulted in </text>
<text top="227" left="904" width="64" height="17" font="13">hospitalizati</text>
<text top="244" left="904" width="35" height="17" font="13">on, or </text>
<text top="261" left="904" width="42" height="17" font="13">death). </text>
<text top="537" left="54" width="41" height="17" font="13">Risk of </text>
<text top="555" left="54" width="62" height="17" font="13">Worsening </text>
<text top="572" left="54" width="36" height="17" font="13">Renal </text>
<text top="589" left="54" width="51" height="17" font="13">Function </text>
<text top="606" left="54" width="28" height="17" font="13">With </text>
<text top="624" left="54" width="68" height="17" font="13">Nesiritide in </text>
<text top="641" left="54" width="49" height="17" font="13">Pts With </text>
<text top="658" left="54" width="44" height="17" font="13">Acutely </text>
<text top="675" left="54" width="66" height="17" font="13">Decompens</text>
<text top="692" left="54" width="51" height="17" font="13">ated HF, </text>
<text top="710" left="54" width="49" height="17" font="13">Sackner-</text>
<text top="727" left="54" width="55" height="17" font="13">Bernstein </text>
<text top="744" left="54" width="56" height="17" font="13">JD, 2005. </text>
<text top="761" left="54" width="55" height="17" font="14">15781736</text>
<text top="761" left="109" width="3" height="17" font="13"> </text>
<text top="778" left="54" width="32" height="17" font="13">(347) </text>
<text top="537" left="139" width="18" height="17" font="13">To </text>
<text top="555" left="139" width="69" height="17" font="13">investigated </text>
<text top="572" left="139" width="51" height="17" font="13">the renal </text>
<text top="589" left="139" width="53" height="17" font="13">effects of </text>
<text top="606" left="139" width="69" height="17" font="13">nesiritide as </text>
<text top="624" left="139" width="73" height="17" font="13">treatment for </text>
<text top="641" left="139" width="40" height="17" font="13">ADHF. </text>
<text top="537" left="229" width="31" height="17" font="13">Meta-</text>
<text top="555" left="229" width="29" height="17" font="13">analy</text>
<text top="572" left="229" width="18" height="17" font="13">sis </text>
<text top="537" left="279" width="49" height="17" font="13">Variable </text>
<text top="555" left="279" width="27" height="17" font="13">(see </text>
<text top="572" left="279" width="43" height="17" font="13">original </text>
<text top="589" left="279" width="35" height="17" font="13">RCTs </text>
<text top="606" left="279" width="62" height="17" font="13">included in </text>
<text top="624" left="279" width="31" height="17" font="13">meta-</text>
<text top="641" left="279" width="55" height="17" font="13">analysis). </text>
<text top="537" left="359" width="31" height="17" font="13">1269 </text>
<text top="555" left="359" width="3" height="17" font="13"> </text>
<text top="572" left="359" width="24" height="17" font="13">797 </text>
<text top="589" left="359" width="3" height="17" font="13"> </text>
<text top="606" left="359" width="24" height="17" font="13">472 </text>
<text top="537" left="473" width="51" height="17" font="13">N/A (see </text>
<text top="555" left="473" width="43" height="17" font="13">original </text>
<text top="572" left="473" width="39" height="17" font="13">RCTs) </text>
<text top="537" left="554" width="62" height="17" font="13">Five RCTs </text>
<text top="555" left="554" width="55" height="17" font="13">(1288 pts </text>
<text top="572" left="554" width="77" height="17" font="13">were enrolled </text>
<text top="589" left="554" width="24" height="17" font="13">and </text>
<text top="606" left="554" width="71" height="17" font="13">randomized, </text>
<text top="624" left="554" width="31" height="17" font="13">1269 </text>
<text top="641" left="554" width="61" height="17" font="13">underwent </text>
<text top="658" left="554" width="69" height="17" font="13">assessment </text>
<text top="675" left="554" width="44" height="17" font="13">of renal </text>
<text top="692" left="554" width="51" height="17" font="13">function) </text>
<text top="710" left="554" width="70" height="17" font="13">reported the </text>
<text top="727" left="554" width="53" height="17" font="13">effects of </text>
<text top="744" left="554" width="70" height="17" font="13">nesiritide on </text>
<text top="761" left="554" width="77" height="17" font="13">renal function </text>
<text top="778" left="554" width="75" height="17" font="13">as measured </text>
<text top="537" left="644" width="196" height="17" font="13">N/A See </text>
<text top="537" left="767" width="116" height="17" font="13">original </text>
<text top="555" left="742" width="35" height="17" font="13">RCTs </text>
<text top="537" left="825" width="25" height="17" font="13">See </text>
<text top="555" left="825" width="43" height="17" font="13">original </text>
<text top="572" left="825" width="35" height="17" font="13">RCTs </text>
<text top="537" left="904" width="44" height="17" font="13">Studies </text>
<text top="555" left="904" width="30" height="17" font="13">were </text>
<text top="572" left="904" width="70" height="17" font="13">reviewed for </text>
<text top="589" left="904" width="21" height="17" font="13">the </text>
<text top="606" left="904" width="69" height="17" font="13">incidence of </text>
<text top="624" left="904" width="59" height="17" font="13">worsening </text>
<text top="641" left="904" width="31" height="17" font="13">renal </text>
<text top="658" left="904" width="46" height="17" font="13">function </text>
<text top="675" left="904" width="67" height="17" font="13">(increase in </text>
<text top="692" left="904" width="52" height="17" font="13">SCr &gt;0.5 </text>
<text top="710" left="904" width="38" height="17" font="13">mg/dL </text>
<text top="727" left="904" width="66" height="17" font="13">recorded at </text>
<text top="744" left="904" width="50" height="17" font="13">any time </text>
<text top="761" left="904" width="58" height="17" font="13">during the </text>
<text top="778" left="904" width="71" height="17" font="13">input portion </text>
<text top="537" left="988" width="24" height="17" font="13">N/A </text>
<text top="537" left="1061" width="24" height="17" font="13">N/A </text>
<text top="537" left="1131" width="24" height="17" font="13">N/A </text>
<text top="537" left="1198" width="52" height="17" font="13">WRF:      </text>
<text top="555" left="1198" width="28" height="17" font="13">21% </text>
<text top="572" left="1198" width="61" height="17" font="13">(nesiritide) </text>
<text top="589" left="1198" width="47" height="17" font="13">vs. 15% </text>
<text top="606" left="1198" width="55" height="17" font="13">(control).  </text>
<text top="624" left="1198" width="32" height="17" font="13">WRF </text>
<text top="641" left="1198" width="51" height="17" font="13">requiring </text>
<text top="658" left="1198" width="46" height="17" font="13">medical </text>
<text top="675" left="1198" width="81" height="17" font="13">intervention:    </text>
<text top="692" left="1198" width="28" height="17" font="13">11% </text>
<text top="710" left="1198" width="61" height="17" font="13">(nesiritide) </text>
<text top="727" left="1198" width="40" height="17" font="13">vs. 4% </text>
<text top="744" left="1198" width="52" height="17" font="13">(control)  </text>
<text top="761" left="1198" width="32" height="17" font="13">WRF </text>
<text top="778" left="1198" width="51" height="17" font="13">requiring </text>
<text top="537" left="1286" width="31" height="17" font="13">Meta-</text>
<text top="555" left="1286" width="51" height="17" font="13">analysis  </text>
<text top="572" left="1286" width="59" height="17" font="13">Inability to </text>
<text top="589" left="1286" width="36" height="17" font="13">adjust </text>
<text top="606" left="1286" width="63" height="17" font="13">statistically </text>
<text top="624" left="1286" width="18" height="17" font="13">for </text>
<text top="641" left="1286" width="64" height="17" font="13">differences </text>
<text top="658" left="1286" width="44" height="17" font="13">in other </text>
<text top="675" left="1286" width="40" height="17" font="13">factors </text>
<text top="692" left="1286" width="44" height="17" font="13">beyond </text>
<text top="710" left="1286" width="55" height="17" font="13">treatment </text>
<text top="727" left="1286" width="35" height="17" font="13">group </text>
<text top="744" left="1286" width="66" height="17" font="13">assignment </text>
<text top="761" left="1286" width="57" height="17" font="13">that could </text>
<text top="778" left="1286" width="30" height="17" font="13">have </text>
<text top="537" left="1372" width="27" height="17" font="13"> N/A </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">170</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="554" width="37" height="17" font="13">by the </text>
<text top="72" left="554" width="71" height="17" font="13">frequency of </text>
<text top="89" left="554" width="57" height="17" font="13">increased </text>
<text top="106" left="554" width="61" height="17" font="13">(SCr) &gt;0.5 </text>
<text top="124" left="554" width="38" height="17" font="13">mg/dL </text>
<text top="141" left="554" width="65" height="17" font="13">forming the </text>
<text top="158" left="554" width="46" height="17" font="13">basis of </text>
<text top="175" left="554" width="31" height="17" font="13">meta-</text>
<text top="192" left="554" width="55" height="17" font="13">analyses. </text>
<text top="55" left="904" width="65" height="17" font="13">of the trial). </text>
<text top="55" left="1198" width="71" height="17" font="13">hemodialysis</text>
<text top="72" left="1198" width="68" height="17" font="13">: 2% vs 2%. </text>
<text top="89" left="1198" width="3" height="17" font="13"> </text>
<text top="106" left="1198" width="80" height="17" font="13">1) p=0.001      </text>
<text top="124" left="1198" width="80" height="17" font="13">2) p=0.03        </text>
<text top="141" left="1198" width="56" height="17" font="13">3) p=0.71 </text>
<text top="158" left="1198" width="3" height="17" font="13"> </text>
<text top="175" left="1198" width="32" height="17" font="13">1) RR</text>
<text top="181" left="1231" width="12" height="11" font="19">MH</text>
<text top="175" left="1243" width="7" height="17" font="13">: </text>
<text top="192" left="1198" width="59" height="17" font="13">1.54; 95% </text>
<text top="210" left="1198" width="60" height="17" font="13">CI: 1.19 to </text>
<text top="227" left="1198" width="73" height="17" font="13">1.98;         2) </text>
<text top="244" left="1198" width="18" height="17" font="13">RR</text>
<text top="250" left="1216" width="12" height="11" font="19">MH</text>
<text top="244" left="1229" width="38" height="17" font="13">: 2.29; </text>
<text top="261" left="1198" width="47" height="17" font="13">95% CI: </text>
<text top="278" left="1198" width="79" height="17" font="13">1.07-4.89;       </text>
<text top="296" left="1198" width="61" height="17" font="13">3) 95% CI: </text>
<text top="313" left="1198" width="62" height="17" font="13">0.50- 2.76; </text>
<text top="55" left="1286" width="59" height="17" font="13">influenced </text>
<text top="72" left="1286" width="21" height="17" font="13">the </text>
<text top="89" left="1286" width="67" height="17" font="13">developmen</text>
<text top="106" left="1286" width="51" height="17" font="13">t of renal </text>
<text top="124" left="1286" width="69" height="17" font="13">dysfunction. </text>
<text top="141" left="1286" width="54" height="17" font="13">WRF is a </text>
<text top="158" left="1286" width="55" height="17" font="13">surrogate </text>
<text top="175" left="1286" width="60" height="17" font="13">marker for </text>
<text top="192" left="1286" width="40" height="17" font="13">clinical </text>
<text top="210" left="1286" width="54" height="17" font="13">outcome. </text>
<text top="331" left="54" width="62" height="17" font="13">Short-term </text>
<text top="348" left="54" width="41" height="17" font="13">Risk of </text>
<text top="365" left="54" width="36" height="17" font="13">Death </text>
<text top="382" left="54" width="29" height="17" font="13">After </text>
<text top="400" left="54" width="60" height="17" font="13">Treatment </text>
<text top="417" left="54" width="28" height="17" font="13">With </text>
<text top="434" left="54" width="55" height="17" font="13">Nesiritide </text>
<text top="451" left="54" width="18" height="17" font="13">for </text>
<text top="469" left="54" width="66" height="17" font="13">Decompens</text>
<text top="486" left="54" width="47" height="17" font="13">ated HF </text>
<text top="503" left="54" width="53" height="17" font="13">A Pooled </text>
<text top="520" left="54" width="63" height="17" font="13">Analysis of </text>
<text top="537" left="54" width="38" height="17" font="13">RCTs, </text>
<text top="555" left="54" width="49" height="17" font="13">Sackner-</text>
<text top="572" left="54" width="55" height="17" font="13">Bernstein </text>
<text top="589" left="54" width="56" height="17" font="13">JD, 2005. </text>
<text top="606" left="54" width="55" height="17" font="14">15840865</text>
<text top="606" left="109" width="3" height="17" font="13"> </text>
<text top="624" left="54" width="32" height="17" font="13">(348) </text>
<text top="331" left="139" width="18" height="17" font="13">To </text>
<text top="348" left="139" width="62" height="17" font="13">investigate </text>
<text top="365" left="139" width="70" height="17" font="13">the safety of </text>
<text top="382" left="139" width="53" height="17" font="13">nesiritide </text>
<text top="400" left="139" width="57" height="17" font="13">relative to </text>
<text top="417" left="139" width="69" height="17" font="13">noninotrope-</text>
<text top="434" left="139" width="60" height="17" font="13">based con </text>
<text top="451" left="139" width="21" height="17" font="13">trol </text>
<text top="469" left="139" width="57" height="17" font="13">therapies, </text>
<text top="486" left="139" width="50" height="17" font="13">primarily </text>
<text top="503" left="139" width="72" height="17" font="13">consisting of </text>
<text top="520" left="139" width="64" height="17" font="13">diuretics or </text>
<text top="537" left="139" width="72" height="17" font="13">vasodilators. </text>
<text top="331" left="229" width="31" height="17" font="13">Meta-</text>
<text top="348" left="229" width="29" height="17" font="13">analy</text>
<text top="365" left="229" width="18" height="17" font="13">sis </text>
<text top="331" left="279" width="49" height="17" font="13">Variable </text>
<text top="348" left="279" width="27" height="17" font="13">(see </text>
<text top="365" left="279" width="43" height="17" font="13">original </text>
<text top="382" left="279" width="35" height="17" font="13">RCTs </text>
<text top="400" left="279" width="62" height="17" font="13">included in </text>
<text top="417" left="279" width="31" height="17" font="13">meta-</text>
<text top="434" left="279" width="55" height="17" font="13">analysis). </text>
<text top="331" left="359" width="24" height="17" font="13">862 </text>
<text top="348" left="359" width="3" height="17" font="13"> </text>
<text top="365" left="359" width="24" height="17" font="13">485 </text>
<text top="382" left="359" width="3" height="17" font="13"> </text>
<text top="400" left="359" width="24" height="17" font="13">377 </text>
<text top="331" left="473" width="51" height="17" font="13">N/A (see </text>
<text top="348" left="473" width="43" height="17" font="13">original </text>
<text top="365" left="473" width="39" height="17" font="13">RCTs) </text>
<text top="331" left="554" width="72" height="17" font="13">Randomized </text>
<text top="348" left="554" width="70" height="17" font="13">double-blind </text>
<text top="365" left="554" width="66" height="17" font="13">study of pts </text>
<text top="382" left="554" width="68" height="17" font="13">with acutely </text>
<text top="400" left="554" width="74" height="17" font="13">decompensat</text>
<text top="417" left="554" width="40" height="17" font="13">ed HF, </text>
<text top="434" left="554" width="44" height="17" font="13">therapy </text>
<text top="451" left="554" width="74" height="17" font="13">administered </text>
<text top="469" left="554" width="52" height="17" font="13">as single </text>
<text top="486" left="554" width="67" height="17" font="13">infusion (&gt;6 </text>
<text top="503" left="554" width="66" height="17" font="13">h), inotrope </text>
<text top="520" left="554" width="21" height="17" font="13">not </text>
<text top="537" left="554" width="75" height="17" font="13">mandated as </text>
<text top="555" left="554" width="68" height="17" font="13">control, and </text>
<text top="572" left="554" width="77" height="17" font="13">reported 30 d </text>
<text top="589" left="554" width="50" height="17" font="13">mortality </text>
<text top="606" left="554" width="53" height="17" font="13">(NSGET, </text>
<text top="624" left="554" width="42" height="17" font="13">VMAC, </text>
<text top="641" left="554" width="73" height="17" font="13">PROACTION</text>
<text top="658" left="554" width="11" height="17" font="13">). </text>
<text top="331" left="644" width="223" height="17" font="13">N/A Variable: </text>
<text top="348" left="742" width="46" height="17" font="13">60-98% </text>
<text top="365" left="742" width="52" height="17" font="13">NYHA III-</text>
<text top="382" left="742" width="58" height="17" font="13">IV, overall </text>
<text top="400" left="742" width="66" height="17" font="13">79% NYHA </text>
<text top="417" left="742" width="33" height="17" font="13">III-IV. </text>
<text top="331" left="825" width="25" height="17" font="13">See </text>
<text top="348" left="825" width="43" height="17" font="13">original </text>
<text top="365" left="825" width="35" height="17" font="13">RCTs </text>
<text top="331" left="904" width="27" height="17" font="13">30 d </text>
<text top="348" left="904" width="70" height="17" font="13">survival was </text>
<text top="365" left="904" width="72" height="17" font="13">assessed by </text>
<text top="382" left="904" width="35" height="17" font="13">meta- </text>
<text top="400" left="904" width="48" height="17" font="13">analysis </text>
<text top="417" left="904" width="43" height="17" font="13">using a </text>
<text top="434" left="904" width="70" height="17" font="13">fixed-effects </text>
<text top="451" left="904" width="61" height="17" font="13">model and </text>
<text top="469" left="904" width="27" height="17" font="13">time-</text>
<text top="486" left="904" width="62" height="17" font="13">dependent </text>
<text top="503" left="904" width="39" height="17" font="13">risk by </text>
<text top="520" left="904" width="42" height="17" font="13">Kaplan-</text>
<text top="537" left="904" width="34" height="17" font="13">Meier </text>
<text top="555" left="904" width="48" height="17" font="13">analysis </text>
<text top="572" left="904" width="51" height="17" font="13">with Cox </text>
<text top="589" left="904" width="68" height="17" font="13">proportional </text>
<text top="606" left="904" width="47" height="17" font="13">hazards </text>
<text top="624" left="904" width="61" height="17" font="13">regression </text>
<text top="641" left="904" width="57" height="17" font="13">modeling. </text>
<text top="331" left="988" width="24" height="17" font="13">N/A </text>
<text top="331" left="1061" width="24" height="17" font="13">N/A </text>
<text top="331" left="1131" width="24" height="17" font="13">N/A </text>
<text top="331" left="1198" width="42" height="17" font="13">1) 30 d </text>
<text top="348" left="1198" width="81" height="17" font="13">mortality:         </text>
<text top="365" left="1198" width="31" height="17" font="13">7.2% </text>
<text top="382" left="1198" width="61" height="17" font="13">(nesiritide) </text>
<text top="400" left="1198" width="51" height="17" font="13">vs. 4.0% </text>
<text top="417" left="1198" width="52" height="17" font="13">(control). </text>
<text top="434" left="1198" width="3" height="17" font="13"> </text>
<text top="451" left="1198" width="66" height="17" font="13">1) p=0.059. </text>
<text top="469" left="1198" width="3" height="17" font="13"> </text>
<text top="486" left="1198" width="70" height="17" font="13">1) RR: 1.74; </text>
<text top="503" left="1198" width="47" height="17" font="13">95% CI: </text>
<text top="520" left="1198" width="59" height="17" font="13">0.97-3.12. </text>
<text top="331" left="1286" width="39" height="17" font="13">1) The </text>
<text top="348" left="1286" width="49" height="17" font="13">NSGET, </text>
<text top="365" left="1286" width="66" height="17" font="13">VMAC, and </text>
<text top="382" left="1286" width="64" height="17" font="13">PROACTIO</text>
<text top="400" left="1286" width="55" height="17" font="13">N studies </text>
<text top="417" left="1286" width="72" height="17" font="13">were not de- </text>
<text top="434" left="1286" width="53" height="17" font="13">signed to </text>
<text top="451" left="1286" width="61" height="17" font="13">definitively </text>
<text top="469" left="1286" width="58" height="17" font="13">determine </text>
<text top="486" left="1286" width="47" height="17" font="13">whether </text>
<text top="503" left="1286" width="65" height="17" font="13">nesiritide is </text>
<text top="520" left="1286" width="62" height="17" font="13">associated </text>
<text top="537" left="1286" width="61" height="17" font="13">with risk of </text>
<text top="555" left="1286" width="38" height="17" font="13">death, </text>
<text top="572" left="1286" width="51" height="17" font="13">although </text>
<text top="589" left="1286" width="30" height="17" font="13">each </text>
<text top="606" left="1286" width="66" height="17" font="13">prospectivel</text>
<text top="624" left="1286" width="68" height="17" font="13">y monitored </text>
<text top="641" left="1286" width="58" height="17" font="13">for deaths </text>
<text top="658" left="1286" width="51" height="17" font="13">following </text>
<text top="675" left="1286" width="51" height="17" font="13">therapy.  </text>
<text top="692" left="1286" width="61" height="17" font="13">2) None of </text>
<text top="710" left="1286" width="73" height="17" font="13">the 3 studies </text>
<text top="727" left="1286" width="52" height="17" font="13">collected </text>
<text top="744" left="1286" width="53" height="17" font="13">complete </text>
<text top="761" left="1286" width="64" height="17" font="13">information </text>
<text top="778" left="1286" width="61" height="17" font="13">on the use </text>
<text top="331" left="1372" width="7" height="17" font="13">  </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">171</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="1286" width="70" height="17" font="13">of additional </text>
<text top="72" left="1286" width="69" height="17" font="13">medications </text>
<text top="89" left="1286" width="14" height="17" font="13">or </text>
<text top="106" left="1286" width="65" height="17" font="13">procedures </text>
<text top="124" left="1286" width="66" height="17" font="13">through the </text>
<text top="141" left="1286" width="63" height="17" font="13">30 d follow-</text>
<text top="158" left="1286" width="58" height="17" font="13">up period. </text>
<text top="175" left="1286" width="53" height="17" font="13">(possible </text>
<text top="192" left="1286" width="68" height="17" font="13">confounders</text>
<text top="210" left="1286" width="14" height="17" font="13">).  </text>
<text top="227" left="1286" width="37" height="17" font="13">3) It is </text>
<text top="244" left="1286" width="72" height="17" font="13">possible that </text>
<text top="261" left="1286" width="73" height="17" font="13">these results </text>
<text top="278" left="1286" width="59" height="17" font="13">are due to </text>
<text top="296" left="1286" width="50" height="17" font="13">chance.  </text>
<text top="318" left="54" width="29" height="17" font="13">BNP-</text>
<text top="335" left="54" width="50" height="17" font="13">CARDS, </text>
<text top="352" left="54" width="47" height="17" font="13">Witteles </text>
<text top="370" left="54" width="60" height="17" font="13">RM, 2007. </text>
<text top="387" left="54" width="55" height="17" font="14">17980248</text>
<text top="387" left="109" width="3" height="17" font="13"> </text>
<text top="404" left="54" width="32" height="17" font="13">(349) </text>
<text top="318" left="139" width="68" height="17" font="13">To evaluate </text>
<text top="335" left="139" width="74" height="17" font="13">the impact of </text>
<text top="352" left="139" width="70" height="17" font="13">nesiritide on </text>
<text top="370" left="139" width="31" height="17" font="13">renal </text>
<text top="387" left="139" width="59" height="17" font="13">function in </text>
<text top="404" left="139" width="45" height="17" font="13">pts with </text>
<text top="421" left="139" width="33" height="17" font="13">acute </text>
<text top="438" left="139" width="70" height="17" font="13">decompensa</text>
<text top="456" left="139" width="64" height="17" font="13">ted HF and </text>
<text top="473" left="139" width="49" height="17" font="13">baseline </text>
<text top="490" left="139" width="31" height="17" font="13">renal </text>
<text top="507" left="139" width="69" height="17" font="13">dysfunction. </text>
<text top="318" left="229" width="101" height="17" font="13">RCT Beta </text>
<text top="335" left="279" width="43" height="17" font="13">blocker </text>
<text top="352" left="279" width="52" height="17" font="13">65%,       </text>
<text top="370" left="279" width="61" height="17" font="13">ACEI/ARB </text>
<text top="387" left="279" width="31" height="17" font="13">49%, </text>
<text top="404" left="279" width="57" height="17" font="13">aldosteron</text>
<text top="421" left="279" width="10" height="17" font="13">e </text>
<text top="438" left="279" width="60" height="17" font="13">antagonist </text>
<text top="456" left="279" width="72" height="17" font="13">13%,             </text>
<text top="473" left="279" width="42" height="17" font="13">digoxin </text>
<text top="490" left="279" width="43" height="17" font="13">(26%),  </text>
<text top="507" left="279" width="58" height="17" font="13">amiodaron</text>
<text top="525" left="279" width="42" height="17" font="13">e (21% </text>
<text top="542" left="279" width="53" height="17" font="13">nesiritide </text>
<text top="559" left="279" width="40" height="17" font="13">vs. 6% </text>
<text top="576" left="279" width="71" height="17" font="13">placebo),      </text>
<text top="593" left="279" width="74" height="17" font="13">CCB 24%,     </text>
<text top="611" left="279" width="66" height="17" font="13">hydralazine </text>
<text top="628" left="279" width="25" height="17" font="13">(5% </text>
<text top="645" left="279" width="53" height="17" font="13">nesiritide </text>
<text top="662" left="279" width="47" height="17" font="13">vs. 25% </text>
<text top="679" left="279" width="54" height="17" font="13">placebo). </text>
<text top="318" left="359" width="17" height="17" font="13">75 </text>
<text top="335" left="359" width="3" height="17" font="13"> </text>
<text top="352" left="359" width="17" height="17" font="13">39 </text>
<text top="370" left="359" width="3" height="17" font="13"> </text>
<text top="387" left="359" width="17" height="17" font="13">36 </text>
<text top="318" left="473" width="61" height="17" font="13">CAD: 77% </text>
<text top="335" left="473" width="61" height="17" font="13">(nesiritide) </text>
<text top="352" left="473" width="47" height="17" font="13">vs. 56% </text>
<text top="370" left="473" width="52" height="17" font="13">(control)  </text>
<text top="318" left="554" width="37" height="17" font="13">Newly </text>
<text top="335" left="554" width="76" height="17" font="13">admitted with </text>
<text top="352" left="554" width="74" height="17" font="13">primary dx of </text>
<text top="370" left="554" width="44" height="17" font="13">ADHF.  </text>
<text top="387" left="554" width="61" height="17" font="13">Calculated </text>
<text top="404" left="554" width="66" height="17" font="13">GFR (using </text>
<text top="421" left="554" width="21" height="17" font="13">the </text>
<text top="438" left="554" width="56" height="17" font="13">Cockcroft-</text>
<text top="456" left="554" width="33" height="17" font="13">Gault </text>
<text top="473" left="554" width="49" height="17" font="13">formula) </text>
<text top="490" left="554" width="67" height="17" font="13">between 15 </text>
<text top="507" left="554" width="70" height="17" font="13">to 60 ml/min </text>
<text top="525" left="554" width="55" height="17" font="13">(changed </text>
<text top="542" left="554" width="76" height="17" font="13">from 15 to 50 </text>
<text top="559" left="554" width="53" height="17" font="13">ml/min in </text>
<text top="576" left="554" width="60" height="17" font="13">December </text>
<text top="593" left="554" width="62" height="17" font="13">2004 to be </text>
<text top="611" left="554" width="59" height="17" font="13">consistent </text>
<text top="628" left="554" width="46" height="17" font="13">with the </text>
<text top="645" left="554" width="56" height="17" font="13">published </text>
<text top="662" left="554" width="66" height="17" font="13">definition of </text>
<text top="679" left="554" width="60" height="17" font="13">“moderate </text>
<text top="697" left="554" width="31" height="17" font="13">renal </text>
<text top="714" left="554" width="83" height="17" font="13">impairment”).   </text>
<text top="731" left="554" width="63" height="17" font="13">Age &gt;18 y. </text>
<text top="318" left="644" width="79" height="17" font="13">Baseline SBP </text>
<text top="335" left="644" width="74" height="17" font="13">&lt;90 mm Hg.  </text>
<text top="352" left="644" width="3" height="17" font="13"> </text>
<text top="370" left="644" width="79" height="17" font="13">Hemodynamic</text>
<text top="387" left="644" width="80" height="17" font="13">ally significant </text>
<text top="404" left="644" width="33" height="17" font="13">aortic </text>
<text top="421" left="644" width="90" height="17" font="13">stenosis.            </text>
<text top="438" left="644" width="66" height="17" font="13">Need for IV </text>
<text top="456" left="644" width="63" height="17" font="13">vasodilator </text>
<text top="473" left="644" width="51" height="17" font="13">therapy.  </text>
<text top="490" left="644" width="74" height="17" font="13">Admission to </text>
<text top="507" left="644" width="31" height="17" font="13">ICU.  </text>
<text top="525" left="644" width="75" height="17" font="13">Hx of cardiac </text>
<text top="542" left="644" width="84" height="17" font="13">transplantation </text>
<text top="559" left="644" width="55" height="17" font="13">Allergy to </text>
<text top="576" left="644" width="60" height="17" font="13">nesiritide.  </text>
<text top="593" left="644" width="29" height="17" font="13">Prior </text>
<text top="611" left="644" width="74" height="17" font="13">enrollment in </text>
<text top="628" left="644" width="47" height="17" font="13">the trial. </text>
<text top="318" left="742" width="233" height="17" font="13">N/A N/A A </text>
<text top="318" left="915" width="117" height="17" font="13">significant </text>
<text top="335" left="904" width="55" height="17" font="13">decline in </text>
<text top="352" left="904" width="31" height="17" font="13">renal </text>
<text top="370" left="904" width="46" height="17" font="13">function </text>
<text top="387" left="904" width="64" height="17" font="13">(defined as </text>
<text top="404" left="904" width="65" height="17" font="13">a peak SCr </text>
<text top="421" left="904" width="64" height="17" font="13">increase of </text>
<text top="438" left="904" width="49" height="17" font="13">&gt;20% at </text>
<text top="456" left="904" width="50" height="17" font="13">any time </text>
<text top="473" left="904" width="58" height="17" font="13">during the </text>
<text top="490" left="904" width="57" height="17" font="13">first 7 d of </text>
<text top="507" left="904" width="64" height="17" font="13">hospitalizati</text>
<text top="525" left="904" width="17" height="17" font="13">on </text>
<text top="542" left="904" width="58" height="17" font="13">compared </text>
<text top="559" left="904" width="46" height="17" font="13">with the </text>
<text top="576" left="904" width="59" height="17" font="13">admission </text>
<text top="593" left="904" width="64" height="17" font="13">creatinine). </text>
<text top="611" left="904" width="59" height="17" font="13">Change in </text>
<text top="628" left="904" width="53" height="17" font="13">SCr from </text>
<text top="645" left="904" width="21" height="17" font="13">the </text>
<text top="662" left="904" width="59" height="17" font="13">admission </text>
<text top="679" left="904" width="46" height="17" font="13">value to </text>
<text top="697" left="904" width="57" height="17" font="13">discharge </text>
<text top="714" left="904" width="64" height="17" font="13">and/or Day </text>
<text top="731" left="904" width="24" height="17" font="13">7 of </text>
<text top="748" left="904" width="64" height="17" font="13">hospitalizati</text>
<text top="766" left="904" width="21" height="17" font="13">on, </text>
<text top="783" left="904" width="59" height="17" font="13">whichever </text>
<text top="318" left="988" width="23" height="17" font="13">Net </text>
<text top="335" left="988" width="50" height="17" font="13">negative </text>
<text top="352" left="988" width="46" height="17" font="13">diuresis </text>
<text top="370" left="988" width="47" height="17" font="13">&gt;1 l/day </text>
<text top="387" left="988" width="49" height="17" font="13">while on </text>
<text top="404" left="988" width="21" height="17" font="13">the </text>
<text top="421" left="988" width="53" height="17" font="13">infusion.  </text>
<text top="438" left="988" width="59" height="17" font="13">Change in </text>
<text top="456" left="988" width="39" height="17" font="13">weight </text>
<text top="473" left="988" width="58" height="17" font="13">during the </text>
<text top="490" left="988" width="53" height="17" font="13">infusion.  </text>
<text top="507" left="988" width="47" height="17" font="13">Need to </text>
<text top="525" left="988" width="55" height="17" font="13">discontinu</text>
<text top="542" left="988" width="31" height="17" font="13">e the </text>
<text top="559" left="988" width="46" height="17" font="13">infusion </text>
<text top="576" left="988" width="38" height="17" font="13">due to </text>
<text top="593" left="988" width="51" height="17" font="13">hypoten- </text>
<text top="611" left="988" width="33" height="17" font="13">sion.  </text>
<text top="628" left="988" width="31" height="17" font="13">Total </text>
<text top="645" left="988" width="43" height="17" font="13">diuretic </text>
<text top="662" left="988" width="55" height="17" font="13">use while </text>
<text top="679" left="988" width="53" height="17" font="13">receiving </text>
<text top="697" left="988" width="21" height="17" font="13">the </text>
<text top="714" left="988" width="53" height="17" font="13">infusion.  </text>
<text top="731" left="988" width="44" height="17" font="13">Median </text>
<text top="748" left="988" width="51" height="17" font="13">length of </text>
<text top="766" left="988" width="33" height="17" font="13">stay.  </text>
<text top="783" left="988" width="51" height="17" font="13">Death or </text>
<text top="318" left="1061" width="132" height="17" font="13">N/A 30 </text>
<text top="318" left="1148" width="66" height="17" font="13">mo </text>
<text top="335" left="1131" width="39" height="17" font="13">(3/04 - </text>
<text top="352" left="1131" width="52" height="17" font="13">8/06); up </text>
<text top="370" left="1131" width="41" height="17" font="13">to 30 d </text>
<text top="387" left="1131" width="35" height="17" font="13">follow </text>
<text top="404" left="1131" width="21" height="17" font="13">up. </text>
<text top="318" left="1198" width="19" height="17" font="13">No </text>
<text top="335" left="1198" width="58" height="17" font="13">significant </text>
<text top="352" left="1198" width="64" height="17" font="13">differences </text>
<text top="370" left="1198" width="33" height="17" font="13">in the </text>
<text top="387" left="1198" width="69" height="17" font="13">incidence of </text>
<text top="404" left="1198" width="38" height="17" font="13">a 20% </text>
<text top="421" left="1198" width="57" height="17" font="13">creatinine </text>
<text top="438" left="1198" width="55" height="17" font="13">rise (23% </text>
<text top="456" left="1198" width="72" height="17" font="13">nesiritide vs. </text>
<text top="473" left="1198" width="28" height="17" font="13">25% </text>
<text top="490" left="1198" width="57" height="17" font="13">placebo).  </text>
<text top="507" left="1198" width="19" height="17" font="13">No </text>
<text top="525" left="1198" width="58" height="17" font="13">significant </text>
<text top="542" left="1198" width="70" height="17" font="13">difference in </text>
<text top="559" left="1198" width="64" height="17" font="13">the change </text>
<text top="576" left="1198" width="73" height="17" font="13">in SCr (-0.05 </text>
<text top="593" left="1198" width="54" height="17" font="13">vs. +0.05 </text>
<text top="611" left="1198" width="82" height="17" font="13">mg/dl).             </text>
<text top="628" left="1198" width="19" height="17" font="13">No </text>
<text top="645" left="1198" width="58" height="17" font="13">significant </text>
<text top="662" left="1198" width="64" height="17" font="13">differences </text>
<text top="679" left="1198" width="33" height="17" font="13">in the </text>
<text top="697" left="1198" width="60" height="17" font="13">secondary </text>
<text top="714" left="1198" width="81" height="17" font="13">end points of   </text>
<text top="731" left="1198" width="68" height="17" font="13">3a) weight (-</text>
<text top="748" left="1198" width="51" height="17" font="13">2.19 vs. -</text>
<text top="766" left="1198" width="58" height="17" font="13">1.58 kg),   </text>
<text top="783" left="1198" width="36" height="17" font="13">3b) IV </text>
<text top="318" left="1286" width="58" height="17" font="13">Small # of </text>
<text top="335" left="1286" width="66" height="17" font="13">participants </text>
<text top="352" left="1286" width="54" height="17" font="13">still could </text>
<text top="370" left="1286" width="60" height="17" font="13">allow for a </text>
<text top="387" left="1286" width="70" height="17" font="13">type II error. </text>
<text top="404" left="1286" width="70" height="17" font="13">Exclusion of </text>
<text top="421" left="1286" width="55" height="17" font="13">important </text>
<text top="438" left="1286" width="61" height="17" font="13">subgroups </text>
<text top="456" left="1286" width="51" height="17" font="13">of ADHF </text>
<text top="473" left="1286" width="23" height="17" font="13">pts, </text>
<text top="490" left="1286" width="52" height="17" font="13">including </text>
<text top="507" left="1286" width="33" height="17" font="13">those </text>
<text top="525" left="1286" width="47" height="17" font="13">needing </text>
<text top="542" left="1286" width="52" height="17" font="13">intensive </text>
<text top="559" left="1286" width="51" height="17" font="13">care and </text>
<text top="576" left="1286" width="33" height="17" font="13">those </text>
<text top="593" left="1286" width="66" height="17" font="13">requiring IV </text>
<text top="611" left="1286" width="63" height="17" font="13">vasodilator </text>
<text top="628" left="1286" width="68" height="17" font="13">therapy; the </text>
<text top="645" left="1286" width="53" height="17" font="13">results of </text>
<text top="662" left="1286" width="46" height="17" font="13">this trial </text>
<text top="679" left="1286" width="66" height="17" font="13">certainly do </text>
<text top="697" left="1286" width="66" height="17" font="13">not exclude </text>
<text top="714" left="1286" width="69" height="17" font="13">a potentially </text>
<text top="731" left="1286" width="55" height="17" font="13">important </text>
<text top="748" left="1286" width="47" height="17" font="13">effect of </text>
<text top="766" left="1286" width="53" height="17" font="13">nesiritide </text>
<text top="783" left="1286" width="64" height="17" font="13">(positive or </text>
<text top="318" left="1372" width="28" height="17" font="13">13% </text>
<text top="335" left="1372" width="72" height="17" font="13">discontinued </text>
<text top="352" left="1372" width="63" height="17" font="13">infusion d/t </text>
<text top="370" left="1372" width="73" height="17" font="13">hypotension; </text>
<text top="387" left="1372" width="28" height="17" font="13">10% </text>
<text top="404" left="1372" width="77" height="17" font="13">transferred to </text>
<text top="421" left="1372" width="83" height="17" font="13">ICU; 10% 30 d </text>
<text top="438" left="1372" width="81" height="17" font="13">mortality; 33% </text>
<text top="456" left="1372" width="27" height="17" font="13">30 d </text>
<text top="473" left="1372" width="85" height="17" font="13">mortality/readm</text>
<text top="490" left="1372" width="83" height="17" font="13">ission (of note: </text>
<text top="507" left="1372" width="87" height="17" font="13">no difference in </text>
<text top="524" left="1372" width="33" height="17" font="13">these </text>
<text top="542" left="1372" width="83" height="17" font="13">SAE/complicati</text>
<text top="559" left="1372" width="81" height="17" font="13">ons compared </text>
<text top="576" left="1372" width="72" height="17" font="13">with placebo </text>
<text top="593" left="1372" width="48" height="17" font="13">control). </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">172</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="904" width="141" height="17" font="13">was sooner.  rehospitali</text>
<text top="72" left="988" width="36" height="17" font="13">zation </text>
<text top="89" left="988" width="52" height="17" font="13">within 30 </text>
<text top="106" left="988" width="17" height="17" font="13">d.  </text>
<text top="124" left="988" width="56" height="17" font="13">Resource </text>
<text top="141" left="988" width="51" height="17" font="13">utilization</text>
<text top="158" left="988" width="56" height="17" font="13">—defined </text>
<text top="175" left="988" width="47" height="17" font="13">by need </text>
<text top="192" left="988" width="18" height="17" font="13">for </text>
<text top="210" left="988" width="47" height="17" font="13">dialysis, </text>
<text top="227" left="988" width="52" height="17" font="13">intensive </text>
<text top="244" left="988" width="27" height="17" font="13">care </text>
<text top="261" left="988" width="51" height="17" font="13">monitorin</text>
<text top="278" left="988" width="14" height="17" font="13">g, </text>
<text top="296" left="988" width="51" height="17" font="13">pulmonar</text>
<text top="313" left="988" width="44" height="17" font="13">y artery </text>
<text top="330" left="988" width="53" height="17" font="13">catheteriz</text>
<text top="347" left="988" width="57" height="17" font="13">ation, and </text>
<text top="365" left="988" width="53" height="17" font="13">intubation</text>
<text top="382" left="988" width="7" height="17" font="13">. </text>
<text top="55" left="1198" width="64" height="17" font="13">furosemide </text>
<text top="72" left="1198" width="71" height="17" font="13">(125 vs. 107 </text>
<text top="89" left="1198" width="49" height="17" font="13">mg), 3c) </text>
<text top="106" left="1198" width="68" height="17" font="13">discontinuati</text>
<text top="124" left="1198" width="31" height="17" font="13">on of </text>
<text top="141" left="1198" width="70" height="17" font="13">infusion due </text>
<text top="158" left="1198" width="14" height="17" font="13">to </text>
<text top="175" left="1198" width="70" height="17" font="13">hypotension </text>
<text top="192" left="1198" width="51" height="17" font="13">(13% vs. </text>
<text top="210" left="1198" width="63" height="17" font="13">6%),     3d) </text>
<text top="227" left="1198" width="27" height="17" font="13">30 d </text>
<text top="244" left="1198" width="67" height="17" font="13">death/hospit</text>
<text top="261" left="1198" width="13" height="17" font="13">al </text>
<text top="278" left="1198" width="70" height="17" font="13">readmission </text>
<text top="296" left="1198" width="51" height="17" font="13">(33% vs. </text>
<text top="313" left="1198" width="32" height="17" font="13">25%) </text>
<text top="330" left="1198" width="3" height="17" font="13"> </text>
<text top="347" left="1198" width="80" height="17" font="13">1) p=0.85        </text>
<text top="365" left="1198" width="80" height="17" font="13">2) p=0.46        </text>
<text top="382" left="1198" width="80" height="17" font="13">3a) p=0.26      </text>
<text top="399" left="1198" width="80" height="17" font="13">3b) p=0.53      </text>
<text top="416" left="1198" width="79" height="17" font="13">3c) p=0.28      </text>
<text top="433" left="1198" width="63" height="17" font="13">3d) p=0.43 </text>
<text top="55" left="1286" width="71" height="17" font="13">negative) on </text>
<text top="72" left="1286" width="31" height="17" font="13">renal </text>
<text top="89" left="1286" width="59" height="17" font="13">function in </text>
<text top="106" left="1286" width="60" height="17" font="13">those pts.  </text>
<text top="124" left="1286" width="52" height="17" font="13">Although </text>
<text top="141" left="1286" width="69" height="17" font="13">trial was not </text>
<text top="158" left="1286" width="64" height="17" font="13">powered to </text>
<text top="175" left="1286" width="50" height="17" font="13">evaluate </text>
<text top="192" left="1286" width="50" height="17" font="13">mortality </text>
<text top="210" left="1286" width="70" height="17" font="13">and hospital </text>
<text top="227" left="1286" width="73" height="17" font="13">readmission, </text>
<text top="244" left="1286" width="62" height="17" font="13">there were </text>
<text top="261" left="1286" width="65" height="17" font="13">nonsignifica</text>
<text top="278" left="1286" width="51" height="17" font="13">nt trends </text>
<text top="296" left="1286" width="67" height="17" font="13">observed in </text>
<text top="313" left="1286" width="44" height="17" font="13">favor of </text>
<text top="330" left="1286" width="50" height="17" font="13">placebo. </text>
<text top="347" left="1286" width="60" height="17" font="13">Due to the </text>
<text top="365" left="1286" width="52" height="17" font="13">relatively </text>
<text top="382" left="1286" width="32" height="17" font="13">small </text>
<text top="399" left="1286" width="72" height="17" font="13">sample size, </text>
<text top="416" left="1286" width="59" height="17" font="13">the lack of </text>
<text top="433" left="1286" width="54" height="17" font="13">statistical </text>
<text top="451" left="1286" width="68" height="17" font="13">significance </text>
<text top="468" left="1286" width="51" height="17" font="13">does not </text>
<text top="485" left="1286" width="44" height="17" font="13">rule out </text>
<text top="502" left="1286" width="64" height="17" font="13">differences </text>
<text top="519" left="1286" width="46" height="17" font="13">in these </text>
<text top="537" left="1286" width="60" height="17" font="13">outcomes. </text>
<text top="555" left="54" width="59" height="17" font="13">Follow-Up </text>
<text top="572" left="54" width="35" height="17" font="13">Serial </text>
<text top="589" left="54" width="66" height="17" font="13">Infusions of </text>
<text top="606" left="54" width="58" height="17" font="13">Nesiritide, </text>
<text top="624" left="54" width="60" height="17" font="13">FUSION I, </text>
<text top="641" left="54" width="65" height="17" font="13">Yancy CW, </text>
<text top="658" left="54" width="34" height="17" font="13">2006. </text>
<text top="675" left="54" width="55" height="17" font="14">16828598</text>
<text top="675" left="109" width="3" height="17" font="13"> </text>
<text top="692" left="54" width="32" height="17" font="13">(350) </text>
<text top="555" left="139" width="62" height="17" font="13">To test the </text>
<text top="572" left="139" width="68" height="17" font="13">feasibility of </text>
<text top="589" left="139" width="69" height="17" font="13">nesiritide as </text>
<text top="606" left="139" width="59" height="17" font="13">adjunctive </text>
<text top="624" left="139" width="62" height="17" font="13">therapy for </text>
<text top="641" left="139" width="45" height="17" font="13">pts with </text>
<text top="658" left="139" width="77" height="17" font="13">advanced HF </text>
<text top="675" left="139" width="66" height="17" font="13">and a Hx of </text>
<text top="692" left="139" width="53" height="17" font="13">recurrent </text>
<text top="710" left="139" width="71" height="17" font="13">hospitalizatio</text>
<text top="727" left="139" width="20" height="17" font="13">ns. </text>
<text top="555" left="229" width="123" height="17" font="13">RCT Diuretics </text>
<text top="572" left="279" width="66" height="17" font="13">100%, beta </text>
<text top="589" left="279" width="49" height="17" font="13">blockers </text>
<text top="606" left="279" width="64" height="17" font="13">75%, ACEI </text>
<text top="624" left="279" width="60" height="17" font="13">56%, ARB </text>
<text top="641" left="279" width="55" height="17" font="13">17%, oral </text>
<text top="658" left="279" width="44" height="17" font="13">nitrates </text>
<text top="675" left="279" width="31" height="17" font="13">49%, </text>
<text top="692" left="279" width="57" height="17" font="13">aldosteron</text>
<text top="710" left="279" width="10" height="17" font="13">e </text>
<text top="727" left="279" width="60" height="17" font="13">antagonist </text>
<text top="744" left="279" width="46" height="17" font="13">36%, IV </text>
<text top="761" left="279" width="53" height="17" font="13">milrinone </text>
<text top="778" left="279" width="46" height="17" font="13">28%, IV </text>
<text top="555" left="359" width="24" height="17" font="13">138 </text>
<text top="572" left="359" width="3" height="17" font="13"> </text>
<text top="589" left="359" width="55" height="17" font="13">49 (0.005 </text>
<text top="606" left="359" width="85" height="17" font="13">g/kg/min)     46 </text>
<text top="624" left="359" width="92" height="17" font="13">(0.010 g/kg/min) </text>
<text top="641" left="359" width="3" height="17" font="13"> </text>
<text top="658" left="359" width="73" height="17" font="13">43 (standard </text>
<text top="675" left="359" width="31" height="17" font="13">care) </text>
<text top="555" left="473" width="54" height="17" font="13">65% ICM </text>
<text top="555" left="554" width="72" height="17" font="13">Adults (aged </text>
<text top="572" left="554" width="41" height="17" font="13">&gt;18 y). </text>
<text top="589" left="554" width="66" height="17" font="13">NYHA III or </text>
<text top="606" left="554" width="77" height="17" font="13">IV HF for &gt;60 </text>
<text top="624" left="554" width="49" height="17" font="13">d before </text>
<text top="641" left="554" width="70" height="17" font="13">randomizatio</text>
<text top="658" left="554" width="17" height="17" font="13">n.  </text>
<text top="675" left="554" width="63" height="17" font="13">&gt;2 hospital </text>
<text top="692" left="554" width="65" height="17" font="13">admissions </text>
<text top="710" left="554" width="14" height="17" font="13">or </text>
<text top="727" left="554" width="73" height="17" font="13">unscheduled </text>
<text top="744" left="554" width="62" height="17" font="13">outpt visits </text>
<text top="761" left="554" width="66" height="17" font="13">requiring IV </text>
<text top="778" left="554" width="61" height="17" font="13">vasoactive </text>
<text top="555" left="644" width="73" height="17" font="13">SBP&lt;90 mm </text>
<text top="572" left="644" width="23" height="17" font="13">Hg. </text>
<text top="589" left="644" width="83" height="17" font="13">Recipient of or </text>
<text top="606" left="644" width="50" height="17" font="13">listed for </text>
<text top="624" left="644" width="43" height="17" font="13">cardiac </text>
<text top="641" left="644" width="91" height="17" font="13">transplantation   </text>
<text top="658" left="644" width="75" height="17" font="13">Placement of </text>
<text top="675" left="644" width="55" height="17" font="13">a BiV PM </text>
<text top="692" left="644" width="35" height="17" font="13">within </text>
<text top="710" left="644" width="77" height="17" font="13">previous 60 d </text>
<text top="727" left="644" width="54" height="17" font="13">or AICDd </text>
<text top="744" left="644" width="35" height="17" font="13">within </text>
<text top="761" left="644" width="81" height="17" font="13">previous 30 d. </text>
<text top="778" left="644" width="53" height="17" font="13">Currently </text>
<text top="555" left="742" width="35" height="17" font="13">100% </text>
<text top="572" left="742" width="67" height="17" font="13">NYHA III-IV </text>
<text top="555" left="825" width="176" height="17" font="13">N/A Safety, </text>
<text top="555" left="945" width="71" height="17" font="13">as </text>
<text top="572" left="904" width="66" height="17" font="13">predetermin</text>
<text top="589" left="904" width="54" height="17" font="13">ed by the </text>
<text top="606" left="904" width="48" height="17" font="13">ability to </text>
<text top="624" left="904" width="66" height="17" font="13">tolerate out-</text>
<text top="641" left="904" width="66" height="17" font="13">pt infusions </text>
<text top="658" left="904" width="66" height="17" font="13">of nesiritide </text>
<text top="675" left="904" width="42" height="17" font="13">without </text>
<text top="692" left="904" width="66" height="17" font="13">evidence of </text>
<text top="710" left="904" width="17" height="17" font="13">an </text>
<text top="727" left="904" width="57" height="17" font="13">increased </text>
<text top="744" left="904" width="44" height="17" font="13">AE rate </text>
<text top="761" left="904" width="58" height="17" font="13">compared </text>
<text top="778" left="904" width="49" height="17" font="13">with SC. </text>
<text top="555" left="988" width="191" height="17" font="13">N/A N/A Enrollme</text>
<text top="572" left="1131" width="51" height="17" font="13">nt period </text>
<text top="589" left="1131" width="44" height="17" font="13">N/A; 12 </text>
<text top="606" left="1131" width="18" height="17" font="13">wk </text>
<text top="624" left="1131" width="36" height="17" font="13">follow-</text>
<text top="641" left="1131" width="21" height="17" font="13">up. </text>
<text top="555" left="1198" width="25" height="17" font="13">The </text>
<text top="572" left="1198" width="71" height="17" font="13">frequency of </text>
<text top="589" left="1198" width="53" height="17" font="13">all-cause </text>
<text top="606" left="1198" width="71" height="17" font="13">hospitalizatio</text>
<text top="624" left="1198" width="74" height="17" font="13">n through wk </text>
<text top="641" left="1198" width="42" height="17" font="13">12 was </text>
<text top="658" left="1198" width="66" height="17" font="13">lower in pts </text>
<text top="675" left="1198" width="73" height="17" font="13">receiving SC </text>
<text top="692" left="1198" width="60" height="17" font="13">plus either </text>
<text top="710" left="1198" width="53" height="17" font="13">nesiritide </text>
<text top="727" left="1198" width="34" height="17" font="13">0.005 </text>
<text top="744" left="1198" width="64" height="17" font="13">g/kg/min or </text>
<text top="761" left="1198" width="53" height="17" font="13">nesiritide </text>
<text top="778" left="1198" width="34" height="17" font="13">0.010 </text>
<text top="555" left="1286" width="57" height="17" font="13">The study </text>
<text top="572" left="1286" width="46" height="17" font="13">was not </text>
<text top="589" left="1286" width="64" height="17" font="13">powered to </text>
<text top="606" left="1286" width="42" height="17" font="13">assess </text>
<text top="624" left="1286" width="60" height="17" font="13">outcomes. </text>
<text top="555" left="1372" width="81" height="17" font="13">AEs related to </text>
<text top="572" left="1372" width="77" height="17" font="13">renal function </text>
<text top="589" left="1372" width="82" height="17" font="13">(i.e., abnormal </text>
<text top="606" left="1372" width="81" height="17" font="13">renal function, </text>
<text top="624" left="1372" width="64" height="17" font="13">acute renal </text>
<text top="641" left="1372" width="40" height="17" font="13">failure, </text>
<text top="658" left="1372" width="57" height="17" font="13">increased </text>
<text top="675" left="1372" width="62" height="17" font="13">blood urea </text>
<text top="692" left="1372" width="51" height="17" font="13">nitrogen, </text>
<text top="710" left="1372" width="85" height="17" font="13">increased SCr, </text>
<text top="727" left="1372" width="87" height="17" font="13">and oliguria, as </text>
<text top="744" left="1372" width="57" height="17" font="13">defined in </text>
<text top="761" left="1372" width="42" height="17" font="13">Coding </text>
<text top="778" left="1372" width="79" height="17" font="13">Symbols for a </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">173</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="279" width="57" height="17" font="13">dobutamin</text>
<text top="72" left="279" width="57" height="17" font="13">e 10%, IV </text>
<text top="89" left="279" width="57" height="17" font="13">dopamine </text>
<text top="106" left="279" width="32" height="17" font="13">11%. </text>
<text top="55" left="554" width="73" height="17" font="13">treatment for </text>
<text top="72" left="554" width="72" height="17" font="13">ADHF within </text>
<text top="89" left="554" width="58" height="17" font="13">the 12 mo </text>
<text top="106" left="554" width="57" height="17" font="13">preceding </text>
<text top="124" left="554" width="70" height="17" font="13">randomizatio</text>
<text top="141" left="554" width="17" height="17" font="13">n.  </text>
<text top="158" left="554" width="31" height="17" font="13">4. <i>&gt;</i>1 </text>
<text top="175" left="554" width="72" height="17" font="13">admission in </text>
<text top="192" left="554" width="21" height="17" font="13">the </text>
<text top="210" left="554" width="68" height="17" font="13">preceding 5 </text>
<text top="227" left="554" width="44" height="17" font="13">to 30 d. </text>
<text top="244" left="554" width="53" height="17" font="13">5. 6MWT </text>
<text top="261" left="554" width="52" height="17" font="13">&lt;400 m.  </text>
<text top="278" left="554" width="67" height="17" font="13">6. Currently </text>
<text top="296" left="554" width="53" height="17" font="13">receiving </text>
<text top="313" left="554" width="63" height="17" font="13">optimal HF </text>
<text top="330" left="554" width="55" height="17" font="13">treatment </text>
<text top="347" left="554" width="53" height="17" font="13">with long-</text>
<text top="365" left="554" width="52" height="17" font="13">term oral </text>
<text top="382" left="554" width="72" height="17" font="13">medications. </text>
<text top="55" left="644" width="80" height="17" font="13">receiving long-</text>
<text top="72" left="644" width="72" height="17" font="13">term dialysis </text>
<text top="89" left="644" width="59" height="17" font="13">or likely to </text>
<text top="106" left="644" width="42" height="17" font="13">require </text>
<text top="124" left="644" width="81" height="17" font="13">dialysis during </text>
<text top="141" left="644" width="53" height="17" font="13">the study </text>
<text top="158" left="644" width="92" height="17" font="13">period.                </text>
<text top="175" left="644" width="59" height="17" font="13">Inability to </text>
<text top="192" left="644" width="74" height="17" font="13">complete a 6 </text>
<text top="210" left="644" width="92" height="17" font="13">m walk test.        </text>
<text top="227" left="644" width="68" height="17" font="13">Evidence of </text>
<text top="244" left="644" width="51" height="17" font="13">acute MI </text>
<text top="261" left="644" width="35" height="17" font="13">within </text>
<text top="278" left="644" width="81" height="17" font="13">previous 30 d. </text>
<text top="55" left="1198" width="50" height="17" font="13">g/kg/min </text>
<text top="72" left="1198" width="74" height="17" font="13">than in those </text>
<text top="89" left="1198" width="73" height="17" font="13">receiving SC </text>
<text top="106" left="1198" width="60" height="17" font="13">only. Also, </text>
<text top="124" left="1198" width="53" height="17" font="13">pts in the </text>
<text top="141" left="1198" width="53" height="17" font="13">nesiritide </text>
<text top="158" left="1198" width="71" height="17" font="13">groups were </text>
<text top="175" left="1198" width="73" height="17" font="13">alive and out </text>
<text top="192" left="1198" width="34" height="17" font="13">of the </text>
<text top="210" left="1198" width="64" height="17" font="13">hospital for </text>
<text top="227" left="1198" width="61" height="17" font="13">more days </text>
<text top="244" left="1198" width="65" height="17" font="13">(median 84 </text>
<text top="261" left="1198" width="59" height="17" font="13">d for the 2 </text>
<text top="278" left="1198" width="73" height="17" font="13">groups) than </text>
<text top="296" left="1198" width="67" height="17" font="13">those in the </text>
<text top="313" left="1198" width="47" height="17" font="13">SC-only </text>
<text top="330" left="1198" width="35" height="17" font="13">group </text>
<text top="347" left="1198" width="65" height="17" font="13">(median 77 </text>
<text top="365" left="1198" width="21" height="17" font="13">d).  </text>
<text top="382" left="1198" width="3" height="17" font="13"> </text>
<text top="399" left="1198" width="53" height="17" font="13">All cause </text>
<text top="416" left="1198" width="71" height="17" font="13">hospitalizatio</text>
<text top="433" left="1198" width="62" height="17" font="13">n: p=0.037 </text>
<text top="451" left="1198" width="57" height="17" font="13">(nesiritide </text>
<text top="468" left="1198" width="34" height="17" font="13">0,005 </text>
<text top="485" left="1198" width="60" height="17" font="13">mg/kg/min </text>
<text top="502" left="1198" width="70" height="17" font="13">vs. standard </text>
<text top="519" left="1198" width="82" height="17" font="13">care alone),     </text>
<text top="537" left="1198" width="48" height="17" font="13">p=0.011 </text>
<text top="554" left="1198" width="57" height="17" font="13">(nesiritide </text>
<text top="571" left="1198" width="34" height="17" font="13">0,010 </text>
<text top="588" left="1198" width="60" height="17" font="13">mg/kg/min </text>
<text top="606" left="1198" width="70" height="17" font="13">vs. standard </text>
<text top="623" left="1198" width="72" height="17" font="13">care alone).  </text>
<text top="640" left="1198" width="60" height="17" font="13">Days alive </text>
<text top="657" left="1198" width="58" height="17" font="13">and out of </text>
<text top="674" left="1198" width="80" height="17" font="13">hospital:          </text>
<text top="692" left="1198" width="48" height="17" font="13">p=0.005 </text>
<text top="709" left="1198" width="57" height="17" font="13">(nesiritide </text>
<text top="726" left="1198" width="70" height="17" font="13">vs. standard </text>
<text top="743" left="1198" width="61" height="17" font="13">care only). </text>
<text top="55" left="1372" width="75" height="17" font="13">Thesaurus of </text>
<text top="72" left="1372" width="49" height="17" font="13">Adverse </text>
<text top="89" left="1372" width="52" height="17" font="13">Reaction </text>
<text top="106" left="1372" width="46" height="17" font="13">Terms), </text>
<text top="124" left="1372" width="64" height="17" font="13">occurred in </text>
<text top="141" left="1372" width="81" height="17" font="13">22% of all pts. </text>
<text top="158" left="1372" width="81" height="17" font="13">An increase in </text>
<text top="175" left="1372" width="66" height="17" font="13">SCr to &gt;0.5 </text>
<text top="192" left="1372" width="71" height="17" font="13">mg/dl higher </text>
<text top="210" left="1372" width="77" height="17" font="13">than baseline </text>
<text top="227" left="1372" width="65" height="17" font="13">occurred at </text>
<text top="244" left="1372" width="60" height="17" font="13">some time </text>
<text top="261" left="1372" width="58" height="17" font="13">during the </text>
<text top="278" left="1372" width="77" height="17" font="13">study in 18 of </text>
<text top="296" left="1372" width="86" height="17" font="13">41 pts (44%) in </text>
<text top="313" left="1372" width="72" height="17" font="13">the standard </text>
<text top="330" left="1372" width="54" height="17" font="13">care-only </text>
<text top="347" left="1372" width="86" height="17" font="13">group, 17 of 49 </text>
<text top="365" left="1372" width="69" height="17" font="13">pts (35%) in </text>
<text top="382" left="1372" width="73" height="17" font="13">the nesiritide </text>
<text top="399" left="1372" width="84" height="17" font="13">0.005 g/kg/min </text>
<text top="416" left="1372" width="79" height="17" font="13">group, and 16 </text>
<text top="433" left="1372" width="87" height="17" font="13">of 46 pts (35%) </text>
<text top="451" left="1372" width="86" height="17" font="13">in the nesiritide </text>
<text top="468" left="1372" width="84" height="17" font="13">0.010 g/kg/min </text>
<text top="485" left="1372" width="35" height="17" font="13">group </text>
<text top="502" left="1372" width="63" height="17" font="13">(p=0.614).  </text>
<text top="519" left="1372" width="55" height="17" font="13">The most </text>
<text top="537" left="1372" width="57" height="17" font="13">frequently </text>
<text top="554" left="1372" width="75" height="17" font="13">reported AEs </text>
<text top="571" left="1372" width="76" height="17" font="13">among all pts </text>
<text top="588" left="1372" width="71" height="17" font="13">with RI were </text>
<text top="606" left="1372" width="79" height="17" font="13">worsening HF </text>
<text top="623" left="1372" width="40" height="17" font="13">(42%), </text>
<text top="640" left="1372" width="79" height="17" font="13">asymptomatic </text>
<text top="657" left="1372" width="70" height="17" font="13">hypotension </text>
<text top="674" left="1372" width="40" height="17" font="13">(16%), </text>
<text top="692" left="1372" width="50" height="17" font="13">dyspnea </text>
<text top="709" left="1372" width="64" height="17" font="13">(13%), and </text>
<text top="726" left="1372" width="72" height="17" font="13">symptomatic </text>
<text top="743" left="1372" width="70" height="17" font="13">hypotension </text>
<text top="760" left="1372" width="40" height="17" font="13">(12%). </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">174</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="45" height="17" font="13">Second </text>
<text top="72" left="54" width="59" height="17" font="13">Follow-Up </text>
<text top="89" left="54" width="35" height="17" font="13">Serial </text>
<text top="106" left="54" width="66" height="17" font="13">Infusions of </text>
<text top="124" left="54" width="58" height="17" font="13">Nesiritide, </text>
<text top="141" left="54" width="64" height="17" font="13">FUSION II, </text>
<text top="158" left="54" width="65" height="17" font="13">Yancy CW, </text>
<text top="175" left="54" width="34" height="17" font="13">2008. </text>
<text top="192" left="54" width="55" height="17" font="14">19808265</text>
<text top="192" left="109" width="3" height="17" font="13"> </text>
<text top="210" left="54" width="32" height="17" font="13">(351) </text>
<text top="55" left="139" width="68" height="17" font="13">To evaluate </text>
<text top="72" left="139" width="70" height="17" font="13">the potential </text>
<text top="89" left="139" width="72" height="17" font="13">clinical utility </text>
<text top="106" left="139" width="48" height="17" font="13">of outpt, </text>
<text top="124" left="139" width="64" height="17" font="13">intermittent </text>
<text top="141" left="139" width="53" height="17" font="13">nesiritide </text>
<text top="158" left="139" width="65" height="17" font="13">infusions in </text>
<text top="175" left="139" width="66" height="17" font="13">ACCF/AHA </text>
<text top="192" left="139" width="58" height="17" font="13">stage C/D </text>
<text top="210" left="139" width="43" height="17" font="13">HF pts. </text>
<text top="55" left="229" width="103" height="17" font="13">RCT Loop </text>
<text top="72" left="279" width="49" height="17" font="13">diuretics </text>
<text top="89" left="279" width="64" height="17" font="13">75%, ACEI </text>
<text top="106" left="279" width="60" height="17" font="13">43%, ARB </text>
<text top="124" left="279" width="59" height="17" font="13">14%, beta </text>
<text top="141" left="279" width="43" height="17" font="13">blocker </text>
<text top="158" left="279" width="31" height="17" font="13">65%, </text>
<text top="175" left="279" width="57" height="17" font="13">aldosteron</text>
<text top="192" left="279" width="10" height="17" font="13">e </text>
<text top="210" left="279" width="60" height="17" font="13">antagonist </text>
<text top="227" left="279" width="31" height="17" font="13">37%, </text>
<text top="244" left="279" width="44" height="17" font="13">nitrates </text>
<text top="261" left="279" width="56" height="17" font="13">18%, ICD </text>
<text top="278" left="279" width="60" height="17" font="13">39%, CRT </text>
<text top="296" left="279" width="32" height="17" font="13">24%. </text>
<text top="55" left="359" width="24" height="17" font="13">911 </text>
<text top="72" left="359" width="3" height="17" font="13"> </text>
<text top="89" left="359" width="24" height="17" font="13">605 </text>
<text top="106" left="359" width="3" height="17" font="13"> </text>
<text top="124" left="359" width="24" height="17" font="13">306 </text>
<text top="55" left="473" width="28" height="17" font="13">64% </text>
<text top="72" left="473" width="52" height="17" font="13">Ischemic </text>
<text top="55" left="554" width="37" height="17" font="13">&gt;2 HF </text>
<text top="72" left="554" width="71" height="17" font="13">hospitalizatio</text>
<text top="89" left="554" width="51" height="17" font="13">ns or the </text>
<text top="106" left="554" width="59" height="17" font="13">equivalent </text>
<text top="124" left="554" width="76" height="17" font="13">within 12 mo, </text>
<text top="141" left="554" width="76" height="17" font="13">with the most </text>
<text top="158" left="554" width="72" height="17" font="13">recent within </text>
<text top="175" left="554" width="66" height="17" font="13">the prior 60 </text>
<text top="192" left="554" width="29" height="17" font="13">d. (A </text>
<text top="210" left="554" width="71" height="17" font="13">hospitalizatio</text>
<text top="227" left="554" width="70" height="17" font="13">n equivalent </text>
<text top="244" left="554" width="69" height="17" font="13">was defined </text>
<text top="261" left="554" width="33" height="17" font="13">as an </text>
<text top="278" left="554" width="73" height="17" font="13">unscheduled </text>
<text top="296" left="554" width="31" height="17" font="13">outpt </text>
<text top="313" left="554" width="73" height="17" font="13">treatment for </text>
<text top="330" left="554" width="62" height="17" font="13">ADHF with </text>
<text top="347" left="554" width="17" height="17" font="13">an </text>
<text top="365" left="554" width="67" height="17" font="13">intravenous </text>
<text top="382" left="554" width="61" height="17" font="13">vasoactive </text>
<text top="399" left="554" width="53" height="17" font="13">drug or 3 </text>
<text top="416" left="554" width="73" height="17" font="13">unscheduled </text>
<text top="433" left="554" width="67" height="17" font="13">intravenous </text>
<text top="451" left="554" width="43" height="17" font="13">diuretic </text>
<text top="468" left="554" width="62" height="17" font="13">treatments </text>
<text top="485" left="554" width="55" height="17" font="13">for ADHF </text>
<text top="502" left="554" width="70" height="17" font="13">within 60 d.) </text>
<text top="519" left="554" width="69" height="17" font="13">LVEF &lt;40% </text>
<text top="537" left="554" width="77" height="17" font="13">within 24 wk.  </text>
<text top="554" left="554" width="67" height="17" font="13">Investigator </text>
<text top="571" left="554" width="74" height="17" font="13">documentatio</text>
<text top="588" left="554" width="24" height="17" font="13">n of </text>
<text top="606" left="554" width="59" height="17" font="13">consistent </text>
<text top="623" left="554" width="66" height="17" font="13">NYHA III or </text>
<text top="640" left="554" width="74" height="17" font="13">IV symptoms </text>
<text top="657" left="554" width="58" height="17" font="13">during the </text>
<text top="674" left="554" width="77" height="17" font="13">previous 60 d </text>
<text top="692" left="554" width="61" height="17" font="13">(estimated </text>
<text top="709" left="554" width="57" height="17" font="13">creatinine </text>
<text top="726" left="554" width="57" height="17" font="13">clearance </text>
<text top="743" left="554" width="68" height="17" font="13">&lt;60 mL/min </text>
<text top="760" left="554" width="75" height="17" font="13">calculated by </text>
<text top="778" left="554" width="21" height="17" font="13">the </text>
<text top="55" left="644" width="52" height="17" font="13">SBP &lt;90 </text>
<text top="72" left="644" width="46" height="17" font="13">mmHg.  </text>
<text top="89" left="644" width="73" height="17" font="13">Dependence </text>
<text top="106" left="644" width="80" height="17" font="13">on (or inability </text>
<text top="124" left="644" width="83" height="17" font="13">to discontinue) </text>
<text top="141" left="644" width="79" height="17" font="13">intermittent or </text>
<text top="158" left="644" width="78" height="17" font="13">continuous IV </text>
<text top="175" left="644" width="61" height="17" font="13">vasoactive </text>
<text top="192" left="644" width="72" height="17" font="13">medications. </text>
<text top="210" left="644" width="55" height="17" font="13">&gt;2 output </text>
<text top="227" left="644" width="66" height="17" font="13">infusions of </text>
<text top="244" left="644" width="61" height="17" font="13">vasoactive </text>
<text top="261" left="644" width="79" height="17" font="13">therapy within </text>
<text top="278" left="644" width="80" height="17" font="13">30 d without a </text>
<text top="296" left="644" width="81" height="17" font="13">hospitalization </text>
<text top="313" left="644" width="71" height="17" font="13">Biventricular </text>
<text top="330" left="644" width="64" height="17" font="13">pacemaker </text>
<text top="347" left="644" width="77" height="17" font="13">within 45 d or </text>
<text top="365" left="644" width="64" height="17" font="13">a single- or </text>
<text top="382" left="644" width="79" height="17" font="13">dual-chamber </text>
<text top="399" left="644" width="68" height="17" font="13">pacemaker, </text>
<text top="416" left="644" width="77" height="17" font="13">ICD within 15 </text>
<text top="433" left="644" width="17" height="17" font="13">d.  </text>
<text top="451" left="644" width="69" height="17" font="13">Cardiogenic </text>
<text top="468" left="644" width="50" height="17" font="13">shock or </text>
<text top="485" left="644" width="43" height="17" font="13">volume </text>
<text top="502" left="644" width="60" height="17" font="13">depletion.  </text>
<text top="519" left="644" width="46" height="17" font="13">Chronic </text>
<text top="537" left="644" width="47" height="17" font="13">dialysis. </text>
<text top="55" left="742" width="35" height="17" font="13">100% </text>
<text top="72" left="742" width="67" height="17" font="13">NYHA III-IV </text>
<text top="55" left="825" width="24" height="17" font="13">N/A </text>
<text top="55" left="904" width="61" height="17" font="13">Time to all-</text>
<text top="72" left="904" width="70" height="17" font="13">cause death </text>
<text top="89" left="904" width="58" height="17" font="13">or the first </text>
<text top="106" left="904" width="64" height="17" font="13">hospitalizati</text>
<text top="124" left="904" width="35" height="17" font="13">on for </text>
<text top="141" left="904" width="68" height="17" font="13">cardiovascul</text>
<text top="158" left="904" width="59" height="17" font="13">ar or renal </text>
<text top="175" left="904" width="70" height="17" font="13">causes from </text>
<text top="192" left="904" width="64" height="17" font="13">randomizati</text>
<text top="210" left="904" width="62" height="17" font="13">on through </text>
<text top="227" left="904" width="55" height="17" font="13">Week 12. </text>
<text top="55" left="988" width="36" height="17" font="13">No. of </text>
<text top="72" left="988" width="53" height="17" font="13">cardiovas</text>
<text top="89" left="988" width="54" height="17" font="13">cular and </text>
<text top="106" left="988" width="31" height="17" font="13">renal </text>
<text top="124" left="988" width="46" height="17" font="13">hospital </text>
<text top="141" left="988" width="55" height="17" font="13">admission</text>
<text top="158" left="988" width="13" height="17" font="13">s. </text>
<text top="175" left="988" width="41" height="17" font="13">D alive </text>
<text top="192" left="988" width="58" height="17" font="13">and out of </text>
<text top="210" left="988" width="21" height="17" font="13">the </text>
<text top="227" left="988" width="53" height="17" font="13">hospital.  </text>
<text top="244" left="988" width="44" height="17" font="13">Time to </text>
<text top="261" left="988" width="53" height="17" font="13">cardiovas</text>
<text top="278" left="988" width="30" height="17" font="13">cular </text>
<text top="296" left="988" width="53" height="17" font="13">death, all </text>
<text top="313" left="988" width="57" height="17" font="13">evaluated </text>
<text top="330" left="988" width="45" height="17" font="13">through </text>
<text top="347" left="988" width="45" height="17" font="13">Wk 12.  </text>
<text top="365" left="988" width="43" height="17" font="13">QoL as </text>
<text top="382" left="988" width="55" height="17" font="13">assessed </text>
<text top="399" left="988" width="16" height="17" font="13">by </text>
<text top="416" left="988" width="57" height="17" font="13">change in </text>
<text top="433" left="988" width="60" height="17" font="13">the KCCQ </text>
<text top="451" left="988" width="54" height="17" font="13">summary </text>
<text top="468" left="988" width="33" height="17" font="13">score </text>
<text top="485" left="988" width="28" height="17" font="13">from </text>
<text top="502" left="988" width="49" height="17" font="13">baseline </text>
<text top="519" left="988" width="59" height="17" font="13">to Wk 13.  </text>
<text top="55" left="1061" width="118" height="17" font="13">N/A Enrollme</text>
<text top="72" left="1131" width="42" height="17" font="13">nt 4/04-</text>
<text top="89" left="1131" width="31" height="17" font="13">6/06. </text>
<text top="106" left="1131" width="40" height="17" font="13">Follow-</text>
<text top="124" left="1131" width="55" height="17" font="13">up ended </text>
<text top="141" left="1131" width="51" height="17" font="13">in 12/06. </text>
<text top="55" left="1198" width="54" height="17" font="13">All-cause </text>
<text top="72" left="1198" width="64" height="17" font="13">mortality or </text>
<text top="89" left="1198" width="68" height="17" font="13">cardiovascul</text>
<text top="106" left="1198" width="69" height="17" font="13">ar and renal </text>
<text top="124" left="1198" width="71" height="17" font="13">hospitalizatio</text>
<text top="141" left="1198" width="62" height="17" font="13">ns through </text>
<text top="158" left="1198" width="52" height="17" font="13">Week 12 </text>
<text top="175" left="1198" width="64" height="17" font="13">occurred in </text>
<text top="192" left="1198" width="72" height="17" font="13">36.8% of the </text>
<text top="210" left="1198" width="46" height="17" font="13">placebo </text>
<text top="227" left="1198" width="57" height="17" font="13">combined </text>
<text top="244" left="1198" width="59" height="17" font="13">group and </text>
<text top="261" left="1198" width="72" height="17" font="13">36.7% of the </text>
<text top="278" left="1198" width="53" height="17" font="13">nesiritide </text>
<text top="296" left="1198" width="57" height="17" font="13">combined </text>
<text top="313" left="1198" width="58" height="17" font="13">group. No </text>
<text top="330" left="1198" width="63" height="17" font="13">statistically </text>
<text top="347" left="1198" width="58" height="17" font="13">significant </text>
<text top="365" left="1198" width="70" height="17" font="13">difference in </text>
<text top="382" left="1198" width="60" height="17" font="13">secondary </text>
<text top="399" left="1198" width="64" height="17" font="13">end-points. </text>
<text top="416" left="1198" width="3" height="17" font="13"> </text>
<text top="433" left="1198" width="52" height="17" font="13">Log-rank </text>
<text top="451" left="1198" width="68" height="17" font="13">test p=0.79. </text>
<text top="468" left="1198" width="3" height="17" font="13"> </text>
<text top="485" left="1198" width="55" height="17" font="13">HR: 1.03; </text>
<text top="502" left="1198" width="47" height="17" font="13">95% CI: </text>
<text top="519" left="1198" width="52" height="17" font="13">0.82-1.3. </text>
<text top="55" left="1286" width="69" height="17" font="13">&#34;Because of </text>
<text top="72" left="1286" width="54" height="17" font="13">the much </text>
<text top="89" left="1286" width="60" height="17" font="13">lower than </text>
<text top="106" left="1286" width="53" height="17" font="13">expected </text>
<text top="124" left="1286" width="68" height="17" font="13">event rates, </text>
<text top="141" left="1286" width="60" height="17" font="13">FUSION II </text>
<text top="158" left="1286" width="25" height="17" font="13">was </text>
<text top="175" left="1286" width="65" height="17" font="13">underpower</text>
<text top="192" left="1286" width="31" height="17" font="13">ed to </text>
<text top="210" left="1286" width="70" height="17" font="13">evaluate the </text>
<text top="227" left="1286" width="47" height="17" font="13">effect of </text>
<text top="244" left="1286" width="70" height="17" font="13">nesiritide on </text>
<text top="261" left="1286" width="65" height="17" font="13">the primary </text>
<text top="278" left="1286" width="57" height="17" font="13">end point. </text>
<text top="296" left="1286" width="25" height="17" font="13">The </text>
<text top="313" left="1286" width="50" height="17" font="13">resulting </text>
<text top="330" left="1286" width="37" height="17" font="13">power </text>
<text top="347" left="1286" width="61" height="17" font="13">calculation </text>
<text top="365" left="1286" width="54" height="17" font="13">based on </text>
<text top="382" left="1286" width="21" height="17" font="13">the </text>
<text top="399" left="1286" width="54" height="17" font="13">observed </text>
<text top="416" left="1286" width="46" height="17" font="13">placebo </text>
<text top="433" left="1286" width="64" height="17" font="13">event rates </text>
<text top="451" left="1286" width="68" height="17" font="13">yielded only </text>
<text top="468" left="1286" width="65" height="17" font="13">37% power </text>
<text top="485" left="1286" width="61" height="17" font="13">to detect a </text>
<text top="502" left="1286" width="72" height="17" font="13">conservative </text>
<text top="519" left="1286" width="66" height="17" font="13">relative risk </text>
<text top="537" left="1286" width="68" height="17" font="13">reduction of </text>
<text top="554" left="1286" width="28" height="17" font="13">15% </text>
<text top="571" left="1286" width="50" height="17" font="13">between </text>
<text top="588" left="1286" width="58" height="17" font="13">groups. In </text>
<text top="605" left="1286" width="72" height="17" font="13">retrospect, a </text>
<text top="623" left="1286" width="68" height="17" font="13">sample size </text>
<text top="640" left="1286" width="64" height="17" font="13">of 3500 pts </text>
<text top="657" left="1286" width="66" height="17" font="13">would have </text>
<text top="674" left="1286" width="31" height="17" font="13">been </text>
<text top="692" left="1286" width="62" height="17" font="13">needed for </text>
<text top="709" left="1286" width="65" height="17" font="13">90% power </text>
<text top="726" left="1286" width="73" height="17" font="13">to detect this </text>
<text top="743" left="1286" width="55" height="17" font="13">treatment </text>
<text top="760" left="1286" width="37" height="17" font="13">effect. </text>
<text top="778" left="1286" width="65" height="17" font="13">However, it </text>
<text top="55" left="1372" width="86" height="17" font="13">SCr &gt;0.5 mg/dl </text>
<text top="72" left="1372" width="51" height="17" font="13">in 32.1% </text>
<text top="89" left="1372" width="80" height="17" font="13">(nesiritide) vs. </text>
<text top="106" left="1372" width="38" height="17" font="13">38.8% </text>
<text top="124" left="1372" width="58" height="17" font="13">(placebo), </text>
<text top="141" left="1372" width="52" height="17" font="13">p=0.046. </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">175</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="554" width="56" height="17" font="13">Cockcroft-</text>
<text top="72" left="554" width="33" height="17" font="13">Gault </text>
<text top="89" left="554" width="71" height="17" font="13">equation; 24 </text>
<text top="106" left="554" width="41" height="17" font="13">h urine </text>
<text top="124" left="554" width="55" height="17" font="13">collection </text>
<text top="141" left="554" width="51" height="17" font="13">was also </text>
<text top="158" left="554" width="66" height="17" font="13">required for </text>
<text top="175" left="554" width="69" height="17" font="13">NYHA class </text>
<text top="192" left="554" width="41" height="17" font="13">III pts). </text>
<text top="210" left="554" width="46" height="17" font="13">Optimal </text>
<text top="227" left="554" width="55" height="17" font="13">treatment </text>
<text top="244" left="554" width="49" height="17" font="13">with oral </text>
<text top="261" left="554" width="69" height="17" font="13">medications </text>
<text top="278" left="554" width="63" height="17" font="13">and device </text>
<text top="296" left="554" width="44" height="17" font="13">therapy </text>
<text top="313" left="554" width="49" height="17" font="13">unless a </text>
<text top="330" left="554" width="71" height="17" font="13">documented </text>
<text top="347" left="554" width="72" height="17" font="13">contraindicati</text>
<text top="365" left="554" width="31" height="17" font="13">on or </text>
<text top="382" left="554" width="64" height="17" font="13">intolerance </text>
<text top="399" left="554" width="73" height="17" font="13">was present. </text>
<text top="55" left="1286" width="57" height="17" font="13">should be </text>
<text top="72" left="1286" width="58" height="17" font="13">noted that </text>
<text top="89" left="1286" width="70" height="17" font="13">on the basis </text>
<text top="106" left="1286" width="70" height="17" font="13">of the actual </text>
<text top="124" left="1286" width="64" height="17" font="13">results, the </text>
<text top="141" left="1286" width="29" height="17" font="13">wide </text>
<text top="158" left="1286" width="63" height="17" font="13">confidence </text>
<text top="175" left="1286" width="67" height="17" font="13">limits with a </text>
<text top="192" left="1286" width="37" height="17" font="13">nearly </text>
<text top="210" left="1286" width="68" height="17" font="13">indistinguish</text>
<text top="227" left="1286" width="60" height="17" font="13">able event </text>
<text top="244" left="1286" width="25" height="17" font="13">rate </text>
<text top="261" left="1286" width="50" height="17" font="13">between </text>
<text top="278" left="1286" width="35" height="17" font="13">active </text>
<text top="296" left="1286" width="55" height="17" font="13">treatment </text>
<text top="313" left="1286" width="70" height="17" font="13">and placebo </text>
<text top="330" left="1286" width="56" height="17" font="13">exclude a </text>
<text top="347" left="1286" width="53" height="17" font="13">benefit in </text>
<text top="365" left="1286" width="65" height="17" font="13">the primary </text>
<text top="382" left="1286" width="70" height="17" font="13">end point as </text>
<text top="399" left="1286" width="48" height="17" font="13">small as </text>
<text top="416" left="1286" width="31" height="17" font="13">15%, </text>
<text top="433" left="1286" width="53" height="17" font="13">making it </text>
<text top="451" left="1286" width="52" height="17" font="13">relatively </text>
<text top="468" left="1286" width="68" height="17" font="13">unlikely that </text>
<text top="485" left="1286" width="72" height="17" font="13">an important </text>
<text top="502" left="1286" width="45" height="17" font="13">positive </text>
<text top="519" left="1286" width="59" height="17" font="13">effect was </text>
<text top="537" left="1286" width="50" height="17" font="13">missed.&#34; </text>
<text top="555" left="54" width="70" height="17" font="13">Acute Study </text>
<text top="572" left="54" width="57" height="17" font="13">of Clinical </text>
<text top="589" left="54" width="67" height="17" font="13">Effectivenes</text>
<text top="606" left="54" width="23" height="17" font="13">s of </text>
<text top="624" left="54" width="68" height="17" font="13">Nesiritide in </text>
<text top="641" left="54" width="66" height="17" font="13">Decompens</text>
<text top="658" left="54" width="51" height="17" font="13">ated HF, </text>
<text top="675" left="54" width="55" height="17" font="13">ASCEND-</text>
<text top="692" left="54" width="23" height="17" font="13">HF, </text>
<text top="710" left="54" width="56" height="17" font="13">O'Connor </text>
<text top="727" left="54" width="60" height="17" font="13">CM, 2011. </text>
<text top="744" left="54" width="55" height="17" font="14">21732835</text>
<text top="744" left="109" width="3" height="17" font="13"> </text>
<text top="761" left="54" width="32" height="17" font="13">(352) </text>
<text top="555" left="139" width="68" height="17" font="13">To evaluate </text>
<text top="572" left="139" width="68" height="17" font="13">the effect of </text>
<text top="589" left="139" width="69" height="17" font="13">nesiritide, in </text>
<text top="606" left="139" width="60" height="17" font="13">addition to </text>
<text top="624" left="139" width="51" height="17" font="13">standard </text>
<text top="641" left="139" width="48" height="17" font="13">care, on </text>
<text top="658" left="139" width="68" height="17" font="13">rates of self-</text>
<text top="675" left="139" width="49" height="17" font="13">reported </text>
<text top="692" left="139" width="74" height="17" font="13">dyspnea at 6 </text>
<text top="710" left="139" width="55" height="17" font="13">and 24 h, </text>
<text top="727" left="139" width="72" height="17" font="13">rehospitalizat</text>
<text top="744" left="139" width="72" height="17" font="13">ion for HF or </text>
<text top="761" left="139" width="62" height="17" font="13">death from </text>
<text top="778" left="139" width="73" height="17" font="13">any cause at </text>
<text top="555" left="229" width="133" height="17" font="13">RCT ACEI/ARB </text>
<text top="572" left="279" width="59" height="17" font="13">60%, beta </text>
<text top="589" left="279" width="43" height="17" font="13">blocker </text>
<text top="606" left="279" width="31" height="17" font="13">58%, </text>
<text top="624" left="279" width="59" height="17" font="13">Aldosteron</text>
<text top="641" left="279" width="10" height="17" font="13">e </text>
<text top="658" left="279" width="60" height="17" font="13">antagonist </text>
<text top="675" left="279" width="31" height="17" font="13">28%, </text>
<text top="692" left="279" width="38" height="17" font="13">nitrate </text>
<text top="710" left="279" width="31" height="17" font="13">23%, </text>
<text top="727" left="279" width="66" height="17" font="13">hydralazine </text>
<text top="744" left="279" width="61" height="17" font="13">7.4%, loop </text>
<text top="761" left="279" width="43" height="17" font="13">diuretic </text>
<text top="778" left="279" width="31" height="17" font="13">95%, </text>
<text top="555" left="359" width="31" height="17" font="13">7007 </text>
<text top="572" left="359" width="3" height="17" font="13"> </text>
<text top="589" left="359" width="92" height="17" font="13">3496 (nesiritide) </text>
<text top="606" left="359" width="3" height="17" font="13"> </text>
<text top="624" left="359" width="85" height="17" font="13">3511 (placebo) </text>
<text top="555" left="473" width="54" height="17" font="13">60% ICM </text>
<text top="555" left="554" width="66" height="17" font="13">Age &gt;17 y.  </text>
<text top="572" left="554" width="21" height="17" font="13">Pts </text>
<text top="589" left="554" width="68" height="17" font="13">hospitalized </text>
<text top="606" left="554" width="62" height="17" font="13">for ADHF.  </text>
<text top="624" left="554" width="21" height="17" font="13">Pts </text>
<text top="641" left="554" width="68" height="17" font="13">hospitalized </text>
<text top="658" left="554" width="69" height="17" font="13">for a reason </text>
<text top="675" left="554" width="59" height="17" font="13">other than </text>
<text top="692" left="554" width="61" height="17" font="13">ADHF, but </text>
<text top="710" left="554" width="60" height="17" font="13">diagnosed </text>
<text top="727" left="554" width="62" height="17" font="13">with ADHF </text>
<text top="744" left="554" width="76" height="17" font="13">within 48 h of </text>
<text top="761" left="554" width="62" height="17" font="13">admission. </text>
<text top="555" left="644" width="70" height="17" font="13">Hospitalized </text>
<text top="572" left="644" width="73" height="17" font="13">&gt;48 h before </text>
<text top="589" left="644" width="84" height="17" font="13">randomization. </text>
<text top="606" left="644" width="53" height="17" font="13">Probable </text>
<text top="624" left="644" width="70" height="17" font="13">discharge in </text>
<text top="641" left="644" width="38" height="17" font="13">&lt;24h.  </text>
<text top="658" left="644" width="72" height="17" font="13">Hypotension </text>
<text top="675" left="644" width="30" height="17" font="13">risk.  </text>
<text top="692" left="644" width="72" height="17" font="13">Uncontrolled </text>
<text top="710" left="644" width="81" height="17" font="13">hypertension.  </text>
<text top="727" left="644" width="75" height="17" font="13">Experimental </text>
<text top="744" left="644" width="63" height="17" font="13">medication </text>
<text top="761" left="644" width="56" height="17" font="13">(including </text>
<text top="778" left="644" width="71" height="17" font="13">nesiritide) or </text>
<text top="555" left="742" width="35" height="17" font="13">100% </text>
<text top="572" left="742" width="67" height="17" font="13">NYHA III-IV </text>
<text top="589" left="742" width="54" height="17" font="13">at time of </text>
<text top="606" left="742" width="64" height="17" font="13">enrollment. </text>
<text top="555" left="825" width="52" height="17" font="13">NYHA III-</text>
<text top="572" left="825" width="61" height="17" font="13">IV; at least </text>
<text top="589" left="825" width="24" height="17" font="13">1 of </text>
<text top="606" left="825" width="51" height="17" font="13">following </text>
<text top="624" left="825" width="35" height="17" font="13">signs: </text>
<text top="641" left="825" width="62" height="17" font="13">respiratory </text>
<text top="658" left="825" width="49" height="17" font="13">rate &gt;20 </text>
<text top="675" left="825" width="57" height="17" font="13">breaths/mi</text>
<text top="692" left="825" width="25" height="17" font="13">n or </text>
<text top="710" left="825" width="61" height="17" font="13">pulmonary </text>
<text top="727" left="825" width="63" height="17" font="13">congestion </text>
<text top="744" left="825" width="55" height="17" font="13">or edema </text>
<text top="761" left="825" width="55" height="17" font="13">with rales </text>
<text top="778" left="825" width="53" height="17" font="13">&gt;1/3 way </text>
<text top="555" left="904" width="27" height="17" font="13">Two </text>
<text top="572" left="904" width="57" height="17" font="13">coprimary </text>
<text top="589" left="904" width="67" height="17" font="13">end points:  </text>
<text top="606" left="904" width="62" height="17" font="13">Composite </text>
<text top="624" left="904" width="34" height="17" font="13">of HF </text>
<text top="641" left="904" width="62" height="17" font="13">rehospitaliz</text>
<text top="658" left="904" width="54" height="17" font="13">ation and </text>
<text top="675" left="904" width="53" height="17" font="13">all-cause </text>
<text top="692" left="904" width="50" height="17" font="13">mortality </text>
<text top="710" left="904" width="28" height="17" font="13">from </text>
<text top="727" left="904" width="64" height="17" font="13">randomizati</text>
<text top="744" left="904" width="62" height="17" font="13">on through </text>
<text top="761" left="904" width="36" height="17" font="13">D 30.  </text>
<text top="778" left="904" width="59" height="17" font="13">Change in </text>
<text top="555" left="988" width="25" height="17" font="13">Self-</text>
<text top="572" left="988" width="49" height="17" font="13">reported </text>
<text top="589" left="988" width="40" height="17" font="13">overall </text>
<text top="606" left="988" width="59" height="17" font="13">well-being </text>
<text top="624" left="988" width="48" height="17" font="13">at 6 and </text>
<text top="641" left="988" width="55" height="17" font="13">24 h after </text>
<text top="658" left="988" width="33" height="17" font="13">study </text>
<text top="675" left="988" width="28" height="17" font="13">drug </text>
<text top="692" left="988" width="55" height="17" font="13">initiation.  </text>
<text top="710" left="988" width="52" height="17" font="13">Composit</text>
<text top="727" left="988" width="24" height="17" font="13">e of </text>
<text top="744" left="988" width="57" height="17" font="13">persistent </text>
<text top="761" left="988" width="14" height="17" font="13">or </text>
<text top="778" left="988" width="59" height="17" font="13">worsening </text>
<text top="555" left="1061" width="27" height="17" font="13">30 d </text>
<text top="572" left="1061" width="53" height="17" font="13">mortality: </text>
<text top="589" left="1061" width="31" height="17" font="13">4.0% </text>
<text top="606" left="1061" width="46" height="17" font="13">placebo </text>
<text top="624" left="1061" width="51" height="17" font="13">vs. 3.6% </text>
<text top="641" left="1061" width="56" height="17" font="13">nesiritide. </text>
<text top="555" left="1131" width="49" height="17" font="13">Enrollme</text>
<text top="572" left="1131" width="42" height="17" font="13">nt 5/07-</text>
<text top="589" left="1131" width="38" height="17" font="13">12/10; </text>
<text top="606" left="1131" width="33" height="17" font="13">study </text>
<text top="624" left="1131" width="28" height="17" font="13">drug </text>
<text top="641" left="1131" width="49" height="17" font="13">infusion, </text>
<text top="658" left="1131" width="43" height="17" font="13">at least </text>
<text top="675" left="1131" width="51" height="17" font="13">24 h and </text>
<text top="692" left="1131" width="55" height="17" font="13">up to 7 d. </text>
<text top="555" left="1198" width="19" height="17" font="13">No </text>
<text top="572" left="1198" width="58" height="17" font="13">significant </text>
<text top="589" left="1198" width="68" height="17" font="13">effect on 30 </text>
<text top="606" left="1198" width="10" height="17" font="13">d </text>
<text top="624" left="1198" width="69" height="17" font="13">rehospitaliza</text>
<text top="641" left="1198" width="59" height="17" font="13">tion (6.0% </text>
<text top="658" left="1198" width="72" height="17" font="13">nesiritide vs. </text>
<text top="675" left="1198" width="31" height="17" font="13">6.1% </text>
<text top="692" left="1198" width="65" height="17" font="13">placebo) or </text>
<text top="710" left="1198" width="27" height="17" font="13">30 d </text>
<text top="727" left="1198" width="50" height="17" font="13">mortality </text>
<text top="744" left="1198" width="35" height="17" font="13">(3.6% </text>
<text top="761" left="1198" width="72" height="17" font="13">nesiritide vs. </text>
<text top="778" left="1198" width="31" height="17" font="13">4.0% </text>
<text top="555" left="1286" width="51" height="17" font="13">Primarily </text>
<text top="572" left="1286" width="61" height="17" font="13">addressed </text>
<text top="589" left="1286" width="36" height="17" font="13">safety </text>
<text top="606" left="1286" width="57" height="17" font="13">concerns, </text>
<text top="624" left="1286" width="62" height="17" font="13">thus broad </text>
<text top="641" left="1286" width="75" height="17" font="13">range of pts.  </text>
<text top="658" left="1286" width="70" height="17" font="13">Rudimentary</text>
<text top="675" left="1286" width="21" height="17" font="13">, pt </text>
<text top="692" left="1286" width="69" height="17" font="13">assessment </text>
<text top="710" left="1286" width="70" height="17" font="13">of dyspnea.  </text>
<text top="727" left="1286" width="66" height="17" font="13">Low clinical </text>
<text top="744" left="1286" width="62" height="17" font="13">event rate. </text>
<text top="555" left="1372" width="80" height="17" font="13">30 d all-cause </text>
<text top="572" left="1372" width="74" height="17" font="13">mortality and </text>
<text top="589" left="1372" width="59" height="17" font="13">worsening </text>
<text top="606" left="1372" width="81" height="17" font="13">renal function: </text>
<text top="623" left="1372" width="57" height="17" font="13">31.4% vs. </text>
<text top="641" left="1372" width="38" height="17" font="13">29.5% </text>
<text top="658" left="1372" width="78" height="17" font="13">(Nesiritide vs. </text>
<text top="675" left="1372" width="51" height="17" font="13">Placebo, </text>
<text top="692" left="1372" width="49" height="17" font="13">p=0.11). </text>
<text top="710" left="1372" width="78" height="17" font="13">2. Higher rate </text>
<text top="727" left="1372" width="83" height="17" font="13">of hypotensive </text>
<text top="744" left="1372" width="40" height="17" font="13">events </text>
<text top="761" left="1372" width="51" height="17" font="13">amongst </text>
<text top="778" left="1372" width="87" height="17" font="13">nesiritide group </text>
</page>
<page number="176" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">176</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="139" width="55" height="17" font="13">30 d, and </text>
<text top="72" left="139" width="31" height="17" font="13">renal </text>
<text top="89" left="139" width="69" height="17" font="13">dysfunction. </text>
<text top="55" left="279" width="50" height="17" font="13">inotropic </text>
<text top="72" left="279" width="59" height="17" font="13">agent 4%, </text>
<text top="89" left="279" width="63" height="17" font="13">vasodilator </text>
<text top="106" left="279" width="32" height="17" font="13">15%. </text>
<text top="55" left="644" width="90" height="17" font="13">device use.        </text>
<text top="72" left="644" width="68" height="17" font="13">Pregnant or </text>
<text top="89" left="644" width="59" height="17" font="13">suspected </text>
<text top="106" left="644" width="64" height="17" font="13">pregnancy. </text>
<text top="55" left="825" width="44" height="17" font="13">up lung </text>
<text top="72" left="825" width="43" height="17" font="13">field; at </text>
<text top="89" left="825" width="53" height="17" font="13">least 1 of </text>
<text top="106" left="825" width="51" height="17" font="13">following </text>
<text top="124" left="825" width="52" height="17" font="13">objective </text>
<text top="141" left="825" width="61" height="17" font="13">measures: </text>
<text top="158" left="825" width="63" height="17" font="13">congestion </text>
<text top="175" left="825" width="55" height="17" font="13">or edema </text>
<text top="192" left="825" width="50" height="17" font="13">on CXR, </text>
<text top="210" left="825" width="60" height="17" font="13">BNP &gt;400 </text>
<text top="227" left="825" width="48" height="17" font="13">pg/ml or </text>
<text top="244" left="825" width="42" height="17" font="13">NT-pro-</text>
<text top="261" left="825" width="29" height="17" font="13">BNP </text>
<text top="278" left="825" width="38" height="17" font="13">&gt;1000 </text>
<text top="296" left="825" width="37" height="17" font="13">pg/ml, </text>
<text top="313" left="825" width="65" height="17" font="13">PCWP &gt;20 </text>
<text top="330" left="825" width="43" height="17" font="13">mmHg, </text>
<text top="347" left="825" width="34" height="17" font="13">LVEF </text>
<text top="365" left="825" width="48" height="17" font="13">&lt;40% in </text>
<text top="382" left="825" width="45" height="17" font="13">prior 12 </text>
<text top="399" left="825" width="24" height="17" font="13">mo. </text>
<text top="55" left="904" width="23" height="17" font="13">self-</text>
<text top="72" left="904" width="49" height="17" font="13">reported </text>
<text top="89" left="904" width="50" height="17" font="13">dyspnea </text>
<text top="106" left="904" width="67" height="17" font="13">symptom at </text>
<text top="124" left="904" width="62" height="17" font="13">6 and 24 h </text>
<text top="141" left="904" width="61" height="17" font="13">after study </text>
<text top="158" left="904" width="28" height="17" font="13">drug </text>
<text top="175" left="904" width="52" height="17" font="13">initiation. </text>
<text top="55" left="988" width="44" height="17" font="13">HF and </text>
<text top="72" left="988" width="53" height="17" font="13">all-cause </text>
<text top="89" left="988" width="50" height="17" font="13">mortality </text>
<text top="106" left="988" width="28" height="17" font="13">from </text>
<text top="124" left="988" width="51" height="17" font="13">randomiz</text>
<text top="141" left="988" width="30" height="17" font="13">ation </text>
<text top="158" left="988" width="45" height="17" font="13">through </text>
<text top="175" left="988" width="46" height="17" font="13">hospital </text>
<text top="192" left="988" width="53" height="17" font="13">discharge</text>
<text top="210" left="988" width="10" height="17" font="13">.  </text>
<text top="227" left="988" width="38" height="17" font="13">3. # of </text>
<text top="244" left="988" width="58" height="17" font="13">days alive </text>
<text top="261" left="988" width="24" height="17" font="13">and </text>
<text top="278" left="988" width="43" height="17" font="13">outside </text>
<text top="296" left="988" width="21" height="17" font="13">the </text>
<text top="313" left="988" width="46" height="17" font="13">hospital </text>
<text top="330" left="988" width="28" height="17" font="13">from </text>
<text top="347" left="988" width="51" height="17" font="13">randomiz</text>
<text top="365" left="988" width="30" height="17" font="13">ation </text>
<text top="382" left="988" width="45" height="17" font="13">through </text>
<text top="399" left="988" width="49" height="17" font="13">Day 30.  </text>
<text top="416" left="988" width="52" height="17" font="13">Composit</text>
<text top="433" left="988" width="44" height="17" font="13">e of CV </text>
<text top="451" left="988" width="58" height="17" font="13">death and </text>
<text top="468" left="988" width="56" height="17" font="13">rehospitali</text>
<text top="485" left="988" width="36" height="17" font="13">zation </text>
<text top="502" left="988" width="58" height="17" font="13">due to CV </text>
<text top="519" left="988" width="42" height="17" font="13">causes </text>
<text top="537" left="988" width="28" height="17" font="13">from </text>
<text top="554" left="988" width="51" height="17" font="13">randomiz</text>
<text top="571" left="988" width="30" height="17" font="13">ation </text>
<text top="588" left="988" width="45" height="17" font="13">through </text>
<text top="605" left="988" width="46" height="17" font="13">Day 30. </text>
<text top="55" left="1198" width="54" height="17" font="13">placebo). </text>
<text top="72" left="1198" width="69" height="17" font="13">p=0.31         </text>
<text top="89" left="1198" width="55" height="17" font="13">Nesiritide </text>
<text top="106" left="1198" width="54" height="17" font="13">improved </text>
<text top="124" left="1198" width="74" height="17" font="13">dyspnea at 6 </text>
<text top="141" left="1198" width="62" height="17" font="13">h and 24 h </text>
<text top="158" left="1198" width="28" height="17" font="13">after </text>
<text top="175" left="1198" width="55" height="17" font="13">treatment </text>
<text top="192" left="1198" width="72" height="17" font="13">compared to </text>
<text top="210" left="1198" width="67" height="17" font="13">placebo but </text>
<text top="227" left="1198" width="75" height="17" font="13">did not reach </text>
<text top="244" left="1198" width="70" height="17" font="13">prespecified </text>
<text top="261" left="1198" width="46" height="17" font="13">level for </text>
<text top="278" left="1198" width="71" height="17" font="13">significance. </text>
<text top="296" left="1198" width="74" height="17" font="13">p=0.03 (6hr), </text>
<text top="313" left="1198" width="48" height="17" font="13">p=0.007 </text>
<text top="330" left="1198" width="36" height="17" font="13">(24hr) </text>
<text top="347" left="1198" width="34" height="17" font="13">3) No </text>
<text top="365" left="1198" width="70" height="17" font="13">difference in </text>
<text top="382" left="1198" width="38" height="17" font="13">rate of </text>
<text top="399" left="1198" width="59" height="17" font="13">worsening </text>
<text top="416" left="1198" width="31" height="17" font="13">renal </text>
<text top="433" left="1198" width="50" height="17" font="13">function. </text>
<text top="451" left="1198" width="45" height="17" font="13">p=0.11. </text>
<text top="468" left="1198" width="3" height="17" font="13"> </text>
<text top="485" left="1198" width="3" height="17" font="13"> </text>
<text top="55" left="1372" width="61" height="17" font="13">(26.6% vs. </text>
<text top="72" left="1372" width="42" height="17" font="13">15.3%, </text>
<text top="89" left="1372" width="56" height="17" font="13">p&lt;0.001). </text>
<text top="623" left="54" width="1377" height="15" font="6">ACCF/AHA indicates American College of Cardiology Foundation/American Heart Association; ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; AE, adverse events; ARB, angiotensin-receptor blocker; ASA, </text>
<text top="639" left="54" width="1375" height="16" font="6">aspirin; BPAP, bilevel positive airway pressure; BNP, b-type natriuretic peptide; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, congestive heart failure; CI, confidence interval; CRT, cardiac resynchronization therapy; CV, cardiovascular; CXR, chest X-ray; ED, </text>
<text top="655" left="54" width="1388" height="15" font="6">emergency department; FUSION, Follow-Up Serial Infusions of Nesiritide; GFR, glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HF, heart failure; HR, hazard ratio; Hx, history; ICD, implantable cardioverter-defibrillator; ICM, ischemic cardiomyopathy; ICU, intensive-care </text>
<text top="671" left="54" width="1386" height="15" font="6">unit; IV, intravenous; JVD, jugular venous distention; KCCQ, Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; MI, myocardial infarction; N/A, not applicable; NSGET, Nesiritide Study Group Efficacy Trial; NSVT, non-sustained ventricular tachycardia; NYHA, New York </text>
<text top="686" left="54" width="1384" height="16" font="6">Heart Association; OU, observation unit; PCWP, pulmonary capillary wedge pressure; pHTN, pulmonary hypertension; PND, paroxysmal nocturnal dyspnea; PROACTION, Prospective Randomized Outcomes study of Acutely decompensated CHF Treated Initially as Outpatients with </text>
<text top="702" left="54" width="648" height="16" font="6">Nesiritide; Pt, patient; RCM, restrictive cardiomyopathy; RCT, randomized controlled trial; RI, renal insuficiency; RR, relative risk; RR</text>
<text top="707" left="702" width="11" height="10" font="19">MH</text>
<text top="702" left="713" width="743" height="15" font="6">, relative risk Mantel-Haenszel fixed-effects model; SAE, serious adverse event; SBP, systolic blood pressure; SC; SCr, serum creatinine; SD, standard </text>
<text top="717" left="54" width="486" height="15" font="6">deviation; UA, unstable angina; and VMAC, Vasodilator in the Management of Acute Heart Failure. </text>
<text top="733" left="54" width="4" height="19" font="7"> </text>
</page>
<page number="177" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">177</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="529" height="21" font="8"><b>Data Supplement 40. Hospitalized Patients – Oral Medications (Section 8.8) </b></text>
<text top="94" left="58" width="171" height="19" font="9"><b>Study Name, Author, Year </b></text>
<text top="94" left="262" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="94" left="399" width="77" height="19" font="9"><b>Study Type </b></text>
<text top="94" left="529" width="72" height="19" font="9"><b>Study Size </b></text>
<text top="94" left="727" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="94" left="1039" width="53" height="19" font="9"><b>Results </b></text>
<text top="75" left="1197" width="74" height="19" font="9"><b>P Values &amp; </b></text>
<text top="94" left="1207" width="53" height="19" font="9"><b>95% CI: </b></text>
<text top="75" left="1297" width="56" height="19" font="9"><b>OR: HR: </b></text>
<text top="94" left="1311" width="28" height="19" font="9"><b>RR: </b></text>
<text top="75" left="1395" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="1378" width="76" height="19" font="9"><b>Limitations </b></text>
<text top="125" left="663" width="114" height="19" font="10"><i><b>Inclusion Criteria </b></i></text>
<text top="125" left="820" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="144" left="54" width="357" height="17" font="15"><b>Beta Blockers During and at Discharge of HF Hospitalization </b></text>
<text top="173" left="54" width="156" height="17" font="13">Fonarow GC, Abraham WT, </text>
<text top="190" left="54" width="155" height="17" font="13">Albert NM et al. Influence of </text>
<text top="208" left="54" width="159" height="17" font="13">Beta blocker Continuation or </text>
<text top="225" left="54" width="175" height="17" font="13">Withdrawal on Outcomes in Pts </text>
<text top="242" left="54" width="169" height="17" font="13">Hospitalized with HF: Findings </text>
<text top="259" left="54" width="135" height="17" font="13">From the OPTIMIZE-HF </text>
<text top="277" left="54" width="152" height="17" font="13">Program. J Am Coll Cardiol </text>
<text top="294" left="54" width="144" height="17" font="13">2008 July 15;52(3):190-9. </text>
<text top="311" left="54" width="58" height="17" font="14">18617067 </text>
<text top="311" left="112" width="32" height="17" font="13">(353) </text>
<text top="173" left="244" width="76" height="17" font="13">To determine </text>
<text top="190" left="244" width="118" height="17" font="13">whether beta-blocker </text>
<text top="208" left="244" width="101" height="17" font="13">therapy should be </text>
<text top="225" left="244" width="71" height="17" font="13">continued or </text>
<text top="242" left="244" width="96" height="17" font="13">withdrawn during </text>
<text top="259" left="244" width="99" height="17" font="13">hospitalization for </text>
<text top="277" left="244" width="114" height="17" font="13">decompensated HF. </text>
<text top="173" left="379" width="49" height="17" font="13">Registry </text>
<text top="190" left="379" width="94" height="17" font="13">(OPTIMIZE-HF)  </text>
<text top="173" left="507" width="101" height="17" font="13">5791 pts admitted </text>
<text top="190" left="507" width="76" height="17" font="13">with HF at 91 </text>
<text top="208" left="507" width="80" height="17" font="13">academic and </text>
<text top="225" left="507" width="115" height="17" font="13">community hospitals </text>
<text top="242" left="507" width="110" height="17" font="13">throughout the U.S. </text>
<text top="173" left="635" width="161" height="17" font="13">Hospitalization for episode of </text>
<text top="190" left="635" width="140" height="17" font="13">worsening HF as primary </text>
<text top="208" left="635" width="112" height="17" font="13">cause of admission. </text>
<text top="173" left="818" width="27" height="17" font="13"> N/A </text>
<text top="173" left="953" width="180" height="17" font="13">Among 2373 pts eligible for beta </text>
<text top="190" left="953" width="200" height="17" font="13">blockers at discharge: 1350 (56.9%) </text>
<text top="208" left="953" width="167" height="17" font="13">receiving beta blockers before </text>
<text top="225" left="953" width="204" height="17" font="13">admission and continued on therapy, </text>
<text top="242" left="953" width="219" height="17" font="13">632 (26.6%) newly started, 79 (3.3%) in </text>
<text top="259" left="953" width="215" height="17" font="13">which therapy was withdrawn, and 303 </text>
<text top="277" left="953" width="178" height="17" font="13">(12.8%) eligible but not treated.  </text>
<text top="294" left="953" width="221" height="17" font="13">Continuation of beta blockers with lower </text>
<text top="311" left="953" width="203" height="17" font="13">risk for death (HR: 0.60; p=0.04) and </text>
<text top="328" left="953" width="186" height="17" font="13">death/rehospitalization (HR: 0.69; </text>
<text top="345" left="953" width="49" height="17" font="13">p=0.01). </text>
<text top="363" left="953" width="211" height="17" font="13">Withdrawal of beta blocker associated </text>
<text top="380" left="953" width="206" height="17" font="13">with higher risk for mortality (HR: 2.3; </text>
<text top="397" left="953" width="212" height="17" font="13">p=0.01), but with similar risk as HF pts </text>
<text top="414" left="953" width="177" height="17" font="13">eligible but not treated with beta </text>
<text top="431" left="953" width="53" height="17" font="13">blockers. </text>
<text top="173" left="1189" width="75" height="17" font="13">95% CI: 0.37-</text>
<text top="190" left="1189" width="72" height="17" font="13">0.99; p=0.04 </text>
<text top="173" left="1291" width="52" height="17" font="13">HR: 0.60 </text>
<text top="173" left="1371" width="49" height="17" font="13">Registry </text>
<text top="449" left="54" width="156" height="17" font="13">Fonarow GC, Abraham WT, </text>
<text top="467" left="54" width="172" height="17" font="13">Albert NM et al. Dosing of Beta </text>
<text top="484" left="54" width="135" height="17" font="13">blocker Therapy Before, </text>
<text top="501" left="54" width="97" height="17" font="13">During, and After </text>
<text top="518" left="54" width="121" height="17" font="13">Hospitalization for HF </text>
<text top="535" left="54" width="167" height="17" font="13">(OPTIMIZE-HF). <i>Am J Cardiol</i> </text>
<text top="553" left="54" width="91" height="17" font="13">2008 December </text>
<text top="570" left="54" width="101" height="17" font="13">1;102(11):1524-9. </text>
<text top="587" left="54" width="58" height="17" font="14">19026308 </text>
<text top="587" left="112" width="32" height="17" font="13">(354) </text>
<text top="604" left="54" width="3" height="17" font="13"> </text>
<text top="449" left="244" width="102" height="17" font="13">The doses of beta </text>
<text top="467" left="244" width="112" height="17" font="13">blockers used in pts </text>
<text top="484" left="244" width="99" height="17" font="13">with HF in routine </text>
<text top="501" left="244" width="87" height="17" font="13">clinical practice </text>
<text top="518" left="244" width="107" height="17" font="13">before, during, and </text>
<text top="535" left="244" width="109" height="17" font="13">after hospitalization </text>
<text top="553" left="244" width="41" height="17" font="13">for HF. </text>
<text top="449" left="379" width="49" height="17" font="13">Registry </text>
<text top="467" left="379" width="94" height="17" font="13">(OPTIMIZE-HF). </text>
<text top="449" left="507" width="101" height="17" font="13">5791 pts admitted </text>
<text top="467" left="507" width="76" height="17" font="13">with HF at 91 </text>
<text top="484" left="507" width="80" height="17" font="13">academic and </text>
<text top="501" left="507" width="115" height="17" font="13">community hospitals </text>
<text top="518" left="507" width="110" height="17" font="13">throughout the U.S. </text>
<text top="449" left="635" width="161" height="17" font="13">Hospitalization for episode of </text>
<text top="467" left="635" width="140" height="17" font="13">worsening HF as primary </text>
<text top="484" left="635" width="112" height="17" font="13">cause of admission. </text>
<text top="449" left="818" width="33" height="17" font="13">None </text>
<text top="449" left="953" width="189" height="17" font="13">The mean total daily dose for beta </text>
<text top="467" left="953" width="220" height="17" font="13">blockers before hospital admission &lt;1/2 </text>
<text top="484" left="953" width="168" height="17" font="13">the recommended target dose </text>
<text top="501" left="953" width="177" height="17" font="13">(carvedilol 21.5 +/- 17.8 mg and </text>
<text top="518" left="953" width="217" height="17" font="13">metoprolol succinate 69.2 +/- 51.9 mg), </text>
<text top="535" left="953" width="196" height="17" font="13">with infrequent up- or down-titration </text>
<text top="553" left="953" width="217" height="17" font="13">during the HF hospitalization. 2/3 of pts </text>
<text top="570" left="953" width="196" height="17" font="13">had no change in their beta blocker </text>
<text top="587" left="953" width="212" height="17" font="13">doses in the first 60-90 d after hospital </text>
<text top="604" left="953" width="64" height="17" font="13">discharge.  </text>
<text top="622" left="953" width="222" height="17" font="13">At 60-90 d postdischarge follow-up, only </text>
<text top="639" left="953" width="194" height="17" font="13">17.5% and 7.9% of pts treated with </text>
<text top="656" left="953" width="222" height="17" font="13">recommended target doses of carvedilol </text>
<text top="673" left="953" width="140" height="17" font="13">and metoprolol succinate </text>
<text top="449" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="449" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="449" left="1371" width="49" height="17" font="13">Registry </text>
</page>
<page number="178" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">178</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="144" height="17" font="13">Gattis WA, O'Connor CM, </text>
<text top="72" left="54" width="142" height="17" font="13">Gallup DS, Hasselblad V, </text>
<text top="89" left="54" width="167" height="17" font="13">Gheorghiade M. Predischarge </text>
<text top="106" left="54" width="155" height="17" font="13">Initiation of Carvedilol in Pts </text>
<text top="124" left="54" width="88" height="17" font="13">Hospitalized for </text>
<text top="141" left="54" width="174" height="17" font="13">Decompensated HF: Results of </text>
<text top="158" left="54" width="145" height="17" font="13">the Initiation Management </text>
<text top="175" left="54" width="145" height="17" font="13">Predischarge: Process for </text>
<text top="192" left="54" width="142" height="17" font="13">Assessment of Carvedilol </text>
<text top="210" left="54" width="160" height="17" font="13">Therapy in HF (IMPACT-HF) </text>
<text top="227" left="54" width="156" height="17" font="13">trial. <i>J Am Coll Cardiol</i> 2004 </text>
<text top="244" left="54" width="121" height="17" font="13">May 5;43(9):1534-41. </text>
<text top="261" left="54" width="58" height="17" font="14">15120808 </text>
<text top="261" left="112" width="32" height="17" font="13">(355) </text>
<text top="55" left="244" width="77" height="17" font="13">To evaluate if </text>
<text top="72" left="244" width="75" height="17" font="13">predischarge </text>
<text top="89" left="244" width="117" height="17" font="13">carvedilol initiation in </text>
<text top="106" left="244" width="74" height="17" font="13">stabilized pts </text>
<text top="124" left="244" width="106" height="17" font="13">hospitalized for HF </text>
<text top="141" left="244" width="77" height="17" font="13">increased the </text>
<text top="158" left="244" width="120" height="17" font="13">number of pts treated </text>
<text top="175" left="244" width="120" height="17" font="13">with beta-blockade at </text>
<text top="192" left="244" width="55" height="17" font="13">60 d after </text>
<text top="210" left="244" width="81" height="17" font="13">randomization </text>
<text top="227" left="244" width="102" height="17" font="13">without increasing </text>
<text top="244" left="244" width="117" height="17" font="13">side effects or length </text>
<text top="261" left="244" width="89" height="17" font="13">of hospital stay. </text>
<text top="55" left="379" width="107" height="17" font="13">RCT (IMPACT-HF) </text>
<text top="55" left="507" width="24" height="17" font="13">363 </text>
<text top="55" left="635" width="131" height="17" font="13">Pts hospitalized for HF. </text>
<text top="55" left="818" width="31" height="17" font="13">  N/A </text>
<text top="55" left="953" width="214" height="17" font="13">At 60 d 165 pts (91.2%) randomized to </text>
<text top="72" left="953" width="220" height="17" font="13">predischarge carvedilol initiation treated </text>
<text top="89" left="953" width="217" height="17" font="13">with a beta blocker, compared with 130 </text>
<text top="106" left="953" width="196" height="17" font="13">pts (73.4%) randomized to initiation </text>
<text top="124" left="953" width="153" height="17" font="13">postdischarge (p &lt; 0.0001). </text>
<text top="141" left="953" width="170" height="17" font="13">Predischarge initiation was not </text>
<text top="158" left="953" width="222" height="17" font="13">associated with increased risk of SAEs.  </text>
<text top="175" left="953" width="204" height="17" font="13">The median length of stay was 5 d in </text>
<text top="192" left="953" width="72" height="17" font="13">both groups. </text>
<text top="55" left="1189" width="55" height="17" font="13">p&lt;0.0001 </text>
<text top="55" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="55" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="279" left="54" width="153" height="17" font="13">Metra M, Torp-Pedersen C, </text>
<text top="296" left="54" width="165" height="17" font="13">Cleland JG et al. Should Beta-</text>
<text top="314" left="54" width="176" height="17" font="13">blocker Therapy be Reduced or </text>
<text top="331" left="54" width="169" height="17" font="13">Withdrawn After an Episode of </text>
<text top="348" left="54" width="164" height="17" font="13">Decompensated HF? Results </text>
<text top="365" left="54" width="172" height="17" font="13">From COMET. <i>Eur J Heart Fail</i> </text>
<text top="382" left="54" width="158" height="17" font="13">2007 September;9(9):901-9. </text>
<text top="400" left="54" width="58" height="17" font="14">17581778 </text>
<text top="400" left="112" width="32" height="17" font="13">(356) </text>
<text top="279" left="244" width="71" height="17" font="13">To study the </text>
<text top="296" left="244" width="116" height="17" font="13">relationship between </text>
<text top="314" left="244" width="90" height="17" font="13">changes in beta </text>
<text top="331" left="244" width="97" height="17" font="13">blocker dose and </text>
<text top="348" left="244" width="83" height="17" font="13">outcome in pts </text>
<text top="365" left="244" width="82" height="17" font="13">surviving a HF </text>
<text top="382" left="244" width="94" height="17" font="13">hospitalization in </text>
<text top="400" left="244" width="51" height="17" font="13">COMET. </text>
<text top="279" left="379" width="79" height="17" font="13">Retrospective </text>
<text top="296" left="379" width="102" height="17" font="13">subgroup analysis </text>
<text top="314" left="379" width="46" height="17" font="13">of RCT. </text>
<text top="279" left="507" width="31" height="17" font="13">3029 </text>
<text top="279" left="635" width="146" height="17" font="13">Pts with LVEF &lt;35, NYHA </text>
<text top="296" left="635" width="163" height="17" font="13">class II-IV HF hospitalized for </text>
<text top="314" left="635" width="150" height="17" font="13">HF were subdivided on the </text>
<text top="331" left="635" width="167" height="17" font="13">basis of the beta blocker dose </text>
<text top="348" left="635" width="132" height="17" font="13">administered at the visit </text>
<text top="365" left="635" width="136" height="17" font="13">following hospitalization, </text>
<text top="382" left="635" width="170" height="17" font="13">compared to that administered </text>
<text top="400" left="635" width="42" height="17" font="13">before. </text>
<text top="279" left="818" width="105" height="17" font="13">Intolerance to beta </text>
<text top="296" left="818" width="49" height="17" font="13">blockers </text>
<text top="279" left="953" width="156" height="17" font="13">752/3029 pts (25%) with HF </text>
<text top="296" left="953" width="183" height="17" font="13">hospitalization. 61 (8%) had beta-</text>
<text top="314" left="953" width="221" height="17" font="13">blocker treatment withdrawn, 162 (22%) </text>
<text top="331" left="953" width="202" height="17" font="13">had a dose reduction and 529 (70%) </text>
<text top="348" left="953" width="168" height="17" font="13">maintained on the same dose. </text>
<text top="365" left="953" width="197" height="17" font="13">1 and 2 y cumulative mortality rates </text>
<text top="382" left="953" width="197" height="17" font="13">28.7% and 44.6% for pts withdrawn </text>
<text top="400" left="953" width="189" height="17" font="13">from study medication, 37.4% and </text>
<text top="417" left="953" width="220" height="17" font="13">51.4% for those with a reduced dosage, </text>
<text top="434" left="953" width="215" height="17" font="13">19.1% and 32.5% for those maintained </text>
<text top="451" left="953" width="208" height="17" font="13">on the same dose (HR: 1.59; 95% CI: </text>
<text top="469" left="953" width="131" height="17" font="13">1.28 to 1.98; p&lt;0.001).  </text>
<text top="486" left="953" width="220" height="17" font="13">No interaction with the beneficial effects </text>
<text top="503" left="953" width="212" height="17" font="13">of carvedilol, compared to metoprolol.  </text>
<text top="279" left="1189" width="72" height="17" font="13">95%CI: 1.28-</text>
<text top="296" left="1189" width="79" height="17" font="13">1.98; p&lt;0.001 </text>
<text top="279" left="1291" width="52" height="17" font="13">HR:1.59  </text>
<text top="279" left="1371" width="52" height="17" font="13">Post-hoc </text>
<text top="296" left="1371" width="48" height="17" font="13">analysis </text>
<text top="521" left="54" width="156" height="17" font="13">Fonarow GC, Abraham WT, </text>
<text top="538" left="54" width="156" height="17" font="13">Albert NM et al. Prospective </text>
<text top="555" left="54" width="170" height="17" font="13">Evaluation of Beta-blocker use </text>
<text top="573" left="54" width="126" height="17" font="13">at the Time of Hospital </text>
<text top="590" left="54" width="105" height="17" font="13">Discharge as a HF </text>
<text top="607" left="54" width="173" height="17" font="13">Performance Measure: Results </text>
<text top="624" left="54" width="177" height="17" font="13">From OPTIMIZE-HF.J Card Fail </text>
<text top="641" left="54" width="93" height="17" font="13">2007;13:722-31. </text>
<text top="659" left="54" width="58" height="17" font="14">17996820 </text>
<text top="659" left="112" width="32" height="17" font="13">(357) </text>
<text top="521" left="244" width="93" height="17" font="13">To prospectively </text>
<text top="538" left="244" width="120" height="17" font="13">evaluate beta blocker </text>
<text top="555" left="244" width="83" height="17" font="13">use at hospital </text>
<text top="573" left="244" width="90" height="17" font="13">discharge as an </text>
<text top="590" left="244" width="116" height="17" font="13">indicator of quality of </text>
<text top="607" left="244" width="121" height="17" font="13">care and outcomes in </text>
<text top="624" left="244" width="68" height="17" font="13">pts with HF. </text>
<text top="521" left="379" width="49" height="17" font="13">Registry </text>
<text top="521" left="507" width="38" height="17" font="13">20118 </text>
<text top="521" left="635" width="160" height="17" font="13">Data from the OPTIMIZE-HF </text>
<text top="538" left="635" width="150" height="17" font="13">registry for pts hospitalized </text>
<text top="555" left="635" width="149" height="17" font="13">with HF from 259 hospitals </text>
<text top="573" left="635" width="157" height="17" font="13">were prospectively collected </text>
<text top="590" left="635" width="163" height="17" font="13">and analyzed. 20118 pts with </text>
<text top="607" left="635" width="140" height="17" font="13">systolic dysfunction were </text>
<text top="624" left="635" width="53" height="17" font="13">included. </text>
<text top="521" left="818" width="31" height="17" font="13">  N/A </text>
<text top="521" left="953" width="202" height="17" font="13">At discharge, 90.6% of pts eligible to </text>
<text top="538" left="953" width="208" height="17" font="13">receive beta blockers, 83.7% ACEI or </text>
<text top="555" left="953" width="32" height="17" font="13">ARB. </text>
<text top="573" left="953" width="179" height="17" font="13">Eligible pts discharged with beta </text>
<text top="590" left="953" width="209" height="17" font="13">blockers significantly more likely to be </text>
<text top="607" left="953" width="189" height="17" font="13">treated at follow-up than those not </text>
<text top="624" left="953" width="208" height="17" font="13">discharged with beta blockers (93.1% </text>
<text top="641" left="953" width="125" height="17" font="13">vs. 30.5%; P&lt;0.0001). </text>
<text top="659" left="953" width="185" height="17" font="13">Discharge use of beta blockers in </text>
<text top="676" left="953" width="200" height="17" font="13">eligible pts lowers risk of death (HR: </text>
<text top="693" left="953" width="213" height="17" font="13">0.48; 95% CI: 0.32-0.74; p&lt;0.001) and </text>
<text top="710" left="953" width="215" height="17" font="13">death/rehospitalization (OR: 0.74; 95% </text>
<text top="727" left="953" width="127" height="17" font="13">CI: 0.55-0.99; p=0.04). </text>
<text top="521" left="1189" width="75" height="17" font="13">95% CI: 0.32-</text>
<text top="538" left="1189" width="79" height="17" font="13">0.74; p&lt;0.001 </text>
<text top="521" left="1291" width="55" height="17" font="13">HR: 0.48  </text>
<text top="521" left="1371" width="49" height="17" font="13">Registry </text>
</page>
<page number="179" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">179</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="156" height="17" font="13">Fonarow GC, Abraham WT, </text>
<text top="72" left="54" width="169" height="17" font="13">Albert NM et al. Carvedilol use </text>
<text top="89" left="54" width="177" height="17" font="13">at Discharge in Pts Hospitalized </text>
<text top="106" left="54" width="142" height="17" font="13">for HF is Associated With </text>
<text top="124" left="54" width="171" height="17" font="13">Improved Survival: an Analysis </text>
<text top="141" left="54" width="173" height="17" font="13">From OPTIMIZE-HF. <i>Am Heart </i></text>
<text top="158" left="54" width="165" height="17" font="22"><i>J</i> 2007 January;153(1):82-11. </text>
<text top="175" left="54" width="58" height="17" font="14">17174643 </text>
<text top="175" left="112" width="32" height="17" font="13">(358) </text>
<text top="55" left="244" width="108" height="17" font="13">Examine effects on </text>
<text top="72" left="244" width="74" height="17" font="13">mortality and </text>
<text top="89" left="244" width="106" height="17" font="13">rehospitalization of </text>
<text top="106" left="244" width="92" height="17" font="13">carvedilol use at </text>
<text top="124" left="244" width="89" height="17" font="13">discharge in pts </text>
<text top="141" left="244" width="106" height="17" font="13">hospitalized for HF </text>
<text top="158" left="244" width="118" height="17" font="13">and LVSD compared </text>
<text top="175" left="244" width="115" height="17" font="13">with outcomes in pts </text>
<text top="192" left="244" width="110" height="17" font="13">who are eligible for, </text>
<text top="210" left="244" width="105" height="17" font="13">but do not receive, </text>
<text top="227" left="244" width="115" height="17" font="13">beta blockers before </text>
<text top="244" left="244" width="60" height="17" font="13">discharge. </text>
<text top="55" left="379" width="238" height="17" font="13">Registry 5791 </text>
<text top="55" left="635" width="161" height="17" font="13">OPTIMIZE-HF </text>
<text top="55" left="717" width="129" height="17" font="13">program </text>
<text top="72" left="635" width="148" height="17" font="13">enrolled 5791 pts admitted </text>
<text top="89" left="635" width="169" height="17" font="13">with HF, web-based registry at </text>
<text top="106" left="635" width="164" height="17" font="13">91 hospitals participating with </text>
<text top="124" left="635" width="167" height="17" font="13">prespecified 60-90 d follow-up </text>
<text top="141" left="635" width="110" height="17" font="13">from March 2003 to </text>
<text top="158" left="635" width="94" height="17" font="13">December 2004. </text>
<text top="55" left="818" width="31" height="17" font="13">  N/A </text>
<text top="55" left="953" width="213" height="17" font="13">2373 (87.2%) eligible to receive a beta </text>
<text top="72" left="953" width="117" height="17" font="13">blocker at discharge. </text>
<text top="89" left="953" width="213" height="17" font="13">Carvedilol prescribed in 1162 (49.0%). </text>
<text top="106" left="953" width="212" height="17" font="13">Discharge carvedilol associated with a </text>
<text top="124" left="953" width="204" height="17" font="13">significant reduction in mortality (HR: </text>
<text top="141" left="953" width="188" height="17" font="13">0.46; p=0.0006) and mortality and </text>
<text top="158" left="953" width="212" height="17" font="13">rehospitalization (OR: 0.71, p=0.0175) </text>
<text top="175" left="953" width="191" height="17" font="13">compared to no predischarge beta </text>
<text top="192" left="953" width="47" height="17" font="13">blocker. </text>
<text top="55" left="1189" width="55" height="17" font="13">p=0.0006 </text>
<text top="55" left="1291" width="52" height="17" font="13">HR: 0.46 </text>
<text top="55" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="262" left="54" width="357" height="17" font="15"><b>Ace-Inhibitors During and at Discharge of HF Hospitalization </b></text>
<text top="287" left="54" width="113" height="17" font="13">Willenheimer R, van </text>
<text top="304" left="54" width="158" height="17" font="13">Veldhuisen DJ, Silke B et al. </text>
<text top="321" left="54" width="123" height="17" font="13">Effect on Survival and </text>
<text top="339" left="54" width="146" height="17" font="13">Hospitalization of Initiating </text>
<text top="356" left="54" width="171" height="17" font="13">Treatment for Chronic HF With </text>
<text top="373" left="54" width="126" height="17" font="13">Bisoprolol Followed by </text>
<text top="390" left="54" width="160" height="17" font="13">Enalapril, as Compared With </text>
<text top="408" left="54" width="135" height="17" font="13">the Opposite Sequence: </text>
<text top="425" left="54" width="151" height="17" font="13">Results of the Randomized </text>
<text top="442" left="54" width="114" height="17" font="13">CIBIS III. Circulation </text>
<text top="459" left="54" width="107" height="17" font="13">2005;112:2426-35. </text>
<text top="476" left="54" width="58" height="17" font="14">16143696 </text>
<text top="476" left="112" width="32" height="17" font="13">(186) </text>
<text top="287" left="244" width="76" height="17" font="13">To determine </text>
<text top="304" left="244" width="68" height="17" font="13">whether the </text>
<text top="321" left="244" width="119" height="17" font="13">sequence of initiation </text>
<text top="339" left="244" width="105" height="17" font="13">of beta blockers or </text>
<text top="356" left="244" width="70" height="17" font="13">ACEI during </text>
<text top="373" left="244" width="115" height="17" font="13">hospitalization make </text>
<text top="390" left="244" width="81" height="17" font="13">a difference in </text>
<text top="408" left="244" width="60" height="17" font="13">outcomes. </text>
<text top="287" left="379" width="32" height="17" font="13">RCT  </text>
<text top="287" left="507" width="24" height="17" font="13">101 </text>
<text top="287" left="635" width="115" height="17" font="13">Mild to moderate HF </text>
<text top="304" left="635" width="98" height="17" font="13">and LVEF ≤35%, </text>
<text top="321" left="635" width="77" height="17" font="13">who were not </text>
<text top="339" left="635" width="116" height="17" font="13">receiving ACEI, beta </text>
<text top="356" left="635" width="90" height="17" font="13">blocker, or ARB </text>
<text top="373" left="635" width="112" height="17" font="13">therapy randomized </text>
<text top="390" left="635" width="75" height="17" font="13">to open-label </text>
<text top="408" left="635" width="95" height="17" font="13">bisoprolol (target </text>
<text top="425" left="635" width="93" height="17" font="13">dose 10 mg QD; </text>
<text top="442" left="635" width="106" height="17" font="13">n=505) or enalapril </text>
<text top="459" left="635" width="107" height="17" font="13">(target dose 10 mg </text>
<text top="476" left="635" width="97" height="17" font="13">BID; n=505) for 6 </text>
<text top="494" left="635" width="89" height="17" font="13">mo, followed by </text>
<text top="511" left="635" width="115" height="17" font="13">their combination for </text>
<text top="528" left="635" width="65" height="17" font="13">6 to 24 mo. </text>
<text top="287" left="764" width="31" height="17" font="13">  N/A </text>
<text top="287" left="953" width="212" height="17" font="13">Bisoprolol-first treatment noninferior to </text>
<text top="304" left="953" width="193" height="17" font="13">enalapril-first treatment (HR: 1.17). </text>
<text top="321" left="953" width="223" height="17" font="13">Primary end point in 178 pts allocated to </text>
<text top="339" left="953" width="175" height="17" font="13">bisoprolol-first treatment vs 186 </text>
<text top="356" left="953" width="195" height="17" font="13">allocated to enalapril-first treatment </text>
<text top="373" left="953" width="170" height="17" font="13">(HR: 0.94; 95% CI: 0.77-1.16). </text>
<text top="390" left="953" width="223" height="17" font="13">Bisoprolol-first treatment: 65 pts died, vs </text>
<text top="408" left="953" width="200" height="17" font="13">73 with enalapril-first treatment (HR: </text>
<text top="425" left="953" width="217" height="17" font="13">0.88; 95% CI: 0.63 to 1.22), and 151 vs </text>
<text top="442" left="953" width="219" height="17" font="13">157 pts hospitalized (HR: 0.95; 95% CI: </text>
<text top="459" left="953" width="63" height="17" font="13">0.76-1.19). </text>
<text top="287" left="1189" width="30" height="17" font="13">p=ns </text>
<text top="287" left="1291" width="52" height="17" font="13">HR: 0.94 </text>
<text top="287" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="546" left="54" width="175" height="17" font="13">Thilly N, Briançon S, Juillière Y, </text>
<text top="563" left="54" width="168" height="17" font="13">Dufay E, Zannad F. Improving </text>
<text top="580" left="54" width="158" height="17" font="13">ACE inhibitor use in patients </text>
<text top="598" left="54" width="169" height="17" font="13">hospitalized with systolic heart </text>
<text top="615" left="54" width="158" height="17" font="13">failure: a cluster randomized </text>
<text top="632" left="54" width="134" height="17" font="13">controlled trial of clinical </text>
<text top="649" left="54" width="173" height="17" font="13">practice guideline development </text>
<text top="666" left="54" width="148" height="17" font="13">and use. J Eval Clin Pract. </text>
<text top="684" left="54" width="130" height="17" font="13">2003 Aug; 9(3):373-82. </text>
<text top="701" left="54" width="58" height="17" font="14">12895159 </text>
<text top="701" left="112" width="32" height="17" font="13">(359) </text>
<text top="546" left="244" width="122" height="17" font="13">To evaluate the effect </text>
<text top="563" left="244" width="101" height="17" font="13">of developing and </text>
<text top="580" left="244" width="113" height="17" font="13">implementing CPGs </text>
<text top="598" left="244" width="118" height="17" font="13">on the quality of care </text>
<text top="615" left="244" width="119" height="17" font="13">given to pts receiving </text>
<text top="632" left="244" width="117" height="17" font="13">ACEI for systolic HF. </text>
<text top="546" left="379" width="32" height="17" font="13">RCT  </text>
<text top="546" left="507" width="106" height="17" font="13">20 cardiology units </text>
<text top="563" left="507" width="55" height="17" font="13">in France </text>
<text top="580" left="507" width="114" height="17" font="13">(Experimental group </text>
<text top="598" left="507" width="82" height="17" font="13">(n=10) in each </text>
<text top="615" left="507" width="101" height="17" font="13">experimental unit, </text>
<text top="632" left="507" width="74" height="17" font="13">doctors were </text>
<text top="649" left="507" width="106" height="17" font="13">involved in drafting </text>
<text top="666" left="507" width="101" height="17" font="13">and implementing </text>
<text top="684" left="507" width="87" height="17" font="13">CPGs; those at </text>
<text top="701" left="507" width="100" height="17" font="13">control units were </text>
<text top="718" left="507" width="28" height="17" font="13">not.) </text>
<text top="546" left="635" width="93" height="17" font="13">HF pts &lt;75 y old </text>
<text top="546" left="764" width="59" height="17" font="13">Age &gt;75 y </text>
<text top="546" left="953" width="202" height="17" font="13">Compliance with the CPG relating to </text>
<text top="563" left="953" width="207" height="17" font="13">ACEI dose on discharge higher in the </text>
<text top="580" left="953" width="172" height="17" font="13">experimental group (p=0.003).  </text>
<text top="546" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="546" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="546" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="736" left="54" width="364" height="17" font="15"><b>Spironolactone During and at Discharge of HF Hospitalization </b></text>
</page>
<page number="180" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">180</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="153" height="17" font="13">Hamaguchi S, Kinugawa S, </text>
<text top="72" left="54" width="160" height="17" font="13">Tsuchihashi-Makaya M et al. </text>
<text top="89" left="54" width="122" height="17" font="13">Spironolactone use at </text>
<text top="106" left="54" width="176" height="17" font="13">Discharge was Associated With </text>
<text top="124" left="54" width="115" height="17" font="13">Improved Survival in </text>
<text top="141" left="54" width="165" height="17" font="13">Hospitalized Pts With Systolic </text>
<text top="158" left="54" width="88" height="17" font="13">HF. Am Heart J </text>
<text top="175" left="54" width="107" height="17" font="13">2010;160:1156-62. </text>
<text top="192" left="54" width="58" height="17" font="14">21146672 </text>
<text top="192" left="112" width="32" height="17" font="13">(360) </text>
<text top="55" left="244" width="70" height="17" font="13">Whether the </text>
<text top="72" left="244" width="80" height="17" font="13">discharge use </text>
<text top="89" left="244" width="109" height="17" font="13">of spironolactone is </text>
<text top="106" left="244" width="87" height="17" font="13">associated with </text>
<text top="124" left="244" width="109" height="17" font="13">better mortality and </text>
<text top="141" left="244" width="92" height="17" font="13">rehospitalization </text>
<text top="158" left="244" width="115" height="17" font="13">among hospitalized s</text>
<text top="175" left="244" width="81" height="17" font="13">ystolic HF pts. </text>
<text top="55" left="379" width="109" height="17" font="13">Prospective cohort  </text>
<text top="55" left="507" width="24" height="17" font="13">946 </text>
<text top="55" left="635" width="110" height="17" font="13">Hospitalized HF pts </text>
<text top="72" left="635" width="107" height="17" font="13">with reduced LVEF </text>
<text top="89" left="635" width="39" height="17" font="13">&lt;40%. </text>
<text top="55" left="764" width="31" height="17" font="13">  N/A </text>
<text top="55" left="953" width="217" height="17" font="13">Spironolactone prescribed at discharge </text>
<text top="72" left="953" width="96" height="17" font="13">in 435 pts (46%). </text>
<text top="89" left="953" width="179" height="17" font="13">Discharge use of spironolactone </text>
<text top="106" left="953" width="218" height="17" font="13">associated with reduction in death (HR: </text>
<text top="124" left="953" width="220" height="17" font="13">0.612; p=0.020) and cardiac death (HR: </text>
<text top="141" left="953" width="93" height="17" font="13">0.524; p=0.013). </text>
<text top="55" left="1189" width="41" height="17" font="13">p=0.02 </text>
<text top="55" left="1291" width="62" height="17" font="13">HR: 0.612  </text>
<text top="55" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="217" left="54" width="166" height="17" font="13">Ko DT, Juurlink DN, Mamdani </text>
<text top="234" left="54" width="161" height="17" font="13">MM et al. Appropriateness of </text>
<text top="251" left="54" width="163" height="17" font="13">Spironolactone Prescribing in </text>
<text top="268" left="54" width="155" height="17" font="13">HF Pts: a Population-Based </text>
<text top="286" left="54" width="174" height="17" font="13">Study. J Card Fail 2006;12:205-</text>
<text top="303" left="54" width="21" height="17" font="13">10. </text>
<text top="320" left="54" width="58" height="17" font="14">16624686 </text>
<text top="320" left="112" width="32" height="17" font="13">(361) </text>
<text top="217" left="244" width="107" height="17" font="13">Appropriateness of </text>
<text top="234" left="244" width="83" height="17" font="13">spironolactone </text>
<text top="251" left="244" width="81" height="17" font="13">prescription at </text>
<text top="268" left="244" width="60" height="17" font="13">discharge. </text>
<text top="217" left="379" width="98" height="17" font="13">Population based </text>
<text top="234" left="379" width="40" height="17" font="13">Cohort </text>
<text top="217" left="507" width="295" height="17" font="13">9165 Hospitalized </text>
<text top="217" left="706" width="117" height="17" font="13">HF </text>
<text top="217" left="726" width="117" height="17" font="13">pts </text>
<text top="234" left="635" width="110" height="17" font="13">in Ontario, Canada, </text>
<text top="251" left="635" width="66" height="17" font="13">1999-2001. </text>
<text top="217" left="764" width="31" height="17" font="13">  N/A </text>
<text top="217" left="953" width="208" height="17" font="13">1502 pts prescribed spironolactone at </text>
<text top="234" left="953" width="60" height="17" font="13">discharge. </text>
<text top="251" left="953" width="166" height="17" font="13">18% had hyperkalemia during </text>
<text top="268" left="953" width="163" height="17" font="13">hospitalization and 23% were </text>
<text top="286" left="953" width="202" height="17" font="13">discharged on concurrent potassium </text>
<text top="303" left="953" width="77" height="17" font="13">supplements. </text>
<text top="320" left="953" width="210" height="17" font="13">Although only 8% of pts with SCr &gt;2.5 </text>
<text top="337" left="953" width="197" height="17" font="13">mg/dL, many with stage III (53.1%), </text>
<text top="354" left="953" width="198" height="17" font="13">stage IV (12.8%), or stage V (3.9%) </text>
<text top="372" left="953" width="148" height="17" font="13">chronic renal insufficiency. </text>
<text top="217" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="217" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="217" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="390" left="54" width="320" height="17" font="15"><b>Digoxin During and at Discharge of HF Hospitalization </b></text>
<text top="410" left="54" width="171" height="17" font="13">Dhaliwal AS, Bredikis A, Habib </text>
<text top="427" left="54" width="166" height="17" font="13">G, Carabello BA, Ramasubbu </text>
<text top="444" left="54" width="144" height="17" font="13">K, Bozkurt B. Digoxin and </text>
<text top="462" left="54" width="161" height="17" font="13">Clinical Outcomes in Systolic </text>
<text top="479" left="54" width="139" height="17" font="13">HF Pts on Contemporary </text>
<text top="496" left="54" width="172" height="17" font="13">Background HF Therapy. Am J </text>
<text top="513" left="54" width="149" height="17" font="13">Cardiol 2008;102:1356-60. </text>
<text top="530" left="54" width="58" height="17" font="14">18993155 </text>
<text top="530" left="112" width="32" height="17" font="13">(362) </text>
<text top="410" left="244" width="76" height="17" font="13">To determine </text>
<text top="427" left="244" width="54" height="17" font="13">the effect </text>
<text top="444" left="244" width="70" height="17" font="13">of digoxin at </text>
<text top="462" left="244" width="89" height="17" font="13">discharge in pts </text>
<text top="479" left="244" width="94" height="17" font="13">hospitalized with </text>
<text top="496" left="244" width="23" height="17" font="13">HF. </text>
<text top="410" left="352" width="294" height="17" font="13">Cohort 347 </text>
<text top="410" left="635" width="185" height="17" font="13">Hospitalized </text>
<text top="410" left="706" width="135" height="17" font="13">pts </text>
<text top="410" left="726" width="140" height="17" font="13">with </text>
<text top="427" left="635" width="23" height="17" font="13">HF. </text>
<text top="410" left="764" width="167" height="17" font="13">Competing non-HF diagnoses </text>
<text top="410" left="953" width="214" height="17" font="13">HF hospitalizations (HR: 1.08; 95% CI: </text>
<text top="427" left="953" width="213" height="17" font="13">0.77-1.50; p=0.66), total mortality (HR: </text>
<text top="444" left="953" width="221" height="17" font="13">1.03; 95% CI: 0.78-1.35, p=0.85), or the </text>
<text top="462" left="953" width="144" height="17" font="13">combined end point of HF </text>
<text top="479" left="953" width="211" height="17" font="13">hospitalization and total mortality (HR: </text>
<text top="496" left="953" width="203" height="17" font="13">1.11, 95% CI: 0.81-1.53, p=0.52) not </text>
<text top="513" left="953" width="190" height="17" font="13">different in pts treated with digoxin </text>
<text top="530" left="953" width="204" height="17" font="13">compared with those not treated with </text>
<text top="548" left="953" width="46" height="17" font="13">digoxin. </text>
<text top="410" left="1189" width="186" height="17" font="13">p=0.66 HR: </text>
<text top="410" left="1315" width="87" height="17" font="13">1.08 </text>
<text top="410" left="1371" width="139" height="17" font="13">Retrospective </text>
<text top="427" left="1371" width="38" height="17" font="13">cohort </text>
<text top="566" left="54" width="171" height="17" font="13">Ahmed A, Allman RM, DeLong </text>
<text top="583" left="54" width="133" height="17" font="13">JF. Inappropriate use of </text>
<text top="600" left="54" width="161" height="17" font="13">Digoxin in Older Hospitalized </text>
<text top="617" left="54" width="161" height="17" font="13">HF Pts. J Gerontol A Biol Sci </text>
<text top="634" left="54" width="168" height="17" font="13">Med Sci 2002;57:M138-M143. </text>
<text top="652" left="54" width="58" height="17" font="14">11818435 </text>
<text top="652" left="112" width="32" height="17" font="13">(363) </text>
<text top="566" left="244" width="76" height="17" font="13">To determine </text>
<text top="583" left="244" width="92" height="17" font="13">the correlates of </text>
<text top="600" left="244" width="92" height="17" font="13">inappropriate dig</text>
<text top="617" left="244" width="62" height="17" font="13">oxin use in </text>
<text top="634" left="244" width="74" height="17" font="13">older HF pts. </text>
<text top="566" left="352" width="294" height="17" font="13">Cohort 603 </text>
<text top="566" left="635" width="148" height="17" font="13">Older </text>
<text top="566" left="669" width="183" height="17" font="13">hospitalized </text>
<text top="583" left="635" width="65" height="17" font="13">HF pts with </text>
<text top="600" left="635" width="105" height="17" font="13">documented LVEF </text>
<text top="617" left="635" width="60" height="17" font="13">and EKG.  </text>
<text top="566" left="764" width="31" height="17" font="13">  N/A </text>
<text top="566" left="953" width="216" height="17" font="13">Digoxin use considered inappropriate if </text>
<text top="583" left="953" width="205" height="17" font="13">pts had preserved LVEF (≥40%) or if </text>
<text top="600" left="953" width="90" height="17" font="13">they had no AF. </text>
<text top="617" left="953" width="206" height="17" font="13">376 pts (62%) discharged on digoxin, </text>
<text top="634" left="953" width="200" height="17" font="13">and 223 (37%) without indication for </text>
<text top="652" left="953" width="202" height="17" font="13">use. Of 132 pts without an indication </text>
<text top="669" left="953" width="204" height="17" font="13">and not already on digoxin, 38 (29%) </text>
<text top="686" left="953" width="76" height="17" font="13">initiated on it. </text>
<text top="566" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="566" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="566" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="704" left="54" width="677" height="17" font="15"><b>Adherence to Performance Measurements or Guidelines for Evidence Based Medication Use During Hospitalization </b></text>
<text top="724" left="54" width="156" height="17" font="13">Krantz MJ, Ambardekar AV, </text>
<text top="741" left="54" width="165" height="17" font="13">Kaltenbach L, Hernandez AF, </text>
<text top="759" left="54" width="169" height="17" font="13">Heidenreich PA, Fonarow GC. </text>
<text top="776" left="54" width="146" height="17" font="13">Patterns and Predictors of </text>
<text top="724" left="244" width="59" height="17" font="13">To assess </text>
<text top="741" left="244" width="107" height="17" font="13">noncontraindicated </text>
<text top="759" left="244" width="89" height="17" font="13">use patterns for </text>
<text top="776" left="244" width="98" height="17" font="13">ACEI/ARBs, beta </text>
<text top="724" left="379" width="95" height="17" font="13">Registry (GTWG-</text>
<text top="741" left="379" width="24" height="17" font="13">HF) </text>
<text top="724" left="507" width="31" height="17" font="13">9474 </text>
<text top="724" left="635" width="31" height="17" font="13">  N/A </text>
<text top="724" left="764" width="31" height="17" font="13">  N/A </text>
<text top="724" left="946" width="215" height="17" font="13">Of those treated before hospitalization, </text>
<text top="741" left="946" width="230" height="17" font="13">continuation rates: 88.5% for ACEI/ARBs, </text>
<text top="759" left="946" width="216" height="17" font="13">91.6% for beta blockers, and 71.9% for </text>
<text top="776" left="946" width="138" height="17" font="13">aldosterone-antagonists. </text>
<text top="724" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="724" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="724" left="1371" width="31" height="17" font="13">  N/A </text>
</page>
<page number="181" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">181</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="156" height="17" font="13">Evidence-Based Medication </text>
<text top="72" left="54" width="115" height="17" font="13">Continuation Among </text>
<text top="89" left="54" width="167" height="17" font="13">Hospitalized HF Pts (from Get </text>
<text top="106" left="54" width="170" height="17" font="13">With the Guidelines-HF). Am J </text>
<text top="124" left="54" width="103" height="17" font="13">Cardiol 2011 June </text>
<text top="141" left="54" width="115" height="17" font="13">15;107(12):1818-23. </text>
<text top="158" left="54" width="58" height="17" font="14">21482418 </text>
<text top="158" left="112" width="32" height="17" font="13">(364) </text>
<text top="55" left="244" width="77" height="17" font="13">blockers, and </text>
<text top="72" left="244" width="68" height="17" font="13">aldosterone </text>
<text top="89" left="244" width="120" height="17" font="13">antagonists using the </text>
<text top="106" left="244" width="109" height="17" font="13">GWTG-HF registry. </text>
<text top="55" left="946" width="192" height="17" font="13">Of pts untreated before admission, </text>
<text top="72" left="946" width="205" height="17" font="13">87.4% started on ACEI/ARBs, 90.1% </text>
<text top="89" left="946" width="167" height="17" font="13">beta blocker and 25.2% on an </text>
<text top="106" left="946" width="165" height="17" font="13">aldosterone antagonist during </text>
<text top="124" left="946" width="170" height="17" font="13">hospitalization or at discharge. </text>
<text top="141" left="946" width="181" height="17" font="13">Admission therapy most strongly </text>
<text top="158" left="946" width="221" height="17" font="13">associated with discharge use (OR: 7.4, </text>
<text top="175" left="946" width="191" height="17" font="13">6.0, and 20.9 for ACEI/ARBs, beta </text>
<text top="192" left="946" width="214" height="17" font="13">blockers, and aldosterone antagonists, </text>
<text top="210" left="946" width="72" height="17" font="13">respectively) </text>
<text top="228" left="54" width="168" height="17" font="13">Fonarow GC, Gheorghiade M, </text>
<text top="245" left="54" width="172" height="17" font="13">Abraham WT. Importance of In-</text>
<text top="262" left="54" width="163" height="17" font="13">hospital Initiation of Evidence-</text>
<text top="279" left="54" width="159" height="17" font="13">based Medical Therapies for </text>
<text top="296" left="54" width="152" height="17" font="13">HF-a Review. <i>Am J Cardiol</i> </text>
<text top="314" left="54" width="165" height="17" font="13">2004 November 1;94(9):1155-</text>
<text top="331" left="54" width="24" height="17" font="13">60.  </text>
<text top="331" left="78" width="62" height="17" font="14">15518610  </text>
<text top="331" left="139" width="32" height="17" font="13">(365) </text>
<text top="228" left="244" width="86" height="17" font="13">Review of AHF </text>
<text top="245" left="244" width="57" height="17" font="13">therapies. </text>
<text top="228" left="379" width="44" height="17" font="13">Review </text>
<text top="228" left="507" width="24" height="17" font="13">N/A </text>
<text top="228" left="635" width="24" height="17" font="13">N/A </text>
<text top="228" left="764" width="24" height="17" font="13">N/A </text>
<text top="228" left="946" width="217" height="17" font="13">Message: Adopting in-hospital initiation </text>
<text top="245" left="946" width="217" height="17" font="13">of HF therapies as the standard of care </text>
<text top="262" left="946" width="224" height="17" font="13">could improve treatment rates, decrease </text>
<text top="279" left="946" width="206" height="17" font="13">the risk of future hospitalizations, and </text>
<text top="296" left="946" width="67" height="17" font="13">prolong life. </text>
<text top="228" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="228" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="228" left="1371" width="79" height="17" font="13">Review paper </text>
<text top="362" left="54" width="141" height="17" font="13">Fonarow GC, Yancy CW, </text>
<text top="379" left="54" width="172" height="17" font="13">Heywood JT. Adherence to HF </text>
<text top="397" left="54" width="174" height="17" font="13">Quality-of-care Indicators in US </text>
<text top="414" left="54" width="141" height="17" font="13">Hospitals: Analysis of the </text>
<text top="431" left="54" width="170" height="17" font="13">ADHERE Registry. <i>Arch Intern </i></text>
<text top="448" left="54" width="83" height="17" font="22"><i>Med</i> 2005 July </text>
<text top="465" left="54" width="115" height="17" font="13">11;165(13):1469-77. </text>
<text top="483" left="54" width="58" height="17" font="14">16009861 </text>
<text top="483" left="112" width="32" height="17" font="13">(366) </text>
<text top="362" left="244" width="96" height="17" font="13">To determine the </text>
<text top="379" left="244" width="86" height="17" font="13">current rates of </text>
<text top="397" left="244" width="85" height="17" font="13">conformity with </text>
<text top="414" left="244" width="80" height="17" font="13">quality of care </text>
<text top="431" left="244" width="98" height="17" font="13">indicators or their </text>
<text top="448" left="244" width="94" height="17" font="13">variability across </text>
<text top="465" left="244" width="55" height="17" font="13">hospitals. </text>
<text top="362" left="379" width="230" height="17" font="13">Registry (ADHERE)  81142 admissions </text>
<text top="362" left="635" width="103" height="17" font="13">81142 admissions </text>
<text top="379" left="635" width="104" height="17" font="13">occurring between </text>
<text top="397" left="635" width="97" height="17" font="13">July 1, 2002, and </text>
<text top="414" left="635" width="115" height="17" font="13">December 31, 2003, </text>
<text top="431" left="635" width="94" height="17" font="13">at 223 academic </text>
<text top="448" left="635" width="105" height="17" font="13">and non-academic </text>
<text top="465" left="635" width="106" height="17" font="13">hospitals in the US </text>
<text top="483" left="635" width="103" height="17" font="13">participating in the </text>
<text top="500" left="635" width="58" height="17" font="13">ADHERE. </text>
<text top="362" left="764" width="31" height="17" font="13">  N/A </text>
<text top="362" left="946" width="208" height="17" font="13">Median rates of conformity with HF-1, </text>
<text top="379" left="946" width="206" height="17" font="13">HF-2, HF-3, and HF-4 24.0%, 86.2%, </text>
<text top="397" left="946" width="179" height="17" font="13">72.0%, and 43.2%, respectively. </text>
<text top="362" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="362" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="362" left="1371" width="49" height="17" font="13">Registry </text>
<text top="518" left="54" width="156" height="17" font="13">Fonarow GC, Abraham WT, </text>
<text top="535" left="54" width="154" height="17" font="13">Albert NM et al. Association </text>
<text top="552" left="54" width="125" height="17" font="13">Between Performance </text>
<text top="570" left="54" width="124" height="17" font="13">Measures and Clinical </text>
<text top="587" left="54" width="169" height="17" font="13">Outcomes for Pts Hospitalized </text>
<text top="604" left="54" width="165" height="17" font="13">With HF. JAMA 2007 January </text>
<text top="621" left="54" width="88" height="17" font="13">3;297(1):61-70. </text>
<text top="638" left="54" width="58" height="17" font="14">17200476 </text>
<text top="638" left="112" width="32" height="17" font="13">(367) </text>
<text top="518" left="244" width="88" height="17" font="13">To examine the </text>
<text top="535" left="244" width="116" height="17" font="13">relationship between </text>
<text top="552" left="244" width="116" height="17" font="13">current (ACCF/AHA) </text>
<text top="570" left="244" width="73" height="17" font="13">performance </text>
<text top="587" left="244" width="95" height="17" font="13">measures for pts </text>
<text top="604" left="244" width="114" height="17" font="13">hospitalized with HF </text>
<text top="621" left="244" width="111" height="17" font="13">and relevant clinical </text>
<text top="638" left="244" width="64" height="17" font="13">outcomes.  </text>
<text top="518" left="379" width="49" height="17" font="13">Registry </text>
<text top="535" left="379" width="90" height="17" font="13">(OPTIMIZE-HF) </text>
<text top="518" left="507" width="102" height="17" font="13">5791 pts at 91 US </text>
<text top="535" left="507" width="52" height="17" font="13">hospitals </text>
<text top="518" left="635" width="96" height="17" font="13">OPTIMIZE-HF, a </text>
<text top="535" left="635" width="68" height="17" font="13">registry and </text>
<text top="552" left="635" width="73" height="17" font="13">performance </text>
<text top="570" left="635" width="75" height="17" font="13">improvement </text>
<text top="587" left="635" width="53" height="17" font="13">program. </text>
<text top="518" left="764" width="91" height="17" font="13">Incomplete data </text>
<text top="518" left="946" width="195" height="17" font="13">Mortality during follow-up 8.6% and </text>
<text top="535" left="946" width="184" height="17" font="13">mortality/rehospitalization 36.2%. </text>
<text top="552" left="946" width="163" height="17" font="13">None of the 5 ACCF/AHA HF </text>
<text top="570" left="946" width="222" height="17" font="13">performance measures was significantly </text>
<text top="587" left="946" width="215" height="17" font="13">associated with reduced early mortality </text>
<text top="604" left="946" width="26" height="17" font="13">risk. </text>
<text top="621" left="946" width="223" height="17" font="13">Only ACEI or ARB use at discharge was </text>
<text top="638" left="946" width="226" height="17" font="13">associated with 60 to 90 d postdischarge </text>
<text top="656" left="946" width="160" height="17" font="13">mortality or rehospitalization. </text>
<text top="673" left="946" width="202" height="17" font="13">Beta-blockade at the time of hospital </text>
<text top="690" left="946" width="187" height="17" font="13">discharge, (not a HF performance </text>
<text top="707" left="946" width="217" height="17" font="13">measure then) strongly associated with </text>
<text top="724" left="946" width="204" height="17" font="13">reduced mortality (HR: 0.48; 95% CI: </text>
<text top="742" left="946" width="115" height="17" font="13">0.30-0.79; p=0.004). </text>
<text top="518" left="1189" width="66" height="17" font="13">p=0.004 for </text>
<text top="535" left="1189" width="78" height="17" font="13">beta- blocker, </text>
<text top="552" left="1189" width="59" height="17" font="13">p&lt;0.05 for </text>
<text top="570" left="1189" width="36" height="17" font="13">ACEI. </text>
<text top="518" left="1291" width="7" height="17" font="13">  </text>
<text top="518" left="1371" width="49" height="17" font="13">Registry </text>
</page>
<page number="182" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">182</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="145" height="17" font="13">Lappe JM, Muhlestein JB, </text>
<text top="72" left="54" width="168" height="17" font="13">Lappe DL et al. Improvements </text>
<text top="89" left="54" width="161" height="17" font="13">in 1 y Cardiovascular Clinical </text>
<text top="106" left="54" width="161" height="17" font="13">Outcomes Associated With a </text>
<text top="124" left="54" width="144" height="17" font="13">Hospital-based Discharge </text>
<text top="141" left="54" width="177" height="17" font="13">Medication Program. <i>Ann Intern </i></text>
<text top="158" left="54" width="122" height="17" font="22"><i>Med</i> 2004 September </text>
<text top="175" left="54" width="101" height="17" font="13">21;141(6):446-53. </text>
<text top="192" left="54" width="58" height="17" font="14">15381518 </text>
<text top="192" left="112" width="32" height="17" font="13">(368) </text>
<text top="55" left="244" width="88" height="17" font="13">To develop and </text>
<text top="72" left="244" width="120" height="17" font="13">implement a program </text>
<text top="89" left="244" width="116" height="17" font="13">ensuring appropriate </text>
<text top="106" left="244" width="81" height="17" font="13">prescription of </text>
<text top="124" left="244" width="113" height="17" font="13">aspirin, statins, beta </text>
<text top="141" left="244" width="112" height="17" font="13">blockers, ACEI, and </text>
<text top="158" left="244" width="107" height="17" font="13">warfarin at hospital </text>
<text top="175" left="244" width="60" height="17" font="13">discharge. </text>
<text top="55" left="379" width="105" height="17" font="13">Prospective cohort </text>
<text top="55" left="507" width="113" height="17" font="13">57465 enrolled from </text>
<text top="72" left="507" width="109" height="17" font="13">10 largest hospitals </text>
<text top="89" left="507" width="101" height="17" font="13">in the Utah-based </text>
<text top="106" left="507" width="79" height="17" font="13">Intermountain </text>
<text top="124" left="507" width="115" height="17" font="13">Health Care system. </text>
<text top="55" left="635" width="107" height="17" font="13">A nonrandomized / </text>
<text top="72" left="635" width="100" height="17" font="13">before-after study </text>
<text top="89" left="635" width="81" height="17" font="13">comparing pts </text>
<text top="106" left="635" width="107" height="17" font="13">hospitalized before </text>
<text top="124" left="635" width="94" height="17" font="13">(1996-1998) and </text>
<text top="141" left="635" width="99" height="17" font="13">after (1999-2002) </text>
<text top="158" left="635" width="111" height="17" font="13">implementation of a </text>
<text top="175" left="635" width="34" height="17" font="13">DMP. </text>
<text top="55" left="764" width="7" height="17" font="13">  </text>
<text top="55" left="946" width="217" height="17" font="13">Rate of prescription of each medication </text>
<text top="72" left="946" width="173" height="17" font="13">increased significantly to &gt;90% </text>
<text top="89" left="946" width="60" height="17" font="13">(p&lt;0.001). </text>
<text top="106" left="946" width="208" height="17" font="13">RR for death and readmission at 30 d </text>
<text top="124" left="946" width="210" height="17" font="13">decreased after DMP implementation; </text>
<text top="141" left="946" width="204" height="17" font="13">HRs for death and readmission: 0.81 </text>
<text top="158" left="946" width="213" height="17" font="13">(95% CI: 0.73-0.89) and 0.92 (95% CI: </text>
<text top="175" left="946" width="187" height="17" font="13">0.87-0.99) (p&lt;0.001 and p=0.017, </text>
<text top="192" left="946" width="76" height="17" font="13">respectively). </text>
<text top="210" left="946" width="215" height="17" font="13">At 1 y, risk for death still low (HR: 0.79; </text>
<text top="227" left="946" width="230" height="17" font="13">95% CI: 0.75-0.84; p&lt;0.001) while risk for </text>
<text top="244" left="946" width="212" height="17" font="13">readmission stabilized (HR: 0.94; 95% </text>
<text top="261" left="946" width="134" height="17" font="13">CI: 0.90-0.98; p=0.002). </text>
<text top="55" left="1189" width="75" height="17" font="13">95% CI: 0.75-</text>
<text top="72" left="1189" width="79" height="17" font="13">0.84; p&lt;0.001 </text>
<text top="55" left="1291" width="52" height="17" font="13">HR: 0.79 </text>
<text top="55" left="1371" width="79" height="17" font="13">Observational </text>
<text top="72" left="1371" width="24" height="17" font="13">and </text>
<text top="89" left="1371" width="85" height="17" font="13">nonrandomized</text>
<text top="106" left="1371" width="84" height="17" font="13">, authors could </text>
<text top="124" left="1371" width="79" height="17" font="13">not control for </text>
<text top="141" left="1371" width="50" height="17" font="13">potential </text>
<text top="158" left="1371" width="85" height="17" font="13">confounders or </text>
<text top="175" left="1371" width="79" height="17" font="13">determine the </text>
<text top="192" left="1371" width="85" height="17" font="13">extent to which </text>
<text top="210" left="1371" width="81" height="17" font="13">secular trends </text>
<text top="227" left="1371" width="78" height="17" font="13">accounted for </text>
<text top="244" left="1371" width="75" height="17" font="13">the observed </text>
<text top="261" left="1371" width="84" height="17" font="13">improvements. </text>
<text top="279" left="54" width="377" height="17" font="15"><b>AHA Scientific Statement for Treatment of Acute HF Syndromes </b></text>
<text top="300" left="54" width="146" height="17" font="13">Weintraub NL, Collins SP, </text>
<text top="317" left="54" width="137" height="17" font="13">Pang PS et al. Acute HF </text>
<text top="334" left="54" width="165" height="17" font="13">Syndromes: ED Presentation, </text>
<text top="351" left="54" width="154" height="17" font="13">Treatment, and Disposition: </text>
<text top="368" left="54" width="176" height="17" font="13">Current Approaches and Future </text>
<text top="386" left="54" width="157" height="17" font="13">Aims: a Scientific Statement </text>
<text top="403" left="54" width="177" height="17" font="13">From the AHA. Circulation 2010 </text>
<text top="420" left="54" width="168" height="17" font="13">November 9;122(19):1975-96. </text>
<text top="437" left="54" width="58" height="17" font="14">20937981 </text>
<text top="437" left="112" width="32" height="17" font="13">(369) </text>
<text top="300" left="244" width="122" height="17" font="13">To characterize acute </text>
<text top="317" left="244" width="115" height="17" font="13">HF syndromes: from </text>
<text top="334" left="244" width="75" height="17" font="13">presentation, </text>
<text top="351" left="244" width="83" height="17" font="13">treatment, and </text>
<text top="368" left="244" width="65" height="17" font="13">disposition. </text>
<text top="300" left="379" width="79" height="17" font="13">AHA scientific </text>
<text top="317" left="379" width="57" height="17" font="13">statement </text>
<text top="300" left="507" width="24" height="17" font="13">N/A </text>
<text top="300" left="635" width="24" height="17" font="13">N/A </text>
<text top="300" left="764" width="31" height="17" font="13">  N/A </text>
<text top="300" left="946" width="31" height="17" font="13">  N/A </text>
<text top="300" left="1189" width="31" height="17" font="13">  N/A </text>
<text top="300" left="1291" width="31" height="17" font="13">  N/A </text>
<text top="300" left="1371" width="31" height="17" font="13">  N/A </text>
<text top="457" left="54" width="414" height="17" font="15"><b>Recent Studies with Other Oral Medications for Treatment of Acute HF </b></text>
<text top="479" left="54" width="169" height="17" font="13">Gheorghiade M, Konstam MA, </text>
<text top="496" left="54" width="174" height="17" font="13">Burnett JC, Jr. et al. Short-term </text>
<text top="513" left="54" width="176" height="17" font="13">Clinical Effects of Tolvaptan, an </text>
<text top="531" left="54" width="175" height="17" font="13">Oral Vasopressin Antagonist, in </text>
<text top="548" left="54" width="153" height="17" font="13">Pts Hospitalized for HF: the </text>
<text top="565" left="54" width="142" height="17" font="13">EVEREST Clinical Status </text>
<text top="582" left="54" width="142" height="17" font="13">Trials. <i>JAMA</i> 2007 March </text>
<text top="599" left="54" width="115" height="17" font="13">28;297(12):1332-43. </text>
<text top="617" left="54" width="58" height="17" font="14">17384438 </text>
<text top="617" left="112" width="32" height="17" font="13">(153) </text>
<text top="479" left="244" width="99" height="17" font="13">To evaluate short-</text>
<text top="496" left="244" width="81" height="17" font="13">term effects of </text>
<text top="513" left="244" width="86" height="17" font="13">tolvaptan when </text>
<text top="531" left="244" width="103" height="17" font="13">added to standard </text>
<text top="548" left="244" width="77" height="17" font="13">therapy in pts </text>
<text top="565" left="244" width="120" height="17" font="13">hospitalized with HF.  </text>
<text top="479" left="379" width="98" height="17" font="13">RCT (EVEREST) </text>
<text top="479" left="507" width="100" height="17" font="13">2048 trial A, 2085 </text>
<text top="496" left="507" width="74" height="17" font="13">(trial B) 4133 </text>
<text top="513" left="507" width="113" height="17" font="13">tolvaptan (30 mg/d), </text>
<text top="531" left="507" width="68" height="17" font="13">or matching </text>
<text top="548" left="507" width="112" height="17" font="13">placebo, within 48 h </text>
<text top="565" left="507" width="76" height="17" font="13">of admission. </text>
<text top="479" left="635" width="105" height="17" font="13">Age ≥18 y; current </text>
<text top="496" left="635" width="99" height="17" font="13">hospitalization for </text>
<text top="513" left="635" width="113" height="17" font="13">CHF with admission </text>
<text top="531" left="635" width="100" height="17" font="13">up to 48 h prior to </text>
<text top="548" left="635" width="84" height="17" font="13">randomization; </text>
<text top="565" left="635" width="75" height="17" font="13">chronic HF is </text>
<text top="582" left="635" width="111" height="17" font="13">defined as requiring </text>
<text top="599" left="635" width="84" height="17" font="13">treatment for a </text>
<text top="617" left="635" width="94" height="17" font="13">minimum of 30 d </text>
<text top="634" left="635" width="42" height="17" font="13">prior to </text>
<text top="651" left="635" width="85" height="17" font="13">hospitalization. </text>
<text top="668" left="635" width="105" height="17" font="13">Subject must have </text>
<text top="685" left="635" width="116" height="17" font="13">signs of extracellular </text>
<text top="703" left="635" width="106" height="17" font="13">volume expansion, </text>
<text top="720" left="635" width="113" height="17" font="13">defined as ≥2 of the </text>
<text top="737" left="635" width="114" height="17" font="13">following: a) JVD; b) </text>
<text top="754" left="635" width="114" height="17" font="13">pitting edema (&gt;1+); </text>
<text top="771" left="635" width="81" height="17" font="13">or c) dyspnea. </text>
<text top="789" left="635" width="115" height="17" font="13">NYHA Class III or IV </text>
<text top="479" left="764" width="168" height="17" font="13">Women who will not adhere to </text>
<text top="496" left="764" width="159" height="17" font="13">the reproductive precautions </text>
<text top="513" left="764" width="123" height="17" font="13">as outlined in the ICF. </text>
<text top="531" left="764" width="165" height="17" font="13">Positive urine pregnancy test. </text>
<text top="548" left="764" width="142" height="17" font="13">Inability to provide written </text>
<text top="565" left="764" width="147" height="17" font="13">informed consent. Cardiac </text>
<text top="582" left="764" width="120" height="17" font="13">surgery within 60 d of </text>
<text top="599" left="764" width="147" height="17" font="13">potential study enrollment, </text>
<text top="617" left="764" width="131" height="17" font="13">excluding PCI. Planned </text>
<text top="634" left="764" width="164" height="17" font="13">revascularization procedures, </text>
<text top="651" left="764" width="132" height="17" font="13">EP device implantation, </text>
<text top="668" left="764" width="153" height="17" font="13">cardiac mechanical support </text>
<text top="685" left="764" width="116" height="17" font="13">implantation, cardiac </text>
<text top="703" left="764" width="134" height="17" font="13">transplantation, or other </text>
<text top="720" left="764" width="150" height="17" font="13">cardiac surgery within 30 d </text>
<text top="737" left="764" width="148" height="17" font="13">following study enrollment. </text>
<text top="754" left="764" width="158" height="17" font="13">Subjects who are on cardiac </text>
<text top="771" left="764" width="146" height="17" font="13">mechanical support. Hx of </text>
<text top="789" left="764" width="164" height="17" font="13">biventricular pacer placement </text>
<text top="479" left="946" width="204" height="17" font="13">Tolvaptan had no effect on long-term </text>
<text top="496" left="946" width="186" height="17" font="13">mortality or HF-related morbidity.  </text>
<text top="513" left="946" width="204" height="17" font="13">Mortality for tolvaptan vs placebo not </text>
<text top="531" left="946" width="213" height="17" font="13">different (HR: 0.98; 95% CI: 0.87-1.11; </text>
<text top="548" left="946" width="49" height="17" font="13">p=0.68). </text>
<text top="565" left="946" width="226" height="17" font="13">Composite of CV death or hospitalization </text>
<text top="582" left="946" width="213" height="17" font="13">for HF not different (HR: 1.04; 95% CI: </text>
<text top="599" left="946" width="108" height="17" font="13">0.95-1.14; p=0.55). </text>
<text top="617" left="946" width="217" height="17" font="13">Secondary end points CV mortality, CV </text>
<text top="634" left="946" width="217" height="17" font="13">death or hospitalization, and worsening </text>
<text top="651" left="946" width="215" height="17" font="13">HF not different between tolvaptan and </text>
<text top="668" left="946" width="50" height="17" font="13">placebo. </text>
<text top="685" left="946" width="178" height="17" font="13">Tolvaptan significantly improved </text>
<text top="703" left="946" width="184" height="17" font="13">secondary end points of Day 1 pt-</text>
<text top="720" left="946" width="217" height="17" font="13">assessed dyspnea, Day 1 body weight, </text>
<text top="737" left="946" width="104" height="17" font="13">and Day 7 edema. </text>
<text top="754" left="946" width="221" height="17" font="13">In pts with hyponatremia, serum sodium </text>
<text top="771" left="946" width="162" height="17" font="13">levels significantly increased. </text>
<text top="479" left="1189" width="75" height="17" font="13">95% CI: 0.87-</text>
<text top="496" left="1189" width="72" height="17" font="13">1.11; p=0.68 </text>
<text top="479" left="1291" width="52" height="17" font="13">HR: 0.98 </text>
<text top="479" left="1371" width="31" height="17" font="13">  N/A </text>
</page>
<page number="183" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">183</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="635" width="75" height="17" font="13">at the time of </text>
<text top="72" left="635" width="85" height="17" font="13">hospitalization. </text>
<text top="89" left="635" width="116" height="17" font="13">LVEF ≤40% within 1 </text>
<text top="106" left="635" width="13" height="17" font="13">y. </text>
<text top="55" left="764" width="129" height="17" font="13">within the last 60 d. Co-</text>
<text top="72" left="764" width="136" height="17" font="13">morbid condition with an </text>
<text top="89" left="764" width="161" height="17" font="13">expected survival less than 6 </text>
<text top="106" left="764" width="133" height="17" font="13">mo. Subjects with acute </text>
<text top="124" left="764" width="116" height="17" font="13">STEMI at the time of </text>
<text top="141" left="764" width="117" height="17" font="13">hospitalization. Hx of </text>
<text top="158" left="764" width="116" height="17" font="13">sustained ventricular </text>
<text top="175" left="764" width="141" height="17" font="13">tachycardia or ventricular </text>
<text top="192" left="764" width="160" height="17" font="13">fibrillation within 30 d, unless </text>
<text top="210" left="764" width="118" height="17" font="13">in the presence of an </text>
<text top="227" left="764" width="127" height="17" font="13">automatic ICD. Hx of a </text>
<text top="244" left="764" width="140" height="17" font="13">cerebrovascular accident </text>
<text top="261" left="764" width="109" height="17" font="13">within the last 30 d. </text>
<text top="278" left="764" width="158" height="17" font="13">Hemodynamically significant </text>
<text top="296" left="764" width="156" height="17" font="13">uncorrected primary cardiac </text>
<text top="313" left="764" width="168" height="17" font="13">valvular disease. Hypertrophic </text>
<text top="330" left="764" width="157" height="17" font="13">cardiomyopathy (obstructive </text>
<text top="347" left="764" width="162" height="17" font="13">or non-obstructive). CHF due </text>
<text top="365" left="764" width="122" height="17" font="13">to uncorrected thyroid </text>
<text top="382" left="764" width="165" height="17" font="13">disease, active myocarditis or </text>
<text top="399" left="764" width="85" height="17" font="13">known amyloid </text>
<text top="416" left="764" width="94" height="17" font="13">cardiomyopathy. </text>
<text top="433" left="764" width="157" height="17" font="13">Subjects with progressive or </text>
<text top="451" left="764" width="164" height="17" font="13">episodic neurological disease </text>
<text top="468" left="764" width="157" height="17" font="13">such as multiple sclerosis or </text>
<text top="485" left="764" width="157" height="17" font="13">Hx of multiple strokes. Hx of </text>
<text top="502" left="764" width="128" height="17" font="13">primary significant liver </text>
<text top="519" left="764" width="137" height="17" font="13">disease or acute hepatic </text>
<text top="537" left="764" width="137" height="17" font="13">failure, as defined by the </text>
<text top="554" left="764" width="139" height="17" font="13">investigator. Hx of poorly </text>
<text top="571" left="764" width="83" height="17" font="13">controlled DM. </text>
<text top="588" left="764" width="147" height="17" font="13">Morbid obesity, defined as </text>
<text top="606" left="764" width="153" height="17" font="13">&gt;159 kg (or 350 lbs) or BMI </text>
<text top="623" left="764" width="154" height="17" font="13">&gt;40. Supine systolic arterial </text>
<text top="640" left="764" width="152" height="17" font="13">blood pressure &lt;90 mmHg. </text>
<text top="657" left="764" width="146" height="17" font="13">SCr &gt;3.5 mg/dL or &gt;309.4 </text>
<text top="674" left="764" width="47" height="17" font="13">mmol/L. </text>
<text top="692" left="764" width="166" height="17" font="13">Serum potassium &gt;5.5 mEq/L </text>
<text top="709" left="764" width="89" height="17" font="13">or &gt;5.5 mmol/L. </text>
<text top="726" left="764" width="165" height="17" font="13">Hgb &lt;9 g/dL or &lt;90 g/L. Hx of </text>
<text top="743" left="764" width="126" height="17" font="13">hypersensitivity and/or </text>
<text top="760" left="764" width="132" height="17" font="13">idiosyncratic reaction to </text>
<text top="778" left="764" width="169" height="17" font="13">benzazepine derivatives (such </text>
</page>
<page number="184" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">184</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="764" width="159" height="17" font="13">as benazapril). Hx of drug or </text>
<text top="72" left="764" width="155" height="17" font="13">medication abuse within the </text>
<text top="89" left="764" width="156" height="17" font="13">past year, or current alcohol </text>
<text top="106" left="764" width="150" height="17" font="13">abuse. Inability to take oral </text>
<text top="124" left="764" width="157" height="17" font="13">medications. Participation in </text>
<text top="141" left="764" width="167" height="17" font="13">another clinical drug or device </text>
<text top="158" left="764" width="136" height="17" font="13">trial within the past 30 d. </text>
<text top="175" left="764" width="156" height="17" font="13">Previous participation in this </text>
<text top="192" left="764" width="163" height="17" font="13">or any other tolvaptan clinical </text>
<text top="210" left="764" width="30" height="17" font="13">trial.. </text>
<text top="228" left="54" width="169" height="17" font="13">Konstam MA, Gheorghiade M, </text>
<text top="245" left="54" width="167" height="17" font="13">Burnett JC, Jr. et al. Effects of </text>
<text top="262" left="54" width="118" height="17" font="13">Oral Tolvaptan in Pts </text>
<text top="279" left="54" width="174" height="17" font="13">Hospitalized for Worsening HF: </text>
<text top="296" left="54" width="165" height="17" font="13">the EVEREST Outcome Trial. </text>
<text top="314" left="54" width="105" height="17" font="13">JAMA 2007 March </text>
<text top="331" left="54" width="115" height="17" font="13">28;297(12):1319-31. </text>
<text top="348" left="54" width="58" height="17" font="14">17384437 </text>
<text top="348" left="112" width="32" height="17" font="13">(154) </text>
<text top="228" left="244" width="101" height="17" font="13">To investigate the </text>
<text top="245" left="244" width="107" height="17" font="13">effects of tolvaptan </text>
<text top="262" left="244" width="79" height="17" font="13">initiated in pts </text>
<text top="279" left="244" width="117" height="17" font="13">hospitalized with HF. </text>
<text top="228" left="379" width="94" height="17" font="13">RCT (EVEREST-</text>
<text top="245" left="379" width="57" height="17" font="13">Outcome) </text>
<text top="228" left="507" width="109" height="17" font="13">4133 (tolvaptan, 30 </text>
<text top="245" left="507" width="95" height="17" font="13">mg once per day </text>
<text top="262" left="507" width="114" height="17" font="13">(n=2072) or placebo </text>
<text top="279" left="507" width="115" height="17" font="13">(2062) within 48 h of </text>
<text top="296" left="507" width="62" height="17" font="13">admission. </text>
<text top="228" left="635" width="108" height="17" font="13">Age ≥18 y. Current </text>
<text top="245" left="635" width="99" height="17" font="13">hospitalization for </text>
<text top="262" left="635" width="97" height="17" font="13">chronic CHF with </text>
<text top="279" left="635" width="107" height="17" font="13">admission up to 48 </text>
<text top="296" left="635" width="52" height="17" font="13">h prior to </text>
<text top="314" left="635" width="84" height="17" font="13">randomization. </text>
<text top="331" left="635" width="78" height="17" font="13">Chronic HF is </text>
<text top="348" left="635" width="111" height="17" font="13">defined as requiring </text>
<text top="365" left="635" width="84" height="17" font="13">treatment for a </text>
<text top="382" left="635" width="94" height="17" font="13">minimum of 30 d </text>
<text top="400" left="635" width="42" height="17" font="13">prior to </text>
<text top="417" left="635" width="85" height="17" font="13">hospitalization. </text>
<text top="434" left="635" width="97" height="17" font="13">The subject must </text>
<text top="451" left="635" width="76" height="17" font="13">have signs of </text>
<text top="469" left="635" width="113" height="17" font="13">extracellular volume </text>
<text top="486" left="635" width="107" height="17" font="13">expansion, defined </text>
<text top="503" left="635" width="69" height="17" font="13">as ≥2 of the </text>
<text top="520" left="635" width="114" height="17" font="13">following: a) JVD; b) </text>
<text top="537" left="635" width="114" height="17" font="13">pitting edema (&gt;1+); </text>
<text top="555" left="635" width="81" height="17" font="13">or c) dyspnea. </text>
<text top="572" left="635" width="115" height="17" font="13">NYHA Class III or IV </text>
<text top="589" left="635" width="75" height="17" font="13">at the time of </text>
<text top="606" left="635" width="85" height="17" font="13">hospitalization. </text>
<text top="624" left="635" width="116" height="17" font="13">LVEF ≤40% within 1 </text>
<text top="641" left="635" width="13" height="17" font="13">y. </text>
<text top="228" left="764" width="168" height="17" font="13">Women who will not adhere to </text>
<text top="245" left="764" width="159" height="17" font="13">the reproductive precautions </text>
<text top="262" left="764" width="123" height="17" font="13">as outlined in the ICF. </text>
<text top="279" left="764" width="165" height="17" font="13">Positive urine pregnancy test. </text>
<text top="296" left="764" width="142" height="17" font="13">Inability to provide written </text>
<text top="314" left="764" width="147" height="17" font="13">informed consent. Cardiac </text>
<text top="331" left="764" width="120" height="17" font="13">surgery within 60 d of </text>
<text top="348" left="764" width="147" height="17" font="13">potential study enrollment, </text>
<text top="365" left="764" width="131" height="17" font="13">excluding PCI. Planned </text>
<text top="382" left="764" width="164" height="17" font="13">revascularization procedures, </text>
<text top="400" left="764" width="132" height="17" font="13">EP device implantation, </text>
<text top="417" left="764" width="153" height="17" font="13">cardiac mechanical support </text>
<text top="434" left="764" width="116" height="17" font="13">implantation, cardiac </text>
<text top="451" left="764" width="134" height="17" font="13">transplantation, or other </text>
<text top="469" left="764" width="150" height="17" font="13">cardiac surgery within 30 d </text>
<text top="486" left="764" width="148" height="17" font="13">following study enrollment. </text>
<text top="503" left="764" width="158" height="17" font="13">Subjects who are on cardiac </text>
<text top="520" left="764" width="146" height="17" font="13">mechanical support. Hx of </text>
<text top="537" left="764" width="164" height="17" font="13">biventricular pacer placement </text>
<text top="555" left="764" width="165" height="17" font="13">within the last 60 d. Comorbid </text>
<text top="572" left="764" width="148" height="17" font="13">condition with an expected </text>
<text top="589" left="764" width="132" height="17" font="13">survival less than 6 mo. </text>
<text top="606" left="764" width="164" height="17" font="13">Subjects with acute STEMI at </text>
<text top="624" left="764" width="164" height="17" font="13">the time of hospitalization. Hx </text>
<text top="641" left="764" width="130" height="17" font="13">of sustained ventricular </text>
<text top="658" left="764" width="141" height="17" font="13">tachycardia or ventricular </text>
<text top="675" left="764" width="160" height="17" font="13">fibrillation within 30 d, unless </text>
<text top="692" left="764" width="118" height="17" font="13">in the presence of an </text>
<text top="710" left="764" width="127" height="17" font="13">automatic ICD. Hx of a </text>
<text top="727" left="764" width="140" height="17" font="13">cerebrovascular accident </text>
<text top="744" left="764" width="109" height="17" font="13">within the last 30 d. </text>
<text top="761" left="764" width="158" height="17" font="13">Hemodynamically significant </text>
<text top="778" left="764" width="156" height="17" font="13">uncorrected primary cardiac </text>
<text top="228" left="946" width="204" height="17" font="13">Tolvaptan had no effect on long-term </text>
<text top="245" left="946" width="182" height="17" font="13">mortality or HF-related morbidity. </text>
<text top="262" left="946" width="228" height="17" font="13">Mortality for tolvaptan versus placebo not </text>
<text top="279" left="946" width="213" height="17" font="13">different (HR: 0.98; 95% CI: 0.87-1.11; </text>
<text top="296" left="946" width="49" height="17" font="13">p=0.68). </text>
<text top="314" left="946" width="226" height="17" font="13">Composite of CV death or hospitalization </text>
<text top="331" left="946" width="213" height="17" font="13">for HF not different (HR: 1.04; 95% CI: </text>
<text top="348" left="946" width="108" height="17" font="13">0.95-1.14; p=0.55). </text>
<text top="365" left="946" width="217" height="17" font="13">Secondary end points CV mortality, CV </text>
<text top="382" left="946" width="217" height="17" font="13">death or hospitalization, and worsening </text>
<text top="400" left="946" width="215" height="17" font="13">HF not different between tolvaptan and </text>
<text top="417" left="946" width="50" height="17" font="13">placebo. </text>
<text top="434" left="946" width="178" height="17" font="13">Tolvaptan significantly improved </text>
<text top="451" left="946" width="184" height="17" font="13">secondary end points of Day 1 pt-</text>
<text top="469" left="946" width="217" height="17" font="13">assessed dyspnea, Day 1 body weight, </text>
<text top="486" left="946" width="104" height="17" font="13">and Day 7 edema. </text>
<text top="503" left="946" width="221" height="17" font="13">In pts with hyponatremia, serum sodium </text>
<text top="520" left="946" width="158" height="17" font="13">levels significantly increased.</text>
<text top="519" left="1105" width="4" height="19" font="7"> </text>
<text top="228" left="1189" width="75" height="17" font="13">95% CI: 0.87-</text>
<text top="245" left="1189" width="72" height="17" font="13">1.11; p=0.68 </text>
<text top="228" left="1291" width="52" height="17" font="13">HR: 0.98 </text>
<text top="228" left="1371" width="31" height="17" font="13">  N/A </text>
</page>
<page number="185" position="absolute" top="0" left="0" height="918" width="1512">
	<fontspec id="32" size="11" family="Times" color="#212121"/>
	<fontspec id="33" size="11" family="Times" color="#000000"/>
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">185</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="764" width="168" height="17" font="13">valvular disease. Hypertrophic </text>
<text top="72" left="764" width="157" height="17" font="13">cardiomyopathy (obstructive </text>
<text top="89" left="764" width="162" height="17" font="13">or non-obstructive). CHF due </text>
<text top="106" left="764" width="122" height="17" font="13">to uncorrected thyroid </text>
<text top="124" left="764" width="165" height="17" font="13">disease, active myocarditis or </text>
<text top="141" left="764" width="85" height="17" font="13">known amyloid </text>
<text top="158" left="764" width="94" height="17" font="13">cardiomyopathy. </text>
<text top="175" left="764" width="157" height="17" font="13">Subjects with progressive or </text>
<text top="192" left="764" width="164" height="17" font="13">episodic neurological disease </text>
<text top="210" left="764" width="157" height="17" font="13">such as multiple sclerosis or </text>
<text top="227" left="764" width="157" height="17" font="13">Hx of multiple strokes. Hx of </text>
<text top="244" left="764" width="128" height="17" font="13">primary significant liver </text>
<text top="261" left="764" width="137" height="17" font="13">disease or acute hepatic </text>
<text top="278" left="764" width="137" height="17" font="13">failure, as defined by the </text>
<text top="296" left="764" width="139" height="17" font="13">investigator. Hx of poorly </text>
<text top="313" left="764" width="83" height="17" font="13">controlled DM. </text>
<text top="330" left="764" width="147" height="17" font="13">Morbid obesity, defined as </text>
<text top="347" left="764" width="153" height="17" font="13">&gt;159 kg (or 350 lbs) or BMI </text>
<text top="365" left="764" width="154" height="17" font="13">&gt;40. Supine systolic arterial </text>
<text top="382" left="764" width="152" height="17" font="13">blood pressure &lt;90 mmHg. </text>
<text top="399" left="764" width="146" height="17" font="13">SCr &gt;3.5 mg/dL or &gt;309.4 </text>
<text top="416" left="764" width="47" height="17" font="13">mmol/L. </text>
<text top="433" left="764" width="166" height="17" font="13">Serum potassium &gt;5.5 mEq/L </text>
<text top="451" left="764" width="89" height="17" font="13">or &gt;5.5 mmol/L. </text>
<text top="468" left="764" width="165" height="17" font="13">Hgb &lt;9 g/dL or &lt;90 g/L. Hx of </text>
<text top="485" left="764" width="126" height="17" font="13">hypersensitivity and/or </text>
<text top="502" left="764" width="132" height="17" font="13">idiosyncratic reaction to </text>
<text top="519" left="764" width="169" height="17" font="13">benzazepine derivatives (such </text>
<text top="537" left="764" width="159" height="17" font="13">as benazapril). Hx of drug or </text>
<text top="554" left="764" width="155" height="17" font="13">medication abuse within the </text>
<text top="571" left="764" width="138" height="17" font="13">past y, or current alcohol </text>
<text top="588" left="764" width="150" height="17" font="13">abuse. Inability to take oral </text>
<text top="606" left="764" width="157" height="17" font="13">medications. Participation in </text>
<text top="623" left="764" width="167" height="17" font="13">another clinical drug or device </text>
<text top="640" left="764" width="136" height="17" font="13">trial within the past 30 d. </text>
<text top="657" left="764" width="156" height="17" font="13">Previous participation in this </text>
<text top="674" left="764" width="163" height="17" font="13">or any other tolvaptan clinical </text>
<text top="692" left="764" width="27" height="17" font="13">trial. </text>
<text top="709" left="54" width="1398" height="15" font="6">ACCF/AHA indicates American College of Cardiology Foundation/American Heart Association; ACEI, angiotensin-converting enzyme inhibitor; ADHERE, Acute Decompensated HF National Registry; AF, atrial fibrillation; AHF, acute heart failure; ARB, angiotensin-receptor blocker; BMI, </text>
<text top="725" left="54" width="1387" height="16" font="6">body mass index; CHF, congestive heart failure; CI, confidence interval; CIBIS, Cardiac Insufficiency Bisoprolol Study; COMET, Carvedilol or Metoprolol European Trial; CPG, clinical practice guidelines; CV, cardiovascular; DM, diabetes mellitus; DMP, discharge medication program; </text>
<text top="741" left="54" width="171" height="15" font="6">ED, emergency department; EKG, </text>
<text top="741" left="225" width="89" height="15" font="32">electrocardiogram</text>
<text top="741" left="314" width="863" height="15" font="6">; EP, electrophysiology; GWTG-HF, Get With the Guidelines-HF; HF, heart failure; Hx, history; ICD, implantable cardioverter-defibrillator; JVD, jugular venous distention<i>;</i> LVEF, l</text>
<text top="741" left="1176" width="147" height="15" font="32">eft ventricular ejection fraction</text>
<text top="741" left="1323" width="41" height="15" font="6">; LVSD, </text>
<text top="741" left="1364" width="72" height="15" font="32">left ventricular </text>
<text top="757" left="54" width="95" height="15" font="32">systolic dysfunction</text>
<text top="757" left="149" width="1297" height="15" font="6">; NS, not significant; NYHA, New York Heart Association; OPTIMIZE-HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Pts with HF; PCI, percutaneous coronary intervention; Pts, patients; RCT, randomized controlled trial; SAE, serious adverse </text>
<text top="772" left="54" width="523" height="15" font="6">event; SCr, serum creatinine, STEMI, ST segment elevation myocardial infarction; and US, United States<i>.</i>  </text>
<text top="788" left="54" width="3" height="17" font="13"> </text>
</page>
<page number="186" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">186</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="54" left="54" width="363" height="21" font="8"><b>Data Supplement 41. Atrial Fibrillation (Section 9.1) </b></text>
<text top="75" left="75" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="74" width="44" height="19" font="9"><b>Name, </b></text>
<text top="113" left="70" width="52" height="19" font="9"><b>Author, </b></text>
<text top="132" left="79" width="33" height="19" font="9"><b>Year </b></text>
<text top="75" left="157" width="87" height="19" font="9"><b>Aim of Study </b></text>
<text top="75" left="275" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="278" width="35" height="19" font="9"><b>Type </b></text>
<text top="75" left="353" width="41" height="19" font="9"><b>Study </b></text>
<text top="94" left="358" width="31" height="19" font="9"><b>Size </b></text>
<text top="75" left="457" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="75" left="716" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="75" left="896" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="75" left="1126" width="121" height="19" font="9"><b> Study Limitations </b></text>
<text top="75" left="1301" width="137" height="19" font="9"><b>Findings/ Comments </b></text>
<text top="153" left="92" width="8" height="19" font="7">  </text>
<text top="153" left="197" width="8" height="19" font="7">  </text>
<text top="153" left="292" width="8" height="19" font="7">  </text>
<text top="153" left="369" width="8" height="19" font="7">  </text>
<text top="153" left="422" width="104" height="17" font="21"><i><b>Inclusion Criteria </b></i></text>
<text top="153" left="548" width="62" height="17" font="21"><i><b>Exclusion </b></i></text>
<text top="170" left="555" width="46" height="17" font="21"><i><b>Criteria </b></i></text>
<text top="153" left="630" width="106" height="17" font="21"><i><b>Primary Endpoint </b></i></text>
<text top="153" left="779" width="70" height="17" font="21"><i><b>Secondary  </b></i></text>
<text top="170" left="783" width="57" height="17" font="21"><i><b>Endpoint </b></i></text>
<text top="153" left="987" width="8" height="19" font="7">  </text>
<text top="172" left="987" width="8" height="19" font="7">  </text>
<text top="191" left="987" width="8" height="19" font="7">  </text>
<text top="153" left="1183" width="8" height="19" font="7">  </text>
<text top="153" left="1366" width="8" height="19" font="7">  </text>
<text top="210" left="54" width="48" height="17" font="13">AF CHF </text>
<text top="227" left="54" width="63" height="17" font="13">Roy, 2008  </text>
<text top="245" left="54" width="55" height="17" font="14">19102036</text>
<text top="245" left="109" width="3" height="17" font="13"> </text>
<text top="262" left="54" width="32" height="17" font="13">(370) </text>
<text top="210" left="150" width="86" height="17" font="13">Rhythm control </text>
<text top="227" left="150" width="97" height="17" font="13">reduces mortality </text>
<text top="245" left="150" width="88" height="17" font="13">as compared to </text>
<text top="262" left="150" width="65" height="17" font="13">rate control </text>
<text top="210" left="265" width="30" height="17" font="13">Multi-</text>
<text top="227" left="265" width="38" height="17" font="13">center </text>
<text top="245" left="265" width="29" height="17" font="13">RCT </text>
<text top="210" left="339" width="162" height="17" font="13">1,376 LVEF </text>
<text top="210" left="454" width="40" height="17" font="13">≤35%, </text>
<text top="227" left="420" width="85" height="17" font="13">history of CHF, </text>
<text top="245" left="420" width="96" height="17" font="13">and history of AF </text>
<text top="210" left="541" width="27" height="17" font="13"> N/A </text>
<text top="210" left="629" width="85" height="17" font="13">Death from CV </text>
<text top="227" left="629" width="42" height="17" font="13">causes </text>
<text top="210" left="751" width="88" height="17" font="13">Death from any </text>
<text top="227" left="751" width="113" height="17" font="13">cause, worsening of </text>
<text top="245" left="751" width="87" height="17" font="13">CHF, or stroke. </text>
<text top="210" left="886" width="187" height="17" font="13">Death from all CV causes: 27% in </text>
<text top="227" left="886" width="195" height="17" font="13">rhytm-control group vs. 25% in rate-</text>
<text top="245" left="886" width="82" height="17" font="13">control group   </text>
<text top="262" left="886" width="206" height="17" font="13">HR: 1.0 6; p=0.59; 95% CI: 0.86-1.30 </text>
<text top="210" left="1108" width="102" height="17" font="13">Results cannot be </text>
<text top="227" left="1108" width="146" height="17" font="13">generalized to pts with HF </text>
<text top="245" left="1108" width="147" height="17" font="13">and preserved LV function </text>
<text top="262" left="1108" width="146" height="17" font="13">(in whom AF is common).  </text>
<text top="210" left="1277" width="184" height="17" font="13">The use of rhythm-control did not </text>
<text top="227" left="1277" width="182" height="17" font="13">reduce the rate of death from CV </text>
<text top="245" left="1277" width="151" height="17" font="13">causes compared with rate-</text>
<text top="262" left="1277" width="121" height="17" font="13">control. No significant </text>
<text top="279" left="1277" width="137" height="17" font="13">differences in secondary </text>
<text top="296" left="1277" width="94" height="17" font="13">outcomes either. </text>
<text top="325" left="54" width="53" height="17" font="13">AFFIRM, </text>
<text top="342" left="54" width="31" height="17" font="13">2002 </text>
<text top="359" left="54" width="55" height="17" font="14">12466506</text>
<text top="359" left="109" width="3" height="17" font="13"> </text>
<text top="377" left="54" width="32" height="17" font="13">(371) </text>
<text top="325" left="150" width="86" height="17" font="13">Rhythm control </text>
<text top="342" left="150" width="97" height="17" font="13">reduces mortality </text>
<text top="359" left="150" width="88" height="17" font="13">as compared to </text>
<text top="377" left="150" width="65" height="17" font="13">rate control </text>
<text top="325" left="265" width="30" height="17" font="13">Multi-</text>
<text top="342" left="265" width="38" height="17" font="13">center </text>
<text top="359" left="265" width="29" height="17" font="13">RCT </text>
<text top="325" left="339" width="34" height="17" font="13">4,060 </text>
<text top="325" left="420" width="100" height="17" font="13">≥65 y with history </text>
<text top="342" left="420" width="88" height="17" font="13">of AF and other </text>
<text top="359" left="420" width="81" height="17" font="13">risk factors for </text>
<text top="377" left="420" width="85" height="17" font="13">stroke or death </text>
<text top="325" left="541" width="31" height="17" font="13">  N/A </text>
<text top="325" left="629" width="92" height="17" font="13">Overall mortality </text>
<text top="325" left="751" width="100" height="17" font="13">Composite death, </text>
<text top="342" left="751" width="89" height="17" font="13">dsabling stroke, </text>
<text top="359" left="751" width="85" height="17" font="13">diabling anoxic </text>
<text top="377" left="751" width="94" height="17" font="13">encephalopathy, </text>
<text top="394" left="751" width="98" height="17" font="13">major bleeding or </text>
<text top="411" left="751" width="78" height="17" font="13">cardiac arrest </text>
<text top="325" left="886" width="206" height="17" font="13">Difference in mortality not statistically </text>
<text top="342" left="886" width="185" height="17" font="13">significant. HR: 1.15 95%CI: 0.99-</text>
<text top="359" left="886" width="79" height="17" font="13">1.34; ; p=0.08 </text>
<text top="325" left="1108" width="107" height="17" font="13">Findings cannot be </text>
<text top="342" left="1108" width="126" height="17" font="13">generalized to pts with </text>
<text top="359" left="1108" width="119" height="17" font="13">more severe AF or to </text>
<text top="377" left="1108" width="133" height="17" font="13">younger pts without risk </text>
<text top="394" left="1108" width="95" height="17" font="13">factors for stroke </text>
<text top="325" left="1277" width="174" height="17" font="13">Rhythm-control strategy did not </text>
<text top="342" left="1277" width="126" height="17" font="13">improve morality when </text>
<text top="359" left="1277" width="141" height="17" font="13">compared to rate-control. </text>
<text top="440" left="54" width="43" height="17" font="13">RE-LY, </text>
<text top="457" left="54" width="64" height="17" font="13">Eikelboom, </text>
<text top="474" left="54" width="31" height="17" font="13">2011 </text>
<text top="491" left="54" width="55" height="17" font="14">21576658</text>
<text top="491" left="109" width="3" height="17" font="13"> </text>
<text top="509" left="54" width="32" height="17" font="13">(372) </text>
<text top="440" left="150" width="100" height="17" font="13">Compare 2 doses </text>
<text top="457" left="150" width="96" height="17" font="13">(110 mg and 150 </text>
<text top="474" left="150" width="100" height="17" font="13">mg) of dabigatran </text>
<text top="491" left="150" width="96" height="17" font="13">2 x d vs. warfarin </text>
<text top="509" left="150" width="55" height="17" font="13">for stroke </text>
<text top="526" left="150" width="94" height="17" font="13">prevention in pts </text>
<text top="543" left="150" width="44" height="17" font="13">with AF </text>
<text top="440" left="265" width="30" height="17" font="13">Multi-</text>
<text top="457" left="265" width="38" height="17" font="13">center </text>
<text top="474" left="265" width="29" height="17" font="13">RCT </text>
<text top="440" left="339" width="41" height="17" font="13">18,113 </text>
<text top="440" left="420" width="103" height="17" font="13">Pts with AF and at </text>
<text top="457" left="420" width="96" height="17" font="13">least 1 additional </text>
<text top="474" left="420" width="75" height="17" font="13">risk factor for </text>
<text top="491" left="420" width="37" height="17" font="13">stroke </text>
<text top="440" left="541" width="31" height="17" font="13">  N/A </text>
<text top="440" left="629" width="84" height="17" font="13">Major bleeding </text>
<text top="440" left="751" width="31" height="17" font="13">  N/A </text>
<text top="440" left="886" width="208" height="17" font="13">Dabigatran 110 mg twice d compared </text>
<text top="457" left="886" width="171" height="17" font="13">with warfain: 2.87% vs. 3.57 % </text>
<text top="474" left="886" width="63" height="17" font="13">(p=0.0002) </text>
<text top="491" left="886" width="165" height="17" font="13">Dabigatran 150 mg twice d vs </text>
<text top="509" left="886" width="196" height="17" font="13">warfarin: 3.31% vs. 3.57% (p=0.32) </text>
<text top="526" left="886" width="169" height="17" font="13">Dabigatran 150 mg twice d vs. </text>
<text top="543" left="886" width="169" height="17" font="13">Dabigatran 110 mg: 3.31% vs. </text>
<text top="560" left="886" width="88" height="17" font="13">2.87%( p=0.04) </text>
<text top="577" left="886" width="3" height="17" font="13"> </text>
<text top="595" left="886" width="3" height="17" font="13"> </text>
<text top="612" left="886" width="3" height="17" font="13"> </text>
<text top="629" left="886" width="3" height="17" font="13"> </text>
<text top="646" left="886" width="3" height="17" font="13"> </text>
<text top="440" left="1108" width="31" height="17" font="13">  N/A </text>
<text top="440" left="1277" width="172" height="17" font="13">Both doses of Dabigatran were </text>
<text top="457" left="1277" width="163" height="17" font="13">associated with lower risks of </text>
<text top="474" left="1277" width="162" height="17" font="13">major bleeding than warfarin. </text>
<text top="491" left="1277" width="165" height="17" font="13">Found an interaction between </text>
<text top="509" left="1277" width="155" height="17" font="13">treatment and age for major </text>
<text top="526" left="1277" width="132" height="17" font="13">bleeding. Both doses of </text>
<text top="543" left="1277" width="184" height="17" font="13">Dabigatran associated with lower </text>
<text top="560" left="1277" width="166" height="17" font="13">risk of extracranial bleeding in </text>
<text top="577" left="1277" width="160" height="17" font="13">pts &lt;75 y, though associated </text>
<text top="595" left="1277" width="178" height="17" font="13">with similar or higher risks in pts </text>
<text top="612" left="1277" width="143" height="17" font="13">≥75 y. Risk of intracranial </text>
<text top="629" left="1277" width="168" height="17" font="13">bleeding was lower with either </text>
<text top="646" left="1277" width="172" height="17" font="13">dose of Dabigatran, regardless </text>
<text top="663" left="1277" width="41" height="17" font="13">of age. </text>
<text top="681" left="54" width="43" height="17" font="13">RE-LY, </text>
<text top="699" left="54" width="76" height="17" font="13">Connolly, SJ, </text>
<text top="716" left="54" width="31" height="17" font="13">2009 </text>
<text top="733" left="54" width="55" height="17" font="14">19717844</text>
<text top="733" left="109" width="3" height="17" font="13"> </text>
<text top="750" left="54" width="32" height="17" font="13">(193) </text>
<text top="681" left="150" width="100" height="17" font="13">Compare 2 doses </text>
<text top="699" left="150" width="96" height="17" font="13">(110 mg and 150 </text>
<text top="716" left="150" width="100" height="17" font="13">mg) of dabigatran </text>
<text top="733" left="150" width="93" height="17" font="13">2x d vs. warfarin </text>
<text top="750" left="150" width="94" height="17" font="13">in  pts with AF at </text>
<text top="768" left="150" width="93" height="17" font="13">increased risk of </text>
<text top="785" left="150" width="37" height="17" font="13">stroke </text>
<text top="681" left="265" width="33" height="17" font="13">Mutli- </text>
<text top="699" left="265" width="38" height="17" font="13">center </text>
<text top="716" left="265" width="29" height="17" font="13">RCT </text>
<text top="681" left="339" width="41" height="17" font="13">18,113 </text>
<text top="681" left="420" width="96" height="17" font="13">Pts with previous </text>
<text top="699" left="420" width="77" height="17" font="13">stroke or TIA, </text>
<text top="716" left="420" width="73" height="17" font="13">LVEF &lt;40%, </text>
<text top="733" left="420" width="94" height="17" font="13">NYHA class II or </text>
<text top="750" left="420" width="38" height="17" font="13">higher </text>
<text top="681" left="541" width="31" height="17" font="13">  N/A </text>
<text top="681" left="629" width="105" height="17" font="13">Stroke or systemic </text>
<text top="699" left="629" width="56" height="17" font="13">embolism </text>
<text top="681" left="751" width="31" height="17" font="13">  N/A </text>
<text top="681" left="886" width="202" height="17" font="13">The 150 mg dose of Dabigatran was </text>
<text top="699" left="886" width="209" height="17" font="13">superior to warfarin in reducing stroke </text>
<text top="716" left="886" width="187" height="17" font="13">and systemic embolism (RR:0.66; </text>
<text top="733" left="886" width="210" height="17" font="13">95% CI: 0.53-0.82; p&lt;0.0001)  but the </text>
<text top="750" left="886" width="153" height="17" font="13">110 mg dose was not when </text>
<text top="768" left="886" width="202" height="17" font="13">compared to warafin (RR: 0.91; 95% </text>
<text top="785" left="886" width="123" height="17" font="13">CI: 0.74-1.11; p=0.34) </text>
<text top="681" left="1108" width="31" height="17" font="13">  N/A </text>
<text top="681" left="1277" width="172" height="17" font="13">Both doses of Dabigatran were </text>
<text top="699" left="1277" width="144" height="17" font="13">noninferior to warafin with </text>
<text top="716" left="1277" width="173" height="17" font="13">respect to the primary outcome </text>
</page>
<page number="187" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">187</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="54" width="77" height="17" font="13">ROCKET AF, </text>
<text top="72" left="54" width="55" height="17" font="13">Fox KAA, </text>
<text top="89" left="54" width="31" height="17" font="13">2011 </text>
<text top="106" left="54" width="55" height="17" font="14">21873708</text>
<text top="106" left="109" width="3" height="17" font="13"> </text>
<text top="124" left="54" width="32" height="17" font="13">(373) </text>
<text top="55" left="150" width="54" height="17" font="13">Compare </text>
<text top="72" left="150" width="93" height="17" font="13">rivaroxaban with </text>
<text top="89" left="150" width="60" height="17" font="13">warfarin in </text>
<text top="106" left="150" width="75" height="17" font="13">prevention of </text>
<text top="124" left="150" width="51" height="17" font="13">stroke or </text>
<text top="141" left="150" width="51" height="17" font="13">systemic </text>
<text top="158" left="150" width="89" height="17" font="13">embolism in pts </text>
<text top="175" left="150" width="44" height="17" font="13">with AF </text>
<text top="55" left="265" width="42" height="17" font="13">Double </text>
<text top="72" left="265" width="58" height="17" font="13">blind RCT </text>
<text top="55" left="339" width="44" height="17" font="13">14,264; </text>
<text top="72" left="339" width="54" height="17" font="13">2,950 pts </text>
<text top="89" left="339" width="25" height="17" font="13">with </text>
<text top="106" left="339" width="55" height="17" font="13">moderate </text>
<text top="124" left="339" width="31" height="17" font="13">renal </text>
<text top="141" left="339" width="64" height="17" font="13">impairment </text>
<text top="55" left="420" width="71" height="17" font="13">Pts with non-</text>
<text top="72" left="420" width="89" height="17" font="13">valvular AF and </text>
<text top="89" left="420" width="86" height="17" font="13">moderate renal </text>
<text top="106" left="420" width="96" height="17" font="13">impairment (CrCl </text>
<text top="124" left="420" width="83" height="17" font="13">30-49 mL/min) </text>
<text top="55" left="541" width="31" height="17" font="13">  N/A </text>
<text top="55" left="629" width="105" height="17" font="13">Stroke or systemic </text>
<text top="72" left="629" width="56" height="17" font="13">embolism </text>
<text top="55" left="751" width="31" height="17" font="13">  N/A </text>
<text top="55" left="886" width="209" height="17" font="13">Primary outcome occurred in 2.32 per </text>
<text top="72" left="886" width="196" height="17" font="13">100 pt-y in rivaroxaban vs. 2.77 per </text>
<text top="89" left="886" width="146" height="17" font="13">100 pt-y in warafin group.  </text>
<text top="106" left="886" width="157" height="17" font="13">Fatal bleeding was 0.28% in </text>
<text top="124" left="886" width="207" height="17" font="13">rivaroxaban vs. 0.74% per 100 pt-y in </text>
<text top="141" left="886" width="200" height="17" font="13">warafin (ITT analysis HR: 0.86; 95% </text>
<text top="158" left="886" width="137" height="17" font="13">CI: 0.63-1.17; p=0.0047) </text>
<text top="55" left="1108" width="146" height="17" font="13">Analysis was not powered </text>
<text top="72" left="1108" width="114" height="17" font="13">to detect differences </text>
<text top="89" left="1108" width="142" height="17" font="13">between drugs in pts with </text>
<text top="106" left="1108" width="98" height="17" font="13">renal insuficiency </text>
<text top="55" left="1277" width="137" height="17" font="13">While not able to show a </text>
<text top="72" left="1277" width="145" height="17" font="13">difference between drugs, </text>
<text top="89" left="1277" width="180" height="17" font="13">rivaroxaban was associated with </text>
<text top="106" left="1277" width="176" height="17" font="13">reduction in fatal bleeding in pts </text>
<text top="124" left="1277" width="134" height="17" font="13">with renal insufieniency. </text>
<text top="196" left="54" width="77" height="17" font="13">ROCKET AF, </text>
<text top="214" left="54" width="57" height="17" font="13">Patel MR, </text>
<text top="231" left="54" width="31" height="17" font="13">2011 </text>
<text top="248" left="54" width="55" height="17" font="14">21830957</text>
<text top="248" left="109" width="3" height="17" font="13"> </text>
<text top="265" left="54" width="32" height="17" font="13">(196) </text>
<text top="283" left="54" width="3" height="17" font="13"> </text>
<text top="196" left="150" width="54" height="17" font="13">Compare </text>
<text top="214" left="150" width="93" height="17" font="13">rivaroxaban with </text>
<text top="231" left="150" width="60" height="17" font="13">warfarin in </text>
<text top="248" left="150" width="75" height="17" font="13">prevention of </text>
<text top="265" left="150" width="51" height="17" font="13">stroke or </text>
<text top="283" left="150" width="51" height="17" font="13">systemic </text>
<text top="300" left="150" width="89" height="17" font="13">embolism in pts </text>
<text top="317" left="150" width="44" height="17" font="13">with AF </text>
<text top="196" left="265" width="42" height="17" font="13">Double </text>
<text top="214" left="265" width="58" height="17" font="13">blind RCT </text>
<text top="196" left="339" width="41" height="17" font="13">14,264 </text>
<text top="196" left="420" width="92" height="17" font="13">Non-valvular AF </text>
<text top="196" left="541" width="31" height="17" font="13">  N/A </text>
<text top="196" left="629" width="105" height="17" font="13">Stroke or systemic </text>
<text top="214" left="629" width="56" height="17" font="13">embolism </text>
<text top="196" left="751" width="31" height="17" font="13">  N/A </text>
<text top="196" left="886" width="186" height="17" font="13">Primary outcome occurred in less </text>
<text top="214" left="886" width="174" height="17" font="13">often in rivaroxaban group than </text>
<text top="231" left="886" width="206" height="17" font="13">warfarin group (2.1 % vs. 2.4% per y) </text>
<text top="248" left="886" width="202" height="17" font="13">ITT analysis noninferiority: HR: 0.88; </text>
<text top="265" left="886" width="161" height="17" font="13">95% CI: 0.74-1.03; p&lt;0.0001 </text>
<text top="196" left="1108" width="104" height="17" font="13">No between group </text>
<text top="214" left="1108" width="119" height="17" font="13">differences in the ITT </text>
<text top="231" left="1108" width="51" height="17" font="13">analysis. </text>
<text top="196" left="1277" width="135" height="17" font="13">Showed noninferiority of </text>
<text top="214" left="1277" width="75" height="17" font="13">rivaroxaban.  </text>
<text top="335" left="54" width="1363" height="17" font="13">AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; CHF, congestive heart failure; CrCl , creatinine clearance; CV, cardiovascular; HR, hazard ratio; ITT, intent-to-treat; LV, left ventricular; LVEF, left </text>
<text top="352" left="54" width="1363" height="17" font="13">ventricular ejection fraction; NYHA, New York Heart Association; Pts, patients; RCT, randomized control trial; RE-LY, randomized evaluation of long-term anticoagulant therapy trial; ROCKET-AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor </text>
<text top="369" left="54" width="848" height="17" font="13">Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; RR, relative risk; and TIA, transient ischemic attack;  </text>
<text top="386" left="54" width="3" height="17" font="13"> </text>
<text top="421" left="54" width="427" height="21" font="8"><b>Data Supplement 42. HF Disease Management (Section 11.2) </b></text>
<text top="443" left="50" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="462" left="50" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="443" left="151" width="86" height="19" font="9"><b>Aim of study </b></text>
<text top="443" left="257" width="167" height="19" font="9"><b>Study Type  Study Size </b></text>
<text top="443" left="500" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="443" left="772" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="443" left="934" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="443" left="1160" width="121" height="19" font="9"><b> Study Limitations </b></text>
<text top="443" left="1317" width="137" height="19" font="9"><b>Findings/ Comments </b></text>
<text top="481" left="89" width="8" height="19" font="7">  </text>
<text top="481" left="190" width="8" height="19" font="7">  </text>
<text top="481" left="292" width="8" height="19" font="7">  </text>
<text top="481" left="384" width="8" height="19" font="7">  </text>
<text top="481" left="439" width="248" height="19" font="10"><i><b>Inclusion Criteria  Exclusion Criteria </b></i></text>
<text top="481" left="724" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="500" left="720" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="481" left="829" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="500" left="834" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="481" left="1025" width="8" height="19" font="7">  </text>
<text top="481" left="1216" width="8" height="19" font="7">  </text>
<text top="481" left="1382" width="8" height="19" font="7">  </text>
<text top="520" left="49" width="84" height="17" font="13">What Works In </text>
<text top="538" left="49" width="76" height="17" font="13">Chronic Care </text>
<text top="555" left="49" width="79" height="17" font="13">Management: </text>
<text top="572" left="49" width="73" height="17" font="13">The Case Of </text>
<text top="589" left="49" width="20" height="17" font="13">HF </text>
<text top="606" left="49" width="58" height="17" font="14">19124869 </text>
<text top="624" left="49" width="32" height="17" font="13">(374) </text>
<text top="520" left="150" width="72" height="17" font="13">The effect of </text>
<text top="538" left="150" width="46" height="17" font="13">delivery </text>
<text top="555" left="150" width="84" height="17" font="13">methods in the </text>
<text top="572" left="150" width="75" height="17" font="13">management </text>
<text top="589" left="150" width="78" height="17" font="13">of HF care on </text>
<text top="606" left="150" width="46" height="17" font="13">hospital </text>
<text top="624" left="150" width="76" height="17" font="13">readmissions </text>
<text top="520" left="251" width="79" height="17" font="13">Meta analysis </text>
<text top="538" left="251" width="48" height="17" font="13">of RCTs </text>
<text top="520" left="352" width="38" height="17" font="13"> 2,028 </text>
<text top="520" left="437" width="80" height="17" font="13"> Not Reported </text>
<text top="520" left="567" width="76" height="17" font="13">Not Reported </text>
<text top="520" left="699" width="100" height="17" font="13">All-cause hospital </text>
<text top="538" left="699" width="100" height="17" font="13">readmissions and </text>
<text top="555" left="699" width="80" height="17" font="13">readmission d </text>
<text top="520" left="815" width="27" height="17" font="13"> N/A </text>
<text top="520" left="928" width="152" height="17" font="13">Pts enrolled in chronic care </text>
<text top="538" left="928" width="174" height="17" font="13">management programs using a </text>
<text top="555" left="928" width="194" height="17" font="13">multidisciplinary team in addition to </text>
<text top="572" left="928" width="175" height="17" font="13">in-person communication had a </text>
<text top="589" left="928" width="198" height="17" font="13">2.9% reduction in readmissions/ mo </text>
<text top="606" left="928" width="133" height="17" font="13">and a 6.4% reduction in </text>
<text top="624" left="928" width="172" height="17" font="13">readmission d/mo compared to </text>
<text top="641" left="928" width="135" height="17" font="13">routine care (p &lt; 0.001). </text>
<text top="520" left="1142" width="135" height="17" font="13">Possible study selection </text>
<text top="538" left="1142" width="120" height="17" font="13">bias; were not able to </text>
<text top="555" left="1142" width="124" height="17" font="13">evaluate cost savings; </text>
<text top="572" left="1142" width="125" height="17" font="13">retrospective analysis. </text>
<text top="520" left="1311" width="148" height="17" font="13">A team-based approach in </text>
<text top="538" left="1311" width="146" height="17" font="13">chronic care management </text>
<text top="555" left="1311" width="113" height="17" font="13">programs for HF pts </text>
<text top="572" left="1311" width="148" height="17" font="13">meets AHA’s principles for </text>
<text top="589" left="1311" width="112" height="17" font="13">high-quality disease </text>
<text top="606" left="1311" width="131" height="17" font="13">management programs </text>
<text top="624" left="1311" width="92" height="17" font="13">and the Disease </text>
<text top="641" left="1311" width="141" height="17" font="13">Management Association </text>
<text top="658" left="1311" width="94" height="17" font="13">of America’s key </text>
<text top="675" left="1311" width="130" height="17" font="13">components of disease </text>
<text top="693" left="1311" width="134" height="17" font="13">management programs. </text>
</page>
<page number="188" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">188</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="46" height="17" font="13">CM in a </text>
<text top="72" left="49" width="85" height="17" font="13">heterogeneous </text>
<text top="89" left="49" width="29" height="17" font="13">CHF </text>
<text top="106" left="49" width="74" height="17" font="13">population: a </text>
<text top="124" left="49" width="29" height="17" font="13">RCT </text>
<text top="141" left="49" width="55" height="17" font="14">12695272</text>
<text top="141" left="103" width="3" height="17" font="13"> </text>
<text top="158" left="49" width="32" height="17" font="13">(375) </text>
<text top="55" left="150" width="81" height="17" font="13">Test the effect </text>
<text top="72" left="150" width="72" height="17" font="13">of CHF case </text>
<text top="89" left="150" width="75" height="17" font="13">management </text>
<text top="106" left="150" width="46" height="17" font="13">with the </text>
<text top="124" left="150" width="65" height="17" font="13">following  4 </text>
<text top="141" left="150" width="87" height="17" font="13">components: 1. </text>
<text top="158" left="150" width="87" height="17" font="13">early discharge </text>
<text top="175" left="150" width="81" height="17" font="13">planning, 2. pt </text>
<text top="192" left="150" width="88" height="17" font="13">and family CHF </text>
<text top="210" left="150" width="74" height="17" font="13">education, 3. </text>
<text top="227" left="150" width="49" height="17" font="13">12 wk of </text>
<text top="244" left="150" width="78" height="17" font="13">telephone f/u, </text>
<text top="261" left="150" width="41" height="17" font="13">and, 4. </text>
<text top="278" left="150" width="72" height="17" font="13">promotion of </text>
<text top="296" left="150" width="72" height="17" font="13">optimal CHF </text>
<text top="313" left="150" width="69" height="17" font="13">medications </text>
<text top="55" left="251" width="32" height="17" font="13"> RCT </text>
<text top="55" left="352" width="27" height="17" font="13"> 287 </text>
<text top="55" left="437" width="60" height="17" font="13">Primary or </text>
<text top="72" left="437" width="115" height="17" font="13">secondary diagnosis </text>
<text top="89" left="437" width="112" height="17" font="13">of CHF, LVD &lt;40%, </text>
<text top="106" left="437" width="70" height="17" font="13">or radiologic </text>
<text top="124" left="437" width="66" height="17" font="13">evidence of </text>
<text top="141" left="437" width="102" height="17" font="13">pulmonary edema </text>
<text top="158" left="437" width="79" height="17" font="13">for which they </text>
<text top="175" left="437" width="110" height="17" font="13">underwent diuresis; </text>
<text top="192" left="437" width="109" height="17" font="13">had to be at risk for </text>
<text top="210" left="437" width="100" height="17" font="13">early readmission </text>
<text top="55" left="568" width="110" height="17" font="13">Discharge to a long-</text>
<text top="72" left="568" width="96" height="17" font="13">term care facility, </text>
<text top="89" left="568" width="90" height="17" font="13">planned cardiac </text>
<text top="106" left="568" width="100" height="17" font="13">surgery, cognitive </text>
<text top="124" left="568" width="68" height="17" font="13">impairment, </text>
<text top="141" left="568" width="108" height="17" font="13">anticipated survival </text>
<text top="158" left="568" width="106" height="17" font="13">of &lt;3 mo, and long-</text>
<text top="175" left="568" width="103" height="17" font="13">term hemodialysis </text>
<text top="55" left="699" width="98" height="17" font="13">90-d readmission </text>
<text top="72" left="699" width="25" height="17" font="13">rate </text>
<text top="55" left="815" width="77" height="17" font="13">Adherence to </text>
<text top="72" left="815" width="82" height="17" font="13">treatment plan </text>
<text top="89" left="815" width="38" height="17" font="13">and pt </text>
<text top="106" left="815" width="69" height="17" font="13">satisfaction  </text>
<text top="55" left="928" width="185" height="17" font="13">There was no difference between </text>
<text top="72" left="928" width="187" height="17" font="13">the 2 groups in 90-d re-admission </text>
<text top="89" left="928" width="176" height="17" font="13">rates (both were 37%, p&gt;0.99).  </text>
<text top="106" left="928" width="172" height="17" font="13">The intervention group showed </text>
<text top="124" left="928" width="193" height="17" font="13">greater adherence to most aspects </text>
<text top="141" left="928" width="190" height="17" font="13">of the treatment plan (p&lt;0.01) and </text>
<text top="158" left="928" width="195" height="17" font="13">pts in this group reported greater pt </text>
<text top="175" left="928" width="118" height="17" font="13">satisfaction (p&lt;0.01). </text>
<text top="192" left="928" width="179" height="17" font="13">Subgroup of pts who live in area </text>
<text top="210" left="928" width="158" height="17" font="13">and received care from local </text>
<text top="227" left="928" width="161" height="17" font="13">cardiologists decreased CHF </text>
<text top="244" left="928" width="167" height="17" font="13">readmission rate (2%vs. 14%; </text>
<text top="261" left="928" width="49" height="17" font="13">p=0.03). </text>
<text top="55" left="1142" width="127" height="17" font="13">Study was not blinded, </text>
<text top="72" left="1142" width="142" height="17" font="13">adherence was assessed </text>
<text top="89" left="1142" width="136" height="17" font="13">via pt self-report; and no </text>
<text top="106" left="1142" width="121" height="17" font="13">consistent method for </text>
<text top="124" left="1142" width="118" height="17" font="13">NYHA classification.  </text>
<text top="55" left="1311" width="132" height="17" font="13">The intervention did not </text>
<text top="72" left="1311" width="139" height="17" font="13">increase costs and study </text>
<text top="89" left="1311" width="107" height="17" font="13">showed that strong </text>
<text top="106" left="1311" width="118" height="17" font="13">working relationships </text>
<text top="124" left="1311" width="117" height="17" font="13">between the CM and </text>
<text top="141" left="1311" width="133" height="17" font="13">cardiologists decreased </text>
<text top="158" left="1311" width="144" height="17" font="13">CHF hospital readmission </text>
<text top="175" left="1311" width="34" height="17" font="13">rates. </text>
<text top="331" left="49" width="85" height="17" font="13">CM for pts with </text>
<text top="348" left="49" width="87" height="17" font="13">chronic systolic </text>
<text top="365" left="49" width="77" height="17" font="13">HF in primary </text>
<text top="382" left="49" width="51" height="17" font="13">care: the </text>
<text top="400" left="49" width="49" height="17" font="13">HICMan </text>
<text top="417" left="49" width="64" height="17" font="13">exploratory </text>
<text top="434" left="49" width="32" height="17" font="13">RCT. </text>
<text top="451" left="49" width="55" height="17" font="14">20478035</text>
<text top="451" left="103" width="3" height="17" font="13"> </text>
<text top="469" left="49" width="32" height="17" font="13">(376) </text>
<text top="331" left="150" width="69" height="17" font="13">To compare </text>
<text top="348" left="150" width="74" height="17" font="13">CM vs. usual </text>
<text top="365" left="150" width="58" height="17" font="13">care on pt </text>
<text top="382" left="150" width="64" height="17" font="13">outcomes.  </text>
<text top="331" left="251" width="32" height="17" font="13"> RCT </text>
<text top="331" left="352" width="24" height="17" font="13">197 </text>
<text top="331" left="437" width="97" height="17" font="13">Adults with LVEF </text>
<text top="348" left="437" width="36" height="17" font="13">≤45% </text>
<text top="331" left="568" width="75" height="17" font="13"> Not reported </text>
<text top="331" left="699" width="91" height="17" font="13">HRQoL, HF self-</text>
<text top="348" left="699" width="69" height="17" font="13">care, and pt-</text>
<text top="365" left="699" width="102" height="17" font="13">reported quality of </text>
<text top="382" left="699" width="31" height="17" font="13">care. </text>
<text top="331" left="815" width="3" height="17" font="13"> </text>
<text top="331" left="928" width="165" height="17" font="13">Nonsignificant between group </text>
<text top="348" left="928" width="181" height="17" font="13">differences for the KCCQ overall </text>
<text top="365" left="928" width="184" height="17" font="13">summary scores favored CM: 1.7 </text>
<text top="382" left="928" width="153" height="17" font="13">(95%CI: -3.0-6.4; p=0.477). </text>
<text top="400" left="928" width="172" height="17" font="13">Heart failure self-care behavior </text>
<text top="417" left="928" width="163" height="17" font="13">scores were significant group </text>
<text top="434" left="928" width="161" height="17" font="13">differences favoring CM: -3.6 </text>
<text top="451" left="928" width="194" height="17" font="13">(95%CI: -5.7- -1.6; Cohen's d 0.55; </text>
<text top="469" left="928" width="52" height="17" font="13">p=0.001) </text>
<text top="486" left="928" width="145" height="17" font="13">Significant between group </text>
<text top="503" left="928" width="197" height="17" font="13">differences quality of chronic illness </text>
<text top="520" left="928" width="151" height="17" font="13">care (0.5; 95% CI : 0.3-0.7; </text>
<text top="537" left="928" width="192" height="17" font="13">p=0.000) and behavior counseling  </text>
<text top="555" left="928" width="201" height="17" font="13">(0.5; 95%CI : 0.3-0.8; p=0.000), with </text>
<text top="572" left="928" width="183" height="17" font="13">moderate effect sizes (Cohen's d </text>
<text top="589" left="928" width="163" height="17" font="13">0.7 for each summary score). </text>
<text top="331" left="1142" width="155" height="17" font="13">Small, unblended sample of </text>
<text top="348" left="1142" width="109" height="17" font="13">patients from a non-</text>
<text top="365" left="1142" width="138" height="17" font="13">representative sample of </text>
<text top="382" left="1142" width="68" height="17" font="13">physicians.  </text>
<text top="331" left="1311" width="138" height="17" font="13">The intervention failed to </text>
<text top="348" left="1311" width="117" height="17" font="13">improve overall QoL, </text>
<text top="365" left="1311" width="145" height="17" font="13">though showed significant </text>
<text top="382" left="1311" width="108" height="17" font="13">improvements in pt-</text>
<text top="400" left="1311" width="129" height="17" font="13">reported quality of care </text>
<text top="417" left="1311" width="141" height="17" font="13">and chronic HF self-care. </text>
<text top="607" left="49" width="64" height="17" font="13">Impact of a </text>
<text top="624" left="49" width="64" height="17" font="13">specialized </text>
<text top="641" left="49" width="77" height="17" font="13">outpatient HF </text>
<text top="659" left="49" width="53" height="17" font="13">follow-up </text>
<text top="676" left="49" width="66" height="17" font="13">program on </text>
<text top="693" left="49" width="81" height="17" font="13">hospitalization </text>
<text top="710" left="49" width="81" height="17" font="13">frequency and </text>
<text top="727" left="49" width="56" height="17" font="13">functional </text>
<text top="745" left="49" width="70" height="17" font="13">status of pts </text>
<text top="762" left="49" width="57" height="17" font="13">with AHF. </text>
<text top="779" left="49" width="55" height="17" font="14">17695729</text>
<text top="779" left="103" width="3" height="17" font="13"> </text>
<text top="607" left="150" width="88" height="17" font="13">To evaluate the </text>
<text top="624" left="150" width="64" height="17" font="13">impact of a </text>
<text top="641" left="150" width="64" height="17" font="13">specialized </text>
<text top="659" left="150" width="77" height="17" font="13">outpatient HF </text>
<text top="676" left="150" width="53" height="17" font="13">follow-up </text>
<text top="693" left="150" width="49" height="17" font="13">program </text>
<text top="607" left="251" width="79" height="17" font="13">Retrospective </text>
<text top="607" left="352" width="27" height="17" font="13"> 147 </text>
<text top="607" left="437" width="75" height="17" font="13"> Not reported </text>
<text top="607" left="568" width="72" height="17" font="13">Not reported </text>
<text top="607" left="699" width="86" height="17" font="13">Frequency and </text>
<text top="624" left="699" width="62" height="17" font="13">duration of </text>
<text top="641" left="699" width="99" height="17" font="13">hospitalization for </text>
<text top="659" left="699" width="100" height="17" font="13">HF and functional </text>
<text top="676" left="699" width="36" height="17" font="13">status </text>
<text top="607" left="815" width="3" height="17" font="13"> </text>
<text top="607" left="928" width="185" height="17" font="13">Significant improvement in NYHA </text>
<text top="624" left="928" width="176" height="17" font="13">class during the mean follow-up </text>
<text top="641" left="928" width="198" height="17" font="13">period: 55% of the pts were in class </text>
<text top="659" left="928" width="200" height="17" font="13">III, 37% in class II, 5% in class I and </text>
<text top="676" left="928" width="147" height="17" font="13">3% in class IV (p&lt;0.0001). </text>
<text top="693" left="928" width="141" height="17" font="13">Hospitalizations for acute </text>
<text top="710" left="928" width="195" height="17" font="13">decompensation of  HF decreased: </text>
<text top="727" left="928" width="179" height="17" font="13">87 at baseline vs. 25 (p&lt;0.0001) </text>
<text top="607" left="1142" width="141" height="17" font="13">Small retrospective study </text>
<text top="607" left="1311" width="141" height="17" font="13">No significant differences </text>
<text top="624" left="1311" width="98" height="17" font="13">were found in the </text>
<text top="641" left="1311" width="92" height="17" font="13">proportion of pts </text>
<text top="659" left="1311" width="143" height="17" font="13">on therapeutic drugs or in </text>
<text top="676" left="1311" width="96" height="17" font="13">mean duration of </text>
<text top="693" left="1311" width="81" height="17" font="13">hospitalization </text>
</page>
<page number="189" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">189</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="32" height="17" font="13">(377) </text>
<text top="78" left="49" width="60" height="17" font="13">Outpatient </text>
<text top="95" left="49" width="70" height="17" font="13">medical and </text>
<text top="112" left="49" width="34" height="17" font="13">nurse </text>
<text top="130" left="49" width="75" height="17" font="13">management </text>
<text top="147" left="49" width="82" height="17" font="13">program in pts </text>
<text top="164" left="49" width="88" height="17" font="13">with chronic HF </text>
<text top="181" left="49" width="54" height="17" font="13">in a large </text>
<text top="198" left="49" width="79" height="17" font="13">territorial area </text>
<text top="216" left="49" width="82" height="17" font="13">in Piedmont. 4 </text>
<text top="233" left="49" width="79" height="17" font="13">y of follow-up<i>. </i></text>
<text top="250" left="49" width="55" height="17" font="14">16444925</text>
<text top="250" left="103" width="3" height="17" font="13"> </text>
<text top="267" left="49" width="32" height="17" font="13">(378) </text>
<text top="78" left="150" width="85" height="17" font="13">To evaluate an </text>
<text top="95" left="150" width="57" height="17" font="13">outpatient </text>
<text top="112" left="150" width="75" height="17" font="13">management </text>
<text top="130" left="150" width="87" height="17" font="13">program for pts </text>
<text top="147" left="150" width="88" height="17" font="13">with chronic HF </text>
<text top="78" left="251" width="68" height="17" font="13">Prospective </text>
<text top="95" left="251" width="23" height="17" font="13">trial </text>
<text top="78" left="352" width="24" height="17" font="13">115 </text>
<text top="78" left="437" width="106" height="17" font="13">Adults with chronic </text>
<text top="95" left="437" width="109" height="17" font="13">HF in the Piedmont </text>
<text top="112" left="437" width="81" height="17" font="13">region of Italy. </text>
<text top="78" left="568" width="7" height="17" font="13">  </text>
<text top="78" left="699" width="83" height="17" font="13">Hospitalization </text>
<text top="95" left="699" width="44" height="17" font="13">and ED </text>
<text top="112" left="699" width="98" height="17" font="13">admissions in the </text>
<text top="130" left="699" width="96" height="17" font="13">12 mo before the </text>
<text top="147" left="699" width="7" height="17" font="13">1</text>
<text top="148" left="706" width="6" height="11" font="19">st</text>
<text top="147" left="712" width="87" height="17" font="13"> evaluation and </text>
<text top="164" left="699" width="71" height="17" font="13">every y after </text>
<text top="181" left="699" width="42" height="17" font="13">referral </text>
<text top="78" left="815" width="90" height="17" font="13">MLWHF, NYHA </text>
<text top="95" left="815" width="91" height="17" font="13">functional class, </text>
<text top="112" left="815" width="93" height="17" font="13">pharmacological </text>
<text top="130" left="815" width="88" height="17" font="13">therapies at the </text>
<text top="147" left="815" width="93" height="17" font="13">referral time and </text>
<text top="164" left="815" width="72" height="17" font="13">at the end of </text>
<text top="181" left="815" width="56" height="17" font="13">follow-up. </text>
<text top="78" left="928" width="184" height="17" font="13">EF improved from 31 +/- 10 to 36 </text>
<text top="95" left="928" width="159" height="17" font="13">+/- 12%. ED admissions and </text>
<text top="112" left="928" width="173" height="17" font="13">hospitalizations decreased (p &lt; </text>
<text top="130" left="928" width="196" height="17" font="13">0.001). NYHA classes I-II improved </text>
<text top="147" left="928" width="169" height="17" font="13">from 65.5 to 87.7% and NYHA </text>
<text top="164" left="928" width="180" height="17" font="13">classes III-IV were reduced from </text>
<text top="181" left="928" width="165" height="17" font="13">34.5 to 12.3%. MLWHF score </text>
<text top="198" left="928" width="172" height="17" font="13">decreased from 25 to 21.9. Pts </text>
<text top="216" left="928" width="195" height="17" font="13">treated with ACEI + ARB increased </text>
<text top="233" left="928" width="195" height="17" font="13">from 91 to 96%, beta blockers from </text>
<text top="250" left="928" width="176" height="17" font="13">35.2 to 69%, potassium sparing </text>
<text top="267" left="928" width="181" height="17" font="13">drugs increased from 54 to 64%. </text>
<text top="78" left="1142" width="81" height="17" font="13">Small trial, not </text>
<text top="95" left="1142" width="90" height="17" font="13">generalizable to </text>
<text top="112" left="1142" width="152" height="17" font="13">populations outside of Italy. </text>
<text top="78" left="1311" width="146" height="17" font="13">Showed a decrease in the </text>
<text top="95" left="1311" width="146" height="17" font="13">number of hospitalizations </text>
<text top="112" left="1311" width="149" height="17" font="13">and improvement in NYHA </text>
<text top="130" left="1311" width="111" height="17" font="13">functional class and </text>
<text top="147" left="1311" width="121" height="17" font="13">adherence to medical </text>
<text top="164" left="1311" width="125" height="17" font="13">therapy. These results </text>
<text top="181" left="1311" width="144" height="17" font="13">kept constant over time in </text>
<text top="198" left="1311" width="111" height="17" font="13">the subsequent 4 y. </text>
<text top="285" left="43" width="1398" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; AHF, acute heart failure; ARB, angiotensin receptor blockers; CHF, congestive heart failure; CM, case management; ED, emergency department; EF, ejection fraction; HF, heart failure; HRQoL, health </text>
<text top="302" left="43" width="821" height="17" font="13">related quality of life; KCCQ, LVD, left ventricular dysfunction; MLHF, Minnesota Living with Heart Failure; NYHA, pts, patients; and QoL, quality of life. </text>
<text top="323" left="54" width="4" height="16" font="7"> </text>
<text top="358" left="54" width="360" height="21" font="8"><b>Data Supplement 43. Telemonitoring (Section 11.2) </b></text>
<text top="379" left="54" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="398" left="54" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="379" left="164" width="86" height="19" font="9"><b>Aim of study </b></text>
<text top="379" left="287" width="41" height="19" font="9"><b>Study </b></text>
<text top="398" left="290" width="35" height="19" font="9"><b>Type </b></text>
<text top="379" left="372" width="41" height="19" font="9"><b>Study </b></text>
<text top="398" left="377" width="31" height="19" font="9"><b>Size </b></text>
<text top="379" left="508" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="379" left="780" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="379" left="944" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="379" left="1156" width="121" height="19" font="9"><b> Study Limitations </b></text>
<text top="379" left="1300" width="137" height="19" font="9"><b>Findings/ Comments </b></text>
<text top="425" left="93" width="8" height="19" font="7">  </text>
<text top="425" left="203" width="8" height="19" font="7">  </text>
<text top="425" left="304" width="8" height="19" font="7">  </text>
<text top="425" left="389" width="8" height="19" font="7">  </text>
<text top="425" left="460" width="63" height="19" font="10"><i><b>Inclusion </b></i></text>
<text top="443" left="466" width="51" height="19" font="10"><i><b>Criteria </b></i></text>
<text top="425" left="567" width="119" height="19" font="10"><i><b>Exclusion Criteria </b></i></text>
<text top="425" left="737" width="54" height="19" font="10"><i><b>Primary </b></i></text>
<text top="443" left="733" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="425" left="840" width="77" height="19" font="10"><i><b>Secondary  </b></i></text>
<text top="443" left="845" width="62" height="19" font="10"><i><b>Endpoint </b></i></text>
<text top="425" left="1034" width="8" height="19" font="7">  </text>
<text top="425" left="1213" width="8" height="19" font="7">  </text>
<text top="425" left="1365" width="8" height="19" font="7">  </text>
<text top="463" left="49" width="85" height="17" font="13">Telemonitoring </text>
<text top="481" left="49" width="73" height="17" font="13">or structured </text>
<text top="498" left="49" width="57" height="17" font="13">telephone </text>
<text top="515" left="49" width="44" height="17" font="13">support </text>
<text top="532" left="49" width="93" height="17" font="13">programs for pts </text>
<text top="550" left="49" width="92" height="17" font="13">with chronic HF: </text>
<text top="567" left="49" width="61" height="17" font="13">systematic </text>
<text top="584" left="49" width="63" height="17" font="13">review and </text>
<text top="601" left="49" width="83" height="17" font="13">meta-analysis. </text>
<text top="618" left="49" width="58" height="17" font="14">17426062 </text>
<text top="618" left="107" width="32" height="17" font="13">(379) </text>
<text top="463" left="157" width="76" height="17" font="13">To determine </text>
<text top="481" left="157" width="89" height="17" font="13">whether remote </text>
<text top="498" left="157" width="61" height="17" font="13">monitoring </text>
<text top="515" left="157" width="62" height="17" font="13">(structured </text>
<text top="532" left="157" width="57" height="17" font="13">telephone </text>
<text top="550" left="157" width="59" height="17" font="13">support or </text>
<text top="567" left="157" width="85" height="17" font="13">telemonitoring) </text>
<text top="584" left="157" width="84" height="17" font="13">without regular </text>
<text top="601" left="157" width="79" height="17" font="13">clinic or home </text>
<text top="618" left="157" width="84" height="17" font="13">visits improves </text>
<text top="636" left="157" width="94" height="17" font="13">outcomes for pts </text>
<text top="653" left="157" width="92" height="17" font="13">with chronic HF. </text>
<text top="463" left="270" width="31" height="17" font="13">Meta </text>
<text top="481" left="270" width="48" height="17" font="13">analysis </text>
<text top="463" left="357" width="190" height="17" font="13">4,264 Published </text>
<text top="463" left="498" width="84" height="17" font="13">RCTs </text>
<text top="481" left="440" width="61" height="17" font="13">comparing </text>
<text top="498" left="440" width="42" height="17" font="13">remote </text>
<text top="515" left="440" width="61" height="17" font="13">monitoring </text>
<text top="532" left="440" width="81" height="17" font="13">programs with </text>
<text top="550" left="440" width="73" height="17" font="13">usual care in </text>
<text top="567" left="440" width="72" height="17" font="13">patients with </text>
<text top="584" left="440" width="63" height="17" font="13">chronic HF </text>
<text top="601" left="440" width="90" height="17" font="13">managed within </text>
<text top="618" left="440" width="87" height="17" font="13">the community. </text>
<text top="463" left="555" width="361" height="17" font="13"> All-cause </text>
<text top="463" left="764" width="205" height="17" font="13">mortality, </text>
<text top="481" left="710" width="91" height="17" font="13">all-cause rate of </text>
<text top="498" left="710" width="72" height="17" font="13">admission to </text>
<text top="515" left="710" width="98" height="17" font="13">hospital, and rate </text>
<text top="532" left="710" width="86" height="17" font="13">of admission to </text>
<text top="550" left="710" width="106" height="17" font="13">hospital as a result </text>
<text top="567" left="710" width="80" height="17" font="13">of chronic HF  </text>
<text top="463" left="832" width="3" height="17" font="13"> </text>
<text top="463" left="933" width="197" height="17" font="13">20% reduction in all-cause mortality </text>
<text top="481" left="933" width="211" height="17" font="13">(95% CI: 8- 31%) with telemonitoring.  </text>
<text top="498" left="933" width="174" height="17" font="13">No change in all-cause hospital </text>
<text top="515" left="933" width="87" height="17" font="13">admission rate. </text>
<text top="532" left="933" width="193" height="17" font="13">Hospital admissions due to chronic </text>
<text top="550" left="933" width="202" height="17" font="13">HF saw a reduction of 21% (95% CI: </text>
<text top="567" left="933" width="181" height="17" font="13">11 -31%) with remote monitoring </text>
<text top="584" left="933" width="72" height="17" font="13">programmes </text>
<text top="463" left="1156" width="89" height="17" font="13">Relatively small </text>
<text top="481" left="1156" width="101" height="17" font="13">number of studies </text>
<text top="498" left="1156" width="99" height="17" font="13">and pts; few trials </text>
<text top="515" left="1156" width="120" height="17" font="13">had follow-up beyond </text>
<text top="532" left="1156" width="34" height="17" font="13">6 mo. </text>
<text top="463" left="1291" width="107" height="17" font="13">Remote monitoring </text>
<text top="481" left="1291" width="118" height="17" font="13">programs for pts with </text>
<text top="498" left="1291" width="111" height="17" font="13">chronic HF reduced </text>
<text top="515" left="1291" width="148" height="17" font="13">admissions to hospital and </text>
<text top="532" left="1291" width="156" height="17" font="13">all-cause mortality by nearly </text>
<text top="550" left="1291" width="24" height="17" font="13">1/5. </text>
</page>
<page number="190" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">190</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="49" width="60" height="17" font="13">Structured </text>
<text top="72" left="49" width="57" height="17" font="13">telephone </text>
<text top="89" left="49" width="59" height="17" font="13">support or </text>
<text top="106" left="49" width="81" height="17" font="13">telemonitoring </text>
<text top="124" left="49" width="93" height="17" font="13">programs for pts </text>
<text top="141" left="49" width="88" height="17" font="13">with chronic HF </text>
<text top="158" left="49" width="58" height="17" font="14">20687083 </text>
<text top="158" left="107" width="32" height="17" font="13">(380) </text>
<text top="55" left="157" width="88" height="17" font="13">To examine the </text>
<text top="72" left="157" width="47" height="17" font="13">effect of </text>
<text top="89" left="157" width="81" height="17" font="13">telemonitoring </text>
<text top="106" left="157" width="82" height="17" font="13">and structured </text>
<text top="124" left="157" width="57" height="17" font="13">telephone </text>
<text top="141" left="157" width="81" height="17" font="13">support on HF </text>
<text top="158" left="157" width="64" height="17" font="13">outcomes.  </text>
<text top="55" left="270" width="31" height="17" font="13">Meta </text>
<text top="72" left="270" width="48" height="17" font="13">analysis </text>
<text top="55" left="357" width="63" height="17" font="13">25 studies, </text>
<text top="72" left="357" width="21" height="17" font="13">16  </text>
<text top="89" left="357" width="58" height="17" font="13">structured </text>
<text top="106" left="357" width="57" height="17" font="13">telephone </text>
<text top="124" left="357" width="69" height="17" font="13">support (n = </text>
<text top="141" left="357" width="31" height="17" font="13">5613 </text>
<text top="158" left="357" width="62" height="17" font="13">) and 11 of </text>
<text top="175" left="357" width="64" height="17" font="13">telemonitori</text>
<text top="192" left="357" width="21" height="17" font="13">ng  </text>
<text top="210" left="357" width="60" height="17" font="13">(n = 2710)<b> </b></text>
<text top="55" left="440" width="100" height="17" font="13">RCTs, adults ≥18 </text>
<text top="72" left="440" width="98" height="17" font="13">y, diagnosed with </text>
<text top="89" left="440" width="66" height="17" font="13">chronic HF. </text>
<text top="55" left="555" width="135" height="17" font="13">Trials of general cardiac </text>
<text top="72" left="555" width="117" height="17" font="13">disorders rather than </text>
<text top="89" left="555" width="93" height="17" font="13">chronic HF were </text>
<text top="106" left="555" width="56" height="17" font="13">excluded. </text>
<text top="55" left="710" width="104" height="17" font="13">All-cause mortality </text>
<text top="55" left="831" width="54" height="17" font="13">All-cause </text>
<text top="72" left="832" width="76" height="17" font="13">readmissions </text>
<text top="89" left="832" width="83" height="17" font="13">to hospital and </text>
<text top="106" left="832" width="64" height="17" font="13">chronic HF-</text>
<text top="124" left="832" width="41" height="17" font="13">related </text>
<text top="141" left="832" width="72" height="17" font="13">admission to </text>
<text top="158" left="832" width="46" height="17" font="13">hospital </text>
<text top="55" left="933" width="107" height="17" font="13">All-cause mortality: </text>
<text top="72" left="933" width="187" height="17" font="13">Telemonitoring RR: 0.66; 95% CI: </text>
<text top="89" left="933" width="117" height="17" font="13">0.54-0.81, p&lt; 0.0001 </text>
<text top="106" left="933" width="190" height="17" font="13">Structured telephone support  RR: </text>
<text top="124" left="933" width="178" height="17" font="13">0.88; 95% CI: 0.76-1.01; p=0.08 </text>
<text top="141" left="933" width="139" height="17" font="13">All-cause hospitalization: </text>
<text top="158" left="933" width="184" height="17" font="13">Telemonitoring RR:0.91; 95% CI: </text>
<text top="175" left="933" width="100" height="17" font="13">0.84-0.99; p=0.02 </text>
<text top="192" left="933" width="187" height="17" font="13">Structured telephone support RR: </text>
<text top="210" left="933" width="178" height="17" font="13">0.92; 95% CI: 0.85-0.99; p=0.02 </text>
<text top="227" left="933" width="198" height="17" font="13">Chronic HF-related hospitalizations: </text>
<text top="244" left="933" width="187" height="18" font="13">Telemonitoring RR: 0.79; 95% CI: </text>
<text top="261" left="933" width="110" height="17" font="13">0.67-0.94; p=0.008. </text>
<text top="278" left="933" width="187" height="17" font="13">Structured telephone support RR: </text>
<text top="296" left="933" width="192" height="17" font="13">0.77; 95% CI: 0.68-0.87; p&lt;0.0001 </text>
<text top="55" left="1156" width="112" height="17" font="13">Unable to stratify by </text>
<text top="72" left="1156" width="105" height="17" font="13">age, sex, or NYHA </text>
<text top="89" left="1156" width="91" height="17" font="13">class. Unable to </text>
<text top="106" left="1156" width="122" height="17" font="13">adjust for the differing </text>
<text top="124" left="1156" width="116" height="17" font="13">lengths of follow-up.  </text>
<text top="55" left="1291" width="109" height="17" font="13">Telemonitoring and </text>
<text top="72" left="1291" width="116" height="17" font="13">structured telephone </text>
<text top="89" left="1291" width="118" height="17" font="13">support interventions </text>
<text top="106" left="1291" width="94" height="17" font="13">for assisting with </text>
<text top="124" left="1291" width="134" height="17" font="13">management of pts with </text>
<text top="141" left="1291" width="63" height="17" font="13">chronic HF </text>
<text top="158" left="1291" width="153" height="17" font="13">are beneficial and may play </text>
<text top="175" left="1291" width="153" height="17" font="13">a significant role in the care </text>
<text top="192" left="1291" width="70" height="17" font="13">of ’standard’ </text>
<text top="210" left="1291" width="155" height="17" font="13">management of chronic HF. </text>
<text top="227" left="1291" width="3" height="17" font="13"> </text>
<text top="325" left="49" width="59" height="17" font="13">Effect of a </text>
<text top="342" left="49" width="74" height="17" font="13">standardized </text>
<text top="359" left="49" width="64" height="17" font="13">nurse case-</text>
<text top="376" left="49" width="75" height="17" font="13">management </text>
<text top="394" left="49" width="57" height="17" font="13">telephone </text>
<text top="411" left="49" width="84" height="17" font="13">intervention on </text>
<text top="428" left="49" width="87" height="17" font="13">resource use in </text>
<text top="445" left="49" width="72" height="17" font="13">patients with </text>
<text top="462" left="49" width="66" height="17" font="13">chronic HF. </text>
<text top="480" left="49" width="58" height="17" font="14">11911726 </text>
<text top="480" left="107" width="32" height="17" font="13">(381) </text>
<text top="325" left="157" width="80" height="17" font="13">To assess the </text>
<text top="342" left="157" width="99" height="17" font="13">effectiveness of a </text>
<text top="359" left="157" width="74" height="17" font="13">standardized </text>
<text top="376" left="157" width="89" height="17" font="13">telephonic case-</text>
<text top="394" left="157" width="75" height="17" font="13">management </text>
<text top="411" left="157" width="100" height="17" font="13">intervention in pts </text>
<text top="428" left="157" width="92" height="17" font="13">with chronic HF. </text>
<text top="325" left="270" width="173" height="17" font="13">RCT 358; </text>
<text top="325" left="384" width="82" height="17" font="13">130 </text>
<text top="342" left="357" width="61" height="17" font="13">(interventio</text>
<text top="359" left="357" width="42" height="17" font="13">n); 228 </text>
<text top="376" left="357" width="72" height="17" font="13">(usual care)  </text>
<text top="325" left="440" width="229" height="17" font="13">N/A N/A </text>
<text top="325" left="710" width="110" height="17" font="13">HF </text>
<text top="325" left="730" width="172" height="17" font="13">hospitalization </text>
<text top="342" left="710" width="31" height="17" font="13">rates </text>
<text top="325" left="832" width="54" height="17" font="13">All-cause </text>
<text top="342" left="832" width="81" height="17" font="13">hospitalization </text>
<text top="359" left="832" width="54" height="17" font="13">rates; HF </text>
<text top="376" left="832" width="70" height="17" font="13">readmission </text>
<text top="394" left="832" width="48" height="17" font="13">rate; HF </text>
<text top="411" left="832" width="56" height="17" font="13">hospital d </text>
<text top="325" left="933" width="189" height="17" font="13">HF hospitalization rate was 45.7% </text>
<text top="342" left="933" width="192" height="17" font="13">lower in the intervention group at 3 </text>
<text top="359" left="933" width="210" height="17" font="13">mo (p=0.03) and 47.8% lower at 6 mo </text>
<text top="376" left="933" width="53" height="17" font="13">(p=0.01). </text>
<text top="394" left="933" width="195" height="17" font="13">HF hospital d (p=0.03) and multiple </text>
<text top="411" left="933" width="156" height="17" font="13">readmissions (p=0.03) were </text>
<text top="428" left="933" width="200" height="17" font="13">significantly lower in the intervention </text>
<text top="445" left="933" width="209" height="17" font="13">group at 6 mo – though not significant </text>
<text top="462" left="933" width="204" height="17" font="13">after adjustment for other covariates. </text>
<text top="325" left="1156" width="118" height="17" font="13">Selection bias due to </text>
<text top="342" left="1156" width="94" height="17" font="13">randomization of </text>
<text top="359" left="1156" width="100" height="17" font="13">physicians, rather </text>
<text top="376" left="1156" width="113" height="17" font="13">than pts. Impossible </text>
<text top="394" left="1156" width="105" height="17" font="13">to completely blind </text>
<text top="411" left="1156" width="74" height="17" font="13">physicians to </text>
<text top="428" left="1156" width="62" height="17" font="13">treatment.  </text>
<text top="325" left="1291" width="93" height="17" font="13">Telephonic case </text>
<text top="342" left="1291" width="139" height="17" font="13">management can reduce </text>
<text top="359" left="1291" width="151" height="17" font="13">HF hospitalization resulting </text>
<text top="376" left="1291" width="149" height="17" font="13">in significant cost savings.  </text>
<text top="498" left="49" width="42" height="17" font="13">RCT of </text>
<text top="515" left="49" width="87" height="17" font="13">telephone case </text>
<text top="532" left="49" width="88" height="17" font="13">management in </text>
<text top="549" left="49" width="70" height="17" font="13">Hispanics of </text>
<text top="566" left="49" width="83" height="17" font="13">Mexican origin </text>
<text top="584" left="49" width="49" height="17" font="13">with HF. </text>
<text top="601" left="49" width="58" height="17" font="14">16624687 </text>
<text top="601" left="107" width="32" height="17" font="13">(382) </text>
<text top="498" left="157" width="62" height="17" font="13">Tested the </text>
<text top="515" left="157" width="89" height="17" font="13">effectiveness of </text>
<text top="532" left="157" width="57" height="17" font="13">telephone </text>
<text top="549" left="157" width="29" height="17" font="13">case </text>
<text top="566" left="157" width="88" height="17" font="13">management in </text>
<text top="584" left="157" width="64" height="17" font="13">decreasing </text>
<text top="601" left="157" width="87" height="17" font="13">hospitalizations </text>
<text top="618" left="157" width="81" height="17" font="13">and improving </text>
<text top="635" left="157" width="62" height="17" font="13">HRQL and </text>
<text top="652" left="157" width="67" height="17" font="13">depression  </text>
<text top="498" left="270" width="173" height="17" font="13">RCT 134; </text>
<text top="498" left="384" width="75" height="17" font="13">69 </text>
<text top="515" left="357" width="61" height="17" font="13">(interventio</text>
<text top="532" left="357" width="35" height="17" font="13">n); 65 </text>
<text top="549" left="357" width="68" height="17" font="13">(usual care) </text>
<text top="498" left="440" width="70" height="17" font="13">Hospitalized </text>
<text top="515" left="440" width="82" height="17" font="13">Hispanics with </text>
<text top="532" left="440" width="63" height="17" font="13">chronic HF </text>
<text top="498" left="555" width="24" height="17" font="13">N/A </text>
<text top="497" left="710" width="36" height="17" font="13">HF re-</text>
<text top="515" left="710" width="81" height="17" font="13">hospitalization </text>
<text top="498" left="832" width="54" height="17" font="13">All-cause </text>
<text top="515" left="832" width="85" height="17" font="13">hospitalization, </text>
<text top="532" left="832" width="44" height="17" font="13">d in the </text>
<text top="549" left="832" width="46" height="17" font="13">hospital </text>
<text top="566" left="832" width="64" height="17" font="13">(HF and all-</text>
<text top="584" left="832" width="44" height="17" font="13">cause), </text>
<text top="601" left="832" width="46" height="17" font="13">multiple </text>
<text top="618" left="832" width="79" height="17" font="13">readmissions, </text>
<text top="635" left="832" width="61" height="17" font="13">acute care </text>
<text top="652" left="832" width="88" height="17" font="13">costs, all-cause </text>
<text top="670" left="832" width="53" height="17" font="13">mortality, </text>
<text top="687" left="832" width="41" height="17" font="13">HRQL, </text>
<text top="704" left="832" width="64" height="17" font="13">depression </text>
<text top="498" left="933" width="206" height="17" font="13">No significant group differences were </text>
<text top="515" left="933" width="158" height="17" font="13">found in HF hospitalizations, </text>
<text top="532" left="933" width="161" height="17" font="13">HF readmission rate, d in the </text>
<text top="549" left="933" width="49" height="17" font="13">hospital, </text>
<text top="566" left="933" width="204" height="17" font="13">HF cost of care, all-cause acute care </text>
<text top="584" left="933" width="120" height="17" font="13">use or cost, mortality, </text>
<text top="601" left="933" width="122" height="17" font="13">HRQL, or depression. </text>
<text top="498" left="1156" width="106" height="17" font="13">Small sample size. </text>
<text top="515" left="1156" width="121" height="17" font="13">Possible confounders </text>
<text top="532" left="1156" width="87" height="17" font="13">included very ill </text>
<text top="549" left="1156" width="104" height="17" font="13">population,  poorly </text>
<text top="566" left="1156" width="57" height="17" font="13">educated, </text>
<text top="584" left="1156" width="106" height="17" font="13">economically poor, </text>
<text top="601" left="1156" width="108" height="17" font="13">and unacculturated </text>
<text top="618" left="1156" width="89" height="17" font="13">into US society. </text>
<text top="498" left="1291" width="33" height="17" font="13">None </text>
<text top="722" left="49" width="85" height="17" font="13">Telemonitoring </text>
<text top="739" left="49" width="85" height="17" font="13">in pts with HF.  </text>
<text top="757" left="49" width="58" height="17" font="14">21080835 </text>
<text top="757" left="107" width="32" height="17" font="13">(383) </text>
<text top="722" left="157" width="48" height="17" font="13">Test the </text>
<text top="739" left="157" width="89" height="17" font="13">effectiveness of </text>
<text top="757" left="157" width="100" height="17" font="13">telemonitoring vs. </text>
<text top="774" left="157" width="64" height="17" font="13">usual care. </text>
<text top="722" left="270" width="179" height="17" font="13">RCT 1653; </text>
<text top="722" left="391" width="82" height="17" font="13">826 </text>
<text top="739" left="357" width="61" height="17" font="13">(interventio</text>
<text top="757" left="357" width="42" height="17" font="13">n); 827 </text>
<text top="774" left="357" width="68" height="17" font="13">(usual care) </text>
<text top="722" left="440" width="98" height="17" font="13">Pts were enrolled </text>
<text top="739" left="440" width="90" height="17" font="13">from 2006-2009 </text>
<text top="757" left="440" width="14" height="17" font="13">at </text>
<text top="774" left="440" width="76" height="17" font="13">33 cardiology </text>
<text top="791" left="440" width="92" height="17" font="13">practices across </text>
<text top="722" left="555" width="140" height="17" font="13">Residence in a long-term </text>
<text top="739" left="555" width="139" height="17" font="13">nursing home; inability to </text>
<text top="757" left="555" width="141" height="17" font="13">participate in the protocol </text>
<text top="774" left="555" width="137" height="17" font="13">for any reason, including </text>
<text top="791" left="555" width="85" height="17" font="13">a low expected </text>
<text top="722" left="710" width="54" height="17" font="13">All-cause </text>
<text top="739" left="710" width="104" height="17" font="13">readmission or  all-</text>
<text top="757" left="710" width="86" height="17" font="13">cause mortality </text>
<text top="774" left="710" width="100" height="17" font="13">(within 180 d post </text>
<text top="791" left="710" width="65" height="17" font="13">enrollment) </text>
<text top="722" left="832" width="20" height="17" font="13">HF </text>
<text top="739" left="832" width="85" height="17" font="13">hospitalization, </text>
<text top="757" left="832" width="44" height="17" font="13">d in the </text>
<text top="774" left="832" width="49" height="17" font="13">hospital, </text>
<text top="791" left="832" width="83" height="17" font="13">and number of </text>
<text top="722" left="933" width="191" height="17" font="13">All-cause readmission or mortality: </text>
<text top="739" left="933" width="185" height="17" font="13">telemonitoring vs. usual care HR: </text>
<text top="757" left="933" width="137" height="17" font="13">1.04; 95% CI: 0.91-1.19. </text>
<text top="774" left="933" width="201" height="17" font="13">No significant differences were seen </text>
<text top="791" left="933" width="204" height="17" font="13">between the 2 groups with respect to </text>
<text top="722" left="1156" width="105" height="17" font="13">Automated system </text>
<text top="739" left="1156" width="109" height="17" font="13">with low adherence </text>
<text top="757" left="1156" width="31" height="17" font="13">rate.  </text>
<text top="722" left="1291" width="125" height="17" font="13">Telemonitoring did not </text>
<text top="739" left="1291" width="145" height="17" font="13">improve outcomes among </text>
<text top="757" left="1291" width="152" height="17" font="13">pts recently hospitalized for </text>
<text top="774" left="1291" width="23" height="17" font="13">HF. </text>
</page>
<page number="191" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">191</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="55" left="440" width="66" height="17" font="13">the US. Pts </text>
<text top="72" left="440" width="68" height="17" font="13">hospitalized </text>
<text top="89" left="440" width="71" height="17" font="13">for HF in the </text>
<text top="106" left="440" width="77" height="17" font="13">previous 30 d </text>
<text top="55" left="555" width="136" height="17" font="13">probability of survival for </text>
<text top="72" left="555" width="139" height="17" font="13">the next 6 mo; inability to </text>
<text top="89" left="555" width="137" height="17" font="13">stand on a scale; severe </text>
<text top="106" left="555" width="120" height="17" font="13">cognitive impairment; </text>
<text top="124" left="555" width="81" height="17" font="13">and a planned </text>
<text top="141" left="555" width="109" height="17" font="13">hospitalization for a </text>
<text top="158" left="555" width="59" height="17" font="13">procedure </text>
<text top="55" left="832" width="239" height="17" font="13">hospitalizations  the secondary endpoints </text>
<text top="176" left="43" width="1097" height="17" font="13">HF indicates heart failure; HR, hazard ratio; HRQL, health related quality of life; NYHA, New York Heart Association; pts, patients; RCT, randomized control trial; RR, relative risk; and US, United States. </text>
<text top="197" left="54" width="4" height="16" font="7"> </text>
<text top="231" left="54" width="544" height="21" font="8"><b>Data Supplement 44. Quality Metrics and Performance Measures (Section 12) </b></text>
<text top="253" left="67" width="86" height="19" font="9"><b>Study Name, </b></text>
<text top="272" left="67" width="85" height="19" font="9"><b>Author, Year </b></text>
<text top="253" left="212" width="86" height="19" font="9"><b>Aim of study </b></text>
<text top="253" left="353" width="41" height="19" font="9"><b>Study </b></text>
<text top="272" left="356" width="35" height="19" font="9"><b>Type </b></text>
<text top="253" left="434" width="41" height="19" font="9"><b>Study </b></text>
<text top="272" left="439" width="31" height="19" font="9"><b>Size </b></text>
<text top="253" left="531" width="123" height="19" font="9"><b>Patient Population </b></text>
<text top="253" left="763" width="70" height="19" font="9"><b>Endpoints </b></text>
<text top="253" left="961" width="189" height="19" font="9"><b>Statistical Analysis (Results) </b></text>
<text top="253" left="1210" width="121" height="19" font="9"><b> Study Limitations </b></text>
<text top="253" left="1364" width="64" height="19" font="9"><b>Findings/ </b></text>
<text top="272" left="1359" width="74" height="19" font="9"><b>Comments </b></text>
<text top="304" left="106" width="8" height="19" font="7">  </text>
<text top="304" left="251" width="8" height="19" font="7">  </text>
<text top="304" left="369" width="8" height="19" font="7">  </text>
<text top="304" left="450" width="8" height="19" font="7">  </text>
<text top="304" left="509" width="52" height="15" font="16"><i><b>Inclusion </b></i></text>
<text top="319" left="514" width="42" height="15" font="16"><i><b>Criteria </b></i></text>
<text top="304" left="584" width="97" height="15" font="16"><i><b>Exclusion Criteria </b></i></text>
<text top="304" left="710" width="95" height="15" font="16"><i><b>Primary Endpoint </b></i></text>
<text top="304" left="836" width="63" height="15" font="16"><i><b>Secondary  </b></i></text>
<text top="319" left="840" width="51" height="15" font="16"><i><b>Endpoint </b></i></text>
<text top="304" left="1051" width="8" height="19" font="7">  </text>
<text top="304" left="1267" width="8" height="19" font="7">  </text>
<text top="304" left="1392" width="8" height="19" font="7">  </text>
<text top="343" left="49" width="106" height="17" font="13">Temporal trends in </text>
<text top="360" left="49" width="40" height="17" font="13">clinical </text>
<text top="377" left="49" width="85" height="17" font="13">characteristics, </text>
<text top="395" left="49" width="89" height="17" font="13">treatments, and </text>
<text top="412" left="49" width="94" height="17" font="13">outcomes for HF </text>
<text top="429" left="49" width="91" height="17" font="13">hospitalizations, </text>
<text top="446" left="49" width="111" height="17" font="13">2002-2004: findings </text>
<text top="464" left="49" width="86" height="17" font="13">from ADHERE. </text>
<text top="481" left="49" width="55" height="17" font="14">17540205</text>
<text top="481" left="103" width="36" height="17" font="13"> (384) </text>
<text top="343" left="183" width="111" height="17" font="13">To assess temporal </text>
<text top="360" left="183" width="91" height="17" font="13">trends in clinical </text>
<text top="377" left="183" width="85" height="17" font="13">characteristics, </text>
<text top="395" left="183" width="104" height="17" font="13">treatments, quality </text>
<text top="412" left="183" width="140" height="17" font="13">indicators, and outcomes </text>
<text top="429" left="183" width="129" height="17" font="13">for HF hospitalizations. </text>
<text top="343" left="339" width="129" height="17" font="13">Prospective  159,168 </text>
<text top="343" left="501" width="24" height="17" font="13">N/A </text>
<text top="343" left="582" width="24" height="17" font="13">N/A </text>
<text top="343" left="697" width="24" height="17" font="13">N/A </text>
<text top="343" left="832" width="24" height="17" font="13">N/A </text>
<text top="343" left="913" width="283" height="17" font="13">Inhospital treatment changed significantly over time </text>
<text top="360" left="913" width="271" height="17" font="13">with inotrope use decreasing from 14.7% to 7.9% </text>
<text top="377" left="913" width="251" height="17" font="13">(p&lt;0 .0001). Discharge instructions increased </text>
<text top="395" left="913" width="256" height="17" font="13">133%; smoking counseling, 132%; LV function </text>
<text top="412" left="913" width="276" height="17" font="13">measurement, 8%; and beta blocker use, 29% (all </text>
<text top="429" left="913" width="66" height="17" font="13">p&lt;0.0001).  </text>
<text top="446" left="913" width="263" height="17" font="13">Clinical outcomes improved over time, including </text>
<text top="464" left="913" width="253" height="17" font="13">need for mechanical ventilation, RR: 0.64, p &lt; </text>
<text top="481" left="913" width="256" height="17" font="13">.0001); length of stay (mean), 6.3 to 5.5 d; and </text>
<text top="498" left="913" width="171" height="17" font="13">mortality, RR: 0.71, p&lt;0.0001). </text>
<text top="343" left="1210" width="270" height="17" font="13">N/A N/A </text>
<text top="516" left="49" width="111" height="17" font="13">Improving evidence-</text>
<text top="533" left="49" width="115" height="17" font="13">based care for HF in </text>
<text top="550" left="49" width="117" height="17" font="13">outpatient cardiology </text>
<text top="568" left="49" width="100" height="17" font="13">practices: primary </text>
<text top="585" left="49" width="74" height="17" font="13">results of the </text>
<text top="602" left="49" width="110" height="17" font="13">Registry to Improve </text>
<text top="619" left="49" width="114" height="17" font="13">the Use of Evidence-</text>
<text top="636" left="49" width="116" height="17" font="13">Based HF Therapies </text>
<text top="654" left="49" width="94" height="17" font="13">in the Outpatient </text>
<text top="671" left="49" width="106" height="17" font="13">Setting (IMPROVE </text>
<text top="688" left="49" width="27" height="17" font="13">HF). </text>
<text top="705" left="49" width="58" height="17" font="14">20660805 </text>
<text top="705" left="107" width="32" height="17" font="13">(385) </text>
<text top="516" left="183" width="88" height="17" font="13">To evaluate the </text>
<text top="533" left="183" width="99" height="17" font="13">effectiveness of a </text>
<text top="550" left="183" width="91" height="17" font="13">practice-specific </text>
<text top="568" left="183" width="73" height="17" font="13">performance </text>
<text top="585" left="183" width="141" height="17" font="13">improvement intervention </text>
<text top="602" left="183" width="128" height="17" font="13">on the use of guideline-</text>
<text top="619" left="183" width="136" height="17" font="13">recommended therapies </text>
<text top="636" left="183" width="38" height="17" font="13">for pts </text>
<text top="654" left="183" width="129" height="17" font="13">with diagnosed HF and </text>
<text top="671" left="183" width="142" height="17" font="13">reduced LVEF or prior MI </text>
<text top="688" left="183" width="72" height="17" font="13">and reduced </text>
<text top="705" left="183" width="105" height="17" font="13">LVEF in outpatient </text>
<text top="722" left="183" width="112" height="17" font="13">cardiology practices </text>
<text top="516" left="339" width="122" height="17" font="13">Prospective  34,810 </text>
<text top="516" left="501" width="62" height="17" font="13">HF or prior </text>
<text top="533" left="501" width="42" height="17" font="13">MI with </text>
<text top="550" left="501" width="34" height="17" font="13">LVEF </text>
<text top="568" left="501" width="36" height="17" font="13">≤35% </text>
<text top="516" left="582" width="63" height="17" font="13">Those with </text>
<text top="533" left="582" width="96" height="17" font="13">noncardiovascula</text>
<text top="550" left="582" width="53" height="17" font="13">r medical </text>
<text top="568" left="582" width="53" height="17" font="13">condition </text>
<text top="585" left="582" width="87" height="17" font="13">associated with </text>
<text top="602" left="582" width="17" height="17" font="13">an </text>
<text top="619" left="582" width="102" height="17" font="13">estimated survival </text>
<text top="636" left="582" width="98" height="17" font="13">of &lt;1 y and those </text>
<text top="654" left="582" width="50" height="17" font="13">who had </text>
<text top="671" left="582" width="62" height="17" font="13">undergone </text>
<text top="688" left="582" width="43" height="17" font="13">cardiac </text>
<text top="705" left="582" width="84" height="17" font="13">transplantation </text>
<text top="516" left="697" width="110" height="17" font="13">7 quality measures: </text>
<text top="533" left="697" width="98" height="17" font="13">use of 1) ACEI or </text>
<text top="550" left="697" width="122" height="17" font="13">ARB, 2) Beta blocker, </text>
<text top="568" left="697" width="82" height="17" font="13">3) aldosterone </text>
<text top="585" left="697" width="78" height="17" font="13">antagonist, 4) </text>
<text top="602" left="697" width="121" height="17" font="13">anticoagulant therapy </text>
<text top="619" left="697" width="103" height="17" font="13">for AF or flutter, 5) </text>
<text top="636" left="697" width="64" height="17" font="13">CRT with a </text>
<text top="654" left="697" width="118" height="17" font="13">defibrillator/CRT with </text>
<text top="671" left="697" width="96" height="17" font="13">a pacemaker,  6) </text>
<text top="688" left="697" width="122" height="17" font="13">ICD (ICD or CRT with </text>
<text top="705" left="697" width="120" height="17" font="13">a defibrillator), and 7) </text>
<text top="722" left="697" width="94" height="17" font="13">HF education for </text>
<text top="740" left="697" width="65" height="17" font="13">eligible pts. </text>
<text top="516" left="832" width="24" height="17" font="13">N/A </text>
<text top="516" left="913" width="275" height="17" font="13">Significant improvement was demonstrated in 5 of </text>
<text top="533" left="913" width="267" height="17" font="13">the 7 quality measures at the practice level at 24 </text>
<text top="550" left="913" width="242" height="17" font="13">mo after implementation of the performance </text>
<text top="568" left="913" width="250" height="17" font="13">improvement intervention, use of aldosterone </text>
<text top="585" left="913" width="247" height="17" font="13">antagonists, CRT, ICD, beta blocker, and HF </text>
<text top="602" left="913" width="117" height="17" font="13">education (p&lt;0.001); </text>
<text top="619" left="913" width="271" height="17" font="13">Use of anticoagulation in eligible patients with AF </text>
<text top="636" left="913" width="245" height="17" font="13">did not improve over time. Use of ACEI/ARB </text>
<text top="654" left="913" width="259" height="17" font="13">increased (+6.8%), but this was not statistically </text>
<text top="671" left="913" width="115" height="17" font="13">significant (p=0.063) </text>
<text top="688" left="913" width="3" height="17" font="13"> </text>
<text top="516" left="1210" width="98" height="17" font="13">Data collected by </text>
<text top="533" left="1210" width="108" height="17" font="13">chart review, which </text>
<text top="550" left="1210" width="110" height="17" font="13">may be incomplete; </text>
<text top="568" left="1210" width="94" height="17" font="13">selection bias as </text>
<text top="585" left="1210" width="82" height="17" font="13">eligible pts not </text>
<text top="602" left="1210" width="110" height="17" font="13">included in analysis </text>
<text top="619" left="1210" width="74" height="17" font="13">may differ by </text>
<text top="636" left="1210" width="118" height="17" font="13">contraindication from </text>
<text top="654" left="1210" width="93" height="17" font="13">those who were; </text>
<text top="671" left="1210" width="118" height="17" font="13">analysis not adjusted </text>
<text top="688" left="1210" width="122" height="17" font="13">for differing lengths of </text>
<text top="705" left="1210" width="59" height="17" font="13">follow up.  </text>
<text top="516" left="1345" width="35" height="17" font="13">Study </text>
<text top="533" left="1345" width="98" height="17" font="13">demonstrates the </text>
<text top="550" left="1345" width="99" height="17" font="13">positive impact of </text>
<text top="568" left="1345" width="49" height="17" font="13">applying </text>
<text top="585" left="1345" width="73" height="17" font="13">performance </text>
<text top="602" left="1345" width="75" height="17" font="13">improvement </text>
<text top="619" left="1345" width="63" height="17" font="13">techniques </text>
<text top="636" left="1345" width="67" height="17" font="13">of guideline-</text>
<text top="654" left="1345" width="88" height="17" font="13">driven care and </text>
<text top="671" left="1345" width="75" height="17" font="13">improvement </text>
<text top="688" left="1345" width="70" height="17" font="13">tools, in real-</text>
<text top="705" left="1345" width="92" height="17" font="13">world cardiology </text>
<text top="722" left="1345" width="56" height="17" font="13">practices. </text>
<text top="758" left="43" width="777" height="17" font="13">ACEI indicates angiotensin-converting-enzyme inhibitor; ADHERE, Acute Decompensated Heart Failure National Registry; AF, atrial fibrillation;</text>
<text top="759" left="820" width="4" height="16" font="7"> </text>
<text top="758" left="824" width="612" height="17" font="13">ARB, angiotensin receptor blockers; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable </text>
<text top="775" left="43" width="560" height="17" font="13">cardioverter-defibrillator; LV, left ventricular; MI, myocardial infarction; pt, patient; and RR, relative risk. </text>
</page>
<page number="192" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">192</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="4" height="15" font="7"> </text>
<text top="91" left="716" width="84" height="21" font="8"><b>References </b></text>
<text top="116" left="756" width="4" height="15" font="9"><b> </b></text>
<text top="152" left="756" width="4" height="15" font="7"> </text>
<text top="171" left="54" width="4" height="15" font="7"> </text>
<text top="171" left="82" width="1078" height="15" font="7">1.   Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol. 2003;41:217-23. </text>
<text top="190" left="54" width="4" height="15" font="7"> </text>
<text top="190" left="82" width="1354" height="15" font="7">2.   Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. </text>
<text top="209" left="108" width="114" height="15" font="7">1997;95:2660-7. </text>
<text top="228" left="54" width="4" height="15" font="7"> </text>
<text top="228" left="82" width="1029" height="15" font="7">3.   Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260-9. </text>
<text top="247" left="54" width="4" height="15" font="7"> </text>
<text top="247" left="82" width="1347" height="15" font="7">4.   Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national </text>
<text top="266" left="108" width="414" height="15" font="7">heart, lung, and blood institute. Circulation. 2009;119:3070-7. </text>
<text top="285" left="54" width="4" height="15" font="7"> </text>
<text top="285" left="82" width="991" height="15" font="7">5.   Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306:856-63. </text>
<text top="304" left="54" width="4" height="15" font="7"> </text>
<text top="304" left="82" width="1355" height="15" font="7">6.   Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical </text>
<text top="323" left="108" width="339" height="15" font="7">signs and symptoms. Eur Heart J. 1994;15:303-10. </text>
<text top="342" left="54" width="4" height="15" font="7"> </text>
<text top="342" left="82" width="1357" height="15" font="7">7.   Holland R, Rechel B, Stepien K, et al. Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J </text>
<text top="361" left="108" width="176" height="15" font="7">Card Fail. 2010;16:150-6. </text>
<text top="380" left="54" width="4" height="15" font="7"> </text>
<text top="380" left="82" width="1369" height="15" font="7">8.   Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure </text>
<text top="399" left="108" width="440" height="15" font="7">staging criteria in the community. Circulation. 2007;115:1563-70. </text>
<text top="418" left="54" width="4" height="15" font="7"> </text>
<text top="418" left="82" width="1330" height="15" font="7">9.   Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation. </text>
<text top="437" left="108" width="122" height="15" font="7">1981;64:1227-34. </text>
<text top="456" left="54" width="4" height="15" font="7"> </text>
<text top="456" left="74" width="1014" height="15" font="7">10.   Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-33. </text>
<text top="475" left="54" width="4" height="15" font="7"> </text>
<text top="475" left="74" width="1202" height="15" font="7">11.   Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-7. </text>
<text top="494" left="54" width="4" height="15" font="7"> </text>
<text top="494" left="74" width="1373" height="15" font="7">12.   O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment </text>
<text top="513" left="108" width="615" height="15" font="7">in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008;156:662-73. </text>
<text top="532" left="54" width="4" height="15" font="7"> </text>
<text top="532" left="74" width="983" height="15" font="7">13.   Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65-75. </text>
<text top="551" left="54" width="4" height="15" font="7"> </text>
<text top="551" left="74" width="1372" height="15" font="7">14.   Fonarow GC, Adams KF, Jr., Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-80. </text>
<text top="570" left="54" width="4" height="15" font="7"> </text>
<text top="570" left="74" width="1318" height="15" font="7">15.   Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ </text>
<text top="589" left="108" width="287" height="15" font="7">Cardiovasc Qual Outcomes. 2010;3:25-32. </text>
<text top="608" left="54" width="4" height="15" font="7"> </text>
<text top="608" left="74" width="1323" height="15" font="7">16.   Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in </text>
<text top="627" left="108" width="635" height="15" font="7">Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56. </text>
<text top="646" left="54" width="4" height="15" font="7"> </text>
<text top="646" left="74" width="1377" height="15" font="7">17.   Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein </text>
<text top="665" left="108" width="801" height="15" font="7">A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11:281-91. </text>
<text top="684" left="54" width="4" height="15" font="7"> </text>
<text top="684" left="74" width="1112" height="15" font="7">18.   Auble TE, Hsieh M, McCausland JB, et al. Comparison of four clinical prediction rules for estimating risk in heart failure. Ann Emerg Med. 2007;50:127-35, 135. </text>
<text top="702" left="54" width="4" height="15" font="7"> </text>
<text top="702" left="74" width="1368" height="15" font="7">19.   Moser DK, Yamokoski L, Sun JL, et al. Improvement in health-related quality of life after hospitalization predicts event-free survival in patients with advanced heart failure. J Card Fail. 2009;15:763-9. </text>
<text top="721" left="54" width="4" height="15" font="7"> </text>
<text top="721" left="74" width="1381" height="15" font="7">20.   Lesman-Leegte I, Jaarsma T, Coyne JC, et al. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. J </text>
<text top="740" left="108" width="176" height="15" font="7">Card Fail. 2009;15:17-23. </text>
<text top="759" left="54" width="4" height="15" font="7"> </text>
<text top="759" left="74" width="909" height="15" font="7">21.   Riegel B, Moser DK, Rayens MK, et al. Ethnic differences in quality of life in persons with heart failure. J Card Fail. 2008;14:41-7. </text>
<text top="778" left="54" width="4" height="15" font="7"> </text>
<text top="778" left="74" width="1354" height="15" font="7">22.   Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005;7:243-51. </text>
</page>
<page number="193" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">193</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="4" height="15" font="7"> </text>
<text top="58" left="74" width="1363" height="15" font="7">23.   Lewis EF, Lamas GA, O'Meara E, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9:83-91. </text>
<text top="77" left="54" width="4" height="15" font="7"> </text>
<text top="77" left="74" width="984" height="15" font="7">24.   Dobre D, de Jongste MJ, Haaijer-Ruskamp FM, et al. The enigma of quality of life in patients with heart failure. Int J Cardiol. 2008;125:407-9. </text>
<text top="96" left="54" width="4" height="15" font="7"> </text>
<text top="96" left="74" width="1387" height="15" font="7">25.   Harrison MB, Browne GB, Roberts J, et al. Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care. 2002;40:271-82. </text>
<text top="115" left="54" width="4" height="15" font="7"> </text>
<text top="115" left="74" width="1184" height="15" font="7">26.   Arena R, Myers J, Abella J, et al. Defining the optimal prognostic window for cardiopulmonary exercise testing in patients with heart failure. Circ Heart Fail. 2010;3:405-11. </text>
<text top="134" left="54" width="4" height="15" font="7"> </text>
<text top="134" left="74" width="1383" height="15" font="7">27.   Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-86. </text>
<text top="153" left="54" width="4" height="15" font="7"> </text>
<text top="153" left="74" width="1191" height="15" font="7">28.   O'Neill JO, Young JB, Pothier CE, et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation. 2005;111:2313-8. </text>
<text top="172" left="54" width="4" height="15" font="7"> </text>
<text top="172" left="74" width="1006" height="15" font="7">29.   Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884-8. </text>
<text top="191" left="54" width="4" height="15" font="7"> </text>
<text top="191" left="74" width="1301" height="15" font="7">30.   Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med. </text>
<text top="210" left="108" width="105" height="15" font="7">1991;90:353-9. </text>
<text top="229" left="54" width="4" height="15" font="7"> </text>
<text top="229" left="74" width="1154" height="15" font="7">31.   Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail. 2008;1:170-7. </text>
<text top="248" left="54" width="4" height="15" font="7"> </text>
<text top="248" left="74" width="1360" height="15" font="7">32.   Butman SM, Ewy GA, Standen JR, et al. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. J Am Coll Cardiol. </text>
<text top="267" left="108" width="114" height="15" font="7">1993;22:968-74. </text>
<text top="286" left="54" width="4" height="15" font="7"> </text>
<text top="286" left="74" width="1373" height="15" font="7">33.   Stein JH, Neumann A, Marcus RH. Comparison of estimates of right atrial pressure by physical examination and echocardiography in patients with congestive heart failure and reasons for discrepancies. </text>
<text top="305" left="108" width="211" height="15" font="7">Am J Cardiol. 1997;80:1615-8. </text>
<text top="324" left="54" width="4" height="15" font="7"> </text>
<text top="324" left="74" width="935" height="15" font="7">34.   Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? JAMA. 1997;277:1712-9. </text>
<text top="343" left="54" width="4" height="15" font="7"> </text>
<text top="343" left="74" width="1298" height="15" font="7">35.   Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574-81. </text>
<text top="362" left="54" width="4" height="15" font="7"> </text>
<text top="362" left="74" width="1324" height="15" font="7">36.   Drazner MH, Rame JE, Dries DL. Third heart sound and elevated jugular venous pressure as markers of the subsequent development of heart failure in patients with asymptomatic left ventricular </text>
<text top="381" left="108" width="278" height="15" font="7">dysfunction. Am J Med. 2003;114:431-7. </text>
<text top="400" left="54" width="4" height="15" font="7"> </text>
<text top="400" left="74" width="1251" height="15" font="7">37.   Meyer P, Ekundayo OJ, Adamopoulos C, et al. A propensity-matched study of elevated jugular venous pressure and outcomes in chronic heart failure. Am J Cardiol. 2009;103:839-44. </text>
<text top="418" left="54" width="4" height="15" font="7"> </text>
<text top="418" left="74" width="1216" height="15" font="7">38.   Schmidt DE, Shah PK. Accurate detection of elevated left ventricular filling pressure by a simplified bedside application of the Valsalva maneuver. Am J Cardiol. 1993;71:462-5. </text>
<text top="437" left="54" width="4" height="15" font="7"> </text>
<text top="437" left="74" width="1342" height="15" font="7">39.   Brunner-La Rocca HP, Weilenmann D, Rickli H, et al. Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure? Chest. </text>
<text top="456" left="108" width="114" height="15" font="7">1999;116:861-7. </text>
<text top="475" left="54" width="4" height="15" font="7"> </text>
<text top="475" left="74" width="1223" height="15" font="7">40.   Givertz MM, Slawsky MT, Moraes DL, et al. Noninvasive determination of pulmonary artery wedge pressure in patients with chronic heart failure. Am J Cardiol. 2001;87:1213-5. </text>
<text top="494" left="54" width="4" height="15" font="7"> </text>
<text top="494" left="74" width="1130" height="15" font="7">41.   Sharma GV, Woods PA, Lambrew CT, et al. Evaluation of a noninvasive system for determining left ventricular filling pressure. Arch Intern Med. 2002;162:2084-8. </text>
<text top="513" left="54" width="4" height="15" font="7"> </text>
<text top="513" left="74" width="946" height="15" font="7">42.   Felker GM, Cuculich PS, Gheorghiade M. The Valsalva maneuver: a bedside &#34;biomarker&#34; for heart failure. Am J Med. 2006;119:117-22. </text>
<text top="532" left="54" width="4" height="15" font="7"> </text>
<text top="532" left="74" width="1188" height="15" font="7">43.   Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840-7. </text>
<text top="551" left="54" width="4" height="15" font="7"> </text>
<text top="551" left="74" width="1294" height="15" font="7">44.   Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41:1797-804. </text>
<text top="570" left="54" width="4" height="15" font="7"> </text>
<text top="570" left="74" width="1357" height="15" font="7">45.   Levy WC, Mozaffarian D, Linker DT, et al. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart Lung Transplant. </text>
<text top="589" left="108" width="105" height="15" font="7">2009;28:231-6. </text>
<text top="608" left="54" width="4" height="15" font="7"> </text>
<text top="608" left="74" width="1376" height="15" font="7">46.   Gorodeski EZ, Chu EC, Chow CH, et al. Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. Circ Heart Fail. 2010;3:706-</text>
<text top="627" left="108" width="25" height="15" font="7">14. </text>
<text top="646" left="54" width="4" height="15" font="7"> </text>
<text top="646" left="74" width="1055" height="15" font="7">47.   Rohde LE, Goldraich L, Polanczyk CA, et al. A simple clinically based predictive rule for heart failure in-hospital mortality. J Card Fail. 2006;12:587-93. </text>
<text top="665" left="54" width="4" height="15" font="7"> </text>
<text top="665" left="74" width="1370" height="15" font="7">48.   Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the </text>
<text top="684" left="108" width="890" height="15" font="7">European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-33. </text>
<text top="703" left="54" width="4" height="15" font="7"> </text>
<text top="703" left="74" width="1130" height="15" font="7">49.   Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3:155-64. </text>
<text top="722" left="54" width="4" height="15" font="7"> </text>
<text top="722" left="74" width="1383" height="15" font="7">50.   Rizzello V, Poldermans D, Biagini E, et al. Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisation: relation to viability and improvement in left ventricular ejection fraction. </text>
<text top="741" left="108" width="159" height="15" font="7">Heart. 2009;95:1273-7. </text>
<text top="760" left="54" width="4" height="15" font="7"> </text>
<text top="760" left="74" width="1356" height="15" font="7">51.   Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-</text>
<text top="779" left="108" width="305" height="15" font="7">analysis. J Am Coll Cardiol. 2002;39:1151-8. </text>
</page>
<page number="194" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">194</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="4" height="15" font="7"> </text>
<text top="58" left="74" width="1369" height="15" font="7">52.   Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the </text>
<text top="77" left="108" width="562" height="15" font="7">degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40:1735-43. </text>
<text top="96" left="54" width="4" height="15" font="7"> </text>
<text top="96" left="74" width="1350" height="15" font="7">53.   Pagley PR, Beller GA, Watson DD, et al. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation. 1997;96:793-800. </text>
<text top="115" left="54" width="4" height="15" font="7"> </text>
<text top="115" left="74" width="1297" height="15" font="7">54.   Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol. </text>
<text top="134" left="108" width="122" height="15" font="7">1999;33:1848-54. </text>
<text top="153" left="54" width="4" height="15" font="7"> </text>
<text top="153" left="74" width="1376" height="15" font="7">55.   Kwon DH, Halley CM, Carrigan TP, et al. Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement </text>
<text top="172" left="108" width="514" height="15" font="7">cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2009;2:34-44. </text>
<text top="191" left="54" width="4" height="15" font="7"> </text>
<text top="191" left="74" width="968" height="15" font="7">56.   Ordovas KG, Higgins CB. Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology. 2011;261:358-74. </text>
<text top="210" left="54" width="4" height="15" font="7"> </text>
<text top="210" left="74" width="1388" height="15" font="7">57.   Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American </text>
<text top="229" left="108" width="642" height="15" font="7">College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216-33. </text>
<text top="248" left="54" width="4" height="15" font="7"> </text>
<text top="248" left="74" width="1207" height="15" font="7">58.   Kasper EK, Agema WR, Hutchins GM, et al. The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol. 1994;23:586-90. </text>
<text top="267" left="54" width="4" height="15" font="7"> </text>
<text top="267" left="74" width="588" height="15" font="7">59.   Fowles RE, Mason JW. Endomyocardial biopsy. Ann Intern Med. 1982;97:885-94. </text>
<text top="286" left="54" width="4" height="15" font="7"> </text>
<text top="286" left="74" width="1359" height="15" font="7">60.   Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic </text>
<text top="305" left="108" width="485" height="15" font="7">procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19:43-7. </text>
<text top="324" left="54" width="4" height="15" font="7"> </text>
<text top="324" left="74" width="1127" height="15" font="7">61.   Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004;147:919-23. </text>
<text top="343" left="54" width="4" height="15" font="7"> </text>
<text top="343" left="74" width="1374" height="15" font="7">62.   Holzmann M, Nicko A, Kuhl U, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures </text>
<text top="362" left="108" width="363" height="15" font="7">over an 11-year period. Circulation. 2008;118:1722-8. </text>
<text top="381" left="54" width="4" height="15" font="7"> </text>
<text top="381" left="74" width="1223" height="15" font="7">63.   Elliott P, Arbustini E. The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines. Heart. 2009;95:759-60. </text>
<text top="400" left="54" width="4" height="15" font="7"> </text>
<text top="400" left="74" width="1104" height="15" font="7">64.   Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-72. </text>
<text top="418" left="54" width="4" height="15" font="7"> </text>
<text top="418" left="74" width="1236" height="15" font="7">65.   Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287:1003-10. </text>
<text top="437" left="54" width="4" height="15" font="7"> </text>
<text top="437" left="74" width="887" height="15" font="7">66.   Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-62. </text>
<text top="456" left="54" width="4" height="15" font="7"> </text>
<text top="456" left="74" width="1129" height="15" font="7">67.   Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men--morbidity, risk factors and prognosis. J Intern Med. 2001;249:253-61. </text>
<text top="475" left="54" width="4" height="15" font="7"> </text>
<text top="475" left="74" width="1331" height="15" font="7">68.   Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. </text>
<text top="494" left="108" width="114" height="15" font="7">1997;278:212-6. </text>
<text top="513" left="54" width="4" height="15" font="7"> </text>
<text top="513" left="74" width="1186" height="15" font="7">69.   Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21:1055-76. </text>
<text top="532" left="54" width="4" height="15" font="7"> </text>
<text top="532" left="74" width="1352" height="15" font="7">70.   Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high </text>
<text top="551" left="108" width="374" height="15" font="7">cardiovascular risk. Arch Intern Med. 2011;171:384-94. </text>
<text top="570" left="54" width="4" height="15" font="7"> </text>
<text top="570" left="74" width="1184" height="15" font="7">71.   Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378:140-6. </text>
<text top="589" left="54" width="4" height="15" font="7"> </text>
<text top="589" left="74" width="1300" height="15" font="7">72.   Pfister R, Cairns R, Erdmann E, et al. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. Int J Cardiol. 2011; </text>
<text top="608" left="54" width="4" height="15" font="7"> </text>
<text top="608" left="74" width="756" height="15" font="7">73.   Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-13. </text>
<text top="627" left="54" width="4" height="15" font="7"> </text>
<text top="627" left="74" width="1074" height="15" font="7">74.   Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119:44-52. </text>
<text top="646" left="54" width="4" height="15" font="7"> </text>
<text top="646" left="74" width="1384" height="15" font="7">75.   Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in </text>
<text top="665" left="108" width="1280" height="15" font="7">Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009;120:1380-9. </text>
<text top="684" left="54" width="4" height="15" font="7"> </text>
<text top="684" left="74" width="1082" height="15" font="7">76.   Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-68. </text>
<text top="703" left="54" width="4" height="15" font="7"> </text>
<text top="703" left="74" width="1333" height="15" font="7">77.   Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. </text>
<text top="722" left="108" width="122" height="15" font="7">2008;52:1769-81. </text>
<text top="741" left="54" width="4" height="15" font="7"> </text>
<text top="741" left="74" width="994" height="15" font="7">78.   Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;CD004816. </text>
<text top="760" left="54" width="4" height="15" font="7"> </text>
<text top="760" left="74" width="1057" height="15" font="7">79.   Abramson JL, Williams SA, Krumholz HM, et al. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285:1971-7. </text>
<text top="779" left="54" width="4" height="15" font="7"> </text>
<text top="779" left="74" width="1141" height="15" font="7">80.   Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2002;136:181-91. </text>
</page>
<page number="195" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">195</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="4" height="15" font="7"> </text>
<text top="58" left="74" width="1039" height="15" font="7">81.   Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29:632-8. </text>
<text top="77" left="54" width="4" height="15" font="7"> </text>
<text top="77" left="74" width="1370" height="15" font="7">82.   Du XL, Xia R, Burau K, et al. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol. 2011;28 </text>
<text top="96" left="108" width="120" height="15" font="7">Suppl 1:S80-S90. </text>
<text top="115" left="54" width="4" height="15" font="7"> </text>
<text top="115" left="74" width="1051" height="15" font="7">83.   Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375-80. </text>
<text top="134" left="54" width="4" height="15" font="7"> </text>
<text top="134" left="74" width="1385" height="15" font="7">84.   McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am </text>
<text top="153" left="108" width="204" height="15" font="7">Coll Cardiol. 2010;55:2140-7. </text>
<text top="172" left="54" width="4" height="15" font="7"> </text>
<text top="172" left="74" width="1082" height="15" font="7">85.   Velagaleti RS, Gona P, Larson MG, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010;122:1700-6. </text>
<text top="191" left="54" width="4" height="15" font="7"> </text>
<text top="191" left="74" width="1003" height="15" font="7">86.   Blecker S, Matsushita K, Kottgen A, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58:47-55. </text>
<text top="210" left="54" width="4" height="15" font="7"> </text>
<text top="210" left="74" width="1346" height="15" font="7">87.   deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. </text>
<text top="229" left="108" width="192" height="15" font="7">JAMA. 2010;304:2494-502. </text>
<text top="248" left="54" width="4" height="15" font="7"> </text>
<text top="248" left="74" width="1351" height="15" font="7">88.   Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. </text>
<text top="267" left="108" width="122" height="15" font="7">2004;43:1019-26. </text>
<text top="286" left="54" width="4" height="15" font="7"> </text>
<text top="286" left="74" width="1361" height="15" font="7">89.   Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular </text>
<text top="305" left="108" width="513" height="15" font="7">enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77. </text>
<text top="324" left="54" width="4" height="15" font="7"> </text>
<text top="324" left="74" width="1379" height="15" font="7">90.   Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327:685-91. </text>
<text top="343" left="54" width="4" height="15" font="7"> </text>
<text top="343" left="74" width="1322" height="15" font="7">91.   Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843-8. </text>
<text top="362" left="54" width="4" height="15" font="7"> </text>
<text top="362" left="74" width="1374" height="15" font="7">92.   Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. </text>
<text top="381" left="108" width="122" height="15" font="7">2006;47:2326-31. </text>
<text top="400" left="54" width="4" height="15" font="7"> </text>
<text top="400" left="74" width="1379" height="15" font="7">93.   de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-</text>
<text top="418" left="108" width="25" height="15" font="7">16. </text>
<text top="437" left="54" width="4" height="15" font="7"> </text>
<text top="437" left="74" width="1365" height="15" font="7">94.   Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized </text>
<text top="456" left="108" width="664" height="15" font="7">study followed by a prospective treatment for erectile dysfunction. Circulation. 2002;106:1097-103. </text>
<text top="475" left="54" width="4" height="15" font="7"> </text>
<text top="475" left="74" width="1346" height="15" font="7">95.   VanSuch M, Naessens JM, Stroebel RJ, et al. Effect of discharge instructions on readmission of hospitalised patients with heart failure: do all of the Joint Commission on Accreditation of Healthcare </text>
<text top="494" left="108" width="661" height="15" font="7">Organizations heart failure core measures reflect better care? Qual Saf Health Care. 2006;15:414-7. </text>
<text top="513" left="54" width="4" height="15" font="7"> </text>
<text top="513" left="74" width="1099" height="15" font="7">96.   Koelling TM, Johnson ML, Cody RJ, et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111:179-85. </text>
<text top="532" left="54" width="4" height="15" font="7"> </text>
<text top="532" left="74" width="1334" height="15" font="7">97.   Linne AB, Liedholm H. Effects of an interactive CD-program on 6 months readmission rate in patients with heart failure - a randomised, controlled trial [NCT00311194]. BMC Cardiovasc Disord. </text>
<text top="551" left="108" width="75" height="15" font="7">2006;6:30. </text>
<text top="570" left="54" width="4" height="15" font="7"> </text>
<text top="570" left="74" width="1374" height="15" font="7">98.   Stromberg A, Dahlstrom U, Fridlund B. Computer-based education for patients with chronic heart failure. A randomised, controlled, multicentre trial of the effects on knowledge, compliance and quality </text>
<text top="589" left="108" width="300" height="15" font="7">of life. Patient Educ Couns. 2006;64:128-35. </text>
<text top="608" left="54" width="4" height="15" font="7"> </text>
<text top="608" left="74" width="1378" height="15" font="7">99.   Ferrante D, Varini S, Macchia A, et al. Long-term results after a telephone intervention in chronic heart failure: DIAL (Randomized Trial of Phone Intervention in Chronic Heart Failure) follow-up. J Am </text>
<text top="627" left="108" width="196" height="15" font="7">Coll Cardiol. 2010;56:372-8. </text>
<text top="646" left="54" width="1151" height="15" font="7">  100.   Boren SA, Wakefield BJ, Gunlock TL, et al. Heart failure self-management education: a systematic review of the evidence. Int J Evid Based Healthc. 2009;7:159-68. </text>
<text top="665" left="54" width="1274" height="15" font="7">  101.   Cruz F, Issa VS, Ayub-Ferreira SM, et al. Effect of a sequential education and monitoring programme on quality-of-life components in heart failure. Eur J Heart Fail. 2010;12:1009-15. </text>
<text top="684" left="54" width="1208" height="15" font="7">  102.   Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215. </text>
<text top="703" left="54" width="1321" height="15" font="7">  103.   Luttik ML, Jaarsma T, Moser D, et al. The importance and impact of social support on outcomes in patients with heart failure: an overview of the literature. J Cardiovasc Nurs. 2005;20:162-9. </text>
<text top="722" left="54" width="1402" height="15" font="7">  104.   Struthers AD, Anderson G, Donnan PT, et al. Social deprivation increases cardiac hospitalisations in chronic heart failure independent of disease severity and diuretic non-adherence. Heart. 2000;83:12-6. </text>
<text top="741" left="54" width="764" height="15" font="7">  105.   Gallager R, Luttik ML, Jaarsma T. Social Support and Self-care in Heart Failure. J Cardiovasc Nurs. 2011; </text>
<text top="760" left="54" width="1231" height="15" font="7">  106.   Dickson VV, Buck H, Riegel B. A qualitative meta-analysis of heart failure self-care practices among individuals with multiple comorbid conditions. J Card Fail. 2011;17:413-9. </text>
</page>
<page number="196" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">196</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1402" height="15" font="7">  107.   Sayers SL, Hanrahan N, Kutney A, et al. Psychiatric comorbidity and greater hospitalization risk, longer length of stay, and higher hospitalization costs in older adults with heart failure. J Am Geriatr Soc. </text>
<text top="77" left="108" width="122" height="15" font="7">2007;55:1585-91. </text>
<text top="96" left="54" width="1228" height="15" font="7">  108.   Sturm HB, Haaijer-Ruskamp FM, Veeger NJ, et al. The relevance of comorbidities for heart failure treatment in primary care: A European survey. Eur J Heart Fail. 2006;8:31-7. </text>
<text top="115" left="54" width="854" height="15" font="7">  109.   Dahlstrom U. Frequent non-cardiac comorbidities in patients with chronic heart failure. Eur J Heart Fail. 2005;7:309-16. </text>
<text top="134" left="54" width="882" height="15" font="7">  110.   Dansky KH, Vasey J, Bowles K. Use of telehealth by older adults to manage heart failure. Res Gerontol Nurs. 2008;1:25-32. </text>
<text top="153" left="54" width="1385" height="15" font="7">  111.   Ambardekar AV, Fonarow GC, Hernandez AF, et al. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-</text>
<text top="172" left="108" width="241" height="15" font="7">HF). Am Heart J. 2009;158:644-52. </text>
<text top="191" left="54" width="1208" height="15" font="7">  112.   Bagchi AD, Esposito D, Kim M, et al. Utilization of, and adherence to, drug therapy among medicaid beneficiaries with congestive heart failure. Clin Ther. 2007;29:1771-83. </text>
<text top="210" left="54" width="1147" height="15" font="7">  113.   Cole JA, Norman H, Weatherby LB, et al. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26:1157-64. </text>
<text top="229" left="54" width="1197" height="15" font="7">  114.   De Smedt RH, Jaarsma T, Haaijer-Ruskamp FM, et al. The impact of perceived adverse effects on medication changes in heart failure patients. J Card Fail. 2010;16:135-41. </text>
<text top="248" left="54" width="1123" height="15" font="7">  115.   Fonarow GC, Albert NM, Curtis AB, et al. Associations between outpatient heart failure process-of-care measures and mortality. Circulation. 2011;123:1601-10. </text>
<text top="267" left="54" width="1389" height="15" font="7">  116.   Karlsson MR, Edner M, Henriksson P, et al. A nurse-based management program in heart failure patients affects females and persons with cognitive dysfunction most. Patient Educ Couns. 2005;58:146-</text>
<text top="286" left="108" width="25" height="15" font="7">53. </text>
<text top="305" left="54" width="1302" height="15" font="7">  117.   Murray MD, Loos B, Tu W, et al. Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions. Am J Health Syst Pharm. 1999;56:225-32. </text>
<text top="324" left="54" width="1401" height="15" font="7">  118.   Ojeda S, Anguita M, Delgado M, et al. Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the </text>
<text top="343" left="108" width="298" height="15" font="7">programme? Eur J Heart Fail. 2005;7:921-6. </text>
<text top="362" left="54" width="1196" height="15" font="7">  119.   Riegel B, Moelter ST, Ratcliffe SJ, et al. Excessive daytime sleepiness is associated with poor medication adherence in adults with heart failure. J Card Fail. 2011;17:340-8. </text>
<text top="381" left="54" width="1260" height="15" font="7">  120.   van der Wal MH, van Veldhuisen DJ, Veeger NJ, et al. Compliance with non-pharmacological recommendations and outcome in heart failure patients. Eur Heart J. 2010;31:1486-93. </text>
<text top="400" left="54" width="1363" height="15" font="7">  121.   Lainscak M, Cleland JG, Lenzen MJ, et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol. 2007;99:31D-7D. </text>
<text top="418" left="54" width="1078" height="15" font="7">  122.   Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med. 2005;353:2025-33. </text>
<text top="437" left="54" width="1396" height="15" font="7">  123.   Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous </text>
<text top="456" left="108" width="877" height="15" font="7">Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation. 2007;115:3173-80. </text>
<text top="475" left="54" width="1265" height="15" font="7">  124.   Ruttanaumpawan P, Logan AG, Floras JS, et al. Effect of continuous positive airway pressure on sleep structure in heart failure patients with central sleep apnea. Sleep. 2009;32:91-8. </text>
<text top="494" left="54" width="1185" height="15" font="7">  125.   Tamura A, Kawano Y, Naono S, et al. Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure. Chest. 2007;131:130-5. </text>
<text top="513" left="54" width="1139" height="15" font="7">  126.   Oldenburg O, Faber L, Vogt J, et al. Influence of cardiac resynchronisation therapy on different types of sleep disordered breathing. Eur J Heart Fail. 2007;9:820-6. </text>
<text top="532" left="54" width="1380" height="15" font="7">  127.   Giannuzzi P, Temporelli PL, Corra U, et al. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and </text>
<text top="551" left="108" width="482" height="15" font="7">Chronic Heart Failure (ELVD-CHF) Trial. Circulation. 2003;108:554-9. </text>
<text top="570" left="54" width="1330" height="15" font="7">  128.   Beckers PJ, Denollet J, Possemiers NM, et al. Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. Eur Heart J. </text>
<text top="589" left="108" width="122" height="15" font="7">2008;29:1858-66. </text>
<text top="608" left="54" width="1374" height="15" font="7">  129.   Karapolat H, Demir E, Bozkaya YT, et al. Comparison of hospital-based versus home-based exercise training in patients with heart failure: effects on functional capacity, quality of life, psychological </text>
<text top="627" left="108" width="515" height="15" font="7">symptoms, and hemodynamic parameters. Clin Res Cardiol. 2009;98:635-42. </text>
<text top="646" left="54" width="1375" height="15" font="7">  130.   Brubaker PH, Moore JB, Stewart KP, et al. Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial. J Am Geriatr Soc. 2009;57:1982-9. </text>
<text top="665" left="54" width="1300" height="15" font="7">  131.   Flynn KE, Pina IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451-9. </text>
<text top="684" left="54" width="1193" height="15" font="7">  132.   Hwang CL, Chien CL, Wu YT. Resistance training increases 6-minute walk distance in people with chronic heart failure: a systematic review. J Physiother. 2010;56:87-96. </text>
<text top="703" left="54" width="1390" height="15" font="7">  133.   Jolly K, Taylor RS, Lip GY, et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: the Birmingham Rehabilitation Uptake Maximisation study for patients </text>
<text top="722" left="108" width="576" height="15" font="7">with Congestive Heart Failure (BRUM-CHF) study. Eur J Heart Fail. 2009;11:205-13. </text>
<text top="741" left="54" width="1326" height="15" font="7">  134.   Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. </text>
<text top="760" left="108" width="105" height="15" font="7">2010;3:659-67. </text>
<text top="779" left="54" width="1192" height="15" font="7">  135.   McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J. 2002;144:23-30. </text>
</page>
<page number="197" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">197</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1228" height="15" font="7">  136.   Miche E, Roelleke E, Wirtz U, et al. Combined endurance and muscle strength training in female and male patients with chronic heart failure. Clin Res Cardiol. 2008;97:615-22. </text>
<text top="77" left="54" width="1345" height="15" font="7">  137.   Nilsson BB, Westheim A, Risberg MA. Long-term effects of a group-based high-intensity aerobic interval-training program in patients with chronic heart failure. Am J Cardiol. 2008;102:1220-4. </text>
<text top="96" left="54" width="1314" height="15" font="7">  138.   O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439-50. </text>
<text top="115" left="54" width="1091" height="15" font="7">  139.   Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328:189. </text>
<text top="134" left="54" width="1230" height="15" font="7">  140.   Pu CT, Johnson MT, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol. 2001;90:2341-50. </text>
<text top="153" left="54" width="1389" height="15" font="7">  141.   Senden PJ, Sabelis LW, Zonderland ML, et al. The effect of physical training on workload, upper leg muscle function and muscle areas in patients with chronic heart failure. Int J Cardiol. 2005;100:293-</text>
<text top="172" left="108" width="33" height="15" font="7">300. </text>
<text top="191" left="54" width="1264" height="15" font="7">  142.   Van Berendoncks AM, Beckers P, Hoymans VY, et al. Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. Clin Sci (Lond). 2010;118:281-9. </text>
<text top="210" left="54" width="1362" height="15" font="7">  143.   van Tol BA, Huijsmans RJ, Kroon DW, et al. Effects of exercise training on cardiac performance, exercise capacity and quality of life in patients with heart failure: a meta-analysis. Eur J Heart Fail. </text>
<text top="229" left="108" width="105" height="15" font="7">2006;8:841-50. </text>
<text top="248" left="54" width="989" height="15" font="7">  144.   Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805. </text>
<text top="267" left="54" width="1052" height="15" font="7">  145.   Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419-28. </text>
<text top="286" left="54" width="1391" height="15" font="7">  146.   Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) </text>
<text top="305" left="108" width="235" height="15" font="7">Trial. J Card Fail. 2010;16:922-30. </text>
<text top="324" left="54" width="1114" height="15" font="7">  147.   Allen LA, Turer AT, Dewald T, et al. Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. Am J Cardiol. 2010;105:1794-7. </text>
<text top="343" left="54" width="1138" height="15" font="7">  148.   Thomson MR, Nappi JM, Dunn SP, et al. Continuous versus intermittent infusion of furosemide in acute decompensated heart failure. J Card Fail. 2010;16:188-93. </text>
<text top="362" left="54" width="912" height="15" font="7">  149.   Peacock WF, De MT, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26. </text>
<text top="381" left="54" width="1273" height="15" font="7">  150.   Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail. 2008;14:388-93. </text>
<text top="400" left="54" width="1382" height="15" font="7">  151.   Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute </text>
<text top="418" left="108" width="428" height="15" font="7">heart failure and renal impairment. J Card Fail. 2008;14:631-40. </text>
<text top="437" left="54" width="1193" height="15" font="7">  152.   Ahmed A, Aronow WS. A propensity-matched study of the association of physical function and outcomes in geriatric heart failure. Arch Gerontol Geriatr. 2008;46:161-72. </text>
<text top="456" left="54" width="1392" height="15" font="7">  153.   Gheorghiade M, Konstam MA, Burnett JC, Jr., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. </text>
<text top="475" left="108" width="183" height="15" font="7">JAMA. 2007;297:1332-43. </text>
<text top="494" left="54" width="1299" height="15" font="7">  154.   Konstam MA, Gheorghiade M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-31. </text>
<text top="513" left="54" width="1399" height="15" font="7">  155.   Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-9. </text>
<text top="532" left="54" width="1033" height="15" font="7">  156.   Domanski M, Tian X, Haigney M, et al. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail. 2006;12:327-32. </text>
<text top="551" left="54" width="1002" height="15" font="7">  157.   Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-64. </text>
<text top="570" left="54" width="1224" height="15" font="7">  158.   Salvador DR, Rey NR, Ramos GC, et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;CD003178. </text>
<text top="589" left="54" width="1323" height="15" font="7">  159.   Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-8. </text>
<text top="608" left="54" width="1346" height="15" font="7">  160.   Rogers HL, Marshall J, Bock J, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. </text>
<text top="627" left="108" width="89" height="15" font="7">2008;14:1-5. </text>
<text top="646" left="54" width="1319" height="15" font="7">  161.   Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-83. </text>
<text top="665" left="54" width="1379" height="15" font="7">  162.   Liang KV, Hiniker AR, Williams AW, et al. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card </text>
<text top="684" left="108" width="148" height="15" font="7">Fail. 2006;12:707-14. </text>
<text top="703" left="54" width="1373" height="15" font="7">  163.   Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart </text>
<text top="722" left="108" width="431" height="15" font="7">Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005;46:2043-6. </text>
<text top="741" left="54" width="1203" height="15" font="7">  164.   Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 2005;46:2047-51. </text>
<text top="760" left="54" width="1360" height="15" font="7">  165.   Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to </text>
<text top="779" left="108" width="345" height="15" font="7">provide the same result. Am J Med. 1994;96:191-9. </text>
</page>
<page number="198" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">198</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1346" height="15" font="7">  166.   Pepi M, Marenzi GC, Agostoni PG, et al. Sustained cardiac diastolic changes elicited by ultrafiltration in patients with moderate congestive heart failure: pathophysiological correlates. Br Heart J. </text>
<text top="77" left="108" width="114" height="15" font="7">1993;70:135-40. </text>
<text top="96" left="54" width="968" height="15" font="7">  167.   Agostoni PG, Marenzi GC, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol. 1993;21:424-31. </text>
<text top="115" left="54" width="1405" height="15" font="7">  168.   Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl </text>
<text top="134" left="108" width="179" height="15" font="7">J Med. 1987;316:1429-35. </text>
<text top="153" left="54" width="1253" height="15" font="7">  169.   Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J. 1999;20:136-9. </text>
<text top="172" left="54" width="1242" height="15" font="7">  170.   Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302. </text>
<text top="191" left="54" width="1358" height="15" font="7">  171.   Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart </text>
<text top="210" left="108" width="406" height="15" font="7">failure. ATLAS Study Group. Circulation. 1999;100:2312-8. </text>
<text top="229" left="54" width="1406" height="15" font="7">  172.   Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. </text>
<text top="248" left="108" width="114" height="15" font="7">1993;342:821-8. </text>
<text top="267" left="54" width="1325" height="15" font="7">  173.   Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. </text>
<text top="286" left="108" width="602" height="15" font="7">Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670-6. </text>
<text top="305" left="54" width="1402" height="15" font="7">  174.   Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: </text>
<text top="324" left="108" width="370" height="15" font="7">the CHARM-Alternative trial. Lancet. 2003;362:772-6. </text>
<text top="343" left="54" width="1387" height="15" font="7">  175.   McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: </text>
<text top="362" left="108" width="348" height="15" font="7">the CHARM-Added trial. Lancet. 2003;362:767-71. </text>
<text top="381" left="54" width="1399" height="15" font="7">  176.   Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906. </text>
<text top="400" left="54" width="1018" height="15" font="7">  177.   Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75. </text>
<text top="418" left="54" width="1379" height="15" font="7">  178.   Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. </text>
<text top="437" left="108" width="122" height="15" font="7">2009;374:1840-8. </text>
<text top="456" left="54" width="1338" height="15" font="7">  179.   Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759-66. </text>
<text top="475" left="54" width="844" height="15" font="7">  180.   CBIS II Authors. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13. </text>
<text top="494" left="54" width="1203" height="15" font="7">  181.   Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7. </text>
<text top="513" left="54" width="953" height="15" font="7">  182.   Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8. </text>
<text top="532" left="54" width="1384" height="15" font="7">  183.   Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur </text>
<text top="551" left="108" width="169" height="15" font="7">Heart J. 2005;26:215-25. </text>
<text top="570" left="54" width="849" height="15" font="7">  184.   A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67. </text>
<text top="589" left="54" width="1367" height="15" font="7">  185.   Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial </text>
<text top="608" left="108" width="423" height="15" font="7">(COMET): randomised controlled trial. Lancet. 2003;362:7-13. </text>
<text top="627" left="54" width="1355" height="15" font="7">  186.   Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the </text>
<text top="646" left="108" width="858" height="15" font="7">opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426-35. </text>
<text top="665" left="54" width="1043" height="15" font="7">  187.   Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859-69. </text>
<text top="684" left="54" width="1138" height="15" font="7">  188.   Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8:428-32. </text>
<text top="703" left="54" width="1336" height="15" font="7">  189.   Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, </text>
<text top="722" left="108" width="759" height="15" font="7">STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-8. </text>
<text top="741" left="54" width="1368" height="15" font="7">  190.   Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure </text>
<text top="760" left="108" width="323" height="15" font="7">(WATCH) trial. Circulation. 2009;119:1616-24. </text>
</page>
<page number="199" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">199</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1396" height="15" font="7">  191.   Echemann M, Alla F, Briancon S, et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart </text>
<text top="77" left="108" width="139" height="15" font="7">Fail. 2002;4:647-54. </text>
<text top="96" left="54" width="1386" height="15" font="7">  192.   Wojnicz R, Nowak J, Szygula-Jurkiewicz B, et al. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up </text>
<text top="115" left="108" width="460" height="15" font="7">results of the randomized trial. Am Heart J. 2006;152:713.e1-713.e7. </text>
<text top="134" left="54" width="987" height="15" font="7">  193.   Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51. </text>
<text top="153" left="54" width="1377" height="15" font="7">  194.   Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events </text>
<text top="172" left="108" width="482" height="15" font="7">(ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12. </text>
<text top="191" left="54" width="994" height="15" font="7">  195.   Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. </text>
<text top="210" left="54" width="951" height="15" font="7">  196.   Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. </text>
<text top="229" left="54" width="1003" height="15" font="7">  197.   Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26:115-7. </text>
<text top="248" left="54" width="1392" height="15" font="7">  198.   Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. </text>
<text top="267" left="108" width="114" height="15" font="7">2006;332:325-9. </text>
<text top="286" left="54" width="1363" height="15" font="7">  199.   Tebbe U, Schellong SM, Haas S, et al. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the </text>
<text top="305" left="108" width="472" height="15" font="7">randomized, controlled CERTIFY study. Am Heart J. 2011;161:322-8. </text>
<text top="324" left="54" width="1363" height="15" font="7">  200.   Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe </text>
<text top="343" left="108" width="338" height="15" font="7">respiratory disease. Am Heart J. 2003;145:614-21. </text>
<text top="362" left="54" width="1344" height="15" font="7">  201.   Turpie AG. Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol. 2000;86:48M-52M. </text>
<text top="381" left="54" width="1215" height="15" font="7">  202.   Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43:642-8. </text>
<text top="400" left="54" width="1090" height="15" font="7">  203.   Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-9. </text>
<text top="418" left="54" width="969" height="15" font="7">  204.   Ray JG, Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62-7. </text>
<text top="437" left="54" width="1015" height="15" font="7">  205.   Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086-92. </text>
<text top="456" left="54" width="1316" height="15" font="7">  206.   Anker SD, Clark AL, Winkler R, et al. Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients. Int J Cardiol. 2006;112:234-42. </text>
<text top="475" left="54" width="1175" height="15" font="7">  207.   Folkeringa RJ, Van Kraaij DJ, Tieleman RG, et al. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail. 2006;12:134-8. </text>
<text top="494" left="54" width="957" height="15" font="7">  208.   Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105-11. </text>
<text top="513" left="54" width="1337" height="15" font="7">  209.   Krum H, Bailey M, Meyer W, et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology. 2007;108:28-34. </text>
<text top="532" left="54" width="1406" height="15" font="7">  210.   Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data </text>
<text top="551" left="108" width="817" height="15" font="7">and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573-8. </text>
<text top="570" left="54" width="922" height="15" font="7">  211.   Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61. </text>
<text top="589" left="54" width="1394" height="15" font="7">  212.   Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-</text>
<text top="608" left="108" width="16" height="15" font="7">9. </text>
<text top="627" left="54" width="1360" height="15" font="7">  213.   Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. </text>
<text top="646" left="108" width="183" height="15" font="7">Lancet. 2008;372:1223-30. </text>
<text top="665" left="54" width="1399" height="15" font="7">  214.   Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur </text>
<text top="684" left="108" width="183" height="15" font="7">J Heart Fail. 2005;7:904-9. </text>
<text top="703" left="54" width="1338" height="15" font="7">  215.   Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. </text>
<text top="722" left="108" width="105" height="15" font="7">2011;57:870-9. </text>
<text top="741" left="54" width="1341" height="15" font="7">  216.   Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) </text>
<text top="760" left="108" width="316" height="15" font="7">Investigators. N Engl J Med. 1989;321:406-12. </text>
</page>
<page number="200" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">200</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1381" height="15" font="7">  217.   Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival </text>
<text top="77" left="108" width="298" height="15" font="7">With Oral d-Sotalol. Lancet. 1996;348:7-12. </text>
<text top="96" left="54" width="1066" height="15" font="7">  218.   Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-87. </text>
<text top="115" left="54" width="1238" height="15" font="7">  219.   The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319:385-92. </text>
<text top="134" left="54" width="1395" height="15" font="7">  220.   Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; </text>
<text top="153" left="108" width="602" height="15" font="7">and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83:52-60. </text>
<text top="172" left="54" width="1401" height="15" font="7">  221.   Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy </text>
<text top="191" left="108" width="237" height="15" font="7">Trial. Circulation. 1996;94:346-52. </text>
<text top="210" left="54" width="1181" height="15" font="7">  222.   Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66:779-85. </text>
<text top="229" left="54" width="1384" height="15" font="7">  223.   Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their </text>
<text top="248" left="108" width="633" height="15" font="7">combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-61. </text>
<text top="267" left="54" width="1093" height="15" font="7">  224.   Littler WA, Sheridan DJ. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. Br Heart J. 1995;73:428-33. </text>
<text top="286" left="54" width="1388" height="15" font="7">  225.   Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-</text>
<text top="305" left="108" width="488" height="15" font="7">Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96:856-63. </text>
<text top="324" left="54" width="1377" height="15" font="7">  226.   Stanton E, Hansen M, Wijeysundera HC, et al. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart </text>
<text top="343" left="108" width="139" height="15" font="7">Fail. 2005;7:557-65. </text>
<text top="362" left="54" width="1406" height="15" font="7">  227.   Udelson JE, DeAbate CA, Berk M, et al. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. Am </text>
<text top="381" left="108" width="177" height="15" font="7">Heart J. 2000;139:503-10. </text>
<text top="400" left="54" width="1294" height="15" font="7">  228.   Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108-12. </text>
<text top="418" left="54" width="1316" height="15" font="7">  229.   Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777-84. </text>
<text top="437" left="54" width="1384" height="15" font="7">  230.   Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern </text>
<text top="456" left="108" width="160" height="15" font="7">Med. 2002;162:265-70. </text>
<text top="475" left="54" width="1392" height="15" font="7">  231.   Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-</text>
<text top="494" left="108" width="307" height="15" font="7">based cohort study. Lancet. 2004;363:1751-6. </text>
<text top="513" left="54" width="1396" height="15" font="7">  232.   Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ. </text>
<text top="532" left="108" width="108" height="15" font="7">2005;330:1370. </text>
<text top="551" left="54" width="1403" height="15" font="7">  233.   Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. </text>
<text top="570" left="108" width="114" height="15" font="7">2009;169:141-9. </text>
<text top="589" left="54" width="1290" height="15" font="7">  234.   Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26:2983-9. </text>
<text top="608" left="54" width="1354" height="15" font="7">  235.   Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In </text>
<text top="627" left="108" width="545" height="15" font="7">macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. </text>
<text top="646" left="54" width="1406" height="15" font="7">  236.   Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with </text>
<text top="665" left="108" width="709" height="15" font="7">New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol. 2007;49:1696-704. </text>
<text top="684" left="54" width="1077" height="15" font="7">  237.   Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-43. </text>
<text top="703" left="54" width="1402" height="15" font="7">  238.   Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label </text>
<text top="722" left="108" width="218" height="15" font="7">trial. Lancet. 2009;373:2125-35. </text>
<text top="741" left="54" width="1218" height="15" font="7">  239.   Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31:824-31. </text>
<text top="760" left="54" width="1394" height="15" font="7">  240.   Giles TD, Elkayam U, Bhattacharya M, et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac </text>
<text top="779" left="108" width="294" height="15" font="7">disease. Congest Heart Fail. 2010;16:111-7. </text>
</page>
<page number="201" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">201</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1384" height="15" font="7">  241.   Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am </text>
<text top="77" left="108" width="204" height="15" font="7">Coll Cardiol. 2008;51:1073-9. </text>
<text top="96" left="54" width="1395" height="15" font="7">  242.   Zile MR, Bourge RC, Bennett TD, et al. Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trial. J </text>
<text top="115" left="108" width="184" height="15" font="7">Card Fail. 2008;14:816-23. </text>
<text top="134" left="54" width="1370" height="15" font="7">  243.   Adamson PB, Gold MR, Bennett T, et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac </text>
<text top="153" left="108" width="702" height="15" font="7">Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011;17:248-54. </text>
<text top="172" left="54" width="1397" height="15" font="7">  244.   Conraads VM, Tavazzi L, Santini M, et al. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. </text>
<text top="191" left="108" width="205" height="15" font="7">Eur Heart J. 2011;32:2266-73. </text>
<text top="210" left="54" width="1403" height="15" font="7">  245.   Abraham WT, Compton S, Haas G, et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest </text>
<text top="229" left="108" width="172" height="15" font="7">Heart Fail. 2011;17:51-5. </text>
<text top="248" left="54" width="1264" height="15" font="7">  246.   Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-66. </text>
<text top="267" left="54" width="1195" height="15" font="7">  247.   Ritzema J, Troughton R, Melton I, et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation. 2010;121:1086-95. </text>
<text top="286" left="54" width="1314" height="15" font="7">  248.   Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-50. </text>
<text top="305" left="54" width="1120" height="15" font="7">  249.   Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49. </text>
<text top="324" left="54" width="1048" height="15" font="7">  250.   Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38. </text>
<text top="343" left="54" width="1000" height="15" font="7">  251.   Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95. </text>
<text top="362" left="54" width="958" height="15" font="7">  252.   Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-16. </text>
<text top="381" left="54" width="1349" height="15" font="7">  253.   Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy </text>
<text top="400" left="108" width="1262" height="15" font="7">(SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. </text>
<text top="418" left="108" width="122" height="15" font="7">2010;122:2660-8. </text>
<text top="437" left="54" width="1284" height="15" font="7">  254.   Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-33. </text>
<text top="456" left="54" width="1260" height="15" font="7">  255.   Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294:1664-70. </text>
<text top="475" left="54" width="1382" height="15" font="7">  256.   Allen LA, Rogers JG, Warnica JW, et al. High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. J Card Fail. 2008;14:661-9. </text>
<text top="494" left="54" width="963" height="15" font="7">  257.   Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359:142-51. </text>
<text top="513" left="54" width="1158" height="15" font="7">  258.   Masip J, Roque M, Sanchez B, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005;294:3124-30. </text>
<text top="532" left="54" width="1082" height="15" font="7">  259.   Kar B, Gregoric ID, Basra SS, et al. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol. 2011;57:688-96. </text>
<text top="551" left="54" width="1156" height="15" font="7">  260.   Thiele H, Lauer B, Hambrecht R, et al. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation. 2001;104:2917-22. </text>
<text top="570" left="54" width="1404" height="15" font="7">  261.   Idelchik GM, Simpson L, Civitello AB, et al. Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device </text>
<text top="589" left="108" width="374" height="15" font="7">implantation. J Heart Lung Transplant. 2008;27:106-11. </text>
<text top="608" left="54" width="1394" height="15" font="7">  262.   Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. </text>
<text top="627" left="108" width="197" height="15" font="7">Eur Heart J. 2009;30:2102-8. </text>
<text top="646" left="54" width="1374" height="15" font="7">  263.   Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of </text>
<text top="665" left="108" width="588" height="15" font="7">cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol. 2008;52:1584-8. </text>
<text top="684" left="54" width="1373" height="15" font="7">  264.   Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional </text>
<text top="703" left="108" width="709" height="15" font="7">therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J. 2006;152:469-8. </text>
<text top="722" left="54" width="1391" height="15" font="7">  265.   Guazzi M, Vicenzi M, Arena R, et al. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results </text>
<text top="741" left="108" width="618" height="15" font="7">of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4:8-17. </text>
<text top="760" left="54" width="1229" height="15" font="7">  266.   Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1:213-9. </text>
<text top="779" left="54" width="1401" height="15" font="7">  267.   Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007;116:1555-62. </text>
</page>
<page number="202" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">202</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1052" height="15" font="7">  268.   Guazzi M, Samaja M, Arena R, et al. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50:2136-44. </text>
<text top="77" left="54" width="1133" height="15" font="7">  269.   Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138:247-53. </text>
<text top="96" left="54" width="1365" height="15" font="7">  270.   Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. </text>
<text top="115" left="108" width="183" height="15" font="7">Lancet. 2002;360:196-202. </text>
<text top="134" left="54" width="1255" height="15" font="7">  271.   Cuffe MS, Califf RM, Adams KF, Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7. </text>
<text top="153" left="54" width="1389" height="15" font="7">  272.   Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003. </text>
<text top="172" left="54" width="1328" height="15" font="7">  273.   Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute </text>
<text top="191" left="108" width="643" height="15" font="7">Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57-64. </text>
<text top="210" left="54" width="1306" height="15" font="7">  274.   Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883-91. </text>
<text top="229" left="54" width="1359" height="15" font="7">  275.   Feldman AM, Oren RM, Abraham WT, et al. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral </text>
<text top="248" left="108" width="598" height="15" font="7">enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007;154:861-9. </text>
<text top="267" left="54" width="1204" height="15" font="7">  276.   Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J. 2007;153:98-104. </text>
<text top="286" left="54" width="1285" height="15" font="7">  277.   Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-75. </text>
<text top="305" left="54" width="1405" height="15" font="7">  278.   O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International </text>
<text top="324" left="108" width="446" height="15" font="7">Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78-86. </text>
<text top="343" left="54" width="1393" height="15" font="7">  279.   Hershberger RE, Nauman D, Walker TL, et al. Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail. </text>
<text top="362" left="108" width="97" height="15" font="7">2003;9:180-7. </text>
<text top="381" left="54" width="1068" height="15" font="7">  280.   Gorodeski EZ, Chu EC, Reese JR, et al. Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320-4. </text>
<text top="400" left="54" width="1359" height="15" font="7">  281.   Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, </text>
<text top="418" left="108" width="659" height="15" font="7">double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009;30:3015-26. </text>
<text top="437" left="54" width="1327" height="15" font="7">  282.   Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J Heart Lung Transplant. </text>
<text top="456" left="108" width="114" height="15" font="7">2004;23:1082-6. </text>
<text top="475" left="54" width="1389" height="15" font="7">  283.   Aranda JM, Jr., Schofield RS, Pauly DF, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. </text>
<text top="494" left="108" width="114" height="15" font="7">2003;145:324-9. </text>
<text top="513" left="54" width="1397" height="15" font="7">  284.   Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized </text>
<text top="532" left="108" width="719" height="15" font="7">Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. 2004;110:975-81. </text>
<text top="551" left="54" width="1074" height="15" font="7">  285.   Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43. </text>
<text top="570" left="54" width="1386" height="15" font="7">  286.   Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll </text>
<text top="589" left="108" width="163" height="15" font="7">Cardiol. 2007;50:741-7. </text>
<text top="608" left="54" width="1123" height="15" font="7">  287.   Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-51. </text>
<text top="627" left="54" width="1242" height="15" font="7">  288.   Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312-21. </text>
<text top="646" left="54" width="1048" height="15" font="7">  289.   Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-96. </text>
<text top="665" left="54" width="1264" height="15" font="7">  290.   Lahpor J, Khaghani A, Hetzer R, et al. European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg. 2010;37:357-61. </text>
<text top="684" left="54" width="1371" height="15" font="7">  291.   Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a </text>
<text top="703" left="108" width="997" height="15" font="7">prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol. 2011;57:1890-8. </text>
<text top="722" left="54" width="810" height="15" font="7">  292.   University of Alabama Birmingham. INTERMACS Manual of Operations V2.3. User's Guide 2008: Available at: </text>
<text top="741" left="108" width="855" height="15" font="11">http://www.uab.edu/ctsresearch/intermacs/Document%20Library/Site%20Users%20Guide%20v2.3%20update%2006052009.pdf</text>
<text top="741" left="963" width="202" height="15" font="7"> . Accessed October 18, 2011. </text>
<text top="760" left="54" width="1282" height="15" font="7">  293.   Grady KL, Meyer PM, Dressler D, et al. Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation. Ann Thorac Surg. 2004;77:1321-7. </text>
<text top="779" left="54" width="996" height="15" font="7">  294.   Elhenawy AM, Algarni KD, Rodger M, et al. Mechanical circulatory support as a bridge to transplant candidacy. J Card Surg. 2011;26:542-7. </text>
</page>
<page number="203" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">203</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1264" height="15" font="7">  295.   Alba AC, Rao V, Ross HJ, et al. Impact of fixed pulmonary hypertension on post-heart transplant outcomes in bridge-to-transplant patients. J Heart Lung Transplant. 2010;29:1253-8. </text>
<text top="77" left="54" width="1370" height="15" font="7">  296.   Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart </text>
<text top="96" left="108" width="223" height="15" font="7">Lung Transplant. 2010;29:201-8. </text>
<text top="115" left="54" width="1349" height="15" font="7">  297.   Greenberg B, Czerska B, Delgado RM, et al. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the </text>
<text top="134" left="108" width="1221" height="15" font="7">Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation. 2008;118:1241-9. </text>
<text top="153" left="54" width="1376" height="15" font="7">  298.   Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction </text>
<text top="172" left="108" width="439" height="15" font="7">complicated by cardiogenic shock. Eur Heart J. 2005;26:1276-83. </text>
<text top="191" left="54" width="1372" height="15" font="7">  299.   Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. </text>
<text top="210" left="108" width="105" height="15" font="7">2011;30:402-7. </text>
<text top="229" left="54" width="1398" height="15" font="7">  300.   Lietz K, Long JW, Kfoury AG, et al. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. </text>
<text top="248" left="108" width="196" height="15" font="7">Circ Heart Fail. 2009;2:3-10. </text>
<text top="267" left="54" width="1401" height="15" font="7">  301.   Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant. 2009;28:44-50. </text>
<text top="286" left="54" width="1385" height="15" font="7">  302.   John R, Pagani FD, Naka Y, et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other </text>
<text top="305" left="108" width="369" height="15" font="7">variables. J Thorac Cardiovasc Surg. 2010;140:174-81. </text>
<text top="324" left="54" width="1373" height="15" font="7">  303.   Cleveland JC, Jr., Naftel DC, Reece TB, et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J </text>
<text top="343" left="108" width="264" height="15" font="7">Heart Lung Transplant. 2011;30:862-9. </text>
<text top="362" left="54" width="1317" height="15" font="7">  304.   Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. </text>
<text top="381" left="108" width="122" height="15" font="7">2010;55:1826-34. </text>
<text top="400" left="54" width="1367" height="15" font="7">  305.   Allen JG, Weiss ES, Schaffer JM, et al. Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation. J Heart Lung Transplant. 2010;29:278-85. </text>
<text top="418" left="54" width="1138" height="15" font="7">  306.   Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003;92:1350-4. </text>
<text top="437" left="54" width="1117" height="15" font="7">  307.   Butler J, Khadim G, Paul KM, et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol. 2004;43:787-93. </text>
<text top="456" left="54" width="1073" height="15" font="7">  308.   Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J. 2004;147:354-60. </text>
<text top="475" left="54" width="1047" height="15" font="7">  309.   Chase P, Arena R, Guazzi M, et al. Prognostic usefulness of the functional aerobic reserve in patients with heart failure. Am Heart J. 2010;160:922-7. </text>
<text top="494" left="54" width="1074" height="15" font="7">  310.   Ferreira AM, Tabet JY, Frankenstein L, et al. Ventilatory efficiency and the selection of patients for heart transplantation. Circ Heart Fail. 2010;3:378-86. </text>
<text top="513" left="54" width="1355" height="15" font="7">  311.   Goda A, Lund LH, Mancini D. The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. J Heart Lung Transplant. </text>
<text top="532" left="108" width="114" height="15" font="7">2011;30:315-25. </text>
<text top="551" left="54" width="1215" height="15" font="7">  312.   Grady KL, Jalowiec A, White-Williams C. Improvement in quality of life in patients with heart failure who undergo transplantation. J Heart Lung Transplant. 1996;15:749-57. </text>
<text top="570" left="54" width="1004" height="15" font="7">  313.   Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med. 1999;340:272-7. </text>
<text top="589" left="54" width="1133" height="15" font="7">  314.   Grady KL, Jalowiec A, White-Williams C. Predictors of quality of life in patients at one year after heart transplantation. J Heart Lung Transplant. 1999;18:202-10. </text>
<text top="608" left="54" width="1061" height="15" font="7">  315.   Salyer J, Flattery MP, Joyner PL, et al. Lifestyle and quality of life in long-term cardiac transplant recipients. J Heart Lung Transplant. 2003;22:309-21. </text>
<text top="627" left="54" width="1143" height="15" font="7">  316.   Habedank D, Ewert R, Hummel M, et al. Changes in exercise capacity, ventilation, and body weight following heart transplantation. Eur J Heart Fail. 2007;9:310-6. </text>
<text top="646" left="54" width="1259" height="15" font="7">  317.   Grady KL, Naftel DC, Young JB, et al. Patterns and predictors of physical functional disability at 5 to 10 years after heart transplantation. J Heart Lung Transplant. 2007;26:1182-91. </text>
<text top="665" left="54" width="1399" height="15" font="7">  318.   Bull DA, Karwande SV, Hawkins JA, et al. Long-term results of cardiac transplantation in patients older than sixty years. UTAH Cardiac Transplant Program. J Thorac Cardiovasc Surg. 1996;111:423-7. </text>
<text top="684" left="54" width="1379" height="15" font="7">  319.   Deng MC, De Meester JM, Smits JM, et al. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and </text>
<text top="703" left="108" width="557" height="15" font="7">Clinical Profiles in Transplantation (COCPIT) Study Group. BMJ. 2000;321:540-5. </text>
<text top="722" left="54" width="1353" height="15" font="7">  320.   Klotz S, Deng MC, Hanafy D, et al. Reversible pulmonary hypertension in heart transplant candidates--pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail. </text>
<text top="741" left="108" width="105" height="15" font="7">2003;5:645-53. </text>
<text top="760" left="54" width="1386" height="15" font="7">  321.   Kirklin JK, Naftel DC, Bourge RC, et al. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J Thorac Cardiovasc Surg. 2003;125:881-90. </text>
<text top="779" left="54" width="1297" height="15" font="7">  322.   Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant. 2003;22:862-8. </text>
</page>
<page number="204" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">204</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1233" height="15" font="7">  323.   Kuppahally SS, Valantine HA, Weisshaar D, et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant. 2007;7:2388-95. </text>
<text top="77" left="54" width="1372" height="15" font="7">  324.   Rasmusson KD, Stehlik J, Brown RN, et al. Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy: a multiinstitutional analysis. J Heart Lung Transplant. 2007;26:1097-104. </text>
<text top="96" left="54" width="1086" height="15" font="7">  325.   Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant. 2010;29:432-8. </text>
<text top="115" left="54" width="1234" height="15" font="7">  326.   Shuhaiber JH, Moore J, Dyke DB. The effect of transplant center volume on survival after heart transplantation: a multicenter study. J Thorac Cardiovasc Surg. 2010;139:1064-9. </text>
<text top="134" left="54" width="988" height="15" font="7">  327.   Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97. </text>
<text top="153" left="54" width="1185" height="15" font="7">  328.   Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation. 2009;119:1899-907. </text>
<text top="172" left="54" width="1254" height="15" font="7">  329.   Flores-Le Roux JA, Comin J, Pedro-Botet J, et al. Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Cardiovasc Diabetol. 2011;10:39. </text>
<text top="191" left="54" width="1133" height="15" font="7">  330.   Berry C, Brett M, Stevenson K, et al. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart. 2008;94:296-304. </text>
<text top="210" left="54" width="984" height="15" font="7">  331.   Garty M, Cohen E, Zuchenko A, et al. Blood transfusion for acute decompensated heart failure--friend or foe? Am Heart J. 2009;158:653-8. </text>
<text top="229" left="54" width="1403" height="15" font="7">  332.   Singer AJ, Emerman C, Char DM, et al. Bronchodilator therapy in acute decompensated heart failure patients without a history of chronic obstructive pulmonary disease. Ann Emerg Med. 2008;51:25-34. </text>
<text top="248" left="54" width="1310" height="15" font="7">  333.   Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135-45. </text>
<text top="267" left="54" width="1182" height="15" font="7">  334.   Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol. 2008;127:228-32. </text>
<text top="286" left="54" width="1176" height="15" font="7">  335.   Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987-96. </text>
<text top="305" left="54" width="1348" height="15" font="7">  336.   Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008;10:188-95. </text>
<text top="324" left="54" width="1408" height="15" font="7">  337.   Cowie MR, Komajda M, Murray-Thomas T, et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in </text>
<text top="343" left="108" width="351" height="15" font="7">heart failure (POSH). Eur Heart J. 2006;27:1216-22. </text>
<text top="362" left="54" width="1141" height="15" font="7">  338.   Komukai K, Ogawa T, Yagi H, et al. Decreased renal function as an independent predictor of re-hospitalization for congestive heart failure. Circ J. 2008;72:1152-7. </text>
<text top="381" left="54" width="1392" height="15" font="7">  339.   Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol. 2004;94:957-</text>
<text top="400" left="108" width="25" height="15" font="7">60. </text>
<text top="418" left="54" width="974" height="15" font="7">  340.   Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268-74. </text>
<text top="437" left="54" width="1332" height="15" font="7">  341.   Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients &gt; or =65 years of age with heart failure. Am J Cardiol. 2000;85:1110-3. </text>
<text top="456" left="54" width="1334" height="15" font="7">  342.   Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-7. </text>
<text top="475" left="54" width="1349" height="15" font="7">  343.   Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a </text>
<text top="494" left="108" width="898" height="15" font="7">Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1:25-33. </text>
<text top="513" left="54" width="1388" height="15" font="7">  344.   Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-</text>
<text top="532" left="108" width="25" height="15" font="7">53. </text>
<text top="551" left="54" width="1069" height="15" font="7">  345.   Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40. </text>
<text top="570" left="54" width="1163" height="15" font="7">  346.   Peacock WF, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005;29:243-52. </text>
<text top="589" left="54" width="1287" height="15" font="7">  347.   Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-91. </text>
<text top="608" left="54" width="1349" height="15" font="7">  348.   Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. </text>
<text top="627" left="108" width="122" height="15" font="7">2005;293:1900-5. </text>
<text top="646" left="54" width="1365" height="15" font="7">  349.   Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, </text>
<text top="665" left="108" width="467" height="15" font="7">placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835-40. </text>
<text top="684" left="54" width="1399" height="15" font="7">  350.   Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide </text>
<text top="703" left="108" width="327" height="15" font="7">[FUSION I] trial). Am J Cardiol. 2006;98:226-9. </text>
<text top="722" left="54" width="1404" height="15" font="7">  351.   Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. </text>
<text top="741" left="108" width="196" height="15" font="7">Circ Heart Fail. 2008;1:9-16. </text>
<text top="760" left="54" width="1065" height="15" font="7">  352.   O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43. </text>
</page>
<page number="205" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">205</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1386" height="15" font="7">  353.   Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J </text>
<text top="77" left="108" width="225" height="15" font="7">Am Coll Cardiol. 2008;52:190-9. </text>
<text top="96" left="54" width="1354" height="15" font="7">  354.   Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in </text>
<text top="115" left="108" width="498" height="15" font="7">Hospitalized Patients with Heart Failure). Am J Cardiol. 2008;102:1524-9. </text>
<text top="134" left="54" width="1382" height="15" font="7">  355.   Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for </text>
<text top="153" left="108" width="732" height="15" font="7">Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534-41. </text>
<text top="172" left="54" width="1408" height="15" font="7">  356.   Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007;9:901-9. </text>
<text top="191" left="54" width="1405" height="15" font="7">  357.   Fonarow GC, Abraham WT, Albert NM, et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail. </text>
<text top="210" left="108" width="114" height="15" font="7">2007;13:722-31. </text>
<text top="229" left="54" width="1376" height="15" font="7">  358.   Fonarow GC, Abraham WT, Albert NM, et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate </text>
<text top="248" left="108" width="753" height="15" font="7">Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;153:82-11. </text>
<text top="267" left="54" width="1398" height="15" font="7">  359.   Thilly N, Briancon S, Juilliere Y, et al. Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and </text>
<text top="286" left="108" width="255" height="15" font="7">use. J Eval Clin Pract. 2003;9:373-82. </text>
<text top="305" left="54" width="1333" height="15" font="7">  360.   Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J. </text>
<text top="324" left="108" width="130" height="15" font="7">2010;160:1156-62. </text>
<text top="343" left="54" width="1179" height="15" font="7">  361.   Ko DT, Juurlink DN, Mamdani MM, et al. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail. 2006;12:205-10. </text>
<text top="362" left="54" width="1314" height="15" font="7">  362.   Dhaliwal AS, Bredikis A, Habib G, et al. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol. 2008;102:1356-60. </text>
<text top="381" left="54" width="1133" height="15" font="7">  363.   Ahmed A, Allman RM, DeLong JF. Inappropriate use of digoxin in older hospitalized heart failure patients. J Gerontol A Biol Sci Med Sci. 2002;57:M138-M143. </text>
<text top="400" left="54" width="1349" height="15" font="7">  364.   Krantz MJ, Ambardekar AV, Kaltenbach L, et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart </text>
<text top="418" left="108" width="288" height="15" font="7">Failure). Am J Cardiol. 2011;107:1818-23. </text>
<text top="437" left="54" width="1232" height="15" font="7">  365.   Fonarow GC, Gheorghiade M, Abraham WT. Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. Am J Cardiol. 2004;94:1155-60. </text>
<text top="456" left="54" width="1265" height="15" font="7">  366.   Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165:1469-77. </text>
<text top="475" left="54" width="1258" height="15" font="7">  367.   Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70. </text>
<text top="494" left="54" width="1389" height="15" font="7">  368.   Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med. 2004;141:446-53. </text>
<text top="513" left="54" width="1388" height="15" font="7">  369.   Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from </text>
<text top="532" left="108" width="433" height="15" font="7">the American Heart Association. Circulation. 2010;122:1975-96. </text>
<text top="551" left="54" width="829" height="15" font="7">  370.   Roy D, Talajic M, Dubuc M, et al. Atrial fibrillation and congestive heart failure. Curr Opin Cardiol. 2009;24:29-34. </text>
<text top="570" left="54" width="1108" height="15" font="7">  371.   Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. </text>
<text top="589" left="54" width="1376" height="15" font="7">  372.   Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized </text>
<text top="608" left="108" width="618" height="15" font="7">evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72. </text>
<text top="627" left="54" width="1405" height="15" font="7">  373.   Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. </text>
<text top="646" left="108" width="205" height="15" font="7">Eur Heart J. 2011;32:2387-94. </text>
<text top="665" left="54" width="1074" height="15" font="7">  374.   Sochalski J, Jaarsma T, Krumholz HM, et al. What works in chronic care management: the case of heart failure. Health Aff (Millwood ). 2009;28:179-89. </text>
<text top="684" left="54" width="1277" height="15" font="7">  375.   Laramee AS, Levinsky SK, Sargent J, et al. Case management in a heterogeneous congestive heart failure population: a randomized controlled trial. Arch Intern Med. 2003;163:809-17. </text>
<text top="703" left="54" width="1399" height="15" font="7">  376.   Peters-Klimm F, Campbell S, Hermann K, et al. Case management for patients with chronic systolic heart failure in primary care: the HICMan exploratory randomised controlled trial. Trials. 2010;11:56. </text>
<text top="722" left="54" width="1387" height="15" font="7">  377.   Correia J, Silva FF, Roque C, et al. Impact of a specialized outpatient heart failure follow-up program on hospitalization frequency and functional status of patients with advanced heart failure. Rev Port </text>
<text top="741" left="108" width="171" height="15" font="7">Cardiol. 2007;26:335-43. </text>
<text top="760" left="54" width="1379" height="15" font="7">  378.   Conte MR, Mainardi L, Iazzolino E, et al. [Outpatient medical and nurse management program in patients with chronic heart failure in a large territorial area in Piedmont. Four years of follow-up]. Ital </text>
<text top="779" left="108" width="203" height="15" font="7">Heart J Suppl. 2005;6:812-20. </text>
</page>
<page number="206" position="absolute" top="0" left="0" height="918" width="1512">
<text top="814" left="54" width="409" height="12" font="5">© American College of Cardiology Foundation and American Heart Association, Inc. </text>
<text top="814" left="486" width="3" height="12" font="5"> </text>
<text top="814" left="540" width="3" height="12" font="5"> </text>
<text top="814" left="594" width="3" height="12" font="5"> </text>
<text top="814" left="648" width="3" height="12" font="5"> </text>
<text top="814" left="702" width="3" height="12" font="5"> </text>
<text top="813" left="756" width="3" height="14" font="6"> </text>
<text top="813" left="810" width="21" height="14" font="6">206</text>
<text top="810" left="831" width="4" height="16" font="7"> </text>
<text top="847" left="54" width="4" height="16" font="7"> </text>
<text top="58" left="54" width="1381" height="15" font="7">  379.   Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ. 2007;334:942. </text>
<text top="77" left="54" width="1305" height="15" font="7">  380.   Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;CD007228. </text>
<text top="96" left="54" width="1362" height="15" font="7">  381.   Riegel B, Carlson B, Kopp Z, et al. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med. 2002;162:705-12. </text>
<text top="115" left="54" width="1212" height="15" font="7">  382.   Riegel B, Carlson B, Glaser D, et al. Randomized controlled trial of telephone case management in Hispanics of Mexican origin with heart failure. J Card Fail. 2006;12:211-9. </text>
<text top="134" left="54" width="1035" height="15" font="7">  383.   Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail. 2007;13:56-62. </text>
<text top="153" left="54" width="1302" height="15" font="7">  384.   Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute </text>
<text top="172" left="108" width="615" height="15" font="7">Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:1021-8. </text>
<text top="191" left="54" width="1396" height="15" font="7">  385.   Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart </text>
<text top="210" left="108" width="609" height="15" font="7">Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585-96. </text>
<text top="229" left="54" width="4" height="15" font="7"> </text>
<text top="248" left="54" width="4" height="15" font="7"> </text>
</page>
</pdf2xml>
